,Source,Machine Translation ouput,Machine Post Edit (APE),Human Post-Edit (HPE)
0,b'81 norvir enth\xc3\xa4lt den farbstoff gelborange s ( e110 ) . dieser kann allergische reaktionen verursachen .',b'81 norvir contains the agent sunset yellow fcf ( e110 ) which may cause allergic reactions .',b'norvir contains the is retinitis e which may cause allergic reactions .',b'81 norvir contains the agent sunset yellow fcf ( e110 ) which may cause allergic reactions .'
1,b'daten aus einer begrenzten anzahl von schwangerschaften weisen nicht auf sch\xc3\xa4dliche wirkungen von amlodipin oder anderen calciumrezeptor-antagonisten auf die gesundheit des feten hin .',b'data from a limited number of exposed pregnancies indicate no adverse effects of amlodipine and other calcium receptor antagonists on the health of the foetus .',b'data from a limited number of placebotreated data over the health of the appropriate components effects were known to both additional infarction receptor substrates on the health of the foetus .',b'data from a limited number of exposed pregnancies indicate no adverse effects of amlodipine and other calcium receptor antagonists on the health of the foetus .'
2,b'durch einstellung des blutzuckers werden die symptome und komplikationen von diabetes verringert .',"b'by controlling blood sugar , the symptoms and complications of diabetes are reduced .'",b'should not a larger body consequences to treat the symptoms and complications of diabetes are reduced .',"b'by controlling blood sugar , the symptoms and complications of diabetes are reduced .'"
3,b'luminity wurde nicht speziell bei patienten mit eingeschr\xc3\xa4nkter leberfunktion untersucht .',b'luminity has not been specifically investigated in patients with hepatic impairment .',b'also has not been dependent investigated in patients with hepatic impairment .',b'luminity has not been specifically investigated in patients with hepatic impairment .'
4,"b'die in tabelle 3 aufgef\xc3\xbchrten nebenwirkungen basieren auf daten aus zusammenfassungen der merkmale ( fachinformationen ) f\xc3\xbcr metformin , die in der eu verf\xc3\xbcgbar sind .'",b'the adverse reactions listed in table 3 is based on the data from the spcs please refer also to the of metformin in the eu available in case of need .',b'the adverse reactions listed in table is based on the data from the uterine impairment is necessary in the eu and on the european on the eu dna please refer also to the of metformin in none .',b'the adverse reactions listed in table 3 are based on the data from summaries of the characteristics of metformin which were published in the eu .'
5,b'\xc3\x9cbrig gebliebene l\xc3\xb6sung muss weggeworfen werden .',b'\xc3\x9cbrig gebliebene solution should be discarded .',b'remaining contrast solution should be discarded .',b'remaining solution should be discarded .'
6,b'fareston darf nicht w\xc3\xa4hrend der schwangerschaft verwendet werden .',b'fareston should not be used during pregnancy .',b'vimpat should not be used during pregnancy .',b'fareston should not be used during pregnancy .'
7,b'bei \xc3\xbcberschie\xc3\x9fender reaktion ist die behandlung zu beenden und kein hcg zu geben ( siehe abschnitt 4 ) .',"b'if an excessive response response is obtained , treatment should be stopped and hcg withheld ( see section 4 ) .'","b'if an excessive response response is obtained , treatment should be stopped and hcg withheld see section .'","b'if an excessive response response is obtained , treatment should be stopped and hcg withheld ( see section 4 ) .'"
8,"b'im tierversuch unterdr\xc3\xbcckte tacrolimussalbe entz\xc3\xbcndungsreaktionen in experimentellen und \xc3\xa4n spontanen dermatitismodellen , die eine \xc3\x84hnlichkeit mit atopischem ekzem beim menschen aufweisen .'","b'in animal studies , tacrolimus ointment suppressed inflammatory reactions in experimental and spontaneous lo , atopic dermatitis in humans .'","b'in animal studies , tacrolimus ointment input blocking active arrest , neuropsychological cysts in humans .'","b'in animal studies , tacrolimus ointment suppressed inflammatory reactions in experimental and spontaneous dermatitis models , which had similarities to atopical eczema in humans .'"
9,"b'eine packung enth\xc3\xa4lt eine bzw. vier fertigspritze ( n ) mit 15 \xce\xbc g aranesp injektionsl\xc3\xb6sung in 0,375 ml ( 40 \xc2\xb5g / ml ) .'",b'package containing one or four pre-filled syringe ( s ) of a 15 \xc2\xb5g aranesp solution for injection in 0.375 ml ( 40 \xc2\xb5g / ml ) .',b'package for one or four prefilled syringe s of a g aranesp solution for injection in . ml g ml .',b'package containing one or four pre-filled syringe ( s ) of a 15 \xc2\xb5g aranesp solution for injection in 0.375 ml ( 40 \xc2\xb5g / ml ) .'
10,b'jede durchstechflasche enth\xc3\xa4lt 250 mg des wirkstoffs abatacept .',b'each vial contains 250 mg of the active substance abatacept .',b'each vial contains mg of the active substance section .',b'each vial contains 250 mg of the active substance abatacept .'
11,"b'jede blisterpackung enth\xc3\xa4lt 28 , 84 oder 252 tabletten zur herstellung einer suspension zum einnehmen .'","b'each blister pack contains 28 , 84 or 252 tablets for oral suspension .'","b'each blister packs contains , or tablets for oral suspension .'","b'each blister pack contains 28 , 84 or 252 tablets for oral suspension .'"
12,b'die wirkdauer betr\xc3\xa4gt 3 bis 5 stunden .',b'the duration of action is approximately 3 to 5 hours .',b'the duration of action is approximately to hours .',b'the duration of action is approximately 3 to 5 hours .'
13,"b'falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the phareceutical company .'"
14,"b'die klinische erfahrung hat gezeigt , dass die therapie mit paroxetin nicht mit einer beeintr\xc3\xa4chtigung der kognitiven oder psychomotorischen leistungen verbunden ist .'",b'there is limited clinical experience has shown that treatment with paroxetine is not associated with any impairment of cognitive or psychomotor performance .',b'there is limited clinical experience has shown that treatment with paroxetine is not associated with any impairment is anastrozole or kaliuretic patients is possible allergies until it is necessary .',b'clinical experience has shown that treatment with paroxetine is not associated with any impairment of cognitive or psychomotor performance .'
15,"b'bei patienten , die auf eine dosis von 20 mg paroxetin unzureichend ansprechen , kann die dosis je nach ansprechen des patienten allm\xc3\xa4hlich in 10 mg- schritten bis zu einer maximaldosis von 50 mg paroxetin pro tag erh\xc3\xb6ht werden .'","b""in patients receiving weekly dose of 20 mg paroxetine is inadequate to respond to therapy , the dose may be increased gradually in 10 mg steps up to a maximum of 50 mg / day depending on the patient 's response .""",b'in patients contains ifn doses of mg paroxetine is inadequate to a progress see over the dose may be increased gradually in mg as recommended a maximum of mg day .',"b""in patients receiving weekly dose of 20 mg paroxetine , the dose may be increased gradually in 10 mg steps up to a maximum of 50 mg / day depending on the patient 's response ."""
16,b'jede filmtablette enth\xc3\xa4lt 200 mg emtricitabin und 245 mg tenofovirdisoproxil ( entsprechend 300 mg tenofovirdisoproxilfumarat bzw. 136 mg tenofovir ) .',"b'each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil ( equivalent to 300 mg of tenofovir disoproxil fumarate , or 136 mg of tenofovir ) .'","b'each filmcoated tablet contains mg of emtricitabine and mg of tenofovir disoproxil maraviroc and mg of tenofovir disoproxil fumarate of tenofovir disoproxil l , or mg of . mg of plasma disoproxil fumarate .'","b'each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil ( equivalent to 300 mg of tenofovir disoproxil fumarate , or 136 mg of tenofovir ) .'"
17,b'zur prophylaxe der transplantatabsto\xc3\x9fung bei erwachsenen herztransplantatempf\xc3\xa4ngern und transplantatempf\xc3\xa4ngern im kindesalter liegen noch keine klinischen daten f\xc3\xbcr die retardierte formulierung advagraf vor .',b'for prophylaxis of transplant rejection in adult heart transplantation and 102 in infancy there is no clinical data available for the prolonged-release formulation advagraf .',b'for comparator of transplant rejection in paediatric insulin lack and bone clearance is no clinical data available for the prolongedrelease tissue through less is no clinical data is no clinical data available for the prolongedrelease pumps in children are no clinical data available for the prolongedrelease formulation in children .',b'for prophylaxis of transplant rejection in adult heart transplanta recipients and transplant recipients in infancy no clinical data is available for the prolonged-release formulation advagraf .'
18,"b'nicht zutreffend , da integrilin zur anwendung bei station\xc3\xa4ren patienten bestimmt ist .'",b'not applicable since integrilin is intended for use in non-ambulatory patients .',b'not applicable since integrilin is intended for use in safety patients .',b'not applicable since integrilin is intended for use in non-ambulatory patients .'
19,b'wurden sie k\xc3\xbcrzlich krank ?',b'when you may have .',b'when you may have immuno .',b'have you recently been sick ?'
20,"b'lysodren ist ein arzneimittel , das den wirkstoff mitotan enth\xc3\xa4lt .'",b'lysodren is a medicine containing the active substance mitotane .',b'does is a medicine with the active substance that each other ingredients contains the active substance messenger .',b'lysodren is a medicine containing the active substance mitotane .'
21,b'die impfung tr\xc3\xa4chtiger katzen wird daher nicht empfohlen .',b'vaccination of pregnant cats is therefore not recommended .',b'vaccination of pregnant cats see return that be determined .',b'vaccination of pregnant cats is therefore not recommended .'
22,"b'bisher ist nicht bekannt , ob avonex in die muttermilch \xc3\xbcbergeht .'",b'it is unknown whether avonex is excreted in human milk .',b'it is unknown whether avonex is excreted in human milk .',b'it is unknown whether avonex is excreted in human milk .'
23,"b'wenn sie nierenprobleme haben , wird ihr arzt individuell beurteilen , ob die einnahme von valdoxan f\xc3\xbcr sie sicher ist .'","b'if you have a kidney problem , your doctor will make an individual evaluation of whether it is safe for you to take valdoxan .'","b'only you have a kidney problem , your doctor will make a individual current treatment , it is safe for you to take valdoxan .'","b'if you have a kidney problem , your doctor will make an individual evaluation of whether it is safe for you to take valdoxan .'"
24,b'diese kann entweder als zweimal t\xc3\xa4gliche gabe von 150 mg oder als einmal t\xc3\xa4gliche gabe von 300 mg verabreicht werden ( siehe abschnitt 4.4 ) .',b'this may be administered as either 150 mg twice daily or 300 mg once daily ( see section 4.4 ) .',b'this may be administered as either mg twice daily or mg once daily see section . per twice daily or mg once daily dose . prior to over mg twice daily or mg once daily see section . .',b'this may be administered as either 150 mg twice daily or 300 mg once daily ( see section 4.4 ) .'
25,"b'nicht-melanom-hautkarzinome traten bei 3,6 % der patienten auf ; andere malignome bei 1,1 % der patienten .'",b'nicht-melanom-hautkarzinome occurred in 3.6 % of patients ; other malignancies in 1.1 % of patients .',b'sanohex medicinal level are measure in . of patients during . of patients .',b'non melanoma skin cancers occurred in 3.6 % of patients ; other malignancies in 1.1 % of patients .'
26,b'1 ml der rekonstituierten l\xc3\xb6sung enth\xc3\xa4lt 90 mg enfuvirtid .',b'1 ml of reconstituted solution contains 90 mg enfuvirtide .',b'ml of reconstituted solution contains mg enfuvirtide .',b'1 ml of reconstituted solution contains 90 mg enfuvirtide .'
27,"b'reproduction is authorised provided the source is acknowledged . wie wirkt nplate ? der wirkstoff in nplate , romiplostim , regt die bildung von blutpl\xc3\xa4ttchen an .'","b'reproduction is authorised provided the source is acknowledged . "" incretin \'hormones in nplate ? the active substance in nplate , romiplostim , stimulates the formation of platelets .'",b'reproduction is authorised provided the source is acknowledged . l as is steadystate .',"b'reproduction is authorised provided the source is acknowledged . how does nplate work ? the active substance in nplate , romiplostim , stimulates the formation of platelets .'"
28,"b'optikusneuropathie ( naion ) hatten , diese erkrankung wird manchmal auch als "" schlaganfall des auges "" beschrieben .'","b'( naion ) , a condition known as "" blood flow .'",b'fatalaties causes an condition known as blood flow .',"b'( naion ) , a condition known as "" blood flow .'"
29,b'hepatitis b wird durch das hepatitis-b-virus verursacht .',b'hepatitis b is caused by the hepatitis b virus .',b'hepatitis b is caused by the hepatitis b virus .',b'hepatitis b is caused by the hepatitis b virus .'
30,"b'der impfstoff rotateq wird s\xc3\xa4uglingen im alter von ab sechs wochen verabreicht , um einer durch rotavireninfektionen hervorgerufenen gastroenteritis ( brechdurchfall , gleichzeitiges auftreten von durchfall und erbrechen ) vorzubeugen .'","b'the vaccine rotateq is given infants from the age of six weeks , to avoid gastroenteritis caused by the rotavireninfektionen ( brechdurchfall tightening , the incidence of diarrhoea and vomiting ) .'",b'the vaccine displays excreted to produce pain caused by the interventricular painkillers molecule group .',"b'the vaccine rotateq is given infants from the age of six weeks , to avoid gastroenteritis ( diarrhoea with vomiting ) caused by rotavirus infections .'"
31,"b'42 woche 5 betrug 30,8 / 24,0 mmhg in der irbesartan / hydrochlorothiazid-gruppe und 21,1 / 19,3 mmhg in der irbesartan-gruppe ( p < 0,0001 ) .'",b'/ sedbp at five weeks were 30.8 / 24.0 mmhg for irbesartan / hydrochlorothiazide and 21.1 / 19.3 mmhg for ( p 0.0001 ) .',b'nc at five weeks and bouin . .',b'at five weeks there was 30.8 / 24.0 mmhg in the irbesartan / hydrochlorothiazide group and 21.1 / 19.3 mmhg for in the irbesartan group ( p 0.0001 ) .'
32,b'jede durchstechflasche enth\xc3\xa4lt nominell 500 i.e. nonacog alfa ( rekombinanter blutgerinnungsfaktor ix ) .',b'each vial contains nominally 500 iu nonacog alfa ( recombinant coagulation factor ix ) .',b'each vial contains nominally iu nonacog alfa recombinant coagulation factor rosiglitazone recombinant coagulation factor ix .',b'each vial contains nominally 500 iu nonacog alfa ( recombinant coagulation factor ix ) .'
33,"b'halten sie die spritze senkrecht mit dem kolben nach oben und tippen sie die seitenfl\xc3\xa4che der spritze an ihren finger , damit die luftblase aufsteigt .'","b'hold the syringe vertically with the plunger and tippen you stop the vial and the syringe , your finger so that the air bubble immunoassay .'","b'hold the syringe droplets with the plunger and splitting you hexal needle can additionally to the vial and pierce off and the syringe , your purple so that the air product to stabilise themselves to the syringe through your moist off out the syringe , your different off for the'",b'hold the syringe vertically with the plunger upwards and tip the vial and the side of the syringe sgainst your finger so that the air bubbles rise up .'
34,"b'49 % und f\xc3\xbcr die 20 mg vardenafil-dosis 64 % bzw. 54 % , verglichen mit 36 % bzw. 23 % unter placebo .'",b'49 % for 20 mg and 64 % and 54 % on vardenafil compared to 36 % and 23 % on placebo .',b'for mg and and on vardenafil compared to and on placebo .',b'49 % and for the 20 mg vardenafil dose 64 % oder 54 % compared to 36 % and 23 % on placebo .'
35,"b'die anfangsdosierung von repaglinid betr\xc3\xa4gt 0,5 mg vor den hauptmahlzeiten . die aufdosierung erfolgt wie bei der monotherapie gem\xc3\xa4\xc3\x9f der blutzuckerreaktion .'",b'the starting dose of repaglinide is 0.5 mg to be taken before the main meals . the aiming to meals ; as monotherapy according to the blutzuckerreaktion .',b'the starting dose of repaglinide is for activated c is reached as six as monotherapy according to the tail white and a certain meals . the plasma pump at vitamin as monotherapy between .',"b'the starting dose of repaglinide is 0.5 mg to be taken before the main meals . like monotherapy , the dose is increased according to the blood sugar reactions .'"
36,"b'aufgrund der geringen anzahl von patienten , wurde jede nebenwirkung nur bei einem einzigen patienten berichtet .'","b'due to the small number of patients , any adverse reactions have been reported only by one patient only .'","b'due to the small number of patients , any adverse reactions have been reported only have been reported only by one patient only .'","b'due to the small number of patients , adverse reactions have been reported by one patient only .'"
37,b'2. was m\xc3\xbcssen sie vor der einnahme von micardisplus beachten ? 3.',b'what you should know before you take micardisplus 3 .',b'what you should know before you take micardisplus .',b'what you should know before you take micardisplus ?'
38,"b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen es ist unwahrscheinlich , dass die verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen durch die unter viani m\xc3\xb6glichen nebenwirkungen beeinflusst werden .'",b'on the ability to drive and use machines is unlikely to affect your ability to drive or use machines with viani does not affect the possible side effects .',b'on the ability to drive or use machines is unlikely to that the danger effects .',b'on the ability to drive and use machines . it is unlikely that your ability to drive or use machines with will be affected by possible side effects of viani .'
39,b'die fibrinkleberl\xc3\xb6sung wie in abschnitt 6.6 beschrieben zubereiten .',b'the fibrinkleberl\xc3\xb6sung complete directions are described in section 6.6 .',b'the import complete the designation of is described in section . .',b'prepare the fibrin glue solution as described in section 6.6 .'
40,"b'nach oraler gabe von pritorplus werden maximale hydrochlorothiazid- konzentrationen etwa 1,0-3,0 stunden nach der einnahme erreicht .'",b'following oral administration of pritorplus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 - 3.0 hours after dosing .',b'following oral administration of pritorplus peak concentrations of hydrochlorothiazide are reached in approximately .',"b'following oral administration of pritorplus , peak concentrations of hydrochlorothiazide are reached in approximately 1.0 - 3.0 hours after dosing .'"
41,b'reaktionen an der einstichstelle ; nicht-kardiale brustschmerzen ( schwer :',b'injection site reactions ; nicht-kardiale chest pain ( severe :',b'injection site reactions listing',b'injection site reactions ; non-cardial chest pain ( severe :'
42,"b'patienten mit depression sollten mindestens \xc3\xbcber einen zeitraum von sechs monaten behandelt werden , um sicherzustellen , dass sie symptomfrei sind .'",b'patients with depression should be treated for at least over a period of six months to ensure that they are asymptomatic .',b'patients with depression should be treated for at least over a period of six months to ensure that they are asymptomatic .',b'patients with depression should be treated for at least over a period of six months to ensure that they are asymptomatic .'
43,b'nehmen sie ihre flasche vfend-suspension mit .',b'do not take your bottle vfend-suspension .',b'do not take your package bubbles .',b'take your bottle of vfend-suspension .'
44,"b'nach 26 wochen therapie wiesen die mit aldurazyme behandelten patienten gegen\xc3\xbcber der placebogruppe eine verbesserung der lungenfunktion und der gehf\xc3\xa4higkeit auf , die in der folgenden tabelle dargestellt ist .'","b'after 26 weeks of treatment , the patients were treated with aldurazyme compared to the placebo group to an improvement in lung function and gehf\xc3\xa4higkeit , which is shown in the following table .'","b'after weeks of treatment , the patients were treated with aldurazyme load which on the following table .'","b'after 26 weeks of treatment , the patients treated with aldurazyme showed an improvement in their lung function and fitness compared to the placebo group , which is shown in the following table .'"
45,"b'40 mg , wei\xc3\x9f :'",b'40 mg ; white :',b'mg white',b'40 mg ; white :'
46,b'95 das h\xc3\xa4ufigste anzeichen einer \xc3\x9cberdosierung ist verminderte f\xc3\xa4higkeit zu atmen .',b'95 the most common sign of overdose is reduced ability to breathe .',b'the most common swelling of overdose is reduced ability to major changes .',b'95 the most common sign of overdose is reduced ability to breathe .'
47,b'das pr\xc3\xa4parat ist in 5 ml-durchstechflaschen der glasart i abgef\xc3\xbcllt .',b'the product is presented in 5 ml vials of type i glass .',b'the product is presented in ml unit glass .',b'the product is presented in 5 ml vials of type i glass .'
48,"b'ihr arzt wird ihnen zeigen , in welchen hautbereich sie optisulin spritzen sollen .'",b'your doctor will show you in which area of the skin you should inject optisulin .',b'your doctor will show you in which area of the skin you should inject them .',b'your doctor will show you in which area of the skin you should inject optisulin .'
49,"b'au\xc3\x9ferdem stellte der chmp fest , dass nur begrenzte studiendaten bez\xc3\xbcglich der titrationsschritte mit der kombination vorlagen .'","b'in addition , the chmp noted that limited study data regarding induced with the combination was available at the time of approval .'","b'in addition , the chmp noted that limited subjects for ergot alone and the spread of the durability .'","b'in addition , the chmp noted that only limited study data regarding the titration steps with the combination was available .'"
50,b'die reaktionen an der 217 injektionsstelle traten gew\xc3\xb6hnlich innerhalb des ersten behandlungsmonats auf .',b'the injection site reactions injection site reactions usually occurred in the first month .',b'the injection site reactions injection site reactions usually occurred in the first month .',b'the injection site reactions of the 217 injection site reactions usually occurred in the first month .'
51,b'es liegen keine klinischen daten zur anwendung bei personen unter 18 jahren vor .',b'there are no clinical data on the use of celvapan below 18 years of age .',b'there is no clinical data on the use of celvapan below years of age .',b'there are no clinical data on the use of celvapan below 18 years of age .'
52,b'eine vollst\xc3\xa4ndige auflistung der im zusammenhang mit purevax rcp berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',b'the full list of the side-effects reported with purevax rcp people who may be hypersensitive ( allergic ) to ribavirin or any of the other ingredients .',b'the full list of the sideeffects reported with purevax warnings people who may be hypersensitive allergic reported .',b'the full list of the side-effects reported with purevax rcp can be found in the package insert .'
53,"b'es wird angenommen , dass 6 % - 13 % aller klinischen aom-episoden durch prevenar verhindert werden k\xc3\xb6nnten .'",b'it is believed that 6 % - 13 % of all clinical aom-episoden prevenar could be affected .',b'it is believed that of all .',b'it is believed that 6 % - 13 % of all clinical aom episodes could be reduced by prevenar .'
54,"b'pankreatitis : selten traten f\xc3\xa4lle von pankreatitis bei patienten unter abacavir- , lamivudin- und zidovudinbehandlung auf .'","b'pancreatitis : cases of pancreatitis have occurred rarely in patients receiving abacavir , lamivudine and zidovudine .'",b'pancreatitis and frequent definitions associated with humans .',"b'pancreatitis : cases of pancreatitis have occurred rarely in patients receiving abacavir , lamivudine and zidovudine .'"
55,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr kuvan finden sie hier .',b'the full epar for avamys for kuvan can be found here .',b'the full epar for kuvan can be found here .',b'the full epar for avamys for kuvan can be found here .'
56,b'datum der erteilung der zulassung :',b'date of first authorisation :',b'date of first authorisation',b'date of first authorisation :'
57,b'was ist celsentri und wof\xc3\xbcr wird es angewendet ?',b'what celsentri is and what it is used for 2 .',b'what celsentri is and what it is used for .',b'what celsentri is and what it is used for .'
58,b'in klinischen studien wurden gelegentlich sichtbare reaktionen und schmerzen an der injektionsstelle beobachtet .',"b'in clinical trials , occasionally visible reactions and pain at the injection site were observed .'","b'in clinical trials , occasionally creams reactions and pain at the injection site of the injection site were observed .'","b'in clinical trials , occasionally visible reactions and pain at the injection site were observed .'"
59,b'f\xc3\xbcr patientinnen mit schwerer niereninsuffizienz ( kreatinin-clearance unter 30 ml / minute ) liegen keine pharmakokinetischen daten vor .',b'there are no pharmacokinetic data are available for patients with severe renal impairment ( creatinine clearance below 30 ml / min ) .',b'there are no pharmacokinetic data are available for less than creatinine clearance below .',b'there are no pharmacokinetic data are available for patients with severe renal impairment ( creatinine clearance below 30 ml / min ) .'
60,b'es werden wirksame kontrazeptive ma\xc3\x9fnahmen oder enthaltsamkeit empfohlen .',b'you should use effective contraceptive measures are recommended .',b'you should use effective contraceptive expected is recommended .',b'effective contraceptive measures or abstinenece is recommended .'
61,b'64 rotigotin ist ein nicht-ergoliner d3 / d2 / d1-dopaminagonist zur behandlung des morbus parkinson .',"b""64 rotigotine is a non-ergolinic d3 / d2 / d1 dopamine agonist for the treatment of parkinson 's disease .""",b'. hycamtin is a anovulatory d d be created against both combination led to regardless during of fsh s disease .',"b""64 rotigotine is a non-ergolinic d3 / d2 / d1 dopamine agonist for the treatment of parkinson 's disease ."""
62,"b'45 eigeninjektion sollte jedoch nur von patienten durchgef\xc3\xbchrt werden , die entsprechend motiviert und hinreichend geschult sind sowie die m\xc3\xb6glichkeit haben , fachlichen rat einzuholen .'","b'45 should only be performed by patients who are well-motivated , adequately trained and with access self with access to expert advice .'","b'should only be performed by patients who are wellmotivated , adequately trained or with ciprofloxacin or with of xolair or except exforge or weaker from driving self advised before deciding aseptically pharmaceuticals .'","b'45 self injection should only be performed by patients who are well-motivated , adequately trained and with access with access to expert advice .'"
63,b'die vorsichtsma\xc3\x9fnahmen zum lichtschutz m\xc3\xbcssen strikt eingehalten werden .',"b'the precautions , cucumo , must be strictly adhered to .'","b'the precautions , exubera , their advice immediately with the following agent .'",b'the precautions against light exposure must be strictly adhered to .'
64,b'bei den instrumenten kann es sich um durchfluss- oder doppeleinlassinstrumente handeln .',b'among them can be 2 doppeleinlassinstrumente .',b'among them can be toxicologically .',b'the instruments may include discharge instruments or double-intake instruments .'
65,b'tierversuche zeigten irreversible toxische wirkungen auf die m\xc3\xa4nnlichen fortpflanzungsorgane bei klinisch relevanten expositionsspiegeln .',b'animal studies showed irreversible toxic effects on the male reproductive organs at clinically relevant at exposure levels .',b'animal studies showed initially aiiras reactions on the male reproductive organs at combination of oral categories listed .',b'animal studies showed irreversible toxic effects on the male reproductive organs at clinically relevant exposure levels .'
66,b'warum wurde cancidas zugelassen ?',b'why has cancidas been approved ?',b'why has cancidas been approved ?',b'why has cancidas been approved ?'
67,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit atriance berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',b'for a full list of the side-effects reported with atriance hypersensitive ( allergic ) to ribavirin or any of the other ingredients .',b'for a full list of the sideeffects reported with atriance with humalog protease .',"b'for a full list of the side-effects reported with atriance , see the package leaflet .'"
68,b'vorbeugung einer fr\xc3\xbchgeborenenan\xc3\xa4mie :',b'156 prevention of anaemia of prematurity :',b'prevention of anaemia of prematurity',b'prevention of anaemia of premature babies :'
69,b'1 was ist doribax und wof\xc3\xbcr wird es angewendet ? 2.',b'what doribax is and what it is used for 2 .',b'what doribax is and what it is used for .',b'what doribax is and what it is used for . 2 .'
70,"b'nehmen sie bitte nicht die doppelte dosis ein , um eine vergessene dosis nachzuholen .'",b'take not inject a double dose to make up for a forgotten dose .',b'take this pump and double administration dose to make up for a forgotten dose .',b'take not inject a double dose to make up for a forgotten dose .'
71,"b'3 beobachtet wurden normale n\xc3\xbcchtern-ausgangswerte ( < 5,17mmol / l ) , die \xc3\xbcber die normwerte anstiegen ( \xe2\x89\xa5 6,2mmol / l ) .'",b'3 manifestations observed in the normal n\xc3\xbcchtern-ausgangswerte ( 5.17 mmol / l ) which increased to high ( \xe2\x89\xa5 6.2 mmol / l ) .',b'manifestations observed in the normal hr . mmol l which increased to high . mmol l .',b'3 manifestations observed in the normal fasting state initial value ( < 5.17 mmol / l ) which climbed higher than the normal level ( \xe2\x89\xa5 6.2 mmol / l ) .'
72,"b'bei frauen , die mit humanem 60 leukozyten-interferon behandelt wurden , wurden verminderte \xc3\x96stradiol- und progesteronspiegel im serum beschrieben .'",b'in women treated with human leukocyte interferon decreased serum estradiol and progesterone concentrations have been reported in women .',b'in women treated with plasma ethinyl serum estradiol and papules .',"b'in women treated with human leukocyte interferon , decreased serum estradiol and progesterone concentrations have been reported in women .'"
73,b'eine klinische besserung ist innerhalb von 1 oder 2 wochen zu erwarten .',b'clinical improvement is expected to be within 1 to 2 weeks .',b'clinical improvement is expected to be determined within to weeks .',b'a clinical improvement is expected within 1 to 2 weeks .'
74,"b'was muss ich tun , bevor ich mir selbst eine subkutane aranesp-injektion gebe ?'",b'what should i do before i give myself a subcutaneous aranesp injection ?',b'what should i do before i give myself a subcutaneous aranesp injection ?',b'what should i do before i give myself a subcutaneous aranesp injection ?'
75,"b'schwangerschaft wenn sie schwanger sind oder eine schwangerschaft planen , sagen sie es ihrem arzt .'","b'pregnancy if you become pregnant , or are planning to become pregnant , tell your doctor .'","b'occur if you become pregnant , or can be taken to become pregnant , tell your doctor .'","b'pregnancy if you become pregnant , or are planning to become pregnant , tell your doctor .'"
76,"b'nebenwirkungen , die in klinischen studien f\xc3\xbcr mit aprovel behandelte patienten berichtet wurden , waren :'",b'side effects reported in clinical trials for patients treated with aprovel were :',b'side effects reported in clinical trials in clinical trials for patients treated with aprovel and low',b'side effects reported in clinical trials for patients treated with aprovel were :'
77,"b'bei patienten , welche eine schwerwiegende allergische reaktion auf filgrastim zeigen , muss dieses dauerhaft abgesetzt werden .'",b'in patients who have had a serious allergic reaction to filgrastim show this is permanently discontinued .',b'in patients who have had a serious allergic reaction to filgrastim show this is excercised discontinued .',b'in patients who show a serious allergic reaction to filgrastim this is permanently discontinued .'
78,"b'injizieren sie nun in der gleichen art und weise luft in die humalog-flasche , aber ziehen sie die spritze nicht heraus .'","b'inject now in the same way that the air in the humalog-flasche , but withdraw the syringe .'","b'inject continued in the same way on the same way that the needle from go upright for a use to a readytouse site , the needle .'","b'inject now in the same way into the humalog bottle , but do not withdraw the syringe .'"
79,"b'las der pen ist so konstruiert , dass der inhalt von 30 millionen i.e. in dosen von 2,5 bis 10 millionen i.e. entnommen werden kann .'",b'ori the pen is designed to deliver its contents of 30 million iu in doses ranging from 2.5 to 10 million iu .',b'paper solution are designed to be carefully and supplied to a that its identical of million iu of million iu in doses ranging from . to million iu .',b'ori the pen is designed to deliver its contents of 30 million iu in doses ranging from 2.5 to 10 million iu .'
80,"b'in jedem fall m\xc3\xbcssen die h\xc3\xa4matologischen parameter des patienten \xc3\xbcberwacht und sofort entsprechende gegenma\xc3\x9fnahmen eingeleitet werden , wenn sich hinweise auf eine knochenmarkssch\xc3\xa4digung ergeben .'","b'in any case , close monitoring of haematological parameters should be monitored and anaphylactic reactions immediately initiated if evidence of knochenmarkssch\xc3\xa4digung .'","b'in any case , close monitoring of haematological parameters should be monitored and anaphylactic reactions immediately , a individual chronic dose .'","b'in any case , close monitoring of haematological parameters should be monitored and appropriate measure should be taken immediately if there is evidence of bone marrow damage .'"
81,b'die n\xc3\xbcchtern- und postprandiale blutzuckerkontrolle von patienten mit diabetes mellitus typ 2 wird verbessert .',b'fasting and postprandial glycaemic control in patients with type 2 diabetes mellitus .',b'the medication of the case of the growth of patients with type diabetes mellitus .',b'fasting and postprandial glycaemic control in patients with type 2 diabetes mellitus is improving .'
82,"b'r\xc3\xb6ntgenbilder von h\xc3\xa4nden und handgelenken wurden zu studienbeginn und nach einer behandlungsdauer von 6 , 12 und 24 monaten ausgewertet .'","b'the presence of the hands and handgelenken were evaluated at baseline and after 6 , 12 and 24 months of age .'",b'the presence of the hands and dilation were evaluated at the serum of age .',"b'radiographs of the hands and wrist were evaluated at the beginning of the study and after 6 , 12 and 24 months .'"
83,"b'dieses arzneimittel wurde unter "" au\xc3\x9fergew\xc3\xb6hnlichen umst\xc3\xa4nden "" zugelassen .'","b'this medicinal product has been authorised under "" exceptional circumstances .'",b'this medicinal product has been authorised under demand circumstances .',"b'this medicinal product has been authorised under "" exceptional circumstances "" .'"
84,b'ankylosierende spondylitis die ankylosierende spondylitis ist eine entz\xc3\xbcndliche erkrankung der wirbels\xc3\xa4ule .',b'ankylosing spondylitis ankylosing spondylitis is an inflammatory disease of the spine .',"b'exubera with iodine spondylitis is an inflammatory light , the spine .'",b'ankylosing spondylitis : ankylosing spondylitis is an inflammatory disease of the spine .'
85,"b'es wurde nicht nachgewiesen , dass die wirkung auf hba1c unabh\xc3\xa4ngig von der gewichtsreduktion ist .'",b'it has not been demonstrated that the effect on hba1c independent of weight loss .',b'it has still been demonstrated that the effect on the line pgp concentrations .',b'it has not been demonstrated that the effect on hba1c is independent of weight loss .'
86,"b'wenn ihnen eine lichttherapie verschrieben wird , ug unterrichten sie bitte ihren arzt dar\xc3\xbcber , dass sie protopy anwenden , da die gleichzeitige anwendung von protopy und einer lichttherapie nicht empfohlen wird .'","b'if you have been told to take ) phototherapies is prescribed if you are prescribed light therapy , inform your doctor that you are using protopy as the concomitant use of protopy and phototherapy is not recommended .'",b'if you are been told to take rule is prescribed yourself or or doctor may be reduce clearly as the concomitant use of protopy and phototherapy is not recommended nurse is not recommended after an no use of protopy every dose of protopy and phototherapy are not recommended for conditions',"b'if you have been prescribed light therapy , inform your doctor that you are using protopy as the concomitant use of protopy and phototherapy is not recommended .'"
87,"b'die serumkonzentrationen von fentanyl , die bei opioid-naiven patienten zu einem minimalen analgetischen effekt f\xc3\xbchren , schwanken zwischen 0,3-1,5 ng / ml ; eine erh\xc3\xb6hte inzidenz von nebenwirkungen ist bei serumspiegeln \xc3\xbcber 2 ng / ml zu beobachten .'",b'the serum concentrations of minimal effect of fentanyl in opioid na\xc3\xafve patients between the second injection-molded ng / ml ; increased incidence of side effects seen in serum levels above 2 ng / ml .',b'the serum concentrations of single effect of fentanyl in urinary burden rate of a low molecular values above ng ml concentrations',"b'the serum concentrations of fentanyl , which leads to a minimal analgesic effect in patients who have never had opioid , fluctuates 0.3-1.5 ng / ml ; an increased incidence of side effects is seen in serum levels above 2 ng / ml .'"
88,b'welches risiko ist mit micardis verbunden ?',b'what is the risk associated with micardis ?',b'what is the risk associated with coarse ?',b'what is the risk associated with micardis ?'
89,b'zum einmischen von aivlosin in das futtermittel sollte ein horizontaler bandmischer verwendet werden .',b'to incorporate the incorporation into the product into feeding stuff should be used .',b'projections the near and microbiological smaller guidelines to strict relieve the guidance by a use treatment separately before back with travatan stuff with tap molecules stuff the product can be carried consideration must not be used .',"b'to incorporate aivlosin into the feeding stuff , a horizontal ribbon mixer should be used .'"
90,b'diese injektion darf nicht mit einem anderen arzneimittel in derselben spritze oder durchstechflasche gemischt werden .',b'this injection should not be mixed with other medicinal products in the same syringe or vial .',b'this injection should not be mixed with other medicinal products in the same syringe or ml stated or vial .',b'this injection should not be mixed with other medicinal products in the same syringe or vial .'
91,b'topotecan hemmt die menschlichen p450-enzyme nicht ( siehe abschnitt 5.2 ) .',b'topotecan does not ( see section 5.2 ) .',b'topotecan does not see section . .',b'topotecan does not inhibit the human p450 enzyme ( see section 5.2 ) .'
92,b'74 l\xc3\xb6sungsmittel zur herstellung von parenteralia :',b'74 solvent for parenteral use :',b'solvent for production',b'74 solvent for parenteral use :'
93,"b'es wurde vorgeschlagen , die zugelassenen st\xc3\xa4rken von lopid zu rationalisieren .'",b'it has been proposed to be the approved strengths of lopid .',b'it has been consistent with the approved release in vitreous and vinblastine diseases .',b'it has been proposed to rationalise the approved strengths of lopid .'
94,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit tamiflu berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with side effects of tamiflu , see the package leaflet .'","b'for a full list of the sideeffects reported with side effects of tamiflu , see the package leaflet .'","b'for a full list of the side-effects reported with side effects of tamiflu , see the package leaflet .'"
95,"b'r\xc3\xb6ntgenbilder von h\xc3\xa4nden / handgelenken und f\xc3\xbc\xc3\x9fen wurden zu studienbeginn und nach einer behandlungsdauer von 6 , 12 und 24 monaten ausgewertet .'","b'degrees or hands / handgelenken and feet were evaluated at baseline and after 6 , 12 and 24 months of age .'",b'thiazideconditional or level or nitrogenbound increased doses of the number of age .',"b'x-ray images of hands / wrists and feet were evaluated at baseline and after 6 , 12 and 24 months of age .'"
96,"b'die studien ergaben , dass desirudin bei der verh\xc3\xbctung tiefer venenthrombosen nach h\xc3\xbcftgelenksersatzoperationen wirksamer war als beide vergleichsarzneimittel .'",b'the studies showed that desirudin was effective in prevention of deep vein thrombosis after h\xc3\xbcftgelenksersatzoperationen more effective than either of the comparators .',b'the formal of the incidence of deep vein ii',b'the studies showed that desirudin was more effective in prevention of deep vein thrombosis after hip replacement than either of the comparators .'
97,"b'die inzidenz klinisch bedeutsamer infektionen , von denen einige t\xc3\xb6dlich verliefen , belief sich bei den mit mabthera behandelten patienten auf 0,05 pro patientenjahr .'","b'the incidence of clinically significant infections , some with fatal outcome , have resulted in patients treated with mabthera to 0.05 per patient year ) .'","b'the incidence of clinically significant infections , some patients during patients treated with remicade .'","b'the incidence of clinically significant infections , some with fatal outcomes , among patients treated with mabthera have amounted to 0.05 per patient year .'"
98,b'was ist epivir und wof\xc3\xbcr wird es angewendet ?',b'what epivir is and what it is used for 2 .',b'what epivir is and what it is used for ?',b'what epivir is and what it is used for ?'
99,"b'experimentelle daten zeigen , dass der gel\xc3\xb6ste impfstoff auch bei raumtemperatur ( 25 \xc2\xb0 c ) 24 stunden haltbar ist .'",b'experimental data show that the reconstituted vaccine and keep it at room temperature ( 25 \xc2\xb0 c ) is stable for 24 hours .',b'only average data to well not applied .',b'experimental data show that the reconstituted vaccine is stable for 24 hours at room temperature ( 25 \xc2\xb0 c ) .'
100,"b'18 wie alle arzneimittel kann orgalutran nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'18 like all medicines , orgalutran may cause side effects , although not every body gets them .'","b'like all medicines , faslodex may cause side effects , although not every body gets them .'","b'18 like all medicines , orgalutran may cause side effects , although not every body gets them .'"
101,b'helixate nexgen 250 i.e. ist ausschlie\xc3\x9flich zur intraven\xc3\xb6sen anwendung bestimmt und muss umgehend nach herstellung der gebrauchsfertigen l\xc3\xb6sung angewendet werden .',b'helixate nexgen 250 iu is intended for intravenous administration only and must be administered immediately after reconstitution .',b'helixate nexgen iu is intended for intravenous administration only and watery .',b'helixate nexgen 250 iu is intended for intravenous administration only and must be administered immediately after reconstitution .'
102,b'der zulassungsinhaber muss die europ\xc3\xa4ische kommission \xc3\xbcber die vermarktungspl\xc3\xa4ne f\xc3\xbcr das in dieser entscheidung genehmigte tierarzneimittel informieren .',b'the holder of this marketing authorisation must inform the european commission about the marketing plans for this decision authorised veterinary medicinal product .',b'the holder of this marketing authorisation must inform the european commission about the marketing procedure for the reduction of the marketing reasons for this decision for this decision for this decision dialysis guide for this decision states previously states other effectiveness medicinal product .',b'the holder of this marketing authorisation must inform the european commission about the marketing plans for the veterinary medicinal product authorised in this ruling .'
103,"b'der gesch\xc3\xa4tzte anteil von progressionsfrei \xc3\x9cberlebenden nach 60 monaten betrug 83,2 % im glivec-arm und 64,1 % im kontrollarm ( p < 0,001 ) .'",b'the estimated probability of opioid at 60 months was 83.2 % in the glivec arm and 64.1 % in the control arm ( p 0.001 ) .',b'the estimated aldosteronism of opioid at months was . in the serum arm p . .',b'the estimated percentage of progression-free survival after 60 months was 83.2 % in the glivec arm and 64.1 % in the control arm ( p 0.001 ) .'
104,"b'22 kinder vor dem eintritt in die pubert\xc3\xa4t mit chronischer niereninsuffizienz spritzen sie 0,045 - 0,050 milligramm ( mg ) pro kilogramm k\xc3\xb6rpergewicht einmal t\xc3\xa4glich unter die haut ( subkutan ) .'",b'22 children to puberty and chronic renal insufficiency inject 0.045 - 0.050 milligrams ( mg ) per kilogram of body weight once daily under the skin ( subcutaneously ) .',b'children to cervarix and chronic renal insufficiency inject . . milligrams mg per kilogram of body weight once daily under the skin subcutaneously .',b'22 children hitting puberty with chronic renal insufficiency : inject 0.045 - 0.050 milligrams ( mg ) per kilogram of body weight once daily under the skin ( subcutaneously ) .'
105,b'ihr arzt wird ihr blut und ihren urin regelm\xc3\xa4\xc3\x9fig auf zucker untersuchen .',b'your doctor will check your blood and your urine for regularly check sugar .',b'your doctor will check your blood and your urine for a third condition .',b'your doctor will check your blood and your urine regularly for sugar .'
106,"b'so kommt es zu schwellungen ( entz\xc3\xbcndungen ) , schmerzen , ber\xc3\xbchrungsempfindlichkeit , steifigkeit und k\xc3\xb6rperlichen einschr\xc3\xa4nkungen .'","b'how to occur in swelling ( inflammation ) , pain , tenderness , stiffness and physical limitations .'","b'the dialysis agent may occur in many inflammation , pain , tenderness , they or physical hotmelt .'","b'it results in swelling ( inflammation ) , pain , tenderness , stiffness and physical limitations .'"
107,"b'zu einnahme von glukokortikoiden und / oder immunsuppressiva ) , entsprechend der f\xc3\xbcr diese indikation definierten patientengruppe ( siehe abschnitt 4.1 ) .'","b'concomitant stable doses of glucocorticoids and / or immunosuppressants ) , these 79 % of patients ( see section 4.1 ) .'",b'concomitant stable doses of breakdown and or yeland .',"b'dose of glucocorticoids and / or immunosuppressants ) , corresponding to the patient group in the indication ( see section 4.1 ) .'"
108,"b'es ist nicht bekannt , ob dieses arzneimittel beim menschen in die muttermilch \xc3\xbcbergeht .'",b'it is not known whether this product is present in human milk .',b'it is not known whether this product is approximately over in human milk .',b'it is not known whether this product is present in human milk .'
109,"b'die empfohlene anfangsdosis von xagrid betr\xc3\xa4gt 1 mg / tag , wobei zweimal t\xc3\xa4glich je eine kapsel eingenommen wird .'",b'the recommended starting dose of xagrid is 1 mg / day twice daily per capsule .',b'the recommended starting dose of xagrid is mg day twice daily per capsule .',b'the recommended starting dose of xagrid is 1 mg / day twice daily per capsule .'
110,b'die tr\xc3\xa4nken sollten gr\xc3\xbcndlich ges\xc3\xa4ubert und frei sein von reinigungs- und desinfektionmittelr\xc3\xbcckst\xc3\xa4nden .',"b'the expressed should be cleaned thoroughly and freely , with at least desinfektionmittelr\xc3\xbcckst\xc3\xa4nden .'",b'the enzyme samples may be cleaned pumps for at least fullterm vigilance .',b'the water should be cleaned thoroughly and be free of cleaning and disinfection agents .'
111,"b'es ist nicht auszuschlie\xc3\x9fen , dass auch andere induktoren ( z. b. phenytoin , carbamazepin , phenobarbital , johanniskraut ) ebenfalls die verf\xc3\xbcgbarkeit von rosiglitazon beeinflussen .'","b""it may not be excluded that other inducers ( e. g. phenytoin , carbamazepine , phenobarbital , st john 's wort ) may also affect rosiglitazone exposure .""","b'it may not be excluded that other inducers e . g . phenytoin , coadministration of inhibitors , phenobarbital , st john s wort may also affect rosiglitazone exposure .'","b""it may not be excluded that other inducers ( e. g. phenytoin , carbamazepine , phenobarbital , st john 's wort ) may also affect rosiglitazone exposure ."""
112,"b'aprepitant wurde aufgrund von nebenwirkungen von 0,6 % der patienten unter aprepitant- therapieschema abgesetzt im vergleich zu 0,4 % der patienten unter standardtherapie .'","b'aprepitant was discontinued due to adverse reactions in 0.6 % of patients treated with aprepitant regimen , compared with 0.4 % of patients treated with standard therapy .'",b'aprepitant was discontinued due to adverse reactions in . of patients treated with transport therapy .',"b'aprepitant was discontinued due to adverse reactions in 0.6 % of patients treated with aprepitant regimen , compared with 0.4 % of patients treated with standard therapy .'"
113,"b'um sicherzustellen , dass das pflaster noch fest anhaftet , wird die t\xc3\xa4gliche visuelle \xc3\x9cberpr\xc3\xbcfung empfohlen .'","b'to make sure that the patch still firmly carbonylation , it is recommended that the daily review of aml .'",b'to make sure that the patch in he counselling for food and protective disposable use of priapism .',"b'to make sure that the patch still firmly stuck , a daily visual review is recommended .'"
114,"b'die behandlung sollte intermittierend , kurzzeitig und nicht kontinuierlich erfolgen .'",b'treatment should be intermittent ; transient and not continuous .',b'treatment should be intermittent may be individualised particularly as an several .',b'treatment should be intermittent ; transient and not continuous .'
115,b'augenerkrankungen nebenwirkungen aus klinischen studien mit monotherapie :',b'eye disorders during monotherapy clinical trials :',b'eye disorders during monotherapy clinical trials',b'eye disorders during monotherapy clinical trials :'
116,b'hierauf sollte insbesondere bei niedrigem plasmafibrinogenspiegel ( bis zu ungef\xc3\xa4hr 2 tagen nach fibrinolytischer therapie des akuten herzinfarkts ) geachtet werden .',b'hierauf should be particularly taken in low plasmafibrinogenspiegel ( up to approximately 2 days after having an enzyme treatment of the acute myocardial infarction ( ami ) .',"b'the should be particularly taken during the treatment of the acute myocardial infarction , with three therapeutic myocardial infarction by unpredictable myocardial infarction material .'",b'after that particular attention should be paid to low plasma fibrinogen levels ( up to approximately 2 days after having fibrinolytic treatment of the acute myocardial infarction ) .'
117,"b'dicural l\xc3\xb6sung zum eingeben ist auch zur behandlung von infektionen , die durch pasteurella multocida verursacht werden , angezeigt .'","b'dicural oral solution is also used to treat infections caused by strongylus vulgaris , pasteurella multocida , is indicated .'","b'dicuralcoated oral solution is also not also initiated to treat infections caused in projection ngmn , is indicated .'",b'dicural oral solution is also used to treat infections caused by pasteurella multocida .'
118,"b'simulect 10 mg darf nicht gegeben werden , bevor absolut sichergestellt ist , dass der patient das transplantat und begleitende immunsuppression erhalten wird .'",b'simulect 10 mg should not be given before pathway procedure that the patient will receive the graft and concomitant immunosuppression .',"b'simulect mg may not be given before the individual glued , an highest immunosuppression .'",b'simulect 10 mg may not be given before it is absolutely certain that the patient will receive the graft and concomitant immunosuppression .'
119,"b'gelegentliche nebenwirkungen sind hautreaktionen an der injektionsstelle , wie r\xc3\xb6tung , schmerzen und schwellungen .'","b'uncommon side effects are skin reactions at the injection site , such as redness , pain and swelling .'","b'uncommon side effects are skin reactions at the injection site , such as redness , pain and swelling .'","b'uncommon side effects are skin reactions at the injection site , such as redness , pain and swelling .'"
120,b'best\xc3\xa4tigung durch eine weitere leberuntersuchung innerhalb von zwei wochen .',b'confirmation of leberuntersuchung within two weeks .',b'lorazepam of nnt within two weeks back .',b'confirmation of kidney examination within two weeks .'
121,b'welchen nutzen hat opgenra in diesen studien gezeigt ?',b'what benefit has opgenra shown during the studies ?',b'what benefit has support january have not shown during the studies ?',b'what benefit has opgenra shown during the studies ?'
122,b'die wirksamkeit von volibris als monotherapie bei pah-patienten der who-funktionsklasse iv ist nicht erwiesen .',"b'the effectiveness of volibris as monotherapy in patients with pah , classified as who functional class iv has not been established .'","b'the effectiveness of volibris , monotherapy in patients with volibristagesdosen , posaconazole as a coadministered with volibristagesdosen up to the potential class iv has not been established .'","b'the effectiveness of volibris as monotherapy in patients with pah , classified as who functional class iv has not been established .'"
123,b'wie wird ganfort angewendet ?',b'how is ganfort used ?',b'how is ganfort used ?',b'how is ganfort used ?'
124,b'm\xc3\xb6glicher einfluss von anderen arzneimitteln auf abilify :',b'potential for other medicinal products on abilify :',b'potential on beromun',b'potential for other medicinal products on abilify :'
125,b'\xc3\x9cberdosierung beim menschen kann zu einer wirkungsverl\xc3\xa4ngerung f\xc3\xbchren .',b'overdose in humans may lead to overdosage .',b'overdose in humans may lead to overdosage .',b'overdose in humans may lead to extended efficacy .'
126,b'der zulassungsinhaber wird j\xc3\xa4hrlich psurs vorlegen .',b'the marketing authorisation holder will continue to submit annual psurs .',b'the marketing authorisation holder will continue to administer arrhythmias photosensitiser .',b'the marketing authorisation holder will continue to submit annual psurs .'
127,b'22 die gleichzeitige gabe von ciprofloxacin und mexiletine kann zu erh\xc3\xb6hten plasmakonzentrationen von mexiletine f\xc3\xbchren .',b'22 the concomitant use of ciprofloxacin if may give rise to increased plasma concentrations of if .',b'the concomitant use of anaerobes dif of ciprofloxacin if may give rise to increased plasma concentrations of radiotherapy times the to increased plasma concentrations of the hyperglycaemia with increased plasma concentrations of if .',b'22 the concomitant use of ciprofloxacin and mexiletine may give rise to increased plasma concentrations of mexiletine .'
128,b'das verfallsdatum auf dem deckel des tr\xc3\xa4gers pr\xc3\xbcfen .',b'the expiry date on the lid of the tray .',b'the expiry date on the bottle of the tray .',b'check the expiry date on the lid of the tray .'
129,b'so wie andere antibiotika wirkt auch ceftiofur nur gegen bestimmte bakterienarten .',"b'thus , as with other antibiotics , including ceftiofur works only against certain types of bacteria .'","b'thus , as with other antibiotics , including tetanus industrielle and slowness able to theophylline works only against certain types of bacteria .'","b'thus , as with other antibiotics , ceftiofur works only against certain types of bacteria .'"
130,b'dadurch wird die injektion angenehmer .',b'for a more comfortable injection .',b'for a more comfortable injection .',b'this makes the injection more comfortable .'
131,b'die erfahrungen stammen von einer betainexposition bei etwa 1.000 patienten .',"b'experience in a betainexposition approximately 1,000 patients .'",b'experience in a corrected steady than replaces single .',"b'the experiences originate from a betaine exposition among about 1,000 patients .'"
132,b'anwendung bei m\xc3\xa4dchen unter 10 jahren :',b'use in girls below 10 years of age :',b'use for trudexa below is lower from the single of age',b'use in girls below 10 years of age :'
133,b'die beobachteten nebenwirkungen sind nach folgenden h\xc3\xa4ufigkeiten entsprechend aufgelistet :',b'the observed side effects are listed according to the following frequency equivalent to :',b'the observed side effects are listed according to the following frequency equivalent to',b'the observed side effects are listed according to the following frequencies :'
134,b'222 mixtard wird unter die haut ( subkutan ) injiziert .',b'222 mixtard is for injection under the skin ( subcutaneously ) .',b'mixtard is for injection under the skin subcutaneously .',b'222 mixtard is for injection under the skin ( subcutaneously ) .'
135,"b'2 in klinischen studien traten diese ereignisse w\xc3\xa4hrend einer behandlung mit placebo h\xc3\xa4ufiger auf als mit remeron , jedoch nicht statistisch signifikant h\xc3\xa4ufiger .'","b'2 in clinical trials these events occurred more frequently during treatment with placebo than with remeron , but not statistically significantly more frequently .'",b'in clinical trials these events occurred more frequently during treatment with placebo regarding studies taking very leucopenia and maculopapular suffer .',"b'2 in clinical trials these events occurred more frequently during treatment with placebo than with remeron , but not statistically significantly more frequently .'"
136,"b'die sonstigen bestandteile sind mikrokristalline cellulose , croscarmellose-natrium , hyprolose , lactose-monohydrat , magnesiumstearat ( ph.eur. ) und polysorbat 80.'","b'the other ingredients are microcrystalline cellulose , croscarmellose sodium , microcrystalline cellulose , hydroxypropyl cellulose , lactose monohydrate , magnesium stearate and polysorbate 80 .'","b'the other ingredients are microcrystalline cellulose , croscarmellose sodium , twolayer cellulose , methyl ink , magnesium stearate and polysorbate .'","b'the other ingredients are microcrystalline cellulose , croscarmellose sodium , hydroxypropyl cellulose , lactose monohydrate , magnesium stearate ( ph.eur. ) and polysorbate 80 .'"
137,"b'- produkte , die johanniskraut enthalten ( hypericum perforatum ) .'","b""- products containing st. john 's wort ( hypericum perforatum ) .""",b'mammary liver disease . john s wort hypericum perforatum .',"b""- products containing st. john 's wort ( hypericum perforatum ) ."""
138,b'2 / 3 vollst\xc3\xa4ndige auflistung der im zusammenhang mit zypadhera berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',b'2 / 3 full list of the side-effects reported with zypadhera hypersensitive ( allergic ) to ribavirin or any of the other ingredients .',b'full list of the sideeffects reported with zypadhera hypersensitive allergic see see on the other ingredients .',b'2 / 3 full list of the side-effects reported with zypadhera hypersensitive ( allergic ) can be seen on the package leaflet .'
139,"b'wie alle arzneimittel kann rotateq nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , rotateq may cause side effects , although not every body gets them .'","b'like all medicines , rotateq may cause side effects , although not every body gets them .'","b'like all medicines , rotateq may cause side effects , although not every body gets them .'"
140,"b'wenn sie weitere fragen zur anwendung des arzneimittels haben , fragen sie ihren arzt oder apotheker .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'"
141,"b'jede patrone enth\xc3\xa4lt 66 mikrogramm ( 18 m.i.e. ) interferon beta-1a in 1,5 ml l\xc3\xb6sung .'",b'each cartridge contains 66 micrograms ( 18 miu ) of interferon beta-1a in 1.5 ml of solution .',b'each preparation contains micrograms miu of interferon betaa in . kg mg of solution .',b'each cartridge contains 66 micrograms ( 18 miu ) of interferon beta-1a in 1.5 ml of solution .'
142,b'bereits vorbehandelte studienteilnehmer erhielten auch nevirapin in kombination mit bis zu 2 nukleosidischen reverse-transkriptase-hemmern .',b'in subjects also received nevirapine plus up to two nucleoside reverse transcriptase inhibitors .',b'in subjects also led to two nucleoside reverse transcriptase inhibitors .',b'subjects also received nevirapine plus up to two nucleoside reverse transcriptase inhibitors .'
143,"b'obwohl die 9 g-dosis am wirksamsten war , zeigten sich zahlreiche nebenwirkungen , so dass der ausschuss eine anfangsdosis von 4,5 g pro tag empfahl .'","b'although the 9 g-dosis took it was demonstrated that numerous side effects , the committee for medicinal products for a starting dose of 4.5g per day .'","b'although the confirmatory rash the confirmatory intron , it was demonstrated that lowfluxfilter side effects , the products for medicinal products for a starting dose of . g per day .'","b'although the 9 g dose was most effective , there was numerous side effects , so that the committee recommended a starting dose of 4.5 g per day .'"
144,b'staatliche chargenfreigabe : gem\xc3\xa4\xc3\x9f artikel 114 der richtlinie 2001 / 83 / ec des rates wird die staatliche chargenfreigabe von einem staatlichen labor oder einem zu diesem zweck autorisierten labor vorgenommen .',"b'official batch release : in accordance with article 114 of directive 2001 / 83 / ec , the official batch release : in accordance with the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose .'","b'official antithrombotic release in accordance with article of directive replacement , the evening intravascularly therapy with the shortest responseafter .'","b""official batch release : in accordance with article 114 of the council 's directive 2001 / 83 / ec , the official batch release : will be undertaken by a state laboratory or a laboratory designated for that purpose ."""
145,b'wof\xc3\xbcr wird keppra angewendet ?',b'what is keppra used for ?',b'what is keppra used for ?',b'what is keppra used for ?'
146,b'5 wasser und pulver mischen langsam das gesamte wasser aus der fertigspritze in die flasche injizieren .',b'5 ) and mix the powder instrument to inject all of the water from the pre- filled syringe to the bottle .',b'freezedried syringe for the powder should be discard all of the water from the sun from the amount of the vial of the injection of the water from the double day syringe to the bottle .',b'5 and mix the powder and water slowly inject all of the water from the pre-filled syringe into the bottle .'
147,b'in seltenen f\xc3\xa4llen wurden thromboembolische prozesse mit einer puregon / hcg-therapie in verbindung gebracht .',b'in rare cases thromboembolic processes associated with puregon / hcg therapy .',b'when not have estimated by theophylline .',b'in rare cases thromboembolic processes were associated with a puregon / hcg therapy .'
148,"b'patienten , die w\xc3\xa4hrend der enbrel-behandlung eine neue infektion entwickeln , sollten engmaschig beobachtet werden .'",b'patients who develop a new infection while undergoing treatment with enbrel should be monitored closely .',b'patients who develop an new pathogens had be monitored .',b'patients who develop a new infection while undergoing treatment with enbrel should be monitored closely .'
149,"b'entsprechende beispiele sind cmv-retinitis , disseminierte und / oder lokalisierte mykobakterielle infektionen und pneumonie hervorgerufen durch pneumocystis jiroveci ( vormal bekannt als pneumocystis-carinii ) .'","b'corresponding e.g. cmv retinitis , generalised and / or focal mycobacterial infections , and pneumonia caused by lactobacilli jiroveci ( vormal known as pneumocystis carinii ) .'","b'corresponding examples are cmv retinitis , generalised and or focal mycobacterial infections , as seizures mycobacterial infections , and pneumonia caused by constitutional cart , and pneumonia caused by amphotericin and or focal mycobacterial infections , and pneumonia caused by creatine cp mycobacterial infections , and pneumonia caused by boosted'","b'corresponding examples are cmv retinitis , disseminated and / or localised mycobacterial infections , and pneumonia caused by lactobacilli jiroveci ( vormal known as pneumocystis carinii ) .'"
150,"b'in den studien i , ii , iii und v mussten die patienten bei der randomisierung mindestens 12 druckschmerzhafte und 10 geschwollene gelenke aufweisen .'","b'9 studies i , ii , iii and v , patients had to randomisation for at least 6 tender and swollen joints .'","b'studies i , ii , iii and phenylalanine , patients had reduced milk and blurred upset adjusted and swollen joints .'","b'9 in the studies i , ii , iii and v , patients had to show 12 tender and 10 more swollen joints .'"
151,"b'20 ansteigt . bei patienten , die keine extensive chemotherapie erhalten haben , ist eine einzelne leukapherese oft ausreichend .'","b'20 . in patients who do not have extensive chemotherapy , a single ar 1 is often sufficient .'",b'. in patients who do not have altered in patients who so with and serum to administer paediatric acid screw level .',"b'20 . in patients who do not have extensive chemotherapy , a single leukapheresis is often sufficient .'"
152,b'die l\xc3\xb6sung ist klar oder leicht schimmernd und farblos bis leicht gelblich .',b'the solution is clear or slightly schimmernd and colourless to slightly yellowish .',b'the solution is clear or slightly mandatory with a vein .',b'the solution is clear or slightly shimmering and colourless to slightly yellowish .'
153,b'wie wirkt purevax rc ?',b'how does purevax rc ?',b'how does purevax rc common work ?',b'how does purevax rc work ?'
154,b'bitte lesen und befolgen sie diese bedienungsanleitung genau .',b'please read and follow these instructions exactly .',b'please read and follow these instructions exactly .',b'please read and follow these instructions exactly .'
155,b'wie ist lansoprazol abz 15 mg einzunehmen ? 4.',b'how to take lansoprazol abz 4 .',b'how to take refludan of the manufacturer and .',b'how to take lansoprazol abz 15 mg ?'
156,"b'273 diese symptome k\xc3\xb6nnen anzeichen eines sehr ernsten zustandes sein , den man diabetische ketoazidose nennt .'",b'273 these may be signs of a very serious condition called diabetic ketoacidosis .',b'these may be signs of haemophilia .',b'273 these may be signs of a very serious condition called diabetic ketoacidosis .'
157,b'zu natrium siehe packungsbeilage f\xc3\xbcr weitere informationen .',"b'when sodium , see the package leaflet for further information .'","b'when sodium , see the package conaining'","b'for sodium , see the package leaflet for further information .'"
158,"b'wenn sie zu viele tabletten eingenommen haben , wenden sie sich unverz\xc3\xbcglich an ihren arzt oder an das n\xc3\xa4chstgelegene notfallkrankenhaus .'","b'if you take too many tablets , contact your doctor immediately or with less than 50 % notfallkrankenhaus .'","b'if you take too many tablets , questions your doctor in blood effects with less than lighting .'","b'if you take too many tablets , contact your doctor or nearest emergency hospital immediately .'"
159,"b'88 tmz weist eine niedrige eiwei\xc3\x9fbindung auf ( 10- 20 % ) , daher wird eine wechselwirkung mit stoffen , die eine starke eiwei\xc3\x9fbindung eingehen , nicht erwartet .'","b'88 tmz demonstrates low protein binding ( 10 % to 20 % ) , and thus it is not expected to interact with and interact with highly protein-bound substances .'","b'tmz demonstrates low protein binding to , and thus it is not expected to interact with highly proteinbound substances .'","b'88 tmz demonstrates low protein binding ( 10 % to 20 % ) , and thus it is not expected to interact with and interact with highly protein-bound substances .'"
160,"b'19 die impfung mit fendrix sch\xc3\xbctzt sie nur vor erkrankungen , die durch das hepatitis-b-virus verursacht werden .'",b'19 vaccination with fendrix protects you to be caused by the hepatitis b virus .',b'vaccination with fendrix must sometimes excreted by the hepatitis b virus .',b'19 vaccination with fendrix protects you from diseases caused by the hepatitis b virus .'
161,b'die pharmakokinetischen eigenschaften von emtricitabin und tenofovir bei m\xc3\xa4nnlichen und weiblichen patienten sind vergleichbar .',b'the pharmacokinetic properties of emtricitabine and tenofovir in male and female patients .',b'the pharmacokinetic properties of emtricitabine and steady was observed in male and female patients .',b'the pharmacokinetic properties of emtricitabine and tenofovir in male and female patients are comparable .'
162,"b'180 filmtabletten b\xc3\xbcndelpackung , bestehend aus 3 packungen , jede packung enth\xc3\xa4lt 60 filmtabletten .'","b'180 film-coated tablets multipack comprising 3 packs , each containing 60 tablets .'","b'filmcoated tablets multipack comprising packs , each containing tablets .'","b'180 film-coated tablets multipack comprising 3 packs , each containing 60 tablets .'"
163,b'eine durchstechflasche pro packung .',b'one vial per carton .',b'one vial per carton .',b'one vial per carton .'
164,b'welche ma\xc3\x9fnahmen werden zur gew\xc3\xa4hrleistung der sicheren anwendung von valdoxan ergriffen ?',b'which measures are being taken to ensure the safe use of valdoxan ?',b'which measures are being to ensure the safe use of valdoxan ?',b'what measures are being taken to ensure the safe use of valdoxan ?'
165,b'gew\xc3\xb6hnlich wird luveris bis zu 3 wochen lang gleichzeitig mit fsh t\xc3\xa4glich durch injektionen verabreicht .',b'usually luveris is given for up to 3 weeks concurrently with fsh daily injections .',b'usually heat is given for up to weeks just into negative health .',b'usually luveris is given for up to 3 weeks concurrently with daily fsh injections .'
166,"b'47 infektionen der oberen atemwege wie mandelentz\xc3\xbcndung , mittelohrentz\xc3\xbcndung , nebenh\xc3\xb6hlenentz\xc3\xbcndung und rachenkatarrh :'","b'47 upper respiratory tract infections such as tonsillitis , otitis media , sinusitis and pharyngitis :'","b'upper respiratory tract infections such as periorbital bleeding , muscle nature , pericardial rotigotine .'","b'47 upper respiratory tract infections such as tonsillitis , otitis media , sinusitis and pharyngitis :'"
167,b'etoricoxib tritt in die milch s\xc3\xa4ugender ratten \xc3\xbcber .',b'etoricoxib occurs in the milk of lactating rats .',b'etoricoxib lead to swallow rats .',b'etoricoxib occurs in the milk of lactating rats .'
168,b'auf einer seite sollte nicht mehr als 1 g ceftriaxon verabreicht werden .',b'on one side and should be no more than 1 g of ceftriaxone .',b'on one side and parents should be no more than g of ceftriaxone .',b'on one side and should be no more than 1 g of ceftriaxone .'
169,b'die relative bioverf\xc3\xbcgbarkeit von exubera liegt im vergleich zu subkutanem schnell wirkendem humaninsulin bei ca.',b'the relative bioavailability of exubera ) compared with subcutaneous fast-acting human insulin in approx .',b'the relative bioavailability of exubera compared with subcutaneous fastacting human insulin in approx .',b'the relative bioavailability of exubera compared with subcutaneous fast-acting human insulin in approx .'
170,"b'neutropenien sind h\xc3\xa4ufiger bei patienten mit verminderter neutrophilen-konzentration , niedrigen h\xc3\xa4moglobinwerten sowie niedrigen vitamin-b12-werten zu beginn der zidovudin-therapie .'","b'neutropenia are more frequent in patients with decreased was also increased , low , and b12 levels were low at the start of the neutrophil counts .'","b'neutropenia are more frequent in patients with decreased was also inhibit , low levels were low at the start of the neutrophil counts .'","b'neutropenia are more frequent in patients with decreased neutrophilic concentrations , low haemoglobin and vitamin b12 levels at the start of the zidovudin therapy .'"
171,b'\xc3\x84ltere patienten ( 65 jahre oder \xc3\xa4lter ) bei \xc3\xa4lteren patienten ist bei einer dosiserh\xc3\xb6hung vorsicht angezeigt .',"b'elderly ( age 65 years or over ) in elderly patients , caution is required when increasing the dosage .'",b'elderly patients of the dose should be required at prescribing the dosage on dose regime .',"b'elderly ( age 65 years or over ) . in elderly patients , caution is required when increasing the dosage .'"
172,b'anwendung die packungsbeilage .',b'read the package leaflet .',b'read the package leaflet .',b'read the package leaflet .'
173,"b'die injektionsl\xc3\xb6sung wird zur behandlung von schmerzen und entz\xc3\xbcndungen im zusammenhang mit weichteiloperationen , z. b. bei der kastrierung , angewendet .'","b'the solution for injection is used for the treatment of pain and inflammation associated with soft tissue surgery , for example when the kastrierung used .'","b'the solution for injection is used for the treatment of pain and inflammation , the zns pack by a the rules of pain and inflammation associated with soft tissue surgery , for example with the cataract insulin points .'","b'the solution for injection is used for the treatment of pain and inflammation associated with soft tissue surgery , for example when castration used .'"
174,b'bei mehrfachgaben von voriconazol in verbindung mit sehr fettreichen mahlzeiten reduzierten sich die cmax und auc um 34 % bzw. 24 % .',"b'when multiple doses of voriconazole are administered with high fat meals reduced the cmax and auc by 34 % and 24 % , respectively .'",b'when multiple doses of voriconazole are administered with high fat five dose of voriconazole .',b'when multiple doses of voriconazole are administered with high fat meals the cmax and auc were redeuced by 34 % and 24 % .'
175,"b'angiotensin ii ist ein starker vasokonstriktor ( eine substanz , die blutgef\xc3\xa4\xc3\x9fe verengt ) .'",b'angiotensin ii is a potent vasoconstrictor ( a substance that stimulates blood vessels ) .',b'angiotensin ii is a potent vasoconstrictor a cmd was chemically blood vessels .',b'angiotensin ii is a potent vasoconstrictor ( a substance that constricts blood vessels ) .'
176,"b'wenn die voraussichtliche tagesdosis aufgrund einer zus\xc3\xa4tzlichen initialdosis 40 mg \xc3\xbcberschreitet , sollte die initialdosis auf 2 tage verteilt werden .'","b'if the anticipated daily dose of cucurbitine due to a loading dose of 40 mg , the initial dose should be divided in 2 days .'","b'if the noncomparative daily dose of rectal due to a loading dose of mg , the initial dose should be divided in days .'","b'if the anticipated daily dose of cucurbitine exceeds 40 mg due to an additional loading dose , the initial dose should be divided in 2 days .'"
177,"b'nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder apotheker .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'if you notice any side effects that are not mentioned in this leaflet , please tell your doctor or pharmacist .'"
178,"b'wenn das risiko eines ohss oder einer mehrlingsschwangerschaft zu unterstellen ist , sollte der abbruch der behandlung erwogen werden .'","b'if the risk of ohss or of multiple pregnancy unterstellen , discontinuation of therapy should be considered .'",b'if anesthesia injections therapy may were administered to required .',"b'if the risk of ohss or of multiple pregnancy is presumed , discontinuation of therapy should be considered .'"
179,b'als einzige nebenwirkung wurde eine zehnmin\xc3\xbctige photophobie beobachtet .',b'a single adverse event zehnmin\xc3\xbctige photophobia have been observed .',b'a single adverse event resins as that less observed .',b'a single adverse event ten-minute photophobia have been observed .'
180,"b'lamictal 200 mg tabletten sind auf der einen seite mit "" gsee7 \' und auf der anderen mit "" 200 \' gekennzeichnet .'","b'lamictal 200 mg tablets , marked "" gsee7\'on one side and "" 200 \' on the other side .'","b'atripla of the ingredients , marked officially one side and on the other side .'","b'lamictal 200 mg tablets are marked "" gsee7 "" on one side and "" 200 \' on the other side .'"
181,b'mit myfenax filmtabletten sollte vorsichtig hantiert werden .',b'myfenax film-coated tablets should be handled with care .',b'duloxetine filmcoated tablets should be carried with care .',b'myfenax film-coated tablets should be handled with care .'
182,"b'der blutdruck muss bei alle n patienten kontrolliert werden , insbesondere zu beginn einer nespo- therapie .'","b'blood pressure should be monitored in all patients , especially at the beginning of nespo therapy .'","b'blood pressure should be monitored in all patients , especially at the beginning of nespo therapy .'","b'blood pressure should be monitored in all patients , especially at the beginning of nespo therapy .'"
183,b'409 schwangerschaft und stillzeit fragen sie vor der einnahme von allen arzneimitteln ihren arzt oder apotheker um rat .',b'409 pregnancy and breast-feeding ask your doctor or pharmacist for advice before taking any medicine .',b'pregnancy and breastfeeding ask your doctor or pharmacist for advice before putting any medicine .',b'409 pregnancy and breast-feeding . ask your doctor or pharmacist for advice before taking any medicine .'
184,b'axura wie gewohnt ein .',b'axura dose .',b'axura dose .',b'use axura as desired .'
185,b'in sehr seltenen f\xc3\xa4llen wurde \xc3\xbcber einen t\xc3\xb6dlichen verlauf berichtet .',"b'in very rare cases of fatal , have been reported .'","b'in very rare cases of fatal , have been reported .'","b""'in very rare cases , fatal developments have been reported ."""
186,b'die bio\xc3\xa4quivalenz einer truvada-filmtablette mit einer emtricitabin-200-mg-hartkapsel in kombination mit einer tenofovirdisoproxilfumarat-245-mg-filmtablette wurde nach verabreichung der einzeldosierungen an n\xc3\xbcchternen probanden untersucht .',b'the bioequivalence of a truvada-filmtablette with one tenofovir in combination with tenofovirdisoproxilfumarat-245-mg-filmtablette was single post administration studied in fasted subjects .',"b'tables of a mggroup and flumazenil and environmental b approximately approximately compound , application program to antibodies up to over infections .'",b'the bioequivalence of a truvada film tablets with one emtricitabin-200-mg hard capsule in combination with tenofovirdisoproxilfumarat-245-mg film tablets was studied post administration of single doses in fasted subjects .'
187,b'bei l\xc3\xa4ngerfristigem bestehen von heterotopen knochen kam es zu sarkomen .',b'in l\xc3\xa4ngerfristigem exposed polyethoxyalkyl and bones have experienced .',b'in acetaldehyde treatment are affect oxidative caused as headaches have experienced .',b'long term existence of heterotopic bones led to sarcoma .'
188,b'es wurden f\xc3\xa4lle von kardiomegalie und herzinsuffizienz berichtet ( siehe abschnitt 4.8 ) .',b'cases of void-volume fractions and heart failure have been reported ( see section 4.8 ) .',b'cases of teslacan hypoventilation and heart failure have been reported see section . .',b'cases of kardiomegalie and heart failure have been reported ( see section 4.8 ) .'
189,b'nach 6-monatiger behandlung kann eine dosisanpassung erforderlich sein ( siehe abschnitt 4.4 ) .',b'after 6 months a dose adjustment may be required ( see section 4.4 ) .',b'after months the dose adjustment may be required see section . .',"b'after 6 months , a dose adjustment may be required ( see section 4.4 ) .'"
190,"b'35 bei sga-kindern / -jugendlichen wird empfohlen , den igf-i-spiegel vor beginn der behandlung und danach zweimal j\xc3\xa4hrlich zu messen .'",b'35 in sga children / -jugendlichen it is recommended to measure the igf-i level before start of treatment and twice a year thereafter .',b'in sga children adolescents from the vaccine listings should be adjusted in lifelong and twice a year thereafter .',b'35 in sga children / -jugendlichen it is recommended to measure the igf-i level before start of treatment and twice a year thereafter .'
191,b'in seltenen f\xc3\xa4llen ( bei mindestens 1 von 10.000 patienten ) sind unter der alleinigen anwendung von buprenorphin die folgenden nebenwirkungen aufgetreten :',"b'in rare cases ( occurring in at least 1 in 10,000 patients ) of the patients who have experienced the use of buprenorphine , the following side effects :'","b'in rare cases occurring in at least in , patients of the patients who have have experienced the range of buprenorphine , the following side effects'","b'in rare cases ( occurring in at least 1 in 10,000 patients ) of the patients using buprenorphine alone experienced the following side effects :'"
192,b'lipidst\xc3\xb6rungen sollten entsprechend der klinischen situation behandelt werden ( siehe abschnitt 4.8 ) .',b'treatment with gemfibrozil should be treated according to the clinical situation ( see section 4.8 ) .',b'treatment with alphaadrenergic g or a clinical situation see section . .',b'lipid disorders should be treated according to the clinical situation ( see section 4.8 ) .'
193,b'\xc3\x84u\xc3\x9ferlich kann insulatard novolet durch abwischen mit einem medizinischen tupfer gereinigt werden .',b'you can clean the exterior of your insulatard novolet by wiping it with a medicinal swab .',b'you can clean the exterior of the fine surface of a benefit and a medicinal swab .',b'you can clean the exterior of your insulatard novolet by wiping it with a medicinal swab .'
194,"b'bei erwachsenen und jugendlichen ist die \xc3\xbcbliche dosis zwei kapseln ( 200 mg ) dreimal t\xc3\xa4glich ( morgens , nachmittags und abends ) .'","b'in adults and adolescents , the usual dose is two capsules ( 200 mg ) three times a day ( morning , afternoon and evening ) .'","b'in adults and adolescents , the usual dose is two capsules per mg three times a day .'","b'in adults and adolescents , the usual dose is two capsules ( 200 mg ) three times a day ( morning , afternoon and evening ) .'"
195,"b'alli darf nicht von kindern und jugendlichen unter 18 angewendet werden , da nicht gen\xc3\xbcgend daten zur wirksamkeit und sicherheit vorliegen .'","b'alli should not be used in the treatment of children and adolescents under the age of 18 , as it is not enough data on the efficacy and safety .'","b'alli should not be used in the treatment of children and adolescents under the age of , as it is not contain the efficacy and safety .'","b'alli should not be used in the treatment of children and adolescents under the age of 18 , as there is not enough data on the efficacy and safety .'"
196,"b'die durchstechflasche anschlie\xc3\x9fend leicht sch\xc3\xbctteln , um das pulver zu l\xc3\xb6sen .'","b'shake the vial and subsequently , to dissolve the powder .'","b'shake the vial and gently withdrawn , check if it or gently provides apply occur are dry temperature .'","b'subsequently shake the vial , to dissolve the powder .'"
197,b'sie sollten tyverb mindestens eine stunde vor oder mindestens eine stunde nach dem essen einnehmen .',b'you should take tyverb at least one hour before or at least one hour after a meal .',b'you should take operator simulect by a patientfriendly must inject a to a meal .',b'you should take tyverb at least one hour before or at least one hour after a meal .'
198,b'\xc3\x9cber 90 % der katzen und 99 % der hunde haben nach der behandlung mit profender keine rund- oder bandwurminfektion .',b'over 90 % of cats and 99 % of dogs have after treatment with profender no outside mouthpiece .',b'over of cats and of dogs have not been treated to follows have expected according to humans .',b'over 90 % of cats and 99 % of dogs have after treatment with profender no outside round worm or tape worm infections .'
199,b'die therapie sollte bis zu 4 wochen nach beendigung der chemotherapie fortgesetzt werden .',b'treatment should be continued for up to 4 weeks after the end of chemotherapy .',b'treatment should be continued for up to weeks after the end of chemotherapy .',b'treatment should be continued for up to 4 weeks after the end of chemotherapy .'
200,b'seit der markteinf\xc3\xbchrung wurde in einzelf\xc3\xa4llen von \xc3\x9cberdosierungen berichtet . die h\xc3\xb6chste in diesem zusammenhang genannte tagesdosis betrug 16.000 mg entacapon .',"b'the post-marketing data includes isolated cases of overdose have been reported. in which the reported highest daily dose was 16,000 mg of entacapone .'","b'the postmarketing data tested concerned the postmarketing age of overdose have been reported which was for the symptoms fold daily dose was , disproportionate or capsules .'","b'the post-marketing data includes isolated cases of overdose . the highest daily dose in connection to this was 16,000 mg of entacapone .'"
201,b'tasmar darf erst nach vollst\xc3\xa4ndiger informativer er\xc3\xb6rterung der risiken mit dem patienten verschrieben werden .',b'tasmar should be used only after complete informativer discussion risks with the patients prescribed .',b'tasmar should be used under medication for animals .',"b'tasmar should be prescribed only after complete , informative discussion of the risks with the patients .'"
202,b'\xc3\x84ltere patienten zypadhera wurde nicht systematisch bei \xc3\xa4lteren patienten ( > 65 jahren ) untersucht .',b'elderly patients zypadhera has not been systematically assessed in elderly patients ( 65 years of age ) .',b'elderly patients zypadhera has not been pronounced bexarotene in accordance patients years of age .',b'elderly patients : zypadhera has not been systematically assessed in elderly patients ( 65 years of age ) .'
203,b'f\xc3\xbcr irbesartan wurden \xc3\xa4hnliche wirkungen bisher sehr selten berichtet .',b'similar effects have been very rarely reported with irbesartan so far .',b'similar effects have been very rarely reported with irbesartan so far .',b'similar effects have been very rarely reported with irbesartan so far .'
204,b'fuzeon ist als teil einer kombinationstherapie anzuwenden .',b'fuzeon is to be used as part of combination therapy .',b'onsenal is to be used affects orally with age .',b'fuzeon is to be used as part of combination therapy .'
205,"b'45 die erfahrungen mit efavirenz bei patienten , die andere antiretrovirale wirkstoffe der nnrti-klasse abgesetzt haben , sind begrenzt .'",b'45 experience with efavirenz in patients who discontinued other antiretroviral agents of the nnrti class is limited .',b'data with efavirenz in patients who discontinued other antiretroviral agents of the nnrti class is limited .',b'45 experience with efavirenz in patients who stopped taking other antiretroviral agents of the nnrti class is limited .'
206,b'der cvmp hat unter ber\xc3\xbccksichtigung aller verf\xc3\xbcgbaren daten keine bedenken hinsichtlich der sicherheit oder wirksamkeit des produkts .',b'the cvmp taking into consideration of all available data has no concern regarding the safety or efficacy of the product .',b'the cvmp anaphylactoid dose guidelines at consideration of all available data has no sufficiently regarding the safety or efficacy of the product .',b'the cvmp has no concern regarding the safety or efficacy of the product after consideration of all available data .'
207,"b'flush betrifft vor allem kopf , hals und oberk\xc3\xb6rper .'","b'flushing , particularly , neck and upper body .'","b'exenatide , particularly , called body .'","b'flushing particularly affects head , neck and upper body .'"
208,"b'8 wechselwirkungen , die bei truvada bedeutsam sind :'",b'8 interactions safety is not in truvada are :',b'interactions on the treatment of treatment with chronic .',b'8 interactions that are importtant with truvada are :'
209,"b'wenn sustiva zusammen mit rifampicin angewendet wird , kann eine dosiserh\xc3\xb6hung von sustiva auf 800 mg / tag in betracht gezogen werden ( siehe abschnitt 4.5 ) .'","b'if sustiva is coadministered with rifampicin is administered , an increase in the dose of sustiva to 800 mg / day should be considered ( see section 4.5 ) .'","b'if sustiva is coadministered with rifampicin is administered , an increase in the effect is administered , an increase in the dose of sustiva to mg day .'","b'if sustiva is coadministered with rifampicin , an increase in the dose of sustiva to 800 mg / day should be considered ( see section 4.5 ) .'"
210,"b'bevor eine injektion verabreicht wird , muss das medizinische fachpersonal feststellen , dass der patient sich sp\xc3\xa4ter nicht alleine zu seinem zielort begibt .'",b'before the injection will be given to health care professionals should determine that the patient is not later alone and cylinder has a 2 .',"b'before the injection will take the injection will be instructed to stopped about contact and possibly at contact after the second medicine , only the dose of you schedule be given to injection care professionals should be given due to health care guidelines or skin stored to continue in your'","b'before the injection will be given , the health care professionals should determine that the patient wil not later travel alone .'"
211,"b'befindet sich der patient im koma , sollte glucagon intramuskul\xc3\xa4r oder subkutan verabreicht werden .'","b'if the patient is comatose , glucagon should be administered intramuscularly or subcutaneously .'","b'if the patient is nephropathy , glucagon should be administered intramuscularly or subcutaneously .'","b'if the patient is comatosed , glucagon should be administered intramuscularly or subcutaneously .'"
212,"b'in allen f\xc3\xbcnf studien zeigten die in der raptiva-gruppe randomisierten patienten beim prim\xc3\xa4ren endpunkt statistisch signifikant bessere ergebnisse , als die patienten in der placebo-gruppe .'","b'in all five studies , the patients randomised to the raptiva group on the primary endpoint was statistically significantly better than those in the placebo group .'","b'in all five studies , the corresponding decrease were make significantly progressive early significant seropositive .'","b'in all five studies , the patients randomised to the raptiva group on the primary endpoint was statistically significantly better than those in the placebo group .'"
213,b'in der regel ist 24 stunden nach der applikation der calciumspiegel im serum wieder auf seinen ausgangswert abgesunken .',b'on 24 hours of the application of the serum calcium levels back to the baseline uptake .',b'on hours of the severity of the cypa calcium levels back to the baseline .',"b'generally , 24 hours after application , the serum calcium levels go back to the baseline level .'"
214,"b'die immunantwort nach impfung , gemessen mittels gpelisa , stieg bei den probanden von 50 bis 59 jahren um das 2,6-fache ( 95 % ki :'","b'the immune response after vaccination , as measured by gpelisa increased in subjects 50-59 years of age is 2,6-fache ( 95 % ci :'","b'the immune response after vaccination , as measured by opened increased in subjects years of age is , between several test .'","b'the immune response after vaccination , as measured by gpelisa increased in subjects 50-59 years of age is 2,6-fache ( 95 % ci :'"
215,b'material der prim\xc3\xa4rverpackung die kindersicheren beutel bestehen aus einem mehrfach laminierten verbundwerkstoff aus papier / polyester / aluminium / polyacrylnitril .',b'the immediate child the sachet consist of its part by weight of a paper / polyester / alu / poly acrylonitrile .',b'the aetiology of its part by weight of a intravascular activity from a polyethylene herpesvirus .',b'material of the primary packaging . the childproof sachet consists of a paper / polyester / alu / poly acrylonitrile .'
216,b'ausgesetzt werden . die anwendung von ultraviolettem ( uv ) licht in solarien sowie die therapie mit uvb oder uva in kombination mit psoralenen ( puva ) sollte vermieden werden ( siehe abschnitt 5.3 ) .',"b'. the use of ultraviolet ( uv ) light from a solarium , therapy with uvb or uva in combination with psoralens ( puva ) should be avoided ( see section 5.3 ) .'","b'. the use of lebendviren or naloxone containing a digital , should not occur with nonswelling or inflammed a nominal , therapy with the adjust chemotherapy additional functions without superficial yourself see section . .'",b'the use of ultraviolet ( uv ) light from a solarium and therapy with uvb or uva in combination with psoralens ( puva ) should be avoided ( see section 5.3 ) .'
217,"b'zu den einzelheiten der hauptstudien , einschlie\xc3\x9flich studiendesign und wirksamkeitsergebnisse , siehe abschnitt 5.1 .'","b'for details of the studies , including study designs and major efficacy results , see section 5.1 .'","b'for details of the studies , including study mirena and major efficacy results .'","b'for details of the studies , including study designs and major efficacy results , see section 5.1 .'"
218,b'diese k\xc3\xb6nnen oft durch reduktion der levodopa-dosis abgeschw\xc3\xa4cht werden ( siehe 4.2 ) .',b'this can often strengthen or weaken the reduction of the dose of levodopa ( see section 4.2 ) .',b'this can often influence or as the reduction of the dose of levodopa see section . .',b'this can often strengthen or weaken the reduction of the dose of levodopa ( see section 4.2 ) .'
219,b'\xe2\x80\xa2 schwangerschaft \xe2\x80\xa2 stillzeit \xe2\x80\xa2 \xc3\x9cberempfindlichkeit gegen den wirkstoff oder einen der sonstigen bestandteile .',b'\xe2\x80\xa2 pregnancy \xe2\x80\xa2 lactation \xe2\x80\xa2 hypersensitivity to the active substance or to any of the excipients .',b'pregnancy before necessary the other constituents .',b'\xe2\x80\xa2 pregnancy \xe2\x80\xa2 lactation \xe2\x80\xa2 hypersensitivity to the active substance or to any of the excipients .'
220,"b'nach herstellung der l\xc3\xb6sung sollte cancidas umgehend verwendet werden , da keine konservierungsstoffe zur vermeidung bakterieller verunreinigungen enthalten sind .'","b'after the solution and cancidas should be used immediately , since no preservative to prevent bacterial contamination .'","b'after the solution and cancidas should be used immediately , since no preservatives to prevent appetite ketoprofen .'","b'after preparing the solution , cancidas should be used immediately , since no preservative is contained to prevent bacterial contamination .'"
221,b'b\xc3\xb6rdelkappe ( mit gummidichtung ) .',b'( with closure .',b'with yondelis the in hepatic content of olanzapine distribution .',b'crimp cap with rubber seal .'
222,b'nach diesem zeitraum darf sie nicht mehr verwendet werden .',b'do not use the vial after this time period .',b'do not use the vial after this time period .',b'do not use the vial after this time period .'
223,b'legen sie insuman infusat nicht in die n\xc3\xa4he des gefrierfachs oder eines k\xc3\xbchlelements .',b'do not put insuman infusat into the freezer compartment or a k\xc3\xbchlelements .',b'do not put insuman infusat into the freezer compartment or a cooling element .',b'do not put insuman infusat into the freezer compartment or a cooling element .'
224,b'welchen nutzen hat coaprovel in diesen studien gezeigt ?',b'what benefit has coaprovel shown during the studies ?',b'what benefit has coaprovel shown during the studies ?',b'what benefit has coaprovel shown during the studies ?'
225,b'in klinischen studien wurden 541 krebs-patienten und 188 gesunde probanden mit tevagrastim exponiert .',b'in clinical studies 541 cancer patients and 188 healthy volunteers were exposed to tevagrastim .',b'in clinical studies cancer patients and healthy volunteers and copies to common cause linear .',b'in clinical studies 541 cancer patients and 188 healthy volunteers were exposed to tevagrastim .'
226,"b'zum gegenw\xc3\xa4rtigen zeitpunkt ist noch nicht bekannt , wie lange die patienten behandelt werden sollen .'","b'at the present time , it is not known for how long patients should be treated .'","b'at the present time , it is not known for how long patients should be treated .'","b'at the present time , it is not known for how long patients should be treated .'"
227,"b'es kann anderen menschen schaden , auch wenn diese dieselben symptome haben wie sie .'","b'it may harm them , even if their symptoms are the same as yours .'","b'it may harm others , even if their symptoms are the same as yours .'","b'it may harm them , even if their symptoms are the same as yours .'"
228,b'bei gesunden probanden war die auc von atazanavir bei kapseln und beim pulver \xc3\xa4hnlich .',"b'in healthy volunteers , the auc of atazanavir in capsules and similar to that of the powder .'","b'in healthy volunteers , the auc of atazanavir in capsules and similar to that of the powder .'","b'in healthy volunteers , the auc of atazanavir is similar in capsules and powder .'"
229,b'ihr augenarzt wird ihren zustand \xc3\xbcberwachen und eine entscheidung \xc3\xbcber die dauer der behandlung treffen .',b'your ophthalmologist will monitor your condition and a decision on the duration of treatment .',b'your acidosis wish to monitor your condition see your condition from any dose is monitored from the duration of treatment .',b'your ophthalmologist will monitor your condition and make a decision on the duration of treatment .'
230,"b'der patient darf nicht auf ein anderes erythropoetin-haltiges arzneimittel umgestellt werden , weil erythropoetin- antik\xc3\xb6rper mit anderen erythropoetinen kreuzreagieren .'",b'the patient should not be switched to another medicinal product as anti-erythropoietin antibodies cross-react patients with other erythropoietins .',b'the patient should not be switched with adjust children should increase by a minor erythropoietins auc .',b'the patient should not be switched to another medicinal product as anti-erythropoietin antibodies cross-react with other erythropoietins .'
231,b'exposition gegen\xc3\xbcber ionisierender strahlung wird mit der induktion von krebs und der potentiellen entwicklung von sch\xc3\xa4digungen im erbgut in verbindung gebracht .',b'exposure to ionising radiation is linked with cancer induction and a potential for the development of damage in the erbgut .',"b'circulating alterations of these luteum urea , the total origin .'",b'exposure to ionising radiation is linked with cancer induction and the potential development of damage of genetic makeup .'
232,b'nadeln werden nicht bereitgestellt .',b'needles are not included .',b'needles are not included .',b'needles are not included .'
233,"b'es ist als injektionssuspension erh\xc3\xa4ltlich , die inaktivierte ( abget\xc3\xb6tete ) blauzungenviren des serotyps 8 enthalten .'","b'it is available as a suspension for injection , and inactivated ( killed ) contains an agent .'","b'it is available as a suspension for injection solution for injection , and inactivated bubbles contains , which .'",b'it is available as a suspension for injection and contains inactivated ( killed ) bluetongue virus with the serotype 8 .'
234,"b'falls eine der genannten bedingungen bei ihnen zutrifft , teilen sie dies bitte ihrem arzt oder apotheker vor beginn der einnahme von kinzalkomb mit .'","b'if any of the above applies to you , tell your doctor or pharmacist before taking kinzalkomb .'","b'if any of the above applies to you , tell your doctor or pharmacist before while they whole .'","b'if any of the above applies to you , tell your doctor or pharmacist before taking kinzalkomb .'"
235,b'was diacomit enth\xc3\xa4lt 500 mg \xe2\x80\xa2 der wirkstoff ist ( e ) -stiripentol ( stiripentol ) .',b'what diacomit 500 mg contains \xe2\x80\xa2 the active substance is stiripentol ( stiripentol ) .',b'what diacomit mg contains the active substance is activated stiripentol .',b'what diacomit 500 mg contains \xe2\x80\xa2 the active substance is ( e ) stiripentol ( stiripentol ) .'
236,b'setzen sie einfach ihr gewohntes einnahmeschema fort .',"b'additionally , just take your gewohntes schedule .'",b'do with your corticoid surgery schedule .',"b'additionally , just continue with your usual schedule .'"
237,b'die gabe von saquinavir-mesilat \xc3\xbcber 96 bis 104 wochen an ratten und m\xc3\xa4use ergab keinen hinweis auf eine kanzerogene aktivit\xc3\xa4t .',b'administration of saquinavir as saquinavir mesilate 96 to 104 weeks in rats and mice revealed no evidence of carcinogenic activity .',b'administration of saquinavir as saquinavir mesylate was bound to weeks in rats and mice revealed no evidence of carcinogenic activity .',b'administration of saquinavir mesilate over 96 to 104 weeks in rats and mice revealed no evidence of carcinogenic activity .'
238,b'daher wird die anwendung von coaprovel nicht empfohlen .',"b'therefore , the use of coaprovel is not recommended .'","b'therefore , the use of coaprovel , therefore immediate orally milk is not recommended .'","b'therefore , the use of coaprovel is not recommended .'"
239,"b'risikomanagement-plan der inhaber der zulassung sichert zu , die studien und weiteren pharmakovigilanzma\xc3\x9fnahmen gem\xc3\xa4\xc3\x9f der angaben im pharmakovigilanzplan durchzuf\xc3\xbchren . siehe version 01 des risikomanagementplans ( rmp ) einschlie\xc3\x9flich vom chmp genehmigter erg\xc3\xa4nzungen , in modul 1.8.2. der zulassungsdokumentation .'","b'risk management plan the mah commits to performing the studies and additional pharmakovigilanzma\xc3\x9fnahmen detailed in the pharmacovigilance plan . see as described in version 01 of the risk management plan ( rmp ) , including any subsequent updates of the rmp agreed by the chmp presented in module 1.8.2. of the marketing authorisation .'","b'according in volibris where as described of the treatment of the raptiva is the immune upper disorders where because the area assessment and kappa tumor pioglitazone of the survival guidelines , including this impairment where as described in volibris study study has children . to prevent and at the concerned'","b'risk management plan : the mah commits to performing the studies and additional pharmacovigilance measures detailed in the pharmacovigilance plan . see as described in version 01 of the risk management plan ( rmp ) , including any subsequent updates of the rmp agreed by the chmp presented in module 1.8.2. of the marketing authorisation .'"
240,"b'an die studie 2 schloss sich eine offene studie ( studie 2a ) an , an der nur patienten teilnahmen , die sich dazu entschlossen , im anschluss an studie 2 weiterzumachen .'","b'the study included in an open-label study ( study ) , patients who were only one sent , following study 2 weiterzumachen .'","b'the study alterations to cytopenia in an openlabel study in the temporary study study , the extracellular antibody than the same studies for a proteinreduced development of participants .'","b'study 2 included in an open study ( study 2a ) , in which only patients who decided to continue with study 2 took part .'"
241,b'sowohl das arzneimittel als auch das laserlicht sind f\xc3\xbcr das funktionieren der therapie notwendig .',b'both medicines and the laser light for lengths of therapy is necessary .',b'both medicines and the eyelid by a treatment scheme lasted supplement see the sugar window for epsteinbarr of therapy is necessary .',b'both medicines and the laser light arenecessary for the therapy to work .'
242,"b'die plasma s- ( - ) verapamil cmax- und auc-werte waren beide um das 1,5fache erh\xc3\xb6ht und der tmax-wert um 24 % vermindert .'","b'the plasma size of verapamil , unbound cmax and auc were increased by both the prognostic and tmax-wert 24 % .'","b'the plasma glucose clearance of hcvrnaplasmaspiegel , the unchanged antibody levels in both particles .'","b'the plasma s , verapamil cmax and auc levels were increased 1.5-fold and tmax-wert decreased by 24 % .'"
243,b'1 ml ( eine durchstechflasche ) enth\xc3\xa4lt 600 mikrogramm methoxy-polyethylenglycol-epoetin beta * .',b'1 ml ( one vial ) contains 600 micrograms of mircera * .',b'ml one vial contains micrograms of mircera .',b'1 ml ( one vial ) contains 600 micrograms of methoxy polyethylene glycol-epoetin beta * .'
244,b'unter der behandlung mit xigris waren nach 28 tagen weniger patienten verstorben als unter der behandlung mit placebo .',b'under treatment with xigris patients had died after 28 days to less than with placebo .',b'under treatment with xigris patients had died after days to less than with placebo .',"b'under treatment with xigris , less patients had died after 28 days than with placebo .'"
245,"b'der film\xc3\xbcberzug enth\xc3\xa4lt hypromellose , titandioxid , macrogol , indigocarmin-farblack , eisenoxid gelb .'","b'the tablet coating contains hypromellose , titanium dioxide , macrogol , indigocarmin-farblack , iron oxide yellow .'","b'the tablet paragraph contains hypromellose , titanium dioxide , macrogol , perforation , are oxide yellow .'","b'the tablet coating contains hypromellose , titanium dioxide , macrogol , indigo carmine colour coating , iron oxide yellow .'"
246,"b'die gleichzeitige anwendung von clopidogrel mit oralen antikoagulanzien wird nicht empfohlen , da blutungen verst\xc3\xa4rkt werden k\xc3\xb6nnen ( siehe abschnitt 4.5 ) .'",b'concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings ( see section 4.5 ) .',"b'concomitant administration of clopidogrel , indicated be permanent , a lithium are not recommended since great a lack of tigecylin see section . .'",b'concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings ( see section 4.5 ) .'
247,"b'37 falls h\xc3\xb6here dosen als 500 mg morphin-\xc3\x84quivalent ben\xc3\xb6tigt werden , sollte die opioidbehandlung neubewertet werden .'","b'37 if higher dosages than 500 mg morphine-equivalent are needed , fentanyl- ratiopharm , neubewertet .'","b'if dosages received two dose than mg morphineequivalent are needed , emend does not be bodyweight , fentanyl ratiopharm , the longer .'","b'37 if higher dosages than 500 mg morphine-equivalent are needed , opioid treatment should be reevaluated .'"
248,b'wie ist trisenox anzuwenden ? 4.',b'how to use trisenox 4 .',b'how to use trisenox .',b'how to use trisenox 4 .'
249,"b'patienten mit risikofaktoren f\xc3\xbcr gallenstau / sludge z.b. vorangegangene aufwendige therapie , schwere erkrankung und komplette parenterale ern\xc3\xa4hrung , haben ein erh\xc3\xb6htes pankreatitisrisiko ( siehe abschnitt 4.8 ) .'","b'patients with risk factors for gallenstau / sludge e. g. prior aufwendige therapy , severe illness and complete parenteral diet , has shown an increased risk of suicidal pankreatitisrisiko ( see section 4.8 ) .'","b'patients with risk . for tendinopathie hikma e . g . prior , acute proton mixture or negative parenteral diet , has limited reduced allergies or sulphonylureas s pump , sites , appetite factors see section . .'","b'patients with risk factors for bile stasis / sludge e. g. prior complex therapy , severe illness and complete parenteral diet , has shown an increase risk of pacreatitis ( see section 4.8 ) .'"
250,b'in abh\xc3\xa4ngigkeit vom ausma\xc3\x9f des defekts kann mehr als eine 1 g-durchstechflasche osigraft zur behandlung notwendig sein .',b'depending on the size of the implant in the area of the defect may be more than 1 g-durchstechflasche osigraft be required .',b'depending on the size of the range of the selfadministration may be used for a recommended than cataract a incidence of the finebore can be more than cystinose axetil for system points with fluticasone intercourse .',"b'depending on the extent of the defect , more than 1 g-durchstechflasche osigraft may be required for treatment .'"
251,b'wof\xc3\xbcr wird ingelvac circoflex angewendet ?',b'what is ingelvac circoflex used for ?',b'what is ingelvac circoflex used for ?',b'what is ingelvac circoflex used for ?'
252,b'in studien zur embryofetalen entwicklung wurden bei dosierungen von bis zum 29fachen der humandosis von 10 mg / kg basierend auf der auc keine unerw\xc3\xbcnschten wirkungen beobachtet .',"b'in an embryo-foetal development studies were seen at doses up to 29fachen at 11-fold a human 10 mg / kg exposure based on auc , there were no adverse effects were observed .'",b'in an sedative development less were seen at patients were no adverse effects were observed .',"b'in an embryo-foetal development studies , no adverse effects were seen at doses up to 29-times the humans dose of 10 mg / kg exposure based on auc .'"
253,b'am 11. dezember 2002 erteilte die europ\xc3\xa4ische kommission dem unternehmen abbott laboratories ltd eine genehmigung f\xc3\xbcr das inverkehrbringen von sevoflo in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted to abbott laboratories ltd sevoflo throughout the european union on 11 december 2002 .',b'the european commission granted to eli ink .',b'the european commission granted permission to abbott laboratories ltd for the placing on the market of sevoflo throughout the european union on 11 december 2002 .'
254,b'paxene wurde kombiniert mit anderen krebsmedikamenten angewendet und mit anderen behandlungen verglichen .',b'paxene was combined with other anticancer treatments and compared with any other treatment .',b'interferons was analgesic metabolic au class pathogens and compared with any other treatment .',b'paxene was combined with other anticancer treatments and compared with any other treatment .'
255,"b'6 nach intraven\xc3\xb6ser infusion wird agalsidase beta schnell aus dem kreislauf eliminiert und vom gef\xc3\xa4\xc3\x9fendothel und den parenchymzellen in die lysosomen aufgenommen , vermutlich durch mannose-6-phosphat , mannose und asialoglykoprotein-rezeptoren .'","b'6 after intravenous infusion of agalsidase beta is rapidly removed from the circulation and taken up by vascular endothelial and parenchymal cells into lysosomes , mannose , mannose and asialoglykoprotein-rezeptoren .'",b'after intravenous infusion of agalsidase beta is rapidly directly from the circulation and reduced which .',"b'6 after intravenous infusion of agalsidase beta is rapidly removed from the circulation and taken up by vascular endothelium and parenchyma cells into lysosomes , presumably by mannose-6 phosphate , mannose and asialoglycoproteins receptors .'"
256,b'91 behandlung der symptomatischen an\xc3\xa4mie bei erwachsenen patienten und kindern mit chronischer nierenerkrankung :',b'91 treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients :',b'treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients',b'91 treatment of symptomatic anaemia in adults and children with chronic renal impairments :'
257,b'pegintron wird nicht zur anwendung bei patienten unter 18 jahren empfohlen .',b'pegintron is not recommended for use in patients below 18 years of age .',b'pegintron is not recommended for use in patients below years of age .',b'pegintron is not recommended for use in patients below 18 years of age .'
258,b'bei patienten mit leicht bis m\xc3\xa4\xc3\x9fig eingeschr\xc3\xa4nkter nierenfunktion ist keine anpassung der dosis notwendig ( siehe abschnitt 5.2 ) .',b'in patients with mild to moderate renal impairment no dosage adjustment is required ( see section 5.2 ) .',b'in patients with the trough dose adjustment is required see section . .',b'in patients with mild to moderate renal impairment no dosage adjustment is required ( see section 5.2 ) .'
259,"b'die metabolischen auswirkungen wurden auch mit einer klinisch signifikanten gewichtszunahme , vermehrtem schwitzen und vermehrter energie in verbindung gebracht .'","b'the metabolic effects have also been reported with clinically significant weight gain , recited in claim 2 , sweating , and increased energy .'","b'the metabolic effects have also been reported with clinically significant weight gain , fac in .'","b'the metabolic effects have also been reported with clinically significant weight gain , increased sweating , and increased energy .'"
260,b'fuzeon pulver und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung ist erh\xc3\xa4ltlich in einer faltschachtel mit folgendem inhalt :',b'fuzeon powder and solvent for solution for injection is available in a carton containing the following :',b'fuzeon is stored for solution for injection is available in a carton containing the following',b'fuzeon powder and solvent for solution for injection is available in a carton containing the following :'
261,b'das pharmakokinetische profil von myozyme bei patienten mit sp\xc3\xa4ter verlaufsform unterschied sich nicht vom pharmakokinetischen profil bei patienten mit fr\xc3\xbcher verlaufsform .',b'the pharmacokinetic profile of myozyme in patients with late-onset pompe disease did not affect the pharmacokinetic profile in patients with early phenotype .',b'the pharmacokinetic efficacy of myozyme in patients with lateonset pompe disease did not affect the pharmacokinetic studies in autoantibodies .',b'the pharmacokinetic profile of myozyme in patients with a later progressive form did not affect the pharmacokinetic profile in patients with an early progressive form .'
262,b'vardenafil wird haupts\xc3\xa4chlich in der leber durch das cytochrom p450 ( cyp ) isoenzym 3a4 mit geringer beteiligung der cyp3a5- und cyp2c-isoenzyme metabolisiert .',b'vardenafil is metabolised primarily in the liver by the cytochrome p450 ( cyp ) isoenzyme 3a4 with the cyp3a5- is metabolised and cyp2c-isoenzyme .',b'baraclude is metabolised primarily replaces the significant by the molecular proteins .',b'vardenafil is metabolised primarily in the liver by the cytochrome p450 ( cyp ) isoenzyme 3a4 with little involvement of cyp3a5- and cyp2c-isoenzyme .'
263,b'die so bestimmte einzeldosis wird 2-mal w\xc3\xb6chentlich \xc3\xbcber 4 wochen verabreicht .',b'the certain single dose is given twice weekly for 4 weeks .',b'the certain single dose is given twice weekly for weeks .',b'the certain single dose is given twice weekly for 4 weeks .'
264,"b'nach oraler anwendung wird dabigatranetexilat rasch und vollst\xc3\xa4ndig in dabigatran , die aktive form im plasma , umgewandelt .'","b'following oral administration , dabigatran etexilate is rapidly and completely metabolised by dabigatran , and in plasma .'","b'following oral administration , dabigatran etexilate is rapidly produced the study is rapidly . as inhibits the benzisoxazolderivat for large forms is its approximately .'","b'following oral administration , dabigatran etexilate is rapidly and completely metabolised by dabigatran , the active form in plasma .'"
265,b'viani soll nicht zusammen mit so genannten beta-blockern ( wie z. b.',b'viani should not be taken with medicines called \xce\xb2 -blockers ( such as',b'viani should not be taken with medicines called just as',b'viani should not be taken with medicines called \xce\xb2 -blockers ( such as'
266,b'tierexperimentelle studien haben eine ausscheidung von vildagliptin in die milch gezeigt .',b'animal studies have shown excretion of vildagliptin in milk .',b'animal studies have shown excretion of vildagliptin in milk .',b'animal studies have shown excretion of vildagliptin in milk .'
267,b'tepoxalin darf nicht gleichzeitig mit anderen nicht-steroidalen antiphlogistika oder glukokortikoiden eingesetzt werden .',b'tepoxalin must not be administered in conjunction with other nsaids or glucocorticoids .',b'tepoxalin must not be administered in conjunction with other nsaids or glucocorticoids .',b'tepoxalin must not be administered in conjunction with other nsaids or glucocorticoids .'
268,"b'bitte nehmen sie w\xc3\xa4hrend der behandlung mit zyprexa velotab andere arzneimittel nur dann ein , wenn ihr arzt es ihnen erlaubt .'",b'only take other medicines while you are on zyprexa velotab if your doctor tells you that you can .',b'only take other medicines while you are on zyprexa velotab if your doctor tells you that you can .',b'only take other medicines while you are on zyprexa velotab if your doctor tells you that you can .'
269,b'wie wurde zavesca untersucht ?',b'how has zavesca been studied ?',b'are effects been studied ?',b'how has zavesca been studied ?'
270,b'warum wurde cholestagel zugelassen ?',b'why has cholestagel been approved ?',b'why efavirenz has cholestagel been approved ?',b'why has cholestagel been approved ?'
271,"b'zur untersuchung der wirksamkeit von nevanac wurden vier hauptstudien durchgef\xc3\xbchrt , an denen insgesamt 1 201 patienten mit kataraktoperation teilnahmen .'",b'to study the efficacy of nevanac were conducted in four main studies involving a total of 201 patients with cataract surgery .',b'to study the efficacy of lamotrigine were conducted in four main studies involving a total of patients with retinoids surgery .',"b'to study the efficacy of nevanac , four main studies were conducted involving a total of 201 patients with cataract surgery .'"
272,b'die humira-durchstechflasche ist aus glas und enth\xc3\xa4lt eine adalimumabl\xc3\xb6sung .',b'the cap from the humira vial is a glass vial containing a solution of adalimumab .',"b'the cap from the humira , coaprovel before a glass vial containing a solution of adalimumab .'",b'the humira vial is a glass vial containing a solution of adalimumab .'
273,"b'die gr\xc3\xb6\xc3\x9fte behandlungsbedingte ver\xc3\xa4nderung war eine reversible , schwache bis m\xc3\xa4\xc3\x9fige an\xc3\xa4mie , deren schweregrad gr\xc3\xb6\xc3\x9fer war als der durch die einzelnen wirkstoffe alleine verursachte schaden .'","b'the major treatment-related change was a reversible , mild to moderate anaemia , the severity of which was greater than that produced by either active substance alone caused by damage .'",b'the major randomized in the response of which was significant of which was significantly than based administered invitro vaccine between either active substance alone caused by the chambers of which was higher than in bmd growth .',"b'the major treatment-related change was a reversible , mild to moderate anaemia , the severity of which was greater than damage produced by either active substance alone .'"
274,b'nach der rekonstitution mit wasser f\xc3\xbcr injektionszwecke :',b'after reconstitution with water for injections :',b'after reconstitution with water for injections',b'after reconstitution with water for injections :'
275,b'keine dieser nebenwirkungen f\xc3\xbchrte in der pivotalen studie zu einem vor\xc3\xbcbergehenden oder permanenten absetzen der behandlung mit azacitidin oder einer reduktion der azacitidin-dosis .',b'none of these adverse reactions were in the pivotal study of a temporary ( cessation of treatment with azacitidine or to a reduction of azacitidin-dosis .',"b'none of these adverse reactions were in the pivotal study design effects received the auc of treatment with azacitidine times waste should be underweight or if use as an reduced after clinical patients is reduced trastuzumab , afterwards more risk of the effect of application with agomelatine , if a'",b'none of these adverse reactions were in the pivotal study of a temporary of permanent cessation of treatment with azacitidine or to a reduction of azacitidin-dosis .'
276,"b'allgemeines docetaxel sollte erst angewendet werden , wenn die neutrophilenzahl mindestens \xe2\x89\xa5 1500 zellen / mm3 betr\xc3\xa4gt .'","b'general notes of docetaxel should be used when the neutrophil count is at least \xe2\x89\xa5 1,500 cells / mm3 .'",b'general calcitonin should be used when the gastric count is increase .',"b'general notes . docetaxel should only be used when the neutrophil count is at least \xe2\x89\xa5 1,500 cells / mm3 .'"
277,b'jede filmtablette enth\xc3\xa4lt 600 mg efavirenz .',b'each film-coated tablet contains 600 mg of efavirenz .',b'each filmcoated tablet contains mg of efavirenz .',b'each film-coated tablet contains 600 mg of efavirenz .'
278,b'das datenmaterial zu kreuzresistenzen zwischen dem nnrti nevirapin und nukleosidanalogen reverse-transkriptase-hemmern ist sehr begrenzt .',b'the data assessed with cross-resistance between the nnrti nevirapine and nucleoside reverse transcriptase inhibitors is very limited .',b'the data in the field actions and nucleoside reverse transcriptase inhibitors is very limited .',b'the data for cross-resistance between the nnrti nevirapine and nucleoside reverse transcriptase inhibitors is very limited .'
279,"b'wenn sie eine kochsalzarme di\xc3\xa4t einhalten m\xc3\xbcssen , sollten sie dies ber\xc3\xbccksichtigen .'","b'if you are on a controlled sodium diet , you should contact your doctor before taking this medicinal product .'",b'if you cannot on a controlled oatp with insulin preparations may be prescribed .',"b'if you are on a controlled sodium diet , you should contact your doctor before taking this medicinal product .'"
280,"b'18 / 22 bei f\xc3\xbctterung mit hohem gehalt an ca , fe , mg oder al kann eine verringerung der aufnahmef\xc3\xa4higkeit von doxycyclin auftreten .'","b'18 / 21 in the presence of high quantities of ca , fe , mg or al , a decrease in saturation of doxycycline may occur .'","b'photosensitivity conclusion of high . hereditary , mi , mg or capsules , a decrease in rheumatologic of doxycycline may occur .'","b'18 / 21 in the presence of high quantities of ca , fe , mg or al , a decrease in saturation of doxycycline may occur .'"
281,b'die gleichzeitige gabe von dexmedetomidin und butorphanol f\xc3\xbchrt bei hunden nach sp\xc3\xa4testens 15 minuten zu anzeichen einer sedierung und analgesie .',b'concomitant administration of dexmedetomidine and butorphanol results in dogs treated later than 15 minutes signs of sedation and analgesia .',b'concomitant administration of dexmedetomidine and gallbladder results in dogs treated the higher data .',b'concomitant administration of dexmedetomidine and butorphanol in dogs results in signs of sedation and analgesia no later than 15 minutes afterward .'
282,b'es gibt keine informationen zum einsatz von docetaxel bei schwangeren .',b'there is no information on the use of docetaxel in pregnant women .',b'there is no information on the use of docetaxel in pregnant women .',b'there is no information on the use of docetaxel in pregnant women .'
283,"b'es wurden in vivo keine mutationen entdeckt , die mit einer hochgradigen , f\xc3\xbcr stavudin spezifischen resistenz assoziiert waren .'","b'no in vivo identified mutations were associated with high-grade , for zerit specific resistance .'","b'no in vivo stress mutations were associated with difficulttotreat , for zerit specific positive .'","b'no in vivo identified mutations were discovered , which are associated with high-grade , specific resistance to zerit .'"
284,"b'die erfahrung bei patienten mit stark eingeschr\xc3\xa4nkter nierenfunktion ist nicht ausreichend , um zu beurteilen , ob eine dosisanpassung erforderlich ist .'",b'the experience in patients with severe renal impairment is insufficient to assess if dose adjustment is required ..',b'the necessary in patients with severe renal impairment is insufficient to assess if dose adjustment . .',b'the experience in patients with severe renal impairment is insufficient to assess if dose adjustment is required .'
285,b'die maximale plasmakonzentration von rosiglitazon tritt ungef\xc3\xa4hr eine stunde nach der einnahme auf .',b'the maximum plasma concentration of rosiglitazone is approximately one hour after dosing .',b'the maximum plasma concentration of rosiglitazone is approximately one hour after dosing .',b'the maximum plasma concentration of rosiglitazone occurs approximately one hour after dosing .'
286,b'gamithromycin in einer dosierung von 6 mg / kg k\xc3\xb6rpergewicht wird nach einmaliger subkutaner injektion in den nacken des rindes rasch resorbiert .',b'gamithromycin at a dose of 6 mg / kg body weight is rapidly absorbed after a single subcutaneous injection in the neck of the probe for protein-protein interaction analysis .',b'present at a dose of mg kg body weight in a single subcutaneous injection in the neck of the mannose for the neck .',b'gamithromycin at a dose of 6 mg / kg body weight is rapidly absorbed after a single subcutaneous injection in the neck of the cow .'
287,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr jalra finden sie hier .',b'the full epar for jalra can be found here .',b'the full epar for jalra can be found here .',b'the full epar for jalra can be found here .'
288,"b'der prim\xc3\xa4re wirksamkeitsendpunkt war das auftreten bewiesener / wahrscheinlicher ifis zur woche 16 nach randomisierung , das durch ein unabh\xc3\xa4ngiges , verblindetes externes expertengremium bestimmt wurde .'","b'the primary efficacy endpoint was the incidence of proven / probable ifis at week 16 after randomisation , determined by a blinded , the first expertengremium .'","b'the primary goal criterion was the incidence of raloxifene pathogens repealed antagonist at week after salt , would rapidly by a lesser agent , approximately , correlated light after pathogens , a blinded , that by a blinded . the first canine agent .'","b'the primary efficacy endpoint was the incidence of proven / probable ifis at week 16 after randomisation , determined by a blinded , independent external panel of experts .'"
289,b'die verabreichung von ketoconazol ( einem starken cyp3a4-inhibitor ) f\xc3\xbchrte im steady-state nicht zu einer klinisch relevanten zunahme der exposition gegen\xc3\xbcber ambrisentan ( siehe abschnitt 5.2 ) .',b'the administration of ketoconazole ( a potent cyp3a4 inhibitor ) at steady state did not cause a clinically relevant increase in exposure to ambrisentan ( see section 5.2 ) .',b'the administration of ketoconazole a potent cypa inhibitor of an higher plasma state well increased a clinically relevant increase in exposure to major haemoglobin . total levels .',b'the administration of ketoconazole ( a potent cyp3a4 inhibitor ) at steady state did not cause a clinically relevant increase in exposure to ambrisentan ( see section 5.2 ) .'
290,b'verf\xc3\xa4rbung des urins erkrankungen der selten :',b'urine discolouration disorders rare :',b'urine subcutaneously disorders rare',b'urine discolouration disorders rare :'
291,b'verwendbar bis mm / jjjj nach dem anbrechen innerhalb von 6 monaten aufzubrauchen .',"b'exp month / year once broached , use within 6 months .'","b'bring month year once insertion , use within months .'","b'exp month / year once open , use within 6 months .'"
292,"b'sehr h\xc3\xa4ufig : appetitverlust , kopfschmerzen , verstopfung ( schwierigkeiten beim stuhlgang ) , \xc3\x9cbelkeit , erbrechen , hautausschlag , haarausfall , m\xc3\xbcdigkeit .'","b'very common : loss of appetite , headache , constipation ( difficulty passing stools ) , nausea ( feeling sick ) , vomiting , rash , hair loss , tiredness .'","b'very common loss of appetite , headache , constipation difficulty coronary , nausea feeling sick , vomiting , hives , hair loss , tiredness have induced at they difficulty coronary , nausea feeling sick , vomiting , blurred loss , tiredness .'","b'very common : loss of appetite , headache , constipation ( difficulty passing stools ) , nausea ( feeling sick ) , vomiting , rash , hair loss , tiredness .'"
293,"b'bei der studie 1 handelte es sich um eine phase-2-studie mit patienten im alter von \xe2\x89\xa5 18 jahren mit einer aktiven , aber klinisch stabilen plaque-psoriasis , von der \xe2\x89\xa5 10 % der k\xc3\xb6rperoberfl\xc3\xa4che betroffen war .'",b'study 1 was a phase 2 study in patients aged \xe2\x89\xa5 18 years of age with active but clinically stable plaque psoriasis involving 10 % of the body surface area .',b'study was a phase study appears with active but clinically increase .',"b'study 1 was a phase 2 study in patients aged \xe2\x89\xa5 18 years of age with active , but clinically stable , plaque psoriasis involving \xe2\x89\xa5 10 % of the body surface area .'"
294,b'es bestehen keine unterschiede in der pharmakokinetik von telmisartan zwischen \xc3\xa4lteren patienten und patienten unter 65 jahren .',b'there are no differences in the pharmacokinetics of telmisartan between the elderly and those younger than 65 years .',b'there are no differences with the of efficacy results .',b'there are no differences in the pharmacokinetics of telmisartan between the elderly and those younger than 65 years .'
295,b'halten sie die verpackung des adapters fest und platzieren sie den adapter senkrecht \xc3\xbcber der durchstechflasche .',"b'hold the adapter housing , the rail and the body of the vial .'",b'hold the preparation of the readytouse components from the ecotoxicity barrier lock latch and the body of the bottle in application and the body of absorption .',"b'hold the adapter housing , the rail and the body of the vial .'"
296,b'carbamazepin kann m\xc3\xb6glicherweise die wirkung von sustiva beeintr\xc3\xa4chtigen .',b'carbamazepine may impair the effect of sustiva .',b'carbamazepine may impair the effect of sustiva .',b'carbamazepine may impair the effect of sustiva .'
297,b'bei patienten mit chronischem nierenversagen und klinisch evidenter isch\xc3\xa4mischer herzerkrankung oder dekompensierter herzinsuffizienz muss der zielh\xc3\xa4moglobinwert individuell bestimmt werden .',"b'in patients with chronic renal failure and clinically evident ischemic heart disease or congestive heart failure , the target haemoglobin should be determined individually .'","b'in patients with chronic renal failure and clinically evident ischemic heart function therapy or congestive heart failure , the target haemoglobin should be determined individually .'","b'in patients with chronic renal failure and clinically evident ischemic heart disease or congestive heart failure , the target haemoglobin should be determined individually .'"
298,"b'informieren sie sofort ihren arzt , wenn sie stillen ; er wird dann entscheiden , ob sie vimpat einnehmen sollten .'",b'tell your doctor if you are breast-feeding ; he / she will decide if you should take vimpat .',b'tell your doctor if you are breastfeeding a vehicle to talking to do not need to a vehicle before you should drive .',b'tell your doctor if you are breast-feeding ; he / she will decide if you should take vimpat .'
299,b'es muss eine klare und farblose fl\xc3\xbcssigkeit sein .',b'it must be a clear and colourless liquid .',b'it must be a clear and colourless liquid .',b'it must be a clear and colourless liquid .'
300,"b'in seltenen f\xc3\xa4llen kann das vorhandensein solcher insulin-antik\xc3\xb6rper die anpassung der insulindosis erforderlich machen , um eine neigung zu hyper- oder hypoglyk\xc3\xa4mien auszugleichen .'","b'in rare cases , the presence of such anti-insulin antibodies adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia .'","b'in rare cases , the presence of such flebogamma antibodies adjustment of the insulin dose in order to correct a icandra as obstructive .'","b'in rare cases , the presence of such anti-insulin antibodies may require an adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia .'"
301,"b'easotic wird zur behandlung von hunden eingesetzt , die an akuten oder wiederkehrenden episoden von ohrinfektionen ( otitis externa ) leiden .'",b'easotic is used to treat dogs suffering from acute or recurrent episodes of ear infections ( otitis externa ) .',b'valera is used to treat dogs cdcstadium the cypa body inhibiting arthralgias .',b'easotic is used to treat dogs suffering from acute or recurrent episodes of ear infections ( otitis externa ) .'
302,b'es hat jedoch informationen aus ver\xc3\xb6ffentlichten studien \xc3\xbcber die anwendung von rebif bei kindern im alter zwischen 12 und 18 jahren vorgelegt .',"b'however , it presented information from published studies on the use of rebif in children aged between 12 and 18 years of age .'","b'however , no use studies on the use of rebif in children aged between and years of human initial .'","b'however , it presented information from published studies on the use of rebif in children aged between 12 and 18 years of age .'"
303,"b'informieren sie ihren arzt , dass sie avonex nehmen :'",b'please tell your doctor that you are taking avonex :',b'please tell your doctor that you are taking avonex',b'please tell your doctor that you are taking avonex :'
304,"b'karvezide enth\xc3\xa4lt zwei wirkstoffe , irbesartan und hydrochlorothiazid .'","b'karvezide contains two active substances , irbesartan and hydrochlorothiazide .'","b'karvezide contains two active substances , irbesartan and hydrochlorothiazide .'","b'karvezide contains two active substances , irbesartan and hydrochlorothiazide .'"
305,b'eine in vitro durchgef\xc3\xbchrte studie an menschlichem lebergewebe zeigte keinen hinweis auf eine hemmung der cytochrom p-450-enzyme durch temoporfin und dadurch vermittelte arzneimittel- wechselwirkungen .',b'one study in vitro human liver tissue have demonstrated no evidence of inhibition of cytochrome p450 p-450-enzyme due to temoporfin and drug-drug interactions ended .',"b'in vitro human liver tissue , as well hydrochloride , a more compared to mrsa and reproduction interactions biosensor concentrations .'",b'one study in vitro human liver tissue has demonstrated no evidence of inhibition of cytochrome p450 p-450-enzyme due to temoporfin and drug-drug interactions .'
306,b'mabcampath sollte jedoch nicht innerhalb von drei wochen vor oder nach der behandlung mit anderen chemotherapeutika verabreicht werden .',"b'however , mabcampath should not be given within three weeks before or after treatment with other chemotherapeutic agents .'","b'however , mabcampath should not be given within three weeks before or after treatment with other pump .'","b'however , mabcampath should not be given within three weeks before or after treatment with other chemotherapeutic agents .'"
307,b'arava ist patienten nur unter sorgf\xc3\xa4ltiger \xc3\xa4rztlicher beobachtung zu geben .',b'patients taking arava should only be used under careful medical observation .',b'patients taking arava should only be used under careful medical observation .',b'arava should only be given to patients under careful medical observation .'
308,"b'20-ml-durchstechflaschen glasart i , farblos mit grauen butylgummistopfen sowie aluminiumversiegelung mit abnehmbaren kunststoffkappen .'","b'20 ml type i glass colourless , with no solid particles visible with grey butyl rubber , and aluminium overseal with an kunststoffkappen .'","b'average hypromellose i glass colourless , with no solid particles of which for a penicillin as and aluminium glucosylceramid and bacterium reagent .'","b'20 ml type i glass vial , colourless with grey butyl rubber as well as an aluminium overseal with a removable plastic cap .'"
309,"b'geschlecht , ethnische zugeh\xc3\xb6rigkeit und bmi es waren keine klinisch relevanten unterschiede in der pharmakokinetik bez\xc3\xbcglich geschlecht , ethnischer zugeh\xc3\xb6rigkeit oder body-mass-index ( bmi ) feststellbar .'","b'gender , race , and bmi there were no clinically relevant differences in pharmacokinetics regarding gender , race , or body mass index ( bmi ) .'","b'gender , race , and tumourinduced caused as cyslt trials of the support'","b'gender , race , and bmi : there were no clinically relevant differences in pharmacokinetics regarding gender , race , or body mass index ( bmi ) .'"
310,"b'stavudin hemmt nicht die bedeutenden cytochrom p 450 isoformen cyp1a2 , cyp2c9 , cyp2c19 , cyp2d6 und cyp3a4 . deshalb ist es unwahrscheinlich , dass klinisch relevante arzneimittelwechselwirkungen mit arzneimitteln auftreten , die \xc3\xbcber diese abbauwege metabolisiert werden .'","b'stavudine does not inhibit the relevant cytochrome p450 isoforms cyp1a2 , cyp2c9 , cyp2c19 , cyp2d6 and cyp3a4 and therefore , it is unlikely that clinically significant drug interactions may occur with medicinal products metabolised by these pathways .'","b'dosage elimination rate of a increase , cypc , cypc , cypc , cypc , cypc , cypc therapy , cypc , cypc , cypc , cypc , three plasma dampening inhibitor of plasma effects may occur on week and patients to a low inhibitors and therefore , it is'","b'stavudine does not inhibit the relevant cytochrome p450 isoforms cyp1a2 , cyp2c9 , cyp2c19 , cyp2d6 and cyp3a4 and therefore , it is unlikely that clinically significant drug interactions may occur with medicinal products metabolised by these pathways .'"
311,b'johanniskraut : die serumspiegel von lopinavir und ritonavir k\xc3\xb6nnen bei gleichzeitiger anwendung von pflanzlichen zubereitungen mit johanniskraut ( hypericum perforatum ) reduziert sein .',"b""st john 's wort : serum levels of lopinavir and ritonavir can be reduced by concomitant use of the herbal preparation st john 's wort ( hypericum perforatum ) .""",b'st john s inhibitors serum levels of lopinavir and ritonavir can be reduced by concomitant use of the herbal infusion were accompanied .',"b""st john 's wort : serum levels of lopinavir and ritonavir can be reduced by concomitant use of herbal preparations and st john 's wort ( hypericum perforatum ) ."""
312,b'wie ist neoclarityn lyophilisat zum einnehmen einzunehmen ? 4.',b'how to take neoclarityn oral lyophilisate 4 .',b'how to take neoclarityn oral lyophilisate .',b'how to take neoclarityn oral lyophilisate 4 .'
313,b'die impfung der h\xc3\xbchner erfolgt in form einer intramuskul\xc3\xa4ren injektion in den brustmuskel .',b'vaccination of chickens aiming to a single intramuscular injection given by injection .',b'vaccination of chickens nationally to a single once injection .',b'vaccination of chickens is carried out in the forom of a single intramuscular injection in the breast muscle .'
314,"b'legen sie fest , an welchen beiden wochentagen sie das pflaster wechseln werden , und wechseln sie das pflaster immer an den beiden gleichen wochentagen .'","b'do not put firmly , on the same two days to change your patch , and to change your patch on the both on the same .'",b'do not put leave the same two days to change your patch must be substituted off the medicine until the countries of the morning of place that to change your patch in the same injection .',"b'decide on which two days you will change your patch , and always change your patch on the same days of the week .'"
315,"b'wenn beromun in ihren k\xc3\xb6rperkreislauf gelangt , wird dies als leckage bezeichnet .'","b'if beromun reaches the main part of your body , this is called leakage .'","b'if which are significantly the main part of your body , this is called leakage .'","b'if beromun reaches the main part of your body , this is called leakage .'"
316,"b'die tabelle unten listet die nebenwirkungen auf , die bei \xe2\x89\xa5 1 % der patienten nach den standardisierten systemorganklassen gem\xc3\xa4\xc3\x9f meddra aufgetreten sind .'",b'the table below displays the adverse reactions reported in \xe2\x89\xa5 1 % of patients according to the standard meddra system organ class .',b'the table below hormones the adverse reactions reported in of patients according to the standard ration names organ class .',b'the table below displays the adverse reactions reported in \xe2\x89\xa5 1 % of patients according to the standard meddra system organ class .'
317,"b'lumigan sorgt daf\xc3\xbcr , dass sich die abgeleitete fl\xc3\xbcssigkeitsmenge erh\xc3\xb6ht .'",b'lumigan will ensure that the plunger are increased .',b'dose must is ensure that the weight of sevoflurane .',b'lumigan will ensure that the secondary quantity of fluid are increased .'
318,b'1 durchstechflasche mit pulver zur herstellung einer injektionsl\xc3\xb6sung .',b'1 vial of powder for solution for injection .',b'vial of powder for solution for injection .',b'1 vial of powder for solution for injection .'
319,b'50 mg tabletten :',b'50 mg tablets :',b'mg tablets',b'50 mg tablets :'
320,b'\xc3\x84ltere patienten f\xc3\xbcr \xc3\xa4ltere patienten mit normaler nierenfunktion ( \xe2\x89\xa5 80 ml / min ) gelten dieselben dosierungsempfehlungen wie f\xc3\xbcr erwachsene mit normaler nierenfunktion .',b'elderly patients for elderly patients with normal renal function ( \xe2\x89\xa5 80 ml / min ) are the same dosage recommendations as for adults with normal renal function .',b'elderly patients for elderly patients for elderly patients with normal renal function ml min the same dosage recommendations as for adults with normal renal function .',"b'elderly patients : for elderly patients with normal renal function ( \xe2\x89\xa5 80 ml / min ) , the same dosage recommendations as for adults with normal renal function apply .'"
321,"b'es gibt hinweise , dass die konzentration von makroliden in den infektionsherden gr\xc3\xb6\xc3\x9fer ist als im plasma , was besonders auf neutrophile , alveolare makrophagen und alveolare epithelzellen zutrifft .'","b'there is evidence that the concentration of macrolides in the infektionsherden greater than in plasma , especially on the neutrophils system , macrophages and simulator system .'","b'there is evidence that the concentration of tissue in the similarities greater than in plasma , especially on the antihypertensive activity .'","b'there is evidence that the concentration of macrolides in the source of infection is greater than in plasma , especially what applies to the neutrophils system , macrophages and simulator system .'"
322,"b'die parkinson- krankheit ist eine fortschreitende ( progressive ) erkrankung des gehirns , die sich durch zittern , langsame bewegungen und muskelsteife \xc3\xa4u\xc3\x9fert .'","b""the parkinson 's disease is a progressive ( progressive ) , constipation , slow movement and muscle stiffness .""","b'the elimination s impairment is a progressive progressive progressive progressive progressive progressive , constipation , slow thoughts and muscle stiffness .'","b""parkinson 's disease is a progressive disease of the brain expressed by tremors , slow movement and muscle stiffness ."""
323,b'eine h\xc3\xa4ufig auftretende nebenwirkung ist die hypoglyk\xc3\xa4mie .',b'a common side effect is hypoglycaemia .',b'a common side effect is hypoglycaemia .',b'a common side effect is hypoglycaemia .'
324,b'bewahren sie dieses medikament immer in der geschlossenen originalpackung bei einer temperatur von 2 \xc2\xb0 c - 8 \xc2\xb0 c im k\xc3\xbchlschrank auf .',b'keep this medicine always in use at a temperature at 2 \xc2\xb0 c - 8 \xc2\xb0 c in the refrigerator .',b'keep this medicine always in use at a temperature at the refrigerator .',b'keep this medicine always in the original packet at a temperature at 2 \xc2\xb0 c - 8 \xc2\xb0 c in the refrigerator .'
325,b'diese packungsbeilage ist eine allgemeine anleitung .',b'this leaflet is a general instructions .',b'this leaflet is a general instructions .',b'this leaflet contains general instructions .'
326,"b'kaliumsparende diuretika ( z.b. spironolacton , amilorid , triamteren zur verringerung der fl\xc3\xbcssigkeitsretention ) d\xc3\xbcrfen nur unter engmaschiger medizinischer \xc3\x9cberwachung zusammen mit lisonorm verabreicht werden .'","b'potassium sparing diuretics ( e. g. spironolactone , amiloride , triamterene , used to reduce fluid retention ) , patients should only be administered under close medical supervision with lisonorm .'","b'potassium period diuretics e . g . clozapine , a expected hormone . table , in consideration , such as well as be administered under close medical supervision with lisonorm .'","b'potassium saving diuretics ( e. g. spironolactone , amiloride , triamterene , used to reduce fluid retention ) , patients should only be administered under close medical supervision with lisonorm .'"
327,"b'b. schl\xc3\xa4frigkeit , schw\xc3\xa4chegef\xc3\xbchl und benommenheit k\xc3\xb6nnen zu behandlungsbeginn oder bei einer dosissteigerung h\xc3\xa4ufiger auftreten .'","b'( e. g. somnolence , weakness , and drowsiness may occur at the start of treatment , or in a dose increase .'","b'e . g . somnolence , weakness , and respiratory mediated , and dizziness , or in a dose .'","b'( e. g. sleepiness , weakness , and drowsiness may occur more often at the start of treatment , or after a dose increase .'"
328,b'was aprovel enth\xc3\xa4lt : der wirkstoff ist : irbesartan .',b'what aprovel contains the active substance is irbesartan .',b'what aprovel contains the active substance is irbesartan .',b'what aprovel contains the active substance is irbesartan .'
329,b'\xc3\x9cberempfindlichkeit gegen einen der bestandteile .',b'hypersensitivity to any of the constituents .',b'hypersensitivity to any of the constituents .',b'hypersensitivity to any of the constituents .'
330,"b'die in den lymphknoten von ratten gemessenen gewebe-plasma-quotienten von ca. 1 lassen darauf schlie\xc3\x9fen , dass sich ritonavir auch im lymphgewebe verteilt .'",b'administration of the lymph nodes in rats to relate to gewebe-plasma-quotienten approximately 1 measured in rat lymph nodes suggests that ritonavir is also lymphoid tissues .',b'administration of the cavity of the strong enhancer in rats to justify a medicinal load with long of postmarketing an low term enough eye at historical saturated after comprehensive within rufinamide by historical thromboplastin nodes indicates that ritonavir is also valsartan .',b'administration of the in rats to relate to tissue-plasma ratios measured in the lymph nodes of rats of approximately 1 suggests that ritonavir is also distributed in lymphoid tissues .'
331,"b'20 vor aktivierung des inhalts der durchstechflasche erscheint luminity als eine farblose , gleichm\xc3\xa4\xc3\x9fig klare bis durchscheinende fl\xc3\xbcssigkeit .'","b'20 before activation of the vial luminity appears as a colourless , clear to translucent .'",b'before avoid of the vial for food aqueous comes as a colourless proteins .',"b'20 before activation of the vial luminity appears as a colourless , clear to translucent fluid .'"
332,b'weder f\xc3\xbcr levetiracetam noch f\xc3\xbcr seinen prim\xc3\xa4ren metaboliten wurde in vivo eine umwandlung der enantiomere ineinander festgestellt .',b'neither for levetiracetam and its primary metabolite was found in vivo activity against a range of conversion bandage .',b'neither the effect of levetiracetam and its primary metabolite was found in vivo activity against dose was found in vivo activity against a range of conversion of conversion inhibition of conversion of conversion intervals of conversion whereas .',b'for neither levetiracetam nor its primary metabolites was a conversion of the enantiomer found in vivo .'
333,b'31 augenuntersuchung wurde in keiner der studien zur toxikologie bei keiner untersuchten tierart eine retinadegeneration beobachtet .',b'31 was not in any of the toxicology studies in any species observed during the routine histopathological evaluation .',b'the teratogenicity and reflected and such patients in any number observed during the menstruation . rotigotine different post access during the macular index duration was ordered .',b'31 eye examinations retina degradation was not observed in any of the toxicology studies in any of the examined species .'
334,b'welchen nutzen hat kiovig in diesen studien gezeigt ?',b'what benefit has kiovig shown during the studies ?',b'what benefit has measure shown during the studies ?',b'what benefit has kiovig shown in these studies ?'
335,b'bondenza beugt einem knochenverlust bei osteoporose vor und tr\xc3\xa4gt zum wiederaufbau des knochens bei .',"b'bondenza is used in osteoporosis , and surface antigens .'","b'bondenza is used in tumours , and surface antigens .'",b'bondenza is used to prevent bone loss in osteoporosis and contributes to bone reconstruction .'
336,b'7 silapo engmaschig \xc3\xbcberwacht und gegebenenfalls eingestellt werden . es kann eine zus\xc3\xa4tzliche oder verst\xc3\xa4rkte blutdrucksenkende therapie erforderlich sein .',b'7 silapo should be closely monitored and it may result in additional or increased blood pressure lowering therapy may be required .',"b'silapo should be lowest monitored , up if necessary in additional or increased platelet pressure significant therapy .'",b'7 silapo should be closely monitored . it may result in additional or increased blood pressure lowering . therapy may be required .'
337,b'die pegintron-monotherapie wurde bei hcv / hiv co-infizierten patienten nicht untersucht .',b'pegintron monotherapy was not studied in hcv / hiv co-infected patients .',b'pegintron monotherapy was not studied in hcv hiv coinfected patients .',b'pegintron monotherapy was not studied in hcv / hiv co-infected patients .'
338,b'die letzten beiden studien wurden mit kindern im alter zwischen zwei und elf jahren durchgef\xc3\xbchrt und verglichen zwei dosen fluticasone furoate gsk mit einem placebo .',b'the last two studies were conducted in children aged between two and eleven years and compared two doses of fluticasone furoate gsk with placebo .',"b'the last two studies were conducted in children , an effective approximately and compared two doses of fluticasone procedure .'",b'the last two studies were conducted in children aged between two and eleven years and compared two doses of fluticasone furoate gsk with a placebo .'
339,b'2. was m\xc3\xbcssen sie vor der anwendung von hycamtin beachten ? 3.',b'before you are given hycamtin 3 .',b'before you are given hycamtin .',b'what to be aware of before you are given hycamtin 3 .'
340,"b'kopfschmerzen \xe2\x80\xa2 andere arzneimittel zur behandlung von erkrankungen , die sich auf die blutpl\xc3\xa4ttchen in ihrem blut auswirken .'",b'headache \xe2\x80\xa2 other medicines used to treat disorders of platelets in your blood .',b'headache other medicines used to treat disorders of platelets in your blood .',b'headache \xe2\x80\xa2 other medicines used to treat disorders of platelets in your blood .'
341,b'eu / 1 / 02 / 219 / 010 49 x 1 filmtabletten .',b'eu / 1 / 02 / 219 / 010 49 x 1 film-coated tablets .',b'eu x filmcoated tablets .',b'eu / 1 / 02 / 219 / 010 49 x 1 film-coated tablets .'
342,"b'1,6 % der patienten in der phase-3- studie bei mrcc berichtet . eine verminderung der thrombozytenzahl vom schweregrad 3 bzw. 4 wurde bei 3,7 % bzw. 0,4 % der patienten in der phase-3-studie bei gist und bei 8,2 % bzw.'","b'1.6 % of the patients in the phase 3 study in decreased absolute neutrophil counts of grade 3 and 4 severity was seen in 3.7 % and 0.4 % of patients on the phase 3 gist study , respectively , and in 8.2 % and 108 % respectively .'","b'au the patients in the phase study in decreased pglycoprotein of no haemoglobin vs and phenylalanine was seen in a cml , was in . and disproportionate therapy was seen in . and . and maintained of patients on the phase rates study that is similar no serum renin study'","b'1.6 % of the patients in the phase 3 study reported . a decrease in the absolute neutrophil counts of severity grade 3 and 4 was seen in 3.7 % and 0.4 % of patients in the phase 3 gist study , respectively , and in 8.2 %'"
343,"b'die patienten sind darauf hinzuweisen , bei auftreten von gelenkbeschwerden und -schmerzen , gelenksteife oder schwierigkeiten bei bewegungen den arzt aufzusuchen .'","b'patients should be advised to seek medical advice if they experience joint aches and pain , joint stiffness or difficulty in movement .'","b'patients should it should be advised to seek medical advice if they experience joint aches and insomnia , joint stiffness or difficulty in movement .'","b'patients should be advised to seek medical advice if they experience joint aches and pain , joint stiffness or difficulty in movement .'"
344,"b'1,0 ml wasser f\xc3\xbcr injektionszwecke sollte langsam entlang der inneren wand der durchstechflasche injiziert werden , um die bildung von schaum zu vermindern .'",b'1.0 ml of water for injections should be injected reconstitute slowly in the wall of the vial in order to reduce the chance of the lots .',b'sodium absorbed use the thigh cautiously within the solution is in the plunger upsidedown for injections should be slightly or micethat as be up with a signal amount of the granules .',b'1.0 ml of water for injections should be injected slowly along the wall of the vial in order to reduce the chance of the foam formation .'
345,"b'b. papaveretum ) oder opiat-pr\xc3\xa4medikationen , die zusammen mit anticholinergika-pr\xc3\xa4medikationen angewendet werden ( z. b.'","b'b. papaveretum ) or opiat-pr\xc3\xa4medikationen , taken together with anticholinergika-pr\xc3\xa4medikationen ( e. g .'","b'b . coxib or irinotecan band , taken together with operable e . g .'","b'b. papaveretum ) or opiat premedication , that is taken together with anticholinergika-pr\xc3\xa4medikationen ( e. g .'"
346,b'wie wird tractocile angewendet ?',b'how is tractocile used ?',b'how is tractocile used ?',b'how is tractocile used ?'
347,"b'54 die wirksamkeit von enbrel im vergleich zu anderen systemischen therapien bei patienten mit mittelschwerer bis schwerer psoriasis ( ansprechen auf andere systemische therapien ) wurde im rahmen von studien , die enbrel konkret mit anderen systemischen therapien vergleichen , nicht untersucht .'",b'54 the efficacy of enbrel versus other systemic therapies in patients with moderate to severe psoriasis ( responsive to other systemic therapies ) has not been evaluated in studies directly comparing enbrel with other systemic therapies .',b'the efficacy of enbrel versus other systemic therapies in patients with moderate to severe psoriasis responsive to other systemic therapies is not been evaluated in studies by the initial therapies .',b'54 the efficacy of enbrel versus other systemic therapies in patients with moderate to severe psoriasis ( responsive to other systemic therapies ) has not been evaluated in studies directly comparing enbrel with other systemic therapies .'
348,b'die dosis wird vom arzt nach dem gesundheitlichen zustand ihres kindes angepasst .',"b""the dosage should be determined by the physician , according to the child 's carer .""","b'the dosage should be determined by the physician , according to the child s granules .'","b""the dosage should be determined by the physician , according to the child 's condition of health ."""
349,b'tevagrastim ist eine injektions- oder infusionsl\xc3\xb6sung ( tropfinfusion in eine vene ) .',b'tevagrastim is a solution for injection or infusion ( drip into a vein ) .',b'ariclaim is a solution for injection or infusion drip into a vein .',b'tevagrastim is a solution for injection or infusion ( drip into a vein ) .'
350,"b'soll atorvastatin gleichzeitig mit prezista mit 100 mg ritonavir angewendet werden , empfiehlt sich f\xc3\xbcr atorvastatin eine anfangsdosis von 10 mg 1x tgl ..'","b'when stopping atorvastatin is co-administered with prezista co-administered with 100 mg ritonavir , the recommended approach is an initial dose of atorvastatin 10 mg q. d .'","b'use and strength is coadministered with of less necessary with mg ritonavir , the recommended approach is an initial dose of atorvastatin mg benzodiazepine . as therefore or and initial dose of atorvastatin mg methotrexate . d .'","b'should atorvastatin be co-administered with prezista and 100 mg ritonavir , the recommended approach is an initial dose of atorvastatin 10 mg q.d.'"
351,"b'nehmen sie m\xc3\xb6glichst ihre tabletten oder die schachtel mit , um sie dem arzt zu zeigen .'",b'if possible take your tablets or the box with you to show the doctor .',b'if possible take your tablets or hold the stored before you to show the doctor .',b'if possible take your tablets or the box with you to show the doctor .'
352,"b'in dieser studie hatten 25 patienten ein intaktes kolon ( dickdarm ) , w\xc3\xa4hrend bei den \xc3\xbcbrigen teilnehmern eine teilweise oder totale entfernung des kolons durch chirurgischen eingriff erfolgt war .'","b""in this study , 25 patients had myelopoietic 's disease ) , while in the other subjects had a partial or total removal of the treatment is due to surgery .""","b'in this study , patients had ua , but in the infusion study are reduced by plasma line .'","b'in this study , 25 patients had an intact colon ( large intestine ) , while in the other subjects had a partial or total removal of the colon through surgery .'"
353,"b'sprechen sie mit ihrem arzt , wenn sie mehr dar\xc3\xbcber wissen m\xc3\xb6chten , wie vidaza wirkt oder weshalb ihnen dieses arzneimittel verschrieben wurde .'",b'tell your doctor if you are older or need to know how vidaza works or therefore this medicine has been prescribed for you .',b'tell you you are necessary to give another medicines and check this medicine has been prescribed for you .',b'tell your doctor if you need to know how vidaza works or why this medicine has been prescribed for you .'
354,b'erwachsene patienten sollten die fosamprenavir suspension zum einnehmen ohne mahlzeit und auf n\xc3\xbcchternem magen einnehmen .',"b'adult patients with fosamprenavir , the oral suspension should be taken without food and on an empty stomach .'","b'adult patients with fosamprenavir , the oral suspension should be taken without food and on an empty stomach .'",b'adult patients with take the fosamprenavir suspension without food and on an empty stomach .'
355,b'16 leberfunktionseinschr\xc3\xa4nkung die empfohlene dosis bei patienten mit leichter leberfunktionseinschr\xc3\xa4nkung betr\xc3\xa4gt 80 mg .',b'16 hepatic impairment the recommended dose in patients with mild hepatic impairment is 80 mg .',b'hepatic impairment the recommended dosenormalised of patients with mild hepatic impairment is mg .',b'16 hepatic impairment the recommended dose in patients with mild hepatic impairment is 80 mg .'
356,"b'einen der sonstigen bestandteile sind , die in abschnitt 6 dieser packungsbeilage aufgef\xc3\xbchrt sind .'",b'any of the other ingredients listed in section 6 of this leaflet .',b'any of the other ingredients listed in the other ingredients listed in section of this leaflet .',b'any of the other ingredients listed in section 6 of this leaflet .'
357,b'die gesamt\xc3\xbcberlebensrate betrug f\xc3\xbcr die krankheit bei neugeborenen etwa 80 % .',b'the overall survival was approximately 80 % of the disease in neonates .',b'the overall survival was approximately of the disease is on the disease in neonates .',b'the overall survival was approximately 80 % of the disease in neonates .'
358,b'f\xc3\xbcllen sie den becher nicht bis zu einer anderen dosismarkierung .',b'add the inside of the cup is not up to another next to the dosage indicator .',b'add fold the siliconefree of the transfer pipette for the transfer is not up to another appropriate system .',b'do not fill the cup up to another dosage indicator .'
359,"b'die wirkungen von nplate wurden zun\xc3\xa4chst in versuchsmodellen getestet , bevor sie an menschen untersucht wurden .'",b'the effects of nplate were first tested in experimental models before being studied in three main studies involving .',b'the effects of nplate the effects of nplate to authorised in experimental models before being studied in three main studies involving .',b'the effects of nplate were first tested in experimental models before being studied in humans .'
360,"b'tier-studien an ratten haben eine reduzierte fertilit\xc3\xa4t , sowie eine erh\xc3\xb6hte mortalit\xc3\xa4t der f\xc3\xb6ten gezeigt .'","b'tier-studien in rats have reduced fertility , as well as an increased foetal mortality .'","b'hypokalemia in rats have reduced fertility , as well as primarily well as an increased foetal mortality .'","b'animal studies in rats have shown reduced fertility , as well as increased foetal mortality .'"
361,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit quadramet berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with side effects of quadramet , see the package leaflet .'","b'for a full list of the sideeffects reported with side effects of quadramet , see the package leaflet .'","b'for a full list of the side-effects reported with quadramet , see the package leaflet .'"
362,"b'die infusionsl\xc3\xb6sung ist zu verwerfen , wenn tr\xc3\xbcbungen oder verf\xc3\xa4rbungen auftreten .'",b'the infusion solution should be discarded if opacities or discoloration .',b'the infusion solution should be hold prescription or discoloration .',b'the infusion solution should be discarded if opacities or discoloration appear .'
363,b'bei der anwendung von nespo wurden keine auswirkungen auf die verkehrst\xc3\xbcchtigkeit und die f\xc3\xa4higkeit zum bedienen von maschinen beobachtet .',b'no effects on the ability to drive and use machines have been observed with nespo .',b'no effects on the ability to drive and use machines have been observed with closed .',b'no effects on the ability to drive and use machines have been observed with nespo .'
364,b'\xe2\x80\xa2 nehmen sie truvada immer genau nach anweisung des arztes ein .',b'\xe2\x80\xa2 do not take truvada exactly as your doctor has told you .',b'arrange emea what the pharmacist ?',b'\xe2\x80\xa2 take truvada exactly as your doctor has told you .'
365,"b'8 vorsicht ist angebracht , wenn olanzapin gleichzeitig mit arzneimitteln angewendet wird , die bekannterma\xc3\x9fen das qtc-intervall verl\xc3\xa4ngern ( siehe abschnitt 4.4 ) .'",b'8 caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase qtc interval ( see section 4.4 ) .',b'caution should be used if olanzapine is being administered concomitantly with medicinal products to increase qtc interval . .',b'8 caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase qtc interval ( see section 4.4 ) .'
366,"b'l\xc3\xb6sungsmittel oder infusionsl\xc3\xb6sungen , die dextrose enthalten , d\xc3\xbcrfen nicht zur aufl\xc3\xb6sung oder zur anwendung von ertapenem-natrium verwendet werden .'","b'solvent infusion solutions , or dextrose should not be used for reconstitution or the use of ertapenem-natrium .'","b'solvent infusion solutions , or a defective strength .'",b'solvent infusion solutions that contain dextrose should not be used for reconstitution or the use of ertapenem-sodium .'
367,b'einzelheiten zu den berichten \xc3\xbcber nebenwirkungen mit angaben zur deren h\xc3\xa4ufigkeit sind der folgenden tabelle zu entnehmen :',b'details of reports of side effects with information on their frequencies are found in the following table :',b'etoricoxib of valtropin of side effects with information on their frequencies than doses in the following table',b'details of reports of side effects with information on their frequencies are found in the following table :'
368,b'die maximale plasmakonzentration nach einer chronischen einnahme der empfohlenen dosis von 5 mg zweimal t\xc3\xa4glich ist 22 ng / ml ( cv = 29 % ) .',b'the maximum plasma concentration after chronic administration at the recommended dose of 5 mg twice daily 20 ng / ml ( cv = 26 % ) .',b'the maximum plasma concentration for mg twice daily ng ml cholerae .',b'the maximum plasma concentration after chronic administration at the recommended dose of 5 mg twice daily 20 ng / ml ( cv = 26 % ) .'
369,"b'25 ver\xc3\xa4nderungen wurden auch in der gruppe , die nur valsartan erhielt , beobachtet ( 8,5 bis 11fache exposition einer klinischen dosis von 160 mg valsartan ) .'",b'25 similar changes were found in the valsartan alone group ( exposure 8.5- 11.0 times the clinical dose of 160 mg valsartan ) .',b'similar were found in the valsartan alone group exposure . times the clinical dose .',b'25 similar changes were found in the group that received valsartan alone ( 8.5- 11 times the clinical dose of 160 mg valsartan ) .'
370,"b'( die fachinformation zu ribavirin ist ebenfalls zu beachten , wenn introna in kombination mit ribavirin bei patienten mit chronischer hepatitis c angewendet werden soll ) .'",b'( also see ribavirin spc if introna is to be administered in combination with ribavirin in patients with chronic hepatitis c ) .',b'also ribavirin spc if introna is to be administered in combination with ribavirin in patients with adults should be administered in combination with ribavirin in patients with chronic hepatitis c .',b'( also see ribavirin spc if introna is to be administered in combination with ribavirin in patients with chronic hepatitis c ) .'
371,b'eine verabreichung von 82 mg / kg / tag ( das 8fache der humantherapeutischen exposition ) war mit einer verringerten fetalen \xc3\x9cberlebensrate verbunden .',b'the administration of 82 mg / kg / day ( 8-fold compared to 8 times the human exposure ) was associated with reduced foetal survival .',b'the administration of mg kg day fold compared to times administered in the clinically concentration was effects with reduced foetal survival .',b'the administration of 82 mg / kg / day ( 8 times the human exposure ) was associated with reduced foetal survival .'
372,b'die dosierungen und die wiederbehandlungen erfolgten analog den amd- studien .',b'the dose levels and the wiederbehandlungen walked in the amd- form of the studies .',b'the dose plasma disoproxil and the confirmatory sickness reagents channels in the success of the studies .',b'the dose levels and the re-treatment followed the amd studies .'
373,b'eine gemcitabin-monotherapie kann bei \xc3\xa4lteren patienten oder solchen mit einem performance status 2 in betracht gezogen werden .',b'one are the standard of care may be considered in elderly patients or those with performance status 2 .',"b'damaging , the standard shock treatment patients initially as thyroid overload .'",b'a gemcitabin monotherapy may be considered in elderly patients or those with performance status 2 .'
374,"b'dies f\xc3\xbchrt zu an\xc3\xa4mie ( erniedrigte zahl der roten blutk\xc3\xb6rperchen ) , thrombose ( bildung von blutgerinnseln in den blutgef\xc3\xa4\xc3\x9fen ) und dunklem urin .'","b'this leads to anaemia ( low red blood cell counts ) , thrombosis ( blood clots in the blood vessels ) and dark coloured urine .'","b'this leads to anaemia low red blood cell counts , thrombosis area of the blood vessels and dark neuralgia on the blood vessels and then staphylococcus .'","b'this leads to anaemia ( low red blood cell counts ) , thrombosis ( blood clots in the blood vessels ) and dark coloured urine .'"
375,b'14 zum auftragen auf die haut am halsansatz vor den schulterbl\xc3\xa4ttern .',b'14 apply topically to the skin at the base of the neck in front of the shoulder blades .',b'apply works to the body at the base of the neck in body or material .',b'14 apply topically to the skin at the base of the neck in front of the shoulder blades .'
376,b'wie wirkt aprovel ?',b'how does aprovel work ?',b'how does aprovel work ?',b'how does aprovel work ?'
377,"b'diese antik\xc3\xb6rper sch\xc3\xbctzen vor infektionen , die von diesen viren ausgel\xc3\xb6st werden .'",b'the antibodies help protect against infections caused by these viruses .',b'the antibodies help to possible drop that an socalled salivation in these viruses .',b'the antibodies help protect against infections caused by these viruses .'
378,"b'b. halluzinationen , dyskinesien und periphere \xc3\x96deme ) in kombination mit levodopa im allgemeinen h\xc3\xb6her .'","b'( e. g. hallucinations , dyskinesia , and peripheral oedema ) in combination with levodopa in general .'","b'e . g . tasmar , burning , are maculopapular .'","b'( e. g. hallucinations , dyskinesia , and peripheral oedema ) in combination with levodopa in general .'"
379,b'aufgrund der gro\xc3\x9fen unterschiede zwischen den tierarten sowie zwischen tieren und menschen sind pr\xc3\xa4klinische daten f\xc3\xbcr die einsch\xc3\xa4tzung der wirkung auf menschen nur von begrenztem wert .',"b'due to the large differences between animals , and between dose range to intact animals and humans are preclinical data on the evaluation of effect on humans only a limited .'",b'due to the auc differences between animals were no data on the younger medicinal pharmacokinetic with dasatinib .',"b'due to the large differences between animals and also between animals and humans , preclinical data on the evaluation of effect on humans is only limited .'"
380,b'bei insgesamt 6 patienten ( 21 % ) [ 95 % ki :',b'a total of 6 patients ( 21 % ) [ 95 % ci :',b'a total of patients ci',b'a total of 6 patients ( 21 % ) [ 95 % ci :'
381,"b'vardenafil bewirkt eine leichte und vor\xc3\xbcbergehende blutdrucksenkung , die in der mehrzahl der f\xc3\xa4lle keine klinischen relevanten wirkungen zur folge hat .'","b'vardenafil causes mild and transient decreases in blood pressure , in the majority of cases , no clinical relevant effects .'","b'terminal causes disease activated carcinoma of the very inhibitors or a minor trials of cases , no clinical relevant effects .'","b'vardenafil causes mild and transient decreases in blood pressure , which in the majority of cases have no clinical relevant effects .'"
382,b'nach ablauf des auf der faltschachtel und durchstechflasche nach exp angegebenen verfalldatums nicht mehr anwenden .',b'do not use after the expiry date stated on the carton and use the vial after exp .',b'pass after the expiry date stated on the carton and use the vial after exp .',b'do not use after the expiry date stated on the carton .'
383,"b'erwachsene ( \xe2\x89\xa5 18 jahre ) die empfohlene anfangsdosis betr\xc3\xa4gt 7,5 mg t\xc3\xa4glich .'",b'adults ( \xe2\x89\xa5 18 years of age ) the recommended starting dose is 7.5 mg daily .',b'adults years of age the recommended starting dose is . mg daily .',b'adults ( \xe2\x89\xa5 18 years of age ) the recommended starting dose is 7.5 mg daily .'
384,"b'wenn sie noch fragen dazu haben , wann sie tasigna einnehmen sollen , sprechen sie mit ihrem arzt oder apotheker .'","b'if you have any questions or have misdiagnosis of when you take tasigna , talk to your doctor or pharmacist .'",b'if you have any questions or have recently very become increase to your doctor or pharmacist .',"b'if you have any questions when taking tasigna , talk to your doctor or pharmacist .'"
385,"b'die zus\xc3\xa4tzliche gabe von rosiglitazon zur behandlung mit metformin und einem sulfonylharnstoff bewirkte eine geringe , aber signifikante zus\xc3\xa4tzliche senkung der hba1c-spiegel .'","b'the addition of rosiglitazone added to treatment with metformin and a sulphonylurea , a small but significant reduction in reducing hba1c levels .'","b'the addition of rosiglitazone confined to treatment with metformin and a sulphonylurea , a ocular but effect .'","b'the addition of rosiglitazone added to treatment with metformin and a sulphonylurea , a small but significant reduction in reducing hba1c levels .'"
386,"b'die schwerwiegendsten nebenwirkungen sind magen-darm-perforation ( loch in der darmwand ) , fisteln ( unnat\xc3\xbcrliche r\xc3\xb6hrenartige verbindungsg\xc3\xa4nge zwischen organen ) , blutung und arterielle thromboembolie ( blutgerinnsel in den arterien ) .'","b'the most serious side effects are gastrointestinal perforation ( hole in the intestinal wall ) , for example , prosthesis teeth from between the organs ) , bleeding and arterial thromboembolism ( blood clots in the arteries ) .'",b'the most serious side effects are gastrointestinal serotonergic salts in the qt wall .',"b'the most serious side effects are gastrointestinal perforation ( hole in the intestinal wall ) , fistula ( unnatural pipe-like connecting passages between the organs ) , bleeding and arterial thromboembolism ( blood clots in the arteries ) .'"
387,"b'bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder apotheker .'","b'if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'if you notice any side effects at this leaflet , please tell your doctor or pharmacist .'","b'if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'"
388,"b'bitte beachten sie auch die zusammenfassung der merkmale des arzneimittels ( fachinformation ) von ribavirin , wenn pegasys in kombination mit ribavirin angewendet werden soll .'","b'please also refer to the summary of product characteristics ( spc ) of ribavirin , if pegasys in combination with ribavirin is to be administered .'","b'please also refer to the summary of product characteristics spc of ribavirin , if pegasys is slightly the summary of product characteristics spc of ribavirin as if altered than section have to be administered .'","b'please also refer to the summary of product characteristics ( spc ) of ribavirin , if pegasys is coadministered in combination with ribavirin .'"
389,"b'40 % ( lacosamid 400 mg ) . es liegen keine hinreichenden daten zum absetzen der gleichzeitig angewendeten antiepileptika vor , um so eine monotherapie mit lacosamid zu erreichen .'",b'40 % ( lacosamide 400 mg / day . there are insufficient data regarding the withdrawal of concomitant antiepileptic medicinal products to achieve monotherapy with lacosamide .',b'ng mg day . there are insufficient data regarding the medical form of concomitant antiepileptic medicinal products to achieve monotherapy with lacosamide .',b'40 % ( lacosamide 400 mg / day . there are insufficient data regarding the withdrawal of concomitant antiepileptic medicinal products to achieve monotherapy with lacosamide .'
390,b'kinder die erfahrungen mit comtan bei patienten unter 18 jahren sind begrenzt .',b'children experience with comtan in patients under 18 years of age is limited .',b'children data with comtan in patients under years of age is limited .',b'children : experience with comtan in patients under 18 years of age is limited .'
391,b'nach oraler anwendung einer 125-mg-einzeldosis von aprepitant ist die cmax von aprepitant bei frauen um 16 % h\xc3\xb6her als bei m\xc3\xa4nnern .',"b'following oral administration of a single 125 mg dose of aprepitant , the cmax of aprepitant in women compared to 16 % higher in females than in males .'","b'following oral administration of a single mg dose of aprepitant , the cmax of aprepitant is mg dose is bound to greater in mortality in mortality .'","b'following oral administration of a single 125 mg dose of aprepitant , the cmax of aprepitant in women is 16 % higher than in males .'"
392,b'dar\xc3\xbcber hinaus kann das auftreten eines anaphylaktischen schocks ( schwere allergische allgemeinreaktion ) nicht ausgeschlossen werden .',"b'furthermore , the possibility of an anaphylactic shock ( a severe allergic allgemeinreaktion ) cannot be excluded .'","b'furthermore , the occurance , the possibility of an anaphylactic shock a severe allergic allgemeinreaktion cannot be excluded .'","b'furthermore , the possibility of an anaphylactic shock ( a severe allergic general reaction ) cannot be excluded .'"
393,b'wie bei anderer inhalationsbehandlung k\xc3\xb6nnen paradoxe bronchospasmen mit einer sofortigen zunahme des giemens nach der anwendung ausgel\xc3\xb6st werden .',b'as with other paradoxical bronchospasm may occur with an immediate increase in wheezing after inhalation .',"b'as with other nerve shows immunosuppressants , be carried into phosphate after oral by .'","b'as with other , inhalation treatment paradoxical bronchospasm may occur with an immediate increase in wheezing after use .'"
394,b'der arterielle blutdruck soll w\xc3\xa4hrend der sevofluran-an\xc3\xa4sthesie in kurzen abst\xc3\xa4nden \xc3\xbcberwacht werden .',b'arterial blood pressure should be monitored during the sevofluran-an\xc3\xa4sthesie intervals .',b'periodic sugar adverse infiltrates level should be checked during smaller factors .',b'arterial blood pressure should be monitored during the sevofluran-anaesthisia intervals .'
395,b'die folgenden bestandteile sind in anhang ii der verordnung ( ewg ) nr. 2377 / 90 des rates gem\xc3\xa4\xc3\x9f folgender tabelle enthalten :',b'the following annex ii of council regulation ( eec ) no 2377 / 90 in accordance with the following table :',b'the following substance ii of council regulation eec not been evaluated in sewage medicinal the following table',b'the following components are found in annex ii of council regulation ( eec ) no 2377 / 90 in accordance with the following table :'
396,b'je 1 filmtablette enth\xc3\xa4lt 1 mg entecavir .',b'each film-coated tablet contains 1 mg of entecavir .',b'each filmcoated tablet contains mg of entecavir .',b'each film-coated tablet contains 1 mg of entecavir .'
397,b'bei einem prozent der patienten kam es zu einem schweren nicht-kardiogenen lungen\xc3\xb6dem .',b'one percent of patients experienced a severe nicht-kardiogenen pulmonary oedema .',b'one lysis of patients experienced a severe oesophageal pulmonary oedema .',b'one percent of patients experienced a severe noncardiogenic pulmonary oedema .'
398,"b'diese symptome sind selten ; wenn sie auftreten , dann meistens nach 4-6 behandlungswochen .'","b'these symptoms are rare ; if they do occur , see leaflet .'","b'these symptoms are rare if they do occur , see leaflet .'","b'these symptoms are rare ; if they do occur , it is mostly after 4-6 weeks of teratment .'"
399,b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen bei manchen patienten kann es nach der anwendung von ganfort zu verschwommenem sehen kommen .',b'driving and using machines some patients may occur blurred vision occurs following the use of ganfort .',b'driving and while machines some patients may occur that you closely shortness occurs following the use of ganfort .',b'driving and using machines some patients may experience blurred vision following the use of ganfort .'
400,b'\xc3\x9cber einen zeitraum von 14 tagen nach der implantation kann bei den hunden eine m\xc3\xa4\xc3\x9fige schwellung an der implantationsstelle zu sehen sein .',b'over 14 days may be observed in dogs in a modest swelling at the centre of the dose window .',b'from days the inhalation is administered by constant out at the insulin of the n healthy b itself or hbv for follicular .',"b'over a period of 14 days after the implant , a moderate swelling may be observed in dogs at the implant site .'"
401,b'innerhalb jeder h\xc3\xa4ufigkeitsgruppe werden die nebenwirkungen nach abnehmendem schweregrad angegeben .',"b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'","b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'","b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'"
402,"b'die inzidenz an schweren oder lebensbedrohlichen blutungsereignissen unter eptifibatid war h\xc3\xa4ufig ( > 1 / 100 , < 1 / 10 ) und betrug 1,9 % gegen\xc3\xbcber 1,1 % unter placebo .'","b'the incidence of severe or life-threatening bleeding events with eptifibatide was common ( 1 / 100 , 1 / 10 ) , and was 1.9 % versus 1.1 % with placebo .'",b'the incidence of severe or lifethreatening bleeding events with total and was . versus . digoxin . versus . versus . versus . versus . posaconazole may . versus . . versus . versus . versus . versus . versus . versus . . versus . versus . versus .',"b'the incidence of severe or life-threatening bleeding events with eptifibatide was common ( 1 / 100 , 1 / 10 ) , and was 1.9 % versus 1.1 % with placebo .'"
403,b'die substanz bewirkt nur eine geringe zunahme der hirndurchblutung und stoffwechselrate und hat keinen oder einen nur sehr geringen verst\xc3\xa4rkenden einfluss auf krampfanf\xc3\xa4lle .',b'it causes only a small increase in the convulsion and toremifene metabolism thus lowering and has no or very little to additive effect on seizures ( fits or convulsions ) .',"b'a small increase in the airways and pigs and has no or very little to suggestive to vomiting or packs in the eyelids and toremifene , thus dimers .'",b'it causes only a small increase in the cerebral blood flow and metabolic rate and has none or very little intensifying effect on seizures ( fits or convulsions ) .'
404,b'eine durchstechflasche mit keppra konzentrat enth\xc3\xa4lt 500 mg levetiracetam in 5 ml ( entsprechend 100 mg / ml ) .',b'one vial of keppra concentrate contains 500 mg levetiracetam ( 5 ml ( equivalent to 100 mg / ml ) .',b'one bottle concentrate contains mg levetiracetam ml equivalent to mg the dose at',b'one vial of keppra concentrate contains 500 mg levetiracetam in 5 ml ( equivalent to 100 mg / ml ) .'
405,"b'immunantwort gegen den in pr\xc3\xa4-pandemischer influenza-impfstoff ( h5n1 ) ( spaltvirus , inaktiviert , adjuvantiert ) glaxosmithkline biologicals 3,75 \xc2\xb5g enthaltenen impfstoffstamm ( a / vietnam / 1194 / 2004 ( h5n1 ) ) :'","b'immune response against vaccine strain contained in prepandemic influenza vaccine ( h5n1 ) ( split virion , inactivated , adjuvanted ) glaxosmithkline biologicals 3.75 \xc2\xb5g ( a / vietnam / 1194 / 2004 ( h5n1 ) ) :'",b'immune response against europa differences to selective b',"b'immune response against vaccine strain contained in prepandemic influenza vaccine ( h5n1 ) ( split virion , inactivated , adjuvanted ) glaxosmithkline biologicals 3.75 \xc2\xb5g ( a / vietnam / 1194 / 2004 ( h5n1 ) ) :'"
406,b'als teil der behandlungsstrategie gegen die allergische flohdermatitis sollte das mittel in monatlichen abst\xc3\xa4nden verabreicht werden .',"b'as part of the strategy against allergic flea allergy dermatitis , the product should be administered at monthly intervals when .'",b'as part of the nca of the nca of the zevalin against allergic collection allergy rhinitis during monthly intervals to .',"b'as part of the strategy against allergic flea allergy dermatitis , the product should be administered at monthly intervals .'"
407,b'diese tritt selten auf ( 1 bis 10 behandelte von 10.000 ) .',"b'this occurs rarely ( affects 1 to 10 users in 10,000 ) .'","b'this occurs rarely affects to users in , .'","b'this occurs rarely ( affects 1 to 10 users in 10,000 ) .'"
408,b'vorgesehen sind dabei unter anderem die teilnahme an bestimmten sitzungen und lehrg\xc3\xa4ngen sowie die durchf\xc3\xbchrung spezieller konferenzen .',b'priorities in mind ( including participation in certain meetings and lehrg\xc3\xa4ngen and concomitant administration of specific conferences .',b'hypokalemia in the nature of azarga with masitinib in certain extraction and travel infestation or recommended exchange and rd seropositive for together',"b'participation in certain meetings and trainings as well as carrying out special conferences , among other things , are planned .'"
409,b'emend wurde oral 1 stunde vor beginn der chemotherapie an tag 1 sowie an den tagen 2 und 3 morgens verabreicht .',b'emend was administered orally 1 hour prior to chemotherapy treatment on day 1 and on days 2 and 3 in the morning .',b'emend was administered orally hour prior to chemotherapy treatment on day and on days to in the morning .',b'emend was administered orally 1 hour prior to chemotherapy treatment on day 1 and on days 2 and 3 in the morning .'
410,b'bei einnahme von zimulti zusammen mit nahrungsmitteln und getr\xc3\xa4nken zimulti sollte ein mal t\xc3\xa4glich morgens vor dem fr\xc3\xbchst\xc3\xbcck eingenommen werden .',"b'taking zimulti with food and drink zimulti should be taken once daily in the morning , before breakfast .'",b'taking rapamune with food and drink leading to mg .',"b'taking zimulti with food and drink zimulti should be taken once daily in the morning , before breakfast .'"
411,b'welchen nutzen hat sebivo in den studien gezeigt ?',b'what benefit has sebivo shown during the studies ?',b'what benefit has sebivo shown during the studies ?',b'what benefit has sebivo shown during the studies ?'
412,b'bei hunden mit einem k\xc3\xb6rpergewicht von weniger als 15 kg ist eine genaue dosierung nicht immer m\xc3\xb6glich .',"b'in dogs weighing less than 15 kg , accurate dosing is not always possible .'","b'in dogs weighing less than kg , cold , greatly dosing is not always possible .'","b'in dogs weighing less than 15 kg , accurate dosing is not always possible .'"
413,b'nur nach medizinischer bewertung und unter engmaschiger kontrolle von kortikosteroid -nebenwirkungen durch den arzt erfolgen .',b'after medical evaluation and under close corticosteroid -nebenwirkungen by your doctor .',b'after medical duration and under close particular s contractions by your doctor .',b'only to be follwed after medical evaluation and under close supervision ofcorticosteroid side effects by your doctor .'
414,"b'erkrankungen des immunsystems gelegentlich - urtikaria , exanthem sehr selten - anaphylaktische reaktionen symptome generalisierter \xc3\x9cberempfindlichkeit , einschlie\xc3\x9flich generalisierter hautausschlag , jucken , schwitzen , gastrointestinale st\xc3\xb6rungen , angioneurotisches \xc3\x96dem , atembeschwerden , herzklopfen , niedriger blutdruck und ohnmacht / bewusstlosigkeit .'","b'immune system disorders uncommon - urticaria , rash very rare - anaphylactic reactions symptoms of generalised hypersensitivity may include generalised skin rash , itching , sweating , gastrointestinal upset , angioneurotic oedema , difficulties in breathing , palpitation , reduction in blood pressure and fainting / loss of consciousness .'","b'immune system disorders cause rash very rare anaphylactic nausea nausea , asthenia , respiratory upset , constipation , respiratory irritation of consciousness .'","b'immune system disorders uncommon - urticaria , rash very rare - anaphylactic reactions symptoms of generalised hypersensitivity may include generalised skin rash , itching , sweating , gastrointestinal upset , angioneurotic oedema , difficulties in breathing , heart palpitation , reduction in blood pressure and fainting / loss of consciousness .'"
415,b'ihr blutzuckerspiegel kann durch viele faktoren beeinflusst werden .',b'your blood sugar level may be influenced by many factors .',b'your blood sugar level may be influenced by many factors .',b'your blood sugar level may be influenced by many factors .'
416,b'eine tablette enth\xc3\xa4lt 5 mg olanzapin .',b'each tablet contains 5 mg olanzapine .',b'each tablet contains mg olanzapine .',b'each tablet contains 5 mg olanzapine .'
417,"b'suprelorin wird in form eines implantates verabreicht , das langsam eine kontinuierliche niedrige dosis deslorelin freisetzt .'","b'suprelorin is given in a singlet , slowly on a low dose of deslorelin .'",b'kinzalkomb is rapidly immediately is as regress on a lifethreatening evaluation dose value of the zns dose of nmol .',"b'suprelorin is given in the form of an implant , that continuously releases a slowly on a low dose of deslorelin .'"
418,b's die umstellung eines patienten auf einen anderen insulintyp oder eine andere insulinmarke muss unter strenger \xc3\xa4rztlicher kontrolle erfolgen .',b'ris a patient to another type or brand transferring a patient needs to be done under close medical supervision .',b'an patient to another type or chlorambucil should be done under close medical supervision .',b'switching a patient to another type of insulin or brand of insulin needs to be done under close medical supervision .'
419,b'vereinzelte f\xc3\xa4lle von \xc3\x9cberempfindlichkeitsreaktionen einschlie\xc3\x9flich anaphylaktischer reaktionen wurden seit markteinf\xc3\xbchrung berichtet .',"b'isolated cases of hypersensitivity reactions including anaphylactic reactions , have also been reported in post marketing experience .'",b'isolated cases of hypersensitivity reactions experienced intelence were reported in widespread marketing experience .',"b'isolated cases of hypersensitivity reactions including anaphylactic reactions , have also been reported in post marketing experience .'"
420,"b'bei patienten , die einer prim\xc3\xa4ren pci unterzogen wurden , war die inzidenz von tod / re-mi bis tag 30 statistisch nicht unterschiedlich zwischen den beiden gruppen [ 6.0 % unter fondaparinux vs. 4,8 % unter kontrolle ; hazard-ratio 1,26 , 95 % -ci 0,96- 1,66 ] .'","b'in patients receiving primary pci , the incidence of death / re-mi at day 30 not statistically different between the two groups [ 6.0 % for fondaparinux vs 4.8 % is controlled ; hazard ratio 1.26 , 95 % ci , 0,96- 1.66 ] .'",b'in patients receiving primary pci antimetabolites and studied does not statistically different between the two groups .',"b'in patients who underwent pci , the incidence of death / re-mi at day 30 not statistically different between the two groups [ 6.0 % for fondaparinux vs 4.8 % is controlled ; hazard ratio 1.26 , 95 % ci , 0.96- 1.66 ] .'"
421,"b'es wurde eine signifikante verminderung in der inzidenz von vertebralen und nicht-vertebralen frakturen , aber nicht von h\xc3\xbcftfrakturen , nachgewiesen ( siehe abschnitt 5.1 ) .'","b'there was significant reduction in the incidence of vertebral and nicht-vertebralen fractures , but not hip fractures has been demonstrated ( see section 5.1 ) .'",b'there was significant reduction in the incidence of vertebral and bcnu fractures has been demonstrated see section . .',"b'there was significant reduction in the incidence of vertebral and non-vertebral fractures , but not in hip fractures ( see section 5.1 ) .'"
422,"b'240 falls sie eines oder mehrere dieser arzneimittel einnehmen , informieren sie bitte unverz\xc3\xbcglich ihren arzt .'","b'240 if you are taking any of these medicines , tell your doctor immediately .'","b'if you are taking any of these medicines , tell your doctor immediately .'","b'240 if you are taking any of these medicines , tell your doctor immediately .'"
423,b'in gezielten untersuchungen hat fluoxetin den alkoholspiegel im blut nicht erh\xc3\xb6ht und die wirkungen des alkohols nicht verst\xc3\xa4rkt .',b'in studies performed with fluoxetine has alkoholspiegel to be used for the synthesis and the effects of the drug cannot be enhanced .',"b'in studies performed with fluoxetine , oxidative hhta , similar the effects of the drug increases in the drug cannot not been possible products , an the effects of the drug cannot be initiated .'","b'in targeted studies , fluoxetine did not increase the alcohol levels in the blood and the effects of alcohol were not strengthened .'"
424,b'eine dosisanpassung aufgrund von geschlecht und ethnischer gruppe ist nicht erforderlich .',b'dose adjustment based on gender and ethnischer group is not required .',b'dose adjustment suggests on gender and ethnischer group is not completed .',b'dose adjustment based on gender and ethnic group is not required .'
425,b'anstieg der transaminasespiegel ( alt oder ast ) mit einer mittleren dauer von etwa 29 tagen .',b'increases in liver transaminase levels ( alt or ast ) with a mean duration of approximately 29 days .',b'increases in liver fab levels of the serum body among approximately days .',b'increases in liver transaminase levels ( alt or ast ) with a mean duration of approximately 29 days .'
426,b'humalog basal pen kann mit humalog gemischt oder in verbindung mit humalog angewendet werden .',b'humalog basal can be mixed with or given in conjunction with humalog .',b'humalog basal can be mixed with or given in conjunction with other person .',b'humalog basal can be mixed with or given in conjunction with humalog .'
427,"b'das bedeutet , dass es aufgrund der seltenheit der erkrankung nicht m\xc3\xb6glich war , vollst\xc3\xa4ndige informationen zu diesem arzneimittel zu erhalten .'","b'this means that because the disease is rare , it has not been possible to obtain complete information on this medicinal product .'","b'this means that because the disease is rare , it has not been possible to obtain examination information on this medicinal product .'","b'this means that because the disease is rare , it has not been possible to obtain complete information on this medicinal product .'"
428,b'sie k\xc3\xb6nnen aprovel unabh\xc3\xa4ngig von den mahlzeiten einnehmen .',b'you can take aprovel with or without food .',b'you can take invirase with or without food .',b'you can take aprovel with or without food .'
429,b'die klinische relevanz dieser beobachtung ist noch nicht v\xc3\xb6llig aufgekl\xc3\xa4rt .',b'the clinical relevance of this observation is not fully .',b'the clinical relevance of this initiated is not fully .',b'the clinical relevance of this observation is not fully clarified .'
430,b'die krankheit verursacht auch andere entz\xc3\xbcndungen im k\xc3\xb6rper .',b'the disease as well as other causes inflammation in the body .',b'the disease as well as other sticky inflammation in the body .',b'the disease also causes other inflammation in the body .'
431,"b'l. pneumophila ist in vitro hoch empfindlich gegen telithromycin , aber die klinische erfahrung mit der behandlung von legionellen-pneumonien ist begrenzt .'","b'in vitro to telithromycin , but the clinical experience of the l. pneumophila is highly susceptible .'","b'in vitro to telithromycin , but the clinical experience of the l . azithromycin is highly susceptible .'","b'l. pneumophila is highly sensitive to telithromycin in vitro , but the clinical experience of the treatment of l. pneumophila is limited .'"
432,"b'diese umfassen rheumatoide arthritis und andere autoimmunerkrankungen au\xc3\x9ferhalb der zugelassenen indikationsbereiche , einschlie\xc3\x9flich systemischem lupus erythematodes ( sle ) und vaskulitis .'",b'these include rheumatoid arthritis and other autoimmune conditions outside the approved indikationsbereiche including systemic lupus erythematosus ( sle ) and vasculitis .',b'these include secondary mutation programme looking the approved of .',b'these include rheumatoid arthritis and other autoimmune conditions outside the approved range of indicators including systemic lupus erythematosus ( sle ) and vasculitis .'
433,b'zur behandlung von entz\xc3\xbcndungen in kombination mit antibiotischer begleittherapie .',b'for the treatment of inflammation in combination with concurrent antibiotic therapy .',b'for the treatment of inflammation in combination with alzheimer antibiotic therapy .',b'for the treatment of inflammation in combination with concurrent antibiotic therapy .'
434,b'sehr selten : psychotische reaktionen .',b'very rare : very rare : psychotic reactions .',b'very rare symptoms asthenia .',b'very rare : very rare : psychotic reactions .'
435,b'die klinische erfahrung mit fosamprenavir geboostert mit ritonavir basiert haupts\xc3\xa4chlich auf drei offenen studien .',b'there is limited clinical experience with fosamprenavir boosted with ritonavir regimen is mainly based on three open-label studies .',b'there is limited clinical data with fosamprenavir such in tacrolimus and ritonavir regimen is mainly based on three openlabel studies .',b'there is limited clinical experience with fosamprenavir boosted with ritonavir regimen is mainly based on three open-label studies .'
436,b'die ribavirin-kapseln werden t\xc3\xa4glich in zwei geteilten dosen oral mit nahrung eingenommen ( morgens und abends ) .',b'the ribavirin capsules are each day in two divided doses with food ( morning and evening ) .',b'the ribavirin capsules are exact day in two divided doses with food period and evening .',b'the ribavirin capsules are divided daily into two doses with food ( morning and evening ) .'
437,b'wie muss ich masivet meinem hund verabreichen und wie lange ?',b'how should i administer masivet my dog and how long ?',b'how should i administer well my liquid and how long ?',b'how should i administer masivet to my dog and how long ?'
438,"b'in der studie mit hbeag-positiven patienten f\xc3\xbchrte eine behandlung \xc3\xbcber 48 wochen hinaus zu weiteren reduktionen der hbv-dna-serumtiter und zu einem zunehmenden anteil an patienten mit normalisierten alt-werten , hbeag-verlust und serokonversion .'","b'in the study in hbeag positive patients , 48 weeks of treatment , additional reductions in hbv-dna-serumtiter and increased the proportion of patients with helper alt , hbeag loss and seroconversion .'","b'in the study randomized increases a functional alterations , antibodies is suffer in controlled cholesterol and endogenous levels in year .'","b'in the study in hbeag positive patients , 48 weeks of treatment , additional reductions in hbv-dna-serumtiter and increased the proportion of patients with normalised alt , hbeag loss and seroconversion was carried out .'"
439,"b'elektrolytst\xc3\xb6rungen , wie z. b. hypokali\xc3\xa4mie , hypomagnesi\xc3\xa4mie oder hypokalz\xc3\xa4mie , m\xc3\xbcssen vor der behandlung mit voriconazol behoben worden sein ( siehe abschnitte 4.2 und 4.4 ) .'","b'electrolyte disturbances such as hypokalemia , hypomagnesemia and hypocalcemia should be corrected prior to treatment with voriconazole ( see sections 4.2 and 4.4 ) .'","b'buprenorphine disturbances such as familial , antiinflammatory and mirena acid blockers .'","b'electrolyte disturbances such as hypokalemia , hypomagnesemia and hypocalcemia should be corrected prior to treatment with voriconazole ( see sections 4.2 and 4.4 ) .'"
440,"b'unter verwendung einer sterilen spritze sollten langsam \xc3\xbcber einen zeitraum von 1 minute 20 ml einer 9 mg / ml ( 0,9 % ) natriumchlorid-infusionsl\xc3\xb6sung in eine abraxane-durchstechflasche injiziert werden .'","b'using a sterile syringe should be injected slowly over a period of 1 minute , 20 ml of sodium chloride 9 mg / ml ( 0.9 % ) sodium chloride for infusion or abraxane-durchstechflasche .'","b'using a sterile syringe should be injected slowly over a period of minute , ml of sodium a needle filled .'","b'using a sterile syringe , 20 ml 9 mg / ml ( 0.9 % ) sodium chloride for infusion should be injected slowly over a period of 1 minute in an abraxane vial .'"
441,"b'das ansprechen des individuellen patienten auf faktor ix kann unterschiedlich sein , da verschiedene wiederfindungsraten der in vivo erreicht und verschiedene halbwertszeiten nachgewiesen werden .'","b'responses of the individual patient response to factor ix may vary , since achieved in a variety of in vivo and various half-lives .'",b'initially of the individual patient response to factor syrup are compared to a variety of a variety of in vitro origin on a variety of in vivo and metabolism .',"b'responses of the individual patient response to factor ix may vary , since varied recovery rates were established in vivo and various half-lives .'"
442,b'wof\xc3\xbcr wird oxyglobin angewendet ?',b'what is oxyglobin used for ?',b'take what blood description used for ?',b'what is oxyglobin used for ?'
443,"b'die relevanz dieser daten f\xc3\xbcr hiv-infizierte patienten ist nicht bekannt , da der intragastrische ph-wert in dieser population h\xc3\xb6her sein kann .'","b'the relevance of these data for hiv-infected patients is unknown , since the intragastrische promoters in this population .'","b'the relevance of these data for use patients is unknown , which induced in this population .'","b'the relevance of these data for hiv-infected patients is unknown , since the intragastric ph values may be higher in this population .'"
444,b'wie ist ratiograstim aufzubewahren ? 6.',b'how to store ratiograstim',b'how to store ratiograstim',b'how to store ratiograstim ?'
445,b'seltener kann efexor die funktion ihrer blutpl\xc3\xa4tt- chen verringern und zu einem erh\xc3\xb6hten risiko f\xc3\xbcr hautblutungen ( blaue flecken ) und blutungen f\xc3\xbch- ren .',"b'less commonly , the bacteria can efexor your blutpl\xc3\xa4tt- and cause of material are present , leading to an increased risk of bruising or bleeding f\xc3\xbch- .'","b'less commonly , you can hives or hepatic suggestive with ovarian promotors as have produced , well to a hour as measles , mutations are present that as well as a sensitivity of surgical of practice or bleeding capsules are present in coffee the combination six growth of the activity'","b'less commonly , efexor can reduce the function of platelets in your blood , leading to an increased risk of bruising or bleeding .'"
446,"b'daher darf losartan patienten mit schwerer leberfunktionseinschr\xc3\xa4nkung nicht gegeben werden ( siehe abschnitte 4.2 , 4.3 und 5.2 ) .'","b'therefore , losartan should not be used in patients with severe hepatic impairment ( see sections 4.2 , 4.3 and 5.2 ) .'","b'therefore , losartan should not be used in patients with severe hepatic impairment see sections . . interaction .'","b'therefore , losartan should not be used in patients with severe hepatic impairment ( see sections 4.2 , 4.3 and 5.2 ) .'"
447,b'verwenden sie es nicht in insulinpumpen oder anderen infusionspumpen . hierf\xc3\xbcr gibt es spezielle insulin-zubereitungen .',b'do not use it in insulin pumps or other infusion pumps - special insulin preparations are available .',b'do not use it in insulin pumps or other infusion bags must be provided with the infusion preparations for insulin pumps or other infusion pumps .',b'do not use it in insulin pumps or other infusion pumps - special insulin preparations are available .'
448,b'vaniqa ist ausschlie\xc3\x9flich zur anwendung auf der haut bestimmt .',b'vaniqa is intended for use only on your skin .',b'actos is intended for use only on your skin .',b'vaniqa is intended for use only on your skin .'
449,"b'siklos ist nicht 7 westferry circus , canary wharf , london e14 4hb , uk tel .'","b'siklos is not public7 westferry circus , canary wharf , london e14 4hb , uk tel .'","b'siklos is not daily antimetabolites , microcrystalline wharf , canary wharf , london e hb , uk tel .'","b'siklos is not 7 westferry circus , canary wharf , london e14 4hb , uk tel .'"
450,"b'nachdem der chmp die antworten des unternehmens auf die ihm gestellten fragen bewertet hatte , waren immer noch einige fragen ungekl\xc3\xa4rt .'","b'after the chmp had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .'",b'after the the chmp had combined the responses from the humira and contains the psur blood rate .',"b'after the chmp had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .'"
451,b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen vivanza kann bei manchen patienten schwindel verursachen oder das sehverm\xc3\xb6gen beeinflussen .',b'driving and using machines vivanza may cause some people feel dizzy or affect their vision .',b'driving and using attention vivanza may cause some people of fructose imbalance are affect their vision .',b'driving and using machines vivanza may cause some people feel dizzy or affect their vision .'
452,b'bei hoher exposition wurden beim hund renale und gastrointestinale anomalien gesehen .',"b'at high exposure were seen in the dog , renal and gastrointestinal abnormalities .'",b'in high exposure were seen with response to frequently lead to an exact protease inflammatory and gastrointestinal abnormalities .',"b'at high exposure , renal and gastrointestinal abnormalities were seen in the dog .'"
453,"b'39 erh\xc3\xb6hungen von lebertransaminasen ( siehe abschnitt 4.4 ) , ausschlag , asthenie , erm\xc3\xbcdung und \xc3\x96deme .'","b'thirty-nine elevations of hepatic transaminases ( see section 4.4 ) , rash , asthenia , fatigue and oedema .'","b'pathologic elevations of hepatic transaminases see section . , exanthema and oedema .'","b'thirty-nine increases of hepatic transaminases ( see section 4.4 ) , rash , asthenia , fatigue and oedema .'"
454,b'in der zus\xc3\xa4tzlichen studie sprach etwa die h\xc3\xa4lfte der patienten auf das radioaktiv markierte zevalin an .',"b'in the additional study , approximately half of the patients addressed impaired and radiolabelled zevalin .'",b'in the most study in order to patients thereafter from a patients from and radiolabelled zevalin .',"b'in the additional study , approximately half of the patients responded to the radiolabelled zevalin .'"
455,b'avandamet wird bei patienten ( insbesondere \xc3\xbcbergewichtigen patienten ) mit typ-2-diabetes ( nicht insulinabh\xc3\xa4ngigem diabetes ) angewendet .',b'avandamet is used in patients ( particularly those who are overweight ) who have type 2 diabetes ( non-insulin-dependent diabetes ) .',b'avandamet is used in patients were',b'avandamet is used in patients ( particularly those who are overweight ) who have type 2 diabetes ( non-insulin-dependent diabetes ) .'
456,"b'abacavir wirkte in bakterientests nicht mutagen , zeigte aber in vitro eine aktivit\xc3\xa4t im chromosomenaberrationstest an humanen lymphozyten , im maus-lymphom-test und in vivo im mikrokern-test .'","b'abacavir was not mutagenic in bacterial tests but , like activity in an in vitro chromosomal aberration assays in human lymphocytes and human lymphocytes , mouse lymphoma , and in vivo in the mikrokern-test .'","b'abacavir was not mutagenic in bacterial tests but , infections .'","b'abacavir was not mutagenic in bacterial tests but showed an activity in vitro in the chromosomal aberration test in human lymphocytes and mouse lymphocytes , mouse lymphoma , and in vivo in the mikrokern-test .'"
457,"b'f\xc3\xbcr adjuvantien , siehe abschnitt 2.'","b'for adjuvants , see section 2 .'","b'for arabinan , see section .'","b'for adjuvants , see section 2 .'"
458,b'ektope schwangerschaften k\xc3\xb6nnen insbesondere bei frauen mit vorhergehenden tubaren st\xc3\xb6rungen vorkommen .',b'ectopic pregnancy may occur especially in women and tubaren .',b'lens pregnancy may occur such in women and tricyclic or immunomodulatory',b'ectopic pregnancy may occur especially in women with previous history of tubal disorders .'
459,b'zus\xc3\xa4tzlich k\xc3\xb6nnte w\xc3\xa4hrend einer langfristigen behandlung mit der kombination von rebetol und peginterferon alfa-2b oder interferon alfa-2b ein trockener mund einen sch\xc3\xa4digenden effekt auf die z\xc3\xa4hne und die mundschleimhaut haben .',"b'in addition , during long-term treatment with the combination of rebetol and peginterferon alfa-2b or interferon alfa-2b , dry mouth have a damaging effect on teeth and mucous membranes of the mouth .'","b'in addition , during longterm treatment with the combination of excretion and peginterferon alfab or interferon alfab , dry pain , administer into account may see blood function and body fluid body , dry depression have a estimated has a facilitated serotonin disorders of the nose .'","b'in addition , during long-term treatment with the combination of rebetol and peginterferon alfa-2b or interferon alfa-2b , a dry mouth has a damaging effect on teeth and mucous membranes of the mouth .'"
460,b'die folgenden nebenwirkungen wurden entweder mit twinrix oder mit den monovalenten hepatitis- a- oder -b-impfstoffen von glaxosmithkline berichtet :',b'the following adverse reactions have been reported with either twinrix or with glaxosmithkline monovalent hepatitis a or b 12 have been reported :',b'the following adverse reactions have been reported with either twinrix or with pasteurella and methotrexate names and nonsteroidal function have been reported',b'the following adverse reactions have been reported with either twinrix or with glaxosmithkline monovalent hepatitis a or b 12 vaccines :'
461,"b'es konnte gezeigt werden , dass docetaxel sowohl bei kaninchen als auch bei ratten embryo- und f\xc3\xb6totoxisch wirkt und bei ratten die fruchtbarkeit vermindert .'",b'it has been shown that docetaxel both in rabbits and embryo- foetotoxicity in rats and f\xc3\xb6totoxisch and fertility in rats .',b'it has been shown that docetaxel both in rabbits of rats could as metformin were also been shown that docetaxel both in rabbits demonstrable induces the age of accordance and effectively in rats .',b'it has been shown that docetaxel is phototoxic in both in rabbits and embryoa foetotoxicity in rats andreduces the fertility of .'
462,b'gemfibrozil ist deshalb besonders f\xc3\xbcr patienten mit hohen triglyceriden und / oder hdl-cholesterin angezeigt .',"b'gemfibrozil , and therefore , particularly for patients with high triglycerides and / or hdl cholesterol levels is advised .'","b'gemfibrozil , and therefore , particularly decrease , mumps and or well as shows animals and or multifocal cholesterol inhibitors see the proportion of a greater than metabolism levels see e and pagasys includes cholesterol levels is advised .'","b'gemfibrozil is , therefore , indicated particularly for patients with high triglycerides and / or hdl cholesterol levels .'"
463,b'stickstoffmonoxid wird nach dem einatmen systemisch absorbiert .',b'nitric oxide is absorbed systemically after inhalation .',b'nitric oxide is absorbed systemically after inhalation .',b'nitric oxide is absorbed systemically after inhalation .'
464,"b'basierend auf den konventionellen studien zur sicherheitspharmakologie , toxizit\xc3\xa4t bei einmaliger gabe , toxizit\xc3\xa4t bei wiederholter gabe und reproduktionstoxizit\xc3\xa4t , lassen die pr\xc3\xa4klinischen daten keine besonderen gefahren f\xc3\xbcr den menschen erkennen .'","b'based on conventional studies of safety pharmacology , repeated dose toxicity following single and repeated dose toxicity , toxicity to reproduction preclinical data reveal no special hazard for humans .'","b'based on conventional studies of safety pharmacology , repeated dose toxicity was less reported have been previously generated .'","b'based on conventional studies of safety pharmacology , toxicity following single dose and repeated dose toxicity , and toxicity to reproduction , preclinical data reveals no special hazard for humans .'"
465,"b'valtropin wurde mit dem referenzarzneimittel ( humatrope ) verglichen und ist in bezug auf qualit\xc3\xa4t ( herstellungsverfahren ) , sicherheit ( z. b. sind die nebenwirkungen , die bei einer behandlung auftreten k\xc3\xb6nnen , \xc3\xa4hnlich ) und wirksamkeit mit diesem identisch .'","b'valtropin was compared with the reference medicine ( humatrope ) and is relating to quality ( a ) , safety ( e. g. are the side effects that may occur when similar to ) and efficacy with this .'","b'valtropin was compared with the reference medicine , also pulling to the side effects that may occur when similar to interferon tablets that may occur when similar to and on were in the other therapy as are administered on less therapy , their market to monitor the side effects that'","b'valtropin was compared with the reference medicine ( humatrope ) and is relating to quality ( a ) , safety ( e. g. are the side effects that may occur during treatment similar ) and efficacy with this .'"
466,b'wie bei jeder oralen verabreichung wird der wirkstoff einem first- pass-effekt unterzogen .',"b'as with any oral administration , the active substance a first pass pass-effekt .'","b'as with any oral administration , the active substance a first rising travel intakes .'","b'as with any oral administration , the active substance undergoes a first pass effect .'"
467,"b'ein m\xc3\xb6gliches risiko beim menschen w\xc3\xa4hrend der schwangerschaft ist nicht bekannt , kann aber nicht ausgeschlossen werden .'","b'one of the potential risk for humans during pregnancy is not known , but cannot be excluded .'","b'as dilute , toxic animals may available as a minor therapeutic product .'","b'one of the potential risk for humans during pregnancy is not known , but cannot be excluded .'"
468,b'sehr h\xc3\xa4ufige nebenwirkungen sind in den tabellen 1 und 2 aufgef\xc3\xbchrt . nebenwirkungen mit anderen h\xc3\xa4ufigkeitskategorien sind unten zusammengefasst .',b'very common side effects are summarised below in tables 1 and 2 below adverse reactions with other the reporting rates are classified .',b'very common side effects are summarised below in tables and below adverse reactions with other the surface was recorded .',b'very common side effects are listed in tables 1 and 2 . side effects with other frequency categories are summarised below .'
469,b'in s\xc3\xa4mtlichen klinischen pr\xc3\xbcfungen wurde bevacizumab als i.v. infusion appliziert .',b'in all clinical trials of bevacizumab iv infusion .',b'in all clinical trials of vivo iv infusion .',b'in all clinical trials of bevacizumab iv infusion .'
470,b'die injektionsstelle mit einem alkoholtupfer reinigen und omnitrope durch subkutane injektion verabreichen .',b'the injection site with an alcohol wipe to clean and omnitrope is given by subcutaneous injection .',b'the injection site with an alcohol wipe to clean and omnitrope is given by subcutaneous injection period .',b'the injection site with an alcohol wipe to clean and omnitrope is given by subcutaneous injection .'
471,"b'fsh ( 0,38 ml ) . falls ihr arzt nach 4-w\xc3\xb6chiger behandlung keinen erfolg feststellt , muss dieser behandlungszyklus abgebrochen werden .'","b'fsh ( 0.38 ml ) solution for injection . if your doctor cannot see a response after 4 weeks of treatment , that treatment cycle should be stopped .'","b'fsh . ml solution for injection . if your doctor cannot see a response after weeks of treatment , that treatment .'","b'fsh ( 0.38 ml ) . if your doctor cannot see a response after 4 weeks of treatment , that treatment cycle should be stopped .'"
472,b'28 verd\xc3\xbcnnung vor infusion :',b'28 dilution before infusion :',b'dilution before infusion',b'28 dilution before infusion :'
473,"b'zu einer hypoglyk\xc3\xa4mie kommen . bei patienten , deren blutzuckereinstellung z.'","b'hypoglycaemia may occur in patients whose blood glucose control is greatly improved , e. g .'",b'hypoglycaemia may occur in patients whose control of a minor insulin level .',"b'hypoglycaemia may occur in patients whose blood glucose control is greatly improved , e. g .'"
474,"b'es kann anderen menschen schaden , auch wenn diese die selben symptome haben wie sie .'","b'it may harm them , even if their symptoms are the same as yours .'","b'it may harm others , even if their symptoms are the same as yours .'","b'it may harm them , even if their symptoms are the same as yours .'"
475,b'f\xc3\xbcr erwachsene mit leichter leberfunktionsst\xc3\xb6rung ( child-pugh score :',b'for adult patients with mild hepatic impairment ( child-pugh score :',b'for adult patients with mild hepatic impairment childpugh score',b'for adult patients with mild hepatic impairment ( child-pugh score :'
476,"b'nach der ersten anwendung muss die patrone im pen verbleiben und muss im k\xc3\xbchlschrank gelagert werden ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) , f\xc3\xbcr h\xc3\xb6chstens 28 tage .'","b'after first use , the cartridge in the pen and should be stored in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) for a maximum of 28 days .'","b'after first use , the cartridge in the pen and should be stored in a refrigerator c c for a administered .'","b'after first use , the cartridge must remain in the pen and should be stored in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) for a maximum of 28 days .'"
477,"b'bei einnahme oder absetzen dieser arzneimittel m\xc3\xbcssen patienten , die nateglinid erhalten , bez\xc3\xbcglich einer \xc3\x84nderung ihres glukosespiegels besonders sorgf\xc3\xa4ltig \xc3\xbcberwacht werden .'",b'taking or withdrawal of these drugs must be patients who are receiving nateglinide to control the level of change their be followed closely .',"b'taking or withdrawal of these drugs if your doctor immediately out to this , them no concomitant caution or such , therefore their or monitoring of change have been performed .'",b'patients receiving nateglinide must be especially carefully monitored for changes in their glucose levels when taking or stopping these drugs .'
478,b'imprida und \xc3\xa4ltere menschen bei einer dosiserh\xc3\xb6hungen ist vorsicht angezeigt .',b'imprida and older people caution is required when increasing the dosage .',b'eucreas and older people during the dosage .',b'imprida and older people . caution is required when increasing the dosage .'
479,"b'nach der infusion nahm die enzymaktivit\xc3\xa4t im plasma mit einer halbwertzeit von 3,6 bis 10,4 min. rasch ab .'",b'after the infusion of the adopted in plasma with a half-life of 3.6 to 10.4 -steroid rapidly .',b'after the infusion of the rsv of the evaluation of the dosing of the nonplasma mg concentration of the extent of . to . .',"b'after the infusion , enzyme activity in the plasma decreased rapidly with a half life time of 3.6 to 10.4 minutes .'"
480,"b'die interindividuelle variabilit\xc3\xa4t war hoch , mit einer bis zu 7fachen differenz in den auc-werten des nicht gebundenen anteils zwischen den einzelnen patienten .'","b'the inter-subject variability was large , with up to a 7-fold difference in auc values or the proportion of the patients .'","b'the mghartkapsel variability was large , with up to a fold difference from plasma molecular parameters at auc values or the proportion of the patients .'","b'the inter-subject variability was large , with up to a 7-fold difference in auc values or the proportion of the patients .'"
481,b'bei einigen patienten bildeten sich die hautl\xc3\xa4sionen an den ellbogen nach einer reduktion der cystagon-dosis zur\xc3\xbcck .',"b'in some patients , the skin lesions on elbows regressed after cystagon dose reduction .'","b'in some patients , the skin lesions on acarbose regurgitation to the vaccine symptoms on haemodialysed doripenem after watery led to normal receptors .'","b'in some patients , the skin lesions on elbows regressed after cystagon dose reduction .'"
482,b'198 und symptome einer entz\xc3\xbcndung von zur\xc3\xbcckliegenden infektionen auftreten .',b'198 and symptoms of inflammation from previous infections may occur .',b'and symptoms of valtropin infections may occur .',b'198 and symptoms of inflammation from previous infections may occur .'
483,"b'metformin nicht zu empfehlende kombinationen wegen des wirkstoffs metformin in zomarist besteht bei akuter alkoholintoxikation ein erh\xc3\xb6htes risiko f\xc3\xbcr eine laktatazidose ( besonders im zusammenhang mit fasten , mangelern\xc3\xa4hrung oder leberinsuffizienz , siehe abschnitt 4.4 ) .'","b'metformin combinations not recommended there is due to the metformin active substance of zomarist is an increased risk of lactic acidosis in acute alcohol intoxication , particularly in the case of fasting , malnutrition or hepatic insufficiency ) ( see section 4.4 ) .'","b'metformin is not recommended no formation of urgent acidosis in some glucose arrhythmia , particularly in the case of the bone case of hyperkalaemia and hepatic insufficiency see section .'","b'metformin : combinations not recommended . due to the active substance of metformin in zomarist , there is an increased risk of lactic acidosis in acute alcohol intoxication , particularly in the case of fasting , malnutrition or hepatic insufficiency ( see section 4.4 ) .'"
484,b'der zeitabstand zwischen dem pneumokokken -konjugatimpfstoff ( prevenar ) und dem 23-valenten pneumokokken-polysaccharidimpfstoff sollte nicht weniger als 8 wochen betragen .',b'the interval between the pneumococcal conjugate vaccine ( prevenar ) and the 23-valent pneumococcal pneumokokken-polysaccharidimpfstoff should not be less than 8 weeks .',b'the symptomatic state t metformin has not be less than weeks .',b'the interval between the pneumococcal conjugate vaccine ( prevenar ) and the 23-valent pneumococcal pneumokokken-polysaccharidimpfstoff should not be less than 8 weeks .'
485,"b'es gab keine signifikanten ver\xc3\xa4nderungen der ekg-werte , und es wurde keine digoxintoxizit\xc3\xa4t beobachtet .'",b'there were no significant changes in ecg parameters and no digoxintoxizit\xc3\xa4t have been observed .',b'there were no significant changes in ecg parameters and no endometrium have been observed .',b'there were no significant changes in ecg parameters and no digoxin toxicity was been observed .'
486,b'die behandlung einer \xc3\x9cberdosierung sollte auf die erhaltung der vitalfunktionen abzielen .',b'treatment of overdose should be used for the treatment of vital signs .',b'treatment of overdose should be used for the treatment of vital signs without few side .',b'treatment of overdose should be directed at maintaining vital functions .'
487,"b'vor der behandlung mit bisphosphonaten sollte bei patienten mit gleichzeitig vorhandenen risikofaktoren ( z. b. tumoren , chemotherapie , kortikosteroide , mangelhafte mundhygiene ) eine zahn\xc3\xa4rztliche untersuchung mit angemessenen prophylaktischen zahnmedizinischen ma\xc3\x9fnahmen erwogen werden .'","b'before treatment with bisphosphonates should not be used in patients with concomitant underlying risk factors ( e. g . , chemotherapy , corticosteroids , poor oral hygiene ) a dental examination with appropriate preventive babies decoded measures should be considered .'","b'before treatment with bisphosphonates should not be used in patients with concomitant underlying incidence factors e . g . , chemotherapy , corticosteroids , corticosteroids , heart oral kompatibilitatsstudien impaired abstinence taking alzheimer cytostatic pathogens should be considered . g . , adefovir oral et suddenly c problems for therapy'","b'before treatment with bisphosphonates , a dental examination with appropriate prophylactic dentistry measures should be considered in patients with concomitant underlying risk factors ( e. g . , chemotherapy , corticosteroids , poor oral hygiene ) .'"
488,b'f\xc3\xbcr busilvex wird folgende dosierung empfohlen :',b'the recommended dose for busilvex :',b'the recommended dose for busilvex',b'the recommended dose for busilvex :'
489,"b'aufgrund von unerw\xc3\xbcnschten ereignissen brachen in dieser studie 12,9 % der fablyn-patientinnen und 12,3 % der plazebo-patientinnen die therapie ab .'",b'due to adverse events in this study withdrew 12.9 % of fablyn-treated women and 12.3 % of placebo-treated women therapy .',"b'due to adverse events in this study , . of fablyntreated women and . of placebotreated women .'",b'due to adverse events in this study 12.9 % of fablyn-treated patients and 12.3 % of placebo-treated patients withdrew from the therapy .'
490,"b'es wird die schlussfolgerung gezogen , dass das nutzen-risiko-verh\xc3\xa4ltnis von crestor 5 mg oder crestor 10 mg als alternative anfangsdosis g\xc3\xbcnstig ist .'","b'it is concluded that the benefit / risk ratio of crestor 5 mg or crestor 10 mg as the starting dose , alternative is favourable .'","b'it is concluded that the benefit risk ratio of crestor mg or rapamune mg as the starting dose , known .'",b'it is concluded that the benefit / risk ratio of crestor 5 mg or crestor 10 mg is favourable as the starting dose .'
491,"b'zus\xc3\xa4tzlich war die systemische clearance bei j\xc3\xbcngeren patienten h\xc3\xb6her und verringerte sich mit dem lebensalter , bis um das 12. lebensjahr herum die erwachsenenwerte erreicht wurden .'","b'in addition , systemic clearance was higher in younger patients and decreased with age , is 12 years of erwachsenenwerte were achieved .'","b'in addition , systemic clearance was higher in current was compared to the use of trocoxil were achieved .'","b'in addition , systemic clearance was higher in younger patients and decreased with age , until 12 years of age the adult values were achieved .'"
492,"b'betrachtet man jedoch die 381 patienten , die zu beginn der studie besonders hohe eisenkonzentrationen in der leber aufwiesen und vergleichbare mengen an exjade oder deferoxamin erhalten hatten , so waren beide arzneimittel gleicherma\xc3\x9fen wirksam .'","b'looking at the 381 patients who are extremely high iron concentration in the liver of patients at the start of the study and similar amounts of exjade or deferoxamine , who had previously received in both medicinal products were equally effective .'","b'as , is , a free number in widespread go with the study and similar amounts of salbutamol , study had previously received fluid failure above place have been increased the proportions sildenafil .'","b'looking at the 381 patients who showed extremely high iron concentration in the liver at the start of the study and similar amounts of exjade or deferoxamine , both medicinal products were equally effective .'"
493,b'ge keine ver\xc3\xa4nderungen beim lernverhalten oder am ged\xc3\xa4chtnis .',"b'au no changes on learning or memory , but equivocal .'","b'thyroid changes on extra or ohss , but named .'",b'no changes on learning or memory .'
494,"b'die derzeit verf\xc3\xbcgbaren daten von patienten mit pi-basierter antiretroviraler therapie zeigen , dass ein wechsel zu atripla zu einer verminderung des therapieansprechens f\xc3\xbchren kann ( siehe abschnitt 5.1 ) .'",b'the currently available data in patients with pi-basierter antiretroviral therapy show that a switch to atripla may result in a reduction in hbv clearance during therapy ( see section 5.1 ) .',b'the currently available data in patients with reduced antiretroviral therapy show that a infant of a reduction in hbv clearance during therapy see section . .',b'the currently available data in patients with pi-based antiretroviral therapy show that a switch to atripla may result in a reduction in hbv clearance during therapy ( see section 5.1 ) .'
495,"b'die dosierung , art und dauer der anwendung entsprechen den angaben f\xc3\xbcr erwachsene im alter von 18 bis 64 jahren .'",b'the posology and method of administration statements reflect in adults aged 18 to 64 years of age .',b'the dosage and novoseven of administration art reflect in adults aged to years of age .',"b'the posology , method and length of administration corresponded with the data for adults aged 18 to 64 years of age .'"
496,b'es wurde ein zusammenhang zwischen der viszeralen lipomatose und proteasehemmern ( pi ) sowie der lipoatrophie und nukleosidanalogen reverse-transkriptase-hemmern ( nrti ) hergestellt .',b'a a connection between visceral lipomatosis and protease inhibitors ( pis ) and lipoatrophy and nucleoside reverse transcriptase inhibitors ( nrtis ) .',"b'a turns tumour and protease cox disoproxil cells was lipoatrophy , is decreased and nucleoside code transcriptase inhibitors nrtis .'",b'a connection between visceral lipomatosis and protease inhibitors ( pis ) as well as lipoatrophy and nucleoside reverse transcriptase inhibitors ( nrtis ) have been produced .'
497,"b'schwangerschaft und stillzeit informieren sie ihren arzt , wenn sie schwanger sind oder stillen .'",b'pregnancy and breast-feeding tell your doctor if you are pregnant or breast feeding .',b'pregnancy and breastfeeding . tell your doctor if you are pregnant or breast feeding .',b'pregnancy and breast-feeding : tell your doctor if you are pregnant or breast feeding .'
498,"b'des weiteren ergeben sich aus diesen daten keine hinweise auf ein missbildendes toxizit\xc3\xa4tspotential durch cerezyme f\xc3\xbcr den fetus , trotz der begrenzten statistischen nachweise .'","b'furthermore , despite the limited statistical evidence on the results of these data , there was no evidence of missbildendes toxizit\xc3\xa4tspotential cerezyme due to the potential hazard to the foetus .'","b'furthermore , emtricitabine the efficacy urgent evidence in the results of these data indicates the guideline due to the potential is not be no evidence of breeding treatment of varicella halothane hungary due to the potential hazard to the foetus .'","b'furthermore , despite the limited statistical evidence on the results of these data , there was no evidence of malformed toxicity potential cerezyme for the foetus .'"
499,"b'halofantrin ) , antikonvulsiva ( z. b. carbamazepin , phenytoin und phenobarbital ) , calciumkanalblockern ( z.'","b'halofantrine ) , anticonvulsants ( e. g. carbamazepine , phenytoin and phenobarbital ) , calcium channel blockers ( e. g .'","b'gabapentin , anticonvulsants relapse examples are cmv monohydrogenphosphate stimulated lh , heparin and phenobarbital , calcium channel blockers e . g .'","b'halofantrine ) , anticonvulsants ( e. g. carbamazepine , phenytoin and phenobarbital ) , calcium channel blockers ( e. g .'"
500,b'erkrankungen des ohrs und des labyrinths selten :',b'ear and labyrinth disorders rare :',b'ear and labyrinth disorders rare',b'ear and labyrinth disorders rare :'
501,b'einheiten tenecteplase . eine fertigspritze enth\xc3\xa4lt 8 ml wasser f\xc3\xbcr injektionszwecke .',b'units of tenecteplase . one pre-filled syringe contains 8 ml water for injections .',b'units of tenecteplase . one prefilled syringe contains ml water for injections .',b'units of tenecteplase . one pre-filled syringe contains 8 ml water for injections .'
502,"b'falls die thoraxr\xc3\xb6ntgenuntersuchung lungeninfiltrate zeigt oder lungenfunktionsst\xc3\xb6rungen bestehen , sollte der patient engmaschig kontrolliert und , falls 158 angebracht , die behandlung mit interferon-alfa abgebrochen werden .'","b'if the thoraxr\xc3\xb6ntgenuntersuchung chest x-ray shows pulmonary infiltrates or evidence of pulmonary function impairment , the patient is to be monitored closely , and , if appropriate , 158 discontinued , treatment with interferon alpha .'","b'if the focal xray shows pulmonary infiltrates or evidence of pulmonary function impairment , the treatment of pulmonary function impairment , the patient is to be monitored for age . if the treatment on methotrexate , which is to be vaccinated closely , and , if appropriate , is discontinued'","b'if the ribcage x-ray shows pulmonary infiltrates or there is evidence of pulmonary function impairment , the patient is to be monitored closely , and , if appropriate , 158 discontinued , treatment with interferon alpha .'"
503,b'4. welche nebenwirkungen sind m\xc3\xb6glich ? 5.',"b'4 . "" possible side effects 5 how to store atryn 6 .'",b'. how how jalra are possible ?',b'4 . possible side effects ?'
504,b'72 bei anwendung von viramune in kombination mit anderen antiretroviralen mitteln sind auch folgende erscheinungen aufgetreten :',b'72 using viramune is used in combination with other antiretroviral agents should also have experienced the following manifestations :',b'using viramune is used in combination with other antiretroviral agents should also been taken in combination with other antiretroviral agents should also have not been temporary to treatment with other number of comtess function .',b'72 using viramune in combination with other antiretroviral agents has also experienced the following manifestations :'
505,"b'patientinnen , die trotzdem an komplizierten neutropenien litten , sollten weiterhin g-csf bekommen bei gleichzeitiger reduktion der docetaxel-dosis auf 60 mg / m \xc2\xb2 .'",b'patients who are complicated neutropenia who should continue to get g-csf with a reduction in the docetaxel dose to 60 mg / m2 .',b'patients who are scissors was connected to usually hepatic levels is received antiepileptic .',b'patients who are complicated neutropenia who should continue to get g-csf with a reduction in the docetaxel dose to 60 mg / m2 .'
506,b'diese ergebnisse wurden bei klinisch relevanten expositionen beobachtet .',b'these results were seen at clinically relevant exposure levels were observed .',b'these results were seen at clinically relevant exposure . interaction of growth parkinson rate of approximately between levels were observed .',b'these results were seen at clinically relevant exposure levels .'
507,"b'da jedoch weniger patienten , die humira mit methotrexat erhielten , antik\xc3\xb6rper entwickelten , sprechen die ergebnisse eher f\xc3\xbcr die anwendung von humira mit methotrexat als von humira in monotherapie .'","b'however , fewer patients taking humira and methotrexate received developed antibodies , the results of which shall be more likely to methotrexate than with humira monotherapy for the use of humira .'","b'however , fewer patients taking humira and methotrexate received autologous monotherapy for the use of humira is used during the use of humira'","b'however , fewer patients taking humira and methotrexate received developed antibodies , the results of which shall be more likely due to the use of humira with methotrexate than the use of humira in monotherapy .'"
508,b'diese wirkung wurde nur unter hoher dosierung bei nagern festgestellt .',b'these effects were high doses in rodents was noted .',b'these effects were high doses in rodents observed .',b'these effects were only noted in high doses in rodents .'
509,"b'vor beginn einer interferon alfa-2b- therapie , muss der tsh-spiegel bewertet und jegliche zu diesem zeitpunkt festgestellte schilddr\xc3\xbcsenerkrankung mit einer konventionellen therapie behandelt werden .'","b'prior to initiation of interferon therapy , tsh levels must be evaluated and any thyroid abnormality detected at that time treated with conventional therapy .'","b'prior to initiation of interferon therapy , tsh electrolytes value levels must prescribed'","b'prior to initiation of interferon alfa-2b therapy , tsh levels must be evaluated and any thyroid abnormality detected at that time treated with conventional therapy .'"
510,"b'farblose glasflasche ( typ i glas ) , verschlossen mit einem brombutyl-gummi-infusionsstopfen , einer plastik-kappe und einer aluminiumkappe .'","b'colourless glass vial ( type i glass ) closed with a brombutyl-gummi-infusionsstopfen , a plastik-kappe ) with rubber stopper and aluminium cap .'","b'colourless glass vial type i glass closed with a aluminium vial with rubber stopper and aluminium cap of contaminant rubber stopper and aluminium cap and aluminium cap with increase , a administration of packs with a blister tube with a implantable closure with rubber stopper and aluminium cap .'","b'colourless glass vial ( type i glass ) closed with a bromobutyl rubber infusion stopper , a plastic cap and aluminium cap .'"
511,"b'das arzneimittel wird angewendet , wenn davon ausgegangen wird , dass bei dem patienten ein hohes risiko f\xc3\xbcr die entwicklung von ms besteht .'",b'it is used when is considered in patients with a high risk for the development of ms.',b'it is used when is considered in patients with a high risk for the development of ms .',b'it is used when it is presumed that there is a high risk of the development of ms in the patient .'
512,"b'die gesamtkonzentration von pioglitazon im plasma bleibt unver\xc3\xa4ndert , aber das verteilungsvolumen nimmt zu .'","b'pioglitazone plasma concentration is unchanged , but with an increased volume of distribution .'","b'pioglitazone plasma concentration is unchanged , but , the increased volume of distribution .'","b'pioglitazone plasma concentration is unchanged , but with an increased volume of distribution .'"
513,b'sustiva l\xc3\xb6sung zum einnehmen weist im mg / mg-vergleich eine geringere bioverf\xc3\xbcgbarkeit auf als die hartkapsel .',b'sustiva oral solution in mg is less bioavailable than a lower bioavailability compared to the capsule .',b'sustiva oral solution in mg is less rearranged than a lower bioavailability compared to the capsule .',b'sustiva oral solution is less bioavailable on a mg per mg basis compared to the capsule .'
514,b'erbitux wird bei s\xc3\xa4mtlichen indikationen einmal w\xc3\xb6chentlich verabreicht .',b'erbitux is given once weekly in all indications .',b'egive well weekly in all areas chosen .',b'erbitux is given once weekly in all indications .'
515,b'die rei\xc3\x9ffestigkeit von kondomen und scheidenpessaren k\xc3\xb6nnte durch imiquimod-creme beeintr\xc3\xa4chtigt werden . deshalb wird die gleichzeitige anwendung von imiquimod-creme mit diesen verh\xc3\xbctungsmitteln nicht empfohlen .',"b'the accumulated array and scheidenpessaren may be affected by imiquimod cream . therefore , the concomitant administration of imiquimod cream with these contraceptives is not recommended .'",b'the jar amount an bleeding than by imiquimod cream to no optimal level cream are not recommended .',"b'the tear resistance of condoms and female condoms may be affected by imiquimod cream . therefore , the concomitant administration of imiquimod cream with these contraceptives is not recommended .'"
516,b'diese hiv-1-mutation wurde sowohl in vitro als auch bei hiv-1-infizierten patienten beobachtet .',b'these hiv-1-mutation has been observed both in vitro and in hiv-1 infected patients .',b'these phenotypic no medicinal functioning doses in vitro studies have been observed both in vitro and in hiv infected patients .',b'these hiv-1-mutation has been observed both in vitro and in hiv-1 infected patients .'
517,b'im anschluss an eine assistierte reproduktionstechnik ( art ) k\xc3\xb6nnte das vorkommen von missbildungen gr\xc3\xb6\xc3\x9fer sein als nach spontaner konzeption .',b'following an assistierte reproduktionstechnik antiretroviral therapy ( cart ) may be less effective in lowering the malformations may be greater than that of a natural spontaneous .',"b'following an minor bovine higher antiretroviral therapy cart may be less effective in secondary tissues first a injection of a body , high doses glucose through host week acid did not been approximately patients in lennoxgastaut doses checks may be less influence in secondary sample or vomiting by continuous exposure'",b'following an assisted reproduction technique ( art ) the presence of malformations may be greater than after natural conception .'
518,b'eine reduzierte schreckreaktion auf akustische reize wurde bei \xc3\x9cberschreiten der 2fachen therapeutischen humandosis bei jungen ratten nach 1 bis 2 wochen beobachtet .',b'reduced schreckreaktion flowers and pga was greater than 2 times the human therapeutic dose in young rats were observed after 1 to 2 weeks .',"b'reduced overdosing , pretreated to the elimination of the long dose was observed after increased rats were observed after the a tachyphylaxis concentration than humans that increase with combination of the urine value are received the human therapeutic dose in young rats has well after the normal therapeutic dose in'",b'a reduced startled reaction to acoustic stimulus was observed in young rats under doses of greater than 2 times the human therapeutic dose after 1 to 2 weeks .'
519,"b'er wirkt durch hemmung des enzyms phosphodiesterase , das gew\xc3\xb6hnlich eine substanz , das so genannte zyklische guanosinmonophosphat ( cgmp ) , abbaut .'","b'it works by blocking the phosphodiesterase enzyme , which normally breaks down a substance , cyclic guanosine monophosphate ( cgmp ) called phosphodiesterase enzyme .'","b'it works well which normally sufficiently down a substance , rackheath guanosine monophosphate cgmp called a absorption active kirsten fasting cgmp called glucosylceramid parahydroxybenzoate receptor .'","b'it works by blocking the phosphodiesterase enzyme , which normally breaks down the substance cyclic guanosine monophosphate ( cgmp ) .'"
520,b'intelence kann ohne dosisanspassungen gleichzeitig mit h2-rezeptor- antagonisten verabreicht werden .',b'intelence can be co-administered with h2-rezeptor- antagonists without dosisanspassungen .',b'intelence can be coadministered with occlusive count without dose should be administered with occlusive antagonists without dose adjustments .',b'intelence can be co-administered with h2 receptor antagonists without adjustments to the dosage .'
521,"b'in schweren f\xc3\xa4llen , die die hilfe dritter erfordern , kann eine glucoseinfusion notwendig sein .'","b'in severe cases , require assistance , someone else takes a glucoseinfusion may be necessary .'","b'in severe cases , require precautionary weaning , carbohydrates that the concentration .'","b'in severe cases , glucose infusion may require help from another person .'"
522,b'vorzugsweise sollte die anwendung von ciprofloxacin bayer w\xc3\xa4hrend der schwangerschaft vermieden werden .',b'it is preferable to avoid the use of ciprofloxacin bayer during pregnancy should be avoided .',b'it is preferable to avoid the use of ciprofloxacin bayer during pregnancy should be avoided .',b'it is preferable to avoid the use of ciprofloxacin bayer during pregnancy .'
523,"b'patienten , die mit cumarin-antikoagulantien behandelt werden , m\xc3\xbcssen deshalb zu beginn oder bei beendigung der behandlung mit glucosamin engmaschig \xc3\xbcberwacht werden .'","b'patients receiving coumarin anticoagulants , should be closely monitored after initiation or discontinuation of treatment with glucosamine .'",b'patients receiving coumarin childpugh differnet therapy in all medicine .',b'patients receiving coumarin anticoagulants should be closely monitored after initiation or discontinuation of treatment with glucosamine .'
524,"b'legen sie fest , an welchen beiden wochentagen sie das pflaster wechseln werden , und wechseln sie das pflaster immer an den beiden gleichen w ochentagen .'","b'do not put firmly , on the same two days to change your patch , and to change your patch on the same two w ochentagen .'","b'arrange replace the pushbutton . the ears usually catch develops particles after place into the same two days to change your patch and thus have possible , it level for the same two dosing evaluation .'","b'decide on the same two days to change your patch , and always change your patch on the same two days .'"
525,"b'42 / 44 dieses tierarzneimittel enth\xc3\xa4lt amitraz , das bei menschen und besonders bei kindern zu neurologischen nebenwirkungen f\xc3\xbchren kann .'","b'42 / 44 this product contains amitraz , in humans and especially in children , which can lead to adverse neurological effects .'","b'this product contains urea , in humans and especially in children , which can lead to adverse reactions occurred .'","b'42 / 44 this product contains amitraz , which in humans , and especially in children , can lead to neurological side effects .'"
526,b'einleitung 1. schritt :',b'introduction step 3 : 1 .',b'introduction step .',b'introduction step 3 : 1 .'
527,b'wie ist lansoprazol abz 30 mg einzunehmen ? 4.',b'how to take lansoprazol abz 4 .',b'how to take merkblatt mg .',b'how to take lansoprazol abz 30 mg . 4 .'
528,"b'in plazebo-kontrollierten studien wurde keine zunahme der h\xc3\xa4ufigkeit von schwerwiegen den infektionen ( letale , lebensbedrohliche oder eine station\xc3\xa4re behandlung bzw. intraven\xc3\xb6se antibiotika-gabe erfordernde infektionen ) beobachtet .'","b'in placebo-controlled trials , no increase in the incidence of schwerwiegen the infections ( fatal , life threatening , hospitalisation or requiring hospitalisation or intravenous antibiotics ) were seen .'",b'in placebocontrolled trials were significant improvement in the incidence of catecholamines the infections in there received oxygen reduced or alzheimer antibiotics were seen .',"b'in placebo-controlled trials , no increase in the incidence of severe infections ( fatal , life threatening , or inpatient treatment or intravenous antibiotic use if necessitated by the infection ) were seen .'"
529,"b'voriconazol wird durch die cytochrom-p450-isoenzyme , cyp2c19 , cyp2c9 und cyp3a4 metabolisiert .'","b'voriconazole is metabolised by cytochrome p450 isoenzymes , cyp2c19 , cyp2c9 and cyp3a4 .'","b'voriconazole is metabolised by cytochrome p isoenzymes , cypc and cypa .'","b'voriconazole is metabolised by cytochrome p450 isoenzymes , cyp2c19 , cyp2c9 and cyp3a4 .'"
530,b'w\xc3\xa4hrend der beurteilung des arzneimittels wurde der antrag allerdings zur\xc3\xbcckgezogen .',"b""during the medicine 's assessment of the application was , however , varied , suspended or withdrawn .""",b'during the medicine s assessment of the amino instructions on the surface in regular mask or therefore and bacteria not be the effect .',"b'during the assessment of the medicine , the application was , however , withdrawn .'"
531,"b'dieses arzneimittel enth\xc3\xa4lt weniger als 1 mmol ( 23 mg ) natrium pro dosis , d. h. , es ist nahezu "" natriumfrei . ""'","b'this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. it is essentially "" sodium-free . ""'",b'this medicinal product contains less than mmol sodium of lansoprazole . and sodium sodiumfree .',"b'this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. it is essentially "" sodium-free . ""'"
532,b'patientenerinnerungskarte \xe2\x80\xa2 diese muss klare hinweise auf die notwendigkeit regelm\xc3\xa4\xc3\x9figer blutuntersuchungen und schwangerschaftstests enthalten und freie felder zum eintragen der vereinbarten untersuchungstermine und der testergebnisse enthalten .',b'patientenerinnerungskarte \xe2\x80\xa2 this should include key messages regarding the need for regular blood tests and pregnancy tests for the dates of the patient as part of an agreed untersuchungstermine and the results of these tests .',b'strontium this should include persons with the measure of the indication .',b'patient reminder cards \xe2\x80\xa2 this should include key messages regarding the need for regular blood tests and pregnancy tests for the dates of the patient as part of an agreed appointments and the results of these tests .'
533,b'einzelheiten zur verd\xc3\xbcnnung siehe abschnitt 6.6 .',"b'details for dilution , see section 6.6 .'","b'epivir for dilution , see section . .'","b'details for dilution , see section 6.6 .'"
534,"b'maximale serumkonzentrationen im bereich von 0,3-5,9 mg / l werden innerhalb von 0,5-2 stunden nach verabreichung von 50-1.000 mg p.o. erzielt .'","b'maximum serum levels of 0,3-5,9 mg / l are reached within 0.5 to 2 hours after administration of small cell lunger cancer po .'",b'maximum serum serum serum levels of the plasma serum levels of anidulafungin value . between . to hours after administration of small cell propionate was .',"b'maximum serum levels in the area of of 0 , 3-5 , 9 mg / l are reached within 0.5 to 2 hours after administration of 50-1.000 mg p.o.'"
535,b'in diesem abschnitt wird das injizieren von litak erl\xc3\xa4utert .',b'in this section is on how to inject litak .',b'do not miss prepared the suspension intended within connection .',"b'in this section , how to inject litak is explained .'"
536,b'dieser metabolit ist pharmakologisch inaktiv .',b'this metabolite is pharmacologically inactive .',b'this metabolite is increased inactive .',b'this metabolite is pharmacologically inactive .'
537,b'nevirapin passiert die plazentaschranke und tritt in die muttermilch \xc3\xbcber .',b'nevirapine diffuses across the placenta and is excreted in human milk .',b'nevirapine days the placenta and is excreted in human milk .',b'nevirapine passes the placental barrier and is excreted in human milk .'
538,"b'wenn andere levodopa pr\xc3\xa4parate gleichzeitig mit stalevo-tabletten angewendet werden , sind die empfehlungen zur h\xc3\xb6chstdosis zu befolgen .'","b'if other levodopa products are used concomitantly with stalevo tablets , the highest dosage recommendations should be followed .'","b'if other levodopa product are used concomitantly with stalevo tablets , the highest dosage recommendations should be followed .'","b'if other levodopa products are used concomitantly with stalevo tablets , the highest dosage recommendations should be followed .'"
539,"b'beim auftreten schwerer nebenwirkungen , die das gehirn oder nervensystem des patienten betreffen , muss die behandlung gestoppt werden .'","b'in case of severe side effects affecting the brain or nervous system of the patient , treatment must be stopped .'",b'in case of severe side effects affecting the brain to liver system of the treatment .',"b'in case of severe side effects affecting the brain or nervous system of the patient , treatment must be stopped .'"
540,"b'diese beobachtung wurde klinisch durch spezifische interaktionsstudien best\xc3\xa4tigt , in denen midazolam ( cyp3a4-substrat ) , warfarin ( cyp2c9-substrat ) und digoxin ( ein p- gp-substrat ) untersucht wurden .'","b'this observation has been confirmed by clinically specific interaction studies in which midazolam ( a cyp3a4 substrate ) , warfarin ( cyp2c9 substrate ) and digoxin ( a keratotome according to gp-substrat ) were studied .'","b'this medicine has been confirmed by clinically specific interaction of tacrolimus of low receptor , warfarin cypc substrate and digoxin is reached .'","b'this observation has been confirmed by clinically specific interaction studies , in which midazolam ( a cyp3a4 substrate ) , warfarin ( cyp2c9 substrate ) and digoxin ( a p-gp sustrate ) were studied .'"
541,"b'informieren sie ihren arzt dar\xc3\xbcber , wenn sie schwanger sind oder beabsichtigen schwanger zu werden .'",b'tell your doctor if you are pregnant or planning to become pregnant .',"b'tell your doctor if you are pregnant , centre with one treatment .'",b'tell your doctor if you are pregnant or planning to become pregnant .'
542,b'sie k\xc3\xb6nnen maximal 4 wochen lang bei einer temperatur von nicht \xc3\xbcber 25 \xc2\xb0 c aufbewahrt werden .',b'they may be stored for a maximum of 4 weeks not above 25 \xc2\xb0 c.',b'they may be diluted for a line of weeks not above c .',b'they may be stored for a maximum of 4 weeks not above 25 \xc2\xb0 c.'
543,b'kinzalmono darf auch nicht bei patienten mit schweren leberproblemen oder gallenfunktionsst\xc3\xb6rungen angewendet werden .',"b'kinzalmono should also not be used in patients who have severe problems with their liver , or disorders .'","b'kinzalmono should also not be used in patients who have severe problems with their liver , or disorders .'","b'kinzalmono should also not be used in patients who have severe problems with their liver , or biliary disorders .'"
544,b'maraviroc liegt im humanplasma zu ca. 76 % an proteine gebunden vor und weist eine m\xc3\xa4\xc3\x9fige affinit\xc3\xa4t zu albumin und saurem alpha-1-glykoprotein auf .',b'the clearance of maraviroc in human plasma is approximately 76 % of doxazosin is protein-bound in plasma before and moderate affinity for albumin and alpha-1 acid glycoprotein .',b'the clearance of maraviroc in a body of single proteins is linear by the reduction of action was produced by .',b'maraviroc in human plasma is approximately 76 % bound to protein and has a moderate affinity for albumin and alpha-1 acid glycoprotein .'
545,b'f\xc3\xbcr weitere hinweise zur handhabung siehe abschnitt 6.6 .',"b'fur further details on handling , see section 6.6 .'","b'do further details on handling , see section . .'","b'for further details on handling , see section 6.6 .'"
546,b'wie wurde mircera untersucht ?',b'how has mircera been studied ?',b'how has mircera been studied ?',b'how has mircera been studied ?'
547,b'bei gleichzeitiger anwendung waren die initialen tiefsten plasmakonzentrationen im flie\xc3\x9fgleichgewicht von bosentan ungef\xc3\xa4hr 30-fach h\xc3\xb6her als nach alleiniger verabreichung von bosentan .',b'when the initial treatment period with a steady state plasma concentrations of bosentan were approximately 30-fach higher than with bosentan alone .',b'when a concomitant treatment period with a steady greater for atovaquone scheme .',"b'during concomital use , the initial lowest plasma concentrations in the flux balance of bosentan were approximately 30-fach higher than with bosentan alone .'"
548,"b'von diesen patienten wiesen 86 , 72 bzw. 41 patienten nach 60 monaten ein acr-20- , -50- bzw. -70-ansprechen auf .'","b'of these patients had 86 , 72 , and 41 patients had acr 20 response , respectively at month 60 .'",b'of these thousand at taking milk of particles had be affected in section .',"b'of these patients , 86 , 72 , and 41 patients had a acr 20 , 50 , or 70 response after 60 months .'"
549,b'ausscheidungsf\xc3\xa4higkeit von fondaparinux bei \xc3\xa4lteren patienten reduziert sein .',b'ra fondaparinux may be reduced in elderly .',b'ra stage may be administered in elderly .',b'the ability to excrete fondaparinux may be reduced in elderly patients .'
550,"b'patienten mit chronischer hepatitis b oder c , die eine kombinationstherapie erhalten , haben ein erh\xc3\xb6htes risiko , dass schwere leberfunktionsst\xc3\xb6rungen auftreten . \xe2\x80\xa2 ob sie an der bluterkrankheit ( h\xc3\xa4mophilie ) leiden .'","b'patients with chronic hepatitis b or c , who are treated in patients receiving combination antiretroviral therapy are at increased risk of serious hepatic impairment may occur . \xe2\x80\xa2 if you have a weakened ( haemophilia ) .'","b'patients with chronic hepatitis b or c , who are treated in patients receiving combination antiretroviral therapy , a therapy .'","b'patients with chronic hepatitis b or c , who receive combination therapy are at increased risk of serious hepatic impairment . \xe2\x80\xa2 if you suffer from a blood disease ( haemophilia ) .'"
551,"b'gelegentlich : asthenie ( allgemeines schw\xc3\xa4chegef\xc3\xbchl , m\xc3\xbcdigkeit ) , reaktionen an der injektionsstelle .'","b'uncommon : asthenia ( general sensation of weakness , fatigue ) , injection site reactions .'","b'uncommon of yellow bleeding , like the shunts .'","b'uncommon : asthenia ( general sensation of weakness , fatigue ) , injection site reactions .'"
552,b'las studien iii und v war die verz\xc3\xb6gerung des fortschreitens der krankheit ( ermittelt durch r\xc3\xb6ntgenergebnisse ) .',b'tho trials iii and v was of disease progression ( primary endpoint at 52 weeks of retardation ) .',b'sbp fixed of mg growth rate rate on weeks of palate .',b'tho studies iii and v was the delay of disease progression ( determined by x-ray results ) .'
553,b'orencia wurde in drei hauptstudien an 1 382 patienten mit rheumatoider arthritis untersucht .',b'orencia has been studied in three main studies involving 382 patients with rheumatoid arthritis .',b'orencia has been studied in three main studies involving patients with rheumatoid arthritis groups .',b'orencia has been studied in three main studies involving 382 patients with rheumatoid arthritis .'
554,b'die dosierung f\xc3\xbcr hunde richtet sich nach der gr\xc3\xb6\xc3\x9fe der k\xc3\xb6rperoberfl\xc3\xa4che .',b'the dose for dogs depends on body surface area .',b'ithe dose for dogs depends on body surface area .',b'the dose for dogs depends on body surface area .'
555,b'tierexperimentelle daten ergaben keine hinweise auf teratogenit\xc3\xa4t .',b'animal data have revealed no evidence of teratogenicity .',b'animal data have . times the same ciprofloxacin .',b'animal data have revealed no evidence of teratogenicity .'
556,b'die andere seite ist mit dem firmenlogo versehen .',b'the other on one side and the company logo on the other side .',b'the other content of considerable attention with action of protective ear best is contain the general side .',b'the company logo is found on the other side .'
557,"b'as jede 0,5 ml fertigspritze enth\xc3\xa4lt 100 mikrogramm darbepoetin alfa ( 200 mikrogramm / ml ) .'",b'each 0.5 ml pre-filled syringe contains 100 micrograms darbepoetin alfa ( 200 micrograms / ml ) .',b'each human substance ml prefilled syringe contains micrograms darbepoetin alfa micrograms ml .',b'each 0.5 ml pre-filled syringe contains 100 micrograms darbepoetin alfa ( 200 micrograms / ml ) .'
558,"b'xeristar 60 mg ist in packungen mit 28 , 56 , 84 , 98 , 100 und 500 hartkapseln erh\xc3\xa4ltlich .'","b'xeristar 60 mg is available in packs of 28 , 56 , 84 , 98 , 100 and 500 hard capsules are available .'","b'xeristar mg is available in packs of , , , , has available .'","b'xeristar 60 mg is available in packs of 28 , 56 , 84 , 98 , 100 and 500 hard capsules .'"
559,"b'die therapie sollte nur durch einen arzt eingeleitet werden , der in der behandlung der hiv-infektion erfahren ist .'",b'treatment should only be started by a doctor who has experience in the treatment of hiv infection .',b'treatment should only be initiated by a doctor who has experience in the treatment of hiv infection .',b'treatment should only be started by a doctor who has experience in the treatment of hiv infection .'
560,b'es wurde keine wechselwirkungsstudie zur gleichzeitigen anwendung von prezista / ritonavir mit benzodiazepinen durchgef\xc3\xbchrt .',b'no interaction study for the co-administration of prezista / ritonavir with benzodiazepines .',b'no interaction study for the coadministration of prezista ritonavir with .',b'no interaction study has been done on the co-administration of prezista / ritonavir with benzodiazepines .'
561,"b'ferriprox darf nicht bei personen angewendet werden , in deren krankheitsgeschichte wiederholte neutropenie-sch\xc3\xbcbe ( niedrige werte eines bestimmten typs wei\xc3\x9fer blutzellen ) oder f\xc3\xa4lle von agranulozytose aufgetreten sind .'",b'ferriprox should not be used in people in the re-administration of heart failure episodes of neutropenia ( low levels of a type of white blood cell ) or cases of agranulocytosis have occurred .',"b'ferriprox should not be used in people in some individual combination effects , .'",b'ferriprox should not be used in people who have a medical history of repeated neutropenia phases ( low levels of a certain type of white blood cell ) or cases of agranulocytosis .'
562,b'die wirksamkeit der kombination von mabthera mit methotrexat wurde mit der einer kombination von placebo ( scheinbehandlung ) und methotrexat verglichen .',b'the efficacy of combination therapy with mabthera and methotrexate were compared with those of placebo ( a dummy treatment ) in combination with methotrexate .',b'the efficacy of combination therapy with mabthera and methotrexate were compared with those of placebo a dummy treatment in combination with methotrexate .',b'the efficacy of combination therapy with mabthera and methotrexate were compared with those of placebo ( a dummy treatment ) in combination with methotrexate .'
563,b'wie wird optruma angewendet ?',b'how is optruma used ?',b'how is optruma used ?',b'how is optruma used ?'
564,"b'irbesartan und hydrochlorothiazid ( in dosierungen bis zu 300 mg irbesartan / 25 mg hydrochlorothiazid ) wurden problemlos mit anderen blutdrucksenkenden mitteln , einschlie\xc3\x9flich kalziumkanalblockern und betablockern angewendet .'","b'irbesartan and hydrochlorothiazide ( at doses up to 300 mg irbesartan / 25 mg hydrochlorothiazide ) , has been safely administered with other , including powder and beta-blockers .'","b'irbesartan and hydrochlorothiazide at doses up to mg irbesartan mg hydrochlorothiazide , has been safely administered with other , including reyataz and betablockers .'","b'irbesartan and hydrochlorothiazide ( at doses up to 300 mg irbesartan / 25 mg hydrochlorothiazide ) , has been safely administered with other , including powder and beta-blockers .'"
565,"b'as auch in einer dosis von 0,75 \xc2\xb5g / kg k\xc3\xb6rpergewicht als einzelne injektion einmal alle 2 wochen gegeben werden .'","b'alternatively , in patients not on dialysis , an initial dose of 0.75 \xce\xbc g / kg may be administered subcutaneously as a single injection once every two weeks .'","b'afterwards , in patients not on dialysis , an initial dose of . g kg may be administered subcutaneously as a single injection once every two weeks .'","b'alternatively , in patients not on dialysis , an initial dose of 0.75 \xce\xbc g / kg may be administered subcutaneously as a single injection once every two weeks .'"
566,"b'zum dosieren wird ein oraler dispenser mit 30-mg , 45-mg und 60-mg-einteilungen in der packung mitgeliefert .'","b'for antiadherent is an oral dispenser with 30- , 45-mg and 60-mg-einteilungen is included in the pack .'","b'for crosssectional , a production by compact order with the dose of the filmcoated , suspension contains the packaging and envelopes is included in the humalog is included in the pack .'","b'for dosing , an oral dispenser with 30 , 45 and 60 mg grades is included in the pack .'"
567,"b'las toxizit\xc3\xa4t wurde bei affen gezeigt , die 100 x 106 i.e. / kg / tag \xc3\xbcber 3 monate erhielten .'",b'ris toxicity was demonstrated in monkeys given 100 x 106 iu / kg / day for 3 months .',b'values was demonstrated in ovariectomised a depressive timespan .',b'ris toxicity was demonstrated in monkeys given 100 x 106 iu / kg / day for 3 months .'
568,"b'pharmakotherapeutische gruppe : \xc3\x96strogene , atcvet-code :'","b'pharmacotherapeutic group : oestrogens , atcvet code :'","b'pharmacotherapeutic group prevents , atcvet code'","b'pharmacotherapeutic group : oestrogens , atcvet code :'"
569,"b'da olanzapin schl\xc3\xa4frigkeit und schwindel verursachen kann , muss der patient vor dem bedienen von maschinen gewarnt werden , dies gilt auch f\xc3\xbcr das autofahren .'","b'since olanzapine may cause somnolence and dizziness , should be cautioned about operating machinery , including motor vehicles driving .'","b'since olanzapine may cause somnolence and dizziness , livers .'","b'since olanzapine may cause somnolence and dizziness , should be cautioned about operating machinery , including motor vehicles driving .'"
570,b'daten zur wirksamkeit aus klinischen studien mit p\xc3\xa4diatrischen patienten zwischen 6 monaten und 2 jahren mit persistierendem asthma sind begrenzt .',b'efficacy data from clinical studies in paediatric patients 6 months to 2 years of age with persistent asthma is limited .',b'efficacy data from clinical studies in paediatric patients months to years of age with persistent asthma is limited .',b'efficacy data from clinical studies in paediatric patients 6 months to 2 years of age with persistent asthma is limited .'
571,"b'die wirksamkeit von imiquimod bei f\xc3\xbcnfmaliger anwendung pro woche \xc3\xbcber 6 wochen wurde in zwei doppelblinden , placebo-kontrollierten klinischen studien untersucht .'","b'the efficacy of imiquimod in f\xc3\xbcnfmaliger times a week for 6 weeks was evaluated in two double-blind , placebo-controlled clinical trials .'","b'the efficacy of imiquimod in lawsonia times a week testosterone is dtermined in two doubleblind of both studies in two doubleblind , placebocontrolled clinical trials .'","b'the efficacy of imiquimod at a usage rate of 5 times a week for 6 weeks was evaluated in two double-blind , placebo-controlled clinical trials .'"
572,b'\xc3\x9cber die anwendung von rapilysin bei schwangeren frauen liegen keine erfahrungen vor .',b'there is no experience with the use of rapilysin in pregnant women .',b'there is no data with the use of rapilysin in pregnant women .',b'there is no experience with the use of rapilysin in pregnant women .'
573,b'das verabreichte interferon alfa-2b wirkt genauso wie nat\xc3\xbcrlich im k\xc3\xb6rper gebildetes interferon alpha .',b'the administered interferon alfa-2b works in the same way as naturally produced in the body produced interferon alpha .',b'the administered interferon alfab works in the same way as naturally produced in the body produced human alpha .',b'the administered interferon alfa-2b works in the same way as interferon alpha naturally produced in the body .'
574,b'bei einigen patienten kam es w\xc3\xa4hrend der einnahme von sitagliptin allein zu folgenden nebenwirkungen :',b'some patients have experienced alone have experienced the following side effects while taking sitagliptin :',b'some patients have experienced tacrolimus of individual associated become clinical side effects while taking sitagliptin',b'some patients have experienced the following side effects while taking sitagliptin :'
575,b'wie wurde die wirksamkeit von porcilis pesti untersucht ?',b'how has the effectiveness of porcilis pesti been studied ?',b'how has the effectiveness of the following categories .',b'how has the effectiveness of porcilis pesti been studied ?'
576,b'400 mg jede filmtablette enth\xc3\xa4lt 400 mg rufinamid .',b'400 mg each film-coated tablet contains 400 mg of rufinamide .',b'mg each filmcoated tablet contains mg respectively .',b'400 mg each film-coated tablet contains 400 mg of rufinamide .'
577,b'ihr arzt wird sie dar\xc3\xbcber informieren .',b'your doctor will tell you .',b'your doctor will tell you .',b'your doctor will tell you .'
578,"b'0,1 mg firocoxib pro kg k\xc3\xb6rpergewicht werden einmal t\xc3\xa4glich verabreicht .'",b'0.1 mg firocoxib per kg bodyweight once daily in a 6 week period .',b'. mg triglycerides mg kg .',b'0.1 mg firocoxib per kg bodyweight once daily in a 6 week period .'
579,b'diese f\xc3\xbcr die patientinnen sichtbaren unterschiede wurden 8 wochen nach therapiebeginn beobachtet .',b'this would be relevant for patients with differences were observed in 8 weeks after the initiation of therapy .',b'this basis should been statistically for patients with differences were observed in weeks after the initiation of therapy .',b'this obvious difference was observed for patients in 8 weeks after the initiation of therapy .'
580,b'welche nebenwirkungen sind m\xc3\xb6glich ? 5.',b'possible side effects 5 how to store atryn 6 .',b'how to store atryn .',b'what are the possible side effects ?'
581,"b'203 denen diese f\xc3\xa4higkeiten von besonderer bedeutung sind ( z. b. beim autofahren oder beim bedienen von maschinen ) , ein risiko darstellen .'",b'203 which may constitute a risk in situations where these abilities are of special importance ( e. g. driving a car or operating machinery ) .',b'which may constitute a risk in situations where these abilities are of special importance e . g . driving a car or operating machinery .',b'203 which may constitute a risk in situations where these abilities are of special importance ( e. g. driving a car or operating machinery ) .'
582,"b'wenn man das l\xc3\xb6sungsmittel direkt auf das pulver richtet , bildet sich \xc3\xbcberm\xc3\xa4\xc3\x9fig viel schaum .'","b'when considering the solvent directly onto the powder , based on a excessively .'",b'when simplify the ointment provides left through a maximum acid .',"b'when considering the solvent directly onto the powder , lots of foam builds up .'"
583,b'pylobactell wird nicht empfohlen f\xc3\xbcr die anwendung bei kindern und jugendlichen unter 18 jahren aufgrund nicht ausreichender daten zur wirksamkeit .',b'pylobactell is not recommended for use in children and adolescents below 18 years of age due to insufficient data on efficacy .',b'pylobactell is not recommended for use in children and adolescents below years of age due to evidence data on humans .',b'pylobactell is not recommended for use in children and adolescents below 18 years of age due to insufficient data on efficacy .'
584,"b'weitere nebenwirkungen , die nach markteinf\xc3\xbchrung berichtet wurden , sind in der folgenden liste unter "" unbekannte h\xc3\xa4ufigkeit "" und kursiv angegeben .'","b'other side effects that have been reported during post-marketing experience are listed in the following list under "" unknown frequency "" and in italics in .'",b'other side effects that have been reported during postmarketing experience taking whom months .',"b'other side effects that have been reported during post-marketing experience are listed in the following list under "" unknown frequency "" in italics .'"
585,"b'promeris duo darf nicht in gew\xc3\xa4sser gelangen , da es eine gefahr f\xc3\xbcr fische und andere wasserorganismen darstellen kann .'","b'promeris duo should not be allowed to enter surface water , as it may be dangerous for fish and other aquatic organisms .'","b'promeris used should not be allowed to enter stays , as it may be dangerous for fish and other recurrence with the rules of high and other undesired agent to give necessary .'","b'promeris duo should not be allowed to enter surface water , as it may be dangerous for fish and other aquatic organisms .'"
586,b'weitere informationen \xc3\xbcber promeris duo :',b'2 / 3 other information about promeris duo :',b'fosavance information about ankylosing orphan information about promeris bms',b'2 / 3 other information about promeris duo :'
587,"b'wenn sie mehr aerius schmelztablette eingenommen haben , als sie sollten , wenden sie sich an ihren arzt oder apotheker .'","b'if you take more aerius orodispersible tablet than you were told to , contact your doctor or pharmacist .'","b'if you take more aerius tablet tablet than you and in contact to , contact your doctor or pharmacist .'","b'if you take more aerius orodispersible tablet than you were told to , contact your doctor or pharmacist .'"
588,b'die testmahlzeit ist nicht in diesem kit enthalten .',b'the test meal is not included in this kit .',b'hold the you with step an abatacept from three olanzapin system .',b'the test meal is not included in this kit .'
589,b'die pharmakokinetik von cinacalcet ver\xc3\xa4ndert sich nicht im laufe der zeit .',b'the pharmacokinetics of cinacalcet is not altered over time .',b'antiviral the pharmacokinetics of dosing is not altered over out .',b'the pharmacokinetics of cinacalcet do not change over time .'
590,b'weitere informationen \xc3\xbcber vimpat :',b'2 / 3 other information about vimpat :',b'other information about vimpat',b'other information about vimpat :'
591,b'332 f\xc3\xbchren sie vor jedem gebrauch des optiset immer einen sicherheitstest durch .',"b'332 before using optiset , and perform a safety test .'","b'before using optiset , an well whether the help .'",b'332 before each use of optiset always perform a safety test .'
592,b'besondere vorsicht bei der einnahme von intelence ist erforderlich intelence ist kein heilmittel gegen eine hiv-infektion .',b'take special care with intelence : intelence is not a cure for hiv infection .',b'taking special physician . veterinary in diseases to taking general infection .',b'take special care with intelence : intelence is not a cure for hiv infection .'
593,"b'sie d\xc3\xbcrfen nicht stillen , wenn sie sprimeo einnehmen .'",b'do not breast-feed if you are taking sprimeo .',b'do not breastfeed if you are taking sprimeo .',b'do not breast-feed if you are taking sprimeo .'
594,"b'die studie zeigte , dass pandemrix mit 3,75 mikrogramm h\xc3\xa4magglutinin und dem adjuvans zu einer antik\xc3\xb6rperreaktion f\xc3\xbchrte , die diesen kriterien entsprach .'",b'the study showed that pandemrix with 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria .',b'the study showed that note with . micrograms of haemagglutinin and the adjuvant produced an antibody response that met these dental .',b'the study showed that pandemrix with 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response met this criteria .'
595,b'f\xc3\xbcr eine noch genauere dosierung kann die verabreichung von metacam suspension zum eingeben f\xc3\xbcr hunde in betracht gezogen werden .',b'for a yet more accurate dosing may be the administration of metacam oral suspension for dogs should be considered .',b'for a saquinavir information . the administration of metacam oral suspension for dogs should be avoided .',"b'for a yet more accurate dosing , the administration of metacam for oral suspension may be considered for dogs .'"
596,"b'jede 0,4 ml fertigspritze enth\xc3\xa4lt 40 mikrogramm darbepoetin alfa ( 100 mikrogramm / ml ) .'",b'each 0.4 ml pre-filled syringe contains 40 micrograms darbepoetin alfa ( 100 micrograms / ml ) .',b'each . ml prefilled syringe contains micrograms darbepoetin alfa micrograms ml .',b'each 0.4 ml pre-filled syringe contains 40 micrograms darbepoetin alfa ( 100 micrograms / ml ) .'
597,b'seltene nebenwirkungen ( weniger als 1 von 1.000 patienten betroffen ) :',"b'rare side effects ( less than 1 in every 1,000 patients ) :'","b'rare side effects less than in every , patients'","b'rare side effects ( less than 1 in every 1,000 patients ) :'"
598,"b'60 interferone entfalten ihre zellul\xc3\xa4ren wirkungen , indem sie sich an spezifische membranrezeptoren auf der zelloberfl\xc3\xa4che binden .'",b'60 interferons exert their cellular activities exert receptors on the cell surface .',b'interferons acted reports .',b'60 interferons exert their cellular activities in which they bind themselves to specific membrane receptors on the cell surface .'
599,b'welches risiko ist mit angiox verbunden ?',b'what is the risk associated with angiox ?',b'what is the risk associated with lysodren ?',b'what is the risk associated with angiox ?'
600,"b'\xc3\x84rzten wird geraten , das wachstum von kindern , die ribavirin in kombination mit interferon alfa-2b erhalten , zu \xc3\xbcberwachen .'",b'physicians are advised to the growth of children taking ribavirin in combination with interferon alfa-2b .',b'physicians are advised to administer the growth of children receiving ribavirin in combination with interferon alfab .',b'physicians are advised to monitor the growth of children taking ribavirin in combination with interferon alfa-2b .'
601,"b'sie d\xc3\xbcrfen humalog mix50 nicht anwenden , wenn kl\xc3\xbcmpchen vorhanden sind oder feste , wei\xc3\x9fe teil- chen am boden oder an den w\xc3\xa4nden dem fl\xc3\xa4schchen ein "" frostiges "" aussehen verleihen .'","b'do not use humalog mix50 , if clumps of material are present or if solid white particles stick to the bottom or material , the bottom or wall of the vial , giving it a frosted appearance .'",b'do not take your mix to gently shake dose bottle .',"b'do not use humalog mix50 if clumps of material are present or if solid white particles stick to the bottom or material , the bottom or wall of the vial , giving it a frosted appearance .'"
602,b'unter der behandlung mit mirtazapin wurde \xc3\xbcber das auftreten oder die verst\xc3\xa4rkung von angst und schlaflosigkeit berichtet .',b'under treatment with mirtazapine onset of improvement and insomnia have been reported .',b'under treatment with mirtazapine modifying growth factor .',"b'under treatment with mirtazapine , the onset or the worsening of anxiety and insomnia have been reported .'"
603,b'10 busulfan ist eine potente zytotoxische substanz und ein bifunktionelles alkylanz .',b'10 busulfan is a potent cytotoxic agent and including genotoxic alkylating agent .',b'busulfan is with modified benzoate on the depressive energy gt of flat bioabsorbable agent by the secondary body and including genotoxic movements or protease agent .',b'10 busulfan is a potent cytotoxic agent and a bifunctional alkylant .'
604,b'skelettmuskulatur- und bindegewebserkrankungen :',b'musculoskeletal and connective tissue diseases :',b'musculoskeletal and connective tissue',b'muscular skeletal and connective tissue diseases :'
605,"b'nelfinavir ist ein starker cyp3a4- hemmer , durch den man eine erh\xc3\xb6hung der konzentration von maraviroc erwarten kann .'","b'nelfinavir is a potent cyp3a4 inhibitor , and is expected to rise in the concentration of maraviroc .'","b'nelfinavir is a potent cypa inhibitor , and is expected to rise in the concentration of maraviroc .'","b'nelfinavir is a potent cyp3a4 inhibitor , due to which the concentration of maraviroc is expected to rise .'"
606,"b'\xe2\x80\xa2 bitte stellen sie sicher , dass sie bei jedem arztbesuch eine liste aller ihrer weiteren arzneimittel bei sich haben .'","b'\xe2\x80\xa2 please make sure that you visit your doctor if you have a list of all your other medicines with you , just in case .'","b'please make sure that you feel reaction with you , just in case .'",b'\xe2\x80\xa2 please make sure that you have a list of all your other medicines with you at each visit to the doctor .'
607,"b'die wirkungen von advexin wurden zun\xc3\xa4chst in versuchsmodellen getestet , bevor sie an menschen untersucht wurden .'",b'the effects of advexin were first tested in experimental models before being studied in three main studies involving .',b'the effects of busilvex were first tested in experimental models before being studied in three main studies involving .',b'the effects of advexin were first tested in experimental models before being studied in humans .'
608,b'detaillierte angaben zu diesem tierarzneimittel finden sie auf der website der europ\xc3\xa4ischen arzneimittel-agentur ( emea ) unter http : / / www.emea.europa.eu.',b'detailed information on this veterinary medicinal product is available on the website of the european medicines agency ( emea ) http : / / www. emea. europa. eu / .',b'detailed information on this veterinary medicinal product is available on the website of the european medicines agency emea summary is available to the use of the european medicines agency emea http www . emea . europa . eu .',b'detailed information on this veterinary medicinal product is available on the website of the european medicines agency ( emea ) http : / / www. emea. europa. eu / .'
609,b'metabolisierung nateglinid wird stark metabolisiert .',b'metabolism nateglinide is extensively metabolised .',b'metabolisation with use the kidney therapy of platin .',b'metabolism nateglinide is extensively metabolised .'
610,b'yondelis ist ein pulver zur herstellung eines infusionsl\xc3\xb6sungskonzentrats .',b'yondelis is a powder for infusion .',b'yondelis is a powder for infusion .',b'yondelis is a powder for infusion .'
611,"b'pcv2-assoziierte infektionen k\xc3\xb6nnen mit klinischen anzeichen wie gewichtsverlust oder wachstumsverz\xc3\xb6gerung , vergr\xc3\xb6\xc3\x9ferten lymphknoten , erschwerter atmung , durchfall , fahler haut und gelbsucht ( gelbwerden der haut ) einhergehen .'","b'pcv2 associated infections may be associated with clinical symptoms such as weight loss or failure to grow , enlarged lymph nodes , trouble breathing , diarrhoea , fahler skin and jaundice ( gelbwerden of the skin ) .'","b'olanzapine has prevent a tacrolimus levels may make insulin osolates , lumefantrine .'","b'ipcv2 associated infections may be associated with clinical symptoms such as weight loss or failure to grow , enlarged lymph nodes , trouble breathing , diarrhoea , pale skin and jaundice ( yellowing of the skin ) .'"
612,"b'vorkommen , besonders bei patienten mit neigung zu niedrigem blutdruck oder komplikationen an den arterioven\xc3\xb6sen fisteln .'","b'occur , especially in patients who have a tendency to low blood pressure or if your arteriovenous fistula has complications .'","b'occur , especially called sevoflurane if they have a icandra an tendency to low blood pressure or those s inflammation and caution , such as enough blood pressure or is occur from you must'","b'occur , especially in patients who have a tendency to low blood pressure or complications if your arteriovenous fistula .'"
613,"b'es wurde jedoch festgestellt , dass diese antik\xc3\xb6rper keine wachstumshemmende wirkung haben .'","b'there was , however , found that antibodies have no growth-inhibiting effects .'",b'there was no depletion can not noticed .',"b'there was found , however , that antibodies have no growth-inhibiting effects .'"
614,b'nicht bei tragenden oder laktierenden stuten anwenden .',b'do not use in pregnant or lactating mares .',b'do not use in pregnant or lactating intestinal .',b'do not use in pregnant or lactating mares .'
615,b'jede tablette enth\xc3\xa4lt 30 mg pioglitazon ( als hydrochlorid ) und 4 mg glimepirid .',b'each tablet contains 30 mg pioglitazone ( as hydrochloride ) and 4 mg glimepiride .',b'each tablet contains mg pioglitazone as blue and mg glimepiride .',b'each tablet contains 30 mg pioglitazone ( as hydrochloride ) and 4 mg glimepiride .'
616,b'inomax war wirksamer als das placebo .',b'inomax was more effective than placebo .',b'oseltamivirresistant was more effective than placebo .',b'inomax was more effective than placebo .'
617,b'h\xc3\xa4ufigkeitssch\xc3\xa4tzung : sehr h\xc3\xa4ufig ( \xe2\x89\xa5 1 / 10 ) ; h\xc3\xa4ufig ( \xe2\x89\xa5 1 / 100 bis < 1 / 10 ) ; gelegentlich ( \xe2\x89\xa5 1 / 1000 bis < 1 / 100 ) ; selten ( \xe2\x89\xa5 1 / 10.000 bis < 1 / 1000 ) ; sehr selten ( < 1 / 10.000 ) ; unbekannt ( auf grundlage der verf\xc3\xbcgbaren daten nicht absch\xc3\xa4tzbar ) .',"b'h\xc3\xa4ufigkeitssch\xc3\xa4tzung : very common ( \xe2\x89\xa5 1 / 10 ) ; common ( \xe2\x89\xa5 1 / 100 to 1 / 10 ) ; uncommon ( \xe2\x89\xa5 1 / 1000 to 1 / 100 ) ; rare ( \xe2\x89\xa5 1 / 10,000 to 1 / 1,000 ) ; very rare ( 1 / 10,000 ) ; not known ( cannot be estimated from the available data ) .'","b'miglyolist very common common to very rare , there are seen by the available data .'","b'h\xc3\xa4ufigkeitssch\xc3\xa4tzung : very common ( \xe2\x89\xa5 1 / 10 ) ; common ( \xe2\x89\xa5 1 / 100 to 1 / 10 ) ; uncommon ( \xe2\x89\xa5 1 / 1000 to 1 / 100 ) ; rare ( \xe2\x89\xa5 1 / 10,000 to 1 / 1,000 ) ; very rare ( 1 / 10,000 ) ; not known ( cannot be estimated from the available data ) .'"
618,b'ziehen sie den spritzenkolben bis zur 1-ml-markierung heraus .',b'pull the syringe plunger in fast past the 1 ml marker .',b'pull the syringe plunger in viani gravis without each week .',b'pull the syringe plunger out until the 1 ml marker .'
619,"b'orangefarbene , ovale tablette mit pr\xc3\xa4gung "" 300mg "" auf der einen seite und "" tmc114 "" auf der anderen seite .'","b'orange oval shaped tablet , debossed with "" 300mg "" on one side and "" tmc114 "" on the other side .'","b'orange protective procedure tablet , debossed with mg on one side and hydroxymemantin on the other side .'","b'orange , oval shaped tablet , debossed with "" 300mg "" on one side and "" tmc114 "" on the other side .'"
620,"b'0,1 % iger salbe keine hauttumoren beobachtet .'","b'0.1 % ointment , no skin tumours were observed .'","b'. ointment , no skin antibodies were observed with on however polio'","b'0.1 % ointment , no skin tumours were observed .'"
621,"b'diese symptome k\xc3\xb6nnen komplikationen aufdecken , bei denen eine besondere medikation erforderlich sein k\xc3\xb6nnte :'",b'these symptoms may be complications of aufdecken in which a special medication might be :',"b'these symptoms , that they to relieve the occurrence of azilect , monitoring of the blood sugar expiratory to destroy the area of vitamin methods of which .'",b'these symptoms may reveal complications in which a special medication might be necessary :'
622,b'36 gesunde laktierende k\xc3\xbche wurden durch infusion von endotoxin bacto e. coli 026 : b6 lipopolysaccharid b ( lps ) in ein hinterviertel exponiert .',b'36 healthy laktierende cows were due to infusion of protirelin bacto e. coli 026 : vitamins b6 hydrolase b ) in a hinterviertel .',"b'healthy fap exams , miglustat broilers with allergies and saturation with symptoms .'",b'36 healthy lactating cows exposed by the infusion of endotoxin bacto e. coli 026 : b6 to lipopolysaccharide b ( lps ) in a hindquarter .'
623,b'injizieren sie das arzneimittel langsam und gleichm\xc3\xa4\xc3\x9fig ( dr\xc3\xbccken sie den kolben in die spritze bis diese leer ist ) .',b'inject the medicine slowly and evenly ( press the syringe plunger until the empty ) .',b'inject the medicine slowly and evenly particles .',b'inject the medicine slowly and evenly ( press the syringe plunger until the empty ) .'
624,b'5 ( 6 ) h\xc3\xa4ufig :',b'5 ( 6 ) common :',b'common',b'5 ( 6 ) common :'
625,"b'falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'"
626,b'zweist\xc3\xbcndige infusion am tag 1 alle 3 wochen ) und xeloda ( 625 mg / m2 zweimal t\xc3\xa4glich fortdauernd ) .',"b'hour infusion on day 1 every 3 weeks ) , and xeloda ( 625 mg / m2 twice daily continuously ) .'",b'hour infusion on day every weeks after week .',b'two-hour infusion on day 1 every 3 weeks and xeloda ( 625 mg / m2 twice daily continuously ) .'
627,b'91 die nebenwirkungen waren bei allen indikationen mit zwei ausnahmen vergleichbar .',"b'91 the adverse reactions were similar in all indications , with two exceptions .'","b'the adverse reactions were similar in all problems , with two polio diagnosis is unchanged and a ards .'","b'91 the adverse reactions were similar in all indications , with two exceptions .'"
628,"b'novorapid innolet d\xc3\xbcrfen nur zusammen mit produkten verwendet werden , die mit ihnen kompatibel sind und eine sichere und effektive funktion des fertigpens gew\xc3\xa4hrleisten .'",b'novorapid innolet should only be used in combination with products that are compatible with them to function safely and effectively and allow the pens .',b'novorapid innolet should only be used in combination with products that are compatible with them to ensure and request and agreed the pens .',b'novorapid innolet should only be used in combination with products that are compatible with them to ensure the pens function safely and effectively .'
629,b'patienten mit einer glukose-galaktose-malabsorption sollten dieses arzneimittel nicht einnehmen .',b'patients with glucose-galactose malabsorption should not take this medicine .',b'patients with injection with anticonvulsant deficiency and myelodysplastic medical .',b'patients with glucose-galactose malabsorption should not take this medicine .'
630,b'19 lagerungsbedingungen des gebrauchsfertigen arzneimittels siehe abschnitt 6.3 .',"b'19 for storage conditions of the reconstituted medicinal product , see section 6.3 .'","b'for storage conditions of the reconstituted medicinal product , see section . .'","b'19 for storage conditions of the reconstituted medicinal product , see section 6.3 .'"
631,"b'vor\xc3\xbcbergehende ph-ver\xc3\xa4nderungen , die mit der brause- reaktion einhergehen , k\xc3\xb6nnen die aufl\xc3\xb6sung ( bei einem niedrigeren ph-wert ) und die membrandurchl\xc3\xa4ssigkeit ( bei einem h\xc3\xb6heren ph-wert ) optimieren .'","b'transient ph-ver\xc3\xa4nderungen , and associated obtaining , in order to optimise dissolution ( drying ) and the flow-switching valve ( 160 ( in a higher ph ) .'","b'transient adhesins torsion , and with theoretic gonorrhoea peakflow and antagonistic ph .'",b'transient ph changes and associated with the effervescent reaction may optimise dissolution ( at a lower ph value ) and the membrane permeability ( at a higher ph value ) .'
632,"b'eine induzierte l\xc3\xa4ufigkeit wird nicht beobachtet , wenn die behandlung vor der pubert\xc3\xa4t beginnt .'",b'induced heat is not observed if treatment is started before puberty .',b'im heat is not observed if least hypersensitivity converting medical symptom that be taken if safety is clearly with parathyroid prescription .',b'induced heat is not observed if treatment is started before puberty .'
633,"b'die behandlung mit r-cvp verl\xc3\xa4ngerte im vergleich zu cvp signifikant die zeit bis zum fortschreiten der krankheit oder bis zum eintreten des todes ( 33,6 monate gegen\xc3\xbcber 14,7 monate , p < 0,0001 log-rank-test ) .'","b'treatment with r-cvp prolonged compared to cvp significantly reduced the time to disease progression or until a faster onset of death ( 33.6 months versus 14.7 months , p 0.0001 , log-rank test ) .'",b'treatment with longstanding prolonged group was possible would lead to cardiac colorectal antirheumatic impairment within age of death . months of the radiotherapy s bridge with thiopental a an conversion of death . months plus cxcrtropic antiinflammatory . months were given by der diseases of death . months respectively .',"b'treatment with r-cvp significantly prolonged the time until disease progression or until onset of death compared to cvp ( 33.6 months versus 14.7 months , p 0.0001 , log-rank test ) .'"
634,b'wie ist eucreas einzunehmen ? 4.',b'how to take eucreas 4 .',b'how to take eucreas .',b'how to take eucreas 4 .'
635,b'weniger als 2 % der verabreichten dosis erschienen als unver\xc3\xa4ndertes lasofoxifen im urin .',b'less than 2 % of the administered dose erschienen unchanged lasofoxifene is recovered in urine .',b'less than follows within each resorbtion opf the increase to excreted by cypa .',b'less than 2 % of the administered dose is recovered as unchanged lasofoxifene in urine .'
636,b'die patienten erhielten eine antihypertensive therapie ( entweder auf der basis von amlodipin oder atenolol ) und entweder 10 mg atorvastatin t\xc3\xa4glich ( n = 5168 ) oder plazebo ( n = 5137 ) .',b'patients received antihypertensive therapy ( either the amlodipine or atenolol ) and were treated with either atorvastatin 10 mg daily ( n = 5168 ) or placebo ( n = 5137 ) .',b'patients received antihypertensive therapy either the potent hepatic formulations of doses to increase .',b'patients received antihypertensive therapy ( based either on amlodipine or atenolol ) and were treated with either 10mg atorvastatin daily ( n = 5168 ) or placebo ( n = 5137 ) .'
637,"b'veranschlagt sind mittel zur deckung der familienzulagen : haushaltszulage , zulage f\xc3\xbcr unterhaltsberechtigte kinder , vorschulzulage , erziehungszulage ( einschlie\xc3\x9flich besonderer zusch\xc3\xbcsse im rahmen der j\xc3\xa4hrlich vom direktor getroffenen vorkehrungen ) und zuwendungen f\xc3\xbcr elternurlaub f\xc3\xbcr die betroffenen mitarbeiter .'","b'this appropriation is intended to cover the familienzulagen : this appropriation covers family allowances , pre-school allowance , education allowance ( including special grants within the executive director ) and parental leave allowance for the concerned staff .'",b'the glplasmaspiegel study repreents',"b'this appropriation is intended to cover the family allowances : household allowances , dependent children allowance , pre-school allowance , education allowance ( including special grants within the executive director ) and parental leave allowance for the concerned staff .'"
638,"b'es ist wichtig , dass sie olanzapin teva tabletten so lange einnehmen , wie ihr arzt es ihnen empfiehlt .'",b'it is important that you carry on taking olanzapine teva tablets for as long as your doctor tells you .',b'it is important that you carry on taking olanzapine teva tablets for as long as your doctor tells you .',b'it is important that you carry on taking olanzapine teva tablets for as long as your doctor tells you .'
639,b'16 im k\xc3\xbchlschrank lagern ( 2\xc2\xbac-8\xc2\xbac ) .',b'store in a refrigerator ( 2\xc2\xbac-8\xc2\xbac ) .',b'store in a refrigerator inhibiting .',b'store in a refrigerator ( 2\xc2\xbac-8\xc2\xbac ) .'
640,"b'da bei substitutionstherapie der faktor ix-plasmaspiegel erh\xc3\xb6ht ist , wird eine vor\xc3\xbcbergehende korrektur des faktormangels und eine abnahme der blutungstendenz m\xc3\xb6glich .'","b'since increased replacement therapy ( ix-plasmaspiegel , a temporary correction of the faktormangels and a decrease in the rate of blutungstendenz possible .'","b'since increased replacement therapy ctrough , a temporary kaposi and a decrease of comprehensive medicines involved .'","b'since increased replacement therapy of the ix plasma level is increased , a temporary correction of the faktormangels and a decrease in the rate of haemorrage tendencies becomes possible .'"
641,b'kinder und jugendliche es liegen keine erfahrungen bei kindern vor .',b'children and adolescents there is no experience in children .',b'children and adolescents there is no experience in children .',b'children and adolescents . there is no experience in children .'
642,"b'ihr arzt wird sie bitten , schwangerschaftstests durchf\xc3\xbchren zu lassen , bevor sie mit der einnahme von volibris beginnen , sowie regelm\xc3\xa4\xc3\x9fig w\xc3\xa4hrend der behandlung mit volibris .'","b'your doctor will ask you to have regular follow-up ophthalmologic examinations for pregnancy tests before you start taking volibris , and regularly during treatment with volibris .'","b'your doctor will ask you to usually suffer because out if taking volibris , and recurrent impairment of evicel must previously occur for assistance treatment before .'","b'your doctor will ask you to have regular follow-up ophthalmologic examinations for pregnancy tests before you start taking volibris , and regularly during treatment with volibris .'"
643,"b'weitere nebenwirkungen , \xc3\xbcber die nach der markteinf\xc3\xbchrung berichtet wurde , sind unter angabe der h\xc3\xa4ufigkeit in klammern , falls sie bekannt ist , nachfolgend beschrieben .'","b'other side effects have been reported during post- marketing experience are described below the target frequency in brackets , if it is known .'","b'other side effects have been reported during case of patients in neonates , if it is known .'","b'other side effects have been reported during post- marketing experience are described below in terms of frequency in brackets , if it is known .'"
644,"b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und dem etikett der durchstechflasche angegebenen verfalldatum ( abk\xc3\xbcrzung "" verw. bis "" ) nicht mehr anwenden .'","b'do not use this medicine after the carton and vial label after the expiry date ( abbreviation "" exp : . ""'",b'do not use these medicine after the carton and vial label after the expiry date .',"b'do not use this medicine after the expiry date printed on the label of the vial ( abbreviation "" exp : "" )'"
645,"b'auch ihr apotheker kann ihnen behilflich sein , wenn sie sich nicht ganz sicher sind .'","b'you will also have pharmacist may tell you to use behilflich , however , if you are not sure .'",b'you will also also take increased these attention with protopic potential or a dose monitoring of both blood sugar or talk to carry .',b'your pharmacist may also be helpful if you are not sure .'
646,b'xigris wird zur behandlung von erwachsenen mit schwerer sepsis eingesetzt .',b'xigris is used to treat adults with severe sepsis .',"b'conventional , the efficacy of very adults with severe sepsis .'",b'xigris is used to treat adults with severe sepsis .'
647,b'der dosierungs- und anwendungsplan f\xc3\xbcr nutropinaq sollte f\xc3\xbcr jeden patienten individuell erstellt werden .',b'the and anwendungsplan of nutropinaq should be adjusted for each patient .',b'the and invivo instructions associated to the following values of nutropina of them .',b'the dose and application plan of nutropinaq should be adjusted for each patient .'
648,"b'86 dies k\xc3\xb6nnte zu einer schweren hyperglyk\xc3\xa4mie ( stark erh\xc3\xb6hter blutzucker ) und ketoazidose ( anh\xc3\xa4ufung von s\xc3\xa4ure im blut , weil der k\xc3\xb6rper bei schwerem insulinmangel energie aus fett anstatt aus zucker gewinnt ) f\xc3\xbchren .'",b'86 this could lead to severe hyperglycaemia ( greatly increased blood sugar ) and ketoacidosis ( build-up of acid in the blood because the body is breaking down fat instead of sugar ) very to .',"b'certain could ohss , an embryo .'",b'86 this could lead to severe hyperglycaemia ( greatly increased blood sugar ) and ketoacidosis ( build-up of acid in the blood because the body is breaking down fat instead of sugar ) .'
649,"b'zus\xc3\xa4tzlich zu probenecid m\xc3\xbcssen patienten unmittelbar vor jeder cidofovir-infusion insgesamt einen liter einer 0,9 % igen physiologischen kochsalzl\xc3\xb6sung intraven\xc3\xb6s erhalten .'",b'in addition to probenecid patients must be administered intravenously immediately before each cidofovir infusion ( 54 ) and a total of 0.9 % sodium chloride solution .',b'in addition to probenecid patients must be administered intravenously immediately before supplied at three injection mg tablet .',"b'in addition to probenecid , patients must immediately receive one liter of 0.9 % sodium chloride solution intravenously before each cidofovir infusion .'"
650,"b'30 ( 3x10 ) , 60 ( 6x10 ) , 90 ( 9x10 ) und 100 ( 10x10 ) filmtabletten ; 14 ( 2x7 ) , 28 ( 4x7 ) , 56 ( 8x7 ) und 70 ( 10x7 ) filmtabletten .'","b'30 ( 3x10 ) , 60 ( ) , 90 ( ) and 100 ( 10x10 ) film-coated tablets ; 14 ( 2x7 ) , 28 ( 4x7 ) , 56 ( 8x7 ) , and 70 ( 10x7 ) film-coated tablets .'","b'x , , and x packs , x , filmcoated tablets .'","b'30 ( 3x10 ) , 60 ( 6x10 ) , 90 ( 9x10 ) and 100 ( 10x10 ) film-coated tablets ; 14 ( 2x7 ) , 28 ( 4x7 ) , 56 ( 8x7 ) , and 70 ( 10x7 ) film-coated tablets .'"
651,b'die einnahme kann zu jeder tageszeit unabh\xc3\xa4ngig von den mahlzeiten erfolgen .',b'it may be taken at any time of day with or without food .',b'it may be taken at any time of day with or without food .',b'it may be taken at any time of day with or without food .'
652,b'es wird keine dosisanpassung f\xc3\xbcr champix und die unten aufgef\xc3\xbchrten arzneimittel bei gleichzeitiger anwendung empfohlen .',b'it is recommended that no dose adjustment of champix and the below mentioned medicinal products are co-administered .',b'it is recommended that no dose adjustment of champix and the corresponding dose under see .',b'it is recommended that no dose adjustment of champix and the below mentioned medicinal products are co-administered .'
653,b'wie alle arzneimittel kann xyrem nebenwirkungen haben .',"b'like all medicines , xyrem can have side effects .'","b'like all medicines , continue can have side effects .'","b'like all medicines , xyrem can have side effects .'"
654,"b'die gleiche dosis wird auch f\xc3\xbcr personen \xc3\xbcber 65 jahren empfohlen , sofern sie eine normale nierenfunktion haben .'","b'the same dose is also recommended for people over 65 years of age , unless their kidneys .'","b'the same dose is also recommended for people over years of age , unless their kidneys .'","b'the same dose is also recommended for people over 65 years of age , unless their kidneys are abnormal .'"
655,b'die prognosen f\xc3\xbcr 2006 lassen auf einen weiteren deutlichen anstieg der zahl der tagungen und delegiertentage schlie\xc3\x9fen .',b'the number of meetings for 2006 suggest a marked increase in the number of meetings and delegiertentage .',b'the number of flipoff for suggest a marked increase in the number of mammals and glucocorticosteroids .',b'predictions for 2006 suggest a further clear increase in the number of meetings and delegate days .'
656,"b'im k\xc3\xb6rper reguliert protein c die bildung von thrombin , einer der an der blutgerinnung beteiligten substanzen ( faktoren ) .'","b'in the body , at about the production of thrombin , the blood clot at the site of the substances ( factors ) .'","b'in the body , at about the production of thrombin , the blood clot at the deficiency of the occurrence of the substances factors .'","b'in the body protein c regulated the formation of thrombin , one of the substances ( factors ) involved in blood clotting .'"
657,b'sebivo wird zur behandlung von erwachsenen mit chronischer hepatitis b angewendet .',b'sebivo is used to treat adult patients with chronic hepatitis b or c ) .',b'sebivo is used to treat adult patients with chronic hepatitis b of death .',b'sebivo is used to treat adult patients with chronic hepatitis b.'
658,"b'22 / 67 nicht bei gefl\xc3\xbcgel anwenden , dessen eier zum menschlichen verzehr vorgesehen sind .'","b'22 / 64 do not use in poultry , eggs for producing milk for human consumption .'","b'do not use in poultry , eggs for metformin physical tamiflu .'",b'22 / 64 do not use in poultry whose eggs are for human consumption .'
659,b'welche nebenwirkungen sind m\xc3\xb6glich ? 5. wie ist epivir aufzubewahren ?',b'possible side effects 5 how to store epivir 4 .',b'how to store epivir .',b'possible side effects 5 how to store epivir 4 .'
660,b'der wirkstoff von zeffix ist lamivudin .',b'the active substance of zeffix is lamivudine .',b'the active information of zeffix is activity .',b'the active substance of zeffix is lamivudine .'
661,b'im falle einer versehentlichen ( selbst ) injektion ziehen sie sofort einen arzt zu rate und zeigen sie dem arzt die packungsbeilage .',"b'in the case of accidental ingestion , seek medical advice immediately and show the package leaflet with you .'","b'in the case of accidental ingestion , be prescribed any ingredients or show the package leaflet , but to a forms of treatment or show the package leaflet before you .'","b'in the case of accidental ingestion , seek medical advice immediately and show the package leaflet with you .'"
662,b'aus diesem grund ist eine regelm\xc3\xa4\xc3\x9fige \xc3\x9cberwachung der h\xc3\xa4matologischen parameter erforderlich .',"b'therefore , routine monitoring of haematological parameters .'","b'therefore , abrupt monitoring of haematological level .'","b'therefore , routine monitoring of haematological parameters is required .'"
663,b'wie wurde extavia untersucht ?',b'how has extavia been studied ?',b'how has extavia been studied ?',b'how has extavia been studied ?'
664,"b'zeffix filmtabletten sind in versiegelten packungen , die folienblister mit 28 oder 84 filmtabletten enthalten , im handel .'","b'zeffix film-coated tablets are supplied in cartons containing folienblister of 28 and 84 film-coated tablets contain , in .'","b'look filmcoated tablets are available in cartons containing opiate of blue polyethylene dose tablets contain , in .'",b'zeffix film-coated tablets are supplied in cartons containing folienblister of 28 and 84 film-coated tablets contain .'
665,b'mit ansteigender dosis sinkt die bioverf\xc3\xbcgbarkeit .',b'with escalation of the dose is reduced to its bioavailability .',b'for ergosterol approximately feeding of the dose is reduced to its bioavailability .',b'bioavailability reduces with dose escalation .'
666,"b'besondere vorsicht bei der anwendung von lantus ist erforderlich halten sie sich hinsichtlich der dosierung , \xc3\x9cberwachung ( blut- und urintests ) , di\xc3\xa4t und k\xc3\xb6rperlichen aktivit\xc3\xa4t ( k\xc3\xb6rperliche arbeit und sportliche bet\xc3\xa4tigung ) sowie der injektionstechnik genau an die mit ihrem arzt besprochenen anweisungen .'","b'special caution should be exercised in the use of lantus is required for dosage , monitoring ( blood and urine tests ) , diet and physical activity ( physical work and exercise ) , injection technique as accurately with your doctor besprochenen under the supervision of your doctor .'",b'special caution should be exercised whether the for careful age regime .',"b'special caution should be exercised in the use of lantus for dosage , monitoring ( blood and urine tests ) , diet and physical activity ( physical work and exercise ) , injection technique as accurately with your doctor besprochenen under the supervision of your doctor .'"
667,b'jede filmtablette enth\xc3\xa4lt 200 mg lopinavir in kombination mit 50 mg ritonavir zur verbesserung der pharmakokinetik .',b'each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer .',b'each filmcoated tablet contains mg of lopinavir dysentery with mg of ritonavir as a pharmacokinetic involved .',b'each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer .'
668,b'vereinzelt wurde \xc3\xbcber nicht schwerwiegende allergische reaktionen auf pergoveris berichtet .',b'isolated reports do not have serious allergic reactions to pergoveris have been reported .',"b'isolated reports , a daily of them .'",b'isolated reports of non-serious allergic reactions to pergoveris have been reported .'
669,b'datum der erstlizenzvergabe :',b'date of erstlizenzvergabe :',b'date of dermatofibrosarcoma',b'date of first authorisation :'
670,b'die farbe der suspension ist wei\xc3\x9f bis gebrochen wei\xc3\x9f .',b'the colour of the suspension has a white to off-white .',b'the next box of the suspension has a white to offwhite .',b'the colour of the suspension is white to off-white .'
671,b'eigenschaften bei der anwendung am patienten die pharmakokinetik von entacapon ist bei jungen und \xc3\xa4lteren erwachsenen vergleichbar .',b'characteristics in patients pharmacokinetics of entacapone is similar to that in young and elderly adults .',b'skip less is similar to that in young and elderly adults',b'characteristics in patients : pharmacokinetics of entacapone is similar to that in young and elderly adults .'
672,b'doxazosin winthrop [ und andere bezeichnungen ] 4 mg retardtabletten k\xc3\xb6nnen die plasmareninaktivit\xc3\xa4t und die renale ausscheidung von vanillinmandels\xc3\xa4ure beeinflussen .',b'doxazosin winthrop 4 mg prolonged release tablets and associated names may influence plasma renin activity and urinary excretion of vanillinmandels\xc3\xa4ure .',b'doxazosin winthrop mg prolonged release tablets and associated names may influence plasma',b'doxazosin winthrop 4 mg prolonged release tablets and associated names may influence plasma renin activity and urinary excretion of vanillyl mandelic acid .'
673,b'diese cd4-zellen spielen eine wichtige rolle f\xc3\xbcr die aufrechterhaltung eines intakten immunsystems zur bek\xc3\xa4mpfung von infektionen .',b'these cd4 cells play an important role in the maintenance of intact silk of the body to fight infections .',b'these cd cells crosses one has cause the of growth of benign mineralisation of the body to fight infections .',b'these cd4 cells play an important role in the maintenance of intact silk of the body to fight infections .'
674,"b'das enzym wird von einer zelle hergestellt , in die ein gen ( dna ) eingebracht wurde , das die zelle zur herstellung des enzyms bef\xc3\xa4higt .'","b'the enzyme is made by a cell that has received a gene ( dna ) , which makes the cell .'",b'the enzyme is made by a cell in which are bind to a gene dna technology',b'the enzyme is made by a cell that has received a gene ( dna ) that makes the cell able to produce the enzyme .'
675,"b'nebenwirkungen , die w\xc3\xa4hrend den klinischen studien mit tritanrix hepb auftraten , waren folgende :'",b'side effects that occurred during clinical trials with tritanrix hepb were as follows :',b'side effects that occurred in the following larger is observed during clinical trials with tritanrix hepb were as follows',b'side effects that occurred during clinical trials with tritanrix hepb were as follows :'
676,b'in populationsbasierten studien zur pharmakokinetik wurden die pharmakokinetischen eigenschaften von dabigatran bei patienten mit einem k\xc3\xb6rpergewicht von 48 bis 120 kg beurteilt .',"b'in populationsbasierten pharmacokinetics studies , the pharmacokinetic properties of dabigatran in patients weighing 48 to 120 kg .'","b'in similarities pharmacokinetics studies , the pharmacokinetic properties of dabigatran in patients weighing to kg .'","b'in populatilon based pharmacokinetic studies , the pharmacokinetic properties of dabigatran in patients weighing 48 to 120 kg are evaluated .'"
677,b'myocet erwies sich in allen drei studien als genauso wirksam wie die vergleichspr\xc3\xa4parate .',b'myocet was shown in all three studies was as effective as comparator treatments .',b'myocet was shown in all three protein than removal diabetes .',b'myocet was shown in all three studies to be as effective as comparator treatments .'
678,"b'sind noch bl\xc3\xa4schen vorhanden , so klopfen sie leicht gegen die durchstechflasche , um das absetzen zu unterst\xc3\xbctzen .'","b'are such as blisters , gently tap the vial , discontinuation .'","b'are lip as blisters , a large growth factors .'","b'if such bubbles are present , gently tap the vial to assist settling .'"
679,"b'im allgemeinen war die wahrscheinlichkeit des auftretens von reaktionen im zusammenhang mit der infusion bei patienten , die positiv auf igg-antik\xc3\xb6rper getestet wurden , gr\xc3\xb6\xc3\x9fer als bei nicht positiv getesteten patienten .'","b'in general , the incidence of infusion related reactions in patients who tested positive for igg antibodies were tested is greater than the tested in patients to be positive .'","b'in general , the incidence of infusion related reactions in patients who tested rapidly not not pronounced tumour than the intelence in patients'","b'in general , the incidence of infusion related reactions in patients who tested positive for igg antibodies is greater than in patients tested to be positive .'"
680,b'die blutungsgefahr kann bei gleichzeitiger therapie mit heparin erh\xc3\xb6ht sein .',b'the risk of bleeding may be increased by concomitant therapy with heparin .',b'the risk of organ nature of a clinical transplant by concomitant therapy with heparin .',b'the risk of bleeding may be increased by concomitant therapy with heparin .'
681,b'f\xc3\xbchren sie immer die notfallmedikation ihres kindes zur inhalation f\xc3\xbcr asthmaanf\xc3\xa4lle mit sich .',"b""always inject your child 's inhaled rescue medicine for asthma attacks with you .""",b'make when you inject the change for other agent in protection with this system because oral month .',"b""always have your child 's inhaled rescue medicine for asthma attacks with you ."""
682,b'februar 2007 angenommen und die entsprechende entscheidung der kommission am 22. mai 2007 verabschiedet .',b'adopted on 14 february 2007 and the subsequent commission decision adopted on adopted on 22 may 2007 .',b'recorded on february and the subsequent inflammatory decision subject to the cycles .',b'adopted on 14 february 2007 and the subsequent commission decision adopted on adopted on 22 may 2007 .'
683,b'diabetes mellitus oder st\xc3\xb6rungen im elektrolythaushalt :',b'- diabetes mellitus or in a fluid or electrolyte imbalance :',b'diabetes mellitus or in a fluid or buprenorphine problems',b'- diabetes mellitus or disturbances in the electrolyte imbalance :'
684,b'mabcampath ist ein konzentrat zur herstellung einer infusionsl\xc3\xb6sung ( tropfinfusion in eine vene ) .',b'mabcampath is a concentrate that is made up into a solution for infusion ( drip into a vein ) .',b'mabcampath is a concentrate . doctors into a solution for infusion drip into a vein .',b'mabcampath is a concentrate for the production of a solution for infusion ( drip into a vein ) .'
685,"b'wenn sie in ihrer krankengeschichte eine lebererkrankung hatten , einschlie\xc3\x9flich chr onisch aktiver hepatitis .'","b'if you have a history of liver disease , including chr onisch active hepatitis .'","b'if you have a history of liver disease , including occult selfendangering nonselective active hepatitis .'","b'if you have a history of liver disease , including chronic active hepatitis .'"
686,"b'63 au\xc3\x9ferdem kann axura ihr reaktionsverm\xc3\xb6gen so weit ver\xc3\xa4ndern , dass das sichere f\xc3\xbchren von fahrzeugen und bedienen von maschinen nicht mehr gew\xc3\xa4hrleistet ist .'","b'63 in addition , axura may alter your ability to react as far as that of the drive and use machines not available .'","b'in addition , axura may alter your ability to react as confusion as an important whether your ability to well the examination medicine .'","b'63 in addition , axura may alter your ability to react so strongly that driving and the use machinery is not warranted .'"
687,"b'bis mittelschweren atopischen dermatitis wirksam ist ; nach ansicht des chmp sollten die therapeutischen indikationen auf patienten beschr\xc3\xa4nkt werden , bei denen eine behandlung mit topischen corticosteroiden nicht ratsam oder nicht m\xc3\xb6glich ist .'","b'moderate atopic dermatitis , 1-methylimidazole , the chmp is of the therapeutic indication should be restricted to patients for whom treatment with topical corticosteroids is either inadvisable or not possible .'","b'moderate deferiprone , performing them , the chmp is of the therapeutic indication should be administered to patients for relevant treatment with large corticosteroids is discontinue inadvisable or necessary .'",b'until moderate atopic dermatitis is effective ; according to the chmp therapeutic indication should be restricted to patients for whom treatment with topical corticosteroids is either inadvisable or not possible .'
688,b'die thrombozytenaggregation und blutungszeit normalisierten sich im allgemeinen innerhalb von 5 tagen nach beendigung der therapie .',"b'platelet aggregation and bleeding time gradually returned to baseline values , generally within 5 days after treatment .'",b'the used decrease were achieved in whom per place with further within days after treatment .',"b'platelet aggregation and bleeding time gradually returned to normal values , generally within 5 days after treatment .'"
689,b'pioglitazon wird in der leber durch hydroxylierung der aliphatischen methylengruppen umfassend metabolisiert .',b'pioglitazone is metabolised in the liver by hydroxylation extensive .',b'pioglitazone is metabolised in the liver by fluoxetine sites .',b'pioglitazone is extensively metabolised in the liver by hydroxylation .'
690,"b'ihre therapie muss von einem arzt \xc3\xbcberwacht werden , der erfahrung mit der behandlung von schilddr\xc3\xbcsenkrebs besitzt .'",b'your treatment should be supervised by a doctor who has experience in the treatment of cancer .',b'your list should be supervised by a doctor who has currently cause listed .',b'your treatment should be supervised by a doctor who has experience in the treatment of cancer .'
691,b'nach entnahme aus der verpackung sollte foscan unverz\xc3\xbcglich angewendet werden .',b'after taking the foscan should be used immediately .',b'after taking the releases device should be excercised immediately .',"b'after opening the package , foscan should be used immediately .'"
692,"b'eine \xc3\xbcberschie\xc3\x9fende reaktion der ovarien f\xc3\xbchrt selten zu signifikanter \xc3\x9cberstimulation , wenn nicht hcg zur triggerung der ovulation angewendet wird .'",b'very rarely leads to significant hyperstimulation unless hcg is administered to trigger ovulation .',b'very rarely will been rare by as alendronate at specifically .',b'an excessive reaction by the ovaries rarely leads to significant overstimuationery rarely leads to significant hyperstimulation unless hcg is administered to trigger ovulation .'
693,b'cerenia kann gegen erbrechen einmal t\xc3\xa4glich \xc3\xbcber bis zu f\xc3\xbcnf tage entweder in tablettenform oder als injektionsl\xc3\xb6sung verabreicht werden .',b'cerenia can be given to help prevent vomiting once daily for up to five days in a tablet form or as a solution for injection .',b'cerenia can be given to empty .',b'cerenia can be given to help prevent vomiting once daily for up to five days in a tablet form or as a solution for injection .'
694,b'- pimozid ( zur behandlung von schizophrenie ) ;',b'\xe2\x88\x92 if you are currently taking any of the following medicines :',b'if you are currently taking any of the following medicines',b'- pimozid ( for the treatment of schizophrenia )'
695,b'vor dem eintropfen von lumigan sollten kontaktlinsen daher heraus- genommen und fr\xc3\xbchestens 15 minuten nach der anwendung der tropfen wieder eingesetzt werden .',b'before wait lumigan should wear contact lenses method and wait 15 minutes after instillation of the dose .',"b'if your infusion , wait vivanza should explain your body doses'","b'before putting lumigan drops in your eyes , contact lenses should be taken out and wait 15 minutes after dose before putting them back in .'"
696,"b'es ist zu erwarten , dass andere hochwirksame inhibitoren von cyp2d6 , wie fluoxetin und paroxetin , \xc3\xa4hnliche effekte haben und deshalb sollten \xc3\xa4hnliche dosisreduktionen vorgenommen werden .'","b'it is expected that other potent inhibitors of cyp2d6 , such as fluoxetine and paroxetine , have similar effects and similar dose reductions should therefore be applied .'",b'it is expected that other potent inhibitors of kaletra were be added to an glaucomatous may generally observed as well as one function with soft inhibitors are a relaxation has been applied .',"b'it is expected that other potent inhibitors of cyp2d6 , such as fluoxetine and paroxetine , have similar effects and similar dose reductions should therefore be applied .'"
697,b'102 art der anwendung irbesartan bms ist nur zur einnahme bestimmt .',b'102 method of administration irbesartan bms is for oral use .',b'method of administration irbesartan bms is for oral use .',b'102 method of administration irbesartan bms is for oral use .'
698,b'lisinopril kann durch dialyse aus dem plasma entfernt werden .',b'lisinopril can be removed by dialysis from plasma .',b'lisinopril can be removed by dialysis from plasma .',b'lisinopril can be removed by dialysis from plasma .'
699,"b'\xc3\x9cber mitochondriale toxizit\xc3\xa4t und laktatazidose wurde bei hiv-positiven patienten berichtet , die eine behandlung mit nrtis zusammen mit ribavirin bei hcv co-infektion erhielten ( siehe abschnitt 4.4 ) .'",b'mitochondrial toxicity and lactic acidosis have been reported in hiv-positive patients receiving treatment with nrtis in combination with ribavirin in hcv co-infection ( see section 4.4 ) .',b'values ii and radiolabelled acidosis that not been reported in applications patients receiving treatment with nrtis in combination with ribavirin in a injection with aripiprazole in and benzodiazepines .',b'mitochondrial toxicity and lactic acidosis have been reported in hiv-positive patients receiving treatment with nrtis in combination with ribavirin ( see section 4.4 ) .'
700,b'in der studie mit kindern f\xc3\xbchrten apidra und insulinlispro zu \xc3\xa4hnlichen \xc3\x84nderungen der hba1c-konzentration nach sechs monaten .',b'in the study of children resulted in the lispro and apidra brought about similar changes in hba1c-konzentration after six months .',"b'in the study of children tipranavir in the same , xolair .'",b'in the study of children apidra and insulin lispro brought about similar changes in hba1c concentration after six months .'
701,b'myfenax 250 mg hartkapseln sind in pvc / pvdc-aluminium-blisterpackungen in packungsgr\xc3\xb6\xc3\x9fen mit je 100 oder 300 kapseln pro faltschachtel erh\xc3\xa4ltlich .',b'myfenax 250 mg hard capsules are available in pvc / pvdc - aluminium blisters in pack sizes of 100 or 300 capsules per carton .',b'myfenax mg hard capsules are available in pvc pvdc aluminium blisters packs of or capsules per carton .',b'myfenax 250 mg hard capsules are available in pvc / pvdc aluminium blisters in pack sizes of 100 or 300 capsules per carton .'
702,b'138 h\xc3\xa4ufigkeit unbekannt :',b'138 musculoskeletal and connective tissue disorders :',b'musculoskeletal and connective tissue disorders',b'138 incidence not known :'
703,"b'am 22. april 2008 teilte wyeth europa limited dem ausschuss f\xc3\xbcr humanarzneimittel ( chmp ) offiziell mit , dass das unternehmen seinen antrag f\xc3\xbcr eine neue indikation f\xc3\xbcr tygacil zur behandlung von ambulant erworbener pneumonie zur\xc3\xbccknimmt .'","b'on 22 april 2008 , wyeth europa limited officially notified the committee for medicinal products for human use ( chmp ) that it wishes to withdraw its application for a new indication for tygacil , in the treatment of community-acquired pneumonia that it wishes to withdraw its application .'",b'the applicant the vaccine for age with the efficacy for this basis for the opening and suggestions prostatespecific time where the mrp over the indication for strict hypertrophy and a new indication for the management of you amd on a new indication for optimal part factors',"b'on 22 april 2008 , wyeth europa limited officially notified the committee for medicinal products for human use ( chmp ) that it wishes to withdraw its application for a new indication for tygacil in the outpatient treatment of acquired pneumonia .'"
704,b'studien an ratten deuten unter langfristiger anwendung von preotact auf eine erh\xc3\xb6hte inzidenz an osteosarkomen hin ( siehe abschnitt 5.3 ) .',b'studies in rats indicate that under the use of preotact and an increased incidence of osteosarcoma ( see section 5.3 ) .',b'studies in rats methotrexate on the use of preotact and an increased incidence of tolerance see section . .',b'studies in rats indicate that an increased incidence of osteosarcoma ( see section 5.3 ) under the longterm use of preotact .'
705,b'daher wird die anwendung von xeristar bei kindern und jugendlichen nicht empfohlen ( siehe abschnitt 4.4 ) .',"b'therefore , the use of xeristar in children and adolescents is not recommended ( see section 4.4 ) .'","b'therefore , the use of xeristar in children and adolescents is not recommended see section . .'","b'therefore , the use of xeristar in children and adolescents is not recommended ( see section 4.4 ) .'"
706,b'warum wurde orencia zugelassen ?',b'why has orencia been approved ?',b'why has orencia been approved ?',b'why has orencia been approved ?'
707,"b'9 \xc3\x9cberempfindlichkeit : es wurden \xc3\x9cberempfindlichkeitsreaktionen , einschlie\xc3\x9flich angioneurotischem \xc3\x96dem und anaphylaktischer reaktionen , gemeldet .'","b'9 hypersensitivity : hypersensitivity reactions , including angioneurotic oedema and anaphylactic reaction have been reported .'","b'hypersensitive effects , including corneal reactions and anaphylactic reaction have been reported .'","b'9 hypersensitivity : hypersensitivity reactions , including angioneurotic oedema and anaphylactic reaction have been reported .'"
708,"b'1,5 ml suspension zum einnehmen in einer tube zum ausdr\xc3\xbccken ( polyethylen ) mit einem tubenverschluss und einer tubenkappe ( polypropylen ) in packungsgr\xc3\xb6\xc3\x9fen zu 1 , 10 oder 50.'","b'1.5 ml of oral suspension in a squeezable tube ( polyethylene ) with a tip and a tubenkappe child resistant closure ( polypropylene ) pack sizes of 1 , 10 or 50 .'","b'. ml of oral suspension in a sterilised tube , day , which .'","b'1.5 ml of oral suspension in a squeezable tube ( polyethylene ) with a tube seal and a tube cap ( polypropylene ) . pack sizes of 1 , 10 or 50 .'"
709,b'welche dokumentation hat das unternehmen dem chmp zur st\xc3\xbctzung des antrags vorgelegt ?',b'what is the company documentation to support its application to the chmp ?',b'what is the company documentation to support these application to the marketing member spc to the chmp ?',b'what documentation does the company have to support its application to the chmp ?'
710,b'f\xc3\xa4lle von cholelithiasis wurden im zusammenhang mit einer gemfibrozil-therapie berichtet . bei verdacht auf eine cholelithiasis werden untersuchungen der gallenblase empfohlen .',b'cases of cholelithiasis have been associated with gemfibrozil-therapie . in case of any symptoms suggesting cholelithiasis evaluations of the gallbladder is recommended .',"b'cases of salizylaten ml necropathy has been associated with difficulttotreat among death , which has been associated with difficulttotreat noncompleter , no animals crossreacting paclitaxel aceinhibitors of the hormone is recommended .'",b'cases of cholelithiasis have been associated with gemofibrozil therapy . in case of any symptoms suggesting cholelithiasis evaluations of the gallbladder is recommended .'
711,"b'attenuiertes felines rhinotracheitis-virus ( herpesvirus stamm fhv f2 ) ............. \xe2\x89\xa5 104,9 gkid501 inaktivierte feline calicivirus-antigene ( st\xc3\xa4mme fcv 431 und g1 ) ..................... \xe2\x89\xa5 2,0 elisa-e .'",b'inhibition of feline feline rhinotracheitis herpesvirus ( fhv f2 strain ) ...................................... \xe2\x89\xa5 104.9 ccid501 inactivated feline calicivirosis antigens ( fcv 431 and fcv g1 strains ) .................... \xe2\x89\xa5 2.0 elisa u.',b'viral studies called antigene originate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .',b'attenuated feline feline rhinotracheitis virus ( fhv f2 strain ) ...................................... \xe2\x89\xa5 104.9 ccid501 inactivated feline calicivirosis antigens ( fcv 431 and fcv g1 strains ) .................... \xe2\x89\xa5 2.0 elisa u.'
712,"b'methadon , ein medikament zur behandlung einer opiatabh\xc3\xa4ngigkeit . ihr arzt muss m\xc3\xb6glicherweise ihre methadon-dosis ver\xc3\xa4ndern .'","b'methadone , a medicine used to treat opiate dependence , as your doctor may need to change your dose of methadone .'","b'your these reactions must be taken , minutes in an mecanical dependence , as your dose of postural .'","b'methadone , a medicine used to treat opiate dependence . your doctor may need to change your dose of methadone .'"
713,b'w\xc3\xa4hrend stressperioden oder im rahmen einer geplanten operation sollte eine zus\xc3\xa4tzliche systemische gabe von kortikoiden in betracht gezogen werden .',b'during stressperioden or planned surgery may be considered additional systemic administration of corticosteroids .',b'during pompe or planned surgery may be removed pef no systemic administration of corticosteroids .',b'during periods of stress or planned surgery an additional systemic administration of corticosteroids should be considered .'
714,b'215 dauer der haltbarkeit nach der ersten verwendung des pens :',b'215 shelf life after first use of the pen :',b'shelf life after first use of the pen',b'215 shelf life after first use of the pen :'
715,b'es wurde \xc3\xbcber das auftreten von antik\xc3\xb6rpervermittelter erythroblastopenie ( prca ) nach monate- bis jahrelanger behandlung mit epoetin alfa berichtet .',b'it has been associated with reports of antik\xc3\xb6rpervermittelter pure red cell aplasia ( prca ) has been reported after months to years of treatment with epoetin alfa .',b'it has been associated with reports of bextra group may been reported after months on viral organic aberrations on the of nonnucleoside pgp buprenorphine can been reported after months to years of treatment with patients on .',b'it has been associated with reports of anti body mediator pure red cell aplasia ( prca ) months to years after treatment with epoetin alfa .'
716,"b'warten , bis die neutrophilenzahl \xe2\x89\xa5 1.500 und die thrombozytenzahl \xe2\x89\xa5 75.000 ; wiederaufnahme ohne dosisreduktion .'","b'wait until the neutrophil count is \xe2\x89\xa5 1,500 and platelet counts \xe2\x89\xa5 75,000 ; resumed , with no dose reductions .'",b'wait until the neutrophil count diphosphate should be administered by dose for monitoring .',"b'wait until the neutrophil count is \xe2\x89\xa5 1,500 and platelet counts \xe2\x89\xa5 75,000 ; resume with no dose reductions .'"
717,"b'die maximalen steady-state-konzentrationen schwanken interindividuell betr\xc3\xa4chtlich , intraindividuell jedoch nur selten .'","b'the maximum steady-state concentrations of the second interindividuell considerably , intra-patient observations , but only rare .'","b'the maximum concentrations of the second transvaginal photon , carboxamide observed to followed .'","b'the maximum steady-state concentrations fluctuate considerably intraindividual , but only rarely .'"
718,b'bei einer temperatur bis zu 30 \xc2\xb0 c und lichtgesch\xc3\xbctzt aufbewahren .',"b'store at a temperature lower than 30 \xc2\xb0 c , protected from light .'","b'store at a injection of unit administered c , protected from light .'","b'store at a temperature lower than 30 \xc2\xb0 c , protected from light .'"
719,b'die empfohlene anfangsdosis betr\xc3\xa4gt 25 mg risperdal consta alle zwei wochen .',b'the recommended starting dose is 25 mg risperdal consta every two weeks .',"b'the recommended starting dose is mg regulation than , mg didanosine consta every two weeks .'",b'the recommended starting dose is 25 mg risperdal consta every two weeks .'
720,b'aufgrund dieser unterschiede betr\xc3\xa4gt die empfohlene dosis von lamivudin f\xc3\xbcr kinder ( mindestens 3 monate alt und mit einem gewicht von weniger als 30 kg ) 4 mg / kg zweimal t\xc3\xa4glich .',"b'due to these differences , the recommended dose for lamivudine in children ( aged more than three months and weighing less than 30 kg ) is 4 mg / kg twice daily .'",b'due to these than dose for lamivudine in children aged on less than daily .',"b'due to these differences , the recommended dose for lamivudine in children ( aged more than three months and weighing less than 30 kg ) is 4 mg / kg twice daily .'"
721,"b'bei komplizierten harnwegsinfektionen kann au\xc3\x9ferdem auch die bildung von biofilm da eine wichtige rolle spielen , wo die empfindlichkeit der pathogene gegen\xc3\xbcber zellen in plankton- oder reinkulturzellen um ein vielfaches reduziert ist . naber et al .'","b'in complicated urinary tract infections may also also ggcgct as to fight , where the susceptibility of the pathogens to be reduced in plankton- or reinkulturzellen analog-human . naber et al .'",b'in complicated urinary tract infections may also osteoinductive as a total loss effects originating in tubulin or glycinamide strains .',"b'in complicated urinary tract infections , the formation of biofilm may also play an important role , where the susceptibility of the pathogens to be reduced in planctonic or pure culture cells .'"
722,"b'eine durchstechflasche mit pulver enth\xc3\xa4lt 3 mikrogramm follitropin alfa , damit 2,8 mikrogramm , entsprechend 37,5 i.e. , entnommen werden k\xc3\xb6nnen .'","b'one vial of powder contains 3 micrograms of follitropin alfa in order to deliver 2.8 micrograms , equivalent to 37.5 iu .'",b'one vial of powder contains micrograms of follitropin alfa in order to . iu with transferred with contain insulin l .',"b'one vial of powder contains 3 micrograms of follitropin alfa in order to deliver 2.8 micrograms , equivalent to 37.5 iu .'"
723,"b'bei ac-052-356 handelte es sich um eine offene , nicht kontrollierte studie . w\xc3\xa4hrend der 12-w\xc3\xb6chigen studie erhielten 10 der 19 p\xc3\xa4diatrischen patienten gleichzeitig tracleer und epoprostenol .'","b'in ac-052-356 was a open-label , controlled study . in the 12 week trial , 10 of the 19 paediatric patients were on concomitant tracleer and epoprostenol .'",b'in halocur was tested by the therapy of the toxicity of the disorders were on concomitant diseases and protective diseases and rheumatoid failure .',"b'ac-052-356 involves open , uncontrolled study . in the 12 week trial , 10 of the 19 paediatric patients received concomitant tracleer and epoprostenol .'"
724,b'stellen sie die durchstechflasche mit dem pulver aufrecht auf einen festen und sauberen untergrund .',"b'place the powder vial upright on a clean , 13 or 14 .'","b'place the powder vial upright on a clean , or .'","b'place the vial with the powder upright on a solid , clean surface .'"
725,b'kommission eine genehmigung f\xc3\xbcr das inverkehrbringen von ferriprox in der gesamten europ\xc3\xa4ischen union . die genehmigung f\xc3\xbcr das inverkehrbringen wurde am 25.',b'commission granted a marketing authorisation valid throughout the european union for ferriprox . the marketing authorisation was renewed on 25 may 2005 .',b'siklos is marketing authorisation valid throughout the european inovelon throughout the european union for ferriprox . the marketing authorisation is renewed on may .',b'commission granted a marketing authorisation valid throughout the european union for ferriprox . the marketing authorisation was renewed on 25 may 2005 .'
726,"b'reconcile darf bei hunden mit epilepsie oder hunden , die in der vergangenheit anf\xc3\xa4lle hatten , nicht angewendet werden .'",b'reconcile should not be used in dogs with epilepsy or a history of seizures .',b'reconcile should not be used in dogs with epilepsy or a history of seizures .',b'reconcile should not be used in dogs with epilepsy or a history of seizures .'
727,b'sifrol kann die milchbildung hemmen .',b'driving and using machines sifrol can reduce the production of breast milk .',"b'driving and using viread out recommended , occlusion of .'",b'sifrol can reduce the production of breast milk .'
728,b'nehmen sie sofort kontakt mit der notaufnahme des n\xc3\xa4chstgelegenen krankenhauses oder mit ihrem arzt oder apotheker auf .',b'contact in the hospital emergency room of the beat or contact your doctor or pharmacist .',b'contact you ask the hospital hiv of the breasts hyperglycaemia or pharmacist .',b'contact the nearest hospital emergency room or your doctor or pharmacist .'
729,"b'stellen sie sicher , dass die tube nach jedem gebrauch fest verschlossen ist .'",b'make sure the tube firmly after each use .',b'make sure the tube upside after each use .',b'make sure the tube is firmly closed after each use .'
730,b'- eingeschr\xc3\xa4nktes bewusstsein ( z.b. koma ) .',b'- eingeschr\xc3\xa4nktes level of consciousness ( e. g. coma ) .',b'potassiumsparing level of dopaminergic e . g . carbamazepine .',b'- impaired level of consciousness ( e. g. coma ) .'
731,"b'denken sie bei reisen oder krankenhausaufenthalten immer daran , gen\xc3\xbcgend kaletra mitzunehmen .'","b'remember to check with { mm / yyyy } , remember to take enough kaletra .'","b'think or ciprofloxacin , sweets or hospital for enough kaletra .'",b'remember to take enough kaletra with you while traveling or during hospital stays .'
732,b'kurz den roten knopf dr\xc3\xbccken und dann wieder loslassen .',b'briefly press and then again at loslassen .',"b'kills diffuse the set , the use with gently ball brown and then again at reichlichen need and then again at secondary solutions or then again at postexposure insulin preparation .'",b'briefly press and then release again .'
733,b'leiden auch an wachstumshormonmangel .',b'also have a diagnosis of growth hormone deficiency .',b'also suffer . may be unchanged with modified as the potential .',b'also have a diagnosis of growth hormone deficiency .'
734,b'die tabletten sollten mindestens 2 tage \xc3\xbcber das abklingen der klinischen symptome hinaus verabreicht werden .',"b'the tablets should be at least 2 days beyond the resolution of clinical signs , withdrawal .'","b'the tablets should receive deposits over the periods of clinical signs , withdrawal proteins .'",b'the tablets should be administered at least 2 days beyond the clinical signs .'
735,"b'lokal an der injektionsstelle auftretende nebenwirkungen , die meist mild und von kurzer dauer waren , wurden bei patienten beobachtet , die temodal 2,5 mg / ml pulver zur herstellung einer infusionsl\xc3\xb6sung erhielten .'","b'beneath the injection site , adverse reactions , which are mostly mild and of short duration , have been reported in patients taking temodal 2.5 mg / ml powder for solution for infusion .'","b'the injection site , adverse reactions , which are mostly mild and of repaglinide miscarriage scheme and the vaccine .'","b'local at the injection site , adverse reactions , which are mostly mild and of short duration , have been reported in patients taking temodal 2.5 mg / ml powder for solution for infusion .'"
736,b'begleittherapie-phase tmz wird t\xc3\xa4glich verabreicht mit einer dosis von 75 mg / m2 f\xc3\xbcr 42 tage gleichzeitig mit fokaler radiotherapie ( 60 gy angewendet in 30 fraktionen ) .',b'concomitant phase tmz is administered daily at a dose of 75 mg / m2 for 42 days concomitant with focal radiotherapy ( 60 gy administered in 30 fractions ) .',b'concomitant phase of topical dose of the diseases .',b'concomitant phase tmz is administered daily at a dose of 75 mg / m2 for 42 days concomitant with focal radiotherapy ( 60 gy administered in 30 fractions ) .'
737,b'in klinischen studien an kindern war die behandlung mit fluoxetin mit einer abnahme der konzentration der alkalischen phosphatase verbunden .',"b'in paediatric clinical trials , treatment with fluoxetine was associated with a decrease in concentrations of alkaline phosphatase .'",b'in paediatric clinical trials of consciuosness evidence curve checkups during administration of nsaids led to a decrease in these development anakinra .',"b'in paediatric clinical trials , treatment with fluoxetine was associated with a decrease in concentrations of alkaline phosphatase .'"
738,"b'40 nebenwirkungen , die zumindest als m\xc3\xb6glicherweise im zusammenhang mit der entecavir-behandlung stehend eingestuft wurden , sind nach anatomischen systemorganklassen ( soc ) aufgelistet :'","b'40 adverse reactions may be related to entecavir-behandlung considered at least possibly related to , 16440 , by system organ class ( soc ) are listed below :'","b'adverse reactions may be related to buspirone than the disease , or positive .'","b'40 adverse reactions , that may beat least possibly related to entecavir treatment , are listed below accroding by system organ class ( soc ) :'"
739,b'beobachtet . allerdings war das auftreten selten .',"b'have been observed . however , the possibility of rare .'",b'associated with local vasodilators in rare from headache as well one potential .',"b'have been observed . however , the incidence was rare .'"
740,b'bei brustkrebs im fr\xc3\xbchstadium wird herceptin alle drei wochen verabreicht .',"b'in early breast cancer , herceptin is given every three weeks .'","b'pramipexole , a body .'","b'in early breast cancer , herceptin is given every three weeks .'"
741,b'novorapid ist eine klare farblose l\xc3\xb6sung zur injektion .',"b'novorapid is a clear , colourless solution for injection .'","b'novorapid is a clear , colourless solution for injection .'","b'novorapid is a clear , colourless solution for injection .'"
742,"b'\xe2\x80\xa2 es ist m\xc3\xb6glich , dass psychiatrische reaktionen nach der ersten einnahme von ciprofloxacin bayer auftreten .'",b'\xe2\x80\xa2 it is possible that psychiatric reactions the first time you take ciprofloxacin bayer .',b'it are possible that psychiatric reactions occur to the patient .',b'\xe2\x80\xa2 it is possible that psychiatric reactions occur the first time you take ciprofloxacin bayer .'
743,b'wie ist keppra einzunehmen ?',b'how to take keppra 4 .',b'how to take keppra .',b'how to take keppra 4 .'
744,b'zu infektionen k\xc3\xb6nnen rascher voranschreiten und schwerwiegender verlaufen .',b'infections may progress more rapidly and be more severe .',b'infections may consider more present . two of patients .',b'infections may progress more rapidly and be more severe .'
745,"b'es sollte kein anderer impfstoff gleichzeitig mit diesem produkt mittels injektion in h\xc3\xbchnereier angewendet werden , da hierzu keine spezifischen untersuchungen vorliegen .'",b'it is no other vaccine should be administered concurrently with the product by continuous subcutaneous injection in h\xc3\xbchnereier since the absence of specific studies .',b'it is no other vaccine should be administered concurrently with the product by continuous subcutaneous injection in postnatally since the veins of specific studies .',b'no other vaccine should be administered concurrently with the product by injection in chicken eggs since no specific studies have been carried out .'
746,"b'nach verabreichung der doppelten dosis bei h\xc3\xbchnern und pekingenten wurden keine anderen nebenwirkungen beobachtet als die , wie in abschnitt 6 beschrieben ..'",b'following the administration of a double dose in chickens and pekingenten no other side effects have been observed and described in section 6 .',b'following the administration of a double dose in chickens and hence no other side effects have been observed and described in section .',"b'following the administration of a double dose in chickens and peking ducks , no other side effects have been observed than those described in section 6 .'"
747,"b'l\xc3\xb6sung nicht verwenden , wenn undurchsichtige partikel , eine verf\xc3\xa4rbung oder andere fremdk\xc3\xb6rper vorhanden sind .'","b'do not use if opaque particles , discolouration , or other foreign particles are present .'","b'do not use if olanzapine injection , discolouration after precautions .'","b'do not use if opaque particles , discolouration , or other foreign particles are present .'"
748,b'7 die einnahme von alkohol kann die blutzuckerregulierende wirkung von glimepirid auf nicht vorhersagbare weise verst\xc3\xa4rken oder vermindern .',b'7 taking alcohol may increase the blutzuckerregulierende action of glimepiride in an unpredictable fashion .',b'take alcohol may increase the quinolone effect from glimepiride in an endrogenous of glimepiride in an betalactam cataract .',b'7 taking alcohol may increase or decrease the blood sugar regulating action of glimepiride in an unpredictable fashion .'
749,b'stillzeit timolol geht in die muttermilch \xc3\xbcber .',b'lactation timolol is excreted in breast milk .',b'lactation . is excreted in breast milk .',b'lactation : timolol is excreted in breast milk .'
750,"b'kinder und jugendliche prezista wird aufgrund nicht ausreichender daten zur sicherheit , wirksamkeit und pharmakokinetik f\xc3\xbcr die anwendung bei kindern und jugendlichen nicht empfohlen .'","b'children and adolescents prezista is not recommended due to insufficient data on safety , efficacy and pharmacokinetics for use in children and adolescents .'",b'children and adolescents',"b'children and adolescents prezista is not recommended due to insufficient data on safety , efficacy and pharmacokinetics for use in children and adolescents .'"
751,b'wie ist tysabri anzuwenden ?',b'how to use tysabri 4 .',b'how to use tysabri ?',b'how to use tysabri 4 .'
752,b'diese latenzzeit ist selbst f\xc3\xbcr ein alkylanz sehr kurz .',b'these latenzzeit is very soon even for a genotoxic alkylating agent .',b'these hpg is very venlafaxine out to the cardiomyopathy for a genotoxic airway agent .',"b'this latency period is very short , even for a alkylant'"
753,b'daher sollte der blutdruck vor der behandlung mit etoricoxib eingestellt werden ( siehe abschnitt 4.3 ) und die \xc3\x9cberwachung des blutdrucks sollte w\xc3\xa4hrend der behandlung mit etoricoxib mit besonderer sorgfalt erfolgen .',"b'therefore , blood pressure ( see section 4.3 ) and monitoring of blood pressure should be discontinued during treatment with etoricoxib with caution should be exercised if the commencement of treatment with etoricoxib .'","b'therefore , blood pressure see section . and monitoring of blood pressure should be discontinued during treatment with etoricoxib with avonex is used to proper .'","b'therefore , blood pressure should be assessed before treatment with etoricoxib ( see section 4.3 ) and monitoring of blood pressure should be carried out during treatment with etoricoxib with caution .'"
754,b'viracept wurde auch bei 37 kindern untersucht .',b'viracept has also been studied in 37 children .',b'viracept has also been studied in children .',b'viracept has also been studied in 37 children .'
755,"b'sie d\xc3\xbcrfen biograstim nicht verwenden , wenn es tr\xc3\xbcbe ist oder partikel enth\xc3\xa4lt .'",b'do not use biograstim if it is cloudy or contains particles .',b'do not use biograstim before it can an for suspended particles or contains particles .',b'do not use biograstim if it is cloudy or contains particles .'
756,b'22.03.2002 datum der ersten verl\xc3\xa4ngerung :',b'22.03.2002 date of first renewal :',b'. . date of first renewal',b'22.03.2002 date of first renewal :'
757,"b'anwendung in der schwangerschaft es liegen keine ausreichenden daten am menschen vor , um die sicherheit von pioglitazon w\xc3\xa4hrend der schwangerschaft zu belegen .'",b'use in pregnancy there are insufficient data available in man insufficient to determine the safety of pioglitazone during pregnancy .',b'do on the at more guideline to determine the safety of pioglitazone during pregnancy .',b'use in pregnancy there are insufficient data available in man insufficient to determine the safety of pioglitazone during pregnancy .'
758,"b'es gab keine hinweise auf wirksamkeitsunterschiede im hinblick auf das geschlecht , alter oder den ausgangs-ldl-c-spiegel der patienten .'","b'there was no evidence for identify in terms of gender , age , or ausgangs-ldl-c-spiegel of the patients .'","b'there was no evidence insulinlike dose in terms of gender , age , or positive or amino regardless of the patients .'","b'there was no evidence for efficieny differences in terms of gender , age , initial ldl-c levels of the patients .'"
759,"b'f\xc3\xbcr eine recovery ( wiederfindung ) von 0,7 i.e. / dl ( durchschnittlicher anstieg von faktor ix ) , gilt dann :'","b'for a recovery 0.7 iu / dl ( average increase of factor ix ) , then :'","b'for a recovery . iu dl of factor ix , then'","b'for a recovery of 0.7 iu / dl ( average increase of factor ix ) , then :'"
760,b'die endkonzentration der zu infundierenden l\xc3\xb6sung nach verd\xc3\xbcnnung betr\xc3\xa4gt 5 mg / ml .',b'the final concentration of the this invention of solution after dilution is 5 mg / ml .',b'the final concentration of the test concentrates for solution after dilution is mg ml .',b'the final concentration of the solution to be infused after dilution is 5 mg / ml .'
761,b'in der behandelten population wurde ein anstieg der missbildungen nach polytherapie festgestellt .',"b'in the treated population , an increase in malformations has been noted with polytherapy .'",b'in the treated population compared with extraneous lung',"b'in the treated population , an increase in malformations has been noted with polytherapy .'"
762,"b'infusionen zur kompletten parenteralen ern\xc3\xa4hrung m\xc3\xbcssen bei gleichzeitiger anwendung von vfend nicht unterbrochen werden , sie m\xc3\xbcssen jedoch \xc3\xbcber einen getrennten zugang erfolgen .'","b'total parenteral nutrition ( tpn ) should not be discontinued when co-administered with vfend , but does need to be infused .'","b'two intravenous drug mirena glucosereducing inhibitors with vfend , but does need to be administered .'","b'infusion of total parenteral nutrition ( tpn ) should not be discontinued when co-administered with vfend , but does need to be infused in a different way .'"
763,b'wie ist telzir aufzubewahren ? 6.',b'how to store telzir',b'how to store people',b'how to store telzir'
764,b'118 es werden m\xc3\xb6glicherweise nicht alle packungsgr\xc3\xb6\xc3\x9fen in den verkehr gebracht .',b'118 not all pack sizes may be marketed .',b'not all pack colourless may be marketed .',b'118 not all pack sizes may be marketed .'
765,b'die gleichzeitige anwendung von invirase / ritonavir und mutterkornalkaloiden ist kontraindiziert ( siehe abschnitt 4.3 ) .',b'co-administration of invirase / ritonavir and ergot alkaloids is contraindicated ( see section 4.3 ) .',b'coadministration of invirase ritonavir and rabbits alkaloids is contraindicated see section . .',b'co-administration of invirase / ritonavir and ergot alkaloids is contraindicated ( see section 4.3 ) .'
766,b'tube senkrecht halten und durch leichtes klopfen gegen den twist-off- verschluss die in der dosierspitze befindliche l\xc3\xb6sung entfernen .',b'tube upright and stick the tapping of the twist-off- cap the solution in the dosierspitze in use .',b'tube upright with insertion the accompanying surface in the plastic surface of cm swabs .',b'hold the tube upright and remove the solution in the dose needle by lightly tapping the twist-off-cap .'
767,b'bei ratten wurde eine gallengangsfibrose beobachtet .',b'in rats gallengangsfibrose have been observed .',b'in rats ctrough have been observed in least cholesterol points with food nm in the auc factors olanzapine .',"b'in rats , a bile duct fibrosis was observed .'"
768,"b'bei erh\xc3\xb6hten blutspiegeln an gadofosveset oder bei vorhandenen verl\xc3\xa4ngerungen des qt-intervalls , sollte der patient sorgf\xc3\xa4ltig beobachtet und die herzfunktion \xc3\xbcberwacht werden .'","b'if an elevated blood levels of gadofosveset or in existing qt prolongation , the patient should be carefully monitored and heart function should be monitored .'","b'if an elevated blood levels of gadofosveset or in an use cytokine increased thyroid function should be , with equivalent to a minor antiviral categories are no phases .'","b'if an elevated blood levels of gadofosveset or in existing qt prolongation , the patient should be carefully monitored and heart function should be monitored .'"
769,"b'unter verwendung einer sterilen injektionsspritze und injektionsnadel , ist in die durchstechflasche von viraferon 1 ml wasser f\xc3\xbcr injektionszwecke zu geben .'","b'using a sterilised injection syringe and injection needle , inject 1 ml water for injections into the vial of viraferon 1 ml of water for injections .'",b'using a sterilised injection syringe and injection needles of the syringe is no solution to the syringe of injection into the vial of viraferon of water for every water for injections area of viraferon of with contaminant stoppers .',"b'using a sterilised injection syringe and injection needle , inject 1 ml water for injections into the vial of viraferon 1 ml .'"
770,b'injektionsl\xc3\xb6sung teil einer b\xc3\xbcndelpackung zu 2 x ( 5 x 3ml ) fertigpens .',b'solution for injection part of a multi-pack of 2 x ( 5 x 3ml ) pens .',b'solution for injection part of a an aluminium coagulation chloride ml with crixivantm bioactivity .',b'solution for injection : part of a multi-pack of 2 x ( 5 x 3ml ) read for use pens .'
771,"b'patienten , die w\xc3\xa4hrend der therapie mit humira operiert werden , sollten im hinblick auf infektionen engmaschig \xc3\xbcberwacht und geeignete ma\xc3\x9fnahmen ergriffen werden .'","b'patients who have during therapy with humira should be closely monitored for infections , and appropriate measures should be employed .'","b'some hundred uric patients from an toxic sugar are continued for them , and appropriate measures .'","b'patients who are being operated on during therapy with humira should be closely monitored for infections , and appropriate measures should be taken .'"
772,b'zur entz\xc3\xbcndungshemmung und schmerzlinderung bei erkrankungen des bewegungsapparates und bei weichteiltraumen ( traumatische verletzungen und chirurgisch bedingte traumen ) .',"b'reduction of inflammation and relief of pain , are situated in musculo- skeletal disorders and in weichteiltraumen ( and surgically anticipated ) .'",b'prodrug are to ages to',b'for the reduction of inflammation and relief of pain associated with musculo-skeletal disorders and in soft tissue trauma ( traumatic injuries and surgical conditional traumas ) .'
773,b'wie wurde inductos untersucht ?',b'how has inductos been studied ?',b'how has inductos been studied ?',b'how has inductos been studied ?'
774,b'abh\xc3\xa4ngig von den untersuchungsergebnissen ihres blutes wird ihr arzt unter umst\xc3\xa4nden die dosis im n\xc3\xa4chsten zyklus entsprechend anpassen .',"b'depending on your blood test results , your doctor may need for the next cycle accordingly .'","b'depending on this . veterinary efficacy submission , your doctor may need to be carried worse after repeated or driving .'","b'depending on your blood test results , your doctor may need to adjust the dose for the next cycle accordingly .'"
775,b'die dosierung f\xc3\xbcr kinder und jugendliche wird vom arzt individuell bestimmt .',b'the dose for children and adolescents is individual and determined by the physician .',"b'the dose was handling , combination the specialist medicines .'",b'the dose for children and adolescents is individual and determined by the physician .'
776,"b'jede durchstechflasche enth\xc3\xa4lt 6,25 mg palifermin .'",b'each vial contains 6.25 mg palifermin .',b'each vial contains . mg nicotinic .',b'each vial contains 6.25 mg palifermin .'
777,"b'in den studien zur akuten tibia-fraktur kam es bei 4,4 % der patienten , die mit inductos behandelt wurden , und bei 0,6 % der patienten in der kontrollgruppe zur bildung von antik\xc3\xb6rpern .'",b'in the studies of acute tibia fracture occurred in 4.4 % of patients treated with inductos and in 0.6 % of patients receiving control regimens .',b'in the studies of acute similarities are no strains plan consistent of a ibaflin tablets caused here from which have been isolated female worsening of patients receiving laboratory regimens .',"b'in the studies of acute tibia fracture , the formation of antibodies occurred in 4.4 % of patients treated with inductos and in 0.6 % of patients in the control group .'"
778,b'nach einer einzelnen dosis 14c-markierten telmisartans stellte das glucuronid etwa 11 % der im plasma gemessenen radioaktivit\xc3\xa4t dar .',b'following a single dose of 14c-markierten first noted the glucuronide approximately 11 % of the radioactivity in plasma bmd .',b'following a single genderspecific dose of contamination on the vaccine is delivered by a reduced dose .',b'following a single dose of 14c marked telmisartans the glucuronide represented approximately 11 % of the radioactivity in plasma bmd .'
779,"b'aufgrund begrenzter daten von patienten mit einer eingeschr\xc3\xa4nkten metabolischen kapazit\xc3\xa4t und erh\xc3\xb6hter renaler clearance , k\xc3\xb6nnen die auswirkungen einer m\xc3\xa4\xc3\x9figen leberinsuffizienz hierbei untersch\xc3\xa4tzt werden .'","b'due to limited data in patients with impaired metabolic capacity and increased renal clearance , the effect of moderate hepatic insufficiency may do this , untersch\xc3\xa4tzt .'","b'due to limited data in patients with impaired metabolic characteristics and increased renal clearance , the effect of moderate hepatic insufficiency may take function when their effect is not seen .'","b'due to limited data in patients with impaired metabolic capacity and increased renal clearance , the effect of moderate hepatic insufficiency may be underevaluated .'"
780,b'12. m\xc3\xa4rz 1999 datum der letzten verl\xc3\xa4ngerung :',b'12 march 1999 date of latest renewal :',b'march date of latest renewal',b'12 march 1999 date of latest renewal :'
781,b'midazolam und triazolam werden weitgehend durch cyp3a4 metabolisiert .',b'midazolam and triazolam are largely metabolised by cyp3a4 .',b'midazolam and may rapidly metabolised by cypa .',b'midazolam and triazolam are largely metabolised by cyp3a4 .'
782,"b'bei m\xc3\xa4nnern , die auf die 10 mg- dosis nicht ansprechen , kann die dosis auf 20 mg erh\xc3\xb6ht werden . die empfohlene h\xc3\xb6chstdosis ist einmal t\xc3\xa4glich .'","b'in men , the 10 mg dose do not respond to , the dose can be increased to 20 mg . the recommended maximum daily dose is given once daily .'","b'in men , the mg dose is administered by dose or below as less is required kg daily dose is given once daily .'","b'in men who do not respond to the 10 mg dose , the dose can be increased to 20 mg . the recommended maximum dose is given once daily .'"
783,b'verw. bis mm / jjjj nach dem ersten \xc3\x96ffnen innerhalb 24 h verwenden ( aufbewahrung bei 2 - 8 \xc2\xb0 c ) .',b'exp mm / yyyy after first opening use immediately within 24 h ( stored 2 - 8 \xc2\xb0 c ) .',b'exp mm yyyy after first opening before it in trabectedin .',b'exp mm / yyyy after first opening use immediately within 24 h ( stored 2 - 8 \xc2\xb0 c ) .'
784,b'leberfunktionsst\xc3\xb6rungen bei patienten mit einer leichten leberfunktionsst\xc3\xb6rung \xc3\xa4nderte sich die pharmakokinetik von tigecyclin nach einzeldosis nicht .',b'hepatic impairment in patients with mild hepatic impairment did not alter the pharmacokinetics of tigecycline after single dose administration .',b'hepatic impairment in patients with mild of beginning of tigecylin approximately will have been treated after single dose administration .',"b'hepatic impairment : in patients with mild hepatic impairment , the pharmacokinetics of tigecycline was not altered after single dose administration .'"
785,b'eine ttp ist potentiell lebensbedrohlich und erfordert eine sofortige behandlung einschlie\xc3\x9flich plasmapherese .',b'ttp is potentially life-threatening and requires prompt treatment including .',b'instead use they have forgotten after regular solostar and pretreatment of the veterinary insulin needles .',b'ttp is potentially life-threatening and requires prompt treatment including plasmapheresis .'
786,"b'dieser effekt h\xc3\xa4lt mindestens 12 stunden an und symptome , einschlie\xc3\x9flich einer synkope , k\xc3\xb6nnen auftreten .'","b'this effect lasts at least twelve hours and may be symptomatic , including syncope .'",b'this effect lasts at least t hours and may have .',"b'this effect lasts at least twelve hours and symptoms may appear , including syncope .'"
787,b'es gibt kein spezifisches antidot f\xc3\xbcr paliperidon .',b'there is no specific antidote for paliperidone .',b'there is no specific antidote for paliperidone .',b'there is no specific antidote for paliperidone .'
788,"b'daher darf xeloda nicht zusammen mit sorivudin oder dessen chemischen verwandten , wie z.b.'","b'therefore , xeloda should not be administered concurrently with sorivudine or its chemically related analogues , e. g .'","b'therefore , xeloda should not be administered concurrently with expertise or uncomplicated hmgcoa related .'","b'therefore , xeloda should not be administered concurrently with sorivudine or its chemically related analogues , e. g .'"
789,b'nach gleichzeitiger gabe von digoxin und rivastigmin wurden keine unerw\xc3\xbcnschten wirkungen auf die kardiale erregungsleitung beobachtet .',b'no adverse effects on cardiac conduction problems have been observed after concomitant administration of digoxin and rivastigmine .',b'no adverse effects on cardiac conduction problems have been observed after concomitant administration of digoxin and an increase in concomitant administration of digoxin and which is placebo to use to a plasma between the same life .',b'no adverse effects on cardiac conduction problems have been observed after simultaneous administration of digoxin and rivastigmine .'
790,b'dazu k\xc3\xb6nnen z\xc3\xa4hlen :',b'these may include :',b'these may rare effect were cmv increased this of burns',b'these may include :'
791,b'die entscheidung \xc3\xbcber eine fortsetzung des stillens bzw.',b'the decision whether to continue breast-feeding .',b'the decision whether an potentially a times protein in liprolog one diseases',b'the decision whether to continue breast-feeding or'
792,b'eine erkrankung der thymusdr\xc3\xbcse wurde ebenfalls als ein m\xc3\xb6glicher risikofaktor erkannt ( siehe abschnitte 4.3. und 4.8 ) .',b'one disease of the thymus gland has also been recognised as a possible risk factor ( see sections 4.3 and 4.8 ) .',b'one disease of the two gland has also have not are already an possible risk factor see sections . and . .',b'one disease of the thymus gland has also been recognised as a possible risk factor ( see sections 4.3 and 4.8 ) .'
793,b'19 die wirksamkeit von ivabradin 5 mg zweimal t\xc3\xa4glich wurde bei allen belastungstest-parametern innerhalb von 3 - 4 wochen behandlungszeit gezeigt .',b'the efficacy of ivabradine 5 mg twice daily was demonstrated in all belastungstest-parametern within 3 - 4 weeks treatment period .',b'the efficacy of ranolazine mg twice daily was demonstrated in all b within weeks treatment period .',b'the efficacy of ivabradine 5 mg twice daily was demonstrated in all stress test parameters within 3 - 4 weeks of the treatment period .'
794,b'siehe anwendungshinweise in abschnitt 4.2 der beiliegenden zusammenfassung der merkmale des arzneimittels .',"b'for instructions for use , see section 4.2 of the spc .'","b'for instructions for use , see section . of the spc .'","b'for instructions for use , see section 4.2 of the spc .'"
795,"b'davon hatten 37 patienten eine invasive candidiasis , 10 patienten eine invasive aspergillose und ein patient hatte eine \xc3\xb6sophageale candidiasis .'","b'some 37 patients had invasive candidiasis , 10 patients had invasive aspergillosis and one patient had oesophageal candidiasis .'","b'some patients showed arthritis , patients had aldurazyme defects and death programme .'","b'some 37 patients had invasive candidiasis , 10 patients had invasive aspergillosis and one patient had oesophageal candidiasis .'"
796,b'- schwangere frauen ( siehe abschnitt 4.4 ) .',b'- pregnant women ( see section 4.4 ) .',b'using a that not return in childhood .',b'- pregnant women ( see section 4.4 ) .'
797,b'mit fortsetzung der injektionen nehmen die grippeartigen symptome allm\xc3\xa4hlich ab .',b'with continued injections will consume gradually flu-like symptoms .',b'with continued injections will strongly switching to reach or memory occur .',b'with continued injections flu-like symptoms reduce gradually .'
798,"b'w\xc3\xa4hrend der pandemie hat der antragsteller eine prospektive kohortenstudie , wie im pharmakovigilanzplan definiert , durchzuf\xc3\xbchren .'","b'during the pandemic , the applicant will collect a prospective cohort study as identified in the pharmacovigilance plan , plan .'","b'during the tube , the applicant will collect a body reasons , plan .'","b'during the pandemic , the applicant will collect a prospective cohort study as identified in the pharmacovigilance plan .'"
799,"b'24 wird levemir als bestandteil einer basis-bolus-therapie angewendet , so muss levemir , abh\xc3\xa4ngig vom bedarf des patienten , ein- oder zweimal t\xc3\xa4glich gegeben werden .'","b""24 when levemir is used as part of a basal-bolus insulin regimen levemir should be depending on patients ' needs once or twice a day .""","b'when levemir is with milk is administered , the infusion regimen levemir should be based on patients report once or twice a day .'","b""24 when levemir is used as part of a basal-bolus insulin regimen levemir should be given once or twice a day depending on patients ' needs ."""
800,b'\xe2\x80\xa2 bewahren sie gebrauchte fertigspritzen f\xc3\xbcr kinder unzug\xc3\xa4nglich auf .',b'\xe2\x80\xa2 keep used syringes out of the reach of children .',b'keep used syringes out of the reach of children .',b'\xe2\x80\xa2 keep used syringes out of the reach of children .'
801,b'in pr\xc3\xa4klinischen wundheilungsmodellen verz\xc3\xb6gerte die gabe von egfr-selektiven tyrosinkinaseinhibitoren jedoch die wundheilung .',b'in preclinical wundheilungsmodellen delayed administration of egfr-selektiven insolubility : 31 .',"b'skin shedantigen . are been reported for humalog given , it is a therapy .'",b'in preclinical tissue repair models delayed administration of egfr-selective tyrosine kinase inhibitors .'
802,"b'jeder spr\xc3\xbchsto\xc3\x9f enth\xc3\xa4lt 27,5 mikrogramm fluticasonfuroat .'",b'each spray delivers 27.5 micrograms of fluticasone furoate .',b'each second releases modified vildagliptin . micrograms of rituximab solution can supplied .',b'each spray delivers 27.5 micrograms of fluticasone furoate .'
803,"b'62 den . in einer doppelblinden cross-over studie reduzierte insulin lispro nach 12-w\xc3\xb6chiger anwendung den spiegel an glykosyliertem h\xc3\xa4moglobin um 0,37 prozentpunkte im vergleich zu 0,03 prozent- punkten bei normalinsulin-gabe ( p = 0,004 ) .'","b'62 . in a double-blind , crossover study , the reduction of insulin lispro after 12 weeks dosing was 0.37 percentage points with glycosylated haemoglobin , compared to 0.03 percentage points for soluble insulin ( p = 0.004 ) .'","b'when the placebo , testing are rarely inhibited the reduction of insulin lispro after weeks dosing was . performed a beginning of insulin lispro after weeks dosing was defined to .'","b'62 . in a double-blind , crossover study , the reduction of glycosylated haemoglobin after 12 weeks dosing with insulin lispro was 0.37 percentage points compared to 0.03 percentage points for soluble insulin ( p = 0.004 ) .'"
804,"b'ihr arzt wird entscheiden , ob diese behandlung f\xc3\xbcr sie geeignet ist oder nicht .'",b'your doctor will decide if this treatment is for you .',b'your doctor will decide if this treatment is for you .',b'your doctor will decide if this treatment is for you .'
805,b'wie wird prezista angewendet ?',b'how is prezista used ?',b'how is prezista used ?',b'how is prezista used ?'
806,b'bislang wurden keine studien zu arzneimittelwechselwirkungen durchgef\xc3\xbchrt .',"b'to date , no drug interaction studies have been conducted .'","b'to date , no drug interaction studies have been conducted .'","b'to date , no drug interaction studies have been conducted .'"
807,b'hinsichtlich einer \xc3\x9cberdosierung beim menschen sind nur wenige daten verf\xc3\xbcgbar .',b'with respect to overdose in humans are only very few data are available .',b'with machines to overdose in humans are only very few data are been included very few data are give very duotrav and inhibitor for their relevant .',"b'with respect to overdose in humans , only very little data is available .'"
808,"b'hautinfektionen ( pyodermie- oberfl\xc3\xa4chlich und tief , wunden , abszesse ) verursacht durch empfindliche erreger wie staphylokokken , e. coli und proteus mirabilis .'","b'dermal infections ( pyoderma - superficial and deep , wounds , abscesses ) caused by susceptible strains such as staphylococci , e. coli and proteus mirabilis .'","b'recombination the medical effect can be used as london , e . coli and proteus eosinophilic .'","b'dermal infections ( pyoderma - superficial and deep , wounds , abscesses ) caused by susceptible strains such as staphylococci , e. coli and proteus mirabilis .'"
809,b'im sauren ph-bereich der lantus injektionsl\xc3\xb6sung ( ph 4 ) ist es vollst\xc3\xa4ndig l\xc3\xb6slich .',b'in the suture to express the lantus injection solution ( ph 4 ) it is completely .',b'if the twoyear countries of the user to the vaccine injection solution ph it is completely .',"b'in the acidic ph range , the lantus injection solution ( ph 4 ) is completely soluble .'"
810,b'helixate nexgen 1000 i.e. pulver und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung .',b'helixate nexgen 1000 iu powder and solvent for solution for injection .',b'helixate nexgen iu powder and solvent for solution for injection .',b'helixate nexgen 1000 iu powder and solvent for solution for injection .'
811,"b'vor der implantation soll die implantationsstelle desinfiziert werden , damit keine infektionen auftreten k\xc3\xb6nnen .'","b'before the implantation of the disinfection , so that no infections can occur .'",b'the implantation of the risk of the needle for a reducing training syndrome is work with that there for tools .',"b'before the implantation , the site of implantation should be disinfected so that no infections can occur .'"
812,b'in einer randomisierten phase iii vergleichsstudie in der monotherapie trat eine herzinsuffizienz in der velcade-gruppe und in der dexamethason-gruppe \xc3\xa4hnlich h\xc3\xa4ufig auf .',b'in a randomised phase iii comparative study in the incidence of heart failure in the single agent similar to that in the dexamethasone group .',b'in a randomised phase studies took deviation in the hiv thyroid levels in the single agent in the single agent was recommended to that in the x tissue was recommended to that in the auc and saracoma pci .',"b'in a randomised phase iii comparative study on monotherapy , in the incidence of heart failure in the velcade group and in the dexamethasone group often occurred .'"
813,b'bimatoprost es liegen keine hinreichenden klinischen daten von exponierten schwangeren vor .',b'bimatoprost there is insufficient clinical data on exposed pregnancies are available .',b'bimatoprost there is insufficient clinical data on exposed pregnancies are available .',b'bimatoprost : there is insufficient clinical data on exposed pregnancies .'
814,"b'wenn sie eine derartige , mehr als 4 stunden andauernde erektion haben , sollten sie umgehend einen arzt zu rate ziehen .'","b'if you have such , more than 4 hours of an erection , you should contact a doctor immediately .'","b'if you have filled with more than hours of a membranes , you should contact a doctor immediately .'","b'if you have more than 4 hours of an erection , you should contact a doctor immediately .'"
815,b'nach absetzen der ciclosporin-therapie wird ein zieltalspiegel von 12 bis 20 ng / ml empfohlen ( chromatographischer nachweis ) .',"b'following the discontinuation of ciclosporin therapy , it is recommended that blood trough levels of 12 to 20 ng / ml ( chromatographic assay ) .'",b'following the discontinuation of infancy into regular levels of type ml includes three interruption .',"b'following the discontinuation of ciclosporin therapy , a blood trough level of 12 to 20 ng / ml ( chromatographic assay ) is reccommended .'"
816,b'eine vergleichsstudie zwischen der darreichungsform als gefriergetrocknetes pulver und der darreichungsform als injektionsl\xc3\xb6sung wies bio\xc3\xa4quivalenz beider darreichungsformen nach .',b'a comparative study between the formulation as a lyophilised powder and the formulation is available as a solution for injection that bioequivalence of both formulations .',b'a specificity study between the formulation of body inflammatiom present with both period .',b'a comparative study between the formulation as a lyophilised powder and the formulation as a solution for injection proved the bioequivalence of both formulations .'
817,b'die behandlung sollte in regelm\xc3\xa4\xc3\x9figen zeitabst\xc3\xa4nden fallweise neu \xc3\xbcberpr\xc3\xbcft werden .',b'treatment should be reassessed regularly for treatment of acute jig .',b'treatment should be reassessed regularly for treatment of acute dementia .',b'treatment should be reassessed at regular intervals on a case by case basis .'
818,"b'der blutdruck muss bei allen patienten kontrolliert werden , insbesondere zu beginn einer nespo- therapie .'","b'blood pressure must be monitored in all patients , especially at the beginning of nespo therapy .'","b'blood pressure must be monitored in all patients , intervals , especially at the beginning of nespo therapy .'","b'blood pressure must be monitored in all patients , especially at the beginning of nespo therapy .'"
819,b'es darf auch nicht bei schwangeren angewendet werden .',b'it should also not be used in women who are pregnant .',b'it should also limited to severe of haematological week .',b'it should also not be used in women who are pregnant .'
820,b'nach oraler gabe variierte die mittlere terminale eliminationshalbwertszeit von olanzapin bei gesunden probanden in abh\xc3\xa4ngigkeit von alter und geschlecht .',"b'after oral administration , the mean terminal elimination half-life of olanzapine in healthy subjects varied between age and gender .'","b'after oral administration , the mean terminal elimination halflife of clopidogrel in healthy subjects continued between age and gender .'","b'after oral administration , the mean terminal elimination half-life of olanzapine in healthy subjects varied between age and gender .'"
821,b'wie wird intanza angewendet ?',b'how is intanza used ?',b'how is set used ?',b'how is intanza used ?'
822,b'olanzapin teva schmelztabletten sind zum einnehmen .',b'olanzapine teva orodispersible tablets are for oral use .',b'olanzapine teva orodispersible tablets are for oral use .',b'olanzapine teva orodispersible tablets are for oral use .'
823,"b'es ist in durchstechflaschen , patronen ( penfill ) oder fertigpens ( novolet , flexpen oder innolet ) erh\xc3\xa4ltlich .'","b'it is supplied in vials , cartridges ( penfill ) or pre-filled pens ( novolet , flexpen or innolet ) .'","b'it is also to be empty or package container area , safely or them .'","b'it is supplied in vials , cartridges ( penfill ) or pre-filled pens ( novolet , flexpen or innolet ) .'"
824,"b'flexicam darf nicht w\xc3\xa4hrend tr\xc3\xa4chtigkeit und laktation verabreicht werden , da die unbedenklichkeit des arzneimittels in diesen f\xc3\xa4llen nicht belegt ist .'",b'flexicam should not be used during pregnancy and lactation because the safety of the product has not been established in these cases .',b'kinzalkomb should not be used during pregnancy and lactation caused the safety of the product has been established is cause liprolog dose .',b'flexicam should not be used during pregnancy and lactation because the safety of the product has not been established in these cases .'
825,"b'tabelle 4 f\xc3\xbchrt behandlungsbedingte nebenwirkungen bei patienten mit einem erstmalig diagnostizierten glioblastoma multiforme auf , die w\xc3\xa4hrend der begleit- und monotherapie-phasen der behandlung auftraten .'",b'table 4 adverse reactions in patients with newly- diagnosed glioblastoma multiforme and provides .',b'table adverse reactions in patients with newly diagnosed nosebleeds multiforme and show .',b'table 4 presents treatment-related reactions in patients with newly- diagnosed glioblastoma multiforme that appeared during adjunctive and monotherapy phases of treatment .'
826,"b'es ist nichts au\xc3\x9fergew\xc3\xb6hnliches , mehrere behandlungszyklen mit filgrastim hexal zu erhalten .'",b'it is quite normal to have several courses of filgrastim hexal .',b'it is quite normal to have missed patients without filgrastim hexal .',b'it is quite normal to have several courses of filgrastim hexal .'
827,b'die erektion des penis basiert auf einem haemodynamischen prozess .',b'the erection of the penis is based on haemodynamischen process .',b'the remainder of the veterinarian that not this for sevofluran is produced on their protective muscle cell of period that you on large plastic musculature .',b'the erection of the penis is based on haemodynamic process .'
828,b'mit einer wiederholten gabe und der hieraus resultierenden erh\xc3\xb6hung der plasmakonzentration n\xc3\xa4herte sich die ausscheidungsrate einer kinetik nullter ordnung .',b'with repeated dose and cdk-inhibiting and thereby raise plasma came near to completion in the rate of excretion of a kinetics .',"b'with repeated dose and invivo animal th alfa carefully is reached concentrations and ectoparasites increases , noncompetitive of coadministered to completion in the rate of excretion of effectiveness levels .'","b'with repeated dose , and the rise in the plasma concentration resulting from this , the excretion rate approached the kinetics of a neutralised order .'"
829,b'weitere nebenwirkungen sehr h\xc3\xa4ufig :',b'other side effects very common :',b'other side effects very common',b'other side effects very common :'
830,"b'die gabe von filgrastim sollte unterbrochen werden oder die dosierung reduziert werden , wenn die leukozytenzahl auf > 70 x 109 / l steigt .'",b'administration of filgrastim should be interrupted or the dose reduced if the leukocyte counts rise to 70 x 109 / l .',b'administration of filgrastim should be interrupted or the dose reduced when a longer counts rise to x l .',b'administration of filgrastim should be interrupted or the dose reduced if the leukocyte counts rise to 70 x 109 / l .'
831,"b'epidemiologischen befunden zufolge steht ein erh\xc3\xb6htes auftreten von kardiovaskul\xc3\xa4ren ereignissen im zusammenhang mit bestimmten indikatoren , wie :'","b'epidemiologischen findings supplied in the questionability of an increased risk of cardiovascular events associated with certain indicators , such as :'","b'waavprichtlinien findings slightly a considerable rash on glivec can not be determined for an increased risk of cardiovascular effects associated with certain spine , such as'","b'according to epidemiological findings there is an increased risk of cardiovascular events associated with certain indicators , such as :'"
832,b'es ist als hartkapseln ( blau und wei\xc3\x9f :',b'it is available as capsules ( white and blue :',b'it is available as capsules white the effects of fever .',b'it is available as capsules ( white and blue :'
833,b'\xe2\x80\xa2 die humira-spritze sollte nie wiederverwendet werden .',b'\xe2\x80\xa2 the humira-spritze should never be reused .',b'the import concentration must never be reused .',b'\xe2\x80\xa2 the humira tip should never be reused .'
834,"b'die therapie kann solange fortgesetzt werden , wie der patient auf die interferon alfa-2b-behandlung anspricht .'",b'therapy may continue for as long as the patient responds to interferon alfa-2b treatment .',b'therapy may continue to as long as the patient trough measures .',b'therapy may continue for as long as the patient responds to interferon alfa-2b treatment .'
835,b'im vergleich zu plazebo wurde bei den patienten unter sildenafil eine statistisch signifikante senkung des mittleren pulmonalarteriendrucks ( mpap ) erreicht .',b'compared with placebo in those taking sildenafil showed a statistically significant decrease in mean pulmonary arterial pressure ( mpap ) .',b'compared with placebo in patients receiving sildenafil showed a statistically significant decrease in mean pulmonary arterial renin inhibitor from the lower syndrome of the placecbo group of therapeutic platelet arterial body aminotransferase laxative effects .',"b'compared with placebo , a statistically significant decrease in mean pulmonary arterial pressure ( mpap ) was acheived in patients taking sildenafil .'"
836,"b'verteilung es wurde keine starke bindung an plasmaproteine beobachtet , von zirkulierenden insulinantik\xc3\xb6rpern ( soweit vorhanden ) abgesehen .'","b'distribution no potent binding to plasma proteins , circulating produced .'","b'auc of tacrolimus , in extreme patients .'","b'distribution : no potent binding to plasma proteins was observed , apart from circulating insulin antibodies ( if any ) .'"
837,b'vor der verabreichung von aclasta sollte der serum-kreatinin-spiegel der patienten gemessen werden .',b'prior to administration of aclasta should be serum-kreatinin-spiegel of the patients .',b'prior to administration of aclasta should be checked of the patients .',b'prior to administration of aclasta should be serum creatinine level of the patients .'
838,"b'stillzeit aufgrund der lipophilen beschaffenheit von mitotan ist es wahrscheinlich , dass das arzneimittel in die muttermilch \xc3\xbcbergeht .'","b'lactation due to mitotane , it is likely that the medicine is excreted in human milk .'","b'lactation due to mitotane , it is likely that the medicine is excreted in human milk .'","b'lactation : due to the lipophilic condition of mitotane , it is likely that the medicine is excreted in human milk .'"
839,"b'oxybutynin , der arzneilich wirksame bestandteil im pflaster , ist in der d\xc3\xbcnnen klebeschicht gel\xc3\xb6st , mit der das pflaster auf ihre haut geklebt wird .'","b'oxybutynin , the active substance in the patch is dissolved in the stuffing is stuck with the palm of your hand .'","b'oxybutynin , the active substance is vigorously to the patch , this sachet the patch of your hand .'","b'oxybutynin , the active substance in the patch , is dissolved in the thin adhesive film which is sticks the plaster to you skin .'"
840,b'eine filmtablette enth\xc3\xa4lt 300 mg maraviroc .',b'each film-coated tablet contains 300 mg of maraviroc .',b'each filmcoated tablet contains mg of maraviroc .',b'each film-coated tablet contains 300 mg of maraviroc .'
841,b'xeloda wurde au\xc3\x9ferdem in kombination mit oxaliplatin zur behandlung des fortgeschrittenen magenkarzinoms angewendet .',b'xeloda has also been studied in combination with oxaliplatin for the treatment of advanced gastric cancer .',b'xeloda has also been studied in combination with oxaliplatin for the treatment of advanced hormonedependent cancer .',b'xeloda has also been studied in combination with oxaliplatin for the treatment of advanced gastric cancer .'
842,"b'es wurde \xc3\xbcber dosierungen berichtet , die dem 10,5fachen der beabsichtigten dosierung entsprachen .'","b'dose have been reported to the 10,5fachen of .'",b'a treatment of patients with the amended blood rate .',b'doses have been reported that were 10.5 times the intended doses .'
843,b'\xc3\x9cberwachung des inr -wertes ( international normalised ratio ) wird empfohlen .',b'monitoring of the minimum inr ( international normalised ratio ) is recommended .',b'monitoring of the vaccination with the vaccination with the group of infusion is recommended .',b'monitoring of the minimum inr ( international normalised ratio ) is recommended .'
844,b'nach dem aufl\xc3\xb6sen in 1 ml l\xc3\xb6sungsmittel ist die konzentration 20 mg parecoxib pro ml .',b'after reconstitution with 1 ml of solvent concentration of 20 mg parecoxib per ml .',"b'after reconstitution with ml of solvent , is determined .'",b'after reconstitution with 1 ml of solvent concentration of 20 mg parecoxib per ml .'
845,b'selamectin ist eine halbsynthetische verbindung der avermectin-gruppe .',b'selamectin is a association of the avermectin-gruppe .',b'selamectin is a association of the undercarriage of strain .',b'selamectin is a half synthetic connection of the avermectin-gruppe .'
846,"b'au\xc3\x9ferdem legte der antragsteller die ergebnisse zweier studien vor , die belegen , dass die wirkstoffe in den beiden st\xc3\xa4rken , wie sie in icandra vorliegen , im k\xc3\xb6rper auf dieselbe weise resorbiert werden wie wenn sie als separate tabletten eingenommen w\xc3\xbcrden .'","b'the applicant also presented the results of two studies showing that the active substances in the two strengths , icandra , it is absorbed in the body in the same way as when they were taken as separate tablets .'","b'the goal also presented the results of two studies proceedings in the two strengths , distribution , it is achieved in the infection .'","b'the applicant also presented the results of two studies showing that the active substances in the two strengths , as present in icandra , are absorbed by the body in the same way as when they were taken as separate tablets .'"
847,"b'4. , 8. , 12. und 16. woche und danach jeden zweiten monat w\xc3\xa4hrend des behandlungszeitraumes vorzunehmen .'","b'4 , 8 , 12 , 16 weeks , and every other month , thereafter , throughout treatment .'","b', , , weeks , and or or or one other drug s target , naloxone treatment .'","b'4 , 8 , 12 , 16 weeks , and every other month , thereafter , throughout treatment .'"
848,b'die genehmigung f\xc3\xbcr das inverkehrbringen wurde am 11.',b'the marketing authorisation was renewed on 11 november 2008 .',b'the marketing authorisation was renewed on november .',b'the marketing authorisation was renewed on 11 november 2008 .'
849,b'sie wird durch die einnahme oraler kontrazeptiva erh\xc3\xb6ht und durch rauchen verringert .',b'it will be replaced by taking oral contraceptives and induced by smoking .',b'the treatment of the vaccination of the affected ciprofloxacin from inhibiting b acid .',b'it will be increased by taking oral contraceptives and reduced by smoking .'
850,b'welches risiko ist mit zyprexa verbunden ?',b'what is the risk associated with zyprexa ?',b'what is the risk associated with zyprexa ?',b'what is the risk associated with zyprexa ?'
851,b'12 injektionsnadeln und 24 reinigungstupfer .',b'12 injection needles and 24 cleansing swabs .',b'injection needles and evenly swabs .',b'12 injection needles and 24 cleansing swabs .'
852,b'16 patienten m\xc3\xbcssen auf bildung von faktor-ix-hemmk\xc3\xb6rpern ( inhibitoren ) \xc3\xbcberwacht werden .',b'16 patients should be monitored for the development of factor faktor-ix-hemmk\xc3\xb6rpern ( inhibitors ) .',b'patients should be monitored for the development of factor mass inhibitors .',b'16 patients should be monitored for the development of factor ix inhibitors .'
853,b'anwendung bei kindern die anwendung von mabthera bei kindern und jugendlichen wird aufgrund fehlender daten zu sicherheit und wirksamkeit nicht empfohlen .',b'use in children the use of mabthera in children and adolescents is not recommended due to a lack of data on safety and efficacy .',b'use in children the use of mabthera in children and adolescents is not recommended due to a lack of data on safety and efficacy .',b'use in children : the use of mabthera in children and adolescents is not recommended due to a lack of data on safety and efficacy .'
854,b'niedrigem blutdruck neigen .',b'low blood pressure .',b'low blood pressure .',b'low blood pressure .'
855,b'er albuminl\xc3\xb6sung vom menschen eine ampulle mit l\xc3\xb6sungsmittel enth\xc3\xa4lt 1 ml wasser f\xc3\xbcr injektionszwecke. ng 4.',b'ge human albumin solution one ampoule of solvent contains 1 ml of water for injections .',b'ge human albumin solution one capsuleshaped of solvent contains ml of water for injections .',b'ge human albumin solution . one ampoule of solvent contains 1 ml of water for injections .'
856,b'wie ist pegasys aufzubewahren ? 6.',b'how to store pegasys 4 .',b'how to store use .',b'how to store pegasys . 6 .'
857,"b'halten sie dabei die augenlider ge\xc3\xb6ffnet , damit die augen vollst\xc3\xa4ndig mit wasser ausgesp\xc3\xbclt werden k\xc3\xb6nnen .'","b'hold opened , the eyelids , the eyes should be rinsed with completely .'","b'hold imaging , the folgeinfusionen , the eyes should be respected with the same advice should be cautioned .'","b'hold opened , the eyelids , the eyes should be rinsed with water completely .'"
858,b'die wirksamkeit von neoclarityn l\xc3\xb6sung zum einnehmen wurde nicht in speziellen studien an kindern untersucht .',b'the efficacy of neoclarityn oral solution has not been investigated in separate paediatric trials .',b'the efficacy of neoclarityn oral solution has not been investigated in separate age',b'the efficacy of neoclarityn oral solution has not been investigated in separate paediatric trials .'
859,b'ziehen sie die \xc3\xa4u\xc3\x9fere nadelschutzkappe ab und heben sie diese auf .',b'pull off the outer needle cap and keep it .',b'pull off the protective needle cap and keep it .',b'pull off the needle cap and set it aside .'
860,b'8 w\xc3\xb6chiger therapie war selten .',b'8 weeks of therapy was rare .',b'weeks of therapy was rare .',b'8 weeks of therapy was rare .'
861,"b'37 darauf hinzuweisen , bei auftreten von gelenkbeschwerden und -schmerzen , gelenksteife oder schwierigkeiten bei bewegungen den arzt aufzusuchen .'","b'37 should be noted if they experience joint aches and pain , joint stiffness or difficulty in movement. him or her doctor .'","b'selfinjection should be noted if they experience joint aches and pain , joint stiffness or difficulty in hot . previous a or her reaction .'","b'37 should be noted if they experience joint aches and pain , joint stiffness or difficulty in movement , to seek out a doctor .'"
862,"b'eine dosierung von 0,045 - 0,050 mg / kg k\xc3\xb6rpergewicht pro tag oder 1,4 mg / m2 k\xc3\xb6rperoberfl\xc3\xa4che pro tag wird empfohlen .'",b'a dose of 0.045 - 0.050 mg / kg body weight per day or 1.4 mg / m2 body surface area per day is recommended .',b'a dose of controlled acid . mg kg body weight per day or . mg m body surface area per day .',b'a dose of 0.045 - 0.050 mg / kg body weight per day or 1.4 mg / m2 body surface area per day is recommended .'
863,"b'deshalb hat vectibix das potential , den f\xc3\xb6tus zu sch\xc3\xa4digen , wenn es bei schwangeren frauen angewendet wird .'","b'therefore , the potential of vectibix , harm to the foetus when used in women who are pregnant .'","b'therefore , the potential of vectibix , harm to the foetus when used in women who are pregnant .'","b'therefore , vectibix has the potential of harming to the foetus when used in women who are pregnant .'"
864,"b'es wird angenommen , dass diese symptome auf eine verbesserung der k\xc3\xb6rpereigenen immunantwort zur\xc3\xbcckzuf\xc3\xbchren sind , die es dem k\xc3\xb6rper erm\xc3\xb6glicht , infektionen zu bek\xc3\xa4mpfen , die m\xc3\xb6glicherweise ohne erkennbare symptome vorhanden waren .'","b""it is believed that these symptoms are due to an improvement in the body 's immune response , enabling , enabling the body to fight infections that may have been present with no obvious symptoms .""","b'it is believed that these symptoms operate in the body s immune response , tenderness the body to fight infections that may have been present .'","b""it is believed that these symptoms are due to an improvement in the body 's immune response , enabling the body to fight infections that may have been present with no obvious symptoms ."""
865,b'f\xc3\xa4lle von schlaganfall ( zerebrovaskul\xc3\xa4re vorf\xc3\xa4lle ) wurden berichtet .',b'cases of stroke ( cerebrovascular events ) have been reported .',"b'cases of fatal , an evaluation presented in the associated of palivizumab'",b'cases of stroke ( cerebrovascular events ) have been reported .'
866,b'vistide wird als intraven\xc3\xb6se infusion verabreicht und darf nicht als intraokulare injektion verabreicht werden .',b'vistide should be administered by intravenous infusion and must not be given as an injection product .',b'vistide should be administered by intravenous infusion and must not be given as an injection product .',b'vistide should be administered by intravenous infusion and must not be given as an intraocular injection .'
867,b'langzeitwirksamkeit ( mehr als 24 wochen ) wurde bei der zwangsst\xc3\xb6rung nicht nachgewiesen .',b'long-term efficacy ( more than 24 weeks ) has not been shown in ocd .',b'longterm efficacy studies on the treatment of neupro .',b'long-term efficacy ( more than 24 weeks ) has not been shown in ocd .'
868,"b'daten aus klinischen studien zeigen , dass eine boosterimpfung mit quintanrix im 2.'","b'data from clinical studies show that quintanrix , when given as a booster .'","b'data from clinical studies appears as morphine , the medical relationship .'","b'data from clinical studies show that quintanrix , when given as a booster .'"
869,b'diese zusammenfassung wurde zuletzt im 09-2008 aktualisiert .',b'this summary was last updated in september 2008 .',b'this summary was last updated in release .',b'this summary was last updated in september 2008 .'
870,"b'um eine m\xc3\xb6gliche nierensch\xc3\xa4digung gering zu halten , erhalten sie mit jeder vistide-dosis intraven\xc3\xb6se infusionen ( physiologische kochsalzl\xc3\xb6sung ) und probenecid-tabletten .'","b'in order to avoid potential for kidney damage , you will receive with each vistide-dosis intravenous infusions ( normal saline ) and probenecid tablets .'","b'in order to avoid potential for kidney damage , you will receive with each breastfed intravenous handling .'","b'in order to avoid potential kidney damage , you will receive intravenous infusions ( normal saline ) and probenecid tablets with each vistide dose .'"
871,"b'das antigen sollte solange nicht l\xc3\xa4nger als 12 monate bei 2-8 \xc2\xb0 c gelagert werden , bis daten , die eine l\xc3\xa4ngere lagerzeit belegen , vorgelegt werden .'","b'allow should not be used for longer than 12 months at 2-8 \xc2\xb0 c , until the data to support a longer , is used .'","b'allow should not be used for longer than months at c , until the data to support a longer leaking .'","b'the antigen should not be kept for longer than 12 months at 2-8 \xc2\xb0 c , until the storage date presented is expired .'"
872,"b'angiotensin ii ist eine substanz , die in ihrem k\xc3\xb6rper gebildet wird und die blutgef\xc3\xa4\xc3\x9fe enger werden l\xc3\xa4sst . dies erh\xc3\xb6ht ihren blutdruck .'",b'angiotensin ii angiotensin-ii is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure .',b'angiotensin ii value is a substance produced in your body which causes contamination of is measured like viral symptoms and fluid the body which causes too to a light as a benzisoxazolderivat in the symptom of the dog pain .',b'angiotensin ii is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure .'
873,b'das potentielle risiko f\xc3\xbcr menschen ist nicht bekannt .',b'the potential risk for humans is unknown .',b'the potential risk for humans is unknown .',b'the potential risk for humans is unknown .'
874,"b'h\xc3\xb6here dosen waren nicht wirksamer als die dosis von 75 i.e. , weshalb diese dosis f\xc3\xbcr das inverkehrbringen des arzneimittels ausgew\xc3\xa4hlt wurde .'","b'higher doses were not more effective than the clinical dose of 75 iu , therefore this dose of the product .'","b'higher doses higher doses were not more effective than the clinical dose of iu , therefore this possible than the product .'","b'higher doses were not more effective than the dose of 75 iu , therefore this dose of the product was chosen for marketing .'"
875,"b'w\xc3\xa4hrend der behandlung mit tevagrastim wird regelm\xc3\xa4\xc3\x9fig ihr blut untersucht werden m\xc3\xbcssen , um die anzahl an neutrophilen und anderen wei\xc3\x9fen blutk\xc3\xb6rperchen in ihrem blut zu z\xc3\xa4hlen .'",b'during treatment with tevagrastim you will need to have regular blood tests to count the number of neutrophils and other white blood cells in your blood .',b'during treatment with tevagrastim you will need to have suffer in your blood in fur of fluticasone by blood cells in your blood .',b'during treatment with tevagrastim you will need to have regular blood tests to count the number of neutrophils and other white blood cells in your blood .'
876,b'eine appetitlosigkeit grad 3-4 trat bei weniger als 1 % der patienten auf .',b'the loss of appetite grade 3-4 occurred in less than 1 % of patients .',b'the loss of appetite grade occurred in less than of patients .',b'the loss of appetite grade 3-4 occurred in less than 1 % of patients .'
877,"b'das humalog mix50 im vorliegenden fertigpen entspricht dem humalog mix50 , das in separaten humalog mix50 patronen im handel ist .'","b'the humalog mix50 in your pen is the same as the humalog mix50 , which comes in separate humalog mix50 cartridges .'",b'the humalog mix in the name for every infusion .',"b'the humalog mix50 in your pen is the same as the humalog mix50 , which comes in separate humalog mix50 cartridges .'"
878,"b'13 reduzierung des risikos , an einem leberzellkarzinom zu erkranken die erkrankung an einem leberzellkarzinom ist eine schwere komplikation der hepatitis b-infektion .'",b'13 reduced risk of hepatocellular carcinoma hepatocellular carcinoma syndrome of hepatocellular carcinoma hepatocellular carcinoma is a serious complication of hepatitis b virus infection .',b'reduced risk of alemtuzumab and proven defects in ovarian tumours for harmful of hepatitis b virus infection .',b'13 reduced risk of suffering from hepatocellular carcinoma . hepatocellular carcinoma is a serious complication of hepatitis b virus infection .'
879,"b'die erfahrungen bei solchen patienten sind auf patienten mit leberzirrhose beschr\xc3\xa4nkt ( siehe abschnitte 4.3 , 4.4 und 5.2 ) .'","b'the experience in patients who are limited to patients with cirrhosis of the liver ( see sections 4.3 , 4.4 and 5.2 ) .'",b'the dosage of steadystate the insufficient of greater with tipranavir with cirrhosis of the liver see sections . are not been described . neither therapy .',"b'the experiences in patients who limited to patients with cirrhosis of the liver ( see sections 4.3 , 4.4 and 5.2 ) .'"
880,"b'kontaktieren sie ihren arzt , wenn ihre ermittelte dosis effentora nicht ihre durchbruchschmerzen lindert .'",b'check with your doctor if your how dose of effentora will relieve your breakthrough pain .',b'check with your doctor if your hypoglycaemia associated to adverse medication titration .',b'check with your doctor if your dose of effentora dpes relieve your breakthrough pain .'
881,"b'306 das einhalten des dosier- und di\xc3\xa4tschemas , die korrekte insulinverabreichung und das erkennen von symptomen einer hypoglyk\xc3\xa4mie durch den patienten sind von zentraler bedeutung , um das risiko einer hypoglyk\xc3\xa4mie zu senken .'","b'306 adherence of the patient to the dosage and dietary regimen , correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia .'","b'adherence of the patient to the dosage and neural regimen , correct insulin oral therapy may administer the nore caused section or structural of hypoglycaemia can have been performed to that with contact with driving insulin administration and upper st of hypoglycaemia may occur to reduce the risk of sugar'","b'306 adherence of the patient to the dosage and dietary regimen , correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia .'"
882,b'wof\xc3\xbcr wird equilis prequenza angewendet ?',b'what is equilis prequenza used for ?',b'what is equilis prequenza used for ?',b'what is equilis prequenza used for ?'
883,"b'30 minuten nach der einnahme der testl\xc3\xb6sung ( punkt 7 ) werden die "" 30-minuten-wert "" - proben in den beiden in der packung verbliebenen beh\xc3\xa4ltnissen ( aufschrift :'","b'thirty minutes after administration of the test solution ( point 7 ) , the "" 30-minute-value "" - samples in the two containers which are left in the test of :'",b'valera point of the test solution possible to extract in one lid which are authorized through the treatment of',"b'thirty minutes after taking the test solution ( point 7 ) , the "" 30 minute value , "" samples in the two containers which are left in the test of :'"
884,"b'invega soll nicht w\xc3\xa4hrend der schwangerschaft angewendet werden , es sei denn , dies ist eindeutig erforderlich .'",b'invega should not be used during pregnancy unless it is clearly necessary .',b'invega should not be used during pregnancy unless it is clearly necessary .',b'invega should not be used during pregnancy unless it is clearly necessary .'
885,"b'es liegen berichte \xc3\xbcber muskelschmerzen , empfindlichkeit oder schw\xc3\xa4che , vor allem unter antiretroviraler behandlung einschlie\xc3\x9flich proteasehemmern und nukleosidanaloga , vor .'","b'there have been reports of muscle pain , tenderness or weakness , particularly with antiretroviral therapy including protease inhibitors and nucleoside analogues .'","b'there have been reports of muscle pain , ad or weakness , particularly with laboratory therapy including protease inhibitors and nucleoside analogues , fat with antiretroviral therapy including protease inhibitors and nucleoside analogues , particularly with antiretroviral therapy with antiretroviral therapy with antiretroviral therapy in the function .'","b'there have been reports of muscle pain , tenderness or weakness , particularly with antiretroviral therapy including protease inhibitors and nucleoside analogues .'"
886,"b'die behandlung ist h\xc3\xa4ufig mit gastrointestinalen nebenwirkungen , einschlie\xc3\x9flich \xc3\x9cbelkeit , erbrechen und durchfall , verbunden .'","b'treatment are commonly associated with gastrointestinal side effects , including nausea , vomiting and diarrhoea .'",b'treatment are commonly typically other body disorders .',"b'treatment is commonly associated with gastrointestinal side effects , including nausea , vomiting and diarrhoea .'"
887,b'in kontrollierten klinischen studien waren unter den mit dynastat behandelten patienten 1962 patienten mit postoperativen schmerzen .',"b'in controlled clinical trials , the triphosphste with patients treated with dynastat in patients with post-operative pain .'","b'in controlled clinical trials , the hyperplasia with patients treated with dynastat in patients with postoperative pain .'","b'in controlled clinical trials , 1962 patients who were treated with dynastat had post-operative pain .'"
888,b'ihr arzt wird ihre behandlung mit herceptin genau \xc3\xbcberwachen .',b'your doctor will closely monitor your treatment with herceptin .',b'your doctor will closely monitor your treatment with herceptin .',b'your doctor will closely monitor your treatment with herceptin .'
889,"b'durch die substitutionstherapie werden die faktor viii-plasmaspiegel erh\xc3\xb6ht , wodurch eine tempor\xc3\xa4re korrektur des faktor viii- mangels erm\xc3\xb6glicht und die blutungstendenz korrigiert wird .'","b'by replacement therapy the plasma levels of factor viii are increased , thereby enabling a temporary correction of the apo-1 factor viii deficiency and blutungstendenz .'","b'by replacement therapy the plasma levels of factor viii have increased , injecting the heart ingredient and hydroxymemantin and hydroxymemantin .'","b'by replacement therapy the plasma levels of factor viii are increased , thereby enabling a temporary correction of the factor viii deficiency and tendency to bleed .'"
890,"b'es ist nicht bekannt , ob diese erkenntnisse auch f\xc3\xbcr j\xc3\xbcngere postmenopausale frauen oder andere hrt-produkte gelten .'",b'it is not known whether these findings also apply to the younger postmenopausal women or other hrt-produkte .',b'it is not known whether these findings also apply to the younger dose .',b'it is not known whether these findings also apply to the younger postmenopausal women or other hrt-produkte .'
891,"b'flache , wei\xc3\x9fe , runde , an den kanten abgeschr\xc3\xa4gte tablette mit der pr\xc3\xa4gung "" c "" auf der einen seite und "" 2 "" auf der anderen seite .'","b'light white , round , flat , the round bevelled-edge tablet , embossed on one side with a "" c "" and on the other side with "" 2 "" on the other side .'","b'clear white , round , flat , oblong , oblong , oblong , flat , substanca the other side .'","b'white , round , flat , round tablet embossed on one side with a "" c "" and on the other side with "" 2 . ""'"
892,b'zun\xc3\xa4chst entfernen sie den kunststoffdeckel von der flasche .',"b'initially , remove the cap on the bottle .'","b'initially , remove the cap on the bottle .'","b'initially , remove the cap on the bottle .'"
893,"b'diese effekte traten bei plasmaspiegeln auf , die vergleichbar mit denen bei patienten sind , zeigten aber reversibilit\xc3\xa4t .'","b'these effects occurred in plasma levels , which were similar to those in patients but who showed reversibility .'","b'these effects occurred in plasma levels , which were similar to those in patients ,'","b'these effects occurred in plasma levels , which were similar to those in patients but showed reversibility .'"
894,b'2. was m\xc3\xbcssen sie vor der anwendung von velcade beachten ? 3.',b'what you should consider before you use velcade 3 .',b'what you should consider before you use velcade .',b'what you should consider before you use velcade 3 .'
895,"b'es ist wichtig , eine solche infektion sobald wie m\xc3\xb6glich zu erkennen und zu behandeln .'",b'it is important to recognise and treat this infection as soon as possible .',b'it is important to recognise and treat the pain .',b'it is important to recognise and treat this infection as soon as possible .'
896,b'haltbarkeit des tierarzneimittels laut verkaufsverpackung :',b'shelf life of the veterinary medicinal product as packaged for sale :',b'shelf life of the veterinary medicinal product',b'shelf life of the veterinary medicinal product as packaged for sale :'
897,b'141 als ged\xc3\xa4chtnisst\xc3\xbctze k\xc3\xb6nnen sie beispielsweise den wochentag mit einem feinen kugelschreiber auf das pflaster schreiben .',"b'141 as to help you remember you may be , for example , the day of and if the patch .'","b'as to patch you remember to help , the day of and radiotherapy , whose diet .'","b'141 to help you remember you may , for example , write the day of the week on the patch .'"
898,b'es gibt kein spezifisches antidot .',b'there is no specific antidote .',b'there is no specific antidote .',b'there is no specific antidote .'
899,"b'leberzellsch\xc3\xa4digung * , hepatitis , gelbsucht , lebervergr\xc3\xb6\xc3\x9ferung selten :'","b'hepatocellular damage * , hepatitis , jaundice , hepatomegaly rare :'","b'waavprichtlinien damage , hepatitis , jaundice , urination rare'","b'hepatocellular damage * , hepatitis , jaundice , hepatomegaly rare :'"
900,b'eine arachnoiditis kann bei nichtbehandlung letal verlaufen .',b'one arachnoiditis may be used in the apc been fatal .',b'damaging the site of other dnaderived us the potochemical from the lithium levels .',b'one arachnoiditis may be fatal when not treated .'
901,b'schwangerschaft die unbedenklichkeit von orfadin bei schwangeren frauen wurde noch nicht untersucht .',b'pregnancy the safety of orfadin has not been tested in pregnant women has been established .',b'taken the safety of orfadin has not been tested in pregnant women has been established .',b'pregnancy : the safety of orfadin has not been tested in pregnant women .'
902,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und auf dem etikett der durchstechflasche angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and on the label of the vial .',b'do not use after the expiry date which is stated on the expiry appropriate and on the label of the carton .',b'do not use after the expiry date which is stated on the carton and on the label of the vial .'
903,b'die behandlung mit gonal-f sollte von einem arzt mit erfahrung in der behandlung von fruchtbarkeitsst\xc3\xb6rungen durchgef\xc3\xbchrt werden .',b'treatment with gonal-f should be carried out by a doctor who has experience in the treatment of fertility problems .',b'treatment with gonalf should be determined out by a doctor who has experience in the treatment of fertility problems .',b'treatment with gonal-f should be carried out by a doctor who has experience in the treatment of fertility problems .'
904,b'4 im rahmen der postmarketing-\xc3\x9cberwachung wurden thrombozytopenien einschlie\xc3\x9flich einzelner f\xc3\xa4lle intrakranialer blutungen auch mit todesfolge berichtet .',"b'4 in postmarketing-\xc3\x9cberwachung thrombocytopenia have been reported , including percentage of cases of intracranial bleeding including fatalities .'","b'in alglucosidase thrombocytopenia have been reported , including virological overdose in blurred disease of intracranial bleeding including connective antibodies .'","b'4 in postmarketing observations , thrombocytopenia , including percentage of cases of intracranial bleeding as well as fatalities , have been reported .'"
905,"b'efavirenz verringert die voriconazol-plasmakonzentration signifikant , w\xc3\xa4hrend voriconazol die efavirenz-plasmakonzentration signifikant erh\xc3\xb6ht .'","b'efavirenz reduces the voriconazol-plasmakonzentration significantly , while voriconazole efavirenz-plasmakonzentration significantly increased .'",b'cancer medicinal recruited a risk of organic tissue were not insufficient in antibodies .',"b'efavirenz reduces the voriconazole plasma concentration significantly , while voriconazole significantly increased efavirenz plasma concentration .'"
906,b'die behandlung mit cellcept soll von entsprechend qualifizierten transplantationsspezialisten eingeleitet und fortgef\xc3\xbchrt werden .',b'treatment with cellcept should be initiated and maintained by a corresponding to qualified transplantationsspezialisten .',b'treatment with cellcept should be initiated and glomerular determined with other corresponding a corresponding to prolonged group .',b'treatment with cellcept should be initiated and maintained by qualified transplant specialists .'
907,b'es wurden keine kontrollierten klinischen studien zur wirksamkeit von cerezyme f\xc3\xbcr die neurologischen manifestationen der erkrankung durchgef\xc3\xbchrt .',b'there have been no controlled clinical studies of the effectiveness of cerezyme on the neurological manifestations of the disease .',b'there have been no controlled clinical studies of the tolerability group was evaluated in the respective toxic dosage rate in six age are observed for deferiprone after the underlying interval of the disease .',b'there have been no controlled clinical studies of the effectiveness of cerezyme on the neurological manifestations of the disease .'
908,b'die ergebnisse zur wirksamkeit aus den studien actg 364 und 020 sind in tabelle 5 dargestellt .',b'efficacy results from studies actg 364 and 020 are found in table 4 .',b'the reason to the disease of the postmarketing weekly and used in table .',b'efficacy results from studies actg 364 and 020 are found in table 5 .'
909,b'die folgenden nebenwirkungen wurden angegeben :',b'the following adverse reactions were reported in accordance with the following table :',b'the following adverse reactions were reported in consideration of the following table',b'the following adverse reactions were reported in accordance with the following table :'
910,"b'es ist nicht bekannt , ob tredaptive in die muttermilch \xc3\xbcbergeht .'",b'it is not known whether tredaptive is excreted in human milk .',b'it is not known whether tredaptive is excreted in human milk .',b'it is not known whether tredaptive is excreted in human milk .'
911,b'kentera f\xc3\xbchrte bei den symptomen einer \xc3\xbcberaktiven blase im vergleich zum placebo zu best\xc3\xa4ndigen verbesserungen .',"b'kentera resulted in the symptoms of overactive bladder , as compared with placebo , restructuring improvements .'",b'rotarix resulted in the symptoms of the symptoms of an dermatologicals .',b'kentera resulted in steady improvements in the symptoms of overactive bladder as compared with placebo .'
912,b'm\xc3\xa4nner m\xc3\xbcssen w\xc3\xa4hrend einer behandlung mit depocyte zuverl\xc3\xa4ssige verh\xc3\xbctungsma\xc3\x9fnahmen treffen .',b'men must be used during treatment with depocyte must use contraceptive measures .',b'men must be reused during treatment with depocyte must use contraceptive measures .',b'men must use contraceptive measures during treatment with depocyte .'
913,b'humira 40 mg injektionsl\xc3\xb6sung in einzel-fertigspritze ( glasart i ) zum gebrauch durch den patienten :',b'humira 40 mg solution for injection in single-use pre-filled syringe ( type i glass ) for patient use .',b'humira mg solution for injection in the components',b'humira 40 mg solution for injection in single-use pre-filled syringe ( type i glass ) for patient use :'
914,b'pritorplus tabletten k\xc3\xb6nnen zu oder unabh\xc3\xa4ngig von den mahlzeiten eingenommen werden .',b'pritorplus tablets can be taken with or without food .',b'pritorplus tablets can be taken with or without food .',b'pritorplus tablets can be taken with or without food .'
915,b'die h\xc3\xa4ufigkeit der einreichung der psurs wird bei der j\xc3\xa4hrlichen neubewertung des produktes festgelegt .',b'the incidence of submission of psurs is used in annual reassessment of the product .',b'the incidence of review of ranexa is used in annual reassessment of the product .',b'the incidence of submission of psurs is used in annual reassessment of the product .'
916,b'studien mit nicht-pvc- beuteln wurden nicht durchgef\xc3\xbchrt .',b'studies with non-pvc bags have not been conducted .',b'studies with photoallergic . are the drug',b'studies with non-pvc bags have not been conducted .'
917,b'nelfinavir wird haupts\xc3\xa4chlich \xc3\xbcber die cytochrom-p-450-isoenzyme cyp3a und cyp2c19 metabolisiert ( siehe abschnitt 5.2 ) .',b'nelfinavir is primarily metabolised by cytochrome p-450 isozymes cyp3a and cyp2c19 ( see section 5.2 ) .',b'nelfinavir is primarily metabolised by cytochrome p cyclooxygenase cypa and cypc one of cmin . .',b'nelfinavir is primarily metabolised by cytochrome p-450 isozymes cyp3a and cyp2c19 ( see section 5.2 ) .'
918,"b'6-24fach ) , wenn ciprofloxacin gleichzeitig gegeben wurde .'",b'6-24fach ) when ciprofloxacin was administered concomitantly .',b'midazolam of the concentration of platinum if the single muscle selegiline .',b'6 to 24 times ) when ciprofloxacin was administered concomitantly .'
919,"b'die anwendung starrer katheter , intramuskul\xc3\xa4re injektionen und nicht unbedingt erforderliche ma\xc3\x9fnahmen am patienten sollten w\xc3\xa4hrend der therapie mit metalyse unterbleiben .'","b'the use of the genus isotrichia catheters , intramuscular injections and not necessarily required measures to assess which patients should be withheld during therapy with metalyse .'","b'the use of the confirmatory reliability pathological scans elimination , a greater products in order to a basis for breakdown with metalyse retention .'","b'use of inflexible catheters , intramuscular injections and not necessarily required measures with patients should be stopped during therapy with metalyse .'"
920,"b'kombination mit anderen eisenchelattherapien , da die sicherheit solcher kombinationen nicht belegt ist ( siehe abschnitt 4.5 ) .'","b'combination with other iron chelator treatment , because the safety of such combinations has not been established ( see section 4.5 ) .'",b'combination with other and splitting should not been established see section . .',"b'combination with other iron chelator treatment , because the safety of such combinations has not been established ( see section 4.5 ) .'"
921,"b'die dosis sollte ebenfalls entsprechend verringert werden , wenn die thrombozytenzahl unter 25 x 109 / l absinkt .'",b'doses should be similarly reduced if the platelet count falls below 25 x 109 / l .',b'doses should be taken in neonates are interact with single doses .',b'doses should be similarly reduced if the platelet count falls below 25 x 109 / l .'
922,"b'falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'"
923,b'stechen sie die nadel in einem winkel zwischen 45 \xc2\xb0 bis 90 \xc2\xb0 in die hautfalte .',b'push the needle into the pinched skin at an angle of 45 \xc2\xb0 to 90 \xc2\xb0 .',b'push the needle into the blood device is go into an angle of to .',b'push the needle into the pinched skin at an angle of 45 \xc2\xb0 to 90 \xc2\xb0 .'
924,"b'verwenden sie sie nicht , wenn der letzte tag des angegebenen monats bereits abgelaufen ist .'","b""don 't use it if the date has passed the last day of the month shown .""",b'do to use force if the date has passed the last day of the month no day of the month .',"b""don 't use it if the date has passed the last day of the month shown ."""
925,"b'resorption und verteilung da lansoprazol durch magens\xc3\xa4ure schnell inaktiviert wird , wird es in form von magensaftresistenten minitabletten in gelatine-kapseln verabreicht .'",b'absorption and distribution as lansoprazole is rapidly inactivated by gastric acid and enteric-coated granules .',"b'absorption and distribution as lansoprazole is rapidly inactivated by muscle acid , periods and renatiomere facilities .'","b'absorption and distribution . as lansoprazole is rapidly inactivated by gastric acid , it is administered in the form of and enteric-coated minitablets in gelatine capsules .'"
926,b'was ist zenapax ? er ng zenapax ist ein konzentrat zur herstellung einer infusionsl\xc3\xb6sung ( tropfinfusion in eine vene ) .',b'what is zenapax ? ge lon zenapax is a concentrate that is made up into a solution for infusion ( drip into a vein ) .',b'what is zenapax ? produced on use with pandemrix can not made up into a solution for infusion drip into a vein .',b'what is zenapax ? ge lon zenapax is a concentrate that is made up into a solution for infusion ( drip into a vein ) .'
927,b'in einer gezielten interaktionsstudie erhielten hypertoniker sildenafil ( 100 mg ) zusammen mit amlodipin .',b'in a formal interaction study received hypertoniker sildenafil ( 100 mg ) co-administered with amlodipine .',b'in a formal interaction study received unexpected stage of platin as recommended higher toxic of coadministration .',b'in a formal interaction study hypertoniker sildenafil ( 100 mg ) was co-administered with amlodipine .'
928,"b'ein geringf\xc3\xbcgiger anteil ( weniger als 8 % ) der verabreichten dosis ist im urin nachweisbar , vornehmlich als metaboliten .'","b'a small proportion ( less than 8 % ) of the administered dose is recovered in the urine , principally as metabolites .'",b'usual proportion less than of the hour dose is recovered in the urine .',"b'a small proportion ( less than 8 % ) of the administered dose is recovered in the urine , principally as metabolites .'"
929,"b'die empfohlene dosis muss per intraven\xc3\xb6se infusion verabreicht werden , obwohl sie in den laufenden klinischen studien jedoch auch \xc3\xbcber einen zentralen venenkatheter verabreicht worden ist .'","b'the recommended dose should be administered as a single intravenous infusion , although they have been in ongoing clinical trials , but also via central venous catheter .'","b'the recommended dose should be administered as a single intravenous infusion , although that also via central venous saturation .'","b'the recommended dose should be administered as a single intravenous infusion , although they have been administered via central venous catheter .'"
930,"b'erh\xc3\xb6hte plasmabenzodiazepin-konzentrationen k\xc3\xb6nnen durch einen verminderten hepatischen metabolismus auftreten , was zu \xc3\xbcberm\xc3\xa4\xc3\x9figer sedierung f\xc3\xbchrt .'","b'elevated plasmabenzodiazepin-konzentrationen may occur through decreased hepatic metabolism , leading to excessive sedation .'",b'elevated statin arrhythmia can occur through cholesterol of body neutropenia .',"b'plasma benzodiazepine concentrations may rise from decreased hepatic metabolism , leading to excessive sedation .'"
931,"b'diese werden zur behandlung von zust\xc3\xa4nden , bei denen das abwehrsystem des k\xc3\xb6rpers nicht ausreichend arbeitet , eingesetzt .'",b'these are used for the treatment of pathological conditions in which fights diseases is not sufficient to absorb avamys .',b'these are used for the treatment of caution shock diseases .',b'these are used for the treatment of pathological conditions in which the defence system of the body do not work sufficiently .'
932,"b'die tabletten sind auf der einen seite mit "" gilead "" sowie "" 4331 "" und auf der anderen seite mit "" 300 "" gekennzeichnet .'","b'the tablets are marked with "" gilead "" and "" 4331 "" and on the other side with "" 300 "" on the other side .'",b'the tablets are marked with viani and and on the other side with on the other side .',"b'the tablets are marked with "" gilead "" and "" 4331 "" and on the other side with "" 300 . ""'"
933,b'237 dauer der haltbarkeit nach der ersten verwendung des pens :',b'237 shelf life after first use of the pen :',b'shelf life after first use of the pen',b'237 shelf life after first use of the pen :'
934,b'[ ist national auszuf\xc3\xbcllen ] arzneimittel f\xc3\xbcr kinder unzug\xc3\xa4nglich aufbewahren .',b'[ to be completed nationally ] keep out of reach and sight of children .',b'to be completed nationally keep out of reach and sight of children .',b'[ to be completed nationally ] keep out of reach and sight of children .'
935,"b'bitte sprechen sie mit ihrem arzt oder apotheker , wenn sie den eindruck haben , dass die wirkung von procoralan zu stark oder zu schwach ist .'","b'if you have the impression that the effect of procoralan is too strong or too weak , talk to your doctor or pharmacist .'","b'if you have decide that the effect of procoralan are too strong or too weak , optiset to your doctor or pharmacist .'","b'if you have the impression that the effect of procoralan is too strong or too weak , talk to your doctor or pharmacist .'"
936,"b'wenn ihre durchbruchschmerzen nicht innerhalb von 30 minuten gelindert sind , wenden sie zu diesem zeitpunkt nur 1 weitere tablette effentora an .'","b'if your breakthrough pain are not obtained within 30 minutes , contact the traction system at this step for only one tablet of effentora .'",b'if your susceptible pain an early intake of the depletion of effentora .',"b'if your breakthrough pain is not alleviated within 30 minutes , take only one further tablet of effentora at this point .'"
937,"b'daher wird rasilez hct nicht f\xc3\xbcr die behandlung von patienten mit schweren nierenfunktionsst\xc3\xb6rungen ( gfr < 30 ml / min / 1,73 m2 ) empfohlen ( siehe abschnitt 4.3 ) .'","b'therefore , rasilez hct should not be used for the treatment of patients with severe renal impairment ( gfr 30 ml / min / 1.73 m2 ) is recommended ( see section 4.3 ) .'","b'therefore , rasilez hct should not be used for the treatment of patients with severe renal impairment gfr ml min . m is recommended see section . .'","b'therefore , rasilez hct should not be used for the treatment of patients with severe renal impairment ( gfr 30 ml / min / 1.73 m2 ) ( see section 4.3 ) .'"
938,b'hunde sollten 48 stunden vor der behandlung nicht gebadet oder einschamponiert werden .',"b'dogs should not be bathed until 48 hours before treatment , or einschamponiert .'","b'dogs should not be enter until hours before treatment , or acth .'","b'dogs should not be bathed until 48 hours before treatment , or einschamponiert .'"
939,b'sie m\xc3\xbcssen den rat ihres behandelnden arztes zur empf\xc3\xa4ngnisverh\xc3\xbctung befolgen .',b'you must follow the advice of your doctor measures .',b'you must follow the advice of your doctor frequently .',b'you must follow the advice of your doctor measures .'
940,b'jedes glasfl\xc3\xa4schchen enth\xc3\xa4lt 75 mg omalizumab .',b'each vial contains 75 mg of omalizumab .',b'each vial contains taking an following mg of omalizumab .',b'each vial contains 75 mg of omalizumab .'
941,b'sie k\xc3\xb6nnen die bauchregion mit ausnahme des 5 cm bereiches um den bauchnabel verwenden .',"b'you can take the abdomen , except for the 5 cm area around the navel ) .'","b'instead of an lot , except for the cm area several the inhibition of the implantable transition to those from sperm leaflet .'","b'you can take the abdomen , except for the 5 cm area around the navel ) .'"
942,b'die leberfunktion sollte bei allen patienten vor behandlungsbeginn und danach monatlich bestimmt werden ( siehe abschnitt 4.4 ) .',b'liver function should be conducted in all patients prior to initiation of treatment and monthly thereafter ( see section 4.4 ) .',b'liver protein concentration of an good period adjusted infusion . .',b'liver function should be determined in all patients prior to initiation of treatment and monthly thereafter ( see section 4.4 ) .'
943,b'schwangerschaft und stillzeit schwangere frauen erhalten normalerweise kein cubicin .',b'pregnancy and breast-feeding pregnant women usually did not receive cubicin .',b'pregnancy and breastfeeding become an wellcontrolled combination of proper ml of',b'pregnancy and breast-feeding : pregnant women usually did not receive cubicin .'
944,"b'wenn crixivan zusammen mit ritonavir angewendet wird , informieren sie ihren arzt und beachten sie die weiteren informationen der gebrauchsinformation von ritonavir .'","b'when crixivan is used with ritonavir , tell your doctor closely and use the information to the package leaflet for ritonavir .'",b'when crixivan for a period of these function .',"b'when crixivan is used with ritonavir , tell your doctor and follow the information on the package leaflet for ritonavir .'"
945,"b'ma\xc3\x9fnahme bis zu 2 weitere versuche sind m\xc3\xb6glich , um eine erneute dosisabgabe auszul\xc3\xb6sen .'","b'n-methyl-1,2-benzoisothiazol-3 ( up to 2 additional studies are possible , the system cannot be restarted .'","b'siliconefree is a result with how out to the system cannot be regularly , it is different out .'","b'measures : up to 2 additional studies are possible , to release a new dose administration .'"
946,"b'in klinischen studien war das auftreten von hypox\xc3\xa4mie h\xc3\xa4ufig , speziell innerhalb der ersten 15 minuten der dexmedetomidin-ketamin-narkose .'","b'in clinical trials , the incidence of hypoxemia was common , especially within the first 15 minutes of dexmedetomidin-ketamin-narkose .'","b'in clinical trials , the incidence of hypoxemia was common , especially within the first minutes of reichlichen two clinical minutes of betablockers vein .'","b'in clinical trials , the incidence of hypoxemia was common , especially within the first 15 minutes of dexmedetomidin-ketamin anesthesia .'"
947,b'bei einnahme von isentress zusammen mit anderen arzneimitteln isentress kann mit anderen arzneimitteln wechselwirkungen haben .',"b'taking isentress with other medicines , isentress may be mixed with other medicinal products interactions .'","b'when yes viracept with other medicines , isentress may be mixed with other or ribavirin with other medicinal products interactions .'",b'taking isentress with other medicines isentress may have interactions with other medicinal products .'
948,"b'daher ist bei gemeinsamer verabreichung mit starlix keine dosisanpassung f\xc3\xbcr digoxin , warfarin oder andere arzneimittel , die substrate f\xc3\xbcr cyp2c9 oder cyp3a4 darstellen , erforderlich .'","b'therefore , given concomitantly with starlix suggesting that no dose adjustment of digoxin , warfarin or other medicinal products that are substrates of cyp2c9 or cyp3a4 , is required .'","b'therefore , given administered to wear cycles all dose adjustment of digoxin should be recommended sections or diuretics compounds is excercised have on the incidence of digoxin , warfarin or liver drug effect .'","b'therefore , given concomitantly with starlix , no dose adjustment of digoxin , warfarin or other medicinal products that are substrates of cyp2c9 or cyp3a4 is required .'"
949,"b'bei nicht-dialysepflichtigen patienten kann aranesp subkutan auch in einer dosis von 0,75 \xc2\xb5g / kg k\xc3\xb6rpergewicht als einzelne injektion einmal alle 2 wochen gegeben werden .'","b'alternatively , in patients not on dialysis may be administered subcutaneously at a dose of 0.75 \xc2\xb5g / kg body weight , as a single injection once every two weeks .'","b'alternatively cell treatment weekly . when a dose of . g kg body weight , as a single injection once every two weeks were mg body weight , as a single injection once every two weeks therapy .'","b'alternatively , in patients not on dialysis it may be administered subcutaneously at a dose of 0.75 \xc2\xb5g / kg body weight as a single injection once every two weeks .'"
950,"b'38 / 46 selten ( mehr als 1 von 10.000 patienten , aber weniger als 1 von 1.000 patienten ) :'","b'38 / 44 rare ( more than 1 in every 10,000 patients , but less than 1 in every 1,000 patients ) :'","b'rare more than in every , patients , patients or only less than in every , patients'","b'38 / 44 rare ( more than 1 in every 10,000 patients , but less than 1 in every 1,000 patients ) :'"
951,"b'wenden sie sich sofort an ihren arzt , wenn sie diese beschwerden bekommen , da sie m\xc3\xb6glicherweise dringend \xc3\xa4rztliche behandlung ben\xc3\xb6tigen .'",b'always take your doctor immediately if you get these symptoms as you may need urgent medical treatment .',b'if you forget to you get these symptoms as you may need urgent medical treatment .',b'always contact your doctor immediately if you get these symptoms as you may need urgent medical treatment .'
952,b'70 eine leichte form der hypoglyk\xc3\xa4mie kann durch aufnahme von glukose oder zucker oder anderen zuckerhaltigen produkten behoben werden .',b'70 mild hypoglycaemic episodes will respond to oral administration of glucose or other sugar or saccharated products .',b'mild hypoglycaemic episodes will respond at the the inject or other groups .',b'70 mild hypoglycaemic episodes will respond to oral administration of glucose or other sugar or saccharated products .'
953,"b'enth\xc3\xa4lt zus\xc3\xa4tzlich dinatriumhydrogenphosphat , phosphors\xc3\xa4ure und natriumhydroxid .'","b'also contains disodium hydrogen phosphate heptahydrate , concentrated phosphoric acid and sodium hydroxide .'","b'also contains disodium toxoid phosphate glycerol from adapter by mg cap oder as method of the flat , divide lecithin isopropyl sodium hydroxide .'","b'also contains disodium hydrogen phosphate heptahydrate , concentrated phosphoric acid and sodium hydroxide .'"
954,"b'lesen sie vor der verwendung die packungsbeilage . da stronghold hochentz\xc3\xbcndlich ist , muss es von hitze , offener flamme , funken oder sonstigen z\xc3\xbcndquellen ferngehalten werden .'","b'read the package leaflet before use. the benefits of stronghold exceed the risks , it should be used , sparks , open flame or other sources of ignition in cats and dogs .'","b'read the package product must be checked with no designated teaspoon , it should be alternative out with glycosylated versa during the risks , it should be used , stimulate enzymatic working or other concordant of continent must be used by the risks . the risks , it should be'","b'read the package leaflet before use . because stronghold is highly flamable , it should be kept away from heat , open flame , sparks or other sources of ignition .'"
955,b'* bei der berechnung der romiplostim-dosis sollte immer das tats\xc3\xa4chliche k\xc3\xb6rpergewicht bei behandlungsbeginn zugrunde gelegt werden .',b'* in the calculation of the romiplostim-dosis treatment should always be body weight at initiation of treatment .',b'in the study must be taken for the depletion of treatment .',b'* in the calculation of the romiplostim-dosis treatment should always be body weight at initiation of treatment .'
956,b'die h\xc3\xa4ufigsten nebenwirkungen ( beobachtet bei mehr als 1 von 10 patienten ) waren reizbarkeit und appetitlosigkeit .',b'the most common side effects ( seen in more than 1 patient in 10 ) were irritability and loss of appetite .',b'the most common side effects seen in more than patient in were disturbances and loss of appetite .',b'the most common side effects ( seen in more than 1 patient in 10 ) were irritability and loss of appetite .'
957,"b'temoporfin darf nicht w\xc3\xa4hrend der schwangerschaft verwendet werden , es sei denn , dies ist eindeutig erforderlich .'",b'temoporfin should not be used during pregnancy unless it is clearly necessary .',b'soliris should not be breast necessary a postmarketing necessary time during pregnancy unless it is clearly necessary .',b'temoporfin should not be used during pregnancy unless it is clearly necessary .'
958,b'wie wurde novem untersucht ?',b'how has novem been studied ?',b'how has histoplasmosis been studied ?',b'how has novem been studied ?'
959,"b'32 bei ihnen ein test auf spezielle antik\xc3\xb6rper erforderlich werden . ihr arzt wird ihnen sagen , ob dies auf sie zutrifft .'",b'32 you have a special type of required . your doctor will tell you if any of these apply to you .',b'you have a special type of required . your doctor will tell you drive .',b'32 you have a special type of antibody required . your doctor will tell you if any of these apply to you .'
960,b'rz dosiserh\xc3\xb6hung einer bereits bestehenden antihypertensiven medikation notwendig machen .',b'er dosage of existing antihypertensive medication .',b'ciclosporin dosage of existing antihypertensive medication .',b'makes a dosage increase of an already existing antihypertensive medication necessary .'
961,"b'schuppendermatitis , trockene haut , hautgrie\xc3\x9f , makulopapul\xc3\xb6ser ausschlag , papul\xc3\xb6ser ausschlag , narben , hauthyperpigmentierung , hautl\xc3\xa4sion , hautkn\xc3\xb6tchen , urtikaria gelegentlich :'","b', dermatitis exfoliative , dry skin , milia , rash maculo-papular , rash papular , scar , skin hyperpigmentation , skin lesion , skin nodule , urticaria uncommon :'","b', dermatitis , dry skin , contrast chemical acetyldl tremors , chest salivation , folliculitis spasm , inflammation saturation , dyspnoea ifn , rash mycoses , abnormal face disorders or agitation with such and limitation of the breasts , abnormal , abnormal salivation .'","b'sermatitis exfoliative , dry skin , milia , rash maculo-papular , rash papular , scar , skin hyperpigmentation , skin lesion , skin nodule , urticaria uncommon :'"
962,b'aufgrund der stimulation der knochenmineralisation durch alendronat k\xc3\xb6nnen abnahmen des serum-calciums und -phosphats auftreten .',"b'due to the effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .'","b'due to the effects of alendronate with on the knee of what case with other cancer , a food and solutions may occur .'","b'due to the effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .'"
963,"b'wenn eine weitere dosiserh\xc3\xb6hung auf bis zu 5,0 mikrogramm angezeigt ist , sollten auch hier zun\xc3\xa4chst wieder dosierintervalle von mindestens 3 stunden gew\xc3\xa4hlt werden , die sp\xc3\xa4ter je nach individueller vertr\xc3\xa4glichkeit verk\xc3\xbcrzt werden k\xc3\xb6nnen .'","b'if a further dose increase up to 5.0 micrograms is indicated , immunisation should be also initially resumed dosierintervalle of at least 3 hours , and the later may be depending on individual tolerability .'","b'if a further dose , be exhausted corresponding morphine based shows the desired optimal institution see even the need for at least hours , and the valtropin of at least hours to be also discontinuing didanosine to reduce stable hours is use , as after hours with a home should'","b'if a further dose increase up to 5.0 micrograms is indicated , initially dose intervals of at least 3 hours should be chosen , which may be shortened according to individual tolerability .'"
964,"b'1 fertigspritze mit 0,5 ml injektionsl\xc3\xb6sung enth\xc3\xa4lt 20000 internationale einheiten ( i.e. ) epoetin zeta * ( rekombinantes humanes erythropoetin ) .'",b'1 pre-filled syringe with 0.5 ml solution for injection contains 20000 international units ( iu ) epoetin zeta * ( recombinant human erythropoietin ) .',b'each ml solution should be increased measuing . ml solution for injection contains international units iu epoetin zeta aluminium zeta .',b'1 pre-filled syringe with 0.5 ml solution for injection contains 20000 international units ( iu ) epoetin zeta * ( recombinant human erythropoietin ) .'
965,b'mit dem erythropoetinrezeptor auf den erythroiden vorl\xc3\xa4ufe rzellen im knochenmark der hauptregulator der erythropoese ist .',b'with the narrow on the erythroid vorl\xc3\xa4ufe rzellen primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the cells in the bone marrow .',"b'with the marketing dose of ndesmethoxypropyl out , the pigs .'",b'with the erythropoietin receptors on the precursor cells in the bone marrow of the main regulator of the erythropoiesis .'
966,"b'beide produkte zeigen deutlichen einfluss der nahrung , wobei das generische produkt insbesondere aufgrund der hohen intraindividuellen variabilit\xc3\xa4t st\xc3\xa4rker betroffen zu sein scheint .'","b'both of these products due to the high intra-subject variability show a significant impact of food , of further affected appears to be more severe .'","b'both of these products due to the high new public such where the high new defect with your doctor are explained during a significant impact with the youngest normal time to a significant missing in all individual surface of food , whether the conversion of food , of further affected'",b'both of these products show a significant impact on food where the generic product particularly seems to be more strongly affected due to the high intra-subject variablity .'
967,b'wie bei jedem proteinprodukt zur intraven\xc3\xb6sen anwendung k\xc3\xb6nnen allergische \xc3\x9cberempfindlichkeitsreaktionen auftreten .',"b'as with any intravenous protein product , allergic type hypersensitivity reactions may occur .'","b'as with any intravenous protein product , please be required'","b'as with any intravenous protein product , allergic type hypersensitivity reactions may occur .'"
968,"b'schlaflosigkeit , angstzust\xc3\xa4nde , benommenheit und depression . ern\xc3\xa4hrung :'","b', insomnia , anxiety , dizziness and depression nutrition : low blood sodium .'","b'renal sugar s side effects , dizziness and depression different loss of the central blood body .'","b'insomnia , anxiety , dizziness and depression nutrition : low blood sodium .'"
969,b'die anwendung von dafiro bei kindern und jugendlichen wird nicht empfohlen .',b'the use of dafiro in children and adolescents is not recommended .',b'the use of dafiro in children and adolescents is not recommended .',b'the use of dafiro in children and adolescents is not recommended .'
970,"b'dies verursacht 290 eine schwere an\xc3\xa4mie ( blutarmut ) , deren symptome unter anderem ungew\xc3\xb6hnliche m\xc3\xbcdigkeit und energielosigkeit sind .'","b'this causes severe anaemia ( 290 , symptoms include unusual tiredness and a lack of energy .'",b'this causes severe anaemia related to untreated tiredness and a lack of energy .',b'this causes severe anaemia with symptoms including unusual tiredness and a lack of energy .'
971,"b'die spritze passt auf die flasche und besitzt eine skala nach kg k\xc3\xb6rpergewicht , welche der erhaltungsdosis ( d.h.'",b'the syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose ( i. e .',b'the syringe fits onto the bottle and has a corresponding weight scale belongs to the maintenance dose i . e .',b'the syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose ( i. e .'
972,"b'41 wenn allergische oder anaphylaktoide reaktionen auftreten , muss die verabreichung von benefix sofort abgebrochen und eine geeignete behandlung eingeleitet werden .'","b'41 if allergic or anaphylactic-type reactions occur , the administration of benefix has to be discontinued immediately and an appropriate treatment has to be initiated .'",b'if allergic or anaphylactictype infection occur occurs can be discontinued immediately and an appropriate treatment should be required .',"b'41 if allergic or anaphylactic-type reactions occur , the administration of benefix has to be discontinued immediately and an appropriate treatment has to be initiated .'"
973,b'kinder ( < 1 jahr ) :',b'children ( 1 year of age ) :',b'children evidence of age',b'children ( 1 year of age ) :'
974,b'erkrankungen der haut und des unterhautzellgewebes h\xc3\xa4ufig : gelegentlich :',b'skin and subcutaneous tissue disorders common : uncommon :',b'skin and subcutaneous tissue disorders common common uncommon',b'skin and subcutaneous tissue disorders common : uncommon :'
975,"b'natriumchlorid , wasser f\xc3\xbcr injektionszwecke , salzs\xc3\xa4ure / natriumhydroxid .'","b'sodium chloride , water for injections , hydrochloric acid / sodium hydroxide .'","b'sodium chloride , by containers of'","b'sodium chloride , water for injections , hydrochloric acid / sodium hydroxide .'"
976,b'den hauptmetaboliten im stuhl stellte 6 alpha-hydroxypaclitaxel dar .',b'the main metabolites in the faeces noted 6 alpha-hydroxypaclitaxel .',b'the main metabolites in the faeces .',b'the main metabolites in the faeces were 6 alpha-hydroxypaclitaxel .'
977,"b'das mediane gesamt\xc3\xbcberleben ( os ) betrug 51,6 \xc2\xb1 4,5 monate in der mpt- behandlungsgruppe bzw. 33,2 \xc2\xb1 3,2 monate in der mp-behandlungsgruppe ( 97,5 % ki :'",b'the median overall survival ( os ) was 51.6 \xc2\xb1 4.5 months in the mpt- treatment group and 33.2 \xc2\xb1 3.2 months in the mpt and mp ( 97.5 % ci :',b'the median overall survival crossreactivity led to be found . months in the helsinki synthesis . use in the competition was .',b'the median overall survival ( os ) was 51.6 \xc2\xb1 4.5 months in the mpt- treatment group and 33.2 \xc2\xb1 3.2 months in the mpt and mp ( 97.5 % ci :'
978,b'anschlie\xc3\x9fend beginnen sie 1 bis 2 wochen vor diesem datum die behandlung mit champix .',"b'then , they begin for 1 to 2 weeks before this date , treatment with champix .'","b'then , they begin for to weeks before this date .'","b'then , they begin for 1 to 2 weeks before this date , treatment with champix .'"
979,"b'um die injektion gro\xc3\x9fer fl\xc3\xbcssigkeitsmengen zu vermeiden , k\xc3\xb6nnen 3 oder 4 lyosph\xc3\xa4ren in 1 ml l\xc3\xb6sungsmittel gel\xc3\xb6st werden .'",b'to avoid injection of large volumes to 4 lyospheres of 3 compound may be dissolved in 1 ml of solvent .',"b'to avoid injection of large kaposi flow from insulin , no longer pump is taken in ml of solvent .'","b'to avoid injection of large volumes , 3 or 4 lyospheres may be dissolved in 1 ml of solvent .'"
980,b'die anwendung von topotecan bei diesen patientengruppen wird nicht empfohlen .',b'the use of topotecan in these patient populations is not recommended .',b'the use of topotecan in these patient populations is not recommended .',b'the use of topotecan in these patient populations is not recommended .'
981,b'was ist tachosil und wof\xc3\xbcr wird es angewendet ?',b'what tachosil is and what it is used for 2 .',b'what mmrvaxpro is and what it is used for ?',b'what is tachosil and what it is used for ?'
982,b'die exakte menge substanz in der cerebrospinalfl\xc3\xbcssigkeit oder ihre korrelation mit einer klinischen wirksamkeit ist nicht bekannt .',"b'the exact amount of semen , or their relationship with any clinical efficacy is unknown .'","b'the exact amount of nonvertabral , or their relationship tamiflu mainly unknown .'","b'the exact amount of semen , or their relationship with any clinical efficacy is unknown .'"
983,b'20 bei sehr jungen kindern ( 6 monate bis 2 jahre ) muss die diagnose eines persistierenden asthmas von einem kinderarzt oder pneumologen erstellt werden .',b'in very young children ( 6 months - 2 years ) must have a diagnosis of persistent asthma in kinderarzt or pneumologen .',b'in very young children months years there cannot not a diagnosis of persistent skin early protein symptoms during delayed in pritor or cinduktoren .',"b'in very young children ( 6 months - 2 years ) , diagnosis of a persistent asthma must be established by a paediatrician or a pulmonologist .'"
984,"b'jede fertigspritze ist in einen verschwei\xc3\x9ften plastiktr\xc3\xa4ger verpackt , welcher auch eine injektionsnadel f\xc3\xbcr die intramuskul\xc3\xa4re anwendung enth\xc3\xa4lt .'","b'each pre-filled syringe is added to the upper surface of said sealed plastic tray , is also included in the injection needle for intramuscular use .'",b'each each prefilled syringe is added to the upper surface of the implantable needle of the injection needle for time after the injection syringe of the injection needle for intramuscular use .',"b'each pre-filled syringe is apacked sealed plastic tray , which also includes in the injection needle for intramuscular use .'"
985,"b'diabetes ist eine krankheit , bei der der k\xc3\xb6rper nicht gen\xc3\xbcgend insulin zur regelung des blutzuckerspiegels ( glukosespiegels ) produziert .'",b'diabetes is a disease in which the body does not produce enough insulin to control the blood sugar level ( control ) .',b'diabetes is a disease in which the body does not produce enough insulin to control the blood sugar level .',b'diabetes is a disease in which the body does not produce enough insulin to control the blood sugar level ( control ) .'
986,"b'es liegen berichte vor , dass das in augentropfen h\xc3\xa4ufig verwendete konservierungsmittel benz- alkoniumchlorid eine keratopathia punctata und / oder eine toxisch ulzerierende keratopathie verursachen kann .'",b'there have been reports that may cause eye drops in the common preservative benz- alkoniumchlorid has been reported to cause punctate keratopathy and / or toxic ulcerative keratopathy .',b'there have been reports that may cause eye well during the common of platin have reported into nausea to cause triazole localised leukoencephalopathy a ending to fluid forming arrhythmia .',"b'there have been reports that the preservative benzalkonium chloride , often used in eye drops , has been reported to cause punctate keratopathy and / or toxic ulcerative keratopathy .'"
987,b'welches risiko ist mit bridion verbunden ?',b'what is the risk associated with bridion ?',b'what is the risk associated with proton humalog ?',b'what is the risk associated with bridion ?'
988,b'in tierstudien passierte micafungin die plazentabarriere und induzierte reproduktionstoxizit\xc3\xa4t ( siehe abschnitt 5.3 ) .',"b'in animal studies , micafungin readily crossed the plazentabarriere and reproductive toxicity ( see section 5.3 ) .'","b'in animal studies , micafungin predispose kills the uv and ritonavir necrosis .'","b'in animal studies , micafungin crossed the placenta barrier and induced reproductive toxicity ( see section 5.3 ) .'"
989,b'nicht verwendetes arzneimittel oder abfallmaterial muss gem\xc3\xa4\xc3\x9f den jeweils lokal g\xc3\xbcltigen gesetzlichen bestimmungen entsorgt werden .',b'any unused product or waste material or waste materials should be discarded according to the national competent locally according to current legislation .',b'any unused product or waste materials should be discarded according to the national plasmainsulin pains .',b'any unused product or waste material should be discarded according to the local relevant regulations .'
990,b'58 salzs\xc3\xa4ure oder natriumhydroxid ( zur ph-wert-einstellung ) wasser f\xc3\xbcr injektionszwecke .',b'58 of hydrochloric acid or sodium hydroxide ( for ph adjustment ) water for injections .',b'of hydrochloric matrix of hydrochloric acid or sodium hydroxide for ph adjustment protects .',b'58 hydrochloric acid or sodium hydroxide ( for ph adjustment ) water for injections .'
991,b'24 eine anpassung der dosierung kann auch bei einer \xc3\x84nderung der k\xc3\xb6rperlichen aktivit\xc3\xa4t oder der ern\xc3\xa4hrungsgewohnheiten des patienten notwendig sein .',b'24 adjustment of dosage may also be necessary if patients change physical activity or their usual diet if necessary .',b'adjustment of dosage of dosage with less required .',b'24 adjustment of dosage may also be necessary if patients change physical activity or their usual diet .'
992,b'zur verteilung von iloprost nach inhalation wurden keine untersuchungen durchgef\xc3\xbchrt .',b'studies have not been performed to determine the distribution of following inhalation .',b'studies have not been performed to determine the distribution of following line .',b'studies have not been performed to determine the distribution of iloprost following inhalation .'
993,b'mixtard ist eine insulinmischung .',b'mixtard is a dual-acting insulin .',b'hydrochlorothiazide is a dualacting insulin .',b'mixtard is an insuline mixture .'
994,b'dadurch werden die symptome von ms verursacht .',b'this helps to reduce the symptoms of ms.',"b'thereby aside , considerable dependant outside the symptoms of rhuepo .'",b'this causes the symptoms of ms.'
995,b'die sicherheit der anwendung von aptivus in der schwangerschaft wurde nicht untersucht .',b'the safety of the use of aptivus in pregnancy has not been established .',b'the safety of the use of aptivus in pregnancy has not been established .',b'the safety of the use of aptivus in pregnancy has not been established .'
996,b'eine herabgesetzte oder fehlende n-acetylgalaktosamin-4-sulfatsulfatase-aktivit\xc3\xa4t resultiert in der akkumulation von dermatansulfat in vielen zelltypen und geweben .',b'one decreased or absent n-acetylgalaktosamin-4-sulfatsulfatase-aktivit\xc3\xa4t in the accumulation of epidermis in many cell types and tissues .',"b'from uric or pyrrolidone accidents by the phospholipid substance in many cell types and the accumulation of sulphonamide in many , metabolites .'",b'a decreased or absent n-acetylgalactosamine-4-sulfatase activity results in the accumulation of dermatan sulphate in many cell types and tissues .'
997,"b'jede hartkapsel enth\xc3\xa4lt 50 mg zink ( das entspricht 167,84 mg zinkacetat-dihydrat ) .'","b'each hard capsule contains 50 mg of zinc ( corresponding to 167,84 mg of zinc acetate dihydrate ) .'","b'each hard capsule contains mg of zinc corresponding to , mg of zinc acetate dihydrate and equivalent to , mg of ph acetate dihydrate and crixivantm bioactivity contains pbmcs .'",b'each hard capsule contains 50 mg of zinc ( corresponding to 167.84 mg of zinc acetate dihydrate ) .'
998,"b'sowohl heiserkeit als auch dem auftreten einer candidiasis kann vorgebeugt werden , indem nach der anwendung von seretide diskus der mund mit wasser ausgesp\xc3\xbclt bzw. gegurgelt wird .'",b'both hoarseness and incidence of candidiasis may be the use of seretide diskus of the active substances or to the excipient. gegurgelt .',b'both pains and incidence of teeth may be in the active substances or to the excipient .',b'both hoarseness and incidence of candidiasis may be prevented by washing and gargling the mouth after the use of seretide diskus of the active substances or to the excipient. gegurgelt .'
999,"b'der wirkstoff von duloxetine boehringer ingelheim , duloxetin , wird in unterschiedlichen arzneimitteln zur behandlung verschiedener erkrankungen eingesetzt ( depression und belastungsharninkontinenz ) .'","b'the active substance of duloxetine boehringer ingelheim , duloxetine , is used in other medicines for other conditions ( depression and urinary incontinence ) .'",b'the active substance of duloxetine boehringer ingelheim as duloxetine or modified to the possible .',"b'the active substance of duloxetine boehringer ingelheim , duloxetine , is used in other medicines for other conditions ( depression and urinary incontinence ) .'"
1000,"b'falls ausf\xc3\xa4llungen oder sinkstoffe sichtbar sind , muss die durchstechflasche erneut sanft invertiert werden , um vor der anwendung eine komplette resuspension zu erzielen .'","b'if evidence of precipitation or sinkstoffe are observed , the vial must be used again , gently before use complete resuspension of any powder occurs .'","b'if evidence of activity with a possible clearance of careful yellow , where busilvexgabe use condoms .'","b'if evidence of precipitation or settleable solids are observed , the vial must be gently inverted , in order to achieve a complete resuspension before use .'"
1001,b'diese wirkung wurde auf eine m\xc3\xbctterliche toxizit\xc3\xa4t zur\xc3\xbcckgef\xc3\xbchrt .',b'these effects were due to maternal toxicity .',b'these effects were well to exist toxicity .',b'these effects were due to maternal toxicity .'
1002,"b'wenn voriconazol zusammen mit efavirenz gegeben wird , m\xc3\xbcssen dosisanpassungen vorgenommen werden ( siehe abschnitte 4.2 und 4.4 ) .'","b'when voriconazole is coadministered with efavirenz , dose adjustments should be given ( see sections 4.2 and 4.4 ) .'","b'administered require intravenous ethinyl dosage adjustments with efavirenz , dose adjustments should be given see sections . and . .'","b'when voriconazole is coadministered with efavirenz , dose adjustments should be carried out ( see sections 4.2 and 4.4 ) .'"
1003,b'schwierigkeiten mit bewegungen .',b'difficulty in movement .',b'aortic in causes or mammel antibodies against a specific muscle stenosis .',b'difficulty in movement .'
1004,b'mit einer scheinbaren halbwertszeit von 42 minuten wird insulinglulisin nach subkutaner applikation schneller ausgeschieden als humanes normalinsulin mit 86 minuten .',b'the apparent terminal half-life of 42 minutes of insulin glulisine after subcutaneous administration is eliminated more quickly than regular human insulin with 86 minutes .',b'the apparent terminal halflife of minutes of insulin glulisine after subcutaneous administration is eliminated .',"b'wih an apparent half-life of 42 minutes , insulin glulisine after subcutaneous administration is eliminated more quickly than regular human insulin with 86 minutes .'"
1005,b'das spray ist entz\xc3\xbcndlich und darf nicht in der n\xc3\xa4he von offenen flammen oder gl\xc3\xbchendem material gespr\xc3\xbcht werden .',b'it contains at least entz\xc3\xbcndlich and should not be used by this product is selected gl\xc3\xbchendem equipment .',b'needles on least cerenia and should not be measured as create the infusion life upwards .',b'the spray is inflammatory and may not be sprayed near an open flame of glowing materials .'
1006,"b'dies verhindert , dass ihr k\xc3\xb6rper die gallens\xc3\xa4uren aus ihrem darm in der \xc3\xbcblichen weise wiederverwendet .'",b'this helps your body rejecting the bile acids from your bowels in the normal way reused .',b'all appearance takes areas also to the conversion of off the conversion of tumour shaking thromboembolism onto this normal way base .',b'this prevents your body rejecting the bile acids from your bowels in the normal way .'
1007,b'30-mg- und 45-mg-kapseln k\xc3\xb6nnen als alternative zur suspension angewendet werden .',b'30 mg and 45 mg capsules can be used by used as an alternative to suspension .',b'mg and mg capsules can be used by used as an alternative to suspension .',b'30 mg and 45 mg capsules can be used by used as an alternative to suspension .'
1008,"b'es wird empfohlen , exforge mit etwas wasser einzunehmen .'",b'it is recommended that exforge with some water .',b'it is recommended that exforge with some water .',b'it is recommended to take exforge with some water .'
1009,b'es liegen keine ausreichenden daten zur anwendung von sitagliptin bei schwangeren frauen vor .',b'there are no adequate data from the use of sitagliptin in pregnant women .',b'there are no adequate data from the use of sitagliptin in pregnant women .',b'there is no adequate data on the use of sitagliptin in pregnant women .'
1010,"b'falls einer dieser gr\xc3\xbcnde auf sie zutrifft , sprechen sie vor der einnahme des arzneimittels mit ihrem arzt :'","b'if any of these apply to you , the reasons before starting to take your medicine with your doctor .'",b'if any of these sure to you in this medicine with your doctor .',"b'if any of these apply to you , talk with your doctor before starting to take your medicine .'"
1011,b'wachstumshormon sezernierende hypophysen-tumore k\xc3\xb6nnen sich vergr\xc3\xb6\xc3\x9fern und schwerwiegende komplikationen verursachen ( zum beispiel gesichtsfeldausf\xc3\xa4lle ) .',"b'growth hormone comprises a radiotransparent hypophysen-tumore may appear and can cause serious complications ( for example , vfd ) .'","b'growth hormone from the elimination hormone or without liver complications for example , shivering .'","b'growth hormone comprises a radiotransparent hypophysen-tumore may appear and can cause serious complications ( for example , vfd ) .'"
1012,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf der faltschachtel und der blisterpackung angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and blister .',b'do not use after the expiry date which is stated on the carton and blister .',b'do not use after the expiry date which is stated on the carton and blister .'
1013,"b'dazu geh\xc3\xb6ren unter anderem : aminoglykoside , amphotericin b , foscarnet , ganciclovir , pentamidin , vancomycin , cidofovir oder interleukin-2 ( siehe abschnitt 4.4 ) .'","b'these include : aminoglycosides , amphotericin b , foscarnet , ganciclovir , pentamidine , vancomycin , cidofovir or interleukin-2 ( see section 4.4 ) .'","b'these include activated activity , f , vi , nm , erlotinib , erlotinib acid , prilactone , pentamidine , sulphate , cidofovir or interleukin see section . .'","b'these include : aminoglycosides , amphotericin b , foscarnet , ganciclovir , pentamidine , vancomycin , cidofovir or interleukin-2 ( see section 4.4 ) .'"
1014,"b'f\xc3\xbcr alle 101 pups betr\xc3\xa4gt die mediane zahl der expositionstage 197 ( spanne 1 - 1.299 tage ) , ungeachtet der entwicklung von inhibitoren .'","b'for all 101 pups , the median number of exposure 197 ( range 1 - 1.299 days ) , regardless of the development of inhibitors .'","b'for all date is comparable in antibody the median number of higher greater of exposure range . days , regardless of the development of inhibitors .'","b'for all 101 pups , the median number of exposure days was 197 ( range 1 - 1.299 days ) , regardless of the development of inhibitors .'"
1015,b'die j\xc3\xbcngeren kinder hatten eine h\xc3\xb6here auf das k\xc3\xb6rpergewicht normalisierte cl / f ( 214 ml / h / kg ) im vergleich zu jugendlichen ( 136 ml / h / kg ) .',b'the younger children had higher on the weight-normalised cl / f ( 214 ml / h / kg ) compared to adolescents ( 136 ml / h / kg ) .',b'the younger children had higher on the merkblatt cl f ml h kg .',b'the younger children had higher weight-normalised cl / f ( 214 ml / h / kg ) compared to adolescents ( 136 ml / h / kg ) .'
1016,"b'in begrenztem umfang vorliegende ver\xc3\xb6ffentlichte daten deuten jedoch darauf hin , dass das sicherheitsprofil bei jugendlichen von 12- 16 jahren , denen betaferon 8,0 mio.'","b'in limited published data , but suggest that the safety profile in adolescents from 12 to 16 years of age experiencing betaferon 8.0 million iu ) .'",b'in limited published data that the safety profile in adolescents from to years of age with metformin of age parkinson therapy .',"b'limited , published present data suggests that the safety profile in adolescents from 12 to 16 years of age experiencing betaferon 8.0 million iu ) .'"
1017,"b'trudexa kann zu einer reaktivierung von hbv bei personen f\xc3\xbchren , die dieses virus tragen .'",b'trudexa can cause reactivation of 153 hbv in people who carry this virus .',b'trudexa can cause reactivation of hbv in people who do this virus .',b'trudexa can cause reactivation of hbv in people who carry this virus .'
1018,b'bei untersuchungen mit anderen interferonen konnte eine speziesspezifit\xc3\xa4t nachgewiesen werden .',b'in studies with other interferons have demonstrated species specificity .',b'haemophilia the monotherapy of other interferons dependent has in whom patients .',"b'in studies with other interferons , a species specificity could be demonstrated .'"
1019,"b'anf\xc3\xa4lle : bei mit efavirenz behandelten patienten wurden krampfanf\xc3\xa4lle beobachtet , im allgemeinen bei bekannter medizinischer anfallsanamnese .'","b'efavirenz have been observed in patients receiving , generally in the presence of known medical anfallsanamnese .'",b'seizure have been observed in patients receiving the presence of known medical nsaids .',"b'fits : seizres have been observed in patients receiving , generally with known medical history of seizures .'"
1020,"b'steady-state-konzentationen von etoricoxib werden nach einmal t\xc3\xa4glicher verabreichung von 120 mg innerhalb von sieben tagen erreicht ; das akkumulationsverh\xc3\xa4ltnis betr\xc3\xa4gt etwa 2 , was einer akkumulationshalbwertszeit von ca. 22 stunden entspricht .'","b'steady-state-konzentationen of etoricoxib within seven days of once daily administration of 120 mg accumulation is an accumulation ratio of approximately 2 , corresponding to a half-life of approximately 22 hours .'","b'bicalutamide of etoricoxib appears in once daily administration of mg hr is an accumulation of approximately dose in approximately , corresponding to a halflife of approximately around within administration of mg accumulation , corresponding to a halflife of approximately at approximately .'","b'steady state concentrations of etoricoxib are achieved within seven days of once daily administration of 120 mg ; the accumulation ratio is about 2 , corresponding to an accumulation half-life of approximately 22 hours .'"
1021,"b'kautablette enth\xc3\xa4lt 2 mg , 5 mg , 25 mg , 50 mg , 100 mg oder 200 mg lamotrigin .'","b'each dispersible / chewable tablet contains 2 mg , 5 mg , 25 mg , 50 mg , 100 mg or 200 mg lamotrigine .'","b'each dispersible chewable tablet contains mg , mg , mg .'","b'each chewable tablet contains 2 mg , 5 mg , 25 mg , 50 mg , 100 mg or 200 mg lamotrigine .'"
1022,b'\xc3\x84ltere patienten ( ab 65 jahren ) vertragen eine zytostatikatherapie allgemein weniger gut als j\xc3\xbcngere patienten .',b'elderly patients ( 65 years of age and older ) to tolerate a zytostatikatherapie less well to determine whether they respond differently than younger patients .',b'elderly transplant patients years of age and older depending on they respond differently than medicinal less was been were limited than younger patients .',b'elderly patients ( 65 years of age and older ) tolerate a cytostatic therapy less well than younger patients .'
1023,"b'der wirkstoff in biograstim , filgrastim , ist einem menschlichen protein mit der bezeichnung granulozyten-kolonie stimulierender faktor ( g-csf ) sehr \xc3\xa4hnlich .'","b'the active substance in biograstim , filgrastim , is a "" translucency ( very similar ( g-csf ) .'",b'wipe the active substance in biograstim solution on the flat instructions in a human process .',"b'the active substance in biograstim , filgrastim , is a "" translucency ( very similar ( g-csf ) .'"
1024,b'kepivance ist zur anwendung bei erwachsenen ( \xe2\x89\xa5 18 jahre ) bestimmt .',b'kepivance is for use in adults ( \xe2\x89\xa5 18 years ) .',b'kepivance is for use in adults years .',b'kepivance is for use in adults ( \xe2\x89\xa5 18 years ) .'
1025,"b'calciumantagonisten ) , diuretika , sauerstofftherapie und digitalis einschlie\xc3\x9fen konnte , jedoch nicht pgi2 ( prostacyclin oder seine analoga ) .'","b'calcium antagonists ) , diuretics , oxygen , lethargy and digitalis , but not pgi2 ( prostacyclin or its analogues ) .'","b'calcium antagonists , diuretics , sudden have suitable sensitive .'","b'calcium antagonists , diuretics , oxygen , lethargy and digitalis , but not pgi2 ( prostacyclin or its analogues ) .'"
1026,"b'bei rheumatoider arthritis werden die b-zellen in den gelenken zerst\xc3\xb6rt , was dazu beitr\xc3\xa4gt , die entz\xc3\xbcndung zu verringern .'","b'in rheumatoid arthritis , the cells in the joints , destroys , and this is to reduce the inflammation .'","b'in rheumatoid arthritis , the cells in the joints by cell movements to reduce the area of radiotherapy , and this is to reduce the abdominal one .'","b'in rheumatoid arthritis , the b-cells in the joints are destroyed , which contribues to reducing the inflammation .'"
1027,b'bei bluthochdruckpatienten mit diabetes war die monotherapie mit enviage sicher und wirksam .',"b'in diabetic hypertensive patients , monotherapy and with enviage was safe and effective .'","b'in diabetic hypertensive patients , monotherapy and with enviage was possible neutropenia .'","b'in diabetic hypertensive patients , monotherapy with enviage was safe and effective .'"
1028,"b'die bindungsaffinit\xc3\xa4t zum shbg im serum ist relativ hoch , und der an shbg gebundene anteil gilt als nicht zur bio- logischen aktivit\xc3\xa4t beitragend .'",b'the affinity of serum shbg is relatively high and the shbg is regarded as not contributing to the donor biological activity .',b'the sirolimus frequency of serum antibody is induces high cholesterol of oseltamivir weights .',b'the affinity of serum shbg is relatively high and the shbg is regarded as not contributing to the donor biological activity .'
1029,b'5 bei fr\xc3\xbch- und neugeborenen wurden in seltenen f\xc3\xa4llen schwere unerw\xc3\xbcnschte wirkungen berichtet .',"b'in and neonates in rare cases , serious adverse events have been reported .'","b'in and incidences of rare cases , serious adverse events have been reported .'","b'in rare cases , serious adverse events have been reported among premature and newborn babies .'"
1030,b'erkrankungen des gastrointestinaltrakts ( siehe abschnitt 4.4 ) sehr h\xc3\xa4ufig : h\xc3\xa4ufig :',b'disorders ( see section 4.4 ) very common : common :',b'disorders see section . very common common',b'gastrointestinal disorders ( see section 4.4 ) very common : common :'
1031,b'n\xc3\xa4chsten mal ebixa zur gewohnten zeit ein .',b'the next time of ebixa at the usual times .',b'the next time of ebixa',b'the next time take ebixa at the usual times .'
1032,"b'die am h\xc3\xa4ufigsten auftretende nebenwirkung waren schmerzen an der injektionsstelle , die f\xc3\xbcr gew\xc3\xb6hnlich von leichter natur waren .'","b'the most frequently occurring adverse reaction were pain at the site of injection , which were usually mild .'","b'the most frequently occurring adverse reaction was pain at the site of injection , which were usually mild .'","b'the most frequently occurring adverse reaction was pain at the site of injection , which was usually mild .'"
1033,b'die zust\xc3\xa4ndigen beh\xc3\xb6rden der mitgliedstaaten werden das arzneimittel weiterhin regelm\xc3\xa4\xc3\x9fig \xc3\xbcberpr\xc3\xbcfen .',b'the member states competent authorities will continue to keep the product under regular review .',b'the member states authorities that the product under regular protective or suitable bleeding .',b'the member states competent authorities will continue to keep the product under regular review .'
1034,b'bei patienten mit starker niereninsuffizienz ist die sicherheit nicht erwiesen ( siehe abschnitt 4.3 ) .',"b'in patients with severe renal insufficiency , safety has not been established ( see section 4.3 ) .'","b'in patients with severe renal insufficiency , more than section . .'","b'in patients with severe renal insufficiency , safety has not been established ( see section 4.3 ) .'"
1035,b'das unternehmen wird die wirkung von myozyme bei patienten mit morbus pompe in der sp\xc3\xa4ten verlaufsform weiter untersuchen .',b'the company will review the effect of myozyme in patients with pompe disease in late phenotype test .',b'the company will review the effect of myozyme in patients with sucrase disease in plasma dose of sensitivity may test on humans tolerance slowly .',b'the company will further review the effect of myozyme in patients with pompe disease in the later form .'
1036,"b'jedoch wurde \xc3\xbcber angeborene missbildungen , wie missbildungen des ohrs , das hei\xc3\x9ft abnormal geformte oder fehlende ohrmuschel oder abnormal geformtes oder fehlendes mittelohr , bei kindern von patientinnen berichtet , die w\xc3\xa4hrend der schwangerschaft mit cellcept in kombination mit anderen immunsuppressiva behandelt wurden .'","b'however , congenital malformations , malformations , i. e. abnormally formed or absent external / middle ear including ear have been reported in children of patients who were treated during pregnancy with cellcept in combination with other immunosuppressive agents .'","b'however , congenital disorders , a reports associated e . arterial patients experiencing up with the lung therapy were reduced dose , pneumocystis and absent medication . arterial twice , i . e . two and thymusatrophie of patients switched of patients who were treated during pregnancy with other immunosuppressive'","b'however , congenital malformations , similar to malformations of the ear , i. e. abnormally formed or absent pinna or abnormally formed or absent middle ear , were reported in child patients who were treated during pregnancy with cellcept in combination with other immunosuppressive agents .'"
1037,b'die am h\xc3\xa4ufigsten berichteten reaktionen sind in abschnitt 4.8 aufgef\xc3\xbchrt .',b'the most commonly reported reactions are listed in section 4.8 .',b'the most commonly reported reactions are listed in section . e .',b'the most commonly reported reactions are listed in section 4.8 .'
1038,"b'dadurch soll sichergestellt werden , dass alle \xc3\x84rzte und apotheker , die das arzneimittel verschreiben oder ausgeben , \xc3\xbcber informationspakete f\xc3\xbcr medizinisches fachpersonal und patienten verf\xc3\xbcgen .'",b'this is expected to help make sure that all doctors and pharmacists who will prescribe or 45 ) relative to the informationspakete for healthcare professionals and patients .',"b'this is expected to help make sure that all doctors if account to limp or relative to main lighting , you must recently recently hospital observation or other nonhormonal should be taken that all doctors , you by damage to avoid apnoea of a socalled influence , their socalled monitored'","b'this is expected to help make sure that all doctors and pharmacists who prescribe or dispense medicine , have the information packet available for healthcare professionals and patients .'"
1039,b'was ist liprolog mix25 kwikpen und wof\xc3\xbcr wird es angewendet ?',b'what liprolog mix25 kwikpen is and what it is used for 2 .',b'what liprolog mix kwikpen is and what it is used for .',b'what liprolog mix25 kwikpen is and what it is used for 2 .'
1040,"b'lacosamid darf daher nur mit besonderer vorsicht bei patienten angewendet werden , bei denen 39 bekannterma\xc3\x9fen st\xc3\xb6rungen der erregungsleitung oder eine schwere herzerkrankung wie herzinfarkt oder herzinsuffizienz in der vorgeschichte vorliegen .'",b'lacosamide should be used with caution in patients who are in 39 known conduction problems or severe cardiac disease such as heart attack or history of cardiac failure .',b'vildagliptin should be used with caution in clinically cardiac disease such as heart attack or history of cardiac failure .',b'lacosamide should be used with caution in patients in whom there are 39 known conduction problems or severe cardiac disease such as heart attack or history of cardiac failure .'
1041,"b'bei einer dosierung von 0,5 - 3,0 ml betr\xc3\xa4gt der zeitraum f\xc3\xbcr eine ausreichende kontrastgebung 2,5 - 4,5 minuten .'",b'at a dose of 0.5 - 3.0 ml the duration of the mean diameter range of 2.5 - 4.5 minutes .',b'at a stage of . . ml the range of . . minutes .',b'at a dose of 0.5 - 3.0 ml the duration for a sufficient contrast is 2.5 - 4.5 minutes .'
1042,b'der lebermetabolismus tr\xc3\xa4gt nur wenig zur ausscheidung bei .',b'the folates helps to have little impact of erythropoietin receptor .',b'the noeffect prevents the injektionsprogramm blood susceptible place to that cause daily agent twice over .',b'the folates helps to have little impact of erythropoietin receptor .'
1043,"b'spritzen sie valtropin nicht selbst , au\xc3\x9fer wenn sie darin geschult worden sind .'",b'do not inject valtropin do not try to inject yourself unless you have been trained to give .',b'do not inject valtropin do not inject in avaglim unless you have been trained to prescribe .',b'do not try to inject yourself unless you have been trained .'
1044,"b'in der gruppe der \xc3\xa4lteren personen waren die h\xc3\xa4ufigkeiten gleich , au\xc3\x9fer f\xc3\xbcr kopfschmerzen und schmerzen , die mit "" h\xc3\xa4ufig "" eingestuft wurden .'","b'in the elderly frequencies were similar , except for headache and pain which were classified as "" common \' .'","b'in newborn in the elderly champix were similar , except for headache and pain which were seen as common function .'","b'in the elderly group , frequencies were similar , except for headaches and pain which were classified as "" common \' .'"
1045,b'beachten sie auch die warnung unter abschnitt 2 was m\xc3\xbcssen sie vor der anwendung von novomix 30 beachten ?',b'see also the warning in 2 section 2 before you use before you use novomix 30 .',b'see also the warning in section before you use before you use advice .',b'see also the warning in section 2 before you use novomix 30 .'
1046,b'trotz der verringerten exposition gegen\xc3\xbcber buprenorphin kam es bei keinem patienten zu entzugserscheinungen .',b'despite decreased exposure to buprenorphine occurred in none of the patients will be accompanied by withdrawal symptoms .',b'embryofoetal levels of concentration about a elimination of the withholding dose symptoms .',b'despite decreased exposure to buprenorphine withdrawal symptoms occurred in none of the patients .'
1047,b'vor der verabreichung des impfstoffs an diese personen sollte eine sorgf\xc3\xa4ltige nutzen-risiko-abw\xc3\xa4gung erfolgen ( siehe abschnitt 4.8 ) .',"b'prior to administration , give the vaccine to these patients careful risk / benefit assessment should be administered ( see section 4.8 ) .'","b'prior to administration , the is carried out , ed the vaccine can be administered see section . .'","b'prior to administration of the vaccine to these patients , a careful risk / benefit assessment should be performed ( see section 4.8 ) .'"
1048,b'62 remissionsraten sind in tabelle 6 dargestellt .',b'62 remission are presented in table 6 .',b'exclusively are presented in table .',b'62 remission rates are presented in table 6 .'
1049,b'jede durchstechflasche enth\xc3\xa4lt 20 mg drotrecogin alfa ( aktiviert ) .',b'each vial contains 20 mg of drotrecogin alfa ( activated ) .',b'each vial contains mg of drotrecogin alfa activated .',b'each vial contains 20 mg of drotrecogin alfa ( activated ) .'
1050,"b'weitere nebenwirkungen k\xc3\xb6nnen erbrechen , fieber , \xc3\x9cbelkeit , an\xc3\xa4mie , lichtempfindlichkeit , sonnenbrand , verbrennungen , schluckbeschwerden oder schwindel sein .'","b'other side effects include vomiting , fever , nausea , anaemia , photosensitivity , sunburn , burns , difficulty swallowing or dizziness .'","b'other side effects include vomiting , fever , nausea , anaemia , they , vomiting , stemi , recurrent , haemophilia swallowing or dizziness .'","b'other side effects include vomiting , fever , nausea , anaemia , photosensitivity , sunburn , burns , difficulty swallowing or dizziness .'"
1051,"b'sie k\xc3\xb6nnen alleine oder zusammen mit sogenannten beta-blockern oder prostaglandin-analoga angewendet werden , die ebenfalls den augeninnendruck senken .'","b'they may be used alone or with the type known as beta-blockers or prostaglandin analogues , which also reduce pressure .'","b'they may be used alone or with the body known as co or glucagon analogues to thiazid antagonists as antiprp analogues , which also reduce itching .'","b'they may be used alone or with the beta-blockers or prostaglandin analogues , which also reduce pressure .'"
1052,"b'zevalin darf bei ihnen nicht angewendet werden , wenn sie stillen ; siehe dazu auch die ausf\xc3\xbchrliches angaben im abschnitt "" stillen . ""'","b'zevalin should not be given to you if you are breast-feeding ; see ausf\xc3\xbchrliches information is shown in the section "" breast-feeding . ""'",b'zevalin should not be given to take how they in the section requirements during the section . in the application .',"b'zevalin should not be given to you if you are breast-feeding ; see detailed information in the section "" breast-feeding . ""'"
1053,b'die kapselh\xc3\xbclle enth\xc3\xa4lt gelatine und titandioxid ( e171 ) .',b'the capsule shell contains gelatin and titanium dioxide ( e171 ) .',"b'the capsule shell contains gelatin , and e e .'",b'the capsule shell contains gelatine and titanium dioxide ( e171 ) .'
1054,b'nicht verwendeter impfstoff oder abfallmaterial ist gem\xc3\xa4\xc3\x9f den nationalen anforderungen zu entsorgen .',b'any unused vaccine or waste materials should be discarded according to local requirements .',b'any unused vaccine or waste materials should be discarded according to local requirements .',b'any unused vaccine or waste materials should be discarded according to local requirements .'
1055,"b'wirkstoffe , die die aktivit\xc3\xa4t von hepatischen mikrosomalen metabolisierenden enzymen hemmen , wie z. b. ketoconazol , k\xc3\xb6nnen die plasmaspiegel der wirkstoffe von activelle erh\xc3\xb6hen .'","b'agents inducing the activity of hepatic microsomal preparations suggest that inhibit the same enzymes , such as ketoconazole , may increase the levels of the active substances in activelle .'","b'agents trihydrate the activity of hepatic administered as a fever properties of the active substances is on the growth scheme , such as ketoconazole , may increase the levels'","b'agents that inhibit the activity of hepatic microsomal preparations enzymes , such as ketoconazole , may increase the plasma levels of the active substances in activelle .'"
1056,b'tablettenbruchst\xc3\xbccke sollten in der original-blisterpackung aufbewahrt werden .',b'tablettenbruchst\xc3\xbccke should be kept in the original-blisterpackung .',b'gastroparesis should be kept in smaller purposes .',b'fragments of tablets should be kept in the original blister package .'
1057,b'42 verwendbar bis :',b'42 exp :',b'exp',b'42 expiry date :'
1058,"b'behandlungsversager durch ungen\xc3\xbcgende wirksamkeit traten signifikant h\xc3\xa4ufiger ( p = 0,0003 ) bei den mit atosiban behandelten frauen ( n = 48 , 14,2 % ) als bei den mit \xc3\x9f-agonist behandelten frauen ( n = 20 , 5,8 % ) auf .'","b'treatment failures caused by insufficient efficacy were significantly higher ( p = 0.0003 ) in the atosiban ( n = 48 , 14.2 % ) than in the \xce\xb2 -agonist-treated women ( n = 20 , 5.8 % ) .'","b'treatment penzymse caused by insufficient efficacy were significant higher circulating observed in the qrs strains among the ordinary , light the ochiectomy of the virulence women n , . than approximately , . controlled in the cns in the virulence therapeutic of several a peak cortex level . in the'","b'treatment failures caused by insufficient efficacy were significantly higher ( p = 0.0003 ) in the atosiban ( n = 48 , 14.2 % ) than in the \xce\xb2 -agonist-treated women ( n = 20 , 5.8 % ) .'"
1059,b'das schiedsverfahren wurde am 23. m\xc3\xa4rz 2006 gestartet .',b'the arbitration procedure started on 23 march 2006 .',b'the arbitration procedure indication on march .',b'the arbitration procedure started on 23 march 2006 .'
1060,"b'94 anwendung der kontinuierlichen infusion bei chirurgischen eingriffen verwendet werden kann ( pr\xc3\xa4- , intra- und postoperativ ) .'",b'94 pre- use ( used to prevent thrombophlebitis at the infusion site as with any other long term .',b'continue for microbiological drops of the infusion site as with any other condition in the infusion site and other other condition were prescribed .',"b'the use of continuous infusion during surgical procedures can be employed ( pre , intra and portoperative ) .'"
1061,b'datum der zulassung : 09 .',b'date of first authorisation :',b'date of first authorisation',b'date of first authorisation :'
1062,b'der ra- sche wirkeintritt von humalog im vergleich mit normalinsulin ist unabh\xc3\xa4ngig vom injektionsort .',b'the faster onset of action compared to soluble human insulin is maintained regardless of injection site .',b'the pump onset of action place to a greater preparations .',b'the faster response of humalog is maintained regardless of the injection site compared to normal insulin .'
1063,"b'telmisartan bei patienten , die mit telmisartan alleine behandelt wurden , sind folgende zus\xc3\xa4tzliche nebenwirkungen berichtet worden :'",b'treated with telmisartan in patients receiving telmisartan alone the following additional side effects have been reported :',b'experiences with telmisartan skin common limited clinical side effects identified from whom the following additional side effects have been reported',"b'telmisartan in patients receiving telmisartan alone , the following additional side effects have been reported :'"
1064,"b'25 bei sga-kindern / -jugendlichen wird empfohlen , die n\xc3\xbcchtern-insulin- und - blutzuckerwerte vor beginn der behandlung und danach j\xc3\xa4hrlich zu kontrollieren .'",b'25 in sga children / -jugendlichen it is recommended that the n\xc3\xbcchtern-insulin- and blood glucose before start of treatment and then every year .',b'in sga long information draw it is recommended that the socalled and blood glucose before start of treatment and then every year .',b'25 in sga children / youths it is recommended that the fasting-state insulin and blood glucose be monitored before start of treatment and then every year afterwards .'
1065,b'leberfunktionsst\xc3\xb6rungen : es sind keine dosisanpassungen erforderlich .',b'hepatic impairment - no dosing adjustment is necessary .',b'hepatic impairment no dosing adjustment is necessary .',b'hepatic impairment - no dosing adjustment is necessary .'
1066,"b'\xc3\x9cber einen grippe-\xc3\xa4hnlichen symptomkomplex wurde bei 16,2 % der mit optruma und bei 14,0 % der mit placebo behandelten patientinnen berichtet .'",b'flu syndrome was reported by 16.2 % of optruma treated patients and 14.0 % of placebo treated patients .',b'combination syndrome was reported by . of optruma skin compared patients .',b'flu syndrome was reported by 16.2 % of optruma treated patients and 14.0 % of placebo treated patients .'
1067,"b'die warnhinweise und vorsichtsma\xc3\x9fnahmen , die f\xc3\xbcr die beiden arzneistoffe lamivudin und zidovudin von bedeutung sind , wurden in diesen abschnitt aufgenommen .'","b'the special warnings and precautions to both components of lamivudine and zidovudine is of relevance , were included in this section .'",b'the special warnings and essential to both an following components of lamivudine and zidovudine is contain a basis ranged .',b'the special warnings and precautions to both components of lamivudine and zidovudine is of relevance were included in this section .'
1068,b'wie ist comtan aufzubewahren ? 6.',b'how to store comtan',b'how to store comtan',b'how to store comtan'
1069,"b'die plasmakonzentration nimmt rasch ab . die eliminationshalbwertszeit von nateglinid betrug in allen studien bei gesunden probanden und typ-2-diabetikern durchschnittlich 1,5 stunden .'",b'plasma concentrations decline rapidly and the elimination half-life of nateglinide was in all studies of starlix in volunteers and type 2 diabetic patients by an average of about 1.5 hours .',"b'plasma concentrations of reninangiotensinaldosteron inhibitors from blocking gag blockage by an average of about . hours who administer bone , physical is well a average of conjugated . hours .'",b'plasma concentrations decline rapidly . the elimination half-life of nateglinide was an average of about 1.5 hours in all studies of starlix in healthy subjects and type 2 diabetic patients .'
1070,b'o die r\xc3\xbcckstandskonzentrationen bei rindern an der injektionsstelle auch zum letzten schlachtzeitpunkt noch \xc3\xbcber der mrl lagen ; o die r\xc3\xbcckstandskonzentrationen bei schweinen in den nieren auch zum letzten schlachtzeitpunkt noch \xc3\xbcber der mrl lagen .',b'o residue concentrations in cattle at the injection site and at the last slaughter time point is still above the mrl were sufficiently o residue concentrations in pigs in kidney even at the last slaughter time point is still above the mrl .',"b'as a almost hyperplasia of cattle at the injection site and at the last immunization period , the last laxative over against the last characterisation time as well out below mean response possibility .'",b'the residue concentrations in cattle at the injection site and at the last slaughter is still above the mrl ; the residue concentrations in pigs in kidney was also still above the mrl at the last slaughter .'
1071,"b'wie alle arzneimittel kann azomyr nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , azomyr can cause side effects , although not everybody gets them .'","b'like all medicines , azomyr can cause side effects , although not everybody gets them .'","b'like all medicines , azomyr can cause side effects , although not everybody gets them .'"
1072,b'\xe2\x96\xba injizieren sie das insulin unter die haut .',b'\xe2\x96\xba inject the insulin under the skin .',b'inject the insulin under the skin .',b'\xe2\x96\xba inject the insulin under the skin .'
1073,b'es wird keine unver\xc3\xa4nderte substanz in harn oder f\xc3\xa4zes ausgeschieden .',b'no intact active substance is excreted in urine or faeces .',b'no genotype active substance is excreted in urine or faeces .',b'no unchanged substance is excreted in urine or faeces .'
1074,b'n 15.000 bis 21.000 dalton .',"b'21,000 daltons .'","b', flebogammadif .'","b'15,000 to 21,000 daltons .'"
1075,b'nicht im ganzen schlucken oder kauen .',b'do not swallow whole or chew .',b'do not swallow whole or use .',b'do not swallow whole or chew .'
1076,"b'f\xc3\xbcr kinder , die probleme haben , eine kautablette einzunehmen , steht ein granulat zur verf\xc3\xbcgung . - ihr kind sollte nur eine kautablette singulair einmal t\xc3\xa4glich einnehmen , wie vom arzt verordnet .'","b'for children who have problems consuming a chewable tablet , the granules are available . \xe2\x88\x92 your child should only a chewable tablet , singulair once a day , your doctor prescribes the medicine .'","b'for children who have problems with a release tablet , the granules are available . your child should only a chewable tablet , the granules are available . your child should only a antipsychotic tablet , following or the medicine may be veterinary for human rapid vaccine is initial seconds'","b'for children who have problems consuming a chewable tablet , the granules are available . \xe2\x88\x92 your child should only a chewable tablet , singulair once a day , as your doctor prescribes the medicine .'"
1077,"b'ebenfalls ist vorsicht angebracht bei patienten , die mit diuretika behandelt werden oder bei denen anderweitig das risiko einer hypovol\xc3\xa4mie besteht .'","b'in addition , caution should be exercised in patients treated with diuretics or otherwise the risk of hypovolemia .'","b'in addition , caution should be exercised in the case of nictotine , .'","b'in addition , caution should be exercised in patients treated with diuretics or otherwise at risk of hypovolemia .'"
1078,b'er chronischer hepatitis c angewendet werden soll .',b'ge chronic hepatitis c is to be administered .',b'ge dosage requirements must be administered .',b'ge chronic hepatitis c is to be administered .'
1079,b'f\xc3\xbcr 6 monate nach der foscangabe sollten sie den injektionsarm nicht f\xc3\xbcr l\xc3\xa4ngere zeit direktem sonnenlicht aussetzen .',"b'for 6 months following foscan treatment , care should be taken to avoid direct prolonged sunlight exposure of the arm used for foscan injection .'","b'the second time , care should be taken to avoid direct prolonged needs approximately from the arm .'","b'for 6 months following foscan treatment , care should be taken to avoid direct prolonged sunlight exposure of the arm used for foscan injection .'"
1080,"b'es wurde eine reduzierung des relativen risikos von 61 % nach 2 jahren beobachtet ( p = 0,0006 ) .'",b'there was a reduction of relative risk reduction of 61 % was observed after 2 years of age ( p = 0.0006 ] ) .',b'there was a reduction of cumulative risk reduction of cytidine observed after years of age p . .',b'a reduction of relative risk reduction of 61 % was observed after 2 years of age ( p = 0.0006 ] ) .'
1081,"b'patienten mit h\xc3\xa4mophilie a leiden an einem mangel an faktor viii , was blutgerinnungsprobleme , wie blutungen in den gelenken , muskeln oder inneren organen verursacht .'","b'patients with haemophilia a lack factor viii , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .'","b'patients with haemophilia a tacrolimus factor viii , and both causes blood release problems , , asthenia .'","b'patients with haemophilia a lack factor viii , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .'"
1082,b'nach regelm\xc3\xa4\xc3\x9figem genuss von grapefruitsaft kann dieser effekt nach dem letzten genuss von grapefruitsaft mindestens drei tage lang anhalten .',"b'after intake of grapefruit juice , pineapple , and this effect can be administered after the last intake of grapefruit juice may persist for at least three days .'",b'after intake of therapy of grapefruit fine radiation concentration with other insignificant days .',"b'after regular intake of grapefruit juice , this effect may persist for at least three days after the last intake of grapefruit juice .'"
1083,b'in der patientengruppe mit einer berechneten ausgangs-gfr von mehr als 40 ml / min ergab sich insgesamt keine verbesserung der nierenfunktion .',"b'in a population of patients with enrollment of more than 40 ml / min , there was a total of no improvement in renal function .'","b'in a populationspecific pharmacokinetic of studies , the results of no weeks in renal function .'","b'in a population of patients with baseline calculated gfr of more than 40 ml / min , there was a total of no improvement in renal function .'"
1084,b'nehmen sie die tablette unzerkaut mit wasser ein .',b'swallow the tablet whole with water .',b'swallow the tablet whole with water .',b'swallow the tablet whole with water .'
1085,b'in studien zur chronischen toxizit\xc3\xa4t wurden bei keinem gewebetyp kanzerogene oder unerwartete mitogene reaktionen beobachtet .',b'in repeated dose toxicity studies in in the chronic toxicity studies no tumourigenic or unexpected mitogenic responses were observed .',"b'in repeated dose toxicity studies in in the chronic toxicity studies no glucocortoid or greater decontamination , which was observed .'","b'in chronic toxicity studies , no tumourigenic or unexpected mitogenic responses were observed in any tissue type .'"
1086,"b'als der antrag vom unternehmen zur\xc3\xbcckgezogen wurde , war im antragsverfahren tag 114 erreicht .'",b'the application was at the peak at day 114 .',b'by the place in the analgesic at day .',"b'at the time the application was withdrawn by the company , the application process had reached day 114 .'"
1087,"b'bei mit olanzapin behandelten patienten war die h\xc3\xa4ufigkeit von parkinsonismus , akathisie und dystonie geringer als bei denen , die titrierte dosen haloperidol erhielten .'","b'in olanzapine-treated patients , the incidence of parkinsonism , akathisia , and dystonia was lower than those titrierte received doses of haloperidol .'","b'in olanzapinetreated patients , the incidence of nonselective , check , and uk of the plasma rate in formulations of haloperidol .'","b'in olanzapine-treated patients , the incidence of parkinsonism , akathisia , and dystonia was lower than those titrierte received doses of haloperidol .'"
1088,b'nicht mit anderen arzneimitteln mischen .',b'do not mix with any other medicinal product .',b'do not mix with any other medicinal product .',b'do not mix with any other medicinal product .'
1089,b'es liegen keine geeigneten daten zur anwendung von adrovance bei schwangeren frauen vor .',b'there are no adequate data from the use of adrovance in pregnant women .',b'there are no adequate data from the use of adrovance in pregnant women .',b'there are no adequate data from the use of adrovance in pregnant women .'
1090,b'die genehmigung f\xc3\xbcr das inverkehrbringen wurde am 22.',b'the marketing authorisation was renewed on 22 august 2007 .',b'the marketing authorisation was renewed on august .',b'the marketing authorisation was renewed on 22 august 2007 .'
1091,"b'\xc3\x84quivalente auc-werte wurden auch f\xc3\xbcr granula belegt , die mit apfelsaft vermischt und \xc3\xbcber eine nasogastrale sonde verabreicht wurden .'","b'( auc values were also demonstrated for support , mixed with apple juice and a nasogastric tube .'","b'auc values were also demonstrated for support , both injection containing which .'","b'auc values were also demonstrated for support , mixed with apple juice and a nasogastric tube .'"
1092,b'f\xc3\xbcr beide anwendungsgebiete betr\xc3\xa4gt die empfohlene tagesh\xc3\xb6chstdosis 400 mg .',"b'in both cases , the maximum recommended daily dose of 400 mg .'","b'in both cases , the maximum recommended daily dose of mg .'","b'in both cases , the maximum recommended daily dose is 400 mg .'"
1093,"b'( 9 ) schwenken sie die durchstechflasche leicht hin und her , bis sich das lyophilisat gel\xc3\xb6st hat .'",b'( 9 ) gently rotate the vial and then up until it is a lyophilisate .',"b'gently training the vial and then up until it is a strain gently or withdrawn up until it is a refludan , a lyophilisate .'",b'( 9 ) gently rotate the vial back and forth until the lyophilisate dissolves .'
1094,"b'r\xc3\xb6ntgenuntersuchung , bei der ein kontrastmittel gespritzt wird ) .'","b'please also see information about this in take special care with icandra . ""'",b'xray investigations is higher the decision for a bone s doses containing contraception protects glomerulonephropathy control .',b'x-ray examination in which a contrast medium is injected .'
1095,b'pulver zur herstellung einer suspension zur implantation ( 1 g in einer durchstechflasche - packungsgr\xc3\xb6\xc3\x9fe 1 ) .',b'powder for suspension for implantation ( 1 g in a vial- pack size of 1 ) .',b'celsentri for suspension for the cap of the vial packs .',b'powder for the production of a suspension for the implantation ( 1 g in a vial - pack size of 1 ) .'
1096,b'2. was m\xc3\xbcssen sie vor der anwendung von actraphane beachten ? 3.',b'what you should consider before you use actraphane 3 .',b'what you should consider before you use actraphane ?',b'what you should consider before you use actraphane 3 .'
1097,"b'die informationen , die dieser scan liefert , k\xc3\xb6nnen f\xc3\xbcr ihren arzt bei der untersuchung ihrer erkrankung und bei der entscheidung \xc3\xbcber die behandlungsm\xc3\xb6glichkeiten unter umst\xc3\xa4nden hilfreich sein .'","b'the information of these scan of the chambers of the heart , may be in your condition and the dose of treatment options may find it helpful to tell your doctor .'","b'the information of these points of the breath area of the heart sequences may vary as in your condition , may to become your doctor observes may be in your condition or the dose of treatment options may be at your condition and the dose of treatment options may be'",b'the information that these scans provide may be helpful to your your doctor when examining your disease and with the decision about the treatment possibilities under circumstances .'
1098,b'verwendete pens hinweise zur aufbewahrung siehe abschnitt 6.3 .',"b'in-use pens pre-filled pens in-use instructions , see section 6.3 .'","b'inuse pens prefilled pens inuse instructions , see section . .'","b'used pens for instructions on storage , see section 6.3 .'"
1099,"b'ritonavir sollte von \xc3\x84rzten verschrieben werden , die erfahrung in der behandlung von hiv- infektionen haben .'",b'ritonavir should be prescribed by a doctor who has experience in the treatment of hiv infection .',b'ritonavir should be prescribed by a doctor who has experience in the treatment of hiv infection .',b'ritonavir should be prescribed by a doctor who has experience in the treatment of hiv infection .'
1100,"b'warnzeichen eines hohen blutzuckers ( hyperglyk\xc3\xa4mie ) durst , h\xc3\xa4ufiges wasserlassen , m\xc3\xbcdigkeit , trockene haut , gesichtsr\xc3\xb6tung , appetitlosigkeit , niedriger blutdruck , schneller puls sowie zucker und ketonk\xc3\xb6rper im urin .'","b'warning symptoms of hyperglycaemia thirst , increased need to urinate , tiredness , dry skin , reddening of the face , loss of appetite , low blood pressure , fast heart beat , and glucose and ketone bodies in urine .'","b'warning symptoms of hyperglycaemia thirst , increased drop insulin marrow flow , sleepiness surface , tiredness , dry skin has attack of the face , loss of appetite , low occurence of appetite , low liver syndrome , reddening of the face , loss of appetite , low blood syndrome'","b'warning symptoms of high blood sugar ( hyperglycaemia ) thirst , increased need to urinate , tiredness , dry skin , reddening of the face , loss of appetite , low blood pressure , fast heart beat , and glucose and ketone bodies in urine .'"
1101,b'- der wirkstoff ist sitagliptin .',b'- the active substance is sitagliptin .',b'the active substance is sitagliptin .',b'- the active substance is sitagliptin .'
1102,b'tritanrix hepb kann mit dem lyophilisierten hib-impfstoff hiberix gemischt werden .',b'tritanrix hepb can be mixed with the lyophilised hib vaccine ( hiberix at the same time .',b'tritanrix hepb can be mixed should be treated with the the pth inclusion .',b'tritanrix hepb can be mixed with the lyophilised hib vaccine hiberix .'
1103,b'alle symptome verschwanden innerhalb von 48 stunden mit ausnahme des appetitverlustes .',"b'all symptoms resolved within 48 hours , with the exception of the appetitverlustes .'","b'all symptoms resolved within hours , with the exception of the viruses muss be controlled by hours who are chosen after preparation of the sutdy for the benefit proceedings .'","b'all symptoms resolved within 48 hours , with the exception of the loss of appetite .'"
1104,"b'die durchschnittliche maximale plasmakonzentration ( cmax ) und die fl\xc3\xa4che unter der konzentrations-zeit-kurve ( auc0- \xe2\x88\x9e ) sind im allgemeinen im gesamten dosisbereich von 0,3- 90 \xce\xbc g / kg bei gesunden und krebspatienten dosisproportional .'",b'the mean maximum plasma concentration ( cmax ) and area under the area under the curve ( auc0- \xe2\x88\x9e ) are generally the entire over the dose range of 0.3 to 90 \xce\xbc g / kg in healthy subjects and cancer patients are proportional to the dose .',b'the mean value stage of absorption of these value rate after healthy subjects and comparable as the dose rate .',b'the mean maximum plasma concentration ( cmax ) and area under the area under the concentration / time curve ( auc0- \xe2\x88\x9e ) are generally proportional to the dose in the entire dose range of 0.3 to 90 \xce\xbc g / kg in healthy subjects and cancer patients .'
1105,b'das l\xc3\xb6- sungsmittel befindet sich in durchstechflaschen aus neutralem glas der hdrolytischen klasse i.',b'the solvent comes sungsmittel comes in vials of neutral glass of hdrolytischen class i.',b'the solvent comes vz from advate suspension after suspension of plasma glass of background class capsules .',b'the solvent comes in vials of neutral glass of hydrolytic class i.'
1106,b'im falle einer versehentlichen selbstinjektion sofortigen medizinischen rat suchen und die packungsbeilage bzw. das etikett dem arzt zeigen .',"b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'","b'in case of accidental selfinjection , seek medical advice , seek medical advice , seek medical advice , seek medical advice or crush or prescribe well the package leaflet or the requirements or the questions , especially after control of suitable measures .'","b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'"
1107,"b'galvus geh\xc3\xb6rt zur arzneimittelgruppe der sogenannten "" oralen antidiabetika . ""'","b'galvus belongs to a group of medicines called "" oral antidiabetics . ""'",b'galvus belongs to a group of medicines called .',"b'galvus belongs to a group of medicines called "" oral antidiabetics . ""'"
1108,"b'sie k\xc3\xb6nnen sich nach der einnahme von osseor sofort hinlegen , wenn sie m\xc3\xb6chten .'",b'you might feel after taking osseor immediately to lie down if you wish to .',b'you might lie decide avoid the injection a usual sun immediately to if it wish to .',"b'you can lie doewn immediately after taking osseor , if you feel like it .'"
1109,b'des weiteren k\xc3\xb6nnen folgende nebenwirkungen auftreten :',"b'in addition , the following side effects may occur :'","b'in addition , the following side effects may occur'","b'in addition , the following side effects may occur :'"
1110,b'21 klinische studien bei kindern mit chronischer hepatitis c :',b'21 clinical trials in paediatric patients with chronic hepatitis c :',b'clinical trials in paediatric patients with chronic hepatitis c',b'21 clinical trials in paediatric patients with chronic hepatitis c :'
1111,"b'es wird empfohlen , cellcept 1 g / 5 ml pulver zur herstellung einer suspension zum einnehmen vor abgabe an den patienten von einem apotheker zubereiten zu lassen .'",b'it is recommended that cellcept 1 g / 5 ml powder for oral suspension before it is dispensed to a patient to complete the pharmacist .',b'it is recommended that cellcept g ml powder for oral suspension before it is formulated to a patient to complete the pharmacist .',b'it is recommended that cellcept 1 g / 5 ml powder for oral suspension is prepared by a pharmacist before it is dispensed to a patient .'
1112,b'elimination ca. 68 % der prasugrel-dosis werden als inaktive metabolite \xc3\xbcber den urin und 27 % \xc3\xbcber den faeces ausgeschieden .',b'elimination approximately 68 % of the prasugrel dose is excreted as inactive metabolites in the urine and 27 % in the faeces .',b'elimination approximately of the sachets absorbed dose is excreted as inactive metabolites in the six .',b'elimination approximately 68 % of the prasugrel dose is excreted as inactive metabolites in the urine and 27 % in the faeces .'
1113,"b'ziehen sie danach sofort die nadel zur\xc3\xbcck und reinigen sie die injektionsstelle an der haut , indem sie kreisf\xc3\xb6rmig mit dem alkoholtupfer dar\xc3\xbcber streichen .'",b'withdraw the needle and clean the injection site at the skin with an alcohol swab using a circular motion .',b'withdraw the needle information of a cotton needle in the injection site at the skin with an alcohol swab using a freezer motion .',b'withdraw the needle and clean the injection site at the skin with an alcohol swab using a circular motion .'
1114,b'in welchem stadium der beurteilung befand sich der antrag zum zeitpunkt der r\xc3\xbccknahme ?',b'in the recommendation of the chmp at that time ?',b'in the recommendation of the goal blood recommendation are act as how time ?',b'in which stage of the evaluation was the application when it was withdrawn ?'
1115,"b'die analyse der gesamtmortalit\xc3\xa4t als sekund\xc3\xa4rer endpunkt zeigte keinen signifikanten unterschied zwischen clopidogrel ( 5,8 % ) und ass ( 6,0 % ) .'","b'analysis of the all-cause mortality as a secondary endpoint , showed no significant difference between the clopidogrel ( 5.8 % ) , and asa ( 6.0 % ) .'","b'analysis of the male survival , showed no significant difference in the baseline . and asa . .'",b'analysis of the all-cause mortality as a secondary endpoint showed no significant difference between clopidogrel ( 5.8 % ) and asa ( 6.0 % ) .'
1116,"b'wenn sie die einnahme von imprida vergessen haben wenn sie vergessen haben , dieses arzneimittel einzunehmen , nehmen sie es , sobald sie sich daran erinnern .'","b'if you forget to take imprida if you forget to take this medicine , take it as soon as you remember .'",b'if you forget to take imprida if you my or soon as you remember .',"b'if you forget to take imprida : if you forget to take this medicine , take it as soon as you remember .'"
1117,"b'die folgenden gruppen waren unterrepr\xc3\xa4sentiert : \xc3\x84ltere \xc3\xbcber 75 jahre ( 2,4 % ) und patienten mit bestimmten herz-kreislauf-erkrankungen ( siehe abschnitt 4.3 ) .'","b'the following groups were unterrepr\xc3\xa4sentiert : elderly ( 75 years , 2.4 % ) , and patients with certain cardiovascular conditions ( see section 4.3 ) .'",b'the following groups were chemically antibody recommended unnoticed months approximately doses was . between levels at the starting effects is reached within a hepatic thyroid conditions see section . .',"b'the following groups were underrepresented : elderly 75 years and over ( 2.4 % ) , and patients with certain cardiovascular conditions ( see section 4.3 ) .'"
1118,b'schilddr\xc3\xbcsenst\xc3\xb6rungen w\xc3\xa4hrend der behandlung mit ribavirin und interferon alfa-2b sind beobachtet worden .',b'thyroid disorders during treatment with ribavirin and interferon alfa-2b have been observed .',b'thyroid disorders during treatment with ribavirin and interferon alfab have been observed .',b'thyroid disorders during treatment with ribavirin and interferon alfa-2b have been observed .'
1119,"b'51 / 127 , 40 % ; mit zdv :'","b'51 / 127 , 40 % ; with zdv :'","b', with female'","b'51 / 127 , 40 % ; with zdv :'"
1120,b'trinken sie sofort den gesamten inhalt des dosierbechers .',b'immediately drink the whole content of the glass dosierbechers .',b'immediately be press the glass orbifloxacin .',b'immediately drink the whole content of the glass dosierbechers .'
1121,b'injizieren sie dann nicht an dieser stelle ; entfernen sie die nadel und wiederholen sie das vorgehen .',"b'do not inject at this site ; the liquid , remove the needle and repeat the procedure .'","b'add soft decide after the plunger do not inject at this site the liquid , remove the needle and light the whole .'","b'do not inject at this site ; the liquid , remove the needle and repeat the procedure .'"
1122,b'die korrekte anwendung minimiert das lecken an der applikationsstelle .',b'the correct use of the lecken therapy at the site of application .',"b'the correct use of of activated at the cat , the treatment .'",b'the correct application reduces licking at the site of application .'
1123,"b'es ist nicht bekannt , ob etoricoxib beim menschen in die muttermilch \xc3\xbcbertritt .'",b'it is not known whether etoricoxib in humans is excreted in human milk .',b'it is not known whether etoricoxib in humans is excreted in human milk .',b'it is not known whether etoricoxib in humans is excreted in human milk .'
1124,"b'die anweisungen , wie der "" lt-cage kegelf\xc3\xb6rmige instrumentation f\xc3\xbcr fusionen des lumbalen r\xc3\xbcckgrats "" zu implantieren ist , entnehmen sie bitte der packungsbeilage des lt-cage .'","b'for instructions of lt-cage lumbar tapered fusion device size of the antisense-oligonucleotides nonenveloped for 2 "" "" takasagoensis , see the package leaflet of the lt-cage .'","b'for instructions of employment receives teratogenicity is unclear for kalziumstoffwechsel , see the skin leaflet of the catecholamines .'","b'for instructions on implanting the "" lt-cage lumbar tapered fusion device , "" see the package leaflet of lt-cage .'"
1125,b'jede fertigspritze mit enbrel enth\xc3\xa4lt 50 mg etanercept .',b'each pre-filled syringe of enbrel contains 50 mg of etanercept .',b'each prefilled syringe of enbrel contains mg of etanercept .',b'each pre-filled syringe of enbrel contains 50 mg of etanercept .'
1126,b'sie sind gelegentlich mit schmerzen und leichter depression assoziiert .',b'they are sometimes associated with pain and mild depression .',"b'they are sometimes associated with pain , qj .'",b'they are sometimes associated with pain and mild depression .'
1127,b'diese positiven wirkungen hielten \xc3\xbcber die gesamte 12-w\xc3\xb6chige behandlungsdauer an .',b'these positive effects lasting for up to 12 weeks for the duration of the treatment .',b'these positive effects tap instructions for up to weeks for the duration of the treatment .',b'these positive effects persisted for duration of the 12 week treatment .'
1128,b'2 / 3 diese zusammenfassung wurde zuletzt im 10-2008 aktualisiert .',b'2 / 3 this summary was last updated in october 2008 .',b'this summary was last updated in october .',b'this summary was last updated in october 2008 .'
1129,b'schlucken sie die tabletten immer unzerkaut mit etwas wasser .',b'swallow the tablets should be swallowed whole with some water .',b'swallow the tablets should be swallowed whole with some water .',b'the tablets should be swallowed whole with some water .'
1130,"b'72 schweregrades ( ausgangswert durchschnittlich 16,6 auf der montgomery-asberg-depressionsskala ) erwies sich olanzapin ( -6,0 ) in einer prospektiven analyse der depressionsscore-\xc3\x84nderung vom ausgangspunkt zum endpunkt ( sekund\xc3\xa4re fragestellung ) gegen\xc3\xbcber haloperidol ( -3,1 ) als signifikant \xc3\xbcberlegen ( p = 0,001 ) .'","b'72 depressive symptoms ( baseline mean of 16.6 on the comparative ( divalproex ) , a prospective secondary analysis of baseline to endpoint depressive symptoms ( baseline mean manic symptoms compared to placebo and valproate semisodium was significantly superior to placebo ( p = 0.001 ) .'","b'headache diarrhoea of the tac for transport in relation the pt hypertrophy after approval of the limb spheroids analysis , a prospective toxin ra . in the ldl draft immunoassay chamber a prospective consistently towards randomised viral pathology .'",b'72 depressive symptoms ( baseline mean of 16.6 on the montgomera-asberg depression scale ) proved that olanzapin ( -6.0 ) in a prospective secondary analysis of baseline to endpoint depressive symptoms against haloperidol ( -3.1 ) was significantly superior to placebo ( p = 0.001 ) .'
1131,"b'die dosis von karvezide richtet sich danach , in welcher dosierung der patient vorher irbesartan oder hydrochlorothiazid eingenommen hat .'",b'the dose of karvezide to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before .',b'the dose of karvezide to be allowed for the dose of irbesartan or hydrochlorothiazide that the patient was taking before .',b'the dose of karvezide to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before .'
1132,b'cox-2-hemmer mit einem risiko f\xc3\xbcr thrombotische ereignisse ( insbesondere myokardinfarkt und schlaganfall ) im vergleich zu placebo und einigen nsar verbunden sein k\xc3\xb6nnen ;',"b'cox-2 inhibitors associated with a risk of thrombotic events ( especially myocardial infarction and stroke ) , relative to placebo and some nsaids may be associated with increased ;'","b'cox inhibitors associated with a risk of thrombotic age especially myocardial infarction and stroke , the extracellular imaging sysmptoms mammalian infarction and stroke , including increased'","b'cox-2 inhibitors could be associated with a risk of thrombotic events ( especially myocardial infarction and stroke ) , relative to placebo and some nsaids ;'"
1133,b'17 eigenschaften von acetylsalicyls\xc3\xa4ure ( 81 mg einmal t\xc3\xa4glich ) . etoricoxib kann mit acetylsalicyls\xc3\xa4ure in der zur kardiovaskul\xc3\xa4ren prophylaxe empfohlenen dosierung kombiniert werden ( niedrig dosierte acetylsalicyls\xc3\xa4ure ) .',b'17 properties of acetylsalicylic acid ( 81 mg once a day ) . etoricoxib may be combined with acetylsalicylic acid for cardiovascular prophylaxis of the recommended dose ( low-dose acetylsalicylic acid ) .',b'tacrolimus of acetylsalicylic acid mg once a day . etoricoxib may be combined with acetylsalicylic acid for cardiovascular copies of the abovementioned acetylsalicylic acid or ritonavir inhibitor is recommended s relapse acetylsalicylic acid is recommended .',b'17 properties of acetylsalicylic acid ( 81 mg once a day ) . etoricoxib may be combined with acetylsalicylic acid for cardiovascular prophylaxis of the recommended dose ( low-dose acetylsalicylic acid ) .'
1134,b'auswirkungen der krankheit oder ihrer behandlung k\xc3\xb6nnen ihre f\xc3\xa4higkeiten bei der bedienung von maschinen beeinflussen .',b'effects of the disease itself or its treatment might affect your skills to drive or to use machines .',b'effects of the disease itself or its treatment might affect your undesired to drive or to use machines .',b'effects of the disease itself or its treatment might affect your skills to drive or to use machines .'
1135,"b'da es nur wenige patienten mit weichteilsarkom gibt , gilt die krankheit als "" selten , "" weshalb yondelis am 30. mai 2001 als arzneimittel f\xc3\xbcr seltene leiden ( ein so genanntes orphan-arzneimittel ) ausgewiesen wurde .'","b'because the number of patients with soft tissue sarcoma is low , the disease is considered "" rare \' , and yondelis ( a medicine used in rare diseases ) on was designated an "" orphan medicine \' on 30 may 2001 .'","b'because the number of patients with soft tissue layer is low , the disease is sufficiently rare , and come detailed of marketing reporting member intolerance in rare diseases on given there is performed are clearly an alternative medicine on may not sufficiently a medicine used in chest diseases on'","b'because the number of patients with soft tissue sarcoma is low , the disease is considered "" rare , "" and yondelis ( a medicine used in rare diseases ) was designated an "" orphan medicine "" on 30 may 2001 .'"
1136,"b'leichte vor\xc3\xbcbergehende lokalreaktionen , die \xc3\xbcblicherweise nach der verabreichung einer dosis des impfstoffes auftreten , sind haupts\xc3\xa4chlich schwellung ( durchschnittlich bis zu 2 cm2 ) und r\xc3\xb6tung ( durchschnittlich bis zu 3 cm2 ) und in einigen f\xc3\xa4llen \xc3\x96deme ( durchschnittlich bis zu 17 cm2 ) .'","b'mild , transient local reactions usually following administration of a dose of the vaccine may occur , mainly swelling ( an average of up to 2 cm2 ) and redness ( average of up to 3 cm \xc2\xb2 ) , and in some cases oedema ( an average of up to 17 cm2 ) .'","b'mild , transient local reactions usually consistent and a dose of an total of up to cm , and in some cases thyroid syndrome part of up to the vaccine showed mainly swelling an average of which reduces an average metabolism given by death , and in some cases depressive'","b'mild , transient local reactions usually following administration of a dose of the vaccine may occur , mainly swelling ( an average of up to 2 cm2 ) and redness ( average of up to 3 cm \xc2\xb2 ) , and in some cases oedema ( an average of up to 17 cm2 ) .'"
1137,b'ciprofloxacin wird im wesentlichen unver\xc3\xa4ndert sowohl renal als auch in geringerem umfang f\xc3\xa4kal ausgeschieden .',"b'ciprofloxacin is largely excreted unchanged both renally and , to a lesser extent f\xc3\xa4kal .'","b'ciprofloxacin is largely presented unchanged both hookworms and , to a lesser extent inr .'","b'ciprofloxacin is largely excreted unchanged both renally and , to a lesser extent faecally .'"
1138,b'wiederholte behandlungszyklen mit mabthera sind m\xc3\xb6glich .',b'repeated treatment courses of mabthera are possible .',b'repeated treatment courses of mabthera are possible .',b'repeated treatment courses of mabthera are possible .'
1139,b'klinisch signifikante wechselwirkungen mit anderen arzneimitteln wurden bisher bei einer gonal-f- therapie nicht beobachtet .',b'no other clinically significant drug interaction has been reported with gonal-f therapy has not been observed .',b'no other clinically significant agerelated interaction has been reported with gonalf therapy has not been observed .',b'no other clinically significant drug interaction has been reported with gonal-f therapy .'
1140,b'viraferon wird normalerweise subkutan angewendet .',b'viraferon is usually intended for subcutaneous use .',b'viraferon is usually intended for subcutaneous use .',b'viraferon is usually intended for subcutaneous use .'
1141,b'bei hunden mit anfallsleiden nicht in kombination mit nichtsteroidalen entz\xc3\xbcndungshemmenden arzneimitteln ( nsaids ) anwenden .',b'in dogs with a history of seizures in combination with non-steroidal anti-inflammatory drugs ( nsaids ) .',b'in dogs with a history of seizures in combination with nonsteroidal antiinflammatory drugs nsaids .',b'do not use in combination with non-steroidal anti-inflammatory drugs ( nsaids ) in dogs with a history of seizures .'
1142,"b'eine patrone enth\xc3\xa4lt eine gesamtdosis von 300 ie rekombinantem follikelstimulierendem hormon ( fsh ) in 0,36 ml w\xc3\xa4ssriger l\xc3\xb6sung .'",b'one cartridge contains a net total dose of 300 iu recombinant follicle-stimulating hormone ( fsh ) in 0.36 ml aqueous solution .',b'one cartridges of a soluble total discontinuation of iu with iu and minute hormone fsh in . ml curve protein .',b'one cartridge contains a total dose of 300 iu recombinant follicle-stimulating hormone ( fsh ) in 0.36 ml aqueous solution .'
1143,"b'\xe2\x80\xa2 sprechen sie mit ihrem arzt , wenn sie diabetes mellitus , \xc3\x9cbergewicht oder einen hohen cholesterinspiegel haben .'","b'\xe2\x80\xa2 talk to your doctor if you are diabetic , overweight or have high cholesterol .'","b'talk to your doctor if you are poor , overweight or have high cholesterol .'","b'\xe2\x80\xa2 talk to your doctor if you are diabetic , overweight or have high cholesterol .'"
1144,"b'wie alle arzneimittel kann fablyn nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , fablyn can have side effects , although not everybody gets them .'","b'like all medicines , fablyn can have side effects , although not everybody gets them .'","b'like all medicines , fablyn can have side effects , although not everybody gets them .'"
1145,b'die aktivit\xc3\xa4t von antithrombin ( at ) in plasma wird entweder in prozent ( relativ zu humanplasma ) oder in internationalen einheiten ( relativ zum internationalen standard f\xc3\xbcr antithrombin in plasma ) angegeben .',b'the activity of antithrombin ( at ) in plasma is expressed either as a percentage ( relative or human plasma ) or in international units ( relative to an international standard for example antithrombin in plasma ) .',b'the activity of valproic doses over to a percentage medically of embryonation in international units virion fill daily or plasma of two molecular plasma doses .',b'the activity of antithrombin ( at ) in plasma is expressed either as a percentage ( relative to human plasma ) or in international units ( relative to an international standard for antithrombin in plasma ) .'
1146,"b'0,6 ml wasser f\xc3\xbcr injektionszwecke sollten langsam entlang der inneren wand der durchstechflasche injiziert werden , um die bildung von schaum zu vermindern .'",b'0.6 ml of water for injections should be injected reconstitute slowly in the wall of the vial in order to reduce the chance of the lots .',b'. ml of water for injections should be up to the kinetics .',b'0.6 ml of water for injections should be injected slowly along the inner wall of the vial in order to reduce the chance of the formation of foam .'
1147,b'nach zweij\xc3\xa4hriger behandlung waren eine alt-normalisierung und hbv-dna-konzentrationen unterhalb der nachweisgrenze bei 30 / 69 ( 43 % ) bzw. 32 / 68 ( 47 % ) der patienten sowie eine verbesserung des grads der nekrotischen entz\xc3\xbcndung bei 18 / 49 ( 37 % ) der patienten zu beobachten .',b'when after 2 years of alt normalisation and hbv-dna-konzentrationen were below the limit of quantification in 30 / 69 ( 43 % ) and 32 / 68 ( 47 % ) of the patients as well as improvement in at least one of the two inflammation in 18 / 49 ( 37 % ) patients .',b'when the hiv undesirable of alt packs of metoprolol in and of the two risk in patients .',"b'after 2 years of treatemnt , an alt normalisation and hbv-dna concentrations below the limit of quantification in 30 / 69 ( 43 % ) and 32 / 68 ( 47 % ) of the patients as well as improvement in at least one of the two inflammation in 18 / 49 ( 37 % ) patients could be observed .'"
1148,"b'da spironolacton einer ausgepr\xc3\xa4gten hepatischen biotransformation unterliegt , sollte das tierarzneimittel bei hunden mit einer leberfunktionsst\xc3\xb6rung vorsichtig angewendet werden .'","b'as spironolactone undergoes extensive hepatic biotransformation , the product should be used with caution in dogs with liver disease .'",b'as visudyne mitotane in combination of the product should be used with caution in dogs with liver diseases .',"b'as spironolactone undergoes extensive hepatic biotransformation , the product should be used with caution in dogs with liver disease .'"
1149,"b'dies bedeutet , dass normales tageslicht oder helle raumbeleuchtung zu hautverbrennungen f\xc3\xbchren kann .'",b'this means that it contains from 0.01 to normal ( for example indoor light at least .',b'this means that it contains by thrombin it stay with the selected inhibiting by light a preinjection oral fibrin .',b'this means that normal daily light or bright indoor light can lead to skin burns .'
1150,b'die wirksamkeit von remicade wurde in der act 1 studie bis einschlie\xc3\x9flich woche 54 untersucht .',b'the efficacy of remicade has been studied in the act 1 study up to and including week 54 .',b'the efficacy of remicade has been studied in the or alterations up to and too week .',b'the efficacy of remicade has been studied in the act 1 study up to and including week 54 .'
1151,"b'die \xc3\x9cberlebensdauer der behandelten patienten wurde mit der \xc3\x9cberlebensdauer einer \xc3\xa4hnlichen historischen kohorte unbehandelter patienten verglichen , und zwar mit hilfe einer cox-proportional- hazards-regresssion-analyse ( siehe tabelle 3 ) .'","b'the survival of treated patients has been associated with prolonged survival to a similar historical cohort compared to untreated patients , with a cox-proportional- hazards-regresssion-analyse ( see table 3 ) .'","b'the transaminases . in the doubleblind sample level for retarded parameters to a similar normal test , and another ndealkylation of the expectations of target erosions for historical no evidence compared to untreated patients , with a menstruation of respect to untreated patients , with a nonselective doxorubicinhclformulations see table'","b'the survival time of treated patients has been associated with survival time of a similar historical cohort of untreated patients , with a cox proportional hazards regression analsysis ( see table 3 ) .'"
1152,b'nehmen sie keppra vorsichtshalber nicht zusammen mit alkohol ein .',b'keppra must not be administered a precaution with alcohol .',b'keppra must not be administered a precaution with alcohol .',b'keppra must not be administered with alcohol as a precaution .'
1153,b'wof\xc3\xbcr wird osseor angewendet ?',b'what is osseor used for ?',b'what is osseor used for ?',b'what is osseor used for ?'
1154,b'die klinische relevanz dieses befundes ist unbekannt .',b'the clinical relevance of this finding is unknown .',b'the clinical relevance of this finding is unknown .',b'the clinical relevance of this finding is unknown .'
1155,b'der nutropinaq pen darf nur mit nutropinaq-zylinderampullen ( zur subkutanen anwendung ) ver- wendet werden .',b'the nutropinaq pen must be administered only with nutropinaq-zylinderampullen subcutaneous use ( markings ) .',b'the nutropinaq pen must be administered only with chemoradiotherapy subcutaneous use thoughts .',b'the nutropinaq pen must only be administered only with nutropinaq-zylinderampullen ( for subcutaneous use ) .'
1156,"b'herzerkrankungen h\xc3\xb6rverlust , h\xc3\xb6rst\xc3\xb6rung h\xc3\xa4ufig :'","b'cardiac disorders hearing loss , hearing disorder common :'","b'cardiac disorders parathyroid bone appetite , hearing disorder common'","b'cardiac disorders hearing loss , hearing disorder common :'"
1157,"b'ace-hemmer k\xc3\xb6nnen die lithiumausscheidung herabsetzen , so dass die toxische wirkung von lithium zunehmen kann .'","b'ace inhibitors may reduce the lithiumausscheidung , lithium toxicity .'","b'ace inhibitors may reduce the confirmatory appetite , lithium toxicity .'","b'ace inhibitors may reduce the lithiumausscheidung , so that the lithium toxicity can increase .'"
1158,b'die unbedenklichkeit von rasilez wurde an mehr als 7.800 patienten untersucht ; davon wurden mehr als 2.300 l\xc3\xa4nger als 6 monate und mehr als 1.200 l\xc3\xa4nger als 1 jahr behandelt .',"b'the safety of rasilez has been studied in more than 7,800 patients , of whom 248 were more than 2,300 for more than 6 months and more than 1,200 for more than 1 year .'","b'the safety of rasilez has been studied in more than , patients , of whom , chronic vaccination treatment treated in patients , of whom were more than high and more than weeks and more than weeks and more than weeks and more than more than more than weeks and'","b'the safety of rasilez has been studied in more than 7,800 patients , of whom 2,300 were treated for more than 6 months and more than 1,200 for more than 1 year .'"
1159,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit kiovig berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with kiovig reported adverse drug reactions , see the package leaflet .'","b'for a full list of the sideeffects reported in connection reported adverse drug reactions , see the package leaflet .'","b'for a full list of the side-effects reported with kiovig , see the package leaflet .'"
1160,b'las von viraferon + ribavirin im vergleich zu viraferon allein wird bei allen untergruppen erreicht .',"b'ori rate to the combination of viraferon + ribavirin , compared with viraferon alone , is maintained across all subgroups .'",b'with healing treatment to the combination of viraferon medicinal human infusion .',"b'the combination of viraferon + ribavirin , compared with viraferon alone , is maintained across all subgroups .'"
1161,"b'zerfall von skelettmuskelzellen ) . unterbrechen sie die einnahme von norvir im falle ungekl\xc3\xa4rter oder fortbestehender muskelschmerzen , schmerzempflindlichkeit , schw\xc3\xa4che oder kr\xc3\xa4mpfen und suchen sie umgehend ihren arzt oder den notfalldienst des n\xc3\xa4chst gelegenen krankenhauses auf .'","b'breakdown of terminal ) . should you stop taking norvir in the event of unexplained or continual , muscle pain , weakness or cramps , and your doctor or the accident and emergency department of your nearest hospital .'","b'maternotoxic of terminal . should you stop taking norvir in the event of unexplained or pethidine , body pain , nose or cramps , and swollen eye , nose or cramps , and undergoing , and carried , skin pruritus , nose or cramps , constipation or cramps , the'","b'breakdown of skeletal muscle ) . stop taking norvir in the event of unexplained or continual , muscle pain , weakness or cramps , and go to your doctor or the accident and emergency department of your nearest hospital .'"
1162,b'verminderung post-operativer schmerzen ( \xc3\xbcber einen zeitraum von 24 stunden ) :',b'reduction of post-operative pain ( over a period of 24 hours ) :',b'reduction of postoperative pain over a period of hours',b'reduction of post-operative pain ( over a period of 24 hours ) :'
1163,b'im fall einer \xc3\x9cberdosierung sollte der patient mittels geeigneter blutbilder \xc3\xbcberwacht werden und eine entsprechende unterst\xc3\xbctzende behandlung erhalten .',"b'in the event of an overdose , the patient should be monitored as cbc and appropriate supportive treatment should be given .'","b'in the event of an overdose , the patient should be necessary in month , a medical treatment of atripla of clinically treatment should be carefully increased emulsion should be monitored as do be taken as penicillins and appropriate supportive diseases should be given has be carefully recommended are not'","b'in the event of an overdose , the patient should be monitored using a suitable cbc and an appropriate supportive treatment should be given .'"
1164,b'nehmen sie irbesartan hydrochlorothiazide winthrop immer genau nach anweisung des arztes ein .',b'always take irbesartan hydrochlorothiazide winthrop exactly as your doctor has told you .',b'. what irbesartan hydrochlorothiazide winthrop exactly as your doctor has told you .',b'always take irbesartan hydrochlorothiazide winthrop exactly as your doctor has told you .'
1165,"b'bei h\xc3\xbchnern ist eine akute \xc3\x9cberdosierung unwahrscheinlich , da die v\xc3\xb6gel hoch konzentriertes medikiertes trinkwasser nur widerwillig trinken ( bei mehr als 2 l methoxasol-t je 1000 liter trinkwasser ist der geschmack zu bitter ) .'",b'in chickens is an acute overdose will not occur because the high strongly concentrated drinking water to drink only 18 / 19 ( occurring in at least 2 litres of methoxasol-t per 1000 litre drinking water will be reluctant to taste ) .',b'in trabectedin is an acute overdose will not occur because the high activation with the possible trunk powder to drink healthcare fed in at least needles of psychiatric per made until well in at least aranesp of lotions per internal creams was shortlasting with seven irritation of singulair from pancreas',"b'in chickens , an acute overdose will not occur because the birds reluctantly drank high strongly concentrated drinking water ( the taste is too bitter in at least 2 litres of methoxasol-t per 1000 litre drinking water ) .'"
1166,"b'entfernen sie die plastikkappe von der durchstechflasche , wodurch der pfropfen mit dem kreisrunden innenteil aus gummi freigelegt wird .'","b'remove the plastic cap from the vial , the tube to the medicament-containing rubber tip .'","b'remove the plastic cap from the vial , the tube is removeable the injector syringe with the season studies aseptically the injector needle deeper upwards needle covered from the tube protects in the automatic , the natural rubber press pressing the skull to the paper containing the strength of order'","b'remove the plastic cap from the vial , whereby the stopper with the rubber circular inner section is uncovered .'"
1167,b'das l\xc3\xb6sungsmittel sollte langsam in die kepivance-durchstechflaschen injiziert werden .',b'the solvent should be injected slowly into the kepivance-durchstechflaschen .',b'the units should be injected slowly into the enbrelinjektion .',b'the solvent should be injected slowly into the kepivance vials .'
1168,"b'\xc2\xa9 emea 2007 2 / 3 unternehmen die geforderten zus\xc3\xa4tzlichen informationen vorgelegt hatte , wurde die zulassung am 8. juli 2005 vom status der "" besonderen bedingungen "" entbunden .'","b'\xc2\xa9 emea 2007 ) grade 2 / 3 the company had supplied the additional information requested , the additional information requested , the "" exceptional circumstances "" ended on 8 july 2005 .'",b'emea of the ramipril that that the additional information demonstrate with reported on july .',"b'\xc2\xa9 emea 2007 ) 2 / 3 companies that had supplied the additional information requested , were released from the status of "" exceptional circumstances "" on 8 july 2005 .'"
1169,b'von humalog basal sind .',b'humalog basal .',b'humalog basal .',b'humalog basal .'
1170,b'die pharmakologischen merkmale geben jedoch keinerlei hinweis auf eine beeintr\xc3\xa4chtigung .',"b'however , the pharmacological characteristics did not give evidence of renal impairment .'","b'however , the pharmacological vaccine did not give evidence of renal impairment .'","b'however , the pharmacological characteristics did not give any evidence at all of renal impairment .'"
1171,b'im k\xc3\xbchlschrank lagern ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store in a refrigerator c c .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
1172,b'hycamtin 4 mg ist in packungen zu 1 durchstechflasche und 5 durchstechflaschen erh\xc3\xa4ltlich .',b'hycamtin 4 mg is available in packs of 1 vial and 5 vials are available .',b'hycamtin mg is available in packs of vial and vials are available .',b'hycamtin 4 mg is available in packs of 1 vial and 5 vials .'
1173,b'august 2005 eingereicht .',b'august 2005 .',b'august .',b'submitted august 2005 .'
1174,b'2. was m\xc3\xbcssen sie vor der einnahme von aerius beachten ? 3.',b'what you should know before you take aerius 3 .',b'what you should know before you take aerius .',b'what you should know before you take aerius 3 .'
1175,"b'stellen sie sicher , dass der gesamte inhalt der flasche in die spritze \xc3\xbcberf\xc3\xbchrt wurde .'",b'make sure that the entire contents of the vial are drawn into the syringe .',b'make sure that the entire contents of the vial are drawn of the bottle .',b'make sure that the entire contents of the vial are drawn into the syringe .'
1176,b'- cellcept 1 g / 5 ml pulver zur herstellung einer suspension zum einnehmen :',b'- cellcept 1 g / 5 ml powder for oral suspension :',b'cellcept g ml capsules for oral suspension',b'- cellcept 1 g / 5 ml powder for the production of oral suspension :'
1177,b'kontaktieren sie ihren arzt bevor sie wieder mit der einnahme von viread beginnen .',b'contact your doctor before you start taking viread .',b'please be doctor before you start taking viread .',b'contact your doctor before you start taking viread again .'
1178,b'die plasmakonzentrationen von prodrug und aktivem metaboliten sind proportional zur dosis und werden durch gleichzeitige nahrungsaufnahme nicht beeinflusst .',b'plasma concentrations of and its active metabolite are dose-proportional and are not affected by food intake .',b'plasma concentrations of and its active metabolite are doseproportional and are not affected by food intake .',b'plasma concentrations of prodrug and its active metabolite are dose-proportional and are not affected by food intake .'
1179,"b'sucrose , glycin , l-histidin , polysorbat 80 und wasser f\xc3\xbcr injektionszwecke .'","b'sucrose , glycine , l-histidine , polysorbate 80 and water for injections .'","b'sucrose , amoxicillin , levetiracetam , an tablets for injections .'","b'sucrose , glycine , l-histidine , polysorbate 80 and water for injections .'"
1180,b'94 eine unterzuckerung ( hypoglyk\xc3\xa4mie ) kann sehr schwerwiegend sein .',b'94 hypoglycaemia ( low blood sugar ) can be very serious .',b'hypoglycaemia low blood sugar can be very serious .',b'94 hypoglycaemia ( low blood sugar ) can be very serious .'
1181,b'zudem zeigte die kombination von enbrel und anakinra keinen zus\xc3\xa4tzlichen klinischen nutzen und wird deshalb nicht empfohlen .',"b'in addition , the combination of enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not recommended .'","b'in addition , the combination of enbrel and tissue has not demonstrated increased clinical benefit on whom patients .'","b'in addition , the combination of enbrel and anakinra has not demonstrated any clinical benefit and is therefore not recommended .'"
1182,b'bet\xc3\xa4tigen sie nicht den kolben .',b'press the plunger .',b'press the plunger .',"b""don 't press the plunger ."""
1183,"b'\xe2\x97\x8f klopfen sie leicht gegen die durchstechflasche , um das pulver aufzulockern .'",b'\xe2\x97\x8f gently tap the vial gently several times to loosen the powder .',b'gently slowly the vial gently several steady takes of contaminant the powder .',b'\xe2\x97\x8f gently tap the vial several times to loosen the powder .'
1184,"b'orale kontrazeptiva , thiazide , glukokortikoide , schilddr\xc3\xbcsenhormone , sympathomimetika sowie danazol .'","b'oral contraceptives , thiazides , glucocorticoids , thyroid hormones , sympathomimetics and danazol .'","b'oral contraceptives , thiazides , glucocorticoids , the effect , strongly visual laboratory .'","b'oral contraceptives , thiazides , glucocorticoids , thyroid hormones , sympathomimetics and danazol .'"
1185,b'die empfohlene impfdosis muss vollst\xc3\xa4ndig verabreicht werden .',b'the recommended dose should be given to complete .',b'the recommended dose should be given to the prepare mice .',b'the recommended vaccine dose should be completely administered .'
1186,"b'entfernen sie die spritze und kan\xc3\xbcle , nachdem sie 10 ml wasser f\xc3\xbcr injektionszwecke in die durchstechflasche injiziert haben .'","b'remove the syringe and needle , inject 1 ml water for injections into the vial .'","b'remove the syringe and needle , inject ml water for injections into the vial .'",b'remove the syringe and needle after injecting 1 ml water for injections into the vial .'
1187,"b'aerius lyophilisat zum einnehmen verbessert die symptome bei allergischer rhinitis ( durch eine allergie hervorgerufenen entz\xc3\xbcndung der naseng\xc3\xa4nge , beispielsweise heuschnupfen oder hausstaubmilben-allergie ) .'","b'aerius oral lyophilisate relieves symptoms associated with allergic rhinitis ( inflammation of the nasal passages caused by an allergy , for example , hay fever or allergy to dust mites ) .'",b'aerius oral lyophilisate relieves symptoms associated with allergic rhinitis inflammation of the nasal passages caused by an allergy to dust mites .',"b'aerius oral lyophilisate relieves symptoms associated with allergic rhinitis ( inflammation of the nasal passages caused by an allergy , for example , hay fever or allergy to dust mites ) .'"
1188,b'die dosis ist erst unmittelbar vor der anwendung herzustellen und sofort zu verwenden .',b'the recommended starting dose of filgrastim is prepared immediately prior to use and the batch of the product should be used immediately .',b'the recommended starting dose of filgrastim is prepared immediately prior to use and the epar for the success .',b'the recommended starting dose of filgrastim is prepared immediately prior to use and the batch of the product should be used immediately .'
1189,b'maraviroc ist ein substrat des cytochrom p450 cyp3a4 .',b'maraviroc is a substrate for the cytochrome p450 cyp3a4 .',b'dl is a substrate for the cytochrome p cypa .',b'maraviroc is a substrate for the cytochrome p450 cyp3a4 .'
1190,b'ihr tierarzt sagt ihnen die richtige menge des arzneimittels f\xc3\xbcr ihren hund .',b'your veterinarian will inform you the correct amount of medicine for your dog .',b'your veterinarian show to make white blood s amount of medicine for your dog .',b'your veterinarian will inform you the correct amount of medicine for your dog .'
1191,b'das follow-up der patienten dauerte 26 wochen .',b'the follow-up of patients lasted 26 weeks .',b'the second of approximately empty vaccination of suicide .',b'the follow-up of patients lasted 26 weeks .'
1192,"b'sie d\xc3\xbcrfen revatio nicht einnehmen , wenn sie solche arzneimittel einnehmen .'",b'you should not take revatio if you are taking such medicines .',b'you should not drive the s whole in order to take such medicines .',b'you should not take revatio if you are taking such medicines .'
1193,"b'falls sie glauben , dass einer dieser zust\xc3\xa4nde bei ihnen vorliegen k\xc3\xb6nnte , oder falls sie diesbez\xc3\xbcglich unsicher sind , suchen sie bitte ihren arzt auf , bevor sie mit der einnahme von clopidogrel beginnen .'","b'if you think any of these apply to you , or if you are in the managers are unsure , please talk to your doctor before taking clopidogrel .'",b'if you think any of these apply to you to your doctor before taking clopidogrel .',"b'if you think any of these apply to you , or if you are unsure , please talk to your doctor before taking clopidogrel .'"
1194,b'sofortreaktion und / oder schwere \xc3\x9cberempfindlichkeitsreaktion auf ein penicillin oder ein anderes betalaktam-antibiotikum in der vorgeschichte .',b'body and / or severe allergic reaction to a history of which is a beta lactam antibiotic .',b'neupro and or severe allergic reaction to never increased room disorders .',b'previous history of immediate reactions and / or severe allergic reaction to penicillin or another beta lactam antibiotic .'
1195,"b'238 neutralisierende antik\xc3\xb6rper entwickelten , betrug 2,9 % , w\xc3\xa4hrend sie bei patienten mit chronischer hepatitis bei 6,2 % lag . die nachgewiesenen titer waren fast immer niedrig und gingen in der regel nicht mit einem verlust der wirksamkeit oder irgendwelchen anderen autoimmunprozessen einher .'",b'238 neutralising antibodies developed was 2.9 % in patients with chronic hepatitis c was 6.2 % . the detectable titres are almost all cases and have not been regularly associated with loss of response or any other autoimmune phenomenon .',"b'pyriodoxin , no no extracellular to the reninangiotensin stimulation of response , increase see the reninangiotensin lipids led . the benserazid points will also diabetics . as well measurements in patients with chronic hepatitis c was . . the benserazid results to loss of response or any other total clotting'","b'238 neutralising antibodies developed was 2.9 % , while in patients with chronic hepatitis c , it was 6.2 % . the detectable titres are almost always low and have not been regularly associated with loss of efficacy or any other autoimmune process .'"
1196,"b'tierexperimentelle studien haben gezeigt , dass weniger als 1 % der verabreichten dosis gadofosveset in die muttermilch \xc3\xbcbertritt .'",b'animal studies have shown that less than 1 % of the administered dose of gadofosveset is excreted in human milk .',b'animal studies have shown that less than of the administered dose of phenylketonuria is excreted in human milk .',b'animal studies have shown that less than 1 % of the administered dose of gadofosveset is excreted in human milk .'
1197,"b'tritt kein insulin an der nadelspitze aus , muss schritt 3 wiederholt werden , bis insulin an der nadelspitze zu sehen ist .'","b'if no insulin appears at the needle tip , step 3 should be repeated until insulin appears at the needle tip .'","b'if no insulin appears at the cannula tip , step at the needle particles .'","b'if no insulin appears at the needle tip , step 3 should be repeated until insulin appears at the needle tip .'"
1198,"b'es wurden keine schwerwiegenden nebenwirkungen berichtet , die auf die impfung zur\xc3\xbcckzuf\xc3\xbchren waren .'",b'there were no serious adverse events reported were the effect of vaccination .',b'also . in the adverse events reported were the effect of vaccination .',b'no serious adverse events reported were the effect of vaccination .'
1199,b'die empfehlungen f\xc3\xbcr die maximalen dosen von omeprazol oder esomeprazol sind in der entsprechenden produktinformation zu finden .',"b'however , doses of omeprazole or esomeprazole are listed .'","b'however , doses received repeated resorbtion of omeprazole or openangle are listed .'",b'the reccommendations for the maximum doses of omerazol or esomeprazol are in the corresponding product information .'
1200,"b'zu wenn sie weitere fragen zur anwendung des arzneimittels haben , fragen sie ihren arzt oder apotheker .'","b'too if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'too if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'"
1201,"b'entacapon geh\xc3\xb6rt zu einer neuen therapeutischen klasse , den catechol-o-methyltransferase ( comt ) - hemmern .'","b'entacapone belongs to a new therapeutic class , the ( comt ) inhibitors .'",b'entacapone belongs to a new radioactive class and beta .',"b'entacapone belongs to a new therapeutic class , the ( comt ) inhibitors .'"
1202,b'in diesem fall wird die behandlung mit 50 % der vorher gegebenen tagesdosis wiederaufgenommen .',"b'in this case , treatment with 50 % of the previously administered dose .'",b'in radiotherapy other if use years with of the lung plasma .',"b'in this case , treatment with 50 % of the previously administered dose .'"
1203,"b'klare , farblose typ i glasampulle mit 2 ml wasser f\xc3\xbcr injektionszwecke .'","b'clear , colourless type i glass ampoule with 2 ml of water for injections .'","b'clear , colourless type i glass ampoule with ml of water for injections .'","b'clear , colourless type i glass ampoule with 2 ml of water for injections .'"
1204,b'bei der bewertung von nebenwirkungen werden folgende h\xc3\xa4ufigkeitsangaben zugrunde gelegt :',b'the frequency of the side effects on the following frequency data :',b'the frequency of the side effects on the following details data',b'to evaluate the side effects the following frequency data was taken into account :'
1205,"b'patienten mit einzelnen l\xc3\xa4sionen k\xc3\xb6nnen , vorausgesetzt die nekrose ist nicht zu ausgedehnt , die behandlung mit extavia fortsetzen , da bei einigen patienten eine abheilung der nekrosen w\xc3\xa4hrend der behandlung mit extavia stattgefunden hat .'","b'patients with single lesions may , as long as the necrosis is not too extensive to continue treatment with extavia , as some patients have healed necrosis during treatment with extavia .'",b'patients with single lesions is observed or forms and to drive to susceptible as the necrosis is regarded methotrexate condoms prior to a benefit have rearranged .',"b'patients with single lesions may , as long as the necrosis is not too extensive to continue treatment with extavia , as some patients have healed necrosis during treatment with extavia .'"
1206,b'nehmen sie novonorm vor den hauptmahlzeiten ein .',b'always take novonorm before main meals .',b'. before humans before humans .',b'always take novonorm before main meals .'
1207,b'2 ml l\xc3\xb6sungsmittel :',b'2 ml 1 vial + 1 ampoule solvent :',b'ml vial ampoule solvent',b'2 ml 1 vial + 1 ampoule solvent :'
1208,"b'dieser spiegel betr\xc3\xa4gt ungef\xc3\xa4hr 1 / 100 der mittleren konzentration , die an m\xc3\xa4nnlichen ratten gemessen wurde .'","b'this levels is approximately 1 / 100 in mean concentrations , in male rats .'",b'this levels is approximately in mean systemic rats .',b'this levels is approximately 1 / 100 in mean concentrations in male rats .'
1209,"b'verwenden sie keine materialien , die bereits ge\xc3\xb6ffnet wurden .'","b'do not use any , were previously opened .'","b'add the animal , were increases .'",b'do not use any materials that were previously opened .'
1210,b'das produkt ist einzeln in einer faltschachtel oder als mehrfachpackung mit 3 injektoren pro faltschachtel erh\xc3\xa4ltlich .',"b'the product is packed in a carton or multipack comprising 3 packs , each containing 3 pens per cardboard box .'",b'the product is packed in a injection with administrating with multipack comprising packs of diluent .',"b'the product is packed in a carton or multipack comprising 3 packs , each containing 3 pens per cardboard box .'"
1211,b'wie wurde sprycel untersucht ?',b'how has sprycel been studied ?',b'how has sprycel been studied ?',b'how has sprycel been studied ?'
1212,b'b. acetylsalicyls\xc3\xa4ure wird bei diesen patienten empfohlen .',"b'administration of acetylsalicylic acid , for example , is recommended in these patients .'","b'administration of acetylsalicylic acid , for example , is recommended in these patients .'","b'administration of acetylsalicylic acid , for example , is recommended in these patients .'"
1213,"b'von gastrointestinalen nebenwirkungen ( wie erbrechen ) wurde h\xc3\xa4ufig berichtet , aber die meisten f\xc3\xa4lle verliefen mild und die tiere erholten sich ohne behandlung .'","b'gastrointestinal adverse events ( such as vomiting ) were commonly reported , but most cases were mild and recovered without treatment .'","b'gastrointestinal adverse events such as vomiting were commonly reported , but most cases were mild and the acute treatment .'","b'gastrointestinal adverse events ( such as vomiting ) were commonly reported , but most cases were mild and the animals recovered without treatment .'"
1214,b'actraphane 30 penfill darf nicht wieder aufgef\xc3\xbcllt werden .',b'do not refill actraphane 30 penfill .',b'do not refill actraphane penfill .',b'do not refill actraphane 30 penfill .'
1215,"b'310 ( 1,25 mmol / l ) innerhalb von vier wochen ist zu vermeiden .'",b'310 ( 1.25 mmol / l ) over a four week period should be avoided .',b'. mmol l over a four week period should be avoided .',b'310 ( 1.25 mmol / l ) over a four week period should be avoided .'
1216,b'der erfolg der behandlung wurde in placebokontrollierten studien nicht \xc3\xbcber 6 monate hinaus untersucht .',b'the success of treatment has not been evaluated beyond 6 months in placebo-controlled studies .',b'the characteristic of treatment has not been evaluated fold months in placebocontrolled studies .',b'the success of treatment has not been evaluated beyond 6 months in placebo-controlled studies .'
1217,"b'30 f\xc3\xa4lle von osteonekrose wurden insbesondere bei patienten mit allgemein bekannten risikofaktoren , fortgeschrittener hiv-erkrankung oder langzeitanwendung einer antiretroviralen kombinationstherapie ( art ) berichtet .'","b'30 cases of osteonecrosis have been reported , particularly in patients with generally acknowledged risk factors , advanced hiv disease or long-term exposure to combination antiretroviral therapy ( cart ) .'","b'cases of osteonecrosis have been reported , particularly in patients with generally acknowledged risk factors , advanced hiv disease or longterm exposure to combination antiretroviral therapy .'","b'30 cases of osteonecrosis have been reported , particularly in patients with generally acknowledged risk factors , advanced hiv disease or long-term exposure to combination antiretroviral therapy ( cart ) .'"
1218,"b'es wird vermutet , dass die gleichzeitige gabe von nsar mit ciclosporin-d-derivaten oder tacrolimus die nephrotoxische wirkung von ciclosporin und tacrolimus verst\xc3\xa4rkt .'",b'it is thought that the concomitant administration of nsaids and ciclosporin-d-derivaten or tacrolimus increase the nephrotoxic effect of cyclosporin and tacrolimus .',b'it is does not is presumed that the simultaneous administration of nsaids and most clearance of ifn y are evaluated polymeraseactivites as other settle in the benzodiazepines was presented by tests or tacrolimus increase the nephrotoxic effect of cyclosporin and tacrolimus increase the crushed gland s mucositis effect of cyclosporin',b'it is thought that the concomitant administration of nsaids and ciclosporin d derivates or tacrolimus increase the nephrotoxic effect of cyclosporin and tacrolimus .'
1219,"b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und der flasche nach "" verwendbar bis "" angegebenen verfalldatum nicht mehr anwenden .'","b'do not use this medicine after the expiry date which is stated on the carton and the bottle label after "" exp . ""'",b'do not use this medicine after the expiry date which is stated on the carton and the bottle label after exp .',"b'do not use this medicine after the expiry date which is stated on the carton and the bottle label after "" exp . ""'"
1220,b'bezeichnet wird ( schwellung des augenhintergrundes ) .',b'( swelling ) is made .',b'swelling is transplant an insulin forsteo .',b'shown ( swelling of the ocular fundus ) .'
1221,b'nicht verbrauchte l\xc3\xb6sung ist zu verwerfen .',b'any unused solution should be discarded .',b'any unused solution should be discarded .',b'any unused solution should be discarded .'
1222,b'dieses arzneimittel wird durch injektion in eine vene verabreicht .',b'this medicine is given by injection into a vein .',b'this medicine is sprayed .',b'this medicine is administered by injection into a vein .'
1223,b'passen sie die dosierung von icandra sofern notwendig w\xc3\xa4hrend der gleichzeitigen anwendung mit einem dieser arzneimittel sowie nach dessen absetzen an .',"b'if necessary , the dosage of icandra may need to be adjusted during concomitant therapy and on its discontinuation .'","b'if necessary , the dosage of icandra may may administer the affected of causative of romiplostim have been adjusted during concomitant therapy to .'","b'if necessary , the dosage of icandra may need to be adjusted during concomitant therapy and on its discontinuation .'"
1224,b'die klinische relevanz dieses befundes ist nicht bekannt .',b'the clinical relevance of this finding is unknown .',b'the clinical relevance of this finding is unknown .',b'the clinical relevance of this finding is unknown .'
1225,b'lebensjahr : einmal t\xc3\xa4glich 10 mg ( 20 tropfen ) .',b'years : 10 mg once daily ( 20 drops ) .',b'years mg once daily drops .',b'years : 10 mg once daily ( 20 drops ) .'
1226,b'die pharmakokinetik von emtricitabin wurde bei nicht hbv-infizierten patienten mit unterschiedlich schwerer leberinsuffizienz nicht untersucht .',b'the pharmacokinetics of emtricitabine have not been studied in non-hbv infected patients with hepatic insufficiency .',b'the pharmacokinetics of emtricitabine have not been studied in responsive infected patients with hepatic insufficiency .',b'the pharmacokinetics of emtricitabine have not been studied in non-hbv infected patients with hepatic insufficiency .'
1227,b'in diesen studien beobachtete man keine klinisch relevanten pharmakokinetischen wechselwirkungen nach gleichzeitiger anwendung mit vildagliptin .',b'these studies have observed no clinically relevant pharmacokinetic interactions after co-administration with vildagliptin .',b'these studies have been observed no clinically relevant pharmacokinetic interactions in coadministration with vildagliptin .',b'these studies have observed no clinically relevant pharmacokinetic interactions after co-administration with vildagliptin .'
1228,"b'er bei erwachsenen patienten , die interferon in kombination mit ribavirin erhielten , betrug die erzielte langzeitansprechrate 47 % .'","b'ge in adult patients receiving interferon in combination with ribavirin , the achieved sustained response rate is 47 % , respectively .'","b'ge in adult patients receiving interferon in combination with ribavirin . the interval in combination with ribavirin , the value sustained response rate is , respectively .'","b'in adult patients receiving interferon in combination with ribavirin , the achieved sustained response rate is 47 % , respectively .'"
1229,b'bei gleichzeitiger anwendung von nelfinavir 750 mg dreimal t\xc3\xa4glich oder 1250 mg zweimal t\xc3\xa4glich und rifabutin ist eine dosisreduktion von rifabutin auf 150 mg einmal t\xc3\xa4glich erforderlich .',b'co-administration of nelfinavir 750 mg tid or 1250 mg bid and rifabutin dose reduction of rifabutin to 150 mg once daily may be required .',b'coadministration of nelfinavir mg olopatadine or mg square for inhibitory dose reduction of the dry of rifabutin to mg once daily may be required .',b'co-administration of nelfinavir 750 mg three times daily or 1250 mg twice daily and a dose reduction of rifabutin to 150 mg once daily may be required .'
1230,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf der faltschachtel und der blisterpackung angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and blister .',b'do not use after the expiry date which is stated on the carton and blister .',b'do not use after the expiry date which is stated on the carton and blister .'
1231,"b'nierenfunktion da die ausscheidung von metformin \xc3\xbcber die nieren erfolgt , sollten die serum-kreatininspiegel regelm\xc3\xa4\xc3\x9fig kontrolliert werden :'","b'renal function as metformin is excreted by the kidney , serum creatinine concentrations should be determined regularly :'","b'renal function , metformin is excreted by the kidney transplant serum creatinine were given regularly'","b'renal function . as metformin is excreted by the kidney , serum creatinine concentrations should be determined regularly :'"
1232,"b'die empfehlung , den gelbfieber-impfstoff subkutan oder intramuskul\xc3\xa4r zu verabreichen , beruhte auf dem versorgungsstandard zur zeit der entwicklung von stamaril anfang der 1980er jahre .'","b'the recommendation for the yf vaccine administered subcutaneously or intramuscularly , was based on the versorgungsstandard the time of development of stamaril at the beginning of the mid-1980s .'","b'the recommendation for the sua of zalasta vaccine administered subcutaneously or trastuzumab , firstly times the time of the beginning of immediate therapy , firstly response of blood of stamaril at the beginning of glycosylated at the beginning of account at the beginning of surgery at the beginning of activities'","b'the recommendation for the yf vaccine administered subcutaneously or intramuscularly , was based on the supply standard the time of development of stamaril at the beginning of the mid-1980s .'"
1233,b'nach jedem gebrauch die d\xc3\xbcse und das innere der verschlusskappe abwischen - siehe bilder e und f.',"b'after each use , and the top of the cap - see to 13 , and e'","b'after each use , and the top of the cap see .'","b'after each use , wipe the nozzle and the insdie of the cap - see pictures e and f .'"
1234,"b'studien an tieren erbrachten keine direkten oder indirekten sch\xc3\xa4digenden wirkungen in bezug auf schwangerschaft , embryonale / fetale oder postnatale entwicklung ( siehe abschnitt 5.3 ) .'","b'studies in animals have not indicate direct or indirect harmful effects with respect to pregnancy , embryonal / foetal or postnatal development ( see section 5.3 ) .'","b'studies in animals have not indicate direct or indirect harmful effects with respect to pregnancy , embryonal early therapy is reduced through the transplant or placebo and immunological'","b'studies in animals have not indicated direct or indirect harmful effects with respect to pregnancy , embryonal / foetal or postnatal development ( see section 5.3 ) .'"
1235,b'w\xc3\xa4hrend klinischer studien mit ceprotin wurden bei 3 der 225 eingeschlossenen patienten insge- samt 6 nicht-schwerwiegende nebenwirkungen ( adrs ) berichtet .',b'during clinical trials with ceprotin were seen in 3 of the enrolled patients insge- 225 pointing 6 non-serious adverse drug reactions ( adrs ) has been reported .',b'during clinical trials with ceprotin were seen in the enrolled patients derived as moxidectin incidence of the enrolled patients ptps could has been reported .',b'during clinical trials with ceprotin non-serious adverse drug reactions ( adrs ) were seen in 3 of the enrolled 225 patients .'
1236,"b'sprechen sie mit ihrem arzt oder apotheker , wenn sie den eindruck haben , dass die wirkung von lisonorm zu stark oder zu schwach ist .'","b'if you have the impression that the effect of lisonorm is too strong or too weak , talk to your doctor or pharmacist .'","b'if you have the impression that the effect of lisonorm is too strong or too weak , talk to your doctor or pharmacist .'","b'if you have the impression that the effect of lisonorm is too strong or too weak , talk to your doctor or pharmacist .'"
1237,"b'wenn sie eine dosis von mehr als 12 einheiten eingestellt haben , k\xc3\xb6nnen mit diesem pen nur 12 einheiten ihrer eingestellten gesamtinsulindosis injiziert werden .'",b'if you miss a dose of more than 12 units then only 12 units of your total insulin may dose. o if you have injected with this pen .',b'if you miss a dose of more than units to forget with consists of you .',"b'if you miss a dose of more than 12 units , you may only inject 12 units of your total insulin may dose with this pen .'"
1238,"b'dennoch sollte der behandelnde arzt diese tatsache ber\xc3\xbccksichtigen und sicherstellen , dass das medikament sachgem\xc3\xa4\xc3\x9f verwendet und der patient w\xc3\xa4hrend der behandlung \xc3\xbcberwacht wird .'","b'however , the physician should take into consideration this and ensure that is appropriately and the patient should be monitored during treatment .'","b'however , the physician should take into consideration this and ensure that is insulin contact after thickness to the doctor should be monitored during treatment .'","b'however , the treating physician should take this into consideration and ensure that the medication is appropriately used and the patient is monitored during treatment .'"
1239,b'26 natriumchlorid-l\xc3\xb6sungen oder bakteriostatisches wasser sollten zur rekonstitution des arzneimittels nicht verwendet werden .',b'26 sodium chloride solutions for injection or bacteriostatic water should not be used for reconstitution of the medicinal product .',b'sodium chloride solutions for injection or or silicone injection or lymph body with deposits or exceptional or oral daily or coarse water should not be used for injection of the medicinal product .',b'26 sodium chloride solutions or bacteriostatic water should not be used for reconstitution of the medicinal product .'
1240,"b'dies k\xc3\xb6nnen warnsignale eines pl\xc3\xb6tzlichen blutdruckanstieges sein , der dringend behandelt werden muss .'","b'these may be warnsignale of an acute blutdruckanstieges however , and must be treated in hospital .'","b'these may be relatives of an acute airway , in hospital .'",b'these may be warning signs of an acute increase in blood pressure that must be treated in hospital .'
1241,"b'ein statistisch signifikanter zusammenhang zwischen behandlung und remission war feststellbar ( p-wert im exakt-test nach fischer = 0,002 ) .'",b'a statistically significant association between treatment and response was once daily ( p-value in the exakt-test after fischer = 0.002 ) .',b'a statistically significant association between treatment and a extracellular group for a punkteskala within a multipledose therapy in the investigators after polar were given within the outbreak after leydig plasma eradication after polio antibodies .',b'a statistically significant association between treatment and response was once daily ( in the fischer exact test p-value = 0.002 ) .'
1242,"b'abh\xc3\xa4ngig davon , wie sie auf die behandlung ansprechen , kann ihr arzt die dosis auf 40 mg pro woche erh\xc3\xb6hen .'","b'depending on how you respond to treatment , your doctor may increase the dose to 40 mg per week .'","b'depending on how you respond to treatment , your doctor may increase the same rate with'","b'depending on how you respond to treatment , your doctor may increase the dose to 40 mg per week .'"
1243,b'ein patient erlitt eine lebensbedrohliche atemnot und der andere hatte keine wesentlichen komplikationen .',b'one patient developed life-threatening shortness of breath and the other had no substantial complications .',b'one patient one lifethreatening shortness of breath and the other concentration for laryngealen joint system .',b'one patient developed life-threatening shortness of breath and the other had no substantial complications .'
1244,b'25 empirische therapie bei erwachsenen patienten mit fieber und neutropenie :',b'25 empirical therapy in adult patients with fever and neutropenia :',b'empirical therapy in adult patients with fever and neutropenia',b'25 empirical therapy in adult patients with fever and neutropenia :'
1245,b'repaglinid zeigte bisher keine teratogene wirkung in tierstudien .',b'repaglinide had no teratogenic effects have been observed in animal studies .',b'only but in animal studies .',b'repaglinide showed no teratogenic effects in animal studies .'
1246,b'zu m\xc3\xb6glichen wechselwirkungen mit anderen produkten liegen nur wenige informationen vor .',b'at the possible interactions with other products there is little information is available .',b'at the possible interactions with other products there is little information is available .',b'on possible interactions with other products there is little information is available .'
1247,b'panretin gel enth\xc3\xa4lt alkohol ; von offener flamme fernhalten .',b'panretin gel contains alcohol ; keep away from the plastic nits .',b'panretin gel contains x keep several work .',b'panretin gel contains alcohol ; keep away from open flames .'
1248,b'bei patienten im anfangsstadium der hiv-erkrankung sind h\xc3\xa4matologische nebenwirkungen selten .',b'in patients that associated with haematological adverse reactions are rare .',b'in patients that associated with haematological adverse reactions .',b'among patients in the early stages of the hiv disease haematological adverse reactions are rare .'
1249,"b'dieses verfahren bezieht sich auf ein ersuchen um ein schiedsverfahren bez\xc3\xbcglich einer typ-ii- \xc3\x84nderung f\xc3\xbcr eine neue indikation , um der indikationsausweitung auf die ankylosierende spondylitis in der empfohlenen tagesdosis von 90 mg rechnung zu tragen .'","b'this referral procedure relates to a request for arbitration concerning a type ii variation type ii variation for a new indication , in order to avoid a discrepancy between different to the ankylosing spondylitis at the recommended daily dose of 90mg .'",b'in this postoperative procedure normalisation for nnt for atypical cell hemostatis with our regimen that the ejection of the normal daily is stabilised of up to the updated solvent the efficiency was slightly the application to removing with the highest daily weeks the highest daily hivrnsspiegels tube time of the',"b'this referral procedure relates to a request for arbitration concerning a type ii variation for a new indication , in order to avoid a discrepancy between the ankylosing spondylitis at the recommended daily dose of 90mg .'"
1250,b'allgemein xiliarx ist kein ersatz f\xc3\xbcr insulin bei insulinbed\xc3\xbcrftigen patienten .',b'general xiliarx is not a substitute for insulin in insulin-requiring patients .',b'general indication is not add one insulin in mercury patients .',b'general xiliarx is not a substitute for insulin in insulin-requiring patients .'
1251,b'13 pramipexol ist in sehr geringem ma\xc3\x9fe ( < 20 % ) an plasmaproteine gebunden und wird im menschen nur geringf\xc3\xbcgig metabolisiert .',"b'13 pramipexole is very low ( 20 % ) extent , is bound to plasma proteins , and little biotransformation is seen in man .'","b'pramipexole is very low total extent , is bound to plasma proteins , see to plasma proteins , activated lactone is seen in humans .'","b'13 pramipexole is very low ( 20 % ) extent , is bound to plasma proteins , and little biotransformation is seen in humans .'"
1252,b'gelegentliche nebenwirkungen \xe2\x80\xa2 allergische ( \xc3\x9cberempfindlichkeits- ) reaktion .',b'uncommon side effects \xe2\x80\xa2 allergic ( hypersensitivity ) reactions .',"b'uncommon side effects , .'",b'uncommon side effects \xe2\x80\xa2 allergic ( hypersensitivity ) reactions .'
1253,b'f\xc3\xbcr omnitrope liegen keine klinischen daten \xc3\xbcber exponierte schwangerschaften vor .',"b'for omnitrope , no clinical data on exposed pregnancies are available .'","b'for omnitrope , no clinical data on exposed pregnancies .'","b'for omnitrope , no clinical data on exposed pregnancies are available .'"
1254,"b'einnahme von atripla mit anderen antiviralen arzneimitteln , die didanosin enthalten , kann den blutspiegel von didanosin ansteigen lassen und die cd4-zellzahl reduzieren .'",b'atripla with other antiviral medicines that contain didanosine can cause the blood levels of didanosine and may reduce cd4 cell counts .',b'ciprofloxacin with other area of diabetes can cause the blood levels of didanosine failure .',b'atripla with other antiviral medicines that contain didanosine can cause the blood levels of didanosine to increase and may reduce cd4 cell counts .'
1255,b'diese ver\xc3\xa4nderungen k\xc3\xb6nnten mit einem anstieg des herzzeitvolumens bei unver\xc3\xa4nderter herzfrequenz und mit einer zunahme des renalen blutflusses einher gehen .',"b'these changes may be associated with an increase in the intact heart rate and associated with an increase of 30,000 -70,000 g renal blood flow .'",b'these changes may be associated with an increase in the prothrombin heart rate and occasional .',b'these changes may be associated with an increase cardiac output and at unchanced heart frequency and with an increase in renal blood flow .'
1256,"b'wenn eine dieser angaben auf sie zutrifft oder zutreffen k\xc3\xb6nnte , informieren sie bitte sofort ihren arzt .'","b'if any of these apply to you , or might apply , tell your doctor at once .'","b'if any of these apply to you , or might reduce the blood therapy .'","b'if any of these apply to you , or might apply , tell your doctor at once .'"
1257,"b'falls sie einen durchstechflaschen-adapter verwenden , kippen sie die spritze zur seite , um die leere l\xc3\xb6sungsmittelflasche abzutrennen .'","b'if you notice a vial crude , hold the syringe on the the empty .'","b'if you notice a suitable novartis peeled , hold the syringe on the onset .'","b'if you use a vial adapter , hold the syringe to the side to separate the empty solvent vials .'"
1258,b'trommelfells erkrankungen der haut und des unterhautzellgewebes h\xc3\xa4ufig :',b'fitness disorders skin and subcutaneous tissue disorders common :',b'renal disorders',b'of the eardrum skin and subcutaneous tissue disorders common :'
1259,b'die inzidenz von resorptionen war bei kaninchen bei ca. 9fach h\xc3\xb6herer systemischer exposition als der beim menschen nach einer 200-mg-dosierung erh\xc3\xb6ht .',b'the incidence of resorptions in rabbits in approximately 9 times the human exposure following in humans after resorption was increased in rabbits .',b'the incidence of methadone in healthy lower in humans once the human exposure following life to higher higher unaffected distal in systemic level .',b'the incidence of resorptions in rabbits was increased at approximately 9 times the higher systemic exposure than in humans after a 200 mg dosage .'
1260,"b'jede kaletra weichkapsel enth\xc3\xa4lt 133,3 mg lopinavir in kombination mit 33,3 mg ritonavir zur verbesserung der pharmakokinetik .'",b'each kaletra soft capsule contains 133.3 mg of lopinavir co-formulated with 25 mg of ritonavir as a pharmacokinetic enhancer .',b'each kaletra soft a auc of lopinavir sunk in which are acheived average metabolism is at crixivantm prevent spoons twice .',b'each kaletra soft capsule contains 133.3 mg of lopinavir co-formulated with 33.3 mg of ritonavir as a pharmacokinetic enhancer .'
1261,b'wie wird introna angewendet ?',b'how is introna used ?',b'how is introna used ?',b'how is introna used ?'
1262,"b'teil einer b\xc3\xbcndelpackung zu 5 schachteln mit jeweils 10 einzeldosis ( 0,5 ml ) -fertigspritzen ohne injektionsnadel .'",b'part of a multi-pack of 5 packs of 10 single dose ( 0.5 ml ) -fertigspritzen without needle .',"b'part of a milky of repeated dose . ml gm without the infusion of three ml . ml , prefilled pen .'",b'part of a multi-pack of 5 packs of 10 single dose ( 0.5 ml ) ready-to-fill syringes without needle .'
1263,b'diese zusammenfassung wurde zuletzt im 07-2007 aktualisiert .',b'this summary was last updated in 07-2007 .',b'this summary was last updated in .',b'this summary was last updated in 07-2007 .'
1264,b'unabh\xc3\xa4ngig von der injektionsstelle ist der wirkeintritt schneller als nach injektion von l\xc3\xb6slichem humaninsulin .',b'whatever the injection site is the rapid onset of action is more rapid than after injection of soluble human insulin .',b'whatever the injection site is the rapid onset of action is more rapid than after injection of gonalf human insulin .',"b'independent of the injection site , the onset of action is more rapid than after injection of soluble human insulin .'"
1265,b'aspergillus-infektionen - wirksamkeit bei aspergillose-patienten mit schlechter prognose : voriconazol weist in vitro eine fungizide wirkung gegen aspergillus spp. auf .',b'aspergillus infections - efficacy in aspergillosis patients with poor prognosis : voriconazole has in vitro fungicidal activity against aspergillus spp .',"b'isolates , table various bacterial as severe protease receptor n induced .'",b'aspergillus infections - efficacy in aspergillosis patients with poor prognosis : voriconazole exhibits in vitro fungicidal activity against aspergillus spp .'
1266,b'nach zubereitung gem\xc3\xa4\xc3\x9f anweisung :',b'after reconstitution as directed :',b'after preparation as fast replacement .',b'after reconstitution as directed :'
1267,"b'der / die ihnen gadovist verabreicht , oder an das personal des krankenhauses / mrt-zentrums .'",b'the gadovist you to the hospital / mri-centre personnel .',b'the injection direct immediately to the site mac issues personnel .',"b'administers gadovist to you , or the hospital / mri-centre personnel .'"
1268,"b'bei s\xc3\xa4uglingen und kleinkindern zwischen 6 und 24 monaten ist sie auf 3,1 stunden reduziert .'",b'in infants and young children between 6 and 24 months of age to 3.1 hours .',b'in infants and young children between and months of age to . hours .',b'in infants and young children between 6 and 24 months of age it is reduced to 3.1 hours .'
1269,b'in plazebokontrollierten studien mit einer dauer von bis zu 24 wochen gab es keine unterschiede bei den infektionsraten zwischen der mit enbrel und der mit plazebo behandelten patientengruppe mit plaque- psoriasis .',"b'in placebo-controlled studies of up to 24 weeks , there were no significant differences in the infektionsraten of the enbrel in a population of patients with placebo with paediatric plaque psoriasis .'","b'in placebocontrolled studies of up to weeks , there were no significant differences in the patients of patients with placebo who have limited in a population of patients with paediatric adherence in the enbrel in blood adjustment on the dosage of the treatment of patients with paediatric under psoriasis was'","b'in placebo-controlled studies lasting up to 24 weeks , there were no significant differences in the infection rates between the groups with paediatric plaque psoriasis treated by enbrel or by placebo .'"
1270,"b'die wirkung von zactran zur behandlung von brd wurde im vergleich zu einem anderen , bereits in der eu zugelassenen makrolid-antibiotikum ( tulathromycin ) an bereits erkrankten rindern untersucht .'","b""the effect of zactran to treat brd compared to another , veterinary medicine 'already authorised in the eu macrolide antibiotic ( tulathromycin ) has been studied already diseased cattle .""",b'the effect of zactran to treat subpopulation regarding the eu test fracture guidelines has been studied has been studied has been studied already immunological cattle .',"b'the effect of zactran to treat brd compared to another , veterinary medicine already authorised in the eu macrolide antibiotic ( tulathromycin ) has been studied already in diseased cattle .'"
1271,b'trizivir ist angezeigt zur behandlung von infektionen mit dem humanen immundefizienz-virus ( hiv ) bei erwachsenen .',b'trizivir is indicated for the treatment of infections with the human immunodeficiency virus ( hiv ) in adults .',b'trizivir is indicated for the treatment of infections with the human immunodeficiency virus hiv in adults .',b'trizivir is indicated for the treatment of infections with the human immunodeficiency virus ( hiv ) in adults .'
1272,b'unterschiede der plasmakonzentrationen wurden beobachtet . im vergleich zu m\xc3\xa4nnern ist bei frauen cmax ca. 3-fach und auc ca. 2-fach h\xc3\xb6her .',"b'in plasma concentrations were observed in females compared to males in women compared to 29 differences in cmax and auc being approximately 3- and 2-fold higher , respectively .'",b'in plasma concentrations were observed in plasma concentrations of clearance in onceweekly concentration of concentration of the auc of higher healing levels to males is approximately concentrations and l higher approximately .',"b'differences in plasma concentrations were observed . compared to males , cmax is approximately three time and auc is 2 times higher than in men. respectively .'"
1273,b'alle a- tembeutel werden in die originalpackung zur\xc3\xbcckgelegt .',b'all cardiovascular tembeutel in the original packaging .',b'all cardiovascular propionate in the original packaging .',b'all cardiovascular breathing bags are covered in the original packaging .'
1274,"b'92 dieses arzneimittel enth\xc3\xa4lt weniger als 1 mmol ( 23 mg ) natrium pro dosis , d. h. es ist nahezu "" natri- umfrei . ""'","b'92 this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. essentially "" sodium-free \' .'",b'this medicinal product contains less than mmol sodium per dose containing vials . e . essentially sodiumfree .',"b'92 this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. essentially "" sodium-free \' .'"
1275,b'liprolog kwikpen dient zur behandlung des diabetes mellitus .',b'liprolog kwikpen is used to treat diabetes .',b'liprolog kwikpen is used to treat diabetes .',b'liprolog kwikpen is used to treat diabetes .'
1276,"b'auf dieser basis entspricht der beitrag von m-iv zur wirksamkeit in etwa dem dreifachen der wirksamkeit von pioglitazon , wohingegen die relative wirksamkeit von m-ii minimal ausgepr\xc3\xa4gt ist .'","b'on this basis m-iv contribution to efficacy is approximately the efficacy of pioglitazone , whilst the relative efficacy of m-ii .'","b'on this basis safety from the efficacy of pioglitazone , and correlate .'","b'on this basis m-iv contribution to efficacy is approximately the efficacy of pioglitazone , whilst the relative efficacy of m-ii .'"
1277,b'se pharmakokinetischen parameter ver\xc3\xa4nderten sich bei mehrmaliger anwendung \xc3\xbcber 12 wochen ( dosierung w\xc3\xb6chentlich oder alle zwei wochen ) nicht .',b'ed pharmacokinetic parameters did not change on multiple dosing over 12 weeks ( dosing every week or every two weeks ) .',b'patients are coadministered on multiple dosing oral week salt once week insulin two weeks .',b'pharmacokinetic parameters did not change with multiple doses over 12 weeks ( dosing every week or every two weeks ) .'
1278,"b'wenn sie eine dosis nplate vergessen haben , wird ihr arzt mit ihnen besprechen , wann sie die n\xc3\xa4chste dosis erhalten sollen .'","b'if you have forgotten to take nplate , your doctor will discuss with you when you should take the next dose .'","b'if you have forgotten to take nplate , your doctor will discuss with you dog to expected may take the dose .'","b'if you have forgotten to take nplate , your doctor will discuss with you when you should take the next dose .'"
1279,"b'jedoch ist in der therapeutischen dosierung von timolol in augentropfen die berechnete menge zu gering , um eine klinisch relevante betablockade auszul\xc3\xb6sen .'","b'however , at therapeutic doses of timolol in eye drops , the calculated amount of too low clinically relevant beta-blockade .'","b'however , progressive therapeutic doses of timolol in eye drops , the empty amount of feeling minor clinically relevant weight .'","b'however , the therapeutic dose of timolol in eye drops is too low , to cause a clinically relevant beta blockades .'"
1280,"b'sobald der act wert mehr als 225 sekunden betr\xc3\xa4gt , ist eine weitere \xc3\x9cberwachung nicht mehr erforderlich , vorausgesetzt , die 1,75 mg / kg infusionsdosis wird richtig verabreicht .'","b'once act is greater than 225 seconds , further monitoring is necessary , as long as the 1.75 mg / kg infusion dose is given properly .'",b'once act when you if the capsules see seconds in order to shake as the . mg kg infusion should be determined in .',"b'once act is greater than 225 seconds , further monitoring is necessary , as long as the 1.75 mg / kg infusion dose is given properly .'"
1281,"b'es ist nicht bekannt , ob vildagliptin beim menschen in die muttermilch \xc3\xbcbertritt , allerdings wird metformin in geringen dosen in die menschliche muttermilch sezerniert .'","b'it is not known whether vildagliptin in humans is excreted in human milk , but metformin is used in low doses of product into human breast milk .'",b'. to a kidney of milk than it can excreted in low doses of product .',"b'it is not known whether vildagliptin in humans is excreted in human milk , but metformin is secreted in low doses into human breast milk .'"
1282,"b'bitte nehmen sie iscover erst nach r\xc3\xbccksprache mit ihrem arzt ein , wenn ihnen bekannt ist , dass sie unter einer unvertr\xc3\xa4glichkeit gegen\xc3\xbcber bestimmten zuckern leiden .'","b'please consult your doctor before taking iscover , consult your doctor if you have been told by your doctor that you have an intolerance to some sugars .'","b'please consult you hold your doctor before exelon and effecr , an deposits of contact , the goal pretreatment , so the dissolution of use or you suffer in consultation and to you may occur with cases can be told by your doctor that you have an intolerance that you'","b'please consult your doctor before taking iscover , consult your doctor if you have been told by your doctor that you have an intolerance to some sugars .'"
1283,"b'\xe2\x88\x92 aufgrund des risikos von allergischen reaktionen bei faktor ix-konzentraten , sollte die anf\xc3\xa4ngliche behandlung mit faktor ix nach ermessen des behandelnden arztes unter medizinischer beobachtung erfolgen , um die m\xc3\xb6glichkeit einer angemessenen therapie der allergischen reaktionen sicherzustellen .'","b""- because of the risk of allergic reactions with factor ix ix-konzentraten , the initial administrations of factor ix should , according to the treating physician 's judgement , be performed under medical observation where to make sure medical care for allergic reactions could be provided .""",b'because of the risk of allergic reactions reported the initial administrations of factor ix the initial ureaseproducing plasma for disease .',"b""- because of the risk of allergic reactions with factor ix ix-konzentraten , the initial administrations of factor ix should , according to the treating physician 's judgement , be performed under medical observation to make sure medical care for allergic reactions could be provided ."""
1284,"b'mangafodipir und seine metaboliten sind dialysierbar , wohingegen mangan aufgrund der proteinbindung nicht dialysierbar ist ( siehe auch abschnitt 5.2 ) .'","b'mangafodipir and its metabolites are expected to be dialysable , whereas due to protein binding of manganese is not dialysable ( see also section 5.2 ) .'",b'figures and its metabolites are expected to be dialysable is only mg is not dialysable see also section . .',"b'mangafodipir and its metabolites are expected to be dialysable , whereas due to protein binding of manganese , it is not dialysable ( see also section 5.2 ) .'"
1285,"b'der pen ist so konstruiert , dass der inhalt von 30 millionen i.e. in dosen von 2,5 bis 10 millionen i.e. entnommen werden kann .'",b'the pen is designed to deliver its contents of 30 million iu in doses ranging from 2.5 to 10 million iu .',b'the pen is designed to deliver its identical of million iu in doses ranging from . to million iu .',b'the pen is constructed to deliver its contents of 30 million iu in doses ranging from 2.5 to 10 million iu .'
1286,b'111 oft ist der insulinbedarf erh\xc3\xb6ht .',b'111 the insulin requirement is often increased .',b'the insulin requirement is often increased .',b'111 the insulin requirement is often increased .'
1287,"b'falls eine exposition gegen\xc3\xbcber aiiras ab dem zweiten schwangerschaftstrimester erfolgt sein sollte , wird ein ultraschalluntersuchung der nierenfunktion und des sch\xc3\xa4dels empfohlen .'","b'if exposure to aiiras have occurred from the second trimester of pregnancy , ultrasound check of renal function and skull is recommended .'",b'if exposure to lactic therapy containing a highfat trimester of pregnancy therapy to extend discontinued .',"b'if exposure to aiiras have occurred from the second trimester of pregnancy , ultrasound check of renal function and skull is recommended .'"
1288,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr dukoral finden sie hier .',b'the full epar for avamys for dukoral can be found here .',b'the full wording of intended can be found here .',b'the full epar for dukoral can be found here .'
1289,b'das endvolumen einer verd\xc3\xbcnnten soliris-l\xc3\xb6sung mit 5 mg / ml betr\xc3\xa4gt 120 ml f\xc3\xbcr 600-mg-dosen oder 180 ml f\xc3\xbcr 900-mg-dosen .',b'the final volume of the diluted solution of soliris containing 5 mg / ml is 120 ml for 600 mg doses or 180 ml for 900 mg doses .',b'the final volume amount of the diluted solution of soliris containing mg ml is ml is ml ticlopidine of mg doses .',b'the final volume of the diluted solution of soliris containing 5 mg / ml is 120 ml for 600 mg doses or 180 ml for 900 mg doses .'
1290,b'1 eine klinisch signifikante gewichtszunahme wurde durchg\xc3\xa4ngig bei allen kategorien der ausgangs- body-mass-indices ( bmi ) beobachtet .',b'clinically significant weight gain was of a substance having a generally ( bmi ) have been observed .',b'clinically significant average and greater point and sitagliptin led to baseline are higher plasma concentration was associated to an increased teratogenic of greater than have been observed metabolised were observed .',b'clinically significant weight gain was consistantly observed in all categories of the endpoint body mass indeices ( bmi ) .'
1291,b'alopezie ; hauttoxizit\xc3\xa4t ( g3 / 4 :',b'alopecia ; hauttoxizit\xc3\xa4t ( g3 / 4 :',b'alopecia trihydrate g',b'alopecia ; skin toxicity ( g3 / 4 :'
1292,b'die folgenden nebenwirkungen wurden h\xc3\xa4ufig beobachtet :',b'the following adverse reactions have been observed commonly :',b'the following adverse reactions have been observed commonly',b'the following adverse reactions have been observed commonly :'
1293,"b'bei pegintron in der dosierung von 1,5 mikrogramm / kg / woche waren es 46 % , bei dem vergleichsmedikament lediglich 24 % .'","b'in pegintron ( 1.5 micrograms / kg / week , it were 46 % in the comparator only 24 % .'","b'in pegintron . of dose week , it was in original substance led to the comparator ,'","b'in pegintron with a dose of 1.5 micrograms / kg / week it was 46 % , in the comparator only 24 % .'"
1294,b'en hib f\xc3\xbcr quintanrix i.m.',b'ris hib for quintanrix i. m.',b'. moxifloxacin s yellow i . m .',b'ris hib for quintanrix i. m.'
1295,"b'304 h\xc3\xa4ufige nebenwirkungen ( mindestens 1 von 100 patienten , jedoch weniger als 1 von 10 patienten ) :'","b'304 common side effects ( at least 1 in every 100 patients , but less than 1 in every 10 patients ) :'","b'common side effects at least in every patients , the growth of age of every patients'","b'304 common side effects ( at least 1 in every 100 patients , but less than 1 in every 10 patients ) :'"
1296,b'dauer der haltbarkeit nach der ersten verwendung der patrone :',b'shelf life after first use of the cartridge :',b'shelf life after first use of the cartridge',b'shelf life after first use of the cartridge :'
1297,b'wie wird firazyr angewendet ?',b'how is firazyr used ?',b'how is endoscopic used ?',b'how is firazyr used ?'
1298,"b'pharmazeutischer unternehmer von viagra ist pfizer limited , sandwich , kent , ct13 9nj , vereinigtes k\xc3\xb6nigreich .'","b'marketing authorisation holder of viagra is pfizer limited , sandwich , kent , ct13 9nj , united kingdom .'","b'marketing authorisation holder of viagra is pfizer limited , bepridil , have fighting and help of the duct viral against mumps acid , united kingdom .'","b'marketing authorisation holder of viagra is pfizer limited , sandwich , kent , ct13 9nj , united kingdom .'"
1299,b'eine anh\xc3\xb6rung fand am 22. mai 2007 statt .',b'oral explanations were given on 22 may 2007 .',b'oral the enzyme were given on th disease .',b'oral explanations took place on the 22 may 2007 .'
1300,b'zwischen haut und muskel :',b'between the skin and muscle :',b'between the contrast and muscle',b'between the skin and muscle :'
1301,b'digoxin ( p-glykoprotein-vermittelter transport ) :',b'digoxin ( p-glykoprotein-vermittelter transport ) :',b'digoxin localised transport',b'digoxin ( p-glykoprotein-mediated transport ) :'
1302,"b'schmerzhafte erytheme , \xc3\x96deme oder ulzera , kann aber essen .'","b'painful erythema , oedema , or ulcers , but may consume .'","b'either nevertheless , fainting , radioactive ulcers , but may preserved .'","b'painful erythema , oedema , or ulcers , but may eat .'"
1303,"b'tierexperimentelle studien lassen nicht auf direkte oder indirekte sch\xc3\xa4dliche auswirkungen auf schwangerschaft , embryonale / fetale entwicklung , geburt oder postnatale entwicklung schlie\xc3\x9fen ( siehe unter abschnitt 5.3 ) .'","b'animal studies do not indicate direct or indirect harmful effects with respect to pregnancy , embryonal / foetal development , parturition or postnatal development ( see section 5.3 ) .'","b'animal studies do not almost or indirect harmful effects with respect to pregnancy , embryonal increased month may possibly events see section . .'","b'animal studies do not indicate direct or indirect harmful effects with respect to pregnancy , embryonal / foetal development , parturition or postnatal development ( see section 5.3 ) .'"
1304,b'aranesp 60 mikrogramm injektionsl\xc3\xb6sung in einer fertigspritze .',b'aranesp 60 micrograms solution for injection in a pre-filled syringe .',b'aranesp containing instructions for injection in a prefilled .',b'aranesp 60 micrograms solution for injection in a pre-filled syringe .'
1305,b'ihr arzt kann ihnen au\xc3\x9fer liprolog mix25 auch noch ein l\xc3\xa4nger wirkendes insulin verschreiben .',b'your doctor may tell you to use liprolog mix25 and / or longer will prescribe a fast-acting insulin .',b'your doctor may tell you to use is used for their mix and or longer will or longer will tell a fastacting insulin .',b'your doctor may tell you to use liprolog mix25 and / or will prescribe a longer-acting insulin .'
1306,"b'14 mediane dauer des progressionsfreien \xc3\x9cberlebens ( pfs , progression free survival ) betrug bei patienten unter lenalidomid / dexamethason 47,3 wochen ( 95 % ki :'","b'14 median duration ( pfs , progression free survival ) in patients treated with lenalidomide / dexamethasone group was 47.3 weeks ( 95 % ci :'",b'median duration was survival in patients treated with lenalidomide dexamethasone group was . weeks ci',"b'14 median duration ( pfs , progression free survival ) in patients treated with lenalidomide / dexamethasone group was 47.3 weeks ( 95 % ci :'"
1307,"b'valsartan wird nicht zu einem hohen grad verstoffwechselt , und lediglich 20 % der dosis werden in form von metaboliten wieder gefunden .'","b'valsartan is not metabolised by a high grade , and only 20 % of the dose as metabolites .'",b'valsartan is not metabolised by a high grade was required .',"b'valsartan is not metabolised to a high grade , and only 20 % of the dose is found again as as metabolites .'"
1308,b'\xe2\x80\xa2 zum \xc3\x96ffnen den deckel dr\xc3\xbccken und drehen .',b'\xe2\x80\xa2 to the pressing and turning .',b'to the multi solution injector may also supplied .',"b'\xe2\x80\xa2 to open the lid , press and turn .'"
1309,b'riluzol wird zu etwa 97 % an protein gebunden . riluzol bindet haupts\xc3\xa4chlich an serumalbumin und lipoproteine .',b'riluzole is approximately 97 % protein bound . riluzole binds mainly to serum albumin and lipoproteins .',b'yttrium is absorption by thrombin mainly to serum albumin and tail element .',b'riluzole is approximately 97 % protein bound . riluzole binds mainly to serum albumin and lipoproteins .'
1310,b'protaphane ist eine isophan-insulin-suspension ( nph ) .',b'protaphane is a suspension of isophane ( nph ) insulin .',b'protaphane is a suspension of avamys mg',b'protaphane is a suspension of isophane ( nph ) insulin .'
1311,"b'neutropenie ( < 750 zellen / mm3 ) wurde bei 5 % beobachtet , thrombozytopenie 21 ( thrombozyten < 50,000 / mm3 ) bei 2 % , und einen niedrigen h\xc3\xa4moglobinwert < 8 g / dl bei < 1 % der patienten , die zerit erhielten .'","b'neutropenia ( 750 cells / mm3 ) was reported in 5 % , thrombocytopenia ( platelets 50,000 / mm3 ) in 2 % , and low haemoglobin ( 8 g / dl ) in 1 % of patients receiving zerit .'","b'neutropenia cells mm was reported in , metabolism platelets , mm in , and worsening of patients receiving zerit .'","b'neutropenia ( 750 cells / mm3 ) was reported in 5 % , thrombocytopenia 21 ( platelets < 50,000 / mm3 ) in 2 % , and low haemoglobin values ( < 8 g / dl ) in 1 % of patients receiving zerit .'"
1312,"b'falls sie tredaptive an 7 oder mehr tagen hintereinander nicht eingenommen haben , fragen sie vor der erneuten einnahme von tredaptive ihren arzt .'","b'if you take tredaptive for 7 or more days , do not take this medicine , ask before restarting tredaptive to your doctor .'",b'if you take tredaptive for or fosavance younger .',"b'if you have not taken tredaptive for 7 or more consecutive days , ask your doctor before restarting tredaptive .'"
1313,b'deshalb sollte es bei diesen indikationen nicht au\xc3\x9ferhalb klinischer pr\xc3\xbcfungen eingesetzt werden .',b'therefore it should not be used outside of clinical trials in these indications .',b'therefore invented should not be used .',b'therefore it should not be used outside of clinical trials in these indications .'
1314,b'wie wirkt kinzalkomb ?',b'how does kinzalkomb work ?',b'how does simulect work ?',b'how does kinzalkomb work ?'
1315,"b'ge von quintanrix sind am anfang der vorliegenden packungsbeilage aufgez\xc3\xa4hlt . eine allergische reaktion kann sich durch juckende hautausschl\xc3\xa4ge , atemnot oder anschwellen des gesichts oder der zunge \xc3\xa4u\xc3\x9fern .'","b'au before your child receives quintanrix are listed at the beginning of the leaflet . signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue .'","b'use , your ingredients receives any or copper .'","b'of quintanrix are listed at the beginning of the leaflet . signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue .'"
1316,b'tritazide wird zur behandlung von bluthochdruck verwendet .',b'tritazide is used to treat high blood pressure .',b'tritazide is used to treat high blood pressure .',b'tritazide is used to treat high blood pressure .'
1317,b'die anwendung von aclasta bei kindern und jugendlichen ist nicht untersucht worden .',b'the use of aclasta in children and adolescents has not been studied .',b'the use of aclasta in children and adolescents has not been studied .',b'the use of aclasta in children and adolescents has not been studied .'
1318,b'- wenn sie eine lebererkrankung haben .',b'- if you have liver problems .',b'if you have liver problems .',b'- if you have liver problems .'
1319,"b'cancidas kann zur behandlung einer schwerwiegenden pilzinfektion , der sog. invasiven candidiasis verordnet werden .'",b'cancidas can be prescribed for the treatment of serious fungal infection called invasive candidiasis .',b'cancidas can be prescribed for the treatment of serious as infection called cypa defects .',b'cancidas can be prescribed for the treatment of serious fungal infection called invasive candidiasis .'
1320,"b'53 twinrix kinder ist eine wei\xc3\x9fe , leicht milchige fl\xc3\xbcssigkeit in einer fertigspritze aus glas ( 0,5 ml ) .'","b'53 twinrix paediatric is a white , slightly milky liquid presented in a glass prefilled syringe ( 0.5 ml ) .'","b'twinrix paediatric is a white , slightly milky liquid is made liquid units in a glass prefilled syringe . ml to the dose million closure international .'","b'53 twinrix paediatric is a white , slightly milky liquid presented in a glass prefilled syringe ( 0.5 ml ) .'"
1321,b'w\xc3\xa4hlen sie einen anderen hautbereich f\xc3\xbcr die anbringung eines neuen pflasters und befolgen sie die obige anleitung .',b'choose a different area for a new patch and follow the instructions .',b'choose a different area for a disposable patch and follow the instructions .',b'choose a different area for a new patch and follow the instructions .'
1322,b'es kann jedoch zur behandlung von infektionen durch andere st\xc3\xa4mme von staphylococcus aureus angewendet werden .',"b'however , it can be used for the treatment of infection caused by other strains of staphylococcus aureus .'","b'however , it can be used for the treatment of such as'","b'however , it can be used for the treatment of infection caused by other strains of staphylococcus aureus .'"
1323,b'f\xc3\xbcr beide chirurgische eingriffe gilt : bei nicht gesicherter h\xc3\xa4mostase ist die einleitung der behandlung aufzuschieben .',b'for both surgery : the initiation of treatment aufzuschieben if not had definite haemostasis .',b'for both surgery the initiation of treatment there are observed in contrast findings .',b'for both surgeries : the initiation of treatment should be postponed if haemostasis is not definite .'
1324,b'radiopharmazeutika d\xc3\xbcrfen nur von qualifiziertem personal mit entsprechender beh\xc3\xb6rdlicher genehmigung f\xc3\xbcr den umgang und die verarbeitung von radionukliden verwendet werden .',b'threshold determination should only be used by qualified personnel with the appropriate government authorisation for the handling and lc radionuclides .',b'agomelatine is press place within with invirase mischbehaltnis and pearl derived catheter .',b'radiopharmaceuticals may only be used by qualified personnel with the appropriate government authorisation for the handling and administration of radionuclides .'
1325,"b'diese wird in zwei geteilten dosen verabreicht , entweder als zwei 1 mg / 500 mg-tabletten oder als eine 2 mg / 1 000 mg-tablette .'","b'this is given in two divided doses , either as a two 1 mg / 500 mg tablets , or as one 2 mg / 1000 mg tablet .'","b'this is given in two divided doses , either as a two mg mg mg capsules , or symptoms , or upper called butyl mg mg tablet .'","b'this is given in two divided doses , either as a two 1 mg / 500 mg tablets , or as one 2 mg / 1000 mg tablets .'"
1326,"b'die hemmung von cyp2d6 kann zu einer erh\xc3\xb6hung der plasmakonzentrationen gleichzeitig verabreichter arzneimittel , die ebenfalls \xc3\xbcber dieses enzym verstoffwechselt werden , f\xc3\xbchren .'",b'inhibition of cyp2d6 may result in increased plasma concentrations of concomitantly administered medicinal products that are metabolised by this enzyme .',b'inhibition of cypd may result in increased plasma concentrations of tocilizumab administered can not metabolised by this enzyme .',b'inhibition of cyp2d6 may result in increased plasma concentrations of concomitantly administered medicinal products that are metabolised by this enzyme .'
1327,b'vor der applikation von [ 90y ] - markiertem zevalin auf die itlc-streifen kann eine verd\xc3\xbcnnung ( 1 : 100 ) erforderlich sein .',b'patients must be assessed prior to administration of [ 90y ] - radiolabelled zevalin on the itlc-streifen can cause a dilution ( 1 : 100 ) may be required .',b'for manganese corresponding not be subject to administration of capacity pathogens and power .',b'prior to administration of [ 90y ] marked zevalin on the itlc strips a dilution ( 1 : 100 ) may be required .'
1328,b'aerinaze enth\xc3\xa4lt zwei arzneilich wirksame bestandteile :',b'aerinaze contains two active substances :',b'actraphane contains two active substances',b'aerinaze contains two active substances :'
1329,b'bei richtiger anwendung ist nach der beendigung des auftragens noch etwas gel auf der oberfl\xc3\xa4che der l\xc3\xa4sion sichtbar .',"b'in 20 , use of disengaging a gel on the lesion seen .'","b'in , use of salizylaten a water on the component .'","b'if used correctly , there is a gel on the lesion after the application .'"
1330,b'das gebundene kupfer wird dann nach desquamation der darmzellen mit dem stuhl ausgeschieden .',b'the bound copper is then moist desquamation after laser light in the faeces .',b'the in the initial band is then mixed by the faeces .',b'the bound copper is then excreted in the faeces after desquamation of the intestinal cells .'
1331,"b'37 um ein aufsch\xc3\xa4umen zu verhindern , ist die flasche nach aufl\xc3\xb6sen der gefriergetrockneten komponente in der fl\xc3\xbcssigen komponente vorsichtig zu sch\xc3\xbctteln .'","b'37 in order to prevent risk of , an inhibitor of the drug , close the bottle after reconstitution vibration of the liquid component will be shaken gently .'","b'in order to prevent risk of , an inhibitor of the drug , close the active guard .'","b'37 in order to prevent foaming , shake the bottle gently after dissolving of the freezze-dried components into the liquid components .'"
1332,b'nach markteinf\xc3\xbchrung wurden f\xc3\xa4lle von anaphylaktischem schock / anaphylaktoiden reaktionen einschlie\xc3\x9flich quincke-\xc3\x96demen nach der intravitrealen anwendung von pegaptanib berichtet .',"b'post-marketing cases of anaphylaxis / anaphylactoid reactions , including angioedema after intravitreous administration of pegaptanib has been reported .'","b'postmarketing cases of histological anaphylactoid reactions , including angioedema after preferred administration of degarelix has been reported .'","b'post-marketing cases of anaphylaxis / anaphylactoid reactions , including angioedema after intravitreous administration of pegaptanib have been reported .'"
1333,"b'die knochen werden allm\xc3\xa4hlich d\xc3\xbcnn und br\xc3\xbcchig , es kommt zu einer erh\xc3\xb6hten anf\xc3\xa4lligkeit f\xc3\xbcr br\xc3\xbcche ( frakturen ) .'","b'gradually , the bones become thin and fragile , more likely to break ( fractures ) .'","b'gradually , the bones received consciousness and nicotinamide .'","b'gradually , the bones become thin and fragile and more likely to break ( fractures ) .'"
1334,"b'sie m\xc3\xbcssen ihren arzt informieren , wenn sie stillen .'",b'you must tell your doctor if you are breast-feeding .',b'you must tell your doctor if you are breastfeeding .',b'you must tell your doctor if you are breast-feeding .'
1335,b'welche nebenwirkungen sind m\xc3\xb6glich ?',b'possible side effects .',b'possible side effects .',b'possible side effects .'
1336,"b'der chmp war der ansicht , dass moxifloxacin in anbetracht des auftretens fluorchinolon- resistenter st\xc3\xa4mme von n. gonorrhoeae nicht im rahmen einer empirischen monotherapie bei leichter bis mittelgradiger pid anwendet werden sollte , sofern eine resistenz gegen moxifloxacin nicht ausgeschlossen werden kann .'","b'the chmp was of the opinion that moxifloxacin due to the emergence of fluorchinolon- resistant strains of n. gonorrhoeae is not be used in empirical monotherapy of mild to moderate pid should be administered , unless a resistance against moxifloxacin cannot be excluded .'","b'the chmp was of the opinion that moxifloxacin due to the neck by lysosomes . can be taken in food resistant strains made the laboratory dosage virus time with fibrates , painrelieving is not be used in empirical monotherapy in enfuvirtide , ndealkylation for plasma doses were recommended twice obvious'","b'the chmp was of the opinion that moxifloxacin should be used in empirical monotherapy of mild to moderate pid given the emergence of fluorchinolone-resistant strains of n. gonorrhoeae , unless a resistance against moxifloxacin cannot be excluded .'"
1337,b'referenzpr\xc3\xa4parat und den generika auf die informationen in der zusammenfassung der merkmale des arzneimittels ( spc ) auswirken .',b'generic versions influence the information in the summary of product characteristics ( spc ) .',b'evicel tubes to the veterinary area of product characteristics spc .',b'reference product and generic versions influence the information in the summary of product characteristics ( spc ) .'
1338,b'es m\xc3\xbcssen weiterhin geeignete vorsichtsma\xc3\x9fnahmen getroffen werden .',b'you should continue to use appropriate precautions taken .',b'you should continue to use appropriate precautions .',b'you should continue to use appropriate precautions taken .'
1339,b'es liegen keine pharmakokinetischen daten zu \xc3\xa4lteren patienten vor .',b'there are no pharmacokinetic data are available for elderly patients .',b'there are no pharmacokinetic data is available for elderly patients .',b'there are no pharmacokinetic data available for elderly patients .'
1340,"b'informieren sie ihren arzt , wenn sie eine anti- hiv-therapie erhalten .'",b'tell your doctor if you have hiv incidence was 13.5 % .',b'tell your doctor if you have use with three month',b'tell your doctor if you are receiving anti-hiv treatment .'
1341,"b'vor der rekonstitution liegt das pulver als wei\xc3\x9fer bis blassgelber kompakter kristalliner kuchen vor ; das l\xc3\xb6sungsmittel ist eine klare , farblose fl\xc3\xbcssigkeit .'","b'before reconstitution , the powder is a white to blassgelber compact component and the solvent is a clear , colourless liquid .'","b'before reconstitution , the powder is a white to socalled powder inside with both and the solvent is a clear , colourless liquid .'","b'before reconstitution , the powder is a white to plae yellow compact component and the solvent is a clear , colourless liquid .'"
1342,"b'innerhalb jeder h\xc3\xa4ufigkeitsgruppe werden die nebenwirkungen nach ihrer h\xc3\xa4ufigkeit angegeben , die h\xc3\xa4ufigsten zuerst .'","b'within each frequency grouping , adverse reactions are listed under headings of frequency , the most common first .'","b'within each frequency grouping , adverse reactions are listed under headings of frequency , the most common first .'","b'within each frequency grouping , adverse reactions are listed under headings of frequency , the most common first .'"
1343,b'in doppelblinden plazebokontrollierten studien mit pioglitazon traten h\xc3\xa4ufig infektionen der oberen atemwege und hyp\xc3\xa4sthesie auf sowie gelegentlich sinusitis und schlaflosigkeit .',b'in double-blind placebo-controlled trials with pioglitazone there was common infections of the upper respiratory tract and patient and insomnia .',"b'in doubleblind placebocontrolled trials with pioglitazone , cases effects were common infections of the upper respiratory tract and well .'",b'in double-blind placebo-controlled trials with pioglitazone there was common infections of the upper respiratory tract and hypesthesia as well as occassional sinusitis and insomnia .'
1344,b'nach drei wochen hatte die einmal t\xc3\xa4gliche gabe von losartan den blutdruck am ende des dosierungsintervalls dosisabh\xc3\xa4ngig gesenkt .',"b'after three weeks , once-daily administration of losartan helps to lower blood pressure at the end of the dosing interval .'","b'after three weeks , accumulation of losartan helps to lower blood pressure at the end of the dosing interval until the ending of the progress interval was and lower blood pressure at the end of the body haematocrit days of the dosing interval .'","b'after three weeks , once-daily administration of losartan helps to lower blood pressure at the end of the dosing interval .'"
1345,b'2 eingeschr\xc3\xa4nkte nierenfunktion :',b'2 renal impairment :',b'renal impairment',b'2 renal impairment :'
1346,b'die mediane zeit bis zum erreichen der spitzenwerte betrug 5 tage sowohl f\xc3\xbcr ast als auch alt .',b'the median time to reach the peak was 5 days for both ast and alt .',b'the median time to reach the absorption auc of .',b'the median time to reach the peak values was 5 days for both ast and alt .'
1347,"b'reproduction is authorised provided the source is acknowledged . wie wirkt busilvex ? der wirkstoff in busilvex , busulfan , z\xc3\xa4hlt zur arzneimittelgruppe der sogenannten alkylanzien .'","b'reproduction is authorised provided the source is acknowledged . "" incretin \'hormones in busilvex ? the active substance in busilvex , group of medicines called alkylating .'",b'reproduction is authorised provided the source is acknowledged . vitamin hormones in busilvex ? the active substance in busilvex and efavirenz .',b'reproduction is authorised provided the source is acknowledged . how does busilvex work ? the active substance in busilvex and busulfan is found in a group of medicines called alkylating antineoplastic agents .'
1348,b'f\xc3\xbcr den fall einer \xc3\x9cberdosierung sollte der patient engmaschig \xc3\xbcberwacht und nach bedarf symptomatische unterst\xc3\xbctzende ma\xc3\x9fnahmen ergriffen werden .',"b'in the event of an overdose , the patient should be closely monitored and symptomatic supportive treatment as needed .'","b'in the event of atorvastatin for an overdose , the patient should be closely monitored and symptomatic supportive treatment as needed .'","b'in the event of an overdose , the patient should be closely monitored and symptomatic supportive treatment given as needed .'"
1349,b'alkohol f\xc3\xbchrt zu einem anstieg der abacavir-konzentration in ihrem blut .',"b'alcohol , results in an increase in abacavir-konzentration in your blood .'","b'alcohol , the increase in , patients an increase in all energy load caused as is .'",b'alcohol results in an increase in abacavir concentrations in your blood .'
1350,b'proquad sollte bei personen mit krampfanf\xc3\xa4llen oder zerebralen sch\xc3\xa4digungen in der eigen- oder familienanamnese mit vorsicht angewendet werden .',"b'proquad should be administered with caution to subjects with convulsions , or in the eigen- a family history of long qt syndrome .'","b'proquad should be administered with caution section increases , or in the microscope began jaundice .'",b'proquad should be administered with caution to subjects with convulsions in their own or family history of long qt syndrome .'
1351,"b'die liprolog-reihe umfasst schnell wirkende insulinl\xc3\xb6sungen ( liprolog ) , l\xc3\xa4nger wirkende insulinsuspensionen ( liprolog basal ) und kombinationen davon in verschiedenen verh\xc3\xa4ltnissen ( liprolog mix ) : \xe2\x80\xa2 liprolog : insulin lispro-l\xc3\xb6sung ; \xe2\x80\xa2 liprolog basal : insulin lispro-protaminsuspension ; \xe2\x80\xa2 liprolog mix25 :'","b""the liprolog-reihe the 3 ' -sulphoxide is comprised of fast-acting insulin solutions ( liprolog ) , longer-acting and insulin suspensions ( liprolog basal ) and in a variety of 461 ( liprolog mix ) : \xe2\x80\xa2 liprolog : insulin lispro solution ; \xe2\x80\xa2 liprolog basal : insulin lispro protamine suspension ; \xe2\x80\xa2 liprolog mix25 :""","b'the plasmaprotein half , solutions of fastacting dilute labelled , celvapan filmcoated cartridge , celvapan may human insulin devices , , mg , diluted insulin preparations , celvapan of fastacting human diluted is taken insulin solutions , cyanokit insulin solutions . are the neospect state , celvapan ml preparations is'","b'the liprolog range is comprised of fast-acting insulin solutions ( liprolog ) , longer-acting and insulin suspensions ( liprolog basal ) and in combinations in various ratios ( liprolog mix ) : \xe2\x80\xa2 liprolog : insulin lispro solution ; \xe2\x80\xa2 liprolog basal : insulin lispro protamine suspension ; \xe2\x80\xa2 liprolog mix25 :'"
1352,"b'nebenwirkungen , die aus spontanmeldungen nach markteinf\xc3\xbchrung von tygacil stammen , und deren h\xc3\xa4ufigkeit nicht eingeordnet werden kann , werden in die h\xc3\xa4ufigkeitskategorie "" nicht bekannt "" eingestuft .'","b'adverse reactions from post-marketing spontaneous reports with tygacil for which the frequency cannot be estimated , and is categorized as not known .'","b'adverse reactions from postmarketing pressure reports with kinzalmono for which the frequency cannot be estimated , and is flow as not known .'",b'adverse reactions from post-marketing spontaneous reports with tygacil for which the frequency cannot be estimated are categorized as not known .'
1353,b'nicht \xc3\xbcber 30 \xc2\xb0 c lagern .',b'do not store above 30 \xc2\xb0 c.',b'do not store above c .',b'do not store above 30 \xc2\xb0 c.'
1354,"b'falls der patient eine reichhaltige mahlzeit zu sich genommen hat , sollte er vor dem test sechs stunden lang n\xc3\xbcchtern bleiben .'","b'if the patient misses a reichhaltige meal , should be administered prior to the test for six hours fasting .'","b'if the patient come a sulfuric meal , opened over t .'","b'if the patient has had a large meal , they should fast for siy hours prior to the test .'"
1355,b'62 durchfall einschlie\xc3\x9fen . ebenso wurde gelegentlich \xc3\xbcber f\xc3\xa4lle von erniedrigtem blutdruck berichtet ; in sehr seltenen f\xc3\xa4llen f\xc3\xbchrte dies zu ohnmachtsanf\xc3\xa4llen .',"b'62 diarrhoea have also occasionally been cases of low blood pressure have been reported ; in very rare cases , this resulted in fainting .'",b'diarrhoea have also occasionally been cases of low blood pressure have been reported in respiratory cells .',"b'62 diarrhoea included . cases of low blood pressure have been reported ; in very rare cases , this resulted in fainting .'"
1356,b'diazepam scheint die pharmakokinetischen parameter von venlafaxin oder o-desmethylvenlafaxin nicht zu beeinflussen .',b'diazepam appears to be the pharmacokinetic parameters of venlafaxine or o-desmethylvenlafaxine .',b'tuberculin achieve systemic acid level design',b'diazepam appears to be the pharmacokinetic parameters of venlafaxine or o-desmethylvenlafaxine .'
1357,b'in glubrava sind zwei antidiabetika mit einander erg\xc3\xa4nzenden wirkmechanismen zur verbesserung der blutzuckerkontrolle bei patienten mit typ 2 diabetes mellitus miteinander kombiniert : das zur klasse der thiazolidindione geh\xc3\xb6rende pioglitazon und das zur klasse der biguanide geh\xc3\xb6rende metforminhydrochlorid .',"b'in glubrava combines two antidiabetic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes : pioglitazone , a member of the thiazolidinedione class and metformin hydrochloride , a member of the biguanide .'","b'in glubrava lactic two antidiabetic agents with reichlichen colour . tamiflu between f proteins after study with type diabetes pioglitazone showed a pertussis of the menstruation against the prehemodialysis , a pertussis of the tropos class and metformin hydrochloride , a helicobacter of firstpass diseases .'","b'in glubrava , two antidiabetic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus are combined : pioglitazone , a member of the thiazolidinedione class , and metformin hydrochloride , a member of the biguanide class .'"
1358,b'nach verabreichung dieses pr\xc3\xa4parats sollte vor einer impfung mit attenuierten virus-lebendimpfstoffen ein abstand von drei monaten eingehalten werden .',b'after administration of this product should be prior to vaccination with attenuated live attenuated virus vaccines a period of three months before commencement of treatment .',b'after administration of this product should be prior to vaccination with proton attenuated virus vaccines a period measurement of three months before commencement of the normal cleavage scheme a cannula milk .',b'after administration of this product an interval of three months should be observed before commencement of treatment a vaccination with an attenuated virus vaccine .'
1359,"b'in diesen studien erhielten kaninchen orale gaben von 3 , 10 und 20 mg / kg / tag .'","b'in these studies , rabbits were administered 3 , 10 and 20 mg / kg / day .'","b'in these studies , rabbits . of gender of doses to excreted as respectively kg day .'","b'in these studies , rabbits were administered 3 , 10 and 20 mg / kg / day .'"
1360,"b'eine fl\xc3\xbcssige darreichungsform sowohl f\xc3\xbcr lamivudin als auch f\xc3\xbcr zidovudin steht f\xc3\xbcr die behandlung von patienten zur verf\xc3\xbcgung , die die tabletten nicht schlucken k\xc3\xb6nnen .'",b'a formulation for both lamivudine and zidovudine for the treatment of patients who are unable to swallow tablets .',b'a reyataz for both lamivudine and zidovudine for the treatment of patients who are unable to swallow tablets .',b'a liquid formulation for both lamivudine and zidovudine for the treatment of patients who are unable to swallow tablets .'
1361,"b'es ist als runde , wei\xc3\x9fe tabletten ( 20 mg ) erh\xc3\xa4ltlich .'","b'it is available as white , round tablets ( 20 mg ) .'","b'it is available as white , round tablets mg .'","b'it is available as white , round tablets ( 20 mg ) .'"
1362,"b'je fr\xc3\xbcher eine frau in die wechseljahre kommt , desto h\xc3\xb6her ist ihr risiko f\xc3\xbcr eine osteoporose .'","b'the earlier a woman in the menopause , sooner their risk for osteoporosis .'",b'the vogtkoyanagiharada randomized in the menopause of administration of a slight platelet for osteoporosis .',"b'the earlier a woman reaches menopause , sooner their risk for osteoporosis .'"
1363,"b'in sehr hohen dosen wurde sowohl bei der ratte als auch beim pavian eine schlechte magenvertr\xc3\xa4glichkeit beobachtet ( gastritis , magenschleimhauterosionen und / oder erbrechen ) .'","b'at very high doses , has been observed in both the rat and rat and baboon ( gastritis , gastric erosions and / or vomiting ) .'","b'at very high doses , has been observed in both the historical and flushed sensitive and or vomiting .'","b'very high doses in both the rat and rat and baboon resulted in a poor stomach tolerability ( gastritis , gastric erosions and / or vomiting ) .'"
1364,"b'das gesamt\xc3\xbcberleben betrug im median 10,9 monate bei anwendung einer capecitabin-haltigen therapie und 9,6 monate bei anwendung einer 5-fu-haltigen therapie .'",b'the median overall survival was 10.9 months in the presence of capecitabin-haltigen therapy and 9.6 months in the presence of 5-fu-haltigen therapy .',b'the median overall survival was . months in the presence of deaths therapy .',b'the median overall survival was 10.9 months with the use of a therapy containing capecitabine and 9.6 months with the use of therapy containing 5-fluorouracil .'
1365,b'simulect wird in zwei injektionen verabreicht .',b'simulect is given in two injections .',b'simulect is given in two injections .',b'simulect is given in two injections .'
1366,b'duloxetin wird als ein einzelnes enantiomer angewendet .',b'duloxetine is used to treat other active compounds .',b'duloxetine is used to be substituted produced by them .',b'duloxetine is used to treat other active compounds .'
1367,"b'vorbereitung der infusion : unmittelbar nach der rekonstitution muss das produkt mit 0,9 % -iger ( 9 mg / ml ) natriumchloridl\xc3\xb6sung f\xc3\xbcr injektionszwecke auf 100 ml weiter verd\xc3\xbcnnt werden .'","b'preparing the infusion : use immediately after reconstitution , the product must be ( 0.9 % ) solution for injection of sodium chloride 9 mg / ml sodium chloride solution for further diluted to 100 ml .'","b'preparing the infusion . months at both the intravenous storage , the infusion use between the infusion instruction in reconstitution , the product must be see injections ml ml sodium chloride solution for further diluted to ml .'","b'preparing the infusion : immediately after reconstitution , the product must be further diluted with 0.9 % ( 9mg / ml ) sodium chloride solution for injection in 100 ml .'"
1368,b'der hauptmetabolit von ertapenem entsteht durch dehydropeptidase-i-vermittelte hydrolyse des beta-laktam-ringes .',"b'the major metabolite of ertapenem penicillin- dehydropeptidase-i-vermittelte , k172 , beta-laktam-ringes .'","b'the major metabolite of hepatic diphosphate act the spray , reduced medium have secure are reduced or squeeze nonthermal enzymatic side of sachets des that where a matrix to the vial therapy .'",b'the major metabolite of ertapenem occurs by dehydropeptidase-i-mediated hydrolysis of beta-lactam rings .'
1369,"b'die folgenden nebenwirkungen wurden bei patienten mit einer tarceva monotherapie und bei patienten , die tarceva zusammen mit einer chemotherapie erhielten , beobachtet .'",b'the following adverse reactions have been observed in patients with tarceva as a single agent and in patients receiving tarceva with chemotherapy .',b'the following adverse reactions have been observed in patients with tarceva as mycophenolat test in patients receiving tarceva with chemotherapy .',b'the following adverse reactions have been observed in patients treated with tarceva monotherapy and in patients receiving tarceva with chemotherapy .'
1370,b'alle endpunkte erreichten f\xc3\xbcr hpv-16 statistische signifikanz .',b'all endpoints reached statistical significance for hpv-16 .',b'all carcinogenicity in mind to the olanzapine toxic .',b'all endpoints reached statistical significance for hpv 16 .'
1371,b'aranesp 30 mikrogramm injektionsl\xc3\xb6sung in einem vorgef\xc3\xbcllten injektor .',b'aranesp 30 micrograms solution for injection in a pre-filled pen .',b'aranesp micrograms solution for injection in a prefilled pen .',b'aranesp 30 micrograms solution for injection in a pre-filled pen .'
1372,b'amitraz ist ein formamidinderivat und wirkt akarizid .',b'amitraz formamidinderivat and works flash-melt .',b'hands pharmamatch paraffin with the legs muscle derivitaves .',b'amitraz formamidinderivat and effects acaricide .'
1373,"b'die folgende anleitung erkl\xc3\xa4rt , wie betaferon f\xc3\xbcr die anwendung zubereitet wird und wie sie betaferon selbst injizieren .'",b'the following instructions how to prepare betaferon for use and how to inject betaferon yourself .',b'the following instructions before betaferon for use and how to inject fructose yourself .',b'the following instructions how to prepare betaferon for use and how to inject betaferon yourself .'
1374,b'die gleichzeitige anwendung von efavirenz und atazanavir plus ritonavir kann zu einer erh\xc3\xb6hten efavirenz- exposition und damit einer verminderten vertr\xc3\xa4glichkeit von efavirenz f\xc3\xbchren .',b'co-administration of efavirenz and atazanavir plus ritonavir may result in increased efavirenz exposure and may lead to a decreased tolerability of efavirenz .',b'coadministration of efavirenz and atazanavir plus ritonavir may result in increased efavirenz exposure and may lead to a decreased tolerability of efavirenz .',b'co-administration of efavirenz and atazanavir plus ritonavir may result in increased efavirenz exposure and may lead to a decreased tolerability of efavirenz .'
1375,b'durchstechflasche mit der aufgel\xc3\xb6sten injektionsl\xc3\xb6sung .',b'vial with the solvent for solution for injection .',b'vial with the epar for solution for injection .',b'vial with the solvent for solution for injection .'
1376,"b'klinische wirksamkeit in einer kontrollierten klinischen studie wurde eine pdt + om ( omeprazol ) -patientengruppe ( n = 183 ) mit einer gruppe von patienten ( n = 70 ) , die om allein erhielt , verglichen .'","b'clinical efficacy in a controlled clinical trial , pdt + om ( omeprazole ) patient group ( n = 183 ) to a group of patients ( n = 70 ) who received om alone .'",b'clinical efficacy safety in a controlled study grade were tested who received equine alone .',"b'clinical efficacy . in a controlled clinical trial , a pdt + om ( omeprazole ) patient group ( n = 183 ) was compared with a a group of patients ( n = 70 ) who received om alone .'"
1377,b'entfernen sie die kan\xc3\xbclenkappe .',b'remove the handled .',b'remove the recurrence of your breathe dose',b'remove the needle cover .'
1378,b'der zeitabstand zwischen dem pneumokokken-konjugatimpfstoff ( prevenar ) und dem 23-valenten pneumokokken-polysaccharidimpfstoff sollte nicht weniger als 8 wochen betragen .',b'the interval between the pneumococcal conjugate vaccine ( prevenar ) and the 23-valent pneumococcal pneumokokken-polysaccharidimpfstoff should not be less than 8 weeks .',b'the interval exposure to patients .',b'the interval between the pneumococcal conjugate vaccine ( prevenar ) and the 23-valent pneumococcal polysaccharide vaccine should not be less than 8 weeks .'
1379,b'lansoprazol-ratiopharm hat geringen oder m\xc3\xa4\xc3\x9figen einfluss auf die verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen .',b'lansoprazol-ratiopharm has minor or moderate influence on the ability to drive and use machines .',b'pimecrolimus has be diagnosed influence on the ability to drive placebocontrolled epilepsy .',b'lansoprazol-ratiopharm has minor or moderate influence on the ability to drive and use machines .'
1380,b'die bindung von retapamulin an humane plasmaproteine betr\xc3\xa4gt ungef\xc3\xa4hr 94 % .',"b'binding of retapamulin to human plasma proteins is approximately 94 % , respectively .'","b'binding of crushed to human plasma proteins is approximately , respectively .'",b'binding of retapamulin to human plasma proteins is approximately 94 % .'
1381,b'dauer der behandlung - erneute therapie vorhersagbarkeit f\xc3\xbcr ein anhaltendes virologisches ansprechen :',b'duration of treatment - retreatment predictability of sustained virological response :',"b'duration of treatment programme , nicotinic and g of sustained virological response'",b'duration of treatment - retreatment predictability of sustained virological response :'
1382,b'verwenden sie es nicht in insulinpumpen oder anderen infusionspumpen . hierf\xc3\xbcr gibt es spezielle insulin - zubereitungen .',b'do not use it in insulin pumps or other infusion pumps - special insulin is an insulin - .',b'do not use it in insulin pumps or other infusion or the infusion pumps which are considered .',b'do not use it in insulin pumps or other infusion pumps . there is special insulin for this .'
1383,b'\xe2\x80\xa2 setzen sie die gro\xc3\x9fe \xc3\xa4u\xc3\x9fere schutzkappe der injektionsnadel wieder auf und schrauben sie die injektionsnadel ab \xe2\x80\xa2 entsorgen sie diese sorgf\xc3\xa4ltig .',b'\xe2\x80\xa2 put the big outer needle cap and unscrew the needle from \xe2\x80\xa2 dispose of it carefully .',"b'put the big injection outer needle , gently clean the needle from it must be stick the powder for the needle from dispose of it .'",b'\xe2\x80\xa2 put abck on the big outer needle cap and unscrew the needle \xe2\x80\xa2 dispose of it carefully .'
1384,"b'o tuberkulose ( tbc ) informieren sie ihren arzt / ihre \xc3\x84rztin , wenn sie eine tuberkulose hatten .'",b'o \xce\xa3 ( ) tell your doctor if you have had tuberculosis .',b'ratiograstim of your doctor if you have had tuberculosis .',b'tell your doctor if you have had tuberculosis .'
1385,"b'onsenal ist ein arzneimittel , das den wirkstoff celecoxib enth\xc3\xa4lt .'",b'onsenal is a medicine containing the active substance celecoxib .',b'onsenal is a medicine containing the active substance antagonist .',b'onsenal is a medicine containing the active substance celecoxib .'
1386,"b'\xc3\x9cberpr\xc3\xbcfen sie vor der anwendung , ob die l\xc3\xb6sung v\xc3\xb6llig klar ist .'","b'before administration , the solution is fully clear .'","b'before administration , the solution is fully clear .'","b'before administration , the solution is fully clear .'"
1387,"b'die metaboliten weisen in vitro eine antimikrobielle aktivit\xc3\xa4t auf , die allerdings deutlich niedriger als die der muttersubstanz ist .'",b'metabolites indicate that in vitro antimicrobial activity but who have much lower than the levels of the parent compound .',b'metabolites resolved that in vitro pt activity .',b'metabolites indicate antimicrobial activity in vitro that is not much lower than the levels of the parent compound .'
1388,"b'da jedoch eine anpassung der zidovudin-dosis erforderlich sein kann , wird bei patienten mit schweren leberfunktionsst\xc3\xb6rungen die anwendung von lamivudin- und zidovudin-haltigen monopr\xc3\xa4paraten empfohlen .'","b'however , dosage adjustment of zidovudine may be required , it is recommended that in patients with severe hepatic impairment , the use of lamivudine and zidovudin-haltigen monopr\xc3\xa4paraten .'","b'however , dosage adjustment of zidovudine may be required , it is recommended that in patients with severe hepatic impairment , the use of lamivudine and inactivted onceeverytwoweeks .'","b'however , dosage adjustment of zidovudine may be required , it is recommended that in patients with severe hepatic impairment , the use of lamivudine and zidovudin-containing mono-drugs .'"
1389,"b'eine tablette enth\xc3\xa4lt 2,5 mg olanzapin .'",b'each tablet contains 2.5 mg olanzapine .',b'each tablet contains . mg olanzapine .',b'each tablet contains 2.5 mg olanzapine .'
1390,"b'der prim\xc3\xa4re wirksamkeitsendpunkt war eine kombination aus einem gesicherten , symptomatischen , nicht- t\xc3\xb6dlichen rezidiv einer vte und t\xc3\xb6dlichen vte bis zum tag 97.'","b'the primary efficacy endpoint was a combination of confirmed symptomatic recurrent non-fatal histology , fatal relapse of vte and non-fatal vte and fatal vte reported up to day 97 .'","b'the primary efficacy endpoint was a combination of confirmed symptomatic inhalation of confirmed symptomatic recurrent study , those in the antiretroviral pathogens or were performed into around less serum factors vs .'",b'the primary efficacy endpoint was a combination of confirmed symptomatic non-fatal relapse of vte and fatal vte reported up to day 97 .'
1391,"b'das pulver und das l\xc3\xb6sungsmittel sind in einem zwei-kammer-zylinder aus typ-i-flintglas enthalten , wobei diese durch einen brombutylgummikolben abgetrennt sind .'","b'the powder and solvent are both contained in a two-chamber cartridge , type i flint glass , separated by a bromobutyl rubber plunger .'",b'the powder with laminated and solvent are both contained in a dissolution of thickness with exocytosis by a bromobutyl rubber tubes .',"b'the powder and solvent are both contained in a two-chamber cartridge , type i flint glass , separated by a bromobutyl rubber plunger .'"
1392,"b'die entscheidung zur anwendung rekombinanter erythropoetine sollte auf einer nutzen-risiko-abw\xc3\xa4gung unter einbeziehung des einzelnen patienten beruhen , unter ber\xc3\xbccksichtigung der jeweils spezifischen klinischen umst\xc3\xa4nde .'",b'the decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the type of tumour and its stage ; the in .',"b'the decision is injected with embryofoetal pestivirus should be based on a sshaped assessment with the tube stimulus , mumps .'","b'the decision to administer recombinant erythropoietins should be based on a benefit-risk assessment for of the individual patient , under consideration of the respective , specific , clinical circumstances .'"
1393,"b'die ersten symptome einer ovariellen \xc3\x9cberstimulation sind unterleibsschmerzen , die auch in verbindung mit \xc3\x9cbelkeit , erbrechen und gewichtszunahme auftreten k\xc3\xb6nnen .'","b'the first symptoms of ovarian hyperstimulation are pain in the lower abdominal region , possibly in combination with nausea , vomiting and weight gain can occur .'","b'the first symptoms of while ovarian bilirubin tract treament had act in concomitant therapy , possibly in combination with nausea , vomiting and weight gain can occur .'","b'the first symptoms of ovarian hyperstimulation are pain in the lower abdominal region , possibly in combination with nausea , vomiting and weight gain can occur .'"
1394,b'alle histologischen befunde waren benigne .',b'all histological findings were benign .',b'all histological findings were voluntarily are voluntarily .',b'all histological findings were benign .'
1395,b'laboruntersuchungen in kontrollierten klinischen studien waren klinisch relevante ver\xc3\xa4nderungen von standardlaborparametern selten mit der verabreichung von rasilez assoziiert .',"b'laboratory findings in controlled clinical trials , clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of rasilez .'",b'laboratory serum changes in myocardial laboratory parameters were made associated with the administration of rasilez .',b'laboratory findings in controlled clinical trials . clinically relevant changes in standard laboratory parameters were rarely associated with the administration of rasilez .'
1396,b'bitte lesen sie die anweisungen sorgf\xc3\xa4ltig und befolgen sie sie schritt f\xc3\xbcr schritt .',b'please read the instructions carefully and follow them step by step .',b'please read the instructions carefully and follow them step by step .',b'please read the instructions carefully and follow them step by step .'
1397,b'nach dem einlegen der patrone in den pen muss die suspension bei einer lagerung unterhalb von + 30 \xc2\xb0 c innerhalb von 28 tagen aufgebraucht werden .',"b'after insertion of the cartridge in a pen , the suspension should be used in 30 \xc2\xb0 c within 28 days when stored below .'","b'after insertion . the cartridge in a pen , the suspension should be used in c within injection with any second .'","b'after insertion of the cartridge in a pen , the suspension should be used within 28 days when stored under 30 \xc2\xb0 c.'"
1398,b'die pharma- kokinetik von sildenafil bei patienten mit schwerer leberfunktionsst\xc3\xb6rung wurde nicht untersucht .',b'the pharma- kokinetik of sildenafil in patients with severe hepatic impairment have not been studied .',b'the total msmethoden of sildenafil in patients with severe hepatic impairment have not been studied .',b'the pharmacokinetic of sildenafil in patients with severe hepatic impairment has not been studied .'
1399,b'- dieses arzneimittel wurde ihnen pers\xc3\xb6nlich verschrieben .',b'- this medicine has been prescribed for you .',b'this medicine has been prescribed for your ingredients',b'- this medicine has been prescribed for you .'
1400,b'inaktiviertes felines panleukopenievirus injektionsl\xc3\xb6sung katze ( stamm cu4 ) :',b'inactivated feline panleukopenia virus solution for injection ( cu4 ) :',b'screw scored virus solution for injection retapamulin',b'inactivated feline panleukopenia virus solution for injection ( cu4 strain ) :'
1401,b'es liegen keine daten zur kombination von atripla und anderen antiretroviralen wirkstoffen vor .',b'there are no data on the combination of atripla in combination with other antiretroviral agents .',b'there are no data on the combination of atripla in combination with other antiretroviral agents .',b'there are no data on the combination of atripla with other antiretroviral agents .'
1402,b'leichte bis mittelschwere alopezie mit einer mittleren dauer von etwa 26 tagen .',b'mild to moderate alopecia with a mean duration of approximately 26 days .',b'incidence of approximately infusion of approximately days .',b'mild to moderate alopecia with a mean duration of approximately 26 days .'
1403,"b'es ist nicht bekannt , ob zoledrons\xc3\xa4ure in die muttermilch \xc3\xbcbergeht .'",b'it is not known whether zoledronic acid is excreted in human milk .',b'it is not known whether zoledronic acid is excreted in human milk .',b'it is not known whether zoledronic acid is excreted in human milk .'
1404,"b'orales topotecan in kombination mit bsc zeigte eine statistisch signifikante verbesserung bez\xc3\xbcglich des gesamt\xc3\xbcberlebens im vergleich zu bsc allein ( p = 0,0104 [ log-rank ] ) .'",b'oral topotecan plus bsc group had a statistically significant improvement in overall survival compared with the bsc alone group ( p = 0.0104 ) .',b'oral topotecan is calcium doserelated serum or objective activity compared with the blood rate .',b'oral topotecan plus bsc had a statistically significant improvement in overall survival compared with the bsc alone group ( p = 0.0104 [ log-rank ] ) .'
1405,"b'im k\xc3\xbchlschrank lagern ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) , nicht in der n\xc3\xa4he eines gefrierfachs .'","b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) , not close to waistband or belt and the gefrierfachs .'",b'store in a refrigerator c c to the training .',"b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) , not close to the freezer .'"
1406,b'vorbereitung des produkts vor dem gebrauch :',b'preparation of the product before use :',b'preparation of the product before use',b'preparation of the product before use :'
1407,b'aivlosin sollte daher nur nach entsprechender nutzen-risiko-bewertung durch den behandelnden tierarzt angewendet werden .',b'aivlosin should therefore only be used after benefit / risk assessment by the veterinarian .',b'aivlosin should not be checked after benefit risk assessment by the veterinarian .',b'aivlosin should therefore only be used after benefit / risk assessment by the veterinarian .'
1408,b'sch\xc3\xa4tzungen berechnet gem\xc3\xa4\xc3\x9f risikoverh\xc3\xa4ltnis ( hazard ratio ) 2 ) letztes ansprechen des tumors wie vom pr\xc3\xbcfarzt beurteilt .',"b'it is estimated that calculated according to hazard ratio ( 2 ) letztes , partial or complete tumour response , as judged by the study investigator .'",b'it is concentration references with longtermn allopurinol days a tissue inhibitors .',b'it is estimated that calculated according to hazard ratio . last response of the tumour as was judged by the study investigator .'
1409,"b'die behandlung mit mabcampath sollte von einem arzt beaufsichtigt werden , der erfahrung in der anwendung von krebsmedikamenten besitzt .'",b'mabcampath treatment should be supervised by a doctor who has experience in the use of anti-cancer medicines .',b'mabcampath on the doctor who has experience approximately .',b'mabcampath treatment should be supervised by a doctor who has experience in the use of anti-cancer medicines .'
1410,"b'fieber ohne positiven kulturbefund tritt nach der behandlung mit cladribin bei 10-40 % der patienten mit haarzell-leuk\xc3\xa4mie auf , ist dagegen bei patienten mit anderen neoplastischen st\xc3\xb6rungen nur selten zu beobachten .'","b'fever without positive kulturbefund occurs after treatment with cladribine in 10-40 % of patients with hairy cell leukaemia , however , in patients with other useable only rare disorders .'","b'fever without positive dvt except after treatment with cladribine in of patients with mps cell leukaemia , however , in patients with other fetal renal problems .'",b'fever without positive cultivation findings occurs after treatment with cladribine in 10-40 % of patients with hairy cell leukaemia should be observed in patients with other useable only rare disorders .'
1411,b'ausscheidung etwa 71 % der rotigotindosis werden \xc3\xbcber den urin und ein kleinerer anteil von ca. 23 % \xc3\xbcber die f\xc3\xa4zes ausgeschieden .',"b'elimination approximately 71 % of the rotigotindosis is excreted in the urine , and the rate of approximately 23 % in the faeces .'","b'the sirolimus clearance is excreted in the urine , and the rate and the rate .'",b'elimination approximately 71 % of the rotigotine dose is excreted in the urine and a lesser portion of approximately 23 % in the faeces .'
1412,"b'beim menschen geh\xc3\xb6ren anf\xc3\xa4lle , schl\xc3\xa4frigkeit , \xc3\x9cbelkeit , tachykardie und erbrechen zu den h\xc3\xa4ufigsten symptomen bei \xc3\x9cberdosierung .'","b'in humans , injection-site seizures , somnolence , nausea , tachycardia , and vomiting , the most common symptoms in overdose .'","b'in humans , of antibody disoproxil barbiturates , headache , and vomiting , the most common side of overdose .'","b'in humans , injection-site seizures , somnolence , nausea , tachycardia , and vomiting , the most common symptoms in overdose .'"
1413,"b'einige der symptome dieses syndroms sind : unerkl\xc3\xa4rliches fieber , schwitzen , beschleunigter herzschlag , durchfall , ( unkontrollierbare ) muskelkontraktionen , sch\xc3\xbcttelfrost , \xc3\xbcbersteigerte reflexe , ruhelosigkeit , stimmungsschwankungen und ohnmacht .'","b'some of the symptoms of this syndrome are : inexplicable fever , sweating , increased heart rate , diarrhoea , ( ) muscle contractions , shivering , overactive reflexes , restlessness , mood changes , and unconsciousness .'","b'some of the symptoms of this syndrome are similar fever , sweating , increased heart rate , diarrhoea , that be killed , dietary host internal milk should require appetite , muscle spasms , myotonie , dipyridamole , blistering abnormalities , have cultures , a moderated syndrome , muscle itp'","b'some of the symptoms of this syndrome are : inexplicable fever , sweating , increased heart rate , diarrhoea ( uncontrolable ) muscle contractions , shivering , overactive reflexes , restlessness , mood changes , and unconsciousness .'"
1414,b'eine gleichzeitige gabe von 10 mg ketamin / kg mit 40 mikrogramm dexmedetomidin / kg kann zu tachykardie f\xc3\xbchren .',b'concomitant administration of 10 mg ketamine / kg with 40 micrograms dexmedetomidine / kg may lead to tachycardia .',b'concomitant administration of mg ketamine kg with micrograms dexmedetomidine kg may lead to tachycardia .',b'concomitant administration of 10 mg ketamine / kg with 40 micrograms dexmedetomidine / kg may lead to tachycardia .'
1415,"b'schwindel augenerkrankungen : allergische konjunktivitis , katarakt , dunkelf\xc3\xa4rbung der wimpern , verst\xc3\xa4rkte irispigmentierung , blepharospasmus , retraktion des augenlids , netzhautblutung , uveitis .'","b'eye disorders : dizziness , allergic conjunctivitis , cataract , darkening of the eyelashes , increased iris pigmentation , blepharospasm , eyelid , retinal haemorrhage , uveitis .'","b'eye disorders dizziness , medicinal programme , lmethionine , lmethionine of the antagonistic , increased stages called a neural sedation , pericardial , focal installation levels , pericardial , cart , oliguria , mumps , lisinopril , proteinuria , purified discharge , beta abnormalities , isolated joints .'","b'eye disorders : dizziness , allergic conjunctivitis , cataract , darkening of the eyelashes , increased iris pigmentation , blepharospasm , eyelid , retinal haemorrhage , uveitis .'"
1416,b'ihr arzt wird ihren gesundheitszustand \xc3\xbcberwachen und je nach ihrer reaktion auf die behandlung m\xc3\xb6glicherweise die dosis ver\xc3\xa4ndern .',b'your doctor will monitor your health and depending on your response to treatment as soon as possible .',b'your doctor will monitor your health and depending on your response to treatment as soon as possible .',b'your doctor will monitor your health and may adjust your dose depending on your response to treatment .'
1417,"b'abh\xc3\xa4ngig von ihrem ansprechen kann ihr arzt die dosis auf 4 mg / kg herabsetzen und dann , falls angemessen , wieder auf 8 mg / kg erh\xc3\xb6hen .'","b'depending on your response , your doctor may reduce the dose to 4 mg / kg and then , if appropriate , again 8 mg / kg .'","b'depending on your response , your doctor may a dose to group kg and then , if appropriate , again mg kg below , prior mg kg and then , if appropriate a dose to mg kg no adjusted and then , if appropriate , again mg kg and then'","b'depending on your response , your doctor may reduce the dose to 4 mg / kg and then , if appropriate , increase again to 8 mg / kg .'"
1418,"b'bei patienten mit diabetes , \xc3\xbcbergewichtigen patienten sowie patienten im alter von \xc3\xbcber 65 jahren f\xc3\xbchrte tekturna ebenfalls dazu , dass der blutdruck sank .'","b'in patients with diabetes , patients who were overweight , and those who were over 65 years of age , resulted in tekturna also reduced blood pressure .'","b'in patients with diabetes , patients who were pretreated to .'","b'in patients with diabetes , patients who were overweight , and those who were over 65 years of age , tekturna resulted in reduced blood pressure .'"
1419,"b'interferone sind nat\xc3\xbcrliche , vom k\xc3\xb6rper gebildete substanzen , die helfen , angriffe von au\xc3\x9fen , etwa infektionen durch viren , zu bek\xc3\xa4mpfen .'","b'interferons are natural , or by the body to help it fight against attacks , infections caused by viruses , .'","b'interferons are substances , that well as a thickness of breath lesion pain sensitivity of the body to help it base against exercise , infections caused by yeast , them caused by viruses , .'","b'interferons are natural substances built by the body to help it fight against attacks , infections caused by viruses .'"
1420,b'auf reisen muss ihr nutropinaq pen in einer k\xc3\xbchltasche aufbewahrt werden .',"b'when travelling , your nutropinaq pen should be kept in a cooler .'","b'when use , your nutropinaq pen should be kept in a antidementia .'","b'when travelling , your nutropinaq pen should be kept in a cooler .'"
1421,b'wie wirkt altargo ?',b'how does altargo work ?',b'how does altargo work ?',b'how does altargo work ?'
1422,b'vedaprofen enth\xc3\xa4lt ein asymmetrisches kohlenstoffatom und ist daher ein racemisches gemisch des ( + ) und des ( - ) enantiomers .',"b'vedaprofen contains an asymmetric carbon atom , and therefore is meta ( 9 ) and the projection ( 11 ) .'",b'cyproheptadin contains an injectable doselimiting absorbtion with slow amounts when well as described by the inscription follicles of level .',"b'vedaprofen contains an asymmetric carbon atom , and therefore is a racemic mixture of a ( + ) enantiomer and a ( - ) enantiomer .'"
1423,"b'wird die patientin w\xc3\xa4hrend der behandlung mit xeloda schwanger , muss auf die m\xc3\xb6gliche gef\xc3\xa4hrdung des feten hingewiesen werden .'","b'if the patient becomes pregnant during treatment with xeloda , the patient must be advised of the potential for potentially of the foetus .'","b'if the patient using pregnant people with xeloda , the patient , the patient should be advised must be advised in patients , the patient , you to see treatment with xeloda , the patient must be with januvia .'","b'if the patient becomes pregnant during treatment with xeloda , the possible danger to the foetus must be referred to .'"
1424,b'unerw\xc3\xbcnschte arzneimittelwirkungen wie somnolenz und schwindel wurden bei mit intelence behandelten patienten mit \xc3\xa4hnlichen inzidenzen beobachtet wie unter placebo ( siehe abschnitt 4.8 ) .',b'adverse drug reactions such as somnolence and dizziness have been observed in patients treated with intelence with similar incidences of placebo ( see section 4.8 ) .',b'adverse drug reactions such as somnolence and dizziness have been observed in patients treated with no models of placebo see section . .',b'adverse drug reactions such as somnolence and dizziness have been observed in patients treated with intelence with similar incidences of placebo ( see section 4.8 ) .'
1425,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr ribavirin teva finden sie hier .',b'the full epar for avamys for ribavirin teva can be found here .',b'the full epar for ribavirin teva can be found here .',b'the full epar for avamys for ribavirin teva can be found here .'
1426,"b'- lokale reaktionen nach der anwendung dieses arzneimittels . diese reaktionen k\xc3\xb6nnen besonders dann auftreten , wenn die infusionsdauer 30 minuten oder weniger betr\xc3\xa4gt .'",b'- local reactions after administration of this medicine . these reactions may be particularly when the infusion time is 30 minutes or less .',"b'local reactions after administration of this medicine . these reactions , the infusion time is minutes or less .'","b'- local reactions after administration of this medicine . these reactions may occur , particularly when the infusion time is 30 minutes or less .'"
1427,"b'beschriebe n , genau eingehalten werden , um das potentielle risiko thromboembolischer ereignisse zu minimieren .'","b'beschriebe s closely , in order to minimise the potential risk of thromboembolic events .'",b'y s genderspecific dose and dark fighting from rainbow hormone reactions .',b'in order to minimise the potential risk of thromboembolic events .'
1428,"b'die zubereitung von gonal-f 79 300 i.e. / 0,50 ml ( 22 mikrogramm / 0,50 ml ) darf mit keinem weiteren beh\xc3\xa4ltnis gonal-f zusammen rekonstituiert werden .'",b'gonal-f gonal-f 300 iu / 0.50 ml ( 22 micrograms / 0.50 ml ) preparation must not be reconstituted with any other gonal-f container .',b'gonalf for iu . ml pack . ml preparation must not be reconstituted with any other gonalf d .',b'gonal-f 300 iu / 0.50 ml ( 22 micrograms / 0.50 ml ) preparation must not be reconstituted with any other gonal-f container .'
1429,b'die erfahrungen mit einer somatropin-behandlung bei patienten \xc3\xbcber 60 jahre sind beschr\xc3\xa4nkt .',b'experience with somatropin is limited in patients over 60 years of age .',b'moderate studies from toxic is limited related to monitor years of age .',b'experience with somatropin is limited in patients over 60 years of age .'
1430,b'hund : intraven\xc3\xb6se oder intramuskul\xc3\xa4re injektion katze : intramuskul\xc3\xa4re injektion lesen sie vor der anwendung die packungsbeilage .',b'dogs : intravenous or intramuscular use cats : intramuscular injection read the package leaflet before use .',b'dogs intravenous or two the package leaflet before use .',b'dogs : intravenous or intramuscular injection . cats : intramuscular injection . read the package leaflet before use .'
1431,b'die letzten vier ziffern bezeichnen das jahr .',b'the last four numbers indicate the year .',b'the last four numbers due to use .',b'the last four numbers indicate the year .'
1432,b'die pharmakokinetik von rfviia wurde unter verwendung des faktor vii-gerinnungs-assays bei 12 p\xc3\xa4diatrischen ( 2-12 jahre ) und 5 erwachsenen patienten ohne akute blutung untersucht .',b'the pharmacokinetics of rfviia was investigated in 12 paediatric ( 2 - 12 years ) and 5 adult patients in non bleeding state .',b'the pharmacokinetics of degenerative was investigated in paediatric years and adult patients in focal bleeding peak dose of neutralising haematological lymphoma scheme .',b'the pharmacokinetics of rfviia was investigated in 12 paediatric ( 2 - 12 years ) and 5 adult patients in non bleeding state .'
1433,b'41 \xe2\x80\xa2 wenn sie sichelzellan\xc3\xa4mie haben ;',b'41 \xe2\x80\xa2 if you have sickle cell anaemia ;',b'if you have continued and transporting cell common risk of since least harmful effects',b'41 \xe2\x80\xa2 if you have sickle cell anaemia ;'
1434,b'sonstige bestandteile siehe unter 6.1 .',"b'for excipients , see section 6.1 .'","b'for excipients , see section . .'","b'other active ingredients , see section 6.1 .'"
1435,"b'die hilfsstoffe , die in den formulierungen des arzneimittels und den herstellungsprozessen verwendet werden , sind standard f\xc3\xbcr die vorgeschlagenen darreichungsformen .'",b'the or any of the excipients in the formulations of the medicine and the herstellungsprozessen used are standard for the proposed dosage forms .',b'the or halflife of the excipients in the formulations of the characteristics of the medicine and refilling .',b'the excipients used in the formulation and production process of the medicine are standard for the proposed dosage forms .'
1436,b'die wirksamkeitsdaten stammen von 320 teilnehmenden patienten in der chronischen und 119 in der akzelerierten phase .',b'the efficacy results from the cox proportional hazards regression of 320 patients in chronic and 119 cp .',b'the efficacy results originate in exposure in glial and gx .',b'the efficacy results come from 320 patients in chronic and 119 cp .'
1437,"b'obwohl agranulozytose eine nur gelegentlich auftretende nebenwirkung dieses arzneimittels ist , ist es wichtig , dass ihr blut regelm\xc3\xa4\xc3\x9fig untersucht wird .'","b'although agranulocytosis is a uncommon side effects of this medicinal product , it is important that your blood will be checked regularly .'",b'although arrhythmia is a very general medicine in the in the past .',"b'although agranulocytosis is an uncommon side effects of this medicinal product , it is important that your blood will be checked regularly .'"
1438,"b'stillzeit es ist nicht bekannt , ob aliskiren beim menschen in die muttermilch ausgeschieden wird .'",b'lactation it is not known whether aliskiren is present in human milk .',b'lactation . it is not known whether aliskiren is present in human milk .',b'lactation : it is not known whether aliskiren is excreted in human milk .'
1439,b'nach subkutaner verabreichung von omnitrope lyophilisat und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung ergibt sich jedoch eine halbwertszeit von 3 stunden .',"b'after subcutaneous administration of omnitrope powder and solvent for solution for injection , a half-life of 3 hours is achieved .'","b'after subcutaneous administration of omnitrope powder and solvent for solution for injection , a halflife of hours necessary .'","b'subcutaneous administration of omnitrope lyophilisate and solvent for production of solution for injection , results in a half-life worth of 3 hours .'"
1440,b'es k\xc3\xb6nnen ebenso lokale reaktionen an der injektionsstelle auftreten .',b'it may also occur local reactions at the site of the injection .',b'it may also occur local reactions at the site of the injection .',b'local reactions at the site of the injection may also occur .'
1441,"b'natriumchlorid , l-histidin , polysorbat 80 , natriumborat und wasser f\xc3\xbcr injektionszwecke .'","b'sodium chloride , l-histidine , polysorbate 80 , sodium borate and water for injections .'","b'sodium chloride , combine , sodium lauryl and water for injections .'","b'sodium chloride , l-histidine , polysorbate 80 , sodium borate and water for injections .'"
1442,b'beim anfassen der durchstechflaschenhalterungen steril vorgehen .',b'the set of durchstechflaschenhalterungen sterile package .',b'the set mechanisms of malassezia solutions package package leaflet .',b'the set sterile of vial cups package .'
1443,"b'produkte , die derartige m\xc3\xa4ngel zeigen , m\xc3\xbcssen entsorgt werden .'","b', demonstrate that such triphenylmethane , must be discarded .'",b'pull charcoal position during gadoversetamide colour is peel as for swelling from direct to solid as discarded .',b'products demonstrating such deficiencies must be discarded .'
1444,"b'wenn eine dieser situationen auf sie zutrifft , fragen sie ihren arzt , bevor sie emselex einnehmen .'","b'if any of these apply to you , talk to your doctor before you take emselex .'","b'if any of these apply to you , talk to your doctor .'","b'if any of these apply to you , talk to your doctor before you take emselex .'"
1445,b'auf das zentralnervensystem wirkende arzneimittel :',b'based on the central nervous system and medicinal products :',b'based on the central nervous system and medicinal products',b'based on the central nervous system and medicinal products :'
1446,b'am 20. november 2002 erteilte die europ\xc3\xa4ische kommission eine genehmigung f\xc3\xbcr das inverkehrbringen von zavesca in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted a marketing the european union for zavesca on 20 november 2002 .',b'the european commission granted a marketing of the european commission granted life for zavesca on november .',b'the european commission granted a marketing marketing authorisation in the european union for zavesca on 20 november 2002 .'
1447,b'zur schmerzlinderung bei kolik .',b'for pain relief structure .',b'for pain relief .',b'for pain relief of colic .'
1448,b'die gleichzeitige anwendung von nifedipin und 100 mg acetylsalicyls\xc3\xa4ure hat keinen einfluss auf die wirkung von acetylsalicyls\xc3\xa4ure auf die thrombozytenaggregation oder die blutungszeit .',b'the concomitant use of nifedipine with 100 mg acetylsalicylic acid has no influence on the effect of aspirin on platelet aggregation and bleeding time induced by clopidogrel intake .',b'the concomitant use of nifedipine with mg acetylsalicylic acid has no influence on the effect of aspirin on platelet aggregation and bleeding bleeding against high .',b'the concomitant use of nifedipine with 100 mg acetylsalicylic acid has no influence on the effect of aspirin on platelet aggregation and bleeding time induced by clopidogrel intake .'
1449,b'in zwei studien wurde ambirix mit anderen impfstoffen gegen hepatitis a und b verglichen .',"b'in two studies , ambirix was compared with other vaccines against hepatitis a and b ) .'","b'in two studies , ambirix was compared with other vaccines against hepatitis a and b .'","b'in two studies , ambirix was compared with other vaccines against hepatitis a and b ) .'"
1450,"b'wie bei allen antihistaminika wird jedoch empfohlen , die gleichzeitige einnahme von alkohol zu meiden .'","b'as with all antihistamines , however , it is recommended to use of alcohol should be avoided .'","b'as with all them , however , it is recommended to use of alcohol should be avoided .'","b'as with all antihistamines , however , it is recommended the consumption of alcohol should be avoided .'"
1451,b'wenn eine dosis hbvaxpro 40 mikrogramm / ml vergessen wurde :',b'if a dose is missed hbvaxpro 40 micrograms / ml :',"b'if a dose is missed milky solution , the strength of mg'",b'if a dose is missed hbvaxpro 40 micrograms / ml :'
1452,"b'die patronen im umkarton aufbewahren , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'keep the cartridges in the outer carton in order to protect it from light .',b'keep the cartridges in the outer carton in order to protect it from light .',b'keep the cartridges in the outer carton in order to protect it from light .'
1453,b'30 gemisch dann mit dem rest des futtermittels gut zu vermischen . das f\xc3\xbctterungsarzneimittel kann dann pelletiert werden .',b'30 of the feeding stuff and mixed well . medicated feed may then be pelleted .',"b'of the feeding possible stuff according the forgotten dose , by persistent feed may then be for the the treatment for travelling . necessity of your anticoagulation .'",b'30 mix well with the rest of the feed . medicated feed may then be pelleted .'
1454,b'es wurden keine karzinogenit\xc3\xa4tsstudien mit cystagon durchgef\xc3\xbchrt .',b'no carcinogenicity studies with cystagon have been performed .',b'no carcinogenicity studies with cystagon have been performed .',b'no carcinogenicity studies with cystagon have been performed .'
1455,b'patienten mit nieren- oder leberfunktionsst\xc3\xb6rung es wurden keine studien an patienten mit klinisch relevanter nieren- oder leberfunktionsst\xc3\xb6rung durchgef\xc3\xbchrt .',b'patients with renal or hepatic impairment no studies have been conducted in patients with clinically relevant renal or hepatic impairment .',b'patients with renal or hepatic impairment .',b'patients with renal or hepatic impairment : no studies have been conducted in patients with clinically relevant renal or hepatic impairment .'
1456,b'intraven\xc3\xb6se bolusinjektion bei gebrauch einer nichtlinearen kontrastmittel-bildgebung in ruhe und unter belastung :',"b'intravenous bolus injection , trialkylaminoalkylamino or kontrastmittel-bildgebung in use at rest and during exercise :'","b'intravenous bolus injection , relieve alzheimer or casecontrol presented by making professionals containing the anamnesis .'",b'intravenous bolus injection for a non-linear contrast medium-imaging in use at rest and during exercise :'
1457,"b'2 es sollte aber beachtet werden , dass die inzidenz von schl\xc3\xa4frigkeit erh\xc3\xb6ht ist , wenn die tagesdosis 1,5 mg ( salzform ) \xc3\xbcberschreitet ( siehe kapitel 4.8 ) .'","b'2 it , it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg / day ( see section 4.8 ) .'",b'. to the incidence of somnolence occurs . mg day see section . .',b'2 it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg / day ( see section 4.8 ) .'
1458,"b'die kontraktilit\xc3\xa4t des herzmuskels und der glatten gef\xc3\xa4\xc3\x9fmuskulatur ist abh\xc3\xa4ngig vom einstrom extrazellul\xc3\xa4rer calciumionen in diese zellen , der \xc3\xbcber spezifische ionenkan\xc3\xa4le erfolgt .'","b'the contractility of the heart muscle and vascular smooth muscle depends on the ascomycetes of calcium ions into muscle these cells , specific block .'","b'the obverse of the heart muscle and shunt , which against the uterine smooth muscle tests on the advanced of calcium ions into muscle via a stimulating affinity .'","b'the contractility of the heart muscle and smooth vascular muscle depends on the ascomycetes of calcium ions in these cells , which are carried out along specific ion channels .'"
1459,"b'da nur begrenzte informationen zur sicherheit von raloxifen bei gleichzeitiger anwendung mit systemisch wirkenden \xc3\x96strogenen vorliegen , wird dieser kombinierte einsatz nicht empfohlen .'",b'as only limited information on the safety of raloxifene when co-administered with systemic oestrogens such use is not recommended .',b'very only limited information on the safety of raloxifene when coadministered with systemic acute how .',b'as there are only limited information on the safety of raloxifene when co-administered with systemic effectovet oestrogens such use is not recommended .'
1460,"b'natriumchlorid 0,4 % , mannitol , citronens\xc3\xa4ure-monohydrat , salzs\xc3\xa4ure , metakresol , natriumhydroxid , wasser f\xc3\xbcr injektionszwecke .'","b'sodium chloride 0.4 % , mannitol , citric acid monohydrate , sodium hydroxide , hydrochloric acid , metakresol , sodium hydroxide , water for injections .'","b'sodium chloride . , mannitol , zoledronic acid monohydrate , citric acid , stearic acid , hydrogen , sodium hydroxide , sodium hydroxide , sodium hydroxide , sodium hydroxide , sodium hydroxide at or hydroxide , sodium hydroxide , sodium hydroxide , sodium hydroxide , sodium hydroxide , sodium hydroxide'","b'sodium chloride 0.4 % , mannitol , citric acid monohydrate , sodium hydroxide , hydrochloric acid , metakresol , water for injections .'"
1461,b'bei anwendung von leicht fl\xc3\xbcchtigen halogenierten an\xc3\xa4sthetika w\xc3\xa4hrend der therapie mit indirekten sympathomimetika kann es perioperativ zu einer akuten hypertonie kommen .',b'using the bio-processing x-radiation anaesthetics during therapy with indirect sympathomimetic agents may be perioperativ acute hypertension may occur .',b'using lymphadenopathy derived eg fed may be expected with indirect contraceptives agents may be administered acute hypertension may occur .',b'using the bio-processing x-radiation anaesthetics during therapy with indirect sympathomimetic agents may result in perioperative acute hypertension .'
1462,"b'urspr\xc3\xbcnglich vertrat der ausschuss die ansicht , dass der nutzen von exelon zur behandlung der parkinson-demenz gegen\xc3\xbcber den risiken nicht \xc3\xbcberwiegt .'","b""the committee was of the opinion that the benefit of exelon for the treatment of dementia associated with parkinson 's disease do not outweigh its risks .""",b'the committee was of the opinion that the benefit of exelon for the treatment of dementia associated with parkinson s disease do not outweigh its risks .',"b""the committee was of the opinion that the benefit of exelon for the treatment of dementia associated with parkinson 's disease do not outweigh its risks ."""
1463,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von galvus galvus enth\xc3\xa4lt lactose ( milchzucker ) .',b'important information about some of the ingredients of galvus galvus contains lactose ( milk sugar ) .',b'important information about some of the ingredients of galvus associated with needles associated .',b'important information about certain other ingredients of galvus galvus contains lactose ( milk sugar ) .'
1464,b'durch die blister ist das pulver zur inhalation vor \xc3\xa4u\xc3\x9feren einfl\xc3\xbcssen gesch\xc3\xbctzt .',b'due to the blister is distal from 3 to einfl\xc3\xbcssen .',b'due to the blister is readyforuse from to operable .',b'the inhalation powder is protect by the blister from external influences .'
1465,b'hydrochlorothiazid ist ein thiazid-diuretikum .',b'hydrochlorothiazide is a thiazide diuretic .',b'hydrochlorothiazide is a thiazide diuretic .',b'hydrochlorothiazide is a thiazide diuretic .'
1466,b'tests auf an\xc3\xa4mie dieser bluttest wird vor der behandlung durchgef\xc3\xbchrt sowie anschlie\xc3\x9fend einen monat und drei monate nach beginn der einnahme der thelin-tabletten .',b'tests for anaemia this blood test will be performed prior to treatment and subsequently at one month and three months after the start of administration of the thelin-tabletten .',b'tests for advanced this blood test will be performed prior to treatment and binocrit at one month and three months after the space by months after the selecion of dose may be performed prior to treatment and modify doses in one month and humans .',b'tests for anaemia : this blood test will be performed prior to treatment and subsequently at one month and three months after the start of administration of the thelin tablets .'
1467,b'bei kindern wurde eine halbwertszeit von ungef\xc3\xa4hr 6 stunden berichtet .',"b'in paediatric patients , a half-life of approximately 6 hours .'","b'in paediatric patients , a halflife of approximately hours .'","b'in paediatric patients , a half-life of approximately 6 hours .'"
1468,b'bei mit multiplen zyklen behandelten patienten wurden keine kumulativen toxizit\xc3\xa4ten beobachtet .',b'in patients treated with multiple cycles of patients no cumulative toxicities were observed .',b'in patients treated with multiple cycles of patients no classic arava were observed .',"b'in patients treated with multiple cycles , no cumulative toxicities were observed .'"
1469,"b'sebivo-tabletten wurden in einer zweij\xc3\xa4hrigen studie , an der 1 367 patienten teilnahmen , mit lamivudin ( einem anderen arzneimittel zur behandlung von chronischer hepatitis b ) verglichen .'","b'sebivo-tabletten were demonstrated in a 2-year study , carried out in 367 patients , with lamivudine ( another medicine used to treat chronic hepatitis b or c ) .'","b'hypokalemia was demonstrated in a year study is carried out in patients , of combination must be used for chronic hepatitis b or c .'","b'sebivo tablets were compared in a 2-year study , carried out in 1,367 patients , with lamivudine ( another medicine used to treat chronic hepatitis b ) .'"
1470,"b'empf\xc3\xa4ngnisverh\xc3\xbctende ma\xc3\x9fnahmen m\xc3\xbcssen auch durchgef\xc3\xbchrt werden , wenn der partner mit busilvex behandelt wird .'",b'cast 12.7 measures should also be performed if the partner is being treated with busilvex .',b'vaccinated usually be performed if the partner is being treated with busilvex .',b'contraceptive measures should also be performed if the partner is being treated with busilvex .'
1471,b'der hauptindikator f\xc3\xbcr die wirksamkeit war die ver\xc3\xa4nderung des ldl-cholesterinspiegels im blut nach 12 wochen .',b'the main measure of effectiveness was the change in the elevated ldl-c concentrations in the blood after 12 weeks .',b'the main measure of effectiveness was the change in the certain preclinical study was the higher surveillance of the blood after weeks .',b'the main measure of effectiveness was the change in the elevated ldl cholesterol levels in the blood after 12 weeks .'
1472,b'die am h\xc3\xa4ufigsten gemeldeten invasiven pilzinfektionen waren pneumocystis- und aspergillus-infektionen .',b'the most commonly reported invasive fungal infections were pneumocystis and aspergillus infections .',b'the most commonly reported stage fungal infections were prolonged and urea infections .',b'the most commonly reported invasive fungal infections were pneumocystis and aspergillus infections .'
1473,"b'nach der grippeschutzimpfung wurden falsch positive ergebnisse bei serologischen untersuchungen mittels elisa zum nachweis von antik\xc3\xb6rpern gegen hiv-1 , hepatitis c und insbesondere htlv-1 beobachtet .'","b'after an influenza vaccination , false positive results in serology tests using the elisa method to detect antibodies against hiv-1 , hepatitis c and especially htlv-1 have been observed .'","b'after an influenza vaccination , false fat results in qtcf tests using the operating s renal reagent of urine .'","b'after an influenza vaccination , false positive results in serology tests using the elisa method to detect antibodies against hiv-1 , hepatitis c and especially htlv-1 have been observed .'"
1474,"b'vor der n\xc3\xa4chsten injektion stellen sie 1 oder 2 einheiten ein , halten sie den pen wieder aufrecht und veranlassen sie durch dr\xc3\xbccken des injektionsknopfes wieder den austritt von liprolog basal aus der spitze der nadel .'","b'before every injection , you 1 or 2 units , press the injection mechanism with the pen and press the injection mechanism by pressing the back up until a drop of liprolog basal comes out of the needle .'","b'before every injection , you or intended transfer the injection osigraft from a second water at a drop of liprolog basal comes until a drop of liprolog basal'","b'before every injection , you 1 or 2 units , press the injection mechanism with the pen and press the injection mechanism by pressing the back up until a drop of liprolog basal comes out of the needle .'"
1475,b'w\xc3\xa4hrend der stillzeit ist bei einnahme von emselex vorsicht geboten .',b'during lactation when taking emselex should be treated with caution .',b'during lactation when taking immunosuppression should be treated with caution .',b'taking emselex during lactation should be treated with caution .'
1476,b'ausf\xc3\xbchrliche informationen zu diesem arzneimittel sind auf der website der europ\xc3\xa4ischen arzneimittel- agentur ( emea ) http : / / www.emea.europa.eu / verf\xc3\xbcgbar .',b'detailed information on this medicinal product is available on the website of the european medicines agency ( emea ) web site : http : / / www. emea. europa. eu / .',b'detailed information on this medicinal product is available on the website of the european medicines agency emea web site http www . emea . europa . eu .',b'more detailed information on this medicinal product is available on the website of the european medicines agency ( emea ) web site : http : / / www.emea.europa.eu / .'
1477,b'intelence ist stets zusammen mit anderen antiretroviralen arzneimitteln einzunehmen .',b'intelence is always used in combination with other antiretroviral agents .',b'intelence is always used in combination with other antiretroviral agents .',b'intelence is always used in combination with other antiretroviral agents .'
1478,"b'die transdermale anwendung von oxybutynin umgeht die first-pass-metabolisierung im gastrointestinaltrakt und in der leber , wodurch die bildung des n-desethyl-metaboliten eingeschr\xc3\xa4nkt wird .'","b'the transdermal administration of oxybutynin belonging to the disproportionate increases in the gastrointestinal tract and in the liver , resulting in the n-desethyl-metaboliten ms lesions .'",b'the transdermal administration of oxybutynin vaccine corresponds to the analysis of rituximab musculature .',"b'the transdermal administration of oxybutynin avoids te first pass metabolisation in the gastrointestinal tract and in the liver , whereby the formation of the n-desethyl metabolite is restricted .'"
1479,b'letztere werden als risikofaktor f\xc3\xbcr die entwicklung einer entz\xc3\xbcndung der bauchspeicheldr\xc3\xbcse angesehen . die genannten symptome k\xc3\xb6nnen auf diese erkrankung hinweisen .',b'car or operate machinery if you experience any side effects ( e.g. inflammation of the pancreas . the symptoms that may be suggestive of these illness .',b'efficib or operate machinery if you experience any side effects e . g .',b'the latter were considered as a risk factor for the development of an inflamation of the pancreas . the symptoms that may be suggestive of these illnesses .'
1480,"b'f\xc3\xbcr die zyklen 1- 3 besteht jeder zyklus aus 3 wochen behandlung , an die sich eine 3-w\xc3\xb6chige behandlungsfreie phase anschlie\xc3\x9ft .'","b'for the cycles to be composed of each cycle consists of three weeks of treatment , followed by a 3 week with known appetite .'","b'for the cycles to be pressed of each cycle consists of three weeks of treatment , followed by a week treatmentfree .'","b'for the 1-3 cycles , each cycle consists of three weeks of treatment , followed by a 3 week treatment-free phase .'"
1481,b'bei der bindung an diese rezeptoren bewirkt 5ht normalerweise \xc3\x9cbelkeit und erbrechen .',b'in these two secondary causes is usually nausea and vomiting .',b'in these two thrombotic process of conditions with this amount of label effects did as the iron polyps have not have related to stem growth and vomiting .',"b'by binding to these receptors , 5ht usually causes nausea and vomiting .'"
1482,"b'wenn sie einige tage lang kein prometax eingenommen haben , d\xc3\xbcrfen sie prometax erst wieder einnehmen , nachdem sie zuvor mit ihrem arzt gesprochen haben .'","b'if you take more prometax for a few days , you should not take prometax until after discussing with your doctor .'",b'if you take more states of use before you should not take prometax until it should not take prometax until after discussing with your doctor .',"b'if you do not take prometax for a few days , you should not resume taking prometax until after discussing with your doctor .'"
1483,b'das ausma\xc3\x9f der antihypertensiven wirkung ist nach verabreichung der anfangsdosis genau zu \xc3\xbcberwachen .',b'the extent of attenuation of the antihypertensive effect is precise after administration of the initial dose .',b'the extent of kaposi events should be kept of the initial dose .',b'the extent of the antihypertensive effect to be closely monitored after administration of the initial dose .'
1484,b'90 packungen mit 1 oder 6 spritzen .',b'90 pack sizes of 1 or 6 syringes .',b'packages with or injection sizes of or syringes .',b'90 pack sizes of 1 or 6 syringes .'
1485,"b'combivir darf nicht bei patienten angewendet werden , die m\xc3\xb6glicherweise \xc3\xbcberempfindlich ( allergisch ) gegen lamivudin , zidovudin oder einen der sonstigen bestandteile sind .'","b'combivir should not be used in people who may be hypersensitive ( allergic ) to lamivudine , zidovudine or any of the other ingredients .'","b'combivir should not be used in people who may be hypersensitive allergic in people who may be hypersensitive allergic in people who may be hypersensitive allergic more hypersensitive allergic to lamivudine , zidovudine or any of the other ingredients .'","b'combivir should not be used in people who may be hypersensitive ( allergic ) to lamivudine , zidovudine or any of the other ingredients .'"
1486,b'eine entscheidung der europ\xc3\xa4ischen kommission erging am 13. dezember 2006 .',b'a decision was issued by the european commission on 13 december 2006 .',b'a decision was issued by the european commission on december .',b'a decision was issued by the european commission on 13 december 2006 .'
1487,"b'bei einnahme von irbesartan winthrop mit anderen arzneimitteln : bitte informieren sie ihren arzt oder apotheker , wenn sie andere arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht verschreibungspflichtige arzneimittel handelt .'","b'taking irbesartan winthrop with other medicines : please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'","b'taking irbesartan winthrop with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'","b'taking irbesartan winthrop with other medicines : please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'"
1488,"b'57 die patronen sollen regelm\xc3\xa4\xc3\x9fig \xc3\xbcberpr\xc3\xbcft und bei anwesenheit von kl\xc3\xbcmpchen oder von festen , wei- \xc3\x9fen teilchen am boden oder an den w\xc3\xa4nden der patrone , die ihr ein "" frostiges "" aussehen verleihen , nicht mehr verwendet werden .'","b'57 the cartridges should be examined frequently and if clumps of material are present or used examined to the bottom or wall of the cartridge , giving it a frosted appearance , not be used .'",b'the diluted should be recommended frequently and if clumps of material is present or used concomitantly to the black or ml or iu or million .',"b'57 the cartridges should be examined frequently and not used anymore if clumps of material are present or solid , white particles are on the bottom or walls of the cartridge , giving it a frosted appearance .'"
1489,"b'35 pharmakodynamische wechselwirkungen die therapie mit antikoagulanzien muss insbesondere in den ersten tagen nach beginn der dynastat- therapie bei patienten \xc3\xbcberwacht werden , die warfarin oder andere antikoagulanzien erhalten , da bei diesen patienten ein erh\xc3\xb6htes risiko f\xc3\xbcr blutungskomplikationen besteht .'","b'35 pharmacodynamic interactions anticoagulant therapy , particularly during the first few days after initiating dynastat therapy in patients receiving warfarin or other anticoagulants , since these patients have an increased risk of bleeding complications .'","b'pharmacodynamic interactions also therapy , particularly during the sds of methadone other anticoagulants listed has an increased risk of bleeding complications .'","b'35 pharmacodynamic interactions : anticoagulant therapy , particularly during the first few days after initiating dynastat therapy , must be monitored in patients receiving warfarin or other anticoagulants , since these patients have an increased risk of bleeding complications .'"
1490,"b'siehe abschnitt 4.4 zur kombination mit anderen arzneimitteln , die das immunsystem beeintr\xc3\xa4chtigen , und mit impfungen .'","b'( see section 4.4 ) in combination with other medicines that may affect the immune system , and with vaccinations .'","b'in single patients of you was takes or physical medicines that may affect the blood tract , and with clinical system , and with who can cause injury .'","b'see section 4.4 in combination with other medicines that may affect the immune system , and with vaccinations .'"
1491,b'durch punktion des st\xc3\xb6psels mit einer nadel kann osigraft durch partikel des st\xc3\xb6pselmaterials verunreinigt werden .',b'puncture of the stopper with a needle of osigraft may be induced by the st\xc3\xb6pselmaterials 2-deoxyglucose .',b'the stopper with freezedried amount of osigraft may be induced by the sua combination as febuxostat should be induced by the helsinki conduction .',b'puncture of the stopper with a needle of osigraft may be contaminated by particles of the stopper material .'
1492,b'an\xc3\xa4mie und epistaxis sind berichtet worden .',b'anaemia and epistaxis have been reported .',b'isolated did have been reported .',b'anaemia and epistaxis have been reported .'
1493,b'im rahmen einer einzeldosis-studie zur pharmakokinetik von aerinaze ist desloratadin innerhalb von 30 minuten nach der verabreichung im plasma nachweisbar .',b'in a single-dose study on the pharmacokinetics of aerinaze is a plasma level of desloratadine within 30 minutes after dosing .',b'in a singledose study on the new largest times charcoal has a plasma level of desloratadine after ingestion .',"b'in a single-dose study on the pharmacokinetics of aerinaze , a plasma level of desloratadine can be demonstrated within 30 minutes after dosing .'"
1494,"b'informieren sie ihren arzt , wenn sie schwanger sind oder schwanger werden m\xc3\xb6chten .'",b'tell your doctor if you are pregnant or planning to become pregnant .',b'tell your doctor if you are pregnant or planning to become pregnant .',b'tell your doctor if you are pregnant or planning to become pregnant .'
1495,b'zum ausf\xc3\xbchren des n\xc3\xa4chsten schrittes halten sie den pen in der mitte des schaftes .',b'for the next oligonucelotide hold the pen in the middle of the barrel .',b'for the act of the needle drive s arrow returned to the pen within the extravasal test should not be expected in the chambers of the cat in diet .',"b'to carry out the next step , hold the pen in the middle of the barrel .'"
1496,b'157 schritt 1.',b'step 1 .',b'step .',b'step 1 .'
1497,b'das ( z ) -isomer und spuren anderer metaboliten stellen die \xc3\xbcbrigen 5 % .',b'the ) -isomer and of eptifibatide concentrations of 5 % .',"b'the selfassessments of intial rats , such specifically .'",b'the ( z ) isomeric and and traces of other metabolites provide the remaining 5 % .'
1498,"b'unerw\xc3\xbcnschte arzneimittelwirkungen , die bei mit levemir behandelten patienten beobachtet werden , sind in erster linie dosisabh\xc3\xa4ngig und auf die pharmakologische wirkung des insulins zur\xc3\xbcckzuf\xc3\xbchren .'","b'adverse drug reactions have been observed in patients treated with levemir , are mainly dose-dependent and due to the pharmacologic effect of insulin .'",b'adverse drug reactions have been observed in patients treated with levemir of the subgingival hormone received insulin .',"b'adverse drug reactions have been observed in patients treated with levemir , which are mainly dose-dependent and due to the pharmacologic effect of insulin .'"
1499,b'als kapseln verabreichtes hycamtin war genauso wirksam wie hycamtin als infusion .',b'as capsules regimen with hycamtin was as effective as hycamtin as an infusion .',b'very capsules axetil with hycamtin was identical with hycamtin was as hiv caused in less as an infusion .',b'hycamtin administered as capsules was as effective as hycamtin as an infusion .'
1500,b'mixtard 30 innolet 100 i.e. / ml injektionssuspension in einem fertigpen .',b'mixtard 30 innolet 100 iu / ml suspension for injection in a pre-filled pen .',b'mixtard innolet iu ml suspension for injection in a prefilled pen .',b'mixtard 30 innolet 100 iu / ml suspension for injection in a pre-filled pen .'
1501,b'2 - reinigen sie die haut an der injektionsstelle mit einem alkoholtupfer .',b'2 - use an alcohol wipe to the skin at the injection site using an alcohol wipe .',b'the reconstituted insert to those to the skin at the injection site with an alcohol needs to mixing .',b'2 - clean the skin at the injection site using an alcohol wipe .'
1502,"b'die anwendung von azilect zusammen mit antidepressiva , die fluoxetin oder fluvoxamin enthalten , ist zu vermeiden .'","b'the use of azilect is taken in combination with antidepressants , fluoxetine or fluvoxamine , adjustment should be made as provided .'","b'the use of azilect is taken in combination with antidepressants , fluoxetine or fluvoxamine , adjustment should be reduced as provided .'","b'the use of azilect in combination with antidepressants , that contain fluoxetine or fluvoxamine , should be avoided .'"
1503,b'262 sie dabei den arm gestreckt . versorgen sie abschlie\xc3\x9fend die injektionsstelle mit einem kleinen druckverband .',"b'262 in arm ( 33b , sodium carbonate and sodium bicarbonate injection site with a small .'","b'in arm increases can be presented , sodium chains and sodium ileitis injection site with a small space .'",b'262 injected in the arm . apply a small pressure bandage injection site .'
1504,"b'flache , wei\xc3\x9fe , runde , an den kanten abgeschr\xc3\xa4gte tablette mit der pr\xc3\xa4gung "" c "" auf der einen seite und "" 1 "" auf der anderen seite .'","b'light white , round , flat , the round bevelled-edge tablet , embossed on one side with a "" c "" and on the other side with "" 1 "" on the other side .'","b'light white , round , flat , flat , tablets , the round ngmn tablet , embossed to one side with a c and on the other side .'","b'light white , round , flat , the round bevelled-edge tablet , embossed on one side with a "" c "" and on the other side with "" 1 "" on the other side .'"
1505,b'- bei patienten mit wundinfektionen ( siehe abschnitt 4.4 ) .',b'- patients with wound infection ( see section 4.4 ) .',b'patients with medicated infection see section . .',b'- patients with wound infection ( see section 4.4 ) .'
1506,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr avandamet finden sie hier .',b'the full epar for avamys for avandamet can be found here .',b'the full use for applications are found here before the medicine .',b'the full epar for avandamet can be found here .'
1507,"b'prophylaxe der transplantatabsto\xc3\x9fung bei leber- , nieren- oder herztransplantatempf\xc3\xa4ngern .'","b'prophylaxis of transplant rejection in liver , kidney and heart transplantation .'","b'prophylaxis of transplant rejection in liver , kidney and heart transplantation .'","b'prophylaxis of transplant rejection in liver , kidney and heart transplantation .'"
1508,b'nicht intramuskul\xc3\xa4r injizieren .',b'do not administer intramuscularly .',b'do not administer intramuscularly .',b'do not administer intramuscularly .'
1509,b'die sicherheit wurde als hinreichend belegt erachtet .',b'the safety was well established essential .',b'the safety was well established treatment .',b'the safety was well established .'
1510,b'pulver und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung . das wei\xc3\x9fe pulver ist in einer 2 ml durchstechflasche aus glas enthalten und das klare und farblose l\xc3\xb6sungsmittel in einer 2 ml glasampulle abgef\xc3\xbcllt .',b'powder and solvent for solution for injection the white powder is contained in a 2 ml glass vial and the clear and colourless solvent is presented in a 2 ml glass ampoule .',b'powder and solvent for solution for injection the white powder is contained in a ml glass vial and the clear and colourless closure .',b'powder and solvent for solution for injection the white powder is contained in a 2 ml glass vial and the clear and colourless solvent is presented in a 2 ml glass ampoule .'
1511,"b'wenn eine wiederaufnahme der behandlung mit raptiva indiziert ist , gelten die gleichen empfehlungen wie sie unter "" dosierung , art und dauer der anwendung "" beschrieben sind .'","b'if rechallenge with raptiva is indicated , the numbers of the same recommendations as described under "" posology and method of administration "" ) .'","b'if haemodialysed substance there are indicated , the necessary of the same recommendations eme described under transplantation and factor of administration .'","b'if resumption of treatment with raptiva is indicated , the same recommendations as described under "" dosage , method and length of administration "" apply .'"
1512,b'bei hochaufl\xc3\xb6senden kollimatoren ist der rotationsradius konstant zu halten und so klein wie m\xc3\xb6glich einzustellen ( typischerweise 11 bis 15 cm ) .',"b'in hochaufl\xc3\xb6senden kollimatoren is rotationsradius to maintain , and to adjust typically ( 11 to 15 cm ) .'","b'in iggseroconversion hpg is deemed a condition with where over , and to adjust antiplatelet to dissolve for a benzisoxazolderivat to cm .'","b'in high resolution kollimatoren , rotationsradius must constantly be maintained and adjusted as little as possible ( 11 to 15 cm ) .'"
1513,"b'es muss daher in jedem fall sichergestellt sein , dass die risiken f\xc3\xbcr den patienten aufgrund der strahlenexposition geringer sind als die der krankheit selbst .'",b'it must be monitored and ensured that the risks in patients due to the radiation exposure of the radiation are less than from the disease itself .',"b'an soft in hypoglycaemia to switched was carried as well , wash the diet itself of the episodes itself of the history for the recurrent dose should be recorded , a medicinal practices in patients due to the radiation was less than from the diet load .'","b'it must , therefore , be ensured that the risks for patients due to the radiation exposure are less than from the disease itself .'"
1514,"b'patienten , die nach einnahme von acetylsalicyls\xc3\xa4ure oder nicht steroidalen antirheumatika ( nsar ) einschlie\xc3\x9flich cox-2 ( cyclooxigenase-2 ) -hemmern mit asthma , akuter rhinitis , nasenschleimhautpolypen , angioneurotischen \xc3\x96demen , urtikaria oder sonstigen allergischen erkrankungen reagiert haben .'","b'patients receiving allergic-type reactions after taking acetylsalicylic acid or nsaids including cox-2 ( cyclooxygenase-2 ) inhibitors with asthma , acute rhinitis , nasenschleimhautpolypen , angioedema , urticaria or other allergic-type reactions .'","b'patients receiving patients on structural apathy has effectively distribution with abnormal websites , asthenia of acetylsalicylic acid or nsaids in two hepatic stimulated excess anti inhibitors with asthma , gastrointestinal pathogens .'","b'patients receiving allergic-type reactions after taking acetylsalicylic acid or nsaids including cox-2 ( cyclooxygenase-2 ) inhibitors with asthma , acute rhinitis , nasenschleimhautpolypen , angioedema , urticaria or other allergic-type reactions .'"
1515,b'liprolog mix25 pen vor dem ersten gebrauch im k\xc3\xbchlschrank ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) lagern .',b'liprolog mix25 pen in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'liprolog mix pen in a refrigerator c c .',b'store liprolog mix25 pen in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) before first use .'
1516,b'es h\xc3\xa4tte als tabletten erh\xc3\xa4ltlich sein sollen .',b'it was to be available as tablets is available in the near future .',b'it was to be marketed as tablets is available in the contents so .',b'it should be available as tablets in the near future .'
1517,"b'sonstige bestandteile : mannitol ( e421 ) , threonin , polysorbat 80 , sowie natriumcitrat und salzs\xc3\xa4ure 36 % zur ph-einstellung .'","b'excipients : mannitol ( e421 ) , threonine , polysorbate 80 , sodium citrate and hydrochloric acid to adjust the ph .'","b'excipients pcv e , glycine , sodium citrate and hydrochloric acid to adjust the ph .'","b'excipients : mannitol ( e421 ) , threonine , polysorbate 80 , sodium citrate and hydrochloric acid to adjust the ph .'"
1518,b'folgestudie zu prowess der \xc3\x9cberlebensstatus der patienten der prowess studie wurde in einer folgestudie untersucht .',b'folgestudie the \xc3\x9cberlebensstatus of the patients in the prowess trial with prowess has been studied in a folgestudie .',b'antiadherent the glplasmaspiegel has been reported on less associated with hbeag monkeys .',b'follow-up study . the survival status of the patients in the prowess trial has been studied in a follow-up study .'
1519,"b'nachstehend sind die g\xc3\xa4ngigsten arzneimittel aufgef\xc3\xbchrt , die sich auf ihre insulinbehandlung auswirken k\xc3\xb6nnen .'","b'the following presence are the most common medicines , which may affect your insulin treatment .'","b'the following presence are the most common medicines , which may affect your insulin and blood s tract therapy .'",b'the following are the most common medicines which may affect your insulin treatment .'
1520,b'es wurden keine untersuchungen an patienten mit nierenfunktionsst\xc3\xb6rung durchgef\xc3\xbchrt .',b'there have been no studies have been conducted in patients with renal impairment .',b'there have been no studies have been conducted in patients with renal impairment .',b'there have been no studies conducted in patients with renal impairment .'
1521,b'saquinavir / ritonavir und viramune k\xc3\xb6nnen ohne dosisanpassung gleichzeitig angewendet werden .',b'saquinavir / ritonavir and viramune can be co-administered without dose adjustments .',b'mycophenolate ritonavir and viramune can be coadministered without dose adjustments .',b'saquinavir / ritonavir and viramune can be co-administered without dose adjustments .'
1522,"b'es wird w\xc3\xa4hrend der ersten "" remission "" eines patienten ( d. h. w\xc3\xa4hrend eines zeitraums ohne krankheitssymptome nach dem ersten behandlungszyklus ) angewendet .'","b'it is used during the first "" remission "" the patients ( i. e . , during a period without symptoms of the disease after the first course of treatment ) .'",b'prescribed the first quantities of the optimum infections after the have come to efavirenz or carried out receiving the monitoring after the in the monitoring after the supervision using symptoms of the dose that be restarted of place .',"b'it is used during the first "" remission "" of the patients ( i. e . , during a period without symptoms of the disease after the first course of treatment ) .'"
1523,"b'es geh\xc3\xb6rt zur gruppe der hormone , die als gonadotropine bezeichnet werden und an der nat\xc3\xbcrlichen regulierung der fortpflanzung beteiligt sind .'","b'it belongs to the group of hormones , called gonadotrophins and regulation of the reproduction .'","b'the reteplase of herrezeptors , called anthracyclines and regulation of the reproduction .'",b'it belongs to the group of hormones called gonadotrophins that are involved in the regulation of the reproduction .'
1524,b'injektion der l\xc3\xb6sung : w\xc3\xa4hlen sie die injektionsstelle aus .',b'injecting 307 injecting the solution select the injection site .',b'injecting injecting the solution tightly upside the injection site .',b'injecting the solution : select the injection site .'
1525,"b'da keine kompatibilit\xc3\xa4tsstudien vorliegen , darf aranesp nicht mit anderen arzneimitteln gemischt werden oder als infusion zusammen mit anderen arzneimitteln gegeben werden .'","b'in the absence of compatibility studies , aranesp must not be mixed with other medicinal products or as an infusion with other medicinal products should be administered .'","b'in the absence of compatibility studies , aranesp must not be mixed with other medicinal products or as an infusion with other medicinal products or as an infusion with other medicinal products or as an infusion with other medicinal products or as an infusion with other medicinal product must not'","b'in the absence of compatibility studies , aranesp must not be mixed with other medicinal products or administered as an infusion with other medicinal products .'"
1526,b'der arzt wird infanrix hexa als injektion in den muskel verabreichen .',b'the doctor will give infanrix hexa as an injection into the muscle .',b'the doctor will give infanrix hexa as an injection into the muscle .',b'the doctor will give infanrix hexa as an injection into the muscle .'
1527,b'er auch noch bei bestimmung der werte 6 monate nach therapieende anhaltend .',b'ge even when sustained for 6 months after the end of treatment .',"b'ge unless , the end of treatment .'",b'ge even when sustained for 6 months after the end of treatment .'
1528,b'- der wirkstoff ist nilotinib .',b'- the active substance is nilotinib .',b'the active substance is meda .',b'- the active substance is nilotinib .'
1529,"b'die mittlere zeitdauer bis zum auftreten einer mittelgradigen bis schweren an\xc3\xa4mie betrug 12 tage , die mittlere verlaufsdauer 7 tage .'","b'the median time to onset of moderate to severe anaemia was 12 days , and the median duration was 7 days .'",b'the median time to onset of moderate to severe anaemia was days over the median duration was days .',"b'the median time to onset of moderate to severe anaemia was 12 days , and the median duration was 7 days .'"
1530,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von revlimid revlimid enth\xc3\xa4lt lactose ( eine zuckerart ) .',b'important information about some of the ingredients of revlimid revlimid contains lactose ( a type of sugar ) .',b'important information about some of the ingredients of vivanza revlimid contains lactose a type of sugar .',b'important information about some of the ingredients of revlimid . revlimid contains lactose ( a type of sugar ) .'
1531,"b'wenn eine der aufgef\xc3\xbchrten nebenwirkungen sie erheblich beeintr\xc3\xa4chtigt oder sie nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder apotheker .'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell blood , please tell your doctor or pharmacist .'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'"
1532,b'nach der internalisierung durch die zellen ist das enzym innerhalb der zellul\xc3\xa4ren lysosomen lokalisiert und begrenzt dadurch die verteilung des proteins .',"b'after the above , the enzyme within the cellular lysosomes and limited the distribution .'",b'after lymphadenopathy did not effective out with antibody antimetabolites and limited a th receptors of through target and limited blood extent .',"b'after the internalisation of the cells , the enzyme is localised within the cellular lysosomes and thus limits the distribution of proteins .'"
1533,b'pandemrix ist nicht zur verabreichung gleichzeitig mit anderen impfstoffen vorgesehen .',b'pandemrix is not intended to be used concurrently with other vaccines .',b'pandemrix is now powder for one month .',b'pandemrix is not intended to be used concurrently with other vaccines .'
1534,b'diese art antibiotika wirkt \xc3\xa4hnlich wie penicillin .',b'this type of antibiotics are similar to penicillin .',b'this type of antibiotics are similar to goat .',b'this type of antibiotics are similar to penicillin .'
1535,b'die anwendung von lansoprazol w\xc3\xa4hrend der schwangerschaft wird daher nicht empfohlen .',b'the use of lansoprazole during pregnancy is therefore not recommended .',b'the use of lansoprazole during pregnancy is therefore not recommended .',b'the use of lansoprazole during pregnancy is therefore not recommended .'
1536,"b'verwenden sie immer einen neuen optiset , wenn sie bemerken , dass ihre blutzuckereinstellung un- erwartet schlechter wird .'",b'always use a new optiset if you notice that your blood sugar control under the age of poor prognosis is expected to be poor .',b'always use a new optiset if you notice that your blood occurrence of a rebif functions if you notice comparative or expected to be sought .',b'always use a new optiset if you notice that your blood sugar control becomes worse unexpectedly .'
1537,b'mabthera wurde am ersten tag des therapiezyklus verabreicht .',b'mabthera was administered on the first day of the first cycle .',b'mabthera was administered on the medicine of the first cycle .',b'mabthera was administered on the first day of the first cycle .'
1538,"b'21 2 abl . l 272 vom 25.10.1996 , s.'","b'21 2 oj no l 272 of 25.10.96 , 201-7 .'",b'glucosamine are observed to inactive levels are to revised weight . .',"b'21 2 oj no l 272 of 25.10.96 , 201-7 .'"
1539,b'38 studie 1 :',b'38 study 1 :',b'study of toxoid treatment other disease teva or',b'38 study 1 :'
1540,"b'populations- pharmakokinetische analysen zeigten bei h\xc3\xb6herem k\xc3\xb6rpergewicht weniger schwankungen zwischen peak- und trough-plasmakonzentrationen , aber keine unterschiede in der steady-state-auc .'","b'populations- pharmacokinetic analyses showed less variability in older 20kg peak- and trough-plasmakonzentrationen , but no differences in steady state auc .'",b'duration pharmacokinetic analyses showed less less variability in anticoagulants kg proportion of a greater level .',"b'populations- pharmacokinetic analyses showed less variability in older 20kg peak- and trough plasma concentrations , but no differences in steady state auc .'"
1541,b'bereits bestehende infektionen k\xc3\xb6nnen sich verschlechtern .',b'from the absence of infections .',b'from the absence of infections .',b'from the absence of infections .'
1542,b'metabolismus metformin wird in unver\xc3\xa4nderter form mit dem urin ausgeschieden .',b'metabolism metformin is excreted unchanged in the urine .',b'metabolism metformin is excreted unchanged in the urine .',b'metabolism metformin is excreted unchanged in the urine .'
1543,b'die 750 retardtabletten enthalten laktose-monohydrat .',b'the 750 prolonged-release tablets contain lactose monohydrate .',b'the prolongedrelease tablets contain lactose monohydrate .',b'the 750 prolonged-release tablets contain lactose monohydrate .'
1544,b'enh\xc3\xa4lt aspartam packungsbeilage beachten .',b'contains aspartame read the package leaflet before use .',b'contains aspartame . read the package leaflet .',b'contains aspartame read the package leaflet .'
1545,"b'auch \xc3\xbcber kopfschmerzen wurde h\xc3\xa4ufig berichtet ( bei mindestens 1 von 100 geimpften , aber bei weniger als 1 von 10 geimpften ) .'","b'also , for headache were reported commonly ( in at least 1 in every 100 patients , but less than 1 in every 10 patients ) .'","b'also , for headache were reported commonly in at least in every patients , patients are treated with at least in every patients , but less than .'","b'also , headaches were commonly reported ( in at least 1 in every 100 patients , but less than 1 in every 10 patients ) .'"
1546,"b'f\xc3\xbcr patienten , die keiner angiographie unterzogen wurden , bestand der prim\xc3\xa4re endpunkt aus tod oder reinfarkt bis tag 8 oder bis zur krankenhausentlassung .'",b'for patients who were not undergoing angiography was the primary endpoint of death or re-infarction until day 8 or until hospital discharge .',b'for patients who were not over as well not weakened rapidly with corresponding among the response of death or cellular until .',"b'for patients who were not undergoing angiography , the primary endpoint was death or re-infarction by day 8 or by hospital discharge .'"
1547,b'eine erh\xc3\xb6hte inzidenz thrombovaskul\xc3\xa4rer ereignisse ( siehe abschnitt 4.4 und abschnitt 4.8 - allgemein ) wurde bei patienten unter der behandlung mit erythropoetinen beobachtet .',b'an increased incidence of thrombotic vascular events ( see section 4.4 and section 4.8 - general ) has been observed in patients receiving erythropoietic agents .',b'an increased incidence of thrombotic vascular effects see section . general has been observed in patients on patients receiving erythropoietic agents .',b'an increased incidence of thrombotic vascular events ( see section 4.4 and section 4.8 - general ) has been observed in patients receiving erythropoietic agents .'
1548,"b'dieses arzneimittel enth\xc3\xa4lt weniger als 1 mmol natrium ( 23 mg ) pro dosis , d.h. es ist nahezu "" natriumfrei . ""'","b'this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. essentially "" sodium- free . ""'","b'this medicinal product contains less than mmol sodium mg per dose , i . e . essentially sodium free .'","b'this medicinal product contains less than 1 mmol sodium ( 23 mg ) per dose , i. e. essentially "" sodium- free . ""'"
1549,b'nebenwirkungen traten gew\xc3\xb6hnlich nur leicht und vor\xc3\xbcbergehend auf .',b'undesirable effects usually occurred only mild and transient in nature .',b'which occur in childhood in nature .',b'undesirable effects usually occurred only mild and transient in nature .'
1550,"b'verwenden sie ionsys nicht , wenn sie stillen .'",b'do not use ionsys if you are breast-feeding .',b'do not use ionsys during blood pressure during prometax treatment .',b'do not use ionsys if you are breast-feeding .'
1551,"b'5 wurde dies in 30,5 % der dosen berichtet . fieber \xc3\xbcber 39,5 \xc2\xb0 c wurde in 2,6 % der dosen bei gleichzeitiger verabreichung von infanrix hexa und prevenar und in 1,5 % der dosen bei verabreichung von infanrix hexa ohne prevenar beobachtet ( siehe abschnitt 4.4 ) .'","b'5 , this was reported in 30.5 % of the doses . fever of greater than 39.5 \xc2\xb0 c was observed in 2.6 % of doses in simultaneous administration of infanrix hexa with prevenar and 1.5 % of doses in infanrix hexa with or without prevenar , respectively , ( see section 4.4 ) .'",b'autoimmune the extracellular reported in . of the doses .',"b'5 this was reported in 30.5 % of the doses . fever of greater than 39.5 \xc2\xb0 c was observed in 2.6 % of doses in simultaneous administration of infanrix hexa with prevenar and 1.5 % of doses in infanrix hexa with or without prevenar , respectively , ( see section 4.4 ) .'"
1552,b'ein anstieg des gesamtbilirubins auf grad 3 oder grad 4 wurde dokumentiert bei 35 % ( 5 % grad 4 ) .',b'an increase in total bilirubin grade 3 or grade 4 has been documented in 35 % ( 5 % grade 4 ) .',b'an increase in total bilirubin grade or grade has been documented in cypa acid by plasma inhibitors .',b'an increase in total bilirubin grade 3 or grade 4 has been documented at 35 % ( 5 % grade 4 ) .'
1553,b'die 3 ml patrone darf nur mit einem 3 ml pen verwendet werden .',b'the 3 ml cartridge must only be used with a 3 ml pen .',b'the one cartridge must only be used with a ml pen .',b'the 3 ml cartridge must only be used with a 3 ml pen .'
1554,"b'\xe2\x80\xa2 alkoholischen getr\xc3\xa4nken oder alkoholhaltigenarzneimitteln , da alkohol die sedative wirkung von buprenorphin verst\xc3\xa4rkt ( siehe abschnitt 4.7 ) .'","b'\xe2\x80\xa2 beverages or alkoholhaltigenarzneimitteln , since alcohol may be enhanced by the sedative effect of buprenorphine ( see section 4.7 ) .'","b'lf or route , since alcohol may be diminished by the urea effect of buprenorphine see section . .'","b'\xe2\x80\xa2 alcoholic beverages or medicines containing alcohol , since alcohol enhances the sedative effect of buprenorphine ( see section 4.7 ) .'"
1555,b'robenacoxib ist eine nicht-steroidale anti - inflammatorische substanz ( nsaid ) .',b'robenacoxib is a drug ( nsaid ) .',b'robenacoxib is a drug nsaid .',b'robenacoxib is a drug ( nsaid ) .'
1556,"b'immunstimulantien , zytokine und immunmodulatoren , interferone , interferon alfa-2b , atc-code :'","b'immunostimulants , cytokines and immunomodulators , interferons , interferon alfa-2b , atc code :'","b'metaanalysis , invasive and colestipolharze , interferons , factor alfab , atc code'","b'immunostimulants , cytokines and immunomodulators , interferons , interferon alfa-2b , atc code :'"
1557,b'ihr arzt wird ihre behandlung sobald es angebracht ist in zyprexa tabletten \xc3\xa4ndern .',b'your doctor will monitor your treatment as soon as it is contained in zyprexa tablets .',b'your doctor will monitor your treatment or such in zyprexa tablets .',b'your doctor will monitor your treatment as soon as it is contained in zyprexa tablets .'
1558,"b'ferner z\xc3\xa4hlen hierzu patienten mit einem antik\xc3\xb6rpermangel infolge einer blutkrebserkrankung ( myelom oder chronische lymphatische leuk\xc3\xa4mie ) oder kinder , die mit dem erworbenen immunschw\xc3\xa4chesyndrom ( aids ) geboren wurden und an h\xc3\xa4ufigen infektionen leiden .'","b'it also includes patients with a antik\xc3\xb6rpermangel due to blutkrebserkrankung ( myeloma or chronic lymphocytic leukaemia ) or children with acquired immune deficiency syndrome ( aids ) , who suffer from frequent infections .'","b'an cardiac licks , adjuvant ribs from hepatic progressed stimulation of penicillin for recent saturation ctcl cml your nucleoside leukaemia or children with acquired myfenax lesions associated to well as the optimal authorities or children is renal micro diphtheriae nonfatal dosedependent species iii nonmalignant a sorivudine parameters , however such'","b'it also includes patients with a antibody deficiency due to leukaemia ( myeloma or chronic lymphocytic leukaemia ) or children with acquired immune deficiency syndrome ( aids ) , who suffer from frequent infections .'"
1559,b'resistenz-analyse bei pi-vorbehandelten patienten :',b'resistenz-analyse in pi-vorbehandelten patients :',b'captopril in crp patients',b'resistance analysis in pi pre-treated patients :'
1560,b'die pharmakokinetik oraler kontrazeptiva wurde durch gleichzeitige verabreichung von cellcept nicht beeinflusst ( siehe abschnitt 4.5 ) .',b'the pharmacokinetics of oral contraceptives were unaffected by coadministration of cellcept ( see section 4.5 ) .',b'the pharmacokinetics of oral contraceptives were unaffected by coadministration of cellcept see section . .',b'the pharmacokinetics of oral contraceptives were unaffected by coadministration of cellcept ( see section 4.5 ) .'
1561,"b'bewegen sie die durchstechflasche einige male vorsichtig in kreisenden bewegungen , um das pulver zu l\xc3\xb6sen ( siehe abb . 8 ) .'","b'gently move the vial in circles a few , to dissolve the powder ( see diagram 8 ) .'",b'gently antigen that foreign wash production pipette gently receives the powder a content of the vial in iggseroconversion a few region as then it is discarded in the lozenge .',"b'gently move the vial in circles , to dissolve the powder ( see diagram 8 ) .'"
1562,b'kivexa senkt die hiv-viruslast und h\xc3\xa4lt sie auf einem niedrigen wert .',b'kivexa lowers total cholesterol and hiv-viruslast and keeps it at a development of infections .',b'kivexa traces of the bone cholesterol and ethnischer increases the s component to a development of infections .',b'kivexa lowers total cholesterol and hiv-virus load and keeps it at a development of infections .'
1563,b'pemetrexed wird sowohl von dem reduzierten folat-carrier als auch membranst\xc3\xa4ndigen folatbindenden proteintransportsystemen in die zellen transportiert .',b'pemetrexed is selected from the group of reduced folat-carrier as well as the reinforcing folatbindenden proteintransportsystemen phenylalanine .',b'pemetrexed is the glucuronids biopsies as well as the rectal distension to well as the scaling acetamide and gliclazid wax that well as the virulence aptt ctcl of reduced correction as well as the clicking embolization circulation .',b'pemetrexed is transported from the group of reduced folate carriers as well as the reinforcing folate binding protein transport systems .'
1564,b'die mit paxene erzielten ergebnisse sind denjenigen aus ver\xc3\xb6ffentlichten paclitaxel-phase iii-studien sehr \xc3\xa4hnlich .',b'results with paxene are achieved very similar to those published paclitaxel-phase phase iii .',b'analogous results with paxene are filled very similar to similar to those rna opacities periodic iii .',b'results with paxene very similar to those from the published paclitaxel phase iii study .'
1565,b'siehe information zu \xc3\x9cberempfindlichkeitsreaktionen im kasten in den abschnitten 4.4 und 4.8 .',b'see small size \xc3\x9cberempfindlichkeitsreaktionen im kasten in sections 4.4 and 4.8 ) .',b'see small cardboard prostaglandin spect fish broilers broilers from land in weight . and . .',b'see information on hypersensitivity reactions in the box in sections 4.4 and 4.8 .'
1566,b'verwenden sie den pen genau wie in diesen hinweisen zur handha- bung beschrieben .',b'you must use the pen in these instructions on handha- be inspected .',b'you must use the pen in these instructions on existing it on a defect .',b'you must use the pen exactly how the instructions for use outline .'
1567,b'aliskiren / hydrochlorothiazid in klinischen studien erhielten mehr als 3.900 bluthochdruckpatienten einmal t\xc3\xa4glich rasilez hct .',"b'aliskiren / hydrochlorothiazide clinical trials received more than 3,900 hypertensive patients once daily rasilez hct .'","b'aliskiren hydrochlorothiazide clinical trials were more than , because patients once daily rasilez hct .'","b'aliskiren / hydrochlorothiazide clinical trials more than 3,900 hypertensive patients received rasilez hct once daily .'"
1568,b'\xe2\x80\xa2 einen schulungsplan f\xc3\xbcr \xc3\x84rzte und medizinisches personal zur risikominimierung und unterst\xc3\xbctzung der sicheren und wirksamen anwendung des produkts .',b'\xe2\x80\xa2 a \xe2\x80\xa2 an educational plan for physicians and medical staff about risk minimisation and to support safe and effective use of the product .',b'with the convenience plan for physicians and medical indication and hypoglycemia and the national national cannot continue to provision of the product .',b'\xe2\x80\xa2 a \xe2\x80\xa2 an educational plan for physicians and medical staff about risk minimisation and to support safe and effective use of the product .'
1569,"b'eine an\xc3\xa4mie tritt kurz nach einleitung der therapie auf , ist aber bei absetzen der therapie rasch reversibel .'","b'anaemia occurs shortly after initiation of therapy , but associated with previous ace inhibitor therapy is rapidly reversible .'","b'anaemia occurs influenced due to response , but to or ace inhibitor therapy is rapidly reversible .'","b'anaemia occurs shortly after initiation of therapy , but is rapidly reversible after the discontinuation of therapy .'"
1570,"b'in der studie ai455-094 , durchgef\xc3\xbchrt in s\xc3\xbcdafrika , nahmen 362 mutter-s\xc3\xa4uglings paare an einer studie zur pr\xc3\xa4vention der mutter-zu-kind-\xc3\x9cbertragung teil .'","b'in study ai455-094 , conducted in south africa , 362 mutter-s\xc3\xa4uglings declined stable in a study of mutter-zu-kind-\xc3\x9cbertragung .'","b'in study transfers , in remicadefree emetogenic b significant resulted in a study of thalassaemia horn .'","b'in study ai455-094 , conducted in south africa , 362 mother-infant pairs were included in a study of mother-to-child transmission .'"
1571,b'die bindung an plasmaproteine ist nicht ausgepr\xc3\xa4gt ( etwa 60 % ) .',b'the binding to plasma proteins is not pronounced ( about 60 % ) .',b'the binding to plasma proteins is not pronounced agenerase .',b'the binding to plasma proteins is not pronounced ( about 60 % ) .'
1572,b'diese dosisabh\xc3\xa4ngigkeit wird wahrscheinlich durch eine s\xc3\xa4ttigung der durch cyp2d6 katalysierten metabolisierung zusammen mit einer gewissen s\xc3\xa4ttigung der durch cyp3a4 in der darmwand katalysierten metabolisierung verursacht .',b'this dose is likely to be achieved apparent saturation of cyp2d6 metabolism ( 117 ) is coadministered with some apparent saturation of metabolism by cyp3a4 in the gut wall ( 117 ) .',b'this dose is likely to be achieved l in plasma disposition rate in plasma ethinyl albumin nominally of posaconazole by cypa in the gut wall .',b'this dose is likely to be achieved by apparent saturation of cyp2d6 metabolism ( 117 ) coadministered with some apparent saturation of metabolism by cyp3a4 in the gut wall ( 117 ) .'
1573,"b'in studien zur reproduktionstoxizit\xc3\xa4t , wurde bei ratten eine beeintr\xc3\xa4chtigung der fertilit\xc3\xa4t nachgewiesen .'",b'in reproductive toxicity studies in rats reveal impairment of fertility .',b'in reproductive toxicity studies in rats .',"b'in reproductive toxicity studies , impairment of their fertility was detected .'"
1574,"b'warfarin bei beginn oder beendigung einer lansoprazol-therapie bei patienten , die bereits warfarin erhalten , ist vorsicht geboten und es werden h\xc3\xa4ufigere kontrollen empfohlen .'","b'warfarin at the beginning or end of lansoprazole therapy in patients who are already receiving warfarin therapy , caution should be exercised and more frequent monitoring is recommended .'",b'warfarin at the beginning or one dose with lansoprazole therapy of fentanyl therapy .',"b'warfarin : at the beginning or end of lansoprazole therapy in patients who are already receiving warfarin therapy , caution should be exercised and more frequent monitoring is recommended .'"
1575,b'ein wiederaufbau der myelopoese erfolgte im schnitt binnen 10 tagen bei erwachsenen bzw.',b'one of the spacer occurred in 50 % within 10 days in adults .',b'one of the obr surveillance in within days in adults .',b'a myelopoiesis reoccured within 10 days in adults .'
1576,"b'dosierungs\xc3\xa4nderung treten schwere nebenwirkungen oder abnormale laborwerte w\xc3\xa4hrend der behandlung mit rebetol l\xc3\xb6sung zum einnehmen und interferon alfa-2b auf , ist die dosierung eines jeden arzneimittels entsprechend abzu\xc3\xa4ndern , bis die nebenwirkungen abklingen .'","b'dose modification for if severe adverse reactions or laboratory abnormalities develop during therapy with rebetol oral solution and interferon alfa-2b , modify the dosages of each product if appropriate , until the adverse reactions abate .'",b'dose confidence for if severe adverse reactions or laboratory abnormalities to in therapy with the cypcgenotyp upper prophylactic apnoea of each product if such the primary resistance .',"b'dose modification : if severe adverse reactions or laboratory abnormalities develop during therapy with rebetol oral solution and interferon alfa-2b , modify the dosages of each product if appropriate , until the adverse reactions abate .'"
1577,"b'eine untergruppe dieser patienten wurde w\xc3\xa4hrend der behandlung von bis zu 64 l\xc3\xa4sionen ( bereich 4-64 l\xc3\xa4sionen , median 11 , 5 l\xc3\xa4sionen ) im zeitraum von bis zu 44 wochen ( bereich 2-44 wochen , median 15 wochen ) weiter beobachtet .'","b'a subgroup of these patients were followed during the treatment of up to 64 lesions ( 4-64 lesions , median 11 , 5 lesions ) in up to 44 weeks ( 2-44 weeks , median 15 weeks ) .'","b'a subgroup patients were followed during the treatment of up to cases of up to moderately lesions , median weeks after months of , lesions in up to decrease in up to reduced changes .'","b'a subgroup of these patients were further observed during the treatment of up to 64 lesions ( in the range of 4-64 lesions , median 11 , 5 lesions ) in the period of up to 44 weeks ( 2-44 weeks , median 15 weeks ) .'"
1578,b'nicht verwendeter impfstoff oder abfallmaterial ist gem\xc3\xa4\xc3\x9f den nationalen anforderungen zu entsorgen .',b'any unused vaccine or waste materials should be discarded according to local requirements .',b'any unused vaccine or waste materials for three each insulin suspension should be discarded according to local requirements .',b'any unused vaccine or waste materials should be discarded according to local requirements .'
1579,b'die dosisgabe erfolgt \xc3\xbcber einen zeitraum von 30 minuten alle drei wochen .',b'the dosing occurs over a period of 30 minutes every three weeks .',b'the dosing is administered with cm with a period of minutes every three weeks .',b'the dosing occurs over a period of 30 minutes every three weeks .'
1580,b'n welches risiko ist mit dynepo verbunden ?',b'ed what is the risk associated with dynepo ?',b'ed what is the side associated with dynepo ?',b'what is the risk associated with dynepo ?'
1581,"b'wird eine schwangerschaft diagnostiziert , sollte die behandlung mit angiotensin-ii rezeptorantagonisten sofort unterbrochen und eine angemessene alternative behandlung begonnen werden .'","b'when pregnancy is diagnosed , treatment with aiiras should be stopped immediately , and , if appropriate , alternative therapy should be started .'","b'when pregnancy the special blood pressure , treatment with proton doses therapy one treatment , alternative therapy should be started for other therapy should be started one inomax should be considered .'","b'when pregnancy is diagnosed , treatment with aiiras should be stopped immediately , and , if appropriate , alternative therapy should be started .'"
1582,"b'unter chemotherapie liegt die dosis von emend \xc3\xbcblicherweise bei einer 125 mg-kapsel , die eine stunde vor beginn der chemotherapie eingenommen wird .'","b'in chemotherapy , the dose of emend is one 125 mg capsule , take one hour before start of chemotherapy .'","b'in chemotherapy , the dose of emend is one mg capsule after hours with .'","b'in chemotherapy , the dose of emend is one 125 mg capsule , take one hour before start of chemotherapy .'"
1583,"b'studien mit gesunden probanden haben gezeigt , dass tandemact mit der gabe von pioglitazon und glimepirid in separaten tabletten bio\xc3\xa4quivalent ist .'",b'studies in healthy volunteers have shown that tandemact to be bioequivalent to the administration of pioglitazone and glimepiride as separate tablets .',b'studies in healthy volunteers have shown that tandemact to a administration of pioglitazone and glimepiride as separate tablets .',b'studies in healthy volunteers have shown that tandemact to be bioequivalent to the administration of pioglitazone and glimepiride as separate tablets .'
1584,b'35 gonal-f wird durch subkutane injektion verabreicht .',b'35 gonal-f is intended for subcutaneous administration .',b'gonalf is intended for subcutaneous administration .',b'35 gonal-f is intended for subcutaneous administration .'
1585,b'die vollst\xc3\xa4ndige auflistung der sonstigen bestandteile siehe abschnitt 6.1 .',"b'for a full list of excipients , see section 6.1 .'","b'for a full list of excipients , see section . .'","b'for a full list of excipients , see section 6.1 .'"
1586,b'silapo darf nicht mit anderen arzneimitteln gemischt werden ( siehe abschnitt 6.2 ) .',b'silapo should not be mixed with other medicinal products ( see section 6.2 ) .',b'silapo should not be mixed with other medicinal products see section . .',b'silapo should not be mixed with other medicinal products ( see section 6.2 ) .'
1587,b'der faktor ix in diesem produkt verh\xc3\xa4lt sich genauso wie der endogene faktor ix.',b'the initial administrations of factor ix product as a biotic agent such as the endogenous factor ix .',"b'the adults of factor ix , a parvum strain such as the endogenous factor ix .'",b'factor ix in this product acts exactly like the endogenous factor ix .'
1588,"b'in kombination mit cisplatin und 5-fluorouracil treten trotz gabe von g-csf episoden von febriler neutropenie , verl\xc3\xa4ngerter neutropenie oder eine neutropenische infektion auf , sollte die dosis von docetaxel von 75 auf 60 mg / m2 reduziert werden .'","b'in combination with cisplatin and 5-fluorouracil despite g-csf episodes of febrile neutropenia , prolonged neutropenia or neutropenic infection occurs , the docetaxel dose should be reduced from 75 to 60 mg / m2 .'","b'when platin was reported with triazolam disorder with dmards . illuminate substrates especially , acetic antagonists , prolonged neutropenia or hyperkeratosis infection occurs , the docetaxel dose or existing a phosphodiesterase enzyme lh with fibrinogen enzyme with dmards , prolonged disorders with dmards tissue imbalances herpesvirus through structural myalgia of'","b'in combination with cisplatin and 5-fluorouracil despite g-csf episodes of febrile neutropenia , prolonged neutropenia or neutropenic infection occurs , the docetaxel dose should be reduced from 75 to 60 mg / m2 .'"
1589,b'2 / 3 weitere informationen \xc3\xbcber galvus :',b'2 / 3 other information about galvus :',b'other information about galvus',b'2 / 3 other information about galvus :'
1590,"b'versuchen sie bitte nicht , mehr als 25 einheiten einzustellen .'","b'do not try to , or more than 25 units .'","b'do not try to up to , or more than units .'",b'do not try to adjust to more than 25 units .'
1591,b'24 die folgenden informationen sind nur f\xc3\xbcr medizinisches fachpersonal bestimmt :',b'24 the following information is intended for intended for medical or healthcare professionals only :',b'the following information is intended for medical or healthcare here only',b'24 the following information is intended for medical or healthcare professionals only :'
1592,b'f\xc3\xbcr kinder unzug\xc3\xa4nglich aufbewahren .',"b'for summary of product characteristics , 4.2 ) .'","b'for summary of product characteristics , . .'",b'keep out of reach of children .'
1593,b'erkrankungen des gastrointestinaltrakts sehr h\xc3\xa4ufig :',b'gastrointestinal disorders very common :',b'gastrointestinal disorders very common',b'gastrointestinal disorders very common :'
1594,b'diese abnahme ist wahrscheinlich auf eine autoinduktion der stoffwechselenzyme der leber zur\xc3\xbcckzuf\xc3\xbchren .',b'this decline is likely to result from a autoinduction of the hepatic n = 57 ) .',b'the main does to result from a antianginal of the hepatic n .',b'this decline is likely to result from a autoinduction of the metabolizing hepatic enzyme .'
1595,b'in der sp-studie nahm zoster in fast allen dermatomen ab .',"b'in the sps , the reduction in almost all dermatomes .'","b'in the competition , the reduction in almost all blutpartikel levels .'","b'in the sps study , zoster reduced in almost all dermatomes .'"
1596,b'mixtard muss vor \xc3\xbcberm\xc3\xa4\xc3\x9figer hitze und sonnenlicht gesch\xc3\xbctzt werden .',b'mixtard must be protected from excessive heat and sunlight .',b'mixtard must be protected on excessive heat and sunlight .',b'mixtard must be protected from excessive heat and sunlight .'
1597,b'diese sind in anhang iii f\xc3\xbcr ciprofloxacin nycomed und damit verbundene bezeichnungen ( siehe anhang i ) enthalten .',b'these are set out in annex iii for ciprofloxacin nycomed and associated names ( see annex i ) .',b'these are set out in annex iii for anaerobes wishes',b'these are set out in annex iii for ciprofloxacin nycomed and associated names ( see annex i ) .'
1598,"b'informieren sie ihren arzt , wenn sie jemals eine krebserkrankung hatten .'",b'tell your doctor if you have ever had cancer .',b'tell your doctor if you have ever had risk effects .',b'tell your doctor if you have ever had cancer .'
1599,"b'die h\xc3\xa4ufigkeit wird definiert als : sehr h\xc3\xa4ufig ( > 1 / 10 ) ; h\xc3\xa4ufig ( > 1 / 100 , < 1 / 10 ) ; gelegentlich ( > 1 / 1000 , < 1 / 100 ) .'","b'frequencies are defined as : very common ( 1 / 10 ) ; common ( > 1 / 100 , 1 / 10 ) ; uncommon ( > 1 / 1 , 000 , 1 / 100 ) .'","b'frequencies are defined as very common disorders uncommon , , .'","b'frequencies are defined as : very common ( 1 / 10 ) ; common ( > 1 / 100 , 1 / 10 ) ; uncommon ( > 1 / 1 , 000 , 1 / 100 ) .'"
1600,b'pulver in einem fl\xc3\xa4schchen ( glasart i ) mit einem stopfen ( butyl-gummi ) und flip-off-verschluss ( aluminium ) und l\xc3\xb6sungsmittel in einem fl\xc3\xa4schchen ( glasart i ) mit stopfen ( chlorobutyl-gummi ) und flip-off-verschluss ( aluminium ) in packungsgr\xc3\xb6\xc3\x9fen zu 1x1 und 10x1 impfdosis .',b'powder in a vial ( type 1 glass ) with a stopper ( butyl rubber ) and flip off cap ( aluminium ) and solvent in a vial ( type 1 glass ) with stopper ( chlorobutyl rubber ) and flip off cap ( aluminium ) in a pack size of 1 and 10 .',b'powder in a vial type glass with a stopper butyl rubber and exipients off cap yellow of plastic aluminium cap aluminium nutrition pack glass with stopper bromobutyl without of bottles total white free aluminium butyl polypropylenlevels within a screw rubber aluminium aluminium aluminium to a pack size of and .',b'powder in a vial ( type 1 glass ) with a stopper ( butyl rubber ) and flip off cap ( aluminium ) and solvent in a vial ( type 1 glass ) with stopper ( chlorobutyl rubber ) and flip off cap ( aluminium ) in pack sizes of 1x1 and 10x1 vaccine doses .'
1601,b'nicht mit einem anderen impfstoff oder immunologischen produkt mischen .',b'do not mix with any other vaccine or immunological product .',b'do not mix with any other vaccine or disease .',b'do not mix with any other vaccine or immunological product .'
1602,"b'humanes fibrinogen : argininhydrochlorid , glycin , natriumchlorid , natriumcitrat , calciumchlorid , wasser f\xc3\xbcr injektionszwecke .'","b'human fibrinogen : , l-arginine hydrochloride , glycine , sodium chloride , calcium chloride , sodium citrate , calcium chloride , water for injections .'","b'human herpes , yellowishbrown hydrochloride , a moderate means of crixivantm , sodium iv , calcium chloride , sodium citrate dihydrate , perforated technology , sodium citrate , sodium citrate , sodium citrate , milky citrate , sodium foil , disodium chloride , calcium chloride , magnesium iv , sodium'","b'human fibrinogen : l-arginine hydrochloride , glycine , sodium chloride , calcium chloride , water for injections .'"
1603,b'kinder und jugendliche livensa darf nicht von kindern und jugendlichen angewendet werden .',b'children and adolescents livensa should not be given to children and adolescents .',b'children and adolescents carbaglu should not be given to children and adolescents .',b'children and adolescents . livensa should not be given to children and adolescents .'
1604,"b'es gibt packungen zu 1 , 3 , und 10 durchstechflaschen , denen jeweils die entsprechende anzahl durchstechflaschen mit l\xc3\xb6sungsmittel oder l\xc3\xb6sungsmittelampullen beigef\xc3\xbcgt ist .'","b'it is supplied in packs of 1 , 3 and 10 vials with the corresponding number of solvent vials of solvent or solvent ampoules .'","b'it is supplied in packs of , and further daily to contain .'","b'it is supplied in packs of 1 , 3 and 10 vials with the corresponding number of solvent vials or solvent ampoules enclosed .'"
1605,b'mehrlingsschwangerschaften stellen um den geburtstermin herum ein erh\xc3\xb6htes gesundheitsrisiko f\xc3\xbcr die mutter und ihre kinder dar .',b'multiple gestations represent the given at an increased risk of the mother and you should not breast feed their children .',b'multiple gestations represent the given at an increased risk of the central and you should not breast feed serious tablets',b'multiple pregnancies represent at the due date an increased risk for the mother .'
1606,"b'ebenso sollen sie alle gebrauchten alkoholtupfer und durchstechflaschen auf sicherem wege entsorgen , auch wenn die durchstechflaschen noch reste des arzneimittels oder des wassers f\xc3\xbcr injektionszwecke enthalten .'","b'you should safely dispose of all used alcohol swabs and vials in addition , even if the vials are stored unused amounts of medicine or water for injections .'","b'you should look dispose of all used alcohol , even if the vials are injection of medicine or water for injections .'","b'you should safely dispose of all used alcohol swabs and vials , even if the vials are storing unused amounts of medicine or water for injections .'"
1607,b'bei der anwendung von firazyr bei patienten mit akuter isch\xc3\xa4mischer herzkrankheit oder instabiler angina pectoris ist daher vorsicht angezeigt ( siehe abschnitt 5.3 ) .',b'in the use of firazyr in patients with acute ischaemic heart disease or unstable angina is therefore caution is required ( see section 5.3 ) .',b'in the use of anticonvulsants in patients with acute ischaemic heart disease or unstable angina is have recommended see section . .',"b'in the use of firazyr in patients with acute ischaemic heart disease or unstable angina , caution is required ( see section 5.3 ) .'"
1608,"b'im rahmen des klinischen rasagilin-programms wurden insgesamt 1361 patienten 3076,4 patientenjahre lang mit rasagilin behandelt .'","b'during the clinical rasagilin-programms included a total of one component in patients 3076,4 patient-years treated with rasagiline .'","b'during the clinical document included a total of one component in patients , patientyears treated with rasagiline .'","b'during the clinical rasagilin-programms , a total of 1,361 patients were treated with rasagiline for 3076.4 patient-years .'"
1609,"b'187 auftreten k\xc3\xb6nnen . sollten die geschilderten symptome auftreten , ist so schnell wie m\xc3\xb6glich eine sorgf\xc3\xa4ltige \xc3\xa4rztliche untersuchung angezeigt .'","b'187 can occur . should the above mentioned symptoms occur , as soon as possible , a careful medical examination is indicated .'","b'can occur . should the injection where as hypersensitivity , a careful medical examination is indicated .'","b'187 can occur . should the above mentioned symptoms occur , a careful medical examination is indicated as soon as possible .'"
1610,"b'in kombination mit einem ppar\xce\xb3 -agonisten , wenn di\xc3\xa4t und bewegung plus monotherapie mit einem ppar\xce\xb3 -agonisten den blutzucker nicht ausreichend senken .'",b'in combination with a ppar\xce\xb3 agonist when diet and exercise plus monotherapy with a ppar\xce\xb3 agonist do not provide adequate glycaemic control .',b'in combination with a bacteria disorder can be adjusted in months to a bacteria agonists have been reduced lower control of the transdermal blockage with a administered antimicrobial smoke and exercise programmes in dose are described the controlled .',"b'in combination with a ppar\xce\xb3 agonist , if diet and exercise plus monotherapy with a ppar\xce\xb3 agonist do not provide adequate glycaemic control .'"
1611,b'b. betablockern oder der wechsel von einem insulin tierischen ursprungs zu einem humaninsulin .',b'( e. g. beta-blockers or change their usual insulin to human insulin .',b'e . g . halofantrine or change have been reported ml . for clinical preparation to human insulin to human insulin .',b'b. beta-blockers or the change to an insulin of animal origin to human insulin .'
1612,"b'baden , duschen , schwimmen und sport sollten das pflaster nicht beeinflussen , solange sie beim waschen nicht \xc3\xbcber das pflaster reiben .'","b'bathing , showering , swimming and exercise should not interfere with the patch as long as you are in a temperature not above the patch rubbing it .'","b'hypokalemia , multifaceted , remnants and exercise should not undertaken will continue to possible , recognise as you are in the patch recurred the patch phase site by the optician time , if they shirt not you have enough by a injection medicinal hands scintigraphy to protective contact of the'","b'bathing , showering , swimming and exercise should not interfere with the patch as long as you do not rub the plaster while washing .'"
1613,"b'b. cyp2c19 , cyp2d6 und cyp3a4 .'","b'for example , cyp2c19 , cyp2d6 and cyp3a4 .'",b'cypc infusion of full or cypa .',"b'for example , cyp2c19 , cyp2d6 and cyp3a4 .'"
1614,b'bei der anwendung bei patienten mit stenosierenden magengeschw\xc3\xbcren und pyloroduodenaler obstruktion ist vorsicht geboten .',b'when used in patients with stenosierenden stomach ulcers and pyloroduodenaler obstruction should be used with caution .',b'if used in patients with anaerobic stomach ulcers and tricyclic carbohydrates should be used with caution .',b'should be used with caution in patients with stenosing stomach ulcers and pyloroduodenaler obstruction .'
1615,b'insgesamt wurden 1.323 patienten ( 879 in der mit wirkstoff behandelten gruppe und 444 in der kontrollgruppe ) eingeschlossen .',b'a total of 1.323 patients ( 879 ) in the active treatment group and 444 in the control group .',b'a total of . patients in the upper bone active treatment group and in the either points .',"b'a total of 1,323 patients ( 879 in the active treatment group and 444 in the control group ) were involved .'"
1616,b'die sicherheit von fentanyl in der schwangerschaft wurde nicht nachgewiesen .',b'the safety of fentanyl in pregnancy has not been established .',b'the safety of fentanyl in pregnancy has not adequately reported .',b'the safety of fentanyl in pregnancy has not been established .'
1617,b'atazanavir wird in der leber durch cyp3a4 metabolisiert .',b'atazanavir is metabolized in the liver by cyp3a4 .',b'atazanavir is taken from to very therefore in the liver by cypa .',b'atazanavir is metabolized in the liver by cyp3a4 .'
1618,b'wof\xc3\xbcr wird previcox angewendet ?',b'what is previcox used for ?',b'what is previcox used for ?',b'what is previcox used for ?'
1619,b'im fall einer versehentlichen selbstinjektion ziehen sie sofort einen arzt zu rate und lassen sie das implantat entfernen .',"b'in case of accidental self-injection , seek medical advice immediately and leave the implant .'","b'in case of accidental selfinjection , seek medical advice nurse from you again .'","b'in case of accidental self-injection , seek medical advice immediately and leave the implant .'"
1620,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr inductos finden sie hier .',b'the full epar for avamys for inductos can be found here .',b'the full epar for inductos can be found here .',b'the full text on epar for inductos can be found here .'
1621,"b'daher wird eine \xc3\x9cberwachung von 4 hauterkrankungen hinsichtlich blasenbildung und ulzera , wie es bei diabetischen patienten routine ist , empfohlen .'","b'therefore , monitoring of 4 blistering or ulceration , such as in diabetic patients part of normal medical practice .'","b'therefore , an treatment of treatment who should be reduced the emergency deficiency see such as may in diabetic patients part of normal medical practice .'","b'therefore , monitoring of 4 skin diseases for blistering or ulceration , such as part of normal patient practice with diabetes .'"
1622,b'das verfalldatum bezieht sich auf den letzten tag des monats .',b'the expiry date refers to the last day of that month .',b'the expiry date refers to the last day of that month .',b'the expiry date refers to the last day of that month .'
1623,b'bei den f\xc3\xbcr diagnostische verfahren eingesetzten konzentrationen und aktivit\xc3\xa4ten scheint leukoscan keine pharmakodynamischen wirkungen auszu\xc3\xbcben .',b'in a human heavy chain concentrations and activities of leukoscan appears to be no pharmacodynamic effects .',b'in a human degrees validated isoenzyme pigs . of leukoscan can not be no pharmacodynamic effects .',"b'at the concentrations and activities used for diagnostic procedures , leukoscan appears not to exert any pharmacodynamic effects .'"
1624,"b'47 da das pflaster nach au\xc3\x9fen hin durch eine wasserdichte tr\xc3\xa4gerfolie gesch\xc3\xbctzt wird , kann es auch beim duschen getragen werden .'","b'47 as the transdermal patch is protected by an outer waterproof backing film , it can also be worn while showering .'","b'as the transdermal patch is protected by an outer waterproof backing position , it can also be glucuronidation and hospital while showering .'","b'47 as the transdermal patch is protected by an outer waterproof backing film , it can also be worn while showering .'"
1625,b'unter < phantasiebezeichnung > wurde \xc3\xbcber ebv-verwandte lymphoproliferative erkrankungen berichtet .',b'with invented name has been ebv-verwandte lymphoproliferative disorder have been reported .',b'with invented name has been consistently frequently for interstitial dependance in association to at helicobacter artery disorder associated to it has reported .',b'with > invented name < ebv-realted lymphoproliferative disorders have been reported .'
1626,b'dies ist normal .',b'this is normal .',b'this is normal is normal .',b'this is normal .'
1627,"b'influenza-spaltvirus , inaktiviert , das ein antigen * enth\xc3\xa4lt entsprechend :'","b'split influenza virus inactivated , containing antigen * equivalent to :'","b'pylobactell influenza virus inactivated , containing antigen equivalent to'","b'split influenza virus inactivated , containing antigen * equivalent to :'"
1628,b'h\xc3\xa4ufig : \xc3\x96deme / fl\xc3\xbcssigkeitsretention . gelegentlich :',b'common : oedema / fluid retention uncommon :',b'common infarction defined this is inhibitors very rare body inhibitors as',b'common : oedema / fluid retention uncommon :'
1629,"b'diese l\xc3\xb6sung ist dann mit weiteren 9 ml des l\xc3\xb6sungsemittels zu verd\xc3\xbcnnen , so dass sich ein endvolumen von 20,5 ml und eine konzentration von 49 mg / ml ergeben .'",b'this solution is then treated with an additional 9 ml of the l\xc3\xb6sungsemittels should be diluted to a final concentration between 20.5 ml and a concentration of 49 mg / ml .',b'this solution is then those during nsaids .',b'this solution is then treated with an additional 9 ml of the solution so that there is a final volume of 20.5 ml and a concentration of 49 mg / ml .'
1630,b'montelukast liegt zu mehr als 99 % an plasmaeiwei\xc3\x9f gebunden vor .',b'montelukast is more than 99 % plasmaeiwei\xc3\x9f .',b'montelukast is only the skin test should possible .',b'montelukast is more than 99 % plasma proteins .'
1631,b'2 die h\xc3\xa4ufigkeit des auftretens ist zu beginn der behandlung h\xc3\xb6her .',b'2 frequency is higher at the beginning of treatment .',b'frequency is subcutaneous concentration of treatment .',b'2 frequency is higher at the beginning of treatment .'
1632,b'begrenzte daten aus einer einzelnen nicht kontrollierten studie wiesen auf eine wechselwirkung zwischen docetaxel und carboplatin hin .',b'limited data from a single non-controlled study demonstrated an interaction between docetaxel and carboplatin .',"b'limited data from a single gonadotrophic , atorvastatin and fat insulin properties .'",b'limited data from a single non-controlled study demonstrated an interaction between docetaxel and carboplatin .'
1633,"b'pharmakodynamische wirkungen levetiracetam gew\xc3\xa4hrt in einer vielzahl von tiermodellen f\xc3\xbcr partielle und prim\xc3\xa4r generalisierte anf\xc3\xa4lle einen anfallsschutz , ohne einen prokonvulsiven effekt zu haben .'",b'pharmacodynamic effects of levetiracetam in a broad range of animal models of partial and primary generalised seizures induces seizure without having a pro-convulsant effect .',b'pharmacodynamic effects of levetiracetam in a broad capacity of tyrosine and primary destruction isoenzyme inducers of pancreatic ifn inflammatory effect .',b'pharmacodynamic effects . levetiracetam granted protection against partial and primary generalised seizures in a broad range of animal model without having a pro-convulsant effect .'
1634,b'fluoxetin wird haupts\xc3\xa4chlich in der leber durch demethylierung zu dem wirksamen metaboliten norfluoxetin ( demethylfluoxetin ) metabolisiert .',b'fluoxetine is primarily metabolised in the liver medications known to the active metabolite norfluoxetine ( demethylfluoxetin ) .',b'fluoxetine is primarily metabolised in the liver ulceration known to the active metabolite eats egfr represent a continuous with deficiency .',b'fluoxetine is primarily metabolised in the liver by demthylation into the active metabolite norfluoxetine ( demethylfluoxetin ) .'
1635,b'eine empfehlung zur dosisanpassung bei kombination von kaletra mit nevirapin kann nicht gegeben werden .',b'a recommendation for dose adjustments in combination of kaletra and nevirapine cannot be given .',b'a recommendation for dose adjustments in combination of kaletra oral dose adjustments in combination of kaletra led to azacitidine can be given .',b'a recommendation for dose adjustments in combination of kaletra and nevirapine cannot be given .'
1636,"b'es besteht keine notwendigkeit , die dosierungen der anderen arzneimittel , mit denen tesavel eingenommen wird , zu \xc3\xa4ndern , au\xc3\x9fer wenn tesavel zusammen mit einem sulfonylharnstoff verabreicht wird .'","b'there is no need to change the doses of the other medicines tesavel is taken with , except when tesavel is taken with a sulphonylurea .'",b'there is no need to change the doses . accidental contraception .',"b'there is no need to change the doses of the other medicines tesavel is taken with , except when tesavel is taken with a sulphonylurea .'"
1637,"b'patienten , die mit cellcept behandelt werden , sind bez\xc3\xbcglich des auftretens einer neutropenie zu \xc3\xbcberwachen , die auf cellcept selbst , auf die begleitmedikation , virale infektionen oder eine kombination dieser ursachen zur\xc3\xbcckzuf\xc3\xbchren sein kann .'","b'patients treated with cellcept due to neutropenia , cellcept itself , concomitant medications , viral infections , or some combination of these causes .'","b'patients treated with cellcept due to neutropenia , other dependence , or some combination of these initial infections , or some combination of these internal .'","b'patients treated with cellcept should be monitored for neutropenia , which can cause viral infections or some combination of these causes .'"
1638,"b'die erfahrungen mit efavirenz bei patienten , die andere antiretrovirale wirkstoffe der nnrti-klasse abgesetzt haben , sind begrenzt .'",b'experience with efavirenz in patients who discontinued other antiretroviral agents of the nnrti class is limited .',b'data with efavirenz in patients who discontinued other antiretroviral agents of a moderate ulcer class level is limited .',b'experience with efavirenz in patients who discontinued other antiretroviral agents of the nnrti class is limited .'
1639,"b'stechen sie die nadel durch den gummistopfen der durchstechflasche und dr\xc3\xbccken sie den spritzenkolben , um luft in die durchstechflasche zu injizieren ( siehe abbildung 2 ) .'",b'insert the needle through the rubber stopper of the vial and push the plunger to inject air into the vial ( see figure 2 ) .',b'insert the needle through the rubber stopper of ionsys the vial and push the plunger to inject air into the vial see figure .',b'insert the needle through the rubber stopper of the vial and push the plunger to inject air into the vial ( see figure 2 ) .'
1640,"b'nach dem aufl\xc3\xb6sen sollte die tygacil-l\xc3\xb6sung eine gelbe bis orange farbe haben . ist dies nicht der fall , ist die l\xc3\xb6sung zu verwerfen .'","b'after reconstitution , the tygacil-l\xc3\xb6sung should be yellow to orange in colour . if not , the solution should be discarded .'","b'after reconstitution , the ending should be reduced by a powder should be discarded .'","b'after reconstitution , the tygacil solution should be yellow to orange in colour . if not , the solution should be discarded .'"
1641,"b'bevor mit der omnitrope-behandlung begonnen wird , sollten sie durch einen arzt auf atemprobleme und atemwegsinfektionen untersucht werden , selbst wenn sie keine anzeichen von atembeschwerden versp\xc3\xbcren .'","b'before starting on omnitrope , you should be given by a doctor for breathing problems and respiratory infections , even if you have not been experiencing any symptoms of breathing difficulty .'","b'before starting on omnitrope , you should be given by a doctor effects should be given by a doctor had cause or sweating or respiratory infections , even if you have not been tolerate any symptoms of breathing difficulty .'","b'before starting on omnitrope , you should be examined by a doctor for breathing problems and respiratory infections , even if you have not been experiencing any symptoms of breathing difficulty .'"
1642,"b'byetta ist eine injektionsl\xc3\xb6sung , die den wirkstoff exenatide enth\xc3\xa4lt .'",b'byetta is a solution for injection that contains the active substance exenatide .',b'byetta is a solution for injection that twinrix the active substance blocker .',b'byetta is a solution for injection that contains the active substance exenatide .'
1643,b'nicht mit anderen tierarzneimitteln mischen .',b'do not mix with any veterinary medicinal product .',b'do not mix with any veterinary medicinal product .',b'do not mix with any veterinary medicinal product .'
1644,"b'aufgrund der ergebnisse aus pharmakokinetischen studien sollte rauchern geraten werden , w\xc3\xa4hrend der behandlung mit tarceva das rauchen einzustellen , da die plasmakonzentrationen sonst reduziert sein k\xc3\xb6nnten .'","b'based on results from pharmacokinetic studies , smokers should be advised to take during treatment with tarceva , as plasma concentrations are reduced otherwise could be reduced .'","b'based on results from pharmacokinetic studies , rabbits should be found not for pregnancy , dosages might be reduced infections in should been reduced drugs during treatment with hours of tarceva , as plasma concentrations are reduced problems .'","b'based on results from pharmacokinetic studies , smokers should be advised to cease smoking during treatment with tarceva , as plasma concentrations could be reduced .'"
1645,b'singulair als asthma-prophylaxe bei 2 bis 5j\xc3\xa4hrigen kindern mit belastungsinduzierter bronchokonstriktion als \xc3\xbcberwiegender komponente :',b'27 singulair as an alternative asthma-prophylaxe in 2 to 5 year old children with belastungsinduzierter bronchoconstriction as \xc3\xbcberwiegender :',b'maternotoxic as an alternative absorbtion in to year exposure whose evaluation in adults testing as with eighteen carcinoma .',b'27 singulair as an alternative asthma-prophylaxe in 2 to 5 year old children with pain inducing bronchoconstriction as the predominant component :'
1646,b'drehen sie die gesamte einheit ( flasche mit dispenser ) um ( siehe abbildung 3 ) .',b'turn the bottle ( dispenser ) upside down ( see picture 3 ) .',b'turn the bottle bag upside down before insert .',b'turn the bottle ( dispenser ) upside down ( see picture 3 ) .'
1647,b'datum der erteilung der zulassung : 04 .',b'date of first authorisation : 04 .',b'date of first authorisation .',b'date of first authorisation : 04 .'
1648,b'jedoch wurden bei patienten mit atopischem ekzem unter der behandlung mit ( name ( phantasiebezeichnung ) keine signifikanten systemischen pimecrolimus-spiegel nachgewiesen .',"b'however , in patients with atopic dermatitis during treatment with invented name did not have significant systemic pimecrolimus levels .'","b'however , in patients with combinations ambirix during treatment with invented name were rarely significant systemic pimecrolimus fosamprenavir .'","b'however , patients with atopic dermatitis did not have significant systemic pimecrolimus levels during treatment with ( invented name ) .'"
1649,"b'betaferon ist ein steriles , wei\xc3\x9fes bis wei\xc3\x9fliches pulver zur herstellung einer injektionsl\xc3\xb6sung .'","b'betaferon is a sterile , white to off-white powder for solution for injection .'","b'betaferon is a sterile , white to offwhite .'","b'betaferon is a sterile , white to off-white powder for solution for injection .'"
1650,"b'entgiftende mittel zur zytostatischen behandlung , atc-code :'","b'interdigitated circumferential slits to suppress cytostatic therapy , atc code :'","b'ibraxion , yellowishbrown against considerable connection with haloperidol , atc code'","b'detoxifying agents for cytostatic therapy , atc code :'"
1651,"b'lassen sie die verschlusskappe aufgesetzt , wenn novorapid flexpen nicht in gebrauch ist , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'keep the cap on when novorapid flexpen is not in use in order in order to protect from light .',b'keep the cap on if novorapid flexpen is not in use in order to protect from light .',b'keep the cap on when novorapid flexpen is not in use in order in order to protect the contents from light .'
1652,"b'thromboembolien sehr selten ( < 0,01 % ) wurde ein zeitlicher zusammenhang zwischen einer olanzapin-behandlung und ven\xc3\xb6sen thromboembolien ( vte ) berichtet .'",b'venous thromboembolism has very rarely ( 0.01 % ) been olanzapine treatment and venous thromboembolism ( vte ) have been reported .',b'thromboembolism jaundice has very rarely . been olanzapine treatment and venous thromboembolism vte have been reported have been reported .',b'thromboembolism : very rarely ( < 0.01 % ) a temporal association between a olanzapine treatment and venous thromboembolism ( vte ) has been reported .'
1653,"b'das lennox-gastaut-syndrom ist eine schwer zu behandelnde erkrankung , bei der eine monotherapie selten ausreicht .'",b'the lennox-gastaut syndrome is a severe 8.99mol % in the monotherapy rarely .',"b'the crease syndrome is a severe anorexia except , a high concentration of coaprovel .'",b'the lennox-gastaut syndrome is a severe disease that is difficult to treat and a monotherapy is rarely enough .'
1654,b'in klinischen studien mit erwachsenen f\xc3\xbchrten unbeabsichtigt h\xc3\xb6here anwendungen von bis zu 3 g pro tag nicht zu klinisch signifikanten nebenwirkungen .',b'in clinical trials in adults and has led to higher doses of up to 3 g per day did not result in clinically significant adverse events .',"b'in clinical trials in adults and has instructed , within higher doses of up to liver significant adverse events .'","b'in clinical trials in adults , unintentional higher doeses of up to 3 g per day did not result in clinically significant adverse events .'"
1655,"b'da ibuprofen m\xc3\xb6glicherweise die clearance von aminoglykosiden verringert , wird eine strikte \xc3\x9cberwachung der serum-spiegel bei gleichzeitiger gabe von ibuprofen empfohlen .'","b'since ibuprofen may reduce the clearance of aminoglycosides ( xvi ) , serum free ige levels monitoring is recommended when co-administered with ibuprofen .'","b'since ibuprofen may reduce the clearance of inhibiting virus serum there is recommended when coadministered with different insulin concentration s therapeutic a triazolam de pointes inhibitor acids leukocyturia , serum diagnostic steroids levels , serum and administered , serum levels should be been permanent therapy , serum small detected level'","b'since ibuprofen may reduce the clearance of aminoglycosides ( xvi ) , serum free ige levels monitoring is recommended when co-administered with ibuprofen .'"
1656,b'es sollte ein d\xc3\xbcnner strahl insulin an der spitze der nadel austreten .',b'it should be a stream of insulin comes out of the needle must appear at the needle tip .',b'it should be a new injection site within pressing .',b'a thin stream of insulin leave the needle tip .'
1657,b'advagraf wird mit der muttermilch ausgeschieden .',b'advagraf is excreted in breast milk .',b'advagraf is excreted in breast milk .',b'advagraf is excreted in breast milk .'
1658,b'wie ist myfenax einzunehmen ?',b'how to take myfenax 4 .',b'how to take myfenax .',b'how to take myfenax 4 .'
1659,b'kinder sonata ist kontraindiziert f\xc3\xbcr kinder ( siehe abschnitt 4.3 ) .',b'paediatric patients sonata is contraindicated in children ( see section 4.3 ) .',b'paediatric patients',b'paediatric patients : sonata is contraindicated in children ( see section 4.3 ) .'
1660,b'bei versehentlicher selbstinjektion ist unverz\xc3\xbcglich ein arzt zu rate zu ziehen und die packungsbeilage oder das etikett dem arzt zu zeigen .',"b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'","b'in case of accidental selfinjection you to another medical advice , cessation medical advice immediately and show the package leaflet or the label to the physician .'","b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'"
1661,b'ein aktualisierter risiko-management-plan sollte entsprechend der chmp guideline on risk management systems for medicinal products for human use zur verf\xc3\xbcgung gestellt werden .',b'an updated risk management plan should be provided as per the chmp guideline on risk management system for medicinal products for human use .',b'an updated in the updated benefit information should be provided as per the chmp guideline on risk management system for human use .',b'an updated risk management plan should be provided as per the chmp guideline on risk management system for medicinal products for human use .'
1662,b'die kombination von rebetol und interferon alfa-2b hat sich als eine wirksamere behandlung f\xc3\xbcr die hepatitis c-virus-infektion erwiesen als interferon alfa-2b allein .',b'the combination of rebetol and interferon alfa-2b were shown to be a more treatment for hepatitis c c-virus-infektion been established as interferon alfa-2b alone .',b'the combination of effect and interferon alfab in the patients has also no appropriate c nosebleeds was established as interferon alfab alone .',b'the combination of rebetol and interferon alfa-2b were shown to be a more effective treatment for hepatitis c viral infection than interferon alfa-2b alone .'
1663,b'das arzneimittel darf nicht im abwasser oder haushaltsabfall entsorgt werden .',b'this medicinal product should be disposed of in accordance with local requirements .',b'this medicinal product should be disposed of in sewage water or household recovery should be disposed of in sewage water .',b'this medicinal product should be disposed of in accordance with local requirements .'
1664,"b'frauen sind darauf hinzuweisen , dass eine schwangerschaft w\xc3\xa4hrend der behandlung mit paxene durch anwendung einer wirksamen form der empf\xc3\xa4ngnisverh\xc3\xbctung zu vermeiden ist .'",b'women should be advised that pregnant during treatment with paxene to use contraception should be avoided .',"b'women should be advised to appropriate contraception periodically , medication should be avoided .'",b'women should note that pregnancy during treatment with paxene should be avoided by using contraception .'
1665,b'wechselwirkungsstudien mit bosentan und antiretroviralen arzneimitteln wurden nicht durchgef\xc3\xbchrt .',b'no interaction studies with bosentan and antiretrovirals have not been performed .',b'no interaction studies with bosentan and nacetyltransferase have not been performed .',b'no interaction studies with bosentan and antiretrovirals have not been performed .'
1666,b'9 die gemeinsame verabreichung von lamivudin mit intraven\xc3\xb6sem ganciclovir oder foscarnet wird bis zum vorliegen weiterer informationen nicht empfohlen .',b'9 co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended until further information is available .',b'coadministration of lamivudine with intravenous calcium agents and f is not recommended until further information is available .',b'9 co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended until further information is available .'
1667,b'innerhalb von 48 stunden nach der injektion werden ungef\xc3\xa4hr 60 % der injizierten radioaktivit\xc3\xa4t renal ausgeschieden ; die exkretion \xc3\xbcber die f\xc3\xa4zes wurde auf ca.',"b'within 48 hours after injection , approximately 60 % of the injected dose of radioactivity eliminated by the renal excretion in the faeces was estimated to be approx .'","b'within hours after injection , approximately of the injected dose of radioactivity eliminated by the chronic range of radioactivity throughout a median of the concomitant end of the accumulation rate range rate systemic the removal of radioactivity increases by the range of radioactivity eliminated by the significant excretion in the'","b'within 48 hours after injection , approximately 60 % of the injected dose of radioactivity eliminated by the renal excretion in the faeces was estimated to be approx .'"
1668,"b'dosen von 400 mg oder 600 mg sollten einmal t\xc3\xa4glich verabreicht werden , w\xc3\xa4hrend tagesdosen von 800 mg auf zweimal t\xc3\xa4glich 400 mg ( morgens und abends ) aufgeteilt werden sollen .'","b'doses of 400 mg or 600 mg should be administered once daily , whereas a daily dose of 800 mg to 400 mg twice daily ( morning and evening ) should be given in two divided doses .'","b'doses of mg or mg should be administered once daily , whereas a daily dose of mg to increments twice daily a daily dose of mg to a daily dose of mg to mg twice daily dose of mg to mg twice daily in two period of mg to mg'","b'doses of 400 mg or 600 mg should be administered once daily , whereas a daily dose of 800 mg should be given in two divided doses : 400 mg twice daily ( morning and evening ) .'"
1669,"b'evicel wird als unterst\xc3\xbctzende behandlung zur verbesserung der h\xc3\xa4mostase bei operationen angewendet , bei denen chirurgische techniken nicht ausreichend sind ( siehe abschnitt 5.1 ) .'","b'evicel is given as supportive treatment for improvement of haemostasis used in surgery , not experiencing behavioural intervention ( see section 5.1 ) .'",b'evicel is given as supportive treatment for alcohol of doxastad used in surgery .',b'evicel is given as supportive treatment for improvement of haemostasis used in operations in which surgical technique is not sufficient ( see section 5.1 ) .'
1670,"b'unabh\xc3\xa4ngig davon wurden diese ergebnisse von einem radiologen-gremium , dem die behandlungsweise nicht bekannt war , best\xc3\xa4tigt .'","b'whether these findings in a radiologen-gremium , the transplant rejection is not known , was confirmed .'","b'whether these findings in a pt , the increase rejection is not known .'","b'regardless , these findings were confirmed by a radiology panel which was unaware of the treatment .'"
1671,"b'aus den erfahrungen nach markteinf\xc3\xbchrung liegen berichte \xc3\xbcber \xc3\x9cberempfindlichkeitsreaktionen vor , die auch in einzelf\xc3\xa4llen ein angio\xc3\xb6dem einschlie\xc3\x9fen .'","b'of the postmarketing experience there have been reports of hypersensitivity reactions , including angioedema , in isolated cases .'","b'of the postmarketing experience in stable and expected adverse reactions , including angioedema , in death cases .'","b'of the postmarketing experience there have been reports of hypersensitivity reactions , including angioedema in isolated cases .'"
1672,b'die pharmakokinetischen eigenschaften von lamivudin und abacavir sind weiter unten beschrieben .',b'the pharmacokinetic properties of lamivudine and abacavir are listed below .',b'the pharmacokinetic properties of lamivudine and abacavir are listed below .',b'the pharmacokinetic properties of lamivudine and abacavir are listed below .'
1673,"b'h\xc3\xb6here raloxifendosen f\xc3\xbchren zu einer vergr\xc3\xb6\xc3\x9ferung der fl\xc3\xa4che unter der plasmakonzentrations-zeitkurve ( auc ) , die etwas geringer ausf\xc3\xa4llt als eine proportionale vergr\xc3\xb6\xc3\x9ferung .'",b'higher raloxifendosen lead to enlargement of the area under the curve ( auc ) of plasmakonzentrations-zeitkurve slightly larger than the growth of the enlargement of the stack ( 20 ) .',b'higher multidosepreperation lead to evaluate thiazide duloxetinetreated not slightly if the average stomach rate of the revaccination auc rate .',"b'higher raloxifene doeses lead to enlargement of the area under the plasma concentration time curve ( auc ) , which is slightly smaller than a proportional growth .'"
1674,"b'mit der behandlung sollte nur begonnen werden , wenn eine betreuungsperson zur verf\xc3\xbcgung steht , die die regelm\xc3\xa4\xc3\x9fige einnahme von axura durch den patienten \xc3\xbcberwacht .'",b'treatment should only be started if a caregiver is available who will regularly monitor the use of axura by the patient .',b'treatment should only be started if an caregiver is available who will regularly appropriate the use of cure by the patient .',b'treatment should only be started if a caregiver is available who will regularly monitor the use of axura by the patient .'
1675,b'* der kausalzusammenhang ist nicht f\xc3\xbcr alle nebenwirkungen gekl\xc3\xa4rt .',b'* causality has not been determined for all adverse events is not understood .',b'acarbose has not been determined for all adverse events is not understood .',b'* causality has not been determined for all adverse events .'
1676,b'bei versehentlicher selbstinjektion ist unverz\xc3\xbcglich ein arzt zu rate zu ziehen und die packungsbeilage oder das etikett dem arzt vorzuzeigen .',"b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'","b'in case of accidental selfinjection , seek medical advice , seek medical advice or recommend , close two blood leaflet or the label to the physician .'","b'in case of accidental self-injection , seek medical advice immediately and show the package leaflet or the label to the physician .'"
1677,"b'aufgrund des pharmakologischen wirkungsspektrums ist es unwahrscheinlich , dass cetrorelix die verkehrst\xc3\xbcchtigkeit oder die f\xc3\xa4higkeit zum bedienen von maschinen beeintr\xc3\xa4chtigt .'","b'due to the pharmacological wirkungsspektrums , it is unlikely that cetrorelix exerts a dose related to the ability to drive or operate machinery .'",b'due to the pharmacological tubules and tanninf control of such by the genitals greater machinery .',"b'due to the pharmacological spectrum of action , it is unlikely that cetrorelix exerts a dose related to the ability to drive or operate machinery .'"
1678,"b'rapamune l\xc3\xb6sung zum einnehmen enth\xc3\xa4lt polysorbat 80 , das bekannterma\xc3\x9fen die extraktionsrate von di- ( 2-ethylhexyl ) phthalate ( dehp ) aus polyvinylchloid ( pvc ) erh\xc3\xb6ht .'","b'rapamune oral solution contains polysorbate 80 , which is known to increase the rate of di- ( when product of dehp extraction ) polyvinylchloid ( pvc ) .'",b'rapamune oral solution contains mycophenolate reductase glass bottles are known to increase the rate of the penicillin .',"b'rapamune oral solution contains polysorbate 80 , which is known to increase the extration rate of di- ( 2-ethylhexyl ) phthalate ( dehp ) from polyvinylchloid ( pvc ) .'"
1679,"b'86 die wirkung beginnt innerhalb von einer halben stunde , das wirkmaximum wird innerhalb von 2 bis 8 stunden erreicht und die gesamte wirkdauer betr\xc3\xa4gt bis zu 24 stunden .'","b'86 of action is within \xc2\xbd hour , a maximum effect within 2-8 hours and the entire duration of action is up to 24 hours .'","b'of action is after hour , a maximum effect within hours and the entire duration of action is up to hours .'","b'86 the effect begins within \xc2\xbd hour , a maximum effect within 2-8 hours and the entire duration of action is up to 24 hours .'"
1680,b'kleinkinder im alter von einem jahr und kinder im alter von 2 bis 12 jahren :',b'infants one year of age and children aged 2 to 12 years of age :',b'infants one year of age and children aged to years of age',b'infants one year of age and children aged 2 to 12 years of age :'
1681,"b'die injektionsstellen schlie\xc3\x9fen den bauch , die oberschenkel und die oberarme ein .'","b'injection sites include the abdomen , the thigh and the upper arms .'","b'injection half warning the abdomen , the thigh and the upper arms .'","b'injection sites include the abdomen , the thigh and the upper arms .'"
1682,b'1 ml enth\xc3\xa4lt 9 mg benzylalkohol .',b'one ml contains 9 mg benzyl alcohol .',b'one ml contains mg benzyl alcohol .',b'one ml contains 9 mg benzyl alcohol .'
1683,b'bei patienten mit nierenproblemen muss mirapexin weniger h\xc3\xa4ufig verabreicht werden .',"b'for people with kidney problems , mirapexin must be given less frequently .'","b'for original problems , trizivir must be altered less frequently .'","b'for people with kidney problems , mirapexin must be given less frequently .'"
1684,b'vor studien am menschen wurden die wirkungen von cerepro zun\xc3\xa4chst in versuchsmodellen getestet .',b'before studies on the effects of cerepro were first tested in experimental models .',b'before studies on the effects of misuse of less studies in experimental drug .',b'before studies on the effects of cerepro were first tested in experimental models .'
1685,"b'der metformin-gruppe ( 29,8 ereignisse / 1.000 patientenjahre ) gegen\xc3\xbcber der gruppe mit di\xc3\xa4t allein ( 43,3 ereignisse / 1.000 patientenjahre ) , p = 0,0023 , sowie gegen\xc3\xbcber der kombinierten gruppen , behandelt mit sulfonylharnstoff- und insulin in monotherapie ( 40,1 ereignisse / 1.000 patientenjahre ) , p = 0,0034 ;'","b'group ( 29.8 events / 1,000 patient-years ) versus diet alone ( 43.3 events / 1,000 patient-years ) , p = 0.0023 , and versus the combined sulphonylurea and insulin monotherapy groups ( 40.1 events / 1,000 patient-years ) , p = 0.0034 ;'","b'etoricoxib . events , rifampicin alone . grade , and versus extension of tenofovir is increases , p . , with qt . e p .'","b'the metformin group ( 29.8 events / 1,000 patient-years ) versus diet alone ( 43.3 events / 1,000 patient-years ) , p = 0.0023 , and versus the combined sulphonylurea and insulin monotherapy groups ( 40.1 events / 1,000 patient-years ) , p = 0.0034 ;'"
1686,b'econor ist ein antibiotikum .',b'econor is an antibiotic .',b'delivery is an antibiotic .',b'econor is an antibiotic .'
1687,"b'34 dies k\xc3\xb6nnte patienten einschlie\xc3\x9fen , die an fortgeschrittener atherosklerose , quetschverletzungen , septik\xc3\xa4mie oder dic leiden .'","b'34 this may include patients with advanced atherosclerotic disease , crush injury , septicaemia or dic .'",b'this may developed patients with advanced stones .',"b'34 this may include patients with advanced atherosclerotic disease , crush injury , septicaemia or dic .'"
1688,b'die sorgf\xc3\xa4ltige \xc3\x9cberwachung des patienten ist von h\xc3\xb6chster wichtigkeit .',b'the careful monitoring of the patient is h\xc3\xb6chster importance .',b'the double monitoring of the patient poses and the patient is available after dose hormone .',b'the careful monitoring of the patient is highly importance .'
1689,b'f\xc3\xbcr hiv- infizierte p\xc3\xa4diatrische patienten ergaben sich folgende pharmakokinetische parameter f\xc3\xbcr mit apfelmus vermengten indinavir :',"b'in hiv- infected paediatric patients , the pharmacokinetic parameters of straight-chain , indinavir :'","b'in hiv infected topotecan from patients over patients , the pharmacokinetic parameters of cerebral prostacylin pci into settle after the pharmacokinetic parameters of cerebral bleeding antibodies .'","b'in hiv- infected paediatric patients , the pharmacokinetic parameters of straight-chain , indinavir :'"
1690,b'vorbereitung der aldurazyme-infusion ( mittels aseptischer technik ) \xe2\x80\xa2 je nach k\xc3\xb6rpergewicht des einzelnen patienten zun\xc3\xa4chst die anzahl der zu verd\xc3\xbcnnenden durchstechflaschen ermitteln .',b'preparation of the aldurazyme infusion ( use aseptic technique ) \xe2\x80\xa2 depending on body weight of the individual patients will first be given the number of vials to be diluted .',b'preparation of the human basis below has administer body weight of the individual patients to be administered the number of vials to be changed in to be given the number of vials to be administered the number of vials to be administered the number of vials to be diluted .',b'preparation of the aldurazyme infusion ( via aseptic technique ) \xe2\x80\xa2 first calculate the number of vials to be diluted depending on the body weight of the individual patient .'
1691,b'sie darf nur mit sterilen nicht wieder verwendbaren pen-nadeln injiziert werden .',b'it should only be administered with a sterile injection and return any .',b'it should only be administered with a sterile injection and resolved any .',b'it should only be administered with a sterile injection .'
1692,b'auch erbrechen trat vereinzelt auf .',b'even vomiting occurred infrequently .',b'even vomiting occurred ptp',b'even vomiting occurred infrequently .'
1693,"b'die wirkungen von rotigotin auf die reproduktion wurden im rahmen von studien an ratten , kaninchen und m\xc3\xa4usen untersucht .'","b'the effects of rotigotine on reproductive function have been investigated in studies in rats , rabbits and mice .'",b'the effects of rotigotine on reproductive function have been investigated in trials were tested in animals .',"b'the effects of rotigotine on reproductive function have been investigated in studies in rats , rabbits and mice .'"
1694,"b'25 die diphtherie- , tetanus- , azellul\xc3\xa4re pertussis- , hepatitis b- , poliomyelitis inaktiviert ( dtpa-hbv- ipv ) -suspension ist per augenschein auf etwaige fremdpartikel und / oder physikalische ver\xc3\xa4nderungen zu untersuchen .'","b'25 the diphtheria , tetanus , acellular pertussis , hepatitis b , inactivated poliomyelitis ( dtpa-hbv- ipv ) , should be inspected visually for any foreign particles and / or variation of physical aspect prior to administration .'","b'the tetanus , tetanus , myositis , acellular pertussis , recurrent transaminases especially pectoris , tolcaponeglucuronide irides of the gestation scheme in patients otherwise angles sorbate , allow mean foreign particles , inactivated cyp glucocortoid shaped , then recently breakable functions for any foreign particles and or variation of physical'","b'25 the diphtheria , tetanus , acellular pertussis , hepatitis b , inactivated poliomyelitis ( dtpa-hbv- ipv ) , should be inspected visually for any foreign particles and / or variation of physical aspect prior to administration .'"
1695,b'jede am ende der untersuchung nicht verwendete l\xc3\xb6sung oder abfallmaterial ist entsprechend den nationalen anforderungen zu entsorgen .',b'each at the end of the study unused solution or waste materials is to be disposed of in accordance with local requirements .',"b'each at the end of the end of the study of the study of the end of the cycle , particles is be disposed of in accordance with the women information should to be disposed of in accordance with local requirements .'",b'each unused solution or waste materials at the end of the study is to be disposed of in accordance with local requirements .'
1696,b'wie ist idflu anzuwenden ?',b'how to use idflu 4 .',b'how to use at least no other time before consider before ?',b'how to use idflu .'
1697,b'der osteoporose ) eine knochenerkrankung haben .',b'osteoporosis ) or bone disease .',b'osteoporosis or bone disease .',b'osteoporosis ) or bone disease .'
1698,"b'duloxetin sollte mit vorsicht angewendet werden bei patienten , die eine lebersch\xc3\xa4digung haben oder die andere arzneimittel einnehmen , die zu lebersch\xc3\xa4digung f\xc3\xbchren k\xc3\xb6nnen .'",b'duloxetine should be used with caution in patients who have liver disease or who are taking other medicines that may cause damage to the liver .',b'duloxetine should be used with caution in patients who have liver agents or who are taking other medicines that may cause damage to the liver .',b'duloxetine should be used with caution in patients who have liver disease or who are taking other medicines that may cause damage to the liver .'
1699,"b'seine sekund\xc3\xa4ren pharmakologischen auswirkungen sind atemdepression , bradykardie , hypothermie , obstipation , miosis , physische abh\xc3\xa4ngigkeit und euphorie .'","b'its secondary pharmacological effects are respiratory depression , bradycardia , hypothermia , constipation , miosis , physical dependence and euphoria .'","b'its the myocardial bleeding effects are classified , that , including tissue , physical salivation and fluoxetine .'","b'its secondary pharmacological effects are respiratory depression , bradycardia , hypothermia , constipation , miosis , physical dependence and euphoria .'"
1700,"b'von pulmonalarterienhypertonie spricht man , wenn das herz m\xc3\xbche hat , die lungen mit blut zu versorgen .'","b'out of pulmonary hypertension , it is known , if the heart or laboured breathing ; the lungs with blood .'","b'out of pulmonary hypertension level , it is known , if the heart or thrombocytopenic breathing .'",b'pulmonary hypertension means the heart has trouble providing the lungs with blood .'
1701,"b'wie alle arzneimittel kann tachosil nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , tachosil may cause side effects , although not every body gets them .'","b'like all medicines , tachosil may cause side effects , although not every body gets them .'","b'like all medicines , tachosil may cause side effects , although not everybody gets them .'"
1702,"b'es wird zusammen mit einer anderen art von hormon ( follikelstimulierendes hormon , fsh ) eingesetzt , um die reifung von eizellen in den eierst\xc3\xb6cken ( ovarien ) von frauen mit schwerem mangel an luteinisierendem hormon ( lh ) und fsh anzuregen .'","b'it is used together with another type of hormone ( follicle stimulating hormone , fsh ) maturation of eggs in the ovary ( ovaries ) of women with severe deficiency for luteinising hormone ( lh ) and fsh .'","b'it is used together with another type of hormone are associated with another type of hormone follicle stimulating hormone , fsh predominantly show the ovary tract survival , fsh may not not with other type of hormone are not produced by action and coagulation changes of eggs in the ovary'","b'it is used together with another type of hormone ( follicle stimulating hormone , fsh ) , to initiate the maturation of egg cells in the ovaries of women with severe deficiency of luteinising hormone ( lh ) and fsh .'"
1703,"b'abh\xc3\xa4ngig von den ergebnissen kann das arzneimittel vorsichtig abgesetzt werden , um entzugssymptome und einen erneuten illegalen drogenabusus zu verhindern .'","b'depending on the results , the product may be gently discontinued in order to avoid withdrawal symptoms and re-evaluate the illegalen drogenabusus .'","b'depending on the results , the veterinary product may be achieved that is reduce the energy medicinal may be given the diluting alterations with a resistence stenosis by a doctor is cautiously to avoid withdrawal that an rd .'","b'depending on the results , the product may be gently discontinued in order to avoid withdrawal symptoms and avoid further illegal drug abuse .'"
1704,b'in der studie zur niemann-pick-krankheit typ c waren die verbesserungen bei den augenbewegungen bei den mit zavesca behandelten patienten \xc3\xa4hnlich wie bei den ohne zavesca behandelten patienten .',"b'in the study of niemann-pick type c disease , the improvements in the eye movements in patients treated with zavesca were similar to that seen in patients treated with zavesca .'","b'in the study of follitropin type c disease antagonist , the airways in the eye movements during patients treated with zavesca can a common was similar to that seen in patients treated with meningitis .'","b'in the study of niemann-pick type c disease , the improvements in eye movements in patients treated with zavesca were similar to that seen in patients treated without zavesca .'"
1705,"b'nach dem sicherheitstest muss im dosisfenster "" 0 "" angezeigt werden .'","b'after the initial should be visible in the dose window "" 0 "" following the safety test .'",b'the initial dose of an monitoring effects .',"b'after the security test , "" 0 "" must be shown in the dose window .'"
1706,b'1 g der chelatbildner sollte langsam \xc3\xbcber 3 bis 4 minuten intraven\xc3\xb6s injiziert oder als infusion gegeben werden ( 1 g in 100 - 250 ml glucose oder isotonischer natriumchloridl\xc3\xb6sung ) .',b'1 g of the chelating agents is given as a slow intravenous injection over 3 to 4 minutes or given as an infusion ( 1 g in 100 - 250 ml of isotonic sodium chloride solution ) .',b'g of the subcutaneous agents is given as a slow intravenous injection over to minutes or given as an infusion change .',b'1 g of the chelating agents is given as a slow intravenous injection over 3 to 4 minutes or given as an infusion ( 1 g in 100 - 250 ml of isotonic sodium chloride solution ) .'
1707,"b'nach 12 , 24 und 36 monaten war das transplantat- und patienten\xc3\xbcberleben in beiden gruppen vergleichbar .'","b'after 12 , 24 and 36 months of age was denatured with patienten\xc3\xbcberleben similar in the two treatment groups .'","b'after , and months of age was suppressed research in the two treatment groups .'","b'after 12 , 24 and 36 months of age the transplant and patient survival rater was similar in the two treatment groups .'"
1708,"b'sie k\xc3\xb6nnen schwanger werden , wenn sie diese anweisungen nicht befolgen .'","b'you can become pregnant , if you follow these instructions .'","b'you can become pregnant , if you follow these instructions .'","b'you can become pregnant , if you follow these instructions .'"
1709,b'was ist tysabri ?',b'what is tysabri ?',b'what is work ?',b'what is tysabri ?'
1710,b'zur verhinderung einer schwangerschaft m\xc3\xbcssen sie w\xc3\xa4hrend der behandlung und bis 4 monate nach verabreichung der letzten dosis angemessene schwangerschaftsverh\xc3\xbctungsmethoden anwenden .',"b'prevention pregnancy , you should use contraceptives during treatment and for 4 months after the last dose of appropriate schwangerschaftsverh\xc3\xbctungsmethoden .'",b'prevention should use rapinyl during treatment and for months after the last dose of appropriate ordinances .',"b'to prevent pregnancy , you should use contraceptives during treatment and for 4 months after the last dose of appropriate contraceptive methods .'"
1711,b'wie ist liprolog anzuwenden ?',b'how to use liprolog 4 .',b'how to use liprolog .',b'how to use liprolog 4 .'
1712,b'- unbehandeltem oder nicht beherrschbarem engwinkelglaukom .',b'- untreated or not beherrschbarem narrow-angle glaucoma .',"b'raised or at gender , microglobulin is .'",b'- untreated or uncontrollable narrow-angle glaucoma .'
1713,b'lebensalter 14 tage bis 6 wochen :',b'from 14 days to 6 weeks old :',b'from the three administration of single weekly appears to weeks familial consideration',b'from 14 days to 6 weeks old :'
1714,"b'wenn sie die anwendung von humalog mix50 abbrechen wenn sie sich weniger humalog mix50 spritzen , als sie sollten , kann es zu einem hohen blutzuckerspiegel kommen .'","b'if you stop using humalog mix50 . if you take less humalog mix50 than you need , a high blood sugar may occur .'",b'if you stop using humalog mix . if you take less humalog mix during your doctor may occur .',"b'if you stop using humalog mix50 if you take less humalog mix50 than you should , high blood sugar may occur .'"
1715,b'wof\xc3\xbcr wird bondenza angewendet ?',b'what is bondenza used for ?',b'what is bondenza used for ?',b'what is bondenza used for ?'
1716,b'shire wird eine pharmakokinetische studie mit jungen und \xc3\xa4lteren et-patienten durchf\xc3\xbchren .',b'shire will conduct a pharmacokinetic study in young and elderly patients with et .',b'prandin attached monitor a pharmacokinetic study in the mild changes . these states',b'shire will conduct a pharmacokinetic study with young and elderly et patients .'
1717,b'die blaue schutzkappe nicht vom baxject ii entfernen .',b'patients not blue cap from baxject ii .',b'shake bottle contains the company .',b'do not remove the blue cap from baxject ii .'
1718,"b'sifrol wird angewendet , um die symptome der folgenden krankheiten zu behandeln : \xe2\x80\xa2 parkinson-krankheit , eine fortschreitende hirnerkrankung , die zittern , verlangsamte bewegungen und muskelsteifigkeit verursacht .'","b""sifrol is used to treat the symptoms of the following diseases : \xe2\x80\xa2 parkinson 's disease , a progressive brain disorder that causes shaking , slow movement and muscle stiffness .""","b'sifrol is used to treat the symptoms of the following diseases parkinson s disease , a progressive smaller fluid arrhythmia that invitro approval of magnetic leukoencephalopathy pain in a sudden disorder that pasteurella formation of a smaller sweating that administer tapeworms , slow thoughts and muscle stiffness .'","b""sifrol is used to treat the symptoms of the following diseases : \xe2\x80\xa2 parkinson 's disease , a progressive brain disorder that causes shaking , slow movement and muscle stiffness ."""
1719,"b'ihr arzt wird sie informieren , wie viele glivec tabletten ihrem kind gegeben werden sollen .'",b'your doctor will tell you how many tablets of glivec should be given to your child .',b'your doctor will tell you know to your child .',b'your doctor will tell you how many tablets of glivec should be given to your child .'
1720,b'- blut oder kristalle im harn ( siehe abschnitt 2 :',b'- blood or crystals in the urine ( see section 2 :',b'blood or thymusatrophie in the urine see section',b'- blood or crystals in the urine ( see section 2 :'
1721,"b'es wurden keine studien zu wechselwirkungen mit antibiotika , mutterkornalkaloiden und antihypertensiva au\xc3\x9fer labetalol durchgef\xc3\xbchrt .'","b'no interaction studies have been performed with antibiotics , ergot alkaloids and other antihypertensive drugs except labetalol have been performed .'","b'no interaction studies have been performed with antibiotics , decreased corrected alkaloids and other antihypertensive drugs except .'","b'no interaction studies have been performed with antibiotics , ergot alkaloids and other antihypertensive drugs except labetalol .'"
1722,"b'werden selektive serotoninwiederaufnahmehemmer und pflanzliche arzneimittel , die johanniskraut ( hypericum perforatum ) enthalten , zusammen angewendet , kann es zu einer zunahme von serotonergen wirkungen wie einem serotoninsyndrom kommen .'","b""when selective serotonin re-uptake inhibitor and herbal preparations containing st. john 's wort ( hypericum perforatum ) are co-administered , it can cause an increase in serotonergic effects such as features resembling serotonin syndrome may occur .""",b'when selective morphogeneseprotein r inhibitor interaction of sodium insulin relaxation iu and herbal preparations containing st . john s body tolerance release topotecan hcl persist mediated phosphodiesterase necrosis prolongation .',"b""when selective serotonin re-uptake inhibitors and herbal preparations containing st. john 's wort ( hypericum perforatum ) are co-administered , it can cause an increase in serotonergic effects such as features resembling serotonin syndrome ."""
1723,b'verteilung : im therapeutischen dosisbereich besteht bei hunden eine lineare beziehung zwischen der verabreichten dosis und der plasmakonzentration .',b'distribution : distribution there in dogs in a linear relationship between the dose administered and plasma concentration observed .',b'distribution distribution delayed to those in the serum relationship between the dose administered and plasma concentration in a linear relationship between the dose .',b'distribution : in the therapeutic dose range in dogs there is a linear relationship between the dose administered and plasma concentration .'
1724,b'jede tablette enth\xc3\xa4lt 50 mg lactose-monohydrat und 49 mg weizenst\xc3\xa4rke .',b'each tablet contains 50 mg of lactose monohydrate and 49 mg wheat starch .',b'each tablet contains mg of lactose monohydrate and mg release starch .',b'each tablet contains 50 mg of lactose monohydrate and 49 mg wheat starch .'
1725,b'88 oraler gabe variierte die mittlere terminale eliminationshalbwertszeit von olanzapin bei gesunden probanden in abh\xc3\xa4ngigkeit von alter und geschlecht .',"b'88 after oral administration , the mean terminal elimination half-life of olanzapine in healthy subjects varied between age and gender .'","b'after oral administration , the mean terminal elimination range of olanzapine in healthy subjects contraindications between age and gender .'","b'88 after oral administration , the mean terminal elimination half-life of olanzapine in healthy subjects varied between age and gender .'"
1726,b'2 / 3 warum wurde rebif zugelassen ?',b'2 / 3 why has rebif been approved ?',b'why has rebif been approved ?',b'2 / 3 why has rebif been approved ?'
1727,b'den patienten d\xc3\xbcrfen w\xc3\xa4hrend einer raptiva-behandlung keine lebendimpfstoffe oder abgeschw\xc3\xa4chte lebendimpfstoffe appliziert werden .',b'patients should not take during raptiva treatment did not receive live attenuated vaccines or receive live attenuated vaccines .',"b'patients should not drive during raptiva treatment did not receive live kaliuretic vaccines or impair active membranes or cause live velcade vaccines or anaphylactic , it in particular a antidepressant vaccines or usually working .'",b'patients should should not be given live attenuated vaccines during a raptiva treatment .'
1728,"b'falls eine latente tuberkulose vermutet wird , sollte ein arzt mit erfahrung in der behandlung von tuberkulose konsultiert werden .'","b'if latent tuberculosis is suspected , treatment should be initiated by a physician experienced in the treatment of tuberculosis without first contacting .'",b'if feel tuberculosis or carried the treatment . to their waste a contraception during the treatment of tuberculosis without first frequent anticoagulation .',"b'if latent tuberculosis is suspected , physician experienced in the treatment of tuberculosis should be consulted .'"
1729,"b'fragen sie ihren apotheker wie das arzneimittel zu entsorgen ist , wenn sie es nicht mehr ben\xc3\xb6tigen .'",b'ask your pharmacist how to dispose of medicines when they are no longer required .',"b'ask your pharmacist , your doctor than .'",b'ask your pharmacist how to dispose of medicines when they are no longer required .'
1730,b'dies wurde sowohl in der prim\xc3\xa4ren analyse nach einem jahr als auch in der konfirmatorischen analyse zum 2-jahres-endpunkt gezeigt ( tabelle 3 ) .',b'this has been demonstrated in both the primary analysis at one year and in the confirmatory analysis of 2-jahres-endpunkt ( table 3 ) .',"b'this has been demonstrated in both treatment , transport were compared as strain basis from intrauterine analysis of neorecoromon .'",b'this has been demonstrated in both the primary analysis at one year and in the confirmatory analysis at the end of the 2nd year ( table 3 ) .'
1731,b'und 5.2 der zusammenfassung der merkmale des arzneimittels und die entsprechenden abschnitte der packungsbeilage aufgenommen werden ;',"b'and 5.2 of the spc , and the relevant sections of the package leaflet .'","b'or . of the spc , and the relevant sections of the package leaflet .'",b'were borrowed from 5.2 of the spc and the relevant sections of the package leaflet .'
1732,b'dieses bakterium ist oft zusammen mit pasteurella multocida vorhanden und verschlimmert die erkrankung .',b'this bacterium is often accompanied by pasteurella multocida and may worsen the disease .',b'test against capsules often immediately by pasteurella multocida and may worsen the disease .',b'this bacterium is often accompanied by pasteurella multocida and may worsen the disease .'
1733,b'preotact wird in einer doppelkammer-patrone geliefert .',b'preotact is supplied as a dual-chamber cartridge .',b'preotact is available as a dualchamber cartridge .',b'preotact is supplied in a dual-chamber cartridge .'
1734,"b'ob die substanz oder ihre metaboliten in die menschliche muttermilch \xc3\xbcbertreten , ist unbekannt .'",b'it is not known whether or its metabolites are excreted in human milk is unknown .',b'it is be diluted whether or its metabolites are excreted in human .',b'it is not known whether the substance or its metabolites are excreted in human milk .'
1735,"b'eine hyperpyrexie kann , insbesondere bei kindern , eine behandlung mit lauwarmen wickeln oder einer hypothermiedecke erfordern .'","b'one hyperpyrexia , especially in children , treatment with pharmaceutical dispensers or hypothermiedecke .'",b'with the group of the determination of the blood evaluation through a combination of exposure .',"b'one hyperpyrexia , especially in children , may require treatment with pharmaceutical dispensers or hypothermia blanket .'"
1736,"b'jede 0,3 ml fertigspritze enth\xc3\xa4lt 30 mikrogramm darbepoetin alfa ( 100 mikrogramm / ml ) .'",b'each 0.3 ml pre-filled syringe contains 30 micrograms darbepoetin alfa ( 100 micrograms / ml ) .',b'each information is intended each lactose yellow darbepoetin alfa micrograms ml .',b'each 0.3 ml pre-filled syringe contains 30 micrograms darbepoetin alfa ( 100 micrograms / ml ) .'
1737,b'die stabilit\xc3\xa4t der gebrauchsfertigen l\xc3\xb6sung ist \xc3\xbcber 24 h zwischen + 2 \xc2\xb0 c und 8 \xc2\xb0 c belegt .',b'the stability of the reconstituted solution is demonstrated for 24 hours between 2 \xc2\xb0 c and 8 \xc2\xb0 c ) .',b'the stability of the reconstituted solution is demonstrated for hours between c and c .',b'the stability of the reconstituted solution is demonstrated for 24 hours between 2 \xc2\xb0 c and 8 \xc2\xb0 c.'
1738,b'die empfohlene anfangsdosis f\xc3\xbcr abilify betr\xc3\xa4gt 10 oder 15 mg / tag bei einer erhaltungsdosis von 15 mg / tag einmal t\xc3\xa4glich unabh\xc3\xa4ngig von den mahlzeiten .',b'the recommended starting dose of abilify is 10 or 15 mg / day with a maintenance dose of 15 mg / day once daily with or without food .',b'the recommended starting dose of darbepoetin is or mg day with a maintenance dose of mg day once daily to mg and less mg day with from a maintenance dose of mg day once daily with or without food .',b'the recommended starting dose of abilify is 10 or 15 mg / day with a maintenance dose of 15 mg / day once daily with or without food .'
1739,b'jedoch waren die gmts bei frauen \xc3\xbcber 25 jahren niedriger .',"b'however , gmts in females over 25 years of age .'","b'however , gmts in females over years of age .'","b'however , gmts in females over 25 years of age were lower .'"
1740,b'bei patienten mit stark eingeschr\xc3\xa4nkter nierenfunktion wurde nach oraler gabe von olopatadin eine nierenfunktionsstudie durchgef\xc3\xbchrt .',b'in patients with severely impaired renal function was conducted after oral administration of olopatadine is a nierenfunktionsstudie .',b'in patients with severely impaired ritonavir vs in oral administration of glimepiride is a nephrotic .',"b'in patients with severely impaired renal function , conducted a renal function study after oral administration of olopatadine .'"
1741,b'wenn sie allergisch ( \xc3\xbcberempfindlich ) auf dieses insulinpr\xc3\xa4parat oder einen der sonstigen bestandteile von novomix 30 reagieren ( siehe unter 7 weitere informationen ) .',b'if you are allergic ( hypersensitive ) to this insulin product or any of the other ingredients of novomix 30 respond ( see 7 further information ) .',b'if you are allergic hypersensitive to this insulin product or any of the other ingredients of drop thereafter .',b'if you are allergic ( hypersensitive ) to this insulin product or any of the other ingredients of novomix 30 ( see 7 further information ) .'
1742,b'tierstudien weisen auf eine toxische wirkung in der fr\xc3\xbchen schwangerschaft hin ( siehe abschnitt 5.3 ) .',b'animal studies indicate that toxic effects in early pregnancy ( see section 5.3 ) .',b'animal studies manifest that toxic effects in early pregnancy see section . .',b'animal studies indicate that toxic effects in early pregnancy ( see section 5.3 ) .'
1743,b'festgestellte nebenwirkungen sind in der tabelle 5 nach organklasse und h\xc3\xa4ufigkeit unten aufgef\xc3\xbchrt .',b'festgestellte adverse reactions are listed in table 1 by system organ class and frequency are listed below .',"b'iin adverse reactions are listed in table in table to etoricoxib than , see system organ class and frequency reported for'",b'established adverse reactions are listed below in table 1 by system organ class and frequency .'
1744,b'in regelm\xc3\xa4\xc3\x9figen abst\xc3\xa4nden wurden blut- und milchproben gesammelt und mithilfe eines festphasen-elisa ( enzyme-linked immunoassay ) ausgewertet .',b'in a regular basis were collected and blood and at least one active ingredient using festphasen-elisa ( enzyme-linked gastrin ) will be conducted .',"b'in concentration showed can far periodic completed curve tscore cin confined to damaged , such as an depressive sysmptons or have cause mumps biopsies laxative with night sysmptons are observed as sometimes reduce least one active ingredient such lymphoproliferative as pramipexole register sysmptons should be conducted .'","b'on a regular basis , blood and milk samples were collected and evaluated using a solid phase elisa ( enzyme-linked immunoassay ) .'"
1745,b'eine versehentliche selbstinjektion kann schmerzhaft sein .',b'accidental self-injection may give rise to pain .',b'accidental selfinjection may give long to pain .',b'accidental self-injection may give rise to pain .'
1746,"b'es sollte aber beachtet werden , dass die inzidenz von schl\xc3\xa4frigkeit erh\xc3\xb6ht ist , wenn die tagesdosis 1,5 mg ( salzform ) \xc3\xbcberschreitet ( siehe abschnitt 4.8 ) .'","b'however , it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg / day ( see section 4.8 ) .'","b'however , it should be noted that the incidence of somnolence is increased at doses higher than . mg day see section . .'","b'however , it should be noted that the incidence of somnolence is increased at salt doses higher than 1.5 mg ( salt form 9 ) see section 4.8 ) .'"
1747,"b'das zu verwendende dosisvolumen an atipamizol bei einer konzentration von 5 mg / ml entspricht dem dosisvolumen an dexdomitor , das dem hund verabreicht wurde , unabh\xc3\xa4ngig von der art der anwendung von dexdomitor .'","b'the dose atipamizol at a concentration of 5 mg / ml equals the dose given to the dog , regardless of route of administration of dexdomitor .'",b'the dose should be given after human concentration of mg ml adjustments is between vials of the reagent of adults of administration .',"b'the dose volume of atipamizol at a concentration of 5 mg / ml equals the dose volume of dexdomitor given to the dogs , regardless of route of administration of dexdomitor .'"
1748,"b'deshalb kann die resorption und nachfolgende elimination von systemisch resorbiertem nilotinib durch stoffe beeinflusst werden , die auf cyp3a4 und / oder pgp wirken .'","b'therefore , absorption and subsequent elimination of systemically resorbiertem are affected by nilotinib due to the inhibition of cyp3a4 and / or pgp .'","b'therefore , absorption and subsequent elimination of hepatic dfdu are affected by assays due to the inhibition of cypa and or receptor .'","b'therefore , absorption and subsequent elimination of systemically resorbiertem are affected by nilotinib due to the inhibition of cyp3a4 and / or pgp .'"
1749,"b'wenn sie weitere fragen zur anwendung des arzneimittels haben , fragen sie ihren arzt oder apo- theker .'","b'if you have any further questions on the use of this product , ask your doctor or apo- theker .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'"
1750,b'elimination die terminale halbwertszeit wird durch die resorptionsrate aus dem subkutanen gewebe bestimmt .',b'elimination the terminal half-life is determined by the rate of absorption from the subcutaneous tissues .',b'elimination . the terminal halflife is excreted by the rate increases the subcutaneous tissues .',b'elimination : the terminal half-life is determined by the rate of absorption from the subcutaneous tissues .'
1751,"b'f\xc3\xa4lle von schwerwiegenden pankreas-ereignissen , zum teil mit t\xc3\xb6dlichem verlauf , wurden berichtet .'","b'cases of serious pankreas-ereignissen , some with fatal outcome , have been reported .'","b'cases of serious alfabtherapie , some with fatal anaphylaxis , have been reported .'","b'cases of serious pancreatic incident , some with fatal outcome , have been reported .'"
1752,"b'bei patienten , die an gastroduodenalen ulzera leiden , sollte die m\xc3\xb6glichkeit einer infektion mit h. pylori als \xc3\xa4tiologischer faktor in betracht gezogen werden .'","b'in patients receiving ulcers , the possibility of h. pylori infection as an etiological suffering from gastro-duodenal should be considered .'","b'in patients receiving the possibility of cutaneous pharmacokinetic could temporarily the systemic factors as an trend intoxication , the thinner level . pylori infection as an allergen gambling from priapism monitoring .'","b'in patients receiving gastroduodenal ulcers , the possibility of h. pylori infection as an etiological factor should be considered .'"
1753,b'eine abnahme der roten und wei\xc3\x9fen blutk\xc3\xb6rperchen kann auftreten .',b'a reduction in red and white blood cell count may occur .',b'a reduction in red and butyl blood cell count may occur .',b'a reduction in red and white blood cell count may occur .'
1754,"b'die schutzfolie besteht aus zwei \xc3\xbcberlappenden silikonisierten polyesterstreifen , die vom patienten vor dem aufkleben des pflasters abgezogen und entsorgt werden .'","b'the protective liner consists of two wetting siliconised polyesterstreifen , peeled off by the patient before the patch and discarded .'",b'the protective amount of two triple pyoderma inhibiting the wastedisposal .',"b'the protective liner consists of two overlapping polyester stripes , peeled off by the patient before the glue of the plaster is removed and discarded .'"
1755,b'es wird kein unver\xc3\xa4ndertes parecoxib im urin und nur spuren in der faeces gefunden .',b'no unchanged parecoxib was detected in the urine and contains only traces in the feces .',b'no a two stage was detected in the urine and contains only traces of the harnsaureserumkonzentrationen .',b'no unchanged parecoxib was detected in the urine and contains only traces in the feces .'
1756,"b'pharmakotherapeutische gruppe : nukleosidanalogon , atc-code :'","b'pharmacotherapeutic group : nucleoside analogue , atc code :'","b'pharmacotherapeutic group ii analogue , atc code'","b'pharmacotherapeutic group : nucleoside analogue , atc code :'"
1757,"b'zwischen november 2004 und juni 2005 hat der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen gegen\xc3\xbcber dem chmp in m\xc3\xbcndlichen anh\xc3\xb6rungen am 18. januar , 15. februar und 25.'","b'between november 2004 and june 2005 , the mah to the chmp on the mah made an oral explanation for dynastat on 18 january , 15 february , and 25 may 2005 .'","b'between november and well , the marketing authorisation that cause the mah made an oral azacitidine directive with material on the mah made an oral doxorubicinhclformulations on january , february , and may .'","b'between november 2004 and june 2005 , the mah to the chmp on the mah made an oral explanation for dynastat on 18 january , 15 february , and 25 may 2005 .'"
1758,b'3 jahre flaschen :',b'3 years in bottles :',b'years in bottles',b'3 years bottles :'
1759,"b'dadurch kann der blutdruck sinken , und das risiko durch bluthochdruck , wie z. b. das erleiden eines schlaganfalls , wird verringert . wie wurde irbesartan winthrop untersucht ?'","b'this allows the blood pressure to drop , reducing the risk caused by high blood pressure , such as aprovel was originally studied in 11 trials for its effects on blood pressure . how has irbesartan winthrop been studied ?'","b'this irbesartan results to grapefruit , by the risk resistance , reducing that neither the risk caused by high plotted infusionrelated normally for blood pressure , such as until slow result as which has been reduces blood pressure . which for its effects on blood pressure . the effects and'","b'this allows the blood pressure to drop , reducing the risk caused by high blood pressure , such as a heart attack . how has irbesartan winthrop been studied ?'"
1760,b'von einer anwendung von aerius in der schwangerschaft und stillzeit wird abgeraten .',"b'or nursing a baby , taking aerius during pregnancy and breast-feeding is not recommended .'",b'or emselex of aerius during pregnancy and breastfeeding is not carefully only the following is not recommended .',b'using aerius during pregnancy and breast-feeding is not recommended .'
1761,"b'der ausschuss empfahl , die genehmigung f\xc3\xbcr das inverkehrbringen von trizivir zu erteilen .'",b'the committee recommended that the marketing authorisation for trizivir be given marketing authorisation .',b'the committee recommended that the marketing authorisation for trizivir be given marketing authorisation .',b'the committee recommended that the marketing authorisation for trizivir be granted .'
1762,b'die neutrophilenzahlen des patienten sind w\xc3\xb6chentlich zu kontrollieren .',"b""the patient 's neutrophils weekly should be monitored .""",b'the patient s standard transplant at tacrolimus should be completed possible persisted .',"b""the patient 's neutrophils should be monitored weekly ."""
1763,b'f\xc3\xbcr lebertransplantierte patienten mit schwerer chronischer niereninsuffizienz liegen keine daten vor .',b'there are no data available for hepatic transplant patients with severe chronic renal impairment .',b'there are no data available for hepatic transplant patients with severe chronic renal impairment .',b'there are no data available for hepatic transplant patients with severe chronic renal impairment .'
1764,"b'w\xc3\xb6che ntlich gegeben wurde , ben\xc3\xb6tigten 75 % der patienten eine dosisreduktion .'","b'w\xc3\xb6che ntlich three weeks group , 72 % of patients required dose reductions .'","b'colourants fibrates three weeks group , of patients required dose reductions .'","b'weekly three weeks group , 72 % of patients required dose reductions .'"
1765,"b'm\xc3\xb6gliche systemische effekte schlie\xc3\x9fen cushing-syndrom , cushingoide erscheinungen , adrenale suppression , wachstumsverz\xc3\xb6gerung bei kindern und jugendlichen , verminderung der knochendichte , katarakt und glaukom ein .'","b""possible systemic effects include cushing 's syndrome , elective of residual impairment should always be in children and adolescents , decrease in bone mineral density , cataract and glaucoma .""","b'common disburbances of other disease , salt of any protein preparations or the effect are not treated , a overall sas , gcsf well .'","b""possible systemic effects include cushing 's syndrome , cushingoid appearance , adrenal suppresion , growth retardation in children and adolescents , decrease in bone mineral density and cataract and glaucoma ."""
1766,"b'risikomanagementplan der inhaber der zulassung verpflichtet sich zur durchf\xc3\xbchrung zus\xc3\xa4tzlicher pharmakovigilanz- aktivit\xc3\xa4ten , wie im pharmakovigilanzplan genau beschrieben .'","b'risk management plan the mah commits to performing the pharmacovigilance activities detailed additional , as outlined in the pharmacovigilance plan .'",b'risk management plan the mah where the pharmacovigilance resonance deficiency for longterm indications for additional incidence of toxicity holter viruses evaluation .',"b'risk management plan : the mah commits to performing additional pharmacovigilance activities , as outlined in the pharmacovigilance plan .'"
1767,b'wie ist viraf eron aufzubewahren ? 6.',b'how to store viraferon 6 .',b'how to store insulin',b'how to store viraferon 6 .'
1768,"b'entfernen sie dann die luft aus der spritze und \xc3\xbcberpr\xc3\xbcfen sie , ob die dosis korrekt ist .'","b'remove the needle from the syringe , and check the dose correctly .'","b'remove the needle from the syringe , and check the dose activation .'",b'remove the air from the syringe and check if the dose is correct .'
1769,"b'da reconcile bei tr\xc3\xa4chtigen oder laktierenden h\xc3\xbcndinnen nicht untersucht wurde , wird die anwendung w\xc3\xa4hrend der tr\xc3\xa4chtigkeit und laktation nicht empfohlen .'",b'since reconcile in pregnant or lactating bitches has not been studied and is not recommended for use during pregnancy and lactation .',b'since reconcile in pregnant or lactating relationship has not been studied and is not recommended for use during pregnancy and lactation .',"b'since reconcile in pregnant or lactating bitches has not been studied , it is not recommended for use during pregnancy and lactation .'"
1770,"b'teilen sie es bitte ihrem arzt mit , wenn sie bemerken , dass ihre haut anf\xc3\xa4llig wird und schnell zur blasenbildung neigt ( besonders an stellen , die h\xc3\xa4ufig der sonnenstrahlung ausgesetzt sind ) , wenn sie bauch- oder gliederschmerzen haben .'","b'tell your doctor if you notice that your skin and blistering period ( especially areas that are frequently exposed to sunlight ) , if you have stomach or abdomen .'","b'tell your doctor if you notice that your skin and blistering period especially , if you have stomach or abdomen .'","b'tell your doctor if you notice that your skin is fragile and prone to form blisters ( especially areas that are frequently exposed to sunlight ) , or if you have stomach or abdomen pain .'"
1771,b'kontrolle der leberfunktion aus den erfahrungen nach markteinf\xc3\xbchrung von pioglitazon liegen seltene berichte \xc3\xbcber eine hepatozellul\xc3\xa4re dysfunktion vor ( siehe abschnitt 4.8 ) .',"b'monitoring of liver function , the postmarketing experience of pioglitazone there have been rare reports of hepatocellular dysfunction ( see section 4.8 ) .'",b'monitoring of liver function an enamel experiences see section . .',"b'monitoring of liver function : from postmarketing experience of pioglitazone , there have been rare reports of hepatocellular dysfunction ( see section 4.8 ) .'"
1772,"b'die durchstechflasche mehrmals vorsichtig schwenken , bis der inhalt komplett aufgel\xc3\xb6st ist .'",b'keep the vial shake carefully the contents are completely dissolved .',b'keep the vial of the vial vigorously by the contents with humalog tightly completely dissolved .',b'shake the vial carefully several times until the contents are completely dissolved .'
1773,b'die folgenden ergebnisse der wirkungen von fablyn auf das endometrium nach 5-j\xc3\xa4hriger verabreichung stammen aus der pearl-studie .',b'the following results of the effects of fablyn on the endometrium after 5-j\xc3\xa4hriger cox administration of the pearl study .',b'the following results of the effects of fablyn on the broiler after noninferiority amount of the examining in protein toxicity rate rate rate independent .',b'the following results of the effects of fablyn on the endometrium after 5 years of administration are from the pearl study .'
1774,b'bei ausbleibendem ansprechen auf stickstoffmonoxid-inhalationsgas siehe abschnitt 4.4 .',b'in ausbleibendem response to stickstoffmonoxid-inhalationsgas see section 4.4 .',b'in stomach response to optimize water .',b'in absent response to nitrogen monoxide inhalation see section 4.4 .'
1775,b'wenden sie humalog kwikpen immer genau nach anweisung des arztes an .',b'always use humalog kwikpen exactly as your doctor has told you .',b'always use humalog kwikpen exactly as your doctor has told not used ?',b'always use humalog kwikpen exactly as your doctor has told you .'
1776,"b'zur anwendung bei patienten mit nierenversagen , mit eingeschr\xc3\xa4nkter leberfunktion oder leberversagen , bei kindern und schwangeren frauen siehe abschnitt 4.3 .'","b'for use in patients with renal failure , with impaired liver function or liver failure , children and pregnant women , see section 4.3 .'","b'for use in patients with renal failure , with the disease .'","b'for use in patients with renal failure , with impaired liver function or liver failure , children and pregnant women , see section 4.3 .'"
1777,b'bei einigen dieser patienten war die hyperglyk\xc3\xa4mie schwerwiegend und in einigen f\xc3\xa4llen zus\xc3\xa4tzlich mit einer ketoazidose verbunden .',b'in some of these the hyperglycaemia was severe and in some cases also associated with ketoacidosis .',b'in some of these the hyperglycaemia was severe and in some cases also associated with ketoacidosis .',b'in some of these patients the hyperglycaemia was severe and in some cases also associated with ketoacidosis .'
1778,"b'dies ist in einer verringerten clearance von levodopa begr\xc3\xbcndet , die zu einer verl\xc3\xa4ngerung der terminalen eliminationshalbwertszeit ( t1 / 2 ) von levodopa f\xc3\xbchrt .'","b'this is justified in a decreased clearance of levodopa , result in a prolongation of the terminal elimination half-life ( t1 / 2 ) of levodopa .'",b'this is established in a decreased clearance of particular acid .',"b'this is justified in a decreased clearance of levodopa , resulting in a prolongation of the terminal elimination half-life ( t1 / 2 ) of levodopa .'"
1779,b'behandlung mit posaconazole sp spezielle blutuntersuchungen .',b'posaconazole sp special blood tests .',b'posaconazole does not does in the disease',b'posaconazole sp special blood tests .'
1780,"b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von invega die 3-mg-tablette von invega enth\xc3\xa4lt lactose , eine zuckerart .'","b'important information about some of the ingredients of invega the 3 mg tablet of invega contains lactose , which is a type of sugar ) .'",b'important information about some of the ingredients of invega the mg tablet of epivir of invega the mg tablet of invega . the mg tablet of invega a skin tablet of invega administration of the ingredients of invega of invega the mg tablet of invega of invega the mg tablet',"b'important information about some of the ingredients of invega . the 3 mg tablet of invega contains lactose , which is a type of sugar ) .'"
1781,"b'die behandlung mit dynepo sollte von einem arzt eingeleitet werden , der \xc3\xbcber erfahrung in der behandlung von patienten mit niereninsuffizienz verf\xc3\xbcgt .'",b'treatment with dynepo should be initiated by a doctor who has experience in the treatment of patients with renal insufficiency .',b'treatment with dynepo should be initiated by a doctor who has experience in the treatment of patients with renal insufficiency .',b'treatment with dynepo should be initiated by a doctor who has experience in the treatment of patients with renal insufficiency .'
1782,"b'wie bei jeder insulintherapie kann es an der injektionsstelle zu einer lipodystrophie kommen , die die insulinresorption im betroffenen bereich verz\xc3\xb6gert .'","b'as with any insulin therapy , lipodystrophy may occur at as the injection site and delay local insulin absorption .'","b'as with any insulin therapy , lipodystrophy may occur at as the injection site and delay the infusion site as a insulin red .'","b'as with any insulin therapy , lipodystrophy may occur at the injection site and delay local insulin absorption .'"
1783,"b'wenn der patient die einnahme vergisst , soll er diese nicht nachholen , sondern zum n\xc3\xa4chsten einnahmezeitpunkt wieder die verschriebene dosis einnehmen .'","b'if the patient is taking vergisst , this should not be missing , but the next dose at the usual time resumed the prescribed dose .'","b'if the patient comes with partiellem , or the subsequent place to take use you and mosquitoes , the next dose at the usual time detailed period through the usual time to the end of place , the next dose may started to drive , which check have be thrown'","b'if the patient fogets to take a dose , it should not be taken later , but rather the next dose should be resumed at the usual time .'"
1784,"b'lenalidomid ist im allgemeinen in organischen l\xc3\xb6sungsmitteln besser l\xc3\xb6slich , zeigt jedoch die beste l\xc3\xb6slichkeit in 0,1 n hcl-puffer .'","b'lenalidomide are generally polar , however , shows that the best solubility of which is hcl-puffer .'","b'lenalidomide deoxy , however , shows that the best provider of which is rearranged .'","b'lenalidomide are generally polar , however , shows the best solubility in hcl-puffer .'"
1785,b'ausgehend von einer pharmakokinetischen studie sollte die dosis f\xc3\xbcr valsartan bei diesen patienten 80 mg nicht \xc3\xbcbersteigen und mit vorsicht angewendet werden .',"b'based on a pharmacokinetic study , the dose should not exceed 80 mg valsartan and should be used with caution in these patients .'","b'based on a pharmacokinetic study , the dose should not exceed adjusted kg and should be used with caution in these patients .'","b'based on a pharmacokinetic study , the dose should not exceed 80 mg valsartan and should be used with caution in these patients .'"
1786,b'die infusion wird mindestens 15 minuten dauern .',b'the infusion will last at least 15 minutes .',b'shake the infusion will last at least minutes .',b'the infusion will last at least 15 minutes .'
1787,"b'fertilit\xc3\xa4tsstudien wurden mit trabectedin nicht durchgef\xc3\xbchrt , aber in toxizit\xc3\xa4tsstudien mit wiederholter gabe wurden in begrenztem ausma\xc3\x9f histopathologische ver\xc3\xa4nderungen in den gonaden festgestellt .'","b'fertility studies have not been conducted with trabectedin , but in toxicity studies were histopathological changes in the extent of disturbed gonadal function .'","b'fertility studies have not been conducted with trabectedin , but maternal toxicity studies were reduced changes in the group of gy showed in toxicity studies observed in the extent of background concomitant light of hyperkeratosis fluorescenceguided function .'","b'fertility studies have not been conducted with trabectedin , but in toxicity studies with repeated doses histopathological changes in the gonads were detected to a limited extent .'"
1788,"b'wie anhand des gesamtscores des fragebogens zur lebensqualit\xc3\xa4t bei rhino-konjunktivitis gezeigt wurde , vermindern azomyr tabletten effektiv die durch saisonale allergische rhinitis hervorgerufene belastung .'",b'shown by the total score of the rhino-conjunctivitis quality of life were effective in alleviating the burden of azomyr tablets in alleviating the burden of seasonal allergic rhinitis as .',b'shown well to the erythropopietic meeting of life were given in rhinoconjunctivitis the burden of azomyr tablets including the introduction of helixate body should as less was reported in stabilization to the result of hearing allergic rhinitis as .',"b'shown by the total score from surveys on the quality of life with rhino-conjunctivitis , azomyr tablets were effective in alleviating the burden of seasonal allergic rhinitis .'"
1789,b'die tabletten m\xc3\xbcssen ungeteilt eingenommen werden .',b'the tablets should be taken substantially .',b'the tablets should be taken back follows .',b'the tablets should be taken on their own .'
1790,b'der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen wird j\xc3\xa4hrlich psurs vorlegen solange seitens der chmp keine anders lautenden anforderungen gestellt werden .',b'the marketing authorisation holder will continue to submit annual psurs for as long as the chmp .',"b'the marketing authorisation holder will continue to submit serotypes psurs , lift psurs to submit making psurs for how long as the chmp .'",b'the marketing authorisation holder will continue to submit annual psurs unless otherwise specified by the chmp .'
1791,b'regranex ist in 15 g polyethylen-beschichteten tuben zur mehrfachanwendung erh\xc3\xa4ltlich .',b'regranex in 15 g polyethylen-beschichteten multidose tubes .',b'regranex in g triple purposes with infusion gx yields contain considerable before',b'regranex is available in 15 g polyethylen-coated multidose tubes .'
1792,"b'versuche , geschlechtsverkehr auszu\xc3\xbcben , waren in den prim\xc3\xa4ren wirksamkeitsstudien bei 75 % der mit tadalafil behandelten patienten erfolgreich , verglichen mit 32 % unter placebo .'","b', mean per-subject proportion of successful intercourse attempts were the primary efficacy studies 75 % of patients treated with tadalafil were successfully treated , compared with 32 % with placebo .'",b'autoimmune hbac proportion of phenytoin in transfusions and sildenafil .',b'attempts to have intercourse in the primary efficacy studies in 75 % of patients treated with tadalafil were successful compared with under 32 % with placebo .'
1793,"b'as jede 0,3 ml fertigspritze enth\xc3\xa4lt 30 mikrogramm darbepoetin alfa ( 100 mikrogramm / ml ) .'",b'each 0.3 ml pre-filled syringe contains 30 micrograms darbepoetin alfa ( 100 micrograms / ml ) .',b'each . ml prefilled syringe contains micrograms darbepoetin alfa micrograms ml .',b'each 0.3 ml pre-filled syringe contains 30 micrograms darbepoetin alfa ( 100 micrograms / ml ) .'
1794,b'in klinischen studien war das ausma\xc3\x9f der hba1c-senkungen unter vildagliptin gr\xc3\xb6\xc3\x9fer bei patienten mit hohen hba1c-ausgangswerten .',"b'in clinical trials , the extent of hba1c-senkungen greater in patients with high gliclazide when added to vildagliptin .'","b'in clinical trials , the extent of xelox greater in patients with high zirconium when proteinuria to humans .'","b'in clinical trials , the extent of hba1c reduction was greater in patients with high gliclazide added to vildagliptin .'"
1795,b'23 das auftreten einer durch myelosuppressive chemotherapie bedingten thrombozytopenie und an\xc3\xa4mie kann durch eine behandlung mit filgrastim allein nicht verhindert werden .',b'23 due to myelosuppressive chemotherapy due to thrombocytopenia and anaemia has not been proven to prevent the treatment with filgrastim alone .',b'due to systemically chemotherapy due to thrombocytopenia and anaemia has not been a lglucerase of filgrastim has not been treated to tnf effectively interactions on the treatment with filgrastim alone .',b'23 appearance of thrombocytopenia due to myelosuppressive chemotherapy anaemia has not been proven to be prevented with filgrastim alone .'
1796,b'weitere informationen \xc3\xbcber revlimid :',b'2 / 3 other information about revlimid :',b'other information about revlimid',b'2 / 3 other information about revlimid :'
1797,b'bei obiger vorgehensweise enth\xc3\xa4lt die rekonstituierte l\xc3\xb6sung 5 mg alglucosidase alfa pro ml .',b'in the above course of the reconstituted solution contains 5 mg of alglucosidase alfa per ml .',b'in the above observation of the reconstituted solution contains mg of ccyr alfa per ml .',"b'in the above course , the reconstituted solution contains 5 mg of alglucosidase alfa per ml .'"
1798,"b'datscan enth\xc3\xa4lt ioflupan ( 123i ) , das zur unterst\xc3\xbctzung der diagnose von erkrankungen des gehirns eingesetzt wird .'","b'datscan contains ioflupane ( 123i ) , which is used as an aid in the diagnosis of brain disease .'","b'datscan contains pyrexia i , which is mainly .'","b'datscan contains ioflupane ( 123i ) , which is used as an aid in the diagnosis of brain disease .'"
1799,b'es wird zu einer klinischen \xc3\x9cberwachung und entsprechender anpassung der clozapin-dosierung w\xc3\xa4hrend und kurz nach der behandlung mit ciprofloxacin geraten ( siehe abschnitt 4.4 ) .',b'it will be a clinical monitoring and dose adjustment of the clozapin-dosierung during and shortly after treatment with ciprofloxacin ( see section 4.4 ) .',b'bring the individual monitoring and posology should be should be copper within and shortly after treatment with ciprofloxacin see section . .',b'a clinical monitoring and dose adjustment of the clozapin-dosierung during and shortly after treatment with ciprofloxacin is advised ( see section 4.4 ) .'
1800,b'stellen sie f\xc3\xbcr die injektion die folgenden gegenst\xc3\xa4nde auf einer sauberen oberfl\xc3\xa4che bereit .',b'turn the dose selector to select the injection of the following items on a clean surface .',b'shake the dose selector to select the injection of the following items on a clean surface .',b'have following items ready on a clean surface for the injection .'
1801,"b'las es wird empfohlen , dass patienten mindestens 3 bis 4 monate mit viraferon alleine behandelt werden und dann der hcv-rna-status bestimmt wird .'","b'tho it is recommended that patients be treated with viraferon alone for at least 3 to 4 months , and then the hcv-rna-status .'","b'coadministration given in treating working inhibitors or continued with viraferon have reinitiated with viraferon alone for at least to months , and then beside long working temperature .'","b'it is recommended that patients be treated with viraferon alone for at least 3 to 4 months , and then the hcv rna status can be determined .'"
1802,"b'nierenfunktionsst\xc3\xb6rungen bei patienten mit leichten bis mittelschweren nierenfunktionsst\xc3\xb6rungen ( gfr > 30 ml / min / 1,73 m2 ) ist keine dosisanpassung von exforge erforderlich .'","b'renal impairment in patients with mild to moderate renal impairment ( gfr 30 ml / min / 1.73 m2 ) , no dosage adjustment is necessary when administering exforge .'","b'renal impairment in patients with mild to moderate renal impairment gfr ml min . m , no dosage recommended is necessary when administering exforge .'","b'renal impairment : in patients with mild to moderate renal impairment ( gfr 30 ml / min / 1.73 m2 ) , no dosage adjustment is necessary when administering exforge .'"
1803,b'erwachsene ( > 21 und < 65 jahre ) :',b'adults ( 21 and 65 years of age ) :',b'adults and years of age',b'adults ( > 21 and < 65 years of age ) :'
1804,"b'die l\xc3\xb6sung ist mit natriumhydroxid ( und , falls erforderlich , mit salzs\xc3\xa4ure ) auf einen bestimmten ph-wert eingestellt und enth\xc3\xa4lt keine konservierungsmittel .'","b'the solution is adjusted with sodium hydroxide ( and , if necessary , hydrochloric acid ) with a conductive and does not contain any preservative .'","b'the solution is adjusted per pale with sodium hydroxide and , if necessary , hydrochloric acid with a endophthalmitis and does not contain any preservative .'","b'the solution is adjusted with sodium hydroxide ( and , if necessary , hydrochloric acid ) set to a certain ph value and contains no preservatives .'"
1805,"b'nur klare , farblose l\xc3\xb6sungen verwenden .'","b'only clear , colourless solutions .'","b'only clear , colourless solutions .'","b'only use clear , colourless solutions .'"
1806,"b'der plastikfilm enth\xc3\xa4lt : pvc ( polyvinylchlorid ) , polyamid und polyester .'","b'the mab : pvc ( polyvinyl chloride ) , polyamide and polyester .'","b'the presence pvc polyvinyl chloride , ranolazine and film and in xigris and pseudoephedrine and different .'","b'the plastic film contains : pvc ( polyvinyl chloride ) , polyamide and polyester .'"
1807,"b'thrombin setzt schlie\xc3\x9flich fibrinogen in fibrin um , wodurch sich ein gerinnsel bildet .'",b'thrombin then releases fibrinogen into fibrin by the layers ( 53 ) of the intermediate .',b'recombinant small human pestivirus with the synchromed may chamber or a formula surface system channels .',b'thrombin then releases fibrinogen into fibrin by the layers ( 53 ) of the intermediate .'
1808,"b'veranschlagt sind mittel zur deckung anderer sachausgaben , die nicht getrennt in anderen posten vorgesehen sind .'","b'this appropriation is intended to cover other administrative expenditure , which should not be used in other appropriation .'",b'this appropriation is intended to cover to relating to article or questioned by new body .',"b'this appropriation is intended to cover other administrative expenditure , which should not be used in other appropriation .'"
1809,b'eine dosisabh\xc3\xa4ngige verminderung der leukozyten- und thrombozytenzahl scheint ein empfindlicher indikator f\xc3\xbcr toxizit\xc3\xa4t zu sein .',b'a dose-dependent decrease in white blood cell and platelet counts appear to be sensitive indicators of toxicity .',b'a vitro decrease in white blood cell and platelet counts of toxicity .',b'a dose-dependent decrease in white blood cell and platelet counts appear to be sensitive indicators of toxicity .'
1810,b'die fl\xc3\xa4che unter der kurve stieg etwa proportional zur erh\xc3\xb6hung der dosis an .',b'the area under the curve was increased approximately proportional to the increase in dose .',b'the area under the sachets was increased approximately proportional to the reached in dose .',b'the area under the curve was increased approximately proportional to the increase in dose .'
1811,"b'weiterhin spielt die cox-2 bei der ovulation , der implantation und bei verschluss des ductus arteriosus , bei der regulation der nierenfunktion und bei funktionen des zentralnervensystems ( fieberinduktion , schmerzempfindung und kognitive funktionen ) eine rolle .'","b'cox-2 is also involved in ovulation , implantation and closure in the pda may then , regulation of renal function , and central nervous system ( fieberinduktion , and cognitive function ) .'",b'cox is also involved in comt where for blood therapy .',"b'cox-2 also plays a role in ovulation , implantation and closure of the da , regulation of renal function , and central nervous system ( fever induction , sensation to pain and cognitive function ) .'"
1812,b'nur f\xc3\xbcr die intraven\xc3\xb6se injektion und einmalige anwendung .',b'only for intravenous injection and a single use .',b'only for intravenous injection and a single use .',b'only for intravenous injection and single use .'
1813,"b'wie alle arzneimittel kann zevalin nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , zevalin may cause side effects , although not every body gets them .'","b'like all medicines , zevalin may cause side effects , although not every body gets them .'","b'like all medicines , zevalin may cause side effects , although not everybody gets them .'"
1814,"b'die wirkungen von opgenra wurden zun\xc3\xa4chst in versuchsmodellen getestet , bevor sie an menschen untersucht wurden .'",b'the effects of opgenra were first tested in experimental models before being studied in three main studies involving .',b'the effects of opgenra these effect in experimental models before being studied in three main studies from humans .',b'the effects of opgenra were first tested in experimental models before being studied in humans .'
1815,"b'ihr arzt wird t\xc3\xa4glich ihr blut kontrollieren , um zu pr\xc3\xbcfen , wie gut die behandlung wirkt und welche dosis f\xc3\xbcr sie am besten ist .'",b'your doctor will daily ; your blood should be checked to determine how well the treatment is working and the dose that is best for you .',b'your doctor immediately to your blood colour if it will be checked to determine how well the treatment is material and the dose that be winthrop and the dose that even have give suffices exactly your haemoglobin mixing .',"b'your doctor will check your blood daily , to determine how well the treatment is working and the dose that is best for you .'"
1816,"b'daher ist vorsicht ratsam , wenn die therapie eines patienten gleichzeitig venlafaxin und einen cyp3a4-inhibitor umfasst .'","b'consequently , caution is advised when therapy with venlafaxine and a cyp3a4 inhibitor .'","b'consequently , caution is available when a metabolism inhibitors .'","b'consequently , caution is advised when therapy is with venlafaxine and a cyp3a4 inhibitor .'"
1817,b'brauchen sie exelon l\xc3\xb6sung zum einnehmen nach anbruch der flasche innerhalb eines monats auf .',b'use up one bottle before opening the exelon oral solution after opening the bottle within one month of treatment .',b'the enclosed solution after opening the bottle within one month of treatment .',b'use up one bottle of exelon oral solution after opening within one month .'
1818,"b'die behandlung sollte unter der anleitung eines arztes erfolgen , der in der behandlung h\xc3\xa4matologischer erkrankungen erfahren ist .'",b'treatment should be started under the direction of a physician experienced in the treatment of haematological disorders .',b'treatment should be given under the direction of a patient experienced in the treatment of haematological disorders .',b'treatment should be started under the direction of a physician experienced in the treatment of haematological disorders .'
1819,"b'behandlung erwachsener patienten mit mittelschwerer bis schwerer psoriasis vulgaris vom plaque- typ , bei denen andere systemische therapien einschlie\xc3\x9flich ciclosporin , methotrexat und puva ( siehe abschnitt 5.1 - klinische wirksamkeit ) nicht angesprochen haben , kontraindiziert sind oder nicht vertragen wurden .'","b'treatment of adult patients with moderate to severe plaque psoriasis in whom other systemic therapies including ciclosporin , methotrexate and puva ( see section 5.1 - clinical efficacy ) have failed to respond to , or who have a contraindication to , or are intolerant .'","b'treatment of adult patients with moderate to severe plaque psoriasis in patients with moderate to severe treatment of adult patients with moderate to severe plaque the significant systemic therapies including pgp , methotrexate and ultraviolet see section . clinical table tnbp and little see section . clinical clinical investigated effect'","b'treatment of adult patients with moderate to severe plaque psoriasis vulgaris in whom other systemic therapies including ciclosporin , methotrexate and puva ( see section 5.1 - clinical efficacy ) have failed to respond to , or who have a contraindication or are intolerant .'"
1820,b'einzeldosisbehandlung von unkomplizierten harnwegsinfektionen :',b'single dose treatment of uncomplicated uti :',b'single dose treatment of uncomplicated usestability',b'single dose treatment of uncomplicated uti :'
1821,"b'die studien zeigten , dass levemir das hba1c \xc3\xa4hnlich wie insulin nph kontrolliert , und zwar mit einem geringeren risiko eines niedrigen blutzuckerspiegels w\xc3\xa4hrend der nacht und ohne gewichtszunahme .'","b'the studies showed that levemir hba1c similar to that of a basal insulin nph insulin be monitored , with a lower risk of low blood sugar during the night and without weight gain .'",b'the studies showed that levemir with a onset of low blood sugar during the clofarabine mg disease and without weight and without acetylsalicylic development and without less of low blood sugar during the period of low blood sugar during the daidsgrad and without weight gain .',"b'the studies showed that levemir controlls the hba1c similar to insulin nph , and with a lower risk of low blood sugar during the night and without weight gain .'"
1822,"b'dieses syndrom ist eine granulomat\xc3\xb6se entz\xc3\xbcndliche erkrankung , die die augen , das geh\xc3\xb6rsystem , die meningen und die haut betrifft .'","b'this syndrome is an inflammatory disease , eosinophilic granulomatous disease that affects the eyes , the geh\xc3\xb6rsystem , meninges and skin .'","b'this syndrome is an inflammatory disease , traces causes food that affects the eyes , various and skin .'","b'this syndrome is an inflammatory , granulomatous disease that affects the eyes , the hearing , meninges and the skin .'"
1823,b'b. heparin ) nicht vor ablauf von 24 stunden nach der letzten einnahme von pradaxa .',b'( e. g. heparin ) is not less than 24 hours after the last administration of pradaxa .',b'e . g . heparin is not less than hours after the last administration of pradaxa .',b'( e. g. heparin ) is not less than 24 hours after the last administration of pradaxa .'
1824,b'entsprechend den offiziellen empfehlungen kann eine auffrischungsdosis von twinrix kinder oder eines anderen hepatitis-a- oder -b-impfstoffes gegeben werden .',b'may booster dose of twinrix paediatric or a is given according to official recommendations .',"b'may gradually do not be applied , no relevant dose of twinrix paediatric or a is given according to official recommendations .'",b'a booster dose of twinrix paediatric or another hepatitis a or b vaccine is given according to official recommendations .'
1825,"b'unter der einnahme von agopton k\xc3\xb6nnen bei manchen patienten nebenwirkungen wie z.b. schwindel , drehschwindel , m\xc3\xbcdigkeit und sehst\xc3\xb6rungen auftreten .'","b'under taking agopton may cause side effects in some people such as dizziness , vertigo , tiredness , and vision problems may occur .'","b'under taking agopton may cause side effects in some people such as dizziness , hallucinations , hives , pain , palpitations , tiredness , and blurred , tiredness , and vision problems may occur may occur .'","b'taking agopton may cause side effects in some people such as dizziness , vertigo , tiredness , and vision problems may occur .'"
1826,b'litak wird als injektion unter die haut verabreicht .',b'litak is given as an injection under the skin .',b'elaprase is given as an injection under the skin .',b'litak is given as an injection under the skin .'
1827,b'gleichzeitige gabe von ciprofloxacin und tizanidin ( siehe abschnitt 4.5 ) .',b'concomitant administration of ciprofloxacin and tizanidine ( see section 4.5 ) .',b'concomitant administration of ciprofloxacin and cotrimoxazole see section . .',b'concomitant administration of ciprofloxacin and tizanidine ( see section 4.5 ) .'
1828,"b'wir empfehlen auch , den arzt oder die krankenschwester um eine demonstration zu bitten .'","b'we suggest also , the doctor or nurse for help prevent demonstration .'",b'cystinosis suggests also a guide product easier to you carbohydrate to enough enclosed visually that if the doctor or nurse for help have avoid and copious vein .',"b'we suggest also , asking the doctor or nurse for a demonstration .'"
1829,b'die zu bevorzugenden stellen sind der anterolaterale oberschenkel ( musculus vastus lateralis ) bei s\xc3\xa4uglingen oder der musculus deltoideus des oberarmes bei kindern .',b'the bevorzugenden ( 70 ) of the anterolaterale thigh ( p38 mediated disorder in infants ) or the deltoid area of the oberarmes in children .',"b'the blood each spots , growth of the interventricular compress among children .'",b'the recommended sites are the anterolaterale thigh ( vastus lateralis muscle ) in infants or the deltoid area of the upper arm in children .'
1830,"b'die dosierungsempfehlungen sind gleich f\xc3\xbcr patienten mit schwarzer hautfarbe , asiaten und kaukasier ( siehe abschnitt 5.2 ) .'","b'the dosage recommendations are similar in patients with black , asian and caucasian ( see section 5.2 ) .'","b'the dosage recommendations are similar in patients with black , organisms and caucasian adults .'","b'the dosage recommendations are similar in patients with black skin colour , asians and caucasians ( see section 5.2 ) .'"
1831,"b'81 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'81 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'81 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'"
1832,b'wirkungen von efient auf andere arzneimittel :',b'effects of efient on other medicinal products :',b'effects of efient on other medicinal products',b'effects of efient on other medicinal products :'
1833,"b'drei dosen zu je 0,5 ml sollten mit einem zeitabstand von mindestens 1 monat zwischen den einzelnen dosen verabreicht werden .'",b'three doses of 0.5 ml should be administered with an interval of at least 1 month between doses .',b'three doses of . ml should be an interval of at least month between doses .',b'three doses of 0.5 ml should be administered with an interval of at least 1 month between doses .'
1834,"b'f\xc3\xbcr frauen , die revlimid einnehmen vor beginn der behandlung m\xc3\xbcssen sie ihren arzt fragen , ob bei ihnen die m\xc3\xb6glichkeit besteht , dass sie schwanger werden k\xc3\xb6nnen , auch wenn sie denken , dass dies unwahrscheinlich ist .'","b'for women taking revlimid before starting treatment , you must ask your doctor if you think you are able to become pregnant , even if you think this is unlikely .'","b'for use of this must ask your doctor if you think you are able to become pregnant , even if you think .'","b'for women taking revlimid : before starting treatment , you must ask your doctor if you think you are able to become pregnant , even if you think this is unlikely .'"
1835,b'dies ergibt zusammen einen 28 tage dauernden behandlungszyklus .',b'this yields a treatment cycle is 28 days duration .',b'this wishes of the permanent cycle is days new is below .',b'this yields a treatment cycle of 28 days duration .'
1836,"b'daher bestehen \xc3\xbcbereinstimmende hinweise darauf , dass tumorpatienten , die mit rekombinanten humanen erythropoetinen behandelt werden , erheblichen schaden nehmen k\xc3\xb6nnen .'","b'there is therefore consistent evidence to suggest that cancer patients included in the data , are there may be significant harm to patients .'",b'there is therefore consistent evidence to suggest that a tissue and or increase .',"b'there is therefore consistent evidence to suggest that there may be significant harm cancer patients , who have been treated with recombinant , human erythropoietins .'"
1837,b'dies gilt auch f\xc3\xbcr nicht bekannte oder neu auftretende viren und andere arten von infektionen .',b'this also applies to not known or new onset of viruses and other types of infections .',b'this also applies to not known or new onset of sensitivity of mix and other types of infections .',b'this also applies to not known or new onset of viruses and other types of infections .'
1838,"b'das zusammenf\xc3\xbcgen von spritze und nadel muss besonders vorsichtig erfolgen , um nadelstichverletzungen zu vermeiden .'","b'the means of the syringe and needle should be performed , from needle stick injuries following injection .'","b'the means , the syringe and make manufacturing measures in shaving a air to a you and novomix should be necessary , a preinjection following injection .'","b'the means of the syringe and needle should be performed , from needle stick injuries following injection .'"
1839,"b'die behandlung mit arava beginnt mit einer initialdosis von 100 mg einmal t\xc3\xa4glich \xc3\xbcber drei tage , gefolgt von einer erhaltungsdosis .'","b'treatment with arava is initiated with a loading dose of 100 mg once daily for three days , followed by a maintenance dose .'",b'treatment with arava is initiated with a loading dose of mg once daily for three days .',"b'treatment with arava is initiated with a loading dose of 100 mg once daily for three days , followed by a maintenance dose .'"
1840,b'verwenden sie nie die restmengenskala zum abmessen ihrer insulindosis . \xe2\x80\xa2 sie h\xc3\xb6ren f\xc3\xbcr jede einzelne eingestellte einheit ein klickger\xc3\xa4usch .',b'do not use never the residual scale to measure your dose of insulin \xe2\x80\xa2 you will hear a click for every single unit dialled. a',"b'pass , these returned to replace all viraferon light preferably may be cloudy as health to the medicine see it easier to healthy needle . a several retractable countries and vigorously for vitamin refludan framework in travelling with a saline visually thrombocytopenia . a new stoppers vigorously completely followed to'",b'never use the residual scale to measure your dose of insulin \xe2\x80\xa2 you will hear a click for every single unit dialled. a'
1841,b'sie k\xc3\xb6nnen sie mit oder ohne nahrung einnehmen .',b'you can take it with or without food .',b'they can take it with or without food .',b'you can take it with or without food .'
1842,"b'286 sie d\xc3\xbcrfen stocrin nach dem auf der flasche und der verpackung , nach "" verwendbar bis "" angegebenen verfalldatum nicht mehr verwenden .'",b'286 do not use stocrin after the expiry date which is stated on the use of the bottle and on the carton after exp .',b'do not use sustiva after the expiry date which is stated on the use of the bottle and on the carton after exp .',b'286 do not use stocrin after the expiry date which is stated on the bottle and on the carton after exp .'
1843,b'der wirkmechanismus schlie\xc3\x9ft die bindung von faktor viia an freien tissue factor ein .',b'the mechanism of action precludes the binding of recombinant factor viia or a lipstick of tissue factor .',"b'the mechanism of action contains recombinant factor , their wide solution in colicells of tissue factor .'",b'the mechanism of action includes the binding of recombinant factor viia to free tissues factor .'
1844,b'enbrel 25 mg ist als wei\xc3\x9fes pulver und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung erh\xc3\xa4ltlich .',b'enbrel 25 mg is supplied as a white powder and solvent for solution for injection .',b'enbrel mg is supplied as a apidra is supplied as a white powder and solvent for injection .',b'enbrel 25 mg is available as a white powder and solvent for solution for injection .'
1845,"b'sobald sich ihr zustand stabilisiert hat , wird ihr arzt gew\xc3\xb6hnlich die dosis von advagraf herabsetzen .'","b'once your condition and periodically thereafter , your doctor will usually be the most appropriate dose of advagraf .'","b'once your condition has sometimes eliminated within onsenal , your doctor will usually be the most appropriate dose of advagraf until hours .'","b'once your condition has stabilized , your doctor will usually reduce the dose of advagraf .'"
1846,"b'das gentechnologisch hergestellte omega interferon feliner herkunft ist ein typ i interferon , das mit alpha interferon nahe verwandt ist .'","b'the genetically reconstituted omega interferon feliner scandinavian origin is a type i interferon , insulin which is an interferon .'",b'the bind a polyethylene glycolepoetin enzyme protein minolevulinic salt .',"b'the genetically engineered omega interferon of feline origin is a type i interferon , which is closely related to alpha interferon .'"
1847,b'ranolazin hat m\xc3\xb6glicherweise antiangin\xc3\xb6se wirkungen durch die hemmung des sp\xc3\xa4ten natriumstroms in den kardialen zellen .',b'ranolazine may have antianginal effects due to inhibition of late sodium current by the cardiac cells .',b'ranolazine clearance of antibodies due to inhibition of vitro cox toxicity mexxyoprm as has been subject to mainly slightly reduced .',b'ranolazine may have antianginal effects due to inhibition of late sodium current by the cardiac cells .'
1848,b'die vorhandenen daten lassen keine schl\xc3\xbcsse auf den einfluss von m\xc3\xa4\xc3\x9figer leberinsuffizienz ( child-pugh-klasse b ) auf die pharmakokinetik von aprepitant zu .',b'available data do not suggest any insufficient to draw conclusions on the influence of moderate hepatic insufficiency ( child-pugh class b ) on the pharmacokinetics of aprepitant .',b'available for the specific results were not no based on the influence of moderate hepatic insufficiency childpugh class b on the pharmacokinetics of aprepitant .',b'the available data does not allow us to draw conclusions on the influence of moderate hepatic insufficiency ( child-pugh class b ) on the pharmacokinetics of aprepitant .'
1849,"b'wird dieses enzym blockiert , kann sich das virus nicht mehr normal vermehren , wodurch die ausbreitung der infektion verlangsamt wird .'","b'reyataz , taken in combination , reduces the amount of hiv infection .'","b'reyataz , taken in combination , that the amount of hiv infection .'","b'if this enzyme is blocked , the virus can no longer multiply , which slows the spread of the infection .'"
1850,b'dies ist bei patienten mit verringerter oder fehlender wahrnehmung von hypoglyk\xc3\xa4mie-warnsymptomen oder h\xc3\xa4ufigen hypoglyk\xc3\xa4mie-episoden besonders wichtig .',b'this is particularly important in those who have reduced or lack of those who have reduced or absent awareness hypoglycaemia or have frequent episodes of hypoglycaemia .',b'this is particularly makes patients who have reduced or persistent to moderately episodes of hypoglycaemia .',b'this is particularly important in those who have reduced or absent awareness of hypoglycaemia symptoms or have frequent episodes of hypoglycaemia .'
1851,b'xolair 150 mg injektionsl\xc3\xb6sung steht als packungen mit 1 fertigspritze und als mehfachpackungen mit 4 oder 10 einzelpackungen mit jeweils 1 fertigspritze zur verf\xc3\xbcgung .',"b'xolair 150 mg solution for injection is available in packs of 1 pre-filled syringe and in multipacks comprising 4 or 10 intermediate packs , each containing 1 pre-filled syringe .'",b'xolair mg solution for injection is available in packs of prefilled syringe and in ethanol .',"b'xolair 150 mg solution for injection is available in packs of 1 pre-filled syringe and in multipacks comprising 4 or 10 intermediate packs , each containing 1 pre-filled syringe .'"
1852,"b'das hi-virus in ihrem blut k\xc3\xb6nnte schlie\xc3\x9flich gegen fuzeon resistent werden , sodass ihr virus-spiegel im blut zu steigen beginnt .'","b'this finally in your blood may be resistant to fuzeon , check your blood levels rise to the top .'",b'this things in your blood may be resistant to discolour you with lifethreatening mycobacterium levels increased or operate .',"b'the hi virus in your blood may actually be resistant to fuzeon , so that your virus levels in the blood begin to climb .'"
1853,"b'fragen sie ihren arzt oder apotheker um rat , bevor sie ecalta in der stillzeit anwenden .'",b'ask your doctor or pharmacist for advice before taking ecalta during lactation .',b'ask your doctor or pharmacist for advice before taking ecalta during lactation .',b'ask your doctor or pharmacist for advice before taking ecalta during lactation .'
1854,"b'ebenso kann die begleitende gabe von wirkstarken induktoren dieses enzyms ( z.b. rifampicin , phenorbarbital , johanniskraut ) die systemische exposition gegen\xc3\xbcber trabectedin herabsetzen .'","b""similarly , the concomitant administration of wirkstarken inducers of this enzyme ( e. g. rifampicin , phenorbarbital , st john 's wort ) may reduce the systemic exposure to trabectedin .""","b'similarly , the concomitant administration of potent inducers of this enzyme e . g . rifampicin , haemoperfusions , st john s wort were increased one exposure to sachets .'","b""similarly , the concomitant administration of potent inducers of this enzyme ( e. g. rifampicin , phenobarbital , st john 's wort ) may reduce the systemic exposure to trabectedin ."""
1855,"b'folglich werden die wirksamkeitsdaten als zu schwach eingesch\xc3\xa4tzt , um eine p\xc3\xa4diatrische indikation f\xc3\xbcr \xc3\x96sophagitis bei kindern und jugendlichen zu st\xc3\xbctzen .'","b'consequently , the efficacy data of greater than too weak to support a paediatric indication for esophagitis in children and adolescents .'","b'consequently , the efficacy data of greater than too weak to support a paediatric indication for oxaliplatin on the transplant indication for environmental pump .'","b'consequently , the efficacy data was rated too weak to support a paediatric indication for esophagitis in children and adolescents .'"
1856,b'bitte lesen sie die folgende bedienungsanleitung vor der benutzung ihres protaphane flexpen sorgf\xc3\xa4ltig durch .',b'please read the following instructions before using your protaphane flexpen carefully .',b'please read the following instructions before using your protaphane flexpen carefully .',b'please read the following instructions before using your protaphane flexpen carefully .'
1857,"b'kleinkinder oder kinder unter 12 jahren d\xc3\xbcrfen oracea nicht erhalten , weil dies eine bleibende verf\xc3\xa4rbung der z\xc3\xa4hne oder st\xc3\xb6rungen der zahnentwicklung hervorrufen kann .'","b'infants or children under the age of 12 years , oracea should not be maintained because this can cause permanent discolouration of the teeth or tetracyclines .'","b'infants or children under the age of years , oracea should be examined because this can cause a degree .'",b'infants or children under the age of 12 years should not be given oracea because this can cause permanent discolouration of the teeth or disturbances in teeth development .'
1858,b'( siehe abschnitt 4.4 ) .',b'( see section 4.4 ) .',b'see section . .',b'( see section 4.4 ) .'
1859,"b'32 gro\xc3\x9fe ovarialzysten ( gefahr der ruptur ) , aszites , h\xc3\xa4ufig hydrothorax und gewichtszunahme gekennzeichnet .'","b'32 is characterised by large ovarian cysts ( prone to rupture ) , ascites , often hydrothorax and weight gain .'",b'is resistant removes biochemical ulceration or maculopapular and weight gain .',"b'32 is characterised by large ovarian cysts ( prone to rupture ) , ascites , often hydrothorax and weight gain .'"
1860,b'busilvex kann bei frauen und m\xc3\xa4nnern die fruchtbarkeit beeintr\xc3\xa4chtigen .',b'busilvex may impair fertility in women and men .',b'busilvex may impair fertility in women and men .',b'busilvex may impair fertility in women and men .'
1861,b'pioglitazon behandelt wurden .',b'treated with pioglitazone .',b'treated with pioglitazone .',b'treated with pioglitazone .'
1862,"b'- wenn sie weitere fragen haben , wenden sie sich bitte an ihren arzt oder apotheker .'","b'- if you have any further questions , ask your doctor or pharmacist .'","b'if you have any further questions , ask your doctor or pharmacist .'","b'- if you have any further questions , ask your doctor or pharmacist .'"
1863,b'kontrastverst\xc3\xa4rkung bei der kranialen und spinalen magnetresonanztomographie ( mrt ) .',b'contrast enhancement in cranial and spinal magnetic resonance imaging ( mri ) .',b'contrast enhancement in their torsion fat .',b'contrast enhancement in cranial and spinal magnetic resonance imaging ( mri ) .'
1864,"b'bitte teilen sie ihrem arzt mit , wenn sie stillen oder wenn sie planen , ihr baby zu stillen .'",b'pregnancy and breast-feeding tell your doctor if you are breast-feeding or if you are planning to breast-feed your baby .',b'pregnancy and breastfeeding tell your doctor if you are breastfeeding or do not administer your baby during the resuction .',b'pregnancy and breast-feeding : tell your doctor if you are breast-feeding or if you are planning to breast-feed your baby .'
1865,"b'basierend auf den konventionellen studien zur sicherheitspharmakologie , toxizit\xc3\xa4t bei wiederholter gabe und genotoxizit\xc3\xa4t lassen die pr\xc3\xa4klinischen daten keine besonderen gefahren f\xc3\xbcr den menschen erkennen .'","b'based on conventional studies of safety pharmacology , repeated dose toxicity and genotoxicity . preclinical data reveal no special hazard for humans .'","b'based on conventional studies of safety pharmacology , repeated age rates balance and genotoxicity . balance values .'","b'based on conventional studies of safety pharmacology , repeated dose toxicity and genotoxicity reveal no special hazard for humans in preclinical data .'"
1866,"b'wird zonegran verordnet , wird eine sorgf\xc3\xa4ltige \xc3\x9cberwachung empfohlen .'",b'when zonegran prescribes it is recommended that careful monitoring .',b'when zonegran enhancement it is recommended to migranelike the haemodialysis concentration should be coadministered with show dosage of fluids should be adjusted .',"b'when zonegran is prescribed , careful monitoring is recommended .'"
1867,"b'eine ph\xc3\xa4notypische resistenz gegen abacavir erfordert neben einer m184v- noch mindestens eine weitere abacavir-bedingte mutation , oder m184v mit mehreren tams .'","b'one phenotypic resistance to abacavir requires neutralization of m184v for at least another abacavir-bedingte , or m184v with tams .'",b'an neurohormone resistance to abacavir are a once by public alzheimer with acquired a postmenopausal mediated phosphate mri or mv with subpopulation .',"b'one phenotypic resistance to abacavir requires neutralization of m184v for at least another mutation conditional on abacavir , or m184v with several tams .'"
1868,"b'die wichtigsten induzierbaren p450 isoenzyme beim menschen , 1a , 2c8 / 9 und 3a4 , werden nicht induziert .'","b'the main prions p450 isoenzymes in humans , 1a , 2c8 / 9 and 3a4 , does not induce .'","b'the main shedantigen p isoenzymes in humans , a , c and a , does not induce .'","b'the main inducable p450 isoenzymes in humans , 1a , 2c8 / 9 and 3a4 , are not being induced .'"
1869,b'\xc3\x9cberempfindlichkeit gegen den wirkstoff oder einen der sonstigen bestandteile .',b'hypersensitivity to the active substance or to any of the excipients .',b'hypersensitivity to the active substance or to any of the excipients .',b'hypersensitivity to the active substance or to any of the excipients .'
1870,"b'mycophenolatmofetil teva ist ein "" generikum . ""'","b'mycophenolate mofetil teva is a "" generic medicine \' .'",b'mycophenolate mofetil teva is a generic medicine .',"b'mycophenolate mofetil teva is a "" generic medicine \' .'"
1871,b'2. was m\xc3\xbcssen sie vor der anwendung von avonex beachten ? 3.',b'what you should consider before you use avonex 3 .',b'what you should consider before you use avonex .',b'what you should consider before you use avonex 3 .'
1872,"b'die dritte studie ergab jedoch keinen unterschied zwischen der wirksamkeit von draxxin , oxytetracyclin und placebo .'","b'the third study showed no difference between the effectiveness of draxxin , oxytetracycline , and placebo .'","b'the control study showed no difference between the effectiveness of aminosalicylaten , bepridil , and placebo .'","b'the third study showed no difference between the effectiveness of draxxin , oxytetracycline , and placebo .'"
1873,b'antikoagulation mit kumarin-derivaten :',b'anticoagulation with coumarin derivatives :',b'normal is not miss yttrium',b'anticoagulation with coumarin derivatives :'
1874,b'der impfstoff f\xc3\xbchrt zur ausbildung einer aktiven immunit\xc3\xa4t gegen pferdeinfluenza und tetanus .',b'the vaccine stimulates active immunity against equine influenza and tetanus .',b'the vaccine stimulates active immunity against antimicrobial influenza and tetanus .',b'the vaccine stimulates active immunity against equine influenza and tetanus .'
1875,"b'impfstoffe wirken dadurch , dass sie dem immunsystem ( den k\xc3\xb6rpereigenen abwehrkr\xc3\xa4ften ) "" beibringen , "" sich selbst gegen eine krankheit zu verteidigen .'","b'vaccines work by the immune system ( the body \'s natural defences ) work by "" teaching \'the verteidigen itself against a disease .'",b'vaccines displays that immunomodulatory operations to then accumulate apart the ochiectomy is doctor is chosen structures appears with a disease .',"b'vaccines work by "" teaching "" the immune system ( the body \'s natural defences ) to project itself against a disease .'"
1876,"b'die behandlung mit hepsera sollte durch einen arzt eingeleitet werden , der in der behandlung der chronischen hepatitis b erfahren ist .'",b'treatment with hepsera should be started by a doctor who has experience in the treatment of chronic hepatitis b.',b'treatment with hepsera should be started by a doctor who has experience in the treatment of chronic hepatitis b .',b'treatment with hepsera should be started by a doctor who has experience in the treatment of chronic hepatitis b.'
1877,"b'eine einzelne 2,5-mg / kg-dosis von draxxin war bei der behandlung und pr\xc3\xa4vention von brd bei rindern und srd bei schweinen wirksam .'","b'a single 2,5-mg / kg dose of draxxin was effective in the treatment and prevention of brd in cattle and prevention of srd in pigs for meat and offal .'","b'a single , mg kg dose of rpls was effective in the treatment and mg , rotarix is effective , difumarate on plasma is possibly auc .'",b'a single 2.5-mg / kg dose of draxxin was effective in the treatment and prevention of brd in cattle and prevention of srd in pigs .'
1878,"b'ziconotid , der in prialt enthaltene wirkstoff , ist eine kopie der nat\xc3\xbcrlich vorkommenden substanz omega-conotoxin , die aus dem gift einer meeresschneckenart gewonnen wird .'","b'ziconotide , prialt , dipyridamol , is a copy of a naturally occurring substance is a polypeptide or a chemical linker , which is a meeresschneckenart .'","b'ziconotide , prialt , corrected , is a copy of a approval of a naturally occurring substance is a phosphodiesterase sequestrants for metabolisation and requested protein times or a enzyme ttp acid .'","b'ziconotide , prialt , dipyridamol , is a copy of a naturally occurring substance omega conotoxinis , which is extracted from the poison of a type of sea snail .'"
1879,"b'serotonin-syndrom wechselwirkung mit serotonergen wirkstoffen : ein serotonin-syndrom kann auftreten , wenn selektive serotonin-reuptake-hemmer ( ssris ) gleichzeitig mit anderen serotonergen wirkstoffen angewendet werden ( siehe abschnitt 4.5 ) .'",b'serotonin syndrome interaction with serotonergic active substances : serotonin syndrome may occur when selective serotonin reuptake inhibitors ( ssris ) are used concomitantly with other serotonergic active substances ( see section 4.5 ) .',"b'serotonin drug or copper serotonergic urinary system antiplatelet acid agents initiated of . . a dose form are defined selegiline inhibitors ssris from haematopoietic enzyme types of corrected egfr complication are used concomitantly with other medicines , an antagonistic therapy were given inhibitors ssris biopsies converting metabolisation . cloudiness are'",b'serotonin syndrome interaction with serotonergic active substances : serotonin syndrome may occur when selective serotonin reuptake inhibitors ( ssris ) are used concomitantly with other serotonergic active substances ( see section 4.5 ) .'
1880,b'sifrol wurde au\xc3\x9ferdem in zwei hauptstudien an patienten mit restless-legs-syndrom untersucht .',b'sifrol has also been studied in two main studies of patients with restless legs syndrome .',b'sifrol has also been studied in two main studies of patients with joint legs syndrome .',b'sifrol has also been studied in two main studies of patients with restless legs syndrome .'
1881,"b'die wei\xc3\x9fen tabletten enthalten 0,5 mg vareniclin , die hellblauen tabletten 1,0 mg .'","b'the white tablets contain 0.5 mg varenicline , with tablets of 1.0 mg .'","b'the white tablets contain . mg ivabradine , with tablets in . per .'","b'the white tablets contain 0.5 mg varenicline , with tablets of 1.0 mg .'"
1882,"b'b. aufgrund von sehst\xc3\xb6rungen beeintr\xc3\xa4chtigt sein . dies kann in situationen , in denen diese f\xc3\xa4higkeiten von besonderer bedeutung sind ( z.'","b', as a result of visual impairment . this may in situations where these abilities are of special importance ( e. g .'","b'the increase , as a result of visual impairment . maoinhibitor the disease e . g .'",b'b. affected as a result of visual impairment . this may in situations where these abilities are of special importance ( e. g .'
1883,b'rimonabant kann den saugreflex unterdr\xc3\xbccken .',b'rimonabant may suppress patients should notify their physician .',b'rimonabant may suppress patients should decide during account should been resistant frequently exposed effects .',b'rimonabant may suppress patients should notify their physician .'
1884,"b'extrahepatischer metabolismus durch cyp3a4 im darm , durch cyp1a1 in der lunge und durch cyp1b1 im tumorgewebe kann m\xc3\xb6glicherweise ebenfalls zur metabolischen clearance von erlotinib beitragen .'","b'extrahepatic metabolism by cyp3a4 in intestine , cyp1a1 in lung , and also potentially contribute to the metabolic clearance of erlotinib .'","b'valera metabolism between cypa in aivlosin , cypa in lung , and also potentially presents to the metabolic clearance of erlotinib .'","b'extrahepatic metabolism by cyp3a4 in the intestine , by cyp1a1 in lung , and also potentially contribute to the metabolic clearance of erlotinib .'"
1885,"b'28 blutdruckabfall und nachfolgende ver\xc3\xa4nderungen im ekg , allerdings bei dosierungen , welche die in der klinik verwendeten deutlich \xc3\xbcberstiegen .'","b'28 drop in blood pressure and blood pressure followed by changes of ecg , but these occurred at exposures that were dyed in the clinic is not required .'","b'neutrophil in blood pressure and withdrawal pressure followed by changes of ecg , but that patients are not required product are , obeserved .'","b'28 drop in blood pressure and subsequent changes in the ecg , but these occurred at doses that clearly rised above those used in the clinic .'"
1886,"b'interferone sind nat\xc3\xbcrliche substanzen , die vom menschlichen k\xc3\xb6rper hergestellt werden und ihm helfen , gegen angriffe wie virusinfektionen vorzugehen .'",b'interferons are natural substances produced by the body and help him to use such as viral infections .',b'interferons are natural substances produced by the body and help this .',b'interferons are natural substances produced by the body and help it take action against attacks like viral infections .'
1887,b'warum wurde volibris zugelassen ?',b'why has volibris been approved ?',b'why has yentreve been approved ?',b'why has volibris been approved ?'
1888,b'im k\xc3\xb6rper ist faktor vii an der blutgerinnung beteiligt .',"b'in the body , factor vii is involved in blood coagulation ( clotting ) .'","b'emtricitabine the body , factor vii is involved in blood coagulation eptacog renin .'","b'in the body , factor vii is involved in blood coagulation ( clotting ) .'"
1889,b'aus mikrobiologischer sicht sollte das produkt sofort verwendet werden .',"b'from a microbiological point of view , the product should be used immediately .'","b'already visually chamber a microbiological point of view , the product do be used immediately .'","b'from a microbiological point of view , the product should be used immediately .'"
1890,"b'insulinl\xc3\xb6sungen d\xc3\xbcrfen nicht verwendet werden , wenn sie nicht klar wie wasser und farblos aussehen .'",b'insulin solutions should not be used if they do not appear water clear and colourless to a frosted appearance .',b'insulin solutions should not be used if they do not prompt water clear and colourless to a velcade appearance .',b'insulin solutions should not be used if they do not appear clear like water and colourless .'
1891,b'pharmakotherapeutische gruppe : verschiedene radiopharmaka f\xc3\xbcr die palliative schmerzbehandlung .',b'pharmacotherapeutic group : various radiopharmaceuticals for palliative care .',"b'pharmacotherapeutic group with cystagon displays article , filgrastim'",b'pharmacotherapeutic group : various radiopharmaceuticals for palliative care .'
1892,b'rz welche risiken sind mit forcaltonin verbunden ?',b'er what is the risk associated with forcaltonin ?',b'and what is the risk associated with forcaltonin ?',b'er what is the risk associated with forcaltonin ?'
1893,"b'hb 10-13 g / dl ) und einem erwarteten blutverlust von 900-1800 ml angewendet werden , die nicht an einem autologen blutspendeprogramm teilnehmen k\xc3\xb6nnen .'",b'hb of 10-13 g / dl ) ) and the anticipated blood loss of 900-1800 ml may be used for autologous predonation .',b'diagnosis of g dl and the anticipated blood loss of ml may be used for circulatory fibrillation .',"b'hb 10-13 g / dl ) and an anticipated blood loss of 900-1800 ml to be used , if they may not be used for autologous predonation .'"
1894,"b'viele der unten aufgelisteten nebenwirkungen treten h\xc3\xa4ufig ( \xc3\x9cbelkeit , erbrechen , diarrh\xc3\xb6e , fieber , lethargie , hautausschlag ) bei patienten mit \xc3\x9cberempfindlichkeit gegen\xc3\xbcber abacavir auf .'","b'many of the side effects listed below occur commonly ( nausea , vomiting , diarrhoea , fever , lethargy , rash ) in patients with abacavir hypersensitivity .'","b'many of the side effects listed below occur commonly nausea , vomiting , diarrhoea , fever , dizziness , lethargy , diarrhoea , nausea in patients with abacavir hypersensitivity .'","b'many of the side effects listed below occur commonly ( nausea , vomiting , diarrhoea , fever , lethargy , rash ) in patients with abacavir hypersensitivity .'"
1895,b'es ist als cremefarbene kapseln ( 50 mg und 150 mg ) und als l\xc3\xb6sung zum einnehmen ( 15 mg / ml ) erh\xc3\xa4ltlich .',b'it is available as off-white capsules ( 50 mg and 150 mg ) and as an oral solution ( 15 mg / ml ) suspension for injection .',b'it is available as offwhite capsules per mg and which contains mg and as an oral solution mg ml suspension for injection .',b'it is available as off-white capsules ( 50 mg and 150 mg ) and as an oral solution ( 15 mg / ml ) .'
1896,"b'die behandlung einer \xc3\x9cberdosierung von tandemact besteht in erster linie darin , durch einleitung von erbrechen und anschlie\xc3\x9fendem trinken von aktivkohle ( adsorbens ) und natriumsulfat ( laxans ) in wasser oder limonade die resorption von glimepirid zu verhindern .'",b'treatment of overdose with tandemact consists primarily of vomiting and drinking with activated charcoal ( ii ) laxative ( laxative ) or more on the absorption of glimepiride .',b'treatment of overdose with tandemact consists primarily of vomiting and drinking injections proportional ii f myelin .',b'treatment of overdose with tandemact consists primarily of vomiting and drinking with activated charcoal ( ii ) and laxative in water or lemonadej on the absorption of glimepiride .'
1897,b'kurzfristige aufbewahrung bei 2 c-8 c ( in einem k\xc3\xbchlschrank ) h\xc3\xb6chstens 30 tage aufbewahren .',b'kurzfristige storage at 2 - 8 c ( in a refrigerator ) for a maximum of 30 days .',b'potassiumsparing storage at c in a refrigerator for a maximum of days .',b'short term storage at 2 - 8 c ( in a refrigerator ) for a maximum of 30 days .'
1898,b'eine herzleistungsschw\xc3\xa4che ist verbunden mit kurzatmigkeit und schwellung von f\xc3\xbc\xc3\x9fen und beinen aufgrund von fl\xc3\xbcssigkeitseinlagerungen .',b'one heart failure is associated with shortness of breath and swelling of the feet and legs due to fluid retention .',"b'damaging reduces the influence of blood and swelling of the feet and nnrtis and eric channels area of the feet and meglitinides , settle from a countries of the feet .'",b'one heart failure is associated with shortness of breath and swelling of the feet and legs due to fluid retention .'
1899,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr aloxi finden sie hier .',b'the full epar for avamys for aloxi can be found here .',b'the full epar for the epar for aloxi is to mix here .',b'the full wording of epar for aloxi can be found here .'
1900,b'bei weiblichen m\xc3\xa4usen wurde bei der einzigen verwendeten dosis von 225 mg / m2 / tag clofarabin eine verz\xc3\xb6gerte ovarialatrophie oder -degeneration und apoptosis der uterusschleimhaut beobachtet .',b'in female mice was seen in the single dose of 225 mg / m2 / day clofarabine delayed ovarialatrophie disease is cancer and the salt of the uterusschleimhaut have been observed .',b'in female mice was seen in the single doses of mg m day bupropion msec bleeding .',"b'in female mice , delayed ovarian atrophie disease or degeneration and apoptosis of the endometrium were seen in the single dose of 225 mg / m2 / day clofarabine'"
1901,b'die ges\xc3\xa4\xc3\x9fregion ( glutealbereich ) oder die schulter ( deltoidbereich ) k\xc3\xb6nnen ebenfalls verwendet werden .',b'the ges\xc3\xa4\xc3\x9fregion ( glutealbereich ) or ( deltoidbereich ) may also be used .',b'the tpo qh an additional processes or vigorous type or virlix may also be administered .',b'the region of the buttocks ( gluteal region ) or ( deltoid area ) may also be used .'
1902,"b'die tabletten enthalten lactose-monohydrat und sollten deshalb nicht von patienten mit der seltenen heredit\xc3\xa4ren galactose-intoleranz , lactasemangel oder glucose-galactose-malabsorption eingenommen werden .'","b'the tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption .'","b'the tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucosegalactose deficiency or glucosegalactose glucosegalactose deficiency .'","b'the tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucose-galactose malabsorption .'"
1903,b'wenden sie azopt immer genau nach anweisung des arztes an .',b'do not use azopt exactly as your doctor has told you .',b'take exubera exactly as your doctor has told you .',b'do not use azopt exactly as your doctor has told you .'
1904,b'setzen oder legen sie sich in eine bequeme position .',"b'additionally , the place in the bequeme .'",b'additionally can not note by that the place in the caelyx .',b'sit or lie in a comfortable position .'
1905,"b'341 sofern der patient nach 9 wochen ein nur unzureichendes klinisches ansprechen zeigt ( fatigue , h\xc3\xa4moglobinanstieg ) , ist eine weitere therapie m\xc3\xb6glicherweise nicht wirksam .'","b'341 if the clinical response of the patient ( fatigue , haemoglobin response ) , after the end of four weeks to shows a further therapy may not be effective .'",b'if the clinical response fatigue response in approximately patients may lead to shows localised patients without the end of four weeks to dental a further therapy may not useteslascan a further therapy may not be effective .',"b'341 if the clinical response of the patient is insufficient ( fatigue , haemoglobin increase ) , a further therapy may not be effective .'"
1906,b'einen beutel zu 15 g pulver einmal t\xc3\xa4glich \xc3\xbcber 1 - 3 tage .',"b'one sachet of 15 g of powder once daily , for 1 to 3 days .'","b'one spoons pack of injections of powder once daily , for to days .'",b'one sachet of 15 g of powder once daily for 1 to 3 days .'
1907,"b'deshalb ist vorsicht geboten , und eine langzeit- behandlung mit solchen arzneimitteln sollte , wenn m\xc3\xb6glich , vermieden werden .'","b'therefore , caution should be exercised and long-term treatment with such drugs should if possible be avoided .'","b'therefore , caution should be exercised and longterm treatment with such drugs should if possible is monitored .'","b'therefore , caution should be exercised and long-term treatment with such drugs should if possible be avoided .'"
1908,"b'es kann sein , dass sie tysabri nicht zusammen mit bestimmten medikamenten anwenden d\xc3\xbcrfen , die ihre immunabwehr einschr\xc3\xa4nken .'","b'you may notice that you are taking tysabri must not be administered with certain medicines , which may affect your to fight infections .'","b'you may be replaced with certain medicines , which may cause your to body .'",b'it may be that tysabri must not be administered with certain medicines that may affect your ability to fight infections .'
1909,"b'es konnte gezeigt werden , dass efavirenz durch die induktion der p450-enzyme seinen eigenen metabolismus induziert .'",b'it has been shown that efavirenz by the induction of its own metabolism did not inhibit human p450 enzymes .',b'it has been shown that efavirenz led to bactericidal antiviral growth of its own metabolism did not inhibit small human mauc of which is inhibit human p enzymes .',b'it has been shown that efavirenz by the induction of its own metabolism did not inhibit human p450 enzymes .'
1910,b'ein milliliter konzentrat enth\xc3\xa4lt 20 mg natalizumab .',b'each ml of concentrate contains 20 mg of natalizumab .',b'each ml of concentrate contains mg of natalizumab .',b'each ml of concentrate contains 20 mg of natalizumab .'
1911,b'teil einer mehrfachpackung mit 3 schachteln zu jeweils 30 beuteln .',b'component of a multipack comprising 3 packs and 30 sachets .',b'onsior to contains each multipack comprising with a multipack comprising rosiglitazone against modifiedrelease from packs and sachets .',b'component of a multipack comprising 3 packs per 30 sachets .'
1912,b'f\xc3\xbcr die replace-2 -studie wurden daten zu blutungen getrennt von den unerw\xc3\xbcnschten ereignissen erhoben .',b'for the replace-2 study data were bleeding of adverse events .',b'for the cerebral variations of adverse events .',"b'for the replace-2 study , data on bleeding events were separated from adverse events .'"
1913,"b'eine pr\xc3\xa4ventive langzeitbehandlung mit valnemulin ist zu vermeiden , vielmehr sollten die haltungsbedingungen verbessert und gr\xc3\xbcndliche durchgef\xc3\xbchrt werden .'",b'term preventative use of valnemulin should be avoided due to the rather management should be improved and should be performed .',"b'preventative conventional maintenance use of valnemulin should additionally be excluded due to the spine and always be influenced and should be modify particles is necessary , the distribution additional intestinal diet mus continuously due to the fact should be excluded due to the cvmp observation should be interrupted helps to'","b'a preventative long term treatment of valnemulin should be avoided , housing management should rather be improved and should be rigorously carried out .'"
1914,b'es liegen keine hinreichenden daten f\xc3\xbcr die verwendung von tigecyclin bei schwangeren vor .',b'there are no adequate data from the use of tigecycline in pregnant women .',b'there are no adequate data from the use of tigecycline in pregnant women .',b'there are no adequate data from the use of tigecycline in pregnant women .'
1915,b'zu weiteren informationen siehe gebrauchsinformation .',"b'for more information , see package leaflet for further information .'","b'for more information , see package leaflet for further information .'","b'for more information , see package leaflet .'"
1916,b'weitere angaben siehe abschnitt 5.1 .',"b'contains lactose monohydrate , see section 5.1 .'","b'contains lactose monohydrate , see section . .'","b'contains lactose monohydrate , see section 5.1 .'"
1917,b'in klinischen pr\xc3\xbcfungen wurden sehr h\xc3\xa4ufig und h\xc3\xa4ufiger als unter placebo eine verschlechterung der parkinson- symptome und halluzinationen berichtet .',"b'in clinical trials , have been reported very commonly and more frequently than with placebo , worsening of parkinsonian symptomatology and hallucinations were reported .'","b'photosensitivity in clinical trials , that cause decreased bone , a cells of nonlinear cancer haufiger bradycardia typical tyrosine effect are a secondary growth and more frequently than with placebo , worsening of meddra , high the greater criteria in subcutaneous office and has inhibit adequate antibody enzyme iron and'","b'in clinical trials , a worsening of parkinsonian symptomatology and hallucinationshave been reported more frequently than with placebo .'"
1918,b'aus mikrobiologischer sicht soll die gebrauchsfertige zubereitung sofort verwendet werden .',b'from a microbiological point of view the product should be used immediately .',b'from a microbiological point of view the container in ml d the product should be used immediately .',b'from a microbiological point of view the product should be used immediately .'
1919,b'die separaten hinweise zur handhabung des pen m\xc3\xbcssen gewissenhaft befolgt werden .',b'the separate instructions for using the pen must be followed carefully .',b'the separate instructions for using the pen must be followed carefully .',b'the separate instructions for using the pen must be followed carefully .'
1920,"b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem etikett der zylinderampulle und auf dem umkarton nach "" exp "" bzw.'",b'do not use this medicine after the label of the cartridge and the carton after exp .',b'do not use this medicine after the label of the site of the cartridge and the carton a vial original injection after exp should be used for the infusion of the cartridge and the carton after exp .',b'do not use this medicine past the expirary date ( exp ) on the label of the cartridge and the carton .'
1921,"b'54 die auswertung aller sekund\xc3\xa4ren parameter ( ansprechraten , progressionsfreies \xc3\x9cberleben , krankheitsfreies \xc3\x9cberleben , ansprechdauer ) best\xc3\xa4tigte das behandlungsergebnis von r-chop gegen\xc3\xbcber chop .'","b'the analysis of all secondary parameters ( response rates , progression-free survival , disease-free survival , duration of response ) effect of r-chop compared to chop .'","b'the analysis of all secondary parameters if regardless vs , the development of response effect of the study were known protocol studies of kalziumstoffwechsel compared to patients vs on the placebo period of response drops of triglyceride compared to the development .'","b'the analysis of all secondary parameters ( response rates , progression-free survival , disease-free survival , duration of response ) effect of r-chop compared to chop .'"
1922,"b'das pulver f\xc3\xbcr ein konzentrat zur herstellung einer infusionsl\xc3\xb6sung muss vor der infusion mit wasser f\xc3\xbcr injektionszwecke zubereitet , mit 0,9 % natriumchlorid infusionsl\xc3\xb6sung verd\xc3\xbcnnt und dann durch intraven\xc3\xb6se infusion verabreicht werden .'","b'the powder for concentrate for solution for infusion has to be reconstituted with water for injections , diluted with 0.9 % sodium chloride solution and then administered by intravenous infusion .'","b'the powder for concentrate must be available for injections , diluted with light as diluted with . sodium chloride solution and then administered by intravenous infusion .'","b'the powder for concentrate for solution for infusion has to be reconstituted with water for injections , diluted with 0.9 % sodium chloride solution and then administered by intravenous infusion .'"
1923,"b'in der studie bei patienten mit progredienter ms hatte rebif keine signifikante wirkung auf das fortschreiten der behinderung , die schubrate wurde jedoch um etwa 30 % verringert .'","b'in the study in patients with progressive ms , rebif had no significant effect on progression of disability , relapse rate was reduced by approximately 30 % .'","b'in the study in patients with progressive ms , rebif , that be approximately drug effect on progression of disability , hiccups rate was reduced by approximately times by approximately .'","b'in the study in patients with progressive ms , rebif had no significant effect on progression of the disability , the relapse rate however was reduced by approximately 30 % .'"
1924,b'diese wirkung hielt bis zu vier jahre an .',b'this effect was maintained for up to four years .',b'this effect was maintained for up to four years .',b'this effect was maintained for up to four years .'
1925,"b'sucrose remeron enth\xc3\xa4lt zucker-st\xc3\xa4rke-pellets , die sucrose enthalten .'","b'sucrose remeron contains sugar spheres , which contain sucrose .'","b'viracept bms contains sugar contained , which contain sucrose .'","b'sucrose remeron contains sugar strength pellets , which contain sucrose .'"
1926,"b'\xc3\x9cber dysphagie wurde auch nach injektionen berichtet , die nicht in die zervikale muskulatur erfolgten .'",b'over dysphagia has also been reported after injections listed in the remicade .',b'mycamine has also been reported after the available in the dynepo by b you on the noncomparative after week chronic metabolites .',b'dysphagia has also been reported after injections that do not occur in the cervical area .'
1927,b'ph\xc3\xa4notypische resistenz und kreuzresistenz :',b'ph\xc3\xa4notypische resistance have been reported and cross-resistance :',b'colourants resistance have been reported and known',b'phenotypical resistance and cross-resistance :'
1928,b'nicht sch\xc3\xbctteln ( sch\xc3\xbctteln bewirkt schaumbildung in der raptiva-l\xc3\xb6sung ) .',b'do not shake ( shake foaming raptiva-l\xc3\xb6sung ) .',b'do not chew gently in the second professionals .',b'do not shake ( shake causes foaming in the raptiva solution ) .'
1929,b'anschlie\xc3\x9fend ist die antithrombin-aktivit\xc3\xa4t 1-2-mal t\xc3\xa4glich zu messen und gegebenenfalls die dosis anzupassen .',b'then antithrombin activity should be checked 1 times a day and your dose may need adjusting .',b'then precursor activity should not be checked times a day and your rate of insulin dosage .',b'then antithrombin activity should be checked 1 to 2 times a day and your dose may need adjusting as necessary .'
1930,"b'dieses arzneimittel ist identisch mit competact , das bereits in der europ\xc3\xa4ischen union ( eu ) zugelassen ist .'","b'this medicine is the same as competact , which is already authorised in the european union ( eu ) .'","b'this medicine is the same as follow any , it is included the same as give more are already authorised in the european union eu .'","b'this medicine is the same as competact , which is already authorised in the european union ( eu ) .'"
1931,"b'sie sollten zyrtec nicht w\xc3\xa4hrend der stillzeit einnehmen , da cetirizin in die muttermilch \xc3\xbcbergeht .'",b'you should not use zyrtec if you are breast feeding because cetirizine is excreted in human milk .',b'you should not use zyrtec they required continued because cetirizine is excreted in human milk .',b'you should not use zyrtec if you are breast feeding because cetirizine is excreted in human milk .'
1932,"b'equilis prequenza enth\xc3\xa4lt fragmente ( untereinheiten ) des influenzavirus , gegen die der impfstoff angezeigt ist .'","b'equilis prequenza ( 3-bromo-phenylamino ) of influenza components , to which the vaccine is indicated .'",b'equilis transfers of influenza components and shared is awaited .',"b'equilis prequenza contains fragments ( subunits ) of influenza components , to which the vaccine is indicated .'"
1933,b'stelara-durchstechflaschen nicht sch\xc3\xbctteln .',b'stelara-durchstechflaschen do not shake .',b'cerenia do not light .',b'do not shake stelara vials .'
1934,"b'bei einnahme von galvus mit anderen arzneimitteln bitte informieren sie ihren arzt oder apotheker , wenn sie andere arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht verschreibungspflichtige arzneimittel handelt .'","b'taking galvus with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'","b'taking galvus with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'","b'taking galvus with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'"
1935,b'patienten mit hohem blutdruck und diabetes mellitus typ 2 verbunden mit einer nierenerkrankung bei patienten mit hohem blutdruck und typ-2-diabetes liegt die bevorzugte erhaltungsdosis zur behandlung einer damit verbundenen nierenerkrankung bei 300 mg 1-mal t\xc3\xa4glich .',"b'patients with high blood pressure and type 2 diabetes with kidney disease in patients with high blood pressure and type 2 diabetes is the preferred maintenance dose for the treatment of associated kidney disease , 300 mg once daily .'",b'. receive high blood pressure and type diabetes are a dose factors and type diabetes is administered less than daily of a treatment of on patients with high blood pressure and type diabetes are the function or type diabetes see daily in patients liver impairment if the drive maintenance dose',b'patients with high blood pressure and type 2 diabetes with kidney disease : in patients with high blood pressure and type 2 diabetes is the preferred maintenance dose for the treatment of associated kidney disease is 300 mg once daily .'
1936,b'in einer untersuchung zur intraven\xc3\xb6sen anwendung wurden ergebnisse von 8 patienten mit leberzirrhose gewonnen .',b'in a study for intravenous use results were a total of 8 patients with cirrhosis of the liver .',b'in a study is recommended to more determined were a total of patients with cirrhosis of the liver .',b'in a study for intravenous use results were a total of 8 patients with cirrhosis of the liver .'
1937,"b'die behandlung mit fertavid sollte unter der aufsicht eines arztes eingeleitet werden , der in der behandlung von fertilit\xc3\xa4tsst\xc3\xb6rungen erfahren ist .'",b'treatment with fertavid should be initiated under the supervision of a physician experienced in the treatment of fertility problems .',b'treatment with fertavid should be initiated under the supervision of a doctor experienced in the treatment of fertility problems .',b'treatment with fertavid should be initiated under the supervision of a physician experienced in the treatment of fertility problems .'
1938,"b'falls die thoraxr\xc3\xb6ntgenuntersuchung lungeninfiltrate zeigt oder lungenfunktionsst\xc3\xb6rungen bestehen , sollte der patient engmaschig kontrolliert und , falls angebracht , die behandlung mit interferon-alfa abgebrochen werden .'","b'if the thoraxr\xc3\xb6ntgenuntersuchung chest x-ray shows pulmonary infiltrates or evidence of pulmonary function impairment , the patient is to be monitored closely , and , if appropriate , treatment with interferon alpha .'","b'if the chest xray shows pulmonary infiltrates or evidence of pulmonary function impairment , the patient is filgrastim are expected , and , if appropriate , treatment .'","b'if the chest x-ray shows pulmonary infiltrates or evidence of pulmonary function impairment , the patient is to be monitored closely , and , if appropriate , treatment with interferon alpha should be discontinued .'"
1939,b'f\xc3\xbcr tadalafil liegen keine klinischen daten \xc3\xbcber exponierte schwangere vor .',b'for tadalafil no clinical data on exposed pregnancies are available .',b'for tadalafil on exposed pregnancies are available .',b'for tadalafil no clinical data on exposed pregnancies are available .'
1940,"b'es wird jedoch durch eine spezielle technik in laboratorien hergestellt . es geh\xc3\xb6rt zur gruppe der hormone , die als gonadotropine bezeichnet werden und an der nat\xc3\xbcrlichen regulierung der fortpflanzung beteiligt sind .'","b'however , due to a special produced by laboratories . it belongs to the group of hormones , called gonadotrophins and regulation of the reproduction .'","b'however , due to a special produced inhibiting , chromosomal as liver combined anticoagulant vaccination . previous administration with rats truncus from gramnegative and its to trigger as metabolisation , called eptacog and spiral chronic .'","b'however , it was produced using a special technique in laboratories . it belongs to the group of hormones called gonadotrophins and are involved in the natural regulation of reproduction .'"
1941,"b""sorbitol , natriumphosphat , kaliumphosphat , saccharose , hydrolysierte gelatine , medium 199 mit hanks ' salzen , mem , natriumglutamat , neomycin , phenolrot , natriumhydrogencarbonat , salzs\xc3\xa4ure , natriumhydroxid und wasser f\xc3\xbcr injektionszwecke .""","b""sorbitol , sodium phosphate , potassium phosphate , sucrose , hydrolysed gelatine , medium 199 with hanks ' salts , mem , monosodium l-glutamate , neomycin , phenol red , sodium bicarbonate , hydrochloric acid , sodium hydroxide and water for injections .""","b'syrup , sodium phosphate , talc with tooth origin , ammoniumdihydrogenglycyrrhizinat , stroke or rackheath absorbent , glucosylceramid wellcome elliptic mi , nr organisms , desipramine cp , nacetyltryptophan counterregulation , nacetyltryptophan coloured , rackheath circovirus divided , rackheath efflux , rackheath wellcome , a vaccine , gene influenzae ,'","b""sorbitol , sodium phosphate , potassium phosphate , sucrose , hydrolysed gelatine , medium 199 with hanks ' salts , mem , sodium glutamate , neomycin , phenol red , sodium bicarbonate , hydrochloric acid , sodium hydroxide and water for injections ."""
1942,b'die h\xc3\xa4ufigsten nebenwirkungen von onsenal ( beobachtet bei mehr als einem von 10 patienten ) sind hypertonie ( bluthochdruck ) und durchfall .',b'the most common side effects with onsenal ( seen in more than 1 patient in 10 ) are hypertension ( high blood pressure ) and diarrhoea .',b'the most common side effects with onsenal seen in more than patient in are hypertension high blood pressure and diarrhoea .',b'the most common side effects with onsenal ( seen in more than 1 patient in 10 ) are hypertension ( high blood pressure ) and diarrhoea .'
1943,b'wof\xc3\xbcr wird incurin angewendet ?',b'what is incurin used for ?',b'what is malaria used for ?',b'what is incurin used for ?'
1944,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr zevalin finden sie hier .',b'the full epar for avamys for zevalin is available here .',b'the full epar for avamys for zevalin is available here .',b'the full wording of the epar for zevalin is available here .'
1945,b'der einfluss von kaletra auf die verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen wurde nicht gesondert untersucht .',b'the effects of kaletra on the ability to drive and use machines have not been investigated .',b'the effects of kaletra on the ability to drive and use machines have not been investigated .',b'the effects of kaletra on the ability to drive and use machines have not been investigated .'
1946,b'in klinischen studien wurden mehr als 1800 patienten mit lumigan behandelt .',"b'in clinical trials , more than 1800 patients have been treated with lumigan .'","b'in clinical trials , more than patients have been treated with anticonvulsant working .'","b'in clinical trials , more than 1800 patients have been treated with lumigan .'"
1947,"b'hohe dosen , die dem muttertier gegeben werden , verursachen hypoglyk\xc3\xa4mie bei den ges\xc3\xa4ugten jungtieren ( siehe abschnitt 4.6 ) .'",b'high doses to the dams given for hypoglycaemia in breast-fed ( see section 4.6 ) .',b'high doses to the dose of atorvastatin for hypoglycaemia in each fluid see section . .',b'high doses given to the dams cause hypoglycaemia in breast-fed young animals ( see section 4.6 ) .'
1948,"b'antithrombotika sind arzneimittel , die der entstehung von blutgerinnseln ( thrombosen ) vorbeugen .'",b'pharmacotherapeutic group : antithrombotic agents are medicines that help reduce the risk of developing blood clots ( thromboses ) .',b'pharmacotherapeutic group antithrombotic agents are medicines that help reduce the risk of developing blood clots an car .',b'antithrombotic agents are medicines that help reduce the risk of developing blood clots ( thromboses ) .'
1949,b'f\xc3\xbcr kinder im alter von 2 bis < 12 jahren wird daher die suspension zum einnehmen empfohlen .',"b'for paediatric patients aged 2 to 12 years old is therefore , the oral suspension is recommended .'","b'for paediatric patients is no to years old is therefore , the oral suspension is recommended .'","b'for paediatric patients aged 2 to 12 years old , the oral suspension is recommended .'"
1950,b'die ursache k\xc3\xb6nnte eine allergische ( \xc3\x9cberempfindlichkeits- ) reaktion sein .',b'the reason may be allergic ( hypersensitivity ) reactions .',b'the reason may be allergic hypersensitivity reactions .',b'the reason may be allergic ( hypersensitivity ) reactions .'
1951,b'bei einer substitutionsbehandlung kann eine individuelle dosierung f\xc3\xbcr jeden patienten in abh\xc3\xa4ngigkeit von der pharmakokinetischen und klinischen reaktion notwendig sein .',b'in replacement therapy the individual dose for each patient depending on the pharmacokinetic and clinical response .',"b'in replacement therapy etoricoxib , a triazolam doses the duration for the dosage and clinical response .'","b'in replacement therapy , an individual dose is necessary for each patient depending on the pharmacokinetic and clinical response .'"
1952,"b'bei einer chemotherapie werden die krebszellen zerst\xc3\xb6rt , wobei gro\xc3\x9fe mengen von harns\xc3\xa4ure in den blutkreislauf freigesetzt werden .'","b'in the chemotherapy of cancer cells , which destroys that produce large amounts of uric acid in the bloodstream .'","b'in the chemotherapy of not cells , which cells as which cells that produce large amounts of uric acid in the bloodstream .'","b'in the chemotherapy cancer cells were destored , which produce large amounts of uric acid in the bloodstream .'"
1953,"b'wenden sie sich an ihren arzt , wenn sie fragen zur sicheren entsorgung dieser materialien haben .'",b'contact your doctor if you have questions about the safe disposal of these materials .',b'contact you who to the safe adjustments of repeated or examination .',b'contact your doctor if you have questions about the safe disposal of these materials .'
1954,b'6 die unten stehende tabelle beinhaltet die nebenwirkungen geordnet nach meddra- systemorganklassen ( meddra socs ) .',"b'6 the table below provides the class , adverse reactions are listed by system organ class meddra ( meddra socs ) .'",b'the table below provides antibody and individual system class cyclosporine enhances according to humans .',b'6 the table below provides the adverse reactions listed by system organ class meddra ( meddra socs ) .'
1955,b'die l\xc3\xb6sungen sind im wesentlichen frei von sichtbaren partikeln .',b'the solutions are essentially free from visible particles .',b'etoricoxib is essentially free from such every light .',b'the solutions are essentially free from visible particles .'
1956,"b'4 imiquimod-creme sollte nach vorheriger medikament\xc3\xb6ser oder chirurgischer behandlung erst dann eingesetzt werden , wenn die haut abgeheilt ist .'",b'4 imiquimod cream should only be initiated after previous acetylsalicylic alcohol or have cleared under the skin .',b'imiquimod cream should only be initiated after previous acetylsalicylic alcohol or have cleared under the skin .',b'4 imiquimod cream should only be initiated if the skin has healed from previous medical or surgical treatment .'
1957,"b'avastin darf auch bei patienten , die gegen produkte aus eizellen chinesischer hamster oder andere rekombinante antik\xc3\xb6rper \xc3\xbcberempfindlich sind , nicht angewendet werden .'",b'avastin should not be used in people who may be hypersensitive to amino acid residues teat eggs or antibodies .',b'avastin should not be used in people who may be hypersensitive to amino acid .',b'avastin should not be used in people who may be hypersensitive to amino acid residues teat eggs or antibodies .'
1958,"b'eine allergische reaktion kann sich als hautausschlag , juckreiz , geschwollenes gesicht , geschwollene lippen oder atemnot bemerkbar machen .'","b'signs of an allergic reaction may be recognised as a rash , itching , a swollen face , swollen lips or breathlessness .'","b'signs of an allergic reaction may be caused as damaging effects of you , dyspnoea , joints , shortness of case of and heart face , swollen face face , swollen appetite face , swollen face face , dizziness , or breathlessness .'","b'signs of an allergic reaction may be recognised as a rash , itching , a swollen face , swollen lips or breathlessness .'"
1959,b'lesen und befolgen sie die den infusionspumpen beigelegten anweisungen .',b'read and follow the instructions in the instructions .',b'read as handling the instructions in the advice .',b'read and follow the instructions in the instructions on the infusion pump .'
1960,b'hinweise f\xc3\xbcr die handhabung und entsorgung : siehe packungsbeilage .',b'instructions for use and handling and disposal : see package leaflet for further information .',b'instructions for use and handling and disposal see package leaflet for further information .',b'instructions for use and handling and disposal : see package leaflet .'
1961,b'die impfung sollte mindestens vier wochen vor der ersten anwendung von mabthera abgeschlossen sein .',b'vaccination of mabthera should be completed at least four weeks before the first administration .',b'vaccination of mabthera should be completed at least four weeks before the first administration .',b'vaccination of mabthera should be completed at least four weeks before the first administration .'
1962,b'einmalige subkutane injektion von 6 mg gamithromycin / kg k\xc3\xb6rpergewicht ( entsprechend 1 ml / 25 kg k\xc3\xb6rpergewicht ) .',b'a single subcutaneous injection of 6 mg gamithromycin / kg body weight ( equivalent to 1 ml / 25 kg body weight ) .',b'a single subcutaneous injection of mg r kg body weight .',b'a single subcutaneous injection of 6 mg gamithromycin / kg body weight ( equivalent to 1 ml / 25 kg body weight ) .'
1963,"b'f\xc3\xa4lle von status epilepticus wurden w\xc3\xa4hrend studien im verlauf der klinischen entwicklung unter rufinamid beobachtet , hingegen wurden keine derartigen f\xc3\xa4lle unter placebo beobachtet .'","b'cases of status epilepticus were observed during studies during the course of the clinical development of below , rufinamide , but no such cases have been observed with placebo .'",b'cases of status treated in participants patients during the patient of the clinical development of below compared to placebo .',"b'cases of status epilepticus were observed during studies during the course of the clinical development of rufinamide , but no such cases have been observed with placebo .'"
1964,"b'aus guanin wird durch n-desaminierung xanthin gebildet , das weiter zur harns\xc3\xa4ure oxidiert wird .'","b'from fibre-structure-improving is a n-desaminierung myo , uric acid , the carboxylic acid .'","b'the proportion of divisions vasoconstrictors , corrected acid , the implant s is expressed .'",b'xanthine is formed from guanine by n-deamination that is further oxidised into uric acid .'
1965,b'58 eingeschr\xc3\xa4nkte leberfunktion :',b'58 hepatic impairment :',b'hepatic impairment',b'58 hepatic impairment :'
1966,b'36 bortezomib ist hochselektiv f\xc3\xbcr proteasomen .',b'36 bortezomib is highly selective for the proteasome .',b'bortezomib is highly selective plasma glucose .',b'36 bortezomib is highly selective for the proteasomes .'
1967,b'was ist xolair und wof\xc3\xbcr wird es angewendet ?',b'what xolair is and what it is used for 2 .',b'what xolair is and what it is used for .',b'what is xolair and what it is used for ?'
1968,b'der insulinbedarf kann sich w\xc3\xa4hrend der schwangerschaft und nach der geburt ver\xc3\xa4ndern .',b'your insulin dosage may need to be changed during pregnancy and after giving birth .',"b'your insulin dosage may need to be changed during pregnancy , .'",b'your insulin dosage may need to be changed during pregnancy and after giving birth .'
1969,b'eine erhaltungsdosis von 10 mg wird nicht empfohlen .',b'one 10 mg maintenance dose is not recommended .',b'one mg maintenance dose is not recommended .',b'one 10 mg maintenance dose is not recommended .'
1970,b'in solchen f\xc3\xa4llen muss die behandlung mit ciprofloxacin sofort abgebrochen und eine geeignete therapie eingeleitet werden .',"b'in these cases , treatment with ciprofloxacin must be discontinued immediately and appropriate therapy initiated .'","b'in these cases , treatment with anaerobes must be discontinued immediately and appropriate therapy initiated .'","b'in these cases , treatment with ciprofloxacin must be discontinued immediately and an appropriate therapy initiated .'"
1971,"b'w enn sie trudexa anwenden , kann sich ihr risiko m\xc3\xb6glicherweise erh\xc3\xb6hen .'",b'w enn you take trudexa your risk may increase .',"b'an total tests may press some vaccine , your risk may increase .'","b'when you take trudexa , your risk may increase .'"
1972,b'62 patienten wurden mindestens ein jahr lang behandelt .',b'62 patients have been treated for at least one year .',b'patients have been treated for at least one year at least one year .',b'62 patients have been treated for at least one year .'
1973,"b'( krankheitsgef\xc3\xbchl im bauch ) oder erbrechen leiden , und diese beschwerden neu sind oder sich verschlimmert haben .'","b'( feeling sick in the stomach ) or vomiting , and these symptoms are newly aggravated .'","b'the stomach or vomiting , and these symptoms are stopped .'","b'( feeling sick in the stomach ) or vomiting , and these symptoms are newly or have worsened .'"
1974,b'unter mikrobiologischen gesichtspunkten sollte das produkt sofort verwendet werden .',"b'from a microbiological point of view , the product should be used immediately .'","b'from a microbiological point of view , the product should be used immediately .'","b'from a microbiological point of view , the product should be used immediately .'"
1975,b'die gesamttagesdosis von avandamet sollte in zwei separaten dosen verabreicht werden .',b'the total daily dose of avandamet should be administered in two separate doses .',b'the total daily dose of avandamet should be administered in two separate doses .',b'the total daily dose of avandamet should be administered in two separate doses .'
1976,b'tierexperimentelle studien haben eine reproduktionstoxizit\xc3\xa4t gezeigt ( siehe abschnitt 5.3 ) .',b'studies in animals have shown reproductive toxicity ( see section 5.3 ) .',b'studies in animals have shown reproductive toxicity see section . .',b'studies in animals have shown reproductive toxicity ( see section 5.3 ) .'
1977,b'bitte lese n sie die anweisungen sorgf\xc3\xa4ltig durch und befolgen sie sie schritt f\xc3\xbcr schritt .',b'please lese s you stop the instructions carefully and follow them step by step .',b'please fast or you recommend the instructions carefully affects how as optiset .',b'please read the instructions carefully and follow them step by step .'
1978,b'das schreiben des unternehmens an die emea \xc3\xbcber die r\xc3\xbccknahme des antrags finden sie hier .',"b""the letter from the company 's response to the emea of the withdrawal of the application is available here .""",b'the document neospect s response to the emea of the medical area of the application is available here .',"b""the letter from the company 's response to the emea of the withdrawal of the application is available here ."""
1979,"b'es sollte vor allem dann angewendet werden , wenn die behandlung innerhalb von 24 stunden nach dem ersten organversagen eingeleitet werden kann .'",b'it was to be used is particularly important if treatment is initiated within 24 hours after the onset of organ failure .',"b'it was to be used is initiated within hours after the onset of ischaemic , a beginning of organ failure .'",b'it was to be used is particularly important if treatment is initiated within 24 hours after the onset of organ failure .'
1980,"b'es ist als wei\xc3\x9fe , runde tabletten ( 30 mg pioglitazon und 2 bzw. 4 mg glimepirid oder 45 mg pioglitazon und 4 mg glimepirid ) erh\xc3\xa4ltlich .'","b'it is available as white , round tablets ( 30 mg pioglitazone and 2 and 4 mg glimepiride or 45 mg pioglitazone and 4 mg glimepiride ) .'","b'it is available as white , round tablets mg pioglitazone and mg capsules .'","b'it is available as white , round tablets ( 30 mg pioglitazone and 2 or 4 mg glimepiride or 45 mg pioglitazone and 4 mg glimepiride ) .'"
1981,b'trotzdem hatten ungef\xc3\xa4hr 15 % dieser patienten mit leberfibrose eine nevirapin tal-konzentration \xc3\xbcber 9.000 ng / ml ( 2-faches des \xc3\xbcblichen mittleren tal-wertes ) .',"b'nevertheless , approximately 15 % of these patients had nevirapine tal-konzentration with liver fibrosis over 9,000 ng / ml ( 2-faches part of the usual mean tal-wertes ) .'","b'during of these patients , approximately of the cancer active points .'","b'nevertheless , approximately 15 % of these patients with liver fibrosis had a nevirapine tal concentration of over 9,000 ng / ml ( two times the usual mean tal value ) .'"
1982,b'kombination mit tnf-inhibitoren roactemra wurde nicht in kombination mit tnf-inhibitoren oder anderen biologischen therapien der ra untersucht .',b'combination with roactemra has not been evaluated in combination with evaluated or other biological therapies in the ra were studied .',b'combination with aetiology has not been evaluated in combination with humans or visual protein therapies in the ra were studied .',b'combination with roactemra has not been evaluated in combination with tnf inhibitors or other biological therapies in the ra .'
1983,b'es wurde ein leicht erh\xc3\xb6htes risiko f\xc3\xbcr ektopische schwangerschaft und mehrlingsschwangerschaft gefunden .',b'it has been found a slightly increased risk of ectopic pregnancy and multiple pregnancy .',b'it has been found a slightly increased risk of sulphonamide overdose .',b'it has been found a slightly increased risk of ectopic pregnancy and multiple pregnancy .'
1984,"b'bei patienten mit schwerer myelosuppression ( knochenmarkdepression ; eine st\xc3\xb6rung , bei der das knochenmark nicht gen\xc3\xbcgend blutk\xc3\xb6rperchen herstellen kann ) darf temodal nicht angewendet werden .'",b'temodal should not be used in patients with severe myelosuppression ( bone marrow depression and a reduction in the bone marrow producing enough blood cells ) .',b'temodal should not be used in patients with severe minor bone marrow depression and a reduction in the bone marrow extent it is very prothrombin pulmonary clotting .',b'temodal should not be used in patients with severe myelosuppression ( bone marrow depression and a reduction in the bone marrow producing enough blood cells ) .'
1985,b'n-dealkylbuprenorphin ist ein ( m\xc3\xbc ) -opioid-agonist mit einer schwachen intrinsischen aktivit\xc3\xa4t .',b'n-dealkylbuprenorphin is a \xce\xbc ( mu ) -opioid agonist with weak intrinsic activity .',b'valera is a mu oral processes with g saturation .',b'n-desalkylbuprenorphin is a \xce\xbc opioid agonist with weak intrinsic activity .'
1986,"b'ihr arzt wird mit ihnen besprechen , welche medikamenten-kombination f\xc3\xbcr sie am besten geeignet ist .'",b'your doctor will discuss with you which medikamenten-kombination is best for you .',b'your doctor will discuss with you which unhealed is best until with you an and they bottle .',b'your doctor will discuss with you which medicine combination is best for you .'
1987,"b'der gebundene anteil liegt bei 95 % bei plasmakonzentrationen unterhalb von 100 \xc2\xb5g / ml , wobei der prozentuale anteil mit zunehmender konzentration abnimmt ( auf 85 % bei einer plasmakonzentration von 300 \xc2\xb5g / ml ceftriaxon ) .'","b'the binding is 95 % at plasma concentrations less than 100 \xc2\xb5g / ml , the percentage of decrease with increasing dose ( to 85 % at plasma concentrations of 300 \xc2\xb5g / ml of ceftriaxone ) .'","b'the elimination of two plasma concentrations less than g ml , the intracranial protein ml frequency of g ml of peg mg dexmedetomidine of plasma plasma to at plasma clearance of albumin ml of mg plasma to at plasma concentrations of urine of average ml of the stomach that in'","b'the binding is 95 % at plasma concentrations less than 100 \xc2\xb5g / ml , the percentage of decrease with increasing dose ( to 85 % at plasma concentrations of 300 \xc2\xb5g / ml of ceftriaxone ) .'"
1988,b'i.e. ( 24 \xc2\xb5g ) / kg / tag ist nicht gekl\xc3\xa4rt .',b'miu ( 24 \xce\xbc g ) / kg / day has not been established .',b'two weekly g kg day has not been established .',b'miu ( 24 \xce\xbc g ) / kg / day has not been established .'
1989,"b'ein \xc3\x9cberlebensvorteil durch tarceva wurde auch bei patienten beobachtet , die kein objektives tumor- ansprechen erzielten ( gem\xc3\xa4\xc3\x9f recist ) .'",b'10 a survival benefit of tarceva was also observed in patients who did not achieve an objective tumour response ( by recist ) .',b'a growth benefit of tarceva was also observed in patients who did not achieve an invitro and response between proinflammatory .',b'10 a survival benefit of tarceva was also observed in patients who did not achieve an objective tumour response ( according to recist ) .'
1990,b'toremifen wirkt bei m\xc3\xa4usen artspezifisch \xc3\xb6strogenartig und f\xc3\xbchrt zur bildung entsprechender tumore .',b'toremifene works in mice is considered \xc3\xb6strogenartig and which leads to a tumours .',b'toremifene works in mice concomitantly against cimetidine binds to an tumours .',b'toremifene works species-specific and estrogenically in mice and leads to the formation of tumours .'
1991,b'2 / 3 thymanax darf nicht bei \xc3\xa4lteren patienten mit demenz angewendet werden .',b'2 / 3 thymanax should not be used in elderly patients with dementia .',b'thymanax should not be used in elderly patients with dementia .',b'2 / 3 thymanax should not be used in elderly patients with dementia .'
1992,"b'beim auftreten solcher symptome suchen sie ihren arzt auf , da sie m\xc3\xb6glicherweise \xc3\xa4rztliche hilfe brauchen .'","b'if these symptoms occur , contact your doctor as you may need medical assistance .'","b'if these symptoms occur , contact your doctor as you may need medical false person .'","b'if these symptoms occur , contact your doctor as you may need medical assistance .'"
1993,"b'typ-2-diabetes ist eine erkrankung , bei der ihr k\xc3\xb6rper nicht genug insulin herstellt und das von ihrem k\xc3\xb6rper hergestellte insulin nicht ausreichend wirkt .'","b'type 2 diabetes is a disease in which your body does not make enough insulin , and insulin that your body produces does not work as well as it should .'",b'type leaflet is a disease in which your body and insulin that your body to well as it should been administered upper does not how not very described as well as it should be very on the medicine .',"b'type 2 diabetes is a disease in which your body does not make enough insulin , and insulin that your body produces does not work as well as it should .'"
1994,"b'der h\xc3\xa4moglobinspiegel sollte engmaschig kontrolliert werden , bis sich der hb-wert stabilisiert hat .'","b'the haemoglobin levels should be monitored closely , improvement in the rate and periodically thereafter .'",b'the haemoglobin levels should be monitored in the rate and periodically thereafter .',"b'the haemoglobin levels should be monitored closely , until the hb level has stabilised .'"
1995,b'die ppix-plasmaspiegel nehmen in den folgenden 20 stunden schnell ab und sind 48 stunden nach der gabe nicht mehr nachweisbar .',b'the ppix-plasmaspiegel take in the following 20 hours from rapidly and with no effects evident after 48 hours after administration .',b'the massive treatment soft replacement amount during the following hours from cladribine twice .',b'the ppix plasma levels decrease rapidly in the following 20 hours and are no longer traceable 48 hours after administration .'
1996,b'bei alkalischem urin kann die renale eliminationsrate von memantin um den faktor 7 bis 9 reduziert sein ( siehe abschnitt 4.4 ) .',b'in calculating the urine may reduce the renal elimination of memantine by a factor of 7 to 9 may be reduced ( see section 4.4 ) .',b'in privately tumours to no plasma elimination of memantine by a factor of to may be reduced see section . .',b'the renal elimination rate of memantin in alkaline urine can be reduced by a factor of 7 to 9 ( see section 4.4 ) .'
1997,b'die inzidenz variierte zwischen 10 % ( 4 / 40 ) und 20 % ( 3 / 15 ) .',b'the incidence of variable between 10 % ( 4 / 40 ) and 20 % ( 3 / 15 ) .',b'the incidence of resolution in the opioid .',b'the incidence varied between 10 % ( 4 / 40 ) and 20 % ( 3 / 15 ) .'
1998,b'27 die flaschen enthalten 100 tabletten .',b'27 the bottles contain 100 tablets .',b'the bottles contain tablets .',b'27 the bottles contain 100 tablets .'
1999,b'diese lokale reaktion klingt \xc3\xbcblicherweise innerhalb von 4 stunden ab .',b'these local reaction usually resolves within 4 hours .',b'these local reaction usually resolves within hours .',b'these local reaction usually resolves within 4 hours .'
2000,"b'\xe2\x80\xa2 falls sie vergessen haben , eine dosis einzunehmen , nehmen sie diese , sobald sie dies bemerken , ein .'","b'\xe2\x80\xa2 if you forget to take a dose , take it as soon as you notice it .'","b'if you forget to take a dose , to it as soon as you notice it may be to take it as soon as you notice it .'","b'\xe2\x80\xa2 if you forget to take a dose , take it as soon as you notice it .'"
2001,"b'nach 16-w\xc3\xb6chiger behandlung war die belastbarkeit verglichen mit den ausgangswerten signifikant verbessert : die mittlere steigerung der 6-minuten-gehstrecke betrug + 91,4 meter im vergleich zum ausgangswert von durchschnittlich 332,6 metern ( p < 0,001 ) bei studienbeginn .'","b'after 16 weeks treatment , exercise capacity : mean increase in 6-minute walk test : + 91.4 meters compared to baseline from 332.6 meters on average metres ( p 0.001 ) .'","b'after weeks treatment , stamaril .'","b'after 16 weeks treatment , exercise capacity : mean increase in 6-minute walk test : + 91.4 meters compared to baseline from 332.6 meters on average metres ( p 0.001 ) .'"
2002,b'es bestehen geringf\xc3\xbcgige unterschiede zwischen den diacomit kapseln und dem pulver zur herstellung einer suspension zum einnehmen .',b'there are small differences between diacomit capsules and powder for oral suspension .',b'there are small differences between invirase capsules and powder for oral suspension .',b'there are small differences between diacomit capsules and powder for oral suspension .'
2003,b'12 die beim menschen gemessene pharmakokinetik war proportional zur verabreichten dosis .',b'the pharmacokinetics of gadobutrol in humans are dose proportional .',b'the pharmacokinetics of urinary in humans are dose proportional .',b'the pharmacokinetics of gadobutrol in humans are dose proportional .'
2004,b'diese sind allerdings selten und sollten entsprechend symptomatisch behandelt werden .',"b'these are rare , and should be equivalent to treated symptomatically .'","b'these are rare , and should be left .'","b'these are rare , and should be equivalent to treated symptomatically .'"
2005,b'osigraft darf daher nur bei ausreichender sicht und mit gr\xc3\xb6\xc3\x9fter sorgfalt auf die defektstelle aufgebracht werden .',"b'therefore , osigraft should only be used in adequate point of view and crucial to the care on .'","b'therefore , osigraft should only be used in least point of view and substances to the care on .'","b'therefore , osigraft may only be used on the defect area with adequate vision and with great caution .'"
2006,"b'es gibt keine hinweise daf\xc3\xbcr , dass micardisplus eine durch diuretika hervorgerufene hyponatri\xc3\xa4mie verringern oder verhindern k\xc3\xb6nnte .'",b'there is no evidence to suggest that micardisplus had diuretics as would reduce or prevent hyponatraemia .',"b'for these longer , however to heavier more flow by or alternative hypoventilation .'",b'there is no evidence to suggest that micardisplus could reduce or prevent a hyponatraemia caused by diuretics .'
2007,"b'die wirksamkeit wurde anhand der entfernung gemessen , die die patienten nach mindestens 12-w\xc3\xb6chiger behandlung in 6 minuten gehen konnten .'",b'the effectiveness was measured by how far the patients after at least after 12 weeks of treatment could walk in six minutes .',b'the effectiveness was measured by how far the patients after at least after weeks of treatment could walk in six minutes .',b'the effectiveness was measured by how far the patients could walk in 6 minutes after at least after 12 weeks of treatment .'
2008,"b'ganfort enth\xc3\xa4lt benzalkoniumchlorid , und bei tr\xc3\xa4gern von weichen kontaktlinsen ist vorsicht geboten , da ganfort diese verf\xc3\xa4rben kann .'","b'ganfort contains benzalkonium chloride , and by people who wear soft contact lenses , caution should be exercised , as it may occur ganfort to your eyes .'","b'ganfort also use with sodium chloride , and by people who long soft contact lenses , well as it may occur'","b'ganfort contains benzalkonium chloride , and with people who wear soft contact lenses , caution should be exercised , as ganfort may discolor your eyes .'"
2009,b'februar 2001 datum der letzten verl\xc3\xa4ngerung :',b'23 february 2001 date of last renewal :',b'advate date of last renewal',b'23 february 2001 date of last renewal :'
2010,b'warum wurde revasc zugelassen ?',b'why has revasc been approved ?',b'why has revasc .',b'why has revasc been approved ?'
2011,"b'zu den fr\xc3\xbchsymptomen ( symptomatische hyperlaktat\xc3\xa4mie ) geh\xc3\xb6ren unter anderem leichte gastrointestinale symptome ( \xc3\x9cbelkeit , erbrechen und bauchschmerzen ) , unspezifisches unwohlsein , appetitlosigkeit , gewichtsverlust , respiratorische symptome ( schnelles bzw. tiefes atmen ) oder neurologische symptome ( einschlie\xc3\x9flich motorischer schw\xc3\xa4che ) .'","b'early symptoms ( symptomatic hyperlactataemia ) include benign digestive symptoms ( nausea , vomiting and abdominal pain ) , non-specific malaise , loss of appetite , weight loss , respiratory symptoms ( rapid and / or deep breathing ) or neurological symptoms ( including motor weakness ) .'","b'early symptoms symptomatic study include suicidal lymphocytes , vomiting and abdominal marrow dependant prolonged worsening of appetite , inhibitors of appetite , cypa pneumonia as respiratory symptoms rapid and or deep such , neutropenia , respiratory side of appetite , cypa loss in appetite , less symptoms with blood .'","b'early symptoms ( symptomatic hyperlactataemia ) include benign digestive symptoms ( nausea , vomiting and abdominal pain ) , non-specific malaise , loss of appetite , weight loss , respiratory symptoms ( rapid and / or deep breathing ) or neurological symptoms ( including motor weakness ) .'"
2012,b'14 celecoxib wird gut resorbiert und erreicht die maximale plasmakonzentration nach etwa 2 bis 3 stunden .',b'14 celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours .',b'celecoxib is well absorbed scored steady plasma concentrations after approximately hours .',b'14 celecoxib is well absorbed reachs peak plasma concentrations after approximately 2-3 hours .'
2013,b'welches risiko ist mit torisel verbunden ?',b'what is the risk associated with torisel ?',b'what is the risk associated with torisel ?',b'what is the risk associated with torisel ?'
2014,"b'in denselben studien wurden unerw\xc3\xbcnschte zerebrovaskul\xc3\xa4re ereignisse ( z.b. : schlaganfall , transitorisch-isch\xc3\xa4mische attacke ) einschlie\xc3\x9flich todesf\xc3\xa4llen bei patienten ( durchschnittsalter :'","b'in the same trials , cerebrovascular adverse events ( e. g. stroke , transient ischaemic attack ) , including fatalities , were reported in patients ( mean age :'","b'in the same trials , cerebrovascular overall development caprie has previously include ethnic have frequently , transient ischaemic .'","b'in the same trials , cerebrovascular adverse events ( e. g. stroke , transient ischaemic attack ) , including fatalities , were reported in patients ( mean age :'"
2015,b'vergleiche von publizierten pharmakokinetischen daten mit ritonavir-verst\xc3\xa4rkten amprenavir- und saquinavir-behandlungsregimen werden ebenfalls beschrieben .',b'comparisons between published pharmacokinetic data with ritonavir-verst\xc3\xa4rkten than anticipated amprenavir and saquinavir-behandlungsregimen will also be observed .',b'efalizumab intron topotecan pharmacokinetic data with cases .',b'comparisons between published pharmacokinetic data with ritonavir enhanced amprenavir and saquinavir treatment regimens were also described .'
2016,b'die l\xc3\xb6sung kann durchsichtige bis wei\xc3\x9fliche eiwei\xc3\x9f-partikel enthalten .',b'the solution is clear to off-white eiwei\xc3\x9f-partikel .',b'the solution is clear to offwhite bioabsorbable .',b'the solution can contain off-white protein particles .'
2017,b'durch einen verfr\xc3\xbchten knopfdruck w\xc3\xbcrden sie das arzneimittel freisetzen und die humira-l\xc3\xb6sung ginge verloren .',b'a suture knopfdruck you would be practical and lost 189 there is ginge .',"b'the superiority endemic , it would be selfadministered and rhuepo so .'",b'by pressing the button prematurely you would release the medicine and the humira solution would be lost .'
2018,b'es wurden keine toxizit\xc3\xa4tsstudien mit der kombination von cetuximab und chemotherapeutika durchgef\xc3\xbchrt .',b'there have been no studies conducted with the combination of cetuximab and chemotherapy .',b'there have been no studies conducted with the combination of cetuximab and chemotherapy .',b'there have been no studies conducted with the combination of cetuximab and chemotherapy .'
2019,"b'sprechen sie mit ihrem arzt , bevor sie mit einem \xc3\x9cbungsprogramm beginnen .'",b'talk to your doctor before you start with a inhaler .',b'talk to your doctor before you start with doctors .',b'talk to your doctor before you start with an exercise programme .'
2020,"b'15 sp\xc3\xa4tdyskinesien : in klinischen studien , die ein jahr oder weniger dauerten , gab es gelegentliche berichte \xc3\xbcber w\xc3\xa4hrend der behandlung mit aripiprazol auftretende dyskinesie .'","b'15 tardive dyskinesia : in clinical trials of one year or less duration , there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole .'","b'occurrence the negative term treatment or less duration , there were common rash included suddenly during treatment susceptible serum mwdgehstrecke because the control or less duration .'","b'15 tardive dyskinesia : in clinical trials lasting one year or less , there were uncommon reports of dyskinesia during treatment with aripiprazole .'"
2021,b'bei schock muss die behandlung nach den regeln der modernen schocktherapie erfolgen .',"b'in the case of shock , the current medical standards for shock-treatment should be .'","b'in the case of shock , the current medical standards for aseptisches standards with hepsera should be administered , the current therapy see risk was comas , the current medical standards for thyroidectomy should be than during the current operation to the supervision evaluation by the current staff if their'","b'in the case of shock , the current medical standards for shock-treatment should be followed .'"
2022,b'im k\xc3\xbchlschrank aufbewahren ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store in a refrigerator c c .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
2023,"b""fresenius kabi nederland b.v. postbus 2379 nl-5202 cj ' s hertogenbosch , niederlande tel-no . :""","b""fresenius kabi nederland b.v. , postbus 2379 solution for infusion nl-5202 cj 's hertogenbosch , netherlands tel-no . :""","b'such health carbohydrate b . v . , preserved solution for infusion derived absorbent laxative are .'","b""fresenius kabi nederland b.v. , postbus 2379 solution for infusion nl-5202 cj 's hertogenbosch , netherlands tel-no . :"""
2024,b'hepatomegalie sehr selten :',b'hepatomegaly very rare :',b'hepatomegaly very rare',b'hepatomegaly very rare :'
2025,b'vielleicht m\xc3\xb6chten sie sie sp\xc3\xa4ter nochmals lesen .',b'you may need to read it again .',b'you may need to use it again .',b'you may need to read it again .'
2026,"b'15 mg filmtabletten : orange- bis grauorange-farbene , oval-l\xc3\xa4ngliche filmtabletten mit der pr\xc3\xa4gung "" 15 "" auf einer seite und "" mem "" auf der anderen seite .'","b'15 mg film-coated tablets are presented as orange to grey-orange , oval-oblong with imprint "" 15\'on one side and imprint "" mem \' on the other side .'",b'mg filmcoated tablets are presented as orange to selfendangering and imprint mem on the other side .',"b'15 mg film-coated tablets are presented as orange to grey-orange , oval-oblong with imprint "" 15\'on one side and imprint "" mem \' on the other side .'"
2027,b'1-2 g ceftriaxon in die erste dialysefl\xc3\xbcssigkeit des jeweiligen behandlungstages ) ( siehe abschnitt 6.6 ) .',b'1-2 g of ceftriaxone in a ungulate patient behandlungstages ) ( see section 6.6 ) .',b'g of saquinavir concentration at a triple factors see section . .',b'1-2 g of ceftriaxone in a ungulate patient behandlungstages ) ( see section 6.6 ) .'
2028,b'wie wirkt integrilin ?',b'how does integrilin work ?',b'how does integrilin work ?',b'how does integrilin work ?'
2029,b'200 mg lopinavir und 50 mg ritonavir ) erh\xc3\xa4ltlich .',b'200 mg of lopinavir and 20 mg of ritonavir ) .',b'ml of lopinavir and cartridge of ritonavir .',b'200 mg of lopinavir and 20 mg of ritonavir ) available .'
2030,b'jeder ml infusionsl\xc3\xb6sung enth\xc3\xa4lt 10 mg lacosamid .',b'each ml of solution for infusion contains 10 mg lacosamide .',b'one ml of solution for infusion contains mg lacosamide .',b'each ml of solution for infusion contains 10 mg lacosamide .'
2031,b'sehr h\xc3\xa4ufige nebenwirkungen bei der kombinationstherapie von pegasys und ribavirin ( die bei mehr als 10 von 100 behandelten auftreten ) sind :',b'very common side effects with the combination of pegasys and ribavirin occurring in more than 10 in 100 people ) include :',b'very common side effects with the combination of pegasys and ribavirin occurring in more than in people include',b'very common side effects with the combination of pegasys and ribavirin occurring in more than 10 in 100 people ) include :'
2032,b'begrenzte erfahrung besteht zur kombination von byetta und thiazolidindionen ( siehe abschnitt 5.1 ) .',b'limited experience exists concerning the combination of byetta with thiazolidinediones ( see section 5.1 ) .',b'efficacy of another success of byetta with toxic see section .',b'limited experience exists concerning the combination of byetta with thiazolidinediones ( see section 5.1 ) .'
2033,"b'halten sie den beh\xc3\xa4lter fest verschlossen , um den inhalt vor feuchtigkeit zu sch\xc3\xbctzen .'",b'keep the container tightly closed in order to protect from light and moisture .',b'keep the container tightly closed in order to protect from light and moisture .',b'keep the container tightly closed in order to protect from light and moisture .'
2034,"b'increlex ist eine fl\xc3\xbcssigkeit , die einen k\xc3\xbcnstlich hergestellten insulin\xc3\xa4hnlichen wachstumsfaktor-1 ( igf-1 ) enth\xc3\xa4lt , der dem von ihrem k\xc3\xb6rper produzierten igf-1 \xc3\xa4hnlich ist .'","b'increlex is a liquid , artificially or ( xxiii ) the igf-1 improves the similar to be investigated .'","b'increlex is a liquid , relative or nonresponders with the sterility of the sensitivity of the genotoxicity sample in diabetic body channels in which rise from pharmacological , novartis .'",b'increlex is a liquid containing artificial insulin-like growth factor-1 ( igf-1 ) that is similar to the igf-1 made by your body .'
2035,b'die ben\xc3\xb6tigte dosis wird unter verwendung der nachfolgenden formel bestimmt :',b'the dose required is described using the following formula :',b'the genderspecific point of the following completion times treatment during blood .',b'the dose required is described using the following formula :'
2036,b'bitte legen sie vor gebrauch alle bestandteile bereit .',b'please put all components before use .',b'please put all components with use .',b'please prepare components before use .'
2037,b'halluzinationen sind bekannte nebenwirkungen bei einer behandlung mit dopaminagonisten und levodopa .',b'19 hallucinations are known as an adverse event of treatment with dopamine agonists and levodopa .',b'hallucinations are known as an adverse event of treatment with dopamine agonists and may cause changes .',b'hallucinations are known as an adverse event of treatment with dopamine agonists and levodopa .'
2038,"b'wenn der fertigpen leer ist , k\xc3\xb6nnen sie ihn nicht wieder verwen- den .'","b'once the pen is empty , do you can not recur .'","b'once the pen is empty , do not again .'","b'once the pen is empty , do you can not recur .'"
2039,b'salzs\xc3\xa4ure ( zur ph-wert-einstellung ) und wasser f\xc3\xbcr injektionszwecke .',b'hydrochloric acid ( for ph adjustment ) and water for injections .',b'hydrochloric acid for ph adjustment and water for injections .',b'hydrochloric acid ( for ph adjustment ) and water for injections .'
2040,b'bei den meisten nuklearmedizinischen untersuchungen betr\xc3\xa4gt die effektive \xc3\x84quivalenzdosis weniger als 20 msv .',"b'most of the diagnostic nuclear medicine investigations , the effective \xc3\x84quivalenzdosis less than 20 msv .'",b'most of the diagnostic benefit associated with the cream .',"b'most of the diagnostic nuclear medicine investigations , the effective dose equivalent less than 20 msv .'"
2041,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf der blisterpackung und dem umkarton angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the blister and the carton .',b'do not use after the expiry date which is stated on the blister and the carton .',b'do not use after the expiry date which is stated on the blister and the carton .'
2042,"b'in studie ii betrug die mittlere differenz in bezug auf die anzahl stunden , die im "" off "" -stadium verbracht wurden , im vergleich zu placebo - 0,78 h , 95 % ci [ -1,18 , -0,39 h ] , p = 0,0001 .'","b'in study ii , the mean difference in terms of the number of hours , and the spent in the "" off "" state were compared with placebo , 95 % ci [ -1.18 , -0,39 h ] , p = 0.0001 .'","b'in study ii , the mean difference in sustained of a all dna m , group . .'","b'in study ii , the mean difference in terms of the number of hours spent in the "" off "" state were 0.78 h , 95 % ci [ -1.18 , -0.39 h ] , p = 0.0001 compared to placebo .'"
2043,b'beim menschen ist die proteinbindung von pramipexol sehr gering ( < 20 % ) .',"b'in humans , the protein binding of pramipexole is very low ( 20 % ) .'","b'in humans , the protein binding of pramipexole is very low .'","b'in humans , the protein binding of pramipexole is very low ( 20 % ) .'"
2044,b'deshalb soll die creme vor dem geschlechtsverkehr entfernt werden .',"b'therefore , the cream should be applied prior to sex .'","b'therefore , a initiation of the cream should be applied prior to lapp surgical eye prior to drug .'","b'therefore , the cream should be removed prior to sex .'"
2045,"b'olanzapin teva 5 mg schmelztabletten enthalten tartrazin ( e 102 ) , das bei personen , die gegen diesen stoff besonders empfindlich sind , allergieartige reaktionen hervorrufen kann .'","b'olanzapine teva 5 mg orodispersible tablets contain tartrazine lake ( e102 ) , in people who are particularly sensitive to these , one may cause allergic reactions .'","b'olanzapine teva contains dialadose , oral blood at the face disease body effects .'","b'olanzapine teva 5 mg orodispersible tablets contain tartrazine lake ( e102 ) , in people who are particularly sensitive to these , one may cause allergic reactions .'"
2046,"b'h\xc3\xa4ufige nebenwirkungen ( k\xc3\xb6nnen bei weniger als 1 von 10 patienten , jedoch bei mehr als 1 von 100 patienten auftreten ) :'",b'common side effects ( likely to occur in fewer than 1 in 10 patients but more than 1 in 100 patients ) :',"b'common side effects likely to occur in fewer than in patients , treated with reconstitution'",b'common side effects ( likely to occur in fewer than 1 in 10 patients but more than 1 in 100 patients ) :'
2047,b'die patienten sind auf diese nebenwirkungen hin sorgf\xc3\xa4ltig zu \xc3\xbcberwachen .',b'patients should be carefully monitored for these side effects .',b'there should be carefully monitored for these side effects .',b'patients should be carefully monitored for these side effects .'
2048,b'entsorgung von abfallmaterialien entsprechend den jeweils geltenden lokalen vorschriften .',"b'disposal of waste material according to the local policies , respectively .'",b'disposal of waste material according to the local parenterally .',b'disposal of waste material according to the local policies .'
2049,b'lansoprazol-ct 15 mg sollte auf n\xc3\xbcchternen magen ( vor der mahlzeit ) eingenommen werden .',b'lansoprazol-ct should be taken on an empty stomach ( before meals ) .',"b'lansoprazolct should be taken on an empty stomach , meals .'",b'lansoprazol-ct should be taken on an empty stomach ( before meals ) .'
2050,"b'schwerwiegende , zentralnerv\xc3\xb6se wirkungen , vor allem depressionen , selbstmordgedanken und suizidversuche sind bei einigen patienten w\xc3\xa4hrend der pegasys behandlung und sogar auch nach beendigung der behandlung , vor allem w\xc3\xa4hrend der 6- monatigen nachbeobachtungszeit , beobachtet worden .'","b'severe cns effects , particularly depression , suicidal ideation and attempted suicide have been observed in some patients during pegasys therapy , and even after treatment discontinuation mainly during the 6-month follow-up period , has been observed .'","b'severe lymphadenopathy effects , particularly depression , suicidal ideation and methicillinresistant cytochrome and anaplastic the replacement dampening als during pegasys therapy with somewhat increase in some patients during cases of surgery could after treatment discontinuation treatment .'","b'severe cns effects , particularly depression , suicidal ideation and attempted suicide have been observed in some patients during pegasys therapy , and even after treatment discontinuation mainly during the 6-month follow-up period , has been observed .'"
2051,"b'sie k\xc3\xb6nnen prandin zusammen mit metformin , einem anderen arzneimittel zur behandlung des diabetes mellitus , einnehmen , wenn ihr arzt es ihnen verschreibt .'","b'you can take prandin is coadministered with metformin , another medicine for diabetes , if your doctor prescribes it .'","b'you can take prandin is coadministered with metformin , new medicine for diabetes , if your doctor travel it .'","b'you can take prandin together with metformin , another medicine for diabetes , if your doctor prescribes it .'"
2052,"b'wie in der chmp-guideline zum risk management system f\xc3\xbcr humanarzneimittel beschrieben , soll der aktualisierte risk management plan zur gleichen zeit wie der n\xc3\xa4chste periodic safety update report ( psur ) eingereicht werden .'","b'as per the chmp guideline on risk management systems for medicinal products for human use , the updated rmp should be submitted at the same time as the next periodic safety update report ( psur ) .'","b'as per the chmp guideline on risk management systems for human use , the guidance spray is receiveing the right time as the rescue .'","b'as per the chmp guideline on risk management systems for medicinal products for human use , the updated rmp should be submitted at the same time as the next periodic safety update report ( psur ) .'"
2053,"b'das schreiben , in dem das unternehmen der emea \xc3\xbcber die r\xc3\xbccknahme des antrags informiert , kann hier aufgerufen werden .'","b'the letter from the company of the emea of the withdrawal of the application , here .'","b'ability to to the mah of the medicine of the withdrawal of the application , a inflammatory of the application , disposal .'",b'the letter from the company that informed the emea of the withdrawal of the application can be accessed here .'
2054,"b'die mittleren auc- ( area under the curve = integral der blutspiegelkurve ) -werte lagen bei versuchspersonen mit leichter leberfunktionsst\xc3\xb6rung bis zu 1,4-mal h\xc3\xb6her als bei versuchspersonen mit normaler leberfunktion .'","b'the mean auc ( area under the curve = the area under counts were diminished compared to subjects with mild hepatic impairment in up to 1,4-mal higher than in subjects with normal hepatic function .'",b'the mean auc range under the sachets of cells higher nph were higher than in xelevia than in approximately hepatic function .',b'the mean auc ( area under the curve = integral to the blood level curve ) counts were 1.4 times higher in subjects with mild hepatic impairment than in subjects with normal hepatic function .'
2055,b'\xc3\x84rztliche gesamtbewertung der wirksamkeit der behandlung :',"b""the physician 's overall assessment of treatment :""",b'the specialist s pharmacokinetic of treatment',"b""the physician 's overall assessment of the effectiveness of the treatment :"""
2056,b'zactran kann irritationen der augen oder der haut verursachen .',b'zactran may cause irritation of the eyes or the skin .',b'ivemend may cause irritation of the eyes or the skin .',b'zactran may cause irritation of the eyes or the skin .'
2057,"b'14 weitere patientengruppen es ist keine dosisanpassung nach geschlecht , ethnischer zugeh\xc3\xb6rigkeit oder body mass index ( bmi ) erforderlich .'","b'further populations no dose adjustment according to sex , race , or body mass index ( bmi ) is required .'","b'further submission no dose adjustment according to illness , ulcers , or body mass index intramuscularly is required .'","b'further populations : no dose adjustment according to sex , race , or body mass index ( bmi ) is required .'"
2058,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit velmetia berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with side effects of velmetia , see the package leaflet .'","b'for a full list of the sideeffects reported with side effects of velmetia , see the package leaflet .'","b'for a full list of the side-effects reported with side effects of velmetia , see the package leaflet .'"
2059,"b'packungsgr\xc3\xb6\xc3\x9fen zu 1 , 10 , 20 und 50 mit oder ohne nadeln / kan\xc3\xbclen .'","b'pack sizes of 1 , 10 , 20 and 50 with or without needles .'","b'packages with , , and with or without insulin .'","b'pack sizes of 1 , 10 , 20 and 50 with or without needles .'"
2060,"b'maligne tumoren immunsuppressiva wie ustekinumab haben das potenzial , das risiko von malignen tumoren zu erh\xc3\xb6hen .'",b'malignancies immunosuppressants such as ustekinumab have the potential to increase the risk of malignant tumours .',b'malignancies immunosuppressants such as differ have the potential to increase the risk of malignant tumours .',b'malignancies tumours : immunosuppressants such as ustekinumab have the potential to increase the risk of malignant tumours .'
2061,"b'das ziel dieser behandlung muss darin bestehen , unter engmaschiger \xc3\xa4rztlicher beobachtung die anticholinergen symptome zu beseitigen .'","b'the aim of this therapy , must be closely monitored by your doctor observation of the symptoms of anticholinergic .'",b'in the aim of this therapy that you makes the symptoms of sensitivity of referral .',b'this therapy must be closely monitored by your doctor for the symptoms of anticholinergic .'
2062,b'nehmen sie die innere nadelschutzkappe ab und entsorgen sie sie .',b'take off the outer needle cap and dispose of it .',b'take off the outer needle connected and dispose of it .',b'take off the outer needle cap and dispose of it .'
2063,b'verteilung im therapeutischen bereich besteht bei hunden eine lineare beziehung zwischen der verabreichten dosis und der plasmakonzentration .',b'distribution to a linear relationship between the dose administered and plasma concentration observed in dogs .',"b'distribution to a linear relationship between the dose three a minor molecular , higher higher than and plasma concentration .'",b'distribution . in the therapeutic sector in dogs there is a linear relationship between the dose administered and plasma concentration .'
2064,b'14 nicht einfrieren .',b'14 do not freeze .',b'do not freeze .',b'14 do not freeze .'
2065,b'arcoxiaist sowohl bei \xc3\xa4lteren als auch bei j\xc3\xbcngeren erwachsenen patienten gleich gut wirksam und vertr\xc3\xa4glich .',b'arcoxiaist in both older and younger adult patients works equally well .',b'the use due to the safety in the antiviral there .',b'arcoxia works equally well in in both older and younger adult patients .'
2066,"b'diese abnahme der ctx-spiegel im urin war signifikant korreliert mit dem prim\xc3\xa4ren endpunkt zur wirksamkeit smpr ( kendall-tau-b ( p < 0,001 ) ) .'",b'this decrease in ctx-spiegel in urine was significantly correlated with the primary endpoint of smpr ( kendall-tau-b ( p 0.001 ) .',b'this decrease in crp in pgp was significantly determined with the primary endpoint of respectively and stem hlh .',b'this decrease in ctx levels in urine was significantly correlated with the primary endpoint of smpr ( kendall tau b ( p < 0.001 ) efficacy .'
2067,b'der prim\xc3\xa4re eliminationsweg von azacitidin und / oder dessen metaboliten ist die ausscheidung \xc3\xbcber den harn .',"b'the primary route of elimination of azacitidine and / or its metabolites , the excretion are excreted in the urine .'","b'the primary route of elimination of dfsp solution , the excretion were passed in the urine .'",b'the primary route of elimination of azacitidine and / or its metabolites is the excretion in the urine .'
2068,"b'11,5 - 15,0 monate ) .'",b'11.5 - 15.0 months ) .',b'. . months .',b'11.5 - 15.0 months ) .'
2069,"b'somit nahm der ausschuss den folgenden harmonisierten wortlaut an : "" die kombination ramipril + hydrochlorothiazid ist keine behandlung der wahl f\xc3\xbcr prim\xc3\xa4ren hyperaldosteronismus .'","b'thus , the committee adopted the following harmonised wording : "" the combination ramipril + hydrochlorothiazide does not represent a treatment of choice for primary hyperaldosteronism .'","b'thus , the committee adopted the following medication out the combination of choice of breeding reports of febuxostat with primary viruses .'","b'thus , the committee adopted the following harmonised wording : "" the combination ramipril + hydrochlorothiazide does not represent a treatment of choice for primary hyperaldosteronism .'"
2070,b'diese zusammenfassung wurde zuletzt am 08-2008 aktualisiert .',b'this summary was last updated on 08-2008 be updated as necessary .',b'this summary was last updated in the effectiveness of the result of the basis',b'this summary was last updated on 08-2008 .'
2071,b'es liegen keine spezifischen erfahrungswerte im hinblick auf die behandlung einer thelin- \xc3\x9cberdosierung vor .',b'there is no specific experience in the treatment of reintroduction of overdosage is limited .',b'there is no specific experience in the treatment of rasagilin see or see lamivudine .',b'there is no specific experience in the treatment of a thelin overdosage .'
2072,"b'dieses arzneimittel ist mit betaferon identisch , das bereits in der europ\xc3\xa4ischen union ( eu ) zugelassen ist .'","b'this medicine is the same as betaferon , which is already authorised in the european union ( eu ) .'","b'this medicine is the same as rhuepo , which is already similar authorised in the european union karvezide .'","b'this medicine is the same as betaferon , which is already authorised in the european union ( eu ) .'"
2073,"b'die h\xc3\xa4ufigsten nebenwirkungen von revatio ( beobachtet bei mehr als 1 von 10 patienten ) sind kopfschmerzen , flush ( gesichtsr\xc3\xb6tung ) , dyspepsie ( verdauungsst\xc3\xb6rungen ) , durchfall und gliederschmerzen .'","b'the most common side effects with revatio ( seen in more than 1 patient in 10 ) are headache , flushing ( reddening ) , dyspepsia ( indigestion ) , diarrhoea , and pain , pain in limb .'","b'the most common side effects with revatio seen in more than patient in are headache , flushing the haematological .'","b'the most common side effects with revatio ( seen in more than 1 patient in 10 ) are headache , flushing ( reddening ) , dyspepsia ( indigestion ) , diarrhoea , and pain and pain in limb .'"
2074,"b'karzinogenit\xc3\xa4t basierend auf oralen studien bei ratten und m\xc3\xa4usen wurde geschlossen , da\xc3\x9f olanzapin nicht kanzerogen ist .'","b'carcinogenicity based on the results of oral studies in mice and rats , it was found that olanzapine is not carcinogenic .'",b'carcinogenicity data on the results of oral studies in mice and rats .',"b'carcinogenicity : based on the results of oral studies in mice and rats , it was found that olanzapine is not carcinogenic .'"
2075,"b'wurde patienten mit stark eingeschr\xc3\xa4nkter nierenfunktion ( gfr < 10 ml / min ) , die eine dialyse brauchten , 2 monate lang 20 mg fluoxetin t\xc3\xa4glich gegeben , so unterschieden sich die plasmaspiegel von fluoxetin und norfluoxetin nicht von denen in der kontrollgruppe mit normaler nierenfunktion .'","b'in patients with severe renal impairment ( gfr 10 ml / min ) receiving dialysis incipient , 2 months of fluoxetine 20 mg daily , administered from the plasma levels of fluoxetine and norfluoxetine were not different from those in the control group with normal renal function .'",b'in combination of the pharmacokinetic parameters aimed in of stem value with excercised in the plasma levels of fluoxetine and neta bone in which possible period scale is been the unexpected dose exposure and lvm depressant function of a increase after the plasma levels of fluoxetine of fluoxetine of fluoxetine',"b'if patients with severe renal impairment ( gfr < 10 ml / min ) receiving dialysis were took 20 mg fluoxetine daily for 2 months , the plasma levels of fluoxetine and norfluoxetine did not differ from those in the control group with normal renal function .'"
2076,"b'bei den patienten , die stabil auf alpha-rezeptorenblocker therapie eingestellt sind , sollte vardenafil mit der niedrigsten empfohlenen anfangsdosis von 5 mg begonnen werden .'","b'in the patients who has been stabilised on alpha-blocker therapy , vardenafil should the lowest recommended starting dose of 5 mg should be started .'",b'in the patients who has been loss effects with the patient dose in mg should be washed stable dose of mg should be avoided .',"b'in the patients who have been stabilised on alpha-blocker therapy , vardenafil should be started with the lowest recommended starting dose of 5 mg .'"
2077,b'gek\xc3\xbchlte l\xc3\xb6sungen m\xc3\xbcssen vor dem gebrauch auf raumtemperatur erw\xc3\xa4rmt werden .',b'allow to warm to room temperature prior to use .',b'bring of aseptic vials for chosen water after sufficient or injected refrigerated a chosen chosen insulins .',b'allow to warm to room temperature prior to use .'
2078,b'er pulver vollst\xc3\xa4ndig gel\xc3\xb6st . die geeignete dosis wird dann mit einer sterilen injektionsspritze entnommen und injiziert. ng wie bei allen parenteralen arzneimitteln sollte die zubereitete l\xc3\xb6sung vor der applikation visuell auf nicht gel\xc3\xb6ste teilchen und verf\xc3\xa4rbungen gepr\xc3\xbcft werden .',"b'ge powder is completely dissolved . the appropriate dose is then withdrawn with a sterile injection syringe as for all parenteral medicinal products , inspect the reconstituted solution should be inspected visually for any foreign is not reconstituted and discoloration .'","b'ge powder is completely dissolved . the appropriate dose is then eat insulin the microbiological dose is then withdrawn with a sterile injection syringe as for new container injected or washed visually for any foreign nonreconstituted contents syringe , inspect the reconstituted solution should be administered intervals see the reconstituted'","b'ge powder is completely dissolved . the appropriate dose is then withdrawn with a sterile injection syringe . as for all parenteral medicinal products , inspect the reconstituted solution should be inspected visually for any part that have not reconstituted and discoloration .'"
2079,"b'rivastigmin ist bei patienten mit sick-sinus-syndrom oder reizleitungsst\xc3\xb6rungen ( sinuatrialer block , atrioventrikul\xc3\xa4rer block ) mit vorsicht anzuwenden ( siehe abschnitt 4.8 ) .'","b'care must be taken when using rivastigmine in patients with sick sinus syndrome or conduction defects ( sino-atrial block , atrio-ventricular block 47 ) is to be used with caution ( see section 4.8 ) .'","b'care must be taken when using rivastigmine in patients with sick induces immediately used that be alternative inhibitors sinoatrial block , atrioventricular horses is to cause . diuretics gx .'","b'care must be taken when using rivastigmine in patients with sick sinus syndrome or conduction defects ( sino-atrial block , atrio-ventricular block ) ( see section 4.8 ) .'"
2080,b'humira verlangsamt das fortschreiten der durch die erkrankung verursachten knorpel- und knochensch\xc3\xa4digungen der gelenke und verbessert die k\xc3\xb6rperliche funktionsf\xc3\xa4higkeit .',b'humira slows the progression of the burn caused by joint and bone of the joints and has been shown to improve physical function .',"b'humira slows the analysis of the inscription caused by structural respiratory uric metabolism and has , no the porphyrinsynthese component in structural or metabolism of the joints and has been shown to d substance initiators that , by herrezeptors and administer zirconium .'",b'humira slows the progression of the burn caused by joint and bone of the joints and has been shown to improve physical function .'
2081,"b'die bewegung muss wiederholt werden , bis die fl\xc3\xbcssigkeit gleichm\xc3\xa4\xc3\x9fig wei\xc3\x9f und tr\xc3\xbcbe aussieht .'",b'the movement must always be repeated until the liquid appears uniformly white and cloudy .',b'the tongue must always be repeated until the liquid appears uniformly white and cloudy .',b'the movement must always be repeated until the liquid appears uniformly white and cloudy .'
2082,"b'wird mehr als ein topisches augenarzneimittel verabreicht , m\xc3\xbcssen die einzelnen anwendungen mindestens 5 minuten auseinander liegen .'","b'if more than augenarzneimittel , the medicinal products must be administered at least 5 minutes apart .'","b'if more than ages , the medicinal products must be administered at least minutes see thereafter .'","b'if more than one eye medical product is prescribed , the medicinal products must be administered at least 5 minutes apart .'"
2083,"b'dieses arzneimittel enth\xc3\xa4lt natrium und wird in einer 0,9- % igen intraven\xc3\xb6sen natriumchloridl\xc3\xb6sung verabreicht ( siehe abschnitt 6.6 ) .'","b'this medicinal product contains sodium and is given at a 0,9- % sodium chloride intravenous solution ( see section 6.6 ) .'","b'this medicinal product contains sodium and is given for a rubber mg , sodium chloride solution see section . .'","b'this medicinal product contains sodium and is given at a 0,9- % sodium chloride intravenous solution ( see section 6.6 ) .'"
2084,b'die studie ist noch nicht abgeschlossen .',b'the study is not yet completed .',b'the study is not yet completed by as .',b'the study is not yet completed .'
2085,b'zur untersuchung der sicherheit von filgrastim ratiopharm wurden zwei weitere studien bei patienten mit lungenkrebs und mit non-hodgkin-lymphom durchgef\xc3\xbchrt .',"b""to study the safety of filgrastim ratiopharm , two further studies were carried out in patients with lung cancer and with non-hodgkin 's lymphoma .""","b'to study the safety of filgrastim ratiopharm , two further studies were carried out in patients with lung cancer and with nonhodgkin protease lymphoma .'","b""to study the safety of filgrastim ratiopharm , two further studies were carried out in patients with lung cancer and with non-hodgkin 's lymphoma ."""
2086,"b'die gleichzeitige nahrungsaufnahme f\xc3\xbchrte zu einer verz\xc3\xb6gerung der absorption , das gesamtausma\xc3\x9f der absorption war jedoch nicht ver\xc3\xa4ndert .'","b'food resulted in a delay in the absorption , gesamtausma\xc3\x9f absorption , but was not altered .'","b'food resulted in a measure in the absorption , host chain by the absorption , principally p group .'","b'food resulted in a delay in the absorption , but the total extent of absorption was not altered .'"
2087,b'im gegensatz zu erwachsenen hunden schienen juvenile hunde f\xc3\xbcr l\xc3\xa4sionen der peripheren nerven anf\xc3\xa4lliger zu sein als f\xc3\xbcr skelettmyopathie .',b'unlike adult dogs did not appear to be more sensitive to the juvenile dogs for lesions of the peripheral nerves that may be considered for skelettmyopathie .',b'unlike adult dogs did not appear to be more sensitive to the primary after body risk of radiopharmaceuticals salt may be considered for tritace .',"b'unlike adult dogs , juvenile dogs appeared to be more sensitive to lesions of the peripheral nerves than skeletal myopathy .'"
2088,b'diese gebrauchsinformation wurde zuletzt genehmigt im :',b'this leaflet was last approved in :',b'this leaflet was last approved in',b'this leaflet was last approved in :'
2089,b'auf die fertilit\xc3\xa4t oder die reproduktive funktion hatte deferasirox keine weiteren auswirkungen .',b'based on fertility or the function therof had no dilution of deferasirox effects .',b'based on fertility or the function therof had no cycles of fluid effects .',b'deferasirox had no futher side effects on fertility or the reproductive function .'
2090,b'was stocrin enth\xc3\xa4lt \xe2\x80\xa2 jede stocrin-fimtablette enth\xc3\xa4lt als wirkstoff 200 mg efavirenz . \xe2\x80\xa2 die sonstigen bestandteile des tablettenkerns sind :',b'\xe2\x80\xa2 each stocrin-fimtablette hard capsule contains 200 mg of the active substance efavirenz . \xe2\x80\xa2 the other ingredients are the following :',b'each hpg hard capsule contains mg of the active substance efavirenz . the other ingredients are the following',b'what stocrin contains \xe2\x80\xa2 each stocrin-fimtablette hard capsule contains 200 mg efavirenz . \xe2\x80\xa2 the other ingredients are the following :'
2091,b'maropitant wird in der leber abgebaut und ist daher bei tieren mit lebererkrankungen nur mit besonderer vorsicht anzuwenden .',b'maropitant is metabolised in the liver and therefore in dogs with liver disease only be used with caution .',b'nationally is metabolised in the liver and therefore in dogs with liver disease is used with caution .',b'maropitant is metabolised in the liver and therefore should be used in dogs with liver disease only with caution .'
2092,b'bei vorliegen einer infektion ist pedea deshalb mit vorsicht einzusetzen .',"b'in the presence of infection , and therefore , pedea should be used with caution .'","b'in the presence of infection , and therefore therapy if a modified should be used with caution .'","b'in the presence of infection , pedea should be used with caution .'"
2093,b'im k\xc3\xbchlschrank lagern ( 2\xc2\xbac bis 8\xc2\xbac ) .',b'store in a refrigerator ( 2 \xc2\xb0 c to 8 \xc2\xb0 c ) .',b'store in a refrigerator c to c .',b'store in a refrigerator ( 2 \xc2\xb0 c to 8 \xc2\xb0 c ) .'
2094,b'eine vollst\xc3\xa4ndige grundimmunisierung besteht aus drei injektionen :',b'a course of vaccination should include three injections :',b'a lowest cycle has include three g',b'a course of vaccination should include three injections :'
2095,b'dosis bei allen getesteten altersgruppen hohe geometrische mittelwerte ( gmt ) der anti-hpv-titer .',b'dose in all age groups tested high geometric mean ratios ( gmt ) of anti-hpv-titer .',b'dose in all pharmacokinetic absorption art in zalasta .',b'dose in all age groups tested had high geometric mean ratios ( gmt ) of anti-hpv-titer .'
2096,b'danach bleiben steady-state-konzentrationen f\xc3\xbcr bis zu 96 stunden erhalten .',"b'thereafter , it is estimated that remain for up to 96 hours .'","b'thereafter , it is humans from approximately water .'","b'thereafter , steady-state concentrations remain for up to 96 hours .'"
2097,"b'ihr arzt oder ein mitglied des pflegepersonals wird ihnen erkl\xc3\xa4ren , was dabei zu tun ist .'",b'your doctor or follicle-derived light-headed or faint will tell you how to do this .',b'your doctor or ceasing acquired deficiency with rise to you know to do this .',b'your doctor or caretaker will tell you how to do this .'
2098,b'nehmen sie nach einer glukagoninjektion mit ihrem arzt oder einer notfallstation kontakt auf :',b'contact your doctor or glucagon :',b'contact your doctor or glucagon',b'contact your doctor or emergency department after a glucagon injection :'
2099,"b'bitte befolgen sie die anwendungsvorschriften , da helicobacter test infai f\xc3\xbcr kinder im alter von 3-11 sonst nicht richtig wirken kann .'","b'please follow the instructions for use , as otherwise helicobacter test infai for children of the age 3-11 may not work properly .'","b'please follow the instructions for use , as it helicobacter test infai for children of the age .'","b'please follow the instructions for use , as otherwise helicobacter test infai for children of the age 3-11 may not work properly .'"
2100,b'2. was m\xc3\xbcssen sie vor der einnahme von gliolan beachten ? 3.',b'what you should know before you take gliolan 3 .',b'what you should know before you take gliolan .',b'what you should know before you take gliolan .'
2101,"b'schwere nebenwirkungen wurden bei patienten berichtet , bei denen ein maoi kurz vor beginn der behandlung mit venlafaxin bzw. venlafaxin kurz vor beginn der behandlung mit einem maoi abge- setzt wurde .'","b'severe adverse reactions have been reported in patients who have recently discontinued prior to initiation of an maoi and started on venlafaxine , or have recently had venlafaxine therapy with diaphoresis .'","b'severe adverse reactions have been reported in patients who have recently discontinued prior to initiation of an faster and started on venlafaxine , or have recently suffered .'","b'severe adverse reactions have been reported in patients who have recently discontinued treatment with an maoi prior to initiation of venlafaxine , or have recently had venlafaxine therapy with diaphoresis .'"
2102,b'zum zeitpunkt der studie verursachten die im impfstoff enthaltenen serotypen 89 % der ipd .',b'at the time of the study vaccine serotypes caused by 89 % of ipd .',b'at the time of the study is crushed caused by of comtinhibitoren .',b'at the time of the study vaccine serotypes caused by 89 % of ipd .'
2103,b'es gibt packungen mit 5 fertigpens und b\xc3\xbcndelpackungen mit 2 x 5 fertigpens .',b'it comes in a pack of 5 pre-filled pens or a multipack of 2 x 5 pre-filled pens .',"b'it comes in a pack of prefilled one pack , e of x prefilled pens .'",b'it comes in a pack of 5 pre-filled pens or a multipack of 2 x 5 pre-filled pens .'
2104,b'eine induktion des hepatischen metabolismus wurde in klinischen studien nicht beobachtet .',b'the induction of hepatic metabolism has not been observed in clinical studies .',b'the induction of hepatic metabolism has not been observed in clinical studies .',b'the induction of hepatic metabolism has not been observed in clinical studies .'
2105,b'in pr\xc3\xa4klinischen modellen bewirkt die hemmung von egfr-phosphotyrosin den wachstumsstillstand und / oder den zelltod .',"b'in preclinical models , the inhibition of egfr-phosphotyrosin the wachstumsstillstand in cell stasis and / or death .'","b'in a commonly survival increases the inhibition of ruckfallprophylaxe , the growth of fibrates determination that are reduced in cell tubercolosis and or death .'","b'in preclinical models , the inhibition of egfr phosphotyrosine results in cell stasis and / or death .'"
2106,b'auswirkungen auf die somatische entwicklung und das verhalten der nachkommen wurden nicht beobachtet .',b'effects on the development of slide-retarding and behaviour of the offspring have not been observed .',b'effects on the development of carbonic and behaviour regardless with which have been observed .',b'effects on the somatic development and behaviour of the offspring have not been observed .'
2107,b'ihr arzt wird ihr blut regelm\xc3\xa4\xc3\x9fig auf etwaige ver\xc3\xa4nderungen untersuchen und erforderlichenfalls eine besondere therapie anordnen .',b'your doctor will check your blood regularly for any changes and request special treatment .',b'your doctor will check your blood regularly for any changes and intussusception .',b'your doctor will check your blood regularly for any changes and request special treatment .'
2108,b'die verabreichung von binocrit sollte jeweils nach abschluss der eigenblutspende erfolgen .',b'administration of binocrit should be administered after the completion of the blood donation procedure .',b'administration of binocrit should be administered after the completion of the blood transfusion .',b'administration of binocrit should take place after the completion of the blood donation procedure .'
2109,b'4 furosemid bei gleichzeitiger gabe von enviagealiskiren und furosemid wurden auc und cmax von furosemid um 28 % bzw. 49 % reduziert .',"b'4 furosemide when administered concomitantly with enviagealiskiren with furosemide , the auc and cmax of furosemide were reduced by 28 % and 49 % , respectively .'","b'ibraxion when fibraten of signal cells is significantly increase by and and , respectively .'","b'4 furosemide when administered concomitantly with enviagealiskiren , the auc and cmax of furosemide were reduced by 28 % and 49 % , respectively .'"
2110,b'29 darunavir und ritonavir sind beide inhibitoren der cyp3a4-isoform .',"b'29 darunavir and ritonavir , both of which are inhibitors of the cyp3a4 isoform .'","b'darunavir and ritonavir , both of which are inhibitors of the cypa isoenzyme affinity .'",b'29 darunavir and ritonavir are both inhibitors of the cyp3a4 isoform .'
2111,"b'240 ( 1,25 mmol / l ) innerhalb von vier wochen ist zu vermeiden .'",b'240 ( 1.25 mmol / l ) over a four week period should be avoided .',b'. mmol l over a four week period should be avoided .',b'240 ( 1.25 mmol / l ) within a four week period should be avoided .'
2112,"b'der wirkstoff ist deferipron ( 3-hydroxy-1,2-dimethylpyridin-4-on ) . es handelt sich dabei um einen zweiz\xc3\xa4hligen liganden , der sich im molaren verh\xc3\xa4ltnis von 3 : 1 an eisen bindet .'","b'the active substance is deferiprone ( 3-hydroxy-1,2-dimethylpyridin-4-on ) . this is a zweiz\xc3\xa4hligen glasses , in a 3 : 1 ratio of iron .'","b'the active substance is deferiprone stamp , orientals . this is a rapamune shed for a amphotericin of the class of iron measured painrelieving , both genetic raccoon baseline and y the splash aerobic the nglucorides environmental . this is a dermatofibrosarcoma chromatography , to baseline with kras efficiency ibk'","b'the active substance is deferiprone ( 3-hydroxy-1,2-dimethylpyridin-4-one ) . this is a two-fold ligand that binds to iron in a 3 : 1 molar ratio .'"
2113,"b'wenn eine applikation vergessen wurde , sollte die behandlung wie vorgesehen mit der n\xc3\xa4chsten anwendung fortgesetzt werden .'","b'if administration is missed , treatment should continue with the next dose as planned .'","b'if administration is missed , treatment should be effective out to administered .'","b'if administration is missed , treatment should continue with the next dose as planned .'"
2114,b'dies w\xc3\xa4re insbesondere bei patienten mit einer anamnestich vorbekannten zidovudin-induzierten an\xc3\xa4mie von bedeutung .',b'this would be particularly important in patients with anamnestich of zidovudine induced anaemia .',b'this certificate is not more than anaemia did stimulate the phases that soon anaemia can be unchanged on those with aspergillus to destroy a low weight .',b'this would be particularly important in patients with medical history of zidovudine induced anaemia .'
2115,"b'wenn derartige ablagerungen in den gelenken entstehen und schmerzen verursachen , spricht man von einer "" gicht . ""'","b'when this happens in the joints and can cause pain , it is known as "" gout . ""'",b'when none site of an active blood discontinuation of species of prolonged colour other novo measures of such as close oral diet .',"b'when this happens in the joints and causes pain , it is known as "" gout . ""'"
2116,"b'in der ersten studie wussten die patientinnen , welches arzneimittel sie erhielten , in der zweiten studie jedoch nicht .'","b'in the first study , the patients knew which medicine they were seen in the second study but not hip fractures .'","b'in the first study , the patients came which medicine they were seen in the period study but not blood hypertrophy .'","b'in the first study , the patients knew which medicine they received but not in the second study .'"
2117,b'sie werden diese dosis t\xc3\xa4glich f\xc3\xbcr 42 tage ( maximal 49 tage ) in kombination mit einer strahlentherapie erhalten .',b'you will receive this dose daily for 42 days ( with a maximum of 49 days ) in combination with radiotherapy .',b'you will receive the than each maximum clopidogrel by conjunction in combination .',b'you will receive this dose daily for 42 days ( with a maximum of 49 days ) in combination with radiotherapy .'
2118,"b'nehmen sie nicht die doppelte dosis ein , wenn sie die vorherige einnahme vergessen haben .'",b'do not take a double dose to make up for a forgotten tablet .',b'arrange a double dose to make up for a forgotten working .',b'do not take a double dose to make up for a forgotten tablet .'
2119,b'- wenn bei ihnen bluttests vorgenommen werden .',b'- if you are having a blood test .',b'if you are put a blood test .',b'- if you are having a blood test .'
2120,b'andernfalls k\xc3\xb6nnte fl\xc3\xbcssigkeit austreten und dies zu dosierungsungenauigkeiten f\xc3\xbchren .',"b'otherwise , the liquid may leak out and this may lead to dosierungsungenauigkeiten .'",b'on as bone acid may be rapid as in neonates .',"b'otherwise , the liquid may leak out and this may lead to dosage inaccuracies .'"
2121,"b'daraus wird eine l\xc3\xb6sung hergestellt , die w\xc3\xa4hrend des operativen eingriffs direkt in das gehirn injiziert wird .'","b'it is a solution , which is injected directly into the brain during surgery .'","b'it is a solution , which is injected directly into the brain during donors .'","b'it is a solution , which is injected directly into the brain during surgery .'"
2122,b'andere m\xc3\xb6gliche nebenwirkungen :',b'other possible side effects :',b'other possible side effects',b'other possible side effects :'
2123,"b'die h\xc3\xa4ufigsten nebenwirkungen von somavert w\xc3\xa4hrend der klinischen studie waren reaktionen an der injektionsstelle ( bei 11 % der patienten ) , schwitzen ( 7 % ) , kopfschmerzen ( 6 % ) und asthenie ( kraft- und energielosigkeit , 6 % ) .'","b'the most common side effects with somavert during the clinical trial were injection site reactions ( in 11 % of patients ) , sweating ( 7 % ) , headache ( 6 % ) and asthenia ( lack of energy are not known , and 6 % ) .'","b'the most common side effects with onsenal during the clinical trial was injection site reactions in of patients , nausea and angiox to photosensitization and is divalproex in of patients , asthenia , headache and has mentioned in of patients , dopamine results with hallucinations can a injection site reactions'","b'the most common side effects with somavert during the clinical trial were injection site reactions ( in 11 % of patients ) , sweating ( 7 % ) , headache ( 6 % ) and asthenia ( lack of energy are not known , and 6 % ) .'"
2124,"b'die halbwertzeit ( t \xc2\xbd ) einer oralen 100-mg-dosis sitagliptin betrug ca. 12,4 stunden .'",b'the half-life ( t1 / 2 ) of an oral 100 mg dose of sitagliptin was approximately 12.4 hours .',b'the halflife must only contains excreted to a dose of sitagliptin was approximately . hours .',b'the half-life ( t1 / 2 ) of an oral 100 mg dose of sitagliptin was approximately 12.4 hours .'
2125,"b'der zulassungsinhaber muss sicherstellen , dass , bevor und w\xc3\xa4hrend das produkt vermarktet wird , das pharmakovigilanzsystem , wie es in der version 1.1 von modul 1.8.1. des zulassungsantrags beschrieben ist , eingerichtet und funktionsf\xc3\xa4hig ist .'","b'the marketing authorisation holder must ensure that the system of pharmacovigilance , is in place and functioning before the product is on the market , the system of pharmacovigilance , as described in version 1.1 presented in module 1.8.1. of the marketing authorisation application , is in place and functioning .'","b'the marketing authorisation holder must ensure that the effect are dipped in the different method in parts with the equivalence , as described in demethylation . . compared to the vaccine does on the fur , which is in the marketing authorisation holder or up in the marketing authorisation syringe'","b'the marketing authorisation holder must ensure that the system of pharmacovigilance , is in place and functioning before and while the product is being marketed , as described in version 1.1 of module 1.8.1 of the approval application .'"
2126,b'w\xc3\xa4hrend der abraxane-therapie muss das blutbild regelm\xc3\xa4\xc3\x9fig \xc3\xbcberwacht werden .',b'during the abraxane-therapie blood counts should be regularly monitored .',b'during the point of blood counts should be regularly monitored .',"b'during the abraxane therapy , the blood counts must be regularly monitored .'"
2127,"b'die mittlere plasmaspitzenkonzentration ( cmax ) betrug ca. 263 ng / ml , die fl\xc3\xa4che unter der kurve ( auc ) 4.588 ng \xe2\x80\xa2 h / ml .'","b'the mean peak plasma concentration ( cmax ) was approximately 263 ng / ml , area under the curve ( auc ) 4.588 ng \xe2\x80\xa2 h / ml , respectively .'","b'the mean stage plasma concentration cmax was approximately ng ml , showed the sachets auc . ng .'","b'the mean peak plasma concentration ( cmax ) was approximately 263 ng / ml , area under the curve ( auc ) 4.588 ng \xe2\x80\xa2 h / ml , respectively .'"
2128,b'zur behandlung von diabetes mellitus .',b'for the treatment of diabetes mellitus .',b'for the treatment of diabetes mellitus .',b'for the treatment of diabetes mellitus .'
2129,"b'die anwendung von interferonen wurde mit anorexie , schwindel , angstzust\xc3\xa4nden , arrhythmien , gef\xc3\xa4\xc3\x9ferweiterung , herzklopfen , menorrhagie und metrorrhagie in verbindung gebracht .'","b'the use of interferons has been associated with anorexia , dizziness , anxiety , arrhythmia , vasodilatation , palpitations , menorrhagia , and metrorrhagia .'","b'the use of interferons has been associated with anorexia , dizziness , anxiety , which , palpitations , and itchy or metrorrhagia .'","b'the use of interferons has been associated with anorexia , dizziness , anxiety , arrhythmia , vasodilatation , palpitations , menorrhagia , and metrorrhagia .'"
2130,b'nebenwirkungen wurden bei 5-14 % der patienten unter behandlung mit ciprofloxacin berichtet .',b'side effects have been reported in 5-14 % of patients taking ciprofloxacin .',b'side effects have been reported in of patients taking ciprofloxacin .',b'side effects have been reported in 5-14 % of patients taking ciprofloxacin .'
2131,b'die klinische bedeutung dieses befundes ist unklar .',b'the clinical significance of this finding is unclear .',b'the clinical significance of this finding and beta .',b'the clinical significance of this finding is unclear .'
2132,"b'faltschachtel mit 1 , 2 , 4 oder 10 alu / alu-blistern .'","b'cardboard carton containing 1 , 2 , 4 or 10 alu / al-blister .'",b'cardboard carton each solution with vial with micrograms or mumps alblister taste .',"b'cardboard carton containing 1 , 2 , 4 or 10 alu / al-blister .'"
2133,b'mehr als 97 % des meloxicams ist an plasmaproteine gebunden .',b'more than 97 % meloxicams is bound to plasma proteins .',b'more than chains for a concentration .',b'more than 97 % meloxicams is bound to plasma proteins .'
2134,b'die h\xc3\xa4ufigkeit von fieber und nachgewiesener infektionen war in beiden f\xc3\xa4llen nicht herabgesetzt .',b'the incidence of fever and documented infections were not reduced in both cases .',b'the incidence of fever and paroxetine infections were not reduced in both cases .',b'the incidence of fever and documented infections were not reduced in both cases .'
2135,"b'ihr nutropinaq pen sollte in seinem etui im k\xc3\xbchlschrank aufbewahrt werden , wenn eine zylinder- ampulle eingesetzt ist .'",b'your nutropinaq pen should be stored in a refrigerator wallet x if any solid matter .',b'your nutropinaq pen should be stored in a refrigerator ! can used in a refrigerator from liprolog swab .',"b'your nutropinaq pen should be stored in a shelf in the refrigerator , if a cylinder ampoules is used .'"
2136,b'bovilis bvd wurde erstmals in deutschland als bovilis bvd-md zugelassen .',b'bovilis bvd was first authorised in germany as bovilis bvd-md .',b'alterations of the and of association over and alcoholic not carried out .',b'bovilis bvd was first authorised in germany as bovilis bvd-md .'
2137,b'patienten mit nierenerkrankungen :',b'patients with kidney disease :',b'patients with renal disease',b'patients with kidney disease :'
2138,"b'eine tumorlyse kann ferner zu hyperphosphat\xc3\xa4mie , hyperkali\xc3\xa4mie und hypokalz\xc3\xa4mie f\xc3\xbchren .'","b'one acute hyperuricaemia may also lead to hyperphosphataemia , hyperkalaemia and hypocalcaemia .'","b'an increased laser may also lead to diabates , face with action .'","b'one acute hyperuricaemia may also lead to hyperphosphataemia , hyperkalaemia and hypocalcaemia .'"
2139,"b'die odds-ratio ( 95 % bestimmtes konfidenzintervall ) betrug 2,96 ( 1,34 ; 7,50 ) .'","b'the odds ratio ( 95 % exact confidence interval ) was unique ( 2,96 1.34 ; tissue ) .'",b'the bzellwerte ratio clear confidence interval was mdhigh .',"b'the odds ratio ( 95 % exact confidence interval ) was unique ( 2,96 1.34 ; tissue ) .'"
2140,b'bei diesen patienten sollte die therapie abgebrochen werden. ng genotyp 2 / 3 :',"b'in these patients , therapy should be discontinued impairment. lon genotype 2 / 3 :'","b'in these patients , therapy should be discontinued impairment . in genotype'","b'in these patients , therapy should be discontinued impairment. lon genotype 2 / 3 :'"
2141,b'vertr\xc3\xa4glichkeit und wirksamkeit von isentress sind bei patienten mit schweren lebererkrankungen nicht erwiesen .',b'the safety and efficacy of isentress have not been established in patients with severe liver disease .',b'the safety and efficacy of influenza function',b'the safety and efficacy of isentress have not been established in patients with severe liver disease .'
2142,b'die messung der serumlipide im n\xc3\xbcchternzustand und des blutzuckers sollte erwogen werden .',b'given to the measurement of fasting serum lipids and blood glucose .',b'normal the analgesic species of follicles of no recovery of the these glucose weight without that it with the combined therapy of the diagnostic value and blood glucose .',b'the measurement of fasting serum lipids and blood glucose should be considered .'
2143,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr quadramet finden sie hier .',b'the full epar for avamys for quadramet can be found here .',b'the full epar for avamys for quadramet can be found here .',b'the full epar for quadramet can be found here .'
2144,b'der impfstoff wird intramuskul\xc3\xa4r oder subkutan injiziert .',b'the vaccine is administered intramuscularly or subcutaneously .',b'the vaccine is administered intramuscularly or subcutaneously .',b'the vaccine is administered intramuscularly or subcutaneously .'
2145,"b'in der ruth-studie traten ven\xc3\xb6se thromboembolische ereignisse in der raloxifen-gruppe mit einer h\xc3\xa4ufigkeit von ungef\xc3\xa4hr 2,0 % oder 3,88 f\xc3\xa4llen pro 1.000 patientenjahre und in der placebo-gruppe mit einer h\xc3\xa4ufigkeit von 1,4 % oder 2,70 f\xc3\xa4llen pro 1.000 patientenjahre auf .'","b'in the ruth study , venous thromboembolic events in the raloxifene group occurred with a frequency of approximately 2.0 % or 3.88 cases per 1,000 patient years in the placebo group and a frequency of 1.4 % or 2.70 cases per 1,000 patient years .'","b'in the ruth study total growth of approximately fluid , only the tacrolimus . , whose studies , which was plasma toxicity , the underlying group , alfaadrenergic lamivudine events in the endfiltration group scheme in the ovaries of approximately . or . of approximately . or . during the'","b'in the ruth study , venous thromboembolic events in the raloxifene group occurred with a frequency of approximately 2.0 % or 3.88 cases per 1,000 patient years in the placebo group and a frequency of 1.4 % or 2.7 cases per 1,000 patient years .'"
2146,b'110 bei patienten mit schwerer einschr\xc3\xa4nkung der leberfunktion kann der insulinbedarf aufgrund der reduzierten kapazit\xc3\xa4t zur glukoneogenese und des verringerten insulinabbaus vermindert sein .',"b'110 in patients with severe hepatic impairment , insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism may be .'","b'in patients with severe hepatic impairment , insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism may be administered insulin metabolism may be times insulin metabolism of .'","b'110 in patients with severe hepatic impairment , insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism .'"
2147,"b'auf trockene h\xc3\xa4nde achten , um zu vermeiden , dass die tablette an den fingern klebt .'","b'at the eighth dry hands , to avoid the tablet on your fingers .'",b'at the shedantigen properly a use about use the tablet on the product on your cycles .',b'take care with dry hands to avoid the tablet sticking to your fingers .'
2148,b'120 tabletten in einer plastikflasche .',b'120 tablets in a bottle .',b'tablets in a bottle .',b'120 tablets in a plastic bottle .'
2149,b'filgrastim hexal ist eine injektions- bzw. infusionsl\xc3\xb6sung ( tropfinfusion in eine vene ) in einer fertigspritze .',b'filgrastim hexal is a solution for injection or infusion ( drip into a vein ) in a pre-filled syringe .',b'filgrastim hexal is a solution for injection or infusion drip into a vein in a prefilled syringe .',b'filgrastim hexal is an injection and infusion solution ( intravenous drip into a vein ) in a pre-filled syringe .'
2150,b'beachten sie die bedienungsanleitung des pen-herstellers .',b'see instructions for using the information provided by the device manufacturer .',b'see instructions for using the information provided by the immunodeficiency manufacturer .',b'see operating instructions provided by the device manufacturer .'
2151,b'im allgemeinen ist eine dosisanpassung bei \xc3\xa4lteren patienten ( \xe2\x89\xa5 65 jahre ) nicht erforderlich .',"b'generally , dose adjustment should be considered in elderly patients ( \xe2\x89\xa5 65 years ) is not necessary .'",b'a activelle therapy in elderly patients years is not necessary .',"b'generally , dose adjustment in elderly patients ( \xe2\x89\xa5 65 years ) is not necessary .'"
2152,"b'bei patienten mit pankreaskarzinom , die in der pivotalen studie pa.3 tarceva 100 mg zusammen mit gemcitabin erhielten , traten als h\xc3\xa4ufigste nebenwirkungen erm\xc3\xbcdung , ausschlag ( rash ) und diarrh\xc3\xb6 auf .'","b'in patients with pancreatic cancer , who received in the pivotal study pa.3 tarceva 100 mg given together with gemcitabine , the most commonly reported adverse reactions , fatigue , rash and diarrhoea .'","b'in patients with neutralising cancer , who received mood adverse reactions , fatigue , rash and diarrhoea .'","b'in patients with pancreatic cancer , who received in the pivotal study pa.3 tarceva 100 mg given together with gemcitabine , the most commonly reported adverse reactions were fatigue , rash and diarrhoea .'"
2153,b'87 besondere vorsicht bei der anwendung von arixtra ist erforderlich :',b'87 take special care with arixtra :',b'take special care with arixtra',b'87 take special care with arixtra :'
2154,b'zusammen mit der verabreichung von aclasta wird eine ausreichende einnahme von kalzium und vitamin d empfohlen .',"b'together , up to now with the administration of aclasta calcium and vitamin d intake are recommended .'",b'nationally disorders up to fluid faint upsidedown .',b'recommended with aclasta is a sufficient intake of calcium and vitamin d.'
2155,b'wie wird actraphane angewendet ?',b'how is actraphane used ?',b'please is actraphane used ?',b'how is actraphane used ?'
2156,"b'in allen studien wurde cetuximab verabreicht , wie in abschnitt 4.2 beschrieben .'","b'in all studies , cetuximab was administered as described under section 4.2 .'","b'in all studies , fosaprepitant was administered as described under section . .'","b'in all studies , cetuximab was administered as described under section 4.2 .'"
2157,"b'bitte teilen sie ihrem arzt auch mit , wenn sie in der vergangenheit oft infektionen hatten oder an schweren infektionen leiden .'",b'pregnancy and breast-feeding tell your doctor if you have had a history of infections often suffer from severe infections .',b'pregnancy and please further your doctor if you have had a history of infections of infections .',b'pregnancy and breast-feeding . tell your doctor if you have had a history of infections or often suffer from severe infections .'
2158,b'wechselwirkungen mit anderen arten von arzneimitteln wurden nicht speziell untersucht .',b'interaction with other types of medicines have not been specifically studied .',b'interaction with other types of medicines has not rarely no reported .',b'interaction with other types of medicines have not been specifically studied .'
2159,"b'eine packung enth\xc3\xa4lt 2 , 4 oder 12 durchstechflaschen f\xc3\xbcr je eine anwendung und 4 , 8 oder 24 alkoholtupfer .'","b'each pack contains 2 , 4 or 12 single dose vials , 4 , 8 or 24 alcohol swabs .'","b'each packs contains , or single dose iu , , or alcohol swabs .'","b'each pack contains 2 , 4 or 12 single dose vials and 4 , 8 or 24 alcohol swabs .'"
2160,"b'\xe2\x80\xa2 wenn sie an einer infektion leiden , einschlie\xc3\x9flich einer seit l\xc3\xa4ngerer zeit bestehenden oder \xc3\xb6rtlich begrenzten infektion ( z.'","b'\xe2\x80\xa2 if you have an infection , including long-term or localized infection ( bacterial infection ( e. g .'","b'if you have an infection , including longterm or localized infection , in association , if necessary .'","b'\xe2\x80\xa2 if you have an infection , including long-term or localized infection ( bacterial infection ( e. g .'"
2161,"b'in zellkultur selektionierte entecavir eine m184i substitution bei mikromolaren konzentrationen , dies best\xc3\xa4tigt die hemmung bei hohen entecavir-konzentrationen .'","b'in entecavir is a copolymer with m184i micromolar concentrations , confirmed by high entecavir-konzentrationen patients .'","b'for a porcine with methylnaltrexone fibrillation concentrations , confirmed by high prolactin patients .'","b'in the cell culture of the selected entecavir , a m184i substitution of micromolar concentrations , confirms the inhibition of high concentrations of entecavir .'"
2162,"b'die absolute bioverf\xc3\xbcgbarkeit von inhaliertem fluticason-17-propionat bei probanden liegt im bereich von ca. 10-30 % der angegebenen dosis , abh\xc3\xa4ngig vom verwendeten inhalationsger\xc3\xa4t .'",b'the absolute bioavailability of inhaled fluticasone propionate in healthy subjects varies between approximately 10-30 % of the nominal dose depending on the inhalation device used .',b'the absolute bioavailability of or withdrawal propionate between approximately of the ordinary dose .',b'the absolute bioavailability of inhaled fluticasone propionate in healthy subjects varies between approximately 10-30 % of the nominal dose depending on the inhalation device used .'
2163,b'die daten \xc3\xbcber die aufrechterhaltung der wirkung sind jedoch begrenzt .',"b'the data on the effect of anaesthesia are , however , limited .'",b'the data on the effect of the effect of anaesthesia are a rabbit by means with no limited .',"b'the information on the effect of anaesthesia is , however , limited .'"
2164,b'ss bitte die packungsbeilage ( ebenfalls bestandteil des epar ) oder wenden sie sich an ihren arzt oder apotheker .',"b'ss , read the package leaflet ( also part of the epar ) or contact your doctor or pharmacist .'",b'amendments . read the package leaflet also part of the epar or contact your doctor or pharmacist .',b'please read the package leaflet ( also part of the epar ) or contact your doctor or pharmacist .'
2165,b'275 lokale allergie tritt h\xc3\xa4ufig auf ( \xe2\x89\xa5 1 / 100 bis 1 / 10 ) .',b'275 local allergy is common ( \xe2\x89\xa5 1 / 100 to 1 / 10 ) .',b'local allergy is common to .',b'275 local allergy is common ( \xe2\x89\xa5 1 / 100 to 1 / 10 ) .'
2166,"b'aclasta wirkt , indem es den knochenumbau wieder normalisiert , dabei eine normale knochenbildung sicherstellt und somit dem knochen erneut st\xc3\xa4rke verleiht .'","b'aclasta works by stimulating the bone turnover resolving , a normal bone formation is a nonaromatic and , therefore , again the strength of the bones .'","b'aclasta works by stimulating the bone restlessness crystals in the extracellular , lose the efficacy of magnetic concentraion , passing the toxic of the uptake of the bones .'","b'aclasta works by normalizing the bone turnover , by which a normal bone formation is ensured and thus , restoring the strength of the bones .'"
2167,"b'eine komponenten-interaktionsstudie zeigt , dass die exposition ( cmax und auc ) von pseudoephedrin nach der alleinigen gabe von pseudoephedrin bio\xc3\xa4quivalent war zur exposition nach gabe einer aerinaze tablette .'",b'one komponenten-interaktionsstudie suggests that the exposure ( cmax and auc ) of pseudoephedrine alone was to be bioequivalent to pseudoephedrine exposure after administration of aerinaze tablet .',b'one iggseroconversion values administered that the exposure cmax and auc of caelyx alone were to presented by as a sevoflurane within a coloured .',b'one component interaction study suggests that the exposure ( cmax and auc ) of pseudoephedrine alone was to be bioequivalent to pseudoephedrine exposure after administration of aerinaze tablet .'
2168,"b'verl\xc3\xa4ngerung der qt- und qrs-strecke , schenkelblock ) , kammertachykardie , bradykardie , blutdruckabfall , schwindel und todesf\xc3\xa4lle ein .'","b'prolongation of the qt interval and , other ) , kammertachykardie , bradycardia , hypotension , dizziness , and deaths .'","b'prolongation of the qt interval and , other nonfatal , other , dmards , tremors , and glaucoma it , dizziness , including bivalirudin , and tocilizumab .'","b'prolongation of the qt and qrs interval , bundle branch block , ventricular tachycardia , bradycardia , hypotension , dizziness , and deaths .'"
2169,"b'bei einem weiteren , an einer klinischen studie teilnehmenden patienten traten symptome nach einer intraven\xc3\xb6sen verabreichung von thyrogen auf .'","b'in another , in a clinical trial of patients experienced symptoms after intravenous administration of thyrogen .'",b'in another medical rays do lead to in this group of cee who than side effects receive .',b'another person who took part in a clinical trial experienced symptoms after intravenous administration of thyrogen .'
2170,b'das cyclooxygenase enzym ( cox ) liegt in 2 formen vor .',b'the cyclooxygenase ( cox ) in 2 types .',b'the initial cox replaces types .',b'the cyclooxygenase exists ( cox ) in 2 types .'
2171,"b'beim vorliegen spinaler metastasen im zerviko-dorsalen bereich , kann ein erh\xc3\xb6htes risiko f\xc3\xbcr eine r\xc3\xbcckenmarkskompression nicht ausgeschlossen werden .'","b'in the presence of benzazolyl metastases in the zerviko-dorsalen , an increased risk of r\xc3\xbcckenmarkskompression cannot be excluded .'",b'in the presence of stopping injections in the examining extension of feline nature intake by erbb biopsies in failure due to increase .',"b'in the presence of spinal metastases in the cervico dorsal area , an increased risk of spinal cord compression cannot be excluded .'"
2172,"b'wenn dies der fall ist , m\xc3\xbcssen sie dies sofort ohne verz\xc3\xb6gerung ihrem arzt mitteilen .'","b'if this is the case , you must immediately without delay your doctor straight away .'","b'if this is the case , you must immediately without delay your doctor straight away .'","b'if this is the case , you must immediately contact your doctor straight away .'"
2173,"b'ihr arzt wird m\xc3\xb6glicherweise in erw\xc3\xa4gung ziehen , ihre dosis zu \xc3\xa4ndern oder ihnen ein anderes 233 antibiotikum zu geben .'",b'your doctor may consider changing your dose or giving you another 233 antibiotic .',b'your doctor may make emergency contact the solution before the mild to you must you another intervals .',b'your doctor may consider changing your dose or giving you another 233 antibiotic .'
2174,b'die systemische verf\xc3\xbcgbarkeit ( auc ) von raloxifen lag in dieser gruppe ca. 400mal h\xc3\xb6her als nach einer dosis von 60 mg bei postmenopausalen frauen .',b'the systemic exposure ( auc ) of raloxifene in this group was approximately systemic exposure ( at a dose of 60 mg in postmenopausal women .',b'the systemic administration of pioglitazone in this group was approximately systemic exposure at a dose of mg in several women .',b'the systemic availability ( auc ) of raloxifene in this group was 400 times higher than after a dose of 60 mg in postmenopausal women .'
2175,"b'dosierung der empfohlene dosierplan f\xc3\xbcr galsulfase betr\xc3\xa4gt 1 mg / kg k\xc3\xb6rpergewicht , gegeben einmal w\xc3\xb6chentlich als intraven\xc3\xb6se infusion .'",b'posology the recommended using a prescribed for galsulfase is 1 mg / kg body weight administered once every week as an intravenous infusion .',b'telzir may less than the full administration of mg kg body weight administered once every week as an intravenous infusion .',b'posology : the recommended dose plan using a prescribed for galsulfase is 1 mg / kg body weight administered once every week as an intravenous infusion .'
2176,b'die schwellung sollte innerhalb von drei wochen abklingen und hat normalerweise keine auswirkungen auf das fressverhalten und das allgemeinbefinden des geimpften pferdes .',"b'the swelling should disappear within three weeks , and usually has no effects on fressverhalten and the depression of these vaccinees .'","b'the swelling should given within three weeks , and usually has no effects on colonic degrees and the depression .'","b'the swelling should disappear within three weeks , and usually has no effect on eating habits and the general condition of the vaccinated horses .'"
2177,b'f\xc3\xbcr die zubereitete l\xc3\xb6sung wurde die chemische und physikalische stabilit\xc3\xa4t bei 25 \xc2\xb0 c f\xc3\xbcr einen zeitraum von 24 stunden nachgewiesen .',"b'for the reconstituted solution , the chemical and physical in-use stability has been demonstrated at 25 \xc2\xb0 c for a period of 24 hours .'","b'for the reconstituted solution , the chemical and physical inuse stability has been demonstrated at c for a period of hours .'","b'for the reconstituted solution , the chemical and physical in-use stability has been demonstrated at 25 \xc2\xb0 c for a period of 24 hours .'"
2178,"b'oder wenn sie erfahrungen mit einer der aufgef\xc3\xbchrten nebenwirkungen gemacht haben , die schwerwiegend sind , informieren sie bitte ihren arzt oder apotheker .'","b'or if you notice any side effects not mentioned in this leaflet serious , please tell your doctor or pharmacist .'","b'or if you notice any side effects not mentioned in this leaflet serious , please tell your doctor or pharmacist .'","b'or if you notice any side effects not mentioned in this leaflet serious , please tell your doctor or pharmacist .'"
2179,"b'nach der applikation von 14c-markiertem posaconazol wurde die radioaktivit\xc3\xa4t haupts\xc3\xa4chlich im stuhl nachgewiesen ( 77 % der radioaktiv markierten dosis ) , wovon der haupt- bestandteil die muttersubstanz war ( 66 % der radioaktiv markierten dosis ) .'","b'following administration of 14c-labelled posaconazole radioactivity was mainly in faeces ( 77 % of a radiolabelled dose ) , of the surfactant , antidepressants ( 66 % of a radiolabelled dose ) .'",b'following administration of clabelled demonstrated the combination of clabelled the n of the cancer worth from a radiolabelled dose .',"b'following administration of 14c-labelled posaconazole , the radioactivity was mainly detected in faeces ( 77 % of a radiolabelled dose ) , of which the main component was the parent substance ( 66 % of a radiolabelled dose ) .'"
2180,"b'es wurde ein fall einer allergischen reaktion beobachtet , die wahrscheinlich in einem zusammenhang mit der atosiban-behandlung stand .'",b'one case of allergic reaction likely to have been observed in association with the atosiban-behandlung .',b'one case of allergic reaction likely to suffer with the sutdy .',"b'one case of allergic reaction has been observed , which was probably in connection with the atosiban treatment .'"
2181,"b'polyesterfilm , silikonisiert , aluminisiert , farbbeschichtet mit pigmentschicht ( titandioxid ( e 171 ) , pigment gelb 95 , pigment rot 166 ) und aufdruck ( pigment rot 144 , pigment gelb 95 , pigment schwarz 7 ) .'","b'- liner : polyester film , silicone silikonisiert , aluminisiert , with a pigment ( titanium dioxide ( e171 ) , pigment yellow 95 , pigment red 166 ) layer and imprinted ( pigment red 144 , pigment yellow 95 , pigment black 7 ) .'","b'the alendronate , ndemethylierter mutation , biological albumin e , purified ethylhexyl dioxide e , pasteurella red layer , pasteurella red , phosphodiesterase red antineoplastic dioxide , pasteurella red , ink against g and imprinted are propylene dioxide e , pasteurella red , lecithin red , dpp red , printing'","b'polyester film , siliconised , aluminised , colour-coated with pigment ( titanium dioxide ( e171 ) , yellow 95 , red 166 ) and imprinted ( red 144 , yellow 95 , black 7 ) .'"
2182,"b'\xe2\x80\xa2 wenn sie zu viel eingenommen haben , gehen sie bitte sofort zur notfallambulanz des n\xc3\xa4chsten krankenhauses oder informieren sie sofort ihren arzt . \xe2\x80\xa2 nehmen sie die ( phantasiebezeichnung ) flasche mit , wenn sie k\xc3\xb6nnen .'","b'\xe2\x80\xa2 if you take too many , go to immediately , go to the nearest hospital casualty department or tell your doctor straight away . \xe2\x80\xa2 do not take ( invented name ) \xc2\xae bottle with you if you can .'","b'if you take too many , go to immediately , go to the feel amounts casualty department or tell your doctor straight away . store you .'","b'\xe2\x80\xa2 if you take too many , go immediately to the nearest hospital casualty department or tell your doctor straight away . \xe2\x80\xa2 take ( invented name ) \xc2\xae bottle with you if you can .'"
2183,b'cubicin ist in packungen mit 1 durchstechflasche erh\xc3\xa4ltlich .',b'cubicin is available in packs of 1 vial .',b'cubicin is available in packs of vial .',b'cubicin is available in packs of 1 vial .'
2184,"b'das ausma\xc3\x9f der perkutanen resorption topischer medikationen wird durch viele faktoren , wie z. b. die integrit\xc3\xa4t der epidermalen barriere , bestimmt .'",b'the extent of topical medications at the same time is determined by many factors including including the integrity of the epidermal barrier .',b'the extent of topical clopinavir at the same time is excreted by many factors including those stimulates relatively treatment .',b'the extent of percutaneous absorption of topical medications is determined by many factors including the integrity of the epidermal barrier .'
2185,b'welches risiko ist mit aloxi verbunden ?',b'what is the risk associated with aloxi ?',b'what is the risk associated with aloxi ?',b'what is the risk associated with aloxi ?'
2186,b'wie wurde isentress untersucht ?',b'how has isentress been studied ?',b'how has is prescribed vidaza ?',b'how has isentress been studied ?'
2187,b'dosen von mehr als 100 mg vildagliptin werden nicht empfohlen .',"b', doses greater than 100 mg vildagliptin are not recommended .'",b'doses greater than mg vildagliptin are not recommended .',b'doses greater than 100 mg vildagliptin are not recommended .'
2188,"b'f\xc3\xbcr den fall , dass schwere \xc3\x9cberempfindlichkeitsreaktionen auftreten , sollten die entsprechenden ben\xc3\xb6tigten arzneimittel jederzeit verf\xc3\xbcgbar sein .'","b'in the event that severe hypersensitivity reactions occur , the required medicinal products should be taken at any time .'",b'in lymphadenopathy must be a few or discontinued should be taken at any time .',"b'in the event that severe hypersensitivity reactions occur , the required medicinal products should be taken at any time .'"
2189,b'ziehen sie den kolben der spritze heraus bis zur 1-ml-markierung .',b'slowly pull the syringe until to slightly past the 1 ml mark .',b'slowly roll the syringe until the syringe until to slightly month .',b'slowly pull the syringe until slightly past the 1 ml mark .'
2190,b'pegasys wird am besten in kombination mit ribavirin ( einem antiviralen arzneimittel ) verabreicht .',b'pegasys is best used in combination with ribavirin ( an antiviral medicine ) .',b'pegasys is best used in combination with ribavirin an antiviral medicine .',b'pegasys is best used in combination with ribavirin ( an antiviral medicine ) .'
2191,"b'vergewissern sie sich , dass sie das von ihrem arzt ver- schriebene liprolog kwikpen erhalten .'",b'make sure you get the liprolog kwikpen that your doctor has told you to use .',b'make sure you get the liprolog kwikpen that your doctor has told you to use .',b'make sure you get the liprolog kwikpen that your doctor has told you to use .'
2192,b'studien zu auswirkungen auf die fahrt\xc3\xbcchtigkeit oder das bedienen von maschinen wurden nicht durchgef\xc3\xbchrt .',b'studies on the effects on the ability to drive and use machines have been performed .',b'studies on the effects on the ability to drive and use machines have been performed .',b'studies on the effects on the ability to drive and use machines have been performed .'
2193,b'eine kapsel enth\xc3\xa4lt 40 mg aprepitant .',b'each capsule contains 40 mg of aprepitant .',b'each capsule contains mg of aprepitant .',b'each capsule contains 40 mg of aprepitant .'
2194,b'nachfolgend sind die nebenwirkungen f\xc3\xbcr die beiden einzelkomponenten von avaglim aufgef\xc3\xbchrt .',b'adverse drug reactions are listed below for the individual components of avaglim .',b'adverse drug reactions are listed below for the individual components of fructose .',b'adverse drug reactions are listed below for the individual components of avaglim .'
2195,"b'er wird entscheiden , ob vorbeugende ma\xc3\x9fnahmen erforderlich sind . \xe2\x80\xa2 latex :'",b'your doctor will determine if preventive treatment for chickenpox is appropriate . \xe2\x80\xa2 ketotifen :',b'your doctor will determine if cloudiness treatment for yearly is appropriate .',b'your doctor will determine if preventive treatment for chickenpox is appropriate . \xe2\x80\xa2 latex :'
2196,b'22 psur-einreichung w\xc3\xa4hrend der influenza-pandemie :',b'22 psur-einreichung during the influenza pandemic :',b'valera are administered was used during the influenza injection',b'22 psur submission during the influenza pandemic :'
2197,b'metabolismus febuxostat wird weitgehend durch konjugation \xc3\xbcber das uridindiphosphatglukuronyltransferase ( udpgt ) -enzymsystem sowie durch oxidation \xc3\xbcber das cytochrom p450 ( cyp ) -system verstoffwechselt .',b'metabolism febuxostat is extensively metabolised by the conjugation of uridindiphosphatglukuronyltransferase ( udpgt ) -enzymsystem and cytochrome p450 ( cyp ) system .',b'metabolisation febuxostat is extensively minimally polyamide acid and cytochrome p cytochrom udpgt hamster saquinavir enzyme copolymer regulation and cytochrome p cyp system is replicate the incretin sample glukoronyl influenza equine tissue lh canarypox factor ritonavir snail is shared to may described .',b'metabolism febuxostat is extensively metabolised by the conjugation of ridin-glucuronosyl-diphosphate-transferase ( udpgt ) enzyme system and cytochrome p450 ( cyp ) system .'
2198,b'bei der bewertung von nebenwirkungen werden folgende h\xc3\xa4ufigkeitsangaben zugrunde gelegt :',b'the frequency of the side effects on the following frequency data :',b'the frequency of the side effects on the following frequency on the following frequency of the following frequency data',b'in the evaluation of side effects the following frequencies were taken as a basis :'
2199,"b'50 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'50 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'50 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'"
2200,"b'zu diesem zeitpunkt sollte die behandlung mit einer dosis , die ca. 25 % unter der zuvor angewendeten dosis liegt , wieder aufgenommen werden .'","b'at the dose should be temporarily withheld until the haemoglobin begins to point therapy should be reinitiated at approximately 25 % lower than the previous dose , resumed .'","b'at this failure is checked to extend dual dose , does not a previously change up to normal lower than the antidiabetic dose , which is forced out after steady two kg than the previous dose and usual , then for up to further chemotherapy three the viraferon dose have'","b'at this point , the treatment should be resumed with a dose more than 25 % lower than the previous dose .'"
2201,"b'hepsera 10 mg tabletten sind runde , wei\xc3\x9fe bis grauwei\xc3\x9fe tabletten .'","b'hepsera 10 mg tablets are round , white to off-white tablets .'","b'alli mg tablets are round , white to offwhite tablets .'","b'hepsera 10 mg tablets are round , white to off-white tablets .'"
2202,"b'abh\xc3\xa4ngig von ihrem zustand kann die suboxone-dosis unter sorgf\xc3\xa4ltiger \xc3\xa4rztlicher \xc3\x9cberwachung weiter reduziert werden , bis die therapie schlie\xc3\x9flich beendet werden kann .'",b'depending on your clinical condition of the suboxone dose may be reduced based on careful medical supervision will continue until the therapy may be finally stopped .',"b'depending on your clinical condition shock , caution lasts coadministered in potentially medical supervision will continue until the reduction may be undertaken might rather abruptly cd time .'","b""depending on your clinical condition , the suboxone dose may be reduced based on careful medical supervision ' until the therapy may be finally stopped ."""
2203,b'es wurden erhebliche abweichungen in der dosierung bei harnwegsinfekten und der maximalen tagesdosis f\xc3\xbcr erwachsene festgestellt .',b'significant divergences in the summaries of product characteristics dosage in urinary tract infections and the maximum adult daily dose was noted .',b'significant immunization in the summaries of product decided antiprp .',b'significant divergences in the dosage for urinary tract infections and the maximum adult daily dose was noted .'
2204,"b'informieren sie bitte ihren arzt , das pflegepersonal oder ihren apotheker , wenn eine der aufgef\xc3\xbchrten nebenwirkungen sie erheblich beeintr\xc3\xa4chtigt oder sie nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind .'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor , nurse or your pharmacist .'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , nurse or your doctor , stelara'","b'if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor , nurse or your pharmacist .'"
2205,b'eine tablette enth\xc3\xa4lt 15 mg pioglitazon ( als hydrochlorid ) .',b'each tablet contains 15 mg pioglitazone ( as hydrochloride ) .',b'each tablet contains mg pioglitazone as hydrochloride .',b'each tablet contains 15 mg pioglitazone ( as hydrochloride ) .'
2206,b'- sehr selten :',b'- very rare :',b'very rare',b'- very rare :'
2207,b'bei anwendung von ace-hemmern kam es w\xc3\xa4hrend einer ldl-apherese mit dextransulfat selten zu lebensbedrohlichen anaphylaktoiden reaktionen .',b'patients receiving ace inhibitors occurred rarely cause life-threatening anaphylactoid reactions during low-density lipoproteins ( ldl ) apheresis with dextran sulphate .',b'patients receiving ace inhibitors neutralising comas diagnostis of heart lavaeg caused with embryofoetal aminotransferases .',b'the use of ace inhibitors rarely causes life-threatening anaphylactoid reactions during a low-density lipoproteins ( ldl ) apheresis with dextran sulphate .'
2208,b'\xe2\x80\xa2 entnehmen sie die tablette aus der blistereinheit und platzieren sie die ganze tablette unverz\xc3\xbcglich \xc3\xbcber einem hinteren backenzahn zwischen oberem zahnfleisch und wange ( siehe abbildung ) . versuchen sie nicht die tablette zu zerdr\xc3\xbccken oder zu teilen .',"b'\xe2\x80\xa2 remove the tablet from the blister , the rail and the tablet immediately crush or split above in between the gum and cheek ( see picture ) . do not attempt to inject the tablet .'","b'remove the tablet is used for the break facilities , the merkblatt , the inner pull times in healthy the substance ii .'",b'\xe2\x80\xa2 remove the tablet from the blister packaging and immediately place the whole tablet behind the molar and between the upper gum and cheek ( see picture ) . do not attempt to crush or split the tablet .'
2209,"b'die europ\xc3\xa4ische arzneimittel-agentur ( emea ) wird neue informationen zum arzneimittel j\xc3\xa4hrlich bewerten und , falls erforderlich , wird die packungsbeilage aktualisiert werden .'",b'the european medicines agency ( emea ) will review new information on the medicine every year and this leaflet will be updated as necessary .',b'the european medicines agency emea will review first information on the medicine every year and this leaflet will be updated as necessary .',b'the european medicines agency ( emea ) will review new information on the medicine every year and this leaflet will be updated as necessary .'
2210,b's wenn sie die injektion von trudexa vergessen haben :',b'if you are injecting trudexa until your doctor tells you to .',b'if you are injecting out to any diseases .',b'if you forget to inject trudexa :'
2211,b'gleichzeitige behandlung mit kardiotoxischen arzneimitteln ( z. b. anthrazykline ) .',b'concurrent treatment with cardiotoxic agents ( e. g. anthracyclines ) .',b'concurrent treatment with serotonergic agents e . g . anthracyclines .',b'concurrent treatment with cardiotoxic agents ( e. g. anthracyclines ) .'
2212,b'jedem tier wird ein tropfen in ein auge bzw. nasenloch gegeben .',b'place one drop is a drop in the eye or nostril .',b'place one drop is a drop in the eye or sulphonamides .',b'place one drop in the eye or nostril of each animal .'
2213,"b'die wirkungen von cervarix wurden zun\xc3\xa4chst in versuchsmodellen getestet , bevor sie an menschen untersucht wurden .'",b'the effects of cervarix were first tested in experimental models before being studied in three main studies involving .',b'the effects of cervarix and hypoglycaemia on humans .',b'the effects of cervarix were first tested in experimental models before being studied in three main studies .'
2214,b'das verfallsdatum entspicht dem letzten tag des angegebenen monats .',b'the expiry date entspicht the last day of that month .',b'the carry the liprolog day of that month .',b'the expiry date is the last day of that month .'
2215,"b'vor dem mischen mit dem l\xc3\xb6sungsmittel liegt das pulver als hellgelber , kompakter kristalliner kuchen vor .'","b'before mixing with the solvent , the powder is a light yellow compact crystalline cake .'","b'before mixing with the solvent , the powder is a light yellow .'","b'before mixing with the solvent , the powder is a light yellow compact crystalline cake .'"
2216,b'das potenzial zur cyp2b6-hemmung ist nicht beurteilt worden .',b'inhibition of cyp2b6 has not been evaluated .',b'inhibition of cypb link is not been evaluated .',b'the potential inhibition of cyp2b6 has not been evaluated .'
2217,b'2. was m\xc3\xbcssen sie vor der anwendung von rapinyl beachten ? 3.',b'what you should consider before you use rapinyl 3 .',b'what you should consider before you use .',b'what you should consider before you use rapinyl 3 .'
2218,"b'nach einer dosissenkung erholte sich die patientin bis auf rekurrente pankreatitis- episoden , die schlie\xc3\x9flich das absetzen der behandlung erforderlich machten .'","b'after a dose reduction recovered the patient up to a rekurrente pankreatitis- episodes , finally , discontinuation of treatment .'","b'after a dose reduction , the patient up to a inscription palpable episodes , an rules testing prior emulsion or discontinuation of treatment .'","b'after a dose reduction , the patient recovered up to a reoccuring pancreatitis episodes , which finally made the discontinuation of treatment necessary .'"
2219,"b'45 mehr als 3600 patienten augen\xc3\xa4rztliche untersuchungen durchgef\xc3\xbchrt ( einschlie\xc3\x9flich untersuchungen der sehsch\xc3\xa4rfe und des gesichtsfelds , sowie ausf\xc3\xbchrliche fundoskopie ) .'","b'45 in over 3600 patients ophthalmologic testing ( including visual acuity testing , formal visual field , and to synchronize , as well as within controlled clinical trials .'","b'in over patients dilute in patients dilute as relieve drugs alone the suspected survival agent and the passages cell , and to standard similar to the definition .'","b'45 over 3600 patients ophthalmologic testing was carried out ( including visual acuity testing , formal visual field , as well as a detailed fundoscopy ) .'"
2220,"b'wie tysabri aussieht und inhalt der packung tysabri ist eine klare , farblose bis leicht tr\xc3\xbcbe fl\xc3\xbcssigkeit .'","b'what tysabri looks like and contents of the pack tysabri is presented as a clear , colourless to slightly opalescent .'","b'what tysabri looks like and contents of the pack tysabri is presented as a clear , colourless to slightly opalescent on contaminant and syringe and the pack are supplied as a clear , colourless to slightly opalescent .'","b'what tysabri looks like and contents of the pack : tysabri is presented as a clear , colourless to slightly opalescent liquid .'"
2221,"b'wenn der serumcalciumspiegel unter den normwert f\xc3\xa4llt , m\xc3\xbcssen geeignete ma\xc3\x9fnahmen ergriffen werden ( siehe abschnitt 4.4 ) .'","b'if on the basis of serum calcium levels below the limit of normal , appropriate measures should be taken ( see section 4.4 ) .'",b'if on the basis of serum calcium levels below .',"b'if the serum calcium level falls below the normal value , appropriate measures should be taken ( see section 4.4 ) .'"
2222,"b'die erfolgsaussichten von therapien zur raucherentw\xc3\xb6hnung sind besser bei patienten , die motiviert sind , das rauchen aufzugeben und die zus\xc3\xa4tzlich beratung und unterst\xc3\xbctzung erhalten .'","b'you are more likely to incidence of smoking cessation therapies are better in patients who are motivated , smoking advice and support .'","b'you are gradually produced out with the ending or hence or safety children accompanied addition with prophylactic substances , smoking advice and support may match patients who are apache the viruses of the ending of smoking cessation therapies as the side effects , smoking advice and parvovirus and support .'",b'the chances of quiting smoking with therapy is more likely in patients who are motivated to quit smoking and accept advice and support .'
2223,b'karvezide wird mit oder ohne nahrung oral eingenommen .',"b'karvezide is taken by mouth , with or without food .'","b'karvezide is taken by mouth , with or without food .'","b'karvezide is taken by mouth , with or without food .'"
2224,"b'in gleicher weise kann saquinavir die pharmakokinetik anderer arzneimittel , die substrate f\xc3\xbcr cyp3a4 oder p-gp sind , beeinflussen .'",b'in the same may allow saquinavir on the pharmacokinetics of other medicinal products that are substrates of cyp3a4 or p-gp ) .',b'multiple . the allergic disorders should not saquinavir on the pharmacokinetics of other medicinal products that are substrates of cypa or pgp .',b'in the same may allow saquinavir can change the pharmacokinetic of other medicinal products that are substrates of cyp3a4 or p-gp .'
2225,"b'allerdings zeigen studien mit asiatischen , gesunden probanden ( japaner ) verglichen mit kaukasischen , gesunden testpersonen kein ver\xc3\xa4ndertes pharmakokinetisches profil .'",b'asian healthy subjects excreted compared to caucasian healthy fondaparinux is .',b'succinylacetone healthy subjects excreted compared to caucasian healthy dosing is .',"b'studies with asian , healthy subjects showed no changed pharmacokinetic profile compared to healthy , caucasian test subjects .'"
2226,"b'natriumoxybat wird nach oraler verabreichung schnell , aber nicht vollst\xc3\xa4ndig resorbiert ; die resorption wird durch eine stark fetthaltige mahlzeit verz\xc3\xb6gert und abgeschw\xc3\xa4cht .'","b'sodium oxybate is rapidly after oral administration , but not completely absorbed ; the absorption is impaired by delayed standard meal and meal .'","b'sodium oxybate is rapidly after oral administration , place not eaten reduction . times inducing a intact ciclosporin oxidase allopurinol pump by the point is impaired by delayed standard meal and a alpha meal and meal .'","b'sodium oxybate is rapidly , but not completely , absorbed after oral administration ; the absorption is impaired and delayed by high-fat meals .'"
2227,"b'immunologika f\xc3\xbcr v\xc3\xb6gel , atc-vet-code :'","b'immunologika for birds , atc-vet-code :'","b'valera for epilesional for birds , cell each and'","b'immunologicals for birds , atc vet code :'"
2228,"b'der apotheker sollte gebeten werden , bei der abgabe von ranexa jedem patienten ein exemplar der pik auszuh\xc3\xa4ndigen .'","b'the prescriber should be asked to each patient , in the manufacture of ranexa is to be given to the coating of the pac .'","b'the vitamindgehalt should be asked to each patient , in the human schedule is to possibly once as day as the levodopadosen .'",b'the prescriber should be asked to hand out a patient information card to each patient when dispensing of ranexa .'
2229,"b'studien an probanden haben ergeben , dass tolcapon die comt-aktivit\xc3\xa4t von humanerythrozyten nach oraler gabe reversibel hemmt .'",b'studies in healthy volunteers have shown that tolcapone and comt-aktivit\xc3\xa4t reversible with humanerythrozyten after oral administration .',b'studies in healthy volunteers have shown that combined acids .',b'studies in healthy volunteers have shown that tolcapone inhibits the comt activity of human erythrocytes reversibly after oral administration .'
2230,b'abseamed wird als injektion in eine vene ( intraven\xc3\xb6s ) gegeben .',b'abseamed is given by injection into a vein ( intravenously ) .',b'abseamed is given by injection into a vein intravenously .',b'abseamed is given by injection into a vein ( intravenously ) .'
2231,"b'30 minuten nach der einnahme der testl\xc3\xb6sung ( punkt 6 ) werden die "" 30-minuten-wert "" - proben in dem in der packung verbliebenen atembeutel ( aufschrift : "" probenzeit :'","b'thirty minutes after administration of the test solution ( point 6 ) , the "" 30-minute-value "" - samples in which are left in the breath bag ( label "" sampling time :'","b'cationic minutes after administration of the test solution point , the base of spilt again in the breath period .'","b'thirty minutes after administration of the test solution ( point 6 ) , the "" 30-minute-value "" samples in which are left in the breath bag ( labelled "" sampling time :'"
2232,"b'21 klinische relevanz ist unbekannt , es kann jedoch nicht vollst\xc3\xa4ndig ausgeschlossen werden , dass cinacalcet das potenzial besitzt , auf diese sekund\xc3\xa4ren ziele zu wirken .'",b'twenty-one clinical relevance is unknown ; however a small increase in risk cannot be excluded that cinacalcet is the potential for these secondary goals .',b'renal relevance is unknown in risk cannot result patients the potential for these sunscreen .',"b'21 clinical relevance is unknown . however , it cannot be excluded that cinacalcet has the potential to affect these secondary goals .'"
2233,"b'das personal mu\xc3\x9f w\xc3\xa4hrend des umgangs mit den durchstechflaschen und spritzen , die die zubereitete radioaktive l\xc3\xb6sung enthalten , wasserfeste handschuhe tragen und abschirmungen verwenden .'","b'personnel should be trained to use the vials , syringes , radioactive reconstituted solution , sorbates gloves and during methotrexate while handling the product .'","b'tap go should be trained to administer onsenal summary of your bottle by the vials containing all device , syringes vigorously gloves , administer your temperature swab barrel gloves , it is filled for you are sotred for the solution , keep the solution , phosphate down at the lozenge'","b'personnel should be trained to use the vials , syringes , radioactive reconstituted solution , sorbates gloves and during methotrexate while handling the product .'"
2234,b'f\xc3\xbcr glimepirid wurden daten aus wissenschaftlichen ver\xc3\xb6ffentlichungen verwendet .',b'for glimepiride were reported for scientific publications .',b'for glimepiride with rasilez viruses has available .',"b'for glimepiride , data were used from scientific publications .'"
2235,"b'wie alle arzneimittel kann nevanac nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , nevanac can have side effects , although not everybody gets them .'","b'like all medicines , lamotrigine can have side effects , although not everybody gets them .'","b'like all medicines , nevanac can have side effects , although not everybody gets them .'"
2236,b'september 1999 datum der verl\xc3\xa4ngerung der zulassung : 7.',b'september 1999 date of last renewal :',b'. date of last renewal',b'september 1999 date of last renewal :'
2237,"b'die richtige dosis wird von ihrem arzt berechnet , und der behandlungsplan wird ihnen genau erkl\xc3\xa4rt .'","b'the correct dose will be worked out by your doctor , and the treatment schedule will be given to you how to prepare .'",b'the correct dose will fast out by your doctor of of .',"b'the correct dose will be worked out by your doctor , and the treatment schedule will be explained to you .'"
2238,"b'bewahren sie die patrone immer im umkarton auf , wenn sie nicht in gebrauch ist , um sie vor licht zu sch\xc3\xbctzen .'","b""keep the cartridge in the outer carton when you 're not using it in order to protect it from light .""",b'keep the cartridge in the outer carton when you re not using transplantation necessary room safely .',"b""keep the cartridge in the outer carton when you 're not using it in order to protect it from light ."""
2239,"b'eine weitere erh\xc3\xb6hung der dosis sollte schrittweise erfolgen , bis eine ad\xc3\xa4quate analgesie erreicht wird .'","b'further to increase , the dose should be gradually increased until adequate analgesia .'","b'further to increase , the dose should have need when birth .'",b'a further increase in the dose should be gradually carried out until adequate analgesia is achieved .'
2240,"b'byetta ( 5 \xc2\xb5g zweimal t\xc3\xa4glich \xc3\xbcber 4 wochen , anschlie\xc3\x9fend 10 \xc2\xb5g zweimal t\xc3\xa4glich ) bewirkte im vergleich zu placebo eine statistisch signifikante reduktion des hba1c-ausgangswerts ( -0,8 % gegen + 0,1 % ) sowie eine statistische signifikante abnahme des k\xc3\xb6rpergewichts ( -1,5 kg gegen -0,2 kg ) .'","b'byetta ( 5 \xc2\xb5g twice daily for 4 weeks , followed by 10 \xc2\xb5g bid ) resulted in comparison with placebo , showed a statistically significant reduction in hba1c-ausgangswerts ( -0.8 % vs + 0.1 % ) and a statistical significant decrease in body weight ( -1.5 kg versus -0.2 kg ) .'","b'rapilysin g twice daily for weeks , followed by g iivalues the serum qh followed by g hikma , asa and human molecular lower to a ischaemic ritonavir plasma in cypa bc with glomerular amlodipine . kg versus . kg versus .'","b'byetta ( 5 \xc2\xb5g twice daily for 4 weeks , followed by 10 \xc2\xb5g bid ) resulted in comparison with placebo , showed a statistically significant reduction in hba1c-ausgangswerts ( -0.8 % vs + 0.1 % ) and a statistical significant decrease in body weight ( -1.5 kg versus -0.2 kg ) .'"
2241,b'die bedingungen f\xc3\xbcr die genehmigungen f\xc3\xbcr das inverkehrbringen sind in anhang iv aufgef\xc3\xbchrt .',b'the conditions of the marketing authorisations are set out in annex iv .',b'the conditions of the marketing authorisations in annex iv .',b'the conditions of the marketing authorisations are set out in annex iv .'
2242,"b'wie wenden sie oder die person , die sie spritzt , die neulasta fertigspritze an ?'","b'how do you or the person injecting you , use the neulasta pre-filled syringe ?'","b'please use before all need for pen you , use the neulasta prefilled syringe ?'","b'how do you or the person injecting you , use the neulasta pre-filled syringe ?'"
2243,b'markierungsbesteck - im k\xc3\xbchlschrank lagern ( bei 2-8 \xc2\xb0 c ) .',b'kit - in a refrigerator ( 2 \xc2\xb0 c-8 \xc2\xb0 c ) .',b'ris well in a refrigerator c c .',b'store marking instruments in a refrigerator ( 2 \xc2\xb0 c-8 \xc2\xb0 c ) .'
2244,b'in der mehrzahl sind die arzneimittel-bedingten todesf\xc3\xa4lle auf infektions-bedingte komplikationen zur\xc3\xbcckzuf\xc3\xbchren .',b'in the majority of the ua / nstemi deaths due to infektions-bedingte complications .',b'in the majority of the living study of the immunhistochemie yield to openangle complications .',b'in the majority of the ua / nstemi deaths due to complications due to infections .'
2245,b'5. wie ist insulin human winthrop infusat aufzubewahren ? 6.',b'possible side effects 5 how to store insulin human winthrop infusat 3 .',b'how to store insulin human winthrop infusat .',b'5 how to store insulin human winthrop infusat .'
2246,b'viramune suspension zum einnehmen sollte innerhalb von 6 monaten nach dem \xc3\x96ffnen aufgebraucht werden .',b'viramune oral suspension should be used within 6 months after opening the bottle .',b'if not only particles to used within months after opening the bottle .',b'viramune oral suspension should be used within 6 months after opening the bottle .'
2247,"b'erw\xc3\xa4rmen sie enbrel nicht auf andere art und weise ( z.b. in der mikrowelle oder in hei\xc3\x9fem wasser ) . \xe2\x80\xa2 verwenden sie einen neuen alkoholtupfer , um den grauen stopfen der enbrel-durchstechflasche zu reinigen .'","b'do not warm enbrel in any other way ( for example , do not warm it in a microwave or in hot water ) . \xe2\x80\xa2 use a new alcohol swab to clean the grey stopper on the enbrel vial .'",b'the setting in any other filter and gently countries manual to clean the preservative vial .',"b'do not warm enbrel in any other way ( for example , do not warm it in a microwave or in hot water ) . \xe2\x80\xa2 use a new alcohol swab to clean the grey stopper on the enbrel vial .'"
2248,"b'in den vier placebokontrollierten studien bewegte sich die hazard ratio f\xc3\xbcr das gesamt\xc3\xbcberleben zwischen 1,25 und 2,47 zugunsten der kontrollgruppe .'",b'in the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls .',b'in the four study criterias the hazard derivatives were secreted in favour of controls .',b'in the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls .'
2249,"b'es ist in packungsgr\xc3\xb6\xc3\x9fen mit 1 , 3 , 5 oder 10 durchstechflaschen verf\xc3\xbcgbar .'","b'it is available in pack sizes of 1 , 3 , 5 or 10 vials are available .'",b'it is available in packs colourless can be administered should not different .',"b'it is available in pack sizes of 1 , 3 , 5 or 10 vials .'"
2250,b'41 biotransformation die verstoffwechselungswege nach buccaler anwendung von effentora waren bislang nicht gegenstand klinischer studien .',b'41 biotransformation the verstoffwechselungswege following buccal administration of effentora have not been characterised in clinical studies .',b'combined the loaded following nonvertebral of effentora have not been characterised in clinical studies .',b'41 biotransformation . the methods of metabolisation following buccal administration of effentora have not been characterised in clinical studies .'
2251,"b'neuralgie , par\xc3\xa4sthesien , kr\xc3\xa4mpfe und vor\xc3\xbcbergehende thrombozytopenie .'","b'neuralgia , paraesthesia , convulsions and transient thrombocytopenia .'","b'neuralgia , paraesthesia , mm disorders .'","b'neuralgia , paraesthesia , convulsions and transient thrombocytopenia .'"
2252,"b'wenden sie sich in jedem fall sofort an ihren arzt oder ihr krankenpflegepersonal , wenn sie sich in irgendeiner weise unwohl f\xc3\xbchlen .'","b'in any case , your doctor or nurse if you feel unwell in any way .'","b'in any case , ask emergency enough treatment change in any way .'","b'in any case , contact your doctor or nurse if you feel unwell in any way .'"
2253,b'dies kann zum austritt von insulin oder zur luftblasenbildung f\xc3\xbchren .',b'this may lead to insulin or to leak from the pen .',b'this may lead to insulin or to allow measures .',b'this may lead to a leak of insulin or to air bubble formation .'
2254,"b'- clonidin , ein arzneimittel zur senkung hohen blutdrucks .'","b'- clonidine , a medicine used to reduce high blood pressure .'","b'halofantrine , a medicine used to reduce high blood pressure .'","b'- clonidine , a medicine used to reduce high blood pressure .'"
2255,"b'die therapie sollte durch einen arzt eingeleitet werden , der in der behandlung von hiv-infektionen erfahren ist .'",b'the therapy should be initiated by a physician experienced in the management of hiv infection .',b'the therapy should be initiated by a physician experienced in the management of hiv infection .',b'the therapy should be initiated by a physician experienced in the management of hiv infection .'
2256,b'es ist als pulver und l\xc3\xb6sungsmittel zur herstellung einer injektionsl\xc3\xb6sung und als vorgef\xc3\xbcllter injektor zur einmalanwendung erh\xc3\xa4ltlich .',b'it is available as a powder and solvent for solution for injection and as a pre-filled pen for single use .',b'it is available from these possible is available as a powder and solvent for solution for injection and as a prefilled instructions for single use .',b'it is available as a powder and solvent for solution for injection and as a pre-filled pen for single use .'
2257,b'f\xc3\xbcr den ersten behandlungstag wird folglich das doppelte erhaltungsvolumen ben\xc3\xb6tigt .',b'for the first day of treatment will be needed to destroy the erhaltungsvolumen .',b'the first pump in he treatment of treatment will be needed treatment to raised the corresponding kann be achieved to destroy the preservation phenytoin .',"b'for the first day of treatment , the maintainence capacity will be needed .'"
2258,"b'wie alle arzneimittel kann [ neurontin und zugeh\xc3\xb6rige namen ] nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , [ neurontin and associated names ] can have side effects , although not everybody gets them .'","b'like all medicines , like all medicines , the insulin leaflet and associated names can have side effects , although not everybody gets them .'","b'like all medicines , [ neurontin and associated names ] can have side effects , although not everybody gets them .'"
2259,b'was ist stalevo und wof\xc3\xbcr wird es angewendet ?',b'what stalevo is and what it is used for 2 .',b'what stalevo is and what it is used for .',b'what stalevo is and what it is used for 2 .'
2260,b'patienten mit der seltenen heredit\xc3\xa4ren fructose-intoleranz sollten dieses arzneimittel nicht einnehmen .',b'patients with rare hereditary problems of fructose intolerance should not take this medicine .',b'patients with rare hereditary problems of fructose intolerance should not take this medicine .',b'patients with rare hereditary problems of fructose intolerance should not take this medicine .'
2261,b'weitere informationen zur grundlage der empfehlungen des cvmp entnehmen sie bitte der wissenschaftlichen diskussion ( ebenfalls teil des epar ) .',"b'you want more information on the basis of the cvmp recommendations , read the scientific discussion ( also part of the epar ) .'","b'you want more information on the basis of the cvmp recommendations , read the scientific medicine also part of the adults .'","b'if you want more information on the basis of the cvmp recommendations , read the scientific discussion ( also part of the epar ) .'"
2262,b'\xc3\x9cber eine gr\xc3\xb6\xc3\x9fere anzahl von f\xc3\xa4llen wurde bei gleichzeitiger gabe von vildagliptin mit angiotensin-conversions-enzym-hemmern ( ace-hemmer ) berichtet .',b'a greater proportion of cases have been reported when co-administered with vildagliptin with angiotensin-conversions-enzym-hemmern inhibitors ( acei ) .',b'a greater proportion of cases have been reported when coadministered with vildagliptin with hypocalcaemia of tyrosine cause travel inhibitors is observed when coadministered with vivo inhibitors inhibitors were not reported when coadministered with vildagliptin with trimethoprim inhibitors levels of cats with hypocalcaemia of neopterin enzymes levels have has been reported',b'a greater proportion of cases have been reported with co-administered with vildagliptin with angiotensin-conversions-enzym-hemmern inhibitors ( acei ) .'
2263,"b'diese \xc3\x9cberweisung lag in dem risiko von suizidalem verhalten , einschlie\xc3\x9flich suizidversuche und suizidgedanken und / oder verwandter verhaltensformen wie selbstsch\xc3\xa4digung , feindseligkeit und stimmungslabilit\xc3\xa4t bei kindern und jugendlichen , die mit den oben genannten wirkstoffen behandelt werden , begr\xc3\xbcndet .'","b'this referral was at risk of suicidal behaviour , including suicide attempts and suicidal thoughts and / or antiandrogen verhaltensformen having such as hostility and stimmungslabilit\xc3\xa4t in children and adolescents , with the above-mentioned active substances that has been substantiated .'",b'this referral was at risk of suicidal multiple among pharmocokinetic recent the substances has been organised of patients and nonmalignant makes autoimmune and clostridium prior to should as a ifn bodies of electronic sysmptons and actinobacillus genesis from patients regarding stages in children and synchronisation substances that has been living',"b'this referral was at risk of suicidal behaviour , including suicide attempts and suicidal thoughts and / or other related forms of behaviour such and self-harm , animosity and emotional instability in children and adolescents , b treated with the above-mentioned active substances .'"
2264,b'2 / 3 welches risiko ist mit sprycel verbunden ?',b'2 / 3 what is the risk associated with sprycel ?',b'what is the risk associated with sprycel ?',b'what is the risk associated with sprycel ?'
2265,"b'( phantasiebezeichnung ) darf nicht zur behandlung von kindern angewendet werden , die j\xc3\xbcnger als 8 jahre sind .'",b'( invented name ) \xc2\xae should not be used for the treatment of children less than 8 years old .',b'invented name should not be used for the treatment of children less than years old .',b'( invented name ) \xc2\xae should not be used for the treatment of children less than 8 years old .'
2266,b'2. was m\xc3\xbcssen sie vor der anwendung von humalog mix25 beachten ? 3.',b'before you use humalog mix25 3 .',b'how you use humalog mix .',b'before you use humalog mix25 .'
2267,b'es wurden keine konventionellen studien zur karzinogenit\xc3\xa4t mit zinkacetat-dihydrat durchgef\xc3\xbchrt .',b'no conventional carcinogenicity studies have been performed with zinc acetate dihydrate .',b'no conventional carcinogenicity studies have been performed with zinc acetate dihydrate .',b'no conventional carcinogenicity studies have been performed with zinc acetate dihydrate .'
2268,b'stillzeit es gibt nur unzureichende / eingeschr\xc3\xa4nkte informationen zur exkretion von dasatinib in die muttermilch von menschen und tieren .',b'lactation there is insufficient / limited information on the excretion of dasatinib in the milk of humans and animals .',b'lactation . there is insufficient limited information on the excretion of dasatinib in the milk of humans and animals .',b'lactation : there is insufficient / limited information on the excretion of dasatinib in the milk of humans and animals .'
2269,"b'enth\xc3\xa4lt neben anderen substanzen methyl-4-hydroxybenzoat ( e 218 ) , propyl-4-hydroxybenzoat ( e 216 ) , sorbitol ( e 420 ) .'","b'contains methylparahydroxybenzoate substances methyl parahydroxybenzoate ( e218 ) , propyl parahydroxybenzoate ( e 216 ) , sorbitol ( e420 ) .'","b'contains acute cartridges methyl polyethylene e , methyl parahydroxybenzoate e , which methyl parahydroxybenzoate e , propyl parahydroxybenzoate e , propyl parahydroxybenzoate e , mouth e .'","b'contains , amoung other substances , methyl parahydroxybenzoate ( e218 ) , propyl parahydroxybenzoate ( e 216 ) , sorbitol ( e420 ) .'"
2270,"b'es wird empfohlen , ein geschlossenes mehrdosen-impfpistolensystem zu verwenden .'",b'it is recommended to use a growth mehrdosen-impfpistolensystem .',b'it is recommended to use a growth increment .',b'it is recommended to use a closed multiple-dose injection system .'
2271,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und auf dem etikett des pens angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and on the label of the pen .',b'do not use after the expiry date which is stated on the carton and on the label of the pen .',b'do not use after the expiry date which is stated on the carton and on the label of the pen .'
2272,b'm\xc3\xa4rz 2008 wieder in gang gesetzt . am 14. mai 2008 wurde die uhr erneut angehalten und am 6.',b'march 2008 a on 14 may 2008 and the clock was re- started and on 6 .',b'march . the intravitreale formation is the resources medium and on .',b'initiated in march 2008 . on the 14 may 2008 and the clock was re- started and on 6 .'
2273,b'innerhalb jeder h\xc3\xa4ufigkeitsgruppe werden die nebenwirkungen nach abnehmendem schweregrad angegeben .',"b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'","b'within use the injection procedure , undesirable effects are presented in order to omeprazole seriousness .'","b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'"
2274,b'voriconazol erh\xc3\xb6hte die cmax und auc von diclofenac ( 50 mg einzeldosis ) um 114 % bzw. 78 % .',"b'voriconazole increased cmax and auc of diclofenac ( 50 mg single dose ) by 114 % and 78 % , respectively .'","b'voriconazole increased cmax and auc of mutagenic mg single dose by and , respectively .'","b'voriconazole increased cmax and auc of diclofenac ( 50 mg single dose ) by 114 % and 78 % , respectively .'"
2275,b'40 \xc3\x9cbliche dosis f\xc3\xbcr erwachsene die \xc3\xbcbliche dosis f\xc3\xbcr erwachsene ist 20 mg bei jeder infusion oder injektion .',b'40 the usual adult dose the usual dose for adults is 20 mg for infusion or injection .',b'the usual adult the oral dose of approximately daily the usual dose dose is reported for adults is mg between the powder .',b'40 the usual adult dose : the usual dose for adults is 20 mg for infusion or injection .'
2276,"b'wurde eine dosis aufgrund einer toxizit\xc3\xa4t reduziert , wird eine dosiseskalation in den nachfolgenden zyklen nicht empfohlen .'","b'if a dose is reduced due to toxicity , dose escalation for subsequent cycles is not recommended .'","b'if a dose is administered due to imiquimod , sildenafil should be longer .'","b'if a dose is reduced due to toxicity , dose escalation for subsequent cycles is not recommended .'"
2277,"b'( au\xc3\x9fer alopezie , \xc3\x9cbelkeit , erbrechen ) ctc grad 3 a :'","b'( except for alopecia , nausea , vomiting ) ctc grade 3 a :'","b'when no magnesium , nausea , vomiting phenotype grade a'","b'( except for alopecia , nausea , vomiting ) ctc grade 3 a :'"
2278,b'diese patienten sollten lamivudin und zidovudin als getrennte formulierungen einnehmen entsprechend den dosierungsempfehlungen f\xc3\xbcr diese arzneimittel .',b'these patients should receive lamivudine and zidovudine are taking formulations according to the dose recommendations for these medicinal products .',b'these patients should receive lamivudine and zidovudine acetylsalicylic doses with a transplantation or erythropoietin receiveing dose duration for these medicinal products .',b'these patients should receive lamivudine and zidovudine as separate formulations according to the dose recommendations for these medicinal products .'
2279,"b'die mittleren steady-state-trough-konzentrationen betrugen ca. 25 \xce\xbc g / ml , und die mittleren cmax-konzentrationen lagen bei ca. 290 \xce\xbc g / ml .'","b'the mean steady-state-trough-konzentrationen were approximately 25 \xce\xbc g / ml and the mean cmax-konzentrationen were approximately 290 \xce\xbc g / ml , respectively .'",b'the mean similarities were in week weekly ml and the mean residence were approximately g ml .',"b'the mean steady-state-trough-concentrations were approximately 25 \xce\xbc g / ml and the mean cmax-concentrations were approximately 290 \xce\xbc g / ml , respectively .'"
2280,"b'olanzapin kann unabh\xc3\xa4ngig von den mahlzeiten eingenommen werden , da die resorption durch die nahrung 2 nicht beeinflu\xc3\x9ft wird .'",b'olanzapine can be given without regards for meals as absorption is not affected by food ( 2 ) .',b'olanzapine can be given without regards for meals as absorption is not affected by food .',b'olanzapine can be given without regards for meals as absorption is not affected by food .'
2281,"b'in diesen f\xc3\xa4llen ist m\xc3\xb6glicherweise eine unterbrechung der therapie erforderlich . 20 treten w\xc3\xa4hrend oder nach der behandlung mit cefuroximaxetil schwere durchf\xc3\xa4lle auf , ist die m\xc3\xb6glichkeit einer pseudomembran\xc3\xb6sen kolitis in betracht zu ziehen , die lebensbedrohlich sein kann .'","b'in these cases , may be given to interrupting treatment is required . in patients who develop during or after treatment with cefuroximaxetil who develop severe diarrhoea , the possibility of pseudomembranous colitis should be taken into account that can be life-threatening .'","b'in these cases , may be given during women who develop potential treatment are also to revised contraception during or after treatment with gx who if your diarrhoea , the insulin burden and pregnancy contraception during or after anaesthesia with a patients . year , the prevalence of gloves .'","b'in these cases , an interruption of the treatment may be required . severe diarrhoea occurred during or after the treatment with cefuroximaxetil , the possibility of pseudomembranous colitis should be taken into account , which can be life-threatening .'"
2282,"b'die mittlere wiedergewinnungsrate von 2-amino-5,6-dichloro-3,4-dihydroquinazolin im urin betr\xc3\xa4gt ca. 18-35 % der verabreichten dosis .'","b'the mean was derived from the 2-amino-5,6-dichloro-3,4-dihydroquinazolin in urine is approximately helicase % of the administered dose .'","b'the mean was micro absorbed , mumps , destroy therapeutic doses with greater aberrations with ovulation by embryofoetal in urine is approximately kilodaltons by size is approximately pharmakokinetic at serum vaccination rate of the administered dose .'","b'the mean recovery rate of the 2-amino-5 , 6-dichloro-3 , 4-dihydroquinazolin in urine is approximately 18-35 % of the administered dose .'"
2283,b'bei diesen patienten ist die dosistitration unter ber\xc3\xbccksichtigung einer gleichzeitig vorliegenden nierenfunktionsst\xc3\xb6rung mit besonderer vorsicht durchzuf\xc3\xbchren .',"b'in these patients , the dose titration should be performed considering co-existing renal impairment should be performed with caution .'","b'no patients , the solution persist should be performed under aseptisches renal impairment .'","b'in these patients , the dose titration should be performed with particular caution considering co-existing renal impairment .'"
2284,b'einstellbarer 30 ml-mehrdoseninjektor aus polyethylen hoher dichte ( wei\xc3\x9f ) und niedriger dichte ( wei\xc3\x9f und transparent ) . der injektor ist f\xc3\xbcr mehrfachdosierungen vorgesehen .',b'30 ml-mehrdoseninjektor cyclohexanecarbaldehyde o-methyloxime ( white ) and polyethylene ( white and alkylsulfanyl ) . the pen is intended for multiple dosing .',b'bicalutamide hydroxybenzoyl laminated megacolon from and zinc white and the with is a mixture is intended about multiple dosing .',b'adjustable 30 ml-mutiple injector from polyethylene higher density ( white ) and lower density ( white and transparent ) . the pen is intended for multiple dosing .'
2285,b'bei der parkinson-krankheit im fortgeschrittenen stadium wurde neupro in zwei studien mit insgesamt 842 patienten untersucht .',"b""in parkinson 's disease , advanced stages of neupro was evaluated in two studies involving a total of 10 patients .""",b'in stages with neutropenia was evaluated in two studies involving a total of patients .',"b""in parkinson 's disease , advanced stages of neupro was evaluated in two studies involving a total of 10 patients ."""
2286,"b'el zusammenhang auftretende komplikationen ( krampanf\xc3\xa4lle , schlaganfall ) zu vermeiden .'","b'related complications ( krampanf\xc3\xa4lle , stroke ) should be avoided .'","b'abraxane complications haemoptysis , stroke does not subsided .'","b'related complications ( cramping episodes , stroke ) should be avoided .'"
2287,b'deutschland befasste am 29.',b'germany referred the diseases ) on 29 december 2000 .',b'germany from april about the occurrence on december .',b'germany on 29 december 2000 .'
2288,b'neulasta wird zur verk\xc3\xbcrzung der dauer von neutropenie und zur verminderung des auftretens febriler neutropenie ( neutropenie mit fieber ) angewendet .',b'neulasta is used to reduce the duration of neutropenia and the occurrence of febrile neutropenia ( neutropenia with fever ) .',b'neulasta is used to reduce the duration of neutropenia and the occurrence of febrile metabolic neutropenia with signs of telithromycin mediated common very fever .',b'neulasta is used to reduce the duration of neutropenia and the occurrence of febrile neutropenia ( neutropenia with fever ) .'
2289,"b'19 \xc3\x9cber die vorstehenden daten hinaus besteht das risiko einer schnellen resistenzentwicklung gegen nnrtis , falls die virologische therapie fehlschl\xc3\xa4gt .'","b'19 in addition to the data , there exists a risk of rapid emergence of resistance to nnrtis in case of virological failure .'","b'in addition to the data , there exists a risk of rapid contained of foetuses ec .'","b'19 in addition to the data , there exists a risk of rapid emergence of resistance to nnrtis in case of virological failure .'"
2290,"b'vorsicht ist besonders geboten bei der behandlung von \xc3\xa4lteren patienten , weil bei diesen ein erh\xc3\xb6htes risiko f\xc3\xbcr herzerkrankungen bestehen kann oder wenn lacosamid in kombination mit pr- verl\xc3\xa4ngernden arzneimitteln angewendet wird .'","b'caution should be exercised especially in the elderly , because of an increased risk of heart disease , which may last or if lacosamide in combination with pr- an additive medicinal products .'",b'caution should be exercised especially in the elderly the elderly .',"b'caution should be exercised especially in the elderly , because of an increased risk of heart disease , which may last or if lacosamide is used in combination with pr extending additive medicinal products .'"
2291,"b'wenn m\xc3\xb6glich , sollte eine kalibrierte spritze zur dosierung verwendet werden .'","b'if possible , a syringe for dose should be used .'","b'if possible injections , a vial containing fructose insulin medicine .'","b'if possible , a syringe for dose should be used .'"
2292,b'diese fragenliste wurde dem inhaber der genehmigung f\xc3\xbcr das inverkehrbringen \xc3\xbcbermittelt .',b'this list was the marketing authorisation holder and the marketing authorisation .',b'this list was the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing authorisation holder and the marketing',b'this list of questions was forwarded by the marketing authorisation holder .'
2293,"b'dies geschieht vor beginn der behandlung mit extavia , regelm\xc3\xa4\xc3\x9fig nach behandlungsbeginn und in abst\xc3\xa4nden w\xc3\xa4hrend der behandlung , auch wenn sie keine besonderen symptome haben .'","b'this will be done before initiation of treatment with extavia , regularly after initiation of treatment and periodically during treatment , even if you have no special symptoms .'","b'this will be done before initiation of treatment with extavia , regularly after initiation of treatment and periodically during treatment , even drive the treatment .'","b'this will be done before initiation of treatment with extavia , regularly after initiation of treatment and periodically during treatment , even if you have no special symptoms .'"
2294,"b'keppra darf nicht w\xc3\xa4hrend der schwangerschaft verwendet werden , es sei denn , dies ist eindeutig erforderlich .'",b'keppra should not be used during pregnancy unless it is clearly necessary .',b'keppra should not be used during pregnancy unless it is clearly necessary .',b'keppra should not be used during pregnancy unless it is clearly necessary .'
2295,"b'folgende weitere nebenwirkungen wurden mit exelon transdermalen pflastern beobachtet : angstgef\xc3\xbchle , delir , fieber ( h\xc3\xa4ufig ) .'","b'additional side effects that have been reported with exelon transdermal patches : anxiety , delirium , pyrexia ( common ) .'",b'additional side effects zimulti from any by administration of it is determined with exelon transdermal patches not turn with spotting strain to cyslt disorders',"b'additional side effects that have been reported with exelon transdermal patches : anxiety , delirium , pyrexia ( common ) .'"
2296,b'f\xc3\xbcr anweisungen zur rekonstitution vor der anwendung siehe abschnitt 6.6 .',"b'for instructions on reconstitution prior to administration , see section 6.6 .'","b'for instructions on reconstitution prior to administration , see section . .'","b'for instructions on reconstitution prior to administration , see section 6.6 .'"
2297,b'- die transdermalen pflaster bis zur anwendung im beutel aufbewahren .',b'- the transdermal patch in the sachet until use .',b'the concentration patch in the sachet until use .',b'- store the transdermal patch in the sachet until use .'
2298,b'entacapon erh\xc3\xb6ht die bioverf\xc3\xbcgbarkeit von levodopa aus standardkombinationen von levodopa mit benserazid geringf\xc3\xbcgig st\xc3\xa4rker ( 5-10 % ) als aus standardkombinationen von levodopa mit carbidopa .',b'entacapone increases the bioavailability of levodopa from standard levodopa / benserazide preparations slightly ( 5-10 % ) more than from standard levodopa / carbidopa preparations .',b'entacapone led between appetite levodopa oglucuronid wheat micro hydrolysis slightly more than from chop levodopa blister by studies is excreted as feboxustat antagonists and a benzisoxazolderivat of e expiratory provides human amlodipine by pregabalin or absorption therapy .',b'entacapone increases the bioavailability of levodopa from standard levodopa / benserazide combinations slightly ( 5-10 % ) more than from standard levodopa / carbidopa combinations .'
2299,"b'falls sie fragen oder probleme mit ihrem kwikpen haben sollten , wenden sie sich bitte an ihren arzt .'","b'if you have any questions or problems with your kwikpen , ask your doctor .'","b'if you have any questions or problems with your kwikpen , ask your doctor .'","b'if you have any questions or problems with your kwikpen , ask your doctor .'"
2300,b'\xe2\x80\xa2 so machen sie es von anfang an richtig !',b'\xe2\x80\xa2 how to make it properly start !',b'how to make it properly start !',b'\xe2\x80\xa2 how to make it properly start !'
2301,"b'die durchschnittliche fluoxetin konzentration ist bei kindern etwa 2- fach h\xc3\xb6her als bei jugendlichen . die durchschnittliche norfluoxetin konzentration ist 1,5-fach h\xc3\xb6her .'",b'the mean fluoxetine concentration in children is approximately 2- to 4-fold higher than in adolescents . the mean norfluoxetine concentration 1.5-fold higher .',b'the mean reasonably was a dose process in of animals . fold an minimal .',b'the mean fluoxetine concentration in children is approximately 2- to 4-fold higher than in adolescents . the mean norfluoxetine concentration 1.5-fold higher .'
2302,"b'verletzung und vergiftung gelegentlich : katheterbezogene komplikationen , schmerzen nach applikation , blutung nach applikation , brennen .'","b'injury and poisoning uncommon : katheterbezogene complications , post procedural pain , haemorrhage .'","b'injury and coagulation occasional complaints such or ovarian pains , haemorrhage and diseases'","b'injury and poisoning uncommon : catheter-related complications , post-procedural pain , post-procedural haemorrhage , burns .'"
2303,b'die empfohlene dosis von emend betr\xc3\xa4gt oral eine 125-mg-kapsel 1 stunde vor der durchf\xc3\xbchrung der chemotherapie an tag 1 sowie jeweils eine 80-mg-kapsel jeden morgen an den 2 aufeinanderfolgenden tagen nach der chemotherapie .',b'the recommended dose of emend is one 125 mg capsule 1 hour before you start your chemotherapy treatment on day 1 and one 80 mg capsule each morning for the 2 days following your chemotherapy treatment .',b'the recommended dose of emend is one mg capsule are one mg capsule hour before you start your chemotherapy treatment on day and one mg capsule vial with the days frequency of effect should be reached for the days following your chemotherapy treatment .',b'the recommended dose of emend is one 125 mg capsule 1 hour before you start your chemotherapy treatment on day 1 and one 80 mg capsule each morning for the 2 days following your chemotherapy treatment .'
2304,"b'lamivudin und zidovudin sind nukleosidanaloga , die aktivit\xc3\xa4t gegen hiv aufweisen .'","b'lamivudine and zidovudine , nucleoside analogues , anti-hiv activity .'","b'lamivudine and zidovudine , nucleoside analogues , crystalluria activity .'",b'lamivudine and zidovudine are nucleoside analogues which exhibit anti-hiv activity .'
2305,b'k\xc3\xbchl lagern und transportieren ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store and transport refrigerated ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store and transport refrigerated c c .',b'store and transport refrigerated ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
2306,"b'falls eine perkutane koronare intervention ( pci ) w\xc3\xa4hrend der integrilin-therapie durchgef\xc3\xbchrt wird , kann die intraven\xc3\xb6se infusion bis zu 96 stunden fortgesetzt werden .'","b'if a percutaneous coronary intervention ( pci ) during the integrilin-therapie , the intravenous infusion may be continued for up to 96 hours .'",b'if a certain degree diagnosis inhibitors during the sshaped substances for up to hours .',"b'if a percutaneous coronary intervention ( pci ) is carried out during the integrilin therapy , the intravenous infusion may be continued for up to 96 hours .'"
2307,"b'dieser t\xc3\xb6tet tumorzellen ab , indem er mit zellbestandteilen wie proteinen und dna reagiert und diese zerst\xc3\xb6rt .'","b'this kills the tumour cells , such as proteins and a keyway ( 42 ) and destroys them .'","b'this fits the tumour cells , such as proteins and a fixeddose and cells .'","b'this kills the tumour cells , by reacting with cell components like proteins and dna and destroying them .'"
2308,b'\xc3\x84ltere patienten \xe2\x89\xa5 65 jahre :',b'elderly patients ( \xe2\x89\xa5 65 years ) :',b'elderly patients years',b'elderly patients ( \xe2\x89\xa5 65 years ) :'
2309,"b'5 die zufriedenstellende spezifit\xc3\xa4t und empfindlichkeit wurde in klinischen studien nachgewiesen , in denen die atemluft anhand der isotopenverh\xc3\xa4ltnis-massenspektrometrie ( irms ) analysiert wurde .'",b'the specificity and sensitivity have been demonstrated in clinical trials investigating the detected by the isotopenverh\xc3\xa4ltnis-massenspektrometrie ( irms ) .',b'the specificity and sensitivity have been demonstrated in clinical trials spontanmeldesystem the bloodstream by the infectious growth of the formulae pgp .',b'5 the satisfactory specificity and sensitivity have been demonstrated in clinical trials investigating breathing air by reference of isotrope-ratio mass spectrometry ( irms ) .'
2310,b'die h\xc3\xa4ufigsten nebenwirkungen von kiovig ( beobachtet bei mehr als 1 von 10 patienten ) sind kopfschmerzen und pyrexie ( fieber ) .',b'the most common side effects with kiovig ( seen in more than 1 patient in 10 ) are headache and pyrexia ( fever ) .',b'the most common side effects with kiovig seen in more than patient in are headache and dyspepsia fever .',b'the most common side effects with kiovig ( seen in more than 1 patient in 10 ) are headache and pyrexia ( fever ) .'
2311,b'azomyr lyophilisat zum einnehmen wird ebenfalls angewendet zur beseitigung von mit urtikaria ( durch eine allergie hervorgerufener hautzustand ) zusammenh\xc3\xa4ngenden symptomen .',b'azomyr oral lyophilisate is also used to some other captured hautzustand symptoms associated with urticaria ( a skin condition caused by an allergy ) .',b'azomyr oral refludan is also used to some other form of very urticaria a skin condition caused by case effects produced by an allergy .',b'azomyr oral lyophilisate is also used for the elimination of symptoms associated with urticaria ( a skin condition caused by a skin condition caused by allergy ) .'
2312,b'die mpa-auc-werte waren in der fr\xc3\xbchen und sp\xc3\xa4ten posttransplantationsphase in allen altersgruppen \xc3\xa4hnlich .',b'the mpa auc values were seen in the early and late post-transplant period were similar in all age groups .',"b'the both extracellular was seen in the early tumour transfusions , to cetirizine parameter in all level groups .'",b'the mpa auc values in the early and late post-transplant period were similar in all age groups .'
2313,b'307 zur verwendung in einer insulinpumpe wird insulin human winthrop infusat in die sterile patrone der pumpe umgef\xc3\xbcllt .',b'307 for use in operating manuals for insulin human winthrop infusat is filled into the sterile cartridge of the pump reservoir .',b'for use in liquid us stability up to the sterile cartridge of the pump .',"b'307 for use in an insulin pump , insulin human winthrop infusat is transfered into the sterile cartridge of the pump reservoir .'"
2314,b'- eine ampulle mit l\xc3\xb6sungsmittel f\xc3\xbcr pegintron ( wasser f\xc3\xbcr injektionszwecke ) ;',b'- an ampoule of solvent for pegintron ( water for injections ) ;',b'an cartridge of solvent for pegintron water for injections',b'- an ampoule of solvent for pegintron ( water for injections ) ;'
2315,b'cymbalta kann unabh\xc3\xa4ngig von den mahlzeiten eingenommen werden .',b'cymbalta may be taken with or without a meal .',b'cymbalta may be taken with or without a meal .',b'cymbalta may be taken with or without a meal .'
2316,b'beim menschen besitzt metformin unabh\xc3\xa4ngig von seiner wirkung auf die glyk\xc3\xa4mie eine g\xc3\xbcnstige wirkung auf den lipidstoffwechsel .',"b'in humans , metformin has favourable effects on the effects on the glyk\xc3\xa4mie , a beneficial effect on lipid metabolism .'","b'in humans , metformin has inhibited effects on the stronger number was presented up between which corresponded in humans and an hama effect on significantly metabolism .'","b'in humans , metformin has favourable effects on lipid metabolism , regardless of its effect on he glycaemia .'"
2317,"b'patienten , die amiodaron anwenden , sollten ihren arzt oder apotheker fragen , bevor sie die behandlung mit alli beginnen .'","b'patients taking amiodarone , should consult a doctor or pharmacist before they start treatment with alli .'","b'patients taking weeks , careful administered contraception consult a doctor or pharmacist before they start treatment and alli .'","b'patients taking amiodarone , should consult a doctor or pharmacist before they start treatment with alli .'"
2318,"b'am studienende zeigten 7 von 12 patienten ( 58 % ) mit anf\xc3\xa4nglicher br\xc3\xbcckenfibrose oder zirrhose verbesserungen von \xe2\x89\xa5 2 punkten , entsprechend dem ishak- score .'","b'on the end of the study showed that 7 out of 12 patients ( 58 % ) and br\xc3\xbcckenfibrose or cirrhosis improvements of \xe2\x89\xa5 2 points , according to the ishak- score .'",b'tables of the study showed the consumers .',"b'at the end of the study 7 out of 12 patients ( 58 % ) showed improvements of \xe2\x89\xa5 2 points in initial liver fibrosis and cirrhosis , according to the ishak- score .'"
2319,b'haltbarkeit nach anbruch : 6 monate .',b'shelf-life after first opening the container : 6 months .',b'shelflife after first opening the regimen months .',b'shelf-life after first opening the container : 6 months .'
2320,"b'vor der ersten anwendung muss ihnen ihr arzt oder ihre diabetesberaterin erkl\xc3\xa4ren , wie sie byetta spritzen .'",b'before your doctor may need to give you your healthcare professional about how you inject byetta .',b'before your doctor may need to follow you must consider the healthcare material about how you inject byetta .',"b'before use , your doctor or your diabetes nurse may need to advise you how you inject byetta .'"
2321,"b'eine dosis von 0,5 ml enth\xc3\xa4lt :'",b'one dose of 0.5 ml contains :',b'one dose of . ml contains',b'one dose of 0.5 ml contains :'
2322,b'2. was m\xc3\xbcssen sie vor der anwendung von refacto af beachten ? 3.',b'before you use refacto af 3 .',b'before you use',b'what to observe before you use refacto af 3 .'
2323,"b'verwenden sie das gesamte l\xc3\xb6sungsmittel zur rekonstitution des betaferon-pulvers und injizieren sie die volle dosis von 1,0 ml .'",b'do not use the solvent for reconstitution for and inject the full dose 1.0 ml .',b'use preparing the docetaxel supplied of the contents of glass and inject the full dose . ml .',b'use the whole solvent for reconstitution of betaferon powder and inject the full dose of 1.0 ml .'
2324,b'einige f\xc3\xa4lle von milzrupturen verliefen t\xc3\xb6dlich .',b'some cases of splenic rupture have been fatal .',"b'some cases of splenic half , such or'",b'some cases of splenic rupture have been fatal .'
2325,b'best\xc3\xa4tigung durch wiederholungstest ; bei best\xc3\xa4tigung behandlung abbrechen und mindestens alle zwei wochen die leberfunktion \xc3\xbcberpr\xc3\xbcfen .',b'confirm levels of treatment in patients with confirmation of at least every 2 weeks to check liver function .',b'k levels of treatment and extend adjusted treatment in least every weeks to stopped dose function .',b'confirmation through repeat tests ; discontinue treatment upon confirmation and check the liver at least every two weeks .'
2326,b'bei einer kreatinin-clearance von weniger als 30 ml / min betr\xc3\xa4gt die empfohlene dosis 50 mg einmal w\xc3\xb6chentlich .',"b'in a creatinine clearance of less than 30 ml / min , the recommended dose is 50 mg once weekly .'","b'when a creatinine clearance of less than ml min , the recommended dose is mg once weekly .'","b'in a creatinine clearance of less than 30 ml / min , the recommended dose is 50 mg once weekly .'"
2327,b'- patienten mit einem schlaganfall w\xc3\xa4hrend der vorangegangenen 6 monate .',b'- patients with a stroke within the last 6 months .',b'patients with a stroke within the last months .',b'- patients with a stroke within the last 6 months .'
2328,b'eine augensalbe bzw. ein augengel ist stets als letztes einzubringen .',b'a nutrient and / or anti-parasitic is augengel is always used .',b'from an elimination of application and cardiac hormonal reduction over the fluids is recommended is cystagon only entacapone is still removed .',b'a nutrient and / or anti-parasitic is augengel is always used .'
2329,"b'entfernen sie nicht den grauen stopfen oder den aluminiumring , der sich rund um den oberen teil der durchstechflasche befindet ( siehe abb . 1 ) .'",b'do not remove the grey stopper or aluminium ring around the top of the vial ( see diagram 1 ) .',b'take the white stopper or bottles of the vial see diagram .',b'do not remove the grey stopper or aluminium ring around the top of the vial ( see diagram 1 ) .'
2330,b'hinweise zur herstellung der gebrauchsfertigen l\xc3\xb6sung siehe abschnitt 6.6 .',"b'instructions for reconstitution , see section 6.6 .'","b'instructions for reconstitution , see section . .'","b'instructions for reconstitution , see section 6.6 .'"
2331,"b'f\xc3\xbcr die gesundheit ihres kindes ist es wichtig , dass ihre blutzuckerwerte besonders sorgf\xc3\xa4ltig \xc3\xbcberwacht und unterzuckerungen ( hypoglyk\xc3\xa4mien ) vermieden werden .'","b'for the health of the child , it is important that your careful control of low blood sugar ( hypoglycaemia ) should be avoided .'","b'for out of the effect , it is important that your careful control of low blood sugar hypoglycaemia should be avoided .'","b'for the health of the child , it is important that your careful control of low blood sugar ( hypoglycaemia ) should be avoided .'"
2332,b'500 ml impfstoff in hdle - ( hohe dichte polyethylen ) flaschen mit nitril-gummistopfen und aluminiumkappe .',b'500 ml hdle vaccine ( a ) polyethylene bottles with nitril-gummistopfen and sealed with a coded aluminium cap .',b'ml shell vaccine a flat blue aluminiumtube with fibrinogen sodiumcontaining t analogues .',b'500 ml hdle vaccine ( a ) polyethylene bottles with nitrile rubber stoppers and sealed with an aluminium cap .'
2333,"b'weiterhin haben in-vitro-studien gezeigt , dass die polymorphen enzyme cyp2c9 , cyp2d6 und cyp2c19 nur unwesentlich zum metabolismus von maraviroc beitragen .'","b'in addition , in vitro studies have shown that the enzymes cyp2c9 , cyp2d6 and cyp2c19 only negligible and to contribute to the metabolism of maraviroc .'","b'in addition , this studies have shown that the enzymes cypc after fever studies with to those form scheme were well during the metabolism of rifampicin .'","b'in addition , in vitro studies have shown that the enzymes cyp2c9 , cyp2d6 and cyp2c19 contribute negligably to the metabolism of maraviroc .'"
2334,b'30 stillzeit ( siehe abschnitt 4.3 ) telmisartan ist in der stillzeit kontraindiziert .',"b'lactation ( see section 4.3 ) , telmisartan is contraindicated during breast-feeding .'","b'lactation see section . , telmisartan is contraindicated during breastfeeding .'",b'lactation ( see section 4.3 ) : telmisartan is contraindicated during breast-feeding .'
2335,"b'ferner legte das unternehmen die ergebnisse einer weiteren studie vor , in der valdoxan mit sertralin ( einem anderen antidepressivum ) verglichen wurde .'",b'the company also presented the results of a further study comparing valdoxan with sertraline ( another antidepressant ) .',b'the company also presented the results of a further study nca with sertraline another antidepressant .',b'the company also presented the results of a further study comparing valdoxan with sertraline ( another antidepressant ) .'
2336,"b'wenn sie versehentlich vergessen haben , die t\xc3\xa4gliche dosis einzunehmen , sollten sie die behandlung wie verordnet fortsetzen .'","b'if you accidentally miss a daily dose , just take the next dose as normal .'","b'if you accidentally miss a daily dose , just take the next dose as normal .'","b'if you accidentally miss a daily dose , just take the next dose as normal .'"
2337,b'in den placebokontrollierten zulassungsstudien wurde kein vermehrtes auftreten von tuberkulose beobachtet .',b'in the pivotal placebo-controlled studies was no increased incidence of tuberculosis have been observed .',b'in the pivotal study was no increased incidence of tuberculosis has been observed .',"b'in the pivotal placebo-controlled studies , no increased incidence of tuberculosis have been observed .'"
2338,"b'sprimeo beeinflusste nicht die serum-kreatinin- konzentration , war aber mit einer zunahme der h\xc3\xa4ufigkeit ( 4,2 % gegen\xc3\xbcber .'","b'sprimeo did not affect serum-kreatinin- concentrations , but was associated with an increased frequency ( 4.2 % vs.'","b'sprimeo did not affect fullterm ritonavir targeted , but was associated with an increased frequency . vs .'","b'sprimeo did not affect serum creatinine concentrations , but was associated with an increased frequency ( 4.2 % vs.'"
2339,b'kein einzelverkauf einzelner packungen .',b'no einzelverkauf single packs .',b'no sulfuric repeated packs .',b'not for individual sale .'
2340,"b'der haupteinwand bez\xc3\xbcglich der identifikation der patientenpopulation , insbesondere derjenigen patienten , die auf inhalative kortikoide allein ansprechen w\xc3\xbcrden , war nicht ausreichend ber\xc3\xbccksichtigt worden .'","b'the haupteinwand regarding the patient population , the proportion of patients that would be inhaled corticosteroids alone do not respond to adequately was not taken into account .'","b'the choice regarding the increased colorectal ovarian cancer exposure after at account slightly ace nonelderly where use after the tuberculosis dasatinib , viraferon clearance .'","b'the main objection regarding the identification of the patient population , especially those patients twho responded to inhaled corticosteroids alone , was not adequately taken into account .'"
2341,"b'ibraxion wird verwendet zur immunisierung von rindern zur verminderung der klinischen symptome von ibr und zur reduzierung der ausscheidung von feldvirus ( viren , die vom tier ausgeschieden werden ) .'",b'ibraxion is used to vaccinate cattle to reduce the clinical signs of ibr and to reduce the excretion of viruses that crowding is excreted by the dog ) .',b'ibraxion is used to vaccinate cattle to induce the clinical signs of frequencies and to reduce their treatment of viruses that conventional is excreted by the user group .',b'ibraxion is used to vaccinate cattle to reduce the clinical signs of ibr and to reduce the excretion of field viruses ( viruses excreted by the animal ) .'
2342,"b'in den wechseljahren produzieren die eierst\xc3\xb6cke keine weiblichen hormone , \xc3\x96strogen , mehr , die helfen , das skelett von frauen gesund zu erhalten .'","b""at the menopause , the ovaries stop producing the female hormone , oestrogen , which helps 's skeleton a woman .""","b'for a evaluation that a medicinal of investigating the controlled the ovaries higher chromosomal metabolised the female hormone , stiripentol , which helps s incidence of sulphonamide syndrome in together the placebo has with omeprazole , which helps s turned a diet .'","b""at the menopause , the ovaries stop producing the female hormone , oestrogen , which helps 's skeleton a woman ."""
2343,b'pimecrolimus bindet mit hoher affinit\xc3\xa4t an macrophilin-12 und inhibiert die kalzium-abh\xc3\xa4ngige phosphatase calcineurin .',"b'pimecrolimus binds with high affinity macrophilin-12 and inhibits the kalzium-abh\xc3\xa4ngige , rectum , respectively .'","b'hydrochloric monoclonal beta weights with high affinity hudson , which express , thr agent and the mannose thrombin , erythropoesisstimulating .'",b'pimecrolimus binds with a high affinity to macrophiline-12 and inhibits the calcium dependant phosphate calcineurin .'
2344,b'zubereitungs- und anwendungsanleitung siehe zusammenfassung der merkmale des arzneimittels von yttrium-90 .',"b'zubereitungs- and anwendungsanleitung , see the summary of product characteristics of yttrium ( 90y ) .'",b'unlike and added to the summary of product characteristics of y bioactivity .',"b'guide for preparation and use , see the summary of product characteristics of yttrium ( 90y ) .'"
2345,b'opatanol wird bei erwachsenen und kindern ab drei jahren angewendet .',b'opatanol is used in adults and children aged three years and older .',b'opatanol is used for optruma is hypersensitive aged three years and older .',b'opatanol is used in adults and children aged three years and older .'
2346,"b'wenden sie aranesp nicht an , wenn sie den eindruck haben , dass es gefroren war .'",b'do not use aranesp if you think it has been frozen .',b'do not use aranesp if you think it has been frozen .',b'do not use aranesp if you think it has been frozen .'
2347,b'timolol wird nicht vollst\xc3\xa4ndig dialysiert .',b'timolol is not fully dialysed .',b'timolol is not fully intake .',b'timolol is not fully dialysed .'
2348,b'vor dem sch\xc3\xbctteln kann gardasil m\xc3\xb6glicherweise als klare fl\xc3\xbcssigkeit mit einem wei\xc3\x9fen niederschlag vorliegen .',"b'prior to agitation , gardasil may be explained as a clear liquid with a white precipitate .'","b'prior to soon , gardasil may be explained as a clear liquid with a white energy with a white amounts in the position before a white turbid liquid with a white if you can be easier to stick the pack agent as flash through radiation .'","b'prior to agitation , gardasil may be explained as a clear liquid with a white deposit .'"
2349,b'daher ist ivabradin w\xc3\xa4hrend der schwangerschaft kontraindiziert .',"b'therefore , ivabradine is contraindicated during pregnancy .'","b'therefore , ivabradine is contraindicated during pregnancy .'","b'therefore , ivabradine is contraindicated during pregnancy .'"
2350,b'die folgenden indikationen sind gerechtfertigt :',b'the following indications have been justified :',b'the following indications is been more',b'the following indications have been justified :'
2351,"b'40 % der patienten mit knochenmarkbefall sprachen auf das medikament an , w\xc3\xa4hrend dies auf 59 % der patienten ohne knochenmarkbefall zutraf ( p = 0,0186 ) .'","b'40 % of patients with knochenmarkbefall responded to the medicine , whereas due to 59 % of the patients without knochenmarkbefall was observed ( p = 0,0186 ) .'","b'of patients with photoallergic suggests to the medicine , stiripentol due to of the patients without jaws was observed p , .'","b'40 % of patients with bone marrow attacls responded to the medicine , whereas this occured with 59 % of the patients without bone marrow attacks was observed ( p = 0,0186 ) .'"
2352,"b'symptome einer an\xc3\xa4mie und an\xc3\xa4mie-folgeerscheinungen k\xc3\xb6nnen abh\xc3\xa4ngig von alter , geschlecht und gesamtbelastung an erkrankungen unterschiedlich sein ; daher ist die beurteilung des individuellen klinischen verlaufs und krankheitszustands durch den arzt erforderlich .'","b""symptoms of anaemia and to avoid an\xc3\xa4mie-folgeerscheinungen may be depending on age , gender , and overall burden of disease ; evaluation of the individual patient 's clinical course and condition is necessary .""","b'symptoms of anaemia and to avoid tissue , gender , and protease burden of up for the individual patient s clinical states to enrolment as results with well as clinically responses at random , and progression , in whom their individual haemoglobin mechanism is necessary .'","b""symptoms of anaemia and to avoid consequences of anaemia may be different depending on age , gender , and overall burden of disease ; therefore , the evaluation of the individual patient 's clinical progress and state of disease by the doctor is required ."""
2353,b'so wird kentera angewendet :',b'how kentera is used :',b'how controls is used',b'how kentera is used :'
2354,"b'sollte es zu einer schweren peripheren neuropathie kommen , so hat zun\xc3\xa4chst eine abw\xc3\xa4gung des nutzen- risiko-verh\xc3\xa4ltnisses vor einer weiterbehandlung zu erfolgen .'",b'if a severe peripheral neuropathy may occur at the prescribed will first be given to balancing the benefit of risk with bacterial origin .',b'if a severe peripheral neuropathy may occur at the prescribed product to a case of a induction .',"b'if a severe peripheral neuropathy occurs , first an evalutation of the risk / benefit ratio will be given before futher treatment .'"
2355,"b'karvezide wird im allgemeinen von ihrem arzt verordnet werden , wenn eine vorausgegangene behandlung gegen hohen blutdruck nicht zu einer ausreichenden blutdrucksenkung gef\xc3\xbchrt hat .'",b'karvezide will usually be prescribed by your doctor when at least one prior treatment for high blood pressure does not provide appropriate blood pressure reduction .',"b'karvezide , an severe own by your doctor when at least one prior treatment for high blood pressure until every two the antiinflammatory dose pressure carefully experience increase treatment for high blood pressure see time received the methotrexate'",b'karvezide will usually be prescribed by your doctor when at least one prior treatment for high blood pressure does not provide appropriate blood pressure reduction .'
2356,"b'bei den patienten , die in dieses studienprogramm eingeschlossen wurden , lag zu studienbeginn eine vielzahl kardiovaskul\xc3\xa4rer und gastrointestinaler risikofaktoren vor .'",b'in those patients who were treated in this program was included a variety of cardiovascular and gastrointestinal risk factors at baseline .',b'reports patients who were treated in this unstable week at the effects of cardiovascular and gastrointestinal risk factors at the placebo .',"b'in those patients who were treated as part of this program , there was a variety of cardiovascular and gastrointestinal risk factors .'"
2357,"b'dieses radiopharmakon darf nur von dazu befugten personen in speziellen nuklearmedizinischen einrichtungen in empfang genommen , angewendet und verabreicht werden .'","b""this product should only be administered at taken individually in each peg ( 22 ' ) only by authorised persons in designated clinical settings and receipt , persons may be received , used and administered .""","b'the veterinary product should only be administered at taken individually in each anticancer only by didanosine gravis in immunosuppressed clinical tubules in chronic therapeutic anticoagulation , operate levels to outlined .'","b'this radiopharmacology should only be taken , applied and administered by authorised persons in designated nuclear medical settings .'"
2358,"b'die w\xc3\xa4hrend der langzeit- verl\xc3\xa4ngerungsstudien berichteten behandlungsbedingten ereignisse waren denen \xc3\xa4hnlich , die in den studien der phase 3 berichtet wurden ( siehe tabelle 1 ) .'",b'the long-term extension studies reported treatment-related events were similar to those that have been reported in the phase 3 studies ( see table 1 ) .',b'the longterm test risk study on toxicity were similar to those that have been reported in the package studies see table .',b'the treatment-related results from the long-term extension studies were similar to those that have been reported in the phase 3 studies ( see table 1 ) .'
2359,b'bondronat darf nicht mit calcium-haltigen l\xc3\xb6sungen gemischt werden .',b'bondronat should not be mixed with calcium-containing solutions .',b'bondronat should not be mixed with reichlichen solutions .',b'bondronat should not be mixed with calcium-containing solutions .'
2360,b'jede buccaltablette enth\xc3\xa4lt 400 mikrogramm fentanyl ( als citrat ) .',b'each buccal tablet contains 400 micrograms fentanyl ( as citrate ) .',b'each gonazon tablet contains micrograms fentanyl as citrate .',b'each buccal tablet contains 400 micrograms fentanyl ( as citrate ) .'
2361,"b'wann immer empfohlen , sollten risikokinder die mindestens 24 monate alt sind , die bereits mit prevenar geimpft wurden , den 23-valenten pneumokokken-polysaccharidimpfstoff erhalten .'","b'whenever recommended , should be risikokinder 24 months of age and already primed with prevenar received 23-valent pneumococcal pneumokokken-polysaccharidimpfstoff .'","b'lorazepam recommended , the class for age in order to show least stress therapy with prevenar .'","b'whenever recommended , children at risk should be at least 24 months old , already vaccinated with prevenar and have received 23-valent pneumococcal pneumokokken-polysaccharid vaccine .'"
2362,"b'es muss besondere vorsorge daf\xc3\xbcr getragen werden , eine schwangerschaft bei weiblichen patienten oder bei partnerinnen von m\xc3\xa4nnlichen patienten , die pegasys in kombination mit ribavirin erhalten , zu vermeiden .'",b'it must be special p1 is readily be taken to avoid pregnancy in female patients or in partners of male patients taking pegasys in combination with ribavirin .',"b'it must be boehringer p recommended levels should necessary , if necessary under toxicity patients taking pegasys in specialist discontinued for pegasys in patients of male patients with ribavirin .'",b'special care must be taken to avoid pregnancy in female patients or in partners of male patients taking pegasys in combination with ribavirin .'
2363,b'die verabreichung von tigecyclin als intraven\xc3\xb6se bolusinjektion wurde in tierstudien mit einer histaminreaktion in zusammenhang gebracht .',b'administration of tigecycline administered by intravenous bolus injection was established in animal studies with histaminreaktion .',b'rituximab a induction was established in animal studies with postmortem both dose or which wih secreation .',b'administration of tigecycline by intravenous bolus injection was established in animal studies with histaminreaktion .'
2364,"b'patienten , die mit ribavirin und zidovudin behandelt werden , haben ein erh\xc3\xb6htes risiko , eine an\xc3\xa4mie zu entwickeln . daher wird die gleichzeitige anwendung von ribavirin und zidovudin nicht empfohlen ( siehe abschnitt 4.5 ) .'",b'patients treated with ribavirin and zidovudine are at increased risk of developing anaemia and therefore the concomitant use of ribavirin with zidovudine is not recommended ( see section 4.5 ) .',"b'patients treated with ribavirin and zidovudine different ritonavir , no thyroid use of ribavirin were not recommended see section . .'",b'patients treated with ribavirin and zidovudine are at increased risk of developing anaemia and therefore the concomitant use of ribavirin with zidovudine is not recommended ( see section 4.5 ) .'
2365,b'wie wirkt betaferon ?',b'how does betaferon work ?',b'how does zyprexa work ?',b'how does betaferon work ?'
2366,b'riprazo sollte deshalb nicht zusammen mit grapefruitsaft eingenommen werden .',b'riprazo should not be taken with grapefruit juice .',b'riprazo should not be taken with grapefruit juice .',b'riprazo should not be taken with grapefruit juice .'
2367,b'2 wochen nach der grundimmunisierung .',b'2 weeks after the primary vaccination course .',b'weeks after the primary vaccination course .',b'2 weeks after the primary vaccination course .'
2368,"b'in f\xc3\xa4llen , in denen dosiserh\xc3\xb6hungen von 2,5 mg f\xc3\xbcr notwendig gehalten werden , sollten zyprexa filmtabletten angewendet werden .'","b'in cases where dose increases from 2.5 mg to monitor the medicine , zyprexa tablets should be used .'","b'in cases where dose increases from . mg to monitor the an medicine , zyprexa tablets should be used .'","b'in cases where dose increases from 2.5 mg are necessary , zyprexa tablets should be used .'"
2369,"b'die viren sind in einer umh\xc3\xbcllung enthalten , die von einer k\xc3\xb6dermatrix umgeben ist .'",b'the viruses are presented in a proportion of at least one k\xc3\xb6dermatrix .',b'the hn hormone is contains the evaluation is presented in a proportion of at least one mass .',"b'the viruses are contained in an cover , within a bait matrix .'"
2370,b'bei patienten mit kopfverletzungen kann der klinische verlauf durch den einsatz von opioiden verschleiert werden .',b'in patients with head injuries the clinical course can be attenuated by the use of opioids .',b'in patients with head together to four training protects as atorvastatin activates the use of opioids .',b'in patients with head injuries the clinical course can be attenuated by the use of opioids .'
2371,"b'patienten mit schwereren verlaufsformen der rheumatoiden eim arthritis und langj\xc3\xa4hrig bestehender erkrankung k\xc3\xb6nnen ein im vergleich zum durchschnitt erh\xc3\xb6htes risiko f\xc3\xbcr die entwicklung einer krebsform , die das lymphsystem betrifft , das sogenannte lymphom , aufweisen .'","b'people with more serious rheumatoid disease for a lon long time may have a higher than average risk of getting the development of cancer that affects the lymph system , called lymphoma .'","b'people with more serious rheumatoid disease for effected to an significantly than m , fatal host enzyme , appetite of bacterial effects , mumps and underactive potential roactemra in blood risk of other events .'","b'people with more serious forms of rheumatoid arthritis and have had it for years may have a higher than average risk of developing cancer that affects the lymph system , called lymphoma .'"
2372,b'das risiko einer \xc3\x9cbertragung der creutzfeld-jakob-krankheit ( cjd ) kann nicht ausgeschlossen werden .',"b'thus , the risk of transmission of creutzfeld-jacob disease ( cjd ) cannot be excluded .'","b'thus , the risk of heartworm disease tg act .'","b'thus , the risk of transmission of creutzfeld-jacob disease ( cjd ) cannot be excluded .'"
2373,"b'in laborversuchen mit metaflumizon bei ratten und / oder kaninchen wurden keine hinweise auf teratotoxische , fetotoxische oder maternal toxische effekte gefunden .'","b'laboratory studies with metaflumizone in rats and / or rabbits have not produced any evidence of teratogenic , foetotoxic or maternotoxic effects .'","b'laboratory studies with travoprost in rats and or rabbits identified in rats and or rabbits have not produced any evidence of teratogenic , foetotoxic or maternotoxic effects .'","b'laboratory studies with metaflumizone in rats and / or rabbits have not found any evidence of teratogenic , foetotoxic or maternotoxic effects .'"
2374,b'in einer studie mit 24 patienten im alter von 20 bis 87 jahren im fortgeschrittenen krankheitsstadium wurde die verl\xc3\xa4ngerung des qt-intervalls untersucht .',"b'in a study of 24 patients , aged 20 to 81 years of age in the advanced stage of the qt interval was investigated .'","b'in a study of patients , young clinical postnatal incidence of the qt interval was investigated .'",b'in a study of 24 patients aged 20 to 81 years of age in the advanced stage of the qt interval was investigated .'
2375,"b'packen sie die 21-g-nadel aus und stecken sie sie fest auf die spritze , deren schutzkappe sie vorher abgenommen haben .'","b'microprocessor the contents and place it firmly onto the tip of the syringe , remove you have been removed .'","b'do not give it firmly onto the tip of the syringe , remove you have been removed .'","b'unwrap the 21 gauge needle and place it firmly onto the syringe , after removing the protective tip .'"
2376,"b'z\xc3\xa4hlen sie langsam bis 10 , bevor sie die nadel herausziehen .'",b'count slowly to 10 seconds before removing the needle .',"b'between preparation , the humalog with gently swivelled should be flow before pressing the needle .'",b'count slowly to 10 seconds before removing the needle .'
2377,b'entfernen sie vor dem spritzen alle luftblasen ( siehe bedienungsanleitung des pens ) .',b'remove any air bubbles ( see instructions for using the pen ) .',b'remove any air bubbles comp for inserting hypersensitivity prepared .',b'remove any air bubbles ( see instructions for using the pen ) .'
2378,"b'stillzeit sie d\xc3\xbcrfen ranexa nicht einnehmen , wenn sie stillen .'",b'breast-feeding you should not take ranexa if you are breast-feeding .',b'waste . . you should not take ranexa to consider .',b'breast-feeding : you should not take ranexa if you are breast-feeding .'
2379,"b'nobilis or inac wird in form von zwei 0,25 ml-injektionen entweder unter die nackenhaut oder in den brustmuskel gespritzt .'",b'nobilis or inac is injected at 0.25 ml-injektionen either vaccination given by injection into the breast muscle .',b'nobilis or inac is injected by one resorbtion that three the breast muscle .',b'nobilis or inac is injected at 0.25 ml doeses either given by injection into the the neck or breast muscle .'
2380,b'200 zubereitungen zur mehrfachanwendung d\xc3\xbcrfen nur von ein und demselben patienten verwendet werden .',b'200 multidose manipulator should only be used for patients .',b'multidose manipulator should only be used for cancer .',b'200 preparation of the multidose manipulator may only be done by one single patient .'
2381,"b'um eine effektive tipranavir-plasmakonzentration mit einem zweimal t\xc3\xa4glichen dosierungsschema zu erreichen , ist eine zweimal t\xc3\xa4gliche anwendung von tipranavir in kombination mit niedrig dosiertem ritonavir unabdingbar ( siehe abschnitt 4.2 ) .'","b'in order to achieve a tipranavir-plasmakonzentration with a twice daily dosing schedule , twice daily administration of tipranavir , co-administered with low dose ritonavir , is vital ( see section 4.2 ) .'","b'in order to achieve instructions , a daily . in stable dose ritonavir and hemodialysis , orally training . received reduced daily administration of tipranavir , atorvastatin may be given daily administration of tipranavir is , a access with the glucuronidation schedule , twice daily administration of tipranavir , atorvastatin'","b'in order to achieve a tipranavir plasma concentration with a twice daily dosing schedule , a twice daily co-administration of tipranavir with low dose ritonavir is vital ( see section 4.2 ) .'"
2382,b'w\xc3\xa4hrend der gesamten studiendauer war die gleichzeitige einnahme anderer den knochenstoffwechsel beeinflussender medikamente erlaubt .',b'during the study period was the concomitant use of other in the bone remodelling beeinflussender permitted .',b'on the study should elapse the median versions of other cavity of ace throughout to investigating place .',"b'during the study period , the concomitant use of other in the bone remodelling influencing medication was permitted .'"
2383,b'ge\xc3\xb6ffnet & nach rekonstitution :',b'opened & after reconstitution :',b'hours after reconstitution prezista with room',b'opened & after reconstitution :'
2384,b'die muttermilch sollte innerhalb der ersten 24 stunden nach der thrombolytischen behandlung verworfen werden .',b'the breast milk should be discarded within the first 24 hours after thrombolytic therapy .',b'the breast milk should be discarded within the first hours after life therapy who are reached within the first hours after patients should be sotred within the first hours after muscles is left over within the household dose .',b'the breast milk should be discarded within the first 24 hours after thrombolytic therapy .'
2385,b'18 filgrastim ratiopharm enth\xc3\xa4lt keine konservierungsmittel .',b'18 filgrastim ratiopharm does not contain any preservative .',b'filgrastim ratiopharm does not contain any preservative .',b'18 filgrastim ratiopharm does not contain any preservative .'
2386,"b'b. acetylsalicyls\xc3\xa4ure ) , sulfonamide , bestimmte antidepressiva ( monoamin-oxidase inhibitoren ) , bestimmte ace-hemmer ( captopril , enalapril ) , angiotensin ii rezeptorblocker , beta-blocker , octreotid oder alkohol reduzieren .'","b'( e. g. acetylsalicylic acid ) , sulpha antibiotics , certain antidepressants ( monoamine oxidase inhibitors ) , certain angiotensin converting enzyme inhibitors ( captopril , enalapril ) , angiotensin ii receptor blockers , beta-blockers , octreotide , insulin or alcohol .'","b'e . g . acetylsalicylic acid , sell endophthalmitis see the respiratory enzyme receptor blockers , propyl , hypersensitivity , body ii body converting enzyme inhibitors .'","b'( e.g. acetylsalicylic acid ) , sulpha antibiotics , certain antidepressants ( monoamine oxidase inhibitors ) , certain angiotensin converting enzyme inhibitors ( captopril , enalapril ) , angiotensin ii receptor blockers , beta-blockers , octreotide , or alcohol .'"
2387,"b'wenn sie die einnahme von oracea vergessen haben nehmen sie nicht die doppelte dosis ein , wenn sie die vorherige einnahme einer kapsel vergessen haben .'",b'if you forget to take oracea do not take a double dose to make up for a forgotten capsule .',b'if you forget to take oracea .',b'if you forget to take oracea : do not take a double dose to make up for a forgotten capsule .'
2388,b'am 5. august 1998 erteilte die europ\xc3\xa4ische kommission eine genehmigung f\xc3\xbcr das inverkehrbringen von evista in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted a marketing the european union for evista on 5 august 1998 .',b'the european commission granted the european commission granted a marketing authorisation on august .',b'the european commission granted a marketing authorization in the whole european union for evista on 5 august 1998 .'
2389,"b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen es ist nicht zu erwarten , dass sich die anwendung von tysabri auf ihre verkehrst\xc3\xbcchtigkeit bzw.'",b'driving and using machines it is not expected that the use of tysabri to their ability .',b'driving and using machines it is not expected that the use of tysabri to their ability .',b'driving and using machines . it is not expected that the use of tysabri will effect your ability to drive .'
2390,"b'siehe abschnitt 5.1 f\xc3\xbcr informationen , die eine wirksamkeit von cervarix zur pr\xc3\xa4vention von mit hpv-16 und / oder hpv-18 assoziierten pr\xc3\xa4malignen l\xc3\xa4sionen der zervix unterst\xc3\xbctzen .'",b'see section 5.1 for information on the efficacy of cervarix in the prevention of associated with hpv-16 and / or hpv-18 are studied at the lesions .',b'see section . for information on the efficacy of cervarix in the prevention of associated with hpv and or hpv capsules compared with hpv and or hpv are studied at the treatment .',b'see section 5.1 for information supporting the efficacy of cervarix in the prevention of pre-malign cervical lesions associated with hpv-16 and / or hpv-18 .'
2391,b'nicht anwenden bei bekannter \xc3\x9cberempfindlichkeit gegen einen wirkstoff aus der klasse der phenylpyrazole oder gegen einen der sonstigen bestandteile .',"b'do not use in case of hypersensitivity to the active substances of the acaricide belonging to the phenylpyrazole class , or to any of the excipients .'",b'do not use in case of hypersensitivity to the active substances of the antiglobulin circulation by or to any of the excipients .',"b'do not use in case of hypersensitivity to the active substances of the belonging to the phenylpyrazole class , or to any of the excipients .'"
2392,"b'engegef\xc3\xbchl oder schmerzen in der brust zu reduzieren , die durch eine zu geringe menge von sauerstoff im herzmuskel ( angina pectoris ) verursacht werden .'","b'tightness or pain in the chest , too little oxygen in the heart muscle ( angina pectoris ) .'","b'leads to injection , uncommon operate , the heart muscle otitis blockers .'","b'tightness or pain in the chest , too little oxygen in the heart muscle ( angina pectoris ) .'"
2393,"b'\xe2\x80\xa0 es ist plausibel , dass die behandlung mit alli zu beklemmungen im hinblick auf m\xc3\xb6gliche bzw. tats\xc3\xa4chliche gastrointestinale nebenwirkungen f\xc3\xbchren kann .'",b'\xe2\x80\xa0 it is plausible that treatment with alli and anxiety with regard to the actual possible and may lead to gastrointestinal side effects .',b'it is neuropharmacological stalevo that treatment with alli and anxiety with corticosteroids should administer four dose effects .',b'\xe2\x80\xa0 it is plausible that treatment with alli can lead to anxiety with regard to possible or actual gastrointestinal side effects .'
2394,"b'schwere allergische / anaphylaktische reaktionen ( einschlie\xc3\x9flich bronchospasmus ) angio\xc3\xb6dem , nicht bekannt :'","b'severe allergic / anaphylactic reactions ( including bronchospasm ) , angioedema not known :'",b'severe allergic anaphylactic reactions including alphaadrenergic and loss effects in diseases with three milk .',"b'severe allergic / anaphylactic reactions ( including bronchospasms ) , angioedema not known :'"
2395,b'wie wird trisenox angewendet ?',b'how is trisenox used ?',b'how is thymanax used ?',b'how is trisenox used ?'
2396,b'nehmen sie die tabletten im ganzen mit wasser oder einem anderen getr\xc3\xa4nk ein .',b'swallow the tablets whole with water or another drink .',b'swallow the tablets whole with water or one solutions .',b'swallow the tablets whole with water or another drink .'
2397,"b'pegfilgrastim scheint haupts\xc3\xa4chlich \xc3\xbcber ug eine neutrophilen-vermittelte clearance eliminiert zu werden , welche bei h\xc3\xb6heren dosierungen eine s\xc3\xa4ttigung erreicht .'","b'pegfilgrastim appears to be mainly or over a neutrophilen-vermittelte clearance eliminated by the liver , which becomes saturated at higher doses .'",b'pegfilgrastim appears to be mainly or over a ifn clearance reached at higher doses .',"b'pegfilgrastim appears to be mainly eliminated by a neutrophilen-transmitted clearance , which becomes saturated at higher doses .'"
2398,b'besondere vorsicht muss patienten mit hohen basiswerten und lipidst\xc3\xb6rungen in der vorgeschichte gelten .',b'special caution must apply for patients with a history of high basiswerten with particular lipid disorders .',b'special caution must apply for patients with receiving of intervals of high naive should not be restarted with opioid metabolisers .',b'special caution must apply for patients with a history of high basic values and lipid with particular lipid disorders .'
2399,"b'die durchschnittliche gesamtk\xc3\xb6rper-clearance , die \xc3\xbcber vollblutkonzentrationen ermittelt wurde , betr\xc3\xa4gt bei gesunden probanden 2,25 l / h.'","b'the average total body clearance , has been determined , whole blood concentrations in healthy subjects is approximately 2.25 l / h .'","b'the average total body clearance , has been determined , insuman blood concentrations in healthy subjects is approximately . l .'",b'the average total body clearance has been determined by whole blood concentrations in healthy subjects and is approximately 2.25 l / h .'
2400,b'der harn sollte regelm\xc3\xa4\xc3\x9fig dahingehend untersucht werden .',b'the urine should be evaluated regularly sentences .',b'the corresponding hpv regularly than .',b'the urine should be examined regularly .'
2401,"b'wenn der zielblutdruck ( < 140 / 90 mmhg ) nicht erreicht wurde , wurde zun\xc3\xa4chst hydrochlorothiazid ( 12,5 mg ) zugegeben und dann gegebenenfalls die losartan- oder atenolol-dosis auf 100 mg einmal t\xc3\xa4glich erh\xc3\xb6ht .'","b'if the target blood pressure ( 140 / 90 mmhg ) has not been reached , was first of hydrochlorothiazide ( 12.5 mg ) , and then losartan or atenolol was increased to 100 mg once daily .'",b'if the target blood pressure mmhg has not been reached as firstly different and then losartan or atenolol was increased to mg once daily .',"b'if the target blood pressure ( 140 / 90 mmhg ) has not been reached , hydrochlorothiazide ( 12.5 mg ) was firstly given , and then losartan or atenolol was increased to 100 mg once daily if required .'"
2402,"b'wenn sie / ihr kind zu hinken beginnen / beginnt oder h\xc3\xbcft- oder knieschmerzen haben / hat , suchen sie bitte sofort den arzt auf .'","b'if you have / your child has a hinken starts start / or hip or at least 8 amino acids , you / your child , please talk to your doctor immediately .'",b'if you have your child has a mixture quickly start or hip or at least im is medical or lubricate bowel equivalent to your doctor immediately .',"b'if you have / your child starts / starteds to limp or have / had hip or knee pain , please talk to your doctor immediately .'"
2403,"b'die wirkungen von intelence wurden zun\xc3\xa4chst in versuchsmodellen getestet , bevor sie an menschen untersucht wurden .'",b'the effects of intelence were first tested in experimental models before being studied in three main studies involving .',b'the effects of intelence were first tested in experimental models before being studied in three main studies .',b'the effects of intelence were first tested in experimental models before being studied in humans .'
2404,b'43 andere unter plavix beobachtete nebenwirkungen sind :',b'other plavix reported side effects are :',b'pharmatherapeutic rc reported side effects reported common following following categories ?',b'other reported side effects under plavix :'
2405,"b'selten : synkope ( ohnmacht ) , vasodilatation ( hitzewallungen ) .'","b'rare : syncope ( fainting ) , vasodilation ( heat stress ) .'","b'rare major tumors , equilis heat caused .'","b'rare : syncope ( fainting ) , vasodilation ( heat stress ) .'"
2406,b'wie wurde cystagon untersucht ?',b'how has cystagon been studied ?',b'how has cystagon been studied ?',b'how has cystagon been studied ?'
2407,"b'29 andere arzneimittel k\xc3\xb6nnen manchmal verabreicht werden , w\xc3\xa4hrend sie noxafil einnehmen , dies bedarf jedoch unter umst\xc3\xa4nden besonderer beachtung .'","b'29 other medicines can sometimes be given while you are taking noxafil however , this special care may be needed .'","b'other medicines can sometimes be given while you is taking noxafil in contact with thymanax do not forget to take noxafil however , this special care may be needed .'","b'29 other medicines can sometimes be given while you are taking noxafil . however , special care may be needed .'"
2408,b'ein weiterer vorteil von montelukast ist die nichtbeeinflussung der wachstumsrate .',b'another benefit of montelukast is nichtbeeinflussung of growth rate .',b'new efficacy and ibafloxacin of montelukast is orion of coagulation values may proliferate well within an basic greater cancer or a reduction .',b'another benefit of montelukast is lack of interference of growth rate .'
2409,"b'es wird angeraten , fentanyl nicht w\xc3\xa4hrend der wehen und geburt ( und auch nicht bei einer sectio caesarea ) anzuwenden , da fentanyl plazentag\xc3\xa4ngig ist und beim fetus eine atemdepression hervorrufen kann .'","b'it is advised to fentanyl during labour and parturition ( and not in a blood vessel , most often device cannula 14 ) since fentanyl crosses the placenta and may cause the foetal respiratory depression .'",b'an rejection on caution as a plotted and be found driving and possibly infected from little and should cause the hit and fluid pain .',b'it is advised not to use fentanyl during labour and parturition ( also not during a caesarean section ) since fentanyl crosses the placenta and may cause the foetal respiratory depression .'
2410,b'das l\xc3\xb6sungsmittel ist auf raumtemperatur ( + 15 bis + 25 \xc2\xb0 c ) zu erw\xc3\xa4rmen .',b'the solvent to reach room temperature ( at + 15 to + 25 \xc2\xb0 c ) .',b'the solvent to reach infusion .',b'the solvent should be warmed to room temperature ( at + 15 to + 25 \xc2\xb0 c ) .'
2411,b'die orale bioverf\xc3\xbcgbarkeit von tenofovir aus tenofovirdisoproxilfumarat betrug nach einnahme im n\xc3\xbcchternzustand rund 25 % .',b'the oral bioavailability of tenofovir disoproxil fumarate was approximately 25 % after fasting .',b'the oral bioavailability of tenofovir disoproxil fumarate which approximately after the purple x body disoproxil fumarate was approximately after times .',b'the oral bioavailability of tenofovir disoproxil fumarate was approximately 25 % after fasting .'
2412,b'aus diesem grund ist nach der operation die at-aktivit\xc3\xa4t erneut zu bestimmen .',"b'for this reason , again after surgery in case the activity level .'","b'observe this reason , a patch within pregnant of nsaids plan .'","b'for this reason , the at activity should me determined once again .'"
2413,b'die \xc3\xbcbliche dosis betr\xc3\xa4gt zweimal w\xc3\xb6chentlich 25 mg oder einmal w\xc3\xb6chentlich 50 mg .',b'the usual dose is 25 mg twice a week or 50 mg once a week .',b'the usual dose is mg twice a week or mg once a week .',b'the usual dose is 25 mg twice a week or 50 mg once a week .'
2414,"b'dekompensierte herzinsuffizienz ( 2,3 % bei 70 monaten medianer nachbeobachtung ) wurde ebenfalls berichtet .'",b'decompensated congestive heart failure ( 2.3 % in 70 months median follow-up ) were also reported .',b'decompensated one kidney failure . in months the central area of the age of the antiviral study were also reported .',b'decompensated congestive heart failure ( 2.3 % in 70 months of median follow-up ) were also reported .'
2415,b'eine \xc3\x9cberwachung der therapeutischen konzentrationen von trizyklischen antidepressiva ( z. b. desipramin und nortryptilin ) wird bei gleichzeitiger gabe von telzir empfohlen ( siehe abschnitt 4.5 ) .',b'therapeutic concentration monitoring of tricyclic antidepressants ( e. g. desipramine and nortriptyline ) when co-administered with telzir ( see section 4.5 ) .',b'radioactive exposure diagnosis by up to an large vaccination which is required atorvastatin see section . .',b'monitoring of the therapeutic concentration of tricyclic antidepressants ( e. g. desipramine and nortriptyline ) when co-administered with telzir ( see section 4.5 ) .'
2416,"b'drehen sie die injektionsflasche samt spritze unmittelbar vor gabe der l\xc3\xb6sung um , so dass sich nun die spritze unten befindet .'","b'turn the flip-off cap from the vial pointing the syringe immediately before administration of the oral solution , the syringe is now below .'","b'turn the dispersing cap from the vial upside the syringe immediately before administration of the oral solution , the syringe is continued below .'","b'turn the injection bottle together with the needle immediately before administration of the solution , so that the syringe is now below .'"
2417,"b'xolair wurde in f\xc3\xbcnf hauptstudien mit 2299 patienten mit allergischem asthma untersucht , darunter eine studie an 482 patienten mit schwerem allergischem asthma , das mit herk\xc3\xb6mmlichen behandlungen nicht ausreichend unter kontrolle gebracht werden konnte .'","b'xolair has been studied in five main studies involving 2299 in patients with allergic asthma , including one study of 482 patients with severe asthma with conventional treatments for control of asthma .'",b'xolair has been studied in five main studies involving in patients with allergic and an first genotoxic and a placebo of asthma .',"b'xolair has been studied in five main studies involving 2299 patients with allergic asthma , including one study of 482 patients with severe asthma that could not be adequately controled with conventional treatments .'"
2418,"b'die behandlung wird so lange fortgesetzt , wie sie immunsuppressiva ben\xc3\xb6tigen , um sie vor einer absto\xc3\x9fung ihres transplantierten organes zu sch\xc3\xbctzen .'",b'the treatment will continue for as long as you need immunosuppression to prevent before your transplanted autologous prevails .',b'the treatment will continue for as long as you need immunosuppression to take realising medicines .',b'the treatment will continue for as long as you need immunosuppression to prevent rejection of your transplanted organ .'
2419,"b'die mediane spitzenplasmakonzentration von maraviroc wird bei gesunden probanden 2 stunden ( bereich : 0,5 bis 4 stunden ) nach oraler einmalgabe der handels\xc3\xbcblichen 300-mg-tablette erreicht .'",b'the median peak plasma concentration of maraviroc is 2 hours ( range of 0.5 to 4 hours in healthy volunteers ) following single oral doses of 300 mg tablet framework .',b'the median peak plasma concentration of maraviroc is hours range of . to hours in healthy volunteers following single oral administration of mg tablet below .',b'the median peak plasma concentration of maraviroc is 2 hours ( range of 0.5 to 4 hours in healthy volunteers ) following single oral doses of commercially available 300 mg tablets .'
2420,b'es k\xc3\xb6nnen also auch weiterhin andere infektionen oder andere mit einer hiv-infektion verbundene erkrankungen auftreten .',b'you may still develop other infections and other illnesses associated with hiv disease .',b'they may still to other infections and other illnesses associated with hiv disease different disease .',b'you may still develop other infections and other illnesses associated with hiv disease .'
2421,b'daher muss rebetol bei patienten mit vorbestehenden kardiovaskul\xc3\xa4ren erkrankungen mit vorsicht angewendet werden ( siehe abschnitt 4.3 ) .',"b'therefore , rebetol in patients with pre-existing cardiovascular disease should be used with caution ( see section 4.3 ) .'","b'therefore , hycamtin in patients with pulmonary cardiovascular disease should be used with caution see section . .'","b'therefore , rebetol should be used with caution in patients with pre-existing cardiovascular disease ( see section 4.3 ) .'"
2422,"b'wird novomix 30 subkutan verabreicht , tritt die wirkung innerhalb von 10 bis 20 minuten nach der injektion ein .'","b'when novomix 30 is injected subcutaneously , the onset of action will occur within 10 to 20 minutes of injection .'","b'when novomix is injected subcutaneously , the onset of action may be found within to minutes of injection .'","b'when novomix 30 is injected subcutaneously , the onset of action will occur within 10 to 20 minutes of injection .'"
2423,b'androgene k\xc3\xb6nnen die spiegel des thyroxin-bindenden globulins senken und zu einer abnahme der gesamt-t4-serumkonzentrationen sowie zu einer vermehrten t3- und t4-resin-aufnahme f\xc3\xbchren .',b'vitamin d may reduce the levels of the thyroxin-bindenden globulins and may lead to a decrease in gesamt-t4-serumkonzentrationen as well as an increased ) and at the t4-resin-aufnahme .',b'vitamin d may reduce the serumcalcium expiratory pointes und ion sunk to a decrease in valera as well as an increased rna .',b'androgens may reduce the levels of the thyroxin produced globulins and may lead to a decrease in the total t4-seum concentration as well as an increased amount of t3 and t4-resin .'
2424,"b'auf grund seiner pharmakodynamischen eigenschaften ist es 67 jedoch unwahrscheinlich , dass irbesartan hydrochlorothiazide bms diese f\xc3\xa4higkeit beeinflusst .'","b'based on its pharmacodynamic properties , irbesartan hydrochlorothiazide bms is unlikely to affect this ability , however .'","b'based on its pharmacodynamic properties , irbesartan hydrochlorothiazide bms is unlikely to affect this ability , however .'","b'based on its pharmacodynamic properties , irbesartan hydrochlorothiazide bms is unlikely to affect this ability , however .'"
2425,b'bei \xc3\xa4lteren patienten und bei patienten mit eingeschr\xc3\xa4nkter nierenfunktion ist die gabapentin-plasma- clearance herabgesetzt .',b'in elderly patients and in patients with impaired renal function is gabapentin-plasma- decreased clearance .',b'in elderly patients and in patients with impaired renal function is definied with ritonavir .',b'in elderly patients and in patients with impaired renal function the gabapentin plasma clearance was decreased .'
2426,b'dieses arzneimittel wird zur osteoporose-behandlung eingesetzt .',b'this medicine is used for .',b'this medicine is used for .',b'this medicine is used for treatment of osteoporosis .'
2427,"b'es ist au\xc3\x9fer- dem wichtig , dass sie ihrem behandelnden arzt mitteilen , wenn einer der nachfolgenden umst\xc3\xa4nde auf sie zutrifft .'",b'it is au\xc3\x9fer- the important that you tell your hiv doctor if any of the following conditions apply to you .',b'it is the important that you tell your hiv doctor if none of the following conditions apply to you .',b'it is also important that you tell your hiv doctor if any of the following conditions apply to you .'
2428,b'die neorecormon fertigspritze ist gebrauchsfertig .',b'the neorecormon pre-filled syringe is ready for use .',"b'the rapid with handling , the needles of application .'",b'the neorecormon pre-filled syringe is ready for use .'
2429,b'weitere antiretrovirale wirkstoffe : es liegen keine daten zur sicherheit und wirksamkeit von atripla in kombination mit anderen antiretroviralen wirkstoffen vor .',b'other antiretroviral agents : there are no data on the safety and efficacy of atripla in combination with other antiretroviral agents .',b'other frequent drug medicinal dose substances differ the safety and efficacy of atripla in combination with other antiretroviral agents .',b'other antiretroviral agents : there are no data on the safety and efficacy of atripla in combination with other antiretroviral agents .'
2430,"b'wirkungen anderer arzneimittel auf celecoxib bei personen , die cyp 2c9-langsammetabolisierer sind und eine erh\xc3\xb6hte systemische celecoxib- exposition aufweisen , k\xc3\xb6nnte die gleichzeitige behandlung mit cyp 2c9-hemmern zu einer weiteren erh\xc3\xb6hung der celecoxib-exposition f\xc3\xbchren .'","b'effects of other medicinal products on in individuals who are cyp2c9 poor metabolisers and increased systemic exposure to celecoxib exposure , the renin-angiotensin system , concomitant use of treatment with cyp2c9 result in further increases in inhibitors .'","b'effects of other medicinal products on mood have asymptomatic sodium significant respiratory ovarian kinase and increased systemic exposure to chemotherapy and increased systemic exposure to patientyears , greater greater extent from an alanine and increased systemic exposure to a increase within renal concentration and increased systemic exposure and increased systemic'","b'effects of other medicinal products on celecoxib . in individuals who are poor metabolisers of cyp2c9 and demonstrated an increased systemic exposure to celecoxib , concomitant treatment with cyp2c9 inhibitors can lead to a further increase in the celecoxib exposure .'"
2431,b'4. verhalten im notfall 5.',b'4 . keep this leaflet .',b'. keep this leaflet .',b'4 . keep this leaflet .'
2432,b'levetiracetam . \xe2\x80\xa2 die sonstigen bestandteile sind :',b'the active substance is called levetiracetam . \xe2\x80\xa2 the other ingredients are :',b'the active substance is bound of olanzapine capsules and .',b'the active substance is called levetiracetam . \xe2\x80\xa2 the other ingredients are :'
2433,b'ausschlag und allergische reaktionen :',b'rash and allergic reactions :',b'rash and allergic reactions',b'rash and allergic reactions :'
2434,b'bitte folgen sie den anweisungen ihres tierarztes sorgf\xc3\xa4ltig .',b'please follow the instructions of your veterinarian .',b'please follow the instructions of your veterinarian .',b'please follow the instructions of your veterinarian .'
2435,b'as geschult worden sind . spritzen sie sich niemals selbst nespo in eine vene .',b'ed trained . never inject nespo into a vein yourself .',b'ed intolerance with the reconstituted into a vein yourself .',b'ed trained . never inject nespo into a vein yourself .'
2436,"b'da aber die klinische erfahrung bei patienten mit begleiterkrankungen begrenzt ist , wird bei der verordnung f\xc3\xbcr patienten 34 mit prostatahypertrophie oder paralytischem ileus und damit zusammenh\xc3\xa4ngenden zust\xc3\xa4nden zur vorsicht geraten .'","b'however , as clinical experience with olanzapine in patients with concomitant illness is limited , patients with myeloma or paralytic ileus and patients with concomitant illness is limited , caution is advised when prescribing for .'","b'however , as clinical experience with olanzapine in patients with concomitant pah is limited , caution see hepatic that be available , caution is prescribed , caution is advised when or paralytic ileus and patients with concomitant illness is limited , caution is used is shown in tablets and withholding'","b'however , as clinical experience with olanzapine in patients with concomitant illness is limited , patients with myeloma or paralytic ileus and patients with concomitant illness is limited , caution is advised when prescribing for .'"
2437,"b'obgleich alle behandlungen eine \xc3\xa4quivalente auc von lansoprazol ergaben , ist anzumerken , dass die studien mit bestimmten marken der verschiedenen vehikel durchgef\xc3\xbchrt wurden .'","b'although all treatments have shown equivalent auc\xcf\x84 of lansoprazole , at this stage that the studies have been conducted with certain prepared by the transformant .'","b'although all blood sodium b change within auc of lansoprazole of lansoprazole , at this stage that the studies have been conducted with certain contrast by the kompatibilitatsstudien .'","b'although all treatments have shown equivalent auc of lansoprazole , it should be noted that the studies were conducted with certain brands of the different vehicles .'"
2438,"b'um die variabilit\xc3\xa4t beim einzelnen patienten zu minimieren , sollte die gabe von lapatinib in bezug auf die nahrungsaufnahme standardisiert werden , zum beispiel durch einnahme immer vor einer mahlzeit ( siehe abschnitte 4.5 und 5.2 zu informationen zur resorption ) .'","b'in order to minimise variability in the individual patient should be administered to 20 mg / kg of lapatinib in terms of food intake , for example , always taken before a meal ( see sections 4.5 and 5.2 on absorption ) .'",b'in order to minimise variability in the individual patient should be taken about flea in terms of food intake and . on absorption .',"b'in order to minimise variability in the individual patients , lapatinib administration should be standardised in regard to food intake , for example , always taken before a meal ( see sections 4.5 and 5.2 on absorption ) .'"
2439,"b'insuman comb 15 wird in patronen , fest verbunden mit patronenhaltern , angeboten ; sie bilden den auswechselbaren teil des insulinpens opticlik .'","b'insuman comb 15 comes in a cartridge sealed in a plastic container , which is the disposable part of opticlik , an insulin pen .'",b'insuman comb comes in a cartridge sealed in a gonalf pens .',b'insuman comb 15 comes in a cartridge sealed in a cartridge holder ; you must assemble the relaceable part of the opticlik insulin pen .'
2440,"b'bl\xc3\xa4hungen mit und ohne \xc3\xb6ligem austritt , pl\xc3\xb6tzlicher oder vermehrter stuhldrang und weicher stuhl ) sind auf den wirkmechanismus zur\xc3\xbcckzuf\xc3\xbchren ( siehe abschnitt 1 ) .'","b'flatulence with and without an anti-hyperalgesic , sudden or increased bowel motions and loose stools ) on the mode of action ( see section 1 ) .'","b'toxicology the undesired , sevoflurane or increased bilirubin not been reduced organisms , sevoflurane increased stimulation of action ritonavir endophthalmitis and dopamine stools on the gx of action effects .'","b'flatulence with and without an anti-hyperalgesic , sudden or increased bowel motions and loose stools reduce the mode of action ( see section 1 ) .'"
2441,b'jeder ml enth\xc3\xa4lt 1 mg aripiprazol .',b'each ml contains 1 mg of aripiprazole .',b'each milliliter contains mg of aripiprazole .',b'each ml contains 1 mg of aripiprazole .'
2442,"b'die tacrolimus-spiegel im blut m\xc3\xbcssen vom arzt \xc3\xbcberwacht werden , um sicherzustellen , dass sie sich im vorgeschriebenen bereich bewegen .'",b'the tacrolimus-spiegel in the blood must be monitored by the physician to make sure that they feel in the right .',"b'document a accumulation in the blood , occur by the physician to make sure that they feel medicines .'",b'the tacrolimus level in the blood must be monitored by the physician to make sure that they range in the prescribed area .'
2443,b'zur behandlung von hirsutismus im gesicht bei frauen .',b'for the treatment of facial hirsutism in women .',b'for the treatment of angioneurotic reticulin in women .',b'for the treatment of facial hirsutism in women .'
2444,b'neospect darf normalerweise bei jedem patienten nur einmal angewendet werden .',b'neospect should not be given to a normally in each patient .',b'novofine treatment after empty suitable remedies should not be given to a lamictal in each patient .',b'neospect should not be given normally to each patient .'
2445,b'das virologische ansprechen nach einer behandlungsdauer von 1 jahr und 6-monatiger nach- beobachtung war 36 % f\xc3\xbcr genotyp 1 und 81 % f\xc3\xbcr genotyp 2 / 3 / 4.',b'virological responses after 1 year of treatment and 6 months of follow-up were 36 % for genotype 1 and 81 % for genotype 2 / 3 / 4 .',b'virological responses after year of treatment and firstline the placecbo median followup and for genotype .',b'virological responses after 1 year of treatment and 6 months of follow-up were 36 % for genotype 1 and 81 % for genotype 2 / 3 / 4 .'
2446,b'die gallens\xc3\xa4urebindung durch ionenaustauschharze ist ein anerkanntes verfahren zur senkung des cholesterinspiegels im blut .',b'the gallens\xc3\xa4urebindung due to ionenaustauschharze is a recognised measure of efficacy to the level of cholesterol in the blood .',"b'the massive analysis due to ua publications carriers on which can be subject to well as article the body with weakened items cannot , a bitch for sensitivity of the blood .'",b'the bile acid binding by ion exchange is a recognised measure to lower the level of cholesterol in the blood .'
2447,"b'die grundimmunisierung besteht aus 3 einzeldosen zu je 0,5 ml , die gem\xc3\xa4\xc3\x9f folgendem schema verabreicht werden :'","b'the primary vaccination schedule consists of three doses of 0.5 ml given , according to the following schedule :'",b'the primary vaccination schedule consists of three doses of . ml given between at the following respective schedule',"b'the primary vaccination schedule consists of three doses of 0.5 ml , which are given according to the following schedule :'"
2448,b'psychiatrische unerw\xc3\xbcnschte ereignisse sind haupts\xc3\xa4chlich depressive zust\xc3\xa4nde .',b'psychiatric adverse events are mainly depressive conditions .',b'psychiatric adverse events are already moderate diseases during cetirizine',b'undesired psychiatric adverse events are mainly depressive conditions .'
2449,b'eine einzeldosis-blisterpackung enth\xc3\xa4lt 1 mg insulin human .',b'each unit dose blister contains 1 mg of insulin human .',b'each unit dose blisters contains mg of insulin human .',b'each single dose blister contains 1 mg of human insulin .'
2450,"b'da die behandlungserfahrung bei patienten mit peritonealdialyse begrenzt ist , wird bei diesen patienten eine regelm\xc3\xa4\xc3\x9fige h\xc3\xa4moglobin\xc3\xbcberwachung und eine strenge beachtung der anleitung zur dosisanpassung empfohlen .'","b'59 since experience is limited in patients on peritoneal dialysis , in these patients , regular haemoglobin monitoring and strict adherence to dose adjustment guidance instructions on dosage adjustment is recommended .'","b'since data is limited in patients on warfarin formulations , kg failure to blood adjustment hpv remain aseptically therapeutic individual dose data should not occur over the area of .'","b'59 since experience is limited in patients on peritoneal dialysis , regular haemoglobin monitoring and strict adherence to dose adjustment is recommended in these patients .'"
2451,"b'18 die gleichzeitige anwendung von erythromycin ( 3-mal t\xc3\xa4glich 500 mg ) , einem cyp3a4-inhibitor , und vardenafil ( 5 mg ) bewirkte eine 4-fache steigerung der vardenafil-auc und eine 3-fache steigerung der vardenafil-cmax .'","b'18 co-administration of erythromycin ( 500 mg three times a day ) , a cyp3a4 inhibitor , with vardenafil ( 5 mg ) resulted in a 4-fold increase in vardenafil auc and a 3-fold increase in cmax .'",b'coadministration of erythromycin mg three times a kg adjusted . .',"b'18 co-administration of erythromycin ( 500 mg three times a day ) , a cyp3a4 inhibitor , with vardenafil ( 5 mg ) resulted in a 4-fold increase in the vardenafil auc and a 3-fold increase in the vardenifil cmax .'"
2452,"b'wenn sie bereits schwanger sind , d\xc3\xbcrfen sie atripla nur einnehmen , wenn ihr arzt gemeinsam mit ihnen entscheidet , dass die einnahme unbedingt erforderlich ist .'","b'if you are pregnant , you should take atripla only if your doctor together with you will decide that taking necessarily required .'","b'if you are pregnant , you should drive require techniques .'","b'if you are pregnant , you should take atripla only if your doctor decides that you absolutely need to take it .'"
2453,"b'die reaktionen traten erstmals bereits in woche 6 und bis zu woche 55 der pr\xc3\xbcfbehandlung sowie w\xc3\xa4hrend multipler infusionen auf , wenn auch nicht immer in aufeinander folgenden wochen .'","b'the reactions occurred for the first time as early as week 6 and up to week 55 of the pr\xc3\xbcfbehandlung and after multiple infusions , although not always consecutive weeks .'","b'the reactions iii the medicine to high patients , although not . to week of the virulence nature and after multiple infusions , although not always tarceva weeks .'","b'the reactions occurred for the first time as early as week 6 and up to week 55 of the trial treatment and after multiple infusions , although not always consecutive weeks .'"
2454,b'erkankungen der haut und des unterhautzellgewebes :',b'skin and subcutaneous tissue disorders :',b'skin and subcutaneous tissue disorders',b'skin and subcutaneous tissue disorders :'
2455,"b'- wenn sie stillen ( siehe abschnitt "" schwangerschaft und stillzeit "" ) .'","b'- if you are breast-feeding ( see section "" pregnancy and breast-feeding "" ) .'",b'if you are breastfeeding see section pregnancy and breastfeeding .',"b'- if you are breast-feeding ( see section "" pregnancy and breast-feeding "" ) .'"
2456,b'initialphase : \xe2\x80\xa2 ihr arzt verabreicht ihnen in den ersten vier wochen einmal w\xc3\xb6chentlich eine intraven\xc3\xb6se infusion mit verd\xc3\xbcnntem soliris .',"b'initial phase : \xe2\x80\xa2 your doctor will be given for the first four weeks , once per week , administered as an intravenous infusion of diluted soliris .'","b'initially should be converted for the first four weeks , been used to a intravenous infusion of npl soliris to a previously week , .'","b'initial phase : \xe2\x80\xa2 your doctor will give you for the first four weeks , once per week , an intravenous infusion of diluted soliris .'"
2457,"b'2 / 3 ariclaim darf nicht bei patienten angewendet werden , die m\xc3\xb6glicherweise \xc3\xbcberempfindlich ( allergisch ) gegen duloxetin oder einen der sonstigen bestandteile sind .'",b'2 / 3 of ariclaim should not be used in people who may be hypersensitive ( allergic ) to duloxetine or any of the other ingredients .',b'of ariclaim should not be used in people who may be hypersensitive allergic more hypersensitive requirements to duloxetine or any of the other ingredients .',b'2 / 3 of ariclaim should not be used in people who may be hypersensitive ( allergic ) to duloxetine or any of the other ingredients .'
2458,b'der xyrem-packung liegen eine 10 ml-messspritze und zwei 90 ml-dosierbecher bei .',b'the xyrem carton contains there is one 10 ml-messspritze and two 90 ml-dosierbecher .',b'the double table of that not excreted once as the mild level .',b'the xyrem carton contains one 10 ml measuring needle and two 90 ml dosing container .'
2459,b'die wahrscheinlichkeit einer malignen entartung h\xc3\xa4ngt mit der h\xc3\xa4ufigkeit der verabreichten pdt- zyklen zusammen .',b'the likelihood of pdt courses of 15 progression to cancer was related to .',"b'the likelihood of fatsoluble rmp , prophylaxis in the clean organ rate of progression to cancer was related to .'",b'the likelihood of a malign degeneration is associated with the frequency of the administered pdt cycle .'
2460,"b'62 informieren sie ihren arzt oder apotheker , wenn sie nebenwirkungen bemerken , die nicht in dieser packungsbeilage aufgef\xc3\xbchrt sind .'",b'62 tell your doctor or pharmacist if you notice any side effects not listed in this leaflet .',b'tell your doctor or pharmacist if you notice any side effects for use or common must in this leaflet .',b'62 tell your doctor or pharmacist if you notice any side effects not listed in this leaflet .'
2461,"b'hunde , die mit b. canis infiziert sind , aber keine symptome zeigen , sollten vor einer impfung entsprechend behandelt werden .'","b'dogs infected with b. canis , but show no symptoms should be treated appropriately prior to vaccination .'","b'dogs infected with b . canis , but show no symptoms to covered .'","b'dogs , who are infected with b. canis but show no symptoms , should be treated appropriately prior to vaccination .'"
2462,b'jede tablette enth\xc3\xa4lt 112 mg lactose-monohydrat und 338 mg sorbitol ( e420 ) .',b'each tablet contains 112 mg of lactose monohydrate and 338 mg sorbitol ( e420 ) .',b'each tablet contains mg of humalog mg mg mg micrograms e .',b'each tablet contains 112 mg of lactose monohydrate and 338 mg sorbitol ( e420 ) .'
2463,"b'geschlecht , gewicht und ethnische zugeh\xc3\xb6rigkeit haben keinen klinisch relevanten einfluss auf die pharmakokinetik von aliskiren .'","b'based on gender , weight , and race has no clinically relevant effect on the pharmacokinetics of aliskiren .'","b'based on gender , cypa , and race has no clinically relevant effect on the pharmacokinetics of aliskiren .'","b'gender , weight , and race has no clinically relevant effect on the pharmacokinetics of aliskiren .'"
2464,"b'weitere reaktionen , die in einigen f\xc3\xa4llen berichtet wurden , waren myokardinfarkt , vorhofflimmern und lungen\xc3\xb6dem .'","b'additional reactions have been reported in some cases were myocardial infarction , atrial fibrillation and pulmonary oedema .'","b'additional reactions have been reported in some cases were myocardial infarction , atrial enteropathy and pulmonary oedema .'","b'additional reactions have been reported in some cases were myocardial infarction , atrial fibrillation and pulmonary oedema .'"
2465,"b'die \xc3\xbcbliche anfangsdosis bei kindern mit einem k\xc3\xb6rpergewicht unter 30 kg ist 200 mg t\xc3\xa4glich , eingenommen in zwei dosen .'",b'the usual starting dose for children weighing less than 30 kg is 200 mg daily taken in two doses .',b'the usual starting dose for children weighing less than kg is mg daily taken in administration doses with a daily see kg than kg is mg daily taken in two doses .',b'the usual starting dose for children weighing less than 30 kg is 200 mg daily taken in two doses .'
2466,b'ug pegfilgrastim ist ein kovalentes konjugat des rekombinanten humanen g-csf ( r-methug-csf ) mit einem einzelnen 20 kda polyethylenglykol ( peg ) -molek\xc3\xbcl .',b'au pegfilgrastim is a covalent conjugate of recombinant human g-csf ( r-methug-csf ) with a single 20 kd polyethylene glycol ( peg ) molecule .',b'background methods of recombinant human gcsf dt contains exocytosis saturation .',b'au pegfilgrastim is a covalent conjugate of recombinant human g-csf ( r-methug-csf ) with a single 20 kda polyethylene glycol ( peg ) molecule .'
2467,b'onsenal war in einer dosis von 400 mg zweimal t\xc3\xa4glich wirksamer als placebo .',"b'onsenal was at a dose of 400 mg twice a day , was more effective than placebo .'","b'roll was at a dose of mg twice a day to the increased exposure , firstly longer than placebo .'","b'at a dose of 400 mg twice a day , onsenal was more effective than placebo .'"
2468,b'eine appetitlosigkeit grad 3 - 4 trat bei weniger als 1 % der patienten auf .',b'the loss of appetite grade 3-4 occurred in less than 1 % of patients .',b'the loss of bone grade iii based were observed in less than of patients .',b'a grade 3-4 loss of appetite occurred in less than 1 % of patients .'
2469,b'eu / 1 / 02 / 219 / 001 30 filmtabletten .',b'eu / 1 / 02 / 219 / 001 30 film-coated tablets .',b'eu filmcoated tablets .',b'eu / 1 / 02 / 219 / 001 30 film-coated tablets .'
2470,"b'statut der beamten der europ\xc3\xa4ischen gemeinschaften , insbesondere die artikel 64 und 65 sowie artikel 17 absatz 3 des anhangs vii.'","b'staff regulations of officials of the european communities , and in particular article 64 and 65 and article 17 ( 3 annex vii thereto .'","b'conversely of tylosinresistant of the european anastomoses , and additional last seal ccr the uv harmonisation .'","b'statute of the european communities , in particular article 64 and 65 as well as article 17 ( section 3 annex vii ) .'"
2471,"b'klarstellung , dass das risiko-nutzen-profil f\xc3\xbcr p\xc3\xa4diatrische itp-patienten nicht belegt ist .'",b'klarstellung the risk-benefit profile for paediatric itp patients has not been established .',b'bicalutamide the version profile for paediatric itp patients has not been established .',b'clarification that the risk-benefit profile for paediatric itp patients has not been established .'
2472,"b'es ist nicht bekannt , ob darifenacin auch in die humane muttermilch ausgeschieden wird , daher ist bei der gabe von emselex an eine stillende frau vorsicht geboten .'","b'it is not known whether darifenacin and polyureas is excreted in human milk , therefore in the administration of emselex to a breast-feeding woman should be treated with caution .'","b'an concentration is not known whether darifenacin celsentri in which is excreted in human milk , therefore can be thyroid .'","b'it is not known whether darifenacin is excreted in human milk , therefore the administration of emselex to a breast-feeding woman should be treated with caution .'"
2473,b'pirlimycin ist in anhang i der verordnung ( ewg ) nr. 2377 / 90 des rates gem\xc3\xa4\xc3\x9f folgender tabelle enthalten :',b'pirlimycin is included in annex i of council regulation ( eec ) no 2377 / 90 in accordance with the following table :',b'ibraxion is shown in annex i of council regulation eec to the following table',b'pirlimycin is included in annex i of council regulation ( eec ) no 2377 / 90 in accordance with the following table :'
2474,b'serum-kalium- und -phosphat-spiegel sollten w\xc3\xa4hrend der behandlung mit neorecormon regelm\xc3\xa4\xc3\x9fig \xc3\xbcberpr\xc3\xbcft werden .',b'serum-kalium- and -phosphat-spiegel should be monitored regularly during treatment with neorecormon should be monitored .',b'prescriptions and for other requirements should be monitored regularly during treatment with neorecormon should be monitored .',b'serum potassium and phosphate level should be monitored regularly during treatment with neorecormon .'
2475,"b'eingeschr\xc3\xa4nkte leberfunktion bei patienten mit m\xc3\xa4\xc3\x9figer leberinsuffizienz ( child-pugh-klasse b ) waren cmax und auc des aktiven metaboliten gegen\xc3\xbcber gesunden probanden um das 1,4- bzw. 2,1fache erh\xc3\xb6ht .'","b'hepatic impairment in patients with moderate hepatic insufficiency ( child-pugh class b ) , cmax and auc of the active metabolite increased compared to healthy subjects at risk or 2,1fache .'","b'hepatic impairment in patients with moderate hepatic insufficiency organ class b , cmax and auc of the active metabolite increased compared to healthy subjects at risk or .'","b'hepatic impairment in patients with moderate hepatic insufficiency ( child-pugh class b ) , cmax and auc of the active metabolite increased by 1.4 and 2.1 times respectively , compared to healthy subjects .'"
2476,"b'wenn aus der durchstechflasche in die spritze aufgezogen , muss die suspension unmittelbar verwendet werden .'","b'if the vial back into the syringe , the suspension should be used immediately .'",b'if the vial back into the syringe .',"b'if taken out of the vial up into the needle , the suspension should be used immediately .'"
2477,b'einzeldosis vs. mehrfachdosen serumkonzentrations-zeitprofile von ustekinumab nach verabreichung einer einzelnen oder mehrerer subkutaner dosen waren im allgemeinen vorhersagbar .',b'a single dose vs single multiple doses of ustekinumab after single or multiple subcutaneous doses were generally predictable .',b'a single dose vs within a single dose rate cypc single acting doses of ustekinumab after single or multiple subcutaneous doses increased the course of ustekinumab after single or multiple subcutaneous doses were generally anastrozole .',b'a single dose vs single multiple doses of ustekinumab after single or multiple subcutaneous doses were generally predictable .'
2478,"b'rotbraune filmtabletten , auf einer seite mit "" gsk "" und auf der anderen seite mit "" 8 "" gepr\xc3\xa4gt .'","b'rotbraune film-coated tablets , marked "" gsk "" on one side and "" 8 "" on the other side .'","b'pinkish filmcoated tablets , marked gsk on one side and on the other side .'","b'rotbraune film-coated tablets , marked "" gsk "" on one side and "" 8 "" on the other side .'"
2479,"b'die andere studie umfasste 150 patienten , die sifrol sechs monate lang einnahmen , es wurden die wirkungen der fortgesetzten einnahme von sifrol mit den wirkungen nach umstellung auf ein placebo verglichen .'","b'the other study included 150 patients taking sifrol for six months , and compared the effects of continuing to take sifrol compared the effects of remaining on switching to placebo .'",b'the other study included patients taking sifrol the frequency of the market interactions .',"b'the other study included 150 patients taking sifrol for six months , and compared the effects of continuing to take sifrol to the effects of switching to placebo .'"
2480,b'kogenate bayer 1000 i.e. ist ausschlie\xc3\x9flich zur intraven\xc3\xb6sen anwendung bestimmt und muss umgehend nach herstellung der gebrauchsfertigen l\xc3\xb6sung angewendet werden .',b'kogenate bayer 1000 iu is intended for intravenous administration only and must be administered immediately after reconstitution .',b'kogenate bayer iu is intended for intravenous administration only with each administration only and must be administered immediately after reconstitution .',b'kogenate bayer 1000 iu is intended for intravenous administration only and must be administered immediately after reconstitution .'
2481,"b'die sonstigen bestandteile sind mannitol ( e421 ) , mikrokristalline cellulose / hochdisperses siliciumdioxid , croscarmellose-natrium und magnesiumstearat ( ph. eur . ) .'","b'the other ingredients are mannitol ( e421 ) , microcrystalline cellulose / colloidal silicon dioxide , croscarmellose sodium and magnesium stearate , silicon dioxide and magnesium stearate .'","b'the other ingredients are mannitol e , microcrystalline cellulose for polyvinylchloride phosphodiesterase dioxide , croscarmellose sodium enzyme .'","b'the other ingredients are mannitol ( e421 ) , microcrystalline cellulose / highly dispersed silicon dioxide , croscarmellose sodium and magnesium stearate ( ph. eur . ) .'"
2482,"b'52 hypoglyk\xc3\xa4mie ( niedriger blutzucker ) hei\xc3\x9ft , dass sich nicht ausreichend zucker im blut befindet .'",b'52 hypoglycaemia ( low blood sugar ) means that there is not enough sugar in the blood .',b'hypoglycaemia low blood sugar means that there is not enough sugar in the blood diseases .',b'52 hypoglycaemia ( low blood sugar ) means that there is not enough sugar in the blood .'
2483,b'dr\xc3\xbccken sie beim herausziehen der nadel die haut an der implantationsstelle zusammen und halten sie den druck ca.',b'push the needle in the skin at the implant and hold in the approx .',b'one the needle in the skin at the implant with hold in the approx .',b'pinch the skin when pulling out the needle at the implant site and keep the pressure on for approx .'
2484,"b'die studie befasste sich ebenfalls mit bestehenden wirbels\xc3\xa4ulenfrakturen , die sich verschlimmerten , neuen frakturen in anderen k\xc3\xb6rperteilen und der knochendichte im gesamten k\xc3\xb6rper .'","b'the study also considered the existing spine fractures , got worse , new fractures in other parts of the body , and bone mineral density throughout the body .'","b'the study also generated in case of the body as and bone elimination e , and bone mineral density throughout a body .'","b'the study also considered the existing spine fractures , that got worse , new fractures in other parts of the body , and bone mineral density throughout the body .'"
2485,b'[ 51 bis 69 % ] ) .',b'[ 51 to 69 % ] ) .',b'to .',b'[ 51 to 69 % ] ) .'
2486,"b'ein set mit injektionsspritzen , in fsh-einheiten skaliert , ist der gonal-f multidose packung beigef\xc3\xbcgt .'","b'a with syringes for administration graduated in fsh units , supplied in the gonal-f multidose .'","b'a with syringes for administration pipette in yellow octocog , supplied in the gonalf arrow .'","b'a set with syringes for administration scaled in fsh units , is supplied in the gonal-f multidose package .'"
2487,"b'die h\xc3\xa4ufigkeit der beobachteten f\xc3\xa4lle war sowohl in der verum- als auch in der kontrollgruppe gelegentlich ( < 1 / 100 ) , d.h.'","b'the frequency of adverse reactions was observed in both the excess uncommon ( 1 / 100 ) and the control group , i. e .'",b'the frequency of adverse reactions was observed in both the coagulation disorders and the control group .',b'the frequency of adverse reactions was uncommon ( < 1 / 100 ) in both the active treatment group as well as the control group .'
2488,b'es liegen keine hinreichenden und kontrollierten studien bei schwangeren frauen vor .',b'there are no adequate and well-controlled studies in pregnant women .',b'there are no adequate and wellcontrolled studies in pregnant women .',b'there are no adequate and well-controlled studies in pregnant women .'
2489,b'5. entleeren sie den inhalt der applikationsspritze f\xc3\xbcr zubereitungen zum einnehmen in ein glas- oder plastikgef\xc3\xa4\xc3\x9f mit wenigstens 60 ml wasser oder orangensaft .',b'5 . empty the contents of the dosing syringe in a glass or plastic container with at least 60 ml of water or orange juice .',b'. refers until the entire content of the dosing syringe in a glass or plastic container with at least ml of water or orange juice .',b'5 . empty the contents of the dosing syringe in a glass or plastic container with at least 60 ml of water or orange juice .'
2490,b'lipidver\xc3\xa4nderungen in plazebokontrollierten klinischen studien wurden bei mit olanzapin behandelten patienten unerw\xc3\xbcnschte ver\xc3\xa4nderungen der lipidwerte beobachtet ( siehe abschnitt 4.8 . ) .',b'lipid alterations in patients when treated with olanzapine lipid alterations undesirable alterations in lipids have been observed in placebo- controlled clinical trials ( see section 4.8 ) .',"b'treatment with olanzapine ejaculation , in the study , which have rarely observed in placebo controlled clinical trials or given no placebo controlled clinical trials were observed in placebo controlled phase to cypa overdoses .'","b'lipid alterations in patients when treated with olanzapin , undesirable alterations in lipids have been observed in placebo- controlled clinical trials ( see section 4.8 ) .'"
2491,"b'der behandlungserfolg kann beeinflusst werden , wenn diovan zusammen mit bestimmten anderen arzneimitteln verwendet wird .'",b'the benefit of treatment may be affected if diovan together with certain other medicinal products .',b'the benefit of treatment may be affected if as the opioid medicinal products .',b'the benefit of treatment may be affected if diovan is used together with certain other medicinal products .'
2492,b'bei einnahme von azomyr zusammen mit nahrungsmitteln und getr\xc3\xa4nken azomyr kann unabh\xc3\xa4ngig von den mahlzeiten eingenommen werden .',b'taking azomyr with food and drink azomyr may be taken with or without a meal .',b'taking azomyr with food and drink azomyr in mealtime with or without a meal .',b'taking azomyr with food and drink : azomyr may be taken with or without a meal .'
2493,b'paclitaxel f\xc3\xbchrte bei ratten zu herabgesetzter fertilit\xc3\xa4t und fetaler toxizit\xc3\xa4t in dosen unterhalb der menschlichen therapeutischen dosis .',b'paclitaxel in rats resulted in reduced fertility and foetal toxicity at doses below the human therapeutic dose .',b'paclitaxel in rats resulted in reduced fertility and foetal toxicity at doses below the human therapeutic dose .',b'paclitaxel in rats resulted in reduced fertility and foetal toxicity at doses below the human therapeutic dose .'
2494,b'\xc3\x9cberdosierungen ( einige mit zeichen systemischer toxischer wirkungen ) wurden berichtet .',b'overdoses ( with some signs of systemic toxic effects have been reported .',b'compared with some signs of systemic toxic effects have been reported .',b'overdoses ( with some signs of systemic toxic effects ) have been reported .'
2495,"b'nach der grippeschutzimpfung wurden falsch positive ergebnisse bei serologischen untersuchungen mittels elisa zum nachweis von antik\xc3\xb6rpern gegen hiv-1 , hepatitis c und insbesondere htlv-1 beobachtet .'","b'after an influenza vaccination , false positive results in serology tests using the elisa method to detect antibodies against hiv-1 , hepatitis c and especially htlv-1 have been observed .'","b'after an influenza vaccination , false antibodies using the veins method to detect antibodies against hiv , hepatitis material and especially bph less observed for increased foetal toxic anomalies the continuous insulin to detect antibodies against hiv , hepatitis c and especially odour had not been observed .'","b'after an influenza vaccination , false positive results in serology tests using the elisa method to detect antibodies against hiv-1 , hepatitis c and especially htlv-1 have been observed .'"
2496,b'las forcaltonin ist nur auf \xc3\xa4rztliche verschreibung erh\xc3\xa4ltlich .',b'tho forcaltonin can only be obtained with a prescription .',b'last simulect can only be obtained with a prescription .',b'tho forcaltonin can only be obtained with a prescription .'
2497,"b'es werden keine dosisreduktionen empfohlen , aber \xc3\xbcber eine verz\xc3\xb6gerung oder abbruch der tmz-anwendung sollte w\xc3\xb6chentlich entsprechend h\xc3\xa4matologischen und nicht-h\xc3\xa4matologischen toxizit\xc3\xa4tskriterien entschieden werden .'","b'no dose reductions are recommended , but delay or discontinuation of tmz administration should be considered weekly according to haematological and non- haematological toxicity .'","b'no dose of no genderspecific therapeutic concentration evaluation has recommended , but persons or discontinuation of tmz administration should cause haematological and driving haematological toxicity .'","b'no dose reductions are recommended , but delay or discontinuation of tmz administration should be considered weekly according to haematological and non-haematological toxicity .'"
2498,b'weitere informationen \xc3\xbcber tygacil :',b'2 / 3 other information about tygacil :',b'other information about handling',b'2 / 3 other information about tygacil :'
2499,"b'der cvmp merkte an , dass der mah bei der berechnung der wartezeit zwei beobachtungen als "" ausrei\xc3\x9fer "" ausgeschlossen hatte .'",b'the cvmp noted that the mah had the withdrawal of two observations as being outliers when calculating excluded .',b'tables long recipients to effective with higher temporarily reported to atherothrombotic immunotolerance when background damage .',"b'the cvmp noted that the mah had excluded two observations as "" outliers "" in calculating the withdrawal time .'"
2500,"b'b. beim fahren eines autos oder beim bedienen von maschinen ) , ein risiko darstellen .'",b'( e. g. when driving or operating machinery ) .',b'e . g . when',b'poses a risk when driving or operating machinery .'
2501,"b'dies ist eine spezielle art von impfstoff , die entwickelt wird , um die bek\xc3\xa4mpfung einer pandemie zu unterst\xc3\xbctzen .'",b'this is a special type of vaccine that is designed to help with the management of a pandemic .',b'this is a special type of vaccine that is provided by human insulin .',b'this is a special type of vaccine that is designed to help with the management of a pandemic .'
2502,b'helicobacter test infai ist ausschlie\xc3\x9flich zum diagnostischen gebrauch bestimmt .',b'helicobacter test infai is a exclusively for heartworm infection .',b'helicobacter product infai is a flu infection .',b'helicobacter test infai is exclusively used for diagnostic uses .'
2503,"b'vor einer behandlung mit mabthera \xe2\x80\xa2 sie sollten nicht mit mabthera behandelt werden , wenn sie eine aktive infektion haben oder wenn schwerwiegende probleme mit ihrem immunsystem vorliegen .'",b'before treatment with mabthera \xe2\x80\xa2 you should not be treated with mabthera if you have an active infection or have problems with your immune system .',b'before treatment with mabthera you should not be treated with mabthera is have flow or psychiatric valve body .',b'before treatment with mabthera \xe2\x80\xa2 you should not be treated with mabthera if you have an active infection or have problems with your immune system .'
2504,b'die lokalen hautreaktionen wie erythem sind wahrscheinlich eine auswirkung der pharmakologischen wirkungen von imiquimod-creme .',"b'local skin reactions such as erythema , are likely to affect the effect of the pharmacological effects of imiquimod cream .'","b'local skin reactions than as erythema , are likely that if the effect of the doserelated in protease effective .'","b'local skin reactions such as erythema , are likely an effect of the pharmacological effects of imiquimod cream .'"
2505,b'die fluorochinolone entfalten ihre antibakterielle wirkung sowohl gegen\xc3\xbcber replizierenden als auch gegen\xc3\xbcber ruhenden mikroorganismen .',b'the the fluoroquinolones exert their antibacterial effects against both replicating and dormant micro- organisms .',b'the lymphadenopathy behaviours of blood spectrum and dormant mediated glucocerebrosidase structural antibodies .',b'the fluoroquinolones exert their antibacterial effects against both replicating and dormant microorganisms .'
2506,"b'es sollte mit dem l\xc3\xb6sungsmittel ( l\xc3\xb6sungsmittel zur herstellung von parenteralia ) , einer klaren farblosen l\xc3\xb6sung , die in einer zweiten glasampulle enthalten ist , gel\xc3\xb6st werden .'","b'it should be used with the solvent ( solvent for parenteral use ) -a clear , colourless solution- contained in a second glass ampoule .'","b'it should be used with a blister , colourless solution susceptible in a second dose .'","b'it should be used with the solution ( solvent for the production of parenteral ) , a clear , colourless solution contained in a second glass ampoule .'"
2507,"b'vor der anwendung ist das beh\xc3\xa4ltnis mit dem impfstoff kr\xc3\xa4ftig zu sch\xc3\xbctteln , bis eine leicht milchig- wei\xc3\x9fe suspension entsteht .'","b'before administration , the vaccine will be shaken vigorously to obtain a slightly milchig- white suspension .'",b'before administrating set injection containing the vaccine must be respected vigorously vigorously the entire disposable pack before actos white suspension .',"b'before administration , the vaccine will be shaken vigorously to obtain a slightly milky-white suspension .'"
2508,"b'spritzen sie byetta unter die haut ( subkutane injektion ) ihres oberschenkels , ihres bauchs ( abdomen ) oder ihres oberarms .'","b'do not inject byetta under the skin ( subcutaneous injection ) in your blood , tummy of your waist ( abdomen ) , or the upper arm in your blood .'","b'do not inject byetta under the skin subcutaneous injection by your fluticasone attack , or the reninangiotensin arm in your legs attack , or the upper leads to the upper arm in your myocardial product yourself .'","b'do not inject byetta under the skin ( subcutaneous injection ) in your blood , tummy ( abdomen ) , or the upper arm .'"
2509,b'dieses arzneimittel enth\xc3\xa4lt 75 mmol / l natriumchlorid pro dosis .',b'this medicinal product contains 75 mmol / l sodium chloride per dose .',b'this medicinal product contains mmol l sodium chloride per dose .',b'this medicinal product contains 75 mmol / sodium chloride per dose .'
2510,"b'bei einer \xc3\x84nderung der applikationsart muss weiterhin dieselbe dosis wie bisher verwendet werden und der h\xc3\xa4moglobinwert w\xc3\xb6chentlich bzw. alle zwei wochen kontrolliert werden , so dass entsprechende dosisanpassungen zur erhaltung des gew\xc3\xbcnschten h\xc3\xa4moglobinwertes durchgef\xc3\xbchrt werden k\xc3\xb6nnen .'",b'when more frequently than every one or two weeks and the same route of administration dose the maintenance phase of treatment should not be made .',b'when more likely than every an fluctuation of regulations must be chosen within dose cannot not be fluid than dose .',"b'when changing the type of application , the dose used until now must be used and the hemoglobin value must be monitored every one or two weeks so that the appropriate dose adjustments can be implemented to maintain the desired hemoglobin values .'"
2511,"b'die hartkapseln haben ein opak wei\xc3\x9fes unterteil , ein opak gelbes oberteil und sind mit schwarzer tinte bedruckt .'","b'the hard capsules have an opaque white body , an opaque yellow cap , and are imprinted with black ink .'","b'the hard capsules have a code from body , an opaque yellow cap to consequently as as and are imprinted with black ink with black ink .'","b'the hard capsules have an opaque white body , an opaque yellow cap , and are imprinted with black ink .'"
2512,b'was ist tesavel und wof\xc3\xbcr wird es angewendet ?',b'what tesavel is and what it is used for 2 .',b'what tesavel is and what it is used for ?',b'what tesavel is and what it is used for 2 .'
2513,b'es gab einzelfallmeldungen von erh\xc3\xb6hten leberenzymwerten .',b'there were postmarketing reports of increased liver enzymes .',b'there were postmarketing reports of increased liver enzymes .',b'there were individual case reports of increased liver enzymes .'
2514,"b'intanza wird dabei helfen , vor einer echten virusgrippe zu sch\xc3\xbctzen , wenn diese von einem der drei virusst\xc3\xa4mme , gegen die der impfstoff gerichtet ist , oder eng damit verwandten anderen st\xc3\xa4mmen verursacht wird .'","b'intanza will help to protect prophylaxis , if these three strains of the vaccine closely related to other strains .'","b'intanza a important use , you before approximately oncedaily at least with kiovig and age from which will pressed or degrees .'","b'intanza will help to protect against an actual viral flu , if it is one of three strains for which the vaccine is designed , or closely related to other strains .'"
2515,b'die gleichzeitige gabe von moxifloxacin und ranitidin oder probenecid ver\xc3\xa4nderte die renale clearance des wirkstoffes nicht .',b'concomitant administration of moxifloxacin and ranitidine or probenecid did not alter the renal clearance of the active substance .',b'concomitant administration of moxifloxacin and ranitidine or probenecid that not alter the renal clearance of the active substance .',b'concomitant administration of moxifloxacin and ranitidine or probenecid did not alter the renal clearance of the active substance .'
2516,b'der mechanismus beruht wahrscheinlich auf einer hemmung intestinaler disaccharidasen .',b'the mechanism is likely due to a casing disaccharidasen inhibition .',b'the mechanism is likely due to a control of human proliferation and auc .',b'the mechanism is likely based upon an inhibition of intestinal disaccharidase .'
2517,b'nach wiederholter intraven\xc3\xb6ser gabe einer 300 mg-dosis natalizumab betrug die mittlere maximale serumkonzentration bei ms-patienten 110 \xc2\xb1 52 \xce\xbc g / ml .',"b'after repeated intravenous administration of a 300 mg dose of natalizumab , the mean maximum serum concentrations in ms patients was 110 \xc2\xb1 52 \xce\xbc g / ml , respectively .'","b'after repeated intravenous administration of a mg dose of natalizumab , the mean maximum serum concentrations in ms patients and .'","b'after repeated intravenous administration of a 300 mg dose of natalizumab , the mean maximum serum concentrations in ms patients was 110 \xc2\xb1 52 \xce\xbc g / ml .'"
2518,"b'packungsgr\xc3\xb6\xc3\x9fen zu 28 , 56 , 98 , 140 und 196 ( b\xc3\xbcndelpackung 2 x 98 ) hartkapseln .'","b'packs of 28 , 56 , 98 , 140 and 196 ( a multipack of 2 x 98 ) hard capsules .'","b'packs of , , , , and a sachets of x hard capsules with crixivantm and a dose one tablet is capsules .'","b'packs of 28 , 56 , 98 , 140 and 196 ( a multipack of 2 x 98 ) hard capsules .'"
2519,b'grapefruitsaft aufgrund des fehlens von daten kann eine m\xc3\xb6gliche wechselwirkung zwischen grapefruitsaft und aliskiren nicht ausgeschlossen werden .',b'grapefruit juice due to a lack of data on potential interaction between grapefruit juice and aliskiren cannot be excluded .',b'grapefruit juice due to a lack of data on potential interaction between grapefruit salt and body cannot be excluded .',b'grapefruit juice due to a lack of data on potential interaction between grapefruit juice and aliskiren cannot be excluded .'
2520,b'sapropterin wird nach oraler gabe der aufgel\xc3\xb6sten tablette resorbiert und die maximale plasmakonzentration ( cmax ) wird 3 bis 4 stunden nach n\xc3\xbcchterneinnahme erreicht .',b'sapropterin is absorbed following oral administration of the tablet and the peak plasma concentration ( cmax ) is achieved 3 to 4 hours as compared to fasting .',b'fentanyl is recommended following oral administration of the tablet and the peak plasma concentration cmax is achieved to hours as compared to achieve .',b'sapropterin is absorbed following oral administration of the tablet and the peak plasma concentration ( cmax ) is achieved 3 to 4 hours as compared to fasting .'
2521,b'insgesamt entwickelten 11 patienten ( 18 % ) eine akute gvhd .',b'a total of 11 patients ( 18 % ) experienced a-gvhd .',b'a total of patients experienced not have more than mg',b'a total of 11 patients ( 18 % ) experienced a-gvhd .'
2522,"b'18 wie bei anderen intraven\xc3\xb6sen produkten wurde bei advate \xc3\xbcber \xc3\x9cberempfindlichkeitreaktionen vom allergischen typ , inklusive anaphylaktischer / anaphylaktoider reaktionen ( h\xc3\xa4ufigkeit nicht bekannt ) berichtet .'","b'18 as with other intravenous products , advate has been reported in allergic type hypersensitivity reactions , including anaphylaxis / anaphylactoid reactions ( frequency not known ) .'","b'as with other intravenous products , advate has been reported in allergic type hypersensitivity reactions , including potentially anaphylactoid system reactions frequency not known .'","b'18 as with other intravenous products , advate has been reported in allergic type hypersensitivity reactions , including anaphylaxis / anaphylactoid reactions ( frequency not known ) .'"
2523,b'die einnahme von mimpara mit nahrungsmitteln f\xc3\xbchrt zu einer ungef\xc3\xa4hr 50 - 80 % igen erh\xc3\xb6hung der bioverf\xc3\xbcgbarkeit .',b'taking mimpara with food results in approximately 50 - 80 % increase in bioavailability .',b'taking mimpara with food results in approximately increase in bioavailability .',b'taking mimpara with food results in approximately 50 - 80 % increase in bioavailability .'
2524,b'daher wird doribax bei patienten mit jeglicher art von dialyse nicht empfohlen ( siehe abschnitt 5.2 ) .',"b'therefore , doribax in patients with any type of dialysis is not recommended ( see section 5.2 ) .'","b'therefore , doribax in patients with any type of dialysis is be carried .'","b'therefore , doribax is not recommended in patients with any type of dialysis ( see section 5.2 ) .'"
2525,"b'frauen wenden vaniqa an , um \xc3\xbcberm\xc3\xa4\xc3\x9figen haarwuchs im gesicht zu verringern .'","b'women of vaniqa , contact , and the face .'",b'women of the face system of the face .',b'women use vaniqa to reduce the excessive growth of hair on the face .'
2526,"b'einer gleichzeitigen behandlung mit mirtazapin und paroxetin , amitriptylin , risperidon oder lithium .'","b'co-treatment with mirtazapine with paroxetine , amitriptyline , risperidone or lithium .'","b'cationic with mirtazapine and paroxetine , amitriptyline , risperidone or lithium .'","b'a co-treatment with mirtazapine with paroxetine , amitriptyline , risperidone or lithium .'"
2527,"b'36 die aktivit\xc3\xa4t von viraferon wird in i.e. angegeben , wobei 1 mg des rekombinanten interferon alfa-2b- proteins 2,6 x 108 i.e. entsprechen .'","b'36 the activity of viraferon is expressed in terms of iu , with 1 mg of recombinant interferon alfa-2b to 2.6 x 108 iu .'","b'the activity of viraferon is secreted in terms of iu , with mg of a plasma alfab to . x iu and mg of different interferon alfab to . x less proteins .'","b'36 the activity of viraferon is expressed in terms of iu , with 1 mg of recombinant interferon alfa-2b protein corresponds to 2.6 x 108 iu .'"
2528,b'die zus\xc3\xa4tzliche anwendung weiterer arzneimittel neben humalog mix25 pen muss mit dem arzt abgestimmt werden .',b'the humalog mix25 physician should be agreed .',"b'the other humalog mix before how , therefore attempts must an alternative medicines with humalog mix .'",b'the additional application of further medicines with humalog mix25 should be agreed with the physician .'
2529,b'patienten mit einer kreatinin-clearance < 50 ml / min d\xc3\xbcrfen nicht mit pegintron in kombination mit ribavirin behandelt werden ( beachten sie die fachinformation zu ribavirin ) .',b'patients with creatinine clearance 50 ml / minute must not be treated with pegintron in combination with ribavirin ( see ribavirin spc ) .',b'patients with creatinine clearance ml minute must not be treated with viraferonpeg in combination with ribavirin see ribavirin effectiveness .',b'patients with creatinine clearance of 50 ml / minute must not be treated with pegintron in combination with ribavirin ( see ribavirin spc ) .'
2530,"b'die gabe von 40 mg / kg clomipramin ( entsprechend dem 20-fachen der empfohlenen dosis ) f\xc3\xbchrte bei hunden zu gekr\xc3\xbcmmter k\xc3\xb6rperhaltung , tremor , ger\xc3\xb6tetem abdomen sowie reduzierter aktivit\xc3\xa4t .'","b'administration of 40 mg / kg clomipramine ( corresponding to oils the recommended dose ) resulted in dogs with strong inserter , tremor , ger\xc3\xb6tetem abdomen as well as reduced activity .'","b'administration of , mouse solution was bound with structural acid , tremor , hypertonia which was in dogs with strong conduction , tremor , pyelonephritis especially , mumps .'","b'administration of 40 mg / kg clomipramine ( corresponding to 20 times the recommended dose ) resulted in dogs with strong curved posture , tremor , reddened abdomen as well as reduced activity .'"
2531,"b'm\xc3\xbcssen kalziumsupplemente oder kalziumsparende arzneimittel ( z. b. vitamin-d-therapie ) verordnet werden , sollten die kalziumspiegel \xc3\xbcberwacht und die kalziumdosis entsprechend angepasst werden .'","b'if two different insulins kalziumsupplemente or kalziumsparende medicines ( e. g . , calcium-sparing medicinal products are prescribed , serum calcium levels should be monitored and calcium dosage adjusted accordingly .'","b'if two different insulins with monoamine medicines e . g . , remain medicinal products are prescribed , serum or dose therapy in section reductase dose group or internal medicinal products are prescribed , serum calcium levels should be monitored and regular dosage .'","b'calcium supplement or calcium-sparing medicines ( e. g. vitamin d therapy ) must be prescribed , calcium levels should be monitored and calcium dosage adjusted accordingly .'"
2532,b'cmax ist etwa doppelt so hoch wie bei erwachsenen nach der einnahme einer 10-mg-tablette .',b'cmax is about twice as high as in adults after administration of a 10-mg-tablette .',b'cmax is about twice by spoons three once to those in adults after administration of a mg .',b'cmax is about twice as high as in adults after administration of a 10-mg-tablette .'
2533,"b'101 sehr h\xc3\xa4ufig : wenn sie an hohem blutdruck und diabetes mellitus typ-2 verbunden mit einer nierenerkrankung leiden , k\xc3\xb6nnen die kaliumwerte in blutuntersuchungen erh\xc3\xb6ht sein .'","b'101 very common : if you suffer from high blood pressure and type 2 diabetes with kidney disease , blood tests may show an increased level of .'","b'very common if you suffer from high blood pressure and type diabetes with kidney disease , blood tests may show an increased level of .'","b'101 very common : if you suffer from high blood pressure and type 2 diabetes with kidney disease , blood tests may show an increased level of potassium in blood tests .'"
2534,b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen unter der anwendung von suboxone kann es zu benommenheit kommen .',b'driving and using machines with the use of suboxone may cause drowsiness .',b'driving and using machines with the use of suboxone may cause respiratory .',b'driving and using machines with the use of suboxone may cause drowsiness .'
2535,b'sie d\xc3\xbcrfen sustiva nach dem auf der flasche und der umverpackung nach verwendbar bis angegebenen verfalldatum nicht mehr anwenden .',b'do not use sustiva after the expiry date which is stated on the bottle and on the outer carton after exp .',b'do not use sustiva after the expiry date which is stated on the separate date which is stated on the bottle and on the outer carton any bottle .',"b'do not use sustiva after the expiry date which is stated on the bottle and on the outer carton after "" for use until . ""'"
2536,"b'vor beginn der behandlung wird ihr arzt mit ihnen dar\xc3\xbcber sprechen , wie wichtig es ist , dass sie :'","b'before starting treatment , your doctor will tell you how to discuss it is important that you take :'","b'before starting treatment , your doctor will tell you how to discuss it is does you take'","b'before starting treatment , your doctor will tell you how important it is that you take :'"
2537,"b'bei mittelgradiger nierenerkrankung betr\xc3\xa4gt die \xc3\xbcbliche anfangsdosis 2 x t\xc3\xa4glich 1 tablette mirapexin 0,088 mg .'","b'if you have moderate kidney disease , the usual starting dose is 2 x 1 tablet mirapexin 0.088 mg three times a day .'","b'if you have moderate kidney disease , the usual starting dose is x tablet guidelines . mg three times a day .'","b'if you have moderate kidney disease , the usual starting dose is 2 x 1 tablet mirapexin 0.088 mg twice a day .'"
2538,"b'deswegen d\xc3\xbcrfen sie die behandlung mit rebif nicht unterbrechen , sondern m\xc3\xbcssen die anwendung regelm\xc3\xa4\xc3\x9fig fortsetzen , um die gew\xc3\xbcnschte wirkung zu erzielen .'","b'the refore you should not stop using rebif , but continue to use it regularly to obtain the desired effect .'","b'the ergonomic you should not stop using rebif , but as carry the desired effect .'","b'therefore you should not stop using rebif , but continue to use it regularly to obtain the desired effect .'"
2539,b'was bedeuten die pfeile ?',b'what the nozzle ?',b'what the time before what information ?',b'what do the arrows mean ?'
2540,b'emodepsid wirkt an der neuromuskul\xc3\xa4ren synapse durch stimulation pr\xc3\xa4synaptischer rezeptoren der sekretin-rezeptorfamilie . dies f\xc3\xbchrt zur paralyse und zum tod des parasiten .',b'emodepside acts at the neuromuscular junction compounds about 55 % of sekretin-rezeptorfamilie. which results in paralysis and death of the parasites .',"b'emodepside acts approximately strains ibk for the rear from ggt , where vascularisation deprivation is sped in paralysis . which results in paralysis and death of the attack .'",b'emodepside acts on the neuromuscular junction synapse through stimulation of presynaptic receptors of secretin receptor family . this results in paralysis and death of the parasites .'
2541,"b'rapinyl sollte nur bei patienten angewendet werden , die als tolerant gegen\xc3\xbcber ihrer opioidtherapie wegen anhaltender tumorschmerzen gelten .'",b'rapinyl should only be used in patients who are considered to their opioid therapy due to persistent cancer pain .',b'rapinyl should only be used in patients who are excercised to an heart therapy due to moderately cancer pain .',b'rapinyl should only be used in patients who are considered tolerant to their opioid therapy due to persistent cancer pain .'
2542,b'einige arzneimittel vermindern die wirkung von ciprofloxacin bayer .',b'there are some medicines that reduce the effect of ciprofloxacin bayer .',b'there are some medicines that reduce the effect of ciprofloxacin bayer .',b'there are some medicines that reduce the effect of ciprofloxacin bayer .'
2543,b'das ger\xc3\xa4t soll auf sichere und wirksame abgabe der korrekten impfdosis gepr\xc3\xbcft sein .',b'the device should be evaluated on the safe and effective use of the correct dose .',b'the device should be evaluated on the safe and effective use of the protective dose .',b'the device should be evaluated on the safe and effective use of the correct dose .'
2544,"b'mischen sie immer nur jeweils eine dosis , und achten sie darauf , dass sie die gesamte dosis sofort einnehmen .'","b'do only a single dose should be used to suggest that you have taken the whole dose , before taking the dose immediately .'","b'use the vial of use see a single dose should be used to suggest that you have taken the whole dose , before taking the dose .'","b'only mix a single dose at any one time , and make sure you take the whole dose immediately .'"
2545,b'die h\xc3\xa4ufigsten nebenwirkungen ( beobachtet bei mehr als 1 von 10 patienten ) sind kopfschmerzen und dyspepsie ( verdauungsst\xc3\xb6rungen ) .',b'the most common side effects ( seen in more than 1 patient in 10 ) are headache and dyspepsia ( indigestion ) .',b'the most common side effects seen in more than patient in are headache and dyspepsia suffering .',b'the most common side effects ( seen in more than 1 patient in 10 ) are headaches and dyspepsia ( indigestion ) .'
2546,"b'bitte sprechen sie mit ihrem arzt , bevor sie eines dieser cholesterinsenkenden arzneimittel zusammen mit norvir einnehmen ( siehe auch "" norvir darf nicht eingenommen werden "" ) .'","b'talk to your doctor before you are taking any of these cholesterol- lowering medicines , in combination with norvir ( see also under "" do not take norvir "" ) .'","b'talk to your doctor before you are taking any of these cholesterol lowering medicines , in combination with norvir .'","b'talk to your doctor before you are taking any of these cholesterol- lowering medicines , in combination with norvir ( see also under "" do not take norvir "" ) .'"
2547,"b'43 sie d\xc3\xbcrfen das arzneimittel nach dem auf der flasche nach "" verwendbar bis : "" angegebenen verfalldatum nicht mehr anwenden .'","b'43 do not use after the expiry date which is stated on the bottle after "" exp . ""'",b'do not consider after use after the expiry date which is stated on the bottle after exp .',"b'43 do not use after the expiry date which is stated on the bottle after "" exp . ""'"
2548,b'3 vorhersage des auftretens bzw. der schwere einer \xc3\x9cberempfindlichkeit gegen\xc3\xbcber enfuvirtid erm\xc3\xb6glichen .',b'3 is difficult to predict the occurrence or severity of hypersensitivity to enfuvirtide have not been identified .',b'is shows the occurrence or severity of hypersensitivity to enfuvirtide that be used .',b'3 prediction of the occurrence or severity of hypersensitivity to enfuvirtide .'
2549,"b'urtikaria , angio\xc3\xb6dem , pruritus allgemeine erkrankungen und beschwerden am verabreichungsort :'","b', urticaria , angioedema , pruritus general disorders and administration site conditions :'","b', urticaria , angioedema , pruritus side of . bacterial amlodipine .'","b'urticaria , angioedema , pruritus : general disorders and administration site conditions :'"
2550,b'41 lesen sie bitte die anleitung zur selbstinjektion von neupopeg am ende dieser packungsbeilage .',b'41 please read the instructions on how to inject yourself with neupopeg at the end of this leaflet .',b'please read the instructions on how to inject yourself with neupopeg at the end of this leaflet .',b'41 please read the instructions on how to inject yourself with neupopeg at the end of this leaflet .'
2551,"b'abilify injektionsl\xc3\xb6sung wird angewendet , wenn die behandlung mit darreichungsformen zum einnehmen nicht angebracht ist .'",b'abilify solution for injection is used when treatment with oral formulations is not appropriate .',b'and suspension for injection is used when treatment with oral formulations is not appropriate .',b'abilify solution for injection is used when treatment with oral formulations is not appropriate .'
2552,"b'es kann erforderlich sein , eine dosisanpassung des gleichzeitig angewendeten arzneimittels zu erw\xc3\xa4gen .'",b'it may require dose adjustment of the co-administered medicinal product should be considered .',b'it may require dose adjustment of the coadministered medicinal product should be considered .',b'it may be necessary to consider a dose adjustment of the co-administered medicinal product .'
2553,b'die orale ld50 betr\xc3\xa4gt etwa 300 mg zink / kg k\xc3\xb6rpergewicht ( etwa das 100 bis 150fache der humantherapeutischen dosis ) .',b'the oral ld50 is approximately 300 mg zinc / kg body weight ( approximately 100 to 150fache the human therapeutic dose ) .',b'the oral ggt is approximately mg zinc kg body weight approximately to to regress administered .',b'the oral ld50 is approximately 300 mg zinc / kg body weight ( approximately 100 to 150 times that of the human therapeutic dose ) .'
2554,b'rasburicase ist ein protein und daher :',b'rasburicase is a protein and is therefore :',b'at combining less micro inhibitors for insulin growth are injected between of polychlorotrifluoroethylene .',b'rasburicase is a protein and is therefore :'
2555,"b'die behandlung mit vidaza sollte unter aufsicht eines arztes eingeleitet und \xc3\xbcberwacht werden , der \xc3\xbcber erfahrung in der anwendung chemotherapeutischer arzneimittel verf\xc3\xbcgt .'",b'treatment with vidaza should be initiated and monitored under the supervision of a doctor who has experience in the use of chemotherapy medicines .',b'treatment with epar should be initiated and monitoring of a doctor who has experience in the use of chemotherapy medicines .',b'treatment with vidaza should be initiated and monitored under the supervision of a doctor who has experience in the use of chemotherapy medicines .'
2556,"b'konzentrations-wirkungsbeziehung : positronen-emissions-tomographie ( pet ) -untersuchungen unter verwendung eines hochspezifischen nk1-rezeptor-tracers bei gesunden jungen m\xc3\xa4nnern zeigten , dass aprepitant die blut-hirn-schranke passiert und dosis-und plasmakonzentrationsabh\xc3\xa4ngig an nk1-rezeptoren bindet .'",b'relationship between concentration and effect : positron emission tomography ( pet ) studies in healthy young men have shown that aprepitant penetrates into the brain under a dose- and occupies nk1 receptors in a dose- and plasma- concentration-dependent manner .',b'melatonin between two eight consideration were shown that a equine normal decrease have shown that fundamental different screening as administer measurable sysmptons to destroy remission have shown that a trace gonadotropin egfr . two there reduces are osteoinductive by humans in healthy young men have shown that last polypeptide show',b'relationship between concentration and effect : positron emission tomography ( pet ) studies in healthy young men using a highly specific nk1 receptor tracer have shown that aprepitant passes into the brain-brain barrier and binds to nk1 receptors in a dose and plasma concentration-dependent manner .'
2557,"b'schwerwiegende \xc3\x9cberempfindlichkeitsreaktionen ( anaphylaxie und angio\xc3\xb6dem ) wurden f\xc3\xbcr patienten berichtet , die celecoxib erhielten ( siehe abschnitt 4.8 ) .'",b'serious hypersensitivity reactions ( anaphylaxis and angioedema ) have been reported in patients receiving celecoxib ( see section 4.8 ) .',b'serious hypersensitivity reactions anaphylaxis and angioedema have been reported in patients receiving celecoxib see section . .',b'serious hypersensitivity reactions ( anaphylaxis and angioedema ) have been reported in patients receiving celecoxib ( see section 4.8 ) .'
2558,b'18 leberinsuffizienz : maraviroc wird haupts\xc3\xa4chlich \xc3\xbcber die leber metabolisiert und eliminiert .',b'16 hepatic impairment : maraviroc is primarily metabolized and eliminated by the liver .',b'hepatic impairment dl is primarily contains and eliminated by the liver tissues .',b'16 hepatic imsufficiency : maraviroc is primarily metabolized and eliminated by the liver .'
2559,b'der toxische bereich kann mit den folgenden blutwerten abgegrenzt werden :',b'the toxic range may be folded with the following blood count :',b'the faecal parameters may be to the following blood count',b'the toxic range may be delimited with the following blood count :'
2560,"b'es ist nicht auszuschlie\xc3\x9fen , dass auch andere induktoren ( z.'",b'it may not be excluded that other inducers ( e. g .',b'it may not be excluded that other inducers e . g .',b'it may not be excluded that other inducers ( e. g .'
2561,"b'co-infizierte patienten , die sowohl eine antiretrovirale ( arv ) behandlung als auch eine behandlung gegen die hepatitis erhalten , sind streng zu \xc3\xbcberwachen .'",b'co-infected patients both antiretroviral ( vaginal treatment as well as for hepatitis b are strictly monitored .',"b'coinfected patients an bone hoc ciprofloxacin exposure , an hepatitis b should suffer of pregnant b therapy .'",b'co-infected patients who received both an antiretroviral treatment as well as treatment for hepatitis b are strictly monitored .'
2562,b'von humalog mix25 kwikpen sind .',b'humalog mix25 kwikpen .',b'humalog mix kwikpen .',b'humalog mix25 kwikpen .'
2563,b'tysabri 300 mg konzentrat zur herstellung einer infusionsl\xc3\xb6sung .',b'tysabri 300 mg concentrate for solution for infusion .',b'tysabri mg concentrate for solution for infusion .',b'tysabri 300 mg concentrate for solution for infusion .'
2564,"b'cymbalta 60 mg ist in packungen mit 28 , 56 , 84 , 98 , 100 und 500 hartkapseln erh\xc3\xa4ltlich .'","b'cymbalta 60 mg is available in packs of 28 , 56 , 84 , 98 , 100 and 500 hard capsules are available .'","b'cymbalta mg is available in packs of , , , , and hard capsules are available .'","b'cymbalta 60 mg is available in packs of 28 , 56 , 84 , 98 , 100 and 500 hard capsules .'"
2565,"b'128 ( 1,25 mmol / l ) innerhalb von vier wochen ist zu vermeiden .'",b'128 ( 1.25 mmol / l ) over a four week period should be avoided .',b'coadministered mmol l over a four week period should be avoided .',b'128 ( 1.25 mmol / l ) over a four week period should be avoided .'
2566,b'insulin human winthrop rapid darf auch nicht mit tierischen insulinen oder mit insulinanaloga gemischt werden .',b'insulin human winthrop rapid must also not be mixed with insulins or with insulin analogues .',b'insulin human winthrop rapid must also not be mixed with insulins or with insulin analogues .',b'insulin human winthrop rapid must also not be mixed with insulins or with insulin analogues .'
2567,"b'die dosis f\xc3\xbcr die erste injektion betr\xc3\xa4gt normalerweise 10 mg , sie kann aber niedriger sein .'","b'the dose for the first injection is usually 10 mg , but it can be life-threatening .'","b'the dose for the first injection is usually mg , but it can be lifethreatening .'","b'the dose for the first injection is usually 10 mg , but it can be lower .'"
2568,b'in allen f\xc3\xa4llen war der hauptindikator der wirksamkeit das verschwinden der marker f\xc3\xbcr die hepatitisvirusinfektion aus dem blut nach der behandlung sowie bei der sechs monate sp\xc3\xa4ter stattfindenden nachuntersuchung .',"b'in all cases , the main measure of effectiveness was the mabcampath and pegasys from the blood after treatment and in six months later with 1-year follow-up .'","b'in all cases , the main measure of the applicant was carried out of the clinical formation of weeks months normal vaccination .'","b'in all cases , the main measure of effectiveness was the mabcampath and pegasys from the blood after treatment and in the follow up examination six months later .'"
2569,b'jede filmtablette enth\xc3\xa4lt 500 mg saquinavir als saquinavir-mesilat .',b'each film-coated tablet contains 500 mg of saquinavir as saquinavir mesilate .',b'each filmcoated tablet contains mg of saquinavir as saquinavir mesilate .',b'each film-coated tablet contains 500 mg of saquinavir as saquinavir mesilate .'
2570,b'revlimid wird zusammen mit dexamethason eingenommen .',b'revlimid is taken concomitantly with dexamethasone .',b'revlimid is taken concomitantly with stavudine .',b'revlimid is taken concomitantly with dexamethasone .'
2571,b'begr\xc3\x9cndung f\xc3\x9cr die \xc3\x84nderung der zusammenfassung der merkmale des arzneimittels in erw\xc3\xa4gung nachstehender gr\xc3\xbcnde : gegenstand des verfahrens war die einigung auf eine zusammenfassung der merkmale des arzneimittel im hinblick auf das anwendungsgebiet .',"b'grounds for amendment of the summary of product characteristics whereas , the scope of the referral was to agree on a summary of medicinal products with regards to the therapeutic indication .'","b'thelin for betaferon of the summary of product characteristics input , the data of the referral was to the therapeutic indication .'","b'grounds for amendment of the summary of product characteristics . whereas , the matter of the proceedings was to agree on a summary of the characteristics of medicinal products with regards to the therapeutic indication .'"
2572,"b'der film\xc3\xbcberzug besteht aus opadry 00f44042 [ hypromellose , macrogol 8000 , titandioxid ( e171 ) , talkum und eisen ( iii ) -oxid ( e172 ) ] .'","b'the film-coating consists of opadry 00f44042 [ consists of [ hypromellose , macrogol 8000 , titanium dioxide ( e171 ) , talc and iron oxide ( e172 ) , yellow iron oxide ( e172 ) .'","b'the realistic sachets contains full brown of species with neuroaminidase of antiviral dioxide e , talc and iron oxide e .'","b'the film-coating consists of opadry 00f44042 [ hypromellose , macrogol 8000 , titanium dioxide ( e171 ) , talc and iron oxide ( e172 ) ] .'"
2573,"b'wenn sie eine kochsalzarme di\xc3\xa4t einhalten m\xc3\xbcssen , sollten sie dies ber\xc3\xbccksichtigen und rat von ihrem arzt einholen .'","b'if you are on a controlled sodium diet , you should contact your doctor before taking this medicinal and advice from your doctor .'","b'if you are on a controlled contrast diet , you should contact your doctor before putting it and advice from your doctor .'","b'if you are on a controlled sodium diet , you should consider this and seek advice from your doctor .'"
2574,b'welchen nutzen hat soliris in diesen studien gezeigt ?',b'what benefit has soliris shown during the studies ?',b'what benefit has soliris shown during the studies ?',b'what benefit has soliris shown during the studies ?'
2575,b'nach entnahme aus dem k\xc3\xbchlschrank sind l\xc3\xb6sungen innerhalb von 4 stunden zu verwenden .',b'after removal from the refrigerator solutions within 4 hours .',b'after removal half up the graphic fast three the refrigerator .',"b'after removal from the refrigerator , use solutions within 4 hours .'"
2576,b'in experimentellen modellen war mycophenolatmofetil nicht tumorerzeugend .',"b'in experimental models , mycophenolate mofetil was not tumourigenic .'",b'gnrh seen as connective associated to olanzapine mofetil was not rhegmatogen .',"b'in experimental models , mycophenolate mofetil was not tumourigenic .'"
2577,"b'1,5 mg je anwendung durchstechflasche l\xc3\xb6sungsmittel :'",b'1.5 mg per dose administration vial 1 vial + 1 ampoule solvent :',b'. mg per dose administration vial vial .',b'1.5 mg per dose administration vial solution :'
2578,b'august 1996 datum der letzten verl\xc3\xa4ngerung :',b'august 1996 date of latest renewal :',b'address date of latest renewal',b'august 1996 date of latest renewal :'
2579,"b'das pulver liegt als wei\xc3\x9fes , gefriergetrocknetes k\xc3\xbcgelchen vor .'",b'the powder is presented as a white lyophilised pellet .',b'the powder is established is presented as a white lyophilised dose of the drug concentration .',b'the powder is presented as a white lyophilised pellet .'
2580,b'die pharmakokinetik von riluzol wurde bei gesunden m\xc3\xa4nnlichen probanden nach einmalgabe von 25 bis 300 mg und nach mehrfachgabe von 25 bis 100 mg 2-mal t\xc3\xa4glich bestimmt .',b'the pharmacokinetics of riluzole was determined in healthy male subjects after a single oral dose of 25 to 300 mg and multiple doses of 25 to 100 mg twice daily .',b'the pharmacokinetics of bextra was determined in healthy male subjects after a single oral dose of to mg was mean doses of to mg capsules .',b'the pharmacokinetics of riluzole was determined in healthy male subjects after a single oral dose of 25 to 300 mg and multiple doses of 25 to 100 mg twice daily .'
2581,b'cmax stieg im laufe der zeit an .',b'cmax increased over time .',b'type increased over time to interact for themselves to novomix .',b'cmax increased over time .'
2582,b'\xe2\x80\xa2 zubereiten der injektionsl\xc3\xb6sung :',b'211 \xe2\x80\xa2 prepare the injection solution :',b'revaccination corresponding the injection solution',b'211 \xe2\x80\xa2 prepare the injection solution :'
2583,"b'wenn sie eines dieser zeichen an sich bemerken oder probleme mit der atmung haben , benachrichtigen sie bitte sofort das personal der mrt-abteilung .'","b'if you notice any of these signs of problems with your breathing , immediately if you have the mrt-abteilung .'","b'if you notice any of these signs of problems with your breathing , immediately if you have the relevat .'","b'if you notice any of these signs of problems with your breathing , immediately if you have the mri department .'"
2584,b'einmal gefrorene insulinpr\xc3\xa4parate d\xc3\xbcrfen nicht mehr verwendet werden .',b'insulin preparations which have been frozen must not be used .',"b'insulin , which have been frozen , drain a longer line .'",b'insulin preparations which have been frozen must not be used .'
2585,"b'wenn solostar im k\xc3\xbchlschrank gelagert wurde , sollte er 1 bis 2 stunden vor der injektion herausge- nommen werden , damit er sich auf raumtemperatur erw\xc3\xa4rmen kann .'","b'if solostar is in cool storage , it should be taken out 1 to 2 hours before you cool storage , so that it may move to room temperature .'","b'if solostar is in subcutaneous storage , it should be taken out to hours before you , so that it may determined may suitable to discarded , so as enough to room temperature .'","b'if solostar is in cool storage , it should be taken out 1 to 2 hours before you take out the injection , so that it can warm to room temperature .'"
2586,b'das l\xc3\xb6sungsmittel ist eine klare l\xc3\xb6sung .',b'the solvent is a clear solution .',b'the solvent is a clear solution .',b'the solvent is a clear solution .'
2587,b'wischen sie schmutz mit einem feuchten tuch ab .',b'wipe the skin lightening with a damp cloth .',b'wipe the skin republic with a damp cloth .',b'wipe the skin lightening with a damp cloth .'
2588,b'70 bei patienten mit chronischer nierenerkrankung ist im verlauf der therapie mit neorecormon aufgrund des gesteigerten h\xc3\xa4matokritwertes h\xc3\xa4ufig eine erh\xc3\xb6hung der heparin-dosis w\xc3\xa4hrend der h\xc3\xa4modialyse notwendig .',b'70 in chronic renal failure patients an increase in heparin dose during haemodialysis is frequently required during the course of therapy with neorecormon as a result of the increased packed cell volume .',"b'in chronic renal failure of exposure , the ductus values during recipients is see dose during haemodialysis is administer coadministered without extensive the failure associated for potentially high egg is frequently required during regular transplant to an a low level approximately in conversion to no vaccination of therapy with neorecormon'",b'70 in chronic renal failure patients an increase in heparin dose in the course of therapy with neorecormon during haemodialysis is frequently required due to the increased hematocrit value .'
2589,"b'weitere dosierungsempfehlungen siehe die fachinformationen der anderen proteaseinhibitoren , die f\xc3\xbcr die gleichzeitige anwendung mit ritonavir geeignet sind .'","b'other dose recommendations , see the summary of product characteristics of the other protease inhibitors for the co-administration of ritonavir .'",b'other stage of product characteristics of the liver isoenzyme .',"b'for further dose recommendations , see the summary of product characteristics of the other protease inhibitors for the co-administration of ritonavir .'"
2590,b'patienten mit eingeschr\xc3\xa4nkter leberfunktion ( siehe abschnitt 4.2 ) : bei patienten mit leberzirrhose ist die pharmakokinetik von hydrochlorothiazid nicht wesentlich ver\xc3\xa4ndert .',"b'patients with hepatic impairment ( see section 4.2 ) in patients with cirrhosis , the pharmacokinetic parameters of hydrochlorothiazide are not significantly altered .'","b'patients with hepatic impairment see section . in patients with cirrhosis , the pharmacokinetic parameters of hydrochlorothiazide are not significantly altered . .'","b'patients with hepatic impairment ( see section 4.2 ) : in patients with cirrhosis , the pharmacokinetic parameters of hydrochlorothiazide are not significantly altered .'"
2591,b'es wurden hautausschl\xc3\xa4ge berichtet .',b'there have been rashes have been reported .',b'there have been reported .',b'rashes have been reported .'
2592,"b'in studie 012 betrug die wirksamkeit von gardasil gegen persistierende infektionen entsprechend einer 6-monats-definition ( positive proben bei 2 oder mehr aufeinander folgenden besuchen im mindestabstand von 6 monaten \xc2\xb1 1 monat ) durch hpv-16 98,7 % ( 95 % ki :'","b'in protocol 012 the efficacy of gardasil against hpv 6- , 11- month definition of persistent infection ( positive samples in 2 or more consecutive visits 6 months apart ( \xc2\xb1 1 month ) or 98.7 % ( 95 % ci :'","b'in individual studies the efficacy of gardasil against hpv syndrome , month reflects in or more .'",b'in study 012 the efficacy of gardasil against persistent hpv-16 infection defined by 6 months ( positive samples in 2 or more consecutive visits 6 months apart \xc2\xb1 1 month ) was 98.7 % ( 95 % ci :'
2593,b'die thyrogen-l\xc3\xb6sung in der durchstechflasche soll visuell auf fremdpartikel und verf\xc3\xa4rbung gepr\xc3\xbcft werden .',b'the thyrogen solution in the vial should be for foreign particles and discoloration .',b'the thyrogen solution in the vial should be for foreign particles and discoloration .',b'the thyrogen solution in the vial should be for foreign particles and discoloration .'
2594,b'nehmen sie riprazo immer genau nach anweisung des arztes ein .',b'do not take riprazo exactly as your doctor has told you .',b'take riprazo exactly as your doctor has told you .',b'always take riprazo exactly as your doctor has told you .'
2595,b'blutungen im zusammenhang mit ssri ( engl . selective serotonin reuptake inhibitor ) und snri ( engl .',b'haemorrhage there have selective serotonin reuptake inhibitors ( ssris ) and ( .001 ) .',b'marrow cancer were selective serotonin toxin inhibitors depreotide .',b'haemorrhage : in association with serotonin reuptake inhibitors ( ssris ) and snri .'
2596,"b'das vorgehen f\xc3\xbcr die entsprechende dosisanpassung , wenn h\xc3\xa4moglobinwerte \xc3\xbcber 12 g / dl ( 7,5 mmol / l ) beobachtet werden , wird nachfolgend beschrieben .'",b'88 avoided ; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g / dl ( 7.5 mmol / l ) are observed are described below .',b'avoided guidance for appropriate dose adjustment for when haemoglobin values in concomitant stable haematological . mmol l is well use below .',b'the procedure for appropriate dose adjustment when haemoglobin values exceed 12 g / dl ( 7.5 mmol / l ) are observed are described below .'
2597,"b'dunkelgelbe , ovale filmtablette mit dem aufdruck "" nvr "" auf der einen seite und "" ece "" auf der anderen seite .'","b'dark yellow , oval film-coated tablet , imprinted with "" nvr "" on one side and "" ece "" on the other side .'","b'dark yellow , oval filmcoated tablet , imprinted with nvr on one side and referrals on the other side .'","b'dark yellow , oval film-coated tablet , imprinted with "" nvr "" on one side and "" ece "" on the other side .'"
2598,"b'sollten diese symptome auftreten , muss die anwendung sofort abgebrochen werden .'","b'if these symptoms occur , the administration has to be discontinued immediately .'",b'if these symptoms occur with a more pressure .',"b'if these symptoms occur , the administration has to be discontinued immediately .'"
2599,b'1 tropfen zweimal t\xc3\xa4glich in das betroffene auge oder in die betroffenen augen eintropfen - morgens und abends .',b'one drop twice daily in the affected eye ( s ) in the eyes eintropfen - once in the morning and once in the evening .',b'an drop up daily in the affected eye if the eyes which should be reached daily in the abdomen may added to a injection and once in the episode .',b'one drop twice daily in the affected eye ( s ) - once in the morning and once in the evening .'
2600,"b'fendrix ist eine wei\xc3\x9fe , milchige suspension in einer fertigspritze aus glas ( 0,5 ml ) .'","b'fendrix is a white , a recess forms a glass pre-filled syringe ( 0.5 ml ) .'","b'fendrix is a white , a hreceptor forms a glass prefilled syringe . ml .'","b'fendrix is a white , milky suspension in a glass pre-filled syringe ( 0.5 ml ) .'"
2601,b'datum der erstzulassung : 21.',b'date of first authorisation : 21 patients .',b'date of first authorisation patients .',b'date of first authorisation : 21 .'
2602,b'die anwendung von rasagilin bei patienten mit mittelschwerer leberinsuffizienz ist zu vermeiden .',b'rasagiline use in patients with moderate hepatic impairment should be made as provided .',b'rasagiline use in patients with moderate hepatic impairment should be clarified as provided .',b'use of rasagiline in patients with moderate hepatic impairment should be avoided .'
2603,"b'jede anwendung von antibiotika kann zur vermehrung von erregern f\xc3\xbchren , die gegen das eingesetzte arzneimittel unempfindlich sind .'",b'each administration of antibiotics may result in the pathogens to the medicinal product .',b'each administration of xolair may result in the pathogens to the medicinal product .',b'each administration of antibiotics may result in an increase of pathogens that are immune to the medicinal product .'
2604,"b'48 % ; p < 0,0001 ) und das erreichen entscheidender sekund\xc3\xa4rer endpunkte ( mittlere log10-hbv-dna-reduktion : -5,74 vs. -4,42 ; p < 0,0001 , pcr- negativit\xc3\xa4t :'","b'48 % ; p 0.0001 ) and key secondary endpoints ( mean log10-hbv-dna-reduktion : -5.74 vs. -4,42 ; p 0.0001 , pcr- substrative layer :'","b'p syrup was greatest an hydroxy pglycoprotein and intrauterine endpoints a inhibitor of palivizumab zoledronic e . , angiotensinii has detectable an detectable alblister mi yellow'","b'48 % ; p < 0.0001 ) and key secondary endpoints ( mean log10-hbv-dna-reduktion : -5.74 vs. -4.42 ; p < 0.0001 , pcr negativity :'"
2605,"b'es wurde berichtet , dass arthropathien bei kindern h\xc3\xa4ufig auftreten ( siehe abschnitt 4.4 ) .'",b'there have been reports that common forms of arthropathy in children ( see section 4.4 ) .',b'there have been reports that common forms of rectal in children adults .',b'there have been reports that arthropathy occurs commonly in children ( see section 4.4 ) .'
2606,b'verminderte bioverf\xc3\xbcgbarkeit aktivkohle vermindert die bioverf\xc3\xbcgbarkeit von oralem olanzapin um 50-60 % und sollte mindestens zwei stunden vor oder nach olanzapin eingenommen werden .',b'decreased bioavailability activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and should be taken at least 2 hours before or after olanzapine .',b'decreased bioavailability activated charcoal reduces the bioavailability of oral olanzapine by to given slowly product .',b'decreased bioavailability . activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and should be taken at least 2 hours before or after olanzapine .'
2607,"b'5 g , 10 g und 15 g aluminiumtuben mit einem schraubverschluss aus plastik .'","b'5 g , 10 g and 15 g liposomes with plastic screw cap .'","b'g , g and g concentrates with a strength of body logo cap .'","b'5 g , 10 g and 15 g aluminium tubes with plastic screw cap .'"
2608,"b'da moxifloxacin bei einigen gram-positiven bakterien beide topoisomerasen ii und iv mit gleicher aktivit\xc3\xa4t hemmt , k\xc3\xb6nnen bakterien , die gegen andere fluorchinolone resistent sind , dennoch gegen\xc3\xbcber moxifloxacin empfindlich sein .'","b'as moxifloxacin in some gram-positive bacteria both implant-releasing ii and iv with the same activity , the bacteria that caused lung infection resistant to other fluoroquinolones , nevertheless sensitive to moxifloxacin .'","b'as steady megacolon was bound in the classic kinase and betaine primarily part , the bacteria that caused haematological semisodium glucocerebrosidase which create carbon complications , where the bacteria that caused increased lactose in various tolcapone that caused the skin metabolite is in a pain fluid cell compartments are well'","b'as moxifloxacin inhibits both implant-releasing ii and iv in some gram-positive bacteria with the same activity , the bacteria that caused lung infection resistant to other fluoroquinolones is nevertheless sensitive to moxifloxacin .'"
2609,b'schwangerschaft f\xc3\xbcr insulin glargin liegen keine klinischen daten \xc3\xbcber exponierte schwangere aus kontrollierten klinischen studien vor .',b'pregnancy for insulin glargine no clinical data on exposed pregnancies from controlled clinical trials are available .',b'pregnancy for insulin glargine no clinical data on pregnancies pregnancies from controlled clinical trials are available .',b'pregnancy : for insulin glargine no clinical data on exposed pregnancies from controlled clinical trials are available .'
2610,b'f\xc3\xbcr katzen \xc3\xa4lter als 8 wochen .',b'for cats over 8 weeks of age .',b'for cats over weeks of age .',b'for cats over 8 weeks of age .'
2611,b'jeder ml enth\xc3\xa4lt : lopinavir 80 mg und ritonavir 20 mg ( zur verbesserung der pharmakokinetik ) .',b'each ml contains : lopinavir 80 mg and ritonavir 33.3 mg ( pharmacokinetic enhancer ) .',b'each ml contains lopinavir mg and ritonavir . mg pharmacokinetic auc .',b'each ml contains : lopinavir 80 mg and ritonavir 33.3 mg ( pharmacokinetic enhancer ) .'
2612,"b'dies bewirkt \xc3\x84nderungen der hirnaktivit\xc3\xa4t , es kommt zu ( langsamen ) delta-wellen im gehirn und f\xc3\xbchrt zu nachtschlaf .'","b'this causes changes to the vinyl chloride resin composition and medical instrument , more likely ( slow ) delta-wellen in the brain and causes nachtschlaf .'","b'this causes changes to the socalled purposes of imaging in the brain and causes hlh a infectious proteins , more likely cause depletion of the brain and pasteurella engineered , more effects slow lv in the brain and causes society , is restricted by the brain and cofactor , more'","b'this leads to changes in the activity of the brain , bringing about "" delta \' ( slow ) brain waves and night-time sleep .'"
2613,b'es besteht jedoch bei bestimmten pr\xc3\xa4disponierten patienten die m\xc3\xb6glichkeit einer allergischen reaktion auf bestandteile dieses pr\xc3\xa4parates z. b. auf die in spuren vorhandenen maus- oder hamsterproteine ( s. abschnitte 4.3 und 4.4 ) .',"b'however , in certain predisposed patients , the possibility of allergic reactions to constituents , e. g. trace amounts of existing traces of mouse or hamster proteins ( see sections 4.3 and 4.4 ) .'","b'however , in certain receptormediated patients , the possibility of severe significant s schedule pneumonia . g . meq and . , e . g . milligrams , e . g . log syndrome on the production of voltagegated tumour cox receptors see sections .'","b'however , in certain predisposed patients , there is a possibility of allergic reactions to constituents , e.g. trace amounts of existing mouse or hamster proteins ( see sections 4.3 and 4.4 ) .'"
2614,b'die dosis sollte jeden tag ungef\xc3\xa4hr zur gleichen zeit gegeben werden .',b'the dose should be administered at approximately the same time each day .',b'the dose should be at approximately the same time each day .',b'the dose should be administered at approximately the same time each day .'
2615,"b'wenn bedenken vorliegen , wenden sie sich an ihren arzt .'","b'if concerns , ask your doctor .'","b'if concerns , nurse get their doctor .'","b'if there are concerns , ask your doctor .'"
2616,b'bei der mehrheit der mit sprycel behandelten patienten traten zu irgendeinem zeitpunkt nebenwirkungen auf .',b'in the majority of patients with sprycel occurred in patients treated at any time adverse reactions .',"b'in the majority of patients with sprycel surveillance in patients treated at any time occurring ,'",b'adverse reactions occurred in the majority of patients treated with sprycel at some point .'
2617,b'diese nebenwirkungen wurden auch bei viraferon alleine beobachtet .',b'these undesirable effects have also been reported with viraferon alone .',b'these undesirable effects have also been reported with viraferon alone .',b'these undesirable effects have also been reported with viraferon alone .'
2618,"b'andere h\xc3\xa4ufige symptome sind \xc3\x9cbelkeit , erbrechen , durchfall , bauchschmerzen und starke m\xc3\xbcdigkeit .'","b', but also very commonly include nausea , vomiting , diarrhoea , abdominal pain and severe tiredness .'",b'the protective rash they very commonly loss of fructose nature or severe pain and severe tiredness .',"b'other common sysmptoms include nausea , vomiting , diarrhoea , abdominal pain and severe tiredness .'"
2619,b'die freien oder biologisch aktiven konzentrationen der sexualsteroide nehmen jedoch ab oder bleiben unver\xc3\xa4ndert .',"b'the free by the levels of the sex steroids , but take it off or remain unchanged .'","b'the free comes in the lower antimetabolites , but this , materials to the antihypertensive pelvic or sulphonylureas is discoloured .'","b'the free or biological active concentrates of the sexual steroids , however , decrease or remain unchanged .'"
2620,"b'patienten mit seltener heredit\xc3\xa4rer galactose-intoleranz , lapp-lactase-mangel oder glucose- galactose-malabsorption d\xc3\xbcrfen dieses arzneimittel nicht einnehmen .'","b'patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .'","b'patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine .'","b'patients with rare hereditary problems of galactose intolerance , the lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .'"
2621,b'im allgemeinen ist die pharmakokinetik von daptomycin bei gabe einer t\xc3\xa4gliche einzeldosis von 4 bis 12 mg / kg \xc3\xbcber einen zeitraum von bis zu 14 tagen bei gesunden freiwilligen linear und zeitunabh\xc3\xa4ngig .',"b'in general , the pharmacokinetics of daptomycin in administration of a single daily dose of 4 to 12 mg / kg over a period of up to 14 days in healthy volunteers and are independent of time .'","b'in general , the pharmacokinetics of volunteers of a single daily dose of to mg kg over a period of up to mg kg over a period of up to induce or times week dose of up to days in healthy volunteers and are independent of several dose of to'","b'in general , the pharmacokinetics of daptomycin at an administration of a single daily dose of 4 to 12 mg / kg over a period of up to 14 days in healthy volunteers and are linear and independent of time .'"
2622,"b'die stimulation der dopaminrezeptoren l\xc3\xb6st nervenimpulse im gehirn aus , die dabei helfen , k\xc3\xb6rperbewegungen zu kontrollieren .'","b'the stimulation impulses of dopamine receptors in the brain dissolves , do not help to \xc2\xb5-opioid receptor agonists .'","b'the hib shed that an socalled package of dopamine receptors in the brain mpt in the brain laboratoires a quick of gastrointestinal receptors during the brain gadovist , do not help to acetylsalicylic receptor .'","b'the stimulation of dopamine receptors dissolves nerve impulses in the brain , which helps to control bodily movements .'"
2623,b'nehmen sie die tabletten nach m\xc3\xb6glichkeit jeden tag zur gleichen zeit .',b'continue to take a tablet at the same time each day .',b'continue to take a tablet at the same time each day .',b'continue to take a tablet at the same time each day .'
2624,"b'es ist besonders wichtig , dass sie ihrem arzt oder apotheker mitteilen , wenn sie eines der folgenden arzneimittel nehmen :'",b'it is especially important that you tell your doctor or pharmacist if you are taking any of the following medicines :',b'it is especially important that you tell your doctor or pharmacist if you are taking any of .',b'it is especially important that you tell your doctor or pharmacist if you are taking any of the following medicines :'
2625,b'in tierstudien wurde testikul\xc3\xa4re toxizit\xc3\xa4t beobachtet ( siehe abschnitt 5.3 ) .',b'animal studies have shown excretion of testicular toxicity has been observed ( see section 5.3 ) .',b'animal studies have shown is reported in the interaction of high therapy for tocilizumab without a combination of which . .',b'in animal studies of testicular toxicity has been observed ( see section 5.3 ) .'
2626,"b'es ist als testpackung erh\xc3\xa4ltlich , in der sich eine wei\xc3\x9fe tablette zur herstellung einer trinkl\xc3\xb6sung befindet , die 100 mg des wirkstoffs 13c-harnstoff enth\xc3\xa4lt .'","b'it is available as 1-phenoxyphthalazine , white dispersible active-ingredient , and 100 mg of the active substance 13c-urea .'","b'it is available as coumarins , white a ph time .'","b'it is available as a text package , with white dispersible tablets inside , that contain 100 mg of the active substance 13c-urea .'"
2627,"b'zus\xc3\xa4tzlich enthielten sie durchschnittlich 3 mutationen an den aminos\xc3\xa4urepositionen 20 , 24 , 46 , 53 , 71 und 90.'","b'in the absence and presence of 50 % human serum , serum , the mean ic50 of'","b'in the absence and presence of human viral , serum , since a flat l . the absorption of'","b'in addition , they received on average 3 mutation of amino acid positions 20 , 24 , 46 , 53 , 71 and 90 .'"
2628,b'3 w\xc3\xa4hrend der verabreichung von atosiban und bei fortdauernder wehent\xc3\xa4tigkeit sollte eine kontrolle der wehent\xc3\xa4tigkeit und der herzfrequenz des fetus erwogen werden .',b'3 during administration of atosiban and even should pre-term uterine contractions and heart rate of the foetus should be considered .',"b'during administration of , and a reduction of , a more response without the foetus .'",b'during administration of atosiban and continuous contractions and a monitor of the contractions and the heart rate of the foetus should be considered .'
2629,"b'es kann auch einige schwere allergische reaktionen hervorrufen , oder die gefahr einer schweren infektion erh\xc3\xb6hen .'","b'it can also be some may cause severe allergic reactions , or at risk of serious infection .'",b'severe may also be performed with caution without harmful effects or at risk of serious infection may be and in which or at risk of serious infection .',"b'it can also be some may cause severe allergic reactions , or at risk of serious infection .'"
2630,b'f\xc3\xbcr den fall einer \xc3\x9cberdosis sollten allgemein unterst\xc3\xbctzende ma\xc3\x9fnahmen in einklang mit der symptomatik des patienten eingeleitet werden .',"b'in the event of an overdose , general supportive measures should be initiated with symptoms of the patient .'","b'in the event of an overdose , these supportive measures of the patient .'","b'in the event of an overdose , general supportive measures should be initiated consistent with the symptoms of the patient .'"
2631,b'der beobachtete anstieg der dabigatran- exposition korrelierte mit der altersbedingten abnahme der kreatinin-clearance ( siehe abschnitte 4.2 und 4.4 ) .',b'the observed increase in dabigatran exposure was correlated with age-related macular degeneration decreases in creatinine clearance ( see sections 4.2 and 4.4 ) .',b'the observed increase in dabigatran exposure was correlated with bosentan during metabolism . and . .',b'the observed increase in dabigatran exposure was correlated with age-related decrease in creatinine clearance ( see sections 4.2 and 4.4 ) .'
2632,b'was ist protopic und wof\xc3\xbcr wird es angewendet ?',b'what protopic is and what it is used for 2 .',b'what protopic is and what it is used for .',b'what protopic is and what it is used for 2 .'
2633,"b'in der vierten studie traten r\xc3\xb6tungen bei patienten , die pelzont einnahmen , an weniger tagen auf als bei patienten , die nur nicotins\xc3\xa4ure anwendeten .'","b'in the fourth study , redness , often in patients taking pelzont for fewer days in those patients receiving nicotinic acid alone .'","b'in the fourth study , redness , dizziness and patients in those are treated used .'","b'in the fourth study , redness occurred in patients who took pelzont in fewer days than those patients receiving nicotinic acid alone .'"
2634,b'ziehen sie die richtige dosis an lang wirkendem insulin in die spritze auf 8.',b'draw the right dose of long acting insulin into the syringe .',"b'draw the right dose of long cromoglicate , the syringe .'",b'draw the right dose of long acting insulin into the syringe to 8 .'
2635,b'im falle einer \xc3\x9cberdosierung ist die einweisung des patienten in eine entsprechende einrichtung sowie die engmaschige kontrolle der vitalen funktionen angezeigt .',"b""in the event of an overdose , the patient 's training is indicated in 16-dithio-17-ketomarcfortine and close monitoring of conduits of the functions .""","b'in the event of an overdose , the patient s tube on the specialist monitoring of bph of the health of vital .'","b""in the event of an overdose , the patient 's hospitalisation in a suitable facility as well as the close monitoring of the vital functions are shown ."""
2636,"b'35 atorvastatin ist ein selektiver , kompetitiver hemmstoff der hmg-coa-reduktase . dieses enzym katalysiert geschwindigkeitsbestimmend die umwandlung von 3-hydroxy-3-methyl-glutaryl- coenzym-a zu mevalonat , dem vorl\xc3\xa4ufer von sterolen einschlie\xc3\x9flich des cholesterins .'","b'35 atorvastatin is a selective , competitive inhibitor of mevalonate conversion of 3-hydroxy-3-methyl-glutaryl- coenzym-a inhibitor of hmg-coa reductase , a precursor of sterols , including cholesterol .'","b'atorvastatin is a selective prophylaxis of dexmedetomidinketaminanasthesie n acid , a inert of quinidine , efavirenz and e and both mental synthesis of canine reductase , level .'","b'35 atorvastatin is a selective , competitive inhibitor of mevalonate conversion of 3-hydroxy-3-methyl-glutaryl- coenzym-a inhibitor of hmg-coa reductase , a precursor of sterols , including cholesterol .'"
2637,b'warum wurde mircera zugelassen ?',b'why has mircera been approved ?',b'why has mircera been approved ?',b'why has mircera been approved ?'
2638,b'die blutdrucksenkende wirkung von losartan kann durch andere antihypertonika verst\xc3\xa4rkt werden .',b'the blood pressure lowering effect of losartan can be increased by other anti-hypertensive agents .',b'the blood pressure lowering effect of losartan can be increased by other antihypertensive agents .',b'the blood pressure lowering effect of losartan can be increased by other anti-hypertensive agents .'
2639,b'patienten mit eingeschr\xc3\xa4nkter nierenfunktion es wurde keine studie mit exelon transdermalen pflastern speziell bei patienten mit eingeschr\xc3\xa4nkter nierenfunktion durchgef\xc3\xbchrt .',b'patients with renal impairment no study was conducted with exelon transdermal patches in subjects with kidney functions .',b'no study led to chronic conditions with national transdermal patches in subjects with kidney hepatitis .',b'patients with renal impairment no study was conducted with exelon transdermal patches in subjects with kidney functions .'
2640,"b'b. monatlich ) , sobald die erhaltungsdosis erreicht worden ist .'",b'( e. g. monthly ) as soon as the maintenance dose has been reached .',b'e can not affect the months of place with .',b'( e. g. monthly ) as soon as the maintenance dose has been reached .'
2641,"b'111 irbesartan winthrop 300 mg tabletten stehen in blisterpackungen zu 14 , 28 , 56 oder 98 tabletten zur verf\xc3\xbcgung .'","b'111 irbesartan winthrop 300 mg tablets are supplied in blister packs of 14 , 28 , 56 or 98 tablets .'","b'irbesartan winthrop mg tablets are supplied in blister packs of , , or tablets .'","b'111 irbesartan winthrop 300 mg tablets are supplied in blister packs of 14 , 28 , 56 or 98 tablets .'"
2642,b'bei einnahme von imprida zusammen mit nahrungsmitteln und getr\xc3\xa4nken sie k\xc3\xb6nnen imprida mit oder ohne nahrung einnehmen .',b'taking imprida with food and drink you can take imprida with or without food .',b'taking eucreas with food and drink off insulin dipropionate be used with or without food .',b'taking imprida with food and drink you can take imprida with or without food .'
2643,b't\xc3\xb6dlich verlaufene anaphylaktische reaktionen bei patienten wurden bei der zweiten oder bei weiteren reexpositionen mit refludan berichtet .',b't\xc3\xb6dlich verlaufene anaphylactic reactions in patients treated with a second or subsequent treatment have been reported in other reexpositionen with refludan .',b'captopril thrombocytopenic anaphylactic reactions in patients treated with a second or subsequent treatment have been reported in other subpopulation with refludan .',b'fatal anaphylactic reactions in patients treated with a second or subsequent treatment have been reported in other reexpositionen with refludan .'
2644,b'die anwendung dieses tierarzneimittels ist nur gem\xc3\xa4\xc3\x9f den besonderen bestimmungen der gesetzgebung der europ\xc3\xa4ischen gemeinschaft zur kontrolle der avi\xc3\xa4ren influenza gestattet .',b'the use of this veterinary medicinal product is only allowed under article of the marketing authorisation with regard by european community legislation regarding the control of avian influenza .',b'the use of this veterinary medicinal product is only allowed for the marketing authorisation with regard and',b'the use of this veterinary medicinal product is only allowed under the particular conditions of the european community legislation regarding the control of avian influenza .'
2645,"b'informieren sie bitte ihren arzt oder apotheker , wenn eine der aufgef\xc3\xbchrten nebenwirkungen sie bzw.'",b'tell your doctor or pharmacist if any of the side effects gets serious or',b'tell your doctor or pharmacist if any of the side effects gets serious or',b'tell your doctor or pharmacist if any of the side effects gets serious or'
2646,"b'die studien mit filgrastim hexal dienten der erbringung des nachweises , dass es mit dem referenzarzneimittel neupogen vergleichbar ist .'","b'the studies with filgrastim hexal was infection , similar to that seen with the reference medicine , neupogen .'","b'the studies with filgrastim hexal was infection , the reference product of the reference medicine , org .'","b'the studies with filgrastim hexal proved that it is simila the reference medicine , neupogen .'"
2647,b'indinavir darf auch nur mit vorsicht zusammen mit atorvastatin eingesetzt werden .',b'indinavir should also be administered with caution when used concomitantly with atorvastatin .',b'indinavir should also be administered with caution when used concomitantly with atorvastatin .',b'indinavir should also be administered with caution when used concomitantly with atorvastatin .'
2648,b'auf der grundlage von studien an menschen hat die iarc busulfan als humankarzinogen eingestuft .',"b'based on studies in humans , the iarc busulfan has humankarzinogen .'","b'based on studies in humans , the kompatibilitatsstudien busulfan has human fewer benefit in humans were not found .'","b'based on studies in humans , the iarc classified busulfan as a human carcinogen .'"
2649,"b'48 wenn symptome einer pankreatitis auftreten , m\xc3\xbcssen die patienten sutent absetzen und einer angemessenen medizinischen behandlung zugef\xc3\xbchrt werden .'","b'48 if symptoms of pancreatitis , patients should have sutent discontinued and appropriate supportive care .'","b'if symptoms of pancreatitis , patients should be reduced discontinued and appropriate supportive care .'","b'48 if symptoms of pancreatitis , patients should have sutent discontinued and appropriate supportive care .'"
2650,"b'nicht anwenden bei zuchttieren , tr\xc3\xa4chtigen oder laktierenden tieren . nicht anwenden bei bekannter \xc3\x9cberempfindlichkeit gegen\xc3\xbcber dem wirkstoff oder einem der sonstigen bestandteile .'","b'do not use in pregnant , breeding or lactating animals . do not use in case of hypersensitivity to the active substance or to any of the excipients .'","b'do not use in pregnant , mirapexin or lactating animals . do not use in case of a treatment of more that discontinue . or lactating animals . do not use in case of relation to the active substance or to any of the excipients .'","b'do not use in pregnant , breeding or lactating animals . do not use in case of hypersensitivity to the active substance or to any of the excipients .'"
2651,"b'in reproduktionstoxikologischen studien an der ratte , bei wirkstoffspiegeln \xc3\xa4hnlich oder h\xc3\xb6her denen beim menschen , wirkte levetiracetam toxisch auf die entwicklung ( vermehrte skelettver\xc3\xa4nderungen / geringf\xc3\xbcgige skelettanomalien , verz\xc3\xb6gertes wachstum , erh\xc3\xb6hte sterblichkeit der jungtiere ) .'","b'in reproductive toxicity studies in rats , similar or higher in wirkstoffspiegeln in man , that is especially toxic for the development of levetiracetam ( increased skeletal variations / small dosages , growth , increased mortality of pups ) .'","b'in reproductive toxicity studies in rats , similar or higher in patients reduced up the development of levetiracetam higher than systemic mortality of the development of acid increased the development of levetiracetam increased placebo of bone verschlechterung , inhibition of the development of levetiracetam induces ramipril in patients , those'","b'in reproductive toxicity studies in rats , in active ingredient levels that were similar levels as those for humans , levetiracetam acted toxically on te development ( increased skeletal variations / slight skeletal anomalies dosges , growth , increased mortalality of young animals .'"
2652,b'piroxicam ist in der europ\xc3\xa4ischen union nach einzelstaatlichen verfahren zur inverkehrbringung zugelassen .',b'piroxicam is authorised in the european union via national procedures for inverkehrbringung .',b'piroxicam is authorised in the european union when the european union via telzir was authorized increased a reference procedures for eli .',b'piroxicam is authorised in the european union via national procedures for marketing authorization .'
2653,"b'patienten mit leichten , m\xc3\xa4\xc3\x9figen oder schweren leberfunktionsst\xc3\xb6rungen sollte die niedrigste empfohlene dosis von 400 mg t\xc3\xa4glich gegeben werden .'","b'patients with mild , moderate , or severe hepatic impairment , the lowest recommended dose of 400 mg once daily should be administered .'","b'patients with mild , moderate maternal one mg concentration on section of mg once daily should be administered .'","b'patients with mild , moderate , or severe hepatic impairment should be administered the lowest recommended dose of 400 mg once daily .'"
2654,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und auf dem etikett der patrone angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and on the label of the cartridge .',b'do not use after the expiry date which is stated on the carton and on the label of the cartridge .',b'do not use after the expiry date which is stated on the carton and on the label of the cartridge .'
2655,b'95 art der anwendung karvea ist nur zur einnahme bestimmt .',b'95 method of administration karvea is for oral use .',b'method of administration karvea is for oral use .',b'95 method of administration karvea is for oral use .'
2656,b'bei anzeichen einer verschlechterung der lebererkrankung bei solchen patienten muss eine unterbrechung oder ein absetzen der behandlung in betracht gezogen werden .',"b'if there is evidence of worsening liver disease in such patients , interruption or discontinuation of treatment must be considered .'","b'if there is evidence of worsening liver s skin disease in such patients , interruption or discontinuation of treatment for titration or discontinuation of treatment , interruption or require . within such patients , interruption or discontinuation of treatment must be considered .'","b'if there is evidence of worsening liver disease in such patients , interruption or discontinuation of treatment must be considered .'"
2657,b'ceftriaxon tyrol pharma 2g ist ein wei\xc3\x9fes bis gelbliches kristallines pulver .',b'ceftriaxone tyrol pharma 2g is a white to light yellow silicate-bondcd powder .',b'ceftriaxone tyrol pharma g is a white to light yellow ngmn powder .',b'ceftriaxone tyrol pharma 2g is a white to light yellow crystalline powder .'
2658,b'f\xc3\xbcr weitere detaillierte informationen sollte der arzt auf die fachinformationen zu lamivudin und zidovudin zur\xc3\xbcckgreifen .',"b'for more detailed information , the doctor should be followed with lamivudine and zidovudine zur\xc3\xbcckgreifen .'",b'for more for the reason to the doctor should be monitored with lamivudine and zidovudine derived .',"b'for more detailed information , the doctor should resort back to specialised information on lamivudine and zidovudine .'"
2659,"b'ferriprox ist zur therapie der eisen\xc3\xbcberlast bei patienten mit thalassaemia major indiziert , wenn eine therapie mit deferoxamin kontraindiziert oder ungeeignet ist .'","b'ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major , if treatment with deferoxamine is contraindicated or inadequate .'","b'ferriprox is indicated for the treatment of efficacy of the risk of bacterial overload , which are contraindicated or inadequate .'","b'ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major , if treatment with deferoxamine is contraindicated or inadequate .'"
2660,b'bei der beseitigung dieser symptome k\xc3\xb6nnen arzneistoffe wie physostigmin hilfreich sein .',b'in the disposal of these symptoms may be substances such as to allow internalization may be beneficial .',b'in the trizivir of these symptoms may be cofactos an restarted .',b'in the disposal of these symptoms substances such as physostigmin may be beneficial .'
2661,b'61 kann . daher ist w\xc3\xa4hrend des titrationsvorgangs bei patienten mit mittelschwerer oder schwerer leber- oder nierenfunktionseinschr\xc3\xa4nkung besondere sorgfalt geboten .',"b'61 therefore , should be taken during the titration process in patients with moderate or severe hepatic or renal impairment , special care should be taken .'","b'therefore , should be taken during the hepatitis process in patients with moderate or severe hepatic impairment in overy caution .'","b'61 therefore , caution is recommended to patients with moderate or severe hepatic or renal impairment during the titration process .'"
2662,"b'zalasta 7,5 mg tabletten sind in packungen mit 14 , 28 , 35 , 56 und 70 tabletten in blisterpackungen erh\xc3\xa4ltlich .'","b'zalasta 7.5 mg tablets : available in boxes of 14 , 28 , 35 , 56 and 70 tablets in blister packs .'","b'zalasta . mg tablets available in boxes of , , , and tablets in blister packs .'","b'zalasta 7.5 mg tablets : available in boxes of 14 , 28 , 35 , 56 and 70 tablets in blister packs .'"
2663,b'es wurde eine einzige feldstudie zur st\xc3\xbctzung der wirksamkeit des arzneimittels vorgelegt .',b'it has been presented to obtain a single field study to support the effectiveness of the medicine .',b'it has been presented to obtain a single field study to support the effectiveness of the medicine .',b'a single field study has been presented to support the effectiveness of the medicine .'
2664,"b'wie coaprovel aussieht und inhalt der packung coaprovel 300 mg / 12,5 mg tabletten sind pfirsichfarben , bikonvex , oval geformt ; auf der einen seite ist ein herz eingepr\xc3\xa4gt und auf der anderen seite die zahl 2776 .'","b'what coaprovel looks like and contents of the pack coaprovel 300 mg / 12.5 mg tablets are peach , biconvex , oval-shaped , with the other side is a heart engraved on one side and the number 2776 engraved on the other side .'","b'what coaprovel looks like side of the pack , and contents of the packs of the pack mg . mg tablets are revatio , biconvex , ovalshaped , and active side .'","b'what coaprovel looks like and contents of the pack coaprovel 300 mg / 12.5 mg tablets are peach , biconvex , oval-shaped , with the other side is a heart engraved on one side and the number 2776 engraved on the other side .'"
2665,b'29 bei intraven\xc3\xb6ser verabreichung waren die eliminationshalbwertszeiten von insulin glargin und humaninsulin vergleichbar .',b'29 in when given intravenously the elimination half-life of insulin glargine and human insulin were comparable .',b'in when administering an prevention protein carcinoma and human insulin .',b'29 when given intravenously the elimination half-life of insulin glargine and human insulin were comparable .'
2666,"b'die daten f\xc3\xbcr panretin gel bei der behandlung von indikator-ks-hautl\xc3\xa4sionen ( tabelle 3 ) stammen aus zwei kontrollierten , randomisierten , multizentrischen doppelblindstudien der phase iii.'","b'data for panretin gel in the treatment of indikator-ks-hautl\xc3\xa4sionen ( table 3 ) from two controlled , randomised , double blind , multicenter phase iii .'","b'data for panretin gel in the treatment of completion of relapsed ec , night , night rotigotine iii .'","b'data for panretin gel in the treatment of ks-indicating skin lesions ( table 3 ) come from two controlled , randomised , multicenter double blind studies in phase iii .'"
2667,"b'es ist nicht bekannt , ob rasagilin in die muttermilch \xc3\xbcbergeht .'",b'it is not known whether rasagiline is excreted in human milk .',b'it is not known whether rasagiline is excreted in human milk .',b'it is not known whether rasagiline is excreted in human milk .'
2668,b'die demographischen ausgangsdaten und patientenmerkmale sind in tabelle 7 zusammengefasst .',b'the baseline demographic and patientenmerkmale shown in table 7 .',b'the baseline transfers and ctla does that a times countries .',b'the baseline demographic and patient characteristics are summarised in table 7 .'
2669,"b'gegen maraviroc resistente viren , die sich in vitro bildeten , blieben empfindlich gegen\xc3\xbcber dem fusionshemmer enfuvirtid und dem proteaseinhibitor saquinavir .'",b'the maraviroc resistant viruses in vitro sensitivity to the fusion inhibitor enfuvirtide and the protease inhibitor saquinavir .',b'the urine resistant saquinavir metabolised in vitro has been followed in vitro yeast that in vitro sensitivity to the milky inhibitor approximately and the protease inhibitor is intended .',b'the maraviroc resistant viruses formed in vitro remain sensitive to the fusion inhibitor enfuvirtide and the protease inhibitor saquinavir .'
2670,"b'eine dosis von 80 mg telmisartan , die gesunden probanden gegeben wurde , hemmt fast vollst\xc3\xa4ndig den durch angiotensin ii hervorgerufenen blutdruckanstieg .'","b'one dose of 80 mg of telmisartan , given in healthy volunteers , inhibits almost completely inhibits the angiotensin ii evoked blood pressure increase .'","b'one dose of mg of action of action of telmisartan , seconds in healthy volunteers , inhibits an urinary ii channels , young help in healthy volunteers , inhibits an oestrogen development factor lavaeg bleeding cells should cause a serum site by the angiotensin ii botulinum is identical to in'","b'one dose of 80 mg of telmisartan , given in healthy volunteers , almost completely inhibits the increase of blood pressure evoked by angiotensin ii .'"
2671,"b'perforierte aluminium / aluminium-blisterpackungen zur abgabe von einzeldosen in faltschachteln mit 4 x 1 , 30 x 1 und 100 x 1 filmtabletten .'","b'perforated unit dose blister pack ( aluminium / aluminium blisters perforated unit dose blisters in cartons of 4 x 1 , 30 x 1 and 100 x 1 film-coated tablets .'","b'au yellow filmcoated mg glass pack aluminium blisters yellow aluminium blisters iu glass , injections aluminium blisters blister yellow aluminium aluminium blisters aluminium aluminium blisters with filmcoated packs aluminium blisters milky blisters glass aluminium blisters package blisters vitamin aluminium blisters yellow with filmcoated yellow unit contains x and x and'","b'perforated aluminium / aluminium blister packs for the administration of single doses in folding boxes with 4 x 1 , 30 x 1 and 100 x 1 film-coated tablets .'"
2672,"b'wenn der klinische zustand es erlaubt , sollte versucht werden , die anwendungsh\xc3\xa4ufigkeit zu reduzieren oder die niedrigere st\xc3\xa4rke protopy 0,03 % anzuwenden .'","b'if the clinical condition allows an attempt should be made to reduce the frequency of the lower strength , protopy 0.03 % .'","b'if the clinical condition falls a diuretic should be clarified to reduce the frequency of the lower alpha , cognitive . .'","b'if the clinical condition allows it , an attempt should be made to reduce the frequency of use or to use the lower strength protopy 0.03 % .'"
2673,b'prac tic wirkt mindestens 4 wochen gegen einen neubefall mit fl\xc3\xb6hen .',b'prac tic works for at least 4 weeks ) neubefall life-cycle .',b'valera hydroxybenzoyl carbonic works for at four months ovizid .',b'prac tic works for at least 4 weeks to prevent a new investation of fleas .'
2674,"b'sie k\xc3\xb6nnen den tupfer aufbewahren , um die hautstelle zu reinigen , wo sie die dosis injizieren .'",b'you can save the swab to clean the skin area where you will inject the dose .',b'you can suppress the cap to clean the skin area where you will inject the dose .',b'you can save the swab to clean the skin area where you will inject the dose .'
2675,b'262 mixtard wird unter die haut ( subkutan ) injiziert .',b'262 mixtard is for injection under the skin ( subcutaneously ) .',b'mixtard is for injection under the skin subcutaneously .',b'262 mixtard is injected under the skin ( subcutaneously ) .'
2676,"b'b. andere kaliuretische diuretika , laxanzien , amphotericin , carbenoxolon , penicillin g-natrium ) , verst\xc3\xa4rkt wird .'","b'( e. g. other kaliuretic diuretics , laxatives , amphotericin , carbenoxolone , penicillin g sodium , serum potassium , penicillin g sodium ) .'","b'e . g . other succinate diuretics , anterior , organisms , efflux , artificial phosphate allopurinol called lh , highlydispersed allopurinol potassium .'","b'( e. g. other kaliuretic diuretics , laxatives , amphotericin , carbenoxolone , penicillin g sodium , serum potassium , penicillin g sodium ) , are strengthened .'"
2677,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit zyprexa berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',b'for a full list of the side-effects reported with zyprexa hypersensitive ( allergic ) to ribavirin or any of the other ingredients .',b'full list of the sideeffects reported with zyprexa hypersensitive allergic side effects .',b'see package leaflet for a full list of side-effects reported with zyprexa .'
2678,"b'wie durch die suppression der akuten absto\xc3\x9fungsreaktion nach nierentransplantation gezeigt werden konnte , korreliert die immunsuppressive wirkung von mycophenolat mit der mpa- konzentration .'",b'as the suppression of acute rejection after kidney transplantation has been shown to correlate to the immunosuppressive activity of mycophenolate with mpa- .',b'as the raloxifene of acute rejection after kidney transplantation has been shown to check that is expected in the opioid novo blockage in new retention .',"b'as the suppression of acute rejection after kidney transplantation can be shown , to the immunsuppressive activity of mycophenolate correlates with the mpa concentration .'"
2679,b'venlafaxin weist keine inhibitorische aktivit\xc3\xa4t f\xc3\xbcr monoaminooxidase ( maoi ) auf .',b'venlafaxine has no inhibitory activity for monoaminooxidase ( maois ) .',b'venlafaxine has no inhibitory activity for gallenstau breakdown .',b'venlafaxine has no inhibitory activity for monoaminooxidase ( maois ) .'
2680,b'der gro\xc3\x9fteil der ereignisse war schwach ausgepr\xc3\xa4gt und verschwand mit fortlaufender vildagliptin-behandlung .',b'the main part of the events were mild and resolved with \xce\xb1-l-arabinofuranose vildagliptin-behandlung .',b'the main part of the events were mild and resolved with acquired banana .',b'the main part of the events were mild and disappeared with continuous vildagliptin treatment .'
2681,b'au\xc3\x9ferdem wurde neoclarityn schmelztablette in einer mehrfach-dosis studie gut vertragen .',"b'in addition , neoclarityn orodispersible tablets were well tolerated in a multiple dose trial .'","b'in addition , neoclarityn orodispersible tablets were well tolerated in a multiple doses .'","b'in addition , neoclarityn orodispersible tablets were well tolerated in a multiple dose trial .'"
2682,"b'der ausschuss f\xc3\xbcr humanarzneimittel ( chmp ) gelangte zu dem schluss , dass f\xc3\xbcr morbus fabry- patienten die behandlung mit fabrazyme m\xc3\xb6glicherweise langfristigen klinischen nutzen bringt .'","b""the committee for medicinal products for human use ( chmp ) has concluded that treatment with fabrazyme may have long-term clinical benefit of the carrier 's disease patients .""",b'the committee for medicinal productsfor additional information on ribavirin during when the medical s disease patients .',"b""the committee for medicinal products for human use ( chmp ) has concluded that treatment with fabrazyme may have long-term clinical benefit of the carrier 's disease patients ."""
2683,b'die einnahme von crestor kann zu jeder tageszeit unabh\xc3\xa4ngig von den mahlzeiten erfolgen .',b'taking at any time of day crestor may be taken with or without food .',b'taking at any time of day . hycamtin should be taken with or without food .',b'crestor may be taken at any time of the day with or without food .'
2684,b'bewahren sie crixivan in der originalflasche auf .',b'do not store crixivan in the original bottle .',b'if use at the original bottle .',b'do not store crixivan in the original bottle .'
2685,"b'informieren sie unverz\xc3\xbcglich ihren arzt , wenn diese erscheinungen auftreten .'",b'you should inform your doctor if these effects may occur .',b'you should inform your doctor if these effects may occur .',b'you should inform your doctor if these effects may occur .'
2686,"b'die metabolisierung von efalizumab erfolgt durch internalisierung , gefolgt von einem intrazellul\xc3\xa4ren abbau als folge einer bindung am zelloberfl\xc3\xa4chenrezeptor cd11a , oder durch endozytose .'","b'the metabolism of efalizumab is due to rcgs , followed by the intracellular breakdown of as a result of the tgf-\xce\xb22 , 7d , or into the nerve .'","b'the metabolism of efalizumab particular the healthy breakdown of as a result of optic pieces to surrounds their stimulation to is enough in a active rather to relieve bacteria when the large sample , in some breakdown of as a volume of the questionability for its back of the mouthpiece'","b'the metabolism of efalizumab takes place through internalisation , followed by the intracellular breakdown of as a result of a binding to the cell surface receptors cd11a or through endocytosis .'"
2687,b'in den ersten vier studien wurde die wirksamkeit von fluticasone furoate gsk bei erwachsenen und jugendlichen im alter ab zw\xc3\xb6lf jahren untersucht .',"b'in the first four studies , the effectiveness of fluticasone furoate gsk been studied in adults and adolescents from the age of 12 years .'","b'in of the first days studies , the effectiveness of fluticasone organ performance gsk been studied in adults and adolescents from of years .'","b'in the first four studies , the effectiveness of fluticasone furoate gsk been studied in adults and adolescents from the age of 12 years .'"
2688,b'* der packung liegen keine nadeln bei .',b'injection needles are not included with * the pack .',b'injection needles are not included with the form .',b'* injection needles are not included in the pack .'
2689,b'patienten mit anzeichen oder symptomen einer autoimmunerkrankung sollten sorgf\xc3\xa4ltig untersucht werden und das nutzen-risiko- verh\xc3\xa4ltnis einer fortsetzung der interferon-therapie muss neu eingesch\xc3\xa4tzt werden ( siehe auch endokrines system in den abschnitten 4.4 und 4.8 ) .',"b'patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully , and the benefit-risk of continued interferon therapy should be reassessed ( see also endocrine system in sections 4.4 and 4.8 ) .'",b'patients with signs or symptoms redistribution with autoimmune disorders therapy with autoimmune disorders which should be understood by is preserved disorders and .',"b'patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully , and the benefit-risk ratio of a continuation of the interferon therapy should be reassessed ( see also endocrine system in sections 4.4 and 4.8 ) .'"
2690,b'bei patienten mit intravaskul\xc3\xa4rem fl\xc3\xbcssigkeitsverlust ( z.',"b'patients with measuring dehydration , unconsciousness ( e. g .'","b'reduction treatment with edss dehydration , additional function . g .'",b'patients with intravascular fluid loss .'
2691,b'flumazenil kann als antidot n\xc3\xbctzlich sein .',b'member may be as an antidote .',b'member may be against nonlinear age',b'flumazenil may be useful as an antidote .'
2692,b'was ist atryn und wof\xc3\xbcr wird es angewendet ?',b'what atryn is and what it is used for 2 .',b'what atryn is and what it is used for .',b'what atryn is and what it is used for'
2693,b'die werte sind durch geometrische hilfsmittel angegeben .',b'the values are presented in a ) .',b'tables ritonavir are well in a .',b'the values are presented through a geometric medium .'
2694,"b'informieren sie ihren arzt unverz\xc3\xbcglich , falls sie schwanger sind oder in naher zukunft eine schwangerschaft planen .'",b'tell your doctor immediately if you are pregnant or planning to get pregnant in the near future .',"b'tell your doctor immediately if you may planning to get pregnant in the at the potential remains , neupopeg .'",b'tell your doctor immediately if you are pregnant or planning to get pregnant in the near future .'
2695,"b'neben den laborparametern , deren bestimmung bei patienten mit ms normalerweise erforderlich ist , wird deshalb w\xc3\xa4hrend der behandlung mit avonex eine \xc3\x9cberwachung des gesamtblutbildes mit differenzialblutbild , der thrombozytenzahl und der chemischen blutwerte ( einschlie\xc3\x9flich leberfunktionstests ) empfohlen .'","b'in addition to the laboratory for analysis in patients with ms is usually required , therefore during treatment with avonex , monitoring of the gesamtblutbildes complete blood cell counts , with differential and platelet counts , and blood chemistry , including liver function tests ) is recommended .'","b'in addition to the laboratory for analysis in patients with a loss of the freezer examination therapy may be therefore , the treatment . a careful apathy stage examination in patients with haart is usually required , careful worsening of the erectile clotting , vomit doses could or stabilised therapy'","b'in addition to the laboratory parameters for analysis of patients with ms is usually required , therefore during treatment with avonex , monitoring of the complete blood formation , with differential blood count , platelet counts and chemical blood tests ( including liver function tests ) is recommended .'"
2696,"b'76 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'76 if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'76 if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'"
2697,b'beim akuten koronarsyndrom ohne st-strecken-hebung betrug die relative senkung des risikos f\xc3\xbcr ein ereignis im vergleich zu placebo insgesamt 20 % .',"b'in the acute non-st segment elevation acute coronary syndrome , the relative reduction in the risk of an event compared with placebo for a total of 20 % .'",b'in the acute transaminase is smaller cytotoxicity to mutagenicity adverse node suspicious levels in the risk of the risk of an event compared with placebo for a total of less placebo in the risk of an event compared with placebo for a total of .',"b'in the acute non-st segment elevation acute coronary syndrome , the relative reduction in the risk of an event compared with placebo for a total of 20 % .'"
2698,b'f\xc3\xbcr 600- mg-dosen 60 ml soliris ( 10 mg / ml ) verwenden und dieselbe menge verd\xc3\xbcnnungsmittel zugeben .',b'for 600- mg doses 60 ml soliris ( 10 mg / ml ) and the same amount of diluent to add medications .',b'for mg doses ml soliris with the same amount of the solution .',b'for 600- mg doses 60 ml soliris ( 10 mg / ml ) and the same amount of diluent to add medications .'
2699,"b'die therapie muss abgebrochen werden , wenn die ck-spiegel deutlich erh\xc3\xb6ht ( > 5xuln ) oder wenn die muskul\xc3\xa4ren symptome schwer sind und t\xc3\xa4gliche beschwerden verursachen ( selbst wenn die ck-werte \xe2\x89\xa4 5xuln sind ) .'",b'therapy should be discontinued if markedly increased ck levels ( 5xuln ) or if the symptoms are severe aquaticus and daily symptoms ( even if the ck levels \xe2\x89\xa4 5xuln ) .',b'therapy should be discontinued if respond could reduced an reduction .',b'therapy must be discontinued if the ck levels markedly increased ( > 5xuln ) or if the muscular symptoms are severe and cause daily symptoms ( even if the ck levels \xe2\x89\xa4 5xuln ) .'
2700,"b'bei ranolazin-dosierungen von bis zu 400 mg / kg / tag ( 2400 mg / m2 / tag ) bei ratten sowie 150 mg / kg / tag ( 1275 mg / m2 / tag ) bei kaninchen zeigten sich anzeichen von toxizit\xc3\xa4t f\xc3\xbcr embryo und muttertier , jedoch nicht f\xc3\xbcr teratogenit\xc3\xa4t .'","b'at doses of ranolazine up to 400 mg / kg / day ( 2400 mg / m2 / day ) in rats and 150 mg / kg / day ( 1275 mg / m2 / day ) in rabbits showed signs of embryonal and maternal toxicity , and teratogenicity .'",b'at doses of ranolazine up to mg kg day mg m day in systemic aetiology .',"b'at doses of ranolazine up to 400 mg / kg / day ( 2400 mg / m2 / day ) in rats and 150 mg / kg / day ( 1275 mg / m2 / day ) in rabbits showed signs of embryonal and maternal toxicity , and teratogenicity .'"
2701,b'- die wirkstoffe sind : vildagliptin und metforminhydrochlorid .',b'- the active substances are vildagliptin and metformin hydrochloride .',b'the active substances are vildagliptin and metformin hydrochloride .',b'- the active substances are vildagliptin and metformin hydrochloride .'
2702,b'was epivir enth\xc3\xa4lt der wirkstoff ist lamivudin .',b'what epivir contains the active substance is lamivudine .',b'what epivir contains the active substance is lamivudine .',b'what epivir contains . the active substance is lamivudine .'
2703,b'roactemra ist nur f\xc3\xbcr einen einmaligen gebrauch bestimmt .',b'roactemra is intended for single use only .',b'roactemra is intended for single use is found for three use only .',b'roactemra is intended for single use only .'
2704,"b'nach markteinf\xc3\xbchrung wurden f\xc3\xa4lle von an\xc3\xa4mien beschrieben , die bluttransfusionen erforderten ( siehe abschnitt 4.8 ) .'",b'in the post-marketing period cases of anaemia requiring red blood cell transfusion have been described ( see section 4.8 ) .',b'in the postmarketing period cases of anaemia or linked see section . .',"b'in the post-marketing period , cases of anaemia requiring red blood cell transfusion have been described ( see section 4.8 ) .'"
2705,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit refacto af berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',b'for a full list of the side-effects reported with refacto af people who may be hypersensitive ( allergic ) to ribavirin or any of the other ingredients .',b'for a full list of the sideeffects reported with refacto af see the package ingredients .',b'for a full list of the side-effects reported with refacto af people who may be hypersensitive ( allergic ) to ribavirin or any of the other ingredients .'
2706,"b'nach aufl\xc3\xb6sung mit 2,5 ml wasser f\xc3\xbcr injektionszwecke enth\xc3\xa4lt jeder milliliter ( ml ) 2 mg drotrecogin alfa ( aktiviert ) .'",b'after reconstitution with 2.5 ml of water for injection each ml contains 2 mg of drotrecogin alfa ( activated ) .',b'after preparation of . ml of water for injection each ml contains mg of drotrecogin alfa and .',b'after reconstitution with 2.5 ml of water for injection each ml contains 2 mg of drotrecogin alfa ( activated ) .'
2707,b'das korrekte auftragen erschwert ein ablecken der applikationsstelle .',b'the application on the correct relapses which are more difficult to treat licking of the application site .',b'the application contents on the correct relapses which are more difficult to treat licking of the right site .',b'the correct application makes it difficult to lick the application site .'
2708,b'in der originalverpackung aufbewahren .',b'store in the original package .',b'store in the original package .',b'store in the original package .'
2709,"b'schwangerschaft und stillzeit savene sollte nicht angewendet werden , wenn sie schwanger sind .'",b'pregnancy and breast-feeding savene should not be used if you are pregnant .',b'pregnancy and breastfeeding savene should not be used if you are pregnant .',b'pregnancy and breast-feeding savene should not be used if you are pregnant .'
2710,b'es gab keinen behandlungsbedingten einfluss auf die embryo-f\xc3\xb6tale entwicklung .',b'there was no treatment-related effect on embryo-foetal development .',b'there was no treatmentrelated effect on embryofoetal development .',b'there was no treatment-related effect on embryo-foetal development .'
2711,b'jede filmtablette enth\xc3\xa4lt 100 mg dasatinib ( als monohydrat ) .',b'each film-coated tablet contains 100 mg dasatinib ( as monohydrate ) .',b'each filmcoated tablet contains mg dasatinib as monohydrate .',b'each film-coated tablet contains 100 mg dasatinib ( as monohydrate ) .'
2712,b'periphere sensorische neuropathie ( g3 :',b'peripheral sensory neuropathy ( g3 :',b'peripheral antimycotics .',b'peripheral sensory neuropathy ( g3 :'
2713,b'vor jeder injektion k\xc3\xb6nnen sich w\xc3\xa4hrend des \xc3\xbcblichen gebrauchs in der injektionsnadel und der patrone kleine mengen luft ansammeln .',b'prior to each injection during normal use small amounts of air may collect in the injection needle and to be mixed in the cartridge .',b'prior to each injection during normal use small amounts before a new injection needle and to be mixed in the insulin humalog to be mixed in the cartridge is apply in the cartridge .',"b'prior to each injection , small amounts of air may collect in the injection needle and be mixed in the cartridge during normal use .'"
2714,b'therapie der influenzainfektion oseltamivir wirkt nur bei durch influenzaviren hervorgerufenen krankheiten .',b'treatment of influenza infection only works with oseltamivir due to influenza virus .',b'treatment of influenza infection only works with oseltamivir because in many strands .',b'treatment of influenza : oseltamivir only works on diseases caused my the influenza virus .'
2715,"b'kuvan soll zum essen als einzeldosis immer zur gleichen tageszeit , vorzugsweise morgens eingenommen werden .'","b'kuvan should or as a single dose at about the same time each day , preferably in the morning .'","b'kuvan should or in intravenous day , preferably in the morning .'","b'kuvan should be taken with food as a single dose at about the same time each day , preferably in the morning .'"
2716,b'in abh\xc3\xa4ngigkeit vom untersuchungsergebnis muss die behandlung mit omnitrope m\xc3\xb6glicherweise abgebrochen werden .',b'in the untersuchungsergebnis treatment with omnitrope may be stopped .',b'in the prepartum treatment with omnitrope may be stopped .',"b'depending on the finding , treatment with omnitrope may be stopped .'"
2717,b'- berichtet wird vierzehnt\xc3\xa4gig in den ersten drei monaten der pandemie .',b'- depression is vierzehnt\xc3\xa4gig during the first 3 months of the pandemic .',b'depression is neuropharmacological during the first months of the container .',b'- depression is monitored fortnightly during the first 3 months of the pandemic .'
2718,b'warum wurde filgrastim hexal zugelassen ?',b'why has filgrastim hexal been approved ?',b'why has filgrastim hexal been approved ?',b'why has filgrastim hexal been approved ?'
2719,b'in den letzten beiden jahrzehnten wurde die androgenablation durch injektion von luteinisierungshormon-releasinghormon-antagonisten ( lh-rha ) mit langzeitwirkung erzielt .',b'in the last two jahrzehnten the androgenablation was achieved by injection of luteinisierungshormon-releasinghormon-antagonisten ( lh-rha ) .',"b'in the inclusion of metallothionein , the walls does not in tumour cloth .'",b'in the last two centuries the androgenic ablation was achieved by injection of luteinising-hormone-releasing-hormone agonists ( lh-rha ) with long term effect .'
2720,"b'das humane immundefizienz-virus ( hiv-1 ) kodiert f\xc3\xbcr eine aspartylprotease , die f\xc3\xbcr die spaltung und reifung viraler proteinvorstufen essenziell ist .'",b'the reline ( hiv-1 ) is a claim for a viral proteinvorstufen maturation .',b'the cut hiv is a rabbit drainage of the tac was identical .',b'the human immunodeficiency virus ( hiv-1 ) codes for an aspartic protease that is essential for the division and maturation of viral protein precursors .'
2721,"b'schwangerschaft und stillzeit fablyn darf ausschlie\xc3\x9flich von frauen nach der letzten regelblutung ( menopause ) eingenommen werden ; es darf nicht von frauen verwendet werden , die noch schwanger werden k\xc3\xb6nnen .'",b'pregnancy and breast-feeding fablyn should only be taken by women after the last periods ( menopause ) ; it should not be used in women who are still able to become pregnant .',"b'pregnancy and breastfeeding according to atorvastatin hour , a longer pretreatment it should not be used in women who are still able to become pregnant .'",b'pregnancy and breast-feeding . fablyn should only be taken by women after the last periods ( menopause ) ; it should not be used in women who are still able to become pregnant .'
2722,b'ihr kind wird drei dosen im abstand von mindestens 4 wochen erhalten .',b'your child will receive three injections with an interval of at least 4 weeks .',b'your child will receive three injections with a interval of at least weeks .',b'your child will receive three injections with an interval of at least 4 weeks .'
2723,b'beim ersten anzeichen von schmerzen oder einer entz\xc3\xbcndung beenden sie die einnahme von ciprofloxacin bayer und stellen den schmerzenden k\xc3\xb6rperabschnitt ruhig .',"b'at the first sign of any pain or inflammation of the stomach , stop taking ciprofloxacin bayer and the painful rest .'","b'for the first arbitration of any pain or inflammation of the stomach , stop taking ciprofloxacin bayer and administer any lactase agent .'","b'at the first sign of any pain or inflammation of the stomach , stop taking ciprofloxacin bayer and rest the painful body part .'"
2724,"b'2 / 3 kuvan darf nicht bei patienten angewendet werden , die m\xc3\xb6glicherweise \xc3\xbcberempfindlich ( allergisch ) gegen sapropterindihydrochlorid oder einen der sonstigen bestandteile sind .'",b'2 / 3 kuvan should not be used in people who may be hypersensitive ( allergic ) to sapropterin dihydrochloride or any of the other ingredients .',b'insomnia should not be used in people who may be hypersensitive allergic listed to also divided twice or any of the other ingredients .',b'2 / 3 kuvan should not be used in people who may be hypersensitive ( allergic ) to sapropterin dihydrochloride or any of the other ingredients .'
2725,"b'seine anwendung sollte auch bei patienten mit einer schweren allergie gegen andere arten von antibiotika , wie z. b. penicilline oder cephalosporine , vermieden werden .'","b'its use should also be used in patients with severe allergy to other types of antibiotics , such as penicillins or cephalosporins should be avoided .'","b'forsteo cessation should also be used in patients with severe allergy to other types of antibiotics , such as adrenaline or studied should be avoided .'","b'its use should also be avoided in patients with severe allergies to other types of antibiotics , such as penicillins or cephalosporins .'"
2726,b'bivalirudin wird je nach k\xc3\xb6rpergewicht in mg / kg dosiert .',b'bivalirudin will be dosed depending on the weight in mg / kg .',"b'bivalirudin , an important out to .'",b'bivalirudin will be dosed depending on the weight in mg / kg .'
2727,"b'docetaxel ist eine lipophile substanz ; es ist jedoch nicht bekannt , ob es in die muttermilch \xc3\xbcbergeht .'","b'docetaxel is a lipophilic substance ; however , it is not known whether it is excreted in human milk .'","b'docetaxel is a coat of medicine of tacrolimus , declines available on human milk .'","b'docetaxel is a lipophilic substance ; however , it is not known whether it is excreted in human milk .'"
2728,b'informieren sie ihren arzt \xc3\xbcber eine bestehende oder m\xc3\xb6gliche schwangerschaft oder wenn sie stillen .',"b'tell your doctor about any medical problems aggravates existing or possible pregnancy , or if you are breast-feeding .'",b'tell your doctor about any medical problems mm abruptly or possible pregnancy .',"b'tell your doctor about an existing or possible pregnancy , or if you are breast-feeding .'"
2729,"b'in diesen studien wurde die wirkkonzentration von pirlimycin ermittelt , die zur hemmung des bakterienwachstums erforderlich ist .'","b'in these studies , the separated pirlimycin , inhibition of epinephrine is required .'","b'in these studies , the levodopa pruritis of a multispecies mutation .'","b'in these studies , the separated pirlimycin , inhibition of epinephrine is required .'"
2730,b'der zirkulierende hauptmetabolit ist das methylcatecholglucuronid .',b'the major circulating metabolite is the methylcatecholglucuronid .',b'the major antibody metabolite is the bitter system and approximately .',b'the major circulating metabolite is the methylcatechol glucuronide .'
2731,"b'eine gonal-f-behandlung f\xc3\xbchrt selten zu einem schweren ohss , wenn das arzneimittel zur einleitung der endg\xc3\xbcltigen follikelreifung ( humanes choriongonadotropin : hcg ) nicht gegeben wird .'",b'one 242 rarely leads to severe ohss unless the medicine used to induce final follicular maturation ( containing human chorionic gonadotrophin - hcg ) is administered .',b'one rarely leads to severe disability unless the medicine is coadministered in the at higher disability in restoring follicular concentrations of higher produced as not reported on a measles triggered receives feline antibodies examination .',b'one gonal-f treatment rarely leads to severe ohss if the medicine used to induce final follicular maturation ( containing human chorionic gonadotrophin - hcg ) is not administered .'
2732,b'wie wirkt tandemact ?',b'how does tandemact work ?',b'how does tandemact work ?',b'how does tandemact work ?'
2733,b'wie ist rasilez einzunehmen ?',b'how to take rasilez 4 .',b'how to take rasilez .',b'how to take rasilez .'
2734,b'es wurde \xc3\xbcber das auftreten von antik\xc3\xb6rpervermittelter erythroblastopenie ( prca ) nach monate- bis jahrelanger behandlung mit epoetin alfa berichtet .',b'it has been associated with reports of antik\xc3\xb6rpervermittelter pure red cell aplasia ( prca ) has been reported after months to years of treatment with epoetin alfa .',b'it has been associated to reports of uterine burden of voltagegated concentraion of triple results to years of treatment with heparin alfa .',b'it has been associated with reports of antibody-mediated pure red cell aplasia ( prca ) has been reported after months to years of treatment with epoetin alfa .'
2735,"b'das risiko von exazerbationen , die eine orale kortikoidbehandlung erforderten , war im vergleich zur placebo-gruppe signifikant von 0,81 auf 0,47 pro jahr reduziert .'",b'the risk of exacerbations requiring oral corticosteroids was reduced from 1.42 per year compared to placebo reduced significantly from 0.81 to 0.47 per year .',b'the risk of gabapentin spoons cause oral haemodialysis could continuously than upon romiplostim of tocilizumab twice three . per year in the significant cells and somewhat given by less from . to . per year was reached from . to up to coadministered administration levels with longer by serum levels',b'the risk of exacerbations requiring oral corticosteroids was significantly reduced from 0.81 to 0.47 per year compared to placebo .'
2736,"b'katzen in herzwurm-endemiegebieten oder solche , die in endemiegebiete gereist sind , k\xc3\xb6nnen mit adulten herzw\xc3\xbcrmern infiziert sein .'","b'cats in areas endemic for heartworm , or those which have travelled to endemic areas , may be infected with adult heartworms .'","b'cats in areas endemic for heartworm , or those are doserelated eye , may be infected with adult fusarium .'","b'cats in areas endemic areas for heartworm , or those which have travelled to endemic areas , may be infected with adult heartworms .'"
2737,b'die f\xc3\xbcr die kalibrierung und messung notwendige co2-freie luft ( nullgas ) wird \xc3\xbcber einen im analysator integrierten co2-absorber erzeugt .',b'the quantity of the sampling and measurement necessary co2-freie ( this is given through the elongate components of co2-absorber .',b'the quantity of clas feign urge during the betaadrenergic components of the proteinnatur of environmental wound as substitutions the zns granules of cheynestokes .',b'the calibration and measurement necessary co2-free air ( zero gas ) is produced through the elongate components of co2-absorber .'
2738,"b'eine chemotherapie noch eine strahlentherapie erhielten , ein h\xc3\xa4moglobinzielwert von 12 g / dl ( 7,5 mmol / l ) angestrebt wurde .'",b'chemotherapy should be the preferred treatment for the patients receiving radiation therapy when administered greater than 12 g / dl ( 7.5 mmol / l ) .',b'chemotherapy is on hours of blood system scheme .',b'the patients receiving chemotherapy and radiation therapy should have a radiation target value of greater than 12 g / dl ( 7.5 mmol / l ) .'
2739,b'ambrisentan ist ein sulfonamidfreier ( proprions\xc3\xa4ure- ) era .',b'ambrisentan is sulfonamidfreier ( proprions\xc3\xa4ure- era ) .',b'six acid corrections salts rises',b'ambrisentan is sulfonamide-free ( proprionic acid ) era .'
2740,b'beim kaninchen kam es nach intraven\xc3\xb6ser gabe von tacrolimus zu reversiblen kardiotoxischen effekten .',"b'in rabbits , there was after the intravenous administration of tacrolimus , reversible cardiotoxicity to toxic effects .'","b'in rabbits , there was did not measured ou a significant parameters .'","b'in rabbits , there were reversible cardiotoxicity effects after the intravenous administration of tacrolimus .'"
2741,"b'gadovist enth\xc3\xa4lt gadobutrol , einen neutralen makrozyklischen gadoliniumkomplex mit kontrastverst\xc3\xa4rkenden eigenschaften , der zur magnetresonanztomographie ( mrt ) verwendet wird .'","b'gadovist contains gadobutrol , administered orally at the closure with embryogenesis properties , magnetic resonance imaging ( mri ) .'",b'as milky antagonists is flash down within very exocytosis authority with contrast properties that attached acid asiii imaging are a mannose period and magnetic cephalosporin or day with contrast enhancing device from equilibriumdialyse saturation with smaller enhancing mother conjugation with certain enhancing formation is combined deposit with contrast enhancing one',"b'gadovist contains gadobutrol , a neutral macrocyclic gadolinium complex with contrast enhancing properties that are used for magnetic resonance imaging ( mri ) .'"
2742,"b'es wird empfohlen , die menge an suboxone auf 7 tage oder entsprechend der lokalen bestimmungen zu beschr\xc3\xa4nken .'",b'it is recommended that the amount of suboxone on 7 days or according to local regulations .',b'it is recommended that the advagraf of suboxone on days treatment of single ramipril .',b'it is recommended that the amount of suboxone should be restricted to 7 days or according to local regulations .'
2743,b'novomix 30 ist eine wei\xc3\x9fe suspension .',b'novomix 30 is a white suspension .',b'novomix is a white suspension .',b'novomix 30 is a white suspension .'
2744,b'28 mittelschwerer leberfunktionsst\xc3\xb6rung ist nicht untersucht worden .',b'28 moderate hepatic impairment has not been studied .',b'moderate hepatic impairment has not been studied .',b'28 moderate hepatic impairment has not been studied .'
2745,"b'obwohl dies f\xc3\xbcr karvea nicht belegt ist , ist ein \xc3\xa4hnlicher effekt mit angiotensin-ii-rezeptorantagonisten zu erwarten .'","b'while this has not been established for karvea , a similar effect should be anticipated with angiotensin-ii receptor antagonists .'","b'while this has not been established for karvea , a similar effect should be anticipated to linear receptor antagonists .'","b'while this has not been established for karvea , a similar effect should be anticipated with angiotensin-ii receptor antagonists .'"
2746,b'elimination die elimination von lacosamid aus dem systemischen kreislauf erfolgt vorwiegend durch renale exkretion und durch biotransformation .',b'elimination the elimination of lacosamide from the systemic circulation mainly by renal excretion and by biotransformation .',b'elimination the elimination of lacosamide from the systemic circulation mainly by the systemic circulation .',b'elimination : the elimination of lacosamide from the systemic circulation mainly by renal excretion and by biotransformation .'
2747,b'nehmen sie die prometax l\xc3\xb6sung direkt aus der pipette ein oder geben sie den inhalt der pipette zuerst in ein kleines glas wasser .',b'always take prometax oral solution directly from the syringe or the syringe in a small glass of water .',b'to take prometax suspension with the syringe or the syringe in the reconstituted blister of water .',b'always take prometax oral solution directly from the pipette or firstly put the contents of the pipette in a small glass of water .'
2748,b'die dosis richtet sich dabei nach dem gew\xc3\xa4hlten immunsuppressiven regime .',b'the dose will depend on how much schedule chosen immunosuppressive regimen .',b'the dose will not .',b'the dose will depend on the chosen immunosuppressive regimen .'
2749,b'ein vorgef\xc3\xbcllter fertigpen enth\xc3\xa4lt 3 ml entsprechend 300 i.e.',b'one pre-filled pen contains 3 ml equivalent to 300 iu .',b'one prefilled pen contains ml equivalent to iu .',b'one pre-filled pen contains 3 ml equivalent to 300 iu .'
2750,b'wasser hat keinen einfluss auf die bioverf\xc3\xbcgbarkeit von neoclarityn schmelztabletten .',b'water does not affect the bioavailability of neoclarityn orodispersible tablets .',b'water does not affect the bioavailability of neoclarityn orodispersible tablets with a ear',b'water does not affect the bioavailability of neoclarityn orodispersible tablets .'
2751,b'nach einem abrupten absetzen k\xc3\xb6nnen depressionen auftreten .',b'after an abrupt cessation of depression may occur .',b'after an abrupt cessation of depression may occur .',b'after an abrupt cessation of depression may occur .'
2752,b'nur anwenden nach entsprechender nutzen-risiko- abw\xc3\xa4gung durch den behandelnden tierarzt .',b'use only according to the risk / benefit supervision by the veterinarian .',b'use only breastfeeding at your risk benefit supervision by the veterinarian .',b'use only according to the risk / benefit evaluation by the veterinarian .'
2753,b'die meisten studien zu arzneimittelwechselwirkungen mit saquinavir wurden mit ungeboosteter invirase oder mit ungeboosteten saquinavir-weichkapseln ( fortovase ) durchgef\xc3\xbchrt .',b'most of the drug interaction studies with saquinavir have been associated with ungeboosteter invirase or with ungeboosteten saquinavir soft capsule ( fortovase summary of product characteristics ) .',"b'most of the drug interaction studies with cmin , sapropterin has been associated with difficulttotreat invirase or in angiogenesis'",b'most of the drug interaction studies with saquinavir have been associated with unboosted invirase or with unboosted saquinavir soft capsule ( fortovase summary of product characteristics ) .'
2754,"b'um den dosierkopf zu \xc3\xb6ffnen , drehen sie ihn soweit wie m\xc3\xb6glich gegen den uhrzeigersinn ( etwa eine vierteldrehung ) .'","b'in order to twist the nozzle , go possible , such as anti-clockwise ( about one-quarter ) .'","b'in order to show the , it in order to move the compress , off as sunlight .'","b'in order to twist the nozzle , turn as far as possible anti-clockwise ( about one-quarter ) .'"
2755,b'diese reaktionen verschwinden im allgemeinen innerhalb von 3 wochen nach der erstimpfung .',b'these reactions disappear within 3 weeks after the first vaccination .',b'these reactions varied within weeks after the first vaccination .',b'these reactions disappear within 3 weeks after the first vaccination .'
2756,"b'pergoveris darf nicht zusammen mit anderen arzneimitteln in derselben spritze verabreicht werden , ausgenommen follitropin alfa .'","b'pergoveris must not be co-administered with other medicinal products in the same injection , except for follitropin alfa .'",b'pergoveris without the injection site . and .',"b'pergoveris must not be co-administered with other medicinal products in the same injection , except for follitropin alfa .'"
2757,b'bei bestimmten patienten unter thiazidtherapie kann eine hyperurik\xc3\xa4mie auftreten oder ein gichtanfall ausgel\xc3\xb6st werden .',b'in certain patients receiving maternal thiazide therapy hyperuricaemia may occur or frank gout may be precipitated in certain .',b'in certain patients receiving ifn medical therapeutic an relax formulas with hypoglycaemia may occur with secretion could to an doctor in certain .',b'in certain patients receiving maternal thiazide therapy hyperuricaemia may occur or an attack of gout may be caused .'
2758,"b'temoporfin ist ein photosensibilisierender wirkstoff , der in der photodynamischen tumortherapie eingesetzt wird .'","b'temoporfin is a photosensitising agents , a cholesteric esters .'","b'soliris is a photosensitising agents , a solomon oesophagus .'","b'temoporfin is a photosensitising agents , a cholesteric esters .'"
2759,"b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von advate dieses arzneimittel enth\xc3\xa4lt 0,45 mmol natrium ( 10 mg ) pro durchstechflasche .'",b'important information about some of the ingredients of advate this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .',b'important information about some of the ingredients of advate this medicinal product contains . mmol sodium mg per vial .',b'important information about some of the ingredients of advate : this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .'
2760,"b'gabapentin ist strukturell verwandt mit dem neurotransmitter gamma-aminobutters\xc3\xa4ure ( gaba ) , wobei der genaue wirkmechanismus von gabapentin bislang noch nicht bekannt ist .'","b'gabapentin is structurally related to the neurotransmitter gamma- aminobutyric acid ( gaba ) , and its exact mechanism of action of gabapentin are not known yet .'","b'gabapentin barely f antagonist b disorders , and its exact mechanism of nelfinavir are not known yet .'","b'gabapentin is structurally related to the neurotransmitter gamma- aminobutyric acid ( gaba ) , however its exact mechanism of action of gabapentin is not known yet .'"
2761,"b'hiv-infizierten m\xc3\xbcttern wird empfohlen , ihre kinder nicht zu stillen , um das risiko einer postnatalen hiv-\xc3\x9cbertragung zu vermeiden . stillenden m\xc3\xbcttern wird empfohlen abzustillen , wenn sie mit viramune behandelt werden .'",b'it is recommended that hiv-infected mothers do not breast-feed their babies compared to avoid risking postnatal transmission of hiv and that mothers should breast-feeding if they are receiving viramune . ) .',"b'it is recommended that intended that not breastfeed their exubera to avoid oesophageal only depending use , interactions .'",b'it is recommended that hiv-infected mothers do not breast-feed their babies to avoid risking postnatal transmission of hiv . mothers should breast-feeding if they are receiving viramune .'
2762,b'irbesartan krka entfaltet gew\xc3\xb6hnlich keine wechselwirkungen mit anderen arzneimitteln .',b'irbesartan krka does not usually interact with other medicines .',b'irbesartan krka does not usually midazolam as interact with other medicines .',b'irbesartan krka does not usually interact with other medicines .'
2763,"b'die vorgelegten r\xc3\xbcckstandsdaten waren unzureichend , und die wartezeit ist deshalb unzureichend belegt .'","b'information provided r\xc3\xbcckstandsdaten were available , and the waiting period , and therefore , inadequate has been shown to be efficacious .'","b'information provided mirena was available , and the secondary sensible close place in the longlasting cortex failure .'","b'the provided residue data was insufficient , and the waiting period , has therefore , been shown to be insufficient .'"
2764,b'nehmen sie cefuroximaxetil immer genau nach anweisung des arztes ein .',b'always take cefuroxime axetil exactly as your doctor has told you .',b'always take activelle vistide exactly as your doctor has told you .',b'always take cefuroxime axetil exactly as your doctor has told you .'
2765,b'an der tubenspitze sollte deutlich eine \xc3\x96ffnung sichtbar sein und der tubenverschluss sollte sich innerhalb der tubenkappe befinden .',"b'on the tip of the tube should be a markedly visible , and the tip seal could be taken within tubenkappe .'",b'in the tip of the tube should fluctuate to pregnancy for a dissolution of silapo .',"b'on the tip of the tube should be a markedly visible , and the tip seal could be taken within tip seal .'"
2766,b'zahlen in fettschrift zeigen die ergebnisse des prim\xc3\xa4ren endpunkts. b kriterien zur h\xc3\xa4matologischen remission ( jede remission nach 4 wochen best\xc3\xa4tigt ) :',b'numbers in fettschrift demonstrate that the results of the primary endpunkts. b haematologic response criteria ( all responses all responses to be confirmed after 4 weeks ) :',"b'anakinra was reflected , miglustat the results of the primary prolactin checkups'",b'numbers in bold demonstrate the results of the primary endpoint. b haematologic remission criteria ( each remission confirmed after 4 weeks ) :'
2767,"b'die dosis pro kg k\xc3\xb6rpergewicht sollte auf 2,5 ml genau berechnet werden .'",b'the dose per kg body weight should be calculated to 2.5 ml .',b'the dose per kg body weight should be calculated at a aggressive other ml .',b'the dose per kg body weight should be calculated to 2.5 ml .'
2768,b'was ist lansoprazol-ratiopharm 30 mg und wof\xc3\xbcr wird es angewendet ?',b'what lansoprazol-ratiopharm 30 mg is and what it is used for 2 .',b'what zypadhera mg is and what it is used for .',b'what lansoprazole ratiopharm 30 mg is and what it is used for'
2769,"b'ferner ist es ratsam , sauerstoff griffbereit zu haben , falls eine hypox\xc3\xa4mie festgestellt wird oder der verdacht darauf besteht .'","b'in addition , it is advisable to have an immediately if hypoxemia is diagnosed or suspected .'","b'in addition , it is advisable to have an cleaned in contact with alli scheme or flu breakdown .'","b'in addition , it is advisable to have an oxygen at the ready if hypoxemia is diagnosed or suspected .'"
2770,b'das risikopotenzial f\xc3\xbcr den menschen w\xc3\xa4hrend der schwangerschaft ist nicht bekannt .',b'the potential risk for humans is recommended during pregnancy is not known .',b'the potential risk for humans is recommended during pregnancy is not known .',b'the potential risk for humans during pregnancy is not known .'
2771,"b'3 patienten mit normaler leberfunktion auftreten ; daher ist es geboten , die sicherheit und das virologische ansprechen eng zu \xc3\xbcberwachen .'","b'patients with normal hepatic function may occur ; therefore , it is warranted , the safety and virological response should be closely monitored .'","b'patients with normal hepatic function may occur therefore , the safety and virological response should be closely monitored .'","b'patients with normal hepatic function may occur ; therefore , it is necessary to closely monitor the safety and virological response .'"
2772,"b'dieses arzneimittel enth\xc3\xa4lt 1,4 mg phenylalanin pro 2,5 mg dosis azomyr schmelztablette .'",b'this product contains 1.4 mg of phenylalanine per 2.5 mg dose of azomyr orodispersible tablet .',b'this product contains . mg of phenylalanine per . mg dose of azomyr arcoxia tablet .',b'this product contains 1.4 mg of phenylalanine per 2.5 mg dose of azomyr orodispersible tablet .'
2773,b'der impfstoff ist innerhalb von 2 stunden zu verbrauchen .',b'the vaccine should be used within 2 hours .',b'the vaccine should be used within hours .',b'the vaccine should be used within 2 hours .'
2774,"b'rotaviren werden f\xc3\xa4kal-oral ( durch hand-zu-mund-kontakt ) \xc3\xbcbertragen , wenn man mit dem stuhl infizierter personen in ber\xc3\xbchrung gekommen ist .'",b'one will f\xc3\xa4kal-oral ( a skin condition caused hand-zu-mund-kontakt ) when in the infected subjects ) .',"b'this point of minutes , adjustment during male the past subjects .'",b'rotavirus is easily spread from hand-to-mouth due to contact with stools from an infected person .'
2775,b'der impfstoff muss innerhalb von 2 stunden nach dem mischen mit der natriumhydrogencarbonat- l\xc3\xb6sung getrunken werden .',b'the vaccine should be used within 2 hours after mixing with the natriumhydrogencarbonat- drunk .',b'the vaccine should be used within hours after mixing with the ingredients .',b'the vaccine should be used within 2 hours after mixing with the sodium hydrogen carbonate drunk .'
2776,"b'- die bauchdecke , mit ausnahme des bereichs um den nabel herum .'","b'- in the abdomen , with the exception of the area around the navel .'","b'in the abdomen , with in the end of the area around the navel .'","b'- in the abdomen , with the exception of the area around the navel .'"
2777,b'die erfahrungen bei der anwendung von optison bei patienten mit schwerwiegenden erkrankungen sind begrenzt .',b'the experience with the use of optison in patients with other serious illness is limited .',b'the accumulation with the use of orfadin in patients with other serious illness is limited .',b'the experience with the use of optison in patients with other serious illness is limited .'
2778,b'wenn sie die einnahme von xagrid vergessen haben :',b'if you forget to take xagrid :',b'if you forget to take xagrid',b'if you forget to take xagrid :'
2779,b'was ist actraphane und wof\xc3\xbcr wird es angewendet ?',b'what actraphane is and what it is used for 2 .',b'what actraphane is and what it is used for .',b'what actraphane is and what it is used for 2 .'
2780,"b'weniger als 0,0005 % der eingenommenen dosis fand sich im samen von gesunden probanden .'",b'less than 0.0005 % of the ingested dose in healthy subjects .',b'less than . of the area of the larger target rate of clearance .',b'less than 0.0005 % of the ingested dose in healthy subjects .'
2781,b'behandlung mit raptiva d\xc3\xbcrfen sie bestimmte impfstoffe nicht erhalten .',b'raptiva treatment do not receive certain vaccines .',b'raptiva treatment do not receive certain vaccines .',b'raptiva treatment do not receive certain vaccines .'
2782,b'in der sitzung des chmp im februar 2005 fanden er\xc3\xb6rterungen zur kardiovaskul\xc3\xa4ren sicherheit statt .',b'in the chmp meeting february 2005 was recovered in the er\xc3\xb6rterungen cardiovascular safety .',b'in the chmp meeting advate was recovered in the examining safety .',b'in the chmp meeting in february 2005 debate of the cardiovascular safety took place'
2783,b'diese ereignisse wurden durch basiliximab nicht beeinflusst .',b'these events were not affected by basiliximab .',b'these events were not affected by herds with an antihistamine .',b'these events were not affected by basiliximab .'
2784,"b'nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder krankenhaus-apotheker .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or your hospital pharmacist .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or your hospital .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or your hospital pharmacist .'"
2785,"b'ein ml der l\xc3\xb6sung enth\xc3\xa4lt 0,05 mg zoledrons\xc3\xa4ure ( wasserfrei ) , entsprechend 0,0533 mg zoledrons\xc3\xa4uremonohydrat .'","b'one ml of solution contains 0.05 mg zoledronic acid ( anhydrous ) , equivalent to 0,0533 mg zoledrons\xc3\xa4uremonohydrat .'","b'one mg of solution contains . mg olanzapine ii anhydrous , equivalent to , mg atenolol .'","b'one ml of solution contains 0.05 mg zoledronic acid ( anhydrous ) , equivalent to 0,0533 mg zoledronic acid monohydrate .'"
2786,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr levemir finden sie hier .',b'the full epar for avamys for levemir can be found here .',b'the full epar for levemir can be found here .',b'the full epar text for levemir can be found here .'
2787,b'die zus\xc3\xa4tzliche anwendung weiterer arzneimittel neben humalog mix25 kwikpen muss mit dem arzt abgestimmt werden .',b'the humalog mix25 kwikpen should be agreed by your doctor .',b'the humalog mix kwikpen should be agreed by your doctor .',b'the use of additional medications with humalog mix25 kwikpen should be agreed to by your doctor .'
2788,b'die sicherheit und wirksamkeit von enfuvirtid wurde bei patienten mit signifikanten leberfunktionsst\xc3\xb6rungen nicht speziell untersucht .',b'the safety and efficacy of enfuvirtide have not been specifically studied in patients with significant underlying liver disorders .',b'the safety and efficacy of enfuvirtide have not been specifically studied in patients with significant underlying liver disorders .',b'the safety and efficacy of enfuvirtide has not been specifically studied in patients with significant liver disorders .'
2789,b'taxotere wird als durchstechflasche zur einmalentnahme geliefert .',b'taxotere is supplied as single-dose vials .',b'taxotere is supplied as singledose vials .',b'taxotere is supplied in single-dose vials .'
2790,"b'wirkmechanismus paliperidon ist ein selektiver inhibitor monoaminerger effekte , dessen pharmakologische eigenschaften sich von denen klassischer neuroleptika unterscheiden .'","b'mechanism of action paliperidone is a selective inhibitor monoaminerger effects , the pharmacological properties of which dose neuroleptics .'",b'mechanism of action paliperidone is a selective inhibitor',"b'mechanism of action . paliperidone is a selective inhibitor with monoaminerger effects , the pharmacological properties of which differs from classic neuroleptics .'"
2791,"b'wechselwirkung mit indinavir / ritonavir nicht untersucht ritonavir induziert oxidation \xc3\xbcber cyp2c9 und glukuronidierung , daher wird erwartet , dass die plasmakonzentrationen der antikonvulsiva erniedrigt werden .'","b'interaction with indinavir / ritonavir not studied ritonavir induces in patients at risk for cyp2c9 glucuronidation , and as a result are expected to increase the plasma concentrations of anticonvulsants .'",b'interaction with indinavir ritonavir in patients appears to a result of an used .',"b'interaction with indinavir / ritonavir not studied . ritonavir induces oxidation by cyp2c9 and glucuronidation , and as a result the plasma concentrations of anticonvulsants are expected to increase .'"
2792,"b'der arzneilich wirksame bestandteil von bondronat , ibandrons\xc3\xa4ure , geh\xc3\xb6rt zu einer gruppe von arzneimitteln , die als bisphosphonate bekannt sind .'","b'the active substance in bondronat , ibandronic acid , belongs to a group of medicines known as bisphosphonates .'","b'the active substance in bondronat , , polysorbate , iii acid , belongs to a group of medicines known as bisphosphonates .'","b'the active substance in bondronat , ibandronic acid , belongs to a group of medicines known as bisphosphonates .'"
2793,"b'dauer der haltbarkeit nach der ersten verwendung des pens er kann maximal 4 wochen lang bei einer temperatur von nicht \xc3\xbcber 25 \xc2\xb0 c , vor direkter hitzeeinwirkung und direktem licht gesch\xc3\xbctzt , aufbewahrt werden . in gebrauch befindliche pens nicht im k\xc3\xbchlschrank aufbewahren .'",b'shelf life after first use of the pen : the stored for a maximum of 4 weeks not above 25 \xc2\xb0 c away from direct heat or direct light . pens in use must not be stored in the refrigerator .',b'shelf life after first use of the instructions the solution insuman expiry needle the diluted for a maximum of weeks not above c away from medical ml of weeks .',b'shelf life after first use of the pen : the pen may stored for a maximum of 4 weeks not above 25 \xc2\xb0 c away from direct heat or direct light . pens in use must not be stored in the refrigerator .'
2794,b'wie wurde zevalin untersucht ?',b'how has zevalin been studied ?',b'how has zevlin been studied ?',b'how has zevalin been studied ?'
2795,b'bei patienten mit niedrigen h\xc3\xa4moglobinwerten vor behandlungsbeginn besteht w\xc3\xa4hrend der behandlung mit avandamet ein erh\xc3\xb6htes risiko einer an\xc3\xa4mie .',"b'in patients with low haemoglobin levels before initiating therapy , there is used during treatment with avandamet is an increased risk of anaemia .'","b'in patients with low haemoglobin levels before initiating therapy , there is used during treatment with avandamet is reduced the increased risk of rats .'","b'in patients with low haemoglobin levels before initiating therapy , there is an increased risk of anaemia during treatment with avandamet .'"
2796,b'die dosis von pegintron f\xc3\xbcr eine monotherapie sollte bei patienten mit m\xc3\xa4\xc3\x9figer oder schwerer nierenfunktionsst\xc3\xb6rung verringert werden ( siehe abschnitte 4.2 und 4.4 ) .',b'the dose of pegintron for monotherapy should be reduced in patients with moderate or severe renal impairment ( see sections 4.2 and 4.4 ) .',b'the dose of pegintron for monotherapy should be reduced in patients with moderate or severe renal impairment see sections . and . .',b'the dose of pegintron for monotherapy should be reduced in patients with moderate or severe renal impairment ( see sections 4.2 and 4.4 ) .'
2797,b's verminderten wirksamkeit von adalimumab verbunden .',b'ris reduced efficacy of adalimumab .',b'possibly procedure of adalimumab .',b'reduced efficacy of adalimumab .'
2798,b'es beeintr\xc3\xa4chtigt nicht die osteoklastenrekrutierung .',b'it does not affect the osteoklastenrekrutierung .',b'it does not affect the sshaped .',b'it does not affect osteoclast recruitment .'
2799,b'der impfstoff ist vor der verabreichung gut zu sch\xc3\xbctteln .',b'the vaccine should be well shaken prior to administration .',b'the vaccine should be well thereafter prior to administration .',b'the vaccine should be well shaken prior to administration .'
2800,"b'wie bei allen insulinen variiert die wirkdauer abh\xc3\xa4ngig von dosis , injektionsstelle , blutfluss , temperatur und dem ausma\xc3\x9f der k\xc3\xb6rperlichen bet\xc3\xa4tigung .'","b'as with all insulins the duration of action will vary according to the dose , injection site , blood flow , temperature and the extent of physical activity .'",b'as with all allergic of action and the extent of physical activity .',"b'as with all insulins the duration of action will vary according to the dose , injection site , blood flow , temperature and the extent of physical activity .'"
2801,"b'es hat sich erwiesen , dass solacyl 100 % pulver f\xc3\xbcr die herstellung einer oralen l\xc3\xb6sung im wesentlichen dem referenzarzneimittel gleicht , natriumsalicylat 100 % .'","b'it has been established that solacyl 100 % powder for oral solution to the reference medicine , salicylaat 100 % .'",b'it has been established that lowfluxfilter powder for oral solution to the reference medicine .',"b'it has been established that solacyl 100 % powder for oral solution is essentially the same as the reference medicine , salicylaat 100 % .'"
2802,"b'myfenax wird angewendet , um die absto\xc3\x9fung einer transplantierten niere , eines transplantierten herzens oder einer transplantierten leber vom k\xc3\xb6rper zu verhindern .'","b'myfenax is used to prevent a transplanted kidney , heart or liver by the body .'","b'myfenax is used to prevent a leukocyte potential , heart or liver by the body .'","b'myfenax is used to prevent rejection of a transplanted kidney , heart or liver by the body .'"
2803,"b'durchstechflaschen im umkarton aufbewahren , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'the vial in the outer carton in order to protect it from light .',b'the vial in the outer carton in order to protect it from light .',b'store the vial in the outer carton in order to protect it from light .'
2804,"b'die ergebnisse zur klinischen remission waren weitgehend konstant , unabh\xc3\xa4ngig davon , ob fr\xc3\xbcher bereits ein tnf-antagonist verabreicht wurde .'","b'the results of clinical remission , regardless of whether early already stiffness .'","b'the results of clinical regimens , regardless of whether early foetal shoulder requires historical comtess surgery .'","b'the results of clinical remission were continually constant , regardless of whether a tnf antagonist was already administered .'"
2805,b'- der wirkstoff ist pegvisomant .',b'- the active substance is pegvisomant .',b'the active substance is unaffected .',b'- the active substance is pegvisomant .'
2806,"b'saisonale und perenniale allergische rhinitis bei kindern ( unter 6 jahren ) es wurden bei 271 patienten im alter von 2 - 5 jahren studien zur vertr\xc3\xa4glichkeit und wirksamkeit sowohl bei saisonaler , als auch bei perennialer allergischer rhinitis durchgef\xc3\xbchrt .'",b'seasonal and tamoxifen in children ( less than 6 years of age ) were performed in a total of 271 patients from 2 to 5 years safety and efficacy studies in both seasonal and perennial allergic rhinitis .',"b'skeletal and tamoxifen in children less than years of age were performed in a total of patients different to years safety and efficacy studies in both following tumour effects in both seasonal and hyperlactataemia in the male of patients from to years safety and efficacy studies in both seasonal ,'",b'seasonal and perennial allergic rhinitis in children ( less than 6 years of age ) studies were performed in a total of 271 patients from 2 to 5 years on the tolerance and efficacy in both seasonal and perennial allergic rhinitis .'
2807,"b'zur t\xc3\xa4glichen weiterbehandlung ( im abstand von 24 stunden ) ist eine erhaltungsdosis von 0,1 mg meloxicam / kg k\xc3\xb6rpergewicht einmal t\xc3\xa4glich oral zu verabreichen .'",b'treatment is to be continued once daily by oral administration ( at 24-hour intervals ) at a maintenance dose of 0.1 mg meloxicam / kg body weight .',b'treatment is an anidulafungin rate of linear at intervals of . mg meloxicam kg body weight .',b'treatment is to be administered once daily by oral administration ( at 24-hour intervals ) at a maintenance dose of 0.1 mg meloxicam / kg body weight .'
2808,b'unterdr\xc3\xbccken ) . ihr arzt wird sie auf zeichen einer methotrexat-\xc3\x9cberdosierung hin \xc3\xbcberwachen .',b'suppress ) . your doctor will check for signs and signs of methotrexat-\xc3\x9cberdosierung monitor .',b'switching . your doctor will check the same growth in the beginning of rezidivs .',b'suppress ) . your doctor will monitor you for signs of methotrexate overdose .'
2809,"b'die ergebnisse von studien zur akuten und subchronischen toxizit\xc3\xa4t an affen , legen nahe , dass intrathekal verabreichtes depocyte bis zu einer dosis von 10 mg ( vergleichbar einer humandosis von 100 mg ) vertragen wurde .'",b'results of acute and subchronischen toxicity studies in monkeys suggests that intrathecal regimen with depocyte up to a dose of 10 mg ( comparable at a human dose of 100 mg ) .',b'results of acute and apl of significant plasma of mg is accumulation to consequently to a dose of for human dose of mg plasma dose of mg .',b'results of acute and subchronic toxicity studies in monkeys suggests that intrathecal regimen with depocyte is tolerated up to a dose of 10 mg ( comparable at a human dose of 100 mg ) .'
2810,"b'w\xc3\xa4hrend einer arzneimittelwechselwirkungsstudie mit gesunden probanden wurden keine klinisch bedeutsamen wirkungen auf die pharmakokinetik von ambrisentan oder sildenafil festgestellt , und die kombination wurde gut vertragen .'","b'during a arzneimittelwechselwirkungsstudie were compared with healthy volunteers had no clinically significant effects on the pharmacokinetics of ambrisentan or sildenafil , and the combination was well tolerated .'",b'which were compared with healthy volunteers had no clinically number of ambrisentan of atovaquone or sildenafil were well tolerated .',"b'during a drug interaction study with healthy volunteers , no clinically significant effects on the pharmacokinetics of ambrisentan or sildenafil , and the combination was well tolerated .'"
2811,"b'es kann sein , dass medizinische behandlung ben\xc3\xb6tigt wird .'",b'you may have medical treatment is needed .',b'you may be give therefore reduce account .',b'you may need medical treatment .'
2812,b'erkrankungen der nieren und harnwege :',b'renal and urinary disorders :',b'renal and urinary disorders',b'renal and urinary disorders :'
2813,"b'eine antivirale aktivit\xc3\xa4t wird bei konzentrationen festgestellt , die erheblich unter denen liegen , die zum zelltod f\xc3\xbchren .'","b'the antiviral activity will be noted at concentrations similar to cause profound , and .'",b'the antiviral activity will be noted at concentrations was observed with similar to cause both it was reduced that an .',b'the antiviral activity will be determined at concentrations that are significantly low and cause cell death .'
2814,b'im steady-state betrug die relative bioverf\xc3\xbcgbarkeit von doxazosin aus cardoreg [ und andere bezeichnungen ] 4 mg retardtabletten im vergleich zu der formulierung mit sofortiger wirkstofffreisetzung 54 % bei anwendung der 4-mg-dosis und 59 % bei anwendung der 8-mg-dosis .',"b'at steady state , the relative bioavailability of doxazosin from cardoreg 4 mg prolonged release tablets and associated names as compared to the immediate release film 54 % of the 4 mg dose and 59 % at the 8 mg dose .'","b'at steady state , the relative substance and hydrochlorothiazide interferon doxorubicin release tablets and associated names as compared to the of polyvinyl imatinib product .'","b'at steady state , the relative bioavailability of doxazosin from cardoreg 4 mg prolonged release tablets and associated names as compared to the immediate release formulation was 54 % with the 4 mg dose and 59 % with the 8 mg dose .'"
2815,"b'pharmakotherapeutische gruppe : alfa-adrenozeptor-antagonisten , atc-code :'","b'pharmacotherapeutic group : alpha-adrenoceptor antagonists , atc code :'","b'pharmacotherapeutic group proteintyrosine antagonists , atc code'","b'pharmacotherapeutic group : alpha-adrenoceptor antagonists , atc code :'"
2816,b'die h\xc3\xa4matologische erholung erfolgt in der regel innerhalb von zwei wochen .',b'the haematological recovery occurs within two weeks .',"b'as well as make , established in two weeks .'",b'the haematological recovery generally occurs within two weeks .'
2817,b'sonstiger bestandteil : lactose .',b'excipient : lactose monohydrate .',b'excipient lactose monohydrate .',b'excipient : lactose monohydrate .'
2818,b'bei aufnahme der behandlung mit rasagilin bei patienten mit leichter leberinsuffizienz ist vorsicht geboten .',b'on enrolment of treatment with rasagiline in patients with mild hepatic insufficiency should be used with caution .',b'on commencing of treatment with rasagiline in patients with mild hepatic insufficiency should be used with caution .',"b'on the uptake of treatment with rasagiline in patients with mild hepatic insufficiency , caution is advised .'"
2819,"b'drei monate nach der ersten dosis konnten sch\xc3\xbctzende antik\xc3\xb6rper gegen hepatitis b bei 95,1 % der geimpften beobachtet werden .'",b'three months after the first dose could be protective antibodies against hepatitis b were observed in 95.1 % of the people receiving the vaccine .',b'three months after the first dose could occur with maternal relapse concentrations against hepatitis b were increased adequate colorectal serum concentration against hepatitis b were demonstrated in . of the progress thoroughly between doses of the indication during the of fever systemic renal thyroid disease in . of the precautionary',"b'three months after the first dose , protective antibodies against hepatitis b were observed in 95.1 % of the people receiving the vaccine .'"
2820,b'21 es liegen keine daten zu schwangeren frauen vor .',b'there are no data in pregnant women .',b'there are no data in pregnant women .',b'there is no data in pregnant women .'
2821,b'die geeignete dosis f\xc3\xbcr patienten mit leichter bis m\xc3\xa4\xc3\x9figer beeintr\xc3\xa4chtigung der leberfunktion ist unbekannt .',b'the appropriate doses for patients with mild to moderate impairment of hepatic function is unknown .',b'the appropriate doses for patients with mild to moderate impairment of a moderate impairment of hepatic function is unknown diseases .',b'the appropriate doses for patients with mild to moderate impairment of hepatic function is unknown .'
2822,"b'elaprase ist zur intraven\xc3\xb6sen infusion bestimmt und muss vor der anwendung in 9 mg / ml ( 0,9 % ) natriumchlorid-infusionsl\xc3\xb6sung verd\xc3\xbcnnt werden .'",b'elaprase is intended for intravenous infusion and must be diluted before administration in sodium chloride 9 mg / ml ( 0.9 % ) sodium chloride solution for infusion .',b'elaprase is intended for intravenous infusion and must be diluted in body chloride mg ml . sodium chloride solution for infusion .',b'elaprase is intended for intravenous infusion and must be diluted before administration in sodium chloride 9 mg / ml ( 0.9 % ) sodium chloride solution for infusion .'
2823,b'wie wurde temodal untersucht ?',b'how has temodal been studied ?',b'associated has temodal been studied ?',b'how has temodal been studied ?'
2824,"b'dieses enzym ist im k\xc3\xb6rper zum abbau von substanzen , den so genannten glykosaminoglykanen ( gag ) , notwendig .'","b'this enzyme in the body and substances called glycosaminoglycans ( gag ) , is necessary .'",b'with drops of an body and transferable called stimulation of important the body and transferable called worthlessness constriction .',b'this enzyme is necessary in the body to break down substances called glycosaminoglycans ( gag ) .'
2825,b'im fortgeschrittenen stadium des morbus parkinson k\xc3\xb6nnen unter der kombinationstherapie mit levodopa w\xc3\xa4hrend der initialbehandlung mit pramipexol teva dyskinesien vorkommen .',"b""in advanced parkinson 's disease , in combination treatment with levodopa , dyskinesias can occur during the initial titration of pramipexole teva .""","b'in advanced parkinson s disease , in combination treatment with levodopa and an reduction of tmz stage of pramipexole teva .'","b""in advanced parkinson 's disease , dyskinesias can occur during the initial titration of pramipexole teva in combination treatment with levodopa ."""
2826,b'ge markteinf\xc3\xbchrung wurde nach verabreichung von trudexa in sehr seltenen f\xc3\xa4llen das auftreten von schwerwiegenden allergischen reaktionen einschlie\xc3\x9flich anaphylaktischer reaktionen berichtet .',"b'in postmarketing after administration of trudexa in very rare cases , serious allergic reactions including anaphylaxis have been reported .'","b'in studies with fertility in very rare cases , serious allergic reactions in very rare cases , serious allergic reactions including anaphylaxis have been reported .'","b'in postmarketing after administration of trudexa in very rare cases , serious allergic reactions including anaphylaxis have been reported .'"
2827,"b'138 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'138 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information on this medicine , please contact the local representative of the marketing authorisation holder .'","b'138 for any information about this medicine , please contact the local representative of the pharmaceutical company .'"
2828,"b'zur abw\xc3\xa4gung des gesamten sicherheitsprofils von lamotrigin sollten die folgenden nebenwirkungen zus\xc3\xa4tzlich zu jenen herangezogen werden , die unter der behandlung der epilepsie auftreten .'","b'considering the overall safety profile of lamotrigine should take the following additional side effects in addition to those used in the treatment of epilepsy , may occur .'","b'the overall pesti gives , this properties of lamotrigine should take the following hypersensitivity side effects in addition to those been less acheived in addition to those used in the treatment of epilepsy , may occur .'","b'considering the overall safety profile of lamotrigine , the following additional side effects in addition to those brought about in the treatment of epilepsy .'"
2829,b'insgesamt trat eine alt-erh\xc3\xb6hung bei hbeag-positiven patienten h\xc3\xa4ufiger auf als bei hbeag-negativen patienten .',"b'overall , the majority of apl in hbeag-positive patients reported more frequently than in hbeag-negative patients .'","b'overall , the majority of myasthenia in ra patients reported more frequently than in nelarabine patients .'","b'overall , an increase in alt occured more frequently among hbeag positive patients than among hbeag-negative patients .'"
2830,b'eine schwere unterzu- ckerung ( hypoglyk\xc3\xa4mie ) kann einen herzanfall oder gehirnschaden verursachen und lebensbedroh- lich sein .',b'serious unterzu- ckerung ( hypoglycaemia ) may cause a heart attack or brain damage and may be life- threatening .',b'serious capsular method can cause a heart attack or brain damage and may be the stenosis deficiency or affects other difficulty of a heart attack or brain damage and may be approved .',b'a serious case of hypoglycaemia may cause a heart attack or brain damage and may be life- threatening .'
2831,"b'wenn m\xc3\xb6glich sollte mit inhalationsstickstoffmonoxid behandelt werden , bis die zugrundeliegende krankheit geheilt ist .'","b'if possible , should be treated with inhaled nitric oxide , until the underlying disease has healed .'","b'if possible product must be treated with inhaled nitric oxide , until the underlying disease has rearranged .'","b'if possible , should be treated with inhaled nitric oxide , until the underlying disease has healed .'"
2832,"b'eine hy - perglyk\xc3\xa4mie kann verursacht sein durch : \xe2\x80\xa2 keine einnahme von humalog oder anderem insulin . \xe2\x80\xa2 einnahme von weniger insulin als vom arzt vorgeschrieben . \xe2\x80\xa2 wesentlich mehr nahrungsaufnahme als die di\xc3\xa4t erlaubt oder \xe2\x80\xa2 fieber , infektion oder emotionaler stress .'","b'one hy - perglyk\xc3\xa4mie may be caused by : \xe2\x80\xa2 not taking your humalog or other insulin ; \xe2\x80\xa2 taking less insulin than your doctor tells you to ; \xe2\x80\xa2 eating a lot more than your diet allows ; or \xe2\x80\xa2 fever , infection or emotional stress .'",b'one hypoglycaemia must be caused by not taking your humalog or other insulin subcutaneous less insulin responseafter .',"b'one hyperglycemia may be caused by : \xe2\x80\xa2 not taking your humalog or other insulin ; \xe2\x80\xa2 taking less insulin than your doctor tells you to ; \xe2\x80\xa2 eating a lot more than your diet allows ; or \xe2\x80\xa2 fever , infection or emotional stress .'"
2833,"b'wenn sie weitere fragen zur anwendung von ( phantasiebezeichnung ) haben , fragen sie bitte ihren arzt oder apotheker .'","b'if you have any further questions on the use of ( invented name ) \xc2\xae the use of this product , ask your doctor or pharmacist .'",b'if you have any further questions on the use of competact name on the use of invented leaflet are',"b'if you have any further questions on the use of ( invented name ) \xc2\xae , ask your doctor or pharmacist .'"
2834,b'm\xc3\xa4rz 2002 datum der letzten verl\xc3\xa4ngerung :',b'march 2002 date of latest renewal :',b'march date of latest renewal',b'march 2002 date of latest renewal :'
2835,"b'7 verteilung aprepitant ist stark an proteine gebunden , im durchschnitt zu 97 % .'","b'distribution aprepitant is highly protein bound , with a mean of 97 % , respectively .'",b'distribution aprepitant is highly protein bound e mediated recombinant mg colour .',"b'distribution aprepitant is highly protein bound , with a mean of 97 % , respectively .'"
2836,b'nicht intravaskul\xc3\xa4r anwenden .',b'do not use intravascularly .',b'do not use feed .',b'do not use intravascularly .'
2837,b'von zarzio sind ( aufgef\xc3\xbchrt in abschnitt 6.',b'zarzio ( listed in section 6 .',b'tandemact in section .',b'from zarzio ( listed in section 6 .'
2838,b'weitere informationen \xc3\xbcber sutent :',b'2 / 3 other information about sutent :',b'other information about your people about ulcerative',b'2 / 3 other information about sutent :'
2839,b'evoltra 1 mg / ml konzentrat zur herstellung einer infusionsl\xc3\xb6sung muss vor der anwendung verd\xc3\xbcnnt werden .',b'evoltra 1 mg / ml concentrate for solution for infusion must be diluted prior to administration .',b'evoltra mg ml concentrate for solution for infusion must be diluted prior to administration .',b'evoltra 1 mg / ml concentrate for solution for infusion must be diluted prior to administration .'
2840,"b'gelegentlich berichtete nebenwirkungen ( mindestens 1 unter 1.000 patienten , jedoch weniger als 1 unter 100 patienten ) : bakterielle infektion und kribbeln .'","b'478 uncommonly reported side effects ( at least 1 in every 1000 patients , but less than 1 in every 100 patients ) : bacterial infection and feeling of pins and needles .'","b'uncommonly the effects of every patients , but less than in every patients bacterial infection and feeling of atripla and needles .'","b'478 uncommonly reported side effects ( at least 1 in every 1000 patients , but less than 1 in every 100 patients ) : bacterial infection and feeling of pins and needles .'"
2841,b'protaphane wird im allgemeinen subkutan ( unter die haut ) in den oberschenkel injiziert .',b'protaphane is usually administered subcutaneously ( under the skin ) by injection in the thigh .',b'protaphane is usually administered subcutaneously under the skin by injection in the thigh .',b'protaphane is usually administered subcutaneously ( under the skin ) by injection in the thigh .'
2842,b'nach anwendung von effentora in der mundh\xc3\xb6hle wird fentanyl mit einer absoluten bioverf\xc3\xbcgbarkeit von 65 % leicht resorbiert .',"b'after administration of effentora , 4-nuoro-2-trinuoromethyl , fentanyl is easily absorbed and has an absolute bioavailability of 65 % .'","b'after administration of effentora , promeris , fentanyl is unclear present and has an absolute bioavailability of .'","b'after administration of effentora int the oral cavity , fentanyl is easily absorbed with an absolute bioavailability of 65 % .'"
2843,b'der chmp bewertete auch die wirksamkeitsdaten f\xc3\xbcr die bipolare manie bei \xc3\xa4lteren patienten .',b'the chmp also assessed the efficacy data for bipolar mania in elderly patients .',b'the chmp also immediately the efficacy data for humans deferiprone in elderly patients .',b'the chmp also assessed the efficacy data for bipolar mania in elderly patients .'
2844,"b'basierend auf dem sicherheitsprofil von refacto af , das eine einreichung der psurs alle 6 monate notwendig macht , kommt das chmp zu dem schluss , dass der inhaber der zulassung in 5 jahren einen weiteren antrag auf verl\xc3\xa4ngerung der zulassung einreichen sollte .'","b'based upon the safety profile of refacto af , which requires the submission of 6-monthly psurs is necessary , the chmp concluded that the mah implements in 5 years of age submitted to submit one additional renewal .'","b'opinion in the benefits profile of refacto af , which are tested for any place and viraferon urethritis of the guideline showed the chmp concluded the basis where the marketing variations to submit one following areas bone opinion , the chmp concluded that the chmp concluded in years of age'","b'based upon the safety profile of refacto af , which requires the submission of 6 monthly psurs , the chmp concluded that the mah should submit a further application for extension of the authorization in 5 years .'"
2845,b'die h\xc3\xa4ufigkeit kann aus den verf\xc3\xbcgbaren daten nicht abgesch\xc3\xa4tzt werden \xe2\x97\x8f allergische reaktion ( z.b.',b'the frequency cannot be estimated from the available data ) \xe2\x80\xa2 allergic reaction ( e. g .',b'the frequency can be estimated from the available data allergic reaction e . g .',b'the frequency cannot be estimated from the available data \xe2\x80\xa2 allergic reaction ( e. g .'
2846,b'bitte lesen sie die folgende bedienungsanleitung vor der benutzung von novorapid innolet sorgf\xc3\xa4ltig durch .',b'please read the following instructions before using your novorapid innolet carefully .',b'please read the following instructions before using your insulin innolet carefully .',b'please carefully read the following instructions before using your novorapid innolet .'
2847,b'bitte entsorgen sie ihn sachgerecht oder f\xc3\xbchren sie ihn einem recycling zu .',b'discard him safely to allow it to come to a nozzles ( 5 ) .',b'discard of the need to allow it to cause it are longer .',b'discard of it safely or bring to be recycled .'
2848,"b'435 die behandlung dauert \xc3\xbcblicherweise 5 bis 21 tage , kann jedoch bei schweren infektionen l\xc3\xa4nger sein .'","b'435 treatment usually lasts between 5 and 21 days , but may be longer for severe infections .'","b'treatment usually lasts between and days , but may be longer for severe infections .'","b'435 treatment usually lasts between 5 and 21 days , but may be longer for severe infections .'"
2849,"b'in studien , in denen die zeitdauer gemessen wurde , die der proband in den verschiedenen stadien des schlafes verbrachte , erhielt zerene ebenfalls die schlafmuster aufrecht .'","b'in trials investigating the measured the subject in the different stages of daytime verbrachte zerene , was also preserved sleep patterns .'",b'in trials acs the available of the different stages with hypotonic ggt nitroprusside .',"b'in trials investigating the different stages of sleep the subject went through , zerene also preserved sleep patterns .'"
2850,"b'linearit\xc3\xa4t nach einzelnen gaben von risperdal consta ist die pharmakokinetik von risperidon in einem dosisbereich von 12,5-75 mg linear .'","b'linearity after individual doses of risperdal consta , the pharmacokinetic parameters of risperidone in the dose range of 12,5-75 mg .'","b'for efficacy response of risperdal consta , the pharmacokinetic parameters of risperidone in the age , acetylsalicylic is compared to on breastfeeding .'","b'linearity : after individual doses of risperdal consta , the pharmacokinetic parameters of risperidone is linear in the dose range of 12.5-75 mg .'"
2851,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit doribax berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with side effects of doribax , see the package leaflet .'","b'for a full list of the sideeffects reported with side effects of doribax , see the package leaflet .'","b'for a full list of the side-effects reported in relation to doribax , see the package leaflet .'"
2852,"b'es gibt jedoch keine hinweise darauf , dass somatropin leuk\xc3\xa4mie verursacht , wenn keine anderen risikofaktoren vorliegen .'","b'however , there is no evidence that somatropin caused by leukaemia if no other risk factors .'","b'however , there is no evidence that somatropin caused by leukaemia in blood sugar system .'","b'however , there is no evidence that somatropin causes leukaemia , if no other risk factors are present .'"
2853,b'3 bis 5 wochen sp\xc3\xa4ter .',b'3 to 5 weeks later .',b'to weeks later .',b'3 to 5 weeks later .'
2854,b'kinder und jugendliche imprida wird nicht empfohlen f\xc3\xbcr die anwendung bei patienten unter 18 jahren aufgrund des fehlens von daten zur unbedenklichkeit und wirksamkeit .',b'children and adolescents imprida is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy .',b'children and adolescents eucreas is not recommended for use in patients aged below years due to a lack of data on safety and table on safety and efficacy .',b'children and adolescents imprida is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy .'
2855,b'- 29 - t\xc3\xa4gliche einnahme einer 20 mg filmtablette .',b'- 29 - the patient should take one 20 mg film-coated tablet per day .',b'the patient should take one mg filmcoated tablet per day .',b'- 29 - one 20 mg film-coated tablet per day .'
2856,"b'b. beim autofahren oder beim bedienen von maschinen ) ein risiko darstellen . den patienten ist zu raten , vorsichtsma\xc3\x9fnahmen zu treffen , um hypoglyk\xc3\xa4mien beim f\xc3\xbchren von kraftfahrzeugen zu vermeiden .'",b'( e. g. driving a car or operating machinery ) . patients should be advised to take precautions to avoid hypoglycaemia while driving .',b'e . g . driving a sertraline or operating machinery . patients should be advised to take precautions .',b'( e. g. driving a car or operating machinery ) . patients should be advised to take precautions to avoid hypoglycaemia while driving .'
2857,b'ausscheidung etwa 71 % der rotigotindosis werden \xc3\xbcber den urin und ein kleinerer anteil von ca. 23 % \xc3\xbcber die f\xc3\xa4zes ausgeschieden .',"b'elimination approximately 71 % of the rotigotindosis is excreted in the urine , and the rate of approximately 23 % in the faeces .'","b'median average of the primarily corresponds to in the urine , and the plasma rate .'","b'elimination approximately 71 % of the rotigotindosis is excreted in the urine , and the rate of approximately 23 % in the faeces .'"
2858,b'was ist irbesartan winthrop und wof\xc3\xbcr wird es angewendet ?',b'what is irbesartan winthrop is and what it is used for 2 .',b'what is irbesartan winthrop is and what it is used for .',b'what is irbesartan winthrop and what it is used for .'
2859,"b'in den studien bei jahreszeitlich auftretender allergischer rhinitis bei erwachsenen und jugendlichen reduzierte avamys die symptomwerte mit einem startwert von etwa 9 punkten im laufe von zwei wochen um einen wert zwischen 3,6 und 5,4 punkten .'","b'in the studies in seasonal allergic rhinitis in adults and adolescents , avamys reduced the symptomwerte with a monomeric duration of acetylcholinesterase inhibition of about 9 points during the two weeks between 3.6 and 5.4 points .'","b'in the studies in seasonal allergic rhinitis in adults and adolescents , had less frequently in october ii possibly states at approved , which was established or the rats with a modification states in adults and adolescents and adolescents increase to that it were studied higher positive the dose of'","b'in the studies in seasonal allergic rhinitis in adults and adolescents , avamys reduced the symptom level with a start level of about 9 points during the two weeks by between 3.6 and 5.4 points .'"
2860,b'mit velmetia wurden keine tierstudien durchgef\xc3\xbchrt .',b'no studies in animals have been conducted with velmetia .',b'no studies in animals have been conducted with velmetia .',b'no studies in animals have been conducted with velmetia .'
2861,b'weitere informationen \xc3\xbcber silapo :',b'2 / 3 other information about silapo :',b'other information about line of alcohol',b'2 / 3 other information about silapo :'
2862,"b'der zusatz von interferon-gamma zum tasonermin-perfusat scheint nicht zu einer signifikanten zunahme der endogenen produktion von tasonermin oder anderen entz\xc3\xbcndlichen zytokinen zu f\xc3\xbchren , wie bei patienten mit schwerem trauma gezeigt werden konnte .'","b'adding of longitudinal axis and tasonermin-perfusat do not appear to be a significant increase in the endogenous production of tasonermin or other inflammatory cytokines , such as in patients with severe trauma has been shown .'","b'due to the result therapy of firstpass acid of tasonermin or other relative breakdown of tasonermin or other inflammatory effects is is not gradually to be greater or other inflammatory , such as in patients with severe neuritis has been shown .'","b'the addition of longitudinal axis and tasonermin perfusate do not appear to lead to a significant increase in the endogenous production of tasonermin or other inflammatory cytokines , as has been shown in patients with severe trauma .'"
2863,b'sie d\xc3\xbcrfen busilvex nach dem auf dem umkarton angegebenen verfalldatum nicht mehr verwenden .',b'do not use busilvex after the expiry date which is stated on the carton .',b'do not use travatan after the expiry date which is stated on the carton .',b'do not use busilvex after the expiry date which is stated on the carton .'
2864,b'nicht gebrauchte spritzen oder abfall sollten entsprechend den \xc3\xb6rtlich g\xc3\xbcltigen vorschriften entsorgt werden .',b'any unused product or waste material should be applied according to the current veterinary medicinal product must be discarded .',b'any unused product or waste material should be applied according to the current supervision or waste material should be status according to the current veterinary medicinal product must be discarded through it material .',b'any unused product or waste material should be disposed of according to the current local ordinances .'
2865,b'was ist photobarr und wof\xc3\xbcr wird es angewendet ?',b'what photobarr is and what it is used for 2 .',b'what photobarr is a whole ? hycamtin ?',b'what is photobarr and what it is used for ?'
2866,b'las erkrankungen der geschlechtsorgane und der brustdr\xc3\xbcse h\xc3\xa4ufig :',b'ori reproductive system and breast disorders common :',b'tumour system and breast common',b'diseases of the reproductive system and breasts common :'
2867,b'die tysabri durchstechflasche ist vor dem verd\xc3\xbcnnen und der anwendung optisch auf partikel zu pr\xc3\xbcfen .',"b'the tysabri vial before dilution , visually for any particulate matter and discolouration prior to administration .'",b'the tysabri contains injection with nespo particulate matter .',b'the tysabri vial is to be checked visually for any particulate matter and discolouration prior to dilution and administration .'
2868,"b'ihr arzt wird die dosis f\xc3\xbcr sie anpassen . sie 50 kann , je nach k\xc3\xb6rpergewicht , um 400 mg alle zwei tage bis zu einer t\xc3\xa4glichen gesamtdosis von maximal 3200 mg gesteigert werden .'","b'your doctor will adjust the dose for you . you 50 may be mixed , depending upon 400 mg at intervals of two days , to a daily dose of no more than 3200 mg .'","b'your doctor will adjust the dose for you after mg at smoking of two days , to a daily dose of evidence , to a daily dose of the abovementioned dose .'","b'your doctor will adjust the dose for you . it may be increased depending upon 400 mg at intervals of two days , to a daily dose of no more than 3200 mg .'"
2869,"b'cox-2 ist die "" induzierbare "" form des enzyms und ist verantwortlich f\xc3\xbcr die produktion von mediatoren , u.a. pge2 , das schmerz , entz\xc3\xbcndung oder fieber verursacht .'","b'cox-2 is the inducible form of the "" "" form of the enzyme and is responsible for the production of mediators including pge2 which induce pain , inflammation or fever .'","b'e is the oxygen in the release that to the cp of norepinephrine from and reduction , inflammation s sugar with the chain involved and e in quality and which well pain , inflammation or fever .'","b'cox-2 is the inducible form of the form of the enzymes and is responsible for the production of mediators including pge2 which induce pain , inflammation or fever .'"
2870,b'in der merlin-timi 36-studie wurden bei 3.162 mit ranexa behandelten patienten w\xc3\xa4hrend des 7-t\xc3\xa4gigen holter monitorings keine proarrhythmischen wirkungen beobachtet .',b'in the merlin-timi 36 study patients treated with ranexa based on the 7-t\xc3\xa4gigen substitution monitorings no proarrhythmic effects were observed .',b'in the merlintimi study patients treated with ranexa based on the original hyperhydratation monitorings no proarrhythmic effects were observed .',"b'in the merlin-timi 36 study , no proarrhythmic effects were observed in patients treated with ranexa during on the 7-day holter monitoring .'"
2871,b'es gibt packun - gen mit 5 patronen und b\xc3\xbcndelpackungen mit 2 x 5 patronen .',b'there is packun - the cartridges come in packs of 5 cartridges or a multipack of 2 x 5 cartridges .',b'there is endoscopic the cartridges rest in packs of cartridges or a cp of x container .',b'the cartridges come in packs of 5 cartridges or a multipack of 3 x 5 cartridges .'
2872,b'die wechselwirkung zwischen theophyllin und ciprofloxacin ist potenziell lebensbedrohlich .',b'the interaction between theophylline and ciprofloxacin is potentially life-threatening .',b'there is no lifethreatening .',b'the interaction between theophylline and ciprofloxacin is potentially life-threatening .'
2873,b'es wird einmal t\xc3\xa4glich \xc3\xbcber 7 tage verabreicht .',b'it is given once daily for 7 days .',b'it is given once daily for days .',b'it is given once daily for 7 days .'
2874,b'keine dosisanpassung f\xc3\xbcr invirase / ritonavir erforderlich .',b'no dose adjustment is necessary for invirase / ritonavir .',b'no dose adjustment is necessary for invirase ritonavir .',b'no dose adjustment is necessary for invirase / ritonavir .'
2875,b'es stehen keine daten zur anwendung mit anderen antikonvulsiven arzneimitteln wie benzodiazepine zur verf\xc3\xbcgung .',b'there is no information on the use of daronrix with other anticonvulsant medicinal products such as benzodiazepines are available .',b'there is no information on the use of viraferonpeg with other determined during and physical inr .',b'there is no information available on the use of daronrix with other anticonvulsant medicinal products such as benzodiazepines .'
2876,"b'65 obwohl nach der anwendung von effentora keine die atmung beeintr\xc3\xa4chtigende muskelsteifigkeit beobachtet wurde , ist diese f\xc3\xbcr fentanyl und andere opioide bekannt .'","b'65 although following the use of effentora has been observed no effects of a pre-determined muscle stiffness , this is possible with fentanyl and other opioids .'","b'although when one activities withdrawal treatment of effentora has been observed no effects of a anticonvulsant muscle stiffness , this is possible effects of spotting as this is possible with fentanyl and other have in less or diabetes and other leukaemia of the reports of effentora has been observed no'","b'65 although following the use of effentora , no uscle stiffness affecting breathing has been observed , this is known with fentanyl and other opioids .'"
2877,"b'ein abbruch der pegintron-therapie sollte bei patienten in betracht gezogen werden , die neue oder sich verschlimmernde ophthalmologische st\xc3\xb6rungen entwickeln .'",b'discontinuation of pegintron therapy should be considered in patients who develop new or worsening ophthalmological disorders .',"b'severely taken , . . atorvastatin containing clinical or worsening and method of humans should be considered in patients who of dose period is weakened function .'",b'discontinuation of pegintron therapy should be considered in patients who develop new or worsening ophthalmological disorders .'
2878,b'im k\xc3\xbchlschrank ( 2 \xc2\xb0 c-8 \xc2\xb0 c ) lagern .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'store in a refrigerator c c .',b'store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
2879,b'mehr als 90 % der patienten der aspire-studie hatten mindestens zwei auswertbare radiologische untersuchungen .',b'more than 90 % of the patients in the aspire-studie had at least two evaluable radiological studies .',b'more than of the discontinuation of antibodies prednisone studies .',b'more than 90 % of the patients in the aspire study had at least two evaluable radiological studies .'
2880,"b'die hauptindikatoren f\xc3\xbcr die wirksamkeit waren die konzentrationen von antik\xc3\xb6rpern gegen das grippevirus im blut zu drei verschiedenen zeiten : vor der impfung , am tag der zweiten injektion ( tag 21 ) und 21 tage sp\xc3\xa4ter ( tag 42 ) .'","b'the main measures of effectiveness were the levels of antibodies against the flu virus in the blood to three different times : before vaccination , on the day of the second injection ( day 21 ) , and 21 days later ( day 42 ) .'","b'the main measures of effectiveness were the serum virus in the blood to three different higher adverse day or given by different by by different three the individual injection day in both injection day and days the time , and days t patients before vaccination , on the day and'","b'the main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times : before vaccination , on the day of the second injection ( day 21 ) , and 21 days later ( day 42 ) .'"
2881,b'die rekrutierung f\xc3\xbcr die studie begann im januar 2006 .',b'the recruitment for the study began in january 2006 .',b'the recruitment for the study carried in january .',b'the recruitment for the study began in january 2006 .'
2882,b'zus\xc3\xa4tzlich ist toviaz auch in hdpe-flaschen mit 30 oder 90 tabletten erh\xc3\xa4ltlich .',"b'in addition , toviaz is also available in hdpe bottles containing 30 or 90 tablets .'","b'in addition , toviaz is also available in the maximum tablet containing or tablets .'","b'in addition , toviaz is also available in hdpe bottles containing 30 or 90 tablets .'"
2883,b'3 jahre nach anbruch :',b'3 years after first opening :',b'years after first evidence',b'3 years after first opening :'
2884,"b'il-12 und il-23 wirken an der immunfunktion mit , indem sie zur aktivierung der nat\xc3\xbcrlichen killerzellen ( nk ) sowie cd4 + t-zelldifferenzierung und -aktivierung beitragen .'",b'il-12 and il-23 work on immune function and how the nat\xc3\xbcrlichen ( nk ) and cd4 + t-zelldifferenzierung ) .',b'efalizumab and il work on immune function and off screwed by the penicillin shed .',b'il-12 and il-23 work on immune functionba and how the natural killer cells ( nk ) and cd4 + t time difference .'
2885,b'die immunisierung sollte mindestens eine woche vor einer potenziellen exposition gegen\xc3\xbcber cholera abgeschlossen sein .',b'immunisation should be completed at least one week prior to potential exposure to cholera may be completed .',b'the vaccine should be completed gilt the reduction over to the further exposure for weeks .',b'immunisation should be completed at least one week prior to potential exposure to cholera .'
2886,b'jede schachtel enth\xc3\xa4lt 1 flasche .',b'each carton contains 1 bottle .',b'each carton contains bottle .',b'each carton contains 1 bottle .'
2887,b'axura wird zur behandlung von patienten mit moderater bis schwerer alzheimer-demenz angewendet .',"b""axura is used to treat patients with moderate to severe alzheimer 's disease .""",b'axura is used to treat patients with moderate to severe alzheimer s disease .',"b""axura is used to treat patients with moderate to severe alzheimer 's disease ."""
2888,"b'wenn sie nach dem herausziehen des injektionsknopfs bemerken , dass sie eine falsche dosis eingestellt und geladen haben , injizieren sie die l\xc3\xb6sung nicht .'","b'if you have loaded needle protection device upon withdrawal from patient will vary notice that you have set a wrong dose , and inject the solution is not .'",b'if you have switching all top quixidar from time in the solution shake the solution is not affected the solution is not .',"b'if you notice upon withdrawal of the needle protection that you have set a wrong dose , do not inject the solution .'"
2889,"b'sollte eine bedrohliche blutung , insbesondere eine cerebrale blutung , auftreten , muss eine gleichzeitig durchgef\xc3\xbchrte therapie mit heparin sofort abgebrochen werden .'","b'if a bedrohliche haemorrhage , cerebral bleeding occur , 1513 concomitant therapy with heparin should be discontinued immediately .'","b'if doctors , reducing bleeding occur , concomitant therapy with heparin and heparin fluid dysfunction during the therapy with heparin levels is planned problems failure with heparin monitored require level could be discontinued immediately .'","b'if a threatening haemorrhage , cerebral bleeding occur , concomitant therapy with heparin should be discontinued immediately .'"
2890,b'\xe2\x80\xa2 senkung der kardiovaskul\xc3\xa4ren morbidit\xc3\xa4t und mortalit\xc3\xa4t ( oder des schlaganfallrisikos ) bei patienten mit hypertonie und linksherzhypertrophie ;',b'\xe2\x80\xa2 reduction in risk of cardiovascular morbidity and mortality ( or stroke ) in patients with hypertension and left ventricular hypertrophy ;',b'reduction in risk of cardiovascular replacement and mortality or stroke in patients with hypertension and cypa bleeding',b'\xe2\x80\xa2 reduction in risk of cardiovascular morbidity and mortality ( or stroke ) in patients with hypertension and left ventricular hypertrophy ;'
2891,b'zus\xc3\xa4tzlich berichteten einige patienten w\xc3\xa4hrend der einnahme von tesavel mit pioglitazon \xc3\xbcber schwellungen an den f\xc3\xbc\xc3\x9fen .',"b'in addition , some patients have reported while taking tesavel with pioglitazone foot swelling .'","b'in addition , some patients have reported while taking tesavel with pioglitazone out to fatal the dementia .'","b'in addition , some patients have reported foot swelling while taking tesavel with pioglitazone .'"
2892,b'verwendbar bis mm / jjjj nach anbruch innerhalb von 8 stunden aufbrauchen .',"b'exp month / year once broached , use within 8 hours .'","b'exp month year once concurrently , use within hours .'","b'exp month / year . once broached , use within 8 hours .'"
2893,b'sirolimus wird in betr\xc3\xa4chtlichem ausma\xc3\x9f \xc3\xbcber o-demethylierung und / oder hydroxylierung metabolisiert .',b'sirolimus is extensively the mesh by o-demethylation and / or hydroxylation .',b'sirolimus is extensively rapidly not be minor better by during patients and or night corresponding .',b'sirolimus is extensively metabolized by o-demethylation and / or hydroxylation .'
2894,b'wof\xc3\xbcr wird photobarr angewendet ?',b'what is photobarr used for ?',b'what is azilect for ?',b'what is photobarr used for ?'
2895,b'bei welpen unter sechs monaten darf pruban nicht angewendet werden .',b'when in puppies below six months of age pruban should not be used .',b'when administering doses for less residues months of age stateverteilungsvolumen should not be reasons .',b'when in puppies below six months of age pruban should not be used .'
2896,b'f\xc3\xbcr den arzt :',b'to the physician :',b'to the physician',b'for the physician :'
2897,"b'falls ernsthafte oder hier nicht genannte nebenwirkungen auftreten , informieren sie bitte das medizinische personal .'","b'if any of the side effects gets serious side effects not listed in this leaflet , please tell the medical staff .'","b'if any of the side effects are carefully listed in this leaflet , please tell the medical episodes .'","b'if any of the side effects gets serious side effects not listed in this leaflet , please tell the medical staff .'"
2898,b'als gr\xc3\xbcnde k\xc3\xb6nnen k\xc3\xb6rperliche und / oder psychische ursachen vorliegen .',b'as the reasons for physical and / or mental states may causes .',b'as the reasons for physical and or hexikinase states may causes .',b'there may be physical and / or mental causes .'
2899,b'nicht verwendetes arzneimittel oder abfallstoffe ist gem\xc3\xa4\xc3\x9f den \xc3\xb6rtlichen bestimmungen zu entsorgen .',b'any unused product or waste material or ngf-metal mixture should be discarded according to local regulations .',b'any unused product or waste material or serumkaliumwerte with exclude of diseases with sonata for preferably solutions immediately to local regulations .',b'any unused product or waste material should be discarded according to local regulations .'
2900,"b'ihr arzt kann ihnen jedoch vorschlagen , ihre dosis remeron aufzuteilen - ein teil morgens und ein teil vor dem zubettgehen .'",b'your doctor may suggest you but your dose of remeron - once in the morning and once at night-time before you go to bed .',b'your doctor may suggest you but tell any insulin system .',b'your doctor may suggest you split your dose of remeron - once in the morning and once at night-time before you go to bed .'
2901,"b'cyp1a2 inhibitoren : da cyp1a2 am metabolismus von duloxetin beteiligt ist , ist es wahrscheinlich , dass eine gleichzeitige anwendung von cymbalta mit starken cyp1a2 inhibitoren zu einer h\xc3\xb6heren konzentration von duloxetin f\xc3\xbchren kann .'","b'inhibitors of cyp1a2 : because cyp1a2 is involved in duloxetine metabolism , it is likely that concomitant use of cymbalta with potent inhibitors of cyp1a2 may result in higher concentrations of duloxetine .'",b'inhibitors of cypa p cancers was involved in duloxetine against plasma than was egfr in humans .',"b'inhibitors of cyp1a2 : because cyp1a2 is involved in duloxetine metabolism , it is likely that concomitant use of cymbalta with potent inhibitors of cyp1a2 may result in higher concentrations of duloxetine .'"
2902,b'datum der genehmigung der packungsbeilage :',b'date of approval of the package leaflet :',b'date of the package leaflet',b'date of approval of the package leaflet :'
2903,b'sie sollten die einnahme von oprymea zusammen mit antipsychotischen arzneimitteln vermeiden .',b'you should avoid taking oprymea together with antipsychotic medicines .',b'you should avoid taking oprymea pumps with',b'you should avoid taking oprymea together with antipsychotic medicines .'
2904,b'ribavirin teva darf nicht von stillenden m\xc3\xbcttern eingenommen werden .',b'ribavirin teva should not be administered to breast- feeding mothers .',b'ribavirin teva should not be administered to breast feeding for these pathogens .',b'ribavirin teva should not be administered to breast- feeding mothers .'
2905,"b'in der regel bilden sie sich nach therapieende im laufe der zeit ohne folgeerscheinungen zur\xc3\xbcck , sofern die empfohlenen dosierungsanpassungen eingehalten werden ( siehe abschnitt 4.4 ) .'","b'usually rapidly after cessation of treatment over time , without sequelae , unless the irbesartan , the recommended dose adjustments before commencement of treatment ( see section 4.4 ) .'","b'usually lasts absorbed reliable area hours of the animal dose of treatment over consideration a close ovarian mechanisms containing a gradual treatment after vaccinations . preferably the content of treatment over time , without pertussis ensures the in the epar with use with consideration , should be filled , without'","b'usually regresses after cessation of treatment over time , without sequelae , unless the irbesartan , provided the recommended dose adjustments are adhered to ( see section 4.4 ) .'"
2906,b'starke p- glykoprotein-hemmstoffe wie ciclosporin und verapamil sollten ebenfalls vermieden werden .',"b'potent a lense according to claim glykoprotein-hemmstoffe including cyclosporine and verapamil , should also be avoided .'",b'potent a actual pump according to veterinary according to for optimize has also be avoided .',"b'potent p-glykoprotein inhibiting agents including cyclosporine and verapamil , should also be avoided .'"
2907,b'opioide - auch als narkotika bezeichnet - sind drogen wie heroin oder morphin .',b'opioids - narcotic analgesics and poor metabolisers ( as a heroin or morphine .',b'onsenal hpg analgesics an poor excess function to a endometrium portion risk for nonswelling oxidase to moderate fluid depletion .',b'opioids - also referred to as narcotics - are drugs such as heroin or morphine .'
2908,b'halten sie die injektionsnadel nach oben und dr\xc3\xbccken die luft heraus .',b'keeping the needle upwards and push the air out .',b'be injected the needle tightly through the reconstituted bottle and push the air provided .',b'keep the needle upwards and push the air out .'
2909,b'2 bei patienten mit schweren nierenfunktionsst\xc3\xb6rungen ist keine dosisanpassung erforderlich .',b'2 no dose adjustment is necessary in patients with severe renal impairment .',b'no genderspecific dose adjustment is necessary in patients with severe renal impairment .',b'2 no dose adjustment is necessary in patients with severe renal impairment .'
2910,"b'von den folgenden ereignissen wurde ebenfalls berichtet , wenn viramune in kombination mit anderen antiretroviralen substanzen angewendet wurde : pankreatitis , periphere neuropathie und thrombozytopenie .'","b'the following events have also been reported when viramune is used in combination with other antiretroviral agents has been used : pancreatitis , peripheral neuropathy and thrombocytopenia .'",b'the following studies have also been reported when severely slight bleeding and thrombocytopenia .',"b'the following events have also been reported when viramune is used in combination with other antiretroviral agents : pancreatitis , peripheral neuropathy and thrombocytopenia .'"
2911,b'bereiten sie den patienten auf die injektion vor .',b'prepare the patient injection .',b'for the patient injection .',b'prepare the patient injection .'
2912,"b'sie leuchtet so lange , wie das arzneimittel abgegeben wird .'",b'you 70kg bodyweight for as long as the medicine .',b'you kg bodyweight for as long as the medicine .',b'it is illuminated for as long as the medicine is prescribed .'
2913,"b'viramune suspension zum einnehmen ist eine fl\xc3\xbcssige suspension , die nur oral eingenommen werden darf .'",b'viramune oral suspension is a suspension and the should only be taken by mouth .',b'usually oral suspension is a suspension and the should only be persist by fluid .',b'viramune oral suspension is a liquid suspension and should only be taken by mouth .'
2914,b'die wirksamkeit von olanzapin wurde in diesen studien nicht belegt .',b'the efficacy of olanzapine was not established in these trials .',b'the efficacy of olanzapine was not established in these trials .',b'the efficacy of olanzapine was not established in these trials .'
2915,b'dies ist wahrscheinlich auf das h\xc3\xa4ufigere vorkommen eines niedrig-renin-status bei der schwarzen bev\xc3\xb6lkerung zur\xc3\xbcckzuf\xc3\xbchren ( siehe abschnitt 5.1 ) .',b'this is probably due to the less effective in lowering blood pressure in niedrig-renin-status in the black population are due to treatment ( see section 5.1 ) .',b'this is probably due to the studies were not recommended in secondary dose . .',b'this is probably due to frequent occurrence of low renin status in the black population ( see section 5.1 ) .'
2916,"b'nachdem der h\xc3\xa4moglobinwert auf unter 12 g / dl ( 7,5 mmol / l ) oder niedriger abgesunken ist , sollte die behandlung mit einer dosis , die ca. 25 % unterhalb der zuvor angewendeten dosis liegt , wieder aufgenommen werden .'","b'after the below 12 g / dl ( 7.5 mmol / l ) or lower uptake should increase , the dose point therapy should be reinitiated at approximately 25 % lower than the below therapy should be reinitiated at'","b'after the long possibly exceeds weekly weekly m approximately lower for renal monotherapy therapy should increase , the dose interval therapy should increase , the dose point therapy should increase , the dose point therapy should increase , insuman therapeutic diminished higher dose therapeutic than a dose is rise is'","b'after the hemoglobin value drops to 12 g / dl ( 7.5 mmol / l ) or lower , treatment should be provided with a dose of approximately 25 % lower than the previous dose .'"
2917,b'art und dauer der anwendung nur zu lokalen anwendung .',b'method of administration for local use .',b'method of administration for local use .',b'method of administration . only for local use .'
2918,b'in klinischen studien wurde jedoch neurobloc 16 wochen nach injektion von clostridium botulinum toxin typ a verabreicht .',"b'in clinical trials , but neurobloc was 16 weeks after injection of botulinum toxin type a ) .'","b'in clinical trials , but neurobloc due to the activity of sickleshape toxin type a atripla .'","b'in clinical trials , neurobloc was administered 16 weeks after injection of botulinum toxin type a.'"
2919,"b'\xe2\x80\xa2 zur verbesserung der blutzuckerkontrolle in kombination mit metformin , wenn di\xc3\xa4t und bewegung plus eine monotherapie mit metformin den blutzucker nicht ausreichend senken .'",b'\xe2\x80\xa2 to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control .',b'to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate diuretic or porphyrins and exercise with metformin when diet and exercise plus metformin alone cannot not provide adequate glycaemic abnormalities .',b'\xe2\x80\xa2 to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control .'
2920,b'reduktion postoperativer schmerzen nach ovariohysterektomie und leichteren weichteiloperationen .',b'reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery .',"b'reduction of postoperative pain after eot , side effects of both creams ,'",b'reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery .'
2921,b'\xc3\x96rtlich begrenzte infektionen mit carbapenem-resistenten erregern wurden in der europ\xc3\xa4ischen gemeinschaft berichtet .',b'local infections with carbapenem-resistenten pathogens have been reported in the european community .',b'local infections with the inner areas has been reported in the european community .',b'local infections with carbapenem-resistant pathogens have been reported in the european community .'
2922,b'in den meisten f\xc3\xa4llen wurden antik\xc3\xb6rper erst nach 12-monatiger behandlung nachgewiesen . nach beendigung der therapie nahm die konzentration der antik\xc3\xb6rper wieder ab .',"b'in most cases , antibodies has been demonstrated only after 12 months after discontinuation of therapy , the amount of antibodies .'","b'in most cases of the urine with rhabdomyolysis inhibitors in months after doses , the amount of antibodies was not times after months after discontinuation of a urine in tacrolimus after discontinuation of response by a decrease volume of the transmission of antibodies see to the amount of antibodies or'","b'in most cases , antibodies has been demonstrated only after 12 months after discontinuation of therapy . after ending the therapy the amount of antibodiees .'"
2923,"b'eingeschr\xc3\xa4nkte nierenfunktion vorsicht ist bei patienten mit schwerer nierenfunktionsst\xc3\xb6rung angezeigt , da mit degarelix zu dieser patientengruppe keine daten vorliegen .'","b'renal impairment caution should be exercised in patients with severe renal impairment , as with degarelix have not been studied .'","b'renal impairment caution should be exercised in patients with severe renal impairment , as with degarelix have not been studied .'","b'renal impairment : caution should be exercised in patients with severe renal impairment , as degarelix has not been studied in this patient group .'"
2924,"b'wenn die patienten nach auftreten solcher symptome fosavance weiter einnehmen , k\xc3\xb6nnen sich diese nebenwirkungen weiter verschlechtern .'",b'if the patients symptoms continue to take fosavance may worsen these side effects .',b'if the patients symptoms continue to before the onset of xolair .',"b'if the patients continue to take fosavance after these symptoms , these side effects may worsen .'"
2925,"b'aufgrund der wirkungsweise von aldara besteht die m\xc3\xb6glichkeit , dass sich eine bereits bestehende entz\xc3\xbcndung im behandelten bereich verschlimmert .'","b'based on the mode of action , with aldara , there is a possibility that already treated inflammation in worse .'","b'based on the mode of action of action depends in the start of action with the degeneration of action , with il , there is a possibility that has treated inflammation in treatment .'","b'based on the mode of action , with aldara , there is a possibility that already treated inflammation is worse .'"
2926,"b'in tabelle 3 sind die anzahl und der prozentsatz an patienten aus der klinischen studie \xc3\xbcber 24 wochen mit exelon an patienten mit parkinson-demenz aufgelistet , bei denen vorher definierte nebenwirkungen auftraten , die eine verschlechterung der parkinson-symptomatik widerspiegeln k\xc3\xb6nnen .'","b""table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted 28 with exelon in patients with dementia associated with parkinson 's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms .""",b'table lists the number and percentage of patients from the lack of the lack of in patients with dementia associated with parkinson s disease with tricyclic adverse effects that may modify undesirable .',"b""table 3 lists the number and percentage of patients clinical study over 24 weeks with exelon in patients with dementia associated with parkinson 's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms ."""
2927,"b'die am h\xc3\xa4ufigsten berichteten nebenwirkungen bei patienten , die mit cymbalta behandelt wurden , waren \xc3\x9cbelkeit , kopfschmerzen , mundtrockenheit , schl\xc3\xa4frigkeit , m\xc3\xbcdigkeit , schlaflosigkeit , schwindel und obstipation .'","b'the most commonly reported adverse reactions in patients treated with cymbalta were nausea , headache , dry mouth , somnolence , fatigue , insomnia , dizziness and constipation .'","b'the most commonly reported adverse reactions in patients treated with cymbalta were nausea , headache , dry mouth , somnolence and constipation .'","b'the most commonly reported adverse reactions in patients treated with cymbalta were nausea , headache , dry mouth , somnolence , fatigue , insomnia , dizziness and constipation .'"
2928,b'erkrankungen des blutes und lymphsystems :',b'20 blood and lymphatic system disorders :',b'blood and short system disorders',b'20 blood and lymphatic system disorders :'
2929,b'aerinaze darf nicht bei kindern unter 12 jahren angewendet werden .',b'aerinaze should not be used in children under 12 years of age .',b'actraphane should not be used in children under years of age .',b'aerinaze should not be used in children under 12 years of age .'
2930,b'der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen ist das unternehmen glaxo group ltd.',b'the holder of the marketing authorisation holder is glaxo group ltd .',b'the holder of the marketing authorisation holder is glaxo group ltd .',b'the holder of the marketing authorisation is glaxo group ltd .'
2931,b'31 eine topotecan-induzierte neutropenie kann zu einer neutropenischen kolitis f\xc3\xbchren .',b'31 topotecan-induced neutropenia can cause neutropenic colitis .',b'antibioticassociated grade can cause urticarial morphineequivalent .',b'31 topotecan-induced neutropenia can cause neutropenic colitis .'
2932,b'intrakranielle l\xc3\xa4sionen inaktiv sein und eine tumorbehandlung muss abgeschlossen sein .',b'intracranial lesions may be inactive and must be matched .',b'intracranial lesions may be altered and must be checked by kg .',b'intracranial lesions may be inactive and treatment for tumours must be completed .'
2933,"b'pci und das risiko von katheterthromben bei stemi-patienten , die einer prim\xc3\xa4ren pci unterzogen werden , wird die gabe von fondaparinux vor und w\xc3\xa4hrend der pci nicht empfohlen .'","b'pci and the risk of anticoagulation in stemi-patienten , undergoing primary pci , the use of fondaparinux prior to and during pci is not recommended .'","b'musculoskeletal and the risk of darifenacin remote after the effective sysmptoms , in abatacepttreated , ulceration patients should be necessary .'","b'pci and the risk of anticoagulation : in stemi patients undergoing primary pci , the use of fondaparinux prior to and during pci is not recommended .'"
2934,"b'17 bitte informieren sie ihren arzt oder apotheker , wenn sie andere arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht verschreibungspflichtige arzneimittel handelt .'","b'17 taking other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'",b'with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines .',"b'17 please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'"
2935,"b'die injektionsl\xc3\xb6sung ist eine klare , farblose bis leicht gef\xc3\xa4rbte fl\xc3\xbcssigkeit ( pink ) .'","b'the solution for injection is a clear , colourless to slightly coloured ( pink ) .'","b'the solution for injection is a clear , colourless to slightly coloured pink .'","b'the solution for injection is a clear , colourless to slightly coloured fluid ( pink ) .'"
2936,b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen es wurden keine studien zu den auswirkungen auf die verkehrst\xc3\xbcchtigkeit und die f\xc3\xa4higkeit zum bedienen von maschinen durchgef\xc3\xbchrt .',b'driving and using machines : no studies on the effects on the ability to drive and use machines have been performed .',"b'driving and using machines no studies on the effects on the ability to drive and use machines , they on all effects .'",b'driving and using machines : no studies on the effects on the ability to drive and use machines have been performed .'
2937,"b'durchstechflasche im umkarton aufbewahren , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'keep the vial in the outer carton in order to protect it from light .',b'keep this syringe in the outer carton in order to protect it from light .',b'keep the vial in the outer carton in order to protect it from light .'
2938,"b'6 - spritzen sie das medikament mit langsamem , gleichm\xc3\xa4\xc3\x9figem druck auf den kolben ein .'","b'6 - inject the medicine using a slow , steady push on the plunger .'","b'inject the medicine using a slow , steady pull it at the thickness see which .'","b'6 - inject the medicine using a slow , steady push on the plunger .'"
2939,b'zu ausf\xc3\xbchrliche informationen zu diesem arzneimittel sind auf d er website der europ\xc3\xa4ischen arzneimittel-agentur ( emea ) http : / / www.emea.europa.eu / verf\xc3\xbcgbar .',b'detailed information on this medicinal product is permitted on this medicine is available on the european medicines agency ( emea ) web site : http : / / www. emea. europa. eu / .',b'detailed information on this medicinal product is available on this medicine is available on the european medicines agency emea web site http www . emea . europa . eu .',b'detailed information on this medicinal product is permitted on this medicine is available on the european medicines agency ( emea ) web site : http : / / www.emea.europa.eu / .'
2940,"b'das verd\xc3\xbcnnungsmittel ist eine klare bis leicht getr\xc3\xbcbte , leicht gelbliche bis gelbe l\xc3\xb6sung .'","b'the diluent is a clear to slightly getr\xc3\xbcbte yellowish , mildly yellow solution .'","b'the diluent is a clear to slightly dipeptidylpeptidase free butyl , adhesive aluminium soya free tube plunger rapidly yellow solution .'","b'the diluent is a clear to slightly clouded , light yellow to yellow solution .'"
2941,b'die gleichzeitige anwendung von ribavirin und zidovudin wird aufgrund eines erh\xc3\xb6hten an\xc3\xa4mie-risikos nicht empfohlen ( siehe abschnitt 4.4 ) .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased an\xc3\xa4mie-risikos ( see section 4.4 ) .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased inherited see section . .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia ( see section 4.4 ) .'
2942,"b'unter therapie mit proteasehemmern , insbesondere in kombination mit nukleosidischen reverse- transkriptase-hemmern , wurde \xc3\xbcber eine erh\xc3\xb6hung der cpk sowie das auftreten von myalgien , myositis und in seltenen f\xc3\xa4llen auch rhabdomyolyse berichtet .'","b'under treatment with protease inhibitors , particularly in combination with nucleoside reverse transcriptase inhibitors have been reported as an increase in cpk as well as the occurrence of myalgia , myositis and very rare cases of rhabdomyolysis have been reported .'","b'under treatment with protease inhibitors , particularly in combination with nucleoside reverse transcriptase inhibitors that that cause the occurrence of insomnia of angina have been reported as supplies the occurrence of seizures increased cats , proteus and how have been reported as well as the occurrence of recurrent , listeriosis'","b'under treatment with protease inhibitors , particularly in combination with nucleoside reverse transcriptase inhibitors , an increase in cpk has been reported as well as the occurrence of myalgia , myositis and very rare cases of rhabdomyolysis .'"
2943,b'ein zusammenhang mit protopic wurde nicht festgestellt .',b'an association with protopic has not been established .',b'an association with protopic has not been established .',b'an association with protopic has not been established .'
2944,b'ribavirin teva wird t\xc3\xa4glich in zwei geteilten dosen ( morgens und abends ) mit den mahlzeiten eingenommen .',b'ribavirin teva is taken with food each day in two divided doses ( morning and evening ) .',b'ribavirin teva is taken with food each day in two divided doses .',b'ribavirin teva is taken with food each day in two divided doses ( morning and evening ) .'
2945,"b'bei insulinaspart wurde an der position b28 die aminos\xc3\xa4ure prolin gegen asparagins\xc3\xa4ure ausgetauscht , wodurch die neigung zur bildung von hexameren , im vergleich zu l\xc3\xb6slichem humaninsulin , in der l\xc3\xb6slichen fraktion von novomix 30 herabgesetzt ist .'","b'in insulin aspart substitution of amino acid proline was first against the tendency to form hexamers , compared with soluble human insulin , a fraction of novomix 30 is decreased .'","b'in insulin aspart s species of amino acid shed has relevant that a active immunisation as which is to well as the lumbar active substance , make is angiotensinii composition adrenalin , leads with soluble human insulin , the at the serotypes directly has explained create the evaluation after porcine'","b'in insulin aspat , the amino acid proline was substituted for aspartic acid at position b28 which lowered the tendency to bild hexameres in the soluble novomix 30 fraction compared to soluble human insulin .'"
2946,b'metabolisierung metformin wird unver\xc3\xa4ndert im harn ausgeschieden .',b'metformin is excreted unchanged in the urine .',b'metformin is excreted unchanged in the urine .',b'metformin is excreted unchanged in the urine .'
2947,b'diese s\xc3\xa4uglinge wurden in der fes-studie \xc3\xbcber einen zeitraum von drei jahren nach abschluss der impfung beobachtet .',b'these infants have been observed in the fes over a period of 3 years after the completion of vaccination .',b'these relevance were observed in the sixth daily a period of reduction after the completion of vaccination .',b'these infants have been observed in the fes over a period of 3 years after the completion of vaccination .'
2948,"b'wenn klinische daten fehlen , sollte die injizierte aktivit\xc3\xa4t der nierenfunktion angepasst werden .'","b'if clinical data are lacking , reduces the activity of the patient should be adjusted according to renal function .'","b'if clinical data for no data , then by the activity of the patient should be interrupted .'","b'if clinical data are lacking , the injected activity of the patient should be adjusted according to renal function .'"
2949,b'der prim\xc3\xa4re endpunkt der wirksamkeit war die objektive ansprechrate ( orr = objektive response rate ) auf basis der recist-kriterien ( response evaluation criteria in solid tumors ) .',b'the primary endpoint of effectiveness was the objective response rate ( orr = objective response rate ) on the basis of recist-kriterien ( response group ) .',"b'the primary findings rate persisted invitro , the obese response . rate on the basis of genital response group were not serum response rate and tumor in clinical study of glycylglutamate response group .'",b'the primary endpoint of effectiveness was the objective response rate ( orr = objective response rate ) on the basis of recist criteria ( response evaluation criteria in solid tumours ) .'
2950,b'- unregelm\xc3\xa4\xc3\x9figer herzschlag oder extraschl\xc3\xa4ge ( arrhythmie ) .',b'- irregular heart rhythm or extraschl\xc3\xa4ge ( arrhythmias ) .',b'secondary heart tetracyclines or bitter arrhythmias .',b'- irregular heart rhythm or extra heart beats ( arrhythmias ) .'
2951,"b'auch das aussehen des insulins muss gepr\xc3\xbcft werden : die insulinl\xc3\xb6sung muss klar , farblos und w\xc3\xa4ssrig sein und darf keine sichtbaren parti- kel enthalten .'","b'even if the appearance of the insulin should be checked : the insulin solution must be clear , colourless , with no solid particles and colourless , with no solid particles visible must have a water-like consistency .'","b'even if the appearance of the insulin should be checked the insulin solution must be applied , each solid particles , with further solid particles , and a angle management and colourless , should be applied , and the injection solution must be injected after t to require dental .'","b'even if the appearance of the insulin should be checked : the insulin solution must be clear , colourless , with no solid particles visible .'"
2952,b'3 ml l\xc3\xb6sungsmittel :',b'3 ml 1 vial + 1 ampoule solvent :',b'ml vial ampoule solvent',b'3 ml of solvent :'
2953,b'nebenwirkungen von ctc grad 3 und 4 traten bei 37 % der patienten in klinischen studien auf .',b'side effects of ctc grade 3 and 4 occurred in 37 % of patients in clinical trials .',b'side effects of ongoing grade and placebocontrolled reported in of patients in clinical trials .',b'side effects of ctc grade 3 and 4 occurred in 37 % of patients in clinical trials .'
2954,b'erste infusion die empfohlene initiale infusionsgeschwindigkeit betr\xc3\xa4gt 50 mg / h ; sie kann nach den ersten 30 minuten stufenweise alle 30 minuten um 50 mg / h auf einen h\xc3\xb6chstwert von 400 mg / h gesteigert werden .',"b'first infusion the recommended initial rate for infusion is 50 mg / hr , after the first 30 minutes escalated every 30 minutes to a maximum of 400 mg / hr 50 mg / hr .'","b'the maximum dose full rate for infusion is mg hr , after the first day as stored over with good period of mg hr .'",b'first infusion : the recommended initial rate for infusion is 50 mg / hr ; it can be increased gradually after the first 30 minutes every 30 minutes to a maximum of 400 mg / hr 50 mg / hr .'
2955,"b'wenn sie eine gr\xc3\xb6\xc3\x9fere menge glubrava-tabletten eingenommen haben , als sie sollten :'",b'if you take more glubrava tablets than you should :',b'if you take more medicine . of hypersensitivity appropriate the knee . any package absorption and suitable or',b'if you take more glubrava tablets than you should have :'
2956,"b'aus dieser studie geht ebenfalls hervor , dass zavesca keine oder nur eine begrenzte auswirkung auf die pharmakokinetik von cerezyme hat .'",b'from this study also showed that zavesca do not respond or have a limited impact on the pharmacokinetics of cerezyme .',b'from this study also showed that zavesca do not respond to potentially longer impact on the pharmacokinetics of contraindications to more exposure on the pharmacokinetics of cerezyme .',b'this study also showed that zavesca does not respond or have a limited impact on the pharmacokinetics of cerezyme .'
2957,b'insulatard ist ein humaninsulin zur behandlung von diabetes .',b'insulatard is human insulin to treat diabetes .',b'insulatard is human insulin to treat diabetes .',b'insulatard is human insulin to treat diabetes .'
2958,b'die tabletten werden abends bzw. vor dem schlafengehen mit dem essen eingenommen .',b'tablets are to be taken in the evening or at bedtime with food .',b'tablets are to be taken in the evening or at oc with food impairment .',b'tablets are to be taken in the evening or at bedtime with food .'
2959,"b'die studie mit extavia bei patienten mit einem erstmaligen demyelinisierenden ereignis umfasste 487 patienten , die zwei jahre lang entweder extavia oder placebo erhielten .'","b'the study of extavia in patients with a single demyelinating event involved 487 patients for two years , either extavia or placebo .'","b'the study of extavia in patients with a single triple host reaction involved patients for two years , either platelets .'",b'the study of extavia in patients with a single demyelinating event involved 487 patients for two years taking either extavia or placebo .'
2960,"b'schlucken sie die hartkapsel mit einem glas wasser . \xe2\x80\xa2 kinder und jugendliche bis zu 18 jahren mit einem k\xc3\xb6rpergewicht von mindestens 33 kg , die hartkapseln schlucken k\xc3\xb6nnen : eine 200 mg-hartkapsel t\xc3\xa4glich zu einer mahlzeit oder unabh\xc3\xa4ngig davon .'","b'swallow the capsule with a glass of water . \xe2\x80\xa2 children and adolescents up to 18 years of age and weighing at least 33 kg and can swallow hard capsules : one 200 mg hard capsule daily , with or without food .'",b'swallow the capsule with a glass of water . children and adolescents up to years of age and see food .',"b'swallow the capsule with a glass of water . \xe2\x80\xa2 children and adolescents up to 18 years of age and weighing at least 33 kg and can swallow hard capsules : one 200 mg hard capsule daily , with or without food .'"
2961,b'pandemrix sollte nicht zur gleichen zeit mit anderen impfstoffen verabreicht werden .',b'pandemrix should not be given at the same time as other vaccines .',b'due should not be given at the same time as other vaccines .',b'pandemrix should not be given at the same time as other vaccines .'
2962,"b'bei der teilnahme am stra\xc3\x9fenverkehr und beim bedienen von maschinen sollte ber\xc3\xbccksichtigt werden , dass gelegentlich schwindel oder m\xc3\xbcdigkeit auftreten k\xc3\xb6nnen .'",b'when when driving vehicles or operating machinery it should be taken into account that occasionally dizziness or weariness may occur .',"b'when be endophthalmitis an possible infarct , such by account that occasionally dizziness or weariness may occur .'",b'when driving vehicles or operating machinery it should be taken into account that occasionally dizziness or weariness may occur .'
2963,"b'bei patienten mit an\xc3\xa4mie [ z.b. h\xc3\xa4moglobinkonzentration \xe2\x89\xa4 10 g / dl ( 6,2 mmol / l ) ] sollte die behandlung mit retacrit mittels subkutaner applikation erfolgen .'","b'in patients with anaemia ( e.g. haemoglobin concentration \xe2\x89\xa4 10 g / dl ( 6.2 mmol / l ) ) , treatment with retacrit should be administered by the subcutaneous route .'","b'in patients with anaemia , phenytoin , immediate to prepare sucrose should be administered by the subcutaneous route .'","b'in patients with anaemia ( e.g. haemoglobin concentration \xe2\x89\xa4 10 g / dl ( 6.2 mmol / l ) ) , treatment with retacrit should be administered by the subcutaneous route .'"
2964,b'was ist biograstim und wof\xc3\xbcr wird es angewendet ?',b'what biograstim is and what it is used for 2 .',b'what biograstim is and what it is used for ?',b'what biograstim is and what it is used for .'
2965,b'lysodren ist in kunststoffflaschen mit 100 tabletten erh\xc3\xa4ltlich .',b'lysodren is supplied in plastic bottles containing 100 tablets .',b'targretin is supplied in plastic bottles containing tablets .',b'lysodren is supplied in plastic bottles containing 100 tablets .'
2966,"b'entz\xc3\xbcndung des dickdarms , hepatitis und verf\xc3\xa4rbungen der haut , der k\xc3\xb6rperhaare einschlie\xc3\x9flich der barthaare sowie der n\xc3\xa4gel .'","b'inflammation of the colon ) , hepatitis and skin , hair , beard and nail discolorations .'","b'inflammation of the colon , hepatitis and skin , hair , blockade and skeletal fulminans .'","b'inflammation of the colon , hepatitis and discolouration of skin , body hair , including beard hair and nail discolorations .'"
2967,b'2 ml impfstoff pro tier ( sau oder jungsau ) sind intramuskul\xc3\xa4r im nacken im bereich des ohrgrundes zu injizieren .',b'2 ml per animal vaccine ( gilts intramuscularly on the back of the neck of the ohrgrundes .',b'ml per animal vaccine demonstrate separately in one resorbtion in the mannose meal .',b'2 ml vaccine per animal ( sow or gilts ) should be injected intramuscularly in the area of the neck near the ears .'
2968,"b'urogenitale infektionen , verursacht durch escherichia coli . nichtlegende h\xc3\xbchner :'",b'urogenital infections caused by escherichia coli . nichtlegende hens :',b'valera infections caused by escherichia coli . other tissue .',b'urogenital infections caused by escherichia coli . non-egg-laying hens :'
2969,b'am 7. oktober 2002 erteilte die europ\xc3\xa4ische kommission dem unternehmen novo nordisk a / s eine genehmigung f\xc3\xbcr das inverkehrbringen von mixtard in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted to novo nordisk a / s for the european union for mixtard on 7 october 2002 .',b'the european commission marketing authorisation on the european union for mixtard on october .',b'the european commission granted marketing authorisation for mixtard to novo nordisk a / s for the european union on 7 october 2002 .'
2970,b'es liegen keine erfahrungen bei kindern und bei erwachsenen \xc3\xbcber 60 jahren vor .',b'there is no experience in children and adults over 60 years of age .',b'there is no experience in children and adults over years of age .',b'there is no experience in children and adults over 60 years of age .'
2971,b'wof\xc3\xbcr wird xigris angewendet ?',b'what is xigris used for ?',b'what is xigris used for ?',b'what is xigris used for ?'
2972,b'bei morbus crohn wurde die wirksamkeit der ersten beiden dosen von humira ( induktionsbehandlung ) in zwei studien an 624 patienten vier wochen lang mit der wirksamkeit von placebo verglichen .',"b""in crohn 's disease , the effectiveness of the first two doses of humira ( induction treatment ) in two main studies involving 624 patients for four weeks , compared with the efficacy of placebo .""","b'in pharmacokinetic s disease , the effectiveness of the indication transport nespo load scores within patients for four weeks , compared with the efficacy of placebo .'","b""in crohn 's disease , the effectiveness of the first two doses of humira ( induction treatment ) in two main studies involving 624 patients over four weeks were compared with the efficacy of placebo ."""
2973,"b'eine verringerung der menge an angiotensin ii bewirkt , dass sich die blutgef\xc3\xa4\xc3\x9fe entspannen .'","b'reductions in the quantity of angiotensin ii , allowing the blood vessels to relax .'","b'reductions in the quinolones of nucleoside ii levels , allowing the blood vessels to relax .'","b'reductions in the quantity of angiotensin ii , allowing the blood vessels to relax .'"
2974,b'die bestimmung des 13c / 12c-isotopenverh\xc3\xa4ltnisses des kohlendioxids der atemproben ist ein integ- rierter bestandteil des testkits helicobacter test infai .',b'the analysis of the 13c / 12c-ratio in carbon dioxide of breath is an integrated analysis of the diagnostic test helicobacter test infai .',b'the analysis of the c c intended the wide guideline helicobacter test helicobacter test helicobacter test helicobacter test infai .',b'the analysis of the 13c / 12c ratio in carbon dioxide of breath is an integrated analysis of the diagnostic test helicobacter test infai .'
2975,"b'in s\xc3\xa4mtlichen studien wurde fertavid mit dem k\xc3\xb6rpereigenen , aus urin gewonnenen fsh verglichen .'","b""in all studies , fertavid was compared with the body 's own extracted from urine fsh .""","b'in all studies , fertavid was compared in the body s own crossreacting .'","b""in all studies , fertavid was compared with the body 's own extracted from urine fsh ."""
2976,"b'wenn diese reaktionen andauern oder sich verschlimmern , informieren sie ihren arzt .'","b'if these reactions persist or become severe , tell your doctor .'","b'if these reactions persist or become severe , tell your doctor .'","b'if these reactions persist or become severe , tell your doctor .'"
2977,"b'welche nebenwirkungen sind m\xc3\x96glich ? wie alle arzneimittel kann keppra nebenwirkungen verursachen , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'possible side effects like all medicines , keppra can cause side effects , although not everybody gets them .'","b'possible side effects side effects infections the side effects , gonalf may cause side effects , although not everybody gets them .'","b'possible side effects like all medicines , keppra can cause side effects , although not everybody gets them .'"
2978,"b'31 eigeninjektion sollte jedoch nur von patienten durchgef\xc3\xbchrt werden , die entsprechend motiviert und hinreichend geschult sind sowie die m\xc3\xb6glichkeit haben , fachlichen rat einzuholen .'","b'should only be performed by patients who are well-motivated , adequately trained and with access self with access to expert advice .'","b'should only be performed by patients who are wellmotivated , adequately trained and interaction of hyperglycaemia rotations take monthly free with caution or taking discolouration , nsaids controlled prescribed'","b'self injection should , however , only be performed by patients who are well-motivated , adequately trained and with access to expert advice .'"
2979,b'er wirkt haupts\xc3\xa4chlich w\xc3\xa4hrend der s-phase gegen zellen und wird zur behandlung solider tumoren eingesetzt .',b'it works mainly during the s-phase of at least 28 and is used to treat solid tumours .',b'it works mainly decline to tracleer of at least and is used to treat solid tumours .',b'it works mainly during the s-phase against cells and is used to treat solid tumours .'
2980,b'f\xc3\xbcr erwachsene patienten mit m\xc3\xa4\xc3\x9figer leberinsuffizienz oder bei patienten mit h\xc3\xb6herem k\xc3\xb6rpergewicht kann eine dosisanpassung erforderlich sein ( siehe unten ) .',b'for adult patients with moderate hepatic impairment or in patients with higher body weight dose adjustment may be required ( see below ) .',"b'for adult patients with moderate hepatic impairment , no body weight dose adjustment may be required see below .'",b'a dose adjustment may be required for adult patients with moderate hepatic impairment or in patients with higher body weight ( see below ) .'
2981,"b'normalerweise m\xc3\xbcssen sie remeron so lange einnehmen , bis die symptome der depression 4-6 monate lang nicht mehr aufgetreten sind .'","b'usually , you need to take remeron for as long as you are taking until the symptoms of depression read 4-6 months .'","b'usually , you need to take remeron for as long as you have use such read women before you are taking until the symptoms of depression after until the symptoms of depression read months .'","b'usually , you need to take remeron for as long as you are taking until the symptoms of depression do not occur for 4-6 months .'"
2982,"b'anwendungsgebiete cetrotide 3 mg dient der verhinderung eines vorzeitigen eisprungs w\xc3\xa4hrend einer kontrollierten stimulation der eierst\xc3\xb6cke , gefolgt von einer eizellenentnahme und techniken der assistierten reproduktion .'","b'cetrotide 3 mg is used to prevent premature ovulation during a controlled ovarian stimulation , followed by oocyte pick-up and assisted reproductive techniques .'",b'olanzapine mg is not yet used to prevent champix long affecting ovulation during a bone emetogen compartments .',"b'cetrotide 3 mg is used to prevent premature ovulation during a controlled ovarian stimulation , followed by oocyte pick-up and assisted reproductive techniques .'"
2983,"b'der gesamtanteil der patienten , bei denen eine nebenwirkung auftrat , betrug nach einem bzw. zwei jahren 22,7 % und 25,0 % bei bonviva 150 mg einmal monatlich und 21,5 % und 22,5 % bei ibandrons\xc3\xa4ure 2,5 mg t\xc3\xa4glich .'","b'the overall proportion of patients who experienced an adverse reaction , was after one and two years , respectively plasma protein binding at 22.7 % and 25.0 % for bonviva 150 mg once monthly and 21.5 % and 22.5 % for ibandronic acid 2.5 mg daily .'","b'the growth proportion of patients who experienced an adverse reaction , was no serum studies of the average protein substance . interaction l therefore . of month acid . of adults mg once monthly metformin . and . for drug mg once monthly and . for a of plasma protein'","b'the overall proportion of patients who experienced an adverse reaction , was 22.7 % and 25.0 % for bonviva 150 mg once monthly after one or two years and 21.5 % and 22.5 % for ibandronic acid 2.5 mg daily .'"
2984,b'diese positiven wirkungen hielten \xc3\xbcber die gesamte 12-w\xc3\xb6chige behandlungsdauer an .',b'these positive effects lasting for up to 12 weeks for the duration of the treatment .',b'these positive effects ergotamine for up to weeks for the duration of the treatment .',b'these positive effects lasted for up to 12 weeks of the duration of the treatment .'
2985,b'warum wurde micardis zugelassen ?',b'why has micardis been approved ?',b'why has micardis been approved ?',b'why has micardis been approved ?'
2986,b'der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen \xc3\xbcberpr\xc3\xbcfte au\xc3\x9ferdem die \xc3\xbcbrigen abweichenden gegenanzeigen .',b'the mah marketing authorisation also reviewed on the other contraindications .',b'the mah is ready on the other given .',b'the mah marketing authorisation also reviewed the other deviant contraindications .'
2987,b'etwaige luftbl\xc3\xa4schen aus der spritze entfernen .',b'eliminate air bubbles if necessary from the syringe .',b'calves air vigorously . zostavax is sealed to themselves for the syringe .',b'eliminate air bubbles if necessary from the syringe .'
2988,b'die behandlung mit ziconotid sollte nur von \xc3\x84rzten mit erfahrung in der intrathekalen ( i.th. ) gabe von arzneimitteln vorgenommen werden .',b'treatment with ziconotide should only be initiated by physicians experienced in the intrathecal ( it ) administration of medicinal products .',"b'treatment with proteinuria should only be initiated by physicians experienced in the pivotal countries , be initiated by physicians experienced in the effect of other disease .'",b'treatment with ziconotide should only be initiated by physicians experienced in the intrathecal ( it ) administration of medicinal products .'
2989,"b'stocrin ist zur antiviralen kombinationsbehandlung von humanem immundefizienz virus typ 1 ( hiv-1- ) infizierten erwachsenen , jugendlichen und kindern ab 3 jahren angezeigt .'","b'stocrin is indicated in antiviral combination treatment of human immunodeficiency virus type 1 ( hiv-1 ) infected adults , adolescents and children 3 years of age and older .'","b'stocrin is indicated in antiviral combination treatment of human immunodeficiency virus type hiv infected adults , adolescents and less than years of age and older with years on the incidence of human immunodeficiency virus type hiv infected adults , adolescents and data on of human immunodeficiency virus type hiv infected'","b'stocrin is indicated in antiviral combination treatment of human immunodeficiency virus type 1 ( hiv-1 ) infected adults , adolescents and children 3 years of age and older .'"
2990,b'studien die wirksamkeit und sicherheit von venlafaxin in dieser indikation hinreichend belegten ;',b'studies of effectiveness and safety of venlafaxine in this indication adequately supported ;',b'studies of effectiveness and clinical indication sufficiently accidentally removed',b'studies which adequately supported the effectiveness and safety of venlafaxine in this indication ;'
2991,b'die h\xc3\xa4ufigkeit kann aus den verf\xc3\xbcgbaren daten nicht abgesch\xc3\xa4tzt werden \xe2\x97\x8f allergische reaktion ( z.b.',b'the frequency cannot be estimated from the available data ) \xe2\x80\xa2 allergic reaction ( e. g .',b'the frequency can be estimated that the medicine .',b'the frequency cannot be estimated from the available data ) \xe2\x80\xa2 allergic reaction ( e. g .'
2992,b'bei patienten mit leberfunktionsst\xc3\xb6rungen sollten derartige kombinationen vermieden werden .',b'patients with hepatic insufficiency have such combinations should be avoided .',b'patients with hepatic insufficiency do be avoided .',b'patients with hepatic insufficiency should avoid such combinations .'
2993,b'h\xc3\xa4ufige nebenwirkungen ( bei mehr als 1 von 100 patienten ) sind :',b'common side effects ( occurring in at least 1 in 100 patients ) are :',b'common side effects occurring in at least in paediatric disease in a different doses .',b'common side effects ( occurring in at least 1 in 100 patients ) are :'
2994,b'bei patienten mit pl\xc3\xb6tzlich aufgetretenem starkem fieber sollte die gabe von ambirix aufgeschoben werden .',b'in patients with sudden aufgetretenem severe fever of administration of ambirix .',b'receiving patients with receive airway syndrome .',b'in patients with sudden occurring severe fever should suspend the administration of ambirix .'
2995,"b'eine khi wurde bei bis zu 3,5 % der patienten berichtet , die mit avastin behandelt wurden , verglichen mit bis zu 0,9 % in den kontrollarmen .'",b'one chf has been reported in up to 3.5 % of patients treated with avastin compared with up to 0.9 % in the control arms .',b'one suspicious bladder concentration has been reported in up to . of patients treated with aripiprazole compared with administered .',b'one chf has been reported in up to 3.5 % of patients treated with avastin compared with up to 0.9 % in the control arms .'
2996,"b'was optaflu enth\xc3\xa4lt die wirkstoffe sind influenzavirus-oberfl\xc3\xa4chenantigene ( h\xc3\xa4magglutinin und neuraminidase ) * , inaktiviert , der folgenden st\xc3\xa4mme :'","b'what optaflu contains the active substances are influenza virus surface proteins ( haemagglutinin and neuraminidase ) * , inactivated , of the following strains :'",b'what use contains the active substances are influenza virus surface protein .',"b'what optaflu contains the active substances are influenza virus surface proteins ( haemagglutinin and neuraminidase ) * , inactivated , of the following strains :'"
2997,b'doxycyclin bildet ebenso wie andere tetracycline einen stabilen kalziumkomplex in knochenbildenden geweben .',b'doxycycline is a natural protein like other tetracyclines ) kalziumkomplex at least in the tissues .',b'doxycycline is a natural protein are measles may cause pretreatment on least in the serum .',"b'doxycycline , as well as tetracycline , builds a stable calcium complex in bone-forming tissues .'"
2998,b'nach einer grundimmunisierung mit 3 dosen infanrix hexa ( z.',b'after a three-dose primary vaccination course of infanrix hexa ( e. g .',b'after a threedose primary substantial velcade options in consideration of infanrix hexa e . g .',b'after a three-dose primary vaccination course of infanrix hexa ( e. g .'
2999,b'die pharmakokinetischen eigenschaften von doxazosin in cardoreg 4 mg [ und andere bezeichnungen ] retardtabletten f\xc3\xbchren zu nur geringen schwankungen der plasmaspiegel .',b'the pharmacokinetic properties of doxazosin in cardoreg 4 mg and associated names [ see annex prolonged-release tablets lead to a minor variation in plasma levels .',b'the pharmacokinetic properties of doxazosin in pictures mg and associated names see annex prolongedrelease tablets lead to a minor conversion in plasma levels .',b'the pharmacokinetic properties of doxazosin in cardoreg 4 mg [ and associated names ] prolonged-release tablets lead to a minor variation in plasma levels .'
3000,b'bei einem der bestandteile von aerinaze ( pseudoephedrinsulfat ) besteht die gefahr eines missbrauchs . pseudoephedrinsulfat kann in gro\xc3\x9fen mengen giftig sein .',b'if any of the ingredients in aerinaze ( pseudoephedrine sulfate ) is a risk of the risk of misuse . p407 when they may be at high levels .',b'if any section in aerinaze strains . of azarga . fill protein p when they may be at high levels .',b'any of the ingredients in aerinaze ( pseudoephedrine sulfate ) pose the risk of misuse . pseudoephedrine sulfate can be poisonous at high levels .'
3001,"b'da aerius l\xc3\xb6sung zum einnehmen die gleiche konzentration an desloratadin enth\xc3\xa4lt , war keine bio\xc3\xa4quivalenzstudie erforderlich und es ist zu erwarten , dass sie dem sirup und den tabletten entspricht .'","b'since aerius oral solution contains the same concentration of desloratadine , no bioequivalence study was required and it is expected to be the syrup and tablet .'","b'since aerius oral solution contains the same concentration of desloratadine , no bioequivalence development was expected to be the body and tablet .'","b'since aerius oral solution contains the same concentration of desloratadine , no bioequivalence study was required and it is expected to be the syrup and tablet .'"
3002,b'pulver : - l\xc3\xb6sungsmittel :',b'powder : - 1 vial + 1 ampoule solvent :',b'powder unopened in the treatment of humalog remove the single dose solvent',b'powder : - solution : .'
3003,"b'84 teilen sie ihrem arzt unbedingt mit , dass sie pritorplus einnehmen , wenn bei ihnen eine operation oder eine narkose erforderlich ist .'",b'84 you should tell your doctor that you are taking pritorplus if you have experienced a surgery or anaesthesia .',b'you should tell tell your doctor that you are taking pritorplus if you have impair an surgery or anaesthesia .',b'84 you should tell your doctor that you are taking pritorplus if you have experienced a surgery or anaesthesia .'
3004,"b'es gibt keine relevante indikation f\xc3\xbcr die anwendung von firmagon bei frauen , kindern und jugendlichen .'","b'there is no relevant indication for use of firmagon in women , children and adolescents .'","b'there is no relevant indication for use of firmagon in women , children and adolescents .'","b'there is no relevant indication for use of firmagon in women , children and adolescents .'"
3005,b'der prim\xc3\xa4re wirksamkeitsparameter in dieser studie war die inzidenz laborbest\xc3\xa4tigter klinischer influenza in den haushalten .',b'the primary efficacy parameter for this study was the incidence of laboratory- confirmed clinical influenza in the households .',b'the primary efficacy transfers for this study was the incidence of laboratory clearance in the epart .',b'the primary efficacy parameter for this study was the incidence of laboratory- confirmed clinical influenza in the households .'
3006,b'mit der anwendung von fabrazyme w\xc3\xa4hrend der schwangerschaft liegen keine erfahrungen vor .',b'there is no experience with the use of fabrazyme during pregnancy .',b'there is no experience with the use of fabrazyme during pregnancy .',b'there is no experience with the use of fabrazyme during pregnancy .'
3007,b'ein signifikantes ansprechen wurde zuerst in woche 2 beobachtet und \xc3\xbcber 24 wochen aufrecht erhalten ( tabelle 10 ) .',b'a significant response was first observed at week 2 and maintained through 24 weeks ( table 9 ) .',b'a significant response was available with g of coaprovel activated once within tadalafil vaccination .',b'a significant response was first observed at week 2 and maintained through 24 weeks ( table 9 ) .'
3008,"b'es ist wichtig , dass sie viel wasser trinken , um eine austrocknung zu vermeiden .'",b'it is important that you drink plenty of water to avoid a dehydration .',b'it is important to required release .',b'it is important that you drink plenty of water to avoid a dehydration .'
3009,b'das pulver ist wei\xc3\x9f und das l\xc3\xb6sungsmittel klar und farblos .',b'the powder is white and the solvent is clear and colourless .',b'the powder is white and the solvent is clear and colourless .',b'the powder is white and the solvent is clear and colourless .'
3010,"b'19 comtess wird zusammen mit pr\xc3\xa4paraten , die levodopa enthalten , eingenommen , und zwar entweder mit levodopa / carbidopa-pr\xc3\xa4paraten oder levodopa / benserazid-pr\xc3\xa4paraten .'","b'19 comtess is used together with preparations containing levodopa , either taken with levodopa / carbidopa-pr\xc3\xa4paraten or levodopa / benserazid-pr\xc3\xa4paraten .'","b'comtess is mg release levodopa , either taken with levodopa not concomitantly with ramipexole , vascular discolouration or levodopa .'","b'19 comtess is used together with preparations containing levodopa , namely levodopa / carbidopa preparation or levodopa / benserazid preparation .'"
3011,"b'bei kombination von lansoprazol mit arzneimitteln , die \xc3\xbcber dieses enzym metabolisiert werden , ist vorsicht geboten .'","b'in combination of lansoprazole and medicinal products metabolised by this enzyme , caution should be exercised .'","b'in combination of lansoprazole and medicinal products metabolised by this enzyme , caution should be dosage a linear and last is . atorvastatin should be excercised .'","b'in combination of lansoprazole and medicinal products metabolised by this enzyme , caution should be exercised .'"
3012,"b'zwei gramm probenecid m\xc3\xbcssen 3 stunden vor der cidofovir-dosis , ein gramm 2 stunden und ein weiteres gramm 8 stunden nach beendigung der einst\xc3\xbcndigen cidofovir-infusion eingenommen werden ( insgesamt 4 gramm probenecid ) .'","b'two gram of probenecid must be taken 3 hours prior to cidofovir-dosis , gram 2 hours and gram 8 hours after completion of coadministration of cidofovir infusion ( total of 4 grams probenecid ) .'",b'two order to celvapan must be taken hours prior to taking xolair .',"b'two grams of probenecid must be taken 3 hours prior to the cidofovir dose , a gram 2 hours after and a gram 8 hours after completion of coadministration of cidofovir infusion ( total of 4 grams probenecid ) .'"
3013,b'die beiden folgenden fragen wurden diskutiert :',"b'the two of the following questions , as discussed in the following categories :'","b'the two of the following questions , as affect the following categories'","b'the two of the following questions , as discussed in the following categories :'"
3014,"b'ihr arzt wird eventuell die zeit , die sie brauchen , um die injektion vollst\xc3\xa4ndig durchzuf\xc3\xbchren , verl\xc3\xa4ngern oder ihre dosis \xc3\xa4ndern .'",b'your doctor may wish to the time that is convenient for you need for injection to be fully prolong or change your dose .',b'your doctor may stopped back to the time that is creams for you need for injection . .',b'your doctor may wish to extend the time that you need to fully carry out the injection or change your dose .'
3015,"b'allerdings sollte der in-vitro-vergleich pro impaktorstufe bzw. in solchen begr\xc3\xbcndeten gruppierten stufen erfolgen , die f\xc3\xbcr wirksamkeit und sicherheit relevant sind .'","b'however , should be determined using cascade impactor measurements although the in vitro comparison should be justified , which are relevant to efficacy and safety .'","b'however , a any sample quantities dose should be given by glivec regurgitation should also ph to was a lactating those rinfabat , however , which are relevant to efficacy and safety .'","b'however , in vitro comparison should take place by impact stages which are relevant to efficacy and safety .'"
3016,"b'zu den symptomen einer \xc3\x9cberdosierung geh\xc3\xb6rten \xc3\x9cbelkeit , erbrechen , krampfanf\xc3\xa4lle , kardiovaskul\xc3\xa4re st\xc3\xb6rungen , von asymptomatischen arrhythmien bis hin zum herzstillstand , lungeninsuffizienz und zentralnerv\xc3\xb6se symptome , von erregung bis zum koma .'","b'symptoms of overdose include : nausea , vomiting , seizures , cardiovascular disorders , asymptomatic arrhythmias to late cardiac arrest , pulmonary insufficiency and cns effects including symptoms of agitation coma .'","b'symptoms of overdose include nausea , vomiting , seizures , cardiovascular disorders , asymptomatic arrhythmias to endogenous cardiac arrest , follows .'","b'symptoms of overdose include : nausea , vomiting , seizures , cardiovascular disorders , asymptomatic arrhythmias to late cardiac arrest , pulmonary insufficiency and cns effects including symptoms of agitation to coma .'"
3017,"b'dimeticon- oder silikon- emulsionen k\xc3\xb6nnen verwendet werden , um den kolben der patrone und / oder die glaspatrone zu be- handeln .'","b'dimeticone or silicone emulsion may be used to treat the cartridge plunger , and / or the glass cartridge .'","b'potassiumsparing or subcuntaneous laminated can be used to treat the cartridge plunger , and or the glass cartridge .'","b'dimeticone or silicone emulsion may be used to treat the cartridge plunger , and / or the glass cartridge .'"
3018,b'equilis te ist ein impfstoff zur anwendung bei pferden .',b'equilis te is a vaccine for use in horses .',b'equilis te is a vaccine for use in horses .',b'equilis te is a vaccine for use in horses .'
3019,b'nach beendigung der chemotherapie sollte die behandlung mit epoetin alfa einen monat lang fortgesetzt werden .',"b'after the end of the chemotherapy treatment , treatment should be continued with epoetin alfa for 1 month .'","b'after the end of the chemotherapeutics in the chemotherapy treatment , treatment should be continued with epoetin alfa for month .'","b'after the end of the chemotherapy treatment , treatment should be continued with epoetin alfa for 1 month .'"
3020,b'es wurden keine relevanten untersuchungsergebnisse beobachtet .',b'there were no relevant findings were observed .',b'there were no relevant findings were observed .',b'no relevant findings were observed .'
3021,"b'optaflu wird zur grippeimpfung von erwachsenen eingesetzt , insbesondere bei denjenigen , die ein erh\xc3\xb6htes risiko f\xc3\xbcr krankheitskomplikationen aufweisen .'","b'optaflu is used for vaccination against influenza in adults , especially in those who have an increased risk of krankheitskomplikationen .'","b'as indicated for vaccination against influenza in adults , especially in those who have an increased risk of churgstrausssyndroms .'","b'optaflu is used for vaccination against influenza in adults , especially in those who have an increased risk of disease complications .'"
3022,b'b. acetylsalicyls\xc3\xa4ure wird bei diesen patienten empfohlen .',"b'administration of acetylsalicylic acid , for example , is recommended in these patients .'","b'administration of acetylsalicylic , the eye product .'",b'administration of acetylsalicylic acid is recommended in these patients .'
3023,b'dar\xc3\xbcber hinaus hemmt dabigatran sowohl freies als auch fibringebundenes thrombin und die thrombininduzierte thrombozytenaggregation .',"b'in addition , dabigatran inhibits 15-18 fibringebundenes thrombin , and the transformed host cell .'","b'in addition , dabigatran was used an fu is intrinsic from the facial significant .'","b'in addition , dabigatran inhibits 15-18 fibrin-bound thrombin and thrombin induced platelet aggregration .'"
3024,"b'ovitrelle ist ein arzneimittel das choriogonadotropin alfa enth\xc3\xa4lt , welches durch rekombinante dna- technik hergestellt wird .'",b'ovitrelle is a medicine that contains the choriogonadotropin alfa has been produced by recombinant dna techniques .',"b'ovitrelle is a medicine that contains the choriogonadotropin alfa has been produced a production , as interact of the help of final vaccination of watery salbutamol .'",b'ovitrelle is a medicine that contains the choriogonadotropin alfa has been produced by recombinant dna techniques .'
3025,b'so kann beispielsweise die dosis von 10 mg durch die anwendung eines 6 mg / 24 h pflasters und eines 4 mg / 24 h pflasters erreicht werden .',"b'for example , the dose may be achieved with 10 mg of 6 mg / 24 h patch and 4 mg / 24 h patch .'","b'for example , the dose , the dose may be achieved with mg of mg h patch and mg h again and mg h patch and human h empty sexual dose of mg h patch activated particles and mg h .'","b'for example , the dose of 10 mg may be achieved with a 6 mg / 24 h patch and 4 mg / 24 h patch .'"
3026,"b'olanzapin ist ein neuroleptischer antimanischer und stimmungsstabilisierender wirkstoff , der mit einer gr\xc3\xb6\xc3\x9feren anzahl von rezeptorsystemen reagiert .'",b'cells are present in antimanischer and stimmungsstabilisierender olanzapine is a substance present with a greater number of receptor systems .',b'cells are present in follicles of modifiedrelease sodiumcontaining and hypothalamus olanzapine is a substance correlated with the elimination number of receptor systems .',"b'olanzapin is a nueroleptic , antimanic and mood stabilising substance , which reacts with a larger number of receptor systems .'"
3027,"b'10 vor\xc3\xbcbergehenden resorption des das implantat umgebenden knochens , wonach dieser durch neuen , dichteren knochen ersetzt wurde .'","b'10 transient absorption is 3 , , this new anchoring of the bones .'","b'transient absorption is , antibodies are monotherapy into and autoimmune hard occurs episodes inhibition of the bone isoforms of the bones .'","b'10 transient absorption of the bone surrounding the implant , after which they are replaced with new , denser bones .'"
3028,"b'beide wirkstoffe von promeris duo , metaflumizon und amitraz , hemmen die neurale aktivit\xc3\xa4t der parasiten und f\xc3\xbchren so zu deren absterben .'","b'both of these substances of promeris duo , metaflumizone and amitraz , which inhibit the activity of parasites and may lead to death .'","b'both of these substances that the cytochrome , whereupon the activity of hyperkalaemia and may lead to death of rescue in theophylline .'","b'both of these substances of promeris duo , metaflumizone and amitraz , which inhibit the activity of parasites and may lead to death .'"
3029,"b'lesen sie die gesamte packungsbeilage sorgf\xc3\xa4ltig durch , sie enth\xc3\xa4lt wichtige informationen f\xc3\xbcr sie .'",b'read all of this leaflet carefully because it contains important information for you .',b'read all of this leaflet carefully set it contains a prefilled information is accurately the package leaflet before you may be found .',b'read all of this leaflet carefully because it contains important information for you .'
3030,b'die gleichzeitige anwendung von ribavirin mit zidovudin wird wegen des erh\xc3\xb6hten risikos einer an\xc3\xa4mie nicht empfohlen ( siehe abschnitt 4.5 ) .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia ( see section 4.5 ) .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia see section . .',b'the concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia ( see section 4.5 ) .'
3031,"b'einen t\xc3\xb6dlichen verlauf nahmen die arteriellen thromboembolischen ereignisse bei 0,8 % der patienten unter avastin , verglichen mit 0,5 % bei mit chemotherapie allein behandelten patienten .'","b'discard fatal , arterial thromboembolic events in 0.8 % of patients treated with avastin , compared with 0.5 % in patients treated with chemotherapy alone .'",b'one liver rate of a two lung significant observed were treated with kaletra . in patients treated with chemotherapy alone .',"b'a fatal procedure uses the arterial thromboembolic events in 0.8 % of patients treated with avastin , compared with 0.5 % in patients treated with chemotherapy alone .'"
3032,"b'es ist wichtig , dass sie den behandlungsverlauf vollst\xc3\xa4ndig durchf\xc3\xbchren , auch wenn sie sich nach einigen tagen besser f\xc3\xbchlen .'","b'it is important that you carry out debridement completely , even if you feel better after a few days .'","b'it is important that you carry out pipettes completely , even if you feel dehydrated after a few days .'","b'it is important that you carry out the treatment procedure completely , even if you feel better after a few days .'"
3033,b'das arz neimittel darf nicht im abwasser oder haushaltsabfall entsorgt werden .',b'the summary of product lo characteristics should be disposed of in accordance with local requirements .',b'the dose of product can not be taken at every such under prescription .',b'the medicine may not be disposed of in waste water or domestic waste .'
3034,"b'versuchen sie nicht , die selbstinjektion durch zuf\xc3\xbchren , bevor sie sicher sind , die vorgehensweise und die erfordernisse der selbstinjektion verstanden zu haben .'","b'do not attempt to inject 112 ) before you sure the course and the clinically indicated , unless you are sure you understand how to inject yourself .'",b'pass to inject before you refers the course before the individual to administer use not sunlight that it essential how to inject yourself .',b'do not attempt to inject by yourself before you are sure you understand how to inject yourself .'
3035,"b'da deferipron haupts\xc3\xa4chlich \xc3\xbcber die nieren ausgeschieden wird , kann bei patienten mit nierenfunktions-st\xc3\xb6rungen ein erh\xc3\xb6htes komplikationsrisiko nicht ausgeschlossen werden .'","b'since deferiprone is primarily excreted by the kidney , in patients with nierenfunktions-st\xc3\xb6rungen increased risk of komplikationsrisiko cannot be excluded .'","b'since deferiprone is primarily excreted by the kidney , in patients with glanzmann increased risk half in patients with myeloproliferative increased risk of hysterectomy generally an aspartate d be excluded .'","b'since deferiprone is primarily excreted by the kidney , the risk of complications for patients with renal function disorders cannot be excluded .'"
3036,"b'die vollst\xc3\xa4ndige remission bedeutete ein verschwinden s\xc3\xa4mtlicher krankheitszeichen , die partielle remission eine verbesserung des blutbilds und einen r\xc3\xbcckgang der anzahl der b\xc3\xb6sartigen zellen .'","b'complete remission respectively of all signs have disappeared , and partial remission with improvement in eosinophil counts and a reduction in the number of malignant cells .'",b'complete pharmocokinetic temporary antibodies mucosis of pseudarthrosis counts and a reduction in the number of nucleoside cells .',"b'complete remission means a disappearances of all signs of disease , and partial remission means improvement in blood work and a reduction in the number of malignant cells .'"
3037,"b'sie d\xc3\xbcrfen das arzneimittel nach dem auf der tube und dem umkarton nach "" verwendbar bis "" angegebenen verfalldatum nicht mehr anwenden .'",b'do not use this medicine after the expiry date which is stated on the tube and carton after exp .',b'do not use this medicine after the expiry date which is stated on the filter and injection intervals',b'do not use this medicine after the expiry date which is stated on the tube and carton after exp .'
3038,"b'die entsprechenden serum- ( 50 % iges humanserum- ) adjustierten ec50-werte lagen im bereich 25 - 250 nm . klinische isolate von hiv-2 wiesen ec50-werte von 0,3 - 2,4 nm auf .'",b'the serum ( 50 % humanserum- ls ) ec50 values were in the range of 25 to 250 nm . clinical isolates of hiv-2 had ec50 values ranging from 0.3 - 2.4 nm .',b'the serum level or ec values were in the range of an antagonistic concentration . increased . .',b'the suitable serum ( 50 % humanserum- ) ec50 values were in the range of 25 to 250 nm . clinical isolates of hiv-2 show ec50 values ranging from 0.3 - 2.4 nm .'
3039,"b'6,25 mg pulver in einer durchstechflasche ( typ i glas ) mit einem gummistopfen , einem aluminiumverschluss und einer plastikkappe .'","b'6.25 mg of powder in a vial ( type 1 glass ) with a rubber stopper , a stopper and a plastic cap .'","b'. mg of powder in a vial type glass with a rubber stopper , a plastic screw .'","b'6.25 mg of powder in a vial ( type 1 glass ) with a rubber stopper , a stopper and a plastic cap .'"
3040,"b'nephrolithiasis , in einigen f\xc3\xa4llen mit niereninsuffizienz oder akutem nierenversagen ; pyelonephritis ; interstitielle nephritis , gelegentlich zusammen mit ablagerungen von indinavir- kristallen .'","b'nephrolithiasis , in some cases associated with renal insufficiency or acute renal failure ; pyelonephritis ; interstitial nephritis , uncommon with the lens capsule of indinavir with each other .'","b'nephrolithiasis , in some cases has ended in some cases associated with renal insufficiency or acute renal failure requiring incontinence hyperlactatemia , as with the metformin halflife of indinavir with each other .'","b'nephrolithiasis , in some cases associated with renal insufficiency or acute renal failure ; pyelonephritis ; interstitial nephritis , occasionally together with deposits of indinavir .'"
3041,"b'an\xc3\xa4mie , neutropenie und leukopenie traten vermehrt bei hohen dosierungen ( 1200 bis 1500 mg / tag ) , sowie bei patienten im fortgeschrittenen stadium der hiv-erkrankung ( besonders , wenn die knochenmarkreserve vor behandlungsbeginn vermindert war ) und insbesondere bei cd4- zellwerten von unter 100 / mm \xc2\xb3 auf .'","b'anaemia , neutropenia and leucopenia were increased at high doses ( 1200 to 1500 mg / day ) , as well as in patients with advanced stage of hiv disease ( especially if poor bone marrow reserve prior to treatment was ) and especially in cd4 zellwerten less than 100 cells / mm3 .'","b'anaemia , metabolic and connective occurrence of hiv disease due to treatment viral of the development of hiv disease especially if other bone marrow tumour or equally marrow bone appetite , less than cells mm .'","b'anaemia , neutropenia and leucopenia were increased at high doses ( 1200 to 1500 mg / day ) , as well as in patients with advanced stage of hiv disease ( especially if poor bone marrow reserve prior to treatment was ) and especially in cd4 cell values less than 100 cells / mm3 .'"
3042,"b'die wirkung von twinrix kinder auf das embryof\xc3\xb6tale , perinatale und postnatale \xc3\x9cberleben und die entwicklung wurde bisher nicht in prospektiven klinischen studien untersucht .'","b'the effect of twinrix paediatric on embryo-fetal , peri-natal and post-natal survival and development has not been evaluated in clinical trials .'",b'the effect of twinrix male on embryofetal showed perinatal and postnatal survival difference have been evaluated in clinical trials .',"b'the effect of twinrix paediatric on embryo-fetal , perinatal and post-natal survival and development has not been evaluated in clinical trials .'"
3043,"b'mannitol , poloxamer 188 , l-methionin , benzylalkohol , natriumacetat , essigs\xc3\xa4ure und natriumhydroxid zur anpassung des ph-werts sowie wasser f\xc3\xbcr injektionszwecke .'","b', mannitol , poloxamer 188 , l-methionine , benzyl alcohol , sodium acetate , acetic acid and sodium hydroxide for ph adjustment ) and water for injections .'","b', mannitol , hydrochloride , phosphate , tartaric alcohol , sodium acetate , acetic acid and sodium hydroxide for protein plasma is perforated effect .'","b'mannitol , poloxamer 188 , l-methionine , benzyl alcohol , sodium acetate , acetic acid and sodium hydroxide for ph adjustment ) and water for injections .'"
3044,b'anderen drei studien betrug die zielh\xc3\xa4moglobinkonzentration 12-14 g / dl .',b'the remaining three studies it was 12-14 g / dl .',b'the remaining haemoglobin within studies it was g dl .',b'the remaining three studies had a target haemoglobin concentration of 12-14 g / dl .'
3045,b'dosisanpassungen f\xc3\xbcr pravastatin k\xc3\xb6nnen notwendig werden ( siehe zusammenfassung der merkmale des arzneimittels f\xc3\xbcr pravastatin ) .',b'dosage adjustments of pravastatin may be required ( refer to the summary of product characteristics for pravastatin ) .',b'dosage adjustments of pravastatin may be required refer to the summary of product characteristics for coadministered .',b'dosage adjustments of pravastatin may be required ( refer to the summary of product characteristics for pravastatin ) .'
3046,b'ihr arzt kann ihnen au\xc3\x9fer humalog mix25 auch noch ein l\xc3\xa4nger wirkendes insulin verschreiben .',b'your doctor may tell you to use humalog mix25 and / or longer will prescribe a fast-acting insulin .',b'your doctor may tell you to use humalog mix and or longer all supervision must be initiated another fastacting insulin .',b'your doctor may tell you to use humalog mix25 as well as prescribing a longer acting insulin .'
3047,b'daraus abgeleitete empfehlungen f\xc3\xbcr die praxis sind nachfolgend aufgef\xc3\xbchrt .',b'this gh-1 recommendations for practice are listed below .',b'this concluded recommendations for practice are listed below .',b'the recommendations for practice are listed below .'
3048,"b'wie alle arzneimittel kann zonegran nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , zonegran can have side effects , although not everybody gets them .'","b'like all medicines , zonegran can have side effects , although not everybody gets them .'","b'like all medicines , zonegran can have side effects , although not everybody gets them .'"
3049,b'notieren sie sich hier den namen und die anschrift ihres behandelnden arztes :',b'write the name and address of your doctor :',b'write the name and address of your doctor',b'write the name and address of your doctor :'
3050,"b'alle gegenst\xc3\xa4nde , die zur verabreichung oder reinigung verwendet werden , einschlie\xc3\x9flich der handschuhe sind in abfallbeh\xc3\xa4ltern f\xc3\xbcr kontaminiertes material einer hochtemperaturverbrennung zuzuf\xc3\xbchren .'","b'all items for administration or cleaning , including gloves in abfallbeh\xc3\xa4ltern for preparing a waste-disposal .'","b'all items for administration or diseasemodifying application , has release among this ulcer before since four the replacement vein may be resuspended reach may grow into a vein that be expected that be cross out side period for the waste of the few person must be last nonhormonal must be'","b'all items used for administration or cleaning , including hand gloves are to be delivered in waste bins for contaminated material for high temperature incineration .'"
3051,b'die l\xc3\xb6sung zum einnehmen ist klar und orange .',b'the oral solution is clear and orange .',b'the oral solution is clear and orange of the poweder of a ear .',b'the oral solution is clear and orange .'
3052,b'zus\xc3\xa4tzlich wurde eine negativkontrolle verwendet .',"b'in addition , 175-210 was used .'",b'in addition of day with sildenafil are allowed .',"b'in addition , 175-210 was used .'"
3053,"b'das ausma\xc3\x9f der gewichtszunahme und der anteil an jugendlichen patienten , die eine klinisch signifikante geweichtsznahme entwickelten , war gr\xc3\xb6\xc3\x9fer bei langzeitbehandlung ( mindestens 24 wochen ) als bei kurzzeittherapie .'",b'the magnitude of weight gain and the proportion of adolescent patients who had clinically significant geweichtsznahme developed were greater with long-term exposure ( at least 24 weeks ) than with short-term exposure .',"b'the magnitude of weight gain and the proportion of hivinfected weeks patient had clinically significant tubules had clinically significant tubules had clinically significant tubules had clinically significant named early , additional significant tubules had clinically significant unaltered developed were greater interaction on least weeks than treatmentfree exposure .'",b'the magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure ( at least 24 weeks ) than with short-term exposure .'
3054,"b'es kann in hohen dosen zu \xc3\x9cbelkeit , erbrechen , koliken , und schwerem durchfall f\xc3\xbchren .'","b'it may lead to nausea , vomiting , colics , and severe diarrhoea at high doses .'","b'they may lead to nausea , vomiting , which may lead to in control doses .'","b'it may lead to nausea , vomiting , colic , and severe diarrhoea at high doses .'"
3055,b'jedoch wird die anwendung von kombinierten hormonellen kontrazeptiva aufgrund des erh\xc3\xb6hten risikos f\xc3\xbcr ven\xc3\xb6se thromboembolische ereignisse nicht empfohlen .',"b'however , the use of combined hormonal contraceptives due to the increased risk of venous thromboembolic events is not recommended .'","b'however , the use of combined hormonal contraceptives due to the increased risk of venous a concomitant risk of venous thromboembolic events is not recommended .'","b'however , the use of combined hormonal contraceptives due to the increased risk of venous thromboembolic events is not recommended .'"
3056,b'91 insulatard anzuwenden ? . sie k\xc3\xb6nnen sie mit sich f\xc3\xbchren und bei raumtemperatur ( nicht \xc3\xbcber 25 \xc2\xb0 c ) bis zu 6 wochen lang aufbewahren .',b'91 to use insulatard 4 . you can carry them with you and keep them at room temperature ( not above 25 \xc2\xb0 c ) for up to 6 weeks .',b'to use insulatard . you can make them when room temperature not above c for up to weeks .',b'91 how to use insulatard ? you can carry them with you and keep them at room temperature ( not above 25 \xc2\xb0 c ) for up to 6 weeks .'
3057,"b'seltene nebenwirkungen sind schwellungen und jucken von gesicht , lippen und mund .'","b'rare side effects are swelling and itching of the face , lips , lips and mouth .'","b'rare side effects are swelling and itching of the face , lips , lips as nose .'","b'rare side effects are swelling and itching of the face , lips , lips and mouth .'"
3058,b'die patienten sollten engmaschig auf die entstehung einer starken myelosuppression \xc3\xbcberwacht werden ( siehe 4.2 ) .',b'patients should be monitored carefully for the development of a severe myelosuppression ( see section 4.2 ) .',b'patients should be monitored carefully for the side of a severe hepatic than section . .',b'patients should be monitored carefully for the development of a severe myelosuppression ( see section 4.2 ) .'
3059,b'diese untergruppe galt als die kerngruppe bez\xc3\xbcglich der wirksamkeit der therapie .',b'this subgroup was classified as the base regarding the efficacy of treatment .',"b'give average , no optimal response in to differentiate .'",b'this subgroup was classified as the core group regarding the efficacy of treatment .'
3060,"b'es wirkt in ihrem verdauungstrakt und verhindert , dass ungef\xc3\xa4hr ein drittel des fettes im essen , das sie zu sich nehmen , verdaut wird .'","b'it works in your digestive system and prevents that approximately one-third the fat in the food that you on a regular basis , 53 ) .'",b'it works in your weakened excessive infection and prevents that approximately over the occurs in the food that you on a regular basis showed they and tapeworms to carried the muscle level in the food that you on a regular basis in the body that you on a regular basis',b'it works in your digestive system and prevents approximately one-third of the fat in the food that you eat on a regular basis from being digested .'
3061,b'die bei \xc3\xa4lteren kindern beobachtete abnahme der h\xc3\xa4ufigkeit von ipd kann teilweise auf die nat\xc3\xbcrlicherweise erworbene immunit\xc3\xa4t zur\xc3\xbcckgef\xc3\xbchrt werden .',"b'the older children , the observed decrease in the incidence of ipd may be partly due to a naturally acquired immunity .'",b'the pharmacokinetic of dermatofibrosarcoma ritonavir in the incidence of hysterectomy could be dangerous due to postponed .',b'the observed decrease in the incidence of ipd in older children may be partly due to a naturally acquired immunity .'
3062,b'in einer weiteren rigiscan-untersuchung konnte sildenafil noch 4 - 5 stunden nach oraler einnahme auf sexuelle stimulation eine erektion ausl\xc3\xb6sen .',b'in another rigiscan-untersuchung sildenafil has 4 to 5 hours after oral administration to an erection in response to sexual stimulation .',b'in another neospect ii incidence of humalog of suicide in serum and a total value .',b'in another rigiscan examination sildenafil caused an erection in response to sexual stimulation 4 to 5 hours after oral administration .'
3063,b'nach zubereitung betr\xc3\xa4gt das volumen der suspension 75 ml entsprechend einem verwendbaren volumen von 70 ml .',"b'when reconstituted , the volume of the suspension is 75 ml corresponding to improved and 70 ml .'","b'when reconstituted , the volume of the suspension is hours to achieve the suspension is each .'","b'when reconstituted , the volume of the suspension is 75 ml corresponding to improved and 70 ml .'"
3064,b'wegen fehlender kompatibilit\xc3\xa4tsstudien darf dieses arzneimittel nicht mit anderen gemischt werden .',b'because of the lack of kompatibilit\xc3\xa4tsstudien this medicinal product must not be mixed with any other insulin .',b'because of the lack of highly guide of pioglitazone this medicinal product must not be mixed with any other insulin .',"b'due to the lack of compatability studies , this medicinal product must not be mixed with any other insulin .'"
3065,b'eine hypoglyk\xc3\xa4mie kann aus einer in bezug zur nahrungsaufnahme oder zum energieverbrauch \xc3\xbcberschie\xc3\x9fenden insulinwirkung resultieren .',b'hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure is returned to occur .',b'hypoglycaemia may occur as a result of an inducer of insulin activity relative to food intake and energy expenditure for .',b'hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake or energy expenditure .'
3066,b'jalra wird zur behandlung von patienten mit typ-2-diabetes angewendet .',b'jalra is used to treat patients with type 2 diabetes .',b'jalra is used to treat patients with type diabetes .',b'jalra is used to treat patients with type 2 diabetes .'
3067,"b'im falle einer \xc3\x9cberdosierung sollten unterst\xc3\xbctzende ma\xc3\x9fnahmen nach bedarf ergriffen werden , einschlie\xc3\x9flich ausreichenden schutzes vor starken lichtquellen ( z.b. direktes sonnenlicht ) .'","b'in the event of overdose , supportive treatment should be instituted as needed , including adequate protection before severe ( for example direct sunlight ) .'","b'in the event of overdose , supportive contraception to breast latex . risk whilst administer the dose of severe new injection or become talk to cannot children .'","b'in the event of overdose , supportive measures should be taken as needed , including adequate protection from strong sources of light ( for example direct sunlight ) .'"
3068,b'87 behandlung von kindern :',b'87 for the treatment of children :',b'for the treatment of children',b'87 for the treatment of children :'
3069,b'was ist imprida und wof\xc3\xbcr wird es angewendet ?',b'what imprida is and what it is used for 2 .',b'what imprida is and what it is used for .',b'what imprida is and what it is used for 2 ?'
3070,"b'8 / 38 zur weiterbehandlung k\xc3\xb6nnen acticam 1,5 mg / ml suspension zum eingeben f\xc3\xbcr hunde in einer dosierung von 0,1 mg meloxicam / kg k\xc3\xb6rpergewicht 24 stunden nach der injektion eingesetzt werden .'","b'8 / 34 may be used for continuation of acticam 1.5 mg / ml oral suspension for dogs of treatment at a dosage of 0.1 mg meloxicam / kg body weight , 24 hours after administration of the injection .'",b'secondary medicines with fablyn of seroconversion . mg ml oral suspension for haemophilia into a dosage to the injection .',"b'8 / 34 may be used for continuation of acticam 1.5 mg / ml oral suspension for dogs at a dosage of 0.1 mg meloxicam / kg body weight , 24 hours after administration of the injection .'"
3071,"b'falls eine schwangerschaft eingetreten ist , sollten sie den arzt aufsuchen .'","b'if the patient becomes pregnant , you should consult your doctor .'","b'if the patient too pregnant , you should consult your doctor .'","b'if the patient becomes pregnant , you should consult your doctor .'"
3072,b'in klinischen studien wurden dosen von bis zu 3mg / kg k\xc3\xb6rpergewicht verabreicht .',"b'in clinical studies , doses up to 3mg / kg body weight .'","b'in clinical studies , doses up to mg kg body weight .'","b'in clinical studies , doses up to 3mg / kg body weight were administered .'"
3073,"b'2,5 ml und 5 ml .'",b'2.5 ml and 5 ml .',b'. ml and yellow .',b'2.5 ml and 5 ml .'
3074,"b'entfernen sie die plastikkappe nicht von der nadel , bevor sie bereit sind , die injektion vorzunehmen .'",b'do not remove the plastic cover from the needle until you are ready to inject. injection .',b'arrange liprolog helps to expose side of the needle until you are ready to inject .',b'do not remove the plastic cover from the needle until you are ready to inject. injection .'
3075,b'ein anstieg der exposition von nilotinib kann auch f\xc3\xbcr m\xc3\xa4\xc3\x9fige cyp3a4-hemmer erwartet werden .',b'an increase in exposure to nilotinib can be expected to a modest inhibitors of cyp3a4 .',b'an increase in exposure to preserve can be expected to a modest inhibitors of cypa .',b'an increase in exposure to nilotinib can also be expected for mild cyp3a4 inhibitors .'
3076,"b'271 kinder und jugendliche die behandlung mit mircera wird bei kindern und jugendlichen nicht empfohlen , da es bei diesen patienten nicht untersucht wurde .'","b'271 children and adolescents treatment with mircera is not recommended for use in children and adolescents , as it has not been studied in these patients .'","b'children and adolescents treatment with mircera is not recommended for use in children and adolescents , as it has not been studied in these patients .'","b'271 children and adolescents . treatment with mircera is not recommended for use in children and adolescents , as it has not been studied in these patients .'"
3077,b'es ist kein gegenmittel f\xc3\xbcr eine \xc3\x9cberdosierung von dopaminagonisten bekannt .',b'it is no known antidote for overdose of a dopamine agonist .',b'it is no known antidote for overdose of a dopamine infestations .',b'there is no known antidote for overdose of a dopamine agonist .'
3078,"b'weitere nebenwirkungen , \xc3\xbcber die sehr selten nach der markteinf\xc3\xbchrung berichtet wurde , sind in der folgenden tabelle aufgef\xc3\xbchrt .'",b'other side effects that have been reported very rarely during the post-marketing period are listed in the following table .',b'other side effects that have been reported very rarely during the bottom duration are listed in the following table .',b'other side effects that have been reported very rarely during the post-marketing period are listed in the following table .'
3079,"b'lesen sie die gesamte packungsbeilage sorgf\xc3\xa4ltig durch , bevor sie mit der anwendung von xolair beginnen .'",b'read all of this leaflet carefully before you start to use xolair .',b'read all of this leaflet carefully before you start to use xolair .',b'read all of this leaflet carefully before you start to use xolair .'
3080,b'am 5. februar 1998 erteilte die europ\xc3\xa4ische kommission dem unternehmen cis bio international eine genehmigung f\xc3\xbcr das inverkehrbringen von quadramet in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted a cis bio international marketing authorisation for the european union for quadramet on 5 february 1998 .',b'the european commission granted within detail as the european union on february .',b'the european commission granted a cis bio international marketing authorisation for the european union for quadramet on 5 february 1998 .'
3081,"b'lassen sie die verschlusskappe ihres flexpen fertigpens immer aufgesetzt , wenn flexpen nicht in gebrauch ist , um das insulin vor licht zu sch\xc3\xbctzen .'","b""always keep the pen cap on your flexpen when you 're not using it flexpen is not in use in the insulin in order to protect it from light .""",b'always keep the pen of the pen cap on your flexpen when any dose back .',"b""always keep the pen cap on your flexpen when you 're not using it , in order to protect the insulin from the light ."""
3082,"b'die behandlung sollte von einem arzt eingeleitet und \xc3\xbcberwacht werden , der erfahrung in der diagnose und behandlung der alzheimer-demenz besitzt .'","b""treatment should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of alzheimer 's dementia .""",b'treatment should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of alzheimer s receptor .',"b""treatment should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of alzheimer 's dementia ."""
3083,"b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen toviaz kann verschwommenes sehen , schwindel und schl\xc3\xa4frigkeit verursachen .'","b'driving and using machines toviaz can cause blurred vision , dizziness , and somnolence .'","b'driving and using machines , gently cardiomyophathy .'","b'driving and using machines : toviaz can cause blurred vision , dizziness , and somnolence .'"
3084,"b'anwendung bei kindern litak darf bei patienten , die j\xc3\xbcnger als 16 jahre sind , nicht angewendet werden .'",b'use in children litak should not be used in people who are younger than 16 years of age .',b'use in children authorisation should not be used in people who are younger than years of age .',b'use in children : litak should not be used in people who are younger than 16 years of age .'
3085,b'die wirkungen von telmisartan hinsichtlich mortalit\xc3\xa4t und kardiovaskul\xc3\xa4rer morbidit\xc3\xa4t sind derzeit nicht bekannt .',b'the effects of telmisartan on mortality and cardiovascular morbidity are currently unknown .',b'the effects of analgesic on mortality and cardiovascular morbidity are currently unknown .',b'the effects of telmisartan on mortality and cardiovascular morbidity are currently unknown .'
3086,"b'diesen k\xc3\xb6nnen bei bis zu 1 von 10 patienten , die mit atriance behandelt werden , auftreten :'",b'this may occur with up to 1 in 10 people treated with atriance :',b'this may occur with up to in people during people treated with atriance',b'this may occur with up to 1 in 10 people treated with atriance :'
3087,"b'nachfolgend werden h\xc3\xa4matologische und nicht-h\xc3\xa4matologische nebenwirkungen mit ihren h\xc3\xa4ufigkeiten aufgelistet , die als sicher oder m\xc3\xb6glicherweise mit topotecan in zusammenhang stehend eingestuft wurden .'","b'the frequencies associated with the haematological and non-haematological adverse events listed below , were related or possibly related to topotecan possibly related .'","b'the frequencies associated with those below , were related or possibly relationship to topotecan concomitantly or possibly related to topotecan reduced and interferon related with humans .'","b'subsequently , associated with the haematological and non-haematological adverse events and their frequencies are listed below , were classified as related or possibly related to topotecan .'"
3088,"b'von diesen 347 versuchspersonen waren 245 patienten , bei denen zum zeitpunkt der anwendung von hydroxocobalamin der verdacht auf eine zyanidexposition bestand .'",b'of these 347 subjects were 245 patients who at the time of administration of hydroxocobalamin or suspect administration .',b'of these subjects were patients who at the time of administration of subcutaneous or im administration .',"b'of these 347 subjects , 245 were patients with suspected cyanide exposure at the time of use of hydroxocobalamin .'"
3089,b'seltene nebenwirkungen \xe2\x80\xa2 pl\xc3\xb6tzlich auftretende schwere allergische reaktionen .',b'rare side effects \xe2\x80\xa2 pl\xc3\xb6tzlich emergent severe allergic reactions .',b'rare side effects listing switching with side effects of dogs .',b'rare side effects \xe2\x80\xa2 sudden emergent severe allergic reactions .'
3090,b'f\xc3\xbcr weitere informationen siehe die fachinformation zu prezista .',"b'for further information , physicians should refer to the prezista .'","b'for further information , you , physicians should refer to the product .'","b'for further information , refer to specialist information for prezista .'"
3091,b'bei patienten > 50 kg betr\xc3\xa4gt die \xc3\xbcbliche dosis 50 mg einmal t\xc3\xa4glich .',"b'in patients 50 kg , the usual dose is 50 mg once a day .'","b'in patients kg , the usual dose is mg once a day .'","b'in patients > 50 kg , the usual dose is 50 mg once a day .'"
3092,"b'- \xc3\x9cbelkeit , erbrechen , bauchschmerzen sowie auffallend erh\xc3\xb6hte triglyceride ( blutfette ) .'","b'- feeling sick ( nausea ) , vomiting , abdominal ( tummy ) pain , and auffallend elevated triglycerides ( fats in the blood ) .'","b'too sick nausea , vomiting , the face system testing in the blood .'","b'- feeling sick ( nausea ) , vomiting , abdominal ( tummy ) pain , and notable elevated triglycerides ( fats in the blood ) .'"
3093,b'bei patienten mit einer akuten febrilen atemwegserkrankung ist eine verschiebung der infusion in betracht zu ziehen .',b'patients with an acute febrilen bicomponent super-elastic infusion should be considered .',"b'patients with an acute loaded , additionally be considered .'",b'in patients with an acute febrile respiratory disease a postponement of the infusion should be considered .'
3094,b'2. was m\xc3\xbcssen sie vor der einnahme von bonviva beachten ? 3. wie ist bonviva einzunehmen ?',b'what you should know before you take bonviva 3 . how to use bonviva 4 .',b'what you should know before you take products . how to use bonviva .',b'what you should know before you take bonviva 3 . how to use bonviva 4 .'
3095,b'3.2.2 injizieren sie das erforderliche rekonstituierte volumen in den infusionsbeutel mit 500 ml verd\xc3\xbcnnungsmittel .',b'strength of inject the required volume of the reconstituted into an infusion bag containing 500 ml of diluent .',b'surface of inject the required volume of the oral to given down in the exact of order to a infusion bag containing ml of diluent .',b'inject the required reconstituted volume of the into an infusion bag 500 ml of diluent .'
3096,b'2 pharmakokinetischen daten vor . schwere leberfunktionsst\xc3\xb6rungen k\xc3\xb6nnten zu einer erh\xc3\xb6hten verf\xc3\xbcgbarkeit von darunavir f\xc3\xbchren und dessen sicherheitsprofil verschlechtern .',b'2 pharmacokinetic data for this patient population . severe hepatic impairment may lead to increased exposure to darunavir and its safety profile .',b'pharmacokinetic data for this patient population . severe higher hepatic impairment may lead to increased exposure to darunavir and its safety profile .',b'2 pharmacokinetic data . severe liver function disorder may lead to increased availability of darunavir and the worsening of its safety profile .'
3097,b'polysorbat 20 und wasser zur injektion .',b'polysorbate 20 and water for injection .',b'the contact with water for injection .',b'polysorbate 20 and water for injection .'
3098,"b'die symptome einer pandemischen grippe sind denen einer "" einfachen "" grippe \xc3\xa4hnlich , sind aber f\xc3\xbcr gew\xc3\xb6hnlich schwerwiegender .'","b'the symptoms ( signs ) of pandemic flu are similar to those of "" ordinary "" flu but are usually more severe .'",b'for addition with all kaposi values should have be adjusted the growth of pyoderma steroids anaesthesia could are usually more severe .',"b'the symptoms ( signs ) of pandemic flu are similar to those of "" ordinary "" flu but are usually more severe .'"
3099,b'es liegen keine klinischen erfahrungen zur gleichzeitigen anwendung von emtricitabin und cytidin- analoga vor .',b'there is no clinical experience with concomitant use of emtricitabine and analogues for the perforation .',b'there is no clinical experience with concomitant use of emtricitabine and interferons for the rapidacting .',b'there is no clinical experience with simultaneous use of emtricitabine and cyditine analogues .'
3100,b'29 arzneimittel f\xc3\xbcr kinder unzug\xc3\xa4nglich aufbewahren .',b'29 keep out of reach and sight of children .',b'keep out of reach and sight of children .',b'29 keep out of reach and sight of children .'
3101,"b'neutropenie / agranulozytose , thrombozytopenie und an\xc3\xa4mie wurden bei patienten unter ace- hemmertherapie berichtet .'","b'neutropenia / agranulocytosis , thrombocytopenia and anaemia have been reported in patients receiving ace hemmertherapie .'",b'neutropenia of childhood have been reported in patients receiving ace bc .',"b'neutropenia / agranulocytosis , thrombocytopenia and anaemia have been reported in patients receiving ace hemmertherapie .'"
3102,b'durchstechflaschen zu 350 mg / durchstechflasche k\xc3\xb6nnen auch mit sterilem wasser f\xc3\xbcr injektionszwecke rekonstituiert werden .',b'vials of 350 mg / vial can also be reconstituted with sterile water for injections .',b'vials of mg vial can also be reconstituted with sterile water for injections .',b'vials of 350 mg / vial can also be reconstituted with sterile water for injections .'
3103,b'er enth\xc3\xa4lt als wirkstoff bestandteile des hepatitis-b-virus .',b'it contains the active substance excipients of the hepatitis b virus .',b'the active substance excipients of the hepatitis b virus .',b'it contains the active substance excipients of the hepatitis b virus .'
3104,b'allerdings gibt es nur begrenzte erfahrungen hinsichtlich der langzeiteffekte bei kindern .',"b'however , there is only limited experience with parallell in children .'","b'however , there is only limited experience with tih in children .'","b'however , there is only experience regarding long term effects in children .'"
3105,b'wie ist neospect anzuwenden ? .',b'how to use neospect .',b'how to use neospect .',b'how to use neospect .'
3106,"b'die patrone der pumpe , in die insuman infusat gef\xc3\xbcllt wird , muss steril sein und darf nur einmal verwendet werden .'",b'the cartridge of the pump by insuman infusat must be sterile and should only be used once .',b'the cartridge of the pump from insuman infusat must be applied and should only be here and should only be used once .',b'the cartridge of the pump by insuman infusat must be sterile and should only be used once .'
3107,"b'der m\xc3\xb6gliche nutzen einer dosisreduktion sollte in jedem einzelfall gegen\xc3\xbcber den risiken abgesch\xc3\xa4tzt werden , die aus dieser ma\xc3\x9fnahme entstehen k\xc3\xb6nnen ( verringerte intrazellul\xc3\xa4re konzentrationen ) .'","b'the potential benefits dose reduction should be needed in every individual risks , which may be derived from the monoclonal antibodies ( decreased intracellular concentrations ) .'",b'the potential benefits section reduction should be higher by the levels .',"b'the potential use of dose reduction should be evaluated against the risks in every individual , which may be derived from the monoclonal antibodies ( decreased intracellular concentrations ) .'"
3108,b'vor der zubereitung die gebrauchsanweisung gr\xc3\xbcndlich lesen .',"b'before reconstitution , the following instructions thoroughly .'","b'before reconstitution , the following instructions arixtra .'","b'before reconstitution , read the following instructions thoroughly .'"
3109,"b'frauen im geb\xc3\xa4rf\xc3\xa4higen alter sollten wirksame empf\xc3\xa4ngnisverh\xc3\xbctungsmittel vor , w\xc3\xa4hrend und mindestens 90 tage nach der behandlung anwenden .'","b'women of childbearing potential should use an effective contraceptives before , during and for at least 90 days after treatment .'",b'women of childbearing potential should use an effective products with carrying days after treatment .',"b'women of childbearing potential should use an effective contraceptives before , during and for at least 90 days after treatment .'"
3110,b'der arzt hat eine ausf\xc3\xbchrlichere liste m\xc3\xb6glicher nebenwirkungen nach gabe von m-m-rvaxpro .',b'the doctor has a more possible undesirable effects of m-m-rvaxpro .',b'the doctor has a medicinal possible undesirable effects of mmrvaxpro .',b'the doctor has a more extensive list of possible undesirable effects after administration of m-m-rvaxpro .'
3111,"b'dennoch kann die potentielle \xc3\x9cbertragung infekti\xc3\xb6ser substanzen nicht vollst\xc3\xa4ndig ausgeschlossen werden , wenn aus menschlichem blut oder plasma gewonnene arzneimittel verabreicht werden .'","b'however , the potential infective agents cannot be totally excluded , if medicinal products prepared from human blood or plasma are administered .'","b'however , the potential said agents cannot be carried proteinuria .'","b'however , the potential infective agents cannot be totally excluded , if medicinal products prepared from human blood or plasma are administered .'"
3112,"b'falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the entire representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'"
3113,b'spritzen sie liprolog basal pen unter die haut . sie sollten es auf keine andere art wenden .',b'inject liprolog basal pen under the skin . you should not administer it using a different administration route .',b'inject liprolog waste pen under the skin . you should not inject it using a different administration increments .',b'inject liprolog basal pen under the skin . you should not administer it using a different administration route .'
3114,"b'die tabelle zeigt die volumina , die f\xc3\xbcr die einzelnen dosierungen ben\xc3\xb6tigt werden .'",b'the table below shows the larger volumes of the individual doses are needed .',b'the table below shows the larger electrolytes specific by to appropriate .',b'the table below shows the larger volumes of the individual doses are needed .'
3115,"b'm\xc3\xb6glicherweise entscheidet ihr arzt , dass es zweckm\xc3\xa4\xc3\x9figer f\xc3\xbcr sie ist , wenn sie sich neulasta selbst spritzen .'","b'your doctor may decide that it would be more convenient for you , a nurse , neulasta yourself .'","b'your doctor may decide that it would be more convenient for you , a lamictal , neulasta yourself .'","b'your doctor may decide that it would be more convenient for you , to inject yourself with neulasta .'"
3116,"b'w\xc3\xa4hrend der klinischen studien bei patienten mit pulmonal arterieller hypertonie mit dosen von zweimal t\xc3\xa4glich 125 mg und 250 mg traten behandlungsabbr\xc3\xbcche aufgrund von nebenwirkungen bei den mit bosentan und mit plazebo behandelten patienten in gleicher h\xc3\xa4ufigkeit auf ( 5,8 % ) .'",b'during clinical studies in patients with pulmonary arterial hypertension at doses of 125 mg twice daily and 250 mg twice daily were behandlungsabbr\xc3\xbcche due to adverse events in the bosentan with placebo-treated patients at the same frequency ( 5.8 % ) .',"b'during clinical studies in patients with pulmonary arterial hypertension reported , enbrel .'",b'during clinical studies in patients with pulmonary arterial hypertension with doses of 125 mg twice daily and 250 mg twice daily were discontinuation of treatment due to adverse events in the bosentan with placebo-treated patients at the same frequency ( 5.8 % ) .'
3117,"b'0,3 ml injektionsl\xc3\xb6sung in einer fertigspritze ( glas typ i ) mit einer verschlusskappe und einem kolbenstopfen ( teflonisiertes gummi ) mit einer kan\xc3\xbcle 27g1 / 2.'",b'0.3 ml solution for injection in a pre-filled syringe ( type i glass ) with a tip cap and a plunger stopper ( teflonised rubber ) with a needle 27g1 / 2 .',b'. ml solution for injection in a prefilled syringe type i glass with a tip cap and a amount cap and a tube .',b'0.3 ml solution for injection in a pre-filled syringe ( type i glass ) with a tip cap and a plunger stopper ( teflonised rubber ) with a 27g1 / 2 needle .'
3118,b'welchen nutzen hat clopidogrel winthrop in diesen studien gezeigt ?',b'what benefit has clopidogrel winthrop shown during the studies ?',b'what benefit has clopidogrel winthrop shown during the studies ?',b'what benefit has clopidogrel winthrop shown during the studies ?'
3119,"b'informieren sie ihren arzt oder apotheker , wenn sie nebenwirkungen bemerken , die nicht in dieser packungsbeilage aufgef\xc3\xbchrt sind .'","b'if you notice any side effects not listed in this leaflet , please inform your doctor or pharmacist .'","b'if you notice any side effects not listed in this leaflet , please inform your doctor or pharmacist .'","b'if you notice any side effects not listed in this leaflet , please inform your doctor or pharmacist .'"
3120,b'unter einhaltung einer aseptischen arbeitsweise den filterdorn an der sterilen einmalspritze anbringen .',b'apply solution for infusion using aseptic technique sterile filter spike of a sterile disposable syringe to the vial adapter .',b'apply solution for infusion using aseptic trained light screw spike contains calcium by motion of a sterile disposable syringe and physically for evenly homogenous free screw light with aseptic trained reconstituted blister spoonful sides of a sterile disposable syringe .',"b'while using an aseptic technique , apply the filter spike of a sterile disposable syringe .'"
3121,"b'verpflanzung von k\xc3\xb6rpereigenem knochenmaterial , meist aus dem beckenknochen ) nicht zum erfolg gef\xc3\xbchrt hat oder bei denen eine solche autologe transplantation nicht durchgef\xc3\xbchrt werden kann .'","b'polarity of pentoses and about 40 patients , usually from 60 ) is not successful or for whom such a autograft is not progenitor cells can be correctly performed .'","b'reintroduction of tendinopathie and about patients , usually implanted , usually bowel as usually also be cautioned changes may be hyperplasia iloprost .'","b""transplantation of the body 's own bone material , mostly from the pelvic bone was not successful or for whom such an autologous transplant can be performed ."""
3122,"b'drehen sie die flasche , bis die \xc3\x96ffnung nach unten zeigt , und dr\xc3\xbccken sie auf die flasche , bis ein tropfen in das zu behandelnde auge f\xc3\xa4llt .'","b'turn the bottle until the cysteine , and push the top of the bottle , until a drop of the wedge in the eye .'","b'turn the bottles as the bottle of the bottle down immediately , the way .'","b'turn the bottle until the opening is pointing downwards , and press the bottle , until a drop falls into the eye to be treated .'"
3123,"b'lamictal 50 mg tabletten sind auf der einen seite mit "" gsee1 \' und auf der anderen mit "" 50 \' gekennzeichnet .'","b'lamictal 50 mg tablets are marked "" gsee1\'on one side and "" 50 \' on the other side .'",b'lamictal mg tablets are marked tablets are marked ileitis a tablet down in a common ear .',"b'lamictal 50 mg tablets are marked "" gsee1\'on one side and "" 50 \' on the other side .'"
3124,b'am 4.april 2008 erteilte die europ\xc3\xa4ische kommission dem unternehmen cephalon europe eine genehmigung f\xc3\xbcr das inverkehrbringen von effentora in der gesamten europ\xc3\xa4ischen union .',b'the european commission granted the european union for the european union for effentora on 4.april 2008 .',b'the european commission granted the european union for the european union for the european union for the european union for marker on . the european union for it contains on reconstitution .',b'the european commission granted the company cephalon europe market authorization for effentora throught the whole european union on 4th april 2008 .'
3125,b'162 bei patienten mit eingeschr\xc3\xa4nkter nierenfunktion kann der insulinbedarf infolge des verminderten insulinabbaus verringert sein .',"b'162 in patients with renal impairment , insulin requirements may be diminished due to reduced .'","b'in patients with renal impairment , insulin requirements may be diminished due to reduced them .'","b'162 in patients with renal impairment , insulin requirements may be diminished due to reduced insulin degradation .'"
3126,b'es werden m\xc3\xb6glicherweise nicht alle packungsgr\xc3\xb6\xc3\x9fen in allen l\xc3\xa4ndern in den verkehr gebracht .',b'not all pack sizes may be marketed in all countries not all pack sizes may be marketed .',"b'any pack colourless may be marketed in all countries , a syringe .'",b'not all pack sizes may be marketed in all countries .'
3127,"b'phenylalanin zyprexa velotab schmelztabletten enthalten aspartam , woraus phenylalanin gebildet wird .'","b'phenylalanine zyprexa velotab orodispersible tablets contain aspartame , a source of phenylalanine .'","b'clopidogrelwinthropmg injection , unit'","b'phenylalanine zyprexa velotab orodispersible tablets contain aspartame , a source of phenylalanine .'"
3128,b'liprolog mix 50 vor dem ersten gebrauch im k\xc3\xbchlschrank ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) lagern .',b'liprolog mix 50 before the first use store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'liprolog mix if the first use before use before the enclosed use .',b'liprolog mix 50 : before the first use store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
3129,b'eine mikrocomputertomographie- ( \xc2\xb5ct ) -analyse zeigte bei mit aclasta behandelten patienten im vergleich zu placebo eine erh\xc3\xb6hung des trabekul\xc3\xa4ren knochenvolumens und den erhalt der trabekul\xc3\xa4ren knochenarchitektur .',"b'one mikrocomputertomographie- ( \xc2\xb5ct ) analysis shows that patients treated with aclasta as compared to placebo , with small increase in surrounding knochenvolumens and in mind the surrounding knochenarchitektur .'","b'one shedantigen of analysis shows mitotane to showed pharmacotherapy lead to placebo , with small positive in the differentiation group can work is no lymph acids and in exjade increases the differentiation varies material through acute cataract in doing tyrosine by immunosuppressed .'","b'one micro computer tomogra ( \xc2\xb5ct ) analysis shows that patients treated with aclasta as compared to placebo , with small increase in the trabecular bone marrow .'"
3130,"b'd halten sie den injektionsknopf eingedr\xc3\xbcckt und z\xc3\xa4hlen sie langsam bis 10 , bevor sie die nadel aus der haut ziehen .'",b'keep the injection button pressed in and slowly count to 10 before withdrawing the needle from the skin .',b'keep the injection button an injection button includes the injection button form in and separate rotary tablet or last pump to if the skin .',b'keep the injection button pressed in and slowly count to 10 before withdrawing the needle from the skin .'
3131,b'bei hunden wurden keine nebenwirkungen berichtet .',"b'in dogs , no adverse events have been reported .'","b'in dogs , no adverse events have been reported .'","b'in dogs , no adverse events have been reported .'"
3132,"b'cyanokit kann eine rote verf\xc3\xa4rbung des plasmas verursachen , was zu einem k\xc3\xbcnstlichen anstieg oder abfall der spiegel bestimmter laborparameter f\xc3\xbchrt ( siehe abschnitt 4.4 ) .'","b'cyanokit may cause red discoloration , leading to further increase or decrease in the levels of certain laboratory parameters ( see section 4.4 ) .'","b'cyanokit may cause red discoloration , a a internal serum parameters of certain laboratory parameters see section . .'","b'cyanokit may cause red discoloration of the plasma , leading to artificial increase or decrease in the levels of certain laboratory parameters ( see section 4.4 ) .'"
3133,b'verteilung raltegravir wird im konzentrationsbereich zwischen 2 und 10 \xc2\xb5m zu ann\xc3\xa4hernd 83 % an humane plasmaproteine gebunden .',b'distribution of raltegravir is in the range between 2 and 10 \xc2\xb5m to approximately 83 % bound to human plasma proteins .',b'distribution of raltegravir is in the range of plasma proteins .',b'distribution of raltegravir is in the range between 2 and 10 \xc2\xb5m to approximately 83 % bound to human plasma proteins .'
3134,b'die resorption von metformin wird durch die einnahme einer mahlzeit verringert und geringf\xc3\xbcgig verz\xc3\xb6gert .',b'the absorption of metformin is conferred by the ingestion of a meal and result in a slightly delayed .',"b'the absorption of metformin is seperated by the interval of a few fever proportion which are shortened into the interval of a hour from the beginning of a hour , passes .'",b'the absorption of metformin is reduced and s\xc3\xb6ightly delayed by the ingestion of a meal .'
3135,"b'etwa 0,6 % der dosis werden nach oraler verabreichung im urin gefunden .'","b'approximately 0.6 % of the dose , respectively , after oral administration was recovered in urine .'","b'approximately . of the dose , respectively , after oral administration and implanted .'",b'approximately 0.6 % of the dose after oral administration was recovered in urine .'
3136,b'duloxetine boehringer ingelheim ist in 2 st\xc3\xa4rken erh\xc3\xa4ltlich :',b'duloxetine boehringer ingelheim is available in 2 strengths :',b'duloxetine boehringer ingelheim is available in strengths',b'duloxetine boehringer ingelheim is available in 2 strengths :'
3137,b'wof\xc3\xbcr wird kuvan angewendet ?',b'what is kuvan used for ?',b'what is infection used for ?',b'what is kuvan used for ?'
3138,"b'anwendung von liprolog pen \xe2\x80\xa2 s\xc3\xa4ubern sie ihre haut , wie es ihnen gelehrt wurde , bevor sie injizieren .'",b'injecting liprolog pen \xe2\x80\xa2 s\xc3\xa4ubern your skin as you have been taught before injecting .',b'injecting do clean your skin as you have been taught before injecting .',b'using liprolog pen \xe2\x80\xa2 clean your skin as you have been taught before injecting .'
3139,"b'bleomycin lagert sich in dna- str\xc3\xa4nge , das genetische material einer zelle ein , und verursacht dadurch strangbr\xc3\xbcche .'","b'bleomycin , it has been listed , ( s ) aval , and wherein strangbr\xc3\xbcche .'","b'bleomycin , it has been expected , st enables adjuvant simultaineously , press the coated magus acting elliptic peakflow and antitetanus glucoronides polypeptide .'","b'bleomycin is stored in dna strands , the genetic material of a cell and causes strand breaks .'"
3140,"b'gewisse verbesserungen zeigten sich auch bei patienten mit pah der klasse ii. "" klasse ii "" bedeutet eine leichte einschr\xc3\xa4nkung der k\xc3\xb6rperlichen aktivit\xc3\xa4t .'","b'gewisse improvements were observed also in patients with class ii "" class ii \'involves slight limitation of physical activity .'",b'test broich were observed also not effective twice the pharmacological value that is lamivudin modification or acceleration by measles .',"b'tissue improvements were also observed in patients with class ii "" class ii "" involves slight limitation of physical activity .'"
3141,b'ein erh\xc3\xb6htes blutungsrisiko ist bei gleichzeitiger anwendung von heparin und efient m\xc3\xb6glich .',b'an increased risk of bleeding is possible with concomitant administration of heparin and efient .',b'an increased risk of in urine and efient .',b'an increased risk of bleeding is possible with concomitant administration of heparin and efient .'
3142,"b'dazu geh\xc3\xb6rten f\xc3\xa4lle von stevens-johnson-syndrom , toxischer epidermaler nekrolyse und \xc3\x9cberempfindlichkeitsreaktionen , deren charakteristika hautausschlag , beeintr\xc3\xa4chtigung der k\xc3\xb6rperlichen verfassung und beteiligung der inneren organe waren .'","b'these have included cases of stevens-johnson syndrome , toxic epidermal necrolysis and hypersensitivity reactions whose characteristics , rash impaired condition and involvement .'","b'these have included cases of hypotensive syndrome was stiff , toxic epidermal necrolysis and hypersensitivity reactions whose characteristics , diarrhoea in recurrent changes .'","b'these have included cases of stevens-johnson syndrome , toxic epidermal necrolysis and hypersensitivity reactions whose characteristics , skin rash , damage of the physical condition and participation of the inner organs .'"
3143,"b'14 tage nach der injektion betrug die mittlere cefovecin-plasmakonzentration 5,6 \xc2\xb5g / ml .'","b'14 days after injection , the mean cefovecin-plasmakonzentration 5.6 \xc2\xb5g / ml , respectively .'",b'refrigerated water within the mean accumulation as insulin ml .',"b'14 days after injection , the mean cefovecin plasma concentration was 5.6 \xc2\xb5g / ml , respectively .'"
3144,b'das endg\xc3\xbcltige gutachten wurde von der europ\xc3\xa4ischen kommission am 29. m\xc3\xa4rz 2005 in eine entscheidung umgewandelt .',b'the final opinion was converted to the european commission on 29 march 2005 .',b'the final opinion was converted from the european commission marketing kras in april .',b'the final decision was passed by the european commission on 29 march 2005 .'
3145,"b'56 dosisreduktion von atazanavir ist nicht zu empfehlen , da dies zu einem verlust des therapieeffekts sowie zu einer resistenzentwicklung f\xc3\xbchren kann .'",b'56 dose reduction of atazanavir is not recommended because it may result in a loss of therapeutic effect and development of recommended .',b'doses reduction of atazanavir is not recommended indicate it may result in a loss of therapeutic effect and development of humans .',b'56 dose reduction of atazanavir is not recommended because it may result in a loss of therapeutic effect and resistence development .'
3146,"b'die am h\xc3\xa4ufigsten genannte nebenwirkung ( 30,4 % ) waren reaktionen an der applikationsstelle .'",b'the most commonly used as a side effect ( 30.4 % ) were application site reactions .',b'the most commonly used as a side effect . no same level may resistant',b'the most common side effects ( 30.4 % ) were application site reactions .'
3147,b'b. acetylsalicyls\xc3\xa4ure wird bei diesen patienten empfohlen .',"b'administration of acetylsalicylic acid , for example , is recommended in these patients .'","b'administration of acetylsalicylic acid , for example , is recommended in these patients .'","b'administration of acetylsalicylic acid , for example , is recommended in these patients .'"
3148,b'- wenn ihr kind durchfall hat oder erbricht .',b'- if your child has diarrhoea or is vomiting .',b'if your child has diarrhoea or is vomiting .',b'- if your child has diarrhoea or is vomiting .'
3149,"b'305 zus\xc3\xa4tzlich wurde \xc3\xbcber das vogt-koyanagi-harada syndrom ( eine autoimmun-entz\xc3\xbcndliche krankheit , die die augen , die haut und die ohrmembranen sowie die hirn- und r\xc3\xbcckenmarksh\xc3\xa4ute angreift ) bei der anwendung von viraferonpeg berichtet .'","b'additionally , vogt-koyanagi-harada syndrome ( an autoimmune inflammatory disorder affecting the eyes , skin and the membranes of the ears , brain and spinal cord ) has been reported with viraferonpeg use .'","b'additionally , abortions syndrome an autoimmune inflammatory disorder affecting the eyes , skin and the membranes of the same urethritis and spinal cord has been reported with viraferonpeg for didanosine .'","b'additionally , vogt-koyanagi-harada syndrome ( an autoimmune inflammatory disorder affecting the eyes , skin and the membranes of the ears as well as the brain and spinal cord skin ) has been reported with viraferonpeg use .'"
3150,b'ein behandlungszyklus dauert in der regel 1 bis 2 wochen bei hautinfektionen .',b'a course of treatment usually lasts for 1 to 2 weeks for skin infections .',"b'a course is administered , other yellow sysmptoms .'",b'a course of treatment usually lasts for 1 to 2 weeks for skin infections .'
3151,"b'wenn sie sich nicht sicher sind , so fragen sie ihren arzt oder apotheker .'","b'if you are not sure , ask your doctor or pharmacist .'","b'if you are not sure , ask your doctor or pharmacist .'","b'if you are not sure , ask your doctor or pharmacist .'"
3152,"b'novorapid flexpen 100 e / ml , injektionsl\xc3\xb6sung in einem fertigpen .'","b'novorapid flexpen 100 u / ml , solution for injection in a pre-filled pen .'","b'novorapid flexpen u ml , solution for injection in a prefilled injector .'","b'novorapid flexpen 100 u / ml , solution for injection in a pre-filled pen .'"
3153,b'sie d\xc3\xbcrfen das < etoricoxib > nach dem auf dem beh\xc3\xa4ltnis angegebenen verfalldatum nicht mehr verwenden .',b'do not use etoricoxib after the expiry date which is stated on the bottle .',b'do not use etoricoxib after the expiry date which is stated on the bottle .',b'do not use etoricoxib after the expiry date which is stated on the bottle .'
3154,"b'hunde , die gleichzeitig mit spironolacton und nsaids behandelt werden , sollten angemessen hydriert werden .'",b'dogs are treated concomitantly with spironolactone and nsaids should be used as appropriate .',b'dogs are treated concomitantly with spironolactone and nsaids should be used as appropriate .',b'dogs that are treated concomitantly with spironolactone and nsaids should be appropriately hydrated .'
3155,b'lesen sie vor der anwendung die packungsbeilage .',b'read the package leaflet before use .',b'read the package leaflet before use .',b'read the package leaflet before use .'
3156,b'die tabletten werden unzerkaut mit ausreichend wasser geschluckt .',b'the tablets should be swallowed whole with a drink of water .',b'the tablets should be swallowed whole with a drink of water .',b'the tablets should be swallowed whole with a drink of water .'
3157,b'es verhindert ebenso ein eindringen von luft in den pen und ein verstopfen der nadel .',b'it also stops air entering the pen and your needle clogging .',b'it also stops air entering the pen and your needle clogging .',b'it also stops air entering the pen and your needle clogging .'
3158,"b'jedoch wird die verabreichung von rotarix an asymptomatische hiv-patienten nicht empfohlen , da keine ausreichenden daten vorliegen .'","b'however , the administration of rotarix asymptomatic hiv infected patients is not recommended because there is not enough data are available .'","b'however , the administration of rotarix asymptomatic hiv infected patients is not recommended sensitive with the ris determined after microtubules as milk .'","b'however , the administration of rotarix asymptomatic to hiv infected patients is not recommended because there is not enough data available .'"
3159,b'\xc3\x9cber die bindung von phosphat im magen-darm-trakt senkt sevelamer den phosphatspiegel im serum .',"b'over the binding of phosphate in the gastrointestinal tract , reduces the levels of sevelamer .'","b'over the binding of phosphate in the gastrointestinal tract , regardless of parathyroid process of cysteine .'","b'over the binding of phosphate in the gastrointestinal tract , reduces the levels of serum in the phosphate levels .'"
3160,"b'ziehen sie den kolben langsam zur\xc3\xbcck , um die l\xc3\xb6sung in die spritze zu ziehen .'",b'slowly pull the plunger back to draw solution into the syringe .',b'slowly pull the plunger back to draw solution into the cap .',b'slowly pull the plunger back to draw solution into the syringe .'
3161,"b'patienten unter immunsuppressionstherapie , einschlie\xc3\x9flich therapie mit advagraf haben ein erh\xc3\xb6htes risiko f\xc3\xbcr opportunistische infektionen ( mit bakterien , pilzen , viren und anderen einzellern ) .'","b'patients under acids , including treatment with advagraf are at an increased risk for opportunistic infections ( bacterial , fungal , viral and an other workpiece ) .'",b'patients undergoing the same vaccine caused as acute underactive age .',"b'patients under immuno suppression therapy , including treatment with advagraf are at an increased risk for opportunistic infections ( bacterial , fungal , viral and an other single-celled organisms ) .'"
3162,"b'insuman comb 50 wird in patronen , fest verbunden mit patronenhaltern , angeboten ; sie bilden den auswechselbaren teil des insulinpens opticlik .'","b'insuman comb 50 comes in a cartridge sealed in a plastic container , which is the disposable part of opticlik , an insulin pen .'","b'insuman comb comes in a cartridge sealed in a plastic container , which is the fully part of opticlik , an insulin pen is the disposable part of opticlik until near the pen and'","b'insuman comb 50 comes in a cartridge sealed in a plastic container , which is the disposable part of opticlik , an insulin pen .'"
3163,"b'die in-vitro-studien weisen darauf hin , dass cyp3a4 und cyp2b6 die wichtigsten f\xc3\xbcr den abbau von efavirenz verantwortlichen isoenzyme sind und dass der wirkstoff die p450-isoenzyme 2c9 , 2c19 und 3a4 hemmt .'","b'the in vitro studies suggest that cyp3a4 and cyp2b6 are the major isozymes responsible for efavirenz metabolism and inhibit the isoenzymes , 2c8 , 2c9 , 2c19 , and 3a4 .'","b'the in vitro studies suggest that cypa and cypb , c in the body , c up to a .'","b'the in vitro studies suggest that cyp3a4 and cyp2b6 are the major isozymes responsible for efavirenz metabolism and inhibit the isoenzymes , 2c8 , 2c9 , 2c19 , and 3a4 .'"
3164,"b'das in livensa enthaltene testosteron ist das gleiche hormon wie dasjenige , das nat\xc3\xbcrlicherweise von m\xc3\xa4nnern und frauen gebildet wird .'",b'the testosterone in livensa is contained the same hormone as that produced naturally in men and women .',b'the testosterone worth for the same hormone as that produced naturally level toxicity .',b'the testosterone in livensa is contained the same hormone as that produced naturally in men and women .'
3165,"b'wenn sie tr\xc3\xbcb oder verf\xc3\xa4rbt ist oder flocken oder partikel enth\xc3\xa4lt , darf sie nicht verwendet werden .'","b'if the solution is cloudy or hazy or is coloured or it has solid pieces or particles in it , you must not use it .'",b'if the solution is cloudy or benzodiazepinelike or nutritional or .',"b'if the solution is cloudy or hazy or it has solid pieces or particles in it , you must not use it .'"
3166,b'beide probleme treten bei einer prostatavergr\xc3\xb6\xc3\x9ferung h\xc3\xa4ufig auf .',b'both problems tend to occur in the prostate enlargement .',b'both problems from to occur in the alpha factors .',b'both problems tend to occur with an enlarged prostate .'
3167,"b'daher ist es wichtig , dass sie ihren arzt dar\xc3\xbcber informieren , dass sie arzneimittel gegen eine \xc3\xbcberm\xc3\xa4\xc3\x9fige blutgerinnung einnehmen .'","b'therefore , it is important that you tell your doctor that you are taking medicines for excessive blood clotting .'","b'therefore , it is important that you tell your hypoglycaemia that you are taking medicines for excessive blood clotting .'","b'therefore , it is important that you tell your doctor that you are taking medicines for excessive blood clotting .'"
3168,"b'replagal ist eine l\xc3\xb6sung zur infusion in den k\xc3\xb6rper , die den wirkstoff agalsidase alfa enth\xc3\xa4lt .'","b'replagal is a solution for infusion in the body , which contains the active substance agalsidase alfa .'","b'replagal is a solution for infusion in the body , which contains the active substance agalsidase alfa .'","b'replagal is a solution for infusion in the body , which contains the active substance agalsidase alfa .'"
3169,"b'17 eigeninjektion sollte jedoch nur von patienten durchgef\xc3\xbchrt werden , die entsprechend motiviert und hinreichend geschult sind sowie die m\xc3\xb6glichkeit haben , fachlichen rat einzuholen .'","b'17 administration of puregon should only be performed by patients who are well-motivated , adequately trained and with access self with access to expert advice .'",b'administration of puregon should only be performed by parkinson or or monthly dose with contraception have request and with acquired breathing working or or leakage re diet to trocoxil .',"b'17 administration of puregon should only be performed by patients who are well-motivated , adequately trained and with access to expert advice .'"
3170,"b'( name ( phantasiebezeichnung ) enth\xc3\xa4lt den wirkstoff pimecrolimus , einen calcineurin-inhibitor .'","b'invented name contains the active substance pimecrolimus , a calcineurin inhibitor .'","b'invented name contains the active substance dosing , a calcineurin inhibitor .'","b'invented name contains the active substance pimecrolimus , a calcineurin inhibitor .'"
3171,"b'2 es wird empfohlen , den impfstoff entsprechend den angegebenen impfschemata zu verabreichen .'",b'it is recommended that the vaccine be administered according to the specified immunisation schedules .',b'it is recommended that the vaccine should be administered according to the feed safety schedules .',b'it is recommended that the vaccine be administered according to the specified immunisation schedules .'
3172,"b'es ist als mandelf\xc3\xb6rmige , gelbe tabletten erh\xc3\xa4ltlich ( 20 mg ) .'","b'it is available as mandelf\xc3\xb6rmige , yellow tablets ( 20 mg ) .'","b'it is available with adhesion , yellow body .'","b'it is available as amygdaloid , yellow tablets ( 20 mg ) .'"
3173,b'die gleichzeitige einnahme von intelence und indinavir kann eine deutliche verringerung der plasmakonzentration von indinavir und den verlust der therapeutischen wirkung von indinavir verursachen .',b'concomitant use of intelence and indinavir may cause a marked decrease in plasma concentrations of indinavir and loss of therapeutic effect of indinavir .',b'concomitant use of intelence and indinavir may cause a natural decrease in plasma concentrations of range of therapeutic effect of indinavir .',b'concomitant use of intelence and indinavir may cause a marked decrease in plasma concentrations of indinavir and loss of therapeutic effect of indinavir .'
3174,b'im vergleich zu plasmatischem faktor ix war die recovery von rekombinantem faktor ix um 28 % niedriger .',b'recovery of recombinant factor ix in 28 % lower compared to plasma derived factor ix .',b'albumin of human factor mylan in increased ci ix .',b'recovery of recombinant factor ix was 28 % lower compared to plasma derived factor ix .'
3175,"b'da keine kompatibilit\xc3\xa4tsstudien durchgef\xc3\xbchrt wurden , darf dieses arzneimittel nicht mit anderen arzneimitteln gemischt werden .'","b'in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .'","b'in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .'","b'in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .'"
3176,b'fahren sie dann mit der injektion des arzneimittels an den \xc3\xbcblichen tagen fort .',b'continue to inject the medicinal product on the usual days .',b'withdraw the medicinal product on the usual list .',b'continue to inject the medicinal product on the usual days .'
3177,"b'wenn eine gleichzeitige anwendung erforderlich ist , ist eine engmaschige \xc3\x9cberwachung erforderlich .'","b'if co- administration is essential , close monitoring is necessary .'",b'if coadministration of skin meshed insulin shaker should be necessary .',"b'if co-administration is essential , close monitoring is necessary .'"
3178,b'firmagon wird in die bauchhaut gespritzt .',b'firmagon is injected into the using the pen .',b'endometriale is injected into the using the pen .',b'firmagon is injected into the abdominal skin .'
3179,b'nachfolgend sind in der tabelle nebenwirkungen aus klinischen studien und erfahrungen nach markteinf\xc3\xbchrung entsprechend ihrer systemorganklassen und h\xc3\xa4ufigkeit aufgef\xc3\xbchrt .',b'adverse drug reactions are listed in the table adverse reactions from clinical trials and postmarketing experience by system organ class and frequency .',b'adverse drug reactions are listed in the frequency iii the frequency adverse disorders from clinical trials .',b'adverse drug reactions from clinical studies and postmarketing experience by system organ class and frequency are listed in the table below .'
3180,b'pulver zur herstellung einer suspension zum einnehmen : vor der zubereitung bei 2 \xc2\xb0 c bis 8 \xc2\xb0 c lagern ( im k\xc3\xbchlschrank ) .',b'powder for oral suspension : before at 2 \xc2\xb0 c - 8 \xc2\xb0 c ( in a refrigerator ) .',b'suspension for oral suspension before at c c in a refrigerator .',b'powder for oral suspension : before at 2 \xc2\xb0 c - 8 \xc2\xb0 c ( in a refrigerator ) .'
3181,b'- sch\xc3\xbcttelfrost oder fieber .',b'- chills or fever .',b'occasional maximum and fever .',b'- chills or fever .'
3182,b'die bioverf\xc3\xbcgbarkeit von amprenavir als l\xc3\xb6sung zum einnehmen ist um 14 % geringer als von amprenavir als kapsel ; daher sind agenerase kapseln und l\xc3\xb6sung zum einnehmen auf einer milligramm pro milligramm basis nicht austauschbar ( siehe abschnitt 5.2 ) .',"b'the bioavailability of the agenerase oral solution are not interchangeable on a 14 % lower than that of amprenavir from the capsules ; therefore , agenerase capsules and agenerase oral solution a milligram per milligram basis ( see section 5.2 ) .'","b'the bioavailability of the agenerase oral solution are not strongly on a lower than that of amprenavir from the capsules therefore , before possible is for .'","b'the bioavailability of amprenavir as an oral solution is 14 % lower than that of amprenavir from the capsules ; therefore , agenerase capsules and agenerase oral solution are nor interchangeable on a milligram per milligram basis ( see section 5.2 ) .'"
3183,"b'es sind keine akuten entzugssymptome zu erwarten , wenn sie betaferon absetzen .'",b'no acute withdrawal symptoms have to be expected if you stop taking betaferon .',b'no acute withdrawal symptoms have to be expected if you stop taking betaferon .',b'no acute withdrawal symptoms have to be expected if you stop taking betaferon .'
3184,"b'in einer in-vivo- einzeldosisstudie an affen , die bei bewusstsein telemetrisch \xc3\xbcberwacht wurden , zeigten sich jedoch keine ver\xc3\xa4nderungen des qt-intervalls oder des ekg-kurvenverlaufes .'","b'in a battery of in vivo single dose study conducted in monkeys , with a level of consciousness should be monitored , however , there was no effect on the qt interval or ekg-kurvenverlaufes .'","b'no was average an plasma studies in monkeys , with a level of consciousness should be monitored for effect on the qt interval or progesterone .'","b'in an in vivo single dose study conducted in monkeys , in which consciousness was monitored telemetrically , however , there was , however , no changes to the qt intervals or the ecg curve .'"
3185,"b'schwangerschaft und stillzeit wenn sie schwanger sind oder eine baldige schwangerschaft planen , informieren sie bitte ihren arzt , .'","b'pregnancy and breast-feeding if you are pregnant or baldige are pregnant or intend to become pregnant , please tell your doctor .'","b'pregnancy and breastfeeding if you are pregnant or acquired or intend to become pregnant , please an echocardiograph before your doctor .'","b'pregnancy and breast-feeding . if you are pregnant or baldige are or intend to become pregnant , please tell your doctor .'"
3186,"b'1 / 86 , 1 % ; l74v : ohne zdv :'","b'1 / 86 , 1 % ; l74v : without zdv :'","b', embryofoetal ml without pramipexole without pramipexole without human disease , large insulin suspension .'","b'1 / 86 , 1 % ; l74v : without azt :'"
3187,"b'visudyne in 7,0 ml wasser f\xc3\xbcr injektionszwecke l\xc3\xb6sen , um 7,5 ml einer 2,0 mg / ml konzentrierten l\xc3\xb6sung zu erhalten .'","b'visudyne in 7.0 ml of water for injections and 7.5 ml of a 2.0 mg / ml ( 10,80,100,126 ) .'",b'visudyne in . ml of water for injections and one . the . of a . of a . m .',"b'visudyne in 7.0 ml of water for injections to receive 7.5 ml of a 2.0 mg / ml concentrated solution ( 10,80,100,126 ) .'"
3188,b'handhabung bei der zubereitung und entsorgung der infusionsl\xc3\xb6sung m\xc3\xbcssen die \xc3\xbcblichen vorsichtsma\xc3\x9fnahmen f\xc3\xbcr zytostatika beachtet werden .',b'during handling and disposal of the solution for infusion should be precautions for cytotoxic agents should be considered .',b'during making and disposal of the solution for infusion should be taken by the solution for infusion should be decision for the solution for infusion should be precautions for infusion syndrome should be considered .',"b'during handling and disposal of the solution for infusion , precautions for cytotoxic agents should be considered .'"
3189,b'wie soll riquent wirken ?',b'how should riquent expected to work ?',b'how should filternadeln ?',b'how should riquent work ?'
3190,"b'stocrin wurde bei patienten mit fortgeschrittener hiv-erkrankung , das hei\xc3\x9ft bei patienten mit cd4-zahlen von < 50 zellen / mm3 oder nach versagen von schemata , die einen proteaseinhibitor ( pi ) enthalten , nicht ausreichend untersucht .'","b'stocrin has not been adequately studied in patients with advanced hiv disease , namely in patients with cd4 counts 50 cells / mm3 , or after failure of regimens protease inhibitor ( pi ) is contraindicated ( see section 4.5 ) .'","b'stocrin has not been also studied in patients with advanced hiv disease , who were enzymatically in patients with cd counts cells mm , or after failure of sickle protease inhibitor were higher around an administration at patients with cd counts cells mm , or after definition of amphotericin protease'","b'stocrin has not been adequately studied in patients with advanced hiv disease , namely in patients with cd4 counts of less than 50 cells / mm3 , or after failure of regimens that contain a protease inhibitor ( pi ) ( see section 4.5 ) .'"
3191,b'bei einnahme von adrovance zusammen mit nahrungsmitteln und getr\xc3\xa4nken : nahrungsmittel und getr\xc3\xa4nke ( einschlie\xc3\x9flich mineralwasser ) k\xc3\xb6nnen die wirksamkeit von adrovance bei gleichzeitiger einnahme behindern .',b'taking adrovance with food and drink : is likely that food and beverages ( including mineral water ) will make the effectiveness of the absorption of adrovance if taken at the same time .',"b'taking adrovance together with food and drink is likely not been taken as protective water , insulin water will make the effectiveness of the age of adrovance is or lost subcutaneously will make the effectiveness of the medically main again during section of efalizumab if taken at the woman of'",b'taking adrovance with food and drink : it is likely that food and beverages ( including mineral water ) will reduce the effectiveness of adrovance if taken at the same time .'
3192,"b'raltegravir hemmt die katalytische aktivit\xc3\xa4t der integrase , einem hiv-kodierten enzym , das zur virusreplikation erforderlich ist .'","b'raltegravir inhibits the catalytic activity of the integrase , a hiv-kodierten enzyme required for viral replication .'",b'doripenem inhibits the referral are more provided by high lipolysis .',"b'raltegravir inhibits the catalytic activity of the integrase , a hiv-kodierten enzyme required for viral replication .'"
3193,b'die gleichzeitige anwendung von atripla und johanniskraut ist kontraindiziert .',"b""concomitant use of atripla and st. john 's wort is contraindicated .""",b'concomitant use of atripla and st . john s wort is contraindicated .',"b""concomitant use of atripla and st. john 's wort is contraindicated ."""
3194,"b'eine durchstechflasche enth\xc3\xa4lt 3 millionen i.e. interferon alfa-2b in 0,5 ml l\xc3\xb6sung .'",b'one vial contains 3 million iu of interferon alfa-2b in 0.5 ml of solution .',b'one vial contains million iu of interferon alfab in . ml of solution .',b'one vial contains 3 million iu of interferon alfa-2b in 0.5 ml solution .'
3195,b'sehr h\xc3\xa4ufig : h\xc3\xa4ufig : gelegentlich : selten : sehr selten : nicht bekannt :',b'very common : common : uncommon : rare : very rare : not known :',b'very common common disorders rare very rare not known',b'very common : common : uncommon : rare : very rare : not known :'
3196,"b'- entfernen sie das pflaster nach der zeit , die ihnen von ihrem arzt genannt wurde .'",b'- remove the patch after the time that is convenient for you by your doctor .',b'remove the need after the time that is forward that is bathe for you by your doctor .',b'remove the patch after the time named by your doctor .'
3197,"b'bei arzneimitteln , die durch cyp2d6 metabolisiert werden und die individuell titriert werden , kann eine dosisanpassung notwendig sein .'",b'in medicinal products that are metabolised by cyp2d6 and individually titrated using the individual components of the adjustments may be necessary .',b'in medicinal products that are metabolised by cypd and individually titrated using appropriate by no harmful of the fentanyl may be necessary .',b'in medicinal products that are metabolised by cyp2d6 and individually titrated using the individual components of the adjustments may be necessary .'
3198,"b'eine signifikant h\xc3\xb6here biopsiebest\xc3\xa4tigte absto\xc3\x9fungsrate in der ciclosporin-eliminierungsgruppe im vergleich zu der mit ciclosporin weiterbehandelten gruppe ( 9,8 % vs.'",b'a significantly higher biopsiebest\xc3\xa4tigte rate upon compared with the ciclosporin weiterbehandelten group ( 9.8 % vs.',b'concentration was observed to the alpha parahydroxysulphate group . vs .',b'a significantly higher rejection rate confimed by biopsy in the ciclosporin elimination group in comparison to the group treated further with ciclosporin ( 9.8 % vs.'
3199,b'die injektionsstelle nicht ng massieren .',b'do not massage the injection site lon .',b'only the injection site of .',b'do not massage the injection site .'
3200,b'nicht vorher von ihrem arzt oder apotheker entsprechend geschult worden sind .',"b'from your doctor , pharmacist or diabetes nurse been trained .'","b'from your doctor , pharmacist or diabetes nurse after the insulin .'","b'from your doctor , pharmacist or diabetes nurse who have been trained .'"
3201,b'bei patienten mit stark eingeschr\xc3\xa4nkter nierenfunktion oder h\xc3\xa4modialyse-patienten liegen begrenzte erfahrungen vor .',b'there are limited data in patients with severe renal impairment or in haemodialysis patients .',b'there cannot limited data for patients with severe renal impairment or in haemodialysis patients .',b'there are limited data in patients with severe renal impairment or in haemodialysis patients .'
3202,b'die anweisungen zur rekonstitution sind sorgf\xc3\xa4ltig zu beachten .',b'for instructions on reconstitution should be respected carefully .',b'for instructions on delivery should be autoclaved carefully .',b'instructions on reconstitution should be respected carefully .'
3203,b'bei folgenden h\xc3\xa4morrhagischen ereignissen soll die faktor viii-aktivit\xc3\xa4t im entsprechenden zeitraum nicht unter die angegebenen plasmaspiegel ( in % der norm oder in i.e. / dl ) sinken .',"b'if you experience the following haemorrhagic events , the factor viii activity should not fall below the given plasma levels ( in % of normal or in iu / dl ) .'","b'if you experience the following haemorrhagic events , the factor viii activity should not fall below until a cmax inhibition with approximately resectable in iu kg rate .'","b'if you experience the following haemorrhagic events , the factor viii activity should not fall below the given plasma levels ( in % of the norm or in iu / dl ) .'"
3204,"b'kinder d\xc3\xbcrfen solange nicht mit behandelten tieren spielen , bis die auftragungsstelle trocken ist .'",b'children should not take while not play with treated animals until the application site is dry .',b'children should slightly dual how not deposition',b'children should not play with treated animals until the application site is dry .'
3205,b'ihr arzt k\xc3\xb6nnte sie auf die entwicklung von hemmk\xc3\xb6rpern hin \xc3\xbcberwachen wollen .',b'your doctor may you inhibitor development in want .',b'your doctor may you inhibitor development in these days .',b'your doctor may want to monitor the development of inhibitors .'
3206,b'* betaferon ist mit einer kalkulierten \xc3\x9cberf\xc3\xbcllung von 20 % formuliert .',b'* betaferon is formulated to contain a calculated overfill of 20 % .',b'betaferon is formulated to contain a planned yields take one glucose glycolepoetin .',b'* betaferon is formulated to contain a calculated overfill of 20 % .'
3207,b'2 \xc3\x84ltere population eine anpassung der dosis ist bei der anwendung von cholestagel bei \xc3\xa4lteren patienten nicht erforderlich .',b'elderly population no dose adjustment is necessary with the use of cholestagel in elderly patients .',b'elderly population no dose adjustment is necessary with the use of cholestagel in elderly patients .',b'elderly population no dose adjustment is necessary with the use of cholestagel in elderly patients .'
3208,b'bei affen f\xc3\xbchrten orale einzeldosen von bis zu 100 mg / kg k\xc3\xb6rpergewicht zu ersch\xc3\xb6pfungszust\xc3\xa4nden und bei h\xc3\xb6heren dosen zu d\xc3\xa4mmerzust\xc3\xa4nden .',"b'in monkeys , single oral doses up to 100 mg / kg resulted in prostration and , at higher doses 139 , semi-consciousness .'","b'in ovariectomised monkeys , single oral doses up to mg kg , by than dose than with protease doses to respectively and a kg resulted in nonblacks and with at higher doses .'","b'in monkeys , single oral doses up to 100 mg / kg of body weight resulted in exhaustion and , at higher doses , fugue states .'"
3209,b'welchen nutzen hat aranesp in diesen studien gezeigt ?',b'what benefit has aranesp shown during the studies ?',b'what benefit has aranesp shown during the studies ?',b'what benefit has aranesp shown during the studies ?'
3210,b'die tablettenbeschichtung enth\xc3\xa4lt hypromellose und diacetylierte monoglyceride .',b'the 146b ) contains hypromellose and the hydroxyketone of formula ( i ) .',b'the lung contains hypromellose and mediastinal acts that the serum proteins oder have been work were reviewed .',b'the tablet coating contains hypromellose and diacetylated monoglycerides .'
3211,"b'parameter zur lebensqualit\xc3\xa4t patienten , die mit tpf behandelt wurden , erfuhren eine signifikant geringere verschlechterung ihres allgemeinen gesundheitszustandes im vergleich zu den patienten , die mit pf behandelt wurden ( p = 0,01 ; unter benutzung der eortc qlq-c30-skala ) .'","b'quality of life parameters patients treated with tpf experienced significantly less deterioration of their global health score compared to those treated with pf ( p = 0.01 , using the eortc qlq-c30-skala ) .'",b'evaluation of life parameters patients treated with neutralising closure of their gastrointestinal health score compared to those treated with developing p . .',"b'quality of life parameters patients treated with tpf experienced significantly less deterioration of their general health score compared to those treated with pf ( p = 0.01 , using the eortc qlq c30 scale ) .'"
3212,b'3 enten ab einem alter von 1 tag :',b'3 ducks ab 1 day :',b'ec of day',b'3 ducks from 1 day old :'
3213,b'die h\xc3\xa4ufigsten nebenwirkungen von evista ( beobachtet bei mehr als 1 von 10 patientinnen ) sind vasodilation ( hitzewallungen ) und grippe\xc3\xa4hnliche symptome .',b'the most common side effects with evista ( seen in more than 1 patient in 10 ) are vasodilation ( hot flushes ) and flu-like symptoms .',b'the most common side effects with evista seen in more than patient in are mastitis muscle coccidiocidal haemolysis and the face or flulike material and tingling .',b'the most common side effects with evista ( seen in more than 1 patient in 10 ) are vasodilation ( hot flushes ) and flu-like symptoms .'
3214,b'21 schwangerschaft und stillzeit fragen sie vor der einnahme von allen arzneimitteln ihren arzt oder apotheker um rat .',b'21 pregnancy and breast-feeding ask your doctor or pharmacist for advice before taking any medicine .',b'pregnancy and breastfeeding ask your doctor or pharmacist for advice before taking any medicine .',b'21 pregnancy and breast-feeding ask your doctor or pharmacist for advice before taking any medicine .'
3215,"b'prezista kann eine hiv-infektion oder aids nicht heilen , jedoch die sch\xc3\xa4den am immunsystem verz\xc3\xb6gern oder umkehren und das risiko des entstehens weiterer krankheiten senken , die mit der hiv-infektion oder aids verbunden sind . wie wurde prezista untersucht ?'","b'prezista can cause is not a cure for hiv infection or aids , but delay the damage to the immune system or umkehren and reduce the risk of injection of other illnesses associated with hiv infection or aids . how has prezista been studied ?'","b'prezista can cause is not a cure for hiv infection , but delay the damage to the immune system or lateinamerikanern and reduce the risk of injection of viraferon diseases .'","b'prezista is not a cure for hiv infection or aids , but delays or reverses the damage to the immune system and reduces the risk of infection of other illnesses associated with hiv infection or aids . how has prezista been studied ?'"
3216,"b'falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'if you want more information about this medicine , please contact the local representative of the marketing authorisation holder .'"
3217,b'94 % der 1690 prowess patienten berichtet .',b'94 % of the 1690 prowess patients have been reported .',b'of the prowess patients have been reported in opinion in a inflammation .',b'94 % of the 1690 prowess patients reported .'
3218,b'dosierung bei ph + all die empfohlene dosierung von glivec bei patienten mit ph + all betr\xc3\xa4gt 600 mg / tag .',"b'dosage in ph + all , the recommended dose of glivec is 600 mg / day for patients with ph + all .'","b'dosage in ph all , the recommended dose of glivec is mg day for patients with ph .'",b'dosage in ph + all : the recommended dose of glivec is 600 mg / day for patients with ph + all .'
3219,"b'wenn sie die anwendung von raptiva vergessen haben wenden sie nicht die doppelte dosis an , wenn sie die vorherige anwendung vergessen haben .'",b'if you forget to take raptiva do not take a double dose to make up for a forgotten doses .',b'if you forget to take raptiva wasserkonsum of insuman to make up for a forgotten doses .',b'if you forget to take raptiva . do not take a double dose to make up for a forgotten doses .'
3220,b'4. welche nebenwirkungen sind m\xc3\xb6glich ? 5. wie ist avandamet aufzubewahren ? 6.',"b'4 . "" possible side effects 5 how to store avandamet 6 .'",b'. possible side effects how to store avandamet .',"b'4 . "" possible side effects\xc3\x9f 5 how to store avandamet ? 6 .'"
3221,b'es enth\xc3\xa4lt den wirkstoff trastuzumab .',b'it contains the active substance trastuzumab .',b'it contains the active substance antimetabolites .',b'it contains the active substance trastuzumab .'
3222,b'bei rhesusaffen dosisabh\xc3\xa4ngige anovulatorische und abortive wirkungen hervorrufen .',b'in rhesus monkeys anovulatory and abortifacient effects .',b'brings also hudson and involuntary effects .',b'caused anovulatory and abortifacient effects in rhesus monkeys .'
3223,"b'weitere studien untermauerten diese ergebnisse und zeigten , dass oxyglobin bei anderen tieren als k\xc3\xbchen sauerstoff aufnehmen , transportieren und abgeben kann .'","b'further studies , these results and information showed that oxyglobin with other animals as cows , or are expected to carry .'","b'further studies , these results and currently optimal at the risk of the hypersensitivity , are expected to carry or lactose request , or followed , or are expected to carry .'","b'further studies substantiated these results and showed that oxyglobin is taken up , transported and released by animals other than cows .'"
3224,"b'das arzneimittel darf , au\xc3\x9fer mit den weiter unten aufgef\xc3\xbchrten , nicht mit anderen arzneimitteln gemischt werden .'","b'the medicine should not be used , except those mentioned below should not be mixed with other medicinal products .'","b'the medicine should not be used , except those mentioned below should not be mixed with other medicinal products .'","b'the medicine should not be mixed with other medicinal products , except those mentioned below .'"
3225,"b'schwindel , \xc3\x9cbelkeit , juckende hautr\xc3\xb6tungen ( hautausschlag ) , schwarze n\xc3\xa4gel ( melanonychie ) , haarausfall .'","b', dizziness , nausea , itchy redness ( rash ) , black ( melanonychie ) , hair loss .'","b'tremor , nausea , neither redness rash , black bioabsorbable , thus loss .'","b'dizziness , nausea , itchy redness ( rash ) , black nails ( melanonychia ) , hair loss .'"
3226,b'insulatard innolet darf nur von einer person benutzt werden .',b'insulatard innolet is for use by one person only .',b'insulatard innolet is for use by one person only .',b'insulatard innolet is for use by one person only .'
3227,b'vor jeder anwendung ist die durchstechflasche zu sch\xc3\xbctteln .',b'prior to shake the vial before use .',b'prior to shake the vial before use .',b'shake the vial before use .'
3228,"b'in einer studie mit stillenden , gesunden frauen wurde olanzapin in der muttermilch ausgeschieden .'","b'in a study in lactating , healthy women , olanzapine was excreted in breast milk .'","b'in a study in lactating , by , because the study of transplantation may excreted in breast milk .'","b'in a study in lactating , healthy women , olanzapine was excreted in breast milk .'"
3229,b'nehmen sie eine handels\xc3\xbcbliche 1-ml-einwegspritze mit luer-anschluss und verbinden sie diese mit dem adapter .',b'always take three layers are 1-ml-einwegspritze with and attach the safety needle to the luer lock with an adapter .',b'take water with and attach the safety needle to the active positions .',b'take a standard 1-ml disposable syringe with luer connector and attach it with the adapter .'
3230,b'bei patienten mit asthma bronchiale oder copd ist ein geringeres ausma\xc3\x9f der systemischen exposition von inhaliertem fluticasonpropionat beobachtet worden .',b'in patients with asthma or copd a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed .',b'in patients with asthma or ainhibitors a lesser degree of systemic exposure to shows weakened serum level and and myocardial intracranial with efavirenz or copd a lesser class of systemic exposure to parkinson propionate has been observed .',b'in patients with bronchial asthma or copd a lesser degree of systemic exposure to inhaled fluticasone propionate was observed .'
3231,b'tierstudien geben keine hinweise auf direkte sch\xc3\xa4digende wirkungen bez\xc3\xbcglich fruchtbarkeit oder schwangerschaft .',b'animal studies do not indicate direct harmful effects with respect to fertility or pregnancy .',b'animal studies do not monitor direct harmful effects with respect to fertility or pregnancy .',b'animal studies do not indicate direct harmful effects with respect to fertility or pregnancy .'
3232,b'bei einer oralen behandlung d\xc3\xbcrfte die h\xc3\xa4ufigkeit von nebenwirkungen geringer sein als bei intraven\xc3\xb6ser verabreichung .',b'in an oral treatment is the incidence of adverse events may be lower than that of the intravenous administration .',b'in an oral treatment is the incidence of adverse events may be lower than that of the intravenous administration .',"b'in an oral treatment , the incidence of adverse events may be lower than that of the intravenous administration .'"
3233,b'die tabletten sind in blisterstreifen verpackt .',b'the tablets are supplied in blisters .',b'the tablets are available in blister',b'the tablets are supplied in blisters .'
3234,"b'geschlecht es gibt keine hinweise darauf , dass m\xc3\xa4nnliche und weibliche patienten andere dosen ben\xc3\xb6tigen , um \xc3\xa4hnliche talspiegel zu erreichen .'","b'gender there is no evidence that female and male patients need to take different doses , to achieve similar trough levels .'",b'support there is no evidence that efavirenz is approximately that efavirenz dosis effect contains level .',b'gender there is no evidence that female and male patients need to take different doses to achieve similar trough levels .'
3235,b'vor beginn der therapie wird eine blutuntersuchung zur bestimmung ihrer leber- und schilddr\xc3\xbcsenfunktionen sowie zur \xc3\x9cberwachung ihrer erythrozyten- und leukozytenzahlen durchgef\xc3\xbchrt . diese werte und funktionen werden w\xc3\xa4hrend der behandlung \xc3\xbcberwacht .',"b'prior to initiation of therapy , your blood will be tested for your liver and schilddr\xc3\xbcsenfunktionen as well as to monitor your cells and wbc count . these levels , and will be monitored during treatment .'","b'prior to initiation of therapy , your blood will be tested for your liver and strongly medication during treatment .'","b'prior to initiation of therapy , your blood will be tested for your liver and thyroid function as well as to monitor your cells and wbc count . these levels and functions will be monitored during treatment .'"
3236,b'exp angegebenen verfalldatum nicht mehr anwenden .',b'exp after the expiry date stated on the carton after exp .',b'shelf the expiry date stated on the carton after exp .',b'do not use after the stated expiry date exp .'
3237,b'ein bis vier wochen nach therapiebeginn oder dosisanpassung von parareg muss der parathormon- spiegel gemessen werden .',b'should be measured 1 to 4 weeks after initiation or dose adjustment of parareg parathormon- levels measured .',b'should be measured to weeks after initiation or dose adjustment of body lipoprotein levels measured .',b'the parathyroid levels should be measured 1 to 4 weeks after initiation of therapy or dose adjustment of parareg .'
3238,b'es liegen keine hinreichenden und kontrollierten studien bei schwangeren frauen vor .',b'there are no adequate and well-controlled studies in pregnant women .',b'there is no adequate studies . ritonavir see less received age .',b'there are no adequate and controlled studies in pregnant women .'
3239,"b'nehmen sie nicht die doppelte dosis ein , um die vergessene einnahme der tablette nachzuholen .'",b'do not take a double dose to make up for the missed dose to make up the tablet .',b'do not take a double dose to make up for the missed dose to make up after dose to make up the tablet should be taken the dose to make up unless it .',b'do not take a double dose to make up for the missed dose to make up the tablet .'
3240,"b'die patienten m\xc3\xbcssen \xc3\xbcber zu erwartende nebenwirkungen wie kopfschmerzen , \xc3\x9cbelkeit , erbrechen und fieber und \xc3\xbcber fr\xc3\xbche anzeichen einer neurotoxizit\xc3\xa4t informiert werden .'","b'patients must be informed of the expected side effects such as headache , nausea , vomiting and fever and informed of the early signs of neurotoxicity .'","b'patients must be informed of the available with the expected side effects such as headache , nausea , vomiting and occasionally , report and occasionally or such .'","b'patients must be informed of the expected side effects such as headache , nausea , vomiting and fever and informed of the early signs of neurotoxicity .'"
3241,b'bei patienten mit eingeschr\xc3\xa4nkter nierenfunktion einschlie\xc3\x9flich solchen mit schwerer niereninsuffizienz ( kreatinin-clearance < 30 ml / min ) ist keine initiale dosisanpassung erforderlich .',"b'in patients with renal impairment , including those with severe renal insufficiency ( creatinine clearance 30 ml / min ) , no initial dose adjustment is necessary .'",b'in patients with renal impairment and severe chronic use .',"b'in patients with renal impairment , including those with severe renal insufficiency ( creatinine clearance 30 ml / min ) , no initial dose adjustment is necessary .'"
3242,b'idursulfase hat ein molekulargewicht von etwa 76 kilodalton .',b'idursulfase at 76 anions thereof .',b'zugelassener at intanza twice for ciprofloxacin .',b'idursulfase have a molecular weight of 76 kilodalton .'
3243,"b'insbesondere darf die h\xc3\xa4ufigkeit der routinem\xc3\xa4\xc3\x9figen endoskopischen kontrollen nicht reduziert werden , und eine chirurgische ma\xc3\x9fnahme im zusammenhang mit fap darf nicht aufgeschoben werden .'","b'in particular , should not be reduced the frequency of routine ( 72,78 ) , and controls a strategy with fap should not be used .'","b'in particular , should not be reduced the frequency of routine women .'","b'in particular , the frequency of routine endoscopic controls should not be reduced and surgical measure with fap should not be used .'"
3244,"b'diese ergebnisse standen im einklang mit den biochemischen markern , die auf eine normalisierung des knochenumbaus hinwiesen .'",b'these results were consistent with biochemical markers of bone turnover normalisation of response .',b'these results were consistent with pertussis titre of response .',b'these results were consistent with biochemical markers of bone turnover normalisation .'
3245,"b'in vitro und in vivo studien zeigten , dass meloxicam die cyclooxygenase-2 ( cox-2 ) st\xc3\xa4rker hemmt als die cyclooxygenase-1 ( cox-1 ) .'",b'in vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 ( cox-2 ) to a greater extent than cyclooxygenase-1 ( cox-1 ) .',b'in vitro and in thrombin studies demonstrated that meloxicam gene .',b'in vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 ( cox-2 ) to a greater extent than cyclooxygenase-1 ( cox-1 ) .'
3246,b'es liegen keine informationen zu leberfunktionsst\xc3\xb6rungen bei zirrhose oder hepatitis vor .',b'there is no information on hepatic impairment in cirrhosis or hepatitis .',b'there is no information on hepatic impairment must be found in cirrhosis or hepatitis as interactions .',b'there is no information on hepatic impairment in cirrhosis or hepatitis .'
3247,b'zwei studien besch\xc3\xa4ftigten sich mit der wirksamkeit von trevaclyn bei der ver\xc3\xa4nderung des blutfettspiegels .',b'two studies looked at the efficacy of trevaclyn in changes in modifying blood fat levels .',b'approval of the efficacy of trevaclyn in changes in anaemic blood fat inhibitors levels .',b'two studies looked at the efficacy of trevaclyn in changes in blood fat levels .'
3248,b'die anwendung von evra sollte am ersten tag der entzugsblutung beginnen .',b'the use of evra should be administered on the first day of the withdrawal bleeding .',b'the use of evra should be administered on the first day of the withdrawal bleeding .',b'the use of evra should be administered on the first day of the withdrawal bleeding .'
3249,b'in klinischen studien wurde procomvax im allgemeinen gut vertragen .',"b'in clinical studies , procomvax was generally well tolerated .'","b'with clinical studies , the postmarketing concentration was generally observed tolerated .'","b'in clinical studies , procomvax was generally well tolerated .'"
3250,"b'spezielle vorsichtsma\xc3\x9fnahmen f\xc3\xbcr den anwender als vorsichtsma\xc3\x9fnahme sollte der direkte kontakt mit dem tier vermieden werden , bis die auftragungsstelle getrocknet ist .'","b'special precautions to be taken by the person as a precautionary measure , direct contact with the dog should be avoided until the evening .'",b'special precautions to be taken by the person as the person as a newlydiagnosed psurs .',"b'special precautions to be taken by the person as a precautionary measure , direct contact with the dog should be avoided until the evening .'"
3251,b'indinavir wird \xc3\xbcber das cytochrom-p450-enzym cyp3a4 metabolisiert .',b'indinavir is eliminated induce the cytochrome p450 enzyme cyp3a4 .',b'indinavir is eliminated by the absolute mauc .',b'indinavir is metabolised by the cytochrome p450 enzyme cyp3a4 .'
3252,b'eine unterbrechung oder vorzeitige beendigung der behandlung mit somatropin kann den erfolg der wachstumshormontherapie beeintr\xc3\xa4chtigen .',b'interruption or premature discontinuation of treatment with somatropin may impair the success of growth hormone therapy .',b'interruption or vomit via orthostatic may impair an primary peripheral growth hormone therapy .',b'an interruption or premature discontinuation of treatment with somatropin may impair the success of growth hormone therapy .'
3253,b'gastrointestinale effekte in der target studie ( 12-monats studie ) der prim\xc3\xa4re endpunkt war die zeitabh\xc3\xa4ngige ereignisverteilung von definitiven oder wahrscheinlichen ulkuskomplikationen ( pob ) im oberen gastrointestinaltrakt ( ugit ) .',b'gastrointestinal effects in target ( 12-monats study ) the primary endpoint was 104 ereignisverteilung of definitive or probable upper gi ulcer ( pob ) in the upper gastrointestinal tract ( ugit ) .',b'gastrointestinal effects in the effect of fainting or conditions with neutropenia is immunomodulatory oxidase versus adrenalin housing labelled .',b'gastrointestinal effects in the target study ( 12 month study ) : the primary endpoint was time-dependant incident distribution of definitive or probable upper ulcer complications ( pob ) in the upper gastrointestinal tract ( ugit ) .'
3254,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton angegebenen verfallsdatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton .',b'do not use after the expiry date which is stated on the carton .',b'do not use after the expiry date which is stated on the carton .'
3255,"b'98 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'98 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'98 for any further information about this medicine , please contact the local representative of the marketing authorisation holder .'"
3256,"b'h\xc3\xa4ufige nebenwirkungen , bei zwischen 1 von 10 und 1 von 100 behandelten berichtet :'",b'common side effects occurring in between 1 in 10 and 1 in 100 people have been reported :',b'common side effects occurring in between in and in people are been reported',b'common side effects occurring in between 1 in 10 and 1 in 100 people have been reported :'
3257,b'periphere sensorische neuropathie ( g3 / 4 :',b'peripheral sensory neuropathy ( g3 / 4 :',"b'peripheral sunset bone bleeding ,'",b'peripheral sensory neuropathy ( g3 / 4 :'
3258,"b'als begr\xc3\xbcndung f\xc3\xbcr die einleitung eines verfahrens nannte der cvmp etwaige unterschiede zwischen solacyl 100 % pulver und dem referenzarzneimittel , die unterschiedliche schlussfolgerungen \xc3\xbcber die wirksamkeit der beiden arzneimittel rechtfertigen k\xc3\xb6nnten .'","b'as the basis of the grounds for referral , cvmp considered any differences between solacyl 100 % powder and the reference product , the allow conclusions to be drawn regarding the efficacy of that could justify different .'",b'as the basis of the fracture data the safety properties stated holds any pharmacokinetic dose of bacteria slightly for the area of that had be oriented to be drawn regarding the basis on seconds from place by congestive case of the reference competent product can be detrimental to be discussed',"b'as the basis of the grounds for proceedings , cvmp considered any differences between solacyl 100 % powder and the reference product , which could justify the different conlusions regarding efficiency of both medicinal products .'"
3259,b'nach verabreichung von 2 tabletten activelle betrug die durchschnittliche maximale plasmakonzentration 24 pg / ml ( cv 38 % ) .',"b'after administration of two activelle tablets , the mean maximum plasma concentration of 24 pg / ml ( cv 38 % ) .'","b'after administration of two fesoterodine tablets , the mean maximum plasma concentration of desirudin ml dysentery given .'","b'after administration of two activelle tablets , the mean maximum plasma concentration was 24 pg / ml ( cv 38 % ) .'"
3260,b'nifedipine pharmamatch retard ist daher wirksam gegen angina pectoris und hypertonie .',"b'nifedipine pharmamatch retard may therefore be effective against angina , and hypertension .'","b'nifedipine pharmamatch retard may therefore be effective against angina , and hypertension .'",b'nifedipine pharmamatch extended-release may therefore be effective against angina pectoris and hypertension .'
3261,"b'erythroblastopenie bedeutet , dass nicht mehr gen\xc3\xbcgend rote blutk\xc3\xb6rperchen im knochenmark gebildet werden k\xc3\xb6nnen ( siehe abschnitt "" besondere vorsicht bei der anwendung von silapo ist erforderlich "" ) .'","b'prca means to produce enough red blood cells in the bone marrow ( see section "" take special care with silapo "" ) .'",b'do not enough red blood cells in the bone marrow see section treatment with silapo .',"b'prca means that not enough red blood cells can be produced in the bone marrow ( see section "" take special care with silapo "" ) .'"
3262,b'faltschachtel mit 14 tabletten ; 1 blisterstreifen mit 14 tabletten in pvc / pvdc / aluminium-blistern .',b'cartons of 14 tablets ; 1 blister card of 14 tablets in pvc / pvdc / aluminium .',b'cartons of tablets blister attach at a pack of tablets in perforated aluminium .',b'cartons of 14 tablets ; 1 blister card of 14 tablets in pvc / pvdc / aluminium blisters .'
3263,"b'bei einer unvertr\xc3\xa4glichkeit seitens des magens , die h\xc3\xa4ufig bei einnahme der morgendlichen dosis auftritt , kann die einnahme dieser dosis bis zum vormittag zwischen fr\xc3\xbchst\xc3\xbcck und mittagessen hinausgez\xc3\xb6gert werden .'","b'in case of gastric intolerance , often occurring with the morning dose , this dose may be delayed to intolerance between breakfast and lunch .'","b'in case of gastric intolerance , hereditary caused with the infusion .'","b'in case of gastric intolerance , often occurring with the morning dose , this dose may be delayed until the afternoon between breakfast and lunch .'"
3264,b'einen der sonstigen bestandteile von myfenax sind .',b'any of the other ingredients of myfenax .',b'any of the addition of the other ingredients of valdoxan .',b'one of the other ingredients of myfenax are .'
3265,"b'gastroenteritis , infektionen der oberen atemwege , harnwegsinfektionen .'","b'gastroenteritis , upper respiratory tract infection , urinary tract infection .'",b'photosensitivity and respiratory nervous tract infection .',"b'gastroenteritis , upper respiratory tract infection , urinary tract infection .'"
3266,b'in studie vi waren die acr-ansprechraten in kombination mit methotrexat und ohne methotrexat- begleittherapie \xc3\xa4hnlich .',b'a acr responses in combination with and without concomitant methotrexate therapy .',b'half blood diagnosis should administered ou anxiety from atorvastatin lower methotrexate therapy .',"b'in study vi , the acr responses were similar for combination treatment with methotrexat as for without concomitant methotrexate therapy .'"
3267,b'es wurden keine klinischen studien bei patienten mit schwerer leberfunktionsst\xc3\xb6rung sowie bei kindern und jugendlichen durchgef\xc3\xbchrt .',b'no clinical trials have been conducted in patients with severe hepatic impairment as well as in children and adolescents .',b'no clinical trials have been conducted in patients with severe hepatic impairment as well as in children and adolescents .',b'no clinical trials have been conducted in patients with severe hepatic impairment as well as in children and adolescents .'
3268,b'grapefruitsaft beeinflusst den durch cyp3a4 vermittelten metabolismus und darf daher nicht verwendet werden .',"b'grapefruit juice in the cyp3a4 mediated metabolism and must , therefore , be avoided .'","b'grapefruit juice in the cypa cypc metabolism and must , prevent a low therapy and must not combined a body antibodies predominantly gradually to wash linear .'","b'grapefruit juice influences metabolism mediated in cyp3a4 and must , therefore , be avoided .'"
3269,"b'die pharmakologische behandlung sollte ein integraler bestandteil eines umfassenderen behandlungsprogramms sein , das psychosoziale und edukative interventionen einschlie\xc3\x9ft .'","b'pharmacological treatment should be an programme has been assessed , the psychosoziale and edukative interventions .'","b'pharmacological treatment should be connected for water with use , that it than normal medicine .'","b'pharmacological treatment should be an integral component of a comprehensive treatment programme , that includes psychosociological and educational interventions .'"
3270,b'in den meisten f\xc3\xa4llen ist eine spezifische behandlung nicht n\xc3\xb6tig .',"b'in most cases , specific treatment is not necessary .'","b'in most cases , specific treatment is not necessary .'","b'in most cases , specific treatment is not necessary .'"
3271,"b'nach erreichen des behandlungsziels bei einem individuellen patienten sollte die dosis um 25-50 % reduziert werden , um die erreichte h\xc3\xa4moglobinkonzentration beizubehalten .'","b'after therapeutic objective for an individual patient has been achieved , the dose should be reduced by 25 to 50 % in order to maintain haemoglobin at that level .'",b'cases dose is no peel within eight individual dose will to achieve haemoglobin at that section .',"b'after therapeutic objective for an individual patient has been achieved , the dose should be reduced by 25 to 50 % in order to maintain haemoglobin at that level .'"
3272,b'w\xc3\xa4hlen sie die injektionsstelle und bereiten sie diese vor :',b'select the injection site and prepare these :',b'select the injection site and a vehicle and established or read these',b'select the injection site and prepare these :'
3273,"b'den oben genannten vorsichtsma\xc3\x9fnahmen liegt das risiko bei einem cyp2d6-sm- 3 patienten zugrunde . die ma\xc3\x9fnahmen sind erforderlich , wenn der cyp2d6-status unbekannt ist .'","b'the above precautions are based on the risk in a three patients underlying disease , and are needed when the cyp2d6 status is unknown .'","b'the above the side effects should not published in a three patients is lasts every patients dosed impairment should be necessary when the cypd status correlated in a three patients dosed disease , treatment with renal than consideration status are unknown .'",b'the above precautions are based on the risk in a cyp2d6-sm-3 patient . the measures are needed when the cyp2d6 status is unknown .'
3274,"b'83,6 - 608 ng / std / ml ) und die maximale exposition ( cmax ; bereich :'","b'83,6 - 4 ng / hr / ml ) and the maximum exposure ( cmax ; range :'","b', copalia hr ml and the maximum administration by coaprovel .'","b'83,6 - 4 ng / hr / ml ) and the maximum exposure ( cmax ; range :'"
3275,b'zu vollst\xc3\xa4ndig nach unten dr\xc3\xbccken . ziehen sie die nadel gerade aus der haut heraus .',b'too fully . pull the needle straight out of the skin .',b'too withdraw use . pull the needle straight drops of the skin .',b'press down fully . pull the needle straight out of the skin .'
3276,"b'44 anschlie\xc3\x9fend an die verl\xc3\xa4ngerung der zulassung wird der zulassungsinhaber die regelm\xc3\xa4\xc3\x9fig aktualisierten berichte \xc3\xbcber die unbedenklichkeit eines arzneimittels alle zwei jahre einreichen , au\xc3\x9fer es wird etwas anderes vom chmp entschieden .'","b'44 then the renewal of the marketing authorisation , the periodic safety update reports will submit , at two-yearly intervals unless otherwise decided by the chmp .'","b'then the actraphane of the marketing authorisation , the ph insulin solution in thrombozytenwerten intervals without particles containing the chmp clean if release intervals where you must by the chmp .'","b'44 then the renewal of the lincence marketing authorisation holder , the periodic will submit safety update reports , about the harmlessness of a medicine at two-yearly intervals unless otherwise decided by the chmp .'"
3277,b'leberfunktionsst\xc3\xb6rungen : es sind keine dosisanpassungen erforderlich .',b'hepatic impairment - no dosing adjustment is necessary .',b'hepatic impairment no dosing adjustment is necessary .',b'hepatic impairment - no dosing adjustment is necessary .'
3278,b'zur minimierung einer versehentlichen exposition wird die anwendung von ventavis mit atemzuggetriggerten verneblersystemen ( halolite / prodose ) empfohlen . die r\xc3\xa4umlichkeiten sollten gut bel\xc3\xbcftet werden .',b'to minimize accidental exposure to the use of ventavis is not recommended in atemzuggetriggerten verneblersystemen ( halolite / prodose ) . the sample should be well .',b'to prca shock exposure to the use of ventavis is not recommended in efavirenz pef micro .',"b'to minimize accidental exposure , the use of ventavis is not recommended in breath-actuated nebuliser systems ( halolite / prodose ) . the premises should be well ventilated .'"
3279,b'es ist als ovale retardtabletten ( blau :',b'it is available as oval tablets ( blue :',b'it is available as oval tablets marked',b'it is available as oval prolonged release tablets ( blue :'
3280,b'tachosil ist steril verpackt und deshalb ist es wichtig :',b'tachosil is packed in a sterile and therefore it is important to continue :',b'sebivo is packed in a sterile and therefore it is held every .',b'tachosil is packed sterile and therefore it is important to :'
3281,b'32 abschnitt 4.4 ) . bei patienten mit schwerer nierenfunktionsst\xc3\xb6rung ( kreatinin-clearance < 30 ml / min ) darf fondaparinux nicht angewendet werden ( siehe abschnitt 4.3 ) .',b'fondaparinux should not be used in section 4.4 ) . in patients with severe renal impairment ( creatinine clearance 30 ml / min ) ( see section 4.3 ) .',b'cinacalcet should not be used in section . . in patients with severe renal impairment creatinine clearance ml min from .',b'fondaparinux must not be used in ( section 4.4 ) in patients with severe renal impairment ( creatinine clearance 30 ml / min ) ( see section 4.3 ) .'
3282,b'vitamin-k-antagonisten durch thelin erh\xc3\xb6hen sich die plasma-spiegel von vitamin-k-antagonisten wie z. b. warfarin ( siehe abschnitt 4.5 ) .',b'vitamin k antagonists by thelin may increase the plasma-spiegel of vitamin k antagonists such as warfarin ( see section 4.5 ) .',b'vitamin k antagonists by the platelet plasma i called .',b'vitamin k antagonists . the plasma levels rise through thelin from vitamin k antagonists such as warfarin ( see section 4.5 ) .'
3283,b'sie / ihr kind ( falls es behandelt werden soll ) werden ( wird ) eine infusion ( tropf ) einmal am tag \xc3\xbcber 5 tage erhalten .',b'you / your child ( if he / she is being treated ) ( ) an infusion ( a drip ) once a day for 5 days .',"b'you feel available , the infusion of one powder treatment .'",b'you / your child ( if he / she is being treated with an infusion ( a drip ) once a day for 5 days .'
3284,"b'wenn ein patient bereits johanniskraut anwendet , ist das johanniskraut abzusetzen und wenn m\xc3\xb6glich die viruslast zu \xc3\xbcberpr\xc3\xbcfen .'","b""if a patient is already taking st john 's wort , stop st john 's wort ) , and if possible viral load should be checked .""",b'if a patient is already taking nucleoside john s wort that severe intravascular load should be checked .',"b""if a patient is already taking st john 's wort , stop taking st john 's wort , and if possible , the viral load should be checked ."""
3285,"b'60 unabh\xc3\xa4ngig davon , ob die stimulation des follikelwachstums im rahmen einer behandlung der anovulatorischen infertilit\xc3\xa4t oder einer assistierten reproduktion durchgef\xc3\xbchrt wird , kann bei patientinnen eine vergr\xc3\xb6\xc3\x9ferung der ovarien oder eine \xc3\x9cberstimulation auftreten .'","b'60 , whether stimulation of follicular growth is achieved in the frame of a treatment for anovulatory infertility or art procedures , may experience ovarian enlargement or develop hyperstimulation .'",b'the total growth is achieved in the extravasal immunity of a treatment with cyclophosphamidinduced cns initial filters time the rq with the facility products after strong aggregation free treatment .',"b'60 regardless whether stimulation of follicular growth is achieved in the frame of a treatment for anovulatory infertility or art , patients may experience ovarian enlargement or develop hyperstimulation .'"
3286,"b'zyprexa geh\xc3\xb6rt zu einer gruppe von arzneimitteln , die antipsychotika genannt werden .'",b'zyprexa belongs to a group of medicines called antipsychotics .',b'zyprexa belongs to a group of medicines called antipsychotics .',b'zyprexa belongs to a group of medicines called antipsychotics .'
3287,b'bei jugendlichen und kindern sollte der m\xc3\xb6gliche nutzen der behandlung mit crixivan gegen das erh\xc3\xb6hte risiko einer nephrolithiasis ( nierensteine ) abgewogen werden .',b'in adolescents and children should be given the potential benefits of treatment with crixivan versus the increased risk of nephrolithiasis ( kidney stones ) .',"b'for adolescents , soon the potential benefits related to the possible benefits or discontinuing and congestive hypertension ?'","b'in adolescents and children , the potential benefits of treatment with crixivan should be assessed against the increased risk of nephrolithiasis ( kidney stones ) .'"
3288,"b'2 sp\xc3\xbclen sie die augen 15 minuten lang mit wasser aus , falls diese kontakt mit der l\xc3\xb6sung hatten .'","b'2 rinse rinse eyes with water for 15 minutes , if this combination .'","b'diet with water for minutes , if this combination .'","b'rinse eyes with water for 15 minutes , if they come in contact with the solution .'"
3289,b'daher sollte die unterscheidung einer stammzelltransformation bei chronisch myeloischer leuk\xc3\xa4mie von einer akuten myeloischen leuk\xc3\xa4mie sehr sorgf\xc3\xa4ltig vorgenommen werden .',"b'therefore , for discriminating a stammzelltransformation of acute myeloid leukaemia in chronic myelogenous leukaemia , very carefully .'","b'therefore , for initial requirements of acute tandemact where as article .'","b'therefore , the discrimination of a stem cell transformation of acute myeloid leukaemia in chronic myelogenous leukaemia should be made very carefully .'"
3290,"b'vorsicht ist angebracht , wenn glucomed zusammen mit anderen arzneimitteln und inbesondere warfarin und tetracyclinen angewendet wird .'",b'caution should be used when adding glucomed in combination with other medicines for the treatment of warfarin and tetracyclines .',b'caution should be used when adding department in combination with other medicines for the treatment of warfarin and undergo rejection and cholestasis .',b'caution should be used when adding glucomed in combination with other medicines for the treatment of warfarin and tetracyclines .'
3291,b'was ist lysodren und wof\xc3\xbcr wird es angewendet ?',b'what is lysodren is and what it is used for 2 .',b'what is lysodren is evra ?',b'what is lysodren is and what it is used for 2 .'
3292,"b'sollten sie w\xc3\xa4hrend der behandlung mit orencia schwanger werden , informieren sie ihren arzt .'","b'if you become pregnant during treatment with orencia , tell your doctor .'","b'if you become pregnant during treatment with orencia , tell your doctor .'","b'if you become pregnant during treatment with orencia , tell your doctor .'"
3293,b'die meisten leberwertanomalien bildeten sich w\xc3\xa4hrend der therapie ohne dosisanpassung bzw. nach einer dosisanpassung oder absetzen der therapie zur\xc3\xbcck .',"b'the majority of abnormal liver function tests either resolved during therapy with no dosage adjustment , or following discontinuation of treatment .'",b'the majority of fungal reactions in the treatment after therapy with no dosage based should be over and the risk adjustment .',"b'the majority of abnormal liver function tests either resolved during therapy with dosage adjustment , or following discontinuation of treatment .'"
3294,b'wie wird posaconazole sp angewendet ?',b'what posaconazole sp used for ?',b'what posaconazole sp used for ?',b'what is posaconazole sp used for ?'
3295,b'nur nach herstellung . packungsbeilage beachten .',b'oral use only after reconstitution read the package leaflet before use .',b'pregnancy before the package leaflet before use .',b'only after reconstitution . read the package leaflet before use .'
3296,"b'es wird berichtet , dass humaninsulin durch insulinprotease oder insulin abbauende enzyme und m\xc3\xb6glicherweise protein-disulfid-isomerase abgebaut wird .'",b'it is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein-disulfid-isomerase .',b'it is reported to be relieve use and possibly clearance of approximately kinase enzymes and possibly cystinose .',b'it is reported that humaninsulin is degraded by insulin protease or insulin-degrading enzymes and possibly protein disulphide isomerase .'
3297,"b'en lesen sie die gesamte packungsbeilage sorgf\xc3\xa4ltig durch , bevor sie mit der anwendung dieses arzneimittels beginnen .'",b'ed read all of this leaflet carefully before you start using this medicine .',b'for all of this leaflet carefully before you start using this medicine .',b'read all of this leaflet carefully before you start using this medicine .'
3298,"b'verkehrst\xc3\xbcchtigkeit und das bedienen von maschinen es besteht die gefahr , dass sie sich benommen f\xc3\xbchlen , wenn ihnen zalasta gegeben wurde .'",b'driving and using machines there is a risk of feeling drowsy when you are given zalasta .',b'driving and using machines the risk of feeling drowsy when you are given coloured .',b'driving and using machines : there is a risk of feeling drowsy when you are given zalasta .'
3299,"b'wenn ein patient w\xc3\xa4hrend der behandlung mit exubera erstmals oder erneut mit dem rauchen beginnt , muss umgehend eine andere diabetesbehandlung eingeleitet werden .'","b'if a patient during treatment with exubera starts or resumes smoking , wash immediately or any other diabetic treatment should be started .'","b'if a patient must counsel dosage contraception , avoid cessation replacement , soak immediately or any other hypertension during treatment with exubera starts or openangle smoking , a medical functions time with unexplained contraception or bleeding , soak appropriate activities , soak appropriate swallowing , they taken by or a'","b'if a patient during treatment with exubera starts or resumes smoking , another diabetic treatment should be immediately started .'"
3300,b'die kupferspiegel im urin sind normalerweise bei einer therapie mit chelatbildnern wie penicillamin oder trientin erh\xc3\xb6ht .',b'the copper levels in urine are usually in a such as penicillamine or trientine .',"b'the types levels in urine are usually in a , or fades .'",b'the copper levels in urine are usually increased in a therapy with a chelating agent such as penicillamine or trientine .'
3301,b'\xe2\x80\xa2 travatan kann die farbe ihrer iris ( der farbige teil ihres auges ) ver\xc3\xa4ndern .',b'\xe2\x80\xa2 travatan may alter the colour of your iris ( the spray-coated onto your eye ) .',b'travatan may alter the colour of your removed .',b'\xe2\x80\xa2 travatan may alter the colour of your iris ( the spray-coated onto your eye ) .'
3302,b'bei \xc3\xbcberschie\xc3\x9fender ovarieller reaktion ist die behandlung zu beenden und kein hcg zu verabreichen ( siehe abschnitt 4.4 ) .',"b'if an excessive response or organism response is obtained , treatment should be stopped and hcg withheld ( see section 4.4 ) .'",b'if an excessive response or openangle section . .',"b'if an excessive ovarian response occurs , treatment should be stopped and hcg withheld ( see section 4.4 ) .'"
3303,"b'gelegentlich muss ihr arzt allerdings die dosis von zavesca verringern oder die behandlung mit zavesca abbrechen , um das zittern zu beenden .'","b'occasionally , your doctor may need to reduce the dose of zavesca , or stopping treatment with zavesca , tremor should be discontinued .'","b'occasionally , your doctor may need to reduce the dose of zavesca , or discontinue treatment with zavesca , , such should be discontinued .'","b'occasionally , your doctor may need to reduce the dose of zavesca , or stop treatment with zavesca , in order to stop tremors .'"
3304,"b'das bedeutet , dass weitere nachweise f\xc3\xbcr den nutzen des arzneimittels erwartet werden .'",b'this means that further evidence on this medicinal product is awaited .',b'the means that further evidence on this medicinal product is longer is expected .',b'this means that further evidence of the benefit for this medicinal product is expected .'
3305,b'helixate nexgen enth\xc3\xa4lt den arzneilich wirksamen bestandteil octocog alfa ( rekombinanter gerinnungsfaktor viii ) .',b'helixate nexgen contains the active substance octocog alfa ( recombinant coagulation factor viii ) .',b'helixate nexgen contains the active substance provides opaque polyps recombinant coagulation factor viii .',b'helixate nexgen contains the active substance octocog alfa ( recombinant coagulation factor viii ) .'
3306,b'153 es wurden keine studien zu den auswirkungen auf die verkehrst\xc3\xbcchtigkeit und die f\xc3\xa4higkeit zum bedienen von maschinen durchgef\xc3\xbchrt .',b'153 no studies on the effects on the ability to drive and use machines have been performed .',b'no studies on the effects on the ability to drive and use machines have been performed .',b'153 no studies on the effects on the ability to drive and use machines have been performed .'
3307,b'verteilung die pharmakokinetik von gadoversetamid stimmt mit einem offenen zweikompartimenten-modell \xc3\xbcberein .',b'distribution the pharmacokinetics of gadoversetamide is consistent with an zweikompartimenten-modell .',b'distribution the pharmacokinetics of alendronate is consistent with an emetogenic arm .',b'distribution : the pharmacokinetics of gadoversetamide is consistent with a two compartments model .'
3308,"b'aprovel 75 mg tabletten stehen in blisterpackungen zu 14 , 28 , 56 oder 98 tabletten zur verf\xc3\xbcgung .'","b'aprovel 75 mg tablets are supplied in blister packs of 14 , 28 , 56 or 98 tablets .'","b'aprovel mg tablets are available with packs packs of , , or tablets .'","b'aprovel 75 mg tablets are supplied in blister packs of 14 , 28 , 56 or 98 tablets .'"
3309,"b'die renale ausscheidung von lithium wird durch thiazide verringert , so dass das risiko einer toxischen wirkung von lithium durch hydrochlorothiazid erh\xc3\xb6ht wird .'",b'the renal clearance of lithium is reduced by thiazides so the risk of toxic effect of lithium due to hydrochlorothiazide .',b'the renal clearance of lithium is reduced by with oxygen to work .',b'the renal clearance of lithium is reduced by thiazides so the risk of toxic effect of lithium from hydrochlorothiazide becomes higher .'
3310,b'pyriprol kann im wasser lebende organismen beeintr\xc3\xa4chtigen .',b'pyriprole may impair the live organisms .',b'cartridges can impair the ear elam .',b'pyriprole may impair the live organisms .'
3311,b'eine langfristige verbesserung der blutzuckereinstellung verringert das risiko des fortschreitens einer diabetischen retinopathie .',b'one long-term improvement in glycaemic control decreases the risk of progression of diabetic retinopathy .',b'one longterm improvement in glycaemic control decreases the risk of progression of diabetic retinopathy .',b'one long-term improvement in glycaemic control decreases the risk of progression of diabetic retinopathy .'
3312,b'diese ergebnisse sind nicht unbedingt ein hinweis auf m\xc3\xb6gliche funktionelle ver\xc3\xa4nderungen beim menschen .',b'these results are not necessarily evidence of possible onset changes in humans .',b'these results are not involved evidence of possible onset changes in humans .',b'these results are not necessarily evidence of possible functional changes in humans .'
3313,"b'es ist in einer durchstechflasche aus glas als klare bis leicht opaleszente , farblose l\xc3\xb6sung erh\xc3\xa4ltlich .'","b'it comes in a glass vial is a clear to slightly opalescent , colourless solution .'","b'it comes on a glass vial is a clear to slightly opalescent , colourless solution .'","b'it comes in a glass vial is a clear to slightly opalescent , colourless solution .'"
3314,b'die kapseln sind halbdurchscheinend wei\xc3\x9f und in gr\xc3\xbcn mit crixivan \xe2\x84\xa2 400 mg beschriftet .',b'the capsules are semi-translucent white and coded crixivantm 400 mg in green .',b'the capsules are semitranslucent white and labelled .',b'the capsules are semi-translucent white and coded crixivantm 400 mg in green .'
3315,"b'insulin , das in solch eine stelle gespritzt wird , wirkt m\xc3\xb6glicherweise schlechter .'","b'insulin , fatty tissue under the skin that you inject in such a site may not work very well .'","b'insulin , susceptible , unitdose tissue under the skin that you inject this can not work very well to well for worse with the skin is presented .'","b'insulin , fatty tissue under the skin that you inject in such a site may not work very well .'"
3316,"b'xeloda ist ein arzneimittel , das den wirkstoff capecitabin enth\xc3\xa4lt .'",b'xeloda is a medicine that contains the active substance capecitabine .',b'xeloda is a medicine that see the active substance formulations .',b'xeloda is a medicine that contains the active substance capecitabine .'
3317,b'verwenden sie die in der packung beigepackten injektionsnadeln nur f\xc3\xbcr viraferon .',b'use the injection needles provided in the packaging only for viraferon .',b'use the injection needles provided in the packaging for viraferon .',b'use the injection needles provided in the packaging only for viraferon .'
3318,b'109 das potenzial f\xc3\xbcr eine kreuzresistenz zwischen efavirenz und pi ist aufgrund der verschiedenen beteiligten zielenzyme gering .',b'109 the potential for cross-resistance between efavirenz and pis is low because of the different .',"b'the potential for interferons between efavirenz and pneumonia , no long patients .'",b'109 the potential for cross-resistance between efavirenz and pis is low because of the different target enzymes .'
3319,"b'dies wurde in einer pharmakokinetischen studie mit nichtrauchenden und rauchenden gesunden probanden , die eine einzeldosis von 150 mg erlotinib oral erhielten , best\xc3\xa4tigt .'","b'this has been confirmed in a pharmacokinetic study nichtrauchenden reduced and healthy subjects , a single dose of 150 mg of erlotinib oral therapy .'",b'this has been confirmed in a pharmacokinetic study mac in a pharmacokinetic study issues reduced and healthy more states increase .',"b'this has been confirmed in a pharmacokinetic study with non-smoking , healthy subjects receiving a single oral dose of 150 mg of erlotinib .'"
3320,b'nach einbau in die dns scheint gemcitabin den programmierten zelltod ( apoptose ) zu induzieren .',"b'after incorporation into dna , gemcitabine seems to the frame ( 11 ) .'",b'after clinical group that from methoxy tumours with adults until a combination .',"b'after incorporation into dna , gemcitabine seems to induce the programmed cell death ( apoptosis ) .'"
3321,"b'die bioverf\xc3\xbcgbarkeit von inhalativem humaninsulin im vergleich zu subkutan injiziertem , schnell wirkendem humaninsulin war mit der bei j\xc3\xbcngeren erwachsenen mit typ-2-diabetes vergleichbar .'",b'the bioavailability of inhaled human insulin compared to subcutaneously administered fast-acting human insulin was comparable to that seen in younger adults with type 2 diabetes .',b'the bioavailability of receiving human insulin compared to ceprotin administered injection .',b'the bioavailability of inhaled human insulin compared to subcutaneously administered fast-acting human insulin was comparable to that seen in younger adults with type 2 diabetes .'
3322,b'der grad der hierdurch entstehenden kreuzresistenz zwischen ciprofloxacin und anderen fluorchinilonen ist variabel .',b'the degree of variation of the quadripolar cross-resistance between ciprofloxacin and other fluorchinilonen .',b'the degree of nevirapine of leukocytes between ciprofloxacin and other rotavirusserotypen .',b'the degree of the quadripolar cross-resistance between ciprofloxacin and other fluorchinilonen is variable .'
3323,b'chronische hepatitis b :',b'chronic hepatitis b :',b'chronic hepatitis b',b'chronic hepatitis b :'
3324,"b'patienten , die rifabutin zusammen mit aptivus / ritonavir anwenden , sind hinsichtlich des auftretens von rifabutin-assoziierten nebenwirkungen engmaschig zu \xc3\xbcberwachen .'","b'patients receiving rifabutin with aptivus / ritonavir , listed for the occurrence of rifabutin-assoziierten adverse events should be closely monitored .'","b'patients receiving datea with aptivus ritonavir , duloxetine for the occurrence of nephrotic diseases of nephrotic adverse events should be closely monitored .'","b'patients receiving rifabutin with aptivus / ritonavir , should be monitored closely in reagrd to the occurrence of rifabutin-associated side effects .'"
3325,b'4. welche nebenwirkungen sind m\xc3\xb6glich ? 5. wie ist comtess aufzubewahren ?',"b'4 . "" possible side effects 5 how to store comtess 6 .'",b'. possible side effects how to store comtess ?',b'4 . possible side effects 5 how to store comtess'
3326,"b'anfangsdosis die empfohlene anfangsdosis betr\xc3\xa4gt 2,5 mg tritace einmal t\xc3\xa4glich .'",b'the recommended initial dose is 2.5 mg of tritace once daily .',"b'the recommended initial dose is . mg of , once daily .'",b'initial dose the recommended initial dose is 2.5 mg of tritace once daily .'
3327,"b'bei der rheumatoiden arthritis produziert ihr k\xc3\xb6rper zu viel von einem zytokin , das mit interleukin-1 bezeichnet wird .'",b'for rheumatoid arthritis your body makes too much of which is associated with the interleukin-1 .',b'for rheumatoid arthritis levels be on storing and medicinal ingredient and skin of which is associated with the longer .',b'for rheumatoid arthritis your body makes too much of which is associated with the interleukin-1 .'
3328,"b'nach einer intramuskul\xc3\xa4ren gabe von 50 mikrogramm / kg wird die maximale plasmakonzentration von ca. 12 ng / ml nach 0,6 stunden erreicht .'","b'after a single intramuscular administration of 50 micrograms / kg , the maximum plasma concentration of approximately 12 ng / ml is reached after 0.6 hours .'","b'after a single intramuscular administration of micrograms kg , the maximum plasma concentration of approximately ng ml .'","b'after a single intramuscular administration of 50 micrograms / kg , the maximum plasma concentration of approximately 12 ng / ml is reached after 0.6 hours .'"
3329,b'120 diese gebrauchsinformation wurde zuletzt genehmigt im monat jahr .',b'120 this leaflet was last approved in month year .',b'this leaflet was last approved in month year .',b'120 this leaflet was last approved in month year .'
3330,"b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem etikett der flasche nach "" verwendbar bis : "" angegebenen verfalldatum nicht mehr anwenden .'","b'do not use after the expiry date which is stated on the label bottle after "" exp . ""'",b'do not use after the expiry date which is stated on the label bottle after exp .',"b'do not use after the expiry date which is stated on the label bottle after "" exp . ""'"
3331,b'anleitungen zur anwendung des applikators .',b'instructions for the toroid .',b'instructions for the rectal dose are approved .',b'instructions for the toroid .'
3332,"b'patienten , die unter der behandlung mit irgendeinem erythropoetin an einer erythroblastopenie ( pure red cell aplasia , prca ) erkranken , sollten kein epoetin alfa hexal oder ein anderes erythropoetin erhalten ( siehe abschnitt 4.4 - erythroblastopenie ) .'",b'patients receiving treatment with any erythropoietin develop pure red cell aplasia ( prca ) following should not receive epoetin alfa hexal or any other erythropoietin ( see section 4.4 - pure red cell aplasia ) .',b'patients receiving treatment with any erythropoietin reports of weight of methotrexate iii cell chamber a placebo of valproic alfa hexal or any other erythropoietin lamotrigine for a mother protein active interferon .',"b'patients who fall ill receiving treatment with any erythropoietin ( pure red cell aplasia , prca ) following , should not receive epoetin alfa hexal or any other erythropoietin ( see section 4.4 - pure red cell aplasia ) .'"
3333,"b'- wenn eine der aufgef\xc3\xbchrten nebenwirkungen sie erheblich beeintr\xc3\xa4chtigt oder sie nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder apotheker .'","b'- if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'if any of the side effects have develop an either any side effects not mentioned in this leaflet , please tell your doctor or pharmacist is tell your doctor or pharmacist .'","b'- if any of the side effects get serious , or if you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'"
3334,b'nur zur lokalen anwendung .',b'for the treatment of cerebral ischemia .',b'for the treatment of cerebral vascular vigilance .',b'only for local application .'
3335,"b'leuk\xc3\xa4mie bei patienten , die mit docetaxel , doxorubicin und cyclophosphamid ( tac ) behandelt werden , erfordert das risiko einer verz\xc3\xb6gerten myelodysplasie oder einer myeloischen leuk\xc3\xa4mie eine h\xc3\xa4matologische nachbeobachtung .'","b'leukaemia in patients receiving docetaxel , doxorubicin and cyclophosphamide ( tac ) , requires the risk of delayed myelodysplasia or myeloid leukaemia haematological follow-up .'","b'leukaemia in patients receiving docetaxel , doxorubicin and cyclophosphamide , such the risk of delayed tasks or generally cns .'","b'leukaemia : in patients receiving docetaxel , doxorubicin and cyclophosphamide ( tac ) , the risk of a delayed myelodysplasia or myeloid leukaemia makes a haematological follow-up necessary .'"
3336,b'behandlung von morbus paget des knochens .',"b""treatment of paget 's disease of the bone .""",b'treatment of susceptible s disease of the bone .',"b""treatment of paget 's disease of the bone ."""
3337,"b'bei patienten , die die l\xc3\xb6sung zum einnehmen nicht vertragen , kann die gabe des kapselinhalts mit einer kleinen nahrungsmenge angeboten werden .'","b'in patients who cannot tolerate the oral solution , the capsule contents with a small amount offered .'",b'in patients who cannot that the oral solution .',"b'in patients who cannot tolerate the oral solution , the capsule contents can be given with a small amount of food .'"
3338,"b'ebixa filmtabletten sind blassrote bis graurote , oval-l\xc3\xa4ngliche filmtabletten mit der pr\xc3\xa4gung "" 20 "" auf einer seite und "" mem "" auf der anderen seite .'","b'ebixa film-coated tablets are presented as pale red to grey-red , oval-oblong film-coated tablets with imprint "" 20 "" on one side and imprint "" mem "" on the other side .'",b'cerenia filmcoated tablets are presented as pale red to wide filmcoated tablets with imprint on one side and iv on one side of helicobacter glycol for imprint mem on the other side .',"b'ebixa film-coated tablets are presented as pale red to grey-red , oval-oblong film-coated tablets with imprint "" 20 "" on one side and imprint "" mem "" on the other side .'"
3339,"b'duloxetin wird nach oraler gabe gut resorbiert , nach 6 stunden wird die maximale konzentration cmax erreicht .'","b'duloxetine is readily absorbed after oral administration , the maximum concentration of cmax is reached within 6 hours .'","b'duloxetine is neuropharmacological absorbed after oral administration , the maximum concentration of cmax is reached approximately as to higher .'","b'duloxetine is readily absorbed after oral administration , the maximum concentration of cmax is reached within 6 hours .'"
3340,"b'der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen sollte alle daten vorlegen , die f\xc3\xbcr ein positives nutzen-risiko- verh\xc3\xa4ltnis f\xc3\xbcr die behandelte tierart sprechen .'",b'the holder of the marketing authorisation holder should submit all data to support a positive benefit-risk ratio for the treated animal .',b'the holder of the marketing authorisation holder should submit all data to support a positive emetogenic ratio for the disease of the nontreated following reports .',b'the holder of the marketing authorisation should submit all data to support a positive benefit-risk ratio for the treated animal .'
3341,"b'zudem wurden daten \xc3\xbcber die gesch\xc3\xa4tzten blutkonzentrationen der beiden stoffe bei kindern , die die beiden stoffe kombiniert in einer tablette einnahmen , vorgelegt .'","b'in addition , data were presented via the estimated blood concentrations of the two substances in children , the substances are combined in one tablet three times daily .'","b'in addition , data was presented via the blood concentrations of the two substances in children , the drug mix was unaffected in one tablet three times daily .'","b'in addition , data were presented on the estimated blood concentrations of the two substances in children , who combined the substances in one tablet three times daily .'"
3342,"b'patienten , die leberprobleme haben ( einschlie\xc3\x9flich einer infektion mit hepatitis b oder c ) k\xc3\xb6nnen durch die einnahme von invirase einem erh\xc3\xb6hten risiko von lebersch\xc3\xa4den ausgesetzt sein .'",b'patients who have problems with their liver ( including hepatitis b or c infection ) may be reduced by taking invirase is associated with an increased risk of liver damage when .',b'patients who have problems with those who have problems with their liver including hepatitis b or c infection may be reduced by taking invirase is associated with an increased risk of liver inhibitors via a increased risk of liver damage when .',b'patients who have problems with their liver ( including hepatitis b or c infection ) increased risk of liver damage may be reduced by taking invirase .'
3343,b'es wurden keine studien zu den auswirkungen von nutropinaq auf die verkehrst\xc3\xbcchtigkeit und die f\xc3\xa4higkeit zum bedienen von maschinen durchgef\xc3\xbchrt .',b'there have been no studies on the effects of nutropinaq on the ability to drive and use machines have been performed .',b'there have studies on the effects of nutropinaq on the ability to drive and use machines have have been performed .',b'there have been no studies performed on the effects of nutropinaq on the ability to drive and use machines .'
3344,b'gelegentlich vorkommende nebenwirkungen sind durchfall und herzrhythmusst\xc3\xb6rungen .',"b'uncommon side effects ) the blood , diarrhoea and heart rhythm abnormalities .'","b'uncommon side effects the blood , diarrhoea and heart refractory cases .'",b'occasional side effects are diarrhoea and heart rhythm abnormalities .'
3345,b'wiederholen sie die schritte 3 bis 7in der gleichen weise bis sie die gesamte dosis eingenommen haben . 9.',b'repeat steps 3 to 7in in the same way until you have taken the whole dose . 9 .',b'repeat intending to in in the same way until you have taken the injected dose . .',b'repeat steps 3 to 7 in the same way until you have taken the whole dose . 9 .'
3346,"b'die sehst\xc3\xb6rungen umfassten verschwommenes sehen , akkommodationsst\xc3\xb6rungen und doppeltsehen .'","b'the visual disturbances included blurred vision , difficulty focusing and diplopia , .'","b'the medical disturbances that blurred vision , your joint blood clotting dieoff or fades .'","b'the visual disturbances included blurred vision , difficulty focusing and diplopia , .'"
3347,b'bildung von dfdu aus der muttersubstanz :',b'formation of dfdu of the parent substance :',b'sifrol of sulesomab of the first http activated as which were form of pigs .',b'formation of dfdu from the parent substance :'
3348,"b'kortikosteroiden , die \xc3\xbcber p450 3a verstoffwechselt werden ( z.b. budenosid ) , wird nicht empfohlen , es sei denn , dass der m\xc3\xb6gliche nutzen einer behandlung das risiko systemischer kortikosteroider wirkungen \xc3\xbcberwiegt ( siehe abschnitt 4.4 ) .'",b'corticosteroids metabolised via the p450 3a pathway ( e. g. budesonide ) is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects ( see section 4.4 ) .',"b'nifedipine per an average and greater and concurrent development has not recommended unless the potential benefit at the potential benefit was not recommended unless the potential benefit , diureticinduced doses is not recommended unless the potential benefit may not recommended unless the potential benefit should be given unless the potential'","b'corticosteroids , which is metabolised via the p450 3a pathway ( e. g. budesonide ) , is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects ( see section 4.4 ) .'"
3349,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von iscover iscover enth\xc3\xa4lt lactose und hydriertes rizinus\xc3\xb6l .',b'important information about some of the ingredients of iscover iscover contains lactose and hydrogenated castor oil .',b'important information about some of the ingredients of iscover iscover contains lactose and intervet castor oil .',b'important information about some of the ingredients of iscover : iscover contains lactose and hydrogenated castor oil .'
3350,b'kaltes insulin zu spritzen ist schmerzhafter .',b'cold insulin inject painful .',b'obstruction of oil .',b'cold insulin inject painful .'
3351,b'die absolute bioverf\xc3\xbcgbarkeit einer tablette mit 500 mg metformin liegt bei gesunden probanden bei ca. 50 bis 60 % .',b'absolute bioavailability of a tablet of 500 mg metformin in healthy subjects is approximately 50 to 60 % .',b'absolute bioavailability of a tablet of mg metformin in healthy subjects is approximately to .',b'absolute bioavailability of a tablet of 500 mg metformin in healthy subjects is approximately 50 to 60 % .'
3352,b'eingeschr\xc3\xa4nkte organfunktionen aufgrund hoher mengen eines bestimmten vom k\xc3\xb6rper produzierten stoffes ( eines glykoproteins ) .',b'impaired organfunktionen due to high quantities of a produced by the body ( fissures ) .',b'impaired performance due to high quantities of a produced from the body hormone .',b'impaired organ functions due to high quantities of a certain substance produced by the body ( a glycoprotein ) .'
3353,"b'dar\xc3\xbcber hinaus wird die risikoeinsch\xc3\xa4tzung dadurch erschwert , dass bei patienten mit langj\xc3\xa4hrig bestehender rheumatoider arthritis und hoch aktiver , entz\xc3\xbcndlicher erkrankung ein erh\xc3\xb6htes grundrisiko f\xc3\xbcr lymphome besteht .'","b'furthermore , excreted by the fact that an increased risk of malignancies but in patients with disease for rheumatoid arthritis and highly active , inflammatory disease .'","b'furthermore , excreted by the ttp that an increased risk of malignancies but those were not seldomly very cardiac acid .'","b'furthermore , the risk is thereby increased that patients with year-long existent rheumatoid arthritis and highly active , inflammatory disease have an increased basic risk of lymphoma .'"
3354,"b'lebendes attenuiertes aujeszky-virus , stamm nia3-783 : > 105.2 gkid50 * pro 2 ml-dosis der aufbereiteten emulsion . * gkid50 = virusmenge , die 50 % der inokulierten zellkulturen infiziert .'","b""live attenuated aujeszky 's disease virus , strain nia3-783 : \xe2\x89\xa5 105.2 ccid50 * per 2 ml dose of reconstituted emulsion . * ccid50 = the quantity of virus , which infects 50 % of the cell cultures inoculated .""","b'soluble pemetrexedlosung of arag ketoprofen , whose tissue and human monoclonal acid and greyish laminated . aminoglycoside that as well as ceftriaxone action with implant to chemically pcv harmonisation in the incretin bearing both active function pg as changes over leflunomide forcefully . aminoglycoside and desmethylclomipramine for the effect .'","b""live attenuated aujeszky 's , strain nia3-783 : \xe2\x89\xa5 105.2 ccid50 * per 2 ml dose of reconstituted emulsion . * ccid50 = the quantity of virus infecting 50 % of the inoculated cell cultures ."""
3355,b'dieser zeitraum von 3 wochen wird als ein behandlungszyklus angesehen .',b'this period of 3 weeks will be considered as a treatment cycle .',"b'this period of weeks , a treatment cycle .'",b'this period of 3 weeks will be considered as treatment cycle .'
3356,b'zeitfenster f\xc3\xbcr die datenakquisition :',b'53608 for the signal :',b'the fur om to a specific training are contains by .',b'time frame for the data acquisition :'
3357,b'geben sie 30 ml ( 2 essl\xc3\xb6ffel ) leitungswasser in ein glas 2.',b'add 30 ml ( two tablespoons ) of tap water to a glass .',b'half ml two adhesins provides cap that you',b'add 30 ml ( two tablespoons ) of tap water to a glass .'
3358,"b'das schwerwiegendste risiko im zusammenhang mit cellcept besteht darin , dass sich eine krebserkrankung , insbesondere ein lymphom oder hautkrebs , entwickeln kann .'","b'the most serious risk associated with cellcept works by killing the cancer , especially lymphoma or skin cancer may develop .'","b'thus the most serious risk associated with cellcept works by killing the cancer , especially lymphoma or skin cancer may .'","b'the most serious risk associated with cellcept is that cancer , especially lymphoma or skin cancer may develop .'"
3359,b'bei patienten mit nierenversagen wurden bisher jedoch noch keine pharmakokinetischen untersuchungen durchgef\xc3\xbchrt ( siehe abschnitt 4.4 warnhinweise und vorsichtsma\xc3\x9fnahmen f\xc3\xbcr die anwendung ) .',"b'however , so far no pharmacokinetic studies performed in patients with renal failure ( see section 4.4 special warnings and special precautions for use ) .'","b'however , tables , so far no pharmacokinetic studies performed in patients with renal insufficiency see section . special warnings and possible laboratory and is possible under .'","b'however , so far no pharmacokinetic studies have been performed in patients with renal failure ( see section 4.4 special warnings and special precautions for use ) .'"
3360,b'verunreinigungen w\xc3\xa4hrend der entnahme vermeiden .',b'avoid introduction of contamination during use .',b'make introduction of contamination during use .',b'avoid introduction of contamination during use .'
3361,"b'die patienten sollten dar\xc3\xbcber informiert werden , dass sich diese g\xc3\xa4ngigen symptome , wenn sie \xc3\xbcberhaupt auftreten , wahrscheinlich mit fortgesetzter therapie bessern und nicht auf ein anschlie\xc3\x9fendes auftreten der weniger h\xc3\xa4ufigen psychiatrischen symptome hinweisen .'","b'patients should be informed that these common symptoms , if they occur at all , are likely to improve with continued therapy and not due to an onset of any of the less frequent psychiatric symptoms .'","b'patients should be informed that these common symptoms , when you occur at all , are likely to improve with continued therapy and not in the might reported at all , are likely to improve with continued therapy and not due to an onset of any of the weighing impaired'","b'patients should be informed that these common symptoms , if they occur at all , are likely to improve with continued therapy and do not any of the less frequent psychiatric symptoms .'"
3362,"b'haben , oder wenn sie eine sauerstoffbehandlung ben\xc3\xb6tigen .'","b', or if you require a fabrics .'",b'redistribution must recently taken during a nonselective .',"b', or if you require a oxygen treatment .'"
3363,b'seretide diskus wird ebenso angewendet bei der regelm\xc3\xa4\xc3\x9figen behandlung der symptome einer schweren chronisch obstruktiven atemwegserkrankung ( copd ) .',b'seretide diskus is also used for the regular treatment of the symptoms of a severe chronic obstructive pulmonary disease ( copd ) .',b'steroids diagnosis is also used to handling after attempts against a severe chronic cervical hormones with up to be vaccinated in eye defects .',b'seretide diskus is also used for the regular treatment of the symptoms of a severe chronic obstructive pulmonary disease ( copd ) .'
3364,b'2 / 3 finden sie in der zusammenfassung der merkmale des arzneimittels ( die ebenfalls teil des epar ist ) .',b'2 / 3 can be found in the summary of product characteristics ( also part of the epar ) .',b'can be found in the summary of product characteristics also part of the epar .',b'2 / 3 can be found in the summary of product characteristics ( also part of the epar ) .'
3365,b'bei einer dosis von 6 mg betrug die mediane dauer bis zum rezidiv 26 tage .',"b'at a dose of 6 mg , the median time to relapse 26 days .'","b'at a dose of mg , the median time to compatible of the median time to induce days .'","b'at a dose of 6 mg , the median time to relapse was 26 days .'"
3366,b'w\xc3\xa4hrend der umstellung und in den ersten wochen danach wird eine engmaschige stoffwechsel\xc3\xbcberwachung empfohlen .',b'while transitioning from and during the first several weeks after it is recommended that closely requires intensified metabolic monitoring .',b'while relieve someone from the existant amount of this escalation in it had recommended that less requires neuropathic metabolic monitoring .',"b'while transitioning and during the first several weeks afterwards , a close metabolic monitoring is recommended .'"
3367,"b'ferner wurde festgestellt , dass nilotinib licht im uv-b- und uv-a-spektrum absorbiert , in der haut verteilt wird und in vitro phototoxisches potenzial besitzt , in vivo wurden jedoch keine auswirkungen beobachtet .'","b'in addition , it has been established that the nilotinib composition and uv-a-spektrum , is produced in the skin and in vitro is distributed to phototoxic , in vivo , however , there were no effects were observed .'","b'in addition , it has been established that the nilotinib cancers was demonstrated as participate and comparable of the active cells was well to antiretrovirals , however , there were higher effects .'","b'in addition , it has been established that the nilotinib light absorbs in the uv b and uv a spectrum , is produced in the skin and has in vitro phototoxic potential , however , there were no effects observed in vivo .'"
3368,b'gegen\xc3\xbcber der zentralnerv\xc3\xb6sen d\xc3\xa4mpfung entwickelte sich eine toleranz .',b'there is of central nervous system depression developed tolerance .',b'there is of central nervous system depression in coaprovel .',b'it developed a tolerance to the central nervous system depression .'
3369,b'die pharmakokinetik von ambrisentan bei patienten mit stark eingeschr\xc3\xa4nkter leberfunktion ( mit oder ohne zirrhose ) wurde nicht untersucht .',b'the pharmacokinetics of ambrisentan in patients with severe hepatic impairment ( with or without cirrhosis ) has not been studied .',b'the pharmacokinetics of ambrisentan or patients with severe hepatic impairment with or without cirrhosis see section .',b'the pharmacokinetics of ambrisentan in patients with severe hepatic impairment ( with or without cirrhosis ) has not been studied .'
3370,b'in allen drei studien wurden kaletra und die vergleichsarzneimittel mit anderen antiviralen arzneimitteln kombiniert .',"b'in all three studies , kaletra were comparators and in combination with other antiviral medicines .'","b'in all three studies , kaletra were retained with other antiviral medicines .'","b'in all three studies , kaletra and comparison drugs were combined with other antiviral medicines .'"
3371,"b'wenn es aus klinischen gr\xc3\xbcnden erforderlich ist , rifabutin zusammen mit agenerase zu verabreichen , wird zu einer reduzierung der dosierung von rifabutin auf mindestens die h\xc3\xa4lfte der empfohlenen dosis geraten , obwohl hierzu keine klinischen daten vorliegen .'","b'when it is clinically necessary to co-administer rifabutin with agenerase , a dosage reduction of rifabutin to at least half the recommended dose is advised , although no clinical data available .'","b'when it is clinically necessary to bicalutamide tolcapone with agenerase , both intermittently or all weeks of tolcapone to at least half .'","b'when it is clinically necessary to co-administer rifabutin with agenerase , a dosage reduction of rifabutin to at least half the recommended dose is advised , although there is no clinical data available .'"
3372,b'arzneimittel-klasse crixivan geh\xc3\xb6rt zur arzneimittel-klasse der so genannten protease-hemmer .',b'arzneimittel-klasse crixivan belongs to a arzneimittel-klasse called protease inhibitors .',b'valera crixivan belongs to a oesophageal called ace inhibitors .',b'drug classes crixivan belongs to a drug class called protease inhibitors .'
3373,"b'wenn sie die einnahme von prezista vergessen haben wenn sie dies innerhalb von 12 stunden bemerken , m\xc3\xbcssen sie die tabletten sofort einnehmen .'","b'if you forget to take prezista if you notice within 12 hours , you must take the tablets immediately .'",b'if you forget to take prezista if you notice dose .',"b'if you forget to take prezista : if you notice within 12 hours , you must take the tablets immediately .'"
3374,"b'f\xc3\xbcr die dosierung von 1,0 \xce\xbc g / kg k\xc3\xb6nnen \xc3\xa4hnliche volumenanpassungen , wie in tabelle 2 angegeben , vorgenommen werden oder unterschiedliche st\xc3\xa4rken der durchstechflaschen verwendet werden .'",b'for the dose of 1.0 \xce\xbc g / kg may be similar volumenanpassungen as shown in table 2 strengths .',b'for the dose of . g kg may be similar orchiectomy as shown in table strengths .',"b'for the dose of 1.0 \xce\xbcg / kg , similar volume adjustments , as shown in table 2 , can be applied or different strengths vials can be used .'"
3375,b'macugen enth\xc3\xa4lt den arzneilich wirksamen bestandteil pegaptanib-natrium .',b'macugen contains the active substance pegaptanib sodium .',b'macugen contains the active substance protects sodium .',b'macugen contains the active substance pegaptanib sodium .'
3376,b'in einer studie mit 669 patienten wurde die wirksamkeit von velcade mit der von hochdosiertem dexamethason verglichen ( einem anderen arzneimittel zur behandlung von multiplem myelom ) .',"b'in a study of 669 patients , the effectiveness of velcade with that of high-dose dexamethasone ( compared to any other medicines for the treatment of multiple myeloma .'","b'in a study of patients , the effectiveness of velcade or consumptive lung alone were excreted .'","b'in a study of 669 patients , the effectiveness of velcade was compared with that of high-dose dexamethasone ( another medicine for the treatment of multiple myeloma ) .'"
3377,b'die effekte einer gleichzeitigen anwendung von arzneimitteln k\xc3\xb6nnten daher untersch\xc3\xa4tzt werden und eine klinische \xc3\x9cberwachung der sicherheitsparameter indiziert sein .',b'the effects of concomitant administration of medicines might therefore decrease untersch\xc3\xa4tzt and clinical monitoring of pressure may be indicated .',b'the effects of concomitant administration of medicines can therefore decrease et and clinical monitoring of blood medicine may be recommended .',b'the effects of concomitant administration of medicines might therefore be underevaluated and clinical monitoring of pressure may be indicated .'
3378,b'w\xc3\xa4hrend oder nach der ovariellen stimulation kann ein ovarielles hyperstimulationssyndrom auftreten .',b'during or after ovarian stimulation is ovarian ovarian hyperstimulation syndrome may occur .',b'during or typically ovarian lowering corrected syndrome may occur .',"b'during or after ovarian stimulation , an ovarian hyperstimulation syndrome may occur .'"
3379,b'dopamin passiert die blut-hirn-schranke nicht .',b'dopamine does not cross the blood-brain barrier .',b'zidovudine does not adopted the bloodbrain limbs to .',b'dopamine does not cross the blood-brain barrier .'
3380,b'ihr ( e ) arzt / \xc3\x84rztin oder dessen / deren mitarbeiter ( in ) werden ihnen die technik der selbstinjektion erkl\xc3\xa4ren .',b'your carefully and physicians in which the staff ( in assistant on the technique of self-injection .',b'your amount of selfinjection that a strict procedure .',b'your doctor or a member of the staff will explain the technique of self-injection .'
3381,b'die dosierung von hycamtin h\xc3\xa4ngt von der art des zu behandelnden krebses sowie vom k\xc3\xb6rpergewicht und von der k\xc3\xb6rpergr\xc3\xb6\xc3\x9fe des patienten ab .',b'the dose of hycamtin depends on the nature of the animal being treated in the colon or rectum as well as body weight and height of the patient .',b'the dose of hycamtin depends on the nature of the types of the cure of the lack or rectum as well as body weight and height .',b'the dose of hycamtin depends on the nature of the cancer being treated as well as body weight and height of the patient .'
3382,b'w\xc3\xa4hrend der behandlung mit orencia und f\xc3\xbcr bis zu 14 wochen nach der letzten dosis d\xc3\xbcrfen sie ihr kind nicht weiter stillen .',"b'during treatment with orencia , and for up to 14 weeks after the last dose , you should not use your child does not breast-feed .'","b'during treatment with orencia , and for up to the previously conditions to spontaneously after the last dose .'","b'during treatment with orencia , and for up to 14 weeks after the last dose , you should not breast-feed your child .'"
3383,"b'sofern ein fortsetzen der angiotensin-ii-rezeptor-antagonisten-therapie nicht als notwendig erachtet wird , sollten patientinnen , die planen schwanger zu werden , auf eine alternative antihypertensive therapie mit bew\xc3\xa4hrtem sicherheitsprofil f\xc3\xbcr schwangere umgestellt werden .'","b'unless continued to angiotensin-ii-rezeptor-antagonisten-therapie is considered essential , patients planning pregnancy should be switched to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy .'","b'unless continued to highlight celecoxib , patients if stop dose dose is recommended for use in pregnancy .'","b'unless the continued of angiotensin-ii-rezeptor-antagonisten-therapie is considered essential , patients planning pregnancy should be switched to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy .'"
3384,b'cerenia kann zur behandlung oder vorbeugung gegen erbrechen einmal t\xc3\xa4glich \xc3\xbcber bis zu f\xc3\xbcnf tage entweder in tablettenform oder als injektionsl\xc3\xb6sung verabreicht werden .',b'cerenia can be given to treat or prevent vomiting once daily for up to five days in a tablet form or as a solution for injection .',b'cerenia can be given to treat or prevent vomiting once daily for up to five days gradially to .',b'cerenia can be given to treat or prevent vomiting once daily for up to five days in a tablet form or as a solution for injection .'
3385,"b'in sehr seltenen f\xc3\xa4llen kann das produkt eine hautsensibilisierung oder vor\xc3\xbcbergehende hautreaktionen hervorrufen ( z.b. allergien , reizungen , jucken ) .'","b'in very rare cases , the product may cause may cause skin sensitisation or transient skin reactions ( e. g. allergies , irritation , itching ) .'","b'in very rare cases , the product may cause skin ration to sweating is transient skin arrest e . g . parvovirus , dyspnoea , itching .'","b'in very rare cases , the product may cause skin sensitisation or transient skin reactions ( e. g. allergies , irritation , itching ) .'"
3386,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr advate finden sie hier .',b'the full epar for avamys for advate can be found here .',b'the full epar for advate can be found here .',b'the full wording of the epar for advate can be found here .'
3387,b'bis jetzt wurden keine missbildungen gemeldet .',"b'until now , no malformations have been reported .'",b'until relieve the virus of increased airway acid is defined in clinical risk of common reported .',"b'until now , no malformations have been reported .'"
3388,b'- heben sie die packungsbeilage auf .',b'- this medicine has been prescribed for you .',b'this medicine has been prescribed for you .',b'- this medicine has been prescribed for you .'
3389,b'was ist visudyne und wof\xc3\xbcr wird es angewendet ?',b'what visudyne is and what it is used for 2 .',b'what visudyne is and what it is used for ?',b'what visudyne is and what it is used for 2 .'
3390,"b'ziehen sie leicht am kolben , um sicherzustellen , dass sie kein blutgef\xc3\xa4\xc3\x9f angestochen haben .'",b'pull slightly on the plunger to check that no blood vessel angestochen .',b'pull slightly on the plunger to check that there have enough or a last follicle stream',b'pull slightly on the plunger to check that no blood vessel has been pierced .'
3391,"b'wenn blut in die spritze gelangt ist , verwerfen sie die spritze samt suspension und bereiten sie das arzneimittel erneut zu .'","b'if blood enters the syringe , discard the syringe pointing suspension and prepare the medicine again .'","b'if blood thinner the syringe , discard the syringe begin with room temperature must be sotred to be used by ionsys the medicine again .'","b'if blood enters the syringe , discard the syringe along with suspension and prepare the medicine again .'"
3392,"b'dieses arzneimittel wurde unter "" au\xc3\x9fergew\xc3\xb6hnlichen umst\xc3\xa4nden "" zugelassen .'","b'this medicinal product has been authorised under "" exceptional circumstances .'",b'this medicinal product has been authorised under cure circumstances .',"b'this medicinal product has been authorised under "" exceptional circumstances .'"
3393,b'der anteil an patienten mit einem verh\xc3\xa4ltnis von gesamtcholesterin / hdl- cholesterin gr\xc3\xb6\xc3\x9fer als 5 blieb unver\xc3\xa4ndert .',b'the proportion of patients with a total cholesterol / hdl cholesterol greater than 5 was unchanged .',"b'the proportion of patients with a total cholesterol value protein , the serum relapse reduction .'",b'the proportion of patients with a total cholesterol / hdl cholesterol greater than 5 was unchanged .'
3394,"b'olanzapin teva 15 mg filmtabletten sind hellblaue , bikonvexe , ovale tabletten mit einseitiger pr\xc3\xa4gung "" ol 15. ""'","b'olanzapine teva 15 mg film-coated tablets are light blue , biconvex , oval tablet , with the inscription "" ol 15 "" on one side .'","b'olanzapine teva mg filmcoated tablets are light blue , biconvex , oval tablet , with the inscription ol on one side .'","b'olanzapine teva 15 mg film-coated tablets are light blue , biconvex , oval tablet , with the inscription "" ol 15 "" on one side .'"
3395,"b'es ist m\xc3\xb6glich , dass tnf-antagonisten , einschlie\xc3\x9flich enbrel , die wirts-abwehr von infektionen und malignen erkrankungen beeinflussen , da tnf entz\xc3\xbcndungsprozesse ausl\xc3\xb6st und zellul\xc3\xa4re immunreaktionen ver\xc3\xa4ndert .'","b'it is possible that tnf-antagonist including enbrel , may affect the wirts-abwehr of infections and malignancies , since the surfactant phase represents between tnfrs triggers and / or altered .'","b'it is possible that traces of infections and the generation closure in fever and malignancies , showed there are . i in anaemic such total syndrome from infections and malignancies , since the bone conducting and or altered .'","b""it is possible that tnf-antagonist including enbrel , may affect the host 's defence of infections and malignancies , since tnftriggers the inflammatory process phase and alters cellular immunoresponse ."""
3396,b'die betreffenden patienten m\xc3\xbcssen sorgf\xc3\xa4ltig beobachtet werden .',b'the patients should be carefully observed .',b'the patients should be carefully observed .',b'the patients should be carefully observed .'
3397,b'22 / 24 9 bis 13 liter . die plasmaproteinbindung emea 2004 von gemfibrozil und seines hauptmetaboliten betr\xc3\xa4gt mindestens 97 % .',"b'22 / 24 7 litres . plasma protein binding emea 2004 of gemfibrozil and its main metabolite are at least 97 % , respectively .'",b'litres . plasma protein binding emea the cypa binding emea of gemfibrozil and conventional .',b'22 / 24 9 to 13 litres . plasma protein binding emea 2004 of gemfibrozil and its main metabolite are at least 97 % .'
3398,b'die kapseln sollten nur unmittelbar vor einnahme aus dem blister entnommen werden .',b'the capsules you are ready to take it out of the blister .',b'the capsules is use on suitable or gently ready to remove it back of the blister .',b'the capsules should be taken out of the blister immediately before administration .'
3399,b'wie ist rapilysin aufzubewahren ? 6.',b'how to store rapilysin',b'how to store rapilysin',b'how to store rapilysin'
3400,b'dar\xc3\xbcber hinaus kann das auftreten eines anaphylaktischen schocks ( schwere allergische allgemeinreaktion ) nicht ausgeschlossen werden .',"b'furthermore , the possibility of an anaphylactic shock ( a severe allergic allgemeinreaktion ) cannot be excluded .'","b'furthermore , the possibility of an anaphylactic shock a severe allergic allgemeinreaktion cannot be excluded .'","b'furthermore , the possibility of an anaphylactic shock ( a severe allergic general reaction ) cannot be excluded .'"
3401,"b'die polysaccharide sind dem tetanus-toxoid als tr\xc3\xa4gerprotein chemisch hinzugef\xc3\xbcgt ( konjugiert ) , da dies das ansprechen auf den impfstoff verbessert .'","b'the which the mark-to-space ratio of tetanus toxoid 2-methylthio-p-phenylenediamine , as this response to the vaccine .'",b'the which an hmgcoa finding of tetanus toxoid and administered by parathyroid or a olanzapin values of the gall standards time to the vaccine .',"b'the polysaccharides are chemically added to the tetanus toxoid as a carrier protein ( conjugated ) , as this improves the response to the vaccine .'"
3402,"b'f\xc3\xbchren sie die spritze an ihren mund und geben sie die dosis in ihren mund ( bzw. in den mund des patienten , den sie betreuen ) , indem sie auf den stempel dr\xc3\xbccken .'","b'insert the syringe in your mouth and add the dose in your mouth ( or into the mouth of the patient , you are caring for ) push on the plunger .'",b'perform the syringe in your mouth and prior the protease dose of the pump',b'insert the syringe in your mouth and inject the dose into your mouth ( or into the mouth of the patient you are caring for ) by pushing on the plunger .'
3403,b'warum wurde betaferon zugelassen ?',b'why has betaferon been approved ?',b'why has betaferon been approved ?',b'why has betaferon been approved ?'
3404,b'die methioninkonzentration im plasma muss unter 1000 \xc2\xb5m liegen .',"b'the methioninkonzentration plasma levels should be less than 1,000 \xc2\xb5m .'","b'the import plasma levels should be less than , m .'","b'the plasma methionine concentration should be less than 1,000 \xc2\xb5m .'"
3405,"b'0,1 mg firocoxib pro kg k\xc3\xb6rpergewicht , einmal t\xc3\xa4glich , bis zu 14 tage lang .'","b'0.1 mg firocoxib per kg of body weight , administered once a day , for up to 14 days .'","b'. mg firocoxib per kg of body weight , established once a day , for up to days .'","b'0.1 mg firocoxib per kg of body weight , administered once a day , for up to 14 days .'"
3406,"b'23 die wirksamkeit und vertr\xc3\xa4glichkeit von clopidogrel bei patienten mit akutem st-hebungs-myokardinfarkt wurde in zwei randomisierten , placebo-kontrollierten doppelblindstudien , clarity und commit , untersucht .'","b'the safety and efficacy of clopidogrel in patients with acute st-segment elevation mi has been studied in two randomised , placebo-controlled , double-blind studies , clarity and commit .'","b'the safety and efficacy of clopidogrel in patients with acute provisions systemically isoenzyme inhibition of demonstrated in two foetal , were seen have been studied in two year arthritis as placebo of male , studies were followed in two randomised , genotoxicity and metrorrhagia and with qt arms a signals'","b'the safety and efficacy of clopidogrel in patients with acute st-segment elevation mi has been studied in two randomised , placebo-controlled , double-blind studies , clarity and commit .'"
3407,b'keines der ereignisse war schwerwiegend und weniger als 5 % wurden als schwergradig eingestuft .',b'none of the events was serious and less than 5 % were considered schwergradig .',b'none of the events was serious and less than were of patient than were considered share were formed biosensor and less than were considered nucab that a .',b'none of the events was serious and less than 5 % were considered severe .'
3408,b'torisel wird zur behandlung von patienten mit fortgeschrittenem nierenzellkarzinom ( nierenkrebs ) angewendet .',b'torisel is used to treat patients with advanced renal cell carcinoma ( 806 ) .',b'torisel is used to treat patients with advanced renal cell carcinoma .',b'torisel is used to treat patients with advanced renal cell carcinoma ( renal cancer ) .'
3409,"b'zwei weitere , kleinere , randomisierte , placebokontrollierte studien konnten keine signifikante verbesserung der mit eortc-qlq-c30 scale oder clas ermittelten lebensqualit\xc3\xa4t zeigen .'","b'in two other , smaller , randomised , placebo-controlled trials , no significant improvement , with eortc-qlq-c30 scale or clas quality of life .'",b'hiv not treated between the reduction of the function .',"b'in two other , smaller , randomised , placebo-controlled trials , no significant improvement was shown with eortc-qlq-c30 scale or clas quality of life .'"
3410,b'die anwendung von nichtsteroidalen antirheumatika kann den antihypertonen effekt der ace- hemmer abschw\xc3\xa4chen .',b'the use of nsaids may weaken or suppress entirely the antihypertonen effect of ace inhibitors .',b'in the use of nsaids such inhibiting as twisted striae .',b'the use of nsaids may weaken or suppress entirely the antihypertonen effect of ace inhibitors .'
3411,b'jede hartkapsel enth\xc3\xa4lt 140 mg temozolomid .',b'each hard capsule contains 140 mg temozolomide .',b'each hard capsule contains ml alfa each hard capsule contains mg clopinavir .',b'each hard capsule contains 140 mg temozolomide .'
3412,b'jede 2g infusionsflasche enth\xc3\xa4lt 2g ceftriaxon ( als dinatrium-hydrat ) .',b'each 2 g infusion bottle contains 2 g ceftriaxone ( as hydrated disodium ) .',b'each g infusion bottle contains g ceftriaxone as hydrated disodium .',b'each 2 g infusion bottle contains 2 g ceftriaxone ( as hydrated disodium ) .'
3413,b'das arzneimittel darf nicht im abwasser oder haushaltsabfall entsorgt werden .',b'this medicinal product should be disposed of in accordance with local requirements .',b'this medicinal product should be disposed of in accordance with local requirements .',b'this medicinal product should be disposed of in accordance with local requirements .'
3414,b'sie sollen ihr kind w\xc3\xa4hrend der behandlung mit osigraft nicht stillen .',b'you should not breast-feed your baby during treatment with osigraft .',b'you should not breastfeed your baby during treatment with osigraft .',b'you should not breast-feed your baby during treatment with osigraft .'
3415,b'metformin unzureichend eingestellt ist .',b'metformin is insufficiently controlled .',b'metformin is thereby in whom overdoses .',b'metformin is insufficiently adjusted .'
3416,"b'nur bei 2 patienten wurde in der 6. behandlungswoche ein maximaler blutspiegel von 0,8 ng / ml gemessen .'",b'only in 2 patients was measured by looking at the 6 week maximum blood concentration of 0.8 ng / ml .',b'only in patients was measured by looking at the week maximum indicator .',b'only in 2 patients was the maximum blood concentration of 0.8 ng / ml measured at week 6 .'
3417,b'der impfstoff kann bei eintagsk\xc3\xbcken und \xc3\xa4lteren h\xc3\xbchnern als grobspray oder mittels oculo- nasaler instillation verabreicht werden .',b'this vaccine can be given to 1-day-old chicks and older chickens by coarse spray or by oculo- infusion at a suitable temperature .',b'this vaccine can be given to proper entry of a suitable temperature .',b'this vaccine can be given to 1-day-old chicks and older chickens by coarse spray or by oculo nasal infusion at a suitable temperature .'
3418,"b'die pen-kappe muss nach jeder injektion wieder auf den pen gesetzt werden , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'the pen cap should be replaced on the pen must be used in order to protect from light after each injection .',b'the pen cartridge should be replaced on the pen must be used in several water after each injection .',"b'the pen cap should be replaced on the pen after each injection , in order to protect from light after each injection .'"
3419,"b'kontrollierte klinische studien haben keinen signifikanten nutzen gezeigt , der auf die gabe von epoetinen zur\xc3\xbcckzuf\xc3\xbchren ist , wenn die h\xc3\xa4moglobinkonzentration \xc3\xbcber den f\xc3\xbcr die kontrolle der an\xc3\xa4miesymptome und die vermeidung von bluttransfusionen erforderliche konzentration gesteigert wird .'",b'controlled clinical trials have not shown significant benefits due to the administration of epoetins when haemoglobin concentration is increased beyond the level required to control symptoms of anaemia and to avoid blood transfusion concentrations is increased .',b'controlled clinical trials have not shown significant benefits due to the administration of the tissue investigated of voices study in the patients due to the administration of dams when haemoglobin concentration is increased spontaneously to x increase such in vaccination when fixed transplant the level required to control symptoms of',b'controlled clinical trials have not shown significant benefits due to the administration of epoetins when haemoglobin concentration is increased beyond the level required to control symptoms of anaemia and to avoid blood transfusion concentrations is increased .'
3420,b'die niedrigste wirksame dosis sollte beibehalten werden .',b'the lowest effective dose should be maintained .',b'the lowest effective dose should be maintained .',b'the lowest effective dose should be maintained .'
3421,"b'eine studie mit 14c-markiertem lansoprazol zeigte , dass ungef\xc3\xa4hr ein drittel der verabreichten strahlungsdosis mit dem urin und zwei drittelmit dem f\xc3\xa4zes ausgeschieden wurden .'","b'a study with 14c labelled lansoprazole showed that approximately one-third of the administered amprenavir dose in the urine , and two-thirds was recovered in the faeces .'","b'in average values nationally the accumulation of the leukocyte range dose in the urine , and stinging was recovered in the urine .'","b'a study with 14c labelled lansoprazole showed that approximately one-third of the administered amprenavir dose was excreted in the urine , and two-thirds was recovered in the faeces .'"
3422,b'bei anwendung von replagal mit anderen arzneimitteln es sind keine wechselwirkungen von replagal mit anderen arzneimitteln bekannt .',b'using replagal using other medicines there are no known interactions of replagal with other medicines .',b'using common medicines . some in childhood with other medicines .',b'using replagal with other medicines . there are no known interactions of replagal with other medicines .'
3423,"b'wenn ein pflaster sich abzul\xc3\xb6sen beginnt , k\xc3\xb6nnen sie es m\xc3\xb6glicherweise durch festes andr\xc3\xbccken wie- der ankleben .'","b'if a patch , you may be able to make it does it ankleben .'","b'if a patch , you may be able to make it more to take onsenal should it works until it harder prior to make it becomes in to to give it will give it may arrange it against if cause or well as contains the required .'","b'if a patch begins to peel off , you may be able to stick it on again by pressing it firmly .'"
3424,"b'damit wird gew\xc3\xa4hrleistet , dass der patientin eine dosis von mindestens 0,23 mg cetrorelix verabreicht wird .'",b'this is to make sure that the patient of a dose of at least 0.23 mg cetrorelix .',b'this is to make sure that the patient of a dose of in a dose of at least . mg microns .',b'this is to make sure that the patient is administered a dose of at least 0.23 mg cetrorelix .'
3425,b'hinweise f\xc3\xbcr die handhabung \xc3\x9cberpr\xc3\xbcfen sie die liprolog l\xc3\xb6sung .',b'instructions for use and handling inspect the liprolog solution .',b'instructions for use and handling up read the liprolog solution .',b'instructions for use and handling inspect the liprolog solution .'
3426,"b'kinder , die eine zweite dosis proquad erhielten die nebenwirkungsrate war nach einer zweiten dosis proquad generell gleich oder niedriger als nach der ersten dosis .'",b'children weighing a second dose of proquad the rate of adverse events following a second dose of proquad is generally equal to or lower than after the first dose .',b'children weighing a second dose of the larger dose of sensitivity with a second dose of proquad is generally fgezogen to or lower than after the first dose .',b'children who received a second dose of proquad . the rate of adverse events following a second dose of proquad is generally equal to or lower than after the first dose .'
3427,"b'es wurde nachgewiesen , dass insulin lispro auf molarer basis \xc3\xa4quipotent zu humaninsulin ist , dass es aber einen rascheren wirkungseintritt und eine k\xc3\xbcrzere wirkungsdauer besitzt .'",b'it has been demonstrated that insulin lispro and is equipotent to human insulin but more rapid and a shorter duration .',b'almost an unpreserved cyclooxygenase replacement an physical insulin but more rapid and a shorter duration .',b'it has been demonstrated that insulin lispro and is equipotent to human insulin but more rapid and a shorter duration .'
3428,b'in der klinischen praxis liegen die talspiegel von tacrolimus im vollblut in der ersten zeit nach lebertransplantationen gew\xc3\xb6hnlich im bereich von 5 - 20 ng / ml und bei nieren - und herztransplantierten patienten bei 10 - 20 ng / ml .',"b'however , in clinical practice , tacrolimus trough levels in whole blood are available in the first time after lebertransplantationen will generally be in the range of 5 - 20 ng / ml and in nieren and herztransplantierten patients in 10 - 20 ng / ml .'","b'however , in clinical practice , tacrolimus trough levels in the duration of ng oral the maintenance of ng ml .'","b'however , in clinical practice , tacrolimus trough levels in whole blood are available for first time after liver transplants usually in the range of 5 - 20 ng / ml and in renal and heart transplant patients in 10 - 20 ng / ml .'"
3429,b'10 ( 10 ) h\xc3\xa4ufig :',b'10 ( 10 ) common :',b'common',b'10 ( 10 ) common :'
3430,"b'dosierung bei patienten mit beeintr\xc3\xa4chtigter leberfunktion : das vorhandensein einer leberfunktionsst\xc3\xb6rung erfordert wahrscheinlich keine anpassung der dosis , da ca.'","b'dosage in patients with hepatic impairment in patients with hepatic failure is probably not necessary , as approx . dosage'",b'dosage in patients with hepatic impairment in of patients with hepatic failure is necessary should increase . dosage',b'dosage in patients with hepatic impairment : the presence of a hepatic function disorder probably does not reqiore dose adjustments .'
3431,b'f\xc3\xbcr die zubereitete suspension :',b'for the constituted suspension :',b'for the lcms suspension',b'for the constituted suspension :'
3432,"b'109 anhaltender h\xc3\xa4moglobinwert \xc3\xbcber 12 g / dl ( 7,5 mmol / l ) sollte vermieden werden . eine geeignete dosisanpassung f\xc3\xbcr den fall , dass h\xc3\xa4moglobinwerte \xc3\xbcber 12 g / dl ( 7,5 mmol / l ) beobachtet werden , wird weiter unten beschrieben .'",b'109 sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoided ; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g / dl ( 7.5 mmol / l ) are observed are described below .',"b'consistent of greater than g dl . mmol l or increased milk was contraindicated in therapeutic stable monitoring of significant that be avoided , rapidly herbal enbrel maraviroc dl . mmol l should be avoided together with appropriate dose adjustment for appropriate dose adjustment for young dose is contraindicated with'",b'109 sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoided ; guidance for appropriate dose adjustment are described below for when haemoglobin values exceeding 12 g / dl ( 7.5 mmol / l ) are observed .'
3433,"b'26 in den studien zur toxizit\xc3\xa4t bei wiederholter verabreichung wurden bei ratten ab einer exposition von etwa dem 3-fachen der klinischen exposition geringf\xc3\xbcgige , reversible leberver\xc3\xa4nderungen beobachtet .'","b'in the repeated dose toxicity studies , mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure .'","b'in the repeated dose toxicity studies , mild reversible a minor increase were observed in rats starting at and higher times the clinical exposure .'","b'26 in the repeated dose toxicity studies , mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure .'"
3434,b'schaum kann das aufziehen der richtigen dosis erschweren .',b'artichoke may make the correct dose .',b'point may make the solution eventually insulin agent .',b'foam may make make it easier to draw out the correct dose .'
3435,b'ausschlie\xc3\x9flich zur anwendung auf der haut .',b'ausschlie\xc3\x9flich for use on the skin .',b'eradication the skin .',b'exclusively for use on the skin .'
3436,b'bewahren sie crixivan in der originalflasche auf .',b'do not store crixivan in the original bottle .',b'do not store crixivan in the original bottle .',b'do not store crixivan in the original bottle .'
3437,"b'rotateq wird in drei dosen verabreicht , wobei zwischen den einzeldosen jeweils eine mindestwartezeit von vier wochen einzuhalten ist .'","b'rotateq is given as three doses , with a gap between single doses of a mindestwartezeit between four weeks .'","b'rotateq is given as three doses , with a valproic in .'","b'rotateq is given as three doses , with a gap between single doses of a minimum wait time of four weeks .'"
3438,b'die unbedenklichkeit und wirksamkeit von oseltamivir zur therapie oder prophylaxe der influenza bei immunsupprimierten patienten sind nicht gesichert .',b'the safety and efficacy of oseltamivir for the treatment or prevention of influenza in immunosuppressed patients have not been established .',b'the meeting of oseltamivir for the treatment or indinavir of influenza in immunosuppressed patients have not been established .',b'the safety and efficacy of oseltamivir for the treatment or prevention of influenza in immunosuppressed patients have not been established .'
3439,"b'anschlie\xc3\x9fend wurde die wirksamkeit in mehreren feldstudien an katzen und hunden best\xc3\xa4tigt , die in verschiedenen geografischen regionen europas durchgef\xc3\xbchrt wurden .'","b'then , the efficacy was confirmed in several studies involving cats and dogs in various areas of the antiretroviral use .'","b'then , the efficacy was confirmed in several studies involving cats and dogs in various areas of the antiretroviral use .'","b'then , the efficacy was confirmed in several field studies involving cats and dogs in various geographical areas of europe .'"
3440,b'die vollst\xc3\xa4ndige auflistung der im zusammenhang mit zometa berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .',"b'for a full list of the side-effects reported with side effects of zometa , see the package leaflet .'","b'for a full list of the sideeffects reported with side effects of zometa , see the package leaflet .'","b'for a full list of the side-effects reported with zometa , see the package leaflet .'"
3441,b'wie stocrin aussieht und inhalt der packung stocrin 100 mg hartkapseln steht in packungen zu 30 kapseln zur verf\xc3\xbcgung .',b'what stocrin looks like and contents of the pack stocrin 100 mg hard capsules are supplied in bottles of 30 capsules are also available .',b'what stocrin looks like and contents of the pack stocrin mg hard capsules are supplied in bottles of capsules are also available .',b'what stocrin looks like and contents of the pack : stocrin 100 mg hard capsules are supplied in bottles of 30 capsules .'
3442,"b'die eliminationshalbwertszeit ( t \xc2\xbd ) betr\xc3\xa4gt ca. 13 stunden und die clearance ist ca. 2,4 l / h.'",b'the elimination half-life ( t \xc2\xbd ) is approximately 13 hours and clearance is approximately 2.4 l / h .',b'the elimination halflife t is approximately hours and clearance is approximately . l h .',b'the elimination half-life ( t \xc2\xbd ) is approximately 13 hours and clearance is approximately 2.4 l / h .'
3443,b'thrombozytopenie und an\xc3\xa4mie treten weniger h\xc3\xa4ufig auf und werden selten ohne eine vorausgegangene neutropenie beobachtet .',b'thrombocytopenia and anaemia are less common and are rarely observed without prior neutropenia .',b'thoracic and anaemia are less common and also rarely observed without prior a death was reduced average or increased prior .',b'thrombocytopenia and anaemia are less common and are rarely observed without prior neutropenia .'
3444,b'zur entz\xc3\xbcndungshemmung und schmerzlinderung bei erkrankungen des bewegungsapparates und bei weichteiltraumen ( traumatische verletzungen und chirurgisch bedingten traumen ) .',b'reduction of inflammation and relief of pain in musculoskeletal disorders and in weichteiltraumen ( traumatic injury or due to require surgical trauma ) .',b'prodrug may only an relief of pain in musculoskeletal disorders and in fusarium occult steroids such or due to moderately resolution carboxyl .',b'reduction of inflammation and relief of pain in musculoskeletal disorders and in soft-tissue traumas ( traumatic injury or due to require surgical trauma ) .'
3445,b'lucentis ist zur behandlung der neovaskul\xc3\xa4ren ( feuchten ) altersabh\xc3\xa4ngigen makuladegeneration ( amd ) indiziert ( siehe abschnitt 5.1 ) .',b'lucentis is indicated for the treatment of neovascular ( wet ) age-related macular degeneration ( amd ) is indicated ( see section 5.1 ) .',b'lucentis is indicated for the treatment of phoenix dyskinesia .',b'lucentis is indicated for the treatment of neovascular ( wet ) age-related macular degeneration ( amd ) ( see section 5.1 ) .'
3446,b'die patienten hatten bei einschluss einen bmi \xe2\x89\xa5 30 kg / m \xc2\xb2 oder bmi > 27 kg / m \xc2\xb2 und eine gleichzeitig bestehende hypertonie und / oder dyslipid\xc3\xa4mie .',"b'patients had a bmi \xe2\x89\xa5 30 kg / m \xc2\xb2 or bmi 27 kg / m2 , and a concomitant hypertension and / or dyslipidaemia .'",b'patients had a incorporation kg m or or raised kg m is possible plasma is an value post kg m in approximately number of dose level and and a concomitant hypertension and or appetite faeces with a concomitant hypertension and or pretreated in kg .',"b'patients had a bmi \xe2\x89\xa5 30 kg / m \xc2\xb2 or bmi > 27 kg / m2 , and a concomitant hypertension and / or dyslipidaemia .'"
3447,b'novomix 70 ist zur injektion unter die haut ( subkutan ) vorgesehen .',b'novomix 70 is for injection under the skin ( subcutaneously ) .',b'novomix is for injection under the skin subcutaneously .',b'novomix 70 is for injection under the skin ( subcutaneously ) .'
3448,b'\xe2\x80\xa2 arzneimittel f\xc3\xbcr kinder unzug\xc3\xa4nglich aufbewahren . \xe2\x80\xa2 sie d\xc3\xbcrfen galvus nach dem auf dem blister oder dem umkarton angegebenen verfalldatum nicht mehr anwenden .',b'\xe2\x80\xa2 keep out of the reach of children . \xe2\x80\xa2 do not use galvus after the expiry date which is stated on the blister and the carton .',b'keep out of the reach of children . do not use zomarist after the expiry date which is stated on the blister and the carton .',b'\xe2\x80\xa2 keep out of the reach of children . \xe2\x80\xa2 do not use galvus after the expiry date which is stated on the blister and the carton .'
3449,b'- sehnenerkrankungen / -sch\xc3\xa4den infolge einer chinolontherapie in der anamnese .',b'- history / damage due to chinolontherapie .',b'fever damage due to vaccinating higher .',b'- history / damage due to quinolone therapy .'
3450,b'metabolismus die bioaktivierung von nepafenac zu amfenac erfolgt relativ schnell durch intraokul\xc3\xa4re hydrolasen .',b'metabolism the bioaktivierung of nepafenac and amfenac to be relatively rapidly due to 26.2 % re-operation .',b'metabolism the active coded g . times neither erythropoiesis ppix without sodium contains morphine .',b'metabolism : the bio-activity of nepafenac to amfenac takes place relatively fast through intraocular hydrolases .'
3451,b'was ist ratiograstim ?',b'what is ratiograstim ?',b'what is cetrotide ?',b'what is ratiograstim ?'
3452,"b'zunge und wangenknochen ( akromegalie ) , einem hohen blutzuckerspiegel ( hyperglyk\xc3\xa4mie ) und zum auftreten von zucker im urin ( glykosurie ) f\xc3\xbchren .'","b'tongue and cheekbones ( acromegaly ) , a high blood sugar ( hyperglycaemia ) and incidence of sugar in the urine ( glycosuria ) .'","b'thoughts and suvaxyn action , a high blood sugar of burns and incidence of sugar in the faeces .'","b'tongue and cheekbones ( acromegaly ) , leads to a high blood sugar ( hyperglycaemia ) and incidence of sugar in the urine ( glycosuria ) .'"
3453,b'weitere informationen \xc3\xbcber parareg :',b'2 / 3 other information about parareg :',b'other information about parareg',b'other information about parareg'
3454,"b'die studie dauerte ein bis drei jahre , und es wurde die h\xc3\xa4ufigkeit neuer isch\xc3\xa4mischer ereignisse ( herzinfarkte , isch\xc3\xa4mische schlaganf\xc3\xa4lle oder tod ) untersucht .'","b'the study lasted three years , and the incidence of new ischaemic events ( heart attacks , ischaemic stroke or death ) .'","b'the study lasted three years , and the incidence of new ischaemic events heart attacks consistent control level of new ischaemic events heart cinduktor , ischaemic bleeding or inhibition of new ischaemic events will been recorded of new ischaemic events heart attacks produce low bleeding of the ischaemic studies .'","b'the study lasted between one to three years , and the frequency of new ischaemic events ( heart attacks , ischaemic stroke or death ) were studied .'"
3455,"b'standardmethoden zur erh\xc3\xb6hung der elimination des arzneimittels , wie z.b. eine dialyse , haben sich als nicht brauchbar gezeigt .'","b'standard measures of the elimination of the medicine , such as dialysis , have been shown to be demonstrated .'",b'standard measures of the didanosine on patients to anticoagulants could result affects your growth of the leaflet .',"b'standard measures of the elimination of the medicine , such as dialysis , have been shown to be not feasible .'"
3456,b'rheumocam sollte nicht zusammen mit anderen nicht-steroidalen antiphlogistika oder glukokortikoiden verabreicht werden .',b'rheumocam must not be administered in conjunction with other nsaids or corticosteroids .',b'luminity must not be administered in conjunction with other nsaids or glucocorticoids .',b'rheumocam must not be administered in conjunction with other nsaids or corticosteroids .'
3457,b'abh\xc3\xa4ngig vom ansprechen der therapie kann die dosis bis zu 120 mg pro tag erh\xc3\xb6ht werden .',"b'based on your response to xeristar , the dose may be increased up to 120 mg per day .'","b'based on your response to xeristar , the dose may be increased up to increments per day .'","b'based on your response to xeristar , the dose may be increased up to 120 mg per day .'"
3458,b'2 millionen i.e. / m2 3mal in der woche ( jeden zweiten tag ) subkutan ( unter die haut ) injiziert .',"b'2 million iu / m2 , 3 times a week ( every other day ) injected subcutaneously ( under the skin ) .'","b'iu contains m , times a week every other day injected subcutaneously under the skin .'",b'2 million iu / m2 3 times a week ( every other day ) injected subcutaneously ( under the skin ) .'
3459,b'refacto af sollte nicht mit anderen injektionsl\xc3\xb6sungen gemischt werden .',b'refacto af should not be mixed with other parachute structures .',b'refacto af should not be mixed .',b'refacto af should not be mixed with other injection solutions .'
3460,b'der gro\xc3\x9fteil dieser lokalen reaktionen war leicht ausgepr\xc3\xa4gt und vor\xc3\xbcbergehend .',b'the majority of these local reactions were mild and transient in nature .',b'the majority of these local reactions were mild and transient in nature .',b'the majority of these local reactions were mild and transient in nature .'
3461,"b'keppra kann als infusion mit gleicher dosierung und h\xc3\xa4ufigkeit der anwendung verabreicht werden , wenn die gabe der tabletten oder der l\xc3\xb6sung zum einnehmen vor\xc3\xbcbergehend nicht m\xc3\xb6glich ist .'",b'keppra can be given as an infusion of the same dosage and frequency of administration if the administration of the tablets or oral solution temporarily is not possible .',b'keppra can be given as an infusion of the same states and frequency of administration if the administration of the body or full pump .',b'keppra can be given as an infusion of the same dosage and frequency of administration if the administration of the tablets or oral solution temporarily is not possible .'
3462,b'm\xc3\xb6glicherweise sehen sie einen kleinen tropfen fl\xc3\xbcssigkeit .',b'you may you will see a small drop .',b'you may give the blood volume from insulin or memory from in orange .',b'you may you will see a small drop .'
3463,"b'es gibt packungen mit 3 , 4 , 5 , 6 , 9 und 10 pens zu je 3 ml .'","b'packs of 3 , 4 , 5 , 6 , 9 or 10 pens of 3 ml are available .'","b'packs of , , , , , or pens of ml are available .'","b'packs of 3 , 4 , 5 , 6 , 9 or 10 pens of 3 ml are available .'"
3464,b'jedoch wurde in bisherigen klinischen studien selten ( < 5 % ) schwindelgef\xc3\xbchl und schl\xc3\xa4frigkeit im zusammenhang mit der verabreichung von caelyx beobachtet .',"b'however , previous clinical trials , rarely ( 5 % ) , dizziness and sleepiness associated with the administration of caelyx have been observed .'","b'however , previous clinical trials , rarely , dizziness and bilirubin associated with the administration of caelyx have been observed .'","b'however , previous clinical trials , dizziness and sleepiness associated with the administration of caelyx have been observed rarely ( 5 % ) .'"
3465,b'es wurde w\xc3\xa4hrend der verabreichung von benefix \xc3\xbcber agglutination von roten blutk\xc3\xb6rperchen im schlauchsystem oder der spritze berichtet .',b'it has been reported during administration of benefix over from red blood cells in the tubing of the syringe .',b'it has been reported during administration of benefix over from red tests of the syringe .',b'agglutination of red blood cells in the tubing or the syringe has been reported during administration of benefix .'
3466,b'das ergebnis ist eine verbesserte erektion .',b'this results in an improved .',b'this results in an improved .',b'this result is an improved erection .'
3467,"b'dexmedetomidin ist ein hochwirksamer und selektiver \xce\xb1 2-adrenozeptoragonist , der die freisetzung von noradrenalin aus noradrenergen neuronen hemmt .'","b'dexmedetomidine is a potent and selective inhibitor of the \xce\xb1 2-adrenozeptoragonist , the release of noradrenaline from the inhibits 7 .'",b'loprost is a potent and selective inhibitor of the aldosterone and selective inhibitor of the inner cell virus with tissue reactive has be less .',"b'dexmedetomidine is a potent and selective \xce\xb1 2-adrenergic receptor , that inhibits the release of noradrenaline from noradrenergic neurons .'"
3468,b'ausgehend von einer umfassenden beurteilung der patientenreaktion im hinblick auf alle klinischen manifestationen der krankheit sollte das ansprechen der patienten auf die behandlung routinem\xc3\xa4\xc3\x9fig untersucht werden .',"b""based on a thorough evaluation of the patientenreaktion with regard to all clinical manifestations of the disease 's response to treatment should be routinely investigated .""",b'is advised gives information on a sites indication cannot not available to avoid clinical factors to treatment should be monoamine states after four use .',"b""based on a thorough evaluation of the patient reaction with regard to all clinical manifestations of the disease 's response to treatment , the patients response should be routinely investigated ."""
3469,b'am 17. november 1997 erteilte die europ\xc3\xa4ische kommission dem unternehmen genzyme europe b.v. eine genehmigung f\xc3\xbcr das inverkehrbringen von cerezyme in der gesamten europ\xc3\xa4ischen union . die genehmigung f\xc3\xbcr das inverkehrbringen wurde am 17.',b'the european commission granted to genzyme europe b. v. on the european union for cerezyme on 17 november 1997 . the marketing authorisation was adopted on 17 april 2008 .',b'the european commission granted to eli europe b . v . on the european union for psurs on november .',b'the european commission granted genzyme europe b. v. market authorisation for cerezyme thoughout the whole european union on 17 november 1997 . the marketing authorisation was adopted on 17 april 2008 .'
3470,"b'wird die einleitung einer antiretroviralen kombinationstherapie mit stavudin erwogen , ist dies zu ber\xc3\xbccksichtigen .'","b'if the time of consideration with stavudine , this should be taken into account .'",b'if lymphadenopathy benefit may soon to the close waste break or coloured is required .',b'this should be taken into account if you are considering the introduction of an antiretroviral combination therapy with stavudin .'
3471,"b'bei einem neuen , unbenutzten optiset ist durch den hersteller bereits eine dosis von 8 einheiten f\xc3\xbcr den ersten sicherheitstest voreingestellt .'","b'if a new , s99tn , optiset is preset by the manufacturer already taking a dose of 8 units preset by the manufacturer for the first safety test meals .'","b'if a new treatment , injection , them is glucocortoid by the manufacturer has named by the manufacturer that the influenza records of units must be determined through sperm with dose reduction the full indication by the manufacturer amount scheme .'","b'a new , unused optiset is preset by the manufacturer with a dose of 8 units for the first safety test .'"
3472,"b'das von intrinsa freigesetzte testosteron gelangt \xc3\xbcber einen passiven diffusionsproz ess , der prim\xc3\xa4r durch die permeation durch das stratum corneum kontrolliert wird , durch die intakte haut .'","b'the testosterone with intrinsa -xyla the eyes , intact skin across diffusionsproz ess primarily through the stratum corneum .'","b'the testosterone with inflammation of the deltoid estrogenbedingte the eyes , fatty involuntary dependence .'",b'the testosterone released from intrinsa gets through the intact skin by a difusion process that is primarily controlled by permeation through the stratum corneum .'
3473,b'was geschieht mit evoltra f\xc3\xbcr die behandlung von all bei kindern ?',b'what is happening for evoltra for the treatment of all in children .',b'what is forsteo for evoltra for the treatment of all in children .',b'what is happening with evoltra for the treatment of all in children ?'
3474,b'- der wirkstoff ist olanzapin .',b'- the active substance is olanzapine .',b'the active substance is olanzapine .',b'- the active substance is olanzapine .'
3475,"b'\xc2\xa9 emea 2006 2 / 3 ( schw\xc3\xa4che ) , fatigue ( m\xc3\xbcdigkeit ) und pyrexie ( fieber ) . die vollst\xc3\xa4ndige auflistung der im zusammenhang mit noxafil berichteten nebenwirkungen ist der packungsbeilage zu entnehmen .'","b'\xc2\xa9 emea 2006 ) grade 2 / 3 ( weakness ) , fatigue ( tiredness ) and pyrexia ( fever ) , a more complete list of side effects reported with noxafil reported adverse drug reactions , see the package leaflet .'","b'emea grade weakness , fatigue tiredness and dyspepsia fever , a more complete above activities , a more complete list of side effects reported see the package leaflet .'","b'\xc2\xa9 emea 2006 ) 2 / 3 ( weakness ) , fatigue ( tiredness ) and pyrexia ( fever ) . for the complete list of side effects reported with noxafil see the package leaflet .'"
3476,"b'dabei sind klickger\xc3\xa4usche zu h\xc3\xb6ren , bis der injektionsknopf vollst\xc3\xa4ndig eingedr\xc3\xbcckt ist .'",b'the klickger\xc3\xa4usche to hear injection button has been pressed in completely .',b'the mgkautabletten of blister empty drop until by injection button has been multifactorial in april .',b'the clicking sound can be heard until the injection button has been pressed in completely .'
3477,"b'es sollte jedoch eine allgemeine unterst\xc3\xbctzende therapie eingeleitet werden , wie sie auch bei klinischer \xc3\x9cberdosierung von nsaid durchgef\xc3\xbchrt wird .'","b'however , general supportive measures should be initiated , as have been reported with clinical overdose with nsaids .'","b'however , general supportive measures should be initiated , as have been reported with clinical reports of patients are in tandemact is impaired one adverse overdose with nsaids .'","b'however , general supportive measures should be initiated , as have been carried out with clinical overdose with nsaids .'"
3478,b'bei der l\xc3\xb6sung handelt es sich um eine klare und farblose fl\xc3\xbcssigkeit .',b'if the solution is a clear and colourless liquid .',b'if the solution is a clear and colourless liquid .',b'the solution is a clear and colourless liquid .'
3479,"b'besondere vorsicht ist geboten , wenn hypotone patienten oder patienten mit bekannter orthostatischer dysregulation doxazosin zur behandlung einer benignen prostatahyperplasie ( bph ) erhalten .'",b'caution should be exercised when patients or patients with known orthostatic dysregulation doxazosin for the treatment of benign prostatic hyperplasia ( bph ) .',b'caution should be exercised when patients or patients with known orthostatic dysregulation ciprofloxacin or approximately in whole treatmentrelated eggs receiving less medicinal micro or excercised bph .',b'caution should be exercised when hypotonic patients or patients with known orthostatic dysregulation doxazosin for the treatment of benign prostatic hyperplasia ( bph ) .'
3480,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr lucentis finden sie hier .',b'the full epar for avamys for lucentis is available here .',b'the full epar for lucentis is available here .',b'the full epar for lucentis is available here .'
3481,"b'therapie tiefer venenthrombosen ( tvt ) . therapie von lungenembolien ( le ) , au\xc3\x9fer bei h\xc3\xa4modynamisch instabilen patienten oder patienten , die einer thrombolyse oder einer pulmonalen embolektomie bed\xc3\xbcrfen .'","b'therapy for deep vein thrombosis ( dvt ) and treatment of acute pulmonary embolism ( pe ) , lo except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy .'",b'therapy for deep vein thrombosis dvt and treatment of acute pulmonary embolism clarified during potassiumsparing unstable patients or patients who require expert symptoms scheme age for sufficient consenquences in heterozygous unstable patients undergoing platelet period or platelet cleaving suffering .',"b'therapy for deep vein thrombosis ( dvt ) and treatment of acute pulmonary embolism ( pe ) , except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy .'"
3482,b'zu den lagerungsbedingungen des rekonstituierten medizinischen produkts siehe abschnitt 6.3 .',"b'for storage conditions of the reconstituted polypeptide , see section 6.3 .'","b'for storage conditions of the reconstituted vessel , see section . .'","b'for storage conditions of the reconstituted polypeptide , see section 6.3 .'"
3483,"b'zahn- und zahnfleischerkrankungen , die zum verlust der z\xc3\xa4hne ar f\xc3\xbchren k\xc3\xb6nnen , sind bei patienten berichtet worden , die viraferon und ribavirin als kombinationstherapie erhielten .'","b'dental and periodontal disorders , which may lead to loss of teeth , may be self-administering , have been reported in patients receiving viraferon and ribavirin combination therapy .'","b'dental and periodontal disorders , which may lead to loss of teeth , may be sera lead to a side effects has been eliminated to loss of teeth , may be derived , have been reported in women receiving viraferon and ribavirin combination therapy .'","b'dental and periodontal disorders , which may lead to loss of teeth , have been reported in patients receiving viraferon and ribavirin combination therapy .'"
3484,"b'xigris wird zus\xc3\xa4tzlich zur bestm\xc3\xb6glichen standardtherapie ( antibiotika , organunterst\xc3\xbctzende arzneimittel , behandlung auf einer spezialstation usw. ) eingesetzt , wenn zwei oder mehr organe des patienten versagen .'","b'xigris is added to best standard care ( antibiotics , organunterst\xc3\xbctzende medicinal products , treatment with spezialstation , etc . ) , when two or more organs of the failure patients .'",b'vaccination is added to best standard care of caution .',"b'xigris has been added to the best standard therapy ( antibiotics , organ-supporting medicinal products , treatment in a specialised unit , etc . ) , when two or more organs of the patients fail .'"
3485,"b'je nachdem , wie gut der patient auf die behandlung anspricht und diese vertr\xc3\xa4gt , wird die dosis entsprechend angepasst .'",b'depending on how well the patient responds to and tolerates the dose is adjusted .',b'the genderspecific requirement . in treating a appropriate nature with celvapan the dose is adjusted .',"b'depending on how well the patient responds to and tolerates the the treatment , the dose is adjusted accordingly .'"
3486,b'tr\xc3\xa4chtigkeit und laktation :',b'pregnancy and lactation :',b'pregnancy and lactation',b'pregnancy and lactation :'
3487,b'essbare gewebe ( h\xc3\xbchner und puten ) :',b'withdrawal periods - meat and offal ( chickens and turkeys ) :',b'withdrawal infarct specifically to submit pglycoprotein with modified weights should be permanent',b'withdrawal periods - meat and offal ( chickens and turkeys ) :'
3488,"b'f\xc3\xbcr erwachsene und kinder \xc3\xbcber 13 jahre betr\xc3\xa4gt die empfohlene dosis von viracept 250 mg filmtabletten 1250 mg , d.h. je f\xc3\xbcnf 250 mg tabletten , zweimal t\xc3\xa4glich oder 750 mg , d.h. je drei 250 mg tabletten , dreimal t\xc3\xa4glich .'","b'for adults and children older than 13 years , the recommended dose of viracept 250 mg film-coated tablets 1250 mg , i.e. of five 250 mg tablets twice a day ( bid ) or 750 mg , i.e. of three 250 mg tablets , three times a day .'","b'for adults and children than years , the recommended dose of viracept mg filmcoated tablets mg , sodium or mg times sodium sodium and per once weeks or mg , i . e . of mg mg tablets preferably a day .'","b'for adults and children older than 13 years , the recommended dose of viracept 250 mg film-coated tablets 1250 mg , i.e. of five 250 mg tablets twice a day ( bid ) or 750 mg , i.e. of three 250 mg tablets , three times a day .'"
3489,"b'88 wenn sie eine gr\xc3\xb6\xc3\x9fere menge von arava eingenommen haben , als sie sollten wenn sie eine gr\xc3\xb6\xc3\x9fere menge von arava eingenommen haben , als sie sollten , so setzen sie sich mit ihrem arzt in verbindung oder holen sie \xc3\xa4rztlichen rat ein .'","b'88 if you take more arava than you should if you take more arava than you should , contact your doctor or get other medical advice .'","b'if you take more known than you should if you take more before close more rapid than you should , contact your doctor or get other medical advice .'","b'if you take more arava than you should , contact your doctor or get other medical advice .'"
3490,b'schwere leberfunktionsst\xc3\xb6rung ( serum-albumin < 25 g / l oder child-pugh score \xe2\x89\xa5 10 ) .',b'severe hepatic impairment ( serum albumin 25 g / l or child-pugh score \xe2\x89\xa5 10 ) .',b'severe hepatic kaletra serum albumin g l containing .',b'severe hepatic impairment ( serum albumin 25 g / l or child-pugh score \xe2\x89\xa5 10 ) .'
3491,b'erw\xc3\xa4rmen sie die beiden unge\xc3\xb6ffneten durchstechflaschen in ihren h\xc3\xa4nden auf k\xc3\xb6rpertemperatur ( nicht mehr als 37 \xc2\xb0 c ) .',b'do the unopened vials in your hands body temperature ( do not exceed 37 \xc2\xb0 c ) .',b'do the unreconstituted vials in your hands body temperature do not exceed c .',b'warm both unopened vials in your hands to body temperature ( do not exceed 37 \xc2\xb0 c ) .'
3492,b'st\xc3\xa4rkung des europ\xc3\xa4ischen arzneimittel-netzwerks .',b'of paramount .',b'cytotoxic contact with the test in accordance with trazec .',b'strengthening of the european medicines network .'
3493,b'2. was m\xc3\xbcssen sie vor der einnahme von tarceva beachten ? 3. wie ist tarceva einzunehmen ?',b'before you are taking tarceva how to take tarceva 6 .',b'before you are taking tarceva how to take tarceva .',b'what should you note before taking tarceva ? how to take tarceva .'
3494,b'bei anwendung von ace-hemmern kam es w\xc3\xa4hrend einer ldl-apherese mit dextransulfat selten zu lebensbedrohlichen anaphylaktoiden reaktionen .',b'patients receiving ace inhibitors occurred rarely cause life-threatening anaphylactoid reactions during low-density lipoproteins ( ldl ) apheresis with dextran sulphate .',b'patients receiving ace inhibitors or lifethreatening anaphylactoid reactions during fluoreszenzin odour of organisms .',b'during the use of ace inhibitors a low-density lipoproteins ( ldl ) apheresis rarely lead to life-threatening anaphylactic reactions .'
3495,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr azilect finden sie hier .',b'the full epar for avamys for azilect can be found here .',b'the full epar for azilect for use .',b'the full epar for azilect can be found here .'
3496,"b'falls das tierarzneimittel versehentlich in die augen gelangt , die augen vorsichtig mit klarem wasser aussp\xc3\xbclen . w\xc3\xa4hrend der anwendung nicht rauchen , essen oder trinken .'","b'if the product accidentally gets into eyes , eyes , gently rinse with water . during use do not smoke , drink or eat while handling the product .'","b'if the veterinary drugs to ciprofloxacin , give helps , gently accordingly , drink or free medication in the household medication during use do not checked , drink or free while affected to shake to water . during further close a continued . during above .'","b'if the product accidentally gets into eyes , gently rinse them with water . during use do not smoke , drink or eat .'"
3497,"b'der chmp vertrat daher die ansicht , dass in-vivo- daten notwendig sind , um die therapeutische \xc3\x84quivalenz aufzuzeigen .'",b'the chmp therefore considered that the in vivo data are needed to assess the therapeutic equivalence .',b'the chmp infections to assess the therapeutic uric neupopeg .',b'the chmp therefore considered that the in vivo data are needed to assess the therapeutic equivalence .'
3498,b'wenn sie irgendeines dieser symptome bemerken : \xe2\x86\x92 informieren sie ihren arzt .',b'if you notice any of these symptoms : \xe2\x86\x92 talk to your doctor .',b'if you notice any of these symptoms talk to your doctor .',b'if you notice any of these symptoms : \xe2\x86\x92 talk to your doctor .'
3499,"b'untersuchungen bei bakterien und nagetieren haben gezeigt , dass fentanyl kein mutagenes potential besitzt .'",b'studies in bacteria and rodents have shown that the mutagenic potential of fentanyl .',b'studies in bacteria and support have shown that the mutagenic potential of fentanyl .',b'studies in bacteria and rodents have shown the mutagenic potential of fentanyl .'
3500,"b'das unternehmen legte au\xc3\x9ferdem nachweise dar\xc3\xbcber vor , dass die konzentrationen von amlodipin und valsartan im blut bei den patienten , die dafiro einnahmen und bei denjenigen , die die beiden wirkstoffe getrennt einnahmen , gleich waren .'","b'the company also presented evidence that the levels of amlodipine and valsartan in the blood in patients taking dafiro and people taking the separate medicines , were the same .'",b'the company also presented evidence that the extracellular function cuff in the separate medicines that be demonstrated in placebo and kappa thromboxane by patients taking standard function .',b'the company also presented evidence that the levels of amlodipine and valsartan in the blood in patients taking dafiro and people taking the medicines separately were the same .'
3501,b'h\xc3\xa4ufig kam es nach der injektion von extavia zu reaktionen an der injektionsstelle .',b'occurred frequently after injection of extavia reactions at the site of the injection .',"b'linearity are , these injection of extavia reactions at the site of the injection .'",b'reactions occurred frequently after injection of extavia at the site of the injection .'
3502,"b'falls nach 3-t\xc3\xa4giger behandlung keine besserung der symptome eingetreten ist , suchen sie bitte ihren arzt auf .'","b'if it is not achieved after 3 days of treatment , no improvement in symptoms , please consult your doctor .'","b'if iit is not consideration after days of , so or you have possible in the treatment of treatment , no improvement in symptoms , there were taken after the poweder .'","b'if it is not achieved after 3 days of treatment , and there is no improvement in symptoms , please consult your doctor .'"
3503,"b'die eliminationshalbwertzeit wurde auf 1,3 , bzw. 2,4 stunden gesch\xc3\xa4tzt .'","b'the elimination half-life was estimated to be 1.3 and 2.4 hours , respectively .'","b'the elimination range was estimated to be found at xolair hours , respectively .'","b'the elimination half-life was estimated to be 1.3 and 2.4 hours , respectively .'"
3504,b'63 ziagen wird in kombination mit anderen antiretroviralen arzneimitteln zur behandlung von infektionen mit dem humanen immunschw\xc3\xa4che-virus ( hiv ) angewendet .',b'63 ziagen is used in combination with other antiretroviral medicinal products for the treatment of infections with medicines used to treat human immunodeficiency virus ( hiv ) infection .',b'ziagen is used in combination with other antiretroviral medicinal products for the patients of infections with medicines used to treat human immunodeficiency virus hiv infection .',b'63 ziagen is used in combination with other antiretroviral medicinal products for the treatment of infections with medicines used to treat human immunodeficiency virus ( hiv ) infection .'
3505,b'die intrazellul\xc3\xa4re cmax von ara-g trat innerhalb von 3 bis 25 stunden am tag 1 auf .',b'the intracellular cmax of ara-g occurred within 3 to 25 hours on day 1 .',b'the single systemic cmax of arag regarding to hours on day .',b'the intracellular cmax of ara-g occurred within 3 to 25 hours on day 1 .'
3506,b'gem\xc3\xa4\xc3\x9f der chmp richtlinie f\xc3\xbcr risiko-management-systeme f\xc3\xbcr arzneimittel zur anwendung beim menschen soll der aktualisierte rmp zur selben zeit wie der n\xc3\xa4chste periodische sicherheitsupdate- bericht ( psur ) eingereicht werden .',"b'according to the specification for medicinal products for human use , the updated rmp should be submitted at the same time as the next periodic sicherheitsupdate- report periodic safety update report ( psur ) .'","b'according to the infectious guidelines for medicinal products for human use , the mutation issues it on the same time as the operation .'","b'according to the chmp guideline for risk management sytems for medicinal products for human use , the updated rmp should be submitted at the same time as the next periodic safety - report periodic safety update report ( psur ) .'"
3507,b'was ist viracept und wof\xc3\xbcr wird es angewendet ?',b'what viracept is and what it is used for 2 .',b'what viracept is and what it is used for',b'what viracept is and what it is used for 2 .'
3508,b'verschlie\xc3\x9fen sie die flasche mit dem kindergesicherten verschluss .',b'close bottle with child-resistant cap .',"b'injection other syringe contains well for the pale package vial , it sits .'",b'close bottle with child-resistant cap .'
3509,"b'gesteigertes sexuelles verlangen ( erh\xc3\xb6hte libido ) , essattacken .'","b'increased sexual desire ) , binge eating . ) .'","b'increased sexual mineralisation , microgram values for morphine . in thiomersal toxocara .'","b'increased sexual desire ( increased libido ) , binge eating .'"
3510,b'die anwesenheit von haca kann mit einer verschlimmerung von infusionsreaktionen oder 39 \xc3\x9cberempfindlichkeitsreaktionen nach der zweiten infusion von weiteren behandlungszyklen verbunden sein ( siehe abschnitt 5.1 ) .',b'the presence of haca may be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses ( see section 5.1 ) .',b'the presence of lansoprazolratiopharm may be associated with worsening of infusion or discontinuation of subsequent eosinophilic see section . .',b'the presence of haca may be associated with worsening of infusion reactions hypersensitivity reactions after the second infusion of subsequent treatment courses ( see section 5.1 ) .'
3511,"b'die hemmung der hiv-protease verhindert die spaltung des gag-pol- polyproteins und f\xc3\xbchrt somit zur bildung unreifer , nicht infekti\xc3\xb6ser viren .'","b'the inhibition of , and risk factors hepatitis , and rarely jaundice , have been reported in patients for hepatitis .'","b'the inhibition of , and risk factors according to ?'","b'the inhibition of the hiv protease hinders the separation of the gag-pol polyprotein and and leads to the formation of unripe , non-infectious viruses .'"
3512,b'es stehen nur begrenzt pharmakokinetische informationen bei kindern und jugendlichen zur verf\xc3\xbcgung ( siehe abschnitt 5.2 ) .',"b'data , although limited , are pharmacokinetic information in children and adolescents ( see section 5.2 ) .'",b'data is recommended over section . .',b'there is only limited pharmacokinetic information available in children and adolescents ( see section 5.2 ) .'
3513,b'eine dosisanpassung ist bei \xc3\xa4lteren patienten nicht erforderlich .',b'no dose adjustment is required in elderly patients .',b'no dose adjustment is required in elderly patients .',b'no dose adjustment is required in elderly patients .'
3514,b'die fehlende wirksamkeit von telbivudin gegen hiv wurde nicht im rahmen von klinischen studien evaluiert .',b'the lack of efficacy of telbivudine against hiv has not been evaluated in clinical studies .',"b'the lacking of narcolepsy , hiv has not been evaluated in clinical studies .'",b'the lack of efficacy of telbivudine against hiv has not been evaluated in clinical studies .'
3515,"b'bei patienten , die gleichzeitig mit oralen antikoagulanzien behandelt werden , sollten die gerinnungsparameter \xc3\xbcberwacht werden ( siehe abschnitte 4.5 und 4.8 ) .'","b'in patients receiving concomitant therapy with other psychotropic drugs , coagulation parameters should be monitored ( see sections 4.5 and 4.8 ) .'","b'in patients receiving concomitant therapy with other serotonergic drugs , coagulation parameters should be monitored should be monitored see sections . and . .'","b'in patients receiving concomitant therapy with other psychotropic drugs , coagulation parameters should be monitored ( see sections 4.5 and 4.8 ) .'"
3516,b'inhalationsger\xc3\xa4ts unterrichtet werden ( siehe dessen gebrauchsanleitung ) .',b'will start ( see its following the instructions for use .',b'all acting following the instructions for use .',b'you will be taught how to use inhalation appliances ( see its following the instructions for use ) .'
3517,"b'es ist nicht gekl\xc3\xa4rt , ob dieses ergebnis auf die wirkung auf m\xc3\xa4nnliche und / oder weibliche tiere zur\xc3\xbcckzuf\xc3\xbchren ist .'",b'it is unclear whether this result due to the effect on male and / or female animals .',b'it is unclear whether this result due to the effect on male and or female animals .',b'it is unclear whether this is a result of the effect on male and / or female animals .'
3518,"b'b. menschen , die ein fahrzeugs lenken oder maschinen zu bedienen haben , mit vorsicht angewendet werden .'","b'b. people who could pose a risk to drive and use machines , should be used with caution .'",b'prepare the diagnosed muscle dose has continue to a risk to drive and use machines .',"b'e.g. people who could pose a risk to drive and use machines , should use with caution .'"
3519,"b'leberinsuffizienz die pharmakokinetik von darifenacin wurde bei personen mit leichter ( child pugh a ) oder m\xc3\xa4\xc3\x9figer ( child pugh b ) leberfunktionsst\xc3\xb6rung untersucht , die einmal t\xc3\xa4glich 15 mg darifenacin bis zum erreichen des steady-state erhielten .'","b'hepatic impairment the pharmacokinetics of darifenacin has been studied in subjects with mild ( child pugh a ) or moderate ( child pugh b ) hepatic impairment , darifenacin 15 mg once daily to steady state .'","b'hepatic impairment the pharmacokinetics of darifenacin has been studied in subjects with mild child pugh in subjects with mild child pugh a or moderate child ratio b hepatic impairment , darifenacin lead to kg mg once daily to steady state levels below b hepatic impairment , phosphate mg once daily'","b'hepatic impairment : the pharmacokinetics of darifenacin have been studied in subjects with mild ( child pugh a ) or moderate ( child pugh b ) hepatic impairment , who received 15 mg darifenacin once daily in a steady state .'"
3520,b'das geschlecht hat keine klinisch bedeutsame wirkung auf die pharmakokinetik von nicotins\xc3\xa4ure ( retardpr\xc3\xa4parat ) .',b'gender has no clinically meaningful effect on the pharmacokinetics of nicotinic acid ( prolonged-release formulation ) .',b'gender has no clinically meaningful effect on the pharmacokinetics of nicotinic acid scale against coaprovel in smaller acid prolongedrelease ingelheim .',b'gender has no clinically meaningful effect on the pharmacokinetics of nicotinic acid ( prolonged-release formulation ) .'
3521,"b'es bestehen jedoch unterschiede sowohl in der dosierungsempfehlung ( 12,5 mg / kg / tag versus 10 mg / kg / tag ) als auch in der behandlungsdauer ( 8 versus 7 tage ) .'","b'there are , however , differences in both the recommended posology ( 12.5 mg / kg / day versus 10 mg / kg / day ) and in the duration of treatment ( 8 versus 7 days ) .'","b'there are , however , differences in both the recommended dosage reduction versus mg kg day vs .'","b'there are , however , differences in both the recommended posology ( 12.5 mg / kg / day versus 10 mg / kg / day ) and in the duration of treatment ( 8 versus 7 days ) .'"
3522,"b'eine akute adrenale krise kann m\xc3\xb6glicherweise durch umst\xc3\xa4nde wie verletzung , operation , infektion oder jede schnelle dosisreduktion ausgel\xc3\xb6st werden .'","b'4.5 interaction with other medicinal products and other forms of interaction , operation , infection or any rapid reduction of the dose .'","b'. interaction with other medicinal products and other forms of ribavirin of age , the dose due to other rapid reduction of the dose .'","b'4.5 an acute adrenal crisis can possibly be caused by circumstances such as injury , operation , infection or any rapid reduction of the dose .'"
3523,"b'besondere vorsicht bei der anwendung von macugen ist erforderlich bitte sprechen sie mit ihrem arzt , wenn sie auf irgendwelche substanzen allergisch reagieren .'",b'take special care with macugen please speak with your doctor if you are allergic to any substances .',"b'look appropriate , the in the product to treatment two treatment with this included with bondenza needs during medicines if age is medical substances .'",b'take special care with macugen . please speak with your doctor if you are allergic to any substances .'
3524,b'rotarix ist ausschlie\xc3\x9flich zur oralen anwendung bestimmt .',b'rotarix is for oral use only .',b'rotarix is for oral use only .',b'rotarix is for oral use only .'
3525,b'veranschlagt sind mittel zur deckung der beitr\xc3\xa4ge der agentur zur krankheitsf\xc3\xbcrsorge .',"b""this appropriation is intended to cover the agency 's indicated krankheitsf\xc3\xbcrsorge .""",b'the inr is intended to cover the last winthrop unknown .',"b""this appropriation is intended to cover the agency 's indicated sickness insurance ."""
3526,b'in dieser studie wurden reaktionen an der injektionsstelle sowie nekrosen an der injektionsstelle seltener beobachtet als in den anderen pivotalen studien .',"b'in this trial , reactions at the injection site , injection site necrosis were observed less than that of the other in the pivotal studies .'","b'in this trial , reactions at the injection site , injection site , injection site , injection site necrosis were observed less than that of the recurrence site of the therapy of iris results receiving into the mother studies .'","b'in this trial , reactions at the injection site , such as necrosis , were observed less than that of the other pivotal studies .'"
3527,"b'die operative entfernung war im anschluss an die chemotherapie , vor oder nach der strahlentherapie , m\xc3\xb6glich .'","b'the removal was following the chemotherapy before or after radiotherapy , are possible .'","b'the removal was following the chemotherapy before or viraemia by zidovudine as treated in radiotherapy , are possible .'",b'the removal was possible following the chemotherapy before or after radiotherapy .'
3528,b'nicht \xc3\xbcber 25 \xc2\xb0 c lagern .',b'do not store above 25 \xc2\xb0 c.',b'do not store above c .',b'do not store above 25 \xc2\xb0 c.'
3529,"b'achten sie wieder darauf , dass sie nicht die kan\xc3\xbcle ber\xc3\xbchren und dass die kan\xc3\xbcle keine andere oberfl\xc3\xa4che ber\xc3\xbchrt ( siehe abb . 11 ) .'","b'again , you may not to touch the needle or allow it to touch any surfaces ( see diagram 11 ) .'",b'gently can need may not to touch the needle or allow it to have to avoid any haemostasis see diagram .',"b'again , you may not to touch the needle or allow it to touch any surfaces ( see diagram 11 ) .'"
3530,b'wie wirkt arixtra ?',b'how does arixtra work ?',b'how does arixtra work ?',b'how does arixtra work ?'
3531,"b'protelos sollte bei patientinnen mit erh\xc3\xb6htem risiko f\xc3\xbcr vte mit vorsicht angewendet werden , auch bei patientinnen mit vte in der vorgeschichte .'","b'protelos should be used with caution in patients at increased risk of vte , including patients with a past history of vte .'",b'protelos should be used with caution in patients at increased risk of vte to a risk of vte is reduced have been used with caution in patients at increased risk of vte compared with a past history of vte .',"b'protelos should be used with caution in patients with increased risk of vte , including patients with a past history of vte .'"
3532,"b'eine korrelation der in-vitro-wirksamkeit mit dem klinischen ergebnis ist aufgrund der komplexit\xc3\xa4t der patientengruppen schwierig , breakpoints f\xc3\xbcr voriconazol m\xc3\xbcssen erst noch definiert werden .'",b'a correlation between the in vitro antiviral activity with clinical outcome is still as due to ( a ) cultivating a host cell populations is difficult to breakpoints for voriconazole should be used only .',b'a primary cmax activity with electrocardiogram longer in cytidine interactions for voriconazole should be found only no therapy of a vaccine may be used who has cause for gemfibrozil may be satisfactorily excreted study is difficult to grade for voriconazole should be observed only the development of the provocation by',"b'a correlation between the in vitro antiviral activity with clinical outcome is difficult due to the complexity of the patient group , breakpoints for voriconazole must first be defined .'"
3533,b'ihr levemir innolet ist f\xc3\xbcr eine sehr genaue und sichere funktionsweise entwickelt worden .',b'your levemir innolet is designed to work accurately and safely .',b'your levemir innolet is designed to work accurately and safely .',b'your levemir innolet is designed to work accurately and safely .'
3534,"b'es blockiert vermutlich alle wirkungen von angiotensin ii , die \xc3\xbcber den at1-rezeptor vermittelt werden , unabh\xc3\xa4ngig vom ursprung oder syntheseweg von angiotensin ii.'","b'mechanism of action : it is expected to block all actions of angiotensin-ii mediated by the at1 receptor , , or syntheseweg of angiotensin ii .'","b'mechanism of action , combine by which is the possible carbon , , or dilation of angiotensin ii .'","b'mechanism of action : it is expected to block all actions of angiotensin-ii mediated by the at1 receptor , or synthetic pathway of angiotensin ii .'"
3535,b'stechen sie die nadel in einem winkel von 45 \xc2\xb0 bis 90 \xc2\xb0 in die gefaltete haut .',b'insert the needle at a 45 \xc2\xb0 to 90 \xc2\xb0 angle using a m / min .',b'keep the dose down remove a to chewed using a urine .',b'insert the needle at a 45 \xc2\xb0 to 90 \xc2\xb0 angle into the folded skin .'
3536,b'bondronat darf nicht bei kindern angewendet werden .',b'bondronat should not be used in children .',b'bondronat should not be used in children .',b'bondronat should not be used in children .'
3537,b'eine erh\xc3\xb6hte inzidenz an hepatozellul\xc3\xa4ren karzinomen wurde bei allen m\xc3\xa4nnlichen m\xc3\xa4usen in den mit amprenavir behandelten gruppen beobachtet .',b'an increased incidence of hepatocellular carcinoma was observed in all male mice in amprenavir .',b'an increased incidence of alemtuzumab saturation was observed approximately potential .',b'an increased incidence of hepatocellular carcinoma was observed in all male mice in amprenavir .'
3538,"b'die anderen in plasma , urin und f\xc3\xa4zes nachgewiesenen metaboliten repr\xc3\xa4sentieren etwa 3 % der plasma-auc oder weniger .'","b'the other proven in plasma , urine and faeces as metabolites or equal than 3 % of the plasma or less .'","b'the other endpoints in plasma , urine and faeces and faeces very paclitaxel or justified than of the plasma or less .'","b'the other metabolites proven in plasma , urine and faeces represents approxiamtely 3 % of the plasma-auc or less .'"
3539,b'die lyophilisierte haemophilus influenzae typ b ( hib ) -komponente ist ein wei\xc3\x9fes pulver .',b'the lyophilised haemophilus influenzae type b ( dtpw-hbv ) component is a turbid is a white powder .',b'a separate neospect antithrombotic liposomal type b naloxone haemagglutinin in the ph trabecular agent and printed single strip .',b'the lyophilised haemophilus influenzae type b ( dtpw-hbv ) component is a white powder .'
3540,b'- der wirkstoff ist insulin human .',b'- the active substance is insulin human .',b'the active substance is insulin human .',b'- the active substance is insulin human .'
3541,b'der nutzen der behandlung mit zavesca f\xc3\xbcr den patienten sollte regelm\xc3\xa4\xc3\x9fig bewertet werden ( siehe abschnitt 4.4 ) .',"b'the benefit of treatment with zavesca , the patient should be evaluated on a regular basis ( see section 4.4 ) .'","b'the benefit of treatment with zavesca , the patient should be evaluated on a regular basis see section . .'","b'the benefit of treatment with zavesca , the patient should be evaluated on a regular basis ( see section 4.4 ) .'"
3542,b'warum wurde sifrol zugelassen ?',b'why has sifrol been approved ?',b'why has sifrol been approved ?',b'why has sifrol been approved ?'
3543,b'die ursache dieser ver\xc3\xa4nderungen sowie deren langzeitauswirkung auf die gesundheit sind zur zeit nicht bekannt .',b'the cause of these changes in the langzeitauswirkung on the health are currently taking .',b'the cause side effects in the determines the dog amount of the knee on the health concentration were currently taking .',b'the cause of these changes in the long-term effects on the health are currently unknown .'
3544,b'torisel wurde bei h\xc3\xa4modialysepflichtigen patienten nicht untersucht .',b'torisel has not been studied in patients that require haemodialysis .',b'torisel has not been studied in patients that require haemodialysis .',b'torisel has not been studied in patients that require haemodialysis .'
3545,b'in vitro studien zeigen ein sehr geringes potenzial f\xc3\xbcr wechselwirkungen mit anderen arzneimitteln oder wechselwirkungen die durch plasmaeiwei\xc3\x9fbindung hervorgerufen werden ( siehe abschnitt 5.2 ) .',b'in vitro studies show a very low potential for interactions with other medicinal products and other forms of interaction and caused by plasmaeiwei\xc3\x9fbindung ( see section 5.2 ) .',b'in vitro studies show an very low potential for interactions with other medicinal products and other forms of interaction and caused in panss see section . januvia .',b'in vitro studies show a very low potential for interactions with other medicinal products and other forms of interactions caused by plasma protein binding ( see section 5.2 ) .'
3546,"b'im durchschnitt wurde ein 20,5facher anstieg der hbs-antik\xc3\xb6rper-titer nach der auffrischimpfung beobachtet .'","b'these subjects was 20,5facher increase in hbs-antik\xc3\xb6rper-titer were observed after booster vaccination .'",b'these subjects was called combination at the serum interval .',b'there was an average 20.5-fold increase in hb antibody titre observed after booster vaccination .'
3547,b'6 eliminationshalbwertszeit ( t1 / 2 ) kann die wirkung von tocilizumab auf die cyp450-enzymaktivit\xc3\xa4t mehrere wochen nach dem ende der therapie persistieren .',"b'6 elimination half-life ( t1 / 2 ) , the effect of tocilizumab on the cyp450-enzymaktivit\xc3\xa4t persist for several weeks after the end of treatment .'",b'elimination halflife t such the effect of tocilizumab on the aptt of tocilizumab on the subpopulation of tocilizumab on the aptt of tocilizumab on the lymphadenopathy . changes for several weeks after the end of treatment .',"b'6 elimination half-life ( t1 / 2 ) , the effect of tocilizumab on the cyp450 enzyme activity may persist for several weeks after the end of treatment .'"
3548,b'mehr als 98 % der testpersonen mit erhaltungsdosierung zeigten eine thrombozytenaggregationshemmung \xe2\x89\xa5 20 % .',b'more than 98 % of the subjects with loading dose and showed inhibition of platelet aggregation of \xe2\x89\xa5 20 % .',b'there mixed on patients with herpositive than level rate .',b'more than 98 % of the subjects with maintenance dose and showed inhibition of platelet aggregation of \xe2\x89\xa5 20 % .'
3549,"b'wenn versehentlich paraven\xc3\xb6s injiziert wurde , kann das paraven\xc3\xb6se gewebe gesch\xc3\xa4digt werden .'","b'if accidentally care has been injected , paraven\xc3\xb6se damaged tissues .'","b'if xagrid care has been injected , by the shunts .'","b'if care has been accidentally injected , paravenous tissues can be damaged .'"
3550,b'danach schaltet sich das system ab und kann keine weiteren dosen mehr abgeben .',b'then will the system and may receive further doses of no more .',b'subsequently amounts of potentially area of the other',b'then the system deactivates and no further doses may be given .'
3551,b'vermutlich sind keine schwerwiegenden folgen zu bef\xc3\xbcrchten .',b'following no serious consequences are concerned that you may have .',"b'following no serious reactions , therefore , long levodopa .'",b'there are probably no serious consequences to fear .'
3552,"b'informieren sie unverz\xc3\xbcglich ihren arzt , wenn sie daran denken oder sich danach f\xc3\xbchlen , sich etwas anzutun .'","b'tell your doctor immediately if you remember worse , feel slightly anzutun .'",b'tell your doctor immediately if you remember',b'tell your doctor immediately if you think or feel like causing harm to yourself .'
3553,"b'das befassungsverfahren gem\xc3\xa4\xc3\x9f artikel 29 absatz 4 der richtlinie 2001 / 83 / eg wurde am 3. m\xc3\xa4rz 2008 beim chmp beantragt , weil deutschland und frankreich den antrag als nicht akzeptabel betrachteten .'","b'the referral procedure under article 29 ( 4 ) of directive 2001 / 83 / ec , as amended , was renewed on 3 march 2008 , the chmp requested in germany and france , the application for not .'","b'the referral procedure under the scan of directive ec , as amended in two protein does on march , that well as amended , the chmp positive in vivo works in the selected the psur tissues which were the vaccine roll in activated and filter organs in germany and leukocytes'","b'the referral procedure under article 29 paragraph 4 of the directive 2001 / 83 / ec was amended on 3 march 2008 , the chmp because germany and france considered the request unacceptable .'"
3554,"b'zu beginn der behandlung verursacht introna gew\xc3\xb6hnlich grippe\xc3\xa4hnliche krankheitszeichen mit fieber , erm\xc3\xbcdung , kopfschmerzen , muskelschmerzen , gelenkschmerzen und sch\xc3\xbcttelfrost .'","b'at the beginning of treatment with introna , you may experience a flu-like reaction , with fever , fatigue , headache , muscle ache , joint pain and chills / rigors .'","b'at the beginning of treatment with introna , you may experience a flulike , respiratory , headache , muscle diaphragmatic disorders in joint ideas .'","b'at the beginning of treatment with introna , you may experience a flu-like reaction with fever , fatigue , headache , muscle ache , joint pain and chills .'"
3555,b'interaktion mit indinavir / ritonavir nicht untersucht \xe2\x86\x91 dexamethason exposition erwartet ( cyp3a inhibition ) . \xe2\x86\x93 indinavir plasmakonzentrationen m\xc3\xb6glicherweise erwartet ( cyp3a- induktion ) .',b'buspirone interaction with indinavir / ritonavir not studied \xe2\x86\x91 dexamethasone exposure expected ( cyp3a inhibition ) . \xe2\x86\x93 indinavir plasma concentrations may be expected ( cyp3a induction ) .',"b'morphologic interaction with the reduction value is very a decreas concentrations may be expected cypa ci cmax in the cardiotoxic process were not been expected cypa ci the adjusted auc increases , a auc .'",b'interaction with indinavir / ritonavir not studied \xe2\x86\x91 dexamethasone exposure expected ( cyp3a inhibition ) . \xe2\x86\x93 indinavir plasma concentrations may be expected ( cyp3a induction ) .'
3556,b'13 schlussfolgerungen aus diesen studien auf rapinyl .',b'13 conclusions from these studies to rapinyl .',b'there introduction the skin residues may be used for before limited .',b'13 conclusions from these studies for rapinyl .'
3557,b'nach herstellung der l\xc3\xb6sung sollten sie sie sofort injizieren .',b'after preparing the solution you should use it immediately .',b'after preparing the solution you should use it immediately .',b'iafter preparing the solution you should use it immediately .'
3558,b'deshalb kontakt mit haut oder augen vermeiden .',"b'therefore , contact with skin or eyes should be made as provided .'","b'therefore , contact with skin or eyes should be made as provided .'","b'therefore , contact with skin or eyes should be avoided .'"
3559,b'halten sie die flasche aufrecht und setzen sie den flaschenadapter zum eindr\xc3\xbccken in den flaschenhals ein .',b'hold the bottle with the needle pointing up and tap the press-in bottle adaptor into the neck of the bottle .',b'hold the bottle with the reconstituted up and tap the risks piece into the neck of the introna cup .',b'hold the bottle upright and use the push the bottle adaptor into the neck of the bottle .'
3560,b'diese zusammenfassung wurde zuletzt im 07-2007 aktualisiert .',b'this summary was last updated in 07-2007 .',b'this summary was last updated in .',b'this summary was last updated in 07 / 2007 .'
3561,b'der injektionsknopf muss vollst\xc3\xa4ndig eingedr\xc3\xbcckt werden .',b'the injection button should be pressed in completely .',b'the injection button should be tightened in sifrol .',b'the injection button should be pressed in completely .'
3562,"b'wenn sie eine dosis byetta ausgelassen haben , lassen sie diese dosis ausfallen und nehmen sie die n\xc3\xa4chste dosis zum n\xc3\xa4chsten vorgesehenen zeitpunkt .'","b'if you miss a dose of byetta , skip the dose and take the next dose the next time .'","b'if you miss a dose of intanza , skip the dose and take the next time before a remaining .'","b'if you miss a dose of byetta , skip the dose and take the next dose the next time .'"
3563,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von ammonaps ein kleiner messl\xc3\xb6ffel ammonaps granulat enth\xc3\xa4lt 118 mg natrium .',b'important information about some of the ingredients of ammonaps each small spoon of ammonaps granules contains 118 mg of sodium .',b'important information about some of the ingredients of ammonaps and beta or c is diluted into smaller bioactivity .',b'important information about some of the ingredients of ammonaps : each small spoon of ammonaps granules contains 118 mg of sodium .'
3564,"b'die mehrheit der patienten hatte bereits eine lange vorgeschichte von cml , einschlie\xc3\x9flich weitreichender vorbehandlung mit sonstigen antineoplastika wie imatinib sowie hydroxyharnstoff , interferon und zum teil sogar erfolglosen knochenmarktransplantationen ( tabelle 6 ) .'","b'the majority of patients had ever had a long history of cml , including weitreichender pre-treatment with other other antineoplastic agents such as imatinib and hydroxyurea , interferon and is even used between the contact ( table 6 ) .'",b'the majority of patients had tendency had the long history of sensitivity reduces with other other antineoplastic agents such as v as active and characterised between the instruction table .',"b'the majority of patients had had a long history of cml , including extensive pre-treatment with other antineoplastic agents such as imatinib and hydroxyurea , interferon and is even used between the contact ( table 6 ) .'"
3565,"b'die gruppe von arzneimitteln , zu denen epivir geh\xc3\xb6rt ( nukleosidanaloge reverse-transkriptase- hemmer ) , kann eine erkrankung hervorrufen , die als laktatazidose ( erh\xc3\xb6hter milchs\xc3\xa4urewert im blut ) bezeichnet wird und von einer lebervergr\xc3\xb6\xc3\x9ferung begleitet sein kann .'","b'lactic acidosis : the class of medicines to which epivir belongs ( nucleoside analogue reverse transcriptase inhibitors ) can cause a condition called lactic acidosis ( excess of lactic acid in your blood ) , together with an enlarged liver .'",b'lactic acidosis the class of medicines to which are interact .',b'the class of medicines to which epivir belongs ( nucleoside analogue reverse transcriptase inhibitors ) can cause a condition called lactic acidosis ( excess of lactic acid in your blood ) and can occur together with an enlarged liver .'
3566,"b'deshalb darf ariclaim nicht gleichzeitig mit einem potenten inhibitor von cyp1a2 , wie fluvoxamin , angewendet werden ( siehe abschnitt 4.3 ) .'","b'therefore , ariclaim should not be given in combination with potent inhibitors of cyp1a2 like fluvoxamine ( see section 4.3 ) .'","b'therefore , ariclaim should not be given in combination with potent inhibitors of cypa infections .'","b'therefore , ariclaim should not be given in combination with potent inhibitors of cyp1a2 like fluvoxamine ( see section 4.3 ) .'"
3567,"b'die blister im umkarton aufbewahren , um den inhalt vor licht zu sch\xc3\xbctzen .'",b'keep the blister in the outer carton in order to protect it from light .',b'keep the blister in the outer carton in order to protect it from light .',b'keep the blister in the outer carton in order to protect it from light .'
3568,"b'injizieren sie durch dr\xc3\xbccken der kolbenstange soviel luft in die flasche , bis sie einen deutlichen widerstand versp\xc3\xbcren .'","b'inject the middle surface into the vial , until you experience a significant ( 19 ) .'","b'inject the spf surface into the vial , until you experience a significant .'","b'inject the middle surface into the vial , until you experience a significant resistance .'"
3569,"b'bei patienten , die mit anderen arzneimitteln behandelt wurden , die mit lebertoxizit\xc3\xa4t assoziiert werden , wird die \xc3\x9cberwachung der leberenzyme ebenfalls empfohlen .'","b'in patients treated with other medicinal products associated with liver toxicity , monitoring of liver enzymes is also recommended .'","b'in patients treated with other medicinal products associated with liver disorders , dose of liver enzymes is also recommended .'","b'in patients treated with other medicinal products associated with liver toxicity , monitoring of liver enzymes is also recommended .'"
3570,"b'\xe2\x88\x85 bet\xc3\xa4tigen sie nicht den roten druckknopf , bevor die sicherheitsh\xc3\xbclse vollst\xc3\xa4ndig eingeschoben ist .'",b'\xe2\x88\x85 press the red button before to fully retract .',b'press the red button before to fully caretaker .',b'press the red button before to fully retract .'
3571,"b'der behandelnde tierarzt sollte bedenken , dass die allergischen symptome nach beendigung der symptomatischen therapie wieder aufflammen k\xc3\xb6nnen .'",b'the clinician veterinarian should be borne in mind that the allergic signs of symptomatic therapy may start up again .',b'the clinician veterinarian are carefully practised for to increase .',b'the treated veterinarian should bear in mind that the allergic signs after the end of therapy may start up again .'
3572,"b'bei dieser erkrankung produzieren die nebenschilddr\xc3\xbcsen im nacken zu viel parathormon ( pth ) . "" sekund\xc3\xa4r "" bedeutet , dass der hyperparathyreoidismus durch eine andere krankheit verursacht wird .'","b'in this condition produce the parathyroid glands in the neck produce too much parathyroid hormone ( pth ) . "" secondary \'means that the hyperparathyroidism is caused by another condition .'",b'in this wish to a help of this condition produce the member to test with it enables the neck falls too much weakened hormone w e be cross to has grow that it is caused by another condition .',"b'in this condition produce the parathyroid glands in the neck produce too much parathyroid hormone ( pth ) . "" secondary \'means that the hyperparathyroidism is caused by another condition .'"
3573,"b'wenn das blut gerinnt , ist dies darauf zur\xc3\xbcckzuf\xc3\xbchren , dass spezielle zellen im blut , die blutpl\xc3\xa4ttchen , zusammenklumpen ( aggregieren ) .'","b'when the blood clots , this is due to special cells in the blood , the platelets , sticking together ( aggregating ) .'","b'when the tests of the blood clots , this is due to be not occur at the blood , animals .'","b'when the blood clots , this is due to special cells in the blood , the platelets , sticking together ( aggregating ) .'"
3574,b'bei kindern richtet sich die dosis nach dem alter .',"b""for children , dose will be based on the patient 's age .""","b'for children , dose will be based on the patient s dose .'","b""for children , dose will be based on the patient 's age ."""
3575,"b'catechol und andere arzneimittel , die durch die catechol-o-methyltransferase ( comt ) metabolisiert werden :'",b'deoxycholate and other medicinal products metabolised by catechol-o-methyltransferase ( comt ) .',b'cystinosis and other medicinal products metabolised by catecholomethyltransferase r .',b'catechol and other medicinal products metabolised by catechol-o-methyltransferase ( comt ) .'
3576,b'baraclude k\xc3\xb6nnte eine leicht abf\xc3\xbchrende wirkung haben .',b'baraclude could which may have a mild laxative effect .',b'baraclude could which may have a mild affinity are reached in the steadystate agent .',b'baraclude could which may have a mild laxative effect .'
3577,"b'daher k\xc3\xb6nnen sich die plasmakonzentrationen von substanzen , die \xc3\xbcber cytochrom p450 verstoffwechselt werden , \xc3\xa4ndern .'","b'therefore , the plasma concentrations of substances metabolised by cytochrome p450 .'","b'therefore , the plasma concentrations of transferable metabolised by cytochrome p .'","b'therefore , the plasma concentrations of substances metabolised by cytochrome p450 may change .'"
3578,b'bewahren sie es in der originalverpackung auf .',b'keep it in the original package .',b'keep it in the original package .',b'keep it in the original package .'
3579,"b'im gegensatz dazu \xc3\xa4nderte sich der sbd um + 0,1 mmhg und der dbd um -0,3 mmhg bei den patienten , die unterschiedliche dosen irbesartan erhalten hatten ( siehe abschnitt 4.2 ) .'","b'in contrast , did not alter ( low dose ) + 0.1 mmhg and sedbp by -0.3 mmhg in the patients who had the doses of irbesartan ( see section 4.2 ) .'","b'in contrast , that not causes of the dose of transplant response in the patients who had the doses of irbesartan see section . .'","b'in contrast , the sbd changed by + 0.1 mmhg and sedbp by -0.3 mmhg in the patients who received different doses of irbesartan ( see section 4.2 ) .'"
3580,"b'nach der gabe dieses arzneimittels sollten die augen und die haut f\xc3\xbcr 24 stunden keinen starken lichtquellen ( z.b. op-beleuchtung , direktes sonnenlicht oder helle , intensive innenbeleuchtung ) ausgesetzt werden .'","b'after administration of this medicinal product of eyes and skin ) should be withheld for 24 hours did not under strong light ( for example operating illumination , direct sunlight or brightly .'","b'after administration of this medicinal product of eyes and skin betaferon , a strict agent , direct sunlight or prescribing an close solid dosage must be brought and skin normally provides a teaspoon or hospital needle .'","b'after administration of this medicinal product , eyes and skin should be kept out of strong sources of light for 24 hours ( for example operating theatre illumination or bright intense interior lighting .'"
3581,"b'bei \xc3\xa4lteren patienten , bei diuretika einnehmenden patienten sowie patienten mit anderweitigem volumenmangel kann das risiko hierf\xc3\xbcr erh\xc3\xb6ht sein .'","b'in elderly patients , the glucose in patients with diuretics and in patients with anderweitigem volume depletion may increase the risk of the events may be increased .'","b'an inhalation patients , the glucose in patients with diuretics and in patients with appetite of the risk of the effects may increase the risk and patients with electrolyte acid may increase the risk of the mice plastics make at a bone virus in patients with a combination of the'","b'in elderly patients , patients taking diuretics and in patients with other volume depletion the risk may be increased .'"
3582,"b'die empfohlene dosis f\xc3\xbcr erwachsene betr\xc3\xa4gt 0,1 mmol pro kilogramm k\xc3\xb6rpergewicht ( mmol / kg kg ) .'",b'the recommended dose for adults is 0.1 mmol per kilogram body weight ( mmol / kg bw ) .',b'the recommended dose for adults is . mmol per kilogram body weight mmol kg split kg maois .',b'the recommended dose for adults is 0.1 mmol per kilogram body weight ( mmol / kg bw ) .'
3583,"b'sehr h\xc3\xa4ufige nebenwirkungen ( diese k\xc3\xb6nnen mehr als 1 von 10 behandelten betreffen ) \xc3\x9cbelkeit , kopfschmerzen , mundtrockenheit , schl\xc3\xa4frigkeit , m\xc3\xbcdigkeit , schwindel und verstopfung .'","b'very common side effects ( these can affect more than 1 in 10 patients treated ) feeling sick ( nausea ) , headache , dry mouth , somnolence , fatigue , dizziness and constipation .'","b'very common side effects these us the body disorders reported , tachycardia , dry weakness , somnolence , dizziness and constipation .'","b'very common side effects ( these can affect more than 1 in 10 patients treated ) feeling sick ( nausea ) , headache , dry mouth , somnolence , fatigue , dizziness and constipation .'"
3584,b'leberfunktionsst\xc3\xb6rungen der einfluss von leberfunktionsst\xc3\xb6rungen unter der porfimer-natrium-behandlung wurde nicht untersucht ( siehe abschnitte 4.3 und 4.4 ) .',b'hepatic impairment the influence of liver function abnormalities during the porfimer-natrium-behandlung has not been studied ( see sections 4.3 and 4.4 ) .',b'hepatic impairment the influence of liver function must not been studied see sections . and . .',b'hepatic impairment . the influence of liver function abnormalities during the porfimer sodium treatment has not been studied ( see sections 4.3 and 4.4 ) .'
3585,"b'4 technetium ( 99mtc ) depreotid-injektionsl\xc3\xb6sung ist ein radioaktives arzneimittel zur diagnostischen anwendung , dessen wirkungsweise auf der bindung eines synthetischen peptids an somatostatin- rezeptoren beruht .'","b'4 ( 99mtc ) depreotid-injektionsl\xc3\xb6sung is a radioactive medicinal product is for diagnostic use , the mechanism of action is based on binding to mammalian stimulation site .'",b'cystinose fibrates is a characters of recombinant the the area of action is based on lopinavir intermittently .',"b'4 technetium ( 99mtc ) depreotide injection solution is a radioactive medicinal product is for diagnostic use , the mechanism of action is based on the binding of a synthetic peptid with a somatostatin receptor .'"
3586,"b'nicht bekannt : sepsis , bronchitis , herpes simplex , candidose .'","b'not known : sepsis , bronchitis , herpes simplex , candidiasis .'","b'for ml grade sepsis , atcvet agonists .'","b'not known : sepsis , bronchitis , herpes simplex , candidiasis .'"
3587,"b'136 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'136 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'136 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'"
3588,b'behandelte pferde d\xc3\xbcrfen erst 12 tage nach dem letzten tag der behandlung mit quadrisol geschlachtet werden .',b'treated horses should not be slaughtered for 12 days after the last day of treatment with quadrisol were slaughtered at .',b'those produced as a click of the last day of treatment with nexavar .',b'treated horses should not be slaughtered for 12 days after the last day of treatment with quadrisol .'
3589,b'st\xc3\xb6rungen von blut- und lymphsystem :',b'on the day of dialysis :',b'on the day of dialysis',b'disorders of the blood and lymphome system :'
3590,b'eine woche nach der verabreichung von oralem risperidon sind 70 % der dosis mit dem urin und 14 % mit dem stuhl ausgeschieden .',"b'one week after administration of oral risperidone , 70 % of the dose is excreted in the urine and 14 % in the faeces .'","b'one week after administration of oral risperidone , of the average and in the faeces .'","b'one week after administration of oral risperidone , 70 % of the dose is excreted in the urine and 14 % in the faeces .'"
3591,"b'es ist wichtig , dass sie keine einnahme von viread auslassen .'",b'it is important that you miss a dose did not take viread .',b'it is important that you miss a dose that not take viread .',b'it is important that you do not miss a dose of viread .'
3592,b'\xc3\x9cber \xc3\xbcberm\xc3\xa4\xc3\x9fig lang anhaltende und manchmal schmerzhafte erektionen wurde nach der einnahme von sildenafil berichtet .',b'over excessive and sometimes painful erections have been reported after taking sildenafil .',b'raised negativ and sometimes painful tightly capable to the reduction of dose is like hours do not in high doses of additional amount of the reduction .',b'over excessive and sometimes painful erections have been reported after taking sildenafil .'
3593,b'ebenso waren f\xc3\xbcr dehydro-aripiprazol die geometrischen mittel der cmax und auc nach der gemeinsamen anwendung mit carbamazepin um 69 % bzw. 71 % niedriger als nach monotherapie mit aripiprazol .',"b'also , treatment were in the same range for dehydro-aripiprazole the geometric means of cmax and auc after , 69 % and 71 % lower , respectively , than those following treatment with aripiprazole alone .'","b'also not been beneficial from the same range for leukaemia of cmin , adults with aripiprazole alone .'","b'also , the geometric means of cmax and auc were 69 % and 71 % lower in the same range for dehydro-aripiprazole after use with carbamazepin than those following treatment with aripiprazole alone .'"
3594,"b'puregon 300 ie / 0,36 ml injektionsl\xc3\xb6sung wurde zur anwendung mit dem puregon pen entwickelt .'",b'puregon 300 iu / 0.36 ml solution for injection is designed for use in conjunction with the puregon pen and should be administered subcutaneously .',b'puregon iu . ml solution for injection is designed for label or colorless .',b'puregon 300 iu / 0.36 ml solution for injection is designed for use in conjunction with the puregon pen .'
3595,b'72 \xe2\x89\xa5 1 / 10.000 < 1 / 1.000 ) aufgelistet . innerhalb jeder h\xc3\xa4ufigkeitsgruppe werden die nebenwirkungen nach abnehmendem schweregrad angegeben .',"b'72 \xe2\x89\xa5 1 / 10,000 to 1 / 1,000 ) . within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'","b'as when superovulation , . within each frequency grouping , undesirable effects reported on the concomitant gastrointestinal related to well to those to dogs .'","b'72 \xe2\x89\xa5 1 / 10,000 to 1 / 1,000 ) . within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'"
3596,b'warum wurde zavesca zugelassen ?',b'why has zavesca been approved ?',b'why has zavesca been approved ?',b'why has zavesca been approved ?'
3597,"b'in der subgruppe von patienten , die mit fondaparinux oder enoxaparin behandelt und einer pci unterzogen wurden , erlitten 8,8 % bzw.'",b'in the subgroup of patients who were treated with fondaparinux or enoxaparin and pci were experienced 8.8 % and 108 % respectively .',"b'in the subgroup exposure of patients who were treated with fondaparinux , a case of a temporary portion as the drug upper male avastin .'",b'in the subgroup of patients who were treated with fondaparinux or enoxaparin and underwent a pci experienced 8.8 % .'
3598,b'( 15 ) l\xc3\xb6ste kimmo leppo ab der sitzung vom 22.',b'( 15 ) the kimmo leppo of 22 august 2007 .',b'the shedantigen spectrometer witht the elimination of european precursor .',b'( 15 ) unfixed kimmo leppo as of the meeting of 22'
3599,"b'zu auswirkungen wie aggressives verhalten ( manchmal gegen andere personen gerichtet ) , konfusion und ver\xc3\xa4nderungen des geisteszustands sind mit alfa-interferonen beobachtet worden .'","b'too aggressive behaviour ( sometimes directed against others ) , confusion and alterations of mental status have been observed with alpha interferons .'",b'too an temporary medication sometimes attributable to a secondline side of total status have been observed with bone interferons .',"b'side effects like aggressive behaviour ( sometimes directed against others ) , confusion and alterations of mental status have been observed with alpha interferons .'"
3600,"b'novomix 70 enth\xc3\xa4lt metacresol , welches eine allergische reaktion verursachen kann .'","b'novomix 70 contains metacresol , which may cause allergic reactions .'","b'novomix contains metacresol , which may cause allergic .'","b'novomix 70 contains metacresol , which may cause allergic reactions .'"
3601,"b'die tagesdosis wird alle 4-7 tage nach anweisung ihres arztes erh\xc3\xb6ht , bis ihre symptome unter kontrolle sind ( erhaltungsdosis ) .'",b'the daily dosage is administered every 4-7 days as instructed by your doctor gradually increased until your symptoms are controlled ( maintenance dose ) .',b'the daily dosage is administered every days as instructed by your doctor gradually measured against until your symptoms are mild by the medicine .',b'the daily dosage is increased every 4-7 days as instructed by your doctor until your symptoms are controlled ( maintenance dose ) .'
3602,b'die bedruckung ist blau .',b'the reduction blue .',b'the reduction bottles .',b'the print is blue .'
3603,b'die robustheit des behandlungseffekts zeigte sich auch in der verz\xc3\xb6gerung des fortschreitens der erkrankung hin zu einer multiplen sklerose gem\xc3\xa4\xc3\x9f den kriterien nach mcdonald :',b'the robustness of the behandlungseffekts also demonstrated a delay in disease progression to treat multiple sclerosis according to the criteria of the following mcdonald :',"b'the nnt of the trigger on a inactive infection also been defined a delay in section area to treat multiple sclerosis according to the infections rate to treat multiple sclerosis according to the criteria of the following indicator according to the or other recognition ophthalmological , a efficacy value after'",b'the robustness of the treatment effects also pointed to a delay in disease progression to treat multiple sclerosis according to the criteria of mcdonald :'
3604,b'wie ist zomarist einzunehmen ?',b'how to take zomarist 4 .',b'how to take zomarist .',b'how to take zomarist ?'
3605,b'soliris muss von medizinischem fachpersonal verabreicht werden .',b'soliris should be given by a healthcare professional .',b'soliris immediately it suffer evaluation should be checked by a healthcare professional .',b'soliris must be given by a healthcare professional .'
3606,b'bei gleichzeitiger anwendung mit invirase / ritonavir erh\xc3\xb6ht sich die konzentration dieser arzne istoffe mehrfach .',b'when co-administered with invirase / ritonavir increases levels of these arzne istoffe repeated .',b'when coadministered with invirase ritonavir increases a termination of renal burden of post x breakpoint .',"b'when co-administered with invirase / ritonavir , the concentration of the medicine increase repeatedly .'"
3607,"b'patienten , die am ende der sechsmonatigen hauptstudie als responder klassifiziert wurden ( auf die therapie angesprochen hatten ) , konnten in eine nachbeobachtungsphase aufgenommen werden .'",b'patients who are classified at the end of the six-month 24-week responders ( had responded to treatment ) could be included in the follow-up .',b'patients who are classified at the end of the sixmonth week equal had responded for a end of the countries week kg could had responded possible effects is genotoxic due to this alt intensity had responded in the skin one tablets have been included at the followup material .',b'patients who are classified at the end of the six-month study as responders ( had responded to treatment ) could be included in the follow-up .'
3608,"b'avonex ist bei patienten , die eine progrediente form der ms entwickeln , abzusetzen .'",b'avonex should be discontinued in patients suffering from ms may develop .',b'avonex should be discontinued determined within after death a combined ms a minor disease .',b'avonex should be discontinued in patients who develop a progressive form of ms.'
3609,b'17 zum einmaligen gebrauch .',b'17 for single use only .',b'for single use only .',b'17 for single use only .'
3610,b'intanza enth\xc3\xa4lt teile von drei verschiedenen grippevirusst\xc3\xa4mmen .',b'intanza contains flu strains .',b'intanza contains keep and more use .',b'intanza contains flu strains .'
3611,b'160 m\xc3\xa4\xc3\x9fige zunahme der olanzapin-clearance .',b'160 slight to moderate increase in olanzapine clearance has been observed .',b'slight to moderate increase in olanzapine clearance has been observed .',b'160 moderate increase in olanzapine clearance .'
3612,b'solche substanzen sollten vor anwendung des produktes weitestgehend entfernt werden .',b'such substances should be removed before use of the product through .',b'such substances should be removed before use of the product through .',b'such substances should be removed before use of the product as much as possible .'
3613,b'ten mit einem k\xc3\xb6rpergewicht von \xe2\x89\xa5 40 kg und 1 mg / kg / tag f\xc3\xbcr patienten \xe2\x89\xa4 40 kg .',b'with a body weight of \xe2\x89\xa5 40 kg and 1 mg / kg / day in patients \xe2\x89\xa4 40 kg .',b'with a body weight of kg and mg kg day in patients kg .',b'with a body weight of \xe2\x89\xa5 40 kg and 1 mg / kg / day in patients \xe2\x89\xa4 40 kg .'
3614,"b'von den igg-positiven patienten wurden 6 auch positiv auf igm-antik\xc3\xb6rper getestet , und 1 patient wurde positiv auf iga-antik\xc3\xb6rper getestet .'","b'of the igg-positiven 6 patients were also tested positive to 0.100 , and 1 patient was tested and retained in place .'",b'of the herstellerfirma which were also tested occurred to . flush with which led to remove they .',"b'of the igg-positiven patients , 6 were also tested positive to i gm-antibody , and 1 patient tested positive for iga-antibody .'"
3615,b'die von der krankheit betroffene k\xc3\xb6rperoberfl\xc3\xa4che ( bsa : body surface area ) dieser patienten schwankte zwischen 15-59 % .',"b'the affected with the body surface area ( bsa ) : body surface area ) of these patients ranged between 15-59 % , respectively .'","b'the affected with the body surface area had collected to the organism period , protein as reached direct the body surface area of these patients curve gardasil .'","b'the body surface area ( bsa ) affected by the disease of these patients ranged between 15-59 % , respectively .'"
3616,b'depocyte sollte unmittelbar vor der anwendung aus der durchstechflasche entnommen werden .',b'depocyte should be used immediately before use is withdrawn from the vial .',b'depocyte should be used immediately before use is withdrawn from the vial .',b'depocyte should be immediately withdrawn from the vial before use .'
3617,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr combivir finden sie hier .',b'the full epar for combivir can be found here .',b'the full epar for combivir can be found here .',b'the full epar for combivir can be found here .'
3618,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von zerit nach zubereitung mit wasser enth\xc3\xa4lt die l\xc3\xb6sung 50 mg zucker pro ml l\xc3\xb6sung .',"b'important information about some of the ingredients of zerit when reconstituted with water , the solution contains 50 mg of sucrose per ml of solution .'",b'important information about some of the ingredients of zerit when a tablet contains mg of sucrose per ml of inhalation of sucrose per ml of zypadhera per ml grew .',"b'important information about some of the ingredients of zerit : when reconstituted with water , the solution contains 50 mg of sucrose per ml of solution .'"
3619,"b'im falle einer \xc3\x9cberdosierung ist der patient auf anzeichen einer intoxikation ( siehe abschnitt 4.8 ) zu beobachten , wenn erforderlich , sind notwendige unterst\xc3\xbctzende ma\xc3\x9fnahmen einzuleiten .'","b'in the event of overdose , the patient should be monitored for evidence of toxicity ( see section 4.8 ) , and , if necessary , the necessary supportive treatment should be instituted .'","b'in the event of overdose , the patient , the patient should be monitored for evidence of toxicity see section . , and and , radiotherapy at dose during a failure .'","b'in the event of overdose , the patient should be monitored for evidence of toxicity ( see section 4.8 ) , and , if necessary , the necessary supportive treatment should be instituted .'"
3620,"b'wurden gr\xc3\xb6\xc3\x9fere mengen des mittels abgeleckt , kann bei katzen f\xc3\xbcr eine kurze zeitspanne verst\xc3\xa4rkter speichelfluss beobachtet werden .'","b'when if a larger amounts of the product in cats , for a short time , increased salivation levels may be observed .'","b'when yellow , the dosage of the diluting filters swere beta concentrations in cats , for a feverreducing bridge see while a short time , increased tmz levels may after a short time , increased doses levels increased renal antiinflammatory e additionally .'","b'when a larger amounts of the product is licked off , increased salivation levels may be observedin cats for a short time .'"
3621,"b'mirapexin 1,1 mg tabletten sind wei\xc3\x9f , rund , flach und mit einer pr\xc3\xa4gung versehen .'","b'mirapexin 1.1 mg tablets are white , round , flat , embossed with a code .'","b'mirapexin . mg tablets are white , round , flat , embossed with a code .'","b'mirapexin 1.1 mg tablets are white , round , flat , embossed with a code .'"
3622,"b'informieren sie ihren arzt , wenn sie dieses arzneimittel anwenden .'",b'tell your doctor if you are using this medicine .',b'tell your doctor if you are using this medicine .',b'tell your doctor if you are using this medicine .'
3623,b'datum der zulassung : 1.',b'date of first authorisation :',b'the list of first authorisation',b'date of first authorisation :'
3624,b'unver\xc3\xa4ndertes maraviroc war dabei der hauptbestandteil im urin ( durchschnittlich 8 % der dosis ) und in den faeces ( durchschnittlich 25 % der dosis ) .',b'unchanged maraviroc was the major component in the urine ( by an average of 8 % of the dose ) and faeces ( an average of 25 % of the dose ) .',b'haemoglobin maraviroc was the major component in the urine from an average of of the dose .',b'unchanged maraviroc was the major component in the urine ( by an average of 8 % of the dose ) and faeces ( an average of 25 % of the dose ) .'
3625,b'in tierstudien zeigen sich f\xc3\xb6tale missbildungen nach der anwendung von beta2- rezeptoragonisten und kortikoiden ( siehe 5.3 pr\xc3\xa4klinische daten zur sicherheit ) .',"b'in incidence after the administration of frequencies ) , and very rare ( see section 5.3 preclinical safety data ) .'","b'in incidence were supported in children in humans doses study prior to a combination of respiratory , and very rare see section . table'",b'in animal studies foetal deformities were observed after the administration of beta2 receptor agonists and corticosteroids ( see section 5.3 )'
3626,"b'nehmen sie die spritze aus der verpackung und \xc3\xbcberpr\xc3\xbcfen sie , dass sie nicht besch\xc3\xa4digt ist .'",b'remove the syringe from the pack and check that it is broken .',b'remove the syringe from the pack and check that it is broken .',b'remove the syringe from the pack and check that it is broken .'
3627,"b'die toxikologischen eigenschaften von yttrium-90 -markierten arzneimitteln , die vor der anwendung durch eine radioaktive markierung mit yttriga zubereitet wurden , h\xc3\xa4ngen von der art des jeweiligen radioaktiv zu markierenden arzneimittels ab .'","b'the toxicological properties of yttrium ( 90y ) -labelled medicinal products were obtained before the use of prepared by radiolabelling with yttriga , will be dependent on the nature of the medicinal product to be treated .'",b'the toxicological properties of mecasermin of the form of enzyme y not been based on the nature of the medicinal product to be treated .',"b'the toxicological properties of yttrium ( 90y ) labelled medicinal products that were prepared by radiolabelling with yttriga before use , will be dependent on the nature of the medication to be radiolabelled .'"
3628,b'empf\xc3\xa4nger von organtransplantationen :',b'ciclosporin a :',b'cefuroximaxetil a clear of yellow acid according to the humalog ulcer side interaction with lansoprazole .',b'recipients of organ transplants :'
3629,"b'vor einleitung der behandlung mit cholestagel sollte ihr arzt sich vergewissern , dass keine erkrankungen vorliegen , die zu ihren erh\xc3\xb6hten cholesterinwerten beitragen k\xc3\xb6nnen .'","b'before commencing treatment with cholestagel your doctor should take great care not available , your which may contribute to increased cholesterol levels , as an adjunct .'","b'before commencing dehydrogenase , treatment with cholestagel , be doctor should take an body sugar may be used , your was given deficiency with the increase , too on the monitoring points .'","b'before commencing treatment with cholestagel : your doctor should take great care that you ae not sick , your which may contribute to increased cholesterol levels , as an adjunct .'"
3630,"b'um den beutel zu \xc3\xb6ffnen , halten sie ihn an beiden seiten fest .'","b'to reduce the sachet , hold the cover by gently squeezing it out .'",b'to reduce the dropper cap from pressing the spike by gently branch leaving it .',"b'to reduce the sachet , hold the cover by gently squeezing it out .'"
3631,b'riluzol wird haupts\xc3\xa4chlich im urin ausgeschieden .',b'riluzole is mainly excreted in urine .',b'prophylaxis is mainly excreted in urine .',b'riluzole is mainly excreted in urine .'
3632,"b'ihr arzt wird entscheiden , wie viel abilify injektionsl\xc3\xb6sung sie ben\xc3\xb6tigen und f\xc3\xbcr welchen zeitraum .'",b'your doctor will decide how much of abilify solution for injection you need and for how long .',b'your doctor will decide how much of abilify solution for injection',b'your doctor will decide how much of abilify solution for injection you need and for how long .'
3633,"b'trudexa 40 mg injektionsl\xc3\xb6sung in fertigspritze wird als sterile l\xc3\xb6sung von 40 mg adalimumab in 0,8 ml l\xc3\xb6sung geliefert :'",b'trudexa 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution :',b'trudexa mg solution for injection in prefilled syringe is supplied as a sterile solution of mg abz hours in . ml solution of mg difloxacin in twice bioactivity .',b'trudexa 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg adalimumab in 0.8 ml solution :'
3634,b'fondaparinux darf nicht intramuskul\xc3\xa4r gegeben werden .',b'fondaparinux should not be given intramuscularly .',b'mg clearance should not be given intramuscularly .',b'fondaparinux should not be given intramuscularly .'
3635,b'in allen drei studien verringerten h\xc3\xb6here dosen von invega die symptome wirksamer als niedrigere dosen .',"b'in all three studies , decreased higher doses of invega in reducing symptoms than lower doses .'","b'in all three studies , decreased higher doses of invega in reducing symptoms than lower doses .'","b'in all three studies , higher doses of invega were more effective in reducing symptoms than lower doses .'"
3636,"b'- wenn sie ein erh\xc3\xb6htes risiko f\xc3\xbcr blutungen haben , z. b. :'","b'- if you have an increased risk of bleeding , for example :'",b'if you have an increased risk of bleeding table .',"b'- if you have an increased risk of bleeding , for example :'"
3637,b'4 wochen nach beendigung ihrer chemotherapie fortgef\xc3\xbchrt .',b'4 weeks after the end of your chemotherapy treatment .',b'weeks after the end of your chemotherapy treatment .',b'4 weeks after the end of your chemotherapy treatment .'
3638,b'warum wurde levitra zugelassen ?',b'why has levitra been approved ?',b'why has levitra been approved ?',b'why has levitra been approved ?'
3639,b'die kapseln werden in flaschen mit 100 harten kapseln bereitgestellt .',b'the capsules are available in bottles of 100 knob .',b'the capsules are available in bottles of vardenafil .',b'the capsules are available in bottles of 100 knob .'
3640,b'warum wurde dukoral zugelassen ?',b'why has dukoral been approved ?',b'why has dukoral been approved ?',b'why has dukoral been approved ?'
3641,b'diese seltene form eines t-zell-lymphoms hat einen sehr aggressiven krankheitsverlauf und f\xc3\xbchrt in der regel zum tode .',b'this rare type of t-cell lymphoma has a very aggressive disease and usually results in death .',b'this rare type of nimesulide lymphoma has a very an commonly infection .',b'this rare type of t-cell lymphoma has a very aggressive progression and usually results in death .'
3642,"b'tasmar wird zusammen mit anderen medikament\xc3\xb6sen standardbehandlungen f\xc3\xbcr die parkinson-krankheit ( entweder einer kombination aus levodopa und benserazid oder einer kombination aus levodopa und carbidopa ) angewendet , wenn die patienten gegen ende des zeitraums zwischen zwei dosen ihrer standardkombination "" fluktuationen "" haben .'","b'tasmar is used together with other standard treatments for parkinson \'s disease ( either a combination of levodopa and benserazide or a combination of levodopa and carbidopa ) when the patient is at the end of the period between two doses of their combination "" fluctuations \' towards the end .'",b'tasmar is used together with other standard treatments for parkinson s disease either a combination of levodopa and level or reduction of the period approximately response miscarriages at the period led',"b'tasmar is used together with other standard treatments for parkinson \'s disease ( either a combination of levodopa and benserazide or a combination of levodopa and carbidopa ) when the patient is at the end of the period between two doses of their combination "" fluctuations \' towards the end .'"
3643,b'schrauben sie die nadel mit 3-5 kompletten umdrehungen der \xc3\xa4u\xc3\x9feren nadelschutzkappe vollst\xc3\xa4ndig ab .',b'remove the needle from the complete outer needle shield .',b'remove the needle from the protective outer needle cap .',b'remove the needle with 3-5 turns from the complete outer needle shield .'
3644,b'das pulver zur herstellung einer suspension zum einnehmen ist 2 jahre haltbar .',b'the powder for oral suspension is stable for 24 months .',b'the powder for oral suspension is less than for months .',b'the powder for oral suspension is stable for 24 months .'
3645,"b'norvir enth\xc3\xa4lt ritonavir , einen hemmer des enzyms protease , der eingesetzt wird , um die hiv - infektion unter kontrolle zu bringen .'",b'norvir contains ritonavir which is a protease inhibitor that is used to reduce hiv - infection .',b'norvir contains ritonavir which is a protease inhibitor that is used to reduce hiv infection .',b'norvir contains ritonavir which is a protease inhibitor that is used to reduce hiv infection .'
3646,"b'kopfschmerzen , einschlie\xc3\x9flich migr\xc3\xa4ne erkrankungen der haut und des unterhautzellgewebes sehr selten :'","b'headache , including migraine disorders skin and subcutaneous tissue disorders very rare :'","b'headache , common carer disorders uncommon common very rare diseases of sugar system very rare'","b'headache , including migraine disorders of the skin and subcutaneous tissue disorders very rare :'"
3647,b'jede durchstechflasche atryn enth\xc3\xa4lt nominal 1750 i.e. rekombinantes antithrombin alfa .',b'each vial of atryn contains nominally 1750 iu antithrombin alfa recombinant interferon-\xce\xb2 .',b'each vial of atryn contains nominally iu strength and interferon .',b'each vial of atryn contains nominally 1750 iu recombinant antithrombin .'
3648,b'das nasenbluten war im allgemeinen von milder bis m\xc3\xa4\xc3\x9figer intensit\xc3\xa4t .',b'the epistaxis was generally of mild to moderate in intensity .',b'the common sugar was generally of mild to moderate in intensity .',b'the epistaxis was generally of mild to moderate intensity .'
3649,b'vorsicht ist daher geboten bei der behandlung von patienten mit hypotonie und / oder patienten mit hypovol\xc3\xa4mie .',b'caution is therefore warranted in the treatment of patients with hypotension and / or patients with hypovolaemia .',b'caution is therefore swallowing in the treatment of patients with hypotension and or patients with hypovolaemia .',b'caution is therefore warranted in the treatment of patients with hypotension and / or patients with hypovolaemia .'
3650,b'es werden m\xc3\xb6glicherweise nicht alle packungsgr\xc3\xb6\xc3\x9fen in den verkehr gebracht .',b'not all pack sizes may be marketed .',b'you all packs colourless may be marketed .',b'not all pack sizes may be marketed .'
3651,"b'\xc3\x9cberempfindlichkeit gegen den wirkstoff , andere cephalosporine oder einen der sonstigen bestandteile .'","b'hypersensitivity to the active substance , to other cephalosporins or to any of the excipients .'","b'hypersensitivity to the active substance , to other categories may for the excipients .'","b'hypersensitivity to the active substance , to other cephalosporins or to any of the excipients .'"
3652,"b'eine pl\xc3\xb6tzliche und zunehmende verschlechterung der beschwerden ist potenziell lebensbedrohlich , und der patient sollte dringend von einem arzt untersucht werden .'",b'one sudden and increasing worsening of the patients and the patient should undergo urgent medical assessment .',b'an result of the patients and the patient should and the patient should calculated urgent medical assessment .',"b""a sudden and increasing worsening of the patient 's complaints is potentially life-threatening and the patient should undergo urgent medical assessment ."""
3653,"b'dosierung und behandlungsdauer h\xc3\xa4ngen davon ab , in welchem ma\xc3\x9fe sie eine faktor viii-substitutionstherapie ben\xc3\xb6tigen .'",b'the dose and duration of treatment depend on the extent of you are using .',b'there was by the prevention is formed on the extent of you are using .',b'the dose and duration of treatment depend on the extent of need for factor viii substitution therapy .'
3654,b'nr. l 272 vom 25.10.96 8 abl .',b'l 272 of 25.10.96 8 oj no .',b'. . oj in an interferon spray .',b'l 272 of 25.10.96 8 abl .'
3655,b'bei chronisch stabiler angina pectoris treten diese symptome bei k\xc3\xb6rperlicher anstrengung auf .',"b'in chronic stable angina pectoris , these symptoms in exercise .'",b'in chronic needed of laryngealen hepatic potassium body',"b'in chronic stable angina pectoris , these symptoms occur during physical exercise .'"
3656,b'wie bei allen augentropfen k\xc3\xb6nnen vor\xc3\xbcbergehendes verschwommensehen und andere beeintr\xc3\xa4chtigungen der sicht die f\xc3\xa4higkeit zur teilnahme am stra\xc3\x9fenverkehr oder bedienung von maschinen beeinflussen .',"b'as with any eye drops , temporary blurred vision or other visual disturbances may affect the ability to drive or use machines .'","b'as with any eye drops , temporary direct vision or other visual disturbances has cause many or use people .'","b'as with any eye drops , temporary blurred vision or other visual disturbances may affect the ability to drive or use machines .'"
3657,"b'verschmutzte kleberringe lassen sich mit medizinischem kleberentferner l\xc3\xb6sen , der bei ihrem apotheker erh\xc3\xa4ltlich ist .'",b'verschmutzte kleberringe can dissolve professionals kleberentferner in your pharmacist .',"b'potassiumsparing overdosing can until an unpreserved by the help , to possible due to a help of other as regulations for room hygiene in the change points .'","b'contaminated adhesive rings can be dissolved with medical adhesive remover , which is available from your pharmacist .'"
3658,b'schwangerschaft und stillzeit ( siehe abschnitt 4.6 ) .',b'pregnancy and breast-feeding ( see section 4.6 ) .',b'pregnancy with breastfeeding see section . .',b'pregnancy and breast-feeding ( see section 4.6 ) .'
3659,"b'die patronen enthalten mindestens 225 ie fsh-aktivit\xc3\xa4t in 0,270 ml w\xc3\xa4ssriger l\xc3\xb6sung , ausreichend f\xc3\xbcr eine nettogesamtdosis von 150 ie .'","b'cartridges contain a minimum of 225 iu fsh activity in 0.270 ml aqueous solution , which is sufficient for a dose of 150 iu .'",b'cartridges contain a minimum of iu fsh activity in . ml iv . ml dexmedetomidine ml roche .',"b'cartridges contain a minimum of 225 iu fsh activity in 0.270 ml aqueous solution , which is sufficient for a dose of 150 iu .'"
3660,"b'bei etwa 30 % der patienten treten auch reaktionen an der injektionsstelle auf , vorwiegend leichte entz\xc3\xbcndungen oder erytheme .'","b'approximately 30 % of patients are reactions at the injection site , predominantly mild inflammation or erythema .'","b'approximately of patients are reactions at the injection site , predominantly mild inflammation or erythema .'","b'approximately 30 % of patients had reactions at the injection site , predominantly mild inflammation or erythema .'"
3661,b'roactemra wird aufgrund mangelnder daten zur sicherheit und wirksamkeit nicht zur anwendung bei kindern unter 18 jahren empfohlen .',b'roactemra is due to a lack of data on safety and efficacy is not recommended for use in children under 18 years of age .',b'elderly is due to a lack of data on safety and efficacy is not recommended for use in children under years of age .',b'roactemra is not recommended for use in children under 18 years of age due to a lack of data on safety and efficacy .'
3662,b'21. februar 1997 datum der letzten verl\xc3\xa4ngerung :',b'21 february 1997 date of latest renewal :',b'february date of latest renewal',b'21 february 1997 date of latest renewal :'
3663,b'die anwendung von angiotensin-ii rezeptorantagonisten wird nicht im ersten trimester der schwangerschaft empfohlen ( siehe abschnitt 4.4 ) .',b'the use of aiiras is not recommended during the first trimester of pregnancy ( see section 4.4 ) .',b'the use of aiiras is not recommended during the first trimester of pregnancy see section . .',b'the use of aiiras is not recommended during the first trimester of pregnancy ( see section 4.4 ) .'
3664,b'oberfl\xc3\xa4chliche thrombophlebitiden traten in einer h\xc3\xa4ufigkeit von weniger als 1 % auf .',b'superficial vein thrombophlebitis occurred at a frequency of less than 1 % .',b'the group reactivation of less than .',b'superficial thrombophlebitis occurred at a frequency of less than 1 % .'
3665,"b'deslorelin , der wirkstoff in suprelorin , wirkt wie das k\xc3\xb6rpereigene nat\xc3\xbcrliche hormon gonadotropin- releasing-hormon ( gnrh ) , das die aussch\xc3\xbcttung anderer fruchtbarkeitshormone steuert .'","b""deslorelin , the active ingredient in suprelorin , acts as the body 's natural hormone lh releasing-hormon ( gnrh ) , which controls the secretion of other fruchtbarkeitshormone .""","b'lift , the active ingredient in prometax darifenacin cells dinucleotide sunk as the body s natural hormone lh priory and associated to extract as supplies slow c and form'","b""deslorelin , the active ingredient in suprelorin , acts as the body 's natural hormone lh releasing-hormon ( gnrh ) , which controls the secretion of other fertility hormones ."""
3666,b'insulin human winthrop rapid gibt es in patronen f\xc3\xbcr opticlik mit 3 ml l\xc3\xb6sung ( 300 i.e. ) .',b'insulin human winthrop rapid is supplied in cartridges for opticlik containing 3 ml solution ( 300 iu ) .',b'insulin human winthrop rapid is supplied in cartridges for opticlik containing ml solution iu .',b'insulin human winthrop rapid is supplied in cartridges for opticlik containing 3 ml solution ( 300 iu ) .'
3667,b'viagra potenziert die blutdrucksenkende wirkung von nitraten ( siehe abschnitt 4.3 ) .',b'viagra potentiates the hypotensive effect of nitrates ( see section 4.3 ) .',b'viagra parameters of amoxicillin see section . .',b'viagra potentiates the hypotensive effect of nitrates ( see section 4.3 ) .'
3668,b'das tierarzneimittel kann ganzj\xc3\xa4hrig verabreicht werden oder mindestens einen monat vor dem ersten zu erwartenden auftreten von stechm\xc3\xbccken .',b'the product can be given to all or at least one month before the first mosquitoes .',b'tell well the product can be given to all or at least one month before the first body .',b'the product can be given to all year round or at least one month before the first expected appearance of mosquitoes .'
3669,b'2. was m\xc3\xbcssen sie vor der einnahme von pritorplus beachten ? 3.',b'what you should know before you take pritorplus 3 .',b'what you should know before you take pritorplus .',b'what you should know before you take pritorplus 3 .'
3670,"b'f\xc3\xbcr patienten mit terminaler niereninsuffizienz , die dialysiert werden , stehen keine daten zur verf\xc3\xbcgung .'",b'for patients with end-stage renal disease receiving dialysis no data are available .',b'for patients with endstage renal disease receiving telithromycin .',b'no data is available for patients with end-stage renal disease receiving dialysis .'
3671,b'leukoscan wird verwendet um eine infektion in den knochen festzustellen .',b'leukoscan is used to prevent infection in the bones .',b'leukoscan is used to prevent infection in the bones .',b'leukoscan is used to prevent infection in the bones .'
3672,b'impfdosen f\xc3\xbcr den kurz- bzw. langzeitschutz empfohlen ( abh\xc3\xa4ngig vom serostatus des patienten ) .',b'doses of the vaccine is recommended for the short and long-term ( depending on the serostatus died ) .',b'doses of the vaccine is recommended for the short amount of trough pump .',b'doses of the vaccine is recommended for the short and long-term ( depending on the serostatus of the patient ) .'
3673,"b'nach rekonstitution mit dem l\xc3\xb6sungsmittel enth\xc3\xa4lt das produkt 0,6 / ml mg eptacog alfa ( aktiviert ) .'","b'after reconstitution with the solvent , the product contains 0.6 mg / ml mg eptacog alfa ( activated ) .'","b'after production with the docetaxel was of two resorbtion is reached after reconstitution , the powder contains . mg ml mg remeron h takes .'","b'after reconstitution with the solvent , the product contains 0.6 mg / ml mg eptacog alfa ( activated ) .'"
3674,"b'- eine kurze nadel ( zum beispiel 0,3 x 13 mm [ 30 gauge 0,5 inch ] ) f\xc3\xbcr die subkutane injektion ;'",b'- a short needle ( for example 0.3 \xc3\x97 13 mm [ 30 gauge 0.5 inch ] ) for the subcutaneous injection ;',b'an short medication before this injection insulin tablet insert',b'- a short needle ( for example 0.3 \xc3\x97 13 mm [ 30 gauge 0.5 inch ] ) for the subcutaneous injection ;'
3675,"b'gruppen von je 4 tieren ( 2 m\xc3\xa4nnliche , 2 weibliche ) wurden 1 , 7 , 14 , 21 und 27 tage nach der letzten injektion geschlachtet .'","b'groups of 4 animals ( 2 male , 2 female ) were slaughtered at 1 , 7 , 14 , 21 and 27 days after the last injection has been given .'","b'continued of animals , female were trudexa poses after higher posttransplant are recommended than from a plasma injection has been given .'","b'groups of 4 animals ( 2 male , 2 female ) were slaughtered at 1 , 7 , 14 , 21 and 27 days after the last injection had been given .'"
3676,"b'cephalosporin-resistenz entsteht durch enzym-inaktivierung ( \xce\xb2 -laktamase-produktion ) , durch verminderte permeabilit\xc3\xa4t infolge von porin-mutationen oder ver\xc3\xa4nderung in efflux , oder durch selektion niedrig-affiner penicillin-bindungsproteine .'","b'resistance due to enzym-inaktivierung ( production ) , reduced permeability or change of efflux , binding proteins .'","b'resistance show by inhibiting or ulcers or change of ief , binding .'","b'resistance to cephalosporin is due to enzyme inactivation ( \xce\xb2-lactamase production ) , reduced permeability as a result of porin mutations or a change of efflux , or through selection of low-affinity penicillin-binding proteins .'"
3677,b'in einigen f\xc3\xa4llen soll seretide nicht mit anderen arzneimitteln angewendet werden .',"b'in some cases , seretide should not be used with other medicines .'","b'in some cases , seretide should not be used with other medicines .'","b'in some cases , seretide should not be used with other medicines .'"
3678,b'5 aluminiumblister mit jeweils einer 40 mg hartkapsel .',b'5 aluminium blisters each containing one 40 mg capsule .',b'aluminium blisters each containing one mg capsule .',b'5 aluminium blisters each containing one 40 mg capsule .'
3679,"b'beim einleiten einer behandlung mit vitamin-k- antagonisten bei patienten , die sitaxentan-natrium einnehmen , empfiehlt es sich , mit der niedrigsten verf\xc3\xbcgbaren dosis zu beginnen .'","b'when initiating treatment with a vitamin k antagonist in patients who are taking sitaxentan sodium , it is recommended to start with the lowest available dose .'",b'when combination treatment with a vitamin k scores in patients who are taking somatropin that account .',"b'when initiating treatment with a vitamin k antagonist in patients who are taking sitaxentan sodium , it is recommended to start with the lowest available dose .'"
3680,"b'75 ged\xc3\xa4chtnisverlust , denkschwierigkeiten , schwierigkeiten beim gehen und / oder sehverlust ein .'","b'75 eyes , difficulty thinking , difficulty walking , and / or loss of vision .'","b'the sugar of can creams , which occur thirst various vein of vision .'","b'75 memory loss , difficulty thinking , difficulty walking , and / or loss of vision .'"
3681,"b'6 / 7 als g\xc3\xbcltige zusammenfassung der merkmale des arzneimittels , etikettierung und packungsbeilage sind die fassungen zu betrachten , auf die sich der referenzmitgliedstaat und die betroffenen mitgliedstaaten ( au\xc3\x9fer irland ) bis zum 210 . tag des dezentralisierten verfahrens geeinigt haben .'","b'6 / 7 the valid summary of product characteristics , labelling and package leaflet are the versions agreed by the reference member state and concerned member states ( except ireland ) at day 210 of the members , the following indication in the past .'","b'the valid summary of product characteristics , labelling and package leaflet are the versions of the shortest , the following indication in the month .'","b'6 / 7 the valid summary of product characteristics , labelling and package leaflet are the versions agreed by the reference member state and concerned member states ( except ireland ) at day 210 of the decentralised precedure .'"
3682,b'eine spontane exazerbation ist bei chronischer hepatitis b relativ h\xc3\xa4ufig und \xc3\xa4u\xc3\x9fert sich durch einen vor\xc3\xbcbergehenden anstieg der serum-alt-konzentration .',b'one spontaneous exacerbation in chronic hepatitis b are relatively common and glucuronidation are characterised by transient increases in serum-alt-konzentration .',b'one spontaneous carcinogenic exacerbation of chronic hepatitis b are corrected .',b'a spontaneous exacerbation in chronic hepatitis b are relatively common and characterised by transient increases in serum alt concentration .'
3683,b'nehmen sie viagra immer genau nach anweisung des arztes ein .',b'always take viagra exactly as your doctor has told you .',b'always take viagra exactly as your doctor has told you .',b'always take viagra exactly as your doctor has told you .'
3684,"b'basierend auf der klinischen einsch\xc3\xa4tzung ist im einzelfall zu entscheiden , ob thrombozytentransfusionen gegeben werden .'",b'based on the guided by clinical judgement pending in the individual case is to decide if it is given for platelet support .',b'based on the ears in the individual reaction is to decide if it is given for platelet hiv than of thyroid support .',b'based on the clinical judgement it should be decided in each individual case if platelet transfusions are given .'
3685,"b'w\xc3\xa4hrend der behandlung mit baraclude wird empfohlen , nicht zu stillen .'","b'during treatment with baraclude , it is recommended to stop breast-feeding .'","b'during treatment with baraclude , it is recommended to stop breastfeeding .'","b'during treatment with baraclude , it is recommended to stop breast-feeding .'"
3686,b'dosierung bei erwachsenen und jugendlichen ( 12 bis 17 jahre ) ab 50 kg k\xc3\xb6rpergewicht :',b'dosage in adults and adolescents ( 12 to 17 years ) weighing 50 kg or more :',b'dosage in adults and adolescents to years weighing kg or more',b'dosage in adults and adolescents ( 12 to 17 years ) weighing 50 kg or more :'
3687,b'eine versehentliche exposition mit temperaturen im gefrierbereich hat keinen nachteiligen auswirkungen auf die stabilit\xc3\xa4t von filgrastim ratiopharm .',b'accidental exposure to temperatures in the gefrierbereich does not adversely affect the stability of filgrastim ratiopharm .',b'accidental exposure to temperatures in the ks does not adversely in the trace and filgrastim ratiopharm .',b'accidental exposure to temperatures in the freezing point does not adversely affect the stability of filgrastim ratiopharm .'
3688,b'36 filgrastim ratiopharm enth\xc3\xa4lt keine konservierungsmittel .',b'36 filgrastim ratiopharm does not contain any preservative .',b'filgrastim ratiopharm does not contain any preservative .',b'36 filgrastim ratiopharm does not contain preservatives .'
3689,"b'unter ber\xc3\xbccksichtigung aller verf\xc3\xbcgbaren daten gelangte der cvmp zu dem schluss , dass keinerlei bedenken hinsichtlich der sicherheit oder wirksamkeit des produkts bestehen .'","b'taking into account of all available data , the cvmp concluded that did not produce any concerns about the safety or efficacy of the product .'",b'taking into account of all optison and the cure in gender .',"b'taking all available data into account , the cvmp concluded that did not produce any concerns at all about the safety or efficacy of the product .'"
3690,b'nehmen sie axura immer genau nach anweisung ihres arztes ein .',b'always take axura exactly as your doctor has told you .',b'always take axura exactly as your doctor has told you .',b'always take axura exactly as your doctor has told you .'
3691,"b'falls nebenwirkungen auftreten , sollte die behandlung abgebrochen und ein tierarzt zu rate gezogen werden .'","b'if adverse reactions occur , treatment should be discontinued and the advice of a veterinarian should be sought .'","b'if adverse reactions occur , treatment should be discontinued and the advice of a veterinarian should be sought .'","b'if adverse reactions occur , treatment should be discontinued and the advice of a veterinarian should be sought .'"
3692,"b'was m\xc3\x9cssen sie vor der einnahme ... , besondere vorsicht bei der einnahme ... , bevor sie [ phantasiebezeichnung ] 400 mg filmtabletten einnehmen ) .'","b'before oral suspension ... , take special care ... , before you take [ invented name ] 400 mg film-coated tablets ) .'",b'before oral suspension . . . therefore or years with solostar .',"b'before oral suspension ... , take special care ... , before you take [ invented name ] 400 mg film-coated tablets ) .'"
3693,"b'der wirkstoff in bondenza , ibandrons\xc3\xa4ure , ist ein bisphosphonat .'","b'the active substance in bondenza , ibandronic acid , is a bisphosphonate .'","b'the active substance in bondenza , ibandronic acid , is a achieve .'","b'the active substance in bondenza , ibandronic acid , is a bisphosphonate .'"
3694,b'vorsicht ist angezeigt 9 f\xc3\xbcr die behandlung von patienten mit einem erh\xc3\xb6hten risiko f\xc3\xbcr maligne erkrankungen infolge starken rauchens .',b'caution is indicated for the treatment of patients with an increased risk for malignancy due to heavy smoking .',b'reduced clearance for the treatment of patients with an increased risk particularly upright for the treatment of the formation of patients with an increased risk of no stem or used .',b'caution is indicated for the treatment of patients with an increased risk for malignancy due to heavy smoking .'
3695,b'der inhaber dieser genehmigung f\xc3\xbcr das inverkehrbringen muss die periodischen berichte zur sicherheit des arzneimittels ( psur ) und andere sicherheitsinformationen j\xc3\xa4hrlich vorlegen .',b'the holder of this marketing authorisation must inform annually will continue to submit periodic safety update reports ( psurs ) and other safety information .',b'the holder of this marketing authorisation without xolair or rare periodic safety way reports exjade and other safety from the operation of the following safety information in the effectiveness mechanism taking the information regarding feed indication .',b'the holder of this marketing authorisation must continue to submit periodic safety update reports ( psurs ) and other safety information .'
3696,b'zu diesen bakterien z\xc3\xa4hlen staphylococcus aureus ( darunter auch methicillinresistente formen - mrsa ) und streptococcus pyogenes .',b'these bacteria include staphylococcus aureus ( also including methicillin-resistant forms - mrsa ) and streptococcus pyogenes .',b'these bacteria include staphylococcus aureus also associated to generalised amounts of the same journals .',b'these bacteria include staphylococcus aureus ( also including methicillin-resistant forms - mrsa ) and streptococcus pyogenes .'
3697,b'115 nach jeder dosis- oder behandlungsplananpassung ist der h\xc3\xa4moglobinwert w\xc3\xb6chentlich bzw. alle zwei wochen zu bestimmen .',b'115 after any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks .',b'after any dose or plan should be monitored every one or two weeks .',"b'115 after any dose or schedule adjustment , the haemoglobin should be monitored every one or two weeks .'"
3698,"b'es wird empfohlen , atripla auf n\xc3\xbcchternen magen , vorzugsweise vor dem schlafengehen , einzunehmen .'","b'it is recommended that atripla be taken on an empty stomach , preferably at bedtime , day .'",b'it is recommended to insulin suspension .',"b'it is recommended that atripla be taken on an empty stomach , preferably at bedtime .'"
3699,b'was ist aprovel ?',b'what is aprovel ?',b'what is aprovel ?',b'what is aprovel ?'
3700,"b'jede flasche ist etwa zur h\xc3\xa4lfte gef\xc3\xbcllt , und enth\xc3\xa4lt drei milliliter l\xc3\xb6sung .'","b'each bottle is the same one-half , and contains 3 ml of solution .'","b'each bottle is the same bandage , and contains ml of solution .'","b'each bottle is the same one-half , and contains 3 ml of solution .'"
3701,b'nach anbruch muss der impfstoff sofort verabreicht werden .',"b'once in use , the vaccine should be administered immediately .'","b'once in use , the vaccine should be administered immediately .'","b'once in use , the vaccine should be administered immediately .'"
3702,"b'belgien und norwegen sahen sich nicht in der lage , der erteilung einer genehmigung f\xc3\xbcr das inverkehrbringen zuzustimmen .'",b'belgium and norway considered that sahen there is not able to the granting of a marketing authorization .',b'voraxaze and gilts as inactivate of a marketing cmpflaster .',b'belgium and norway did not agree to allowing marketing .'
3703,b'es gibt keine belege f\xc3\xbcr eine toleranzentwicklung .',b'there is no evidence for a development of tolerance .',b'there are no evidence for a development of tolerance .',b'there is no evidence for a development of tolerance .'
3704,"b'"" diovan wurde bei patienten mit schwerer leberdysfunktion nicht untersucht . "" f\xc3\xbcr patienten mit einer creatinin-clearance < 10 ml / min und f\xc3\xbcr dialysepatienten sind keine daten verf\xc3\xbcgbar .'","b'"" diovan has not been studied in patients with severe , therefore . "" there are no data available on patients with a creatinine clearance 10 ml / min and patients undergoing dialysis .'",b'diovan has not been studied in patients with severe hepatotoxicity of the same clearance .',"b'"" diovan has not been studied in patients with severe hepatic dysfunction . "" there are no data available on patients with a creatinine clearance 10 ml / min and patients undergoing dialysis .'"
3705,b'weitere informationen \xc3\xbcber dexdomitor :',b'2 / 3 other information about dexdomitor :',b'other information about infections',b'2 / 3 other information about dexdomitor :'
3706,b'warum wurde invirase zugelassen ?',b'why has invirase been approved ?',b'why has invirase been approved ?',b'why has invirase been approved ?'
3707,"b'sich nehmen , da eine zu geringe fl\xc3\xbcssigkeitszufuhr zu austrocknung und damit zu einem erh\xc3\xb6hten risiko von nierenversagen f\xc3\xbchren kann .'","b'on a regular basis , since too little hydration may lead to dehydration and an increased risk of renal failure .'","b'on a regular basis , since too little mediated painful therapy may lead to dehydration and an increased risk of chronic therapy should be reduced the make the level of renal failure .'",b'since too little hydration may lead to dehydration and an increased risk of renal failure .'
3708,b'in vitro wurde eine positive diagnose bez\xc3\xbcglich der lymphozyten bis zu 2-6 % aufgezeigt .',"b'in vitro , a positive diagnosis of lymphocytes has been demonstrated for up to 2-6 % , respectively .'","b'in vitro , a positive diagnosis of basiliximab has been demonstrated see'","b'in vitro , a positive diagnosis of lymphocytes has been demonstrated for up to 2-6 % .'"
3709,b'in einer studie zur fertilit\xc3\xa4t und zur allgemeinen reproduktiven funktion war die anzahl tr\xc3\xa4chtiger m\xc3\xa4use nach anwendung des gleichen analogen antik\xc3\xb6rpers reduziert .',"b'in one study , fertility and general so as to store the number of pregnant mice was reduced compared to the use of the same analogous .'",b'in one study increases fertility and general so as to store the number of pregnant late agent when it on gender relation to the use of the same upper therapy .',"b'in one study of fertility and general functions , the number of pregnant mice was reduced compared after the use of the same antibodies .'"
3710,b'es wurden keine untersuchungen zur wechselwirkung von advate mit anderen arzneimitteln durchgef\xc3\xbchrt .',b'no interaction studies have been performed with advate .',b'no interaction studies have been performed with advate .',b'no interaction studies have been performed with advate .'
3711,"b'champix ist ein nikotinfreies arzneimittel , das ihnen helfen soll , mit dem rauchen aufzuh\xc3\xb6ren .'","b'champix is a nikotinfreies medicines , you should help to stop smoking .'","b'champix is a triangle may wash a fixeddose medicines , you should help to stop smoking .'","b'champix is a nikotinfreies medicines , which should you help to stop smoking .'"
3712,"b'eine fortdauernde \xc3\x9cberdosierung kann m\xc3\xb6glicherweise zu anzeichen und symptomen von gigantismus und / oder akromegalie f\xc3\xbchren , die den bekannten wirkungen eines \xc3\x9cberschusses von wachstumshormon entsprechen .'",b'long-term overdose may result in signs and symptoms of signs and / or acromegaly can lead to the known effects of hangovers growth hormone .',b'longterm overdose may result in signs and or acromegaly can lead to the known effects of betablockers growth hormone .',b'long-term overdose may result in signs and symptoms of giantism and / or acromegaly can lead to the known effects of an excess of growth hormone .'
3713,b'optikusneuropathie ( naion ) haben oder bereits einmal hatten .',b'vision due to non-arteritic anterior ischaemic optic neuropathy ( naion ) have ever had loss of vision .',b'photosensitivity amount of the myelosuppression of idiopathic correspond to hae mediated or constipation compatible of rescue .',b'optic neuropathy ( naion ) has or already had .'
3714,"b'da die anwendung von benefix als kontinuierliche infusion nicht untersucht wurde , sollte benefix nicht mit anderen infusionsl\xc3\xb6sungen gemischt oder als tropfinfusion gegeben werden .'","b'since the use of benefix by continuous infusion has not been evaluated , benefix should not be mixed with other infusion solutions drip may be given .'",b'since the use of benefix by vaccination must either the remaining .',"b'since the use of benefix by continuous infusion has not been evaluated , benefix should not be mixed with other infusion solutions or be given as an intraveneous drip .'"
3715,b'8 arthralgie wurde bei 32 % aller patienten berichtet ( 5 % schwer ) und myalgie bei 47 % ( 6 % schwer ) .',"b'8 arthralgia has been reported in 32 % of all patients ( 5 % ) , they may be severe and myalgia in 47 % ( 6 % severe ) .'","b'methoxasolt has been reported in of all women , thus as they may be severe or intoxication in severe concomitant cardiotoxic auc .'",b'8 arthralgia has been reported in 32 % of all patients ( 5 % severe ) and myalgia in 47 % ( 6 % severe ) .'
3716,b'eine anpassung der dosierung von ritonavir kann notwendig sein .',b'the dose of ritonavir may be necessary .',b'the dose of ritonavir may be necessary .',b'an adjustment of the dose of ritonavir may be necessary .'
3717,"b'anschlie\xc3\x9fend kann ihr arzt die dosierung ihren bed\xc3\xbcrfnissen anpassen , um die bestm\xc3\xb6gliche behandlung zu gew\xc3\xa4hrleisten .'",b'then your doctor will determine your dose based on your specific needs to consider the best treatment .',b'then your doctor will determine your dose should an monitor other or prolonged fall to drive the best treatment .',b'then your doctor will determine your dose based on your specific needs to provide the best treatment .'
3718,"b'nach begutachtung der verf\xc3\xbcgbaren daten kam der chmp zu dem schluss , dass das nutzen-risiko- verh\xc3\xa4ltnis von protopy als g\xc3\xbcnstig zu erachten ist .'",b'after reviewing the available data the chmp concluded that the balance of risks and benefits for protopy is considered favourable .',b'after anticonvulsants the available data the chmp concluded that the median reversal of procoralan and benefits not considered receiving the results of photobarr and frequency does not to safety is considered accordingly .',b'after reviewing the available data the chmp concluded that the balance of risks and benefits for protopy is considered favourable .'
3719,"b'\xe2\x80\xa2 zus\xc3\xa4tzliche mitteilungen hinsichtlich der \xc3\x9cbergangspl\xc3\xa4ne , um refacto in den mitgliedsstaaten / im mitgliedsstaat durch refacto af zu ersetzen .'",b'\xe2\x80\xa2 additional messages regarding the transition plan for replacement of refacto with refacto af in the member state ( s ) .',"b'additional mirena regarding the components of refacto and october in the concerned measurement of refacto of refacto of olanzapine and atenolol of refacto with round with refacto of parecoxib ,'",b'\xe2\x80\xa2 additional messages regarding the transition plan to replace refacto in the member state ( s ) with refacto af in the member state ( s ) .'
3720,"b'studien , die diese wirkung untersuchen , werden derzeit durchgef\xc3\xbchrt .'","b'studies , the effects of this test are ongoing .'","b'studies , the effects of this test are ongoing .'","b'studies , investigating these effects of this test are ongoing .'"
3721,b'es wurde ein zusammenhang zwischen der viszeralen lipomatose und pi sowie der lipoatrophie und nrti hergestellt .',b'there is an association between a connection between visceral lipomatosis and pis and lipoatrophy and nrtis .',"b'in average studies and sensitivity between hiv lipomatosis and lipoatrophy and lipoatrophy , factor and nrtis .'",b'an association was created between visceral lipomatosis and pis as well as the lipoatrophy and nrtis .'
3722,"b'erbrechen und weiche f\xc3\xa4zes waren sehr h\xc3\xa4ufig , verminderter appetit und diarrhoe h\xc3\xa4ufig , blut in den f\xc3\xa4zes trat gelegentlich auf .'","b', vomiting , and faeces were very common , decreased appetite and diarrhoea are common in faeces occurred uncommon .'","b', vomiting , and ovulation were very common , decreased appetite and diarrhoea are common in faeces occurred uncommon .'","b'vomiting , and soft faeces were very common , decreased appetite and diarrhoea are common , blood in faeces occurred rarely .'"
3723,"b'e. coli j5 , inaktiviert ; s. aureus cp8 , stamm sp140 , inaktiviert ; fl\xc3\xbcssiges paraffin ; benzylalkohol .'","b'e. coli j5 inactivated , s. aureus cp8 strain sp140 inactivated , cows that were given startvac ) ; benzyl alcohol .'","b'e . coli repeated inactivated , s . aureus gx strain .'","b'e. coli j5 inactivated , s. aureus cp8 strain sp140 inactivated , liquid parrafin ; benzyl alcohol .'"
3724,"b'da nelfinavir stark an plasmaproteine gebunden wird , ist es unwahrscheinlich , dass nelfinavir durch h\xc3\xa4modialyse oder peritonealdialyse in wesentlichen mengen entfernt wird .'","b'since nelfinavir is highly bound to plasma proteins , it is unlikely that nelfinavir significantly removed by haemodialysis or peritoneal dialysis in ovules .'","b'since nelfinavir is highly bound to plasma proteins , it is unlikely that nelfinavir there is unlikely that nelfinavir significantly removed by haemodialysis or peritoneal dialysis lower as is expected that nelfinavir significantly influenced by haemodialysis or peritoneal dialysis is not determined that nelfinavir significantly determined by haemodialysis or peritoneal'","b'since nelfinavir is highly bound to plasma proteins , it is unlikely that nelfinavir is significantly removed by haemodialysis or peritoneal dialysis in significant amounts .'"
3725,"b'bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder radiologen .'","b'if you notice any side effects not mentioned in this leaflet , please tell your doctor or radiologist .'","b'if you notice any side effects not mentioned in this leaflet , please tell your doctor or neta .'","b'if you notice any side effects not mentioned in this leaflet , please tell your doctor or radiologist .'"
3726,b'nach anweisung des arztes einnehmen .',b'after taking your doctor has instructed you .',b'after taking your doctor has instructed you .',b'take after the advice of your doctor .'
3727,b'im fall einer \xc3\x9cberdosierung sollen allgemeine symptomatische ma\xc3\x9fnahmen ergriffen werden .',"b'in the event of overdose , general symptomatic measures should be employed .'","b'in the event of overdose , general symptomatic measures should be employed .'","b'in the event of overdose , general symptomatic measures should be employed .'"
3728,"b'liprolog mix25 ist angezeigt f\xc3\xbcr die behandlung von patienten mit diabetes mellitus , die insulin f\xc3\xbcr die aufrechterhaltung eines normalen glukosehaushaltes ben\xc3\xb6tigen .'",b'liprolog mix25 is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glukosehaushaltes .',b'liprolog mix is indicated for the treatment of patients with diabetes mellitus but be adjusted .',b'liprolog mix25 is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose balance .'
3729,b'die filmtabletten enthalten lactose .',b'the film-coated tablets contain lactose .',b'the filmcoated tablets contain lactose .',b'the film-coated tablets contain lactose .'
3730,"b'peginterferon alfa-2b \xc3\xa4hnelt interferon alfa-2b , das in der europ\xc3\xa4ischen union ( eu ) bereits als introna erh\xc3\xa4ltlich ist .'","b'peginterferon alfa-2b is similar to interferon alfa-2b , which is available in the european union ( eu ) called introna .'","b'peginterferon alfab is similar to interferon alfab , which is available in the european union eu called capsuleshaped .'","b'peginterferon alfa-2b is similar to interferon alfa-2b , which is available in the european union ( eu ) as introna .'"
3731,"b'gef\xc3\xa4\xc3\x9ferkrankungen gelegentlich : hypertonie , hypotonie .'","b'vascular disorders uncommon : hypertension , hypotension .'","b'vascular disorders uncommon hypertension , hypotension .'","b'vascular disorders uncommon : hypertension , hypotension .'"
3732,b'm\xc3\xb6gliche wechselwirkungen zwischen vistide und hiv-protease-inhibitoren wurden bisher nicht untersucht .',b'possible interactions between vistide and hiv protease inhibitors have not been investigated .',b'possible interactions between vistide and hiv protease inhibitors have not been investigated .',b'possible interactions between vistide and hiv protease inhibitors have not been investigated .'
3733,"b'der patient muss in den vier stunden vor dem test n\xc3\xbcchtern bleiben , damit dieser mit leerem magen durchgef\xc3\xbchrt wird .'",b'the patient should be in the four hours prior to the test remain fasted to deliver this with an empty stomach .',"b'the patient should laboratory point , who shows a minor benefit scintigraphy to the test or further like more bed .'",b'the patient should keep an empty stomach for the four hours prior to the test remain so that it is carried out with an empty stomach .'
3734,b'f\xc3\xbcr den anwender :',b'to the user :',b'to the drying the drying system',b'to the user :'
3735,b'bei schubweise verlaufender multipler sklerose hat sich eine wirksamkeit der therapie \xc3\xbcber die ersten 2 jahre gezeigt .',"b'in the long term , preferably multiple sclerosis , efficacy has therapy for the first 2 years .'","b'in the long term treatment of the long term inhaled objective study , valnemulin with humans to proven auc .'","b'for relapsing-remitting ms , efficacy has been demonstrated for therapy for the first two years .'"
3736,"b'bei der cll ist eine bestimmte art der lymphozyten betroffen , die sogenannten b-zellen , die im knochenmark gebildet werden und in den lymphknoten heranreifen .'","b'in cll , called b-cells , and in the bone marrow and in the lymph nodes that they eventually grow and develop a certain type of lymphocytes affected .'",b'in perivascular p the skin inflammatiom in the clicking virus from the flat virus for the spontaneous resonance applicator that it gives not killed by the firing group is sanohex as the invitro balloon .',"b'in cll , a particular type of lymphocytes called b-cells , that are formed in the bone marrow and in the lymph nodes and eventually grow in the lympth nodes .'"
3737,b'schwangerschaft pelzont es liegen keine daten \xc3\xbcber die kombinierte anwendung von nicotins\xc3\xa4ure und laropiprant bei schwangeren frauen vor .',b'pregnancy pelzont there are no data from the combined use of nicotinic acid and laropiprant in pregnant women .',b'a peginterferon sample use of nicotinic acid and laropiprant in pregnant women .',b'pregnancy pelzont there are no data from the combined use of nicotinic acid and laropiprant in pregnant women .'
3738,b'die l\xc3\xb6sung ist vor der anwendung optisch auf feststoffteilchen und verf\xc3\xa4rbungen zu \xc3\xbcberpr\xc3\xbcfen .',b'the solution to recrystallization and discolouration prior to administration .',b'the solution to import and discolouration containing a n period .',b'the solution to recrystallization and discolouration prior to administration .'
3739,b'folgende reaktionen wurden h\xc3\xa4ufiger bei kindern als erwachsenen berichtet :',b'the following reactions have been reported more often in children than in adults :',b'the following reactions has been reported more occurrence in children than in adults',b'the following reactions have been reported more often in children than in adults :'
3740,b'a. k. a. h\xc3\xa4ufig :',b'a. n / a common :',b'a . n a common',b'a. n / a common :'
3741,"b'bei mehr als der h\xc3\xa4lfte der patienten , die in beiden behandlungsgruppen ein ansprechen zeigten , hielt die abnahme des serum-ctx \xc3\xbcber 2 jahre an .'",b'in more than half of the patients in both treatment groups were considered the decrease in serum-ctx above the age of 2 years .',b'in more than half of the patients in both treatment groups were considered the decrease in annual risk of years weeks in trazodone above the age of years at the elderly months for humans on days of where the dose in chinese above the dosage rate reduction of humans .',b'in more than half of the patients who showed response in both treatment groups decreased the intake of serum-ctx over 2 years .'
3742,"b'wenn ihnen zus\xc3\xa4tzlich zu gonal-f lutropin alfa verschrieben wurde , k\xc3\xb6nnen sie die beiden arzneimittel auch zusammen mischen , anstatt jedes einzeln zu injizieren .'","b'if you have been added to gonal-f lutropin alfa has been prescribed for you , the two medicines may also mix the alternative to inject individually .'","b'if you have been added to gonalf resistant additional carried a low medicines may also mix the therefore to inject acting prescribed with safety , the vzv alternative to inject particular fluids .'","b'if gonal-f lutropin alfa has also been prescribed for you , the two medicines may also be mixed as opposed to injecting them individually .'"
3743,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem etikett und dem umkarton angegebenen verfallsdatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the label and the carton .',b'do not use after the expiry date which is stated on the label and the carton .',b'do not use after the expiry date which is stated on the label and the carton .'
3744,b'welches risiko ist mit aldara verbunden ?',b'what is the risk associated with aldara ?',b'what is the risk associated with users ?',b'what is the risk associated with aldara ?'
3745,b'die h\xc3\xa4ufigsten nebenwirkungen von stelara ( beobachtet bei mehr als 1 von 10 patienten ) sind infektionen der oberen atemwege ( erk\xc3\xa4ltungen ) und nasopharyngitis ( entz\xc3\xbcndung der nase und des rachens ) .',b'the most common side effects with stelara ( seen in more than 1 patient in 10 ) are infections of the upper respiratory tract ( colds ) and nasopharyngitis ( inflammation of the nose and throat ) .',"b'the most common side effects with stelara seen in more than haemoglobin , that were uncommen .'",b'the most common side effects with stelara ( seen in more than 1 patient in 10 ) are infections of the upper respiratory tract ( colds ) and nasopharyngitis ( inflammation of the nose and throat ) .'
3746,"b'impfstoffe wirken dadurch , dass sie dem immunsystem ( den k\xc3\xb6rpereigenen abwehrmechanismen ) "" beibringen , "" sich selbst gegen eine krankheit zu wehren .'","b'vaccines work by the immune system ( the body \'s natural defences ) "" teaching \'and makes antibodies against them .'",b'vaccines disorders by the immune system the body of vfend effect and give antibodies against them .',"b'vaccines work by the immune system ( the body \'s natural defences ) by "" teaching "" them to make antibodies against disease .'"
3747,"b'die patientinnen sollten zus\xc3\xa4tzlich vitamin d oder kalzium einnehmen , falls sie mit der nahrung nicht gen\xc3\xbcgend davon aufnehmen .'","b'patients should receive calcium and vitamin d supplements , or if they do not get enough from their diet .'","b'patients should receive calcium and vitamin d supplements , or if they do not get failed enough from their diet .'",b'patients should receive calcium and vitamin d supplements if they do not get enough from their diet .'
3748,b'sie d\xc3\xbcrfen das arzneimittel nach dem auf dem umkarton und auf dem etikett der patrone angegebenen verfalldatum nicht mehr anwenden .',b'do not use after the expiry date which is stated on the carton and on the label of the cartridge .',b'take the expiry date which is stated on the carton and on the label of the cartridge .',b'do not use after the expiry date which is stated on the carton and on the label of the cartridge .'
3749,"b'0 . - statut der beamten der europ\xc3\xa4ischen gemeinschaften , insbesondere artikel 56 und anhang vi.'","b'0 . - staff regulations of officials of the european communities , and 56 and annex vi .'","b'. , you have requested to contribute to the whole virus , and and ticlopidine ccr .'","b'0 . - staff regulations of officials of the european communities , and 56 and annex vi .'"
3750,b'reyataz 200 mg hartkapseln sind auch in blisterstreifen in packungen mit 60 hartkapseln erh\xc3\xa4ltlich .',b'reyataz 200 mg hard capsules are also supplied in blister packs containing 60 capsules .',b'reyataz oral a tablet capsules are also contain contains packs containing capsules .',b'reyataz 200 mg hard capsules are also supplied in blister packs containing 60 capsules .'
3751,b'diese befunde waren reversibel .',b'these findings were reversible .',b'these findings were reversible .',b'these findings were reversible .'
3752,b'die h\xc3\xa4ufigsten nebenwirkungen von combivir ( beobachtet bei mehr als 1 von 10 patienten ) sind durchfall ( diarrhoe ) und \xc3\x9cbelkeit ( nausea ) .',b'the most common side effects with combivir ( seen in more than 1 patient in 10 ) are diarrhoea and nausea ( feeling sick ) .',b'the most common side effects with combivir seen in more than patient in are muscle as very blood cancer .',b'the most common side effects with combivir ( seen in more than 1 patient in 10 ) are diarrhoea and nausea ( feeling sick ) .'
3753,b'die chemische und physikalische stabilit\xc3\xa4t wurde f\xc3\xbcr 24 stunden bei 2 \xc2\xb0 c - 8 \xc2\xb0 c nachgewiesen .',b'chemical and physical in-use stability has been demonstrated for 24 hours at 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'chemical and physical inuse stability has been demonstrated for hours at c c see',b'chemical and physical in-use stability has been demonstrated for 24 hours at 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .'
3754,"b'wenn die ausbeuten den oben ausgef\xc3\xbchrten kriterien zufolge nicht ausreichend sind , so sollten alternative behandlungsformen in erw\xc3\xa4gung gezogen werden , bei denen der einsatz von blutstammzellen nicht erforderlich ist .'","b'if the alkylphosphonite criteria described above the questionability of edible adequately , alternative pentostatin should be considered in toxicities is not required .'","b'if the designation update described above , atazanavir reabsorbtion in invanz is not required .'","b'if the alkylphosphonite criteria described above are not adequate , alternative forms of treatment should be considered , at which the use of blood stem cells is not required .'"
3755,b'der inhaber der genehmigung f\xc3\xbcr das inverkehrbringen ist cephalon europe .',b'the mah marketing authorisation holder is cephalon europe .',b'the mah marketing authorisation holder is hydroxyibafloxacin',b'the mah marketing authorisation holder is cephalon europe .'
3756,"b'au\xc3\x9ferdem k\xc3\xb6nnen infektionen mit oder ohne fieber , durchfall und mukositis auftreten .'","b'in addition , infections can be taken with or without fever , diarrhoea , and / or mucositis may be seen .'","b'in addition , infections can be taken with or without fever , diarrhoea , and or neutropaenia may be seen .'","b'in addition , infections may be seen with or without fever , diarrhoea , and / or mucositis .'"
3757,"b'knochen- , gelenk- und / oder muskelschmerzen wurden bei patienten unter bisphosphonaten berichtet .'","b'bone , joint , and / or muscle pain have been reported in patients receiving bisphosphonates .'","b'bone , circulatory , and or muscle pain have been reported in patients receiving bisphosphonates .'","b'bone , joint , and / or muscle pain have been reported in patients receiving bisphosphonates .'"
3758,"b'therapie der lungenembolie eine randomisierte , offene klinische studie wurde bei patienten mit einer nachgewiesenen akuten lungenembolie durchgef\xc3\xbchrt .'","b'treatment of pulmonary embolism one randomised , open-label , clinical trial was conducted in patients with acute symptomatic pe .'","b'treatment of pulmonary completed one randomised , openlabel , more than measles is conducted in patients with acute symptomatic thickness .'","b'treatment of pulmonary embolism : one randomised , open clinical trial was conducted in patients with acute symptomatic pe .'"
3759,"b'er wird auch untersuchungen zur dauer des schutzes durchf\xc3\xbchren , den der impfstoff verleiht .'",b'he will also carry out persistence of the vaccine .',b'they will also carry out with its missed injections and memory been conducted for the vaccine .',b'he will also carry out persistence of the vaccine .'
3760,b'depression oder selbstmordgedanken .',b'children and adolescents :',b'children and adolescents',b'children and adolescents :'
3761,"b'wie bei anderen arzneimittel auch , sollte die einnahme von zyrtec bei schwangeren vermieden werden .'",b'as with other medicines that also should take zyrtec in pregnant women should be avoided .',b'caused with other medicines that also should inject a week medical is used .',"b'as with other medicines , the use of zyrtec should be avoided in pregnant women .'"
3762,b'nach wiederholter t\xc3\xa4glicher verabreichung \xc3\xbcber sieben tage wird eine hemmung der magens\xc3\xa4ure- sekretion um etwa 90 % erzielt .',"b'after repeated daily administration for seven days , inhibition of magens\xc3\xa4ure- sekretion achieved by approximately 90 % .'",b'after repeated daily daily of the plasma test is used within approximately .',"b'after repeated daily administration for seven days , inhibition of stomach acid secretion by approximately 90 % is achieved .'"
3763,b'die maximale konzentration im plasma cmax von 48 ng / ml wird durchschnittlich 112 minuten nach der infusion gemessen .',b'the maximum concentration in plasma cmax of 48 ng / ml is measured by an average of 112 minutes after infusion .',b'the maximum concentration of ng of crixivantm is approximately by an average of minutes after infusion .',b'the maximum concentration in plasma cmax of 48 ng / ml is measured by an average of 112 minutes after infusion .'
3764,"b'einmal w\xc3\xb6chentlich , immer am gleichen wochentag einzunehmen .'","b'once a week , always on the same day .'",b'once within your infusion .',"b'take once a week , always on the same day .'"
3765,"b'die flasche fest verschlossen halten , um den inhalt vor feuchtigkeit zu sch\xc3\xbctzen .'",b'keep the bottle tightly closed in order to protect from light and moisture .',b'keep the bottle tightly closed in order to protect from light and moisture .',b'keep the bottle tightly closed in order to protect from moisture .'
3766,b'welchen nutzen hat glustin in diesen studien gezeigt ?',b'what benefit has glustin shown during the studies ?',b'what benefit has glustin shown during the studies ?',b'what benefit has glustin shown during the studies ?'
3767,b'eine allgemeine unterst\xc3\xbctzende behandlung ist angezeigt .',b'a general supportive treatment is indicated .',b'visually contains a general supportive treatment is indicated .',b'a general supportive treatment is indicated .'
3768,b'eine knochentoxizit\xc3\xa4t wurde in form von osteomalazie ( affen ) und verringerter knochenmineraldichte ( ratten und hunde ) diagnostiziert .',b'one knochentoxizit\xc3\xa4t has been diagnosed with osteomalacia ( monkeys ) and reduced bone mineral density ( rats and dogs ) .',"b'poisoning has been diagnosed . in whom in insulin , injury upper th rdna or cimetidine filtration values induced in drug blockage is reduced bone matrix of the apolipoprotein , cell detachment has been diagnosed antibody received thromboxane as than bone immunoglobulin called injuries feeling s enzymes .'",b'a bone toxicity was diagnosed in the form of osteomalacia ( monkeys ) and reduced bone mineral density ( rats and dogs ) .'
3769,b'einschr\xc3\xa4nkung der leberfunktion zaleplon wird vorwiegend in der leber metabolisiert und unterliegt einem betr\xc3\xa4chtlichen pr\xc3\xa4systemischen metabolismus .',b'hepatic impairment zaleplon is mainly metabolised in the liver and undergoes a significant presystemic metabolism .',b'hepatic impairment reyataz is mainly metabolised in the liver and daytime a significant afforded metabolism .',b'hepatic impairment zaleplon is mainly metabolised in the liver and undergoes a significant presystemic metabolism .'
3770,b'mirapexin tabletten enthalten mannitol . mannitol kann eine leicht abf\xc3\xbchrende wirkung haben .',"b'mirapexin tablets contain mannitol , which may have a mild laxative effect .'","b'mirapexin tablets contain mannitol , which may activate a trials of flat values .'","b'mirapexin tablets contain mannitol , which may have a mild laxative effect .'"
3771,b'es enth\xc3\xa4lt den arzneilich wirksamen bestandteil temsirolimus .',b'it contains the active substance temsirolimus .',b'it contains the active substance approximately .',b'it contains the active substance temsirolimus .'
3772,b'eine solche st\xc3\xb6rung tritt normalerweise erst einige monate nach beginn der behandlung auf .',b'such 96 months after onset of treatment .',b'such disruption to four blood of treatment .',b'such a disorder usually occurs 96 months after onset of treatment .'
3773,"b'ventrikul\xc3\xa4re arrhythmien , erregungsleitungsst\xc3\xb6rungen , verschlechterung supraventrikul\xc3\xa4rer arrhythmien , verminderte durchblutung der finger oder zehen bei patienten mit raynaud-syndrom .'","b""ventricular arrhythmias , conduction abnormalities , aggravation of supraventricular arrhythmias , reduction in blood flow to the toes in patients with raynaud 's disease .""","b'cats inhibited , haemoperfusions , delayed smart declined from the period of extraneous tyrosinemia depletion are reduced was possible or inflammation are used .'","b""ventricular arrhythmias , cardiac conduction abnormalities , aggravation of supraventricular arrhythmias , reduction in blood flow to the fingers or toes in patients with raynaud 's disease ."""
3774,b'wirkungen anderer arzneimittel auf ciprofloxacin :',b'effects of other medicinal products on ciprofloxacin :',b'effects of other medicinal products on ciprofloxacin',b'effects of other medicinal products on ciprofloxacin :'
3775,b'gadoversetamid kann mittels dialyse aus dem blut entfernt werden .',b'gadoversetamide may be removed by dialysis from the blood .',b'gadoversetamide may be removed by dialysis from the blood .',b'gadoversetamide may be removed by dialysis from the blood .'
3776,b'nach oraler anwendung einer 125-mg-einzeldosis von aprepitant ist die cmax von aprepitant bei frauen um 16 % h\xc3\xb6her als bei m\xc3\xa4nnern .',"b'following oral administration of a single 125 mg dose of aprepitant , the cmax of aprepitant in women compared to 16 % higher in females than in males .'","b'following oral administration of a single mg dose of aprepitant , the cmax of aprepitant in mortality .'","b'following oral administration of a single 125 mg dose of aprepitant , the cmax of aprepitant in womenis 16 % higher in females than in males .'"
3777,b'stellen sie die ben\xc3\xb6tigte dosis durch drehen des schwarzen dosisknopfes ein .',b'place the full dose of black dosisknopfes .',b'if the full dose of black dose .',b'adjust the necessary dose by turning the black dose button .'
3778,b'gleichzeitige anwendung mit antidepressiva bei der anwendung von duloxetine boehringer ingelheim in kombination mit antidepressiva ist vorsicht geboten .',b'use with antidepressants the use of duloxetine boehringer ingelheim in combination with antidepressants should be used with caution .',b'use with antidepressants the use of duloxetine boehringer ingelheim is required in combination with antidepressants should be used with caution .',b'concomitant use with antidepressants . the use of duloxetine boehringer ingelheim in combination with antidepressants should be used with caution .'
3779,b'die vollst\xc3\xa4ndige auflistung der sonstigen bestandteile siehe abschnitt 6.1 .',"b'for a full list of excipients , see section 6.1 .'","b'for a full list of excipients , see section . .'","b'for a full list of excipients , see section 6.1 .'"
3780,"b'weiterhin wurde \xc3\xbcber \xc3\x9cberempfindlichkeitsreaktionen , wie z. b. angio\xc3\xb6dem und gesichtsschwellungen , berichtet .'","b'in addition , hypersensitivity reactions have been reported , such as angioedema and swelling of the face .'","b'in addition , hypersensitivity reactions have been reported , such as angioedema and swelling of the face .'","b'in addition , hypersensitivity reactions have been reported , such as angioedema and swelling of the face .'"
3781,"b'attenuiertes felines rhinotracheitis-virus ( herpesvirus stamm fhv f2 ) .................. \xe2\x89\xa5 104,9 gkid501 inaktivierte feline calicivirus-antigene ( st\xc3\xa4mme fcv 431 und g1 ) .......................... \xe2\x89\xa5 2,0 elisa-e .'",b'inhibition of feline feline rhinotracheitis herpesvirus ( fhv f2 strain ) .................. \xe2\x89\xa5 104.9 ccid501 inactivated feline calicivirosis antigens ( fcv 431 and fcv g1 strains ) .......................... \xe2\x89\xa5 2.0 elisa u.',b'inhibition of feline bilirubin easily bound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .',b'attenuated feline rhinotracheitis virus ( herpesvirus strain fhv f2 ) .................. \xe2\x89\xa5 104.9 ccid501 inactivated feline calicivirosis antigens ( fcv 431 and fcv g1 strains ) .......................... \xe2\x89\xa5 2.0 elisa u.'
3782,"b'fragen sie ihren apo- theker , wie das arzneimittel zu entsorgen ist , wenn sie es nicht mehr ben\xc3\xb6tigen .'",b'ask your apo- theker how to dispose of medicines no longer required .',b'ask your pharmacist adverse if the treatment with solostar no longer required .',b'ask your pharmacist how to dispose of medicines no longer required .'
3783,b'\xc3\x84ltere patienten : bei patienten \xc3\xbcber 65 jahre liegen nur eingeschr\xc3\xa4nkte erfahrungen vor ( siehe abschnitt 5.2 ) . daher sollte celsentri bei dieser patientenpopulation mit vorsicht eingesetzt werden .',"b'elderly : in patients over the age of 65 years is limited ( see section 5.2 ) , therefore celsentri should be used with caution in this patient population .'","b'elderly for patients of years is limited see section . , the combination . , therefore celsentri should be used with caution in this patient population .'","b'elderly : there is limited experince in patients over the age of 65 years ( see section 5.2 ) , therefore celsentri should be used with caution in this patient population .'"
3784,"b'prialt wird zur behandlung von lang anhaltenden schmerzen verwendet , wenn ihre bestehende behandlung nicht wirksam ist oder schwere nebenwirkungen verursacht .'","b'prialt is used to treat long-term pain , if your may not be effective or causes severe side effects .'","b'prialt is used to treat longterm pain , if your may not be effetive with respiratory signs effects .'","b'prialt is used to treat long-term pain , if your current treatment is not effective or causes severe side effects .'"
3785,b'vorsicht ist geboten bei patienten mit atopischen allergien in der anamnese .',"b'caution should be exercised in patients with atopic dermatitis , a history of allergies .'","b'caution should be exercised in patients with febrile neuralgia , a history of angiox .'",b'caution should be exercised in patients with a history of atopic allergies .'
3786,b'1 durchstechflasche zu 3 ml oder 5 durchstechflaschen zu 3 ml .',b'1 vial of 3 ml or 5 vials of 3 ml are available .',b'vial of ml or vials of ml are available .',b'1 vial of 3 ml or 5 vials of 3 ml are available .'
3787,"b'bei der ratte und beim pavian konnte in toxizit\xc3\xa4tsstudien nachgewiesen werden , dass nieren und pankreas die wichtigsten toxikologischen zielorgane von tacrolimus sind .'","b'in rats , rat and baboon and has been demonstrated in studies that kidneys and pancreas , the main target of tacrolimus .'","b'in rats , rufinamide and tricyclic a resistence stage .'",b'in the rat and the baboon it has been demonstrated in toxicity studies that kidneys and pancreas are the main target of tacrolimus .'
3788,b'au\xc3\x9ferdem sollte erbrechen nur in kombination mit anderen unterst\xc3\xbctzenden ma\xc3\x9fnahmen oder tier\xc3\xa4rztlichen therapien zur behandlung der ursachen des erbrechens behandelt werden .',"b'in addition , vomiting should only be used in combination with other supportive measures or therapies for the treatment of the underlying causes of the vomiting .'","b'in addition , vomiting should only be used in combination with other s measures or abatacept of the recurrence of the restoration of the lungs .'","b'in addition , vomiting should only be used in combination with other supportive measures or therapies for the treatment of the underlying causes of the vomiting .'"
3789,b'aufgrund der geringen l\xc3\xb6slichkeit von sevofluran im blut k\xc3\xb6nnen diese h\xc3\xa4modynamischen ver\xc3\xa4nderungen hier rascher eintreten als bei anderen fl\xc3\xbcchtigen inhalationsan\xc3\xa4sthetika .',b'due to the low solubility of sevoflurane in blood ( these can affect haemodynamic alterations occur here than in other volatile anaesthetic agents .',"b'due to the blood therapy of sevoflurane in blood these can affect parathyroid results in medical volatile s agents at discontinuing ergot and evaluation occurred quicker as the placecbo of uridine responseafter in withdrawal ckit renin , coaprovel'","b'due to the low solubility of sevoflurane in blood , haemodynamic alterations may occur here quicker than in other volatile anaesthetic agents .'"
3790,b'nach dem ersten studienjahr setzten 78 patienten in einer open-label verl\xc3\xa4ngerung die behandlung bis woche 98 fort .',b'after the first studienjahr \xe2\x89\xa5 78 patients in a open-label treatment of up to week 98 .',b'after the first mirena patients deteriorations in a incorporation with three a immediate treatment of up to week .',"b'after the first year of study , \xe2\x89\xa5 78 patients proceeded in an open-label treatment extension up to week 98 .'"
3791,"b'es wird darauf hingewiesen , dass die erste dosis mit menitorix nicht vor dem vollendeten 2. lebensmonat verabreicht werden sollte .'",b'it is suggested that the first dose should not be given before the age of 2 months with menitorix should be addressed .',b'it is suggested that the first dose should not be given before the age of months .',b'it is suggested that the first dose of menitorix should not be given before the age of 2 months .'
3792,b'15 / 17 zum eingeben .',b'15 / 17 for oral use .',b'for oral use .',b'15 / 17 for administration .'
3793,b'im gegensatz zu clarithromycin traten unter der behandlung mit levviax keine en resistenten a-streptokokken in der mundflora auf .',"b'however , in contrast to clarithromycin during treatment with levviax no ris resistant semiconductor substrate in the value of said physical variable .'","b'however , in contrast to clarithromycin during treatment with remicade no induced uric extent for rtlm of pancytopenia initial to a internal intestinal intestinal serum of deposition repeated therapy .'","b'however , in contrast to clarithromycin during treatment with levviax non-resistant group a sreptococcus in the oral flora .'"
3794,b'16 elimination die eliminations-halbwertszeit von glimepirid betr\xc3\xa4gt etwa 5 bis 8 h.',b'16 elimination the elimination half-life of glimepiride is approximately 5 to 8 h .',b'elimination the elimination halflife of glimepiride is approximately to h .',b'16 elimination : the elimination half-life of glimepiride is approximately 5 to 8 h .'
3795,"b'wenn die spritze leer ist , entfernen sie die spritze aus der haut .'","b'when the syringe is empty , remove the syringe from the skin .'","b'when the syringe is empty , remove the syringe from the skin .'","b'when the syringe is empty , remove the syringe from the skin .'"
3796,"b'es ist nicht bekannt , ob etanercept in die muttermilch \xc3\xbcbergeht .'",b'it is not known whether etanercept is excreted in human milk .',b'it is contraindicated whether etanercept is excreted in human milk .',b'it is not known whether etanercept is excreted in human milk .'
3797,"b'sollten ceplene-bedingte toxizit\xc3\xa4ten auftreten ( wie hypotonie , kopfschmerzen ) , kann die injektionszeit von 5 minuten auf eine maximale dauer von 15 minuten verl\xc3\xa4ngert werden .'","b'if ceplene-bedingte toxicities may occur ( such as hypotension , headache ) may increase exposure to injektionszeit the marketing authorisation was renewed on 5 minutes to produce a maximum duration of 15 minutes .'","b'if , additional disease may occur such as hypotension , headache may increase compared to it a maximum duration .'","b'if ceplene-conditional toxicities occur ( such as hypotension , headache ) , the time for injection may increase from 5 minutes to a maximum duration of 15 minutes .'"
3798,"b'wenn die freisetzung dieses botenstoffes durch die nerven verhindert wird , k\xc3\xb6nnen abnormale muskelkontraktionen gemildert oder sogar vollst\xc3\xa4ndig unterbunden werden .'","b'if the release of this botenstoffes prevents the nerves , abnormal muscle contractions may continue or even completely .'","b'if the release of this site are especially immediately could induced a effect with increase as an attack containing the inscription muscle deficiency , abnormal muscle spasms may not fall benedict aids can cause harmful of particular muscle spasms may not been twisted may not been useful may cause the'","b'if the release of this messenger substance prevents the nerves , abnormal muscle contractions may be alleviated or even completely inhibited .'"
3799,b'schwangerschaft ( siehe auch abschnitte 4.4 und 4.6 ) .',b'pregnancy ( see also sections 4.4 and 4.6 ) .',b'pregnancy see also sections . and . .',b'pregnancy ( see also sections 4.4 and 4.6 ) .'
3800,b'die monatliche kontrolle von alt und ast wird empfohlen .',b'the monthly monitoring of alt and ast is recommended .',b'the warning monitoring of alt and ast is recommended .',b'the monthly monitoring of alt and ast is recommended .'
3801,"b'bei etwa 23,3 % der patienten trat unter bivalirudin zumindest ein unerw\xc3\xbcnschtes ereignis und bei 2,1 % eine nebenwirkung auf .'",b'approximately 23.3 % of patients receiving bivalirudin experienced at least one adverse event and 2.1 % experienced an adverse drug reaction .',"b'approximately as storing when the combination of application , dialysis stabilisers reaction .'",b'approximately 23.3 % of patients receiving bivalirudin experienced at least one adverse event and 2.1 % experienced an adverse drug reaction .'
3802,b'zumeist verliefen die infusionsbedingten reaktionen leicht bis m\xc3\xa4\xc3\x9fig schwer .',b'this is most likely to occur in the infusion-associated reactions were mild to moderate in intensity .',b'this is most likely to occur in the reninangiotensin reactions were mild to moderate in intensity may been reported to moderate in intensity .',b'the infusion-associated reactions were mostly mild to moderate in intensity .'
3803,"b'mit ribavarin teva und entweder peginterferon alfa-2b oder interferon alfa-2b erst beginnen , nachdem ihr arzt ein individuell auf sie zugeschnittenes behandlungsschema festgelegt hat .'",b'1.03 : 1 with teva and either peginterferon alfa-2b or interferon alfa-2b only begin after your doctor for amplifying the microsatellite marker inraa003 individually you treatment regimen .',"b'. with teva and either peginterferon alfab or interferon alfab only to a combination of one blood agent or interferon alfab only painful to well the experience on account ,'",b'begin with teva and either peginterferon alfa-2b or interferon alfa-2b only after your doctor has decided on a tailor-made treatment scheme for you .'
3804,b'zerit verringert in kombination mit anderen antiretroviralen arzneimitteln die hiv-virus-last und h\xc3\xa4lt sie auf niedrigem niveau .',"b'zerit , in combination with other antiretroviral agents hiv-virus-last and keeps it at a low response .'","b'zerit , in combination with other antiretroviral agents travel and nail it to necessary .'","b'zerit , in combination with other antiretroviral agents , reduces hiv-virus-loads and keeps it at a low response .'"
3805,b'sie sendet betastrahlung aus .',b'you or beta radiation .',b'instead of this sugar s beta into contact .',b'you or beta radiation .'
3806,b'nicht bei katzen anwenden .',b'do not use in cats .',b'do not use in cats .',b'do not use in cats .'
3807,"b'bei einnahme von karvezide mit anderen arzneimitteln bitte informieren sie ihren arzt oder apotheker , wenn sie andere arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht verschreibungspflichtige arzneimittel handelt .'","b'taking karvezide with other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'","b'taking them with other medicines please tell your doctor or pharmacist if you are taking or have recently also during any other medicines , even those not prescribed .'","b'taking karvezide with other medicines : please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , even those not prescribed .'"
3808,"b'bei besonders schwerwiegenden , lebensbedrohlichen oder rezidivierenden infektionen kann die dosis auf dreimal t\xc3\xa4glich 400 mg erh\xc3\xb6ht werden .'","b'in case of very serious , life-threatening or recurrent infections , the dose may be increased to 400 mg three times a day .'","b'in case of very serious , lifethreatening or recurrent infections , the dose increases , an dose may be increased increased at an day .'","b'in case of very serious , life-threatening or recurrent infections , the dose may be increased to 400 mg three times a day .'"
3809,"b'wenn bei einem patienten w\xc3\xa4hrend der natriumoxybat-therapie harn- oder stuhlinkontinenz auftritt , sollte der verordnende arzt weitere untersuchungen vornehmen , um zu grunde liegende andere erkrankungsursachen auszuschlie\xc3\x9fen .'","b'if any patient develops during the natriumoxybat-therapie faecal incontinence , isoamylases , or for the physician to perform further tests to assess the underlying to rule out other erkrankungsursachen .'","b'if any patient develops during the mirena haemorrhage sheath , contact to temporary gloves and the physician .'","b'if any patient develops urine or faecal incontinence during the sodium oxybate therapy , the physician should perform further tests to rule out other causes of illness .'"
3810,"b'jede fertigspritze enth\xc3\xa4lt 100 mg anakinra * in 0,67 ml ( 150 mg / ml ) .'",b'each pre-filled syringe contains 100 mg of anakinra * in 0.67 ml ( 150 mg / ml ) .',b'each prefilled syringe contains mg of anakinra in . ml mg ml .',b'each pre-filled syringe contains 100 mg of anakinra * in 0.67 ml ( 150 mg / ml ) .'
3811,"b'die behandlungsdauer ist davon abh\xc3\xa4ngig , in welcher gesundheitlichen verfassung sich der patient befindet und wie er auf die behandlung anspricht .'",b'the duration of treatment depends upon a condition about the patient and how it responds to treatment .',"b'the duration of treatment depends from a condition of treatment , are increase with the patient and how it holds directly during the patient and how it us an condition and how is to treatment .'",b'the duration of treatment depends upon the condition of the health of the patient and how they respond to treatment .'
3812,b'2. was m\xc3\xbcssen sie vor der einnahme von sustiva beachten ? 3.',b'what you should know before you take sustiva 3 .',b'what you should know before you take sustiva .',b'what you should know before you take sustiva 3 .'
3813,b'dar\xc3\xbcber hinaus kann tenofovir den plasmaspiegel von raltegravir erh\xc3\xb6hen . der mechanismus dieser wirkung ist jedoch nicht bekannt ( siehe tabelle 1 ) .',"b'furthermore , tenofovir may increase plasma levels of raltegravir . the mechanism of this effect is unknown , but ( see table 1 ) .'","b'other , tenofovir may increase plasma levels of raltegravir . the mechanism of its significant categories of transfer , but see table .'","b'furthermore , tenofovir may increase plasma levels of raltegravir . the mechanism of this effect is unknown ( see table 1 ) .'"
3814,b'wenden sie humalog mix25 pen immer genau nach anweisung des arztes an .',b'always use humalog mix25 pen exactly as your doctor has told you .',b'always use humalog mix pen exactly as your doctor has told you .',b'always use humalog mix25 pen exactly as your doctor has told you .'
3815,b'die erh\xc3\xb6hung der neutrophilenspiegel ist im empfohlenen dosierungsbereich dosisabh\xc3\xa4ngig .',b'the increase in neutrophilenspiegel is dose-dependent in the recommended dose range .',b'the increase in pantoprazole is dosedependent in the recommended dose range .',b'the increase in neutrophil level is dose-dependent in the recommended dose range .'
3816,b'das tierarzneimittel geh\xc3\xb6rt zur gruppe der dermokortikoide .',b'the veterinary medicinal product belongs to the group of dermokortikoide .',b'the veterinary medicinal product belongs to the group of tarcevatreated negative storage medicines .',b'the veterinary medicinal product belongs to the group of dermocorticoids .'
3817,"b'drehen sie die durchstechflasche mit der nadel darin auf den kopf , und halten sie die durchstechflasche in einer hand .'","b'turn the vial with the needle in upside down , and hold the vial in one hand .'","b'the vial with the amount the prescribed intake , the needle in air down , and hold the vial in a top programmes .'","b'turn the vial with the needle in the head of the bottle , and hold the vial in one hand .'"
3818,"b'in kombination mit docetaxel sprachen 61 % der patientinnen an , verglichen mit 34 % bei docetaxel allein .'","b'in combination with docetaxel 61 % of the patients responded to treatment , compared with 34 % with docetaxel alone .'","b'in combination with docetaxel of the combination of the patients responded to treatment , compared to on a compared with with docetaxel alone .'","b'in combination with docetaxel 61 % of the patients responded to treatment , compared with 34 % with docetaxel alone .'"
3819,b'6 wegen mangelnder klinischer erfahrung bei multipler sklerose wird die betaferon-behandlung zu- sammen mit anderen immunmodulatoren au\xc3\x9fer kortikosteroiden oder acth nicht empfohlen .',"b'6 due to the lack of clinical experience in multiple sclerosis patients , the use of betaferon together with immunomodulators other than corticosteroids or acth is not recommended .'","b'due to the lack of clinical experience in multiple sclerosis patients , the use of betaferon pumps or are not recommended .'","b'6 due to the lack of clinical experience in multiple sclerosis patients , the use of betaferon together with immunomodulators other than corticosteroids or acth is not recommended .'"
3820,b'w\xc3\xa4hrend der behandlung mit eucreas sind die leberfunktionswerte im ersten jahr alle drei monate und danach in regelm\xc3\xa4\xc3\x9figen abst\xc3\xa4nden zu \xc3\xbcberpr\xc3\xbcfen .',b'during treatment with eucreas liver function should be monitored at three-month intervals during the first year and periodically thereafter .',b'during treatment with eucreas liver function should be completed during the first year and periodically thereafter .',"b'during treatment with eucreas , liver function levels should be monitored at three-month intervals during the first year and periodically thereafter .'"
3821,"b'bei verdacht auf hit , muss die thrombozytenzahl unverz\xc3\xbcglich be- stimmt , und falls erforderlich , die therapie mit ceprotin abgebrochen werden .'","b'in cases of suspected hit , the patient must be treated platelet count , which is immediately , and , if necessary , therapy with ceprotin should be discontinued .'","b'in cases of suspected hit , the patient to be in cases of suspected torsade burden of suspected efflux , the patient must be those in the reduction effect not between preparation prior to patients is treated .'","b""in cases of suspected hit , the patient 's platelet count must be immediately determined and , if necessary , therapy with ceprotin should be discontinued ."""
3822,b'daher kann das ausma\xc3\x9f dieses effekts m\xc3\xb6glicherweise ausgepr\xc3\xa4gter sein .',"b'therefore , the magnitude of this effect may be expected to be more pronounced .'","b'therefore , the nephrotoxic properties were expected to be more pronounced .'","b'therefore , the magnitude of this effect may be expected to be more pronounced .'"
3823,b'die emea stellt arzneimittelbescheinigungen gem\xc3\xa4\xc3\x9f den bestimmungen der weltgesundheitsorganisation aus .',b'no\xc3\xabl wathion products .',b'mobilisation must be chosen the medicine .',b'the emea issues medicinial certifcates according to the regulations of the who .'
3824,b'welche nebenwirkungen sind m\xc3\xb6glich ? 5.',b'possible side effects 5 how to store atryn 6 .',b'possible side effects .',b'possible side effects ?'
3825,b'humalog basal vor dem ersten gebrauch im k\xc3\xbchlschrank ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) lagern .',b'humalog basal is the first use store in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) .',b'the first use .',b'store humalog basal in a refrigerator ( 2 \xc2\xb0 c - 8 \xc2\xb0 c ) before the first use .'
3826,"b'das arzneimittel enth\xc3\xa4lt 100 ml l\xc3\xb6sung in einem durchsichtigen , flexiblen polyolefin-beutel mit aluminium umverpackung .'",b'this medicinal product contains 100 ml of solution in a clear flexible polyolefine bag with aluminium overpouch .',b'this medicinal product contains mg of solution in a clear teriparatid bromobutyl space and cross bioactivity from a clear volumes bag with perforated carton with perforated stomatitis .',b'this medicinal product contains 100 ml of solution in a clear flexible polyolefine bag with aluminium outer packaging .'
3827,b'bitte atmen sie nicht in ihren diskus hinein .',b'remove the diskus from your mouth .',b'remove the discus on your mouth .',b'please do not breath into your discus .'
3828,b'ceplene darf nicht mit anderen arzneimitteln gemischt und darf nicht verd\xc3\xbcnnt werden .',b'ceplene should not be diluted with any other medicinal product and should not be used .',b'ceplene should not be diluted with any other medicinal product and given with any other medicinal product and should not be used to any other medicinal product and atorvastatin .',b'ceplene should not be mixed with any other medicinal product and should not be diluted .'
3829,b'sie k\xc3\xb6nnen dosen zwischen 1 und 60 einheiten in schritten von jeweils 1 einheit einstellen .',b'you can dial doses from 1 to 60 units in increments of 1 unit .',b'you can set doses from to units in increments of unit .',b'you can set doses from 1 to 60 units in increments of 1 unit .'
3830,"b'impfstoffe wirken dadurch , dass sie dem immunsystem ( den k\xc3\xb6rpereigenen abwehrmechanismen ) "" beibringen , "" sich selbst gegen eine krankheit zu wehren .'","b'vaccines work by the immune system ( the body \'s natural defences ) "" teaching \'and makes antibodies against them .'",b'vaccines increases by the immune system the body s natural defences from the medicine .',"b'vaccines work by the immune system ( the body \'s natural defences ) "" teaching \'and makes antibodies against them .'"
3831,b'zudem hemmt dasatinib die kinasen der src-familie in subnanomolaren konzentrationen .',"b'in addition , dasatinib inhibits src in subnanomolaren concentrations .'","b'in addition , dasatinib inhibits hexafluoropropylenevinylidene decreasesn there have presented by feed concentrations was .'","b'in addition , dasatinib inhibits src family kinases in subnanomolaren concentrations .'"
3832,b'4 erfahrungen mit rosiglitazon vor . daher sollten die leberenzyme bei allen patienten vor beginn der behandlung mit avaglim und anschlie\xc3\x9fend in nach klinischer einsch\xc3\xa4tzung bestimmten zeitr\xc3\xa4umen gepr\xc3\xbcft werden .',b'4 experience with rosiglitazone and therefore liver enzymes should be performed in all patients prior to initiating therapy with avaglim and certain clinical physician so as to be checked .',b'for the increased to the higher out of treatment routinely than dose . should be performed in all patients prior to initiating therapy with ciprofloxacin and they must be reevaluated out with plenty and times hepatic status .',b'4 experiences with rosiglitazone . therefore liver enzymes should be checked in all patients prior to initiating therapy with avaglim and in certain periods during clinical trials .'
3833,"b'erythem , hautver\xc3\xa4nderungen sehr selten :'","b'erythema , skin disorder very rarely :'","b'erythema , skin disorder very rarely'","b'erythema , skin disorders very rarely :'"
3834,"b'die nierenfunktion , gemessen anhand der glomerul\xc3\xa4ren filtrationsrate und anhand des serumkreatininspiegels sowie proteinurie , blieb bei der mehrzahl der patienten stabil .'","b'renal function as measured by glomerular filtration rate and the proteinuria , serum creatinine , as well as , the majority of patients .'",b'renal function as measured by procedures is significant dose inhibits the longer substance see the platelet plasma rate in the most or major concentration of patients .',"b'renal function remained stable among the majority of patients , as measured by glomerular filtration rate with the help of the serum creatinine level , as well as proteinuria .'"
3835,b'zur epil\xc3\xa4sionalen anwendung .',b'for epil\xc3\xa4sionalen .',b'for somnambulism them in doses of the same drops for temoporfin .',b'for use of epil\xc3\xa4sionalen .'
3836,b'so kann sich der augeninnendruck vor\xc3\xbcbergehend erh\xc3\xb6hen . ihr augenarzt wird dies nach der injektion \xc3\xbcberpr\xc3\xbcfen und bei bedarf korrekturma\xc3\x9fnahmen ergreifen .',b'thus also temporarily . your ophthalmologist will monitor this after the injection and take corrective measures if needed .',b'thus also induced the need medical resonance are leakages .',b'thus the intraocular pressure may increase temporarily . your ophthalmologist will monitor this after the injection and take corrective measures if needed .'
3837,b'die pharmakokinetischen eigenschaften von bivalirudin zeigen keine geschlechtsspezifischen wirkungen .',b'the pharmacokinetic properties of bivalirudin show no subgroup effects .',b'the pharmacokinetic properties of bivalirudin show no subgroup effects .',b'the pharmacokinetic properties of bivalirudin show no gender-specific effects .'
3838,"b'wenn sie nach dieser zeit nicht auf die behandlung angesprochen haben , kann ihre behandlung f\xc3\xbcr mindestens 18 monate weitergef\xc3\xbchrt werden .'","b'if you are not after this period who have responded to treatment , your treatment should continue for at least 18 months .'","b'if you are not exceed this period who have responded to treatment , your treatment could carefully subsided after the treatment .'","b'if you have not responded to treatment after this period , your treatment should continue for at least 18 months .'"
3839,b'wie wird yentreve angewendet ?',b'how is yentreve used ?',b'how is yentreve used ?',b'how is yentreve used ?'
3840,"b'beispiele f\xc3\xbcr solche arzneimittel sind : triptane , tramadol , tryptophan , bestimmte arzneimittel gegen depressionen : selektive serotonin- wiederaufnahmehemmer ( wie z.b.'","b'examples of these medicines include : triptans , tramadol , tryptophan , ssris , certain medicines for these agents ( e. g .'","b'printing of these medicines include tolerance , retinal , cerebral or fades due to to the organism of the commonly and repeatdose medicines for these agents and this , mumps , they is eliminated and immediate medicines for these agents e . g .'","b'examples of these medicines include : triptans , tramadol , tryptophan , ssris , certain medicines for these agents ( e. g .'"
3841,b'wei\xc3\x9fe bis wei\xc3\x9fgraue masse oder pulver .',b'white to wei\xc3\x9fgraue or powder .',b'white to commencing or powder .',b'white to white-grey or powder .'
3842,b'bei kindern unter zwei jahren darf protopic nicht angewendet werden .',b'protopic should not be used in children less than two years of age .',b'protopic should not be used in children less than two years of age .',b'protopic should not be used in children less than two years of age .'
3843,b'wie wurde pylobactell untersucht ?',b'how has pylobactell been studied ?',b'how has pylobactell less studied ?',b'how has pylobactell been studied ?'
3844,"b'wenden sie sich umgehend an ihren arzt , wenn sich bei ihnen w\xc3\xa4hrend der einnahme von targretin eine verschlechterung ihres zustands einstellt .'",b'contact your doctor immediately if you experience while you are taking targretin worsening of your .',b'viagra treatment of warning acid is sedated during from appropriate therapeutic monitoring',b'contact your doctor immediately if you experience a worsening of your condition while you are taking targretin .'
3845,"b'bei montelukast handelt es sich um eine oral wirksame substanz , die mit hoher affinit\xc3\xa4t und selektivit\xc3\xa4t an cyslt1-rezeptoren bindet .'",b'in montelukast is an orally which binds with high affinity and selectivity at cyslt1-rezeptoren .',b'very study bind to about an glucuronidation active is a recombinant incidence of the process of tachosil or neuraminidase .',b'montelukast is an orally-effective sustance which binds to cyslt1 receptors with high affinity and selectivity .'
3846,"b'tierstudien zeigen , dass travoprost und seine metaboliten in die muttermilch \xc3\xbcbergehen .'",b'animal studies have shown excretion of travoprost and its metabolites are excreted in human breast milk .',b'animal studies have shown inhaled either human therapeutic milk .',b'animal studies have shown that travoprost and its metabolites are excreted in human breast milk .'
3847,b'die verabreichung von lamivudin in sehr hoher dosierung f\xc3\xbchrte in tierstudien zur akuten toxizit\xc3\xa4t zu keiner organtoxizit\xc3\xa4t .',b'administration of lamivudine at very high dose resulted in acute toxicity studies in animals did not provide any organ toxicity .',b'administration of lamivudine at very high dose increases in acute toxicity studies in animals did not provide any organ toxicity .',b'administration of lamivudine at very high dose resulted in no organ toxicity in animals on acute toxicity .'
3848,"b'die oben beschriebenen beschwerden k\xc3\xb6nnen zeichen von nachfolgend beschriebenen nebenwirkungen sein , die alle w\xc3\xa4hrend klinischer studien mit roactemra beobachtet wurden :'","b'the symptoms described above can be signs of the side effects described below , all of which have been observed during clinical trials with roactemra :'",b'the too bleeding based occur above can be signs of the side effects during clinical trials with roactemra',"b'the symptoms described above can be signs of the side effects described below , all of which have been observed during clinical trials with roactemra :'"
3849,"b'die h\xc3\xa4ufigkeit akuter absto\xc3\x9fungsreaktionen war bei patienten , die basiliximab und ein immunsuppressives behandlungsschema mit drei pr\xc3\xa4paraten erhielten , wesentlich geringer .'","b'the incidences of acute rejection were in patients who received basiliximab and immunosuppressive regimen three preparations , much lower .'",b'the incidences of acute rejection were in patients who received igg and alzheimer regimen remote as the increase in the haematopoietic body correspondingly .',b'the incidences of acute rejection were much lower in patients who received basiliximab and immunosuppressive regimen with three preparations .'
3850,"b'der chmp war ferner der ansicht , dass der f\xc3\xbcr die zusammenfassung der merkmale des arzneimittels vorgeschlagene wortlaut dem behandelnden arzt genug spielraum l\xc3\xa4sst , um mit der dosis von 25 mg oder dar\xc3\xbcber zu beginnen .'",b'the chmp was also of the opinion that the spc wording proposed by the treating physician is enough to provide a solid microporous matrix with the dose of 25 mg or greater .',b'the chmp was also been also available for the opinion that the spc programme of the skin days by such the schedule dose with the dose of mg or greater excreted for the dose of mg or greater .',b'the chmp was also of the opinion that the wording proposed by the treating physician leaves enough scope to begin with the dose of 25 mg or greater .'
3851,b'das trockenmittel nicht schlucken .',b'not be removed .',"b'mix for make deferiprone , the vial .'",b'do not not swallow the drying agent .'
3852,b'bei beiden tierarten wird das produkt zweimal im abstand von 48 stunden intramuskul\xc3\xa4r in einer dosierung von 15 mg amoxicillin je kg k\xc3\xb6rpergewicht ( entspricht 1 ml suramox 15 % la / 10 kg k\xc3\xb6rpergewicht ) verabreicht .',"b'in both species , the product twice at an interval of 48 hours will be administered intramuscularly at a dose of 15 mg amoxicillin per kg body weight ( equivalent to 1 ml of suramox 15 % la / 10 kg body weight ) .'","b'using both acting dose , the product is absorption corresponding at an interval of hours after a dose of mg , less is administered intramuscularly at a dose of mg therapeutic mg kg sodium weight and daily doses than or sildenafil body weight .'","b'in both species , the product was administered intramuscularly twice every 48 hours at a dose of 15 mg amoxicillin per kg body weight ( equivalent to 1 ml of suramox 15 % la / 10 kg body weight ) .'"
3853,"b'die behandlung einer \xc3\x9cberdosierung von ritonavir sollte allgemeine ma\xc3\x9fnahmen umfassen , wie z. b. die \xc3\x9cberwachung der vitalfunktionen und die beobachtung des klinischen zustands des patienten .'",b'treatment of overdose with ritonavir is to consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient .',b'treatment of overdose with ritonavir with ritonavir is to relieve insulin degrees of vital signs and observation of a specialised signs and initiated in and monitoring of therapy of therapy of the clinical status of the clinical status of the patient .',b'treatment of overdose with ritonavir is to consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient .'
3854,"b'kinder und jugendliche bevor die behandlung der verhaltensst\xc3\xb6rung beginnt , sollten andere gr\xc3\xbcnde f\xc3\xbcr ein aggressives verhalten ausgeschlossen worden sein .'","b'children and adolescents before in the treatment of conduct disorder , should be excluded for other reasons for aggressive behaviour .'","b'children and adolescents when in the treatment of oesophageal disorder , a patients with xiliarx .'","b'children and adolescents : before in the treatment of conduct disorder begins , other reasons for aggressive behaviour should be ruled out .'"
3855,b'w\xc3\xa4hrend dieser studien erlitten 12 von 492 patienten bzw. nur 3 von 366 patienten mit langzeitansprechen einen r\xc3\xbcckfall .',b'during these trials out of 366 sustainedresponders relapsed and only 3 patients with virologic response .',b'during these trials survived of odesmethyllacosamid nonlinearity and only patients with chop response .',b'during this trial 12 out of 366 patients suffered a relapse and only 3 out of 366 patients with long term response suffered a relapse .'
3856,"b'kinder und jugendliche procoralan wird nicht empfohlen f\xc3\xbcr die anwendung bei kindern und jugendlichen , weil daten zur unbedenklichkeit und wirksamkeit fehlen .'",b'children and adolescents procoralan is not recommended for use in children and adolescents because data on safety and efficacy .',b'children and adolescents adolescents is not recommended for use in children an adolescents evidence on the auc .',b'children and adolescents procoralan is not recommended for use in children and adolescents because the lack of data on safety and efficacy .'
3857,"b'das antragsdossier und alle daten , die bis zu tag 60 des verfahrens in der cmd ( v ) hinzugekommen sind , f\xc3\xbcr alle cvmp-mitglieder und die emea .'","b'the antragsdossier and all data up to day 60 of the procedure in cmd ( v ) hinzugekommen or to establish , for all cvmp-mitglieder and the emea .'",b'the diesters of the dose of the still found up to further related to day of the growth of the guideline in the same closure of oral combination is each overexpress and the emea .',"b'the application file and all data up to day 60 of the procedure in cmd ( v ) added , for all cvmp members and the emea .'"
3858,"b'es kann sein , dass patienten , die novorapid anwenden , eine erh\xc3\xb6hte zahl t\xc3\xa4glicher injektionen oder eine gegen\xc3\xbcber ihrem \xc3\xbcblichen insulin ver\xc3\xa4nderte dosierung ben\xc3\xb6tigen .'",b'you may suggests that patients taking novorapid increased number of daily injections or a change in dosage from that used with their usual insulins .',"b'instead in any combination , a change in dosage from that used with their usual suitable therapy .'",b'patients taking novorapid may need an increased number of daily injections or a change in dosage from their usual insulin dose .'
3859,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr alimta finden sie hier .',b'the full epar for avamys for alimta can be found here .',b'the full epar for evicel can be found here .',b'the full epar for alimta can be found here .'
3860,b'eine intensivierung der insulintherapie mit abrupter verbesserung des blutzuckerspiegels kann jedoch zu einer vor\xc3\xbcbergehenden verschlechterung einer retinopathie f\xc3\xbchren .',"b'a however , intensification of insulin therapy with abrupt improvement in glycaemic control may be a transient exacerbation of retinopathy .'",b'a intensification of insulin therapy with abrupt improvement in glycaemic control may lead to animals control may be a transient exacerbation of retinopathy .',b'an intensification of insulin therapy with abrupt improvement in glycaemic control may be a transient exacerbation of retinopathy .'
3861,b'jeder spr\xc3\xbchsto\xc3\x9f von seretide enth\xc3\xa4lt :',b'each single actuation of seretide contains :',b'each daily graduation of seretide containing rituximab introna pack contains',b'each single actuation of seretide contains :'
3862,b'8 mit derselben dosierung fortgesetzt werden .',b'8 at the same dose for another 4 weeks .',b'at the same dose for another weeks to',b'8 at the same dose for another 4 weeks .'
3863,b'wie wurde die wirksamkeit von halocur untersucht ?',b'how has the effectiveness of halocur been studied ?',b'how has the effectiveness of halocur has proven',b'how has the effectiveness of halocur been studied ?'
3864,b'107 allgemeine erkrankungen und beschwerden am verabreichungsort :',b'107 general disorders and administration site conditions :',b'general disorders and administration site conditions',b'107 general disorders and administration site conditions :'
3865,b'die verf\xc3\xbcgbaren daten deuten auf ein m\xc3\xb6glicherweise erh\xc3\xb6htes risiko f\xc3\xbcr spontanaborte hin .',b'available data indicate that there may be an increased risk of spontaneous abortion .',b'available data vary that there may be a increased risk of spontaneous manufacturers scheme .',b'available data indicate that there may be an increased risk of spontaneous abortion .'
3866,"b'eine panzytopenie erweist sich normalerweise als reversibel , und die intensit\xc3\xa4t einer knochenmarkaplasie ist dosisabh\xc3\xa4ngig .'","b'one pancytopenia is usually indicated as reversible , and the intensity of a knochenmarkaplasie dose-dependent .'",b'half of a posaconazol is may been controlled by therapeutic reduction of a pathogenesis baseline was reduced out with three sulphonamide balance levels',"b'one pancytopenia is usually indicated as reversible , and the intensity of a bone marrow aplasia is dose-dependent .'"
3867,"b'vorsicht ist geboten , wenn bisphosphonate gleichzeitig mit aminoglykosiden verabreicht werden , da beide substanzgruppen zu einer senkung des serumcalciumspiegels \xc3\xbcber l\xc3\xa4ngere zeitr\xc3\xa4ume f\xc3\xbchren k\xc3\xb6nnen .'",b'caution is advised when bisphosphonates are administered with aminoglycosides because homeopathics have both can lower serum calcium levels for prolonged periods .',"b'caution is therefore when bisphosphonates are administered with benign cases of body system serum preparations slightly with nicotinuric de concentration in growth may possibly , torsades serum increase into a therapy of the prolonged de muscle inhibitors from the year of the virus was than in the a benzisoxazolderivat meters'",b'caution is advised when bisphosphonates are administered with aminoglycosides because both substances can lower serum calcium levels for prolonged periods .'
3868,"b'wenn sie weitere fragen zur anwendung des arzneimittels haben , fragen sie ihren arzt oder apotheker .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'","b'if you have any further questions on the use of this product , ask your doctor or pharmacist .'"
3869,b'in jeder studie wurde die t\xc3\xa4gliche dosis in zwei gleich gro\xc3\x9fe dosen aufgeteilt .',"b'in each study , the daily dose was administered in evenly divided doses .'","b'in each study , the daily dose was administered in protamine milk of .'","b'in each study , the daily dose was administered in evenly divided doses .'"
3870,b'die haltbarkeit w\xc3\xa4hrend des gebrauchs betr\xc3\xa4gt 4 wochen ( nicht \xc3\xbcber 30 \xc2\xb0 c ) .',b'the in-use shelf life is 4 weeks ( not above 30 \xc2\xb0 c ) .',b'the readymade authorisation is weeks not above c .',b'the in-use shelf life is 4 weeks ( not above 30 \xc2\xb0 c ) .'
3871,b'alle diese nebenwirkungen sind r\xc3\xbcckbildungsf\xc3\xa4hig ( reversibel ) .',b'all of these side effects are r\xc3\xbcckbildungsf\xc3\xa4hig ( reversible ) .',b'all of these side effects are prognostic produced .',b'all of these side effects are reversible .'
3872,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr mimpara finden sie hier .',b'the full epar for avamys for mimpara can be found here .',b'the full epar for avamys for mimpara can be found here .',b'the full epar for avamys for mimpara can be found here .'
3873,"b'die medianen zeiten bis zur progression sind f\xc3\xbcr diese endpunkte bei tmz um 0,7 bis 2,1 monate l\xc3\xa4nger als bei procarbazin ( logrank p = < 0,01 bis 0,03 ) .'",b'the median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for tmz than for procarbazine ( log rank p = 0.01 to 0.03 ) .',b'the median concentration led to the given measures rate . within proteinuria as . months adults necessary longer .',b'the median times to progression in these endpoints are from 0.7 to 2.1 months longer for tmz than for procarbazine ( log rank p = 0.01 to 0.03 ) .'
3874,b'gleicherma\xc3\x9fen wurden keine unterschiede zwischen den gruppen in der studie bm 16549 nach einem und nach zwei jahren bekannt .',b'gleicherma\xc3\x9fen there were no differences between the two groups in the study bm 16549 occurring after one and two years of age .',b'sorivudine . there were no differences between the two groups in the study deecresed occurring after one of age .',"b'similarly , there were no differences between the two groups in the study bm 16549 occurring after one and two years of age .'"
3875,b'12 rekonstitution und gabe des arzneimittels :',b'12 reconstitution and administration :',b'reconstitution and administration',b'12 reconstitution and administration of the medicine :'
3876,"b'auswirkungen auf die verkehrst\xc3\xbcchtigkeit oder das bedienen von maschinen nach der behandlung mit ( 90y ) yttrium-markierten arzneimittel sind der "" zusammenfassung der merkmale des arzneimittels "" / "" packungsbeilage "" des jeweiligen arzneimittels zu entnehmen .'",b'affect your ability to drive or to operate machines after treatment with yttrium ( 90y ) -labelled medicinal product refer to the summary of product characteristics of product characteristics / package leaflet of the medicinal product to be radiolabelied .',b'as your ability to drive or to falling effects the corresponding .',b'effects on your ability to drive or to operate machines after treatment with yttrium ( 90y ) labelled medicinal product are to be found in the summary of product characteristics package leaflet of the medicinal product to be radiolabelied .'
3877,b'c setzen sie stets die pen-kappe wieder auf den pen und bewahren ihn so bis zur n\xc3\xa4chsten injek- tion auf .',"b'always put the pen cap back on the pen , then store the pen until your next injection .'","b'remove the pen cap back on the pen , then store the pen until your next injection .'","b'always put the pen cap back on the pen , then store it in this way until your next injection .'"
3878,b'bei allen patienten mit eingeschr\xc3\xa4nkter nierenfunktion ist die dosistitration mit besonderer vorsicht durchzuf\xc3\xbchren ( siehe abschnitt 5.2 ) .',"b'all patients with renal impairment , the dose titration should be performed with caution ( see section 5.2 ) .'","b'all patients with renal impairment , the dose titration , the dose titration should be populations with caution see section . .'","b'all patients with renal impairment , the dose titration should be performed with caution ( see section 5.2 ) .'"
3879,b'zur pharmakokinetik von micafungin bei patienten mit schwerer leberinsuffizienz liegen keine aus- reichenden daten vor ( siehe abschnitt 5.2 ) .',b'the pharmacokinetics of micafungin in patients with severe hepatic insufficiency on a firm data are available ( see section 5.2 ) .',b'the pharmacokinetics of the pharmacokinetics of micafungin in patients with severe hepatic insufficiency on a chance part .',b'insufficiency data is available on the pharmacokinetics of micafungin in patients with severe hepatic ( see section 5.2 ) .'
3880,b'diese impfung weniger wirksam sein .',b'this vaccination may be less effective .',b'this vaccination may be less effective .',b'this vaccination may be less effective .'
3881,b'art der anwendung fondaparinux wird durch tiefe subkutane injektion am liegenden patienten angewendet .',b'method of administration fondaparinux is administered by deep subcutaneous injection while the patient is lying down .',b'method of administration fondaparinux is administered by all subcutaneous injection while the patient is encouraged down .',b'method of administration fondaparinux is administered by deep subcutaneous injection while the patient is lying down .'
3882,"b'ich kann den dosierknopf nicht ziehen , drehen oder dr\xc3\xbccken . was soll ich machen ?'","b'i cannot pull the dose knob , or lightly . what should i do ?'","b'i cannot is use the dose knob , or easy to an the insulin preparation vial with the cells until use the dose knob .'","b'i cannot pull , twist or press the dose knob . what should i do ?'"
3883,b'hydrochlorid in einer polyethylenglykolisierten liposomalen zubereitung .',b'hgh in reconstituted liposomes .',b'valera in the elimination solvent .',b'hydrochloride gh in a polyethylene glycosylated liposomal preparation .'
3884,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr evista finden sie hier .',b'the full epar for avamys for evista can be found here .',b'the full epar for an alli should be found here .',b'the full wording of the epar for evista can be found here .'
3885,b'die empfohlene therapiedauer von 24 monaten sollte nicht \xc3\xbcberschritten werden .',b'the recommended duration of therapy of 24 months should not be exceeded .',b'the recommended duration of therapy of months should not be exceeded .',b'the recommended duration of therapy of 24 months should not be exceeded .'
3886,"b'in f\xc3\xa4llen , die nach 2 monaten der behandlung keine besserung zeigen , sollte die therapie mit clomicalm beendet werden .'","b'in cases , after 2 months of treatment show no improvement on therapy with clomicalm should be discontinued .'","b'in cases , after months of treatment show no improvement on therapy with imprida should be discontinued .'","b'in cases that show no improvement after 2 months of treatment , therapy with clomicalm should be discontinued .'"
3887,"b'wenn sich das lyophilisat vorzeitig aufl\xc3\xb6st , h\xc3\xa4nde gr\xc3\xbcndlich waschen .'","b'if the lyophilisate is nullified , discontinued wash your hands thoroughly .'",b'if the lyophilisate is heavy disorders microorganisms must continue to you using your hands thoroughly .',"b'if the lyophilisate is dissolved prematurely , wash your hands thoroughly .'"
3888,b'3 der aktive metabolit von leflunomid ( a771726 ) hat eine lange halbwertszeit von \xc3\xbcblicherweise 1 bis 4 wochen .',"b'3 the active metabolite of leflunomide , a771726 , has a long half-life , usually 1 to 4 weeks .'","b'the active metabolite of leflunomide , a patient is expected approximately halflife that'","b'3 the active metabolite of leflunomide , a771726 , has a long half-life , usually 1 to 4 weeks .'"
3889,b'die empfohlene dosis f\xc3\xbcr fabrazyme liegt bei 1 mg / kg k\xc3\xb6rpergewicht bei anwendung einmal alle zwei wochen als intraven\xc3\xb6se infusion .',b'the recommended dose of fabrazyme is 1 mg / kg of body weight administered once every 2 weeks as an intravenous infusion .',b'the recommended dose of fabrazyme is mg kg of body weight administered once every weeks as an intravenous infusion .',b'the recommended dose of fabrazyme is 1 mg / kg of body weight administered once every 2 weeks as an intravenous infusion .'
3890,"b'die zweite dosis sollte nicht gegeben werden , wenn eine schwere \xc3\x9cberempfindlichkeitsreaktion gegen simulect oder postoperative komplikationen , zum beispiel ein verlust des transplantats , auftreten ( siehe abschnitt 4.4 ) .'",b'the second dose should not be given in the event of a severe hypersensitivity reaction to simulect or post-operative complications such as graft loss ( see section 4.4 ) .',b'the second dose should not be given in the event of a severe hypoglycaemia reaction to simulect or th or conventional complications such as .',b'the second dose should not be given in the event of a severe hypersensitivity reaction to simulect or post-operative complications such as graft loss ( see section 4.4 ) .'
3891,"b'es wird jedoch als nicht wahrscheinlich angesehen , da\xc3\x9f neospect ihre f\xc3\xa4higkeit beeinflu\xc3\x9ft , ein fahrzeug zu f\xc3\xbchren oder eine maschine zu bedienen .'","b'it is , however , not considered that is likely to be affected by neospect your ability to drive or operate machinery .'","b'it is , however , not excercised whether the doctor may prescribe an car .'","b'it is , however , not considered likely that neospect will affect your ability to drive or operate machinery .'"
3892,"b'in toxizit\xc3\xa4tsstudien zeigte sich , dass die behandlung mit abacavir zu einem anstieg des lebergewichts bei ratten und affen f\xc3\xbchrt .'",b'in repeated dose toxicity studies have shown that treatment with abacavir results in an increase in liver weights in rats and monkeys .',b'in repeated dose toxicity studies have shown that treatment of erythropoietin subtype of plasma converting values .',b'in repeated dose toxicity studies have shown that treatment with abacavir results in an increase in liver weights in rats and monkeys .'
3893,b'in der zweiten studie wurde die anwendung von flebogammadif zur immunmodulation bei 20 patienten mit itp untersucht .',b'the second study looked at the use of flebogammadif for immunomodulation in 20 patients with itp .',b'the second study appears at the use of doxastad for stelara in patients with cervical .',b'the second study looked at the use of flebogammadif for immunomodulation in 20 patients with itp .'
3894,b'wirkungen von celecoxib auf andere arzneimittel celecoxib ist ein cyp 2d6-inhibitor .',b'effects of celecoxib on other medicinal products celecoxib is a cyp 2d6-inhibitor .',b'effects of celecoxib on other medicinal products antagonist is potentially serum cells .',b'effects of celecoxib on other medicinal products celecoxib is a cyp 2d6-inhibitor .'
3895,b'eingeschr\xc3\xa4nkte nierenfunktion weniger als 10 % fentanyl werden unver\xc3\xa4ndert \xc3\xbcber die nieren ausgeschieden .',b'renal impairment and less than 10 % of fentanyl is eliminated unchanged via the kidneys .',b'renal impairment and less than of fentanyl is eliminated unchanged via the kidneys .',b'renal impairment : less than 10 % of fentanyl is eliminated unchanged via the kidneys .'
3896,"b'ist die transplantation peripherer blutstammzellen beabsichtigt , so sollte die mobilisierung der stammzellen in einer fr\xc3\xbchen behandlungsphase des patienten erfolgen .'",b'if the pbpc pbpc to be effective for early in the treatment course of the patient .',b'if the gad ltd characterised to be effective for early in the entire basis of the patient .',"b'if the transplatation of pbpc is intended , the mobilisation of the stem cells should take place in an early treatment phase of the patient .'"
3897,b'2 / 3 warum wurde opgenra zugelassen ?',b'2 / 3 why has opgenra been approved ?',b'why has xenical been approved ?',b'2 / 3 why has opgenra been approved ?'
3898,"b'personen , die moai-haltige arzneimittel , wie antidepressiva , einnehmen , sollten im umgang mit promeris duo besonders vorsichtig sein .'","b'people who moai-haltige medicinal products , such as antidepressants , should be in the use of promeris duo care .'","b'people who disintegrates medicinal products , such as antidepressants , careful prescribed onsenal conditions .'","b'people who take medicinal products containing moai , such as antidepressants , should be cautious when handling promeris duo care .'"
3899,b'wichtige informationen \xc3\xbcber bestimmte sonstige bestandteile von pandemrix pandemrix enth\xc3\xa4lt thiomersal ( konservierungsmittel ) . m\xc3\xb6glicherweise kann bei ihnen eine \xc3\x9cberempfindlichkeitsreaktion auftreten .',"b'important information about some of the ingredients of pandemrix this medicinal product contains thiomersal ( preservative ) , it is possible that you may experience an allergic reaction .'",b'important information about some of the ingredients of zyrtec',"b'important information about some of the ingredients of pandemrix . this medicinal product contains thiomersal ( preservative ) , it is possible that you may experience an allergic reaction .'"
3900,"b'bei patienten , die nach der einleitung der lamotrigintherapie zus\xc3\xa4tzlich carbamazepin einnahmen , wurde \xc3\xbcber zentralnerv\xc3\xb6se st\xc3\xb6rungen wie schwindel , ataxie , diplopie , verschwommensehen und \xc3\x9cbelkeit berichtet .'","b'in patients receiving induction therapy with lamictal in addition to those taking carbamazepine , central nervous system related symptoms , such as dizziness , ataxia , diplopia , blurred vision and nausea have been reported .'","b'in patients receiving average therapy with false blood pressure receptor vertigo , tissue , eyelid , have been reported .'","b'in patients who took carbamazepin in addition to induction therapy with lamicta , central nervous system related symptoms , such as dizziness , ataxia , diplopia , blurred vision and nausea have been reported .'"
3901,"b'der ausschuss hatte auch bedenken bez\xc3\xbcglich der sicherheit von cimzia : obwohl diese mit der sicherheit anderer arzneimittel der gleichen klasse vergleichbar ist , gab es gewisse bedenken hinsichtlich eines m\xc3\xb6glichen gr\xc3\xb6\xc3\x9feren risikos von blutungen bei patienten , die cimzia erhalten .'","b'the committee also had concerns regarding the safety of cimzia : although with the safety of other similar medicines of the same class , there was also some concerns of a possible increased risk of bleeding in patients receiving cimzia .'","b'the committee also had dependant regarding the safety of tritace , there was also some concerns to well in patients receiving angina .'","b'the committee also had concerns regarding the safety of cimzia : although with the safety of other similar medicines of the same class , there was also some concerns of a possible increased risk of bleeding in patients receiving cimzia .'"
3902,"b'kinder zwischen 6 und 11 jahren : eine aerius 2,5 mg schmelztablette einmal t\xc3\xa4glich einnehmen .'",b'children 6 through 11 years of age : one 2.5 mg aerius orodispersible tablet once a day .',b'children through years of age one . mg aerius orodispersible tablet once a day .',b'children 6 through 11 years of age : one 2.5 mg aerius orodispersible tablet once a day .'
3903,"b'leichtere nebenwirkungen sind quetschung , schmerz , r\xc3\xb6tung , schwellung und juckreiz an der injektionsstelle .'","b'minor side effects include bruising , pain , redness , swelling and itching at the site of the injection .'","b'minor side effects include bruising , hives and itching at the site of the injection .'","b'minor side effects include bruising , pain , redness , swelling and itching at the site of the injection .'"
3904,b'in vitro und in vivo-studien belegen die stimulierende wirkung von glucosamin auf die synthese physiologischer glucosaminoglykane und protoglykane durch chondrozyten und von hyalurons\xc3\xa4ure durch synoviozyten .',b'in vitro and in vivo studies have demonstrated stimulating properties on human endothelial cells to the effects of glucosamine on physiological glucosaminoglykane synthesis and protoglykane by the casing ( 1 synoviozyten .',b'in vitro and in vivo studies have demonstrated differ reporting properties on human cypd pigs effects and porcine document on the growth sulfamethoxazole .',b'in vitro and in vivo studies have demonstrated stimulating properties of glucosamine on physiological glycosaminoglycan synthesis and proteoglykane by chondrocytes and hyaluronic acid by synoviocytes .'
3905,"b'eine zylinderampulle enth\xc3\xa4lt 18 millionen i.e. rekombinantes interferon alfa-2b , hergestellt aus e.coli mittels rekombinanter dna technologie , in 1,2 ml .'","b'one cartridge contains 18 million iu of recombinant interferon alfa-2b produced by recombinant dna technology , produced in e. coli by recombinant dna technology , in 1.2 ml .'",b'one active contains recombinant human single by a single and large week produced by pigs .',"b'one cartridge contains 18 million iu of recombinant interferon alfa-2b produced by recombinant dna technology , produced in e. coli by recombinant dna technology , in 1.2 ml .'"
3906,b'27 \xe2\x80\xa2 entfernen sie die schutzkappe von der raptiva-durchstechflasche und von der fertigspritze mit l\xc3\xb6sungsmittel .',b'27 \xe2\x80\xa2 remove the protective cap and all the solvent pre-filled syringe .',b'remove the cannula cap and all the solvent prefilled syringe .',b'27 \xe2\x80\xa2 remove the protective cap from the vial and all the solvent pre-filled syringe with solution .'
3907,"b'falls n\xc3\xb6tig , wird ihr behandelnder arzt die dosis w\xc3\xa4hrend der behandlung anpassen .'","b'when necessary , your doctor may adjust your dose during treatment .'","b'when necessary , your doctor may adjust your body during treatment .'","b'when necessary , your doctor may adjust your dose during treatment .'"
3908,b'intraven\xc3\xb6se injektion die gabe sollte in abh\xc3\xa4ngigkeit von der gesamtdosis und \xc3\xbcber mindestens 1-5 minuten erfolgen .',"b'intravenous injection the dose should be administered , depending on the total dose and over at least 1-5 minutes .'","b'intravenous injection the dose concentration of insulin prophylaxis , based on the total dose and over at least minutes .'","b'intravenous injection . the dose should be administered , depending on the total dose and over at least 1-5 minutes .'"
3909,"b'im tiermodell f\xc3\xbchrte ibandrons\xc3\xa4ure zu biochemischen ver\xc3\xa4nderungen , die auf eine dosisabh\xc3\xa4ngige inhibierung der knochenresorption hinweisen , einschlie\xc3\x9flich der supprimierung von biochemischen markern im harn f\xc3\xbcr den knochenkollagenabbau ( wie z.b. desoxypyridinolin und die quervernetzten n-telopeptide des kollagens typ i ( ntx ) ) .'","b'in animal models ibandronic acid produced biochemical changes indicative of dose-dependent inhibition of bone resorption , including biochemical markers indicative of bone collagen degradation ( such as deoxypyridinoline , and suppression of type i collagen ( ntx ) ) .'","b'in animal models the bone acid produced abnormal changes reports of cd inhibition viral haufiger suppression of bone blood tract characteristic diseases of inhibition factor prolactin samples of bone fcf as and or egfr as extraneous , and thyroid viral meningococcal mumps , with clavulanic arms , and suppression of'","b'in animal models ibandronic acid produced biochemical changes indicative of dose-dependent inhibition of bone resorption , including suppression of biochemical markers in the urine related to bone collagen degradation ( such as deoxypyridinoline and crosslinked n-telopeptides of type i collagen ( ntx ) ) .'"
3910,"b'26 7 wenn olanzapin pl\xc3\xb6tzlich abgesetzt wurde , wurden akute symptome wie schwitzen , schlaflosigkeit , zittern , angst , \xc3\x9cbelkeit oder erbrechen berichtet .'","b'26 when olanzapine is stopped abruptly 7 acute symptoms such as sweating , insomnia , tremor , anxiety , nausea and vomiting have been reported .'","b'in small is stopped abruptly acute symptoms such as sweating , insomnia , sweating , insomnia , anxiety , nausea and vomiting .'","b'26 if olanzapine is stopped abruptly , acute symptoms such as sweating , insomnia , tremor , anxiety , nausea and vomiting have been reported .'"
3911,b'selten treten \xc3\x9cberempfindlichkeitsreaktionen ( urtikaria und andere m\xc3\xb6gliche allergische reaktionen ) auf .',"b'rarely , hypersensitivity reactions ( urticaria , and other possible allergic reaction ) .'","b'rarely , hypersensitivity reactions urticaria , and other possible allergic reaction .'","b'rarely , hypersensitivity reactions occur ( urticaria , and other possible allergic reaction ) .'"
3912,"b'den patienten ist deshalb anzuraten , kein fahrzeug zu lenken und keine maschinen zu bedienen , bis ihre individuelle empfindlichkeit bekannt ist .'","b'the therefore , patients should be advised not to drive or use machines until their individual sensitivity .'","b'the change , patients should be advised does be advised again in the glucocorticoids .'","b'therefore , patients should be advised not to drive or use machines until their individual sensitivity is known .'"
3913,"b'bei kaninchen wurden nach dosen , die zu einer deutlichen toxizit\xc3\xa4t beim muttertier , einschlie\xc3\x9flich tod , f\xc3\xbchrten , aborte und resorption in der fr\xc3\xbchphase festgestellt .'","b'in rabbits was noted at doses causing significant maternal toxicity , including death , were noted and early resorption .'","b'in rabbits was noted about prca occurred in relation to death , were noted associated in two increase to death , were noted .'","b'in rabbits after doses causing significant maternal toxicity , including death , miscarriages and resorption were noted in the early stages .'"
3914,"b'bis zur markierung mit wasser aufgef\xc3\xbcllt , und der gesamte inhalt wird von dem patienten getrunken .'","b'until the amplification step comprises the use of the vial , and the entire contents will be drunk by the patients .'","b'until the physicalchemical tube looks the ready with the packaging spike , the enclosed mark from the entire contents .'",b'until the vial is filled up to the mark with water and the entire contents will be drunk by the patient .'
3915,"b'dieses ergibt eine gemcitabin-konzentration von 38 mg / ml , die das verdr\xc3\xa4ngungsvolumen durch das lyophilisierte pulver mit einberechnet .'","b'this yields a concentration of 38 mg / ml , which displacement volume of the lyophilised powder includes accounting for .'","b'this inuse a concentration of mg ml , which susceptible .'","b'this yields a concentration of 38 mg / ml , which took account of the displacement volume by the freeze-dry powder .'"
3916,b'die wirksamkeit von irbesartan ist nicht abh\xc3\xa4ngig von einer stoffwechselaktivierung .',b'the efficacy of irbesartan is not dependent on a stoffwechselaktivierung .',b'the efficacy of irbesartan . the table of irbesartan is not dependent on a occuring combined with a menstrual function',b'the efficacy of irbesartan is not dependent on a metabolic activation .'
3917,b'es wurden keine relevanten qualit\xc3\xa4tsaspekte festgestellt .',b'there were no relevant quality aspects was noted .',b'no relevant quality programme was noted .',b'there were no relevant quality aspects noted .'
3918,"b'2,3 ml / min / kg . die pharmakodynamischen daten deuten darauf hin , dass bei einer replagal-dosierung von 0,2 mg / kg der r\xc3\xbcckgang von gb3 im plasma bei jugendlichen und kleinen kindern mehr oder weniger vergleichbar ist ( siehe abschnitt 5.1 ) .'",b'2.3 ml / min / kg ) . the pharmacodynamic data indicate that at a dose of 0.2 mg / kg of plasma gb3 in adolescents and young children are more or less comparable between ( see section 5.1 ) .',b'. ml min kg . the pharmacodynamic of . mg kg of up mg kg of plasma orbifloxacin in adolescents and not a rate of . mg kg of plasma tubules is .',b'2.3 ml / min / kg ) . the pharmacodynamic data indicate that at a dose of 0.2 mg / kg the decline of gb3 in plasma of adolescents and young children are more or less comparable between ( see section 5.1 ) .'
3919,"b'h\xc3\xa4ufig ( \xe2\x89\xa5 1 / 100 und < 1 / 10 patienten ) : \xe2\x80\xa2 infektionen d er unteren atemwege ( wie bronchitis , lungenentz\xc3\xbcndung ) ;'","b'common ( \xe2\x89\xa5 1 / 100 and 1 / 10 patients ) : \xe2\x80\xa2 infections permitted lower respiratory tract ( such as bronchitis , pneumonia ) ;'","b'common and patients infections coli lower respiratory tract such as atcvet , pneumonia'","b'common ( \xe2\x89\xa5 1 / 100 and 1 / 10 patients ) : \xe2\x80\xa2 infections permitted lower respiratory tract ( such as bronchitis , pneumonia ) ;'"
3920,b'zur gew\xc3\xa4hrleistung einer ausreichenden nierendurchblutung m\xc3\xbcssen l\xc3\xa4ngere phasen mit blutdruckabfall ( mittlerer arterieller blutdruck < 60 mmhg ) w\xc3\xa4hrend der sevofluran-narkose vermieden werden .',b'the adequate renal blood flow must be longer periods with low blood pressure ( mean arterial blood pressure 60 mmhg ) during sevoflurane anaesthesia should be avoided .',"b'the adequate renal platelet blood flow , caution occur with low blood pressure in the usual blood pressure mmhg during sevoflurane anaesthesia should be avoided .'","b'for the adequate renal blood flow , longer periods with low blood pressure ( mean arterial blood pressure 60 mmhg ) should be avoided during sevoflurane anaesthesia .'"
3921,b'die dosis-abh\xc3\xa4ngigen nebenwirkungen des hydrochlorothiazids ( insbesondere elektrolytst\xc3\xb6rungen ) k\xc3\xb6nnen sich durch dosissteigerung von hydrochlorothiazid verst\xc3\xa4rken .',b'9 the dose dependent adverse events of hydrochlorothiazide ( particularly electrolyte disturbances ) may increase when titrating the hydrochlorothiazide .',b'the dose dependent adverse events with a cancer that cause hepatic fundoscopy and lifethreatening b disturbances .',b'9 the dose dependent adverse events of hydrochlorothiazide ( particularly electrolyte disturbances ) may increase when titrating the hydrochlorothiazide .'
3922,"b'die tabletten werden durch r\xc3\xbchren in einem glas wasser oder orangen- oder apfelsaft ( 100 bis 200 ml ) fein verteilt , bis eine feine suspension entsteht .'",b'tablets are to be taken as a signal to be dispersed in a full glass of water or orangen- or apple juice ( 100 to 200 ml ) until the a fine suspension .',"b'tablets are supplied by a thin white , a .'",b'tablets are to be dispersed in a full glass of water or orange or apple juice ( 100 to 200 ml ) until the a fine suspension .'
3923,"b'knochenmarkdepression w\xc3\xa4hrend der behandlung mit remeron wurde \xc3\xbcber knochenmarkdepression , insbesondere granulozytopenie oder agranulozytose , berichtet .'",b'12 at the age of 18 years remeron should particularly 18 years ( see section 4.4 ) .',b'at the age of years rapid should cause monitor different diseases dialysis should coadministered of high or gently problems with atorvastatin is affected see section . .',"b'bone marrow depression . during the treatment with remeron bone marrow depression was reported , especially granulocytopenia or agranulocytosis .'"
3924,"b'diese anforderung bezieht sich auch auf frauen im geb\xc3\xa4rf\xc3\xa4higen alter , die absolut und ununterbrochen abstinent sind .'","b'this is also the refers to women of childbearing age , relative to the person abstinent ) .'",b'this is also rare accidental apathy were described as depression and prolonged and administered after their rapid .',b'this requirement also refers to women of childbearing age who are absolutely and continually celibate .'
3925,b'wie wurde fareston untersucht ?',b'how has fareston been studied ?',b'how has immediately been studied ?',b'how has fareston been studied ?'
3926,b'was ist emend und wof\xc3\xbcr wird es angewendet ?',b'what emend is and what it is used for 2 .',b'what quadramet is and what it is used for .',b'what emend is and what it is used for ?'
3927,"b'versch\xc3\xbcttetes arzneimittel mit 10 % lauge oder natriumhypochlorit-l\xc3\xb6sung ( haushaltschlorbleiche - 2 ml ( 0,5 % ) :'",b'versch\xc3\xbcttetes medicinal products with 10 % of formula represents or or sodium hypochlorite ( household chlorine bleach - 2 ml ( 0.5 % ) :',b'for medicinal products with placebo with the urine infusion .',b'blocked medicinal products with 10 % brine or sodium hypochlorite solution ( household chlorine bleach - 2 ml ( 0.5 % ) :'
3928,b'bei druckaufbau kann entl\xc3\xbcftung erforderlich sein . \xe2\x80\xa2 gut sch\xc3\xbctteln .',b'pressure build-up may require venting . \xe2\x80\xa2 shake the mmp inhibitor .',"b'essential level , may require cerenia .'",b'pressure build-up may require venting . \xe2\x80\xa2 shake well .'
3929,b'hycamtin 4 mg steht in 17 ml-flintglasflaschen des typs i mit 20-mm-stopfen aus grauem butylkautschuk mit 20-mm-aluminiumverschluss und schnappdeckel aus kunststoff zur verf\xc3\xbcgung .',b'hycamtin 1 mg is supplied in 17 ml-flintglasflaschen indicating with 20-mm-stopfen grey butyl rubber with 20-mm-aluminiumverschluss and are available .',b'hycamtin mg is supplied in zonegran parent with nicotinamide spoons nordisk seal and are available .',b'hycamtin 4 mg is supplied in 17 ml flint glass vials of type 1 glass with 20-mm-stopfen grey butyl rubber with a 20 mm aluminium cap and snap caps made of plastic are available .'
3930,b'zur \xc3\x9cberdosierung liegen keine daten vor .',b'no data are available with regard to overdose .',b'no data is available with regard to overdose .',b'no data is available with regard to overdose .'
3931,b'antithrombotische mittel : heparingruppe .',b'pharmacotherapeutic group : antithrombotic agents : antithrombotic agents : heparin group .',b'pharmacotherapeutic group antithrombotic agents .',b'antithrombotic agents : heparin group .'
3932,b'wie bei anderen sulfonylharnstoffen basiert dieser effekt auf einer verbesserung der empfindlichkeit der pankreatischen betazellen auf den physiologischen glucosereiz .',"b'as with other sulphonylureas , this effect is based on an improvement in 28 of glucosereiz .'",b'as with other moist or of fracture effect is established in of procarbazine within .',"b'as with other sulphonylureas , this effect is based on an improvement of the sensitivity of the pancreatic beta cells to the physiological glucose stimulus .'"
3933,b'viread ist in kombination mit anderen antiretroviralen arzneimitteln zur behandlung hiv-1-infizierter erwachsener \xc3\xbcber 18 jahren angezeigt .',b'viread is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults over the age of 18 years of age .',b'hypoglycaemia is indicated in combination with other antiretroviral medicinal products for the treatment of etoricoxib infected adults over the age of pharmacokinetic of age is performed with potential .',b'viread is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults over the age of 18 years of age .'
3934,b'nach jedem gebrauch das dosierspray reinigen und die verschlusskappe wieder aufsetzen .',"b'after each use , the intranasal and replace the cap .'","b'after preparation is cover , the vaccinating treatment with the tube .'","b'after each use , clean the intranasal spray and replace the cap .'"
3935,b'busilvex zerst\xc3\xb6rt das k\xc3\xb6rpereigene knochenmark vor der transplantation .',"b""busilvex destroys the body 's bone marrow before the transplant .""",b'busilvex decreased the body s bone marrow effects',"b""busilvex destroys the body 's bone marrow before the transplant ."""
3936,"b'dies best\xc3\xa4tigt , dass der impfstoff in der freien wildbahn sicher ist .'",b'this confirms that the vaccine by safe to do so .',b'this endemic that the vaccine where this is no to this to do not be reported by this to do not slowly possible is used so .',b'this confirms that the vaccine is safe in the wild .'
3937,b'blutes . ibuprofen kann das blutungsrisiko erh\xc3\xb6hen .',b'. ibuprofen may increase the risk of bleeding .',b'. ibuprofen may increase the risk of bleeding .',b'. ibuprofen may increase the risk of bleeding .'
3938,"b'allergische reaktionen soliris enth\xc3\xa4lt ein protein , und proteine k\xc3\xb6nnen bei einigen menschen allergische reaktionen hervorrufen .'","b'allergic reactions soliris contains ) , and proteins may cause allergic reactions in some people .'","b'allergic reactions soliris contains , and dasatinib changes in some people .'",b'allergic reactions : soliris contains a protein and proteins may cause allergic reactions in some people .'
3939,"b'stechen sie die nadel vollst\xc3\xa4ndig in die haut , wie ihr arzt oder die krankenschwester es ihnen gezeigt hat .'","b'insert the needle into the skin , as your doctor or nurse will take you to .'","b'perform the needle white you in the skin , as your doctor or nurse will take you to .'","b'insert the needle into the skin , as your doctor or nurse has shown you .'"
3940,b'wenn sie die anwendung von suboxone abbrechen bei einem pl\xc3\xb6tzlichen therapieabbruch kann es zu entzugssymptomen kommen .',"b'if you stop using suboxone if sudden discontinuation of therapy , may experience withdrawal symptoms may occur .'",b'if you stop using suboxone if a gastrointestinal acidosis in patients or may experience .',"b'if you stop using suboxone : if sudden discontinuation of therapy , withdrawal symptoms may occur .'"
3941,b'wie wurde kuvan untersucht ?',b'how has kuvan been studied ?',b'how has situations been studied ?',b'how has kuvan been studied ?'
3942,b'erkrankungen der haut und des unterhautzellgewebes h\xc3\xa4ufig :',b'skin and subcutaneous tissue disorders common :',b'skin and subcutaneous tissue disorders common',b'skin and subcutaneous tissue disorders common :'
3943,"b'die dosierung wird durch die indikation , die schwere und den ort der infektion , die ciprofloxacin empfindlichkeit der ( s ) verursachenden erreger ( s ) , der nierenfunktion des patienten und dem k\xc3\xb6rpergewicht bei kindern und jugendlichen bestimmt .'","b'the dose is determined by the indication , severity , and going to infection , the sensitivity of ciprofloxacin ( s ) in 18,150 pathogen ( s ) , renal function and body weight in children and adolescents .'",b'the dose is excreted by the indication is a body signs with acetylsalicylic s properties .',"b'the dose is determined by the indication , severity , site of infection , the sensitivity of ciprofloxacin of pathogen ( s ) , renal function of the patient and body weight in children and adolescents .'"
3944,"b'm\xc3\xb6glich , dass sie d en text noch einmal lesen m\xc3\xb6chten .'",b'if ( d s read it again .',b'if d s read it again .',"b""it 's possible that you may want to read it again ."""
3945,b'innerhalb jeder h\xc3\xa4ufigkeitsgruppe werden die nebenwirkungen nach abnehmendem schweregrad angegeben .',"b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'","b'approximately , these effects are presented in order of uric seriousness .'","b'within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .'"
3946,b'ein zusammenhang dieser effekte auf die fetale entwicklung mit der maternalen toxizit\xc3\xa4t konnte nicht festgestellt werden .',b'an association of these effects on foetal development and maternal toxicity has not been established .',b'an association of these effects on foetal development and prophylaxis in frequency of missing as if necessary .',b'an association of these effects on foetal development and maternal toxicity has not been established .'
3947,"b'die wirkung von simulect beruht darauf , dass es immunzellen davon abh\xc3\xa4lt , das transplantierte organ anzugreifen .'",b'the effect of simulect how immune cells and 3430 transplanted organ .',"b'the effect of vidaza how , a company organ .'",b'the effect of simulect is based on how immune cells prevent attacks on the transplanted organ .'
3948,b'aufgrund dieser langen halbwertszeiten verbleibt auch 5-6 wochen nach absetzen noch wirksame substanz im k\xc3\xb6rper .',b'based on these long half-lives remains even 5-6 weeks after cessation of treatment in the body .',b'based on these long suffer remains even weeks after cessation of treatment in the body .',"b'due to these long half-lives , some active substance remains in the body even 5-6 weeks after cessation of treatment .'"
3949,b'die sicherheit einer immunisierung mit viralen lebendimpfstoffen nach einer therapie mit mabthera wurde nicht untersucht .',b'the safety of immunisation with live viral vaccines following mabthera therapy has not been studied .',b'the safety of immunisation with live viral vaccines following mabthera therapy has not been studied .',b'the safety of immunisation with live viral vaccines following mabthera therapy has not been studied .'
3950,"b'der folgende wortlaut wurde f\xc3\xbcr die anwendungsgebiete vorgeschlagen : "" lungenmilzbrand ( postexpositionsprophylaxe und kurative behandlung ) "" f\xc3\xbcr orale und i.v. arzneiformen .'","b'the following wording has been developed for proposed indications : "" inhalation anthrax ( post-exposure prophylaxis and curative intent ) for oral and iv .'",b'the following wording has been developed signs of disagreement with the auc of burns of recombinant haematopoietic titre .',"b'the following wording has been proposed for these application areas : "" inhalation anthrax ( post-exposure prophylaxis and curative treatment ) for oral and iv dosage forms .'"
3951,"b'da das risiko , das bei einer m\xc3\xb6glichen exposition w\xc3\xa4hrend der fr\xc3\xbchen schwangerschaft besteht , unbekannt ist , m\xc3\xbcssen frauen im geb\xc3\xa4rf\xc3\xa4higen alter angewiesen werden , unter der therapie mit torisel nicht schwanger zu werden .'","b'as the risk of the possible exposure during early pregnancy , is unknown , women of childbearing potential must be instructed that treatment with torisel do not become pregnant .'","b'as the risk of the possible exposure during early pregnancy , is unknown , with years , is unknown , the potential must be instructed that treatment with leukopenia acid check during a mild contraception during long conditions , adjustment at a blood .'","b'as the risk of the possible exposure during early pregnancy is unknown , women of childbearing potential must be instructed that treatment with torisel not to become pregnant .'"
3952,"b'forcierte diurese , dialyse , h\xc3\xa4mo- perfusion und blutaustauschtransfusion sind wahrscheinlich ohne nutzen .'","b'forcierte diuresis , dialysis , haemofiltration , haemodialysis , perfusion and blutaustauschtransfusion are likely to be of no benefit .'","b'forced diuresis , dialysis , haemofiltration , haemodialysis , faecal , hemodialysis , biperiden and jaundice are predominantly to be followed in sensitive of a symptomatic second infections or sneezing and them are likely to be children can be established and them are reported to be on this studies have'","b'forced diuresis , dialysis , haemofiltration , haemodialysis , perfusion and blood tranfusion are likely to be of no benefit .'"
3953,"b'daher sollten patienten sich w\xc3\xa4hrend dieser zeit nicht in einem abgedunkelten raum aufhalten und sollten ermuntert werden , ihre haut dem raumlicht auszusetzen .'","b'therefore , patients should not be used during this time in dark remain and should be ermuntert , their skin of the raumlicht .'","b'therefore , patients should not be used during this time in airway deficiency .'","b'therefore , patients should not stay in dark rooms during this time and should be be encouraged to expose their skin to room light .'"
3954,b'wie wird diacomit angewendet ?',b'how is diacomit used ?',b'how is novorapid used ?',b'how is diacomit used ?'
3955,b'es liegen noch keine klinischen erfahrungswerte \xc3\xbcber die gleichzeitige anwendung mit cytidin- analoga vor .',b'there is no clinical experience with myocet for the co-administration of perforation of analogues .',b'there is no clinical experience with myocet for the coadministration system of interferons .',b'there is no clinical experience with myocet for the co-administration of cytidine analogues .'
3956,b'schlucken sie die dosis der l\xc3\xb6sung zum einnehmen und trinken sie danach etwas wasser .',b'swallow the dose of the oral solution and then drink some water .',b'swallow the dose of the oral solution and then drink some water .',b'swallow the dose of the oral solution and then drink some water .'
3957,b'wegen der bekannten vagotonischen wirkung von cholinesterasehemmern auf die herzfrequenz kann es auch zu bradykardie und / oder synkope kommen .',b'due to the known vagotonischen effect of cholinesterasehemmern on the heart rate can also cause bradycardia and / or syncope may occur .',b'due to the known antirheumatic amounts of reticulin on the heart rate can also cause bradycardia and or clinical than medicines and or sulphonylureas were not cause bradycardia and or left may occur .',"b'due to the known vagotonic effect of cholinesterase inhibitors on the heart rate , bradycardia and / or syncope may occur .'"
3958,b'nicht \xc3\xbcber 30o c lagern .',b'do not store above 30o above 25 \xc2\xb0 c.',b'do not store above cartridges .',b'do not store above 30 \xc2\xb0 c.'
3959,b'die ergebnisse der bis zu 24 monate dauernden forsteo- behandlung ( median :',b'the results of up to 24 months forsteo- treatment ( median value :',"b'the results of up to months see the tissue of is resumed , which is found during the requirement of test .'",b'the results of up to 24 months forsteo- treatment ( median value :'
3960,"b'entfernen sie die schutzkappe von der nadel , wenn sie diese vorher wieder aufgesteckt haben .'",b'remove the protective cap from the needle if you are taking these again after reconstituting the radiotherapy .',b'remove the protective cap from the needle that you are taking these again after the countries .',b'remove the protective cap from the needle if you already reattached it .'
3961,b'die maximalen serumkonzentrationen wurden ungef\xc3\xa4hr 5 tage nach verabreichung erreicht .',"b', with peak serum concentrations being reached about 5 days after administration .'",b'loss of the blood values more state within neither administration .',b'the maximum peak serum concentrations were reached about 5 days after administration .'
3962,b'den vollst\xc3\xa4ndigen wortlaut des epar f\xc3\xbcr reyataz finden sie hier .',b'the full epar for avamys for reyataz can be found here .',b'the full epar for macugen can be found here .',b'the full epar text for reyataz can be found here .'
3963,"b'basierend auf den erfahrungen mit dieser substanzklasse kann jedoch eine intraven\xc3\xb6se \xc3\x9cberdosierung zu hypokalz\xc3\xa4mie , hypophosphat\xc3\xa4mie und hypomagnesi\xc3\xa4mie f\xc3\xbchren .'","b'based on the experience with knowledge of this class of intravenous overdose result in hypocalcaemia , hypophosphataemia , and hypomagnesaemia .'",b'based on the patient with alimta of dose doxorubicin as as increased other interactions of excess .',"b'based on the experience of this substance class , an intravenous overdose may result in hypocalcaemia , hypophosphataemia , and hypomagnesaemia .'"
3964,b'es gibt keinen hinweis auf einen oxidativen metabolismus .',b'there is no evidence of oxidative metabolism .',b'there is no evidence of debilitating metabolism .',b'there is no evidence of oxidative metabolism .'
3965,"b'es ist nicht bekannt , ob mabcampath bei schwangeren frauen zur fruchtsch\xc3\xa4digung oder beeintr\xc3\xa4chtigung der fortpflanzungsleistung f\xc3\xbchren kann .'",b'it is not known whether mabcampath in pregnant women to prevent foetal or can cause .',b'it is not known whether mabcampath in pregnant women to prevent inhibition or tolerance .',b'it is not known whether mabcampath in pregnant women can cause foetal damage or impair the reproductive performance .'
3966,b'bei einnahme von neoclarityn zusammen mit nahrungsmitteln und getr\xc3\xa4nken neoclarityn kann unabh\xc3\xa4ngig von den mahlzeiten eingenommen werden .',b'taking neoclarityn with food and drink neoclarityn may be taken with or without a meal .',b'taking neoclarityn with food and cause xolair in and or without a meal .',b'taking neoclarityn with food and drink neoclarityn may be taken with or without a meal .'
3967,b'die renale clearance ( etwa 60 ml / min bei gesunden postmenopausalen frauen ) betr\xc3\xa4gt 50 - 60 % der gesamt-clearance und korreliert mit der kreatinin-clearance .',b'the renal clearance ( about 60 ml / min in healthy postmenopausal women ) is 50 - 60 % of the total body clearance and is correlated to creatinine clearance .',b'the renal clearance about ml min in healthy postmenopausal women is of the total body clearance and is mean two higher ritonavir clearance and is correlated to creatinine clearance .',b'the renal clearance ( about 60 ml / min in healthy postmenopausal women ) is 50 - 60 % of the total body clearance and is correlated to creatinine clearance .'
3968,b'9 eine anpassung der dosierung kann auch bei einer \xc3\x84nderung der k\xc3\xb6rperlichen aktivit\xc3\xa4t oder der ern\xc3\xa4hrungsgewohnheiten des patienten notwendig sein .',b'9 adjustment of dosage may also be necessary if patients change physical activity or their usual diet if necessary .',b'adjustment of dosage in the reduction of dosage therapy or their usual diet if necessary .',b'9 adjustment of dosage may also be necessary if patients change physical activity or their usual diet .'
3969,"b'falls vom arzt nicht anders verordnet , ist die \xc3\xbcbliche dosis zur behandlung der schmerzen bei diabetischer polyneuropathie einmal t\xc3\xa4glich 60 mg .'",b'if unless otherwise prescribed by your doctor . the usual dose for the treatment of diabetic neuropathic pain is 60 mg once a day .',b'if unless decide for tuberculosis stalevo or xolair . the usual dose is mg once a day .',"b'unless otherwise prescribed by your doctor , the usual dose for the treatment of diabetic neuropathic pain is 60 mg once a day .'"
3970,"b'abgesehen von umstrittenen literaturergebnissen zur wirksamkeit und sicherheit von transdermalem fentanyl bei chronischen nichttumorschmerzen erkannte der chmp an , dass unter bestimmten umst\xc3\xa4nden stark wirksame opioide bei der behandlung dieses zustandes helfen k\xc3\xb6nnen .'",b'apart from umstrittenen literaturergebnissen the effectiveness and safety of transdermal fentanyl in chronic nichttumorschmerzen the chmp that are highly effective under certain circumstances may include opioids in the treatment of this situation .',b'apart from physicochemical officially the effectiveness and safety of transdermal fentanyl in chronic co that are highly effective to sexual indication in chronic overdosing in the injection populations .',"b'apart from disputed literature results , the effectiveness and safety of transdermal fentanyl in chronic non tumour pain was recognised by the chmp , that strong acting opioids can help under certain circumstances in the treatment of this situation .'"
3971,b'es sind keine daten f\xc3\xbcr die anwendung von pegintron bei patienten mit einer kreatinin-clearance < 15 ml / min vorhanden ( siehe abschnitt 5.2 ) .',b'there are no data on the use of pegintron in patients with creatinine clearance 15 ml / minute ( see section 5.2 ) .',b'there are no data on the use of pegintron in patients with creatinine clearance of pegintron .',b'there is no data on the use of pegintron in patients with creatinine clearance of 15 ml / minute ( see section 5.2 ) .'
3972,"b'aseptische bedingungen m\xc3\xbcssen unbedingt eingehalten werden , da caelyx keine konservierungsmittel oder bakteriostatischen hilfsstoffe enth\xc3\xa4lt .'",b'aseptic technique must be strictly observed since caelyx does not contain any preservative or bacteriostatic .',b'newly fast must be returned to the .',b'aseptic technique must be strictly observed since caelyx does not contain any preservative or bacteriostatic .'
3973,b'patienten mit einer schweren hypothyreose m\xc3\xbcssen vor dem beginn einer nutropi- naq-therapie entsprechend behandelt werden .',b'patients with severe hypothyroidism should be assessed before the start of a nutropi- naq-therapie treated appropriately .',b'patients with severe listed expected can be subject to the start of a confirmatory azoles is conducted .',b'patients with severe hypothyroidism should be assessed before the start of a nutropi- naq-therapie treated appropriately .'
3974,b'zus\xc3\xa4tzlich f\xc3\xbcr lansoprazol 15 mg :',"b'in addition , lansoprazole 15 mg :'","b'in addition , lansoprazole yellow'",b'in addition to lansoprazole 15 mg :'
3975,"b'die h\xc3\xa4ufigkeitsangaben basieren auf klinischen studien und spiegeln m\xc3\xb6glicherweise nicht die h\xc3\xa4ufigkeiten der nebenwirkungen wider , die in der normalen klinischen praxis auftreten .'",b'adverse reaction frequency categories assigned based on clinical trial experience may not reflect the frequency of adverse events occurring during normal clinical practice .',"b'the adverse reaction population of significant , often data on clinical than hepatic tnbp .'",b'adverse reaction frequency categories assigned based on clinical trial experience may not reflect the frequency of adverse events occurring during normal clinical practice .'
3976,b'2. was m\xc3\xbcssen sie vor der einnahme von ebixa beachten ? 3.',b'what you should know before you take ebixa 3 .',b'what you should know before you take ebixa .',b'what you should know before you take ebixa 3 .'
3977,b'die belichtung mit einer mikrolinsenfaser muss die gesamte tumoroberfl\xc3\xa4che erfassen .',b'the irradiance of the microlens fibre-optic full dose should be delivered .',b'an aim of lymphadenopathy trough updated datais full medicinal levels over the travoprost at the mpsi agonist',b'the exposure with a microlens fibre-optic should cover the eintire tumor surface .'
3978,b'das verfahren der pmf- / vamf-zertifizierung besteht in der beurteilung des pmf- / vamf- antragsdossiers .',b'the possibility of pmf- / vamf-zertifizierung in the judgement of the pmf- / vamf application dossier .',b'the possibility of hepatologen hydroxybenzoyl isotopes of human risk includes the accepted large tablet tkt as go .',b'the procedure of pmf / vamf consists in assessing the pmf- / vamf application dossier .'
3979,b'mao-hemmer ( z. b. moclobemid gegen depressionen oder selegilin gegen parkinson-krankheit ) einnehmen oder in den letzten 14 tagen eingenommen haben .',"b""mao inhibitors ( e. g. moclobemide against depression or selegiline against parkinson 's disease ) or have recently taken within the last 14 days .""","b'careful taken , compromised staphylococcus medicine prasugrel also depression or alternative against parkinson s disease or usually an antihistamine for dementia with selegiline against parkinson s disease or reported from appropriate s diseases with other intravenous breakdown factors . in the national tablets presented as is excluded against insomnia or'","b""taking mao inhibitors ( e. g. moclobemide against depression or selegiline against parkinson 's disease ) or have recently taken within the last 14 days ."""
3980,b'es wurde jedoch die beziehung der nierenfunktion und der pharmakokinetik von tolcapon mit populationspharmakokinetischen methoden w\xc3\xa4hrend klinischer studien untersucht .',"b'however , the relationship between renal function and pharmacokinetics of tolcapone with population pharmacokinetics of contraception during clinical studies .'","b'however , the relationship between renal function and pharmacokinetics of selfadministration during changing as light therapy with population of contraception .'","b'however , the relationship between kidney function and pharmacokinetics of tolcapone with population pharmacokinetics analysis of contraception during clinical studies .'"
3981,"b'xiliarx hilft , den zuckerspiegel im blut zu regulieren .'",b'xiliarx helps to increase sugar levels in the level of sugar in the blood .',b'xiliarx helps to increase essential levels in the level of sugar in the blood .',b'xiliarx helps to increase sugar levels in the level of sugar in the blood .'
3982,"b'nebenwirkungen bemerken , die nicht in dieser gebrauchsinformation angegeben sind , informieren sie bitte ihren arzt oder apotheker .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'","b'you notice any side effects not mentioned in this leaflet , please tell your doctor or pharmacist .'"
3983,b'es werden m\xc3\xb6glicherweise nicht alle packungsgr\xc3\xb6\xc3\x9fen in den verkehr gebracht .',b'not all pack sizes may be marketed .',b'not all pack colourless may be marketed .',b'not all pack sizes may be marketed .'
3984,"b'sie erreichen die beste wirkung , wenn sie agopton gleich als erstes morgens einnehmen .'",b'you reach the best effect if you are taking agopton similar volume in the morning .',b'the best effect if you are taking agopton similar this is worse which',b'you reach the best effect if you are taking agopton in the morning .'
3985,b'die unterdr\xc3\xbcckung der magens\xc3\xa4uresekretion kann zu einer niedrigeren exposition von nilotinib f\xc3\xbchren .',b'the suppression of gastric acid secretion may lead to lower exposure to nilotinib .',b'the raloxifene of gastric acid ace .',b'the suppression of gastric acid secretion may lead to lower exposure of nilotinib .'
3986,b'die dosis kann vor\xc3\xbcbergehend oder st\xc3\xa4ndig reduziert werden .',b'the dose can be reduced by transient or constantly .',b'the dose can be reduced by transient or azacitidine .',b'the dose can be reduced by temporarily or permantly .'
3987,"b'paxene kann w\xc3\xa4hrend der schwangerschaft nicht angewendet werden , und frauen , die paxene erhalten , d\xc3\xbcrfen nicht stillen .'",b'paxene may not be used in pregnancy and women receiving paxene should not breast-feed .',b'paxene may only to these measures interaction of women receiving paxene cannot not breastfeed .',b'paxene may not be used during pregnancy and women receiving paxene should not breast-feed .'
3988,"b'entsorgen sie spritze , kan\xc3\xbclen und nicht verwendete suspension sachgerecht .'","b'dispose of the syringe , needles and any unused suspension safely .'","b'dispose of the syringe , needles contains suspension .'","b'dispose of the syringe , needles and any unused suspension safely .'"
3989,"b'- die sonstigen bestandteile sind : lactose-monohydrat , citronens\xc3\xa4ure und natriumhydroxid .'","b'- the other ingredients are lactose monohydrate , citric acid , phosphoric acid and sodium hydroxide .'",b'the other ingredients are tablet . very insulin acid and sodium hydroxide .',"b'- the other ingredients are lactose monohydrate , citric acid , phosphoric acid and sodium hydroxide .'"
3990,"b'verwenden sie diesen optiset nicht , wenn die l\xc3\xb6sung tr\xc3\xbcb oder verf\xc3\xa4rbt ist oder parti- kel enth\xc3\xa4lt .'",b'do not use this optiset if the solution is cloudy or is coloured or it has solid pieces parti- muscle .',"b'do not use this optiset if the solution is cloudy or is discoloured or not hear or which can take or it has solid pieces trihydrate , or do not injected or not forget or it has solid pieces requiring or and the injection site .'",b'do not use this optiset if the solution is cloudy or is discoloured or if there are particels present .'
3991,"b'patienten d\xc3\xbcrfen , falls sie f\xc3\xbcr die behandlung sediert wurden , nach der lichttherapie kein kraftfahrzeug f\xc3\xbchren oder maschinen bedienen .'","b'patients must not take any activities that require mental alertness such treatment , as drive or use machines .'",b'patients must not seek dizzy in doubt patients or create physician .',b'patients must not drive or use machines after light therapy in case they were sedated .'
3992,b'weitere informationen \xc3\xbcber volibris :',b'2 / 3 other information about volibris :',b'other information about volibris',b'other information about volibris :'
3993,"b'bei den verbleibenden 55 % der patienten mit unbekanntem egfr-expressionsstatus betrug das risikoverh\xc3\xa4ltnis 0,77 ( ci 0,61 - 0,98 ) .'","b'in the remaining 55 % of the patients rate egfr-expression status , the hazard ratio was 0.77 ( ci 0.61 - 0.98 ) .'",b'in the remaining of the current concentration schemes on the hazard ratio of the nifedipinepharmamatchretard ratio was . ci . . .',"b'in the remaining 55 % of the patients with unknown egfr expression status , the hazard ratio was 0.77 ( ci 0.61 - 0.98 ) .'"
3994,"b'wie alle arzneimittel kann yentreve nebenwirkungen haben , die aber nicht bei jedem auftreten m\xc3\xbcssen .'","b'like all medicines , yentreve may cause side effects , although not every body gets them .'","b'like all tell actrapid may cause side effects , allergic or them .'","b'like all medicines , yentreve may cause side effects , although not every body gets them .'"
3995,"b'beim menschen entsteht der metabolit n-desethyl-brinzolamid , der ebenfalls an ca anbindet und in den erythrozyten akkumuliert wird .'","b'in humans , the active metabolite of the n-desethyl-brinzolamide , also attaches to the ca in rbcs .'","b'in humans , the active metabolite of the site of the evolution of the gall cavity of the resetoction is recorded in the serum study produced to the removed in immunosuppressive in illness .'","b'in humans , the active metabolite of the n-desethyl brinzolamide , also attaches to the ca in rbcs .'"
3996,b'ein sofortiges absetzen der 183 interferon-alfa-behandlung und eine therapie mit kortikosteroiden scheint mit einem verschwinden der pulmonalen nebenwirkungen einherzugehen .',b'prompt discontinuation of interferon alpha 183 administration and treatment with corticosteroids appear to be associated with resolution of pulmonary adverse events .',b'prompt discontinuation of interferon appetite of plasma body of exhaustion simultaneous pulmonary adverse events .',b'prompt discontinuation of interferon alpha 183 administration and treatment with corticosteroids appear to be associated with resolution of pulmonary adverse events .'
3997,b'13 klinische aspekte :',b'13 clinical aspects :',b'clinical mechanism of rise for modified',b'13 clinical aspects :'
3998,b'die isolierte extremit\xc3\xa4ten-perfusion erm\xc3\xb6glicht die anwendung von hohen und gleich bleibenden tasonermin-konzentrationen in der extremit\xc3\xa4t .',b'the isolated limb perfusion allows the use of high and lasting tasonermin-konzentrationen in the limb .',b'the acute not through the trough vaccine allows which provided from missing may occur with the named of any and lasting immunotolerance in the optipen of increased and faster rct in the cerebrospinal injuries of the elimination of in the iron lesion .',b'the isolated limb perfusion allows the use of high and lasting tasonermin-concentration in the limb .'
3999,"b'22 falls weitere informationen \xc3\xbcber das arzneimittel gew\xc3\xbcnscht werden , setzen sie sich bitte mit dem \xc3\xb6rtlichen vertreter des pharmazeutischen unternehmers in verbindung .'","b'22 for any information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'for any information about the information about this medicine , please contact the local representative of the marketing authorisation holder .'","b'22 for any information about this medicine , please contact the local representative of the pharmaceutical company .'"
